Activation	O
-	O
dependent	O
transcriptional	O
regulation	O
of	O
the	O
human	O
Fas	O
promoter	O
requires	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
p50	O
-	O
p65	O
recruitment	O
.	O

Fas	O
(	O
CD95	O
)	O
and	O
Fas	O
ligand	O
(	O
CD95L	O
)	O
are	O
an	O
interacting	O
receptor	O
-	O
ligand	O
pair	O
required	O
for	O
immune	O
homeostasis	O
.	O

Lymphocyte	O
activation	O
results	O
in	O
the	O
upregulation	O
of	O
Fas	O
expression	O
and	O
the	O
acquisition	O
of	O
sensitivity	O
to	O
FasL	O
-	O
mediated	O
apoptosis	O
.	O

Although	O
Fas	O
upregulation	O
is	O
central	O
to	O
the	O
preservation	O
of	O
immunologic	O
tolerance	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
machinery	O
underlying	O
this	O
process	O
.	O

To	O
investigate	O
the	O
events	O
involved	O
in	O
activation	O
-	O
induced	O
Fas	O
upregulation	O
,	O
we	O
have	O
examined	O
mRNA	O
accumulation	O
,	O
fas	O
promoter	O
activity	O
,	O
and	O
protein	O
expression	O
in	O
the	O
Jurkat	O
T	O
-	O
cell	O
line	O
treated	O
with	O
phorbol	O
myristate	O
acetate	O
and	O
ionomycin	O
(	O
P	O
/	O
I	O
)	O
,	O
pharmacological	O
mimics	O
of	O
T	B-Complex
-	I-Complex
cell	I-Complex
receptor	I-Complex
activation	O
.	O

Although	O
resting	O
Jurkat	O
cells	O
express	O
Fas	O
,	O
Fas	O
mRNA	O
was	O
induced	O
approximately	O
10	O
-	O
fold	O
in	O
2	O
h	O
upon	O
P	O
/	O
I	O
stimulation	O
.	O

Using	O
sequential	O
deletion	O
mutants	O
of	O
the	O
human	O
fas	O
promoter	O
in	O
transient	O
transfection	O
assays	O
,	O
we	O
identified	O
a	O
47	O
-	O
bp	O
sequence	O
(	O
positions	O
-	O
306	O
to	O
-	O
260	O
relative	O
to	O
the	O
ATG	O
)	O
required	O
for	O
activation	O
-	O
driven	O
fas	O
upregulation	O
.	O

Sequence	O
analysis	O
revealed	O
the	O
presence	O
of	O
a	O
previously	O
unrecognized	O
composite	O
binding	O
site	O
for	O
both	O
the	O
Sp1	O
and	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
transcription	O
factors	O
at	O
positions	O
-	O
295	O
to	O
-	O
286	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
supershift	O
analyses	O
of	O
this	O
region	O
documented	O
constitutive	O
binding	O
of	O
Sp1	O
in	O
unactivated	O
nuclear	O
extracts	O
and	O
inducible	O
binding	O
of	O
p50	O
-	O
p65	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
heterodimers	O
after	O
P	O
/	O
I	O
activation	O
.	O

Sp1	O
and	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
transcription	O
factor	O
binding	O
was	O
shown	O
to	O
be	O
mutually	O
exclusive	O
by	O
EMSA	O
displacement	O
studies	O
with	O
purified	O
recombinant	O
Sp1	O
and	O
recombinant	O
p50	O
.	O

The	O
functional	O
contribution	O
of	O
the	O
kappaB	B-Complex
-	O
Sp1	O
composite	O
site	O
in	O
P	O
/	O
I	O
-	O
inducible	O
fas	O
promoter	O
activation	O
was	O
verified	O
by	O
using	O
kappaB	B-Complex
-	O
Sp1	O
concatamers	O
(	O
-	O
295	O
to	O
-	O
286	O
)	O
in	O
a	O
thymidine	O
kinase	O
promoter	O
-	O
driven	O
reporter	O
construct	O
and	O
native	O
promoter	O
constructs	O
in	O
Jurkat	O
cells	O
overexpressing	O
IkappaB	O
-	O
alpha	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
critical	O
guanine	O
nucleotides	O
in	O
the	O
kappaB	B-Complex
-	O
Sp1	O
element	O
documented	O
the	O
essential	O
role	O
of	O
this	O
site	O
in	O
activation	O
-	O
dependent	O
fas	O
promoter	O
induction	O
.	O

Correlation	O
of	O
activity	O
regulation	O
and	O
substrate	O
recognition	O
of	O
the	O
ADP	O
-	O
ribosyltransferase	O
that	O
regulates	O
nitrogenase	O
activity	O
in	O
Rhodospirillum	O
rubrum	O
.	O

In	O
Rhodospirillum	O
rubrum	O
,	O
nitrogenase	O
activity	O
is	O
regulated	O
posttranslationally	O
through	O
the	O
ADP	O
-	O
ribosylation	O
of	O
dinitrogenase	O
reductase	O
by	O
dinitrogenase	O
reductase	O
ADP	O
-	O
ribosyltransferase	O
(	O
DRAT	O
)	O
.	O

Several	O
DRAT	O
variants	O
that	O
are	O
altered	O
both	O
in	O
the	O
posttranslational	O
regulation	O
of	O
DRAT	O
activity	O
and	O
in	O
the	O
ability	O
to	O
recognize	O
variants	O
of	O
dinitrogenase	O
reductase	O
have	O
been	O
found	O
.	O

This	O
correlation	O
suggests	O
that	O
these	O
two	O
properties	O
are	O
biochemically	O
connected	O
.	O

Delimitation	O
of	O
two	O
regions	O
in	O
the	O
90	O
-	O
kDa	O
heat	O
shock	O
protein	O
(	O
Hsp90	O
)	O
able	O
to	O
interact	O
with	O
the	O
glucocorticosteroid	O
receptor	O
(	O
GR	O
)	O
.	O

The	O
role	O
of	O
the	O
90	O
-	O
kDa	O
heat	O
shock	O
protein	O
(	O
Hsp90	O
)	O
as	O
a	O
chaperone	O
and	O
its	O
regulatory	O
functions	O
for	O
cellular	O
proteins	O
such	O
as	O
the	O
glucocorticosteroid	O
receptor	O
(	O
GR	O
)	O
depends	O
on	O
the	O
direct	O
interaction	O
of	O
the	O
Hsp90	O
with	O
the	O
corresponding	O
protein	O
as	O
part	O
of	O
a	O
multiprotein	O
complex	O
.	O

The	O
search	O
for	O
the	O
amino	O
acid	O
sequence	O
(	O
s	O
)	O
in	O
Hsp90	O
involved	O
in	O
interaction	O
with	O
the	O
human	O
GR	O
has	O
been	O
carried	O
out	O
by	O
mutational	O
deletion	O
analysis	O
in	O
whole	O
cells	O
,	O
studying	O
the	O
effects	O
of	O
interaction	O
on	O
the	O
nucleocytoplasmic	O
distributions	O
of	O
transiently	O
expressed	O
Hsp90	O
and	O
GR	O
derivatives	O
in	O
COS	O
-	O
7	O
cells	O
.	O

Using	O
a	O
recently	O
developed	O
confocal	O
microscopic	O
immunofluorescence	O
method	O
that	O
allows	O
quantification	O
of	O
the	O
nucleocytoplasmic	O
ratios	O
of	O
the	O
proteins	O
in	O
individual	O
cells	O
and	O
statistical	O
comparison	O
of	O
cell	O
populations	O
,	O
two	O
subregions	O
of	O
the	O
Hsp90	O
molecule	O
have	O
been	O
defined	O
that	O
allow	O
interaction	O
with	O
GR	O
(	O
residues	O
206	O
-	O
291	O
and	O
446	O
-	O
581	O
)	O
.	O

The	O
latter	O
region	O
may	O
play	O
a	O
fundamental	O
role	O
in	O
the	O
interaction	O
,	O
while	O
the	O
former	O
may	O
merely	O
stabilize	O
the	O
binding	O
to	O
GR	O
of	O
the	O
intact	O
Hsp90	O
molecule	O
.	O

Moreover	O
,	O
the	O
dissection	O
of	O
the	O
Hsp90	O
molecule	O
allowed	O
us	O
to	O
define	O
two	O
regions	O
displaying	O
nuclear	O
localization	O
activity	O
(	O
residues	O
1	O
-	O
206	O
and	O
381	O
-	O
581	O
)	O
,	O
followed	O
by	O
two	O
regions	O
having	O
a	O
predominantly	O
cytoplasmic	O
localization	O
activity	O
(	O
residues	O
287	O
-	O
381	O
and	O
581	O
-	O
728	O
)	O
and	O
counteracting	O
the	O
nuclear	O
localization	O
activities	O
.	O

Interferon	O
-	O
alpha	O
activates	O
multiple	O
STAT	O
proteins	O
and	O
upregulates	O
proliferation	O
-	O
associated	O
IL	O
-	O
2Ralpha	O
,	O
c	O
-	O
myc	O
,	O
and	O
pim	O
-	O
1	O
genes	O
in	O
human	O
T	O
cells	O
.	O

Interferon	O
-	O
alpha	O
(	O
IFN	O
-	O
alpha	O
)	O
is	O
a	O
pleiotropic	O
cytokine	O
that	O
has	O
antiviral	O
,	O
antiproliferative	O
,	O
and	O
immunoregulatory	O
functions	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
IFN	O
-	O
alpha	O
has	O
an	O
important	O
role	O
in	O
T	O
-	O
cell	O
biology	O
.	O

We	O
have	O
analyzed	O
the	O
expression	O
of	O
IL	O
-	O
2Ralpha	O
,	O
c	O
-	O
myc	O
,	O
and	O
pim	O
-	O
1	O
genes	O
in	O
anti	O
-	O
CD3	O
-	O
activated	O
human	O
T	O
lymphocytes	O
.	O

The	O
induction	O
of	O
these	O
genes	O
is	O
associated	O
with	O
interleukin	O
-	O
2	O
(	O
IL	O
-	O
2	O
)	O
-	O
induced	O
T	O
-	O
cell	O
proliferation	O
.	O

Treatment	O
of	O
T	O
lymphocytes	O
with	O
IFN	O
-	O
alpha	O
,	O
IL	O
-	O
2	O
,	O
IL	B-Complex
-	I-Complex
12	I-Complex
,	O
and	O
IL	O
-	O
15	O
upregulated	O
IL	O
-	O
2Ralpha	O
,	O
c	O
-	O
myc	O
,	O
and	O
pim	O
-	O
1	O
gene	O
expression	O
.	O

IFN	O
-	O
alpha	O
also	O
sensitized	O
T	O
cells	O
to	O
IL	O
-	O
2	O
-	O
induced	O
proliferation	O
,	O
further	O
suggesting	O
that	O
IFN	O
-	O
alpha	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
T	O
-	O
cell	O
mitogenesis	O
.	O

When	O
we	O
analyzed	O
the	O
nature	O
of	O
STAT	O
proteins	O
capable	O
of	O
binding	O
to	O
IL	O
-	O
2Ralpha	O
,	O
pim	O
-	O
1	O
,	O
and	O
IRF	O
-	O
1	O
GAS	O
elements	O
after	O
cytokine	O
stimulation	O
,	O
we	O
observed	O
IFN	O
-	O
alpha	O
-	O
induced	O
binding	O
of	O
STAT1	O
,	O
STAT3	O
,	O
and	O
STAT4	O
,	O
but	O
not	O
STAT5	O
to	O
all	O
of	O
these	O
elements	O
.	O

Yet	O
,	O
IFN	O
-	O
alpha	O
was	O
able	O
to	O
activate	O
binding	O
of	O
STAT5	O
to	O
the	O
high	O
-	O
affinity	O
IFP53	O
GAS	O
site	O
.	O

IFN	O
-	O
alpha	O
enhanced	O
tyrosine	O
phosphorylation	O
of	O
STAT1	O
,	O
STAT3	O
,	O
STAT4	O
,	O
STAT5a	O
,	O
and	O
STAT5b	O
.	O

IL	B-Complex
-	I-Complex
12	I-Complex
induced	O
STAT4	O
and	O
IL	O
-	O
2	O
and	O
IL	O
-	O
15	O
induced	O
STAT5	O
binding	O
to	O
the	O
GAS	O
elements	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
IFN	O
-	O
alpha	O
,	O
IL	O
-	O
2	O
,	O
IL	B-Complex
-	I-Complex
12	I-Complex
,	O
and	O
IL	O
-	O
15	O
have	O
overlapping	O
activities	O
on	O
human	O
T	O
cells	O
.	O

These	O
findings	O
thus	O
emphasize	O
the	O
importance	O
of	O
IFN	O
-	O
alpha	O
as	O
a	O
T	O
-	O
cell	O
regulatory	O
cytokine	O
.	O

Evidence	O
for	O
suppressed	O
activity	O
of	O
the	O
transcription	O
factor	O
NFAT1	O
at	O
its	O
proximal	O
binding	O
element	O
P0	O
in	O
the	O
IL	O
-	O
4	O
promoter	O
associated	O
with	O
enhanced	O
IL	O
-	O
4	O
gene	O
transcription	O
in	O
T	O
cells	O
of	O
atopic	O
patients	O
.	O

Allergen	O
-	O
specific	O
T	O
cells	O
in	O
atopic	O
patients	O
are	O
polarized	O
IL	O
-	O
4	O
-	O
producing	O
Th2	O
cells	O
,	O
promoting	O
IgE	B-Complex
synthesis	O
by	O
B	O
cells	O
.	O

The	O
molecular	O
basis	O
for	O
increased	O
IL	O
-	O
4	O
gene	O
expression	O
in	O
atopy	O
is	O
not	O
fully	O
understood	O
.	O

IL	O
-	O
4	O
gene	O
regulation	O
in	O
general	O
involves	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
family	O
of	O
transcription	O
factors	O
,	O
of	O
which	O
NFAT1	O
and	O
NFAT2	O
are	O
most	O
prominent	O
in	O
peripheral	O
T	O
cells	O
.	O

Recently	O
,	O
a	O
unique	O
inhibitory	O
role	O
of	O
NFAT1	O
in	O
IL	O
-	O
4	O
gene	O
control	O
was	O
shown	O
in	O
the	O
mouse	O
.	O

In	O
a	O
series	O
of	O
electrophoretic	O
mobility	O
shift	O
assays	O
with	O
protein	O
extracts	O
of	O
highly	O
polarized	O
Th2	O
clones	O
from	O
atopics	O
and	O
Th1	O
clones	O
from	O
controls	O
we	O
compared	O
DNA	O
-	O
binding	O
activities	O
at	O
the	O
two	O
NFAT	O
-	O
binding	O
elements	O
P0	O
and	O
P1	O
of	O
the	O
crucial	O
proximal	O
human	O
IL	O
-	O
4	O
promoter	O
.	O

At	O
the	O
most	O
proximal	O
P0	O
site	O
,	O
NFAT	O
-	O
containing	O
complexes	O
devoid	O
of	O
NFAT2	O
were	O
readily	O
inducible	O
in	O
the	O
Th1	O
clones	O
,	O
but	O
hardly	O
or	O
not	O
in	O
the	O
Th2	O
clones	O
.	O

In	O
contrast	O
,	O
both	O
in	O
Th1	O
and	O
Th2	O
clones	O
NFAT	O
-	O
containing	O
complexes	O
were	O
strongly	O
inducible	O
at	O
the	O
P1	O
site	O
,	O
consisting	O
of	O
NFAT2	O
and	O
a	O
P0	O
-	O
compatible	O
NFAT	O
activity	O
,	O
without	O
apparent	O
differences	O
between	O
Th1	O
and	O
Th2	O
clones	O
.	O

Like	O
in	O
Th2	O
clones	O
,	O
suppressed	O
NFAT	O
-	O
P0	O
complex	O
formation	O
was	O
observed	O
also	O
at	O
the	O
polyclonal	O
level	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
of	O
three	O
of	O
five	O
severe	O
atopic	O
dermatitis	O
patients	O
with	O
strongly	O
elevated	O
serum	O
IgE	B-Complex
levels	O
,	O
but	O
not	O
in	O
control	O
PBMC	O
.	O

These	O
findings	O
suggest	O
that	O
high	O
-	O
level	O
IL	O
-	O
4	O
production	O
in	O
atopic	O
Th2	O
cells	O
is	O
associated	O
with	O
selective	O
reduction	O
of	O
suppressive	O
NFAT1	O
activity	O
at	O
the	O
IL	O
-	O
4	O
P0	O
element	O
and	O
that	O
some	O
patients	O
with	O
this	O
multifactorial	O
disease	O
may	O
have	O
a	O
putative	O
systemic	O
disorder	O
at	O
this	O
level	O
.	O

Phosphorylation	O
of	O
TRAF2	O
inhibits	O
binding	O
to	O
the	O
CD40	O
cytoplasmic	O
domain	O
.	O

TRAF2	O
is	O
a	O
signal	O
transducing	O
adaptor	O
molecule	O
which	O
binds	O
to	O
the	O
CD40	O
cytoplasmic	O
domain	O
.	O

We	O
have	O
found	O
that	O
it	O
is	O
phosphorylated	O
,	O
predominantly	O
on	O
serine	O
residues	O
,	O
when	O
transiently	O
overexpressed	O
in	O
293	O
cells	O
.	O

The	O
phosphorylation	O
appears	O
to	O
be	O
related	O
to	O
the	O
signaling	O
events	O
that	O
are	O
activated	O
by	O
TRAF2	O
under	O
these	O
circumstances	O
,	O
since	O
two	O
nonfunctional	O
mutants	O
were	O
found	O
to	O
be	O
phosphorylated	O
significantly	O
less	O
than	O
the	O
wild	O
-	O
type	O
protein	O
.	O

Furthermore	O
,	O
the	O
phosphorylation	O
status	O
of	O
TRAF2	O
had	O
significant	O
effects	O
on	O
the	O
ability	O
of	O
the	O
protein	O
to	O
bind	O
to	O
CD40	O
,	O
as	O
evidenced	O
by	O
our	O
observations	O
that	O
the	O
CD40	O
cytoplasmic	O
domain	O
interacted	O
preferentially	O
with	O
underphosphorylated	O
TRAF2	O
and	O
that	O
phosphatase	O
treatment	O
significantly	O
enhanced	O
the	O
binding	O
of	O
TRAF2	O
to	O
CD40	O
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
the	O
phosphorylation	O
of	O
TRAF2	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
regulating	O
signaling	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
influence	O
the	O
CD40	O
-	O
TRAF2	O
interaction	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Regulation	O
of	O
G	O
protein	O
-	O
coupled	O
receptor	O
kinases	O
by	O
caveolin	O
.	O

G	O
protein	O
-	O
coupled	O
receptor	O
kinases	O
(	O
GRKs	O
)	O
have	O
been	O
principally	O
characterized	O
by	O
their	O
ability	O
to	O
phosphorylate	O
and	O
desensitize	O
G	O
protein	O
-	O
coupled	O
receptors	O
.	O

However	O
,	O
recent	O
studies	O
suggest	O
that	O
GRKs	O
may	O
have	O
more	O
diverse	O
protein	O
/	O
protein	O
interactions	O
in	O
cells	O
.	O

Based	O
on	O
the	O
identification	O
of	O
a	O
consensus	O
caveolin	O
binding	O
motif	O
within	O
the	O
pleckstrin	O
homology	O
domain	O
of	O
GRK2	O
,	O
we	O
tested	O
the	O
direct	O
binding	O
of	O
purified	O
full	O
-	O
length	O
GRK2	O
to	O
various	O
glutathione	O
S	O
-	O
transferase	O
-	O
caveolin	O
-	O
1	O
fusion	O
proteins	O
,	O
and	O
we	O
discovered	O
a	O
specific	O
interaction	O
of	O
GRK2	O
with	O
the	O
caveolin	O
scaffolding	O
domain	O
.	O

Interestingly	O
,	O
analysis	O
of	O
GRK1	O
and	O
GRK5	O
,	O
which	O
lack	O
a	O
pleckstrin	O
homology	O
domain	O
,	O
revealed	O
in	O
vitro	O
binding	O
properties	O
similar	O
to	O
those	O
of	O
GRK2	O
.	O

Maltose	O
-	O
binding	O
protein	O
caveolin	O
and	O
glutathione	O
S	O
-	O
transferase	O
-	O
GRK	O
fusion	O
proteins	O
were	O
used	O
to	O
map	O
overlapping	O
regions	O
in	O
the	O
N	O
termini	O
of	O
both	O
GRK2	O
and	O
GRK5	O
that	O
appear	O
to	O
mediate	O
conserved	O
GRK	O
/	O
caveolin	O
interactions	O
.	O

In	O
vivo	O
association	O
of	O
GRK2	O
and	O
caveolin	O
was	O
suggested	O
by	O
co	O
-	O
fractionation	O
of	O
GRK2	O
with	O
caveolin	O
in	O
A431	O
and	O
NIH	O
-	O
3T3	O
cells	O
and	O
was	O
further	O
supported	O
by	O
co	O
-	O
immunoprecipitation	O
of	O
GRK2	O
and	O
caveolin	O
in	O
COS	O
-	O
1	O
cells	O
.	O

Functional	O
significance	O
for	O
the	O
GRK	O
/	O
caveolin	O
interaction	O
was	O
demonstrated	O
by	O
the	O
potent	O
inhibition	O
of	O
GRK	O
-	O
mediated	O
phosphorylation	O
of	O
both	O
receptor	O
and	O
peptide	O
substrates	O
by	O
caveolin	O
-	O
1	O
and	O
-	O
3	O
scaffolding	O
domain	O
peptides	O
.	O

These	O
data	O
reveal	O
a	O
novel	O
mode	O
for	O
the	O
regulation	O
of	O
GRKs	O
that	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
their	O
cellular	O
function	O
.	O

The	O
Schizosaccharomyces	O
pombe	O
Pzh1	O
protein	O
phosphatase	O
regulates	O
Na	O
+	O
ion	O
influx	O
in	O
a	O
Trk1	O
-	O
independent	O
fashion	O
.	O

We	O
have	O
previously	O
shown	O
that	O
fission	O
yeast	O
encodes	O
a	O
PPZ	O
-	O
like	O
phosphatase	O
,	O
designated	O
Pzhl	O
,	O
which	O
is	O
an	O
important	O
determinant	O
of	O
cation	O
homeostasis	O
.	O

pzh1	O
delta	O
mutants	O
display	O
increased	O
tolerance	O
to	O
Na	O
+	O
ions	O
,	O
but	O
they	O
are	O
hypersensitive	O
to	O
KC1	O
[	O
Balcells	O
,	O
L	O
.	O
,	O
Gomez	O
,	O
N	O
.	O
,	O
Casamayor	O
,	O
A	O
.	O
,	O
Clotet	O
,	O
J	O
.	O
&	O
Arino	O
,	O
J	O
.	O
(	O
1997	O
)	O
Eur	O
.	O
J	O
.	O
Biochem	O
.	O
250	O
,	O
476	O
-	O
483	O
]	O
.	O

We	O
have	O
immunodetected	O
Pzh1	O
in	O
yeast	O
extracts	O
and	O
found	O
that	O
this	O
phosphatase	O
is	O
largely	O
associated	O
with	O
particulate	O
fractions	O
.	O

Cells	O
defective	O
in	O
Pzh1	O
do	O
not	O
show	O
altered	O
efflux	O
of	O
Na	O
+	O
or	O
Li	O
+	O
ions	O
,	O
but	O
they	O
accumulate	O
these	O
cations	O
more	O
slowly	O
than	O
wild	O
-	O
type	O
cells	O
.	O

K	O
+	O
ion	O
content	O
of	O
pzh1	O
delta	O
cells	O
is	O
about	O
twice	O
that	O
of	O
wild	O
-	O
type	O
cells	O
,	O
and	O
this	O
can	O
be	O
explained	O
by	O
decreased	O
efflux	O
of	O
K	O
+	O
.	O

Therefore	O
,	O
Pzh1	O
may	O
regulate	O
both	O
Na	O
+	O
influx	O
and	O
K	O
+	O
efflux	O
in	O
fission	O
yeast	O
.	O

To	O
test	O
the	O
possible	O
relationship	O
between	O
K	O
+	O
uptake	O
,	O
Na	O
+	O
tolerance	O
and	O
Pzh1	O
function	O
,	O
we	O
deleted	O
the	O
trk1	O
+	O
gene	O
,	O
which	O
encodes	O
a	O
putative	O
high	O
-	O
affinity	O
transporter	O
of	O
K	O
+	O
ions	O
.	O
trkl	O
delta	O
mutants	O
grew	O
well	O
even	O
at	O
relatively	O
low	O
concentrations	O
of	O
KCl	O
and	O
did	O
not	O
show	O
significantly	O
altered	O
content	O
or	O
influx	O
of	O
K	O
+	O
ions	O
.	O

However	O
,	O
they	O
showed	O
a	O
Na	O
(	O
+	O
)	O
-	O
sensitive	O
phenotype	O
which	O
was	O
greatly	O
intensified	O
by	O
deletion	O
of	O
the	O
sod2	O
+	O
gene	O
(	O
which	O
encodes	O
the	O
major	O
determinant	O
for	O
efflux	O
of	O
Na	O
+	O
ions	O
)	O
,	O
and	O
clearly	O
ameliorated	O
by	O
deletion	O
of	O
the	O
pzh1	O
phosphatase	O
,	O
as	O
well	O
as	O
by	O
moderate	O
concentrations	O
of	O
KCl	O
in	O
the	O
medium	O
.	O

These	O
results	O
suggest	O
that	O
Trk1	O
does	O
not	O
mediate	O
the	O
effect	O
of	O
Pzh1	O
on	O
NaCl	O
tolerance	O
and	O
that	O
fission	O
yeast	O
contains	O
efficient	O
systems	O
,	O
other	O
than	O
Trk1	O
,	O
for	O
uptake	O
of	O
K	O
+	O
ions	O
.	O

Engagement	O
of	O
natural	O
cytotoxicity	O
programs	O
regulates	O
AP	B-Complex
-	I-Complex
1	I-Complex
expression	O
in	O
the	O
NKL	O
human	O
NK	O
cell	O
line	O
.	O

NK	O
cell	O
cytotoxicity	O
is	O
a	O
fast	O
and	O
efficient	O
mechanism	O
of	O
target	O
cell	O
lysis	O
.	O

Using	O
transcription	O
analysis	O
,	O
such	O
as	O
multiplex	O
messenger	O
assays	O
,	O
we	O
show	O
here	O
that	O
natural	O
cytotoxicity	O
exerted	O
by	O
the	O
human	O
NKL	O
cell	O
line	O
correlates	O
with	O
mRNA	O
accumulation	O
of	O
very	O
early	O
activator	B-Complex
protein	I-Complex
(	I-Complex
AP	I-Complex
)	I-Complex
-	I-Complex
1	I-Complex
transcription	O
factor	O
genes	O
such	O
as	O
JunB	O
,	O
FosB	O
and	O
c	O
-	O
Fos	O
.	O

In	O
addition	O
,	O
DNA	O
-	O
binding	O
activities	O
of	O
Jun	O
-	O
Fos	O
heterodimers	O
were	O
observed	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
during	O
the	O
course	O
of	O
natural	O
cytotoxicity	O
.	O

Interaction	O
between	O
immunoglobulin	O
-	O
like	O
transcript	O
-	O
2	O
/	O
leukocyte	O
Ig	O
-	O
like	O
receptor	O
1	O
on	O
NKL	O
cells	O
and	O
HLA	O
-	O
B27	O
on	O
target	O
cells	O
leads	O
to	O
an	O
impairment	O
of	O
NKL	O
natural	O
cytotoxicity	O
,	O
which	O
correlates	O
with	O
an	O
absence	O
of	O
JunB	O
,	O
FosB	O
,	O
and	O
c	O
-	O
Fos	O
transcription	O
,	O
as	O
well	O
as	O
an	O
absence	O
of	O
their	O
DNA	O
-	O
binding	O
activity	O
.	O

Our	O
studies	O
thus	O
indicate	O
that	O
,	O
despite	O
the	O
rapidity	O
of	O
NK	O
cell	O
-	O
mediated	O
lysis	O
,	O
AP	B-Complex
-	I-Complex
1	I-Complex
transcription	O
factor	O
is	O
activated	O
during	O
the	O
early	O
stage	O
of	O
NK	O
cell	O
cytolytic	O
programs	O
and	O
that	O
engagement	O
of	O
NK	O
cell	O
inhibitory	O
receptors	O
for	O
MHC	B-Complex
class	I-Complex
I	I-Complex
molecules	O
impairs	O
the	O
very	O
early	O
activation	O
of	O
AP	B-Complex
-	I-Complex
1	I-Complex
.	O

SHP2	O
-	O
interacting	O
transmembrane	O
adaptor	O
protein	O
(	O
SIT	O
)	O
,	O
a	O
novel	O
disulfide	O
-	O
linked	O
dimer	O
regulating	O
human	O
T	O
cell	O
activation	O
.	O

T	O
lymphocytes	O
express	O
several	O
low	O
molecular	O
weight	O
transmembrane	O
adaptor	O
proteins	O
that	O
recruit	O
src	O
homology	O
(	O
SH	O
)	O
2	O
domain	O
-	O
containing	O
intracellular	O
molecules	O
to	O
the	O
cell	O
membrane	O
via	O
tyrosine	O
-	O
based	O
signaling	O
motifs	O
.	O

We	O
describe	O
here	O
a	O
novel	O
molecule	O
of	O
this	O
group	O
termed	O
SIT	O
(	O
SHP2	O
interacting	O
transmembrane	O
adaptor	O
protein	O
)	O
.	O

SIT	O
is	O
a	O
disulfide	O
-	O
linked	O
homodimeric	O
glycoprotein	O
that	O
is	O
expressed	O
in	O
lymphocytes	O
.	O

After	O
tyrosine	O
phosphorylation	O
by	O
src	O
and	O
possibly	O
syk	O
protein	O
tyrosine	O
kinases	O
SIT	O
recruits	O
the	O
SH2	O
domain	O
-	O
containing	O
tyrosine	O
phosphatase	O
SHP2	O
via	O
an	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibition	O
motif	O
.	O

Overexpression	O
of	O
SIT	O
in	O
Jurkat	O
cells	O
downmodulates	O
T	B-Complex
cell	I-Complex
receptor	I-Complex
-	O
and	O
phytohemagglutinin	O
-	O
mediated	O
activation	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
by	O
interfering	O
with	O
signaling	O
processes	O
that	O
are	O
probably	O
located	O
upstream	O
of	O
activation	O
of	O
phospholipase	O
C	O
.	O

However	O
,	O
binding	O
of	O
SHP2	O
to	O
SIT	O
is	O
not	O
required	O
for	O
inhibition	O
of	O
NF	O
-	O
AT	O
induction	O
,	O
suggesting	O
that	O
SIT	O
not	O
only	O
regulates	O
NF	O
-	O
AT	O
activity	O
but	O
also	O
controls	O
NF	O
-	O
AT	O
unrelated	O
pathways	O
of	O
T	O
cell	O
activation	O
involving	O
SHP2	O
.	O

GrpL	O
,	O
a	O
Grb2	O
-	O
related	O
adaptor	O
protein	O
,	O
interacts	O
with	O
SLP	O
-	O
76	O
to	O
regulate	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
activation	O
.	O

Propagation	O
of	O
signals	O
from	O
the	O
T	B-Complex
cell	I-Complex
antigen	I-Complex
receptor	I-Complex
(	O
TCR	B-Complex
)	O
involves	O
a	O
number	O
of	O
adaptor	O
molecules	O
.	O

SH2	O
domain	O
-	O
containing	O
protein	O
76	O
(	O
SLP	O
-	O
76	O
)	O
interacts	O
with	O
the	O
guanine	O
nucleotide	O
exchange	O
factor	O
Vav	O
to	O
activate	O
the	O
nuclear	O
factor	O
of	O
activated	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
,	O
and	O
its	O
expression	O
is	O
required	O
for	O
normal	O
T	O
cell	O
development	O
.	O

We	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
Grb2	O
-	O
like	O
adaptor	O
molecule	O
designated	O
as	O
Grb2	O
-	O
related	O
protein	O
of	O
the	O
lymphoid	O
system	O
(	O
GrpL	O
)	O
.	O

Expression	O
of	O
GrpL	O
is	O
restricted	O
to	O
hematopoietic	O
tissues	O
,	O
and	O
it	O
is	O
distinguished	O
from	O
Grb2	O
by	O
having	O
a	O
proline	O
-	O
rich	O
region	O
.	O

GrpL	O
can	O
be	O
coimmunoprecipitated	O
with	O
SLP	O
-	O
76	O
but	O
not	O
with	O
Sos1	O
or	O
Sos2	O
from	O
Jurkat	O
cell	O
lysates	O
.	O

In	O
contrast	O
,	O
Grb2	O
can	O
be	O
coimmunoprecipitated	O
with	O
Sos1	O
and	O
Sos2	O
but	O
not	O
with	O
SLP	O
-	O
76	O
.	O

Moreover	O
,	O
tyrosine	O
-	O
phosphorylated	O
LAT	O
/	O
pp36	O
/	O
38	O
in	O
detergent	O
lysates	O
prepared	O
from	O
anti	O
-	O
CD3	O
stimulated	O
T	O
cells	O
associated	O
with	O
Grb2	O
but	O
not	O
GrpL	O
.	O

These	O
data	O
reveal	O
the	O
presence	O
of	O
distinct	O
complexes	O
involving	O
GrpL	O
and	O
Grb2	O
in	O
T	O
cells	O
.	O

A	O
functional	O
role	O
of	O
the	O
GrpL	O
-	O
SLP	O
-	O
76	O
complex	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
GrpL	O
to	O
act	O
alone	O
or	O
in	O
concert	O
with	O
SLP	O
-	O
76	O
to	O
augment	O
NF	O
-	O
AT	O
activation	O
in	O
Jurkat	O
T	O
cells	O
.	O

A	O
role	O
for	O
Ctr9p	O
and	O
Paf1p	O
in	O
the	O
regulation	O
G1	O
cyclin	O
expression	O
in	O
yeast	O
.	O

Entry	O
into	O
the	O
cell	O
cycle	O
in	O
budding	O
yeast	O
involves	O
transcriptional	O
activation	O
of	O
G1cyclin	O
genes	O
and	O
DNA	O
synthesis	O
genes	O
when	O
cells	O
reach	O
a	O
critical	O
size	O
in	O
late	O
G1	O
.	O

Expression	O
of	O
G1cyclins	O
CLN1	O
and	O
CLN2	O
is	O
regulated	O
by	O
the	O
transcription	O
factor	O
SBF	B-Complex
(	O
composed	O
of	O
Swi4p	O
and	O
Swi6p	O
)	O
and	O
depends	O
on	O
the	O
cyclin	O
-	O
dependent	O
Cdc28	O
protein	O
kinase	O
and	O
cyclin	O
Cln3p	O
.	O

To	O
identify	O
novel	O
regulators	O
of	O
SBF	B-Complex
-	O
dependent	O
gene	O
expression	O
we	O
screened	O
for	O
mutants	O
that	O
fail	O
to	O
activate	O
transcription	O
of	O
G1cyclins	O
.	O

We	O
found	O
mutations	O
in	O
a	O
gene	O
called	O
CTR9	O
.	O

ctr9	O
mutants	O
are	O
inviable	O
at	O
37	O
degrees	O
C	O
and	O
accumulate	O
large	O
cells	O
.	O

CTR9	O
is	O
identical	O
to	O
CDP1	O
.	O

CTR9	O
encodes	O
a	O
conserved	O
nuclear	O
protein	O
of	O
125	O
kDa	O
containing	O
several	O
TPR	O
repeats	O
implicated	O
in	O
protein	O
-	O
protein	O
interactions	O
.	O

We	O
show	O
that	O
Ctr9p	O
is	O
a	O
component	O
of	O
a	O
high	O
molecular	O
weight	O
protein	O
complex	O
.	O

Using	O
immuno	O
-	O
affinity	O
chromatography	O
we	O
found	O
that	O
Ctr9p	O
associates	O
with	O
polypeptides	O
of	O
50	O
and	O
65	O
kDa	O
.	O

By	O
mass	O
spectrometry	O
these	O
were	O
identified	O
as	O
Cdc73p	O
and	O
Paf1p	O
.	O

We	O
show	O
that	O
Paf1p	O
,	O
like	O
Ctr9p	O
,	O
is	O
required	O
for	O
efficient	O
CLN2	O
transcription	O
,	O
whereas	O
Cdc73p	O
is	O
not	O
.	O

Paf1p	O
and	O
Cdc73p	O
were	O
previously	O
reported	O
to	O
be	O
RNA	O
poly	O
-	O
merase	O
II	O
-	O
associated	O
proteins	O
,	O
suggesting	O
that	O
the	O
Ctr9p	O
complex	O
may	O
interact	O
with	O
the	O
general	O
transcription	O
apparatus	O
.	O

Tcf	O
-	O
1	O
-	O
mediated	O
transcription	O
in	O
T	O
lymphocytes	O
:	O
differential	O
role	O
for	O
glycogen	O
synthase	O
kinase	O
-	O
3	O
in	O
fibroblasts	O
and	O
T	O
cells	O
.	O

Beta	O
-	O
catenin	O
is	O
the	O
vertebrate	O
homolog	O
of	O
the	O
Drosophila	O
segment	O
polarity	O
gene	O
Armadillo	O
and	O
plays	O
roles	O
in	O
both	O
cell	O
-	O
cell	O
adhesion	O
and	O
transduction	O
of	O
the	O
Wnt	O
signaling	O
cascade	O
.	O

Recently	O
,	O
members	O
of	O
the	O
Lef	O
/	O
Tcf	O
transcription	O
factor	O
family	O
have	O
been	O
identified	O
as	O
protein	O
partners	O
of	O
beta	O
-	O
catenin	O
,	O
explaining	O
how	O
beta	O
-	O
catenin	O
alters	O
gene	O
expression	O
.	O

Here	O
we	O
report	O
that	O
in	O
T	O
cells	O
,	O
Tcf	O
-	O
1	O
also	O
becomes	O
transcriptionally	O
active	O
through	O
interaction	O
with	O
beta	O
-	O
catenin	O
,	O
suggesting	O
that	O
the	O
Wnt	O
signal	O
transduction	O
pathway	O
is	O
operational	O
in	O
T	O
lymphocytes	O
as	O
well	O
.	O

However	O
,	O
although	O
Wnt	O
signals	O
are	O
known	O
to	O
inhibit	O
the	O
activity	O
of	O
the	O
negative	O
regulatory	O
protein	O
kinase	O
glycogen	O
synthase	O
kinase	O
-	O
3beta	O
(	O
GSK	O
-	O
3beta	O
)	O
,	O
resulting	O
in	O
increased	O
levels	O
of	O
beta	O
-	O
catenin	O
,	O
we	O
find	O
no	O
evidence	O
for	O
involvement	O
of	O
GSK	O
-	O
3beta	O
in	O
Tcf	O
-	O
mediated	O
transcription	O
in	O
T	O
cells	O
.	O

That	O
is	O
,	O
a	O
dominant	O
negative	O
GSK	O
-	O
3beta	O
does	O
not	O
specifically	O
activate	O
Tcf	O
transcription	O
and	O
stimuli	O
(	O
lithium	O
or	O
phytohemagglutinin	O
)	O
that	O
inhibit	O
GSK	O
-	O
3beta	O
activity	O
also	O
do	O
not	O
activate	O
Tcf	O
reporter	O
genes	O
.	O

Thus	O
,	O
inhibition	O
of	O
GSK	O
-	O
3beta	O
is	O
insufficient	O
to	O
activate	O
Tcf	O
-	O
dependent	O
transcription	O
in	O
T	O
lymphocytes	O
.	O

In	O
contrast	O
,	O
in	O
C57MG	O
fibroblast	O
cells	O
,	O
lithium	O
inactivates	O
GSK	O
-	O
3beta	O
and	O
induces	O
Tcf	O
-	O
controlled	O
transcription	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
that	O
lithium	O
can	O
alter	O
gene	O
expression	O
of	O
Tcf	O
-	O
responsive	O
genes	O
,	O
and	O
points	O
to	O
a	O
difference	O
in	O
regulation	O
of	O
Wnt	O
signaling	O
between	O
fibroblasts	O
and	O
lymphocytes	O
.	O

The	O
evolutionarily	O
conserved	O
sequence	O
upstream	O
of	O
the	O
human	O
Ig	O
heavy	O
chain	O
S	O
gamma	O
3	O
region	O
is	O
an	O
inducible	O
promoter	O
:	O
synergistic	O
activation	O
by	O
CD40	O
ligand	O
and	O
IL	O
-	O
4	O
via	O
cooperative	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
and	O
STAT	O
-	O
6	O
binding	O
sites	O
.	O

Germline	O
C	O
gamma	O
gene	O
transcription	O
is	O
a	O
crucial	O
event	O
in	O
the	O
process	O
that	O
leads	O
to	O
switch	O
DNA	O
recombination	O
to	O
IgG	B-Complex
,	O
but	O
its	O
regulation	O
in	O
the	O
human	O
is	O
poorly	O
understood	O
.	O

We	O
took	O
advantage	O
of	O
our	O
monoclonal	O
model	O
of	O
germinal	O
center	O
B	O
cell	O
differentiation	O
,	O
IgM	B-Complex
+	O
IgD	B-Complex
+	O
CL	O
-	O
01	O
cells	O
,	O
to	O
define	O
the	O
role	O
of	O
the	O
I	O
gamma	O
3	O
evolutionarily	O
conserved	O
sequence	O
(	O
ECS	O
)	O
in	O
the	O
germline	O
transcriptional	O
activation	O
of	O
the	O
human	O
C	O
gamma	O
3	O
gene	O
.	O

The	O
I	O
gamma	O
3	O
ECS	O
lies	O
upstream	O
of	O
the	O
major	O
I	O
gamma	O
3	O
transcription	O
initiation	O
site	O
and	O
displays	O
more	O
than	O
90	O
%	O
identity	O
with	O
the	O
corresponding	O
human	O
I	O
gamma	O
1	O
,	O
I	O
gamma	O
2	O
,	O
and	O
I	O
gamma	O
4	O
regions	O
.	O

Reporter	O
luciferase	O
gene	O
vectors	O
containing	O
the	O
human	O
gamma	O
3	O
ECS	O
were	O
used	O
to	O
transfect	O
CL	O
-	O
01	O
cells	O
,	O
which	O
have	O
been	O
shown	O
to	O
undergo	O
Smu	O
-	O
-	O
>	O
S	O
gamma	O
3	O
DNA	O
recombination	O
,	O
upon	O
engagement	O
of	O
CD40	O
by	O
CD40	O
ligand	O
(	O
CD40L	O
)	O
and	O
exposure	O
to	O
IL	O
-	O
4	O
.	O

In	O
these	O
transfected	O
CL	O
-	O
01	O
cells	O
,	O
CD40	O
:	O
CD40L	O
engagement	O
and	O
exposure	O
to	O
IL	O
-	O
4	O
synergistically	O
induced	O
gamma	O
3	O
ECS	O
-	O
dependent	O
luciferase	O
reporter	O
gene	O
activation	O
.	O

Targeted	O
mutational	O
analysis	O
demonstrated	O
that	O
a	O
tandem	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
Rel	I-Complex
binding	O
motif	O
is	O
critical	O
for	O
the	O
gamma	O
3	O
ECS	O
responsiveness	O
to	O
both	O
CD40L	O
and	O
IL	O
-	O
4	O
,	O
while	O
a	O
STAT	O
-	O
6	O
-	O
binding	O
site	O
is	O
additionally	O
required	O
for	O
IL	O
-	O
4	O
inducibility	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
p50	O
/	O
p65	O
/	O
c	O
-	O
Rel	O
and	O
STAT	O
-	O
6	O
are	O
effectively	O
induced	O
by	O
CD40L	O
and	O
IL	O
-	O
4	O
,	O
respectively	O
,	O
and	O
bind	O
to	O
specific	O
DNA	O
motifs	O
within	O
the	O
ECS	O
.	O

These	O
partially	O
overlapping	O
CD40L	O
and	O
IL	O
-	O
4	O
responsive	O
elements	O
are	O
functionally	O
cooperative	O
as	O
the	O
disruption	O
of	O
one	O
of	O
them	O
prevents	O
synergistic	O
promoter	O
activation	O
.	O

Thus	O
,	O
the	O
gamma	O
3	O
ECS	O
is	O
an	O
inducible	O
promoter	O
containing	O
cis	O
elements	O
that	O
critically	O
mediate	O
CD40L	O
and	O
IL	O
-	O
4	O
-	O
triggered	O
transcriptional	O
activation	O
of	O
the	O
human	O
C	O
gamma	O
3	O
gene	O
.	O

Thrombin	O
-	O
induced	O
p65	O
homodimer	O
binding	O
to	O
downstream	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
site	O
of	O
the	O
promoter	O
mediates	O
endothelial	O
ICAM	O
-	O
1	O
expression	O
and	O
neutrophil	O
adhesion	O
.	O

We	O
investigated	O
the	O
mechanisms	O
by	O
which	O
proinflammatory	O
mediator	O
,	O
thrombin	O
,	O
released	O
during	O
intravascular	O
coagulation	O
and	O
tissue	O
injury	O
,	O
induces	O
ICAM	O
-	O
1	O
(	O
CD54	O
)	O
expression	O
in	O
endothelial	O
cells	O
.	O

Stimulation	O
of	O
HUVEC	O
with	O
thrombin	O
resulted	O
in	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
increases	O
in	O
ICAM	O
-	O
1	O
mRNA	O
and	O
cell	O
surface	O
expression	O
and	O
in	O
ICAM	O
-	O
1	O
-	O
dependent	O
endothelial	O
adhesivity	O
toward	O
polymorphonuclear	O
leukocytes	O
.	O

Transient	O
transfection	O
of	O
endothelial	O
cells	O
with	O
ICAM	O
-	O
1	O
promoter	O
luciferase	O
reporter	O
gene	O
(	O
ICAM	O
-	O
1LUC	O
)	O
constructs	O
indicated	O
that	O
deletion	O
of	O
upstream	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
site	O
(	O
-	O
533	O
bases	O
from	O
translation	O
start	O
site	O
)	O
had	O
no	O
effect	O
on	O
thrombin	O
responsiveness	O
,	O
whereas	O
mutation	O
/	O
deletion	O
of	O
downstream	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
site	O
(	O
-	O
223	O
bases	O
from	O
the	O
translation	O
start	O
site	O
)	O
prevented	O
the	O
activation	O
of	O
ICAM	O
-	O
1	O
promoter	O
,	O
indicating	O
that	O
the	O
downstream	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
site	O
is	O
critical	O
for	O
thrombin	O
inducibility	O
.	O

NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
-	O
directed	O
luciferase	O
activity	O
increased	O
approximately	O
3	O
-	O
fold	O
when	O
cells	O
transfected	O
with	O
the	O
plasmid	O
pNF	O
-	O
kappa	O
BLUC	O
containing	O
five	O
copies	O
of	O
consensus	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
site	O
linked	O
to	O
a	O
minimal	O
adenovirus	O
E1B	O
promoter	O
-	O
luciferase	O
gene	O
were	O
exposed	O
to	O
thrombin	O
,	O
indicating	O
that	O
activation	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
was	O
essential	O
for	O
thrombin	O
response	O
.	O

Gel	O
supershift	O
assays	O
demonstrated	O
that	O
thrombin	O
induced	O
binding	O
of	O
NF	O
-	O
kappa	O
Bp65	O
(	O
Rel	O
A	O
)	O
to	O
downstream	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
site	O
of	O
the	O
ICAM	O
-	O
1	O
promoter	O
.	O

Thrombin	O
receptor	O
activation	O
peptide	O
,	O
a	O
14	O
-	O
amino	O
-	O
acid	O
peptide	O
representing	O
the	O
new	O
NH2	O
terminus	O
of	O
proteolytically	O
activated	O
receptor	O
-	O
1	O
,	O
mimicked	O
thrombin	O
'	O
s	O
action	O
in	O
inducing	O
ICAM	O
-	O
1	O
expression	O
.	O

These	O
data	O
indicate	O
that	O
thrombin	O
activates	O
endothelial	O
ICAM	O
-	O
1	O
expression	O
and	O
polymorphonuclear	O
leukocyte	O
adhesion	O
by	O
NF	O
-	O
kappa	O
Bp65	O
binding	O
to	O
the	O
downstream	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
site	O
of	O
ICAM	O
-	O
1	O
promoter	O
after	O
proteolytically	O
activated	O
receptor	O
-	O
1	O
activation	O
.	O

A	O
newly	O
identified	O
member	O
of	O
tumor	O
necrosis	O
factor	O
receptor	O
superfamily	O
(	O
TR6	O
)	O
suppresses	O
LIGHT	O
-	O
mediated	O
apoptosis	O
.	O

TR6	O
(	O
decoy	O
receptor	O
3	O
(	O
DcR3	O
)	O
)	O
is	O
a	O
new	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR	O
)	O
family	O
.	O

TR6	O
mRNA	O
is	O
expressed	O
in	O
lung	O
tissues	O
and	O
colon	O
adenocarcinoma	O
,	O
SW480	O
.	O

In	O
addition	O
,	O
the	O
expression	O
of	O
TR6	O
mRNA	O
was	O
shown	O
in	O
the	O
endothelial	O
cell	O
line	O
and	O
induced	O
by	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
/	O
ionomycin	O
in	O
Jurkat	O
T	O
leukemia	O
cells	O
.	O

The	O
open	O
reading	O
frame	O
of	O
TR6	O
encodes	O
300	O
amino	O
acids	O
with	O
a	O
29	O
-	O
residue	O
signal	O
sequence	O
but	O
no	O
transmembrane	O
region	O
.	O

Using	O
histidine	O
-	O
tagged	O
recombinant	O
TR6	O
,	O
we	O
screened	O
soluble	O
forms	O
of	O
TNF	O
-	O
ligand	O
proteins	O
with	O
immunoprecipitation	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
TR6	O
specifically	O
binds	O
two	O
cellular	O
ligands	O
,	O
LIGHT	O
(	O
herpes	O
virus	O
entry	O
mediator	O
(	O
HVEM	O
)	O
-	O
L	O
)	O
and	O
Fas	O
ligand	O
(	O
FasL	O
/	O
CD95L	O
)	O
.	O

These	O
bindings	O
were	O
confirmed	O
with	O
HEK	O
293	O
EBNA	O
cells	O
transfected	O
with	O
LIGHT	O
cDNA	O
by	O
flow	O
cytometry	O
.	O

TR6	O
inhibited	O
LIGHT	O
-	O
induced	O
cytotoxicity	O
in	O
HT29	O
cells	O
.	O

It	O
has	O
been	O
shown	O
that	O
LIGHT	O
triggers	O
apoptosis	O
of	O
various	O
tumor	O
cells	O
including	O
HT29	O
cells	O
that	O
express	O
both	O
lymphotoxin	O
beta	O
receptor	O
(	O
LTbetaR	O
)	O
and	O
HVEM	O
/	O
TR2	O
receptors	O
.	O

Our	O
data	O
suggest	O
that	O
TR6	O
inhibits	O
the	O
interactions	O
of	O
LIGHT	O
with	O
HVEM	O
/	O
TR2	O
and	O
LTbetaR	O
,	O
thereby	O
suppressing	O
LIGHT	O
-	O
mediated	O
HT29	O
cell	O
death	O
.	O

Thus	O
,	O
TR6	O
may	O
play	O
a	O
regulatory	O
role	O
for	O
suppressing	O
in	O
FasL	O
-	O
and	O
LIGHT	O
-	O
mediated	O
cell	O
death	O
.	O

Non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
inhibit	O
the	O
expression	O
of	O
cytokines	O
and	O
induce	O
HSP70	O
in	O
human	O
monocytes	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
the	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
activate	O
heat	O
shock	O
transcription	O
factor	O
(	O
HSF1	O
)	O
from	O
a	O
latent	O
cytoplasmic	O
form	O
to	O
a	O
nuclear	O
,	O
DNA	O
binding	O
state	O
.	O

As	O
HSF1	O
can	O
function	O
as	O
both	O
an	O
activator	O
of	O
heat	O
shock	O
genes	O
and	O
a	O
repressor	O
of	O
non	O
-	O
heat	O
shock	O
genes	O
such	O
as	O
IL1B	O
and	O
c	O
-	O
fos	O
,	O
we	O
have	O
examined	O
the	O
potential	O
role	O
of	O
HSF1	O
in	O
the	O
effects	O
of	O
NSAIDs	O
on	O
gene	O
expression	O
in	O
a	O
human	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
.	O

We	O
found	O
that	O
two	O
members	O
of	O
the	O
NSAIDs	O
,	O
sodium	O
salicylate	O
and	O
sulindac	O
repress	O
the	O
IL1B	O
promoter	O
to	O
similar	O
degree	O
to	O
heat	O
shock	O
or	O
HSF1	O
overexpression	O
.	O

In	O
addition	O
,	O
sodium	O
salicylate	O
and	O
additional	O
NSAIDs	O
used	O
at	O
concentrations	O
that	O
activate	O
HSF1	O
also	O
inhibited	O
the	O
expression	O
of	O
other	O
monocytic	O
genes	O
(	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
IL	O
-	O
10	O
,	O
ICAM	O
-	O
1	O
)	O
activated	O
by	O
exposure	O
to	O
a	O
pro	O
-	O
inflammatory	O
stimulus	O
(	O
lipopolysaccharide	O
,	O
LPS	O
)	O
.	O

At	O
least	O
in	O
the	O
case	O
of	O
the	O
IL1B	O
promoter	O
,	O
repression	O
did	O
not	O
seem	O
to	O
involve	O
another	O
factor	O
whose	O
activity	O
is	O
affected	O
by	O
the	O
NSAIDs	O
,	O
NFkappaB	B-Complex
as	O
the	O
IL1B	O
promoter	O
fragment	O
used	O
in	O
our	O
studies	O
is	O
not	O
NFkappaB	B-Complex
responsive	O
and	O
binds	O
specifically	O
to	O
HSF1	O
.	O

Exposure	O
to	O
NSAIDs	O
had	O
a	O
complex	O
effect	O
on	O
HSP	O
gene	O
expression	O
and	O
while	O
sulindac	O
activated	O
the	O
stress	O
responsive	O
HSP70B	O
promoter	O
,	O
sodium	O
salicylate	O
did	O
not	O
.	O

In	O
addition	O
,	O
only	O
a	O
subset	O
of	O
the	O
NSAIDs	O
induced	O
HSP70	O
mRNA	O
species	O
.	O

These	O
findings	O
reflect	O
the	O
properties	O
of	O
HSF1	O
which	O
can	O
be	O
activated	O
to	O
at	O
least	O
two	O
DNA	O
binding	O
forms	O
only	O
one	O
of	O
which	O
activates	O
heat	O
shock	O
promoters	O
and	O
suggest	O
that	O
individual	O
NSAID	O
family	O
members	O
may	O
differentially	O
induce	O
one	O
or	O
other	O
of	O
these	O
forms	O
.	O

Overall	O
therefore	O
,	O
exposure	O
to	O
NSAIDs	O
leads	O
to	O
a	O
profound	O
switch	O
in	O
gene	O
expression	O
in	O
monocytic	O
cells	O
,	O
with	O
suppression	O
of	O
genes	O
involved	O
in	O
macrophage	O
activation	O
and	O
induction	O
of	O
stress	O
genes	O
and	O
HSF1	O
appears	O
to	O
play	O
a	O
regulatory	O
role	O
in	O
these	O
effects	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Nuclear	O
localization	O
and	O
formation	O
of	O
beta	O
-	O
catenin	O
-	O
lymphoid	O
enhancer	O
factor	O
1	O
complexes	O
are	O
not	O
sufficient	O
for	O
activation	O
of	O
gene	O
expression	O
.	O

In	O
response	O
to	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
,	O
beta	O
-	O
catenin	O
accumulates	O
in	O
the	O
nucleus	O
,	O
where	O
it	O
cooperates	O
with	O
LEF	O
/	O
TCF	O
(	O
for	O
lymphoid	O
enhancer	O
factor	O
and	O
T	O
-	O
cell	O
factor	O
)	O
transcription	O
factors	O
to	O
activate	O
gene	O
expression	O
.	O

The	O
mechanisms	O
by	O
which	O
beta	O
-	O
catenin	O
undergoes	O
this	O
shift	O
in	O
location	O
and	O
participates	O
in	O
activation	O
of	O
gene	O
transcription	O
are	O
unknown	O
.	O

We	O
demonstrate	O
here	O
that	O
beta	O
-	O
catenin	O
can	O
be	O
imported	O
into	O
the	O
nucleus	O
independently	O
of	O
LEF	O
/	O
TCF	O
binding	O
,	O
and	O
it	O
may	O
also	O
be	O
exported	O
from	O
nuclei	O
.	O

We	O
have	O
introduced	O
a	O
small	O
deletion	O
within	O
beta	O
-	O
catenin	O
(	O
Delta19	O
)	O
that	O
disrupts	O
binding	O
to	O
LEF	O
-	O
1	O
,	O
E	O
-	O
cadherin	O
,	O
and	O
APC	B-OOS
but	O
not	O
axin	O
.	O

This	O
Delta19	O
beta	O
-	O
catenin	O
mutant	O
localizes	O
to	O
the	O
nucleus	O
because	O
it	O
may	O
not	O
be	O
efficiently	O
sequestered	O
in	O
the	O
cytoplasm	O
.	O

The	O
nuclear	O
localization	O
of	O
Delta19	O
definitively	O
demonstrates	O
that	O
the	O
mechanisms	O
by	O
which	O
beta	O
-	O
catenin	O
localizes	O
in	O
the	O
nucleus	O
are	O
completely	O
independent	O
of	O
LEF	O
/	O
TCF	O
factors	O
.	O

beta	O
-	O
Catenin	O
and	O
LEF	O
-	O
1	O
complexes	O
can	O
activate	O
reporter	O
gene	O
expression	O
in	O
a	O
transformed	O
T	O
-	O
lymphocyte	O
cell	O
line	O
(	O
Jurkat	O
)	O
but	O
not	O
in	O
normal	O
T	O
lymphocytes	O
,	O
even	O
though	O
both	O
factors	O
are	O
nuclear	O
.	O

Thus	O
,	O
localization	O
of	O
both	O
factors	O
to	O
the	O
nucleus	O
is	O
not	O
sufficient	O
for	O
activation	O
of	O
gene	O
expression	O
.	O

Excess	O
beta	O
-	O
catenin	O
can	O
squelch	O
reporter	O
gene	O
activation	O
by	O
LEF	O
-	O
1	O
-	O
beta	O
-	O
catenin	O
complexes	O
but	O
not	O
activation	O
by	O
the	O
transcription	O
factor	O
VP16	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
a	O
third	O
component	O
is	O
necessary	O
for	O
gene	O
activation	O
and	O
that	O
this	O
third	O
component	O
may	O
vary	O
with	O
cell	O
type	O
.	O

Feedback	O
regulation	O
of	O
beta	O
-	O
arrestin1	O
function	O
by	O
extracellular	O
signal	O
-	O
regulated	O
kinases	O
.	O

The	O
functions	O
of	O
beta	O
-	O
arrestin1	O
to	O
facilitate	O
clathrin	B-Complex
-	O
mediated	O
endocytosis	O
of	O
the	O
beta2	O
-	O
adrenergic	O
receptor	O
and	O
to	O
promote	O
agonist	O
-	O
induced	O
activation	O
of	O
extracellular	O
signal	O
-	O
regulated	O
kinases	O
(	O
ERK	O
)	O
are	O
regulated	O
by	O
its	O
phosphorylation	O
/	O
dephosphorylation	O
at	O
Ser	O
-	O
412	O
.	O

Cytoplasmic	O
beta	O
-	O
arrestin1	O
is	O
almost	O
stoichiometrically	O
phosphorylated	O
at	O
Ser	O
-	O
412	O
.	O

Dephosphorylation	O
of	O
beta	O
-	O
arrestin1	O
at	O
the	O
plasma	O
membrane	O
is	O
required	O
for	O
targeting	O
a	O
signaling	O
complex	O
that	O
includes	O
the	O
agonist	O
-	O
occupied	O
receptors	O
to	O
the	O
clathrin	B-Complex
-	O
coated	O
pits	O
.	O

Here	O
we	O
demonstrate	O
that	O
beta	O
-	O
arrestin1	O
phosphorylation	O
and	O
function	O
are	O
modulated	O
by	O
an	O
ERK	O
-	O
dependent	O
negative	O
feedback	O
mechanism	O
.	O

ERK1	O
and	O
ERK2	O
phosphorylate	O
beta	O
-	O
arrestin1	O
at	O
Ser	O
-	O
412	O
in	O
vitro	O
.	O

Inhibition	O
of	O
ERK	O
activity	O
by	O
a	O
dominant	O
-	O
negative	O
MEK1	O
mutant	O
significantly	O
attenuates	O
beta	O
-	O
arrestin1	O
phosphorylation	O
,	O
thereby	O
increasing	O
the	O
concentration	O
of	O
dephosphorylated	O
beta	O
-	O
arrestin1	O
.	O

Under	O
such	O
conditions	O
,	O
beta	O
-	O
arrestin1	O
-	O
mediated	O
beta2	O
-	O
adrenergic	O
receptor	O
internalization	O
is	O
enhanced	O
as	O
is	O
its	O
ability	O
to	O
bind	O
clathrin	B-Complex
.	O

In	O
contrast	O
,	O
if	O
ERK	O
-	O
mediated	O
phosphorylation	O
is	O
increased	O
by	O
transfection	O
of	O
a	O
constitutively	O
active	O
MEK1	O
mutant	O
,	O
receptor	O
internalization	O
is	O
inhibited	O
.	O

Our	O
results	O
suggest	O
that	O
dephosphorylated	O
beta	O
-	O
arrestin1	O
mediates	O
endocytosis	O
-	O
dependent	O
ERK	O
activation	O
.	O

Following	O
activation	O
,	O
ERKs	O
phosphorylate	O
beta	O
-	O
arrestin1	O
,	O
thereby	O
exerting	O
an	O
inhibitory	O
feedback	O
control	O
of	O
its	O
function	O
.	O

SLP	O
-	O
76	O
and	O
Vav	O
function	O
in	O
separate	O
,	O
but	O
overlapping	O
pathways	O
to	O
augment	O
interleukin	O
-	O
2	O
promoter	O
activity	O
.	O

SLP	O
-	O
76	O
and	O
Vav	O
,	O
two	O
hematopoietic	O
cell	O
specific	O
molecules	O
,	O
are	O
critical	O
for	O
T	O
cell	O
development	O
and	O
activation	O
.	O

Following	O
T	B-Complex
cell	I-Complex
antigen	I-Complex
receptor	I-Complex
stimulation	O
,	O
SLP	O
-	O
76	O
and	O
Vav	O
both	O
undergo	O
tyrosine	O
phosphorylation	O
and	O
associate	O
with	O
each	O
other	O
via	O
the	O
SH2	O
domain	O
of	O
Vav	O
and	O
phosphorylated	O
tyrosines	O
of	O
SLP	O
-	O
76	O
.	O

Furthermore	O
,	O
SLP	O
-	O
76	O
and	O
Vav	O
have	O
a	O
synergistic	O
effect	O
on	O
interleukin	O
(	O
IL	O
)	O
-	O
2	O
promoter	O
activity	O
in	O
T	O
cells	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
two	O
tyrosines	O
,	O
Tyr	O
-	O
113	O
and	O
Tyr	O
-	O
128	O
,	O
of	O
SLP	O
-	O
76	O
are	O
required	O
for	O
its	O
binding	O
to	O
Vav	O
,	O
both	O
in	O
vitro	O
and	O
in	O
intact	O
cells	O
.	O

Surprisingly	O
,	O
we	O
find	O
also	O
that	O
the	O
interaction	O
between	O
SLP	O
-	O
76	O
and	O
Vav	O
is	O
not	O
required	O
for	O
their	O
cooperation	O
in	O
augmenting	O
IL	O
-	O
2	O
promoter	O
activity	O
,	O
as	O
the	O
two	O
molecules	O
appear	O
to	O
function	O
in	O
different	O
signaling	O
pathways	O
upstream	O
of	O
IL	O
-	O
2	O
gene	O
expression	O
.	O

Overexpression	O
of	O
SLP	O
-	O
76	O
in	O
the	O
Jurkat	O
T	O
cell	O
line	O
potentiates	O
the	O
activities	O
of	O
both	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
and	O
AP	B-Complex
-	I-Complex
1	I-Complex
transcription	O
factors	O
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
Vav	O
leads	O
to	O
enhanced	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
activity	O
without	O
affecting	O
AP	B-Complex
-	I-Complex
1	I-Complex
.	O

Additionally	O
,	O
overexpression	O
of	O
Vav	O
,	O
but	O
not	O
SLP	O
-	O
76	O
,	O
augments	O
CD28	O
-	O
induced	O
IL	O
-	O
2	O
promoter	O
activity	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
synergy	O
between	O
SLP	O
-	O
76	O
and	O
Vav	O
in	O
regulating	O
IL	O
-	O
2	O
gene	O
expression	O
reflects	O
the	O
cooperation	O
between	O
different	O
signaling	O
pathways	O
.	O

Once	O
properly	O
positioned	O
,	O
the	O
yeast	O
spindle	O
elongates	O
through	O
the	O
bud	O
neck	O
.	O

Elongation	O
of	O
the	O
spindle	O
reflects	O
concerted	O
changes	O
in	O
kinetochore	O
,	O
pole	O
to	O
pole	O
,	O
and	O
interdigitating	O
microtubules	O
that	O
undergo	O
simultaneous	O
polymerization	O
,	O
depolymerization	O
,	O
and	O
sliding	O
within	O
the	O
nucleus	O
,	O
as	O
well	O
as	O
pulling	O
forces	O
on	O
the	O
nucleus	O
generated	O
by	O
cytoplasmic	O
microtubules	O
.	O

It	O
follows	O
a	O
biphasic	O
pattern	O
consisting	O
of	O
an	O
initial	O
rapid	O
elongation	O
phase	O
followed	O
by	O
a	O
period	O
of	O
slower	O
continued	O
elongation	O
.	O

The	O
initial	O
phase	O
of	O
spindle	O
elongation	O
was	O
mildly	O
reduced	O
in	O
bim1Delta	O
cells	O
,	O
at	O
0	O
.	O
41	O
mum	O
/	O
min	O
,	O
compared	O
to	O
0	O
.	O
59	O
mum	O
/	O
min	O
in	O
BIM1	O
cells	O
(	O
P	O
=	O
0	O
.	O
07	O
,	O
n	O
=	O
7	O
)	O
,	O
while	O
the	O
slow	O
phases	O
were	O
equivalent	O
at	O
0	O
.	O
18	O
mum	O
/	O
min	O
in	O
bim1Delta	O
cells	O
and	O
0	O
.	O
22	O
mum	O
/	O
min	O
in	O
BIM1	O
cells	O
.	O

This	O
small	O
decrease	O
in	O
the	O
initial	O
,	O
rapid	O
phase	O
of	O
spindle	O
elongation	O
in	O
bim1Delta	O
cells	O
suggests	O
a	O
subtle	O
effect	O
of	O
Bim1p	O
on	O
some	O
microtubule	O
populations	O
later	O
in	O
the	O
cell	O
cycle	O
,	O
and	O
it	O
could	O
be	O
due	O
to	O
an	O
effect	O
on	O
either	O
nuclear	O
(	O
pushing	O
)	O
or	O
cytoplasmic	O
(	O
pulling	O
)	O
microtubules	O
.	O

Repression	O
by	O
Ikaros	O
and	O
Aiolos	O
is	O
mediated	O
through	O
histone	O
deacetylase	O
complexes	O
.	O

Here	O
we	O
show	O
that	O
the	O
lymphoid	O
lineage	O
-	O
determining	O
factors	O
Ikaros	O
and	O
Aiolos	O
can	O
function	O
as	O
strong	O
transcriptional	O
repressors	O
.	O

This	O
function	O
is	O
mediated	O
through	O
two	O
repression	O
domains	O
and	O
is	O
dependent	O
upon	O
the	O
promoter	O
context	O
and	O
cell	O
type	O
.	O

Repression	O
by	O
Ikaros	O
proteins	O
correlates	O
with	O
hypo	O
-	O
acetylation	O
of	O
core	O
histones	O
at	O
promoter	O
sites	O
and	O
is	O
relieved	O
by	O
histone	O
deacetylase	O
inhibitors	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
Ikaros	O
and	O
its	O
repression	O
domains	O
can	O
interact	O
in	O
vivo	O
and	O
in	O
vitro	O
with	O
the	O
mSin3	O
family	O
of	O
co	O
-	O
repressors	O
which	O
bind	O
to	O
histone	O
deacetylases	O
.	O

Based	O
on	O
these	O
and	O
our	O
recent	O
findings	O
of	O
associations	O
between	O
Ikaros	O
and	O
Mi	O
-	O
2	O
-	O
HDAC	O
,	O
we	O
propose	O
that	O
Ikaros	O
family	O
members	O
modulate	O
gene	O
expression	O
during	O
lymphocyte	O
development	O
by	O
recruiting	O
distinct	O
histone	O
deacetylase	O
complexes	O
to	O
specific	O
promoters	O
.	O

IL	B-Complex
-	I-Complex
12	I-Complex
induces	O
IFN	O
regulating	O
factor	O
-	O
1	O
(	O
IRF	O
-	O
1	O
)	O
gene	O
expression	O
in	O
human	O
NK	O
and	O
T	O
cells	O
.	O

IL	B-Complex
-	I-Complex
12	I-Complex
is	O
a	O
critical	O
immunoregulatory	O
cytokine	O
that	O
promotes	O
cell	O
-	O
mediated	O
immune	O
responses	O
and	O
the	O
differentiation	O
of	O
naive	O
CD4	O
+	O
cells	O
to	O
Th1	O
cells	O
;	O
however	O
,	O
relatively	O
few	O
IL	B-Complex
-	I-Complex
12	I-Complex
target	O
genes	O
have	O
been	O
identified	O
.	O

To	O
better	O
clarify	O
the	O
molecular	O
basis	O
of	O
IL	B-Complex
-	I-Complex
12	I-Complex
action	O
,	O
we	O
set	O
out	O
to	O
characterize	O
genes	O
up	O
-	O
regulated	O
by	O
IL	B-Complex
-	I-Complex
12	I-Complex
,	O
first	O
by	O
contrasting	O
IL	B-Complex
-	I-Complex
12	I-Complex
-	O
and	O
IFN	O
-	O
alpha	O
-	O
inducible	O
genes	O
.	O

We	O
identified	O
several	O
genes	O
up	O
-	O
regulated	O
by	O
IL	B-Complex
-	I-Complex
12	I-Complex
,	O
namely	O
,	O
MIP	O
-	O
1alpha	O
,	O
MIP	O
-	O
1beta	O
,	O
IL	O
-	O
1RA	O
,	O
and	O
IFN	O
regulatory	O
factor	O
-	O
1	O
(	O
IRF	O
-	O
1	O
)	O
.	O

IRF	O
-	O
1	O
is	O
a	O
transcription	O
factor	O
regulated	O
by	O
IFNs	O
that	O
is	O
also	O
essential	O
for	O
Th1	O
responses	O
.	O

We	O
demonstrated	O
that	O
IL	B-Complex
-	I-Complex
12	I-Complex
directly	O
up	O
-	O
regulates	O
IRF	O
-	O
1	O
to	O
the	O
same	O
extent	O
as	O
IFN	O
-	O
alpha	O
in	O
normal	O
human	O
T	O
cells	O
and	O
in	O
NK	O
cells	O
.	O

We	O
showed	O
that	O
IL	B-Complex
-	I-Complex
12	I-Complex
had	O
a	O
direct	O
effect	O
on	O
IRF	O
-	O
1	O
,	O
an	O
effect	O
not	O
mediated	O
indirectly	O
by	O
the	O
induction	O
of	O
IFN	O
-	O
gamma	O
production	O
.	O

Furthermore	O
,	O
IL	O
-	O
2	O
and	O
IL	B-Complex
-	I-Complex
12	I-Complex
synergistically	O
induced	O
IRF	O
-	O
1	O
,	O
whereas	O
IFN	O
-	O
alpha	O
and	O
IL	B-Complex
-	I-Complex
12	I-Complex
did	O
not	O
.	O

The	O
participation	O
of	O
STAT4	O
in	O
the	O
regulation	O
of	O
IRF	O
-	O
1	O
was	O
demonstrated	O
in	O
two	O
ways	O
.	O

First	O
,	O
STAT4	O
was	O
required	O
for	O
the	O
IL	B-Complex
-	I-Complex
12	I-Complex
-	O
dependent	O
transactivation	O
of	O
an	O
IRF	O
-	O
1	O
reporter	O
construct	O
,	O
and	O
second	O
,	O
STAT4	O
binding	O
to	O
the	O
IRF	O
-	O
1	O
promoter	O
was	O
shown	O
using	O
EMSA	O
.	O

In	O
contrast	O
to	O
IL	B-Complex
-	I-Complex
12	I-Complex
,	O
no	O
up	O
-	O
regulation	O
of	O
IRF	O
-	O
1	O
was	O
found	O
in	O
IL	O
-	O
4	O
-	O
stimulated	O
cells	O
,	O
and	O
IL	O
-	O
4	O
did	O
not	O
block	O
IL	B-Complex
-	I-Complex
12	I-Complex
-	O
dependent	O
up	O
-	O
regulation	O
of	O
IRF	O
-	O
1	O
.	O

Therefore	O
,	O
IRF	O
-	O
1	O
may	O
be	O
an	O
important	O
contributor	O
to	O
IL	B-Complex
-	I-Complex
12	I-Complex
signaling	O
,	O
and	O
we	O
speculate	O
that	O
the	O
defective	O
IL	B-Complex
-	I-Complex
12	I-Complex
responses	O
seen	O
in	O
IRF	O
-	O
1	O
-	O
/	O
-	O
mice	O
might	O
be	O
attributable	O
,	O
in	O
part	O
,	O
to	O
the	O
absence	O
of	O
this	O
transcription	O
factor	O
.	O

Binding	O
of	O
YY1	O
and	O
Oct1	O
to	O
a	O
novel	O
element	O
that	O
downregulates	O
expression	O
of	O
IL	O
-	O
5	O
in	O
human	O
T	O
cells	O
.	O

BACKGROUND	O
:	O
IL	O
-	O
5	O
controls	O
development	O
of	O
eosinophilia	O
and	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
allergic	O
diseases	O
.	O

In	O
both	O
atopic	O
and	O
nonatopic	O
asthma	O
,	O
elevated	O
IL	O
-	O
5	O
has	O
been	O
detected	O
in	O
peripheral	O
blood	O
and	O
the	O
airways	O
.	O

IL	O
-	O
5	O
is	O
produced	O
mainly	O
by	O
activated	O
T	O
cells	O
,	O
and	O
its	O
expression	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
focuses	O
on	O
the	O
functional	O
analysis	O
of	O
the	O
human	O
IL	O
-	O
5	O
(	O
hIL	O
-	O
5	O
)	O
promoter	O
and	O
characterization	O
of	O
cis	O
-	O
regulatory	O
elements	O
and	O
transcription	O
factors	O
involved	O
in	O
the	O
suppression	O
of	O
IL	O
-	O
5	O
transcription	O
in	O
T	O
cells	O
.	O

METHODS	O
:	O
Methods	O
used	O
in	O
this	O
study	O
include	O
DNase	O
I	O
footprint	O
assays	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
and	O
functional	O
analysis	O
by	O
mammalian	O
cell	O
transfection	O
involving	O
deletion	O
analysis	O
and	O
site	O
-	O
directed	O
mutagenesis	O
.	O

RESULTS	O
:	O
We	O
identified	O
5	O
protein	O
binding	O
regions	O
(	O
BRs	O
)	O
located	O
within	O
the	O
proximal	O
hIL	O
-	O
5	O
promoter	O
.	O

Functional	O
analysis	O
indicates	O
that	O
the	O
BRs	O
are	O
involved	O
in	O
control	O
of	O
hIL	O
-	O
5	O
promoter	O
activity	O
.	O

Two	O
of	O
these	O
regions	O
,	O
BR3	O
and	O
BR4	O
located	O
at	O
positions	O
-	O
102	O
to	O
-	O
73	O
,	O
have	O
not	O
previously	O
been	O
described	O
as	O
regulators	O
of	O
IL	O
-	O
5	O
expression	O
in	O
T	O
cells	O
.	O

We	O
show	O
that	O
the	O
BR3	O
sequence	O
contains	O
a	O
novel	O
negative	O
regulatory	O
element	O
located	O
at	O
positions	O
-	O
90	O
to	O
-	O
79	O
of	O
the	O
hIL	O
-	O
5	O
promoter	O
,	O
which	O
binds	O
Oct1	O
,	O
octamer	O
-	O
like	O
,	O
and	O
YY1	O
nuclear	O
factors	O
.	O

Substitution	O
mutations	O
,	O
which	O
abolished	O
binding	O
of	O
these	O
proteins	O
to	O
the	O
BR3	O
sequence	O
,	O
significantly	O
increased	O
hIL	O
-	O
5	O
promoter	O
activity	O
in	O
activated	O
T	O
cells	O
.	O

CONCLUSION	O
:	O
We	O
suggest	O
that	O
Oct1	O
,	O
YY1	O
,	O
and	O
octamer	O
-	O
like	O
factors	O
binding	O
to	O
the	O
-	O
90	O
/	O
-	O
79	O
sequence	O
within	O
the	O
proximal	O
IL	O
-	O
5	O
promoter	O
are	O
involved	O
in	O
suppression	O
of	O
IL	O
-	O
5	O
transcription	O
in	O
T	O
cells	O
.	O

Direct	O
interaction	O
of	O
hematopoietic	O
transcription	O
factors	O
PU	O
.	O
1	O
and	O
GATA	O
-	O
1	O
:	O
functional	O
antagonism	O
in	O
erythroid	O
cells	O
.	O

Malignant	O
transformation	O
usually	O
inhibits	O
terminal	O
cell	O
differentiation	O
but	O
the	O
precise	O
mechanisms	O
involved	O
are	O
not	O
understood	O
.	O

PU	O
.	O
1	O
is	O
a	O
hematopoietic	O
-	O
specific	O
Ets	O
family	O
transcription	O
factor	O
that	O
is	O
required	O
for	O
development	O
of	O
some	O
lymphoid	O
and	O
myeloid	O
lineages	O
.	O

PU	O
.	O
1	O
can	O
also	O
act	O
as	O
an	O
oncoprotein	O
as	O
activation	O
of	O
its	O
expression	O
in	O
erythroid	O
precursors	O
by	O
proviral	O
insertion	O
or	O
transgenesis	O
causes	O
erythroleukemias	O
in	O
mice	O
.	O

Restoration	O
of	O
terminal	O
differentiation	O
in	O
the	O
mouse	O
erythroleukemia	O
(	O
MEL	O
)	O
cells	O
requires	O
a	O
decline	O
in	O
the	O
level	O
of	O
PU	O
.	O
1	O
,	O
indicating	O
that	O
PU	O
.	O
1	O
can	O
block	O
erythroid	O
differentiation	O
.	O

Here	O
we	O
investigate	O
the	O
mechanism	O
by	O
which	O
PU	O
.	O
1	O
interferes	O
with	O
erythroid	O
differentiation	O
.	O

We	O
find	O
that	O
PU	O
.	O
1	O
interacts	O
directly	O
with	O
GATA	O
-	O
1	O
,	O
a	O
zinc	O
finger	O
transcription	O
factor	O
required	O
for	O
erythroid	O
differentiation	O
.	O

Interaction	O
between	O
PU	O
.	O
1	O
and	O
GATA	O
-	O
1	O
requires	O
intact	O
DNA	O
-	O
binding	O
domains	O
in	O
both	O
proteins	O
.	O

PU	O
.	O
1	O
represses	O
GATA	O
-	O
1	O
-	O
mediated	O
transcriptional	O
activation	O
.	O

Both	O
the	O
DNA	O
binding	O
and	O
transactivation	O
domains	O
of	O
PU	O
.	O
1	O
are	O
required	O
for	O
repression	O
and	O
both	O
domains	O
are	O
also	O
needed	O
to	O
block	O
terminal	O
differentiation	O
in	O
MEL	O
cells	O
.	O

We	O
also	O
show	O
that	O
ectopic	O
expression	O
of	O
PU	O
.	O
1	O
in	O
Xenopus	O
embryos	O
is	O
sufficient	O
to	O
block	O
erythropoiesis	O
during	O
normal	O
development	O
.	O

Furthermore	O
,	O
introduction	O
of	O
exogenous	O
GATA	O
-	O
1	O
in	O
both	O
MEL	O
cells	O
and	O
Xenopus	O
embryos	O
and	O
explants	O
relieves	O
the	O
block	O
to	O
erythroid	O
differentiation	O
imposed	O
by	O
PU	O
.	O
1	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
stoichiometry	O
of	O
directly	O
interacting	O
but	O
opposing	O
transcription	O
factors	O
may	O
be	O
a	O
crucial	O
determinant	O
governing	O
processes	O
of	O
normal	O
differentiation	O
and	O
malignant	O
transformation	O
.	O

A	O
polymorphism	O
that	O
affects	O
OCT	O
-	O
1	O
binding	O
to	O
the	O
TNF	O
promoter	O
region	O
is	O
associated	O
with	O
severe	O
malaria	O
[	O
see	O
comments	O
]	O

Genetic	O
variation	O
in	O
cytokine	O
promoter	O
regions	O
is	O
postulated	O
to	O
influence	O
susceptibility	O
to	O
infection	O
,	O
but	O
the	O
molecular	O
mechanisms	O
by	O
which	O
such	O
polymorphisms	O
might	O
affect	O
gene	O
regulation	O
are	O
unknown	O
.	O

Through	O
systematic	O
DNA	O
footprinting	O
of	O
the	O
TNF	O
(	O
encoding	O
tumour	O
necrosis	O
factor	O
,	O
TNF	O
)	O
promoter	O
region	O
,	O
we	O
have	O
identified	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
that	O
causes	O
the	O
helix	O
-	O
turn	O
-	O
helix	O
transcription	O
factor	O
OCT	O
-	O
1	O
to	O
bind	O
to	O
a	O
novel	O
region	O
of	O
complex	O
protein	O
-	O
DNA	O
interactions	O
and	O
alters	O
gene	O
expression	O
in	O
human	O
monocytes	O
.	O

The	O
OCT	O
-	O
1	O
-	O
binding	O
genotype	O
,	O
found	O
in	O
approximately	O
5	O
%	O
of	O
Africans	O
,	O
is	O
associated	O
with	O
fourfold	O
increased	O
susceptibility	O
to	O
cerebral	O
malaria	O
in	O
large	O
case	O
-	O
control	O
studies	O
of	O
West	O
African	O
and	O
East	O
African	O
populations	O
,	O
after	O
correction	O
for	O
other	O
known	O
TNF	O
polymorphisms	O
and	O
linked	O
HLA	O
alleles	O
.	O

Correlation	O
between	O
MRI	O
and	O
clinico	O
-	O
pathological	O
manifestations	O
in	O
Lewis	O
rats	O
protected	O
from	O
experimental	O
allergic	O
encephalomyelitis	O
by	O
acylated	O
synthetic	O
peptide	O
of	O
myelin	O
basic	O
protein	O
.	O

Experimental	O
allergic	O
encephalomyelitis	O
(	O
EAE	O
)	O
is	O
an	O
autoimmune	O
disease	O
of	O
the	O
central	O
nervous	O
system	O
which	O
constitutes	O
an	O
accepted	O
animal	O
model	O
for	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
.	O

The	O
disease	O
can	O
take	O
an	O
acute	O
or	O
chronic	O
form	O
depending	O
on	O
the	O
injection	O
route	O
,	O
animal	O
strain	O
and	O
nature	O
of	O
the	O
disease	O
-	O
inducing	O
antigen	O
administered	O
.	O

The	O
neuroinflammation	O
associated	O
with	O
the	O
acute	O
form	O
can	O
be	O
detected	O
with	O
T2	O
-	O
weighted	O
,	O
T1	O
-	O
weighted	O
and	O
diffusion	O
MRI	O
,	O
and	O
blood	O
-	O
brain	O
barrier	O
changes	O
can	O
be	O
investigated	O
with	O
Gd	O
-	O
DTPA	O
-	O
enhanced	O
T1	O
-	O
weighted	O
imaging	O
,	O
similar	O
to	O
that	O
of	O
MS	O
patients	O
.	O

A	O
synthetic	O
peptide	O
of	O
myelin	O
basic	O
protein	O
(	O
MBP	O
)	O
encephalitogenic	O
for	O
the	O
Lewis	O
rat	O
(	O
MBP	O
68	O
-	O
86	O
)	O
was	O
acylated	O
by	O
the	O
attachment	O
of	O
a	O
palmitoyl	O
residue	O
(	O
PAL68	O
-	O
86	O
)	O
,	O
and	O
was	O
shown	O
to	O
confer	O
almost	O
complete	O
protection	O
against	O
EAE	O
,	O
when	O
administered	O
to	O
rats	O
before	O
and	O
after	O
an	O
encephalitogenic	O
challenge	O
.	O

In	O
this	O
study	O
,	O
treatment	O
of	O
Lewis	O
rats	O
with	O
PAL68	O
-	O
86	O
prevented	O
the	O
appearance	O
of	O
clinical	O
signs	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
after	O
challenge	O
with	O
the	O
native	O
peptide	O
(	O
p68	O
-	O
86	O
)	O
in	O
complete	O
Freund	O
'	O
s	O
adjuvant	O
(	O
CFA	O
)	O
,	O
and	O
reduced	O
considerably	O
the	O
MRI	O
and	O
histopathological	O
signs	O
of	O
the	O
disease	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Measurement	O
of	O
the	O
gadolinium	O
leakage	O
due	O
to	O
neuroinflammation	O
revealed	O
a	O
significant	O
decrease	O
in	O
permeability	O
from	O
4	O
.	O
09	O
+	O
/	O
-	O
2	O
.	O
1	O
to	O
2	O
.	O
95	O
+	O
/	O
-	O
1	O
.	O
79	O
%	O
pixels	O
>	O
mean	O
+	O
2	O
SD	O
(	O
p	O
=	O
0	O
.	O
011	O
)	O
.	O

Therefore	O
,	O
quantitative	O
MRI	O
measurements	O
correlate	O
very	O
well	O
with	O
the	O
reduced	O
cellular	O
infiltration	O
in	O
the	O
CNS	O
and	O
the	O
absence	O
of	O
clinical	O
signs	O
in	O
the	O
EAE	O
-	O
protected	O
animal	O
.	O

Identification	O
of	O
a	O
novel	O
region	O
critical	O
for	O
calcineurin	B-Complex
function	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Calcineurin	B-Complex
is	O
a	O
Ca2	O
+	O
/	O
calmodulin	O
-	O
regulated	O
protein	O
phosphatase	O
that	O
plays	O
critical	O
functional	O
roles	O
in	O
T	O
-	O
cell	O
activation	O
and	O
other	O
Ca2	O
+	O
-	O
mediated	O
signal	O
transduction	O
pathways	O
in	O
mammalian	O
cells	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
calcineurin	B-Complex
regulates	O
the	O
transcription	O
of	O
several	O
genes	O
involved	O
in	O
maintaining	O
ion	O
homeostasis	O
(	O
PMC1	O
,	O
PMR1	O
,	O
and	O
PMR2	O
)	O
and	O
cell	O
wall	O
synthesis	O
(	O
FKS2	O
)	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
11	O
single	O
amino	O
acid	O
substitutions	O
in	O
the	O
yeast	O
calcineurin	B-Complex
catalytic	O
subunit	O
Cna1p	O
.	O

We	O
show	O
that	O
six	O
substitutions	O
(	O
R177G	O
,	O
F211S	O
,	O
S232F	O
,	O
D258V	O
,	O
L259P	O
,	O
and	O
A262P	O
)	O
affect	O
the	O
stability	O
of	O
calcineurin	B-Complex
and	O
that	O
two	O
substitutions	O
(	O
V385D	O
and	O
M400R	O
)	O
disrupt	O
the	O
interaction	O
between	O
Cna1p	O
and	O
the	O
calcineurin	B-Complex
regulatory	O
subunit	O
Cnb1p	O
.	O

We	O
also	O
identify	O
three	O
mutations	O
(	O
S373P	O
,	O
H375L	O
,	O
and	O
L379S	O
)	O
that	O
are	O
clustered	O
between	O
the	O
catalytic	O
and	O
the	O
calcineurin	B-OOS
B	I-OOS
subunit	O
-	O
binding	O
domains	O
.	O

These	O
mutations	O
do	O
not	O
significantly	O
affect	O
the	O
ability	O
of	O
Cna1p	O
to	O
interact	O
with	O
Cnb1p	O
,	O
calmodulin	O
,	O
or	O
Fkb1p	O
(	O
FK506	O
-	O
binding	O
protein	O
)	O
.	O

However	O
,	O
these	O
residue	O
substitutions	O
dramatically	O
affect	O
calcineurin	B-Complex
activity	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Thus	O
,	O
by	O
using	O
a	O
random	O
mutagenesis	O
approach	O
,	O
we	O
have	O
shown	O
for	O
the	O
first	O
time	O
that	O
the	O
linker	O
region	O
of	O
the	O
calcineurin	B-Complex
catalytic	O
subunit	O
,	O
as	O
defined	O
by	O
the	O
Ser373	O
,	O
His375	O
,	O
and	O
Leu379	O
residues	O
,	O
is	O
crucial	O
for	O
its	O
function	O
as	O
a	O
phosphatase	O
.	O

Regulation	O
of	O
Hsp27	O
oligomerization	O
,	O
chaperone	O
function	O
,	O
and	O
protective	O
activity	O
against	O
oxidative	O
stress	O
/	O
tumor	O
necrosis	O
factor	O
alpha	O
by	O
phosphorylation	O
.	O

The	O
small	O
heat	O
shock	O
proteins	O
(	O
sHsps	O
)	O
from	O
human	O
(	O
Hsp27	O
)	O
and	O
mouse	O
(	O
Hsp25	O
)	O
form	O
large	O
oligomers	O
which	O
can	O
act	O
as	O
molecular	O
chaperones	O
in	O
vitro	O
and	O
protect	O
cells	O
from	O
heat	O
shock	O
and	O
oxidative	O
stress	O
when	O
overexpressed	O
.	O

In	O
addition	O
,	O
mammalian	O
sHsps	O
are	O
rapidly	O
phosphorylated	O
by	O
MAPKAP	O
kinase	O
2	O
/	O
3	O
at	O
two	O
or	O
three	O
serine	O
residues	O
in	O
response	O
to	O
various	O
extracellular	O
stresses	O
.	O

Here	O
we	O
analyze	O
the	O
effect	O
of	O
sHsp	O
phosphorylation	O
on	O
its	O
quaternary	O
structure	O
,	O
chaperone	O
function	O
,	O
and	O
protection	O
against	O
oxidative	O
stress	O
.	O

We	O
show	O
that	O
in	O
vitro	O
phosphorylation	O
of	O
recombinant	O
sHsp	O
as	O
well	O
as	O
molecular	O
mimicry	O
of	O
Hsp27	O
phosphorylation	O
lead	O
to	O
a	O
significant	O
decrease	O
of	O
the	O
oligomeric	O
size	O
.	O

We	O
demonstrate	O
that	O
both	O
phosphorylated	O
sHsps	O
and	O
the	O
triple	O
mutant	O
Hsp27	O
-	O
S15D	O
,	O
S78D	O
,	O
S82D	O
show	O
significantly	O
decreased	O
abilities	O
to	O
act	O
as	O
molecular	O
chaperones	O
suppressing	O
thermal	O
denaturation	O
and	O
facilitating	O
refolding	O
of	O
citrate	O
synthase	O
in	O
vitro	O
.	O

In	O
parallel	O
,	O
Hsp27	O
and	O
its	O
mutants	O
were	O
analyzed	O
for	O
their	O
ability	O
to	O
confer	O
resistance	O
against	O
oxidative	O
stress	O
when	O
overexpressed	O
in	O
L929	O
and	O
13	O
.	O
S	O
.	O
1	O
.	O
24	O
cells	O
.	O

While	O
wild	O
type	O
Hsp27	O
confers	O
resistance	O
,	O
the	O
triple	O
mutant	O
S15D	O
,	O
S78D	O
,	O
S82D	O
cannot	O
protect	O
against	O
oxidative	O
stress	O
effectively	O
.	O

These	O
data	O
indicate	O
that	O
large	O
oligomers	O
of	O
sHsps	O
are	O
necessary	O
for	O
chaperone	O
action	O
and	O
resistance	O
against	O
oxidative	O
stress	O
whereas	O
phosphorylation	O
down	O
-	O
regulates	O
these	O
activities	O
by	O
dissociation	O
of	O
sHsp	O
complexes	O
to	O
tetramers	O
.	O

A	O
general	O
requirement	O
for	O
the	O
Sin3	B-OOS
-	O
Rpd3	O
histone	B-OOS
deacetylase	I-OOS
complex	O
in	O
regulating	O
silencing	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
Sin3	B-OOS
-	O
Rpd3	O
histone	B-OOS
deacetylase	I-OOS
complex	O
,	O
conserved	O
between	O
human	O
and	O
yeast	O
,	O
represses	O
transcription	O
when	O
targeted	O
by	O
promoter	O
-	O
specific	O
transcription	O
factors	O
.	O

SIN3	B-OOS
and	O
RPD3	O
also	O
affect	O
transcriptional	O
silencing	O
at	O
the	O
HM	O
mating	O
loci	O
and	O
at	O
telomeres	O
in	O
yeast	O
.	O

Interestingly	O
,	O
however	O
,	O
deletion	O
of	O
the	O
SIN3	B-OOS
and	O
RPD3	O
genes	O
enhances	O
silencing	O
,	O
implying	O
that	O
the	O
Sin3	B-OOS
-	O
Rpd3	O
complex	O
functions	O
to	O
counteract	O
,	O
rather	O
than	O
to	O
establish	O
or	O
maintain	O
,	O
silencing	O
.	O

Here	O
we	O
demonstrate	O
that	O
Sin3	B-OOS
,	O
Rpd3	O
,	O
and	O
Sap30	O
,	O
a	O
novel	O
component	O
of	O
the	O
Sin3	B-OOS
-	O
Rpd3	O
complex	O
,	O
affect	O
silencing	O
not	O
only	O
at	O
the	O
HMR	O
and	O
telomeric	O
loci	O
,	O
but	O
also	O
at	O
the	O
rDNA	O
locus	O
.	O

The	O
effects	O
on	O
silencing	O
at	O
all	O
three	O
loci	O
are	O
dependent	O
upon	O
the	O
histone	O
deacetylase	O
activity	O
of	O
Rpd3	O
.	O

Enhanced	O
silencing	O
associated	O
with	O
sin3Delta	O
,	O
rpd3Delta	O
,	O
and	O
sap30Delta	O
is	O
differentially	O
dependent	O
upon	O
Sir2	O
and	O
Sir4	O
at	O
the	O
telomeric	O
and	O
rDNA	O
loci	O
and	O
is	O
also	O
dependent	O
upon	O
the	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
Rad6	O
(	O
Ubc2	O
)	O
.	O

We	O
also	O
show	O
that	O
the	O
Cac3	O
subunit	O
of	O
the	O
CAF	B-Complex
-	I-Complex
I	I-Complex
chromatin	I-Complex
assembly	I-Complex
factor	I-Complex
and	O
Sin3	B-OOS
-	O
Rpd3	O
exert	O
antagonistic	O
effects	O
on	O
silencing	O
.	O

Strikingly	O
,	O
deletion	O
of	O
GCN5	O
,	O
which	O
encodes	O
a	O
histone	O
acetyltransferase	O
,	O
enhances	O
silencing	O
in	O
a	O
manner	O
similar	O
to	O
deletion	O
of	O
RPD3	O
.	O

A	O
model	O
that	O
integrates	O
the	O
effects	O
of	O
rpd3Delta	O
,	O
gcn5Delta	O
,	O
and	O
cac3Delta	O
on	O
silencing	O
is	O
proposed	O
.	O

Identification	O
and	O
characterization	O
of	O
the	O
human	O
peroxin	O
PEX3	O
.	O

The	O
biogenesis	O
of	O
peroxisomes	O
requires	O
the	O
interaction	O
of	O
several	O
peroxins	O
,	O
encoded	O
by	O
PEX	O
genes	O
and	O
is	O
well	O
conserved	O
between	O
yeast	O
and	O
humans	O
.	O

We	O
have	O
cloned	O
the	O
human	O
cDNA	O
of	O
PEX3	O
based	O
on	O
its	O
homology	O
to	O
different	O
yeast	O
PEX3	O
genes	O
.	O

The	O
deduced	O
peroxin	O
HsPEX3	O
is	O
a	O
peroxisomal	O
membrane	O
protein	O
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
42	O
.	O
1	O
kDa	O
.	O

We	O
created	O
N	O
-	O
and	O
C	O
-	O
terminal	O
tagged	O
PEX3	O
to	O
assay	O
its	O
topology	O
at	O
the	O
peroxisomal	O
membrane	O
by	O
immunofluorescence	O
microscopy	O
.	O

Our	O
results	O
and	O
the	O
one	O
predicted	O
transmembrane	O
spanning	O
region	O
are	O
in	O
line	O
with	O
the	O
assumption	O
that	O
H	O
sPEX3	O
is	O
an	O
integral	O
peroxisomal	O
membrane	O
protein	O
with	O
the	O
N	O
-	O
terminus	O
inside	O
the	O
peroxisome	O
and	O
the	O
C	O
-	O
terminus	O
facing	O
the	O
cytoplasm	O
.	O

The	O
farnesylated	O
peroxisomal	O
membrane	O
protein	O
PEX19	O
interacts	O
with	O
HsPEX3	O
in	O
a	O
mammalian	O
two	O
-	O
hybrid	O
assay	O
in	O
human	O
fibroblasts	O
.	O

The	O
physical	O
interaction	O
could	O
be	O
confirmed	O
by	O
coimmunoprecipitation	O
of	O
the	O
two	O
in	O
vitro	O
transcribed	O
and	O
translated	O
proteins	O
.	O

To	O
address	O
the	O
targeting	O
of	O
PEX3	O
to	O
the	O
peroxisomal	O
membrane	O
,	O
the	O
expression	O
of	O
different	O
N	O
-	O
and	O
C	O
-	O
terminal	O
PEX3	O
truncations	O
fused	O
to	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
was	O
investigated	O
in	O
human	O
fibroblasts	O
.	O

The	O
N	O
-	O
terminal	O
33	O
amino	O
acids	O
of	O
PEX3	O
were	O
necessary	O
and	O
sufficient	O
to	O
direct	O
the	O
reporter	O
protein	O
GFP	O
to	O
peroxisomes	O
and	O
seemed	O
to	O
be	O
integrated	O
into	O
the	O
peroxisomal	O
membrane	O
.	O

The	O
expression	O
of	O
a	O
1	O
-	O
16	O
PEX3	O
-	O
GFP	O
fusion	O
protein	O
did	O
not	O
result	O
in	O
a	O
peroxisomal	O
localization	O
,	O
but	O
interestingly	O
,	O
this	O
and	O
several	O
other	O
truncated	O
PEX3	O
fusion	O
proteins	O
were	O
also	O
localized	O
to	O
tubular	O
and	O
/	O
or	O
vesicular	O
structures	O
representing	O
mitochondria	O
.	O

Bcl	O
-	O
2	O
-	O
mediated	O
drug	O
resistance	O
:	O
inhibition	O
of	O
apoptosis	O
by	O
blocking	O
nuclear	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
(	O
NFAT	O
)	O
-	O
induced	O
Fas	O
ligand	O
transcription	O
.	O

Bcl	O
-	O
2	O
inhibits	O
apoptosis	O
induced	O
by	O
a	O
variety	O
of	O
stimuli	O
,	O
including	O
chemotherapy	O
drugs	O
and	O
glucocorticoids	O
.	O

It	O
is	O
generally	O
accepted	O
that	O
Bcl	O
-	O
2	O
exerts	O
its	O
antiapoptotic	O
effects	O
mainly	O
by	O
dimerizing	O
with	O
proapoptotic	O
members	O
of	O
the	O
Bcl	O
-	O
2	O
family	O
such	O
as	O
Bax	O
and	O
Bad	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
the	O
antiapoptotic	O
effects	O
is	O
unclear	O
.	O

Paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	O
dynamics	O
kill	O
cells	O
in	O
a	O
Fas	O
/	O
Fas	O
ligand	O
(	O
FasL	O
)	O
-	O
dependent	O
manner	O
;	O
antibody	O
to	O
FasL	O
inhibits	O
paclitaxel	O
-	O
induced	O
apoptosis	O
.	O

We	O
have	O
found	O
that	O
Bcl	O
-	O
2	O
overexpression	O
leads	O
to	O
the	O
prevention	O
of	O
chemotherapy	O
(	O
paclitaxel	O
)	O
-	O
induced	O
expression	O
of	O
FasL	O
and	O
blocks	O
paclitaxel	O
-	O
induced	O
apoptosis	O
.	O

The	O
mechanism	O
of	O
this	O
effect	O
is	O
that	O
Bcl	O
-	O
2	O
prevents	O
the	O
nuclear	O
translocation	O
of	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
,	O
a	O
transcription	O
factor	O
activated	O
by	O
microtubule	O
damage	O
)	O
by	O
binding	O
and	O
sequestering	O
calcineurin	B-Complex
,	O
a	O
calcium	B-OOS
-	I-OOS
dependent	I-OOS
phosphatase	I-OOS
that	O
must	O
dephosphorylate	O
NFAT	O
to	O
move	O
to	O
the	O
nucleus	O
.	O

Without	O
NFAT	O
nuclear	O
translocation	O
,	O
the	O
FasL	O
gene	O
is	O
not	O
transcribed	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	O
function	O
kill	O
cells	O
at	O
least	O
in	O
part	O
through	O
the	O
induction	O
of	O
FasL	O
.	O

Furthermore	O
,	O
Bcl	O
-	O
2	O
antagonizes	O
drug	O
-	O
induced	O
apoptosis	O
by	O
inhibiting	O
calcineurin	B-Complex
activation	O
,	O
blocking	O
NFAT	O
nuclear	O
translocation	O
,	O
and	O
preventing	O
FasL	O
expression	O
.	O

The	O
effects	O
of	O
Bcl	O
-	O
2	O
can	O
be	O
overcome	O
,	O
at	O
least	O
partially	O
,	O
through	O
phosphorylation	O
of	O
Bcl	O
-	O
2	O
.	O

Phosphorylated	O
Bcl	O
-	O
2	O
cannot	O
bind	O
calcineurin	B-Complex
,	O
and	O
NFAT	O
activation	O
,	O
FasL	O
expression	O
,	O
and	O
apoptosis	O
can	O
occur	O
after	O
Bcl	O
-	O
2	O
phosphorylation	O
.	O

C	O
/	O
EBPbeta	O
and	O
GATA	O
-	O
1	O
synergistically	O
regulate	O
activity	O
of	O
the	O
eosinophil	O
granule	O
major	O
basic	O
protein	O
promoter	O
:	O
implication	O
for	O
C	O
/	O
EBPbeta	O
activity	O
in	O
eosinophil	O
gene	O
expression	O
.	O

Eosinophil	O
granule	O
major	O
basic	O
protein	O
(	O
MBP	O
)	O
is	O
expressed	O
exclusively	O
in	O
eosinophils	O
and	O
basophils	O
in	O
hematopoietic	O
cells	O
.	O

In	O
our	O
previous	O
study	O
,	O
we	O
demonstrated	O
a	O
major	O
positive	O
regulatory	O
role	O
for	O
GATA	O
-	O
1	O
and	O
a	O
negative	O
regulatory	O
role	O
for	O
GATA	O
-	O
2	O
in	O
MBP	O
gene	O
transcription	O
.	O

Further	O
analysis	O
of	O
the	O
MBP	O
promoter	O
region	O
identified	O
a	O
C	O
/	O
EBP	O
(	O
CCAAT	O
/	O
enhancer	O
-	O
binding	O
protein	O
)	O
consensus	O
binding	O
site	O
6	O
bp	O
upstream	O
of	O
the	O
functional	O
GATA	O
-	O
binding	O
site	O
in	O
the	O
MBP	O
gene	O
.	O

In	O
the	O
cell	O
line	O
HT93A	O
,	O
which	O
is	O
capable	O
of	O
differentiating	O
towards	O
both	O
the	O
eosinophil	O
and	O
neutrophil	O
lineages	O
in	O
response	O
to	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
C	O
/	O
EBPalpha	O
mRNA	O
expression	O
decreased	O
significantly	O
concomitant	O
with	O
eosinophilic	O
and	O
neutrophilic	O
differentiation	O
,	O
whereas	O
C	O
/	O
EBPbeta	O
expression	O
was	O
markedly	O
increased	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
showed	O
that	O
recombinant	O
C	O
/	O
EBPbeta	O
protein	O
could	O
bind	O
to	O
the	O
potential	O
C	O
/	O
EBP	O
-	O
binding	O
site	O
(	O
bp	O
-	O
90	O
to	O
-	O
82	O
)	O
in	O
the	O
MBP	O
promoter	O
.	O

Furthermore	O
,	O
we	O
have	O
demonstrated	O
that	O
both	O
C	O
/	O
EBPbeta	O
and	O
GATA	O
-	O
1	O
can	O
bind	O
simultaneously	O
to	O
the	O
C	O
/	O
EBP	O
-	O
and	O
GATA	O
-	O
binding	O
sites	O
in	O
the	O
MBP	O
promoter	O
.	O

To	O
determine	O
the	O
functionality	O
of	O
both	O
the	O
C	O
/	O
EBP	O
-	O
and	O
GATA	O
-	O
binding	O
sites	O
,	O
we	O
analyzed	O
whether	O
C	O
/	O
EBPbeta	O
and	O
GATA	O
-	O
1	O
can	O
stimulate	O
the	O
MBP	O
promoter	O
in	O
the	O
C	O
/	O
EBPbeta	O
and	O
GATA	O
-	O
1	O
negative	O
Jurkat	O
T	O
-	O
cell	O
line	O
.	O

Cotransfection	O
with	O
C	O
/	O
EBPbeta	O
and	O
GATA	O
-	O
1	O
expression	O
vectors	O
produced	O
a	O
5	O
-	O
fold	O
increase	O
compared	O
with	O
cotransfection	O
with	O
the	O
C	O
/	O
EBPbeta	O
or	O
GATA	O
-	O
1	O
expression	O
vectors	O
individually	O
.	O

In	O
addition	O
,	O
GST	O
pull	O
-	O
down	O
experiments	O
demonstrated	O
a	O
physical	O
interaction	O
between	O
human	O
GATA	O
-	O
1	O
and	O
C	O
/	O
EBPbeta	O
.	O

Expression	O
of	O
FOG	O
(	O
riend	O
ATA	O
)	O
,	O
which	O
binds	O
to	O
GATA	O
-	O
1	O
and	O
acts	O
as	O
a	O
cofactor	O
for	O
GATA	O
-	O
binding	O
proteins	O
,	O
decreased	O
transactivation	O
activity	O
of	O
GATA	O
-	O
1	O
for	O
the	O
MBP	O
promoter	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Our	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
both	O
GATA	O
-	O
1	O
and	O
C	O
/	O
EBPbeta	O
synergistically	O
transactivate	O
the	O
promoter	O
of	O
an	O
eosinophil	O
-	O
specific	O
granule	O
protein	O
gene	O
and	O
that	O
FOG	O
may	O
act	O
as	O
a	O
negative	O
cofactor	O
for	O
the	O
eosinophil	O
lineage	O
,	O
unlike	O
its	O
positively	O
regulatory	O
function	O
for	O
the	O
erythroid	O
and	O
megakaryocyte	O
lineages	O
.	O

Induction	O
of	O
a	O
functional	O
vitamin	O
D	O
receptor	O
in	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
-	O
induced	O
monocytic	O
differentiation	O
of	O
M2	O
-	O
type	O
leukemic	O
blast	O
cells	O
.	O

Different	O
types	O
of	O
acute	O
myeloid	O
leukemia	O
blast	O
cells	O
were	O
induced	O
to	O
differentiate	O
in	O
vitro	O
with	O
all	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
vitamin	O
D3	O
(	O
VD	O
)	O
.	O

M0	O
/	O
M1	O
leukemic	O
cells	O
are	O
not	O
sensitive	O
to	O
differentiating	O
agents	O
,	O
whereas	O
M3	O
leukemic	O
cells	O
are	O
induced	O
to	O
undergo	O
granulocytic	O
differentiation	O
after	O
ATRA	O
treatment	O
but	O
are	O
not	O
sensitive	O
to	O
VD	O
.	O

M2	O
leukemic	O
blast	O
cells	O
behave	O
differently	O
because	O
they	O
undergo	O
monocytic	O
differentiation	O
with	O
both	O
the	O
differentiation	O
inducers	O
.	O

To	O
gain	O
some	O
insight	O
into	O
the	O
maturation	O
of	O
M2	O
-	O
type	O
leukemic	O
cells	O
,	O
we	O
studied	O
the	O
molecular	O
mechanisms	O
underlying	O
monocytic	O
differentiation	O
induced	O
by	O
ATRA	O
and	O
VD	O
in	O
spontaneous	O
M2	O
blast	O
cells	O
as	O
well	O
as	O
in	O
Kasumi	O
-	O
1	O
cells	O
(	O
an	O
acute	O
myeloid	O
leukemia	O
M2	O
-	O
type	O
cell	O
line	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
ATRA	O
as	O
well	O
as	O
VD	O
efficiently	O
increases	O
the	O
nuclear	O
abundance	O
of	O
VD	O
receptor	O
(	O
VDR	O
)	O
and	O
promotes	O
monocytic	O
differentiation	O
.	O

VDR	O
is	O
functionally	O
active	O
in	O
ATRA	O
-	O
treated	O
Kasumi	O
-	O
1	O
cells	O
because	O
it	O
efficiently	O
heterodimerizes	O
with	O
retinoid	O
X	O
receptor	O
,	O
binds	O
to	O
a	O
DR3	O
-	O
type	O
vitamin	O
D	O
-	O
responsive	O
element	O
,	O
and	O
activates	O
the	O
transcription	O
of	O
a	O
vitamin	O
D	O
-	O
responsive	O
element	O
-	O
regulated	O
reporter	O
gene	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
VD	O
-	O
responsive	O
genes	O
are	O
induced	O
by	O
ATRA	O
treatment	O
of	O
Kasumi	O
-	O
1	O
cells	O
,	O
suggesting	O
that	O
the	O
genetic	O
program	O
underlying	O
monocytic	O
differentiation	O
is	O
activated	O
.	O

The	O
molecular	O
mechanism	O
by	O
which	O
ATRA	O
increases	O
the	O
nuclear	O
abundance	O
of	O
a	O
functional	O
VDR	O
is	O
still	O
unknown	O
,	O
but	O
our	O
data	O
clearly	O
indicate	O
that	O
the	O
M2	O
leukemic	O
cell	O
context	O
is	O
only	O
permissive	O
of	O
monocytic	O
differentiation	O
.	O

AML1	O
(	O
CBFalpha2	O
)	O
cooperates	O
with	O
B	O
cell	O
-	O
specific	O
activating	O
protein	O
(	O
BSAP	O
/	O
PAX5	O
)	O
in	O
activation	O
of	O
the	O
B	O
cell	O
-	O
specific	O
BLK	O
gene	O
promoter	O
.	O

AML1	O
plays	O
a	O
critical	O
role	O
during	O
hematopoiesis	O
and	O
chromosomal	O
translocations	O
involving	O
AML1	O
are	O
commonly	O
associated	O
with	O
different	O
forms	O
of	O
leukemia	O
,	O
including	O
pre	O
-	O
B	O
acute	O
lymphoblastic	O
leukemia	O
.	O

To	O
understand	O
the	O
function	O
of	O
AML1	O
during	O
B	O
cell	O
differentiation	O
,	O
we	O
analyzed	O
regulatory	O
regions	O
of	O
B	O
cell	O
-	O
specific	O
genes	O
for	O
potential	O
AML1	O
-	O
binding	O
sites	O
and	O
have	O
identified	O
a	O
putative	O
AML1	O
-	O
binding	O
site	O
in	O
the	O
promoter	O
of	O
the	O
B	O
cell	O
-	O
specific	O
tyrosine	O
kinase	O
gene	O
,	O
blk	O
.	O

Gel	O
mobility	O
shift	O
assays	O
and	O
transient	O
transfection	O
assays	O
demonstrate	O
that	O
AML1	O
binds	O
specifically	O
to	O
this	O
site	O
in	O
the	O
blk	O
promoter	O
and	O
this	O
binding	O
site	O
is	O
important	O
for	O
blk	O
promoter	O
activity	O
.	O

Furthermore	O
,	O
in	O
vitro	O
binding	O
analysis	O
revealed	O
that	O
the	O
AML1	O
runt	O
DNA	O
-	O
binding	O
domain	O
physically	O
interacts	O
with	O
the	O
paired	O
DNA	O
-	O
binding	O
domain	O
of	O
BSAP	O
,	O
a	O
B	O
cell	O
-	O
specific	O
transcription	O
factor	O
.	O

BSAP	O
has	O
been	O
shown	O
previously	O
to	O
be	O
important	O
for	O
B	O
cell	O
-	O
specific	O
regulation	O
of	O
the	O
blk	O
gene	O
.	O

Physical	O
interaction	O
of	O
AML1	O
with	O
BSAP	O
correlates	O
with	O
functional	O
cooperativity	O
in	O
transfection	O
studies	O
where	O
AML1	O
and	O
BSAP	O
synergistically	O
activate	O
blk	O
promoter	O
transcription	O
by	O
more	O
than	O
50	O
-	O
fold	O
.	O

These	O
results	O
demonstrate	O
physical	O
and	O
functional	O
interactions	O
between	O
AML1	O
and	O
BSAP	O
and	O
suggest	O
that	O
AML1	O
is	O
an	O
important	O
factor	O
for	O
regulating	O
a	O
critical	O
B	O
cell	O
-	O
specific	O
gene	O
,	O
blk	O
.	O

Substitution	O
of	O
Arg527	O
and	O
Arg531	O
in	O
factor	O
VIII	O
associated	O
with	O
mild	O
haemophilia	O
A	O
:	O
characterization	O
in	O
terms	O
of	O
subunit	O
interaction	O
and	O
cofactor	O
function	O
.	O

The	O
functional	O
defect	O
caused	O
by	O
substitution	O
of	O
Arg527	O
(	O
-	O
-	O
>	O
Trp	O
)	O
and	O
Arg531	O
(	O
-	O
-	O
>	O
Gly	O
,	O
His	O
)	O
in	O
factor	O
VIII	O
(	O
FVIII	O
)	O
,	O
was	O
explored	O
by	O
employing	O
FVIII	O
derived	O
from	O
patient	O
plasma	O
and	O
recombinant	O
FVIII	O
variants	O
.	O

Mutation	O
of	O
these	O
residues	O
is	O
associated	O
with	O
mild	O
haemophilia	O
A	O
.	O

For	O
both	O
FVIII	O
-	O
R527W	O
and	O
FVIII	O
-	O
R531H	O
,	O
activity	O
was	O
lower	O
than	O
antigen	O
,	O
indicating	O
a	O
functional	O
defect	O
for	O
both	O
variants	O
.	O

In	O
contrast	O
to	O
FVIII	O
-	O
R527W	O
,	O
the	O
amount	O
of	O
FVIII	O
-	O
R531H	O
heterodimer	O
present	O
in	O
plasma	O
was	O
reduced	O
compared	O
to	O
heavy	O
and	O
light	O
chain	O
levels	O
.	O

Factor	O
X	O
(	O
FX	O
)	O
activation	O
experiments	O
employing	O
recombinant	O
FVIII	O
-	O
R531G	O
revealed	O
that	O
the	O
activated	O
FVIII	O
-	O
R531G	O
heterotrimer	O
was	O
less	O
stable	O
than	O
normal	O
FVIIIa	O
,	O
apparently	O
due	O
to	O
rapid	O
dissociation	O
of	O
the	O
A2	O
domain	O
.	O

These	O
findings	O
suggest	O
that	O
Arg531	O
is	O
involved	O
in	O
maintaining	O
the	O
stability	O
of	O
both	O
the	O
heterodimer	O
and	O
the	O
activated	O
FVIII	O
heterotrimer	O
.	O

Recombinant	O
FVIII	O
-	O
R527W	O
displayed	O
reduced	O
stimulation	O
of	O
FX	O
activation	O
,	O
suggesting	O
a	O
defect	O
in	O
interaction	O
with	O
factor	O
IXa	O
(	O
FIXa	O
)	O
.	O

The	O
contribution	O
of	O
Arg527	O
in	O
the	O
interaction	O
with	O
FIXa	O
was	O
supported	O
by	O
the	O
observation	O
that	O
FVIII	O
-	O
derived	O
synthetic	O
peptide	O
Tyr511	O
-	O
Leu530	O
was	O
able	O
to	O
inhibit	O
FX	O
activation	O
and	O
that	O
this	O
inhibition	O
could	O
be	O
overcome	O
by	O
addition	O
of	O
increasing	O
concentrations	O
of	O
FIXa	O
.	O

Furthermore	O
,	O
in	O
the	O
three	O
-	O
dimensional	O
FVIII	O
model	O
residues	O
Val517	O
-	O
Arg527	O
are	O
located	O
near	O
the	O
FIXa	O
binding	O
site	O
Ser558	O
-	O
Gln565	O
.	O

Therefore	O
we	O
propose	O
that	O
Arg527	O
is	O
part	O
of	O
an	O
extended	O
FIXa	O
binding	O
site	O
,	O
comprising	O
residues	O
Ser558	O
-	O
Gln565	O
and	O
Val517	O
-	O
Arg527	O
.	O

Competitive	O
interaction	O
of	O
seven	O
in	O
absentia	O
homolog	O
-	O
1A	O
and	O
Ca2	O
+	O
/	O
calmodulin	O
with	O
the	O
cytoplasmic	O
tail	O
of	O
group	O
1	O
metabotropic	O
glutamate	O
receptors	O
.	O

BACKGROUND	O
:	O
Group	O
1	O
metabotropic	O
glutamate	O
receptors	O
(	O
mGluR1	O
and	O
mGluR5	O
)	O
are	O
coupled	O
to	O
inositol	O
trisphosphate	O
/	O
Ca2	O
+	O
signaling	O
via	O
G	O
proteins	O
and	O
play	O
an	O
important	O
role	O
in	O
excitatory	O
synaptic	O
transmission	O
.	O

To	O
explore	O
the	O
regulation	O
of	O
group	O
1	O
mGluR	O
function	O
,	O
we	O
applied	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
using	O
the	O
intracellular	O
carboxy	O
-	O
terminal	O
domain	O
of	O
group	O
1	O
mGluRs	O
(	O
group	O
1	O
ct	O
-	O
mGluRs	O
)	O
and	O
attempted	O
to	O
identify	O
novel	O
protein	O
-	O
protein	O
interactions	O
of	O
group	O
1	O
mGluRs	O
.	O

RESULTS	O
:	O
The	O
two	O
-	O
hybrid	O
screening	O
revealed	O
a	O
specific	O
interaction	O
between	O
group	O
1	O
ct	O
-	O
mGluRs	O
and	O
Siah	O
-	O
1A	O
,	O
the	O
mammalian	O
homolog	O
of	O
Drosophila	O
seven	O
in	O
absentia	O
which	O
is	O
involved	O
in	O
photoreceptor	O
cell	O
differentiation	O
via	O
the	O
ubiquitin	O
/	O
proteasome	B-Complex
-	O
dependent	O
mechanism	O
.	O

This	O
interaction	O
occurs	O
within	O
a	O
homologous	O
27	O
-	O
28	O
amino	O
acid	O
stretch	O
within	O
group	O
1	O
ct	O
-	O
mGluRs	O
and	O
requires	O
the	O
latter	O
two	O
-	O
thirds	O
of	O
Siah	O
-	O
1A	O
.	O

Following	O
coexpression	O
in	O
COS	O
-	O
7	O
cells	O
,	O
myc	O
-	O
tagged	O
Siah	O
-	O
1A	O
was	O
coimmunoprecipitated	O
with	O
the	O
flag	O
-	O
tagged	O
ct	O
-	O
mGluR1	O
by	O
anti	O
-	O
flag	O
antibody	O
.	O

Furthermore	O
,	O
in	O
vitro	O
binding	O
revealed	O
that	O
Siah	O
-	O
1A	O
and	O
Ca2	O
+	O
/	O
calmodulin	O
(	O
CaM	O
)	O
binding	O
sites	O
overlap	O
,	O
such	O
that	O
Siah	O
-	O
1A	O
binding	O
is	O
competitively	O
inhibited	O
by	O
CaM	O
in	O
a	O
Ca2	O
+	O
-	O
dependent	O
manner	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
demonstrate	O
a	O
direct	O
interaction	O
between	O
group	O
1	O
mGluRs	O
and	O
Siah	O
-	O
1A	O
and	O
suggest	O
a	O
novel	O
modulatory	O
mechanism	O
mediated	O
by	O
a	O
competitive	O
interaction	O
between	O
Ca2	O
+	O
/	O
CaM	O
and	O
Siah	O
-	O
1A	O
.	O

c	O
-	O
Maf	O
induces	O
monocytic	O
differentiation	O
and	O
apoptosis	O
in	O
bipotent	O
myeloid	O
progenitors	O
.	O

The	O
transcriptional	O
mechanisms	O
that	O
drive	O
colony	O
-	O
forming	O
unit	O
granulocyte	O
-	O
macrophage	O
(	O
CFU	O
-	O
GM	O
)	O
myeloid	O
progenitors	O
to	O
differentiate	O
into	O
cells	O
of	O
either	O
the	O
granulocytic	O
or	O
monocytic	O
lineage	O
are	O
not	O
fully	O
understood	O
.	O

We	O
have	O
shown	O
that	O
the	O
c	O
-	O
Maf	O
and	O
c	O
-	O
Myb	O
transcription	O
factors	O
physically	O
interact	O
in	O
myeloid	O
cells	O
to	O
form	O
inhibitory	O
complexes	O
that	O
hinder	O
transactivation	O
of	O
c	O
-	O
Myb	O
target	O
genes	O
through	O
direct	O
binding	O
to	O
Myb	O
consensus	O
sites	O
.	O

These	O
complexes	O
arise	O
in	O
a	O
developmentally	O
regulated	O
pattern	O
,	O
peaking	O
at	O
the	O
promyelocyte	O
stage	O
,	O
or	O
in	O
cell	O
model	O
systems	O
,	O
appearing	O
soon	O
after	O
the	O
induction	O
of	O
monocytic	O
differentiation	O
.	O

We	O
wished	O
to	O
determine	O
if	O
this	O
developmentally	O
related	O
interaction	O
is	O
a	O
consequence	O
of	O
myeloid	O
differentiation	O
or	O
an	O
intrinsic	O
differentiating	O
stimulus	O
.	O

Because	O
the	O
elevated	O
Myb	O
:	O
Maf	O
status	O
seen	O
in	O
differentiating	O
cells	O
can	O
be	O
recapitulated	O
by	O
overexpression	O
of	O
c	O
-	O
Maf	O
in	O
myeloid	O
cell	O
lines	O
,	O
we	O
inducibly	O
expressed	O
the	O
c	O
-	O
Maf	O
cDNA	O
in	O
2	O
bipotent	O
human	O
myeloid	O
progenitor	O
cells	O
.	O

Elevated	O
levels	O
of	O
c	O
-	O
Maf	O
protein	O
led	O
to	O
marked	O
increases	O
in	O
Myb	O
:	O
Maf	O
complexes	O
and	O
the	O
accumulation	O
of	O
monocyte	O
/	O
macrophage	O
cells	O
,	O
followed	O
by	O
eventual	O
programmed	O
cell	O
death	O
.	O

Analysis	O
of	O
targets	O
that	O
could	O
mediate	O
these	O
phenotypic	O
changes	O
indicated	O
that	O
c	O
-	O
Maf	O
likely	O
plays	O
a	O
key	O
role	O
in	O
myeloid	O
cell	O
development	O
through	O
dual	O
mechanisms	O
;	O
inhibition	O
of	O
a	O
select	O
set	O
of	O
c	O
-	O
Myb	O
regulated	O
targets	O
,	O
such	O
as	O
Bcl	O
-	O
2	O
and	O
CD13	O
/	O
APN	O
,	O
coupled	O
with	O
the	O
activation	O
of	O
as	O
yet	O
undefined	O
differentiation	O
-	O
promoting	O
genes	O
.	O

The	O
RAG1	O
homeodomain	O
recruits	O
HMG1	O
and	O
HMG2	O
to	O
facilitate	O
recombination	O
signal	O
sequence	O
binding	O
and	O
to	O
enhance	O
the	O
intrinsic	O
DNA	O
-	O
bending	O
activity	O
of	O
RAG1	O
-	O
RAG2	O
.	O

V	O
(	O
D	O
)	O
J	O
recombination	O
is	O
initiated	O
by	O
the	O
specific	O
binding	O
of	O
the	O
RAG1	O
-	O
RAG2	O
(	O
RAG1	O
/	O
2	O
)	O
complex	O
to	O
the	O
heptamer	O
-	O
nonamer	O
recombination	O
signal	O
sequences	O
(	O
RSS	O
)	O
.	O

Several	O
steps	O
of	O
the	O
V	O
(	O
D	O
)	O
J	O
recombination	O
reaction	O
can	O
be	O
reconstituted	O
in	O
vitro	O
with	O
only	O
RAG1	O
/	O
2	O
plus	O
the	O
high	O
-	O
mobility	O
-	O
group	O
protein	O
HMG1	O
or	O
HMG2	O
.	O

Here	O
we	O
show	O
that	O
the	O
RAG1	O
homeodomain	O
directly	O
interacts	O
with	O
both	O
HMG	O
boxes	O
of	O
HMG1	O
and	O
HMG2	O
(	O
HMG1	O
,	O
2	O
)	O
.	O

This	O
interaction	O
facilitates	O
the	O
binding	O
of	O
RAG1	O
/	O
2	O
to	O
the	O
RSS	O
,	O
mainly	O
by	O
promoting	O
high	O
-	O
affinity	O
binding	O
to	O
the	O
nonamer	O
motif	O
.	O

Using	O
circular	O
-	O
permutation	O
assays	O
,	O
we	O
found	O
that	O
the	O
RAG1	O
/	O
2	O
complex	O
bends	O
the	O
RSS	O
DNA	O
between	O
the	O
heptamer	O
and	O
nonamer	O
motifs	O
.	O

HMG1	O
,	O
2	O
significantly	O
enhance	O
the	O
binding	O
and	O
bending	O
of	O
the	O
23RSS	O
but	O
are	O
not	O
essential	O
for	O
the	O
formation	O
of	O
a	O
bent	O
DNA	O
intermediate	O
on	O
the	O
12RSS	O
.	O

A	O
transient	O
increase	O
of	O
HMG1	O
,	O
2	O
concentration	O
in	O
transfected	O
cells	O
increases	O
the	O
production	O
of	O
the	O
final	O
V	O
(	O
D	O
)	O
J	O
recombinants	O
in	O
vivo	O
.	O

There	O
are	O
several	O
lines	O
of	O
evidence	O
that	O
support	O
the	O
view	O
that	O
the	O
KLC1	O
mutation	O
we	O
made	O
is	O
functionally	O
null	O
with	O
respect	O
to	O
the	O
phenotypes	O
observed	O
,	O
in	O
spite	O
of	O
the	O
presence	O
of	O
a	O
KLC1	O
fragment	O
of	O
low	O
abundance	O
.	O

First	O
,	O
Western	O
blots	O
of	O
brain	O
tissue	O
from	O
mutant	O
animals	O
suggest	O
that	O
only	O
a	O
very	O
small	O
amount	O
of	O
the	O
KLC1	O
fragment	O
relative	O
to	O
wild	O
-	O
type	O
KLC1	O
is	O
present	O
.	O

Second	O
,	O
immunofluorescence	O
of	O
sensory	O
and	O
motor	O
neuron	O
cell	O
bodies	O
in	O
DRG	O
and	O
spinal	O
cord	O
reveals	O
only	O
faintly	O
detectable	O
staining	O
of	O
the	O
KLC1	O
fragment	O
relative	O
to	O
the	O
robust	O
staining	O
ordinarily	O
seen	O
in	O
wild	O
-	O
type	O
.	O

Third	O
,	O
immunoprecipitation	O
experiments	O
from	O
whole	O
brain	O
provide	O
no	O
evidence	O
for	O
the	O
association	O
of	O
the	O
KLC1	O
fragment	O
with	O
KIF5A	O
or	O
KIF5B	O
.	O

Fourth	O
,	O
the	O
sites	O
of	O
aberrant	O
accumulation	O
of	O
KIF5A	O
or	O
KIF5B	O
in	O
DRG	O
or	O
spinal	O
cord	O
do	O
not	O
exhibit	O
costaining	O
with	O
KLC	O
antibodies	O
in	O
mutants	O
,	O
suggesting	O
that	O
the	O
aberrantly	O
behaving	O
KHC	O
chains	O
do	O
so	O
as	O
a	O
result	O
of	O
the	O
absence	O
of	O
KLC	O
,	O
rather	O
than	O
an	O
active	O
influence	O
of	O
the	O
KLC1	O
fragment	O
.	O

Fifth	O
,	O
the	O
overall	O
abundance	O
of	O
KIF5A	O
and	O
KLC2	O
are	O
unchanged	O
,	O
even	O
though	O
KLC1	O
has	O
been	O
removed	O
.	O

Thus	O
,	O
there	O
appears	O
to	O
be	O
a	O
larger	O
than	O
normal	O
pool	O
of	O
KIF5A	O
lacking	O
associated	O
KLC	O
,	O
a	O
suggestion	O
that	O
was	O
confirmed	O
by	O
sucrose	O
gradient	O
analysis	O
.	O

Sixth	O
,	O
heterozygotes	O
are	O
normal	O
with	O
respect	O
to	O
all	O
phenotypes	O
we	O
observed	O
,	O
suggesting	O
that	O
the	O
fragment	O
does	O
not	O
actively	O
exert	O
cellular	O
effects	O
.	O

It	O
remains	O
formally	O
possible	O
that	O
the	O
low	O
abundance	O
KLC1	O
fragment	O
does	O
have	O
some	O
residual	O
function	O
,	O
but	O
if	O
so	O
,	O
we	O
have	O
failed	O
to	O
detect	O
it	O
.	O

The	O
Saccharomyces	O
cerevisiae	O
homologue	O
of	O
human	O
Wiskott	O
-	O
Aldrich	O
syndrome	O
protein	O
Las17p	O
interacts	O
with	O
the	O
Arp2	B-Complex
/	I-Complex
3	I-Complex
complex	O
.	O

Yeast	O
Las17	O
protein	O
is	O
homologous	O
to	O
the	O
Wiskott	O
-	O
Aldrich	O
Syndrome	O
protein	O
,	O
which	O
is	O
implicated	O
in	O
severe	O
immunodeficiency	O
.	O

Las17p	O
/	O
Bee1p	O
has	O
been	O
shown	O
to	O
be	O
important	O
for	O
actin	O
patch	O
assembly	O
and	O
actin	O
polymerization	O
.	O

Here	O
we	O
show	O
that	O
Las17p	O
interacts	O
with	O
the	O
Arp2	B-Complex
/	I-Complex
3	I-Complex
complex	O
.	O

LAS17	O
is	O
an	O
allele	O
-	O
specific	O
multicopy	O
suppressor	O
of	O
ARP2	O
and	O
ARP3	O
mutations	O
;	O
overexpression	O
restores	O
both	O
actin	O
patch	O
organization	O
and	O
endocytosis	O
defects	O
in	O
ARP2	O
temperature	O
-	O
sensitive	O
(	O
ts	O
)	O
cells	O
.	O

Six	O
of	O
seven	O
ARP2	O
ts	O
mutants	O
and	O
at	O
least	O
one	O
ARP3	O
ts	O
mutant	O
are	O
synthetically	O
lethal	O
with	O
las17Delta	O
ts	O
confirming	O
functional	O
interaction	O
with	O
the	O
Arp2	B-Complex
/	I-Complex
3	I-Complex
complex	O
.	O

Further	O
characterization	O
of	O
las17Delta	O
cells	O
showed	O
that	O
receptor	O
-	O
mediated	O
internalization	O
of	O
alpha	O
factor	O
by	O
the	O
Ste2	O
receptor	O
is	O
severely	O
defective	O
.	O

The	O
polarity	O
of	O
normal	O
bipolar	O
bud	O
site	O
selection	O
is	O
lost	O
.	O

Las17	O
-	O
gfp	O
remains	O
localized	O
in	O
cortical	O
patches	O
in	O
vivo	O
independently	O
of	O
polymerized	O
actin	O
and	O
is	O
required	O
for	O
the	O
polarized	O
localization	O
of	O
Arp2	B-Complex
/	I-Complex
3	I-Complex
as	O
well	O
as	O
actin	O
.	O

Coimmunoprecipitation	O
of	O
Arp2p	O
with	O
Las17p	O
indicates	O
that	O
Las17p	O
interacts	O
directly	O
with	O
the	O
complex	O
.	O

Two	O
hybrid	O
results	O
also	O
suggest	O
that	O
Las17p	O
interacts	O
with	O
actin	O
,	O
verprolin	O
,	O
Rvs167p	O
and	O
several	O
other	O
proteins	O
including	O
Src	O
homology	O
3	O
(	O
SH3	O
)	O
domain	O
proteins	O
,	O
suggesting	O
that	O
Las17p	O
may	O
integrate	O
signals	O
from	O
different	O
regulatory	O
cascades	O
destined	O
for	O
the	O
Arp2	B-Complex
/	I-Complex
3p	I-Complex
complex	O
and	O
the	O
actin	O
cytoskeleton	O
.	O

Assembly	O
of	O
AUF1	O
oligomers	O
on	O
U	O
-	O
rich	O
RNA	O
targets	O
by	O
sequential	O
dimer	O
association	O
.	O

Many	O
labile	O
mammalian	O
mRNAs	O
are	O
targeted	O
for	O
rapid	O
cytoplasmic	O
turnover	O
by	O
the	O
presence	O
of	O
A	O
+	O
U	O
-	O
rich	O
elements	O
(	O
AREs	O
)	O
within	O
their	O
3	O
'	O
-	O
untranslated	O
regions	O
.	O

These	O
elements	O
are	O
selectively	O
recognized	O
by	O
AUF1	O
,	O
a	O
component	O
of	O
a	O
multisubunit	O
complex	O
that	O
may	O
participate	O
in	O
the	O
initiation	O
of	O
mRNA	O
decay	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
recognition	O
of	O
AREs	O
by	O
AUF1	O
in	O
vitro	O
using	O
oligoribonucleotide	O
substrates	O
.	O

Gel	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
U	O
-	O
rich	O
RNA	O
targets	O
were	O
specifically	O
bound	O
by	O
AUF1	O
,	O
generating	O
two	O
distinct	O
RNA	O
-	O
protein	O
complexes	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Chemical	O
cross	O
-	O
linking	O
revealed	O
the	O
interaction	O
of	O
AUF1	O
dimers	O
to	O
form	O
tetrameric	O
structures	O
involving	O
protein	O
-	O
protein	O
interactions	O
in	O
the	O
presence	O
of	O
high	O
affinity	O
RNA	O
targets	O
.	O

From	O
these	O
data	O
,	O
a	O
model	O
of	O
AUF1	O
association	O
with	O
AREs	O
involving	O
sequential	O
dimer	O
binding	O
was	O
developed	O
.	O

Using	O
fluorescent	O
RNA	O
substrates	O
,	O
binding	O
parameters	O
of	O
AUF1	O
dimer	O
-	O
ARE	O
and	O
tetramer	O
-	O
ARE	O
equilibria	O
were	O
evaluated	O
in	O
solution	O
by	O
fluorescence	O
anisotropy	O
measurements	O
.	O

Using	O
two	O
AUF1	O
deletion	O
mutants	O
,	O
sequences	O
C	O
-	O
terminal	O
to	O
the	O
RNA	O
recognition	O
motifs	O
are	O
shown	O
to	O
contribute	O
to	O
the	O
formation	O
of	O
the	O
AUF1	O
tetramer	O
.	O
ARE	O
complex	O
but	O
are	O
not	O
obligate	O
for	O
RNA	O
binding	O
activity	O
.	O

Kinetic	O
studies	O
demonstrated	O
rapid	O
turnover	O
of	O
AUF1	O
.	O
ARE	O
complexes	O
in	O
solution	O
,	O
suggesting	O
that	O
these	O
interactions	O
are	O
very	O
dynamic	O
in	O
character	O
.	O

Taken	O
together	O
,	O
these	O
data	O
support	O
a	O
model	O
where	O
ARE	O
-	O
dependent	O
oligomerization	O
of	O
AUF1	O
may	O
function	O
to	O
nucleate	O
the	O
formation	O
of	O
a	O
trans	O
-	O
acting	O
,	O
RNA	O
-	O
destabilizing	O
complex	O
in	O
vivo	O
.	O

Characterization	O
of	O
the	O
cytosolic	O
tuberin	O
-	O
hamartin	O
complex	O
.	O

Tuberin	O
is	O
a	O
cytosolic	O
chaperone	O
for	O
hamartin	O
.	O

Tuberous	O
sclerosis	O
(	O
TSC	O
)	O
is	O
an	O
autosomal	O
dominant	O
disorder	O
characterized	O
by	O
a	O
broad	O
phenotypic	O
spectrum	O
that	O
includes	O
seizures	O
,	O
mental	O
retardation	O
,	O
renal	O
dysfunction	O
and	O
dermatological	O
abnormalities	O
.	O

Mutations	O
to	O
either	O
the	O
TSC1	O
or	O
TSC2	O
gene	O
are	O
responsible	O
for	O
the	O
disease	O
.	O

The	O
TSC1	O
gene	O
encodes	O
hamartin	O
,	O
a	O
130	O
-	O
kDa	O
protein	O
without	O
significant	O
homology	O
to	O
other	O
known	O
mammalian	O
proteins	O
.	O

Analysis	O
of	O
the	O
amino	O
acid	O
sequence	O
of	O
tuberin	O
,	O
the	O
200	O
-	O
kDa	O
product	O
of	O
the	O
TSC2	O
gene	O
,	O
identified	O
a	O
region	O
with	O
limited	O
homology	O
to	O
GTPase	O
-	O
activating	O
proteins	O
.	O

Previously	O
,	O
we	O
demonstrated	O
direct	O
binding	O
between	O
tuberin	O
and	O
hamartin	O
.	O

Here	O
we	O
investigate	O
this	O
interaction	O
in	O
more	O
detail	O
.	O

We	O
show	O
that	O
the	O
complex	O
is	O
predominantly	O
cytosolic	O
and	O
may	O
contain	O
additional	O
,	O
as	O
yet	O
uncharacterized	O
components	O
alongside	O
tuberin	O
and	O
hamartin	O
.	O

Furthermore	O
,	O
because	O
oligomerization	O
of	O
the	O
hamartin	O
carboxyl	O
-	O
terminal	O
coiled	O
coil	O
domain	O
was	O
inhibited	O
by	O
the	O
presence	O
of	O
tuberin	O
,	O
we	O
propose	O
that	O
tuberin	O
acts	O
as	O
a	O
chaperone	O
,	O
preventing	O
hamartin	O
self	O
-	O
aggregation	O
.	O

MEKK3	O
directly	O
regulates	O
MEK5	O
activity	O
as	O
part	O
of	O
the	O
big	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
1	O
(	O
BMK1	O
)	O
signaling	O
pathway	O
.	O

Big	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
(	O
BMK1	O
)	O
,	O
also	O
known	O
as	O
ERK5	O
,	O
is	O
a	O
member	O
of	O
the	O
MAP	O
kinase	O
family	O
whose	O
cellular	O
activity	O
is	O
elevated	O
in	O
response	O
to	O
growth	O
factors	O
,	O
oxidative	O
stress	O
,	O
and	O
hyperosmolar	O
conditions	O
.	O

Previous	O
studies	O
have	O
identified	O
MEK5	O
as	O
a	O
cellular	O
kinase	O
directly	O
regulating	O
BMK1	O
activity	O
;	O
however	O
,	O
signaling	O
molecules	O
that	O
directly	O
regulate	O
MEK5	O
activity	O
have	O
not	O
yet	O
been	O
defined	O
.	O

Through	O
utilization	O
of	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
,	O
we	O
have	O
identified	O
MEKK3	O
as	O
a	O
molecule	O
that	O
physically	O
interacts	O
with	O
MEK5	O
.	O

This	O
interaction	O
appears	O
to	O
take	O
place	O
in	O
mammalian	O
cells	O
as	O
evidenced	O
by	O
the	O
fact	O
that	O
cellular	O
MEK5	O
and	O
MEKK3	O
co	O
-	O
immunoprecipitate	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
a	O
dominant	O
active	O
form	O
of	O
MEKK3	O
stimulates	O
BMK1	O
activity	O
through	O
MEK5	O
.	O

Moreover	O
,	O
we	O
demonstrate	O
that	O
MEKK3	O
activity	O
is	O
required	O
for	O
growth	O
factor	O
mediated	O
cellular	O
activation	O
of	O
endogenous	O
BMK1	O
.	O

Taken	O
together	O
,	O
these	O
results	O
identify	O
MEKK3	O
as	O
a	O
kinase	O
that	O
regulates	O
the	O
activity	O
of	O
MEK5	O
and	O
BMK1	O
during	O
growth	O
factor	O
-	O
induced	O
cellular	O
stimulation	O
.	O

Effect	O
of	O
ligand	O
and	O
DNA	O
binding	O
on	O
the	O
interaction	O
between	O
human	O
transcription	O
intermediary	O
factor	O
1alpha	O
and	O
estrogen	O
receptors	O
.	O

Hormonal	O
regulation	O
of	O
gene	O
activity	O
is	O
mediated	O
by	O
nuclear	O
receptors	O
acting	O
as	O
ligand	O
-	O
activated	O
transcription	O
factors	O
.	O

To	O
achieve	O
efficient	O
regulation	O
of	O
gene	O
expression	O
,	O
these	O
receptors	O
must	O
interact	O
with	O
different	O
type	O
of	O
molecules	O
:	O
1	O
)	O
the	O
steroid	O
hormone	O
,	O
2	O
)	O
the	O
DNA	O
response	O
element	O
,	O
and	O
3	O
)	O
various	O
proteins	O
acting	O
as	O
transcriptional	O
cofactors	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
how	O
ligand	O
and	O
DNA	O
binding	O
influence	O
the	O
in	O
vitro	O
interaction	O
between	O
estrogen	O
receptors	O
(	O
ERs	O
)	O
and	O
the	O
transcription	O
intermediary	O
factor	O
hTIF1alpha	O
(	O
human	O
transcriptional	O
intermediary	O
factor	O
1alpha	O
)	O
.	O

We	O
first	O
optimized	O
conditions	O
for	O
the	O
coactivator	O
-	O
dependent	O
receptor	O
ligand	O
assay	O
to	O
lower	O
ED50	O
,	O
and	O
we	O
then	O
analyzed	O
the	O
ability	O
of	O
various	O
natural	O
and	O
synthetic	O
estrogens	O
to	O
allow	O
the	O
binding	O
of	O
the	O
two	O
types	O
of	O
proteins	O
.	O

Results	O
were	O
compared	O
with	O
the	O
respective	O
affinities	O
of	O
these	O
ligands	O
for	O
the	O
receptor	O
.	O

We	O
then	O
developed	O
a	O
protein	O
-	O
protein	O
-	O
DNA	O
assay	O
allowing	O
the	O
quantification	O
of	O
cofactor	O
-	O
ER	O
-	O
estrogen	O
response	O
element	O
(	O
ERE	O
)	O
complex	O
formation	O
in	O
the	O
presence	O
of	O
ligand	O
and	O
used	O
measurements	O
of	O
fluorescence	O
anisotropy	O
to	O
define	O
the	O
equilibrium	O
binding	O
parameters	O
of	O
the	O
interaction	O
.	O

We	O
demonstrated	O
that	O
the	O
leucine	O
-	O
charged	O
domain	O
of	O
hTIF1alpha	O
is	O
sufficient	O
to	O
interact	O
with	O
ERE	O
-	O
bound	O
ERalpha	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
and	O
showed	O
that	O
binding	O
of	O
ERalpha	O
onto	O
DNA	O
does	O
not	O
significantly	O
affect	O
its	O
hormone	O
-	O
dependent	O
association	O
with	O
TIF1alpha	O
.	O

Finally	O
,	O
we	O
show	O
that	O
,	O
mainly	O
in	O
the	O
absence	O
of	O
hormone	O
,	O
hTIF1alpha	O
interacts	O
better	O
with	O
ERbeta	O
than	O
with	O
ERalpha	O
independently	O
of	O
the	O
presence	O
of	O
ERE	O
.	O

Gemin3	O
:	O
A	O
novel	O
DEAD	O
box	O
protein	O
that	O
interacts	O
with	O
SMN	O
,	O
the	O
spinal	O
muscular	O
atrophy	O
gene	O
product	O
,	O
and	O
is	O
a	O
component	O
of	O
gems	O
.	O

The	O
survival	O
of	O
motor	O
neurons	O
(	O
SMN	O
)	O
gene	O
is	O
the	O
disease	O
gene	O
of	O
spinal	O
muscular	O
atrophy	O
(	O
SMA	O
)	O
,	O
a	O
common	O
motor	O
neuron	O
degenerative	O
disease	O
.	O

The	O
SMN	O
protein	O
is	O
part	O
of	O
a	O
complex	O
containing	O
several	O
proteins	O
,	O
of	O
which	O
one	O
,	O
SIP1	O
(	O
SMN	O
interacting	O
protein	O
1	O
)	O
,	O
has	O
been	O
characterized	O
so	O
far	O
.	O

The	O
SMN	O
complex	O
is	O
found	O
in	O
both	O
the	O
cytoplasm	O
and	O
in	O
the	O
nucleus	O
,	O
where	O
it	O
is	O
concentrated	O
in	O
bodies	O
called	O
gems	O
.	O

In	O
the	O
cytoplasm	O
,	O
SMN	O
and	O
SIP1	O
interact	O
with	O
the	O
Sm	B-Complex
core	I-Complex
proteins	O
of	O
spliceosomal	O
small	B-Complex
nuclear	I-Complex
ribonucleoproteins	I-Complex
(	O
snRNPs	B-Complex
)	O
,	O
and	O
they	O
play	O
a	O
critical	O
role	O
in	O
snRNP	B-Complex
assembly	O
.	O

In	O
the	O
nucleus	O
,	O
SMN	O
is	O
required	O
for	O
pre	O
-	O
mRNA	O
splicing	O
,	O
likely	O
by	O
serving	O
in	O
the	O
regeneration	O
of	O
snRNPs	B-Complex
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
another	O
component	O
of	O
the	O
SMN	O
complex	O
,	O
a	O
novel	O
DEAD	O
box	O
putative	O
RNA	O
helicase	O
,	O
named	O
Gemin3	O
.	O

Gemin3	O
interacts	O
directly	O
with	O
SMN	O
,	O
as	O
well	O
as	O
with	O
SmB	O
,	O
SmD2	O
,	O
and	O
SmD3	O
.	O

Immunolocalization	O
studies	O
using	O
mAbs	O
to	O
Gemin3	O
show	O
that	O
it	O
colocalizes	O
with	O
SMN	O
in	O
gems	O
.	O

Gemin3	O
binds	O
SMN	O
via	O
its	O
unique	O
COOH	O
-	O
terminal	O
domain	O
,	O
and	O
SMN	O
mutations	O
found	O
in	O
some	O
SMA	O
patients	O
strongly	O
reduce	O
this	O
interaction	O
.	O

The	O
presence	O
of	O
a	O
DEAD	O
box	O
motif	O
in	O
Gemin3	O
suggests	O
that	O
it	O
may	O
provide	O
the	O
catalytic	O
activity	O
that	O
plays	O
a	O
critical	O
role	O
in	O
the	O
function	O
of	O
the	O
SMN	O
complex	O
on	O
RNPs	B-Complex
.	O

The	O
above	O
results	O
suggest	O
that	O
the	O
action	O
of	O
a	O
Eps15	O
-	O
Hrb	O
complex	O
must	O
somehow	O
be	O
exerted	O
at	O
the	O
cytosolic	O
level	O
.	O

In	O
search	O
of	O
a	O
possible	O
mechanism	O
,	O
we	O
measured	O
the	O
steady	O
state	O
levels	O
of	O
Rev	O
in	O
the	O
presence	O
of	O
Eps15	O
alone	O
or	O
in	O
combination	O
with	O
Hrb	O
/	O
Hrbl	O
.	O

Transfection	O
of	O
Eps15	O
or	O
Hrb	O
or	O
Hrbl	O
,	O
together	O
with	O
Rev	O
,	O
caused	O
a	O
modest	O
increase	O
in	O
the	O
steady	O
state	O
levels	O
of	O
Rev	O
(	O
Fig	O
.	O
4	O
C	O
)	O
.	O

However	O
,	O
when	O
Rev	O
was	O
cotransfected	O
with	O
Eps15	O
with	O
either	O
Hrb	O
or	O
Hrbl	O
,	O
a	O
four	O
-	O
to	O
sixfold	O
increase	O
in	O
Rev	O
levels	O
was	O
detected	O
(	O
Fig	O
.	O
4	O
C	O
)	O
.	O

These	O
differences	O
were	O
not	O
due	O
to	O
variable	O
transfection	O
efficiency	O
,	O
since	O
all	O
cellular	O
lysates	O
displayed	O
the	O
same	O
amount	O
of	O
beta	O
-	O
galactosidase	O
activity	O
,	O
which	O
was	O
expressed	O
by	O
the	O
cotransfected	O
plasmid	O
pCMVbeta	O
-	O
gal	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
,	O
and	O
used	O
as	O
an	O
internal	O
standard	O
.	O

Expression	O
of	O
a	O
prenylation	O
-	O
deficient	O
Rab4	O
interferes	O
with	O
propagation	O
of	O
insulin	O
signaling	O
through	O
insulin	O
receptor	O
substrate	O
-	O
1	O
.	O

Rab	O
proteins	O
are	O
small	O
GTP	O
-	O
binding	O
proteins	O
of	O
the	O
Ras	O
superfamily	O
that	O
function	O
in	O
the	O
regulation	O
of	O
vesicle	O
transport	O
processes	O
.	O

The	O
Rab4	O
isoform	O
has	O
been	O
implicated	O
in	O
insulin	O
action	O
.	O

For	O
instance	O
,	O
overexpression	O
of	O
a	O
prenylation	O
-	O
deficient	O
form	O
of	O
Rab4	O
has	O
been	O
shown	O
to	O
inhibit	O
insulin	O
-	O
dependent	O
GLUT4	O
translocation	O
.	O

Other	O
steps	O
affected	O
by	O
Rab4	O
in	O
the	O
cascade	O
of	O
events	O
resulting	O
from	O
insulin	O
receptor	O
activation	O
have	O
not	O
been	O
elucidated	O
.	O

In	O
the	O
present	O
studies	O
,	O
we	O
measured	O
effects	O
on	O
insulin	O
-	O
signaling	O
proteins	O
in	O
3T3	O
-	O
L1	O
adipocytes	O
transiently	O
expressing	O
cytoplasmic	O
forms	O
of	O
Rab4	O
and	O
Rab5	O
.	O

Expression	O
of	O
a	O
mutant	O
Rab4	O
lacking	O
a	O
prenylation	O
site	O
resulted	O
in	O
reduced	O
insulin	O
-	O
dependent	O
phosphorylation	O
ofcytoplasmic	O
and	O
internal	O
membrane	O
-	O
associated	O
insulin	O
receptor	O
substrate	O
-	O
1	O
,	O
leading	O
to	O
decreased	O
insulin	O
receptor	O
substrate	O
-	O
1	O
-	O
associated	O
phosphatidylinositol	O
3	O
'	O
-	O
OH	O
kinase	O
activation	O
and	O
decreased	O
Akt	O
activation	O
.	O

These	O
effects	O
were	O
not	O
observed	O
upon	O
introduction	O
of	O
a	O
similar	O
mutant	O
form	O
of	O
Rab5	O
.	O

These	O
data	O
indicate	O
that	O
Rab4	O
or	O
a	O
Rab4	O
-	O
associated	O
protein	O
is	O
involved	O
at	O
one	O
or	O
more	O
steps	O
in	O
propagating	O
the	O
insulin	O
signal	O
,	O
in	O
addition	O
to	O
any	O
role	O
it	O
may	O
play	O
in	O
the	O
regulation	O
of	O
GLUT4	O
vesicle	O
translocation	O
.	O

Our	O
results	O
support	O
models	O
of	O
insulin	O
signaling	O
in	O
which	O
regulation	O
of	O
internal	O
membrane	O
trafficking	O
plays	O
a	O
role	O
in	O
transduction	O
of	O
the	O
insulin	O
signal	O
.	O

Inhibition	O
of	O
protein	O
palmitoylation	O
,	O
raft	O
localization	O
,	O
and	O
T	O
cell	O
signaling	O
by	O
2	O
-	O
bromopalmitate	O
and	O
polyunsaturated	O
fatty	O
acids	O
.	O

The	O
ability	O
of	O
the	O
Src	O
family	O
kinases	O
Fyn	O
and	O
Lck	O
to	O
participate	O
in	O
signaling	O
through	O
the	O
T	B-Complex
cell	I-Complex
receptor	I-Complex
is	O
critically	O
dependent	O
on	O
their	O
dual	O
fatty	O
acylation	O
with	O
myristate	O
and	O
palmitate	O
.	O

Here	O
we	O
identify	O
a	O
palmitate	O
analog	O
,	O
2	O
-	O
bromopalmitate	O
,	O
that	O
effectively	O
blocks	O
Fyn	O
fatty	O
acylation	O
in	O
general	O
and	O
palmitoylation	O
in	O
particular	O
.	O

Treatment	O
of	O
COS	O
-	O
1	O
cells	O
with	O
2	O
-	O
bromopalmitate	O
blocked	O
myristoylation	O
and	O
palmitoylation	O
of	O
Fyn	O
and	O
inhibited	O
membrane	O
binding	O
and	O
localization	O
of	O
Fyn	O
to	O
detergent	O
-	O
resistant	O
membranes	O
(	O
DRMs	O
)	O
.	O

In	O
Jurkat	O
T	O
cells	O
,	O
2	O
-	O
bromopalmitate	O
blocked	O
localization	O
of	O
the	O
endogenous	O
palmitoylated	O
proteins	O
Fyn	O
,	O
Lck	O
,	O
and	O
LAT	O
to	O
DRMs	O
.	O

This	O
resulted	O
in	O
impaired	O
signaling	O
through	O
the	O
T	B-Complex
cell	I-Complex
receptor	I-Complex
as	O
evidenced	O
by	O
reductions	O
in	O
tyrosine	O
phosphorylation	O
,	O
calcium	O
release	O
,	O
and	O
activation	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
.	O

We	O
also	O
examined	O
the	O
ability	O
of	O
long	O
chain	O
polyunsaturated	O
fatty	O
acids	O
(	O
PUFAs	O
)	O
to	O
inhibit	O
protein	O
fatty	O
acylation	O
.	O

PUFAs	O
have	O
been	O
reported	O
to	O
inhibit	O
T	O
cell	O
signaling	O
by	O
excluding	O
Src	O
family	O
kinases	O
from	O
DRMs	O
.	O

Here	O
we	O
show	O
that	O
the	O
PUFAs	O
arachidonic	O
acid	O
and	O
eicosapentaenoic	O
acid	O
inhibit	O
Fyn	O
palmitoylation	O
and	O
consequently	O
block	O
Fyn	O
localization	O
to	O
DRMs	O
.	O

We	O
propose	O
that	O
inhibition	O
of	O
protein	O
palmitoylation	O
represents	O
a	O
novel	O
mechanism	O
by	O
which	O
PUFAs	O
exert	O
their	O
immunosuppressive	O
effects	O
.	O

Structural	O
determinants	O
of	O
post	O
-	O
translational	O
modification	O
and	O
catalytic	O
specificity	O
for	O
the	O
lipoyl	O
domains	O
of	O
the	O
pyruvate	B-Complex
dehydrogenase	I-Complex
multienzyme	O
complex	O
of	O
Escherichia	O
coli	O
.	O

The	O
lipoyl	O
domains	O
of	O
the	O
dihydrolipoyl	B-OOS
acyltransferase	I-OOS
(	O
E2p	O
,	O
E2o	O
)	O
components	O
of	O
the	O
pyruvate	B-Complex
and	I-Complex
2	I-Complex
-	I-Complex
oxoglutarate	I-Complex
dehydrogenase	I-Complex
multienzyme	O
complexes	O
are	O
specifically	O
recognised	O
by	O
their	O
cognate	O
2	B-Complex
-	I-Complex
oxo	I-Complex
acid	I-Complex
decarboxylase	I-Complex
(	O
E1p	O
,	O
E1o	O
)	O
.	O

A	O
prominent	O
surface	O
loop	O
links	O
the	O
first	O
and	O
second	O
beta	O
-	O
strands	O
in	O
all	O
lipoyl	O
domains	O
,	O
close	O
in	O
space	O
to	O
the	O
lipoyl	O
-	O
lysine	O
beta	O
-	O
turn	O
.	O

This	O
loop	O
was	O
subjected	O
to	O
various	O
modifications	O
by	O
directed	O
mutagenesis	O
of	O
a	O
sub	O
-	O
gene	O
encoding	O
a	O
lipoyl	O
domain	O
of	O
Escherichia	O
coli	O
E2p	O
.	O

Deletion	O
of	O
the	O
loop	O
(	O
four	O
residues	O
)	O
rendered	O
the	O
domain	O
incapable	O
of	O
reductive	O
acetylation	O
by	O
E	O
.	O
coli	O
E1p	O
in	O
the	O
presence	O
of	O
pyruvate	O
,	O
but	O
insertion	O
of	O
a	O
new	O
loop	O
(	O
six	O
residues	O
)	O
corresponding	O
to	O
that	O
in	O
the	O
E2o	O
lipoyl	O
domain	O
partly	O
restored	O
this	O
ability	O
,	O
albeit	O
with	O
a	O
much	O
lower	O
rate	O
.	O

However	O
,	O
the	O
modified	O
domain	O
remained	O
unable	O
to	O
undergo	O
reductive	O
succinylation	O
by	O
E1o	O
in	O
the	O
presence	O
of	O
2	O
-	O
oxoglutarate	O
.	O

Additional	O
exchange	O
of	O
the	O
two	O
residues	O
on	O
the	O
C	O
-	O
terminal	O
side	O
of	O
the	O
loop	O
(	O
V14A	O
,	O
E15T	O
)	O
had	O
no	O
effect	O
.	O

Insertion	O
of	O
a	O
different	O
four	O
-	O
residue	O
loop	O
also	O
restored	O
a	O
limited	O
ability	O
to	O
undergo	O
reductive	O
acetylation	O
,	O
but	O
still	O
significantly	O
less	O
than	O
that	O
of	O
the	O
wild	O
-	O
type	O
domain	O
.	O

Exchanging	O
the	O
residue	O
on	O
the	O
N	O
-	O
terminal	O
side	O
of	O
the	O
lipoyl	O
-	O
lysine	O
beta	O
-	O
turn	O
in	O
the	O
E2p	O
and	O
E2o	O
domains	O
(	O
G39T	O
)	O
,	O
both	O
singly	O
and	O
in	O
conjunction	O
with	O
the	O
loop	O
exchange	O
,	O
had	O
no	O
effect	O
on	O
the	O
ability	O
of	O
the	O
E2p	O
domain	O
to	O
be	O
reductively	O
acetylated	O
but	O
did	O
confer	O
a	O
slight	O
increase	O
in	O
susceptibility	O
to	O
reductive	O
succinylation	O
.	O

All	O
mutant	O
E2p	O
domains	O
,	O
apart	O
from	O
that	O
with	O
the	O
loop	O
deletion	O
(	O
LD	O
)	O
,	O
were	O
readily	O
lipoylated	O
in	O
vitro	O
by	O
E	O
.	O
coli	O
lipoate	O
protein	O
ligase	O
A	O
;	O
the	O
E2p	O
LD	O
mutant	O
could	O
be	O
lipoylated	O
only	O
at	O
a	O
significantly	O
lower	O
rate	O
.	O

Likewise	O
,	O
this	O
domain	O
exhibited	O
1D	O
and	O
2D	O
NMR	O
spectra	O
characteristic	O
of	O
a	O
partially	O
folded	O
protein	O
,	O
whereas	O
the	O
spectra	O
of	O
mutants	O
with	O
modified	O
loops	O
were	O
similar	O
to	O
those	O
of	O
the	O
wild	O
-	O
type	O
domain	O
.	O

The	O
surface	O
loop	O
is	O
evidently	O
important	O
to	O
the	O
structural	O
integrity	O
of	O
the	O
domain	O
and	O
may	O
help	O
to	O
stabilize	O
the	O
thioester	O
bond	O
linking	O
the	O
acyl	O
group	O
to	O
the	O
reduced	O
lipoyl	O
-	O
lysine	O
swinging	O
arm	O
as	O
part	O
of	O
the	O
catalytic	O
mechanism	O
.	O

Recognition	O
of	O
the	O
lipoyl	O
domain	O
by	O
its	O
partner	O
E1	B-Complex
appears	O
to	O
be	O
a	O
complex	O
process	O
and	O
not	O
attributable	O
to	O
any	O
single	O
determinant	O
on	O
the	O
domain	O
.	O

Saccharomyces	O
cerevisiae	O
Arc35p	O
works	O
through	O
two	O
genetically	O
separable	O
calmodulin	O
functions	O
to	O
regulate	O
the	O
actin	O
and	O
tubulin	O
cytoskeletons	O
.	O

Analysis	O
of	O
the	O
arc35	O
-	O
1	O
mutant	O
has	O
revealed	O
previously	O
that	O
this	O
component	O
of	O
the	O
Arp2	B-Complex
/	I-Complex
3	I-Complex
complex	O
is	O
involved	O
in	O
organization	O
of	O
the	O
actin	O
cytoskeleton	O
.	O

Further	O
characterization	O
uncovered	O
a	O
cell	O
division	O
cycle	O
phenotype	O
with	O
arrest	O
as	O
large	O
-	O
budded	O
cells	O
.	O

Cells	O
with	O
correctly	O
positioned	O
metaphase	O
spindles	O
accumulated	O
at	O
the	O
restrictive	O
temperature	O
.	O

The	O
observed	O
metaphase	O
arrest	O
most	O
likely	O
occurs	O
by	O
activation	O
of	O
the	O
spindle	O
assembly	O
checkpoint	O
,	O
because	O
arc35	O
-	O
1	O
was	O
synthetically	O
lethal	O
with	O
a	O
deletion	O
of	O
BUB2	O
.	O

Arc35p	O
activity	O
is	O
required	O
late	O
in	O
G	O
(	O
1	O
)	O
for	O
its	O
cell	O
cycle	O
function	O
.	O

Both	O
the	O
actin	O
and	O
microtubule	O
defects	O
of	O
arc35	O
-	O
1	O
can	O
be	O
suppressed	O
by	O
overexpression	O
of	O
calmodulin	O
.	O

Analysis	O
of	O
a	O
collection	O
of	O
ts	O
cmd1	O
mutants	O
for	O
their	O
ability	O
to	O
suppress	O
the	O
actin	O
and	O
/	O
or	O
microtubule	O
defect	O
revealed	O
that	O
the	O
two	O
defects	O
observed	O
in	O
arc35	O
-	O
1	O
are	O
genetically	O
separable	O
.	O

These	O
data	O
suggest	O
that	O
the	O
actin	O
defect	O
is	O
probably	O
not	O
the	O
cause	O
of	O
the	O
microtubule	O
defect	O
.	O

Membrane	O
cofactor	O
protein	O
(	O
MCP	O
;	O
CD46	O
)	O
:	O
isoform	O
-	O
specific	O
tyrosine	O
phosphorylation	O
.	O

Membrane	O
cofactor	O
protein	O
(	O
MCP	O
;	O
CD46	O
)	O
is	O
a	O
widely	O
expressed	O
type	O
1	O
transmembrane	O
glycoprotein	O
that	O
inhibits	O
complement	O
activation	O
on	O
host	O
cells	O
.	O

It	O
also	O
is	O
a	O
receptor	O
for	O
several	O
pathogens	O
including	O
measles	O
virus	O
,	O
Streptococcus	O
pyogenes	O
,	O
Neisseria	O
gonorrhea	O
,	O
and	O
Neisseria	O
meningitidis	O
.	O

That	O
MCP	O
may	O
have	O
signaling	O
capability	O
was	O
suggested	O
by	O
its	O
microbial	O
interactions	O
.	O

That	O
is	O
,	O
binding	O
of	O
MCP	O
on	O
human	O
monocytes	O
by	O
measles	O
virus	O
hemagglutinin	O
or	O
cross	O
-	O
linking	O
by	O
an	O
anti	O
-	O
MCP	O
Ab	O
resulted	O
in	O
IL	B-Complex
-	I-Complex
12	I-Complex
down	O
-	O
regulation	O
,	O
while	O
binding	O
to	O
MCP	O
by	O
Neisseria	O
on	O
epithelial	O
cells	O
produced	O
a	O
calcium	O
flux	O
.	O

Through	O
alternative	O
splicing	O
,	O
MCP	O
is	O
expressed	O
on	O
most	O
cells	O
with	O
two	O
distinct	O
cytoplasmic	O
tails	O
of	O
16	O
(	O
CYT	O
-	O
1	O
)	O
or	O
23	O
(	O
CYT	O
-	O
2	O
)	O
amino	O
acids	O
.	O

These	O
play	O
pivotal	O
roles	O
in	O
intracellular	O
precursor	O
processing	O
and	O
basolateral	O
localization	O
.	O

We	O
investigated	O
the	O
putative	O
signal	O
transduction	O
pathway	O
mediated	O
by	O
MCP	O
and	O
demonstrate	O
that	O
CYT	O
-	O
2	O
,	O
but	O
not	O
CYT	O
-	O
1	O
,	O
is	O
phosphorylated	O
on	O
tyrosine	O
.	O

We	O
examined	O
MCP	O
tail	O
peptides	O
and	O
performed	O
Ab	O
cross	O
-	O
linking	O
experiments	O
on	O
several	O
human	O
cell	O
lines	O
and	O
MCP	O
isoform	O
transfectants	O
.	O

We	O
found	O
an	O
MCP	O
peptide	O
of	O
CYT	O
-	O
2	O
was	O
phosphorylated	O
by	O
a	O
src	O
kinase	O
system	O
.	O

Western	O
blots	O
of	O
the	O
cells	O
lines	O
demonstrated	O
that	O
cells	O
bearing	O
CYT	O
-	O
2	O
were	O
also	O
phosphorylated	O
on	O
tyrosine	O
.	O

Additionally	O
,	O
we	O
provide	O
genetic	O
and	O
biochemical	O
evidence	O
that	O
the	O
src	O
family	O
of	O
kinases	O
is	O
responsible	O
for	O
the	O
latter	O
phosphorylation	O
events	O
.	O

In	O
particular	O
,	O
the	O
src	O
kinase	O
,	O
Lck	O
,	O
is	O
required	O
for	O
phosphorylation	O
of	O
MCP	O
in	O
the	O
Jurkat	O
T	O
cell	O
line	O
.	O

Taken	O
together	O
,	O
these	O
studies	O
suggest	O
a	O
src	O
family	O
-	O
dependent	O
pathway	O
for	O
signaling	O
through	O
MCP	O
.	O

PILRalpha	O
,	O
a	O
novel	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibitory	O
motif	O
-	O
bearing	O
protein	O
,	O
recruits	O
SHP	O
-	O
1	O
upon	O
tyrosine	O
phosphorylation	O
and	O
is	O
paired	O
with	O
the	O
truncated	O
counterpart	O
PILRbeta	O
.	O

SHP	O
-	O
1	O
-	O
mediated	O
dephosphorylation	O
of	O
protein	O
tyrosine	O
residues	O
is	O
central	O
to	O
the	O
regulation	O
of	O
several	O
cell	O
signaling	O
pathways	O
,	O
the	O
specificity	O
of	O
which	O
is	O
dictated	O
by	O
the	O
intrinsic	O
affinity	O
of	O
SH2	O
domains	O
for	O
the	O
flanking	O
sequences	O
of	O
phosphotyrosine	O
residues	O
.	O

By	O
using	O
a	O
modified	O
yeast	O
two	O
-	O
hybrid	O
system	O
and	O
SHP	O
-	O
1	O
as	O
bait	O
,	O
we	O
have	O
cloned	O
a	O
human	O
cDNA	O
,	O
PILRalpha	O
,	O
encoding	O
a	O
303	O
-	O
amino	O
acid	O
immunoglobulin	O
-	O
like	O
transmembrane	O
receptor	O
bearing	O
two	O
cytoplasmic	O
tyrosines	O
positioned	O
within	O
an	O
immunoreceptor	O
tyrosine	O
-	O
based	O
inhibitory	O
motif	O
.	O

Substrate	O
trapping	O
in	O
combination	O
with	O
pervanadate	O
treatment	O
of	O
293T	O
cells	O
confirms	O
that	O
PILRalpha	O
associates	O
with	O
SHP	O
-	O
1	O
in	O
vivo	O
upon	O
tyrosine	O
phosphorylation	O
.	O

Mutation	O
of	O
the	O
tyrosine	O
residues	O
in	O
PILRalpha	O
indicates	O
the	O
pivotal	O
role	O
of	O
the	O
Tyr	O
-	O
269	O
residue	O
in	O
recruiting	O
SHP	O
-	O
1	O
.	O

Surface	O
plasmon	O
resonance	O
analysis	O
further	O
suggests	O
that	O
the	O
association	O
between	O
PILRalpha	O
-	O
Tyr	O
-	O
269	O
and	O
SHP	O
-	O
1	O
is	O
mediated	O
primarily	O
via	O
the	O
amino	O
-	O
terminal	O
SH2	O
domain	O
of	O
the	O
latter	O
.	O

Polymerase	O
chain	O
reaction	O
amplification	O
of	O
cDNA	O
in	O
combination	O
with	O
genomic	O
sequence	O
analysis	O
revealed	O
a	O
second	O
gene	O
,	O
PILRbeta	O
,	O
coding	O
for	O
a	O
putative	O
activating	O
receptor	O
as	O
suggested	O
by	O
a	O
truncated	O
cytoplasmic	O
tail	O
and	O
a	O
charged	O
lysine	O
residue	O
in	O
its	O
transmembrane	O
region	O
.	O

The	O
PILRalpha	O
and	O
PILRbeta	O
genes	O
are	O
localized	O
to	O
chromosome	O
7	O
which	O
is	O
in	O
contrast	O
with	O
the	O
mapping	O
of	O
known	O
members	O
of	O
the	O
inhibitory	O
receptor	O
superfamily	O
.	O

pannier	O
acts	O
upstream	O
of	O
wingless	O
to	O
direct	O
dorsal	O
eye	O
disc	O
development	O
in	O
Drosophila	O
.	O

The	O
dorsoventral	O
midline	O
of	O
the	O
Drosophila	O
eye	O
disc	O
is	O
a	O
source	O
of	O
signals	O
that	O
stimulate	O
growth	O
of	O
the	O
eye	O
disc	O
,	O
define	O
the	O
point	O
at	O
which	O
differentiation	O
initiates	O
,	O
and	O
direct	O
ommatidial	O
rotation	O
in	O
opposite	O
directions	O
in	O
the	O
two	O
halves	O
of	O
the	O
eye	O
disc	O
.	O

This	O
boundary	O
region	O
seems	O
to	O
be	O
established	O
by	O
the	O
genes	O
of	O
the	O
iroquois	O
complex	O
,	O
which	O
are	O
expressed	O
in	O
the	O
dorsal	O
half	O
of	O
the	O
disc	O
and	O
inhibit	O
fringe	O
expression	O
there	O
.	O

Fringe	O
controls	O
the	O
activation	O
of	O
Notch	O
and	O
the	O
expression	O
of	O
its	O
ligands	O
,	O
with	O
the	O
result	O
that	O
Notch	O
is	O
activated	O
only	O
at	O
the	O
fringe	O
expression	O
boundary	O
at	O
the	O
midline	O
.	O

The	O
secreted	O
protein	O
Wingless	O
activates	O
the	O
dorsal	O
expression	O
of	O
the	O
iroquois	O
genes	O
.	O

We	O
show	O
here	O
that	O
pannier	O
,	O
which	O
encodes	O
a	O
GATA	O
family	O
transcription	O
factor	O
expressed	O
at	O
the	O
dorsal	O
margin	O
of	O
the	O
eye	O
disc	O
from	O
embryonic	O
stages	O
on	O
,	O
acts	O
upstream	O
of	O
wingless	O
to	O
control	O
mirror	O
and	O
fringe	O
expression	O
and	O
establish	O
the	O
dorsoventral	O
boundary	O
.	O

Loss	O
of	O
pannier	O
function	O
leads	O
to	O
the	O
formation	O
of	O
an	O
ectopic	O
eye	O
field	O
and	O
the	O
reorganization	O
of	O
ommatidial	O
polarity	O
,	O
and	O
ubiquitous	O
pannier	O
expression	O
can	O
abolish	O
the	O
eye	O
field	O
.	O

Pannier	O
is	O
thus	O
the	O
most	O
upstream	O
element	O
yet	O
described	O
in	O
dorsoventral	O
patterning	O
of	O
the	O
eye	O
disc	O
.	O

Disrupting	O
the	O
geranylgeranylation	O
at	O
the	O
C	O
-	O
termini	O
of	O
the	O
shrimp	O
Ras	O
by	O
depriving	O
guanine	O
nucleotide	O
binding	O
at	O
the	O
N	O
-	O
terminal	O
.	O

In	O
order	O
to	O
assess	O
the	O
effects	O
of	O
guanine	O
nucleotide	O
binding	O
on	O
the	O
geranylgeranylation	O
at	O
the	O
CAAX	O
box	O
of	O
the	O
shrimp	O
Ras	O
,	O
we	O
experimented	O
with	O
the	O
shrimp	O
Penaeus	O
japonicus	O
Ras	O
(	O
S	O
-	O
Ras	O
)	O
which	O
is	O
geranylgeranylated	O
at	O
the	O
C	O
-	O
termini	O
,	O
shares	O
85	O
%	O
homology	O
with	O
mammalian	O
K	O
(	O
B	O
)	O
-	O
Ras	O
protein	O
and	O
demonstrates	O
identity	O
in	O
the	O
guanine	O
nucleotide	O
binding	O
domains	O
(	O
Huang	O
C	O
-	O
F	O
,	O
Chuang	O
N	O
-	O
N	O
.	O
1999	O
.	O
J	O
Exp	O
Zool	O
283	O
:	O
510	O
-	O
521	O
)	O
.	O

Several	O
point	O
mutations	O
in	O
the	O
S	O
-	O
ras	O
gene	O
were	O
generated	O
at	O
codons	O
12	O
(	O
G12V	O
)	O
,	O
61	O
(	O
Q61K	O
)	O
,	O
and	O
116	O
(	O
N116I	O
)	O
.	O

The	O
bacterially	O
expressed	O
mutant	O
S	O
-	O
Ras	O
proteins	O
,	O
G12V	O
and	O
Q61K	O
,	O
were	O
bound	O
with	O
GTP	O
without	O
hydrolysis	O
.	O

In	O
contrast	O
,	O
the	O
mutant	O
S	O
-	O
Ras	O
N116I	O
was	O
defective	O
in	O
its	O
ability	O
to	O
bind	O
any	O
guanine	O
nucleotides	O
.	O

Autoradiography	O
studies	O
showed	O
that	O
the	O
purified	O
shrimp	O
protein	O
geranylgeranyltransferase	B-Complex
I	I-Complex
(	O
Lin	O
R	O
-	O
S	O
,	O
Chuang	O
N	O
-	O
N	O
.	O
1998	O
.	O
J	O
Exp	O
Zool	O
281	O
:	O
565	O
-	O
573	O
)	O
was	O
unable	O
to	O
catalyze	O
the	O
transfer	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
-	O
geranylgeranylpyrophosphate	O
to	O
this	O
mutant	O
N116I	O
but	O
very	O
competently	O
caused	O
the	O
geranylgeranylation	O
of	O
GTP	O
-	O
locked	O
mutants	O
,	O
G12V	O
and	O
Q61K	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
geranylgeranylation	O
at	O
the	O
CAAX	O
box	O
of	O
the	O
shrimp	O
Ras	O
protein	O
requires	O
the	O
proper	O
binding	O
of	O
guanine	O
nucleotide	O
at	O
its	O
N	O
-	O
terminal	O
region	O
.	O

J	O
.	O

Exp	O
.	O

Zool	O
.	O

286	O
:	O
441	O
-	O
449	O
,	O
2000	O
.	O

Interleukin	O
(	O
IL	O
)	O
-	O
7	O
induces	O
rapid	O
activation	O
of	O
Pyk2	O
,	O
which	O
is	O
bound	O
to	O
Janus	O
kinase	O
1	O
and	O
IL	O
-	O
7Ralpha	O
.	O

Interleukin	O
-	O
7	O
(	O
IL	O
-	O
7	O
)	O
receptor	O
signaling	O
begins	O
with	O
activation	O
of	O
the	O
Janus	O
tyrosine	O
kinases	O
Jak1	O
and	O
Jak3	O
,	O
which	O
are	O
associated	O
with	O
the	O
receptor	O
complex	O
.	O

To	O
identify	O
potential	O
targets	O
of	O
these	O
kinases	O
,	O
we	O
examined	O
Pyk2	O
(	O
a	O
member	O
of	O
the	O
focal	O
adhesion	O
kinase	O
family	O
)	O
using	O
an	O
IL	O
-	O
7	O
-	O
dependent	O
murine	O
thymocyte	O
line	O
,	O
D1	O
.	O

We	O
demonstrate	O
that	O
stimulation	O
of	O
D1	O
(	O
or	O
normal	O
pro	O
-	O
T	O
)	O
cells	O
by	O
IL	O
-	O
7	O
rapidly	O
increased	O
tyrosine	O
phosphorylation	O
and	O
enzymatic	O
activity	O
of	O
Pyk2	O
,	O
with	O
kinetics	O
slightly	O
lagging	O
that	O
of	O
Jak1	O
and	O
Jak3	O
phosphorylation	O
.	O

Conversely	O
,	O
IL	O
-	O
7	O
withdrawal	O
resulted	O
in	O
a	O
marked	O
decrease	O
of	O
Pyk2	O
phosphorylation	O
.	O

Pyk2	O
was	O
found	O
to	O
be	O
physically	O
associated	O
with	O
Jak1	O
prior	O
to	O
IL	O
-	O
7	O
stimulation	O
and	O
to	O
increase	O
its	O
association	O
with	O
IL	O
-	O
7Ralpha	O
chain	O
following	O
IL	O
-	O
7	O
stimulation	O
.	O

Pyk2	O
appeared	O
to	O
be	O
involved	O
in	O
cell	O
survival	O
,	O
because	O
antisense	O
Pyk2	O
accelerated	O
the	O
cell	O
death	O
process	O
.	O

Activation	O
of	O
Pyk2	O
via	O
the	O
muscarinic	O
and	O
nicotinic	O
receptors	O
using	O
carbachol	O
or	O
via	O
intracellular	O
Ca	O
(	O
2	O
+	O
)	O
rise	O
using	O
ionomycin	O
/	O
phorbol	O
myristate	O
acetate	O
promoted	O
survival	O
in	O
the	O
absence	O
of	O
IL	O
-	O
7	O
.	O

These	O
data	O
support	O
a	O
role	O
for	O
Pyk2	O
in	O
coupling	O
Jak	O
signaling	O
to	O
the	O
trophic	O
response	O
.	O

The	O
retinoblastoma	O
-	O
interacting	O
zinc	O
-	O
finger	O
protein	O
RIZ	O
is	O
a	O
downstream	O
effector	O
of	O
estrogen	O
action	O
.	O

Co	O
-	O
immunoprecipitation	O
experiments	O
in	O
cell	O
extract	O
from	O
cultured	O
cells	O
or	O
target	O
tissues	O
indicated	O
that	O
estrogen	O
receptor	O
was	O
complexed	O
with	O
the	O
retinoblastoma	O
binding	O
protein	O
RIZ	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
.	O

Mapping	O
of	O
interaction	O
sites	O
indicated	O
that	O
in	O
both	O
proteins	O
the	O
same	O
regions	O
and	O
motifs	O
responsible	O
for	O
the	O
interaction	O
of	O
transcriptional	O
co	O
-	O
activator	O
and	O
nuclear	O
receptors	O
were	O
involved	O
.	O

In	O
cultured	O
cells	O
,	O
estradiol	O
induced	O
a	O
redistribution	O
of	O
RIZ	O
protein	O
within	O
the	O
nucleus	O
and	O
in	O
the	O
cytoplasm	O
.	O

A	O
similar	O
effect	O
was	O
produced	O
in	O
vivo	O
,	O
in	O
prepuberal	O
rat	O
endometrium	O
,	O
by	O
administration	O
of	O
a	O
physiological	O
dose	O
of	O
estradiol	O
.	O

Therefore	O
,	O
RIZ	O
protein	O
could	O
be	O
a	O
specific	O
effector	O
of	O
estrogen	O
action	O
downstream	O
of	O
the	O
hormone	O
-	O
receptor	O
interaction	O
,	O
presumably	O
involved	O
in	O
proliferation	O
control	O
.	O

A	O
protein	O
complex	O
containing	O
Inscuteable	O
and	O
the	O
Galpha	O
-	O
binding	O
protein	O
Pins	O
orients	O
asymmetric	O
cell	O
divisions	O
in	O
Drosophila	O
.	O

BACKGROUND	O
:	O
In	O
the	O
fruit	O
fly	O
Drosophila	O
,	O
the	O
Inscuteable	O
protein	O
localises	O
to	O
the	O
apical	O
cell	O
cortex	O
in	O
neuroblasts	O
and	O
directs	O
both	O
the	O
apical	O
-	O
basal	O
orientation	O
of	O
the	O
mitotic	O
spindle	O
and	O
the	O
basal	O
localisation	O
of	O
the	O
protein	O
determinants	O
Numb	O
and	O
Prospero	O
during	O
mitosis	O
.	O

Asymmetric	O
localisation	O
of	O
Inscuteable	O
is	O
initiated	O
during	O
neuroblast	O
delamination	O
by	O
direct	O
binding	O
to	O
Bazooka	O
,	O
an	O
apically	O
localised	O
protein	O
that	O
contains	O
protein	O
-	O
interaction	O
motifs	O
known	O
as	O
PDZ	O
domains	O
.	O

How	O
apically	O
localised	O
Inscuteable	O
directs	O
asymmetric	O
cell	O
divisions	O
is	O
unclear	O
.	O

RESULTS	O
:	O
A	O
novel	O
70	O
kDa	O
protein	O
called	O
Partner	O
of	O
Inscuteable	O
(	O
Pins	O
)	O
and	O
a	O
heterotrimeric	O
G	O
-	O
protein	O
alpha	O
subunit	O
were	O
found	O
to	O
bind	O
specifically	O
to	O
the	O
functional	O
domain	O
of	O
Inscuteable	O
in	O
vivo	O
.	O

The	O
predicted	O
sequence	O
of	O
Pins	O
contained	O
tetratrico	O
-	O
peptide	O
repeats	O
(	O
TPRs	O
)	O
and	O
motifs	O
implicated	O
in	O
binding	O
Galpha	O
proteins	O
.	O

Pins	O
colocalised	O
with	O
Inscuteable	O
at	O
the	O
apical	O
cell	O
cortex	O
in	O
interphase	O
and	O
mitotic	O
neuroblasts	O
.	O

Asymmetric	O
localisation	O
of	O
Pins	O
required	O
both	O
Inscuteable	O
and	O
Bazooka	O
.	O

In	O
epithelial	O
cells	O
,	O
which	O
do	O
not	O
express	O
inscuteable	O
,	O
Pins	O
was	O
not	O
apically	O
localised	O
but	O
could	O
be	O
recruited	O
to	O
the	O
apical	O
cortex	O
by	O
ectopic	O
expression	O
of	O
Inscuteable	O
.	O

In	O
pins	O
mutants	O
,	O
these	O
epithelial	O
cells	O
were	O
not	O
affected	O
,	O
but	O
neuroblasts	O
showed	O
defects	O
in	O
the	O
orientation	O
of	O
their	O
mitotic	O
spindle	O
and	O
the	O
basal	O
asymmetric	O
localisation	O
of	O
Numb	O
and	O
Miranda	O
during	O
metaphase	O
.	O

Although	O
localisation	O
of	O
Inscuteable	O
in	O
pins	O
mutants	O
was	O
initiated	O
correctly	O
during	O
neuroblast	O
delamination	O
,	O
Inscuteable	O
became	O
homogeneously	O
distributed	O
in	O
the	O
cytoplasm	O
during	O
mitosis	O
.	O

CONCLUSIONS	O
:	O
Pins	O
and	O
Inscuteable	O
are	O
dependent	O
on	O
each	O
other	O
for	O
asymmetric	O
localisation	O
in	O
delaminated	O
neuroblasts	O
.	O

The	O
binding	O
of	O
Pins	O
to	O
Galpha	O
protein	O
offers	O
the	O
intriguing	O
possibility	O
that	O
Inscuteable	O
and	O
Pins	O
might	O
orient	O
asymmetric	O
cell	O
divisions	O
by	O
localising	O
or	O
locally	O
modulating	O
a	O
heterotrimeric	O
G	O
-	O
protein	O
signalling	O
cascade	O
at	O
the	O
apical	O
cell	O
cortex	O
.	O

A	O
murine	O
ATFa	O
-	O
associated	O
factor	O
with	O
transcriptional	O
repressing	O
activity	O
.	O

The	O
ATFa	O
proteins	O
,	O
which	O
are	O
members	O
of	O
the	O
CREB	O
/	O
ATF	O
family	O
of	O
transcription	O
factors	O
,	O
have	O
previously	O
been	O
shown	O
to	O
interact	O
with	O
the	O
adenovirus	O
E1a	O
oncoprotein	O
and	O
to	O
mediate	O
its	O
transcriptional	O
activity	O
;	O
they	O
heterodimerize	O
with	O
Jun	O
,	O
Fos	O
or	O
related	O
transcription	O
factors	O
,	O
possibly	O
altering	O
their	O
DNA	O
-	O
binding	O
specificity	O
;	O
they	O
also	O
stably	O
bind	O
JNK2	O
,	O
a	O
stress	O
-	O
induced	O
protein	O
kinase	O
.	O

Here	O
we	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
a	O
novel	O
protein	O
isolated	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
using	O
the	O
N	O
-	O
terminal	O
half	O
of	O
ATFa	O
as	O
a	O
bait	O
.	O

This	O
1306	O
-	O
residue	O
protein	O
(	O
mAM	O
,	O
for	O
mouse	O
ATFa	O
-	O
associated	O
Modulator	O
)	O
is	O
rather	O
acidic	O
(	O
pHi	O
4	O
.	O
5	O
)	O
and	O
contains	O
high	O
proportions	O
of	O
Ser	O
/	O
Thr	O
(	O
21	O
%	O
)	O
and	O
Pro	O
(	O
11	O
%	O
)	O
residues	O
.	O

It	O
colocalizes	O
and	O
interacts	O
with	O
ATFa	O
in	O
mammalian	O
cells	O
,	O
contains	O
a	O
bipartite	O
nuclear	O
localization	O
signal	O
and	O
possesses	O
an	O
ATPase	O
activity	O
.	O

Transfection	O
experiments	O
show	O
that	O
mAM	O
is	O
able	O
to	O
downregulate	O
transcriptional	O
activity	O
,	O
in	O
an	O
ATPase	O
-	O
independent	O
manner	O
.	O

Our	O
results	O
indicate	O
that	O
mAM	O
interacts	O
with	O
several	O
components	O
of	O
the	O
basal	O
transcription	O
machinery	O
(	O
TFIIE	B-Complex
and	O
TFIIH	B-Complex
)	O
,	O
including	O
RNAPII	O
itself	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
mAM	O
may	O
be	O
involved	O
in	O
the	O
fine	O
-	O
tuning	O
of	O
ATFa	O
-	O
regulated	O
gene	O
expression	O
,	O
by	O
interfering	O
with	O
the	O
assembly	O
or	O
stability	O
of	O
specific	O
preinitiation	O
transcription	O
complexes	O
.	O

A	O
Nedd8	O
conjugation	O
pathway	O
is	O
essential	O
for	O
proteolytic	O
targeting	O
of	O
p27Kip1	O
by	O
ubiquitination	O
.	O

Temporal	O
control	O
of	O
p27	O
(	O
Kip1	O
)	O
(	O
p27	O
)	O
degradation	O
imposes	O
periodicity	O
in	O
its	O
activity	O
during	O
cell	O
cycle	O
progression	O
and	O
its	O
accumulation	O
during	O
cell	O
cycle	O
exit	O
.	O

Degradation	O
of	O
p27	O
is	O
initiated	O
by	O
phosphorylation	O
of	O
p27	O
at	O
Thr	O
-	O
187	O
,	O
which	O
marks	O
the	O
protein	O
for	O
ubiquitination	O
by	O
SCF	B-Complex
(	I-Complex
Skp2	I-Complex
)	I-Complex
and	O
subsequent	O
proteolysis	O
by	O
the	O
26S	B-Complex
proteasome	I-Complex
.	O

Here	O
we	O
show	O
that	O
the	O
p27	O
ubiquitination	O
activity	O
in	O
cell	O
extracts	O
depends	O
on	O
the	O
presence	O
of	O
the	O
ubiquitin	O
-	O
like	O
protein	O
Nedd8	O
and	O
enzymes	O
that	O
catalyze	O
Nedd8	O
conjugation	O
to	O
proteins	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
reconstitution	O
of	O
the	O
p27	O
ubiquitination	O
activity	O
of	O
recombinant	O
SCF	B-Complex
(	I-Complex
Skp2	I-Complex
)	I-Complex
also	O
requires	O
Nedd8	O
conjugation	O
pathway	O
components	O
.	O

Inactivation	O
of	O
the	O
Nedd8	O
conjugation	O
pathway	O
by	O
a	O
dominant	O
negative	O
mutant	O
of	O
the	O
Nedd8	O
-	O
conjugating	O
enzyme	O
Nce1	O
/	O
Ubc12	O
blocks	O
the	O
ubiquitination	O
and	O
degradation	O
of	O
p27	O
in	O
cell	O
extracts	O
.	O

Consistent	O
with	O
a	O
role	O
in	O
cell	O
-	O
cycle	O
progression	O
,	O
Nedd8	O
is	O
expressed	O
in	O
proliferating	O
cells	O
and	O
is	O
itself	O
down	O
-	O
regulated	O
upon	O
cellular	O
differentiation	O
.	O

These	O
results	O
suggest	O
that	O
the	O
Nedd8	O
conjugation	O
pathway	O
may	O
regulate	O
the	O
turnover	O
of	O
p27	O
(	O
Kip1	O
)	O
,	O
independently	O
of	O
p27	O
phosphorylation	O
,	O
and	O
further	O
establishes	O
the	O
identity	O
of	O
protein	O
components	O
involved	O
in	O
p27	O
ubiquitination	O
.	O

Finally	O
,	O
these	O
findings	O
provide	O
a	O
direct	O
demonstration	O
of	O
a	O
function	O
for	O
Nedd8	O
in	O
a	O
biological	O
process	O
.	O

Identification	O
of	O
a	O
novel	O
chemokine	O
(	O
CCL28	O
)	O
,	O
which	O
binds	O
CCR10	O
(	O
GPR2	O
)	O
.	O

We	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
a	O
novel	O
CC	O
chemokine	O
designated	O
CCL28	O
and	O
its	O
receptor	O
CCR10	O
,	O
known	O
previously	O
as	O
orphan	O
G	O
-	O
protein	O
-	O
coupled	O
receptor	O
GPR2	O
.	O

Human	O
and	O
mouse	O
CCL28	O
share	O
83	O
%	O
identity	O
at	O
the	O
amino	O
acid	O
and	O
76	O
%	O
at	O
the	O
nucleic	O
acid	O
levels	O
.	O

We	O
also	O
identified	O
the	O
mouse	O
homologues	O
of	O
CCL28	O
and	O
of	O
CCR10	O
,	O
which	O
map	O
to	O
mouse	O
chromosomes	O
13	O
and	O
11	O
,	O
respectively	O
.	O

CCL28	O
is	O
expressed	O
in	O
a	O
variety	O
of	O
human	O
and	O
mouse	O
tissues	O
,	O
and	O
it	O
appears	O
to	O
be	O
predominantly	O
produced	O
by	O
epithelial	O
cells	O
.	O

Both	O
human	O
and	O
mouse	O
CCL28	O
induce	O
calcium	O
mobilization	O
in	O
human	O
and	O
mouse	O
CCR10	O
-	O
expressing	O
transfectants	O
.	O

CCL28	O
desensitized	O
the	O
calcium	O
mobilization	O
induced	O
in	O
CCR10	O
transfectants	O
by	O
CCL27	O
,	O
indicating	O
that	O
these	O
chemokines	O
share	O
this	O
new	O
chemokine	O
receptor	O
.	O

In	O
vitro	O
,	O
recombinant	O
human	O
CCL28	O
displays	O
chemotactic	O
activity	O
for	O
resting	O
CD4	O
or	O
CD8	O
T	O
cells	O
.	O

Structure	O
-	O
function	O
relationships	O
in	O
yeast	O
tubulins	O
.	O

A	O
comprehensive	O
set	O
of	O
clustered	O
charged	O
-	O
to	O
-	O
alanine	O
mutations	O
was	O
generated	O
that	O
systematically	O
alter	O
TUB1	O
,	O
the	O
major	O
alpha	O
-	O
tubulin	O
gene	O
of	O
Saccharomyces	O
cerevisiae	O
.	O

A	O
variety	O
of	O
phenotypes	O
were	O
observed	O
,	O
including	O
supersensitivity	O
and	O
resistance	O
to	O
the	O
microtubule	O
-	O
destabilizing	O
drug	O
benomyl	O
,	O
lethality	O
,	O
and	O
cold	O
-	O
and	O
temperature	O
-	O
sensitive	O
lethality	O
.	O

Many	O
of	O
the	O
most	O
benomyl	O
-	O
sensitive	O
tub1	O
alleles	O
were	O
synthetically	O
lethal	O
in	O
combination	O
with	O
tub3Delta	O
,	O
supporting	O
the	O
idea	O
that	O
benomyl	O
supersensitivity	O
is	O
a	O
rough	O
measure	O
of	O
microtubule	O
instability	O
and	O
/	O
or	O
insufficiency	O
in	O
the	O
amount	O
of	O
alpha	O
-	O
tubulin	O
.	O

The	O
systematic	O
tub1	O
mutations	O
were	O
placed	O
,	O
along	O
with	O
the	O
comparable	O
set	O
of	O
tub2	O
mutations	O
previously	O
described	O
,	O
onto	O
a	O
model	O
of	O
the	O
yeast	O
alpha	O
-	O
beta	O
-	O
tubulin	O
dimer	O
based	O
on	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
bovine	O
tubulin	O
.	O

The	O
modeling	O
revealed	O
a	O
potential	O
site	O
for	O
binding	O
of	O
benomyl	O
in	O
the	O
core	O
of	O
beta	O
-	O
tubulin	O
.	O

Residues	O
whose	O
mutation	O
causes	O
cold	O
sensitivity	O
were	O
concentrated	O
at	O
the	O
lateral	O
and	O
longitudinal	O
interfaces	O
between	O
adjacent	O
subunits	O
.	O

Residues	O
that	O
affect	O
binding	O
of	O
the	O
microtubule	O
-	O
binding	O
protein	O
Bim1p	O
form	O
a	O
large	O
patch	O
across	O
the	O
exterior	O
-	O
facing	O
surface	O
of	O
alpha	O
-	O
tubulin	O
in	O
the	O
model	O
.	O

Finally	O
,	O
the	O
positions	O
of	O
the	O
mutations	O
suggest	O
that	O
proximity	O
to	O
the	O
alpha	O
-	O
beta	O
interface	O
may	O
account	O
for	O
the	O
finding	O
of	O
synthetic	O
lethality	O
of	O
five	O
viable	O
tub1	O
alleles	O
with	O
the	O
benomyl	O
-	O
resistant	O
but	O
otherwise	O
entirely	O
viable	O
tub2	O
-	O
201	O
allele	O
.	O

Hypoxia	O
inducible	O
factor	O
-	O
alpha	O
binding	O
and	O
ubiquitylation	O
by	O
the	O
von	O
Hippel	O
-	O
Lindau	O
tumor	O
suppressor	O
protein	O
.	O

The	O
von	O
Hippel	O
-	O
Lindau	O
tumor	O
suppressor	O
protein	O
(	O
pVHL	O
)	O
has	O
emerged	O
as	O
a	O
key	O
factor	O
in	O
cellular	O
responses	O
to	O
oxygen	O
availability	O
,	O
being	O
required	O
for	O
the	O
oxygen	O
-	O
dependent	O
proteolysis	O
of	O
alpha	O
subunits	O
of	O
hypoxia	B-Complex
inducible	I-Complex
factor	I-Complex
-	I-Complex
1	I-Complex
(	O
HIF	O
)	O
.	O

Mutations	O
in	O
VHL	O
cause	O
a	O
hereditary	O
cancer	O
syndrome	O
associated	O
with	O
dysregulated	O
angiogenesis	O
,	O
and	O
up	O
-	O
regulation	O
of	O
hypoxia	O
inducible	O
genes	O
.	O

Here	O
we	O
investigate	O
the	O
mechanisms	O
underlying	O
these	O
processes	O
and	O
show	O
that	O
extracts	O
from	O
VHL	O
-	O
deficient	O
renal	O
carcinoma	O
cells	O
have	O
a	O
defect	O
in	O
HIF	O
-	O
alpha	O
ubiquitylation	O
activity	O
which	O
is	O
complemented	O
by	O
exogenous	O
pVHL	O
.	O

This	O
defect	O
was	O
specific	O
for	O
HIF	O
-	O
alpha	O
among	O
a	O
range	O
of	O
substrates	O
tested	O
.	O

Furthermore	O
,	O
HIF	O
-	O
alpha	O
subunits	O
were	O
the	O
only	O
pVHL	O
-	O
associated	O
proteasomal	O
substrates	O
identified	O
by	O
comparison	O
of	O
metabolically	O
labeled	O
anti	O
-	O
pVHL	O
immunoprecipitates	O
from	O
proteosomally	O
inhibited	O
cells	O
and	O
normal	O
cells	O
.	O

Analysis	O
of	O
pVHL	O
/	O
HIF	O
-	O
alpha	O
interactions	O
defined	O
short	O
sequences	O
of	O
conserved	O
residues	O
within	O
the	O
internal	O
transactivation	O
domains	O
of	O
HIF	O
-	O
alpha	O
molecules	O
sufficient	O
for	O
recognition	O
by	O
pVHL	O
.	O

In	O
contrast	O
,	O
while	O
full	O
-	O
length	O
pVHL	O
and	O
the	O
p19	O
variant	O
interact	O
with	O
HIF	O
-	O
alpha	O
,	O
the	O
association	O
was	O
abrogated	O
by	O
further	O
N	O
-	O
terminal	O
and	O
C	O
-	O
terminal	O
truncations	O
.	O

The	O
interaction	O
was	O
also	O
disrupted	O
by	O
tumor	O
-	O
associated	O
mutations	O
in	O
the	O
beta	O
-	O
domain	O
of	O
pVHL	O
and	O
loss	O
of	O
interaction	O
was	O
associated	O
with	O
defective	O
HIF	O
-	O
alpha	O
ubiquitylation	O
and	O
regulation	O
,	O
defining	O
a	O
mechanism	O
by	O
which	O
these	O
mutations	O
generate	O
a	O
constitutively	O
hypoxic	O
pattern	O
of	O
gene	O
expression	O
promoting	O
angiogenesis	O
.	O

The	O
findings	O
indicate	O
that	O
pVHL	O
regulates	O
HIF	O
-	O
alpha	O
proteolysis	O
by	O
acting	O
as	O
the	O
recognition	O
component	O
of	O
a	O
ubiquitin	O
ligase	O
complex	O
,	O
and	O
support	O
a	O
model	O
in	O
which	O
its	O
beta	O
domain	O
interacts	O
with	O
short	O
recognition	O
sequences	O
in	O
HIF	O
-	O
alpha	O
subunits	O
.	O

Ectopic	O
scute	O
induces	O
Drosophila	O
ommatidia	O
development	O
without	O
R8	O
founder	O
photoreceptors	O
.	O

During	O
development	O
of	O
the	O
Drosophila	O
peripheral	O
nervous	O
system	O
,	O
different	O
proneural	O
genes	O
encoding	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
transcription	O
factors	O
are	O
required	O
for	O
different	O
sensory	O
organs	O
to	O
form	O
.	O
atonal	O
(	O
ato	O
)	O
is	O
the	O
proneural	O
gene	O
required	O
for	O
chordotonal	O
organs	O
and	O
R8	O
photoreceptors	O
,	O
whereas	O
the	O
achaete	O
-	O
scute	O
complex	O
contains	O
proneural	O
genes	O
for	O
external	O
sensory	O
organs	O
such	O
as	O
the	O
macrochaetae	O
,	O
large	O
sensory	O
bristles	O
.	O

Whereas	O
ectopic	O
ato	O
expression	O
induces	O
chordotonal	O
organ	O
formation	O
,	O
ectopic	O
scute	O
expression	O
produces	O
external	O
sensory	O
organs	O
but	O
not	O
chordotonal	O
organs	O
in	O
the	O
wing	O
.	O

Proneural	O
genes	O
thus	O
appear	O
to	O
specify	O
the	O
sensory	O
organ	O
type	O
.	O

In	O
the	O
ommatidium	O
,	O
or	O
unit	O
eye	O
,	O
R8	O
is	O
the	O
first	O
photoreceptor	O
to	O
form	O
and	O
appears	O
to	O
recruit	O
other	O
photoreceptors	O
and	O
support	O
cells	O
.	O

In	O
the	O
atonal	O
(	O
1	O
)	O
(	O
ato	O
(	O
1	O
)	O
)	O
mutant	O
,	O
R8	O
photoreceptors	O
fail	O
to	O
form	O
,	O
thereby	O
resulting	O
in	O
the	O
complete	O
absence	O
of	O
ommatidia	O
.	O

To	O
our	O
surprise	O
,	O
we	O
found	O
that	O
ectopic	O
scute	O
expression	O
in	O
the	O
ato	O
(	O
1	O
)	O
mutant	O
induces	O
the	O
formation	O
of	O
ommatidia	O
,	O
which	O
occasionally	O
sprout	O
ectopic	O
macrochaetae	O
.	O

Remarkably	O
,	O
many	O
scute	O
-	O
induced	O
ommatidia	O
lack	O
R8	O
although	O
they	O
contain	O
outer	O
photoreceptors	O
.	O

A	O
dominant	O
-	O
negative	O
UBC12	O
mutant	O
sequesters	O
NEDD8	O
and	O
inhibits	O
NEDD8	O
conjugation	O
in	O
vivo	O
.	O

NEDD8	O
,	O
a	O
novel	O
ubiquitin	O
-	O
like	O
protein	O
,	O
has	O
been	O
shown	O
to	O
conjugate	O
to	O
proteins	O
in	O
a	O
manner	O
analogous	O
to	O
ubiquitination	O
and	O
sentrinization	O
.	O

Recently	O
,	O
human	O
UBC12	O
was	O
identified	O
as	O
a	O
putative	O
NEDD8	O
conjugation	O
enzyme	O
(	O
E2	O
)	O
.	O

While	O
investigating	O
the	O
in	O
vivo	O
function	O
of	O
UBC12	O
,	O
we	O
found	O
that	O
the	O
point	O
mutant	O
,	O
UBC12	O
(	O
C111S	O
)	O
,	O
showed	O
a	O
dominant	O
-	O
negative	O
effect	O
on	O
NEDD8	O
conjugation	O
.	O

This	O
mutant	O
,	O
with	O
a	O
single	O
Cys	O
-	O
to	O
-	O
Ser	O
substitution	O
at	O
the	O
conserved	O
Cys	O
residue	O
in	O
the	O
E2	O
family	O
,	O
could	O
specifically	O
inhibit	O
NEDD8	O
conjugation	O
.	O

We	O
observed	O
the	O
dominant	O
-	O
negative	O
effect	O
on	O
NEDD8	O
conjugation	O
to	O
substrates	O
,	O
including	O
the	O
C	O
-	O
terminal	O
fragment	O
of	O
cullin	O
-	O
2	O
(	O
Cul	O
-	O
2	O
-	O
DeltaN	O
)	O
,	O
full	O
-	O
length	O
cullin	O
-	O
1	O
,	O
and	O
also	O
other	O
uncharacterized	O
target	O
proteins	O
.	O

Interestingly	O
,	O
UBC12	O
(	O
C111S	O
)	O
formed	O
a	O
heterodimeric	O
conjugate	O
with	O
NEDD8	O
.	O

This	O
conjugate	O
was	O
stable	O
under	O
stringent	O
conditions	O
,	O
including	O
6	O
m	O
guanidine	O
HCl	O
,	O
8	O
m	O
urea	O
,	O
2	O
%	O
SDS	O
,	O
or	O
5	O
%	O
beta	O
-	O
mercaptoethanol	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
UBC12	O
(	O
C111S	O
)	O
sequesters	O
the	O
NEDD8	O
monomer	O
by	O
forming	O
a	O
UBC12	O
(	O
C111S	O
)	O
-	O
NEDD8	O
conjugate	O
and	O
,	O
in	O
turn	O
,	O
inhibits	O
the	O
subsequent	O
transfer	O
of	O
NEDD8	O
to	O
its	O
targets	O
.	O

To	O
examine	O
the	O
biological	O
role	O
of	O
NEDD8	O
conjugation	O
,	O
this	O
dominant	O
-	O
negative	O
form	O
of	O
UBC12	O
was	O
applied	O
to	O
a	O
cell	O
growth	O
assay	O
.	O

Overexpression	O
of	O
UBC12	O
(	O
C111S	O
)	O
led	O
to	O
inhibition	O
of	O
growth	O
in	O
U2OS	O
and	O
HEK293	O
cells	O
.	O

Thus	O
,	O
this	O
dominant	O
-	O
negative	O
form	O
of	O
UBC12	O
could	O
be	O
useful	O
in	O
defining	O
the	O
role	O
of	O
NEDD8	O
modification	O
in	O
other	O
biological	O
systems	O
.	O

The	O
finding	O
that	O
JIL	O
-	O
1	O
associates	O
with	O
the	O
MSL	B-Complex
complex	O
is	O
based	O
on	O
physical	O
interaction	O
assays	O
such	O
as	O
coimmunoprecipitation	O
and	O
GST	O
pull	O
-	O
down	O
experiments	O
.	O

These	O
approaches	O
require	O
a	O
fairly	O
stable	O
interaction	O
between	O
JIL	O
-	O
1	O
and	O
the	O
MSL	B-Complex
complex	O
making	O
it	O
unlikely	O
that	O
this	O
association	O
depends	O
on	O
the	O
presence	O
of	O
the	O
roX	O
RNAs	O
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
MLE	O
product	O
that	O
is	O
not	O
found	O
as	O
part	O
of	O
the	O
MSL	B-Complex
complex	O
during	O
chromatographic	O
separation	O
(	O
Copps	O
et	O
al	O
.	O
1998	O
)	O
,	O
a	O
finding	O
consistent	O
with	O
it	O
being	O
the	O
only	O
one	O
of	O
the	O
known	O
MSL	B-Complex
complex	O
proteins	O
to	O
be	O
lost	O
from	O
the	O
male	O
X	O
chromosomes	O
upon	O
treatment	O
with	O
RNase	O
(	O
Richter	O
et	O
al	O
.	O
1996	O
)	O
.	O

Moreover	O
,	O
the	O
finding	O
that	O
addition	O
of	O
GST	O
-	O
JIL	O
-	O
1	O
fusion	O
protein	O
to	O
S2	O
cell	O
extracts	O
can	O
be	O
used	O
to	O
pull	O
down	O
the	O
MSL	B-Complex
complex	O
indicates	O
that	O
this	O
association	O
can	O
occur	O
in	O
vitro	O
and	O
suggests	O
that	O
the	O
JIL	O
-	O
1	O
kinase	O
can	O
interact	O
with	O
the	O
preassembled	O
MSL	B-Complex
complex	O
.	O

However	O
,	O
since	O
this	O
preassembled	O
complex	O
may	O
already	O
contain	O
endogenous	O
JIL	O
-	O
1	O
it	O
does	O
not	O
address	O
whether	O
the	O
formation	O
of	O
the	O
MSL	B-Complex
complex	O
requires	O
the	O
presence	O
of	O
JIL	O
-	O
1	O
protein	O
or	O
whether	O
JIL	O
-	O
1	O
is	O
present	O
in	O
the	O
MSL	B-Complex
complex	O
in	O
stoichiometric	O
amounts	O
.	O

Activation	O
of	O
H	O
-	O
ras61L	O
-	O
specific	O
signaling	O
pathways	O
does	O
not	O
require	O
posttranslational	O
processing	O
of	O
H	O
-	O
ras	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
H	O
-	O
ras61L	O
retained	O
transforming	O
activity	O
when	O
lacking	O
C	O
-	O
terminal	O
lipid	O
modifications	O
,	O
provided	O
that	O
plasma	O
membrane	O
localization	O
was	O
restored	O
by	O
an	O
N	O
-	O
terminal	O
transmembrane	O
domain	O
.	O

Since	O
several	O
ras	O
-	O
activated	O
pathways	O
contribute	O
to	O
the	O
transformed	O
phenotype	O
,	O
we	O
utilized	O
a	O
novel	O
set	O
of	O
transmembrane	O
domain	O
-	O
anchored	O
H	O
-	O
ras	O
derivatives	O
to	O
examine	O
if	O
lipids	O
are	O
required	O
for	O
activation	O
of	O
any	O
specific	O
signaling	O
pathways	O
.	O

We	O
demonstrate	O
here	O
that	O
H	O
-	O
ras61L	O
-	O
induced	O
activation	O
of	O
the	O
Raf	O
/	O
MEK	O
/	O
MAPK	O
pathway	O
,	O
including	O
recruitment	O
of	O
Raf	O
to	O
the	O
plasma	O
membrane	O
and	O
activation	O
of	O
Raf	O
and	O
MAPK	O
,	O
does	O
not	O
require	O
C	O
-	O
terminal	O
processing	O
of	O
H	O
-	O
ras61L	O
.	O

Biochemical	O
fractionation	O
experiments	O
confirm	O
the	O
localization	O
of	O
TM	O
-	O
ras	O
derivatives	O
to	O
the	O
plasma	O
membrane	O
,	O
as	O
well	O
as	O
the	O
ras	O
-	O
mediated	O
recruitment	O
of	O
c	O
-	O
Raf	O
-	O
1	O
.	O

Changes	O
in	O
the	O
actin	O
cytoskeleton	O
,	O
controlled	O
by	O
H	O
-	O
ras61L	O
-	O
mediated	O
activation	O
of	O
the	O
Rac	O
/	O
Rho	O
pathway	O
,	O
as	O
well	O
as	O
PI	O
3	O
-	O
kinase	O
activation	O
,	O
can	O
also	O
occur	O
in	O
the	O
absence	O
of	O
C	O
-	O
terminal	O
lipid	O
modifications	O
.	O

Finally	O
,	O
downstream	O
events	O
,	O
such	O
as	O
the	O
induction	O
of	O
the	O
immediate	O
-	O
early	O
gene	O
c	O
-	O
fos	O
or	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
,	O
are	O
stimulated	O
by	O
the	O
expression	O
of	O
plasma	O
membrane	O
-	O
anchored	O
,	O
nonlipidated	O
H	O
-	O
ras6lL	O
.	O

These	O
results	O
demonstrate	O
that	O
H	O
-	O
ras	O
can	O
be	O
functionally	O
targeted	O
to	O
the	O
plasma	O
membrane	O
using	O
a	O
transmembrane	O
domain	O
sequence	O
and	O
that	O
several	O
signal	O
transduction	O
pathways	O
downstream	O
of	O
H	O
-	O
ras	O
can	O
be	O
activated	O
without	O
the	O
presence	O
of	O
normal	O
lipid	O
modifications	O
.	O

Multiple	O
aspects	O
of	O
Rab	O
protein	O
action	O
in	O
the	O
secretory	O
pathway	O
:	O
focus	O
on	O
Rab3	O
and	O
Rab6	O
.	O

Rab	O
proteins	O
form	O
the	O
largest	O
branch	O
of	O
the	O
Ras	O
superfamily	O
of	O
GTPases	O
.	O

They	O
are	O
localized	O
to	O
the	O
cytoplasmic	O
face	O
of	O
organelles	O
and	O
vesicles	O
involved	O
in	O
the	O
biosynthetic	O
/	O
secretory	O
and	O
endocytic	O
pathways	O
in	O
eukaryotic	O
cells	O
.	O

It	O
is	O
now	O
well	O
established	O
that	O
Rab	O
proteins	O
play	O
an	O
essential	O
role	O
in	O
the	O
processes	O
that	O
underlie	O
the	O
targeting	O
and	O
fusion	O
of	O
transport	O
vesicles	O
with	O
their	O
appropriate	O
acceptor	O
membranes	O
.	O

They	O
perform	O
this	O
task	O
through	O
interactions	O
with	O
a	O
wide	O
variety	O
of	O
effector	O
molecules	O
.	O

In	O
this	O
review	O
,	O
we	O
illustrate	O
recent	O
advances	O
in	O
the	O
field	O
of	O
Rab	O
GTPases	O
,	O
taking	O
as	O
examples	O
two	O
proteins	O
involved	O
in	O
the	O
biosynthetic	O
pathway	O
,	O
Rab3	O
and	O
Rab6	O
.	O

PQBP	O
-	O
1	O
/	O
Npw38	O
,	O
a	O
nuclear	O
protein	O
binding	O
to	O
the	O
polyglutamine	O
tract	O
,	O
interacts	O
with	O
U5	O
-	O
15kD	O
/	O
dim1p	O
via	O
the	O
carboxyl	O
-	O
terminal	O
domain	O
.	O

PQBP	O
-	O
1	O
was	O
identified	O
as	O
a	O
binding	O
protein	O
to	O
the	O
polyglutamine	O
tract	O
present	O
in	O
various	O
transcription	O
-	O
related	O
factors	O
and	O
causative	O
genes	O
for	O
neurodegenerative	O
disorders	O
.	O

This	O
novel	O
gene	O
contains	O
at	O
least	O
two	O
functional	O
domains	O
,	O
WW	O
domain	O
and	O
carboxyl	O
-	O
terminal	O
domain	O
(	O
CTD	O
)	O
,	O
strictly	O
conserved	O
beyond	O
species	O
.	O

Although	O
human	O
PQBP	O
-	O
1	O
additionally	O
contains	O
the	O
polar	O
amino	O
acid	O
-	O
rich	O
domain	O
by	O
which	O
it	O
binds	O
to	O
the	O
polyglutamine	O
tract	O
,	O
genuine	O
physiological	O
function	O
(	O
s	O
)	O
have	O
not	O
been	O
clarified	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
U5	O
-	O
15kD	O
,	O
human	O
homologue	O
of	O
fission	O
yeast	O
dim1p	O
,	O
is	O
a	O
partner	O
molecule	O
of	O
PQBP	O
-	O
1	O
binding	O
to	O
CTD	O
.	O

This	O
finding	O
suggests	O
physiological	O
functions	O
of	O
PQBP	O
-	O
1	O
in	O
splicing	O
,	O
cell	O
cycle	O
,	O
and	O
ubiquitination	O
,	O
through	O
which	O
we	O
can	O
speculate	O
the	O
pathological	O
roles	O
of	O
PQBP	O
-	O
1	O
in	O
triplet	O
repeat	O
diseases	O
.	O

Error	O
-	O
prone	O
bypass	O
of	O
certain	O
DNA	O
lesions	O
by	O
the	O
human	O
DNA	O
polymerase	O
kappa	O
.	O

The	O
Escherichia	O
coli	O
protein	O
DinB	O
is	O
a	O
newly	O
identified	O
error	O
-	O
prone	O
DNA	B-OOS
polymerase	I-OOS
.	O

Recently	O
,	O
a	O
human	O
homolog	O
of	O
DinB	O
was	O
identified	O
and	O
named	O
DINB1	O
.	O

We	O
report	O
that	O
the	O
DINB1	O
gene	O
encodes	O
a	O
DNA	B-OOS
polymerase	I-OOS
(	O
designated	O
polkappa	O
)	O
,	O
which	O
incorporates	O
mismatched	O
bases	O
on	O
a	O
nondamaged	O
template	O
with	O
a	O
high	O
frequency	O
.	O

Moreover	O
,	O
polkappa	O
bypasses	O
an	O
abasic	O
site	O
and	O
N	O
-	O
2	O
-	O
acetylaminofluorene	O
(	O
AAF	O
)	O
-	O
adduct	O
in	O
an	O
error	O
-	O
prone	O
manner	O
but	O
does	O
not	O
bypass	O
a	O
cis	O
-	O
syn	O
or	O
(	O
6	O
-	O
4	O
)	O
thymine	O
-	O
thymine	O
dimer	O
or	O
a	O
cisplatin	O
-	O
adduct	O
.	O

Therefore	O
,	O
our	O
results	O
implicate	O
an	O
important	O
role	O
for	O
polkappa	O
in	O
the	O
mutagenic	O
bypass	O
of	O
certain	O
types	O
of	O
DNA	O
lesions	O
.	O

Heterogeneity	O
of	O
cardiac	O
rat	O
and	O
human	O
elongation	O
factor	O
2	O
.	O

Elongation	O
factor	O
2	O
(	O
EF	O
-	O
2	O
)	O
catalyses	O
the	O
last	O
step	O
of	O
the	O
elongation	O
cycle	O
,	O
translocation	O
,	O
in	O
the	O
course	O
of	O
protein	O
biosynthesis	O
.	O

A	O
system	O
for	O
analyzing	O
post	O
-	O
translational	O
modifications	O
of	O
EF	O
-	O
2	O
,	O
which	O
is	O
a	O
single	O
polypeptide	O
of	O
857	O
amino	O
acids	O
,	O
is	O
reported	O
and	O
its	O
application	O
to	O
cytosolic	O
extracts	O
of	O
cultured	O
neonatal	O
rat	O
heart	O
myocytes	O
,	O
neonatal	O
and	O
adult	O
rat	O
cardiac	O
tissue	O
,	O
and	O
extracts	O
of	O
human	O
left	O
ventricular	O
myocardium	O
is	O
described	O
.	O

Comparing	O
different	O
pH	O
ranges	O
in	O
immobilized	O
pH	O
gradient	O
-	O
isoelectric	O
focusing	O
(	O
IPG	O
-	O
IEF	O
)	O
,	O
a	O
range	O
of	O
pH	O
3	O
-	O
10	O
and	O
4	O
-	O
9	O
resulted	O
in	O
a	O
highly	O
defined	O
and	O
reproducible	O
resolution	O
of	O
six	O
different	O
EF	O
-	O
2	O
variants	O
of	O
all	O
extracts	O
in	O
the	O
first	O
dimension	O
.	O

These	O
six	O
variants	O
were	O
detected	O
by	O
the	O
"	O
imaging	O
plate	O
"	O
(	O
phosphor	O
radiation	O
image	O
sensor	O
)	O
after	O
specific	O
labeling	O
with	O
Pseudomonas	O
exotoxin	O
A	O
catalyzed	O
[	O
32P	O
]	O
ADP	O
-	O
ribosylation	O
.	O

This	O
finding	O
could	O
be	O
confirmed	O
in	O
Western	O
blot	O
analysis	O
with	O
a	O
specific	O
polyclonal	O
rabbit	O
antibody	O
.	O

Using	O
two	O
-	O
dimensional	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
2	O
-	O
D	O
-	O
PAGE	O
)	O
,	O
five	O
to	O
six	O
EF	O
-	O
2	O
variants	O
could	O
be	O
demonstrated	O
in	O
all	O
extracts	O
.	O

By	O
application	O
of	O
a	O
second	O
IPG	O
indicator	O
strip	O
to	O
the	O
2	O
-	O
D	O
gel	O
,	O
they	O
could	O
be	O
aligned	O
with	O
corresponding	O
spots	O
in	O
a	O
silver	O
-	O
stained	O
2	O
-	O
D	O
separation	O
of	O
human	O
myocardial	O
tissue	O
,	O
revealing	O
that	O
the	O
EF	O
-	O
2	O
variants	O
belong	O
to	O
the	O
group	O
of	O
low	O
-	O
abundance	O
proteins	O
.	O

Structure	O
of	O
a	O
c	O
-	O
Cbl	O
-	O
UbcH7	O
complex	O
:	O
RING	O
domain	O
function	O
in	O
ubiquitin	O
-	O
protein	O
ligases	O
.	O

Ubiquitin	O
-	O
protein	O
ligases	O
(	O
E3s	O
)	O
regulate	O
diverse	O
cellular	O
processes	O
by	O
mediating	O
protein	O
ubiquitination	O
.	O

The	O
c	O
-	O
Cbl	O
proto	O
-	O
oncogene	O
is	O
a	O
RING	O
family	O
E3	O
that	O
recognizes	O
activated	O
receptor	O
tyrosine	O
kinases	O
,	O
promotes	O
their	O
ubiquitination	O
by	O
a	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
(	O
E2	O
)	O
and	O
terminates	O
signaling	O
.	O

The	O
crystal	O
structure	O
of	O
c	O
-	O
Cbl	O
bound	O
to	O
a	O
cognate	O
E2	O
and	O
a	O
kinase	O
peptide	O
shows	O
how	O
the	O
RING	O
domain	O
recruits	O
the	O
E2	O
.	O

A	O
comparison	O
with	O
a	O
HECT	O
family	O
E3	O
-	O
E2	O
complex	O
indicates	O
that	O
a	O
common	O
E2	O
motif	O
is	O
recognized	O
by	O
the	O
two	O
E3	O
families	O
.	O

The	O
structure	O
reveals	O
a	O
rigid	O
coupling	O
between	O
the	O
peptide	O
binding	O
and	O
the	O
E2	O
binding	O
domains	O
and	O
a	O
conserved	O
surface	O
channel	O
leading	O
from	O
the	O
peptide	O
to	O
the	O
E2	O
active	O
site	O
,	O
suggesting	O
that	O
RING	O
E3s	O
may	O
function	O
as	O
scaffolds	O
that	O
position	O
the	O
substrate	O
and	O
the	O
E2	O
optimally	O
for	O
ubiquitin	O
transfer	O
.	O

Escherichia	O
coli	O
alpha	O
-	O
hemolysin	O
(	O
HlyA	O
)	O
is	O
heterogeneously	O
acylated	O
in	O
vivo	O
with	O
14	O
-	O
,	O
15	O
-	O
,	O
and	O
17	O
-	O
carbon	O
fatty	O
acids	O
.	O

alpha	O
-	O
Hemolysin	O
(	O
HlyA	O
)	O
is	O
a	O
secreted	O
protein	O
virulence	O
factor	O
observed	O
in	O
certain	O
uropathogenic	O
strains	O
of	O
Escherichia	O
coli	O
.	O

The	O
active	O
,	O
mature	O
form	O
of	O
HlyA	O
is	O
produced	O
by	O
posttranslational	O
modification	O
of	O
the	O
protoxin	O
that	O
is	O
mediated	O
by	O
acyl	O
carrier	O
protein	O
and	O
an	O
acyltransferase	O
,	O
HlyC	O
.	O

We	O
have	O
now	O
shown	O
using	O
mass	O
spectrometry	O
that	O
these	O
modifications	O
,	O
when	O
observed	O
in	O
protein	O
isolated	O
in	O
vivo	O
,	O
consist	O
of	O
acylation	O
at	O
the	O
epsilon	O
-	O
amino	O
groups	O
of	O
two	O
internal	O
lysine	O
residues	O
,	O
at	O
positions	O
564	O
and	O
690	O
,	O
with	O
saturated	O
14	O
-	O
(	O
68	O
%	O
)	O
,	O
15	O
-	O
(	O
26	O
%	O
)	O
,	O
and	O
17	O
-	O
(	O
6	O
%	O
)	O
carbon	O
amide	O
-	O
linked	O
side	O
chains	O
.	O

Thus	O
,	O
HlyA	O
activated	O
in	O
vivo	O
consists	O
of	O
a	O
heterogeneous	O
family	O
of	O
up	O
to	O
nine	O
different	O
covalent	O
structures	O
,	O
and	O
the	O
substrate	O
specificity	O
of	O
the	O
HlyC	O
acyltransferase	O
appears	O
to	O
differ	O
from	O
that	O
of	O
the	O
closely	O
related	O
CyaC	O
acyltransferase	O
expressed	O
by	O
Bordetella	O
pertussis	O
.	O

Pyk2	O
and	O
FAK	O
regulate	O
neurite	O
outgrowth	O
induced	O
by	O
growth	O
factors	O
and	O
integrins	O
.	O

Integration	O
of	O
signalling	O
pathways	O
initiated	O
by	O
receptor	O
tyrosine	O
kinases	O
and	O
integrins	O
is	O
essential	O
for	O
growth	O
-	O
factor	O
-	O
mediated	O
biological	O
responses	O
.	O

Here	O
we	O
show	O
that	O
co	O
-	O
stimulation	O
of	O
growth	O
-	O
factor	O
receptors	O
and	O
integrins	O
activates	O
the	O
focal	O
-	O
adhesion	O
kinase	O
(	O
FAK	O
)	O
family	O
to	O
promote	O
outgrowth	O
of	O
neurites	O
in	O
PC12	O
and	O
SH	O
-	O
SY5Y	O
cells	O
.	O

Pyk2	O
and	O
FAK	O
associate	O
with	O
adhesion	O
-	O
based	O
complexes	O
that	O
contain	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
receptors	O
,	O
through	O
their	O
carboxy	O
-	O
and	O
amino	O
-	O
terminal	O
domains	O
.	O

Expression	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
Pyk2	O
or	O
of	O
FAK	O
is	O
sufficient	O
to	O
block	O
neurite	O
outgrowth	O
,	O
but	O
not	O
activation	O
of	O
extracellular	O
-	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
.	O

Moreover	O
,	O
activation	O
and	O
autophosphorylation	O
of	O
Pyk2	O
/	O
FAK	O
,	O
as	O
well	O
as	O
of	O
effectors	O
of	O
their	O
adhesion	O
-	O
targeting	O
domains	O
,	O
such	O
as	O
paxillin	O
,	O
are	O
important	O
for	O
propagation	O
of	O
signals	O
that	O
control	O
neurite	O
formation	O
.	O

Thus	O
,	O
Pyk2	O
/	O
FAK	O
have	O
important	O
functions	O
in	O
signal	O
integration	O
proximal	O
to	O
integrin	O
/	O
growth	O
-	O
factor	O
receptor	O
complexes	O
in	O
neurons	O
.	O

Alternative	O
O	O
-	O
glycosylation	O
/	O
O	O
-	O
phosphorylation	O
of	O
the	O
murine	O
estrogen	O
receptor	O
beta	O
.	O

Estrogen	O
receptor	O
beta	O
,	O
a	O
homologue	O
to	O
estrogen	O
receptor	O
alpha	O
,	O
is	O
a	O
new	O
member	O
of	O
the	O
steroid	O
hormone	O
receptor	O
family	O
.	O

Recently	O
,	O
we	O
documented	O
that	O
estrogen	O
receptor	O
alpha	O
,	O
like	O
other	O
transcription	O
factors	O
,	O
is	O
modified	O
by	O
O	O
-	O
linked	O
N	O
-	O
acetylglucosamine	O
(	O
O	O
-	O
GlcNAc	O
)	O
,	O
a	O
ubiquitous	O
transitory	O
posttranslational	O
modification	O
on	O
nuclear	O
and	O
cytoplasmic	O
proteins	O
.	O

Here	O
,	O
we	O
report	O
that	O
estrogen	O
receptor	O
beta	O
is	O
alternatively	O
modified	O
by	O
either	O
O	O
-	O
GlcNAc	O
or	O
O	O
-	O
phosphate	O
.	O

Lectin	O
chromatography	O
of	O
in	O
vitro	O
translated	O
protein	O
first	O
suggested	O
that	O
murine	O
estrogen	O
receptor	O
beta	O
(	O
mER	O
-	O
beta	O
)	O
is	O
O	O
-	O
GlcNAcylated	O
.	O

Structural	O
characterization	O
of	O
the	O
carbohydrate	O
moieties	O
on	O
mER	O
-	O
beta	O
,	O
overexpressed	O
in	O
insect	O
Sf9	O
cells	O
,	O
confirmed	O
the	O
presence	O
of	O
O	O
-	O
GlcNAc	O
.	O

mER	O
-	O
beta	O
,	O
overexpressed	O
in	O
mammalian	O
cells	O
,	O
is	O
also	O
O	O
-	O
GlcNAcylated	O
.	O

The	O
major	O
site	O
of	O
O	O
-	O
GlcNAc	O
on	O
mER	O
-	O
beta	O
from	O
Sf9	O
cells	O
is	O
Ser	O
(	O
16	O
)	O
near	O
the	O
N	O
-	O
terminus	O
.	O

Concomitant	O
analyses	O
also	O
documented	O
the	O
O	O
-	O
phosphorylation	O
of	O
mER	O
-	O
beta	O
at	O
Ser	O
(	O
16	O
)	O
.	O

MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
showed	O
alternative	O
occupancy	O
of	O
this	O
locus	O
by	O
these	O
two	O
abundant	O
and	O
dynamic	O
posttranslational	O
modifications	O
.	O

The	O
localization	O
of	O
a	O
major	O
O	O
-	O
GlcNAc	O
/	O
O	O
-	O
phosphate	O
site	O
in	O
proximity	O
of	O
the	O
transactivation	O
domain	O
and	O
as	O
part	O
of	O
a	O
PEST	O
region	O
(	O
target	O
sequences	O
for	O
rapid	O
protein	O
degradation	O
)	O
on	O
mER	O
-	O
beta	O
suggests	O
that	O
these	O
modifications	O
may	O
play	O
a	O
role	O
in	O
regulating	O
estrogen	O
receptor	O
beta	O
transactivation	O
and	O
turnover	O
.	O

M	O
-	O
ficolin	O
is	O
expressed	O
on	O
monocytes	O
and	O
is	O
a	O
lectin	O
binding	O
to	O
N	O
-	O
acetyl	O
-	O
D	O
-	O
glucosamine	O
and	O
mediates	O
monocyte	O
adhesion	O
and	O
phagocytosis	O
of	O
Escherichia	O
coli	O
.	O

Ficolins	O
are	O
a	O
group	O
of	O
multimeric	O
proteins	O
that	O
contain	O
collagen	B-Complex
-	O
like	O
and	O
fibrinogen	O
-	O
like	O
(	O
FBG	O
)	O
sequences	O
.	O

Three	O
types	O
of	O
ficolins	O
have	O
been	O
characterized	O
:	O
H	O
-	O
,	O
L	O
-	O
and	O
M	O
-	O
ficolins	O
.	O

Both	O
H	O
-	O
and	O
L	O
-	O
ficolins	O
have	O
demonstrated	O
lectin	O
activities	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
FBG	O
domain	O
of	O
M	O
-	O
ficolin	O
was	O
expressed	O
and	O
shown	O
to	O
bind	O
to	O
N	O
-	O
acetyl	O
-	O
D	O
-	O
glucosamine	O
.	O

M	O
-	O
ficolin	O
mRNA	O
was	O
expressed	O
in	O
monocytes	O
but	O
not	O
in	O
the	O
more	O
differentiated	O
macrophages	O
and	O
dendritic	O
cells	O
.	O

By	O
flow	O
cytometry	O
,	O
surface	O
biotinylation	O
and	O
immunoprecipitation	O
,	O
we	O
showed	O
that	O
M	O
-	O
ficolin	O
was	O
associated	O
with	O
the	O
surface	O
of	O
promonocytic	O
U937	O
cells	O
.	O

M	O
-	O
ficolin	O
transiently	O
expressed	O
in	O
COS	O
-	O
7	O
cells	O
was	O
also	O
clearly	O
detected	O
on	O
the	O
cell	O
surface	O
by	O
immunoprecipitation	O
.	O

By	O
flow	O
cytometry	O
,	O
M	O
-	O
ficolin	O
was	O
detected	O
on	O
peripheral	O
blood	O
monocytes	O
but	O
not	O
on	O
lymphocytes	O
or	O
granulocytes	O
.	O

Immobilized	O
rabbit	O
anti	O
-	O
M	O
-	O
ficolin	O
F	O
(	O
ab	O
'	O
)	O
2	O
mediated	O
U937	O
cell	O
adhesion	O
,	O
and	O
the	O
antibody	O
also	O
inhibited	O
phagocytosis	O
of	O
Escherichia	O
coli	O
K	O
-	O
12	O
by	O
U937	O
cells	O
.	O

Therefore	O
,	O
M	O
-	O
ficolin	O
might	O
act	O
as	O
a	O
phagocytic	O
receptor	O
or	O
adaptor	O
on	O
circulating	O
monocytes	O
for	O
micro	O
-	O
organism	O
recognition	O
and	O
may	O
potentially	O
mediate	O
monocyte	O
adhesion	O
.	O

Phosphorylation	O
of	O
p300	O
at	O
serine	O
89	O
by	O
protein	O
kinase	O
C	O
.	O

CREB	O
-	O
binding	O
protein	O
(	O
CBP	O
)	O
/	O
p300	O
plays	O
an	O
important	O
role	O
in	O
the	O
connection	O
of	O
many	O
different	O
signal	O
transduction	O
pathways	O
and	O
the	O
promotion	O
of	O
certain	O
differentiation	O
and	O
proliferation	O
processes	O
.	O

This	O
role	O
depends	O
upon	O
the	O
ability	O
of	O
CBP	O
/	O
p300	O
to	O
serve	O
as	O
coactivator	O
for	O
transcription	O
factors	O
.	O

It	O
has	O
been	O
suggested	O
that	O
CBP	O
/	O
p300	O
is	O
regulated	O
by	O
phosphorylation	O
,	O
but	O
the	O
nature	O
of	O
the	O
phosphorylation	O
,	O
the	O
responsible	O
kinase	O
in	O
vivo	O
,	O
and	O
its	O
physiological	O
significance	O
are	O
still	O
unclear	O
.	O

Here	O
,	O
we	O
demonstrate	O
the	O
first	O
identification	O
of	O
an	O
in	O
vivo	O
phosphorylation	O
site	O
,	O
conserved	O
serine	O
89	O
,	O
in	O
p300	O
.	O

Signal	O
-	O
dependent	O
protein	O
kinase	O
C	O
is	O
able	O
to	O
phosphorylate	O
serine	O
89	O
and	O
mediates	O
this	O
phosphorylation	O
event	O
in	O
vivo	O
.	O

Different	O
from	O
other	O
phosphorylation	O
observed	O
so	O
far	O
in	O
CBP	O
/	O
p300	O
,	O
this	O
serine	O
89	O
-	O
specific	O
phosphorylation	O
represses	O
the	O
transcriptional	O
activity	O
of	O
p300	O
.	O

This	O
phosphorylation	O
-	O
mediated	O
regulation	O
of	O
p300	O
function	O
represents	O
a	O
previously	O
unrecognized	O
signal	O
transduction	O
pathway	O
for	O
protein	O
kinase	O
C	O
to	O
regulate	O
cell	O
growth	O
and	O
differentiation	O
.	O

Discrete	O
roles	O
for	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
gamma	O
and	O
retinoid	O
X	O
receptor	O
in	O
recruiting	O
nuclear	O
receptor	O
coactivators	O
.	O

Peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
gamma	O
(	O
PPARgamma	O
)	O
plays	O
a	O
major	O
role	O
in	O
adipogenesis	O
.	O

PPARgamma	O
binds	O
to	O
DNA	O
as	O
a	O
heterodimer	O
with	O
retinoid	O
X	O
receptor	O
(	O
RXR	O
)	O
,	O
and	O
PPARgamma	O
-	O
RXR	O
can	O
be	O
activated	O
by	O
ligands	O
specific	O
for	O
either	O
receptor	O
;	O
the	O
presence	O
of	O
both	O
ligands	O
can	O
result	O
in	O
a	O
cooperative	O
effect	O
on	O
the	O
transactivation	O
of	O
target	O
genes	O
.	O

How	O
these	O
ligands	O
mediate	O
transactivation	O
,	O
however	O
,	O
remains	O
unclear	O
.	O

PPARgamma	O
is	O
known	O
to	O
interact	O
with	O
both	O
the	O
p160	O
/	O
SRC	O
-	O
1	O
family	O
of	O
coactivators	O
and	O
the	O
distinct	O
,	O
multisubunit	O
coactivator	O
complex	O
called	O
DRIP	B-Complex
.	O

A	O
single	O
DRIP	B-Complex
subunit	O
,	O
DRIP205	O
(	O
TRAP220	O
,	O
PBP	O
)	O
,	O
binds	O
directly	O
to	O
PPARgamma	O
.	O

Here	O
we	O
report	O
that	O
PPARgamma	O
and	O
RXR	O
selectively	O
interacted	O
with	O
DRIP205	O
and	O
p160	O
proteins	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
.	O

At	O
physiological	O
concentrations	O
,	O
RXR	O
-	O
specific	O
ligands	O
only	O
induced	O
p160	O
binding	O
to	O
RXR	O
,	O
and	O
PPARgamma	O
-	O
specific	O
ligands	O
exclusively	O
recruited	O
DRIP205	O
but	O
not	O
p160	O
coactivators	O
to	O
PPARgamma	O
.	O

This	O
selectivity	O
was	O
not	O
observed	O
in	O
interaction	O
assays	O
off	O
DNA	O
,	O
implying	O
that	O
the	O
specificity	O
of	O
coactivator	O
binding	O
in	O
response	O
to	O
ligand	O
is	O
strongly	O
influenced	O
by	O
the	O
allosteric	O
effects	O
of	O
DNA	O
-	O
bound	O
heterodimers	O
.	O

These	O
coactivator	O
-	O
selective	O
effects	O
were	O
also	O
observed	O
in	O
transient	O
-	O
transfection	O
assays	O
in	O
the	O
presence	O
of	O
overexpressed	O
p160	O
or	O
DRIP	B-Complex
coactivators	O
.	O

The	O
results	O
suggest	O
that	O
the	O
cooperative	O
effects	O
of	O
PPARgamma	O
-	O
and	O
RXR	O
-	O
specific	O
ligands	O
may	O
occur	O
at	O
the	O
level	O
of	O
selective	O
coactivator	O
recruitment	O
.	O

The	O
specific	O
activities	O
of	O
human	O
digestive	O
lipases	O
measured	O
from	O
the	O
in	O
vivo	O
and	O
in	O
vitro	O
lipolysis	O
of	O
test	O
meals	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
The	O
lipolytic	O
potential	O
of	O
digestive	O
lipases	O
in	O
vivo	O
has	O
always	O
been	O
deduced	O
so	O
far	O
from	O
their	O
in	O
vitro	O
activities	O
under	O
nonphysiologic	O
conditions	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
specific	O
activities	O
of	O
human	O
gastric	O
lipase	O
(	O
HGL	O
)	O
and	O
pancreatic	O
lipase	O
(	O
HPL	O
)	O
were	O
measured	O
on	O
dietary	O
triglycerides	O
(	O
TGs	O
)	O
during	O
test	O
meal	O
lipolysis	O
.	O

METHODS	O
:	O
Healthy	O
human	O
volunteers	O
ingested	O
a	O
liquid	O
or	O
solid	O
meal	O
.	O

The	O
specific	O
activities	O
of	O
HGL	O
and	O
HPL	O
were	O
estimated	O
from	O
the	O
lipase	O
and	O
free	O
fatty	O
acid	O
(	O
FFA	O
)	O
outputs	O
at	O
the	O
postpyloric	O
and	O
duodenal	O
levels	O
,	O
respectively	O
.	O

Based	O
on	O
the	O
in	O
vivo	O
data	O
,	O
lipolysis	O
was	O
also	O
performed	O
in	O
vitro	O
by	O
mixing	O
the	O
meal	O
either	O
with	O
gastric	O
juice	O
and	O
subsequently	O
with	O
pancreatic	O
juice	O
and	O
bile	O
or	O
with	O
purified	O
HGL	O
and	O
HPL	O
.	O

FFAs	O
were	O
measured	O
by	O
thin	O
-	O
layer	O
chromatography	O
,	O
and	O
the	O
specific	O
activities	O
of	O
HGL	O
and	O
HPL	O
were	O
expressed	O
as	O
micromoles	O
of	O
FFA	O
per	O
minute	O
per	O
milligram	O
of	O
lipase	O
.	O

RESULTS	O
:	O
In	O
vitro	O
,	O
the	O
specific	O
activities	O
on	O
the	O
liquid	O
meal	O
TGs	O
were	O
32	O
(	O
gastric	O
juice	O
)	O
and	O
34	O
(	O
pure	O
lipase	O
)	O
micromol	O
x	O
min	O
(	O
-	O
1	O
)	O
x	O
mg	O
(	O
-	O
1	O
)	O
with	O
HGL	O
and	O
47	O
(	O
pancreatic	O
juice	O
)	O
and	O
43	O
(	O
pure	O
lipase	O
)	O
micromol	O
x	O
min	O
(	O
-	O
1	O
)	O
.	O

mg	O
(	O
-	O
1	O
)	O
with	O
HPL	O
.	O

The	O
specific	O
activities	O
on	O
the	O
solid	O
meal	O
TGs	O
were	O
33	O
(	O
gastric	O
juice	O
)	O
and	O
32	O
(	O
pure	O
lipase	O
)	O
micromol	O
x	O
min	O
(	O
-	O
1	O
)	O
x	O
mg	O
(	O
-	O
1	O
)	O
with	O
HGL	O
and	O
12	O
(	O
pancreatic	O
juice	O
)	O
and	O
15	O
(	O
pure	O
lipase	O
)	O
micromol	O
x	O
min	O
(	O
-	O
1	O
)	O
x	O
mg	O
(	O
-	O
1	O
)	O
with	O
HPL	O
.	O

The	O
in	O
vivo	O
values	O
obtained	O
were	O
in	O
the	O
same	O
range	O
.	O

The	O
secretory	O
lipase	O
outputs	O
were	O
21	O
.	O
6	O
+	O
/	O
-	O
14	O
.	O
5	O
mg	O
HGL	O
and	O
253	O
.	O
5	O
+	O
/	O
-	O
95	O
.	O
5	O
mg	O
HPL	O
with	O
the	O
liquid	O
test	O
meal	O
and	O
15	O
.	O
2	O
+	O
/	O
-	O
5	O
.	O
1	O
mg	O
HGL	O
and	O
202	O
.	O
9	O
+	O
/	O
-	O
96	O
.	O
1	O
mg	O
HPL	O
with	O
the	O
solid	O
test	O
meal	O
.	O

CONCLUSIONS	O
:	O
The	O
specific	O
activities	O
of	O
HGL	O
and	O
HPL	O
on	O
meal	O
TGs	O
were	O
much	O
lower	O
than	O
those	O
measured	O
in	O
vitro	O
under	O
optimized	O
assay	O
conditions	O
(	O
1300	O
-	O
8000	O
)	O
.	O

However	O
,	O
these	O
low	O
specific	O
activities	O
are	O
enough	O
for	O
the	O
meal	O
TGs	O
to	O
be	O
completely	O
lipolysed	O
,	O
given	O
the	O
amounts	O
of	O
HGL	O
and	O
HPL	O
secreted	O
during	O
a	O
meal	O
.	O

Longitudinal	O
gradients	O
of	O
KCNQ4	O
expression	O
in	O
spiral	O
ganglion	O
and	O
cochlear	O
hair	O
cells	O
correlate	O
with	O
progressive	O
hearing	O
loss	O
in	O
DFNA2	O
.	O

Mutations	O
in	O
the	O
human	O
KCNQ4	O
gene	O
were	O
recently	O
found	O
by	O
Kubisch	O
et	O
al	O
.	O

[	O
Cell	O
96	O
(	O
1999	O
)	O
437	O
-	O
446	O
]	O
to	O
cause	O
a	O
non	O
-	O
syndromic	O
,	O
autosomal	O
dominant	O
,	O
progressive	O
hearing	O
loss	O
,	O
DFNA2	O
.	O

The	O
mouse	O
Kcnq4	O
orthologue	O
was	O
previously	O
localized	O
to	O
the	O
outer	O
hair	O
cells	O
(	O
OHCs	O
)	O
of	O
the	O
inner	O
ear	O
,	O
suggesting	O
the	O
pathophysiological	O
effects	O
were	O
due	O
to	O
dysfunctional	O
OHCs	O
.	O

Yet	O
,	O
OHC	O
dysfunction	O
does	O
not	O
provide	O
a	O
plausible	O
explanation	O
for	O
the	O
progressive	O
nature	O
of	O
the	O
frequency	O
specific	O
hearing	O
loss	O
.	O

We	O
have	O
re	O
-	O
examined	O
and	O
extended	O
the	O
expression	O
analyses	O
of	O
KCNQ4	O
in	O
the	O
murine	O
inner	O
ear	O
using	O
RT	O
-	O
PCR	O
and	O
whole	O
mount	O
in	O
situ	O
hybridization	O
.	O

Our	O
results	O
confirmed	O
that	O
the	O
rat	O
KCNQ4	O
orthologue	O
is	O
expressed	O
in	O
both	O
inner	O
and	O
outer	O
hair	O
cells	O
.	O

Reciprocal	O
longitudinal	O
gradients	O
were	O
found	O
in	O
inner	O
hair	O
cells	O
(	O
IHCs	O
)	O
and	O
OHCs	O
.	O

The	O
strongest	O
expression	O
of	O
KCNQ4	O
in	O
IHCc	O
was	O
in	O
the	O
base	O
of	O
the	O
cochlea	O
and	O
in	O
the	O
apex	O
for	O
OHCs	O
.	O

Similar	O
to	O
the	O
IHCs	O
,	O
a	O
basal	O
to	O
apical	O
gradient	O
was	O
present	O
in	O
the	O
spiral	O
sensory	O
neurons	O
.	O

IHCs	O
mediate	O
hearing	O
via	O
their	O
afferent	O
sensory	O
neurons	O
,	O
whereas	O
OHCs	O
function	O
as	O
active	O
cochlear	O
amplifiers	O
.	O

The	O
complete	O
absence	O
of	O
OHCs	O
leads	O
only	O
to	O
severe	O
sensitivity	O
reduction	O
,	O
but	O
not	O
complete	O
hearing	O
loss	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
primary	O
defect	O
leading	O
to	O
initial	O
high	O
frequency	O
loss	O
and	O
subsequent	O
progressive	O
hearing	O
loss	O
for	O
all	O
frequencies	O
may	O
be	O
due	O
to	O
spiral	O
ganglion	O
and	O
/	O
or	O
IHC	O
dysfunction	O
,	O
rather	O
than	O
an	O
OHC	O
aberration	O
.	O

Rapid	O
initial	O
removal	O
of	O
chylomicron	O
remnants	O
by	O
the	O
mouse	O
liver	O
does	O
not	O
require	O
hepatically	O
localized	O
apolipoprotein	O
E	O
.	O

Apolipoprotein	O
E	O
(	O
apoE	O
)	O
is	O
a	O
ligand	O
for	O
the	O
low	O
density	O
lipoprotein	O
receptor	O
(	O
LDLR	O
)	O
and	O
the	O
low	O
density	O
lipoprotein	O
receptor	O
-	O
related	O
protein	O
(	O
LRP	O
)	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
clarify	O
the	O
role	O
of	O
hepatically	O
localized	O
apoE	O
in	O
the	O
rapid	O
initial	O
removal	O
of	O
chylomicron	O
remnants	O
by	O
using	O
the	O
isolated	O
perfused	O
liver	O
.	O

Radiolabeled	O
chylomicron	O
remnants	O
were	O
perfused	O
in	O
a	O
single	O
nonrecirculating	O
pass	O
into	O
the	O
livers	O
of	O
C57BL	O
/	O
6J	O
(	O
wild	O
-	O
type	O
)	O
mice	O
,	O
apoE	O
-	O
knockout	O
mice	O
,	O
and	O
apoE	O
/	O
LDLR	O
-	O
knockout	O
mice	O
for	O
a	O
period	O
of	O
20	O
min	O
.	O

Aliquots	O
of	O
the	O
perfusate	O
leaving	O
the	O
liver	O
were	O
collected	O
at	O
regular	O
intervals	O
and	O
the	O
rate	O
of	O
removal	O
of	O
radioactivity	O
was	O
determined	O
.	O

At	O
a	O
trace	O
concentration	O
of	O
chylomicron	O
remnants	O
(	O
0	O
.	O
05	O
microgram	O
of	O
protein	O
per	O
ml	O
)	O
,	O
wild	O
-	O
type	O
mouse	O
livers	O
removed	O
at	O
a	O
steady	O
state	O
of	O
50	O
-	O
55	O
%	O
of	O
total	O
chylomicron	O
remnants	O
perfused	O
per	O
pass	O
;	O
livers	O
from	O
apoE	O
-	O
knockout	O
mice	O
had	O
the	O
same	O
capacity	O
as	O
wild	O
-	O
type	O
mouse	O
livers	O
.	O

When	O
the	O
concentration	O
of	O
remnants	O
was	O
increased	O
to	O
12	O
microgram	O
of	O
protein	O
per	O
ml	O
,	O
a	O
level	O
at	O
which	O
it	O
has	O
been	O
shown	O
that	O
LDL	O
receptor	O
and	O
LRP	O
are	O
near	O
saturation	O
,	O
the	O
capacity	O
of	O
the	O
wild	O
-	O
type	O
mouse	O
livers	O
to	O
remove	O
chylomicron	O
remnants	O
was	O
decreased	O
to	O
10	O
-	O
25	O
%	O
per	O
pass	O
,	O
confirming	O
that	O
the	O
removal	O
mechanisms	O
were	O
nearing	O
saturation	O
.	O

However	O
,	O
instead	O
of	O
finding	O
a	O
greater	O
reduction	O
in	O
the	O
removal	O
rates	O
or	O
impairment	O
in	O
chylomicron	O
remnant	O
removal	O
,	O
livers	O
from	O
apoE	O
-	O
knockout	O
mice	O
were	O
just	O
as	O
efficient	O
as	O
those	O
from	O
wild	O
-	O
type	O
mice	O
in	O
removing	O
remnants	O
.	O

Livers	O
of	O
mice	O
that	O
lacked	O
both	O
apoE	O
and	O
the	O
LDLR	O
also	O
had	O
a	O
similar	O
rate	O
of	O
removal	O
at	O
relatively	O
low	O
remnant	O
concentrations	O
(	O
0	O
.	O
05	O
-	O
0	O
.	O
5	O
microgram	O
/	O
ml	O
)	O
,	O
but	O
had	O
reduced	O
capacity	O
in	O
removing	O
remnants	O
at	O
a	O
relatively	O
high	O
concentration	O
(	O
4	O
-	O
12	O
microgram	O
/	O
ml	O
)	O
of	O
chylomicron	O
remnants	O
(	O
approximately	O
20	O
%	O
per	O
pass	O
)	O
.	O

The	O
rate	O
of	O
removal	O
at	O
these	O
concentrations	O
,	O
however	O
,	O
was	O
similar	O
to	O
that	O
attributed	O
to	O
the	O
LRP	O
in	O
previous	O
studies	O
.	O

Chylomicron	O
remnants	O
,	O
whose	O
apolipoproteins	O
were	O
disrupted	O
by	O
trypsinization	O
,	O
were	O
removed	O
at	O
a	O
normal	O
rate	O
by	O
wild	O
-	O
type	O
mouse	O
livers	O
but	O
there	O
was	O
almost	O
no	O
removal	O
by	O
apoE	O
-	O
knockout	O
mouse	O
livers	O
.	O

At	O
higher	O
concentrations	O
,	O
however	O
,	O
the	O
removal	O
of	O
apolipoprotein	O
-	O
disrupted	O
chylomicron	O
remnants	O
was	O
decreased	O
.	O

Our	O
present	O
findings	O
do	O
not	O
support	O
the	O
hypothesis	O
that	O
hepatically	O
localized	O
apoE	O
is	O
a	O
critical	O
factor	O
in	O
the	O
rapid	O
initial	O
removal	O
of	O
chylomicron	O
remnants	O
by	O
either	O
of	O
the	O
major	O
pathways	O
but	O
do	O
suggest	O
that	O
hepatically	O
localized	O
apoE	O
can	O
be	O
added	O
to	O
lipoproteins	O
to	O
accelerate	O
their	O
uptake	O
,	O
although	O
this	O
process	O
may	O
have	O
a	O
limited	O
capacity	O
to	O
compensate	O
for	O
apoE	O
deficiency	O
on	O
lipoproteins	O
.	O

Conversion	O
of	O
a	O
gene	O
-	O
specific	O
repressor	O
to	O
a	O
regional	O
silencer	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
gene	O
silencing	O
at	O
the	O
HMR	O
and	O
HML	O
loci	O
is	O
normally	O
dependent	O
on	O
Sir2p	O
,	O
Sir3p	O
,	O
and	O
Sir4p	O
,	O
which	O
are	O
structural	O
components	O
of	O
silenced	O
chromatin	O
.	O

Sir2p	O
is	O
a	O
NAD	O
+	O
-	O
dependent	O
histone	O
deacetylase	O
required	O
for	O
silencing	O
.	O

Silencing	O
can	O
be	O
restored	O
in	O
cells	O
lacking	O
Sir	O
proteins	O
by	O
a	O
dominant	O
mutation	O
in	O
SUM1	O
,	O
which	O
normally	O
acts	O
as	O
a	O
mitotic	O
repressor	O
of	O
meiotic	O
genes	O
.	O

This	O
study	O
found	O
that	O
mutant	O
Sum1	O
-	O
1p	O
,	O
but	O
not	O
wild	O
-	O
type	O
Sum1p	O
,	O
associated	O
directly	O
with	O
HM	O
loci	O
.	O

The	O
origin	B-Complex
recognition	I-Complex
complex	I-Complex
(	O
ORC	B-Complex
)	O
was	O
required	O
for	O
Sum1	O
-	O
1p	O
-	O
mediated	O
silencing	O
,	O
and	O
mutations	O
in	O
ORC	B-Complex
genes	O
reduced	O
association	O
of	O
Sum1	O
-	O
1p	O
with	O
the	O
HM	O
loci	O
.	O

Sum1	O
-	O
1p	O
-	O
mediated	O
silencing	O
also	O
depended	O
on	O
HST1	O
,	O
a	O
paralog	O
of	O
SIR2	O
.	O

Both	O
Sum1	O
-	O
1p	O
and	O
wild	O
-	O
type	O
Sum1p	O
interacted	O
with	O
Hst1p	O
in	O
coimmunoprecipitation	O
experiments	O
.	O

Therefore	O
,	O
the	O
SUM1	O
-	O
1	O
mutation	O
did	O
not	O
change	O
the	O
affinity	O
of	O
Sum1p	O
for	O
Hst1p	O
,	O
but	O
rather	O
relocalized	O
Sum1p	O
to	O
the	O
HM	O
loci	O
.	O

Sum1	O
-	O
1	O
-	O
Hst1p	O
action	O
led	O
to	O
hypoacetylation	O
of	O
the	O
nucleosomes	O
at	O
HM	O
loci	O
.	O

Thus	O
,	O
Sum1	O
-	O
1p	O
and	O
Hst1p	O
could	O
substitute	O
for	O
Sir	O
proteins	O
to	O
achieve	O
silencing	O
through	O
formation	O
of	O
a	O
compositionally	O
distinct	O
type	O
of	O
heterochromatin	O
.	O

Sharp	O
,	O
an	O
inducible	O
cofactor	O
that	O
integrates	O
nuclear	O
receptor	O
repression	O
and	O
activation	O
.	O

A	O
yeast	O
two	O
-	O
hybrid	O
screen	O
using	O
the	O
conserved	O
carboxyl	O
terminus	O
of	O
the	O
nuclear	O
receptor	O
corepressor	O
SMRT	O
as	O
a	O
bait	O
led	O
to	O
the	O
isolation	O
of	O
a	O
novel	O
human	O
gene	O
termed	O
SHARP	O
(	O
SMRT	O
/	O
HDAC1	O
Associated	O
Repressor	O
Protein	O
)	O
.	O

SHARP	O
is	O
a	O
potent	O
transcriptional	O
repressor	O
whose	O
repression	O
domain	O
(	O
RD	O
)	O
interacts	O
directly	O
with	O
SMRT	O
and	O
at	O
least	O
five	O
members	O
of	O
the	O
NuRD	B-Complex
complex	O
including	O
HDAC1	O
and	O
HDAC2	O
.	O

In	O
addition	O
,	O
SHARP	O
binds	O
to	O
the	O
steroid	O
receptor	O
RNA	O
coactivator	O
SRA	O
via	O
an	O
intrinsic	O
RNA	O
binding	O
domain	O
and	O
suppresses	O
SRA	O
-	O
potentiated	O
steroid	O
receptor	O
transcription	O
activity	O
.	O

Accordingly	O
,	O
SHARP	O
has	O
the	O
capacity	O
to	O
modulate	O
both	O
liganded	O
and	O
nonliganded	O
nuclear	O
receptors	O
.	O

Surprisingly	O
,	O
the	O
expression	O
of	O
SHARP	O
is	O
itself	O
steroid	O
inducible	O
,	O
suggesting	O
a	O
simple	O
feedback	O
mechanism	O
for	O
attenuation	O
of	O
the	O
hormonal	O
response	O
.	O

The	O
evolutionarily	O
conserved	O
region	O
of	O
the	O
U	O
snRNA	O
export	O
mediator	O
PHAX	O
is	O
a	O
novel	O
RNA	O
-	O
binding	O
domain	O
that	O
is	O
essential	O
for	O
U	O
snRNA	O
export	O
.	O

In	O
metazoa	O
,	O
a	O
subset	O
of	O
spliceosomal	O
U	O
snRNAs	O
are	O
exported	O
from	O
the	O
nucleus	O
after	O
transcription	O
.	O

This	O
export	O
occurs	O
in	O
a	O
large	O
complex	O
containing	O
a	O
U	O
snRNA	O
,	O
the	O
nuclear	B-Complex
cap	I-Complex
binding	I-Complex
complex	I-Complex
(	O
CBC	B-Complex
)	O
,	O
the	O
leucine	O
-	O
rich	O
nuclear	O
export	O
signal	O
receptor	O
CRM1	O
/	O
Xpo1	O
,	O
RanGTP	O
,	O
and	O
the	O
recently	O
identified	O
phosphoprotein	O
PHAX	O
(	O
phosphorylated	O
adaptor	O
for	O
RNA	O
export	O
)	O
.	O

Previous	O
results	O
indicated	O
that	O
PHAX	O
made	O
direct	O
contact	O
with	O
RNA	O
,	O
CBC	B-Complex
,	O
and	O
Xpo1	O
in	O
the	O
U	B-Complex
snRNA	I-Complex
export	I-Complex
complex	I-Complex
.	O

We	O
have	O
now	O
performed	O
a	O
systematic	O
characterization	O
of	O
the	O
functional	O
domains	O
of	O
PHAX	O
.	O

The	O
most	O
evolutionarily	O
conserved	O
region	O
of	O
PHAX	O
is	O
shown	O
to	O
be	O
a	O
novel	O
RNA	O
-	O
binding	O
domain	O
that	O
is	O
essential	O
for	O
U	O
snRNA	O
export	O
.	O

In	O
addition	O
,	O
PHAX	O
contains	O
two	O
major	O
nuclear	O
localization	O
signals	O
(	O
NLSs	O
)	O
that	O
are	O
required	O
for	O
its	O
recycling	O
to	O
the	O
nucleus	O
after	O
export	O
.	O

The	O
interaction	O
domain	O
of	O
PHAX	O
with	O
CBC	B-Complex
is	O
at	O
least	O
partly	O
distinct	O
from	O
the	O
RNA	O
-	O
binding	O
domain	O
and	O
the	O
NLSs	O
.	O

Thus	O
,	O
the	O
different	O
interaction	O
domains	O
of	O
PHAX	O
allow	O
it	O
to	O
act	O
as	O
a	O
scaffold	O
for	O
the	O
assembly	O
of	O
U	B-Complex
snRNA	I-Complex
export	I-Complex
complexes	I-Complex
.	O

Prenylated	O
Rab	O
acceptor	O
protein	O
is	O
a	O
receptor	O
for	O
prenylated	O
small	O
GTPases	O
.	O

Localization	O
of	O
Ras	O
and	O
Ras	O
-	O
like	O
proteins	O
to	O
the	O
correct	O
subcellular	O
compartment	O
is	O
essential	O
for	O
these	O
proteins	O
to	O
mediate	O
their	O
biological	O
effects	O
.	O

Many	O
members	O
of	O
the	O
Ras	O
superfamily	O
(	O
Ha	O
-	O
Ras	O
,	O
N	O
-	O
Ras	O
,	O
TC21	O
,	O
and	O
RhoA	O
)	O
are	O
prenylated	O
in	O
the	O
cytoplasm	O
and	O
then	O
transit	O
through	O
the	O
endomembrane	O
system	O
on	O
their	O
way	O
to	O
the	O
plasma	O
membrane	O
.	O

The	O
proteins	O
that	O
aid	O
in	O
the	O
trafficking	O
of	O
the	O
small	O
GTPases	O
have	O
not	O
been	O
well	O
characterized	O
.	O

We	O
report	O
here	O
that	O
prenylated	O
Rab	O
acceptor	O
protein	O
(	O
PRA1	O
)	O
,	O
which	O
others	O
previously	O
identified	O
as	O
a	O
prenylation	O
-	O
dependent	O
receptor	O
for	O
Rab	O
proteins	O
,	O
also	O
interacts	O
with	O
Ha	O
-	O
Ras	O
,	O
RhoA	O
,	O
TC21	O
,	O
and	O
Rap1a	O
.	O

The	O
interaction	O
of	O
these	O
small	O
GTPases	O
with	O
PRA1	O
requires	O
their	O
post	O
-	O
translational	O
modification	O
by	O
prenylation	O
.	O

The	O
prenylation	O
-	O
dependent	O
association	O
of	O
PRA1	O
with	O
multiple	O
GTPases	O
is	O
conserved	O
in	O
evolution	O
;	O
the	O
yeast	O
PRA1	O
protein	O
associates	O
with	O
both	O
Ha	O
-	O
Ras	O
and	O
RhoA	O
.	O

Earlier	O
studies	O
reported	O
the	O
presence	O
of	O
PRA1	O
in	O
the	O
Golgi	O
,	O
and	O
we	O
show	O
here	O
that	O
PRA1	O
co	O
-	O
localizes	O
with	O
Ha	O
-	O
Ras	O
and	O
RhoA	O
in	O
the	O
Golgi	O
compartment	O
.	O

We	O
suggest	O
that	O
PRA1	O
acts	O
as	O
an	O
escort	O
protein	O
for	O
small	O
GTPases	O
by	O
binding	O
to	O
the	O
hydrophobic	O
isoprenoid	O
moieties	O
of	O
the	O
small	O
GTPases	O
and	O
facilitates	O
their	O
trafficking	O
through	O
the	O
endomembrane	O
system	O
.	O

Cloning	O
and	O
identification	O
of	O
MYPT3	O
:	O
a	O
prenylatable	O
myosin	O
targetting	O
subunit	O
of	O
protein	B-Complex
phosphatase	I-Complex
1	I-Complex
.	O

To	O
identify	O
novel	O
protein	B-Complex
phosphatase	I-Complex
1	I-Complex
(	O
PP1	B-Complex
)	O
-	O
interacting	O
proteins	O
,	O
a	O
yeast	O
two	O
-	O
hybrid	O
3T3	O
-	O
L1	O
adipocyte	O
cDNA	O
library	O
was	O
screened	O
with	O
the	O
catalytic	O
subunit	O
of	O
PP1	B-Complex
as	O
bait	O
.	O

In	O
the	O
present	O
work	O
,	O
the	O
isolation	O
,	O
identification	O
and	O
initial	O
biochemical	O
characterization	O
of	O
a	O
novel	O
PP1	B-Complex
-	O
interacting	O
protein	O
,	O
MYPT3	O
,	O
which	O
is	O
homologous	O
with	O
the	O
myosin	B-Complex
phosphatase	I-Complex
targetting	O
subunit	O
(	O
MYPT	O
)	O
family	O
,	O
is	O
described	O
.	O

MYPT3	O
aligns	O
>	O
99	O
%	O
with	O
a	O
region	O
of	O
mouse	O
genomic	O
DNA	O
clone	O
RP23	O
-	O
156P23	O
and	O
localizes	O
to	O
chromosome	O
15	O
,	O
between	O
markers	O
at	O
44	O
.	O
1	O
-	O
46	O
.	O
5	O
cM	O
,	O
as	O
demonstrated	O
by	O
radiation	O
hybrid	O
mapping	O
.	O

The	O
gene	O
consists	O
of	O
ten	O
exons	O
that	O
encode	O
for	O
a	O
524	O
-	O
amino	O
acid	O
sequence	O
with	O
a	O
predicted	O
molecular	O
mass	O
of	O
57529	O
Da	O
.	O

The	O
N	O
-	O
terminal	O
region	O
of	O
MYPT3	O
consists	O
of	O
a	O
consensus	O
PP1	B-Complex
-	O
binding	O
site	O
and	O
multiple	O
ankyrin	O
repeats	O
.	O

MYPT3	O
is	O
distinguished	O
from	O
related	O
approximately	O
110	O
-	O
130	O
kDa	O
MYPT	O
subunits	O
by	O
its	O
molecular	O
mass	O
of	O
58	O
kDa	O
,	O
and	O
a	O
unique	O
C	O
-	O
terminal	O
region	O
that	O
contains	O
several	O
potential	O
signalling	O
motifs	O
and	O
a	O
CaaX	O
prenylation	O
site	O
.	O

We	O
have	O
shown	O
that	O
affinity	O
-	O
purified	O
glutathione	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
-	O
MYPT3	O
is	O
prenylated	O
by	O
purified	O
recombinant	O
farnesyltransferase	B-OOS
in	O
vitro	O
.	O

Endogenous	O
PP1	B-Complex
from	O
3T3	O
-	O
L1	O
lysates	O
specifically	O
interacts	O
with	O
MYPT3	O
.	O

Additionally	O
,	O
purified	O
PP1	B-Complex
activity	O
was	O
inhibited	O
by	O
GST	O
-	O
MYPT3	O
toward	O
phosphorylase	O
a	O
,	O
myosin	O
light	O
chain	O
and	O
myosin	O
substrate	O
in	O
vitro	O
.	O

Overall	O
,	O
our	O
findings	O
identify	O
a	O
novel	O
prenylatable	O
subunit	O
of	O
PP1	B-Complex
that	O
defines	O
a	O
new	O
subfamily	O
of	O
MYPT	O
.	O

Tyrosine	O
phosphorylation	O
of	O
p85	O
relieves	O
its	O
inhibitory	O
activity	O
on	O
phosphatidylinositol	O
3	O
-	O
kinase	O
.	O

Under	O
resting	O
conditions	O
,	O
the	O
p85	O
regulatory	O
subunit	O
of	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI3K	O
)	O
serves	O
to	O
both	O
stabilize	O
and	O
inactivate	O
the	O
p110	O
catalytic	O
subunit	O
.	O

The	O
inhibitory	O
activity	O
of	O
p85	O
is	O
relieved	O
by	O
occupancy	O
of	O
the	O
NH	O
(	O
2	O
)	O
-	O
terminal	O
SH2	O
domain	O
of	O
p85	O
by	O
phosphorylated	O
tyrosine	O
.	O

Src	O
family	O
kinases	O
phosphorylate	O
tyrosine	O
688	O
in	O
p85	O
,	O
a	O
process	O
that	O
we	O
have	O
shown	O
to	O
be	O
reversed	O
by	O
the	O
activity	O
of	O
the	O
p85	O
-	O
associated	O
SH2	O
domain	O
-	O
containing	O
phosphatase	O
SHP1	O
.	O

We	O
demonstrate	O
that	O
phosphorylation	O
of	O
the	O
downstream	O
PI3K	O
target	O
Akt	O
is	O
increased	O
in	O
cells	O
lacking	O
SHP1	O
,	O
implicating	O
phosphorylation	O
of	O
p85	O
in	O
the	O
regulation	O
of	O
PI3K	O
activity	O
.	O

Furthermore	O
,	O
the	O
in	O
vitro	O
specific	O
activity	O
of	O
PI3K	O
associated	O
with	O
tyrosine	O
-	O
phosphorylated	O
p85	O
is	O
higher	O
than	O
that	O
associated	O
with	O
nonphosphorylated	O
p85	O
.	O

Expression	O
of	O
wild	O
-	O
type	O
p85	O
inhibits	O
PI3K	O
enzyme	O
activity	O
as	O
indicated	O
by	O
PI3K	O
-	O
dependent	O
Akt	O
phosphorylation	O
.	O

The	O
inhibitory	O
activity	O
of	O
p85	O
is	O
accentuated	O
by	O
mutation	O
of	O
tyrosine	O
688	O
to	O
alanine	O
and	O
reversed	O
by	O
mutation	O
of	O
tyrosine	O
688	O
to	O
aspartic	O
acid	O
,	O
changes	O
that	O
block	O
and	O
mimic	O
tyrosine	O
phosphorylation	O
,	O
respectively	O
Strikingly	O
,	O
mutation	O
of	O
tyrosine	O
688	O
to	O
aspartic	O
acid	O
completely	O
reverses	O
the	O
inhibitory	O
activity	O
of	O
p85	O
on	O
cell	O
viability	O
and	O
activation	O
of	O
the	O
downstream	O
targets	O
Akt	O
and	O
NFkappaB	B-Complex
,	O
indicative	O
of	O
the	O
physiological	O
relevance	O
of	O
p85	O
phosphorylation	O
.	O

Tyrosine	O
phosphorylation	O
of	O
Tyr	O
(	O
688	O
)	O
or	O
mutation	O
of	O
tyrosine	O
688	O
to	O
aspartic	O
acid	O
is	O
sufficient	O
to	O
allow	O
binding	O
to	O
the	O
NH	O
(	O
2	O
)	O
-	O
terminal	O
SH2	O
domain	O
of	O
p85	O
.	O

Thus	O
an	O
intramolecular	O
interaction	O
between	O
phosphorylated	O
Tyr	O
(	O
688	O
)	O
and	O
the	O
NH	O
(	O
2	O
)	O
-	O
terminal	O
SH2	O
domain	O
of	O
p85	O
can	O
relieve	O
the	O
inhibitory	O
activity	O
of	O
p85	O
on	O
p110	O
.	O

Taken	O
together	O
,	O
the	O
data	O
indicate	O
that	O
phosphorylation	O
of	O
Tyr	O
(	O
688	O
)	O
in	O
p85	O
leads	O
to	O
a	O
novel	O
mechanism	O
of	O
PI3K	O
regulation	O
.	O

Nck	O
and	O
phosphatidylinositol	O
4	O
,	O
5	O
-	O
bisphosphate	O
synergistically	O
activate	O
actin	O
polymerization	O
through	O
the	O
N	O
-	O
WASP	O
-	O
Arp2	B-Complex
/	I-Complex
3	I-Complex
pathway	O
.	O

The	O
Wiskott	O
-	O
Aldrich	O
syndrome	O
protein	O
(	O
WASP	O
)	O
and	O
its	O
relative	O
neural	O
WASP	O
(	O
N	O
-	O
WASP	O
)	O
regulate	O
the	O
nucleation	O
of	O
actin	O
filaments	O
through	O
their	O
interaction	O
with	O
the	O
Arp2	B-Complex
/	I-Complex
3	I-Complex
complex	O
and	O
are	O
regulated	O
in	O
turn	O
by	O
binding	O
to	O
GTP	O
-	O
bound	O
Cdc42	O
and	O
phosphatidylinositol	O
4	O
,	O
5	O
-	O
bisphosphate	O
.	O

The	O
Nck	O
Src	O
homology	O
(	O
SH	O
)	O
2	O
/	O
3	O
adaptor	O
binds	O
via	O
its	O
SH3	O
domains	O
to	O
a	O
proline	O
-	O
rich	O
region	O
on	O
WASP	O
and	O
N	O
-	O
WASP	O
and	O
has	O
been	O
implicated	O
in	O
recruitment	O
of	O
these	O
proteins	O
to	O
sites	O
of	O
tyrosine	O
phosphorylation	O
.	O

We	O
show	O
here	O
that	O
Nck	O
SH3	O
domains	O
dramatically	O
stimulate	O
the	O
rate	O
of	O
nucleation	O
of	O
actin	O
filaments	O
by	O
purified	O
N	O
-	O
WASP	O
in	O
the	O
presence	O
of	O
Arp2	B-Complex
/	I-Complex
3	I-Complex
in	O
vitro	O
.	O

All	O
three	O
Nck	O
SH3	O
domains	O
are	O
required	O
for	O
maximal	O
activation	O
.	O

Nck	O
-	O
stimulated	O
actin	O
nucleation	O
by	O
N	O
-	O
WASP	O
.	O
Arp2	B-Complex
/	I-Complex
3	I-Complex
complexes	O
is	O
further	O
stimulated	O
by	O
phosphatidylinositol	O
4	O
,	O
5	O
-	O
bisphosphate	O
,	O
but	O
not	O
by	O
GTP	O
-	O
Cdc42	O
,	O
suggesting	O
that	O
Nck	O
and	O
Cdc42	O
activate	O
N	O
-	O
WASP	O
by	O
redundant	O
mechanisms	O
.	O

These	O
results	O
suggest	O
the	O
existence	O
of	O
an	O
Nck	O
-	O
dependent	O
,	O
Cdc42	O
-	O
independent	O
mechanism	O
to	O
induce	O
actin	O
polymerization	O
at	O
tyrosine	O
-	O
phosphorylated	O
Nck	O
binding	O
sites	O
.	O

TcRho1	O
,	O
a	O
farnesylated	O
Rho	O
family	O
homologue	O
from	O
Trypanosoma	O
cruzi	O
:	O
cloning	O
,	O
trans	O
-	O
splicing	O
,	O
and	O
prenylation	O
studies	O
.	O

Rho	O
GTPases	O
are	O
members	O
of	O
the	O
Ras	O
superfamily	O
and	O
are	O
involved	O
in	O
signal	O
transduction	O
pathways	O
,	O
including	O
maintenance	O
of	O
cell	O
morphology	O
and	O
motility	O
,	O
cell	O
cycle	O
progression	O
,	O
and	O
transcription	O
activation	O
.	O

We	O
report	O
the	O
molecular	O
identification	O
in	O
trypanosomatids	O
(	O
Trypanosoma	O
cruzi	O
)	O
of	O
the	O
first	O
member	O
of	O
the	O
Rho	O
family	O
.	O

The	O
cloned	O
Rho	O
protein	O
,	O
TcRho1	O
,	O
shares	O
approximately	O
40	O
%	O
homology	O
with	O
other	O
members	O
of	O
the	O
Rho	O
family	O
.	O

Southern	O
blot	O
analysis	O
revealed	O
that	O
TcRHO1	O
is	O
a	O
single	O
copy	O
gene	O
per	O
haploid	O
genome	O
,	O
and	O
Northern	O
blot	O
assays	O
showed	O
a	O
transcript	O
of	O
1200	O
nucleotides	O
in	O
length	O
.	O

Mapping	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
of	O
TcRHO1	O
transcripts	O
revealed	O
at	O
least	O
five	O
different	O
transcripts	O
derived	O
from	O
differential	O
trans	O
-	O
splicing	O
.	O

Three	O
of	O
the	O
five	O
transcripts	O
contain	O
the	O
trans	O
-	O
splicing	O
site	O
within	O
the	O
coding	O
region	O
of	O
the	O
TcRHO1	O
gene	O
.	O

TcRho1	O
also	O
contains	O
the	O
C	O
-	O
terminal	O
sequence	O
CQLF	O
(	O
CAAX	O
motif	O
)	O
,	O
which	O
is	O
predicted	O
to	O
direct	O
post	O
-	O
translation	O
prenylation	O
of	O
the	O
cysteine	O
residue	O
.	O

A	O
synthetic	O
peptide	O
containing	O
this	O
C	O
-	O
terminal	O
motif	O
,	O
when	O
tested	O
against	O
Q	O
-	O
Sepharose	O
chromatography	O
fractions	O
from	O
T	O
.	O
cruzi	O
cytosol	O
,	O
was	O
shown	O
to	O
be	O
efficiently	O
farnesylated	O
,	O
but	O
not	O
geranylgeranylated	O
,	O
despite	O
the	O
fact	O
that	O
the	O
CAAX	O
motif	O
with	O
X	O
=	O
Phe	O
specifies	O
geranylgeranylation	O
by	O
mammalian	O
protein	O
geranylgeranyltransferase	B-Complex
I	I-Complex
.	O

Furthermore	O
,	O
immunoblot	O
analyses	O
of	O
epimastigote	O
protein	O
with	O
anti	O
-	O
S	O
-	O
farnesylcysteine	O
methyl	O
ester	O
and	O
anti	O
-	O
TcRho1	O
antisera	O
strongly	O
suggested	O
that	O
TcRho1	O
is	O
farnesylated	O
in	O
vivo	O
.	O

The	O
farnesylation	O
of	O
proteins	O
such	O
as	O
Rho	O
GTPases	O
could	O
be	O
the	O
basis	O
for	O
the	O
selective	O
cytotoxic	O
action	O
of	O
protein	O
farnesyltransferase	B-OOS
inhibitors	O
on	O
trypanosomatids	O
versus	O
mammalian	O
cells	O
.	O

Thiopalmitoylation	O
of	O
myelin	O
proteolipid	O
protein	O
epitopes	O
enhances	O
immunogenicity	O
and	O
encephalitogenicity	O
.	O

Proteolipid	O
protein	O
(	O
PLP	O
)	O
is	O
the	O
most	O
abundant	O
protein	O
of	O
CNS	O
myelin	O
,	O
and	O
is	O
posttranslationally	O
acylated	O
by	O
covalent	O
attachment	O
of	O
long	O
chain	O
fatty	O
acids	O
to	O
cysteine	O
residues	O
via	O
a	O
thioester	O
linkage	O
.	O

Two	O
of	O
the	O
acylation	O
sites	O
are	O
within	O
epitopes	O
of	O
PLP	O
that	O
are	O
encephalitogenic	O
in	O
SJL	O
/	O
J	O
mice	O
(	O
PLP	O
(	O
104	O
-	O
117	O
)	O
and	O
PLP	O
(	O
139	O
-	O
151	O
)	O
)	O
and	O
against	O
which	O
increased	O
immune	O
responses	O
have	O
been	O
detected	O
in	O
some	O
multiple	O
sclerosis	O
patients	O
.	O

It	O
is	O
known	O
that	O
attachment	O
of	O
certain	O
types	O
of	O
lipid	O
side	O
chains	O
to	O
peptides	O
can	O
result	O
in	O
their	O
enhanced	O
immunogenicity	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
thioacylated	O
PLP	O
peptides	O
,	O
as	O
occur	O
in	O
the	O
native	O
protein	O
,	O
are	O
more	O
immunogenic	O
than	O
their	O
nonacylated	O
counterparts	O
,	O
and	O
whether	O
thioacylation	O
influences	O
the	O
development	O
of	O
autoreactivity	O
and	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

The	O
results	O
show	O
that	O
in	O
comparison	O
with	O
nonacylated	O
peptides	O
,	O
thioacylated	O
PLP	O
lipopeptides	O
can	O
induce	O
greater	O
T	O
cell	O
and	O
Ab	O
responses	O
to	O
both	O
the	O
acylated	O
and	O
nonacylated	O
peptides	O
.	O

They	O
also	O
enhanced	O
the	O
development	O
and	O
chronicity	O
of	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

Synthetic	O
peptides	O
in	O
which	O
the	O
fatty	O
acid	O
was	O
attached	O
via	O
an	O
amide	O
linkage	O
at	O
the	O
N	O
terminus	O
were	O
not	O
encephalitogenic	O
,	O
and	O
they	O
induced	O
greater	O
proportions	O
of	O
CD8	O
+	O
cells	O
in	O
initial	O
in	O
vitro	O
stimulation	O
.	O

Therefore	O
,	O
the	O
lability	O
and	O
the	O
site	O
of	O
the	O
linkage	O
between	O
the	O
peptide	O
and	O
fatty	O
acid	O
may	O
be	O
important	O
for	O
induction	O
of	O
encephalitogenic	O
CD4	O
+	O
T	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
immune	O
responses	O
induced	O
by	O
endogenous	O
thioacylated	O
lipopeptides	O
may	O
contribute	O
to	O
the	O
immunopathogenesis	O
of	O
chronic	O
experimental	O
demyelinating	O
diseases	O
and	O
multiple	O
sclerosis	O
.	O

We	O
have	O
identified	O
Mba1	O
as	O
one	O
such	O
other	O
component	O
that	O
is	O
in	O
contact	O
with	O
insertion	O
intermediates	O
as	O
they	O
integrate	O
into	O
the	O
lipid	O
bilayer	O
.	O

Like	O
Oxa1	O
,	O
Mba1	O
is	O
required	O
for	O
efficient	O
protein	O
insertion	O
of	O
both	O
mitochondrially	O
and	O
nuclear	O
-	O
encoded	O
proteins	O
.	O

Mba1	O
and	O
Oxa1	O
overlap	O
not	O
only	O
in	O
substrate	O
specificity	O
,	O
but	O
most	O
likely	O
also	O
in	O
their	O
function	O
.	O

In	O
the	O
presence	O
of	O
Oxa1	O
,	O
Mba1	O
is	O
largely	O
dispensable	O
,	O
indicating	O
that	O
Oxa1	O
can	O
function	O
independently	O
of	O
Mba1	O
.	O

In	O
contrast	O
,	O
Mba1	O
is	O
unable	O
to	O
replace	O
Oxa1	O
completely	O
even	O
upon	O
overexpression	O
,	O
but	O
restores	O
the	O
defective	O
insertion	O
of	O
the	O
Oxa1	O
precursor	O
in	O
a	O
Deltaoxa1	O
mutant	O
.	O

This	O
partial	O
suppression	O
may	O
be	O
explained	O
by	O
the	O
observation	O
that	O
Mba1	O
needs	O
Oxa1	O
to	O
interact	O
with	O
Cox2	O
,	O
whereas	O
its	O
interaction	O
with	O
Cox3	O
is	O
independent	O
of	O
Oxa1	O
.	O

ATR	O
-	O
mediated	O
checkpoint	O
pathways	O
regulate	O
phosphorylation	O
and	O
activation	O
of	O
human	O
Chk1	O
.	O

Chk1	O
is	O
an	O
evolutionarily	O
conserved	O
protein	O
kinase	O
that	O
regulates	O
cell	O
cycle	O
progression	O
in	O
response	O
to	O
checkpoint	O
activation	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
agents	O
that	O
block	O
DNA	O
replication	O
or	O
cause	O
certain	O
forms	O
of	O
DNA	O
damage	O
induce	O
the	O
phosphorylation	O
of	O
human	O
Chk1	O
.	O

The	O
phosphorylated	O
form	O
of	O
Chk1	O
possessed	O
higher	O
intrinsic	O
protein	O
kinase	O
activity	O
and	O
eluted	O
more	O
quickly	O
on	O
gel	O
filtration	O
columns	O
.	O

Serines	O
317	O
and	O
345	O
were	O
identified	O
as	O
sites	O
of	O
phosphorylation	O
in	O
vivo	O
,	O
and	O
ATR	O
(	O
the	O
ATM	O
-	O
and	O
Rad3	O
-	O
related	O
protein	O
kinase	O
)	O
phosphorylated	O
both	O
of	O
these	O
sites	O
in	O
vitro	O
.	O

Furthermore	O
,	O
phosphorylation	O
of	O
Chk1	O
on	O
serines	O
317	O
and	O
345	O
in	O
vivo	O
was	O
ATR	O
dependent	O
.	O

Mutants	O
of	O
Chk1	O
containing	O
alanine	O
in	O
place	O
of	O
serines	O
317	O
and	O
345	O
were	O
poorly	O
activated	O
in	O
response	O
to	O
replication	O
blocks	O
or	O
genotoxic	O
stress	O
in	O
vivo	O
,	O
were	O
poorly	O
phosphorylated	O
by	O
ATR	O
in	O
vitro	O
,	O
and	O
were	O
not	O
found	O
in	O
faster	O
-	O
eluting	O
fractions	O
by	O
gel	O
filtration	O
.	O

These	O
findings	O
demonstrate	O
that	O
the	O
activation	O
of	O
Chk1	O
in	O
response	O
to	O
replication	O
blocks	O
and	O
certain	O
forms	O
of	O
genotoxic	O
stress	O
involves	O
phosphorylation	O
of	O
serines	O
317	O
and	O
345	O
.	O

In	O
addition	O
,	O
this	O
study	O
implicates	O
ATR	O
as	O
a	O
direct	O
upstream	O
activator	O
of	O
Chk1	O
in	O
human	O
cells	O
.	O

Human	O
pex19p	O
binds	O
peroxisomal	O
integral	O
membrane	O
proteins	O
at	O
regions	O
distinct	O
from	O
their	O
sorting	O
sequences	O
.	O

The	O
molecular	O
machinery	O
underlying	O
peroxisomal	O
membrane	O
biogenesis	O
is	O
not	O
well	O
understood	O
.	O

The	O
observation	O
that	O
cells	O
deficient	O
in	O
the	O
peroxins	O
Pex3p	O
,	O
Pex16p	O
,	O
and	O
Pex19p	O
lack	O
peroxisomal	O
membrane	O
structures	O
suggests	O
that	O
these	O
molecules	O
are	O
involved	O
in	O
the	O
initial	O
stages	O
of	O
peroxisomal	O
membrane	O
formation	O
.	O

Pex19p	O
,	O
a	O
predominantly	O
cytosolic	O
protein	O
that	O
can	O
be	O
farnesylated	O
,	O
binds	O
multiple	O
peroxisomal	O
integral	O
membrane	O
proteins	O
,	O
and	O
it	O
has	O
been	O
suggested	O
that	O
it	O
functions	O
as	O
a	O
soluble	O
receptor	O
for	O
the	O
targeting	O
of	O
peroxisomal	O
membrane	O
proteins	O
(	O
PMPs	O
)	O
to	O
the	O
peroxisome	O
.	O

An	O
alternative	O
view	O
proposes	O
that	O
Pex19p	O
functions	O
as	O
a	O
chaperone	O
at	O
the	O
peroxisomal	O
membrane	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
peroxisomal	O
sorting	O
determinants	O
and	O
the	O
Pex19p	O
-	O
binding	O
domains	O
of	O
a	O
number	O
of	O
PMPs	O
are	O
distinct	O
entities	O
.	O

In	O
addition	O
,	O
we	O
extend	O
the	O
list	O
of	O
peroxins	O
with	O
which	O
human	O
Pex19p	O
interacts	O
to	O
include	O
the	O
PMP	O
Pex16p	O
and	O
show	O
that	O
Pex19p	O
'	O
s	O
CaaX	O
prenylation	O
motif	O
is	O
an	O
important	O
determinant	O
in	O
the	O
affinity	O
of	O
Pex19p	O
for	O
Pex10p	O
,	O
Pex11pbeta	O
,	O
Pex12p	O
,	O
and	O
Pex13p	O
.	O

Etiological	O
point	O
mutations	O
in	O
the	O
hereditary	O
multiple	O
exostoses	O
gene	O
EXT1	O
:	O
a	O
functional	O
analysis	O
of	O
heparan	O
sulfate	O
polymerase	O
activity	O
.	O

Hereditary	O
multiple	O
exostoses	O
(	O
HME	O
)	O
,	O
a	O
dominantly	O
inherited	O
genetic	O
disorder	O
characterized	O
by	O
multiple	O
cartilaginous	O
tumors	O
,	O
is	O
caused	O
by	O
mutations	O
in	O
members	O
of	O
the	O
EXT	O
gene	O
family	O
,	O
EXT1	O
or	O
EXT2	O
.	O

The	O
corresponding	O
gene	O
products	O
,	O
exostosin	O
-	O
1	O
(	O
EXT1	O
)	O
and	O
exostosin	O
-	O
2	O
(	O
EXT2	O
)	O
,	O
are	O
type	O
II	O
transmembrane	O
glycoproteins	O
which	O
form	O
a	O
Golgi	O
-	O
localized	O
heterooligomeric	O
complex	O
that	O
catalyzes	O
the	O
polymerization	O
of	O
heparan	O
sulfate	O
(	O
HS	O
)	O
.	O

Although	O
the	O
majority	O
of	O
the	O
etiological	O
mutations	O
in	O
EXT	O
are	O
splice	O
-	O
site	O
,	O
frameshift	O
,	O
or	O
nonsense	O
mutations	O
that	O
result	O
in	O
premature	O
termination	O
,	O
12	O
missense	O
mutations	O
have	O
also	O
been	O
identified	O
.	O

Furthermore	O
,	O
two	O
of	O
the	O
reported	O
etiological	O
missense	O
mutations	O
(	O
G339D	O
and	O
R340C	O
)	O
have	O
been	O
previously	O
shown	O
to	O
abrogate	O
HS	O
biosynthesis	O
(	O
McCormick	O
et	O
al	O
.	O
1998	O
)	O
.	O

Here	O
,	O
a	O
functional	O
assay	O
that	O
detects	O
HS	O
expression	O
on	O
the	O
cell	O
surface	O
of	O
an	O
EXT1	O
-	O
deficient	O
cell	O
line	O
was	O
used	O
to	O
test	O
the	O
remaining	O
missense	O
mutant	O
exostosin	O
proteins	O
for	O
their	O
ability	O
to	O
rescue	O
HS	O
biosynthesis	O
in	O
vivo	O
.	O

Our	O
results	O
show	O
that	O
EXT1	O
mutants	O
bearing	O
six	O
of	O
these	O
missense	O
mutations	O
(	O
D164H	O
,	O
R280G	O
/	O
S	O
,	O
and	O
R340S	O
/	O
H	O
/	O
L	O
)	O
are	O
also	O
defective	O
in	O
HS	O
expression	O
,	O
but	O
surprisingly	O
,	O
four	O
(	O
Q27K	O
,	O
N316S	O
,	O
A486V	O
,	O
and	O
P496L	O
)	O
are	O
phenotypically	O
indistinguishable	O
from	O
wild	O
-	O
type	O
EXT1	O
.	O

Three	O
of	O
these	O
four	O
"	O
active	O
"	O
mutations	O
affect	O
amino	O
acids	O
that	O
are	O
not	O
conserved	O
among	O
vertebrates	O
and	O
invertebrates	O
,	O
whereas	O
all	O
of	O
the	O
HS	O
-	O
biosynthesis	O
null	O
mutations	O
affect	O
only	O
conserved	O
amino	O
acids	O
.	O

Further	O
,	O
substitution	O
or	O
deletion	O
of	O
each	O
of	O
these	O
four	O
residues	O
does	O
not	O
abrogate	O
HS	O
biosynthesis	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
several	O
of	O
the	O
reported	O
etiological	O
mutant	O
EXT	O
forms	O
retain	O
the	O
ability	O
to	O
synthesize	O
and	O
express	O
HS	O
on	O
the	O
cell	O
surface	O
.	O

The	O
corresponding	O
missense	O
mutations	O
may	O
therefore	O
represent	O
rare	O
genetic	O
polymorphisms	O
in	O
the	O
EXT1	O
gene	O
or	O
may	O
interfere	O
with	O
as	O
yet	O
undefined	O
functions	O
of	O
EXT1	O
that	O
are	O
involved	O
in	O
HME	O
pathogenesis	O
.	O

TGIF2	O
interacts	O
with	O
histone	O
deacetylase	O
1	O
and	O
represses	O
transcription	O
.	O

TG	O
-	O
interacting	O
factor	O
(	O
TGIF	O
)	O
is	O
a	O
transcriptional	O
repressor	O
,	O
which	O
represses	O
transcription	O
by	O
binding	O
directly	O
to	O
DNA	O
or	O
interacts	O
with	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
beta	O
)	O
-	O
activated	O
Smads	O
,	O
thereby	O
repressing	O
TGF	O
beta	O
-	O
responsive	O
gene	O
expression	O
.	O

Mutation	O
of	O
TGIF	O
in	O
humans	O
causes	O
holoprosencephaly	O
,	O
a	O
severe	O
genetic	O
disorder	O
affecting	O
craniofacial	O
development	O
.	O

Searching	O
human	O
expressed	O
sequence	O
tag	O
data	O
bases	O
revealed	O
the	O
presence	O
of	O
clones	O
encoding	O
a	O
TGIF	O
-	O
related	O
protein	O
(	O
TGIF2	O
)	O
,	O
which	O
contains	O
two	O
regions	O
of	O
high	O
sequence	O
identity	O
with	O
TGIF	O
.	O

Here	O
we	O
show	O
that	O
,	O
like	O
TGIF	O
,	O
TGIF2	O
recruits	O
histone	O
deacetylase	O
,	O
but	O
in	O
contrast	O
to	O
TGIF	O
,	O
is	O
unable	O
to	O
interact	O
with	O
the	O
corepressor	O
CtBP	O
.	O

TGIF2	O
and	O
TGIF	O
have	O
very	O
similar	O
DNA	O
-	O
binding	O
homeodomains	O
,	O
and	O
TGIF2	O
represses	O
transcription	O
when	O
bound	O
to	O
DNA	O
via	O
a	O
TGIF	O
binding	O
site	O
.	O

TGIF2	O
interacts	O
with	O
TGF	O
beta	O
-	O
activated	O
Smads	O
and	O
represses	O
TGF	O
beta	O
-	O
responsive	O
transcription	O
.	O

TGIF2	O
appears	O
to	O
be	O
a	O
context	O
-	O
independent	O
transcriptional	O
repressor	O
,	O
which	O
can	O
perform	O
similar	O
functions	O
to	O
TGIF	O
and	O
may	O
play	O
a	O
role	O
in	O
processes	O
,	O
which	O
,	O
when	O
disrupted	O
by	O
mutations	O
in	O
TGIF	O
,	O
cause	O
holoprosencephaly	O
.	O

Role	O
of	O
PML	O
and	O
PML	O
-	O
RARalpha	O
in	O
Mad	O
-	O
mediated	O
transcriptional	O
repression	O
.	O

Fusion	O
of	O
the	O
promyelocytic	O
leukemia	O
(	O
PML	O
)	O
protein	O
to	O
the	O
retinoic	O
acid	O
receptor	O
-	O
alpha	O
(	O
RARalpha	O
)	O
generates	O
the	O
transforming	O
protein	O
of	O
acute	O
promyelocytic	O
leukemias	O
.	O

PML	O
appears	O
to	O
be	O
involved	O
in	O
multiple	O
functions	O
,	O
including	O
apoptosis	O
and	O
transcriptional	O
activation	O
by	O
RAR	O
,	O
whereas	O
PML	O
-	O
RARalpha	O
blocks	O
these	O
functions	O
of	O
PML	O
.	O

However	O
,	O
the	O
mechanisms	O
of	O
leukemogenesis	O
by	O
PML	O
-	O
RARalpha	O
remain	O
elusive	O
.	O

Here	O
we	O
show	O
that	O
PML	O
interacts	O
with	O
multiple	O
corepressors	O
(	O
c	O
-	O
Ski	O
,	O
N	O
-	O
CoR	O
,	O
and	O
mSin3A	O
)	O
and	O
histone	O
deacetylase	O
1	O
,	O
and	O
that	O
this	O
interaction	O
is	O
required	O
for	O
transcriptional	O
repression	O
mediated	O
by	O
the	O
tumor	O
suppressor	O
Mad	O
.	O

PML	O
-	O
RARalpha	O
has	O
the	O
two	O
corepressor	O
-	O
interacting	O
sites	O
and	O
inhibits	O
Mad	O
-	O
mediated	O
repression	O
,	O
suggesting	O
that	O
aberrant	O
binding	O
of	O
PML	O
-	O
RARalpha	O
to	O
the	O
corepressor	O
complexes	O
may	O
lead	O
to	O
abrogation	O
of	O
the	O
corepressor	O
function	O
.	O

These	O
mechanisms	O
may	O
contribute	O
to	O
events	O
leading	O
to	O
leukemogenesis	O
.	O

Ten	O
ERK	O
-	O
related	O
proteins	O
in	O
three	O
distinct	O
classes	O
associate	O
with	O
AP	B-Complex
-	I-Complex
1	I-Complex
proteins	O
and	O
/	O
or	O
AP	B-Complex
-	I-Complex
1	I-Complex
DNA	O
.	O

We	O
have	O
identified	O
seven	O
ERK	O
-	O
related	O
proteins	O
(	O
"	O
ERPs	O
"	O
)	O
,	O
including	O
ERK2	O
,	O
that	O
are	O
stably	O
associated	O
in	O
vivo	O
with	O
AP	B-Complex
-	I-Complex
1	I-Complex
dimers	O
composed	O
of	O
diverse	O
Jun	O
and	O
Fos	O
family	O
proteins	O
.	O

These	O
complexes	O
have	O
kinase	O
activity	O
.	O

We	O
designate	O
them	O
as	O
"	O
class	O
I	O
ERPs	O
.	O
"	O
We	O
originally	O
hypothesized	O
that	O
these	O
ERPs	O
associate	O
with	O
DNA	O
along	O
with	O
AP	B-Complex
-	I-Complex
1	I-Complex
proteins	O
.	O

We	O
devised	O
a	O
DNA	O
affinity	O
chromatography	O
-	O
based	O
analytical	O
assay	O
for	O
DNA	O
binding	O
,	O
the	O
"	O
nucleotide	O
affinity	O
preincubation	O
specificity	O
test	O
recognition	O
"	O
(	O
NAPSTER	O
)	O
assay	O
.	O

In	O
this	O
assay	O
,	O
class	O
I	O
ERPs	O
do	O
not	O
associate	O
with	O
AP	B-Complex
-	I-Complex
1	I-Complex
DNA	O
.	O

However	O
,	O
several	O
new	O
"	O
class	O
II	O
"	O
ERPs	O
do	O
associate	O
with	O
DNA	O
.	O

p41	O
and	O
p44	O
are	O
ERK1	O
/	O
2	O
-	O
related	O
ERPs	O
that	O
lack	O
kinase	O
activity	O
and	O
associate	O
along	O
with	O
AP	B-Complex
-	I-Complex
1	I-Complex
proteins	O
with	O
AP	B-Complex
-	I-Complex
1	I-Complex
DNA	O
.	O

Class	O
I	O
ERPs	O
and	O
their	O
associated	O
kinase	O
activity	O
thus	O
appear	O
to	O
bind	O
AP	B-Complex
-	I-Complex
1	I-Complex
dimers	O
when	O
they	O
are	O
not	O
bound	O
to	O
DNA	O
and	O
then	O
disengage	O
and	O
are	O
replaced	O
by	O
class	O
II	O
ERPs	O
to	O
form	O
higher	O
order	O
complexes	O
when	O
AP	B-Complex
-	I-Complex
1	I-Complex
dimers	O
bind	O
DNA	O
.	O

p97	O
is	O
a	O
class	O
III	O
ERP	O
,	O
related	O
to	O
ERK3	O
,	O
that	O
associates	O
with	O
AP	B-Complex
-	I-Complex
1	I-Complex
DNA	O
without	O
AP	B-Complex
-	I-Complex
1	I-Complex
proteins	O
.	O

With	O
the	O
exception	O
of	O
ERK2	O
,	O
none	O
of	O
the	O
10	O
ERPs	O
appear	O
to	O
be	O
known	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
superfamily	O
members	O
.	O

Rat	O
protein	O
tyrosine	O
phosphatase	O
eta	O
physically	O
interacts	O
with	O
the	O
PDZ	O
domains	O
of	O
syntenin	O
.	O

The	O
tyrosine	O
phosphatase	O
r	O
-	O
PTPeta	O
is	O
able	O
to	O
suppress	O
the	O
malignant	O
phenotype	O
of	O
rat	O
thyroid	O
tumorigenic	O
cell	O
lines	O
.	O

To	O
identify	O
r	O
-	O
PTPeta	O
interacting	O
proteins	O
,	O
a	O
yeast	O
two	O
-	O
hybrid	O
screening	O
was	O
performed	O
and	O
an	O
insert	O
corresponding	O
to	O
the	O
full	O
-	O
length	O
syntenin	O
cDNA	O
was	O
isolated	O
.	O

It	O
encodes	O
a	O
protein	O
containing	O
two	O
PDZ	O
domains	O
that	O
mediates	O
the	O
binding	O
of	O
syntenin	O
to	O
proteins	O
such	O
as	O
syndecan	O
,	O
proTGF	O
-	O
alpha	O
,	O
beta	O
-	O
ephrins	O
and	O
neurofascin	O
.	O

We	O
show	O
that	O
r	O
-	O
PTPeta	O
is	O
able	O
to	O
interact	O
with	O
syntenin	O
also	O
in	O
mammalian	O
cells	O
,	O
and	O
although	O
syntenin	O
is	O
a	O
tyrosine	O
-	O
phosphorylated	O
protein	O
it	O
is	O
not	O
a	O
substrate	O
of	O
r	O
-	O
PTPeta	O
.	O

The	O
integrity	O
of	O
both	O
PDZ	O
domains	O
of	O
syntenin	O
and	O
the	O
carboxy	O
-	O
terminal	O
region	O
of	O
r	O
-	O
PTPeta	O
are	O
required	O
for	O
the	O
interaction	O
between	O
syntenin	O
and	O
r	O
-	O
PTPeta	O
.	O

DNA	O
polymerase	O
beta	O
-	O
mediated	O
long	O
patch	O
base	O
excision	O
repair	O
.	O

Poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
-	O
1	O
stimulates	O
strand	O
displacement	O
DNA	O
synthesis	O
.	O

Recently	O
,	O
photoaffinity	O
labeling	O
experiments	O
with	O
mouse	O
cell	O
extracts	O
suggested	O
that	O
PARP	O
-	O
1	O
functions	O
as	O
a	O
surveillance	O
protein	O
for	O
a	O
stalled	O
BER	O
intermediate	O
.	O

To	O
further	O
understand	O
the	O
role	O
of	O
PARP	O
-	O
1	O
in	O
BER	O
,	O
we	O
examined	O
the	O
DNA	O
synthesis	O
and	O
flap	O
excision	O
steps	O
in	O
long	O
patch	O
BER	O
using	O
a	O
reconstituted	O
system	O
containing	O
a	O
34	O
-	O
base	O
pair	O
BER	O
substrate	O
and	O
five	O
purified	O
human	O
enzymes	O
:	O
uracil	O
-	O
DNA	O
glycosylase	O
,	O
apurinic	O
/	O
apyrimidinic	O
endonuclease	O
,	O
DNA	O
polymerase	O
beta	O
,	O
flap	O
endonuclease	O
-	O
1	O
(	O
FEN	O
-	O
1	O
)	O
,	O
and	O
PARP	O
-	O
1	O
.	O

PARP	O
-	O
1	O
stimulates	O
strand	O
displacement	O
DNA	O
synthesis	O
by	O
DNA	O
polymerase	O
beta	O
in	O
this	O
system	O
;	O
this	O
stimulation	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
FEN	O
-	O
1	O
.	O

PARP	O
-	O
1	O
and	O
FEN	O
-	O
1	O
,	O
therefore	O
,	O
cooperate	O
to	O
activate	O
long	O
patch	O
BER	O
.	O

The	O
results	O
are	O
discussed	O
in	O
the	O
context	O
of	O
a	O
model	O
for	O
BER	O
sub	O
-	O
pathway	O
choice	O
,	O
illustrating	O
a	O
dual	O
role	O
for	O
PARP	O
-	O
1	O
as	O
a	O
surveillance	O
protein	O
for	O
a	O
stalled	O
BER	O
intermediate	O
and	O
an	O
activating	O
factor	O
for	O
long	O
patch	O
BER	O
DNA	O
synthesis	O
.	O

Regulation	O
of	O
pyruvate	B-Complex
dehydrogenase	I-Complex
activity	O
through	O
phosphorylation	O
at	O
multiple	O
sites	O
.	O

The	O
enzymic	O
activity	O
of	O
the	O
mammalian	O
pyruvate	B-Complex
dehydrogenase	I-Complex
complex	O
is	O
regulated	O
by	O
the	O
phosphorylation	O
of	O
three	O
serine	O
residues	O
(	O
sites	O
1	O
,	O
2	O
and	O
3	O
)	O
located	O
on	O
the	O
E1	B-Complex
component	O
of	O
the	O
complex	O
.	O

Here	O
we	O
report	O
that	O
the	O
four	O
isoenzymes	O
of	O
protein	O
kinase	O
responsible	O
for	O
the	O
phosphorylation	O
and	O
inactivation	O
of	O
pyruvate	B-Complex
dehydrogenase	I-Complex
(	O
PDK1	O
,	O
PDK2	O
,	O
PDK3	O
and	O
PDK4	O
)	O
differ	O
in	O
their	O
abilities	O
to	O
phosphorylate	O
the	O
enzyme	O
.	O

PDK1	O
can	O
phosphorylate	O
all	O
three	O
sites	O
,	O
whereas	O
PDK2	O
,	O
PDK3	O
and	O
PDK4	O
each	O
phosphorylate	O
only	O
site	O
1	O
and	O
site	O
2	O
.	O

Although	O
PDK2	O
phosphorylates	O
site	O
1	O
and	O
2	O
,	O
it	O
incorporates	O
less	O
phosphate	O
in	O
site	O
2	O
than	O
PDK3	O
or	O
PDK4	O
.	O

As	O
a	O
result	O
,	O
the	O
amount	O
of	O
phosphate	O
incorporated	O
by	O
each	O
isoenzyme	O
decreases	O
in	O
the	O
order	O
PDK1	O
>	O
PDK3	O
>	O
or	O
=	O
PDK4	O
>	O
PDK2	O
.	O

Significantly	O
,	O
binding	O
of	O
the	O
coenzyme	O
thiamin	O
pyrophosphate	O
to	O
pyruvate	B-Complex
dehydrogenase	I-Complex
alters	O
the	O
rates	O
and	O
stoichiometries	O
of	O
phosphorylation	O
of	O
the	O
individual	O
sites	O
.	O

First	O
,	O
the	O
rate	O
of	O
phosphorylation	O
of	O
site	O
1	O
by	O
all	O
isoenzymes	O
of	O
kinase	O
is	O
decreased	O
.	O

Secondly	O
,	O
thiamin	O
pyrophosphate	O
markedly	O
decreases	O
the	O
amount	O
of	O
phosphate	O
that	O
PDK1	O
incorporates	O
in	O
sites	O
2	O
and	O
3	O
and	O
that	O
PDK2	O
incorporates	O
in	O
site	O
2	O
.	O

In	O
contrast	O
,	O
the	O
coenzyme	O
does	O
not	O
significantly	O
affect	O
the	O
total	O
amount	O
of	O
phosphate	O
incorporated	O
in	O
site	O
2	O
by	O
PDK3	O
and	O
PDK4	O
,	O
but	O
instead	O
decreases	O
the	O
rate	O
of	O
phosphorylation	O
of	O
this	O
site	O
.	O

Furthermore	O
,	O
pyruvate	B-Complex
dehydrogenase	I-Complex
complex	O
phosphorylated	O
by	O
the	O
individual	O
isoenzymes	O
of	O
kinase	O
is	O
reactivated	O
at	O
different	O
rates	O
by	O
pyruvate	O
dehydrogenase	O
phosphatase	O
.	O

Both	O
isoenzymes	O
of	O
phosphatase	O
(	O
PDP1	O
and	O
PDP2	O
)	O
readily	O
reactivate	O
the	O
complex	O
phosphorylated	O
by	O
PDK2	O
.	O

When	O
pyruvate	B-Complex
dehydrogenase	I-Complex
is	O
phosphorylated	O
by	O
other	O
isoenzymes	O
,	O
the	O
rates	O
of	O
reactivation	O
decrease	O
in	O
the	O
order	O
PDK4	O
>	O
or	O
=	O
PDK3	O
>	O
PDK1	O
.	O

Taken	O
together	O
,	O
results	O
reported	O
here	O
strongly	O
suggest	O
that	O
the	O
major	O
determinants	O
of	O
the	O
activity	O
state	O
of	O
pyruvate	B-Complex
dehydrogenase	I-Complex
in	O
mammalian	O
tissues	O
include	O
the	O
phosphorylation	O
site	O
specificity	O
of	O
isoenzymes	O
of	O
kinase	O
in	O
addition	O
to	O
the	O
absolute	O
amounts	O
of	O
kinase	O
and	O
phosphatase	O
protein	O
expressed	O
in	O
mitochondria	O
.	O

The	O
brain	O
-	O
specific	O
synaptotagmin	O
1	O
member	O
of	O
the	O
synaptotagmin	O
family	O
appears	O
to	O
exhibit	O
tissue	O
-	O
specific	O
endocytosis	O
,	O
a	O
relatively	O
rare	O
phenomenon	O
.	O

Although	O
synaptotagmin	O
1	O
is	O
readily	O
internalized	O
by	O
the	O
neuronal	O
-	O
like	O
PC12	O
cells	O
,	O
in	O
transfected	O
fibroblasts	O
it	O
was	O
found	O
mostly	O
on	O
the	O
cell	O
surface	O
.	O

This	O
suggested	O
that	O
cells	O
of	O
the	O
neuroendocrine	O
lineage	O
possess	O
an	O
endocytotic	O
mechanism	O
lacking	O
in	O
nonneuronal	O
cells	O
.	O

To	O
try	O
to	O
understand	O
this	O
mechanism	O
,	O
we	O
have	O
examined	O
the	O
internalization	O
of	O
synaptotagmin	O
1	O
and	O
its	O
chimeras	O
into	O
neuronal	O
and	O
nonneuronal	O
cell	O
lines	O
.	O

Surprisingly	O
,	O
the	O
AP2	O
binding	O
site	O
in	O
the	O
C2B	O
domain	O
is	O
not	O
needed	O
for	O
internalization	O
of	O
chimeras	O
.	O

By	O
contrast	O
,	O
we	O
find	O
evidence	O
for	O
an	O
internalization	O
signal	O
in	O
the	O
COOH	O
-	O
terminal	O
domain	O
of	O
synaptotagmin	O
1	O
.	O

The	O
internalization	O
signal	O
is	O
sufficient	O
to	O
mediate	O
internalization	O
of	O
chimeras	O
in	O
the	O
absence	O
of	O
the	O
C2B	O
domain	O
,	O
and	O
can	O
be	O
recognized	O
by	O
the	O
endocytotic	O
machinery	O
even	O
in	O
nonneuronal	O
cells	O
.	O

The	O
C2B	O
domain	O
acts	O
as	O
a	O
regulator	O
of	O
internalization	O
since	O
in	O
fibroblast	O
cells	O
it	O
normally	O
conceals	O
the	O
synaptotagmin	O
1	O
internalization	O
signal	O
.	O

In	O
PC12	O
cells	O
,	O
little	O
inhibition	O
of	O
the	O
COOH	O
-	O
terminal	O
internalization	O
signal	O
by	O
the	O
C2B	O
domain	O
is	O
seen	O
unless	O
mutations	O
are	O
made	O
in	O
the	O
C2B	O
domain	O
,	O
in	O
particular	O
in	O
a	O
dilysine	O
motif	O
that	O
has	O
already	O
been	O
implicated	O
in	O
endocytosis	O
by	O
the	O
synprint	O
experiments	O
of	O
.	O

Endocytosis	O
of	O
synaptotagmin	O
1	O
appears	O
to	O
be	O
controlled	O
by	O
a	O
latent	O
internalization	O
signal	O
that	O
is	O
activated	O
by	O
a	O
neuroendocrine	O
-	O
specific	O
mechanism	O
acting	O
via	O
the	O
C2B	O
domain	O
.	O

Thus	O
,	O
synaptotagmin	O
1	O
internalization	O
resembles	O
ligand	O
-	O
activated	O
endocytosis	O
of	O
surface	O
receptors	O
,	O
except	O
that	O
the	O
activation	O
is	O
intracellular	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
human	O
sterol	O
12alpha	O
-	O
hydroxylase	O
gene	O
(	O
CYP8B1	O
)	O
:	O
roles	O
of	O
heaptocyte	O
nuclear	O
factor	O
4alpha	O
in	O
mediating	O
bile	O
acid	O
repression	O
.	O

Sterol	O
12alpha	O
-	O
hydroxylase	O
catalyzes	O
the	O
synthesis	O
of	O
cholic	O
acid	O
and	O
controls	O
the	O
ratio	O
of	O
cholic	O
acid	O
over	O
chenodeoxycholic	O
acid	O
in	O
the	O
bile	O
.	O

Transcription	O
of	O
CYP8B1	O
is	O
inhibited	O
by	O
bile	O
acids	O
,	O
cholesterol	O
,	O
and	O
insulin	O
.	O

To	O
study	O
the	O
mechanism	O
of	O
CYP8B1	O
transcription	O
by	O
bile	O
acids	O
,	O
we	O
have	O
cloned	O
and	O
determined	O
3389	O
base	O
pairs	O
of	O
the	O
5	O
'	O
-	O
upstream	O
nucleotide	O
sequences	O
of	O
the	O
human	O
CYP8B1	O
.	O

Deletion	O
analysis	O
of	O
CYP8B1	O
/	O
luciferase	O
reporter	O
activity	O
in	O
HepG2	O
cells	O
revealed	O
that	O
the	O
sequences	O
from	O
-	O
57	O
to	O
+	O
300	O
were	O
important	O
for	O
basal	O
and	O
liver	O
-	O
specific	O
promoter	O
activities	O
.	O

Hepatocyte	O
nuclear	O
factor	O
4alpha	O
(	O
HNF4alpha	O
)	O
strongly	O
activated	O
human	O
CYP8B1	O
promoter	O
activities	O
,	O
whereas	O
cholesterol	O
7alpha	O
-	O
hydroxylase	O
promoter	O
factor	O
(	O
CPF	O
)	O
,	O
an	O
NR5A2	O
family	O
of	O
nuclear	O
receptors	O
,	O
had	O
much	O
less	O
effect	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
identified	O
an	O
overlapping	O
HNF4alpha	O
-	O
and	O
CPF	O
-	O
binding	O
site	O
in	O
the	O
+	O
198	O
/	O
+	O
227	O
region	O
.	O

The	O
human	O
CYP8B1	O
promoter	O
activities	O
were	O
strongly	O
repressed	O
by	O
bile	O
acids	O
,	O
and	O
the	O
bile	O
acid	O
response	O
element	O
was	O
localized	O
between	O
+	O
137	O
and	O
+	O
220	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
the	O
HNF4alpha	O
-	O
binding	O
site	O
markedly	O
reduced	O
promoter	O
activity	O
and	O
its	O
response	O
to	O
bile	O
acid	O
repression	O
.	O

On	O
the	O
other	O
hand	O
,	O
mutation	O
of	O
the	O
CPF	O
-	O
binding	O
site	O
had	O
little	O
effect	O
on	O
promoter	O
activity	O
and	O
bile	O
acid	O
inhibition	O
.	O

A	O
negative	O
nuclear	O
receptor	O
,	O
small	O
heterodimer	O
partner	O
markedly	O
inhibited	O
transactivation	O
of	O
CYP8B1	O
by	O
HNF4alpha	O
.	O

Mammalian	O
two	O
-	O
hybrid	O
assay	O
confirmed	O
that	O
HNF4alpha	O
interacted	O
with	O
small	O
heterodimer	O
partner	O
.	O

Furthermore	O
,	O
bile	O
acids	O
and	O
farnesoid	O
X	O
receptor	O
reduced	O
the	O
expression	O
of	O
nuclear	O
HNF4alpha	O
in	O
HepG2	O
cells	O
and	O
rat	O
livers	O
and	O
its	O
binding	O
to	O
DNA	O
.	O

Bile	O
acids	O
and	O
farnesoid	O
X	O
receptor	O
also	O
inhibited	O
mouse	O
HNF4alpha	O
gene	O
transcription	O
.	O

In	O
summary	O
,	O
our	O
data	O
revealed	O
the	O
critical	O
roles	O
HNF4alpha	O
play	O
on	O
CYP8B1	O
transcription	O
and	O
its	O
repression	O
by	O
bile	O
acids	O
.	O

Bile	O
acids	O
repress	O
human	O
CYP8B1	O
transcription	O
by	O
reducing	O
the	O
transactivation	O
activity	O
of	O
HNF4alpha	O
through	O
interaction	O
of	O
HNF4alpha	O
with	O
SHP	O
and	O
reduction	O
of	O
HNF4alpha	O
expression	O
in	O
the	O
liver	O
.	O

The	O
albumin	O
binding	O
of	O
unconjugated	O
bilirubin	O
in	O
serum	O
.	O

1	O
.	O

The	O
limited	O
bilirubin	O
binding	O
capacity	O
of	O
human	O
serum	O
albumin	O
,	O
and	O
the	O
fact	O
that	O
kernicterus	O
can	O
occur	O
once	O
the	O
serum	O
unconjugated	O
bilirubin	O
concentration	O
exceeds	O
this	O
capacity	O
,	O
makes	O
the	O
assessment	O
of	O
non	O
-	O
albumin	O
bound	O
free	O
bilirubin	O
valuable	O
in	O
cases	O
of	O
severe	O
neonatal	O
hyperbilirubinemia	O
.	O

2	O
.	O

Present	O
methodology	O
for	O
this	O
assessment	O
utilizes	O
Sephadex	O
column	O
chromatography	O
,	O
and	O
is	O
somewhat	O
tedious	O
and	O
slow	O
.	O

3	O
.	O

We	O
have	O
developed	O
a	O
procedure	O
for	O
assessing	O
the	O
albumin	O
binding	O
capacity	O
of	O
serum	O
by	O
titrating	O
a	O
sample	O
of	O
the	O
serum	O
with	O
T	O
-	O
20	O
Dextran	O
coated	O
charcoal	O
.	O

4	O
.	O

The	O
method	O
requires	O
2	O
ml	O
of	O
serum	O
,	O
takes	O
90	O
minutes	O
to	O
complete	O
and	O
is	O
highly	O
reproducible	O
.	O

5	O
.	O

By	O
this	O
method	O
,	O
we	O
can	O
determine	O
the	O
reported	O
secondary	O
loose	O
binding	O
capacity	O
of	O
the	O
albumin	O
as	O
well	O
as	O
the	O
tight	O
binding	O
capacity	O
which	O
is	O
determined	O
by	O
existing	O
methods	O
.	O

6	O
.	O

The	O
tight	O
binding	O
capacity	O
of	O
a	O
pool	O
of	O
normal	O
adult	O
human	O
serum	O
was	O
found	O
to	O
be	O
20	O
mg	O
/	O
dl	O
of	O
serum	O
.	O

7	O
.	O

This	O
is	O
in	O
agreement	O
with	O
existing	O
methods	O
.	O

The	O
loose	O
binding	O
capacity	O
was	O
found	O
to	O
be	O
an	O
additional	O
10	O
mg	O
/	O
dl	O
of	O
serum	O
.	O

Added	O
phenobarbital	O
was	O
found	O
to	O
lower	O
the	O
tight	O
binding	O
capacity	O
,	O
but	O
not	O
the	O
secondary	O
capacity	O
.	O

Phosphatidylethanolamine	O
has	O
an	O
essential	O
role	O
in	O
Saccharomyces	O
cerevisiae	O
that	O
is	O
independent	O
of	O
its	O
ability	O
to	O
form	O
hexagonal	O
phase	O
structures	O
.	O

Two	O
yeast	O
enzymes	O
,	O
Psd1p	O
and	O
Psd2p	O
,	O
catalyze	O
the	O
decarboxylation	O
of	O
phosphatidylserine	O
to	O
produce	O
phosphatidylethanolamine	O
(	O
PtdEtn	O
)	O
.	O

Mitochondrial	O
Psd1p	O
provides	O
approximately	O
90	O
%	O
of	O
total	O
cellular	O
phosphatidylserine	O
decarboxylase	O
activity	O
.	O

When	O
the	O
PSD1	O
gene	O
is	O
deleted	O
,	O
the	O
resultant	O
strain	O
(	O
psd1Delta	O
)	O
grows	O
normally	O
at	O
30	O
degrees	O
C	O
in	O
glucose	O
and	O
in	O
the	O
absence	O
of	O
exogenous	O
choline	O
or	O
ethanolamine	O
.	O

However	O
,	O
at	O
elevated	O
temperature	O
(	O
37	O
degrees	O
C	O
)	O
or	O
on	O
the	O
nonfermentable	O
carbon	O
source	O
lactate	O
,	O
the	O
growth	O
of	O
psd1Delta	O
strains	O
is	O
minimal	O
without	O
ethanolamine	O
supplementation	O
.	O

The	O
reduced	O
growth	O
and	O
viability	O
correlate	O
with	O
a	O
PtdEtn	O
content	O
below	O
4	O
%	O
of	O
total	O
phospholipid	O
.	O

These	O
results	O
suggest	O
that	O
there	O
is	O
a	O
critical	O
level	O
of	O
PtdEtn	O
required	O
to	O
support	O
growth	O
.	O

This	O
theory	O
is	O
supported	O
by	O
growth	O
data	O
revealing	O
that	O
a	O
psd1Delta	O
psd2Delta	O
dpl1Delta	O
strain	O
can	O
only	O
grow	O
in	O
the	O
presence	O
of	O
ethanolamine	O
.	O

In	O
contrast	O
,	O
a	O
psd1Delta	O
psd2Delta	O
strain	O
,	O
which	O
makes	O
low	O
levels	O
of	O
PtdEtn	O
from	O
sphingolipid	O
breakdown	O
,	O
can	O
be	O
rescued	O
by	O
ethanolamine	O
,	O
choline	O
,	O
or	O
the	O
ethanolamine	O
analogue	O
propanolamine	O
.	O

psd1Delta	O
psd2Delta	O
cells	O
grown	O
in	O
2	O
mm	O
propanolamine	O
accumulate	O
a	O
novel	O
lipid	O
,	O
which	O
was	O
determined	O
by	O
mass	O
spectrometry	O
to	O
be	O
phosphatidylpropanolamine	O
(	O
PtdPrn	O
)	O
.	O

PtdPrn	O
can	O
comprise	O
up	O
to	O
40	O
%	O
of	O
the	O
total	O
phospholipid	O
content	O
in	O
supplemented	O
cells	O
at	O
the	O
expense	O
of	O
phosphatidylcholine	O
and	O
PtdEtn	O
.	O

The	O
absolute	O
level	O
of	O
PtdEtn	O
required	O
for	O
growth	O
when	O
PtdPrn	O
is	O
present	O
appears	O
to	O
be	O
1	O
%	O
of	O
the	O
total	O
phospholipid	O
content	O
.	O

The	O
essential	O
function	O
of	O
the	O
PtdEtn	O
in	O
the	O
presence	O
of	O
propanolamine	O
does	O
not	O
appear	O
to	O
be	O
the	O
formation	O
of	O
hexagonal	O
phase	O
lipid	O
,	O
insofar	O
as	O
PtdPrn	O
readily	O
forms	O
hexagonal	O
phase	O
structures	O
detectable	O
by	O
(	O
31	O
)	O
P	O
NMR	O
.	O

Phosphoisoprenoids	O
modulate	O
association	O
of	O
Rab	B-Complex
geranylgeranyltransferase	I-Complex
with	O
REP	O
-	O
1	O
.	O

Rab	B-Complex
geranylgeranyltransferase	I-Complex
(	O
RabGGTase	B-Complex
or	O
GGTase	B-Complex
-	I-Complex
II	I-Complex
)	O
catalyzes	O
the	O
post	O
-	O
translational	O
prenylation	O
of	O
Rab	O
proteins	O
.	O

Rab	O
proteins	O
are	O
recognized	O
as	O
substrates	O
only	O
when	O
they	O
are	O
complexed	O
to	O
Rab	O
Escort	O
Protein	O
(	O
REP	O
)	O
.	O

The	O
classical	O
model	O
of	O
prenylation	O
complex	O
assembly	O
assumes	O
initial	O
formation	O
of	O
the	O
Rab	O
.	O
REP	O
binary	O
complex	O
,	O
which	O
subsequently	O
binds	O
to	O
RabGGTase	B-Complex
loaded	O
with	O
the	O
isoprenoid	O
donor	O
geranylgeranyl	O
pyrophosphate	O
(	O
GGpp	O
)	O
.	O

We	O
demonstrate	O
here	O
that	O
REP	O
-	O
1	O
can	O
also	O
associate	O
with	O
RabGGTase	B-Complex
in	O
the	O
absence	O
of	O
Rab	O
protein	O
and	O
that	O
this	O
interaction	O
is	O
dramatically	O
strengthened	O
by	O
the	O
presence	O
of	O
phosphoisoprenoids	O
such	O
as	O
GGpp	O
.	O

The	O
GGpp	O
-	O
dependent	O
interaction	O
between	O
RabGGTase	B-Complex
and	O
REP	O
-	O
1	O
was	O
observed	O
using	O
affinity	O
precipitations	O
and	O
gel	O
filtration	O
and	O
was	O
quantitated	O
on	O
the	O
basis	O
of	O
fluorescence	O
assays	O
.	O

In	O
the	O
presence	O
of	O
GGpp	O
,	O
REP	O
-	O
1	O
binds	O
to	O
RabGGTase	B-Complex
with	O
a	O
K	O
(	O
d	O
)	O
value	O
of	O
approximately	O
10	O
nm	O
,	O
while	O
in	O
its	O
absence	O
the	O
affinity	O
between	O
the	O
two	O
proteins	O
is	O
in	O
the	O
micromolar	O
range	O
.	O

We	O
further	O
demonstrate	O
that	O
binding	O
of	O
Rab7	O
to	O
the	O
RabGGTase	B-Complex
.	O
GGpp	O
.	O
REP	O
-	O
1	O
complex	O
occurs	O
without	O
prior	O
dissociation	O
of	O
REP	O
-	O
1	O
.	O

Analysis	O
of	O
binding	O
and	O
prenylation	O
rate	O
constants	O
indicate	O
that	O
the	O
RabGGTase	B-Complex
.	O
GGpp	O
.	O
REP	O
-	O
1	O
complex	O
can	O
function	O
as	O
a	O
kinetically	O
competent	O
intermediate	O
of	O
the	O
prenylation	O
reaction	O
.	O

We	O
conclude	O
that	O
,	O
depending	O
on	O
the	O
prevailing	O
concentrations	O
,	O
binding	O
of	O
REP	O
-	O
1	O
to	O
RabGGTase	B-Complex
in	O
the	O
presence	O
of	O
GGpp	O
may	O
serve	O
as	O
an	O
alternative	O
pathway	O
for	O
the	O
assembly	O
of	O
the	O
prenylation	O
machinery	O
in	O
vivo	O
.	O

Implications	O
of	O
these	O
findings	O
for	O
the	O
role	O
of	O
REP	O
-	O
1	O
in	O
the	O
prenylation	O
reaction	O
are	O
discussed	O
.	O

Inhibition	O
of	O
human	O
brain	O
tumor	O
cell	O
growth	O
by	O
the	O
anti	O
-	O
inflammatory	O
drug	O
,	O
flurbiprofen	O
.	O

Despite	O
many	O
efforts	O
to	O
alter	O
the	O
relentlessly	O
aggressive	O
progression	O
of	O
tumors	O
of	O
neural	O
origin	O
,	O
individuals	O
bearing	O
these	O
tumors	O
exhibit	O
poor	O
prognosis	O
for	O
long	O
-	O
term	O
survival	O
.	O

In	O
an	O
attempt	O
to	O
find	O
an	O
effective	O
treatment	O
,	O
we	O
examined	O
the	O
efficacy	O
of	O
the	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
flurbiprofen	O
,	O
to	O
suppress	O
the	O
growth	O
of	O
tumor	O
cell	O
lines	O
derived	O
from	O
medulloblastoma	O
and	O
glioblastoma	O
multiforme	O
.	O

Results	O
from	O
cell	O
proliferation	O
assays	O
have	O
revealed	O
that	O
flurbiprofen	O
effectively	O
inhibits	O
the	O
growth	O
of	O
various	O
tumor	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
causes	O
a	O
noticeable	O
change	O
in	O
the	O
progression	O
of	O
cells	O
through	O
cell	O
cycle	O
stages	O
.	O

Treatment	O
of	O
tumor	O
cells	O
with	O
flurbiprofen	O
reduced	O
the	O
number	O
of	O
cells	O
in	O
G1	O
and	O
G2	O
,	O
and	O
significantly	O
increased	O
their	O
numbers	O
in	O
S	O
phase	O
,	O
suggesting	O
that	O
,	O
flurbiprofen	O
accelerates	O
G1	O
/	O
S	O
entry	O
,	O
and	O
/	O
or	O
delays	O
cell	O
exit	O
from	O
S	O
to	O
G2	O
/	O
M	O
stages	O
.	O

Results	O
from	O
RNase	O
protection	O
assay	O
and	O
Western	O
blot	O
analysis	O
showed	O
that	O
while	O
treatment	O
of	O
cells	O
with	O
flurbiprofen	O
causes	O
a	O
minor	O
change	O
in	O
the	O
RNA	O
level	O
of	O
different	O
cyclins	O
,	O
there	O
is	O
a	O
significant	O
decrease	O
in	O
the	O
level	O
of	O
cyclin	O
B	O
protein	O
upon	O
flurbiprofen	O
treatment	O
.	O

Examination	O
of	O
tumor	O
suppressors	O
by	O
RNase	O
protection	O
technique	O
showed	O
a	O
subtle	O
increase	O
in	O
the	O
levels	O
of	O
several	O
tumor	O
suppressors	O
upon	O
flurbiprofen	O
treatment	O
.	O

Interestingly	O
,	O
at	O
the	O
protein	O
level	O
,	O
p53	O
tumor	O
suppressor	O
was	O
substantially	O
increased	O
upon	O
flurbiprofen	O
treatment	O
,	O
yet	O
the	O
level	O
of	O
p21	O
,	O
a	O
downstream	O
target	O
for	O
p53	O
remained	O
unchanged	O
.	O

Curiously	O
,	O
treatment	O
of	O
the	O
cells	O
with	O
flurbiprofen	O
enhanced	O
the	O
level	O
of	O
COX	O
-	O
2	O
expression	O
.	O

Results	O
from	O
co	O
-	O
immunoprecipitation	O
showed	O
association	O
of	O
COX	O
-	O
2	O
with	O
p53	O
in	O
tumor	O
cells	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
interaction	O
of	O
COX	O
-	O
2	O
with	O
p53	O
may	O
cause	O
p21	O
-	O
independent	O
suppression	O
of	O
tumor	O
cell	O
growth	O
upon	O
flurbiprofen	O
treatment	O
.	O

Chemistry	O
of	O
gene	O
silencing	O
:	O
the	O
mechanism	O
of	O
NAD	O
+	O
-	O
dependent	O
deacetylation	O
reactions	O
.	O

The	O
Sir2	O
enzyme	O
family	O
is	O
responsible	O
for	O
a	O
newly	O
classified	O
chemical	O
reaction	O
,	O
NAD	O
(	O
+	O
)	O
-	O
dependent	O
protein	O
deacetylation	O
.	O

New	O
peptide	O
substrates	O
,	O
the	O
reaction	O
mechanism	O
,	O
and	O
the	O
products	O
of	O
the	O
acetyl	O
transfer	O
to	O
NAD	O
(	O
+	O
)	O
are	O
described	O
for	O
SIR2	O
.	O

The	O
final	O
products	O
of	O
SIR2	O
reactions	O
are	O
the	O
deacetylated	O
peptide	O
and	O
the	O
2	O
'	O
and	O
3	O
'	O
regioisomers	O
of	O
O	O
-	O
acetyl	O
ADP	O
ribose	O
(	O
AADPR	O
)	O
,	O
formed	O
through	O
an	O
alpha	O
-	O
1	O
'	O
-	O
acetyl	O
ADP	O
ribose	O
intermediate	O
and	O
intramolecular	O
transesterification	O
reactions	O
(	O
2	O
'	O
-	O
-	O
>	O
3	O
'	O
)	O
.	O

The	O
regioisomers	O
,	O
their	O
anomeric	O
forms	O
,	O
the	O
interconversion	O
rates	O
,	O
and	O
the	O
reaction	O
equilibria	O
were	O
characterized	O
by	O
NMR	O
,	O
HPLC	O
,	O
18O	O
exchange	O
,	O
and	O
MS	O
methods	O
.	O

The	O
mechanism	O
of	O
acetyl	O
transfer	O
to	O
NAD	O
(	O
+	O
)	O
includes	O
(	O
1	O
)	O
ADP	O
ribosylation	O
of	O
the	O
peptide	O
acyl	O
oxygen	O
to	O
form	O
a	O
high	O
-	O
energy	O
O	O
-	O
alkyl	O
amidate	O
intermediate	O
,	O
(	O
2	O
)	O
attack	O
of	O
the	O
2	O
'	O
-	O
OH	O
group	O
on	O
the	O
amidate	O
to	O
form	O
a	O
1	O
'	O
,	O
2	O
'	O
-	O
acyloxonium	O
species	O
,	O
(	O
3	O
)	O
hydrolysis	O
to	O
2	O
'	O
-	O
AADPR	O
by	O
the	O
attack	O
of	O
water	O
on	O
the	O
carbonyl	O
carbon	O
,	O
and	O
(	O
4	O
)	O
an	O
SIR2	O
-	O
independent	O
transesterification	O
equilibrating	O
the	O
2	O
'	O
-	O
and	O
3	O
'	O
-	O
AADPRs	O
.	O

This	O
mechanism	O
is	O
unprecedented	O
in	O
ADP	O
-	O
ribosyl	O
transferase	O
enzymology	O
.	O

The	O
2	O
'	O
-	O
and	O
3	O
'	O
-	O
AADPR	O
products	O
are	O
candidate	O
molecules	O
for	O
SIR2	O
-	O
initiated	O
signaling	O
pathways	O
.	O

Hormone	O
-	O
dependent	O
,	O
CARM1	O
-	O
directed	O
,	O
arginine	O
-	O
specific	O
methylation	O
of	O
histone	O
H3	O
on	O
a	O
steroid	O
-	O
regulated	O
promoter	O
.	O

Activation	O
of	O
gene	O
transcription	O
involves	O
chromatin	O
remodeling	O
by	O
coactivator	O
proteins	O
that	O
are	O
recruited	O
by	O
DNA	O
-	O
bound	O
transcription	O
factors	O
.	O

Local	O
modification	O
of	O
chromatin	O
structure	O
at	O
specific	O
gene	O
promoters	O
by	O
ATP	O
-	O
dependent	O
processes	O
and	O
by	O
posttranslational	O
modifications	O
of	O
histone	O
N	O
-	O
terminal	O
tails	O
provides	O
access	O
to	O
RNA	B-Complex
polymerase	I-Complex
II	I-Complex
and	O
its	O
accompanying	O
transcription	B-Complex
initiation	I-Complex
complex	I-Complex
.	O

While	O
the	O
roles	O
of	O
lysine	O
acetylation	O
,	O
serine	O
phosphorylation	O
,	O
and	O
lysine	O
methylation	O
of	O
histones	O
in	O
chromatin	O
remodeling	O
are	O
beginning	O
to	O
emerge	O
,	O
low	O
levels	O
of	O
arginine	O
methylation	O
of	O
histones	O
have	O
only	O
recently	O
been	O
documented	O
,	O
and	O
its	O
physiological	O
role	O
is	O
unknown	O
.	O

The	O
coactivator	O
CARM1	O
methylates	O
histone	O
H3	O
at	O
Arg17	O
and	O
Arg26	O
in	O
vitro	O
and	O
cooperates	O
synergistically	O
with	O
p160	O
-	O
type	O
coactivators	O
(	O
e	O
.	O
g	O
.	O
,	O
GRIP1	O
,	O
SRC	O
-	O
1	O
,	O
ACTR	O
)	O
and	O
coactivators	O
with	O
histone	O
acetyltransferase	O
activity	O
(	O
e	O
.	O
g	O
.	O
,	O
p300	O
,	O
CBP	O
)	O
to	O
enhance	O
gene	O
activation	O
by	O
steroid	O
and	O
nuclear	O
hormone	O
receptors	O
(	O
NR	O
)	O
in	O
transient	O
transfection	O
assays	O
.	O

In	O
the	O
current	O
study	O
,	O
CARM1	O
cooperated	O
with	O
GRIP1	O
to	O
enhance	O
steroid	O
hormone	O
-	O
dependent	O
activation	O
of	O
stably	O
integrated	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
promoters	O
,	O
and	O
this	O
coactivator	O
function	O
required	O
the	O
methyltransferase	O
activity	O
of	O
CARM1	O
.	O

Chromatin	O
immunoprecipitation	O
assays	O
and	O
immunofluorescence	O
studies	O
indicated	O
that	O
CARM1	O
and	O
the	O
CARM1	O
-	O
methylated	O
form	O
of	O
histone	O
H3	O
specifically	O
associated	O
with	O
a	O
large	O
tandem	O
array	O
of	O
MMTV	O
promoters	O
in	O
a	O
hormone	O
-	O
dependent	O
manner	O
.	O

Thus	O
,	O
arginine	O
-	O
specific	O
histone	O
methylation	O
by	O
CARM1	O
is	O
an	O
important	O
part	O
of	O
the	O
transcriptional	O
activation	O
process	O
.	O

Structural	O
basis	O
of	O
Smad1	O
activation	O
by	O
receptor	O
kinase	O
phosphorylation	O
.	O

Phosphorylation	O
of	O
Smad1	O
at	O
the	O
conserved	O
carboxyl	O
terminal	O
SVS	O
sequence	O
activates	O
BMP	O
signaling	O
.	O

Here	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
the	O
Smad1	O
MH2	O
domain	O
in	O
a	O
conformation	O
that	O
reveals	O
the	O
structural	O
effects	O
of	O
phosphorylation	O
and	O
a	O
molecular	O
mechanism	O
for	O
activation	O
.	O

Within	O
a	O
trimeric	O
subunit	O
assembly	O
,	O
the	O
SVS	O
sequence	O
docks	O
near	O
two	O
putative	O
phosphoserine	O
binding	O
pockets	O
of	O
the	O
neighboring	O
molecule	O
,	O
in	O
a	O
position	O
ready	O
to	O
interact	O
upon	O
phosphorylation	O
.	O

The	O
MH2	O
domain	O
undergoes	O
concerted	O
conformational	O
changes	O
upon	O
activation	O
,	O
which	O
signal	O
Smad1	O
dissociation	O
from	O
the	O
receptor	O
kinase	O
for	O
subsequent	O
heteromeric	O
assembly	O
with	O
Smad4	O
.	O

Biochemical	O
and	O
modeling	O
studies	O
reveal	O
unique	O
favorable	O
interactions	O
within	O
the	O
Smad1	O
/	O
Smad4	O
heteromeric	O
interface	O
,	O
providing	O
a	O
structural	O
basis	O
for	O
their	O
association	O
in	O
signaling	O
.	O

Characterisation	O
of	O
cis	O
-	O
acting	O
sequences	O
reveals	O
a	O
biphasic	O
,	O
axon	O
-	O
dependent	O
regulation	O
of	O
Krox20	O
during	O
Schwann	O
cell	O
development	O
.	O

In	O
Schwann	O
cells	O
(	O
SC	O
)	O
,	O
myelination	O
is	O
controlled	O
by	O
the	O
transcription	O
factor	O
gene	O
Krox20	O
/	O
Egr2	O
.	O

Analysis	O
of	O
cis	O
-	O
acting	O
elements	O
governing	O
Krox20	O
expression	O
in	O
SC	O
revealed	O
the	O
existence	O
of	O
two	O
separate	O
elements	O
.	O

The	O
first	O
,	O
designated	O
immature	O
Schwann	O
cell	O
element	O
(	O
ISE	O
)	O
,	O
was	O
active	O
in	O
immature	O
but	O
not	O
myelinating	O
SC	O
,	O
whereas	O
the	O
second	O
,	O
designated	O
myelinating	O
Schwann	O
cell	O
element	O
(	O
MSE	O
)	O
,	O
was	O
active	O
from	O
the	O
onset	O
of	O
myelination	O
to	O
adulthood	O
in	O
myelinating	O
SC	O
.	O

In	O
vivo	O
sciatic	O
nerve	O
regeneration	O
experiments	O
demonstrated	O
that	O
both	O
elements	O
were	O
activated	O
during	O
this	O
process	O
,	O
in	O
an	O
axon	O
-	O
dependent	O
manner	O
.	O

Together	O
the	O
activity	O
of	O
these	O
elements	O
reproduced	O
the	O
profile	O
of	O
Krox20	O
expression	O
during	O
development	O
and	O
regeneration	O
.	O

Genetic	O
studies	O
showed	O
that	O
both	O
elements	O
were	O
active	O
in	O
a	O
Krox20	O
mutant	O
background	O
,	O
while	O
the	O
activity	O
of	O
the	O
MSE	O
,	O
but	O
likely	O
not	O
of	O
the	O
ISE	O
,	O
required	O
the	O
POU	O
domain	O
transcription	O
factor	O
Oct6	O
at	O
the	O
time	O
of	O
myelination	O
.	O

The	O
MSE	O
was	O
localised	O
to	O
a	O
1	O
.	O
3	O
kb	O
fragment	O
,	O
35	O
kb	O
downstream	O
of	O
Krox20	O
.	O

The	O
identification	O
of	O
multiple	O
Oct6	O
binding	O
sites	O
within	O
this	O
fragment	O
suggested	O
that	O
Oct6	O
directly	O
controls	O
Krox20	O
transcription	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
,	O
although	O
Krox20	O
is	O
expressed	O
continuously	O
from	O
15	O
.	O
5	O
dpc	O
in	O
SC	O
,	O
the	O
regulation	O
of	O
its	O
expression	O
is	O
a	O
biphasic	O
,	O
axon	O
-	O
dependent	O
phenomenon	O
involving	O
two	O
cis	O
-	O
acting	O
elements	O
that	O
act	O
in	O
succession	O
during	O
development	O
.	O

In	O
addition	O
,	O
they	O
provide	O
insight	O
into	O
the	O
complexity	O
of	O
the	O
transcription	O
factor	O
regulatory	O
network	O
controlling	O
myelination	O
.	O

Subnuclear	O
distribution	O
of	O
topoisomerase	O
I	O
is	O
linked	O
to	O
ongoing	O
transcription	O
and	O
p53	O
status	O
.	O

The	O
nonconserved	O
,	O
hydrophilic	O
N	O
-	O
terminal	O
domain	O
of	O
eukaryotic	O
DNA	O
topoisomerase	O
I	O
(	O
topo	O
I	O
)	O
is	O
dispensable	O
for	O
catalytic	O
activity	O
in	O
vitro	O
but	O
essential	O
in	O
vivo	O
.	O

There	O
are	O
at	O
least	O
five	O
putative	O
nuclear	O
localization	O
signals	O
and	O
a	O
nucleolin	O
-	O
binding	O
signal	O
within	O
the	O
first	O
215	O
residues	O
of	O
the	O
topo	O
I	O
N	O
-	O
terminal	O
domain	O
.	O

We	O
have	O
investigated	O
physiological	O
functions	O
of	O
the	O
topo	O
I	O
N	O
-	O
terminal	O
domain	O
by	O
fusing	O
it	O
to	O
an	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
)	O
.	O

The	O
first	O
170	O
residues	O
of	O
the	O
N	O
-	O
terminal	O
domain	O
allow	O
efficient	O
import	O
of	O
chimeric	O
proteins	O
into	O
nuclei	O
and	O
nucleoli	O
.	O

The	O
nucleolar	O
localization	O
of	O
this	O
protein	O
does	O
not	O
depend	O
on	O
its	O
interaction	O
with	O
nucleolin	O
,	O
whereas	O
ongoing	O
rDNA	O
transcription	O
clearly	O
is	O
crucial	O
.	O

Immunoprecipitation	O
experiments	O
reveal	O
that	O
the	O
topo	O
I	O
N	O
terminus	O
(	O
topoIN	O
)	O
-	O
EGFP	O
fusion	O
protein	O
associates	O
with	O
the	O
TATA	O
-	O
binding	O
protein	O
in	O
cells	O
.	O

Furthermore	O
,	O
DNA	O
damage	O
results	O
in	O
extensive	O
nuclear	O
redistribution	O
of	O
the	O
topoIN	O
-	O
EGFP	O
chimeric	O
product	O
.	O

The	O
redistribution	O
is	O
also	O
p53	O
-	O
dependent	O
and	O
the	O
N	O
terminus	O
of	O
topo	O
I	O
appears	O
to	O
interact	O
with	O
p53	O
in	O
vivo	O
.	O

These	O
results	O
show	O
that	O
the	O
topo	O
I	O
localization	O
to	O
the	O
nucleolus	O
is	O
related	O
to	O
the	O
p53	O
and	O
DNA	O
damage	O
,	O
as	O
well	O
as	O
changes	O
in	O
transcriptional	O
status	O
.	O

Nucleolar	O
release	O
of	O
topo	O
I	O
under	O
conditions	O
of	O
cellular	O
duress	O
may	O
represent	O
an	O
important	O
,	O
antecedent	O
step	O
in	O
tumor	O
cell	O
killing	O
by	O
topoisomerase	O
active	O
agents	O
.	O

Direct	O
interaction	O
between	O
Rab3b	O
and	O
the	O
polymeric	O
immunoglobulin	O
receptor	O
controls	O
ligand	O
-	O
stimulated	O
transcytosis	O
in	O
epithelial	O
cells	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
rab3b	O
in	O
epithelial	O
cells	O
.	O

In	O
MDCK	O
cells	O
,	O
rab3b	O
localizes	O
to	O
vesicular	O
structures	O
containing	O
the	O
polymeric	O
immunoglobulin	O
receptor	O
(	O
pIgR	O
)	O
and	O
located	O
subjacent	O
to	O
the	O
apical	O
surface	O
.	O

We	O
found	O
that	O
GTP	O
-	O
bound	O
rab3b	O
directly	O
interacts	O
with	O
the	O
cytoplasmic	O
domain	O
of	O
pIgR	O
.	O

Binding	O
of	O
dIgA	O
to	O
pIgR	O
causes	O
a	O
dissociation	O
of	O
the	O
interaction	O
with	O
rab3b	O
,	O
a	O
process	O
that	O
requires	O
dIgA	O
-	O
mediated	O
signaling	O
,	O
Arg657	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
pIgR	O
,	O
and	O
possibly	O
GTP	O
hydrolysis	O
by	O
rab3b	O
.	O

Binding	O
of	O
dIgA	O
to	O
pIgR	O
at	O
the	O
basolateral	O
surface	O
stimulates	O
subsequent	O
transcytosis	O
to	O
the	O
apical	O
surface	O
.	O

Overexpression	O
of	O
GTP	O
-	O
locked	O
rab3b	O
inhibits	O
dIgA	O
-	O
stimulated	O
transcytosis	O
.	O

Together	O
,	O
our	O
data	O
demonstrate	O
that	O
a	O
rab	O
protein	O
can	O
bind	O
directly	O
to	O
a	O
specific	O
cargo	O
protein	O
and	O
thereby	O
control	O
its	O
trafficking	O
.	O

PARP	O
-	O
1	O
modifies	O
the	O
effectiveness	O
of	O
p53	O
-	O
mediated	O
DNA	O
damage	O
response	O
.	O

The	O
tumour	O
suppressor	O
protein	O
p53	O
plays	O
a	O
key	O
role	O
in	O
the	O
cell	O
'	O
s	O
decision	O
to	O
arrest	O
the	O
cell	O
cycle	O
or	O
undergo	O
apoptosis	O
following	O
a	O
genotoxic	O
insult	O
.	O

p53	O
is	O
stabilized	O
and	O
activated	O
after	O
DNA	O
damage	O
,	O
however	O
the	O
cascade	O
of	O
events	O
signalling	O
from	O
DNA	O
lesions	O
to	O
p53	O
stabilization	O
and	O
activation	O
is	O
still	O
controversial	O
.	O

Poly	O
(	O
ADP	O
-	O
ribosylation	O
)	O
of	O
different	O
nuclear	O
acceptors	O
by	O
PARP	O
-	O
1	O
is	O
an	O
early	O
event	O
when	O
a	O
single	O
strand	O
DNA	O
lesion	O
is	O
produced	O
.	O

We	O
present	O
here	O
evidences	O
that	O
interplay	O
between	O
PARP	O
-	O
1	O
and	O
p53	O
is	O
dependent	O
on	O
the	O
type	O
of	O
damage	O
induced	O
to	O
DNA	O
.	O

Primary	O
mouse	O
embryonic	O
fibroblasts	O
derived	O
from	O
parp	O
-	O
1	O
-	O
/	O
-	O
mice	O
exhibited	O
decreased	O
p53	O
accumulation	O
and	O
activation	O
following	O
gamma	O
-	O
irradiation	O
compared	O
to	O
parp	O
-	O
1	O
proficient	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
treatment	O
with	O
the	O
single	O
alkylating	O
agent	O
2	O
'	O
-	O
methyl	O
-	O
2	O
'	O
-	O
nitrose	O
-	O
urea	O
(	O
MNU	O
)	O
,	O
resulted	O
in	O
the	O
rapid	O
and	O
sustained	O
accumulation	O
and	O
activation	O
of	O
p53	O
in	O
parp	O
-	O
1	O
-	O
deficient	O
cells	O
,	O
while	O
very	O
little	O
accumulation	O
was	O
observed	O
in	O
parp	O
-	O
1	O
+	O
/	O
+	O
cells	O
.	O

After	O
IR	O
,	O
the	O
turnover	O
of	O
the	O
p53	O
inhibitory	O
protein	O
MDM	O
-	O
2	O
is	O
perturbed	O
and	O
the	O
level	O
of	O
phosphorylation	O
of	O
p53	O
at	O
serine	O
-	O
15	O
is	O
blunted	O
in	O
parp	O
-	O
1	O
-	O
/	O
-	O
cells	O
.	O

PARP	O
-	O
1	O
is	O
determinant	O
in	O
the	O
cytotoxic	O
response	O
to	O
alkylating	O
agents	O
but	O
only	O
partially	O
contributes	O
to	O
radiation	O
-	O
induced	O
cell	O
killing	O
,	O
as	O
determined	O
by	O
colony	O
forming	O
assay	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
PARP	O
-	O
1	O
participates	O
in	O
the	O
p53	O
response	O
following	O
irradiation	O
,	O
resides	O
upstream	O
of	O
p53	O
and	O
indirectly	O
modulates	O
the	O
level	O
of	O
phosphorylation	O
of	O
key	O
substrates	O
in	O
this	O
pathway	O
while	O
treatment	O
with	O
MNU	O
results	O
in	O
an	O
enhanced	O
p53	O
-	O
mediated	O
response	O
in	O
parp	O
-	O
1	O
-	O
null	O
cells	O
.	O

Human	O
receptors	O
for	O
sweet	O
and	O
umami	O
taste	O
.	O

The	O
three	O
members	O
of	O
the	O
T1R	O
class	O
of	O
taste	O
-	O
specific	O
G	O
protein	O
-	O
coupled	O
receptors	O
have	O
been	O
hypothesized	O
to	O
function	O
in	O
combination	O
as	O
heterodimeric	O
sweet	O
taste	O
receptors	O
.	O

Here	O
we	O
show	O
that	O
human	O
T1R2	O
/	O
T1R3	O
recognizes	O
diverse	O
natural	O
and	O
synthetic	O
sweeteners	O
.	O

In	O
contrast	O
,	O
human	O
T1R1	O
/	O
T1R3	O
responds	O
to	O
the	O
umami	O
taste	O
stimulus	O
l	O
-	O
glutamate	O
,	O
and	O
this	O
response	O
is	O
enhanced	O
by	O
5	O
'	O
-	O
ribonucleotides	O
,	O
a	O
hallmark	O
of	O
umami	O
taste	O
.	O

The	O
ligand	O
specificities	O
of	O
rat	O
T1R2	O
/	O
T1R3	O
and	O
T1R1	O
/	O
T1R3	O
correspond	O
to	O
those	O
of	O
their	O
human	O
counterparts	O
.	O

These	O
findings	O
implicate	O
the	O
T1Rs	O
in	O
umami	O
taste	O
and	O
suggest	O
that	O
sweet	O
and	O
umami	O
taste	O
receptors	O
share	O
a	O
common	O
subunit	O
.	O

Autoubiquitination	O
of	O
the	O
BRCA1	O
*	O
BARD1	O
RING	O
ubiquitin	O
ligase	O
.	O

The	O
RING	O
finger	O
of	O
BRCA1	O
confers	O
ubiquitin	O
ligase	O
activity	O
that	O
is	O
markedly	O
enhanced	O
when	O
complexed	O
with	O
another	O
RING	O
-	O
containing	O
protein	O
,	O
BARD1	O
,	O
and	O
is	O
required	O
for	O
the	O
function	O
of	O
this	O
tumor	O
suppressor	O
protein	O
in	O
protecting	O
genomic	O
integrity	O
.	O

Here	O
,	O
we	O
report	O
that	O
co	O
-	O
expression	O
of	O
BRCA1	O
-	O
(	O
1	O
-	O
639	O
)	O
and	O
BARD1	O
in	O
bacteria	O
can	O
assemble	O
a	O
potent	O
ubiquitin	O
ligase	O
activity	O
.	O

Purified	O
BRCA1	O
-	O
(	O
1	O
-	O
639	O
)	O
*	O
BARD1	O
stimulated	O
the	O
Ubc5c	O
-	O
mediated	O
monoubiquitination	O
of	O
histone	O
H2A	O
/	O
H2AX	O
in	O
vitro	O
,	O
suggesting	O
a	O
possible	O
role	O
for	O
BRCA1	O
*	O
BARD1	O
in	O
modifying	O
chromatin	O
structure	O
.	O

Moreover	O
,	O
the	O
truncated	O
BRCA1	O
*	O
BARD1	O
complex	O
exhibited	O
efficient	O
autoubiquitination	O
activity	O
in	O
vitro	O
capable	O
of	O
assembling	O
non	O
-	O
lysine	O
48	O
-	O
linked	O
polyubiquitin	O
chains	O
on	O
both	O
BRCA1	O
-	O
(	O
1	O
-	O
639	O
)	O
and	O
BARD1	O
.	O

When	O
co	O
-	O
expressed	O
in	O
cells	O
by	O
transient	O
transfection	O
,	O
the	O
recombinant	O
BRCA1	O
-	O
(	O
1	O
-	O
300	O
)	O
.	O
BARD1	O
complex	O
was	O
found	O
to	O
be	O
associated	O
with	O
polyubiquitin	O
chains	O
,	O
suggesting	O
that	O
BRCA1	O
-	O
(	O
1	O
-	O
300	O
)	O
*	O
BARD1	O
was	O
ubiquitinated	O
in	O
vivo	O
as	O
well	O
.	O

These	O
results	O
raise	O
the	O
possibility	O
that	O
BRCA1	O
*	O
BARD1	O
acts	O
to	O
assemble	O
non	O
-	O
lysine	O
48	O
-	O
linked	O
polyubiquitin	O
chains	O
that	O
may	O
serve	O
as	O
part	O
of	O
a	O
signaling	O
platform	O
required	O
for	O
coordinating	O
DNA	O
repair	O
-	O
related	O
events	O
.	O

Human	O
origin	B-Complex
recognition	I-Complex
complex	I-Complex
large	O
subunit	O
is	O
degraded	O
by	O
ubiquitin	O
-	O
mediated	O
proteolysis	O
after	O
initiation	O
of	O
DNA	O
replication	O
.	O

Eukaryotic	O
cells	O
possess	O
overlapping	O
mechanisms	O
to	O
ensure	O
that	O
DNA	O
replication	O
is	O
restricted	O
to	O
the	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

The	O
levels	O
of	O
hOrc1p	O
,	O
the	O
largest	O
subunit	O
of	O
the	O
human	O
origin	B-Complex
recognition	I-Complex
complex	I-Complex
,	O
vary	O
during	O
the	O
cell	O
division	O
cycle	O
.	O

In	O
rapidly	O
proliferating	O
cells	O
,	O
hOrc1p	O
is	O
expressed	O
and	O
targeted	O
to	O
chromatin	O
as	O
cells	O
exit	O
mitosis	O
and	O
prereplicative	O
complexes	O
are	O
formed	O
.	O

Later	O
,	O
as	O
cyclin	O
A	O
accumulates	O
and	O
cells	O
enter	O
S	O
phase	O
,	O
hOrc1p	O
is	O
ubiquitinated	O
on	O
chromatin	O
and	O
then	O
degraded	O
.	O

hOrc1p	O
destruction	O
occurs	O
through	O
the	O
proteasome	B-Complex
and	O
is	O
signaled	O
in	O
part	O
by	O
the	O
SCF	B-Complex
(	I-Complex
Skp2	I-Complex
)	I-Complex
ubiquitin	O
-	O
ligase	O
complex	O
.	O

Other	O
hORC	B-Complex
subunits	O
are	O
stable	O
throughout	O
the	O
cell	O
cycle	O
.	O

The	O
regulation	O
of	O
hOrc1p	O
may	O
be	O
an	O
important	O
mechanism	O
in	O
maintaining	O
the	O
ploidy	O
in	O
human	O
cells	O
.	O

Interaction	O
of	O
transcriptional	O
intermediary	O
factor	O
2	O
nuclear	O
receptor	O
box	O
peptides	O
with	O
the	O
coactivator	O
binding	O
site	O
of	O
estrogen	O
receptor	O
alpha	O
.	O

The	O
activation	O
function	O
2	O
/	O
ligand	O
-	O
dependent	O
interaction	O
between	O
nuclear	O
receptors	O
and	O
their	O
coregulators	O
is	O
mediated	O
by	O
a	O
short	O
consensus	O
motif	O
,	O
the	O
so	O
-	O
called	O
nuclear	O
receptor	O
(	O
NR	O
)	O
box	O
.	O

Nuclear	O
receptors	O
exhibit	O
distinct	O
preferences	O
for	O
such	O
motifs	O
depending	O
both	O
on	O
the	O
bound	O
ligand	O
and	O
on	O
the	O
NR	O
box	O
sequence	O
.	O

To	O
better	O
understand	O
the	O
structural	O
basis	O
of	O
motif	O
recognition	O
,	O
we	O
characterized	O
the	O
interaction	O
between	O
estrogen	O
receptor	O
alpha	O
and	O
the	O
NR	O
box	O
regions	O
of	O
the	O
p160	O
coactivator	O
TIF2	O
.	O

We	O
have	O
determined	O
the	O
crystal	O
structures	O
of	O
complexes	O
between	O
the	O
ligand	O
-	O
binding	O
domain	O
of	O
estrogen	O
receptor	O
alpha	O
and	O
12	O
-	O
mer	O
peptides	O
from	O
the	O
Box	O
B2	O
and	O
Box	O
B3	O
regions	O
of	O
TIF2	O
.	O

Surprisingly	O
,	O
the	O
Box	O
B3	O
module	O
displays	O
an	O
unexpected	O
binding	O
mode	O
that	O
is	O
distinct	O
from	O
the	O
canonical	O
LXXLL	O
interaction	O
observed	O
in	O
other	O
ligand	O
-	O
binding	O
domain	O
/	O
NR	O
box	O
crystal	O
structures	O
.	O

The	O
peptide	O
is	O
shifted	O
along	O
the	O
coactivator	O
binding	O
site	O
in	O
such	O
a	O
way	O
that	O
the	O
interaction	O
motif	O
becomes	O
LXXYL	O
rather	O
than	O
the	O
classical	O
LXXLL	O
.	O

However	O
,	O
analysis	O
of	O
the	O
binding	O
properties	O
of	O
wild	O
type	O
NR	O
box	O
peptides	O
,	O
as	O
well	O
as	O
mutant	O
peptides	O
designed	O
to	O
probe	O
the	O
Box	O
B3	O
orientation	O
,	O
suggests	O
that	O
the	O
Box	O
B3	O
peptide	O
primarily	O
adopts	O
the	O
"	O
classical	O
"	O
LXXLL	O
orientation	O
in	O
solution	O
.	O

These	O
results	O
highlight	O
the	O
potential	O
difficulties	O
in	O
interpretation	O
of	O
protein	O
-	O
protein	O
interactions	O
based	O
on	O
co	O
-	O
crystal	O
structures	O
using	O
short	O
peptide	O
motifs	O
.	O

VEGF165	O
mediates	O
formation	O
of	O
complexes	O
containing	O
VEGFR	O
-	O
2	O
and	O
neuropilin	O
-	O
1	O
that	O
enhance	O
VEGF165	O
-	O
receptor	O
binding	O
.	O

Co	O
-	O
expression	O
of	O
NRP1	O
and	O
(	O
VEGFR	O
-	O
2	O
)	O
KDR	O
on	O
the	O
surface	O
of	O
endothelial	O
cells	O
(	O
EC	O
)	O
enhances	O
VEGF165	O
binding	O
to	O
KDR	O
and	O
EC	O
chemotaxis	O
in	O
response	O
to	O
VEGF165	O
.	O

Overexpression	O
of	O
NRP1	O
by	O
prostate	O
tumor	O
cells	O
in	O
vivo	O
results	O
in	O
increased	O
tumor	O
angiogenesis	O
and	O
growth	O
.	O

We	O
investigated	O
the	O
molecular	O
mechanisms	O
underlying	O
NRP1	O
-	O
mediated	O
angiogenesis	O
by	O
analyzing	O
the	O
association	O
of	O
NRP1	O
and	O
KDR	O
.	O

An	O
intracellular	O
complex	O
containing	O
NRP1	O
and	O
KDR	O
was	O
immunoprecipitated	O
from	O
EC	O
by	O
anti	O
-	O
NRP1	O
antibodies	O
only	O
in	O
the	O
presence	O
of	O
VEGF165	O
.	O

In	O
contrast	O
,	O
VEGF121	O
,	O
which	O
does	O
not	O
bind	O
to	O
NRP1	O
,	O
did	O
not	O
support	O
complex	O
formation	O
.	O

Complexes	O
containing	O
VEGF165	O
,	O
NRP1	O
,	O
and	O
KDR	O
were	O
also	O
formed	O
in	O
an	O
intercellular	O
fashion	O
by	O
co	O
-	O
culture	O
of	O
EC	O
expressing	O
KDR	O
only	O
,	O
with	O
cells	O
expressing	O
NRP1	O
only	O
,	O
for	O
example	O
,	O
breast	O
carcinoma	O
cells	O
.	O

VEGF165	O
also	O
mediated	O
the	O
binding	O
of	O
a	O
soluble	O
NRP1	O
dimer	O
to	O
cells	O
expressing	O
KDR	O
only	O
,	O
confirming	O
the	O
formation	O
of	O
such	O
complexes	O
.	O

Furthermore	O
,	O
the	O
formation	O
of	O
complexes	O
containing	O
KDR	O
and	O
NRP1	O
markedly	O
increased	O
125I	O
-	O
VEGF165	O
binding	O
to	O
KDR	O
.	O

Our	O
results	O
suggest	O
that	O
formation	O
of	O
a	O
ternary	O
complex	O
of	O
VEGF165	O
,	O
KDR	O
,	O
and	O
NRP1	O
potentiates	O
VEGF165	O
binding	O
to	O
KDR	O
.	O

These	O
complexes	O
are	O
formed	O
on	O
the	O
surface	O
of	O
EC	O
and	O
in	O
a	O
juxtacrine	O
manner	O
via	O
association	O
of	O
tumor	O
cell	O
NRP1	O
and	O
EC	O
KDR	O
.	O

Association	O
and	O
regulation	O
of	O
casein	B-Complex
kinase	I-Complex
2	I-Complex
activity	O
by	O
adenomatous	O
polyposis	O
coli	O
protein	O
.	O

Mutations	O
in	O
the	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
are	O
responsible	O
for	O
familial	O
adenomatous	O
polyposis	O
coli	O
and	O
also	O
sporadic	O
colorectal	O
cancer	O
development	O
.	O

By	O
using	O
antibodies	O
raised	O
against	O
the	O
N	O
-	O
terminal	O
region	O
of	O
APC	O
protein	O
,	O
we	O
have	O
detected	O
the	O
variable	O
masses	O
of	O
endogenous	O
APC	O
proteins	O
in	O
individual	O
cell	O
lines	O
established	O
from	O
human	O
colorectal	O
carcinomas	O
caused	O
by	O
nonsense	O
mutations	O
of	O
the	O
gene	O
.	O

Phosphorylation	O
of	O
immunoprecipitates	O
of	O
full	O
-	O
length	O
and	O
truncated	O
APC	O
were	O
observed	O
in	O
in	O
vitro	O
kinase	O
reaction	O
,	O
indicating	O
association	O
of	O
APC	O
with	O
protein	O
kinase	O
activity	O
.	O

The	O
kinase	O
activity	O
complexed	O
with	O
APC	O
was	O
sensitive	O
to	O
heparin	O
and	O
used	O
GTP	O
as	O
phosphoryl	O
donor	O
,	O
suggesting	O
an	O
involvement	O
of	O
casein	B-Complex
kinase	I-Complex
2	I-Complex
(	O
CK2	B-Complex
)	O
.	O

Both	O
CK2alpha	O
-	O
and	O
beta	O
-	O
subunits	O
were	O
found	O
to	O
associate	O
with	O
APC	O
in	O
immunoprecipitates	O
as	O
well	O
as	O
in	O
pull	O
-	O
down	O
assays	O
,	O
with	O
preferential	O
interaction	O
of	O
APC	O
with	O
tetrameric	O
CK2	B-Complex
holoenzyme	O
.	O

In	O
synchronized	O
cell	O
populations	O
,	O
the	O
association	O
of	O
APC	O
with	O
CK2	B-Complex
was	O
cell	O
cycle	O
dependent	O
,	O
with	O
the	O
highest	O
association	O
in	O
G	O
(	O
2	O
)	O
/	O
M	O
.	O

Unexpectedly	O
,	O
APC	O
immunoprecipitates	O
containing	O
full	O
-	O
length	O
APC	O
protein	O
inhibited	O
CK2	B-Complex
in	O
vitro	O
,	O
whereas	O
immunoprecipitates	O
of	O
truncated	O
APC	O
had	O
little	O
effect	O
.	O

This	O
was	O
confirmed	O
by	O
using	O
recombinant	O
APC	O
,	O
and	O
the	O
inhibitory	O
region	O
was	O
localized	O
to	O
the	O
C	O
terminus	O
of	O
APC	O
between	O
residues	O
2086	O
and	O
2394	O
.	O

Overexpression	O
of	O
this	O
fragment	O
in	O
SW480	O
cells	O
suppressed	O
cell	O
proliferation	O
rates	O
as	O
well	O
as	O
tumorigenesis	O
.	O

These	O
results	O
demonstrate	O
a	O
previously	O
uncharacterized	O
functional	O
interaction	O
between	O
the	O
tumor	O
suppressor	O
protein	O
APC	O
and	O
CK2	B-Complex
and	O
suggest	O
that	O
growth	O
-	O
inhibitory	O
effects	O
of	O
APC	O
may	O
be	O
regulated	O
by	O
inhibition	O
of	O
CK2	B-Complex
.	O

Congenital	O
disorders	O
of	O
glycosylation	O
type	O
Ig	O
is	O
defined	O
by	O
a	O
deficiency	O
in	O
dolichyl	O
-	O
P	O
-	O
mannose	O
:	O
Man7GlcNAc2	O
-	O
PP	O
-	O
dolichyl	O
mannosyltransferase	O
.	O

Type	O
I	O
congenital	O
disorders	O
of	O
glycosylation	O
(	O
CDG	O
I	O
)	O
are	O
diseases	O
presenting	O
multisystemic	O
lesions	O
including	O
central	O
and	O
peripheral	O
nervous	O
system	O
deficits	O
.	O

The	O
disease	O
is	O
characterized	O
by	O
under	O
-	O
glycosylated	O
serum	O
glycoproteins	O
and	O
is	O
caused	O
by	O
mutations	O
in	O
genes	O
encoding	O
proteins	O
involved	O
in	O
the	O
stepwise	O
assembly	O
of	O
dolichol	O
-	O
oligosaccharide	O
used	O
for	O
protein	O
N	O
-	O
glycosylation	O
.	O

We	O
report	O
that	O
fibroblasts	O
from	O
a	O
type	O
I	O
CDG	O
patient	O
,	O
born	O
of	O
consanguineous	O
parents	O
,	O
are	O
deficient	O
in	O
their	O
capacity	O
to	O
add	O
the	O
eighth	O
mannose	O
residue	O
onto	O
the	O
lipid	O
-	O
linked	O
oligosaccharide	O
precursor	O
.	O

We	O
have	O
characterized	O
cDNA	O
corresponding	O
to	O
the	O
human	O
ortholog	O
of	O
the	O
yeast	O
gene	O
ALG12	O
that	O
encodes	O
the	O
dolichyl	O
-	O
P	O
-	O
Man	O
:	O
Man	O
(	O
7	O
)	O
GlcNAc	O
(	O
2	O
)	O
-	O
PP	O
-	O
dolichyl	O
alpha6	O
-	O
mannosyltransferase	O
that	O
is	O
thought	O
to	O
accomplish	O
this	O
reaction	O
,	O
and	O
we	O
show	O
that	O
the	O
patient	O
is	O
homozygous	O
for	O
a	O
point	O
mutation	O
(	O
T571G	O
)	O
that	O
causes	O
an	O
amino	O
acid	O
substitution	O
(	O
F142V	O
)	O
in	O
a	O
conserved	O
region	O
of	O
the	O
protein	O
.	O

As	O
the	O
pathological	O
phenotype	O
of	O
the	O
fibroblasts	O
of	O
the	O
patient	O
was	O
largely	O
normalized	O
upon	O
transduction	O
with	O
the	O
wild	O
type	O
gene	O
,	O
we	O
demonstrate	O
that	O
the	O
F142V	O
substitution	O
is	O
the	O
underlying	O
cause	O
of	O
this	O
new	O
CDG	O
,	O
which	O
we	O
suggest	O
be	O
called	O
CDG	O
Ig	O
.	O

Finally	O
,	O
we	O
show	O
that	O
the	O
fibroblasts	O
of	O
the	O
patient	O
are	O
capable	O
of	O
the	O
direct	O
transfer	O
of	O
Man	O
(	O
7	O
)	O
GlcNAc	O
(	O
2	O
)	O
from	O
dolichol	O
onto	O
protein	O
and	O
that	O
this	O
N	O
-	O
linked	O
structure	O
can	O
be	O
glucosylated	O
by	O
UDP	O
-	O
glucose	O
:	O
glycoprotein	O
glucosyltransferase	O
in	O
the	O
endoplasmic	O
reticulum	O
.	O

Yeast	O
Pescadillo	O
is	O
required	O
for	O
multiple	O
activities	O
during	O
60S	B-Complex
ribosomal	I-Complex
subunit	I-Complex
synthesis	O
.	O

The	O
Pescadillo	O
protein	O
was	O
identified	O
via	O
a	O
developmental	O
defect	O
and	O
implicated	O
in	O
cell	O
cycle	O
progression	O
.	O

Here	O
we	O
report	O
that	O
human	O
Pescadillo	O
and	O
its	O
yeast	O
homolog	O
(	O
Yph1p	O
or	O
Nop7p	O
)	O
are	O
localized	O
to	O
the	O
nucleolus	O
.	O

Depletion	O
of	O
Nop7p	O
leads	O
to	O
nuclear	O
accumulation	O
of	O
pre	O
-	O
60S	B-Complex
particles	O
,	O
indicating	O
a	O
defect	O
in	O
subunit	O
export	O
,	O
and	O
it	O
interacts	O
genetically	O
with	O
a	O
tagged	O
form	O
of	O
the	O
ribosomal	O
protein	O
Rpl25p	O
,	O
consistent	O
with	O
a	O
role	O
in	O
subunit	O
assembly	O
.	O

Two	O
pre	O
-	O
rRNA	O
processing	O
pathways	O
generate	O
alternative	O
forms	O
of	O
the	O
5	O
.	O
8S	O
rRNA	O
,	O
designated	O
5	O
.	O
8S	O
(	O
L	O
)	O
and	O
5	O
.	O
8Ss	O
.	O

In	O
cells	O
depleted	O
for	O
Nop7p	O
,	O
the	O
27SA3	O
pre	O
-	O
rRNA	O
accumulated	O
,	O
whereas	O
later	O
processing	O
intermediates	O
and	O
the	O
mature	O
5	O
.	O
8Ss	O
rRNA	O
were	O
depleted	O
.	O

Less	O
depletion	O
was	O
seen	O
for	O
the	O
5	O
.	O
8S	O
(	O
L	O
)	O
pathway	O
.	O

TAP	O
-	O
tagged	O
Nop7p	O
coprecipitated	O
precursors	O
to	O
both	O
5	O
.	O
8S	O
(	O
L	O
)	O
and	O
5	O
.	O
8Ss	O
but	O
not	O
the	O
mature	O
rRNAs	O
.	O

We	O
conclude	O
that	O
Nop7p	O
is	O
required	O
for	O
efficient	O
exonucleolytic	O
processing	O
of	O
the	O
27SA3	O
pre	O
-	O
rRNA	O
and	O
has	O
additional	O
functions	O
in	O
60S	B-Complex
subunit	O
assembly	O
and	O
transport	O
.	O

Nop7p	O
is	O
a	O
component	O
of	O
at	O
least	O
three	O
different	O
pre	O
-	O
60S	B-Complex
particles	O
,	O
and	O
we	O
propose	O
that	O
it	O
carries	O
out	O
distinct	O
functions	O
in	O
each	O
of	O
these	O
complexes	O
.	O

Transcription	O
factor	O
AP	B-OOS
-	I-OOS
2	I-OOS
interacts	O
with	O
the	O
SUMO	O
-	O
conjugating	O
enzyme	O
UBC9	O
and	O
is	O
sumolated	O
in	O
vivo	O
.	O

The	O
members	O
of	O
the	O
AP	B-OOS
-	I-OOS
2	I-OOS
family	O
of	O
transcription	O
factors	O
are	O
developmentally	O
regulated	O
and	O
have	O
distinct	O
yet	O
overlapping	O
functions	O
in	O
the	O
regulation	O
of	O
many	O
genes	O
governing	O
growth	O
and	O
differentiation	O
.	O

All	O
AP	B-OOS
-	I-OOS
2	I-OOS
factors	O
appear	O
to	O
be	O
capable	O
of	O
binding	O
very	O
similar	O
DNA	O
recognition	O
sites	O
,	O
and	O
the	O
determinants	O
of	O
functional	O
specificity	O
remain	O
to	O
be	O
elucidated	O
.	O

AP	B-OOS
-	I-OOS
2	I-OOS
transcription	O
factors	O
have	O
been	O
shown	O
to	O
act	O
both	O
as	O
transcriptional	O
activators	O
and	O
repressors	O
in	O
a	O
promoter	O
-	O
specific	O
manner	O
.	O

Although	O
several	O
mediators	O
of	O
their	O
activation	O
function	O
have	O
been	O
suggested	O
,	O
few	O
mechanisms	O
for	O
the	O
repression	O
or	O
down	O
-	O
regulation	O
of	O
transactivation	O
have	O
been	O
described	O
.	O

In	O
a	O
two	O
-	O
hybrid	O
screen	O
for	O
proteins	O
interacting	O
with	O
AP	B-OOS
-	I-OOS
2	I-OOS
factors	O
,	O
we	O
have	O
identified	O
the	O
UBC9	O
gene	O
that	O
encodes	O
the	O
E2	O
(	O
ubiquitin	O
carrier	O
protein	O
)	O
-	O
conjugating	O
enzyme	O
for	O
the	O
small	O
ubiquitin	O
-	O
like	O
modifier	O
,	O
SUMO	O
.	O

The	O
interaction	O
domain	O
resides	O
in	O
the	O
C	O
-	O
terminal	O
half	O
of	O
AP	B-OOS
-	I-OOS
2	I-OOS
,	O
which	O
contains	O
the	O
conserved	O
DNA	O
binding	O
and	O
dimerization	O
domains	O
.	O

We	O
have	O
detected	O
sumolated	O
forms	O
of	O
endogenous	O
AP	B-OOS
-	I-OOS
2	I-OOS
in	O
mammalian	O
cells	O
and	O
have	O
further	O
mapped	O
the	O
in	O
vivo	O
sumolation	O
site	O
to	O
conserved	O
lysine	O
10	O
.	O

Transient	O
transfection	O
studies	O
indicate	O
that	O
sumolation	O
of	O
AP	B-OOS
-	I-OOS
2	I-OOS
decreases	O
its	O
transcription	O
activation	O
potential	O
,	O
and	O
we	O
discuss	O
the	O
possible	O
mechanisms	O
for	O
the	O
observed	O
suppression	O
of	O
AP	B-OOS
-	I-OOS
2	I-OOS
transactivation	O
.	O

Yeast	O
RSC	B-Complex
function	O
is	O
required	O
for	O
organization	O
of	O
the	O
cellular	O
cytoskeleton	O
via	O
an	O
alternative	O
PKC1	O
pathway	O
.	O

RSC	B-Complex
is	O
a	O
15	O
-	O
protein	O
ATP	O
-	O
dependent	O
chromatin	O
-	O
remodeling	O
complex	O
related	O
to	O
Snf	B-Complex
-	I-Complex
Swi	I-Complex
,	O
the	O
prototypical	O
ATP	O
-	O
dependent	O
nucleosome	O
remodeler	O
in	O
budding	O
yeast	O
.	O

Despite	O
insight	O
into	O
the	O
mechanism	O
by	O
which	O
purified	O
RSC	B-Complex
remodels	O
nucleosomes	O
,	O
little	O
is	O
known	O
about	O
the	O
chromosomal	O
targets	O
or	O
cellular	O
pathways	O
in	O
which	O
RSC	B-Complex
acts	O
.	O

To	O
better	O
understand	O
the	O
cellular	O
function	O
of	O
RSC	B-Complex
,	O
a	O
screen	O
was	O
undertaken	O
for	O
gene	O
dosage	O
suppressors	O
of	O
sth1	O
-	O
3ts	O
,	O
a	O
temperature	O
-	O
sensitive	O
mutation	O
in	O
STH1	O
,	O
which	O
encodes	O
the	O
essential	O
ATPase	O
subunit	O
.	O

Slg1p	O
and	O
Mid2p	O
,	O
two	O
type	O
I	O
transmembrane	O
stress	O
sensors	O
of	O
cell	O
wall	O
integrity	O
that	O
function	O
upstream	O
of	O
protein	O
kinase	O
C	O
(	O
Pkc1p	O
)	O
,	O
were	O
identified	O
as	O
multicopy	O
suppressors	O
of	O
sth1	O
-	O
3ts	O
cells	O
.	O

Although	O
the	O
sth1	O
-	O
3ts	O
mutant	O
exhibits	O
defects	O
characteristic	O
of	O
PKC1	O
pathway	O
mutants	O
(	O
caffeine	O
and	O
staurosporine	O
sensitivities	O
and	O
an	O
osmoremedial	O
phenotype	O
)	O
,	O
only	O
upstream	O
components	O
and	O
not	O
downstream	O
effectors	O
of	O
the	O
PKC1	O
-	O
MAP	O
kinase	O
pathway	O
can	O
suppress	O
defects	O
conferred	O
by	O
sth1	O
-	O
3ts	O
,	O
suggesting	O
that	O
RSC	B-Complex
functions	O
in	O
an	O
alternative	O
PKC1	O
-	O
dependent	O
pathway	O
.	O

Moreover	O
,	O
sth1	O
-	O
3ts	O
cells	O
display	O
defects	O
in	O
actin	O
cytoskeletal	O
rearrangements	O
and	O
are	O
hypersensitive	O
to	O
the	O
microtubule	O
depolymerizing	O
drug	O
,	O
TBZ	O
;	O
both	O
of	O
these	O
defects	O
can	O
be	O
corrected	O
by	O
the	O
high	O
-	O
copy	O
suppressors	O
.	O

Together	O
,	O
these	O
data	O
reveal	O
an	O
important	O
functional	O
connection	O
between	O
the	O
RSC	B-Complex
remodeler	O
and	O
PKC1	O
-	O
dependent	O
signaling	O
in	O
regulating	O
the	O
cellular	O
architecture	O
.	O

Giant	O
axonal	O
neuropathy	O
(	O
GAN	O
)	O
,	O
an	O
autosomal	O
recessive	O
disorder	O
caused	O
by	O
mutations	O
in	O
GAN	O
,	O
is	O
characterized	O
cytopathologically	O
by	O
cytoskeletal	O
abnormality	O
.	O

Based	O
on	O
its	O
sequence	O
,	O
gigaxonin	O
contains	O
an	O
NH2	O
-	O
terminal	O
BTB	O
domain	O
followed	O
by	O
six	O
kelch	O
repeats	O
,	O
which	O
are	O
believed	O
to	O
be	O
important	O
for	O
protein	O
-	O
protein	O
interactions	O
(	O
Adams	O
,	O
J	O
.	O
,	O
R	O
.	O
Kelso	O
,	O
and	O
L	O
.	O
Cooley	O
.	O
2000	O
.	O
Trends	O
Cell	O
Biol	O
.	O
10	O
:	O
17	O
-	O
24	O
.	O
)	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
a	O
neuronal	O
binding	O
partner	O
of	O
gigaxonin	O
.	O

Results	O
obtained	O
from	O
yeast	O
two	O
-	O
hybrid	O
screening	O
,	O
cotransfections	O
,	O
and	O
coimmunoprecipitations	O
demonstrate	O
that	O
gigaxonin	O
binds	O
directly	O
to	O
microtubule	O
-	O
associated	O
protein	O
(	O
MAP	O
)	O
1B	O
light	O
chain	O
(	O
LC	O
;	O
MAP1B	O
-	O
LC	O
)	O
,	O
a	O
protein	O
involved	O
in	O
maintaining	O
the	O
integrity	O
of	O
cytoskeletal	O
structures	O
and	O
promoting	O
neuronal	O
stability	O
.	O

Studies	O
using	O
double	O
immunofluorescent	O
microscopy	O
and	O
ultrastructural	O
analysis	O
revealed	O
physiological	O
colocalization	O
of	O
gigaxonin	O
with	O
MAP1B	O
in	O
neurons	O
.	O

Furthermore	O
,	O
in	O
transfected	O
cells	O
the	O
specific	O
interaction	O
of	O
gigaxonin	O
with	O
MAP1B	O
is	O
shown	O
to	O
enhance	O
the	O
microtubule	O
stability	O
required	O
for	O
axonal	O
transport	O
over	O
long	O
distance	O
.	O

At	O
least	O
two	O
different	O
mutations	O
identified	O
in	O
GAN	O
patients	O
(	O
Bomont	O
,	O
P	O
.	O
,	O
L	O
.	O
Cavalier	O
,	O
F	O
.	O
Blondeau	O
,	O
C	O
.	O
Ben	O
Hamida	O
,	O
S	O
.	O
Belal	O
,	O
M	O
.	O
Tazir	O
,	O
E	O
.	O
Demir	O
,	O
H	O
.	O
Topaloglu	O
,	O
R	O
.	O
Korinthenberg	O
,	O
B	O
.	O
Tuysuz	O
,	O
et	O
al	O
.	O
2000	O
.	O
Nat	O
.	O
Genet	O
.	O
26	O
:	O
370	O
-	O
374	O
.	O
)	O
lead	O
to	O
loss	O
of	O
gigaxonin	O
-	O
MAP1B	O
-	O
LC	O
interaction	O
.	O

The	O
devastating	O
axonal	O
degeneration	O
and	O
neuronal	O
death	O
found	O
in	O
GAN	O
patients	O
point	O
to	O
the	O
importance	O
of	O
gigaxonin	O
for	O
neuronal	O
survival	O
.	O

Our	O
findings	O
may	O
provide	O
important	O
insights	O
into	O
the	O
pathogenesis	O
of	O
neurodegenerative	O
disorders	O
related	O
to	O
cytoskeletal	O
abnormalities	O
.	O

The	O
anti	O
-	O
HIV	O
cytokine	O
midkine	O
binds	O
the	O
cell	O
surface	O
-	O
expressed	O
nucleolin	O
as	O
a	O
low	O
affinity	O
receptor	O
.	O

The	O
growth	O
factor	O
midkine	O
(	O
MK	O
)	O
is	O
a	O
cytokine	O
that	O
inhibits	O
the	O
attachment	O
of	O
human	O
immunodeficiency	O
virus	O
particles	O
by	O
a	O
mechanism	O
similar	O
to	O
the	O
nucleolin	O
binding	O
HB	O
-	O
19	O
pseudopeptide	O
.	O

Here	O
we	O
show	O
that	O
the	O
binding	O
of	O
MK	O
to	O
cells	O
occurs	O
specifically	O
at	O
a	O
high	O
and	O
a	O
low	O
affinity	O
binding	O
site	O
.	O

HB	O
-	O
19	O
prevents	O
the	O
binding	O
of	O
MK	O
to	O
the	O
low	O
affinity	O
binding	O
site	O
only	O
.	O

Confocal	O
immunofluorescence	O
laser	O
microscopy	O
revealed	O
the	O
colocalization	O
of	O
MK	O
and	O
the	O
cell	O
-	O
surface	O
-	O
expressed	O
nucleolin	O
at	O
distinct	O
spots	O
.	O

The	O
use	O
of	O
various	O
deletion	O
constructs	O
of	O
nucleolin	O
then	O
indicated	O
that	O
the	O
extreme	O
C	O
-	O
terminal	O
end	O
of	O
nucleolin	O
,	O
containing	O
repeats	O
of	O
the	O
amino	O
acid	O
motif	O
RGG	O
,	O
is	O
the	O
domain	O
that	O
binds	O
MK	O
.	O

The	O
specific	O
binding	O
of	O
MK	O
to	O
cells	O
is	O
independent	O
of	O
heparan	O
sulfate	O
and	O
chondroitin	O
sulfate	O
expression	O
.	O

After	O
binding	O
to	O
cells	O
,	O
MK	O
enters	O
cells	O
by	O
an	O
active	O
process	O
.	O

Interestingly	O
,	O
the	O
cross	O
-	O
linking	O
of	O
surface	O
-	O
bound	O
MK	O
with	O
a	O
specific	O
antibody	O
results	O
in	O
the	O
clustering	O
of	O
surface	O
nucleolin	O
along	O
with	O
glycosylphosphatidylinositol	O
-	O
linked	O
proteins	O
CD90	O
and	O
CD59	O
,	O
thus	O
,	O
pointing	O
out	O
that	O
MK	O
binding	O
induces	O
lateral	O
assemblies	O
of	O
nucleolin	O
with	O
specific	O
membrane	O
components	O
of	O
lipid	O
rafts	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
cell	O
surface	O
-	O
expressed	O
nucleolin	O
serves	O
as	O
a	O
low	O
affinity	O
receptor	O
for	O
MK	O
and	O
could	O
be	O
implicated	O
in	O
its	O
entry	O
process	O
.	O

Sumoylation	O
of	O
topoisomerase	O
I	O
is	O
involved	O
in	O
its	O
partitioning	O
between	O
nucleoli	O
and	O
nucleoplasm	O
and	O
its	O
clearing	O
from	O
nucleoli	O
in	O
response	O
to	O
camptothecin	O
.	O

Previous	O
studies	O
identified	O
a	O
small	O
fraction	O
of	O
putatively	O
sumoylated	O
topoisomerase	O
I	O
(	O
TOP1	O
)	O
under	O
basal	O
conditions	O
(	O
approximately	O
1	O
%	O
)	O
,	O
and	O
anticancer	O
camptothecins	O
that	O
trap	O
the	O
TOP1	O
-	O
DNA	O
covalent	O
intermediate	O
markedly	O
increase	O
the	O
sumoylation	O
of	O
TOP1	O
(	O
<	O
or	O
=	O
10	O
%	O
)	O
.	O

To	O
study	O
the	O
role	O
of	O
the	O
sumoylation	O
of	O
TOP1	O
,	O
we	O
mutated	O
sites	O
on	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
-	O
TOP1	O
corresponding	O
to	O
the	O
consensus	O
sequence	O
for	O
protein	O
sumoylation	O
(	O
PsiKXE	O
,	O
where	O
Psi	O
is	O
a	O
hydrophobic	O
residue	O
)	O
and	O
assayed	O
the	O
mutants	O
for	O
basal	O
and	O
camptothecin	O
-	O
induced	O
sumoylation	O
.	O

Only	O
one	O
of	O
the	O
eight	O
mutants	O
,	O
K117R	O
,	O
located	O
in	O
the	O
highly	O
charged	O
NH2	O
-	O
terminal	O
region	O
,	O
showed	O
a	O
substantial	O
reduction	O
(	O
approximately	O
5	O
-	O
fold	O
)	O
in	O
basal	O
and	O
camptothecin	O
-	O
induced	O
sumoylation	O
;	O
thus	O
,	O
Lys	O
-	O
117	O
appears	O
to	O
be	O
the	O
major	O
sumoylation	O
site	O
.	O

A	O
triple	O
mutant	O
having	O
the	O
PsiKXE	O
sequences	O
flanking	O
K117R	O
additionally	O
mutated	O
(	O
K103R	O
/	O
K117R	O
/	O
K153R	O
)	O
showed	O
little	O
if	O
any	O
sumoylation	O
,	O
but	O
was	O
degraded	O
like	O
wild	O
-	O
type	O
GFP	O
-	O
TOP1	O
during	O
camptothecin	O
treatment	O
.	O

However	O
,	O
K103R	O
/	O
K117R	O
/	O
K153R	O
-	O
GFP	O
-	O
TOP1	O
was	O
markedly	O
concentrated	O
within	O
nucleoli	O
,	O
depleted	O
from	O
the	O
remainder	O
of	O
nucleus	O
,	O
and	O
failed	O
to	O
be	O
cleared	O
from	O
nucleoli	O
in	O
response	O
to	O
camptothecin	O
treatment	O
.	O

These	O
data	O
are	O
consistent	O
with	O
a	O
model	O
wherein	O
basal	O
transient	O
sumoylation	O
of	O
the	O
NH2	O
-	O
terminal	O
,	O
highly	O
charged	O
,	O
disordered	O
region	O
prevents	O
TOP1	O
binding	O
to	O
sites	O
in	O
nucleoli	O
,	O
thus	O
driving	O
it	O
to	O
bind	O
in	O
the	O
nucleoplasm	O
;	O
and	O
camptothecin	O
treatment	O
,	O
which	O
increases	O
TOP1	O
sumoylation	O
,	O
further	O
shifts	O
the	O
binding	O
resulting	O
in	O
delocalization	O
of	O
TOP1	O
from	O
nucleoli	O
to	O
nucleoplasm	O
.	O

Interaction	O
of	O
protein	O
phosphatase	O
1	O
delta	O
with	O
nucleolin	O
in	O
human	O
osteoblastic	O
cells	O
.	O

We	O
examined	O
the	O
expression	O
and	O
cytolocalization	O
of	O
the	O
protein	O
phosphatase	O
type	O
1	O
delta	O
(	O
PP1delta	O
)	O
isoform	O
and	O
nucleolin	O
in	O
human	O
osteoblastic	O
MG63	O
and	O
Saos	O
-	O
2	O
cells	O
.	O

Cellular	O
fractionation	O
of	O
MG63	O
cells	O
was	O
done	O
and	O
protein	O
was	O
prepared	O
from	O
each	O
fraction	O
.	O

Anti	O
-	O
nucleolin	O
antibody	O
interacted	O
with	O
the	O
100	O
-	O
and	O
95	O
-	O
kD	O
proteins	O
present	O
in	O
the	O
whole	O
-	O
cell	O
lysate	O
.	O

The	O
100	O
-	O
kD	O
protein	O
was	O
detected	O
in	O
nuclear	O
and	O
nucleolar	O
fractions	O
.	O

The	O
95	O
-	O
kD	O
protein	O
was	O
detected	O
in	O
cytosolic	O
and	O
nucleoplasmic	O
fractions	O
.	O

PP1delta	O
and	O
nucleolin	O
were	O
co	O
-	O
localized	O
in	O
the	O
nucleolus	O
in	O
MG63	O
and	O
Saos	O
-	O
2	O
cells	O
revealed	O
by	O
an	O
immunofluorescence	O
method	O
.	O

PP1delta	O
and	O
nucleolin	O
were	O
also	O
co	O
-	O
immunoprecipitated	O
with	O
anti	O
-	O
nucleolin	O
and	O
anti	O
-	O
PP1delta	O
antibodies	O
.	O

In	O
the	O
actinomycin	O
D	O
-	O
treated	O
cells	O
,	O
the	O
subcellular	O
localization	O
of	O
PP1delta	O
and	O
nucleolin	O
was	O
changed	O
.	O

Expression	O
of	O
PP1delta	O
was	O
upregulated	O
with	O
actinomycin	O
D	O
treatment	O
.	O

The	O
level	O
of	O
100	O
-	O
kD	O
protein	O
did	O
not	O
change	O
in	O
the	O
actinomycin	O
D	O
-	O
treated	O
cells	O
.	O

However	O
,	O
the	O
level	O
of	O
the	O
95	O
-	O
kD	O
band	O
increased	O
with	O
actinomycin	O
D	O
treatment	O
.	O

These	O
results	O
indicate	O
that	O
PP1delta	O
was	O
associated	O
with	O
nucleolin	O
in	O
the	O
nucleolus	O
of	O
MG63	O
and	O
Saos	O
-	O
2	O
cells	O
and	O
that	O
nucleolin	O
is	O
a	O
possible	O
candidate	O
substrate	O
for	O
PP1delta	O
.	O

Cbl	O
-	O
directed	O
monoubiquitination	O
of	O
CIN85	O
is	O
involved	O
in	O
regulation	O
of	O
ligand	O
-	O
induced	O
degradation	O
of	O
EGF	O
receptors	O
.	O

Addition	O
of	O
ubiquitin	O
or	O
ubiquitin	O
chains	O
to	O
target	O
proteins	O
leads	O
to	O
their	O
mono	O
-	O
or	O
polyubiquitination	O
,	O
respectively	O
.	O

Whereas	O
polyubiquitination	O
targets	O
proteins	O
for	O
degradation	O
,	O
monoubiquitination	O
is	O
thought	O
to	O
regulate	O
receptor	O
internalization	O
and	O
endosomal	O
sorting	O
.	O

Cbl	O
proteins	O
are	O
major	O
ubiquitin	O
ligases	O
that	O
promote	O
ligand	O
-	O
dependent	O
polyubiquitination	O
and	O
degradation	O
of	O
receptor	O
tyrosine	O
kinases	O
.	O

They	O
also	O
recruit	O
CIN85	O
-	O
endophilin	O
in	O
the	O
complex	O
with	O
activated	O
receptors	O
,	O
thus	O
controlling	O
receptor	O
endocytosis	O
.	O

Here	O
we	O
show	O
that	O
the	O
adaptor	O
protein	O
CIN85	O
and	O
its	O
homologue	O
CMS	O
are	O
monoubiquitinated	O
by	O
Cbl	O
/	O
Cbl	O
-	O
b	O
after	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
stimulation	O
.	O

Monoubiquitination	O
of	O
CIN85	O
required	O
direct	O
interactions	O
between	O
CIN85	O
and	O
Cbl	O
,	O
the	O
intact	O
RING	O
finger	O
domain	O
of	O
Cbl	O
and	O
a	O
ubiquitin	O
acceptor	O
site	O
present	O
in	O
the	O
carboxyl	O
terminus	O
of	O
CIN85	O
.	O

Cbl	O
-	O
b	O
and	O
monoubiquitinated	O
CIN85	O
are	O
found	O
in	O
the	O
complex	O
with	O
polyubiquitinated	O
EGF	O
receptors	O
during	O
prolonged	O
EGF	O
stimulation	O
and	O
are	O
degraded	O
together	O
in	O
the	O
lysosome	O
.	O

Dominant	O
interfering	O
forms	O
of	O
CIN85	O
,	O
which	O
have	O
been	O
shown	O
previously	O
to	O
delay	O
EGF	O
receptor	O
degradation	O
,	O
were	O
also	O
impaired	O
in	O
their	O
monoubiquitination	O
.	O

Thus	O
,	O
our	O
data	O
demonstrate	O
that	O
Cbl	O
/	O
Cbl	O
-	O
b	O
can	O
mediate	O
polyubiquitination	O
of	O
cargo	O
as	O
well	O
as	O
monoubiquitination	O
of	O
CIN85	O
to	O
control	O
endosomal	O
sorting	O
and	O
degradation	O
of	O
receptor	O
tyrosine	O
kinases	O
.	O

Age	O
-	O
related	O
changes	O
in	O
human	O
bone	O
proteoglycan	O
structure	O
.	O

Impact	O
of	O
osteogenesis	O
imperfecta	O
.	O

Proteoglycans	O
(	O
PGs	O
)	O
are	O
a	O
family	O
of	O
molecules	O
that	O
undergo	O
extensive	O
post	O
-	O
translational	O
modifications	O
that	O
include	O
addition	O
of	O
glycosaminoglycan	O
(	O
GAG	O
)	O
chains	O
as	O
well	O
as	O
N	O
-	O
and	O
O	O
-	O
linked	O
oligosaccharides	O
to	O
the	O
protein	O
core	O
.	O

PG	O
composition	O
and	O
structure	O
have	O
been	O
reported	O
to	O
alter	O
with	O
age	O
.	O

To	O
test	O
whether	O
the	O
post	O
-	O
translational	O
modifications	O
to	O
PGs	O
can	O
serve	O
as	O
in	O
vitro	O
surrogate	O
end	O
point	O
markers	O
for	O
chronological	O
age	O
,	O
the	O
extent	O
of	O
GAG	O
modifications	O
was	O
determined	O
for	O
PGs	O
derived	O
from	O
normal	O
human	O
bone	O
cells	O
of	O
14	O
donors	O
(	O
age	O
range	O
,	O
fetal	O
to	O
60	O
years	O
)	O
.	O

Isolated	O
cells	O
were	O
steady	O
state	O
radiolabeled	O
with	O
(	O
35	O
)	O
SO	O
(	O
4	O
)	O
(	O
2	O
-	O
)	O
and	O
[	O
(	O
3	O
)	O
H	O
]	O
GlcN	O
.	O

For	O
biglycan	O
and	O
decorin	O
,	O
iduronate	O
content	O
was	O
linearly	O
correlated	O
with	O
age	O
(	O
increased	O
1	O
.	O
5x	O
between	O
fetal	O
and	O
age	O
60	O
years	O
)	O
.	O

For	O
the	O
syndecan	O
-	O
like	O
heparan	O
sulfate	O
PG	O
,	O
the	O
N	O
-	O
sulfation	O
of	O
post	O
-	O
natal	O
cells	O
increased	O
over	O
3	O
.	O
5	O
-	O
fold	O
until	O
reaching	O
a	O
plateau	O
during	O
the	O
4th	O
decade	O
of	O
life	O
.	O

The	O
amount	O
of	O
O	O
-	O
linked	O
oligosaccharides	O
was	O
also	O
found	O
to	O
decrease	O
as	O
a	O
function	O
of	O
increasing	O
normal	O
donor	O
age	O
,	O
whereas	O
the	O
specific	O
activity	O
of	O
the	O
metabolic	O
precursor	O
pool	O
remained	O
constant	O
regardless	O
of	O
donor	O
age	O
.	O

These	O
age	O
-	O
related	O
changes	O
in	O
post	O
-	O
translational	O
modifications	O
were	O
then	O
used	O
to	O
demonstrate	O
that	O
osteoblasts	O
derived	O
from	O
patients	O
with	O
osteogenesis	O
imperfecta	O
did	O
not	O
exhibit	O
facets	O
of	O
a	O
pre	O
-	O
mature	O
aging	O
,	O
but	O
rather	O
were	O
arrested	O
in	O
a	O
fetal	O
-	O
like	O
phenotypic	O
state	O
.	O

A	O
growth	O
matrix	O
rich	O
in	O
thrombospondin	O
altered	O
PG	O
metabolism	O
in	O
osteoblastic	O
cells	O
,	O
resulting	O
in	O
the	O
production	O
and	O
secretion	O
of	O
the	O
fetal	O
-	O
like	O
(	O
rich	O
in	O
O	O
-	O
linked	O
oligosaccharides	O
)	O
forms	O
of	O
decorin	O
and	O
biglycan	O
.	O

This	O
effect	O
was	O
qualitatively	O
different	O
from	O
the	O
effect	O
of	O
transforming	O
growth	O
factor	O
-	O
beta	O
,	O
which	O
predominantly	O
altered	O
GAGs	O
rather	O
than	O
O	O
-	O
linked	O
oligosaccharides	O
.	O

No	O
other	O
Arg	O
-	O
Gly	O
-	O
Asp	O
protein	O
(	O
fibronectin	O
,	O
vitronectin	O
,	O
type	B-Complex
I	I-Complex
collagen	I-Complex
,	O
osteopontin	O
,	O
and	O
bone	O
sialoprotein	O
)	O
showed	O
any	O
detectable	O
effect	O
on	O
PG	O
metabolism	O
in	O
bone	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
a	O
proper	O
matrix	O
stoichiometry	O
is	O
critical	O
for	O
metabolism	O
of	O
PGs	O
.	O

Chaperone	O
-	O
dependent	O
E3	O
ubiquitin	O
ligase	O
CHIP	O
mediates	O
a	O
degradative	O
pathway	O
for	O
c	O
-	O
ErbB2	O
/	O
Neu	O
.	O

Overexpression	O
of	O
the	O
transmembrane	O
receptor	O
tyrosine	O
kinase	O
ErbB2	O
is	O
common	O
in	O
multiple	O
malignancies	O
,	O
including	O
breast	O
and	O
ovarian	O
cancer	O
.	O

ErbB2	O
is	O
resistant	O
to	O
degradation	O
mediated	O
by	O
c	O
-	O
Cbl	O
,	O
the	O
E3	O
ubiquitin	O
ligase	O
responsible	O
for	O
ligand	O
-	O
induced	O
ubiquitination	O
of	O
ErbB1	O
(	O
epidermal	O
growth	O
factor	O
receptor	O
)	O
.	O

Because	O
of	O
its	O
resistance	O
to	O
degradation	O
,	O
ErbB2	O
is	O
the	O
preferred	O
dimerization	O
partner	O
for	O
other	O
members	O
of	O
the	O
ErbB	O
family	O
,	O
and	O
its	O
overexpression	O
in	O
vivo	O
is	O
associated	O
with	O
poor	O
prognosis	O
.	O

We	O
now	O
show	O
that	O
the	O
chaperone	O
-	O
binding	O
ubiquitin	O
ligase	O
CHIP	O
efficiently	O
ubiquitinates	O
and	O
down	O
-	O
regulates	O
ErbB2	O
.	O

CHIP	O
expression	O
shortens	O
the	O
half	O
-	O
life	O
of	O
both	O
nascent	O
and	O
mature	O
ErbB2	O
protein	O
.	O

In	O
vitro	O
ubiquitination	O
assay	O
shows	O
that	O
CHIP	O
serves	O
as	O
a	O
ubiquitin	O
ligase	O
for	O
ErbB2	O
,	O
and	O
both	O
exogenously	O
expressed	O
and	O
endogenous	O
CHIP	O
coprecipitate	O
with	O
the	O
kinase	O
.	O

Furthermore	O
,	O
CHIP	O
association	O
with	O
ErbB2	O
requires	O
a	O
chaperone	O
intermediate	O
and	O
is	O
increased	O
by	O
the	O
chaperone	O
-	O
binding	O
drug	O
geldanamycin	O
,	O
a	O
potent	O
stimulator	O
of	O
ErbB2	O
ubiquitination	O
and	O
degradation	O
.	O

These	O
data	O
describe	O
a	O
previously	O
unrecognized	O
pathway	O
,	O
amenable	O
to	O
pharmacologic	O
manipulation	O
,	O
that	O
mediates	O
ErbB2	O
stability	O
.	O

Role	O
of	O
the	O
unfolded	O
protein	O
response	O
pathway	O
in	O
regulation	O
of	O
INO1	O
and	O
in	O
the	O
sec14	O
bypass	O
mechanism	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

INO1	O
,	O
encoding	O
inositol	O
1	O
-	O
phosphate	O
synthase	O
,	O
is	O
the	O
most	O
highly	O
regulated	O
of	O
a	O
class	O
of	O
genes	O
containing	O
the	O
repeated	O
element	O
,	O
UAS	O
(	O
INO	O
)	O
,	O
in	O
their	O
promoters	O
.	O

Transcription	O
of	O
UAS	O
(	O
INO	O
)	O
-	O
containing	O
genes	O
is	O
modulated	O
by	O
the	O
availability	O
of	O
exogenous	O
inositol	O
and	O
by	O
signals	O
generated	O
by	O
alteration	O
of	O
phospholipid	O
metabolism	O
.	O

The	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
pathway	O
also	O
is	O
involved	O
in	O
INO1	O
expression	O
and	O
the	O
ire1Delta	O
and	O
hac1Delta	O
mutants	O
are	O
inositol	O
auxotrophs	O
.	O

We	O
examined	O
the	O
role	O
of	O
the	O
UPR	O
in	O
transmitting	O
a	O
signal	O
generated	O
in	O
response	O
to	O
inositol	O
deprivation	O
and	O
to	O
alteration	O
of	O
phospholipid	O
biosynthesis	O
created	O
in	O
the	O
sec14	O
(	O
ts	O
)	O
cki1Delta	O
genetic	O
background	O
.	O

We	O
report	O
that	O
the	O
UPR	O
is	O
required	O
for	O
sustained	O
high	O
-	O
level	O
INO1	O
expression	O
in	O
wild	O
-	O
type	O
strains	O
,	O
but	O
not	O
for	O
transient	O
derepression	O
in	O
response	O
to	O
inositol	O
deprivation	O
.	O

Moreover	O
,	O
the	O
UPR	O
is	O
not	O
required	O
for	O
expression	O
or	O
regulation	O
of	O
INO1	O
in	O
response	O
to	O
the	O
change	O
in	O
lipid	O
metabolism	O
that	O
occurs	O
in	O
the	O
sec14	O
(	O
ts	O
)	O
cki1Delta	O
genetic	O
background	O
.	O

Thus	O
,	O
the	O
UPR	O
signal	O
transduction	O
pathway	O
is	O
not	O
involved	O
directly	O
in	O
transcriptional	O
regulation	O
of	O
INO1	O
and	O
other	O
UAS	O
(	O
INO	O
)	O
-	O
containing	O
genes	O
.	O

However	O
,	O
we	O
discovered	O
that	O
inactivation	O
of	O
Sec14p	O
leads	O
to	O
activation	O
of	O
the	O
UPR	O
,	O
and	O
that	O
sec14	O
cki1	O
strains	O
exhibit	O
defective	O
vacuolar	O
morphology	O
,	O
suggesting	O
that	O
the	O
mechanism	O
by	O
which	O
the	O
cki1Delta	O
mutation	O
suppresses	O
the	O
growth	O
and	O
secretory	O
defect	O
of	O
sec14	O
does	O
not	O
fully	O
restore	O
wild	O
-	O
type	O
morphology	O
.	O

Finally	O
,	O
synthetic	O
lethality	O
involving	O
sec14	O
and	O
UPR	O
mutations	O
suggests	O
that	O
the	O
UPR	O
plays	O
an	O
essential	O
role	O
in	O
survival	O
of	O
sec14	O
cki1	O
strains	O
.	O

Expression	O
of	O
the	O
suppressor	O
of	O
cytokine	O
signaling	O
-	O
5	O
(	O
SOCS5	O
)	O
negatively	O
regulates	O
IL	O
-	O
4	O
-	O
dependent	O
STAT6	O
activation	O
and	O
Th2	O
differentiation	O
.	O

The	O
development	O
of	O
helper	O
T	O
(	O
Th	O
)	O
cell	O
subsets	O
,	O
which	O
secrete	O
distinct	O
cytokines	O
,	O
plays	O
an	O
important	O
role	O
in	O
determining	O
the	O
type	O
of	O
immune	O
response	O
.	O

The	O
IL	O
-	O
4	O
-	O
mediated	O
Janus	O
kinase	O
-	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
signaling	O
pathway	O
is	O
crucial	O
for	O
mediating	O
Th2	O
cell	O
development	O
.	O

Notably	O
,	O
this	O
pathway	O
is	O
selectively	O
impaired	O
in	O
Th1	O
cells	O
,	O
although	O
the	O
molecular	O
basis	O
of	O
this	O
impairment	O
remains	O
unclear	O
.	O

We	O
show	O
here	O
that	O
during	O
Th1	O
differentiation	O
a	O
reduction	O
in	O
the	O
association	O
of	O
Janus	O
kinase	O
1	O
with	O
the	O
IL	B-Complex
-	I-Complex
4	I-Complex
receptor	I-Complex
(	O
IL	B-Complex
-	I-Complex
4R	I-Complex
)	O
correlated	O
with	O
the	O
appearance	O
of	O
the	O
suppressor	O
of	O
cytokine	O
signaling	O
-	O
5	O
(	O
SOCS5	O
)	O
.	O

SOCS5	O
protein	O
was	O
preferentially	O
expressed	O
in	O
committed	O
Th1	O
cells	O
and	O
interacted	O
with	O
the	O
cytoplasmic	O
region	O
of	O
the	O
IL	O
-	O
4Ralpha	O
chain	O
irrespective	O
of	O
receptor	O
tyrosine	O
phosphorylation	O
.	O

This	O
unconventional	O
interaction	O
of	O
SOCS5	O
protein	O
with	O
the	O
IL	B-Complex
-	I-Complex
4R	I-Complex
resulted	O
in	O
the	O
inhibition	O
of	O
IL	O
-	O
4	O
-	O
mediated	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
-	O
6	O
activation	O
.	O

T	O
cells	O
from	O
transgenic	O
mice	O
constitutively	O
expressing	O
SOCS5	O
exhibited	O
a	O
significant	O
reduction	O
of	O
IL	O
-	O
4	O
-	O
mediated	O
Th2	O
development	O
.	O

Therefore	O
,	O
the	O
induced	O
SOCS5	O
protein	O
in	O
Th1	O
differentiation	O
environment	O
may	O
play	O
an	O
important	O
role	O
by	O
regulating	O
Th1	O
and	O
Th2	O
balance	O
.	O

Zinc	O
-	O
dependent	O
interaction	O
between	O
dishevelled	O
and	O
the	O
Drosophila	O
Wnt	O
antagonist	O
naked	O
cuticle	O
.	O

During	O
Drosophila	O
development	O
,	O
the	O
naked	O
cuticle	O
(	O
nkd	O
)	O
gene	O
attenuates	O
wingless	O
/	O
Wnt	O
signaling	O
through	O
a	O
negative	O
feedback	O
loop	O
mechanism	O
.	O

Fly	O
and	O
vertebrate	O
Nkd	O
proteins	O
contain	O
a	O
putative	O
calcium	O
-	O
binding	O
EF	O
-	O
hand	O
motif	O
,	O
the	O
EFX	O
domain	O
,	O
that	O
interacts	O
with	O
the	O
basic	O
/	O
PDZ	O
region	O
of	O
the	O
Wnt	O
signal	O
transducer	O
,	O
dishevelled	O
(	O
Dsh	O
)	O
.	O

Here	O
we	O
show	O
that	O
Dsh	O
binding	O
by	O
Drosophila	O
Nkd	O
in	O
vitro	O
is	O
mediated	O
by	O
the	O
EFX	O
domain	O
as	O
well	O
as	O
an	O
adjacent	O
C	O
-	O
terminal	O
sequence	O
.	O

In	O
vivo	O
data	O
suggest	O
that	O
both	O
of	O
these	O
regions	O
contribute	O
to	O
the	O
ability	O
of	O
Nkd	O
to	O
antagonize	O
Wnt	O
signaling	O
.	O

Mutations	O
in	O
the	O
Nkd	O
EF	O
-	O
hand	O
designed	O
to	O
eliminate	O
potential	O
ion	O
binding	O
affected	O
Nkd	O
-	O
Dsh	O
interactions	O
in	O
the	O
yeast	O
two	O
-	O
hybrid	O
assay	O
but	O
not	O
in	O
the	O
glutathione	O
S	O
-	O
transferase	O
pull	O
-	O
down	O
assay	O
.	O

Addition	O
of	O
the	O
chelating	O
agent	O
EDTA	O
abolished	O
the	O
in	O
vitro	O
Nkd	O
-	O
Dsh	O
interaction	O
.	O

Surprisingly	O
zinc	O
,	O
but	O
not	O
calcium	O
,	O
was	O
able	O
to	O
restore	O
Nkd	O
-	O
Dsh	O
binding	O
,	O
suggesting	O
a	O
zinc	O
-	O
mediated	O
interaction	O
.	O

Calcium	O
45	O
-	O
and	O
zinc	O
65	O
-	O
blotting	O
experiments	O
show	O
that	O
Nkd	O
is	O
a	O
zinc	O
-	O
binding	O
metalloprotein	O
.	O

The	O
results	O
further	O
clarify	O
how	O
Nkd	O
may	O
antagonize	O
Wnt	O
signaling	O
via	O
interaction	O
with	O
Dsh	O
,	O
and	O
identify	O
a	O
novel	O
zinc	O
-	O
binding	O
domain	O
in	O
Drosophila	O
Nkd	O
that	O
collaborates	O
with	O
the	O
conserved	O
EFX	O
domain	O
to	O
bind	O
Dsh	O
.	O

CP110	O
,	O
a	O
cell	O
cycle	O
-	O
dependent	O
CDK	O
substrate	O
,	O
regulates	O
centrosome	O
duplication	O
in	O
human	O
cells	O
.	O

Centrosome	O
duplication	O
and	O
separation	O
are	O
linked	O
inextricably	O
to	O
certain	O
cell	O
cycle	O
events	O
,	O
in	O
particular	O
activation	O
of	O
cyclin	O
-	O
dependent	O
kinases	O
(	O
CDKs	O
)	O
.	O

However	O
,	O
relatively	O
few	O
CDK	O
targets	O
driving	O
these	O
events	O
have	O
been	O
uncovered	O
.	O

Here	O
,	O
we	O
have	O
performed	O
a	O
screen	O
for	O
CDK	O
substrates	O
and	O
have	O
isolated	O
a	O
target	O
,	O
CP110	O
,	O
which	O
is	O
phosphorylated	O
by	O
CDKs	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Human	O
CP110	O
localizes	O
to	O
centrosomes	O
.	O

Its	O
expression	O
is	O
strongly	O
induced	O
at	O
the	O
G1	O
-	O
to	O
-	O
S	O
phase	O
transition	O
,	O
coincident	O
with	O
the	O
initiation	O
of	O
centrosome	O
duplication	O
.	O

RNAi	O
-	O
mediated	O
depletion	O
of	O
CP110	O
indicates	O
that	O
this	O
protein	O
plays	O
an	O
essential	O
role	O
in	O
centrosome	O
duplication	O
.	O

Long	O
-	O
term	O
disruption	O
of	O
CP110	O
phosphorylation	O
leads	O
to	O
unscheduled	O
centrosome	O
separation	O
and	O
overt	O
polyploidy	O
.	O

Our	O
data	O
suggest	O
that	O
CP110	O
is	O
a	O
physiological	O
centrosomal	O
CDK	O
target	O
that	O
promotes	O
centrosome	O
duplication	O
,	O
and	O
its	O
deregulation	O
may	O
contribute	O
to	O
genomic	O
instability	O
.	O

Distinct	O
nongenomic	O
signal	O
transduction	O
pathways	O
controlled	O
by	O
17beta	O
-	O
estradiol	O
regulate	O
DNA	O
synthesis	O
and	O
cyclin	O
D	O
(	O
1	O
)	O
gene	O
transcription	O
in	O
HepG2	O
cells	O
.	O

Estrogens	O
induce	O
cell	O
proliferation	O
in	O
target	O
tissues	O
by	O
stimulating	O
progression	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Activation	O
of	O
cyclin	O
D	O
(	O
1	O
)	O
gene	O
expression	O
is	O
a	O
critical	O
feature	O
of	O
this	O
hormonal	O
action	O
.	O

The	O
existence	O
of	O
rapid	O
/	O
nongenomic	O
estradiol	O
-	O
regulated	O
protein	O
kinase	O
C	O
(	O
PKC	O
-	O
alpha	O
)	O
and	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
signal	O
transduction	O
pathways	O
,	O
their	O
cross	O
talk	O
,	O
and	O
role	O
played	O
in	O
DNA	O
synthesis	O
and	O
cyclin	O
D	O
(	O
1	O
)	O
gene	O
transcription	O
have	O
been	O
studied	O
herein	O
in	O
human	O
hepatoma	O
HepG2	O
cells	O
.	O

17Beta	O
-	O
estradiol	O
was	O
found	O
to	O
rapidly	O
activate	O
PKC	O
-	O
alpha	O
translocation	O
and	O
ERK	O
-	O
2	O
/	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
phosphorylation	O
in	O
this	O
cell	O
line	O
.	O

These	O
actions	O
were	O
independent	O
of	O
each	O
other	O
,	O
preceding	O
the	O
increase	O
of	O
thymidine	O
incorporation	O
into	O
DNA	O
and	O
cyclin	O
D	O
(	O
1	O
)	O
expression	O
,	O
and	O
did	O
not	O
involve	O
DNA	O
binding	O
by	O
estrogen	O
receptor	O
.	O

The	O
results	O
obtained	O
with	O
specific	O
inhibitors	O
indicated	O
that	O
PKC	O
-	O
alpha	O
pathway	O
is	O
necessary	O
to	O
mediate	O
the	O
estradiol	O
-	O
induced	O
G1	O
-	O
S	O
progression	O
of	O
HepG2	O
cells	O
,	O
but	O
it	O
does	O
not	O
exert	O
any	O
effect	O
(	O
s	O
)	O
on	O
cyclin	O
D	O
(	O
1	O
)	O
gene	O
expression	O
.	O

On	O
the	O
contrary	O
,	O
ERK	O
-	O
2	O
cascade	O
was	O
strongly	O
involved	O
in	O
both	O
G1	O
-	O
S	O
progression	O
and	O
cyclin	O
D	O
(	O
1	O
)	O
gene	O
transcription	O
.	O

Deletion	O
of	O
its	O
activating	O
protein	O
-	O
1	O
responsive	O
element	O
motif	O
resulted	O
in	O
attenuation	O
of	O
cyclin	O
D	O
(	O
1	O
)	O
promoter	O
responsiveness	O
to	O
estrogen	O
.	O

These	O
results	O
indicate	O
that	O
estrogen	O
-	O
induced	O
cyclin	O
D	O
(	O
1	O
)	O
transcription	O
can	O
occur	O
in	O
HepG2	O
cells	O
independently	O
of	O
the	O
transcriptional	O
activity	O
of	O
estrogen	O
receptor	O
,	O
sustaining	O
the	O
pivotal	O
role	O
played	O
by	O
nongenomic	O
pathways	O
of	O
estrogen	O
action	O
in	O
hormone	O
-	O
induced	O
proliferation	O
.	O

The	O
cysteine	O
-	O
rich	O
sprouty	O
translocation	O
domain	O
targets	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
inhibitory	O
proteins	O
to	O
phosphatidylinositol	O
4	O
,	O
5	O
-	O
bisphosphate	O
in	O
plasma	O
membranes	O
.	O

Sprouty	O
(	O
Spry	O
)	O
proteins	O
have	O
been	O
revealed	O
as	O
inhibitors	O
of	O
the	O
Ras	O
/	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
cascade	O
,	O
a	O
pathway	O
crucial	O
for	O
developmental	O
processes	O
initiated	O
by	O
activation	O
of	O
various	O
receptor	O
tyrosine	O
kinases	O
.	O

In	O
COS	O
-	O
1	O
and	O
Swiss	O
3T3	O
cells	O
,	O
all	O
Spry	O
isoforms	O
translocate	O
to	O
the	O
plasma	O
membrane	O
,	O
notably	O
ruffles	O
,	O
following	O
activation	O
.	O

Here	O
we	O
show	O
that	O
microinjection	O
of	O
active	O
Rac	O
induced	O
the	O
translocation	O
of	O
Spry	O
isoforms	O
,	O
indicating	O
that	O
the	O
target	O
of	O
the	O
Spry	O
translocation	O
domain	O
(	O
SpryTD	O
)	O
is	O
downstream	O
of	O
active	O
Rac	O
.	O

Targeted	O
disruption	O
of	O
actin	O
polymerization	O
revealed	O
that	O
the	O
SpryTD	O
target	O
appeared	O
upstream	O
of	O
cytoskeletal	O
rearrangements	O
.	O

Accumulated	O
evidence	O
indicated	O
that	O
phosphatidylinositol	O
4	O
,	O
5	O
-	O
bisphosphate	O
[	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P	O
(	O
2	O
)	O
]	O
is	O
the	O
likely	O
SpryTD	O
target	O
.	O

Human	O
Spry2TD	O
(	O
hSpry2TD	O
)	O
binds	O
to	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P	O
(	O
2	O
)	O
in	O
vesicle	O
-	O
binding	O
assays	O
.	O

hSpry2TD	O
colocalizes	O
with	O
the	O
pleckstrin	O
homology	O
domain	O
of	O
phospholipase	O
Cdelta	O
,	O
which	O
binds	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P	O
(	O
2	O
)	O
.	O

The	O
plasma	O
membrane	O
localization	O
of	O
hSpry2TD	O
was	O
abolished	O
in	O
ionomycin	O
-	O
treated	O
MDCK	O
cells	O
or	O
when	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P	O
(	O
2	O
)	O
was	O
specifically	O
dephosphorylated	O
by	O
overexpression	O
of	O
an	O
engineered	O
,	O
green	O
fluorescent	O
protein	O
-	O
tagged	O
inositol	O
5	O
-	O
phosphatase	O
.	O

Similarly	O
,	O
Spred	O
,	O
a	O
novel	O
Ras	O
/	O
MAPK	O
inhibitor	O
recently	O
found	O
to	O
contain	O
the	O
conserved	O
cysteine	O
-	O
rich	O
SpryTD	O
,	O
also	O
translocated	O
to	O
peripheral	O
membranes	O
and	O
bound	O
to	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P	O
(	O
2	O
)	O
.	O

Alignment	O
of	O
the	O
Spry	O
and	O
Spred	O
proteins	O
led	O
us	O
to	O
identify	O
a	O
translocation	O
-	O
defective	O
point	O
mutant	O
,	O
hSpry2	O
D252	O
.	O

Targeting	O
of	O
hSpry2	O
to	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P	O
(	O
2	O
)	O
was	O
shown	O
to	O
be	O
essential	O
for	O
the	O
down	O
-	O
regulation	O
of	O
Ras	O
/	O
MAPK	O
signaling	O
.	O

Ubc9	O
is	O
essential	O
for	O
viability	O
of	O
higher	O
eukaryotic	O
cells	O
.	O

Ubc9	O
is	O
an	O
enzyme	O
involved	O
in	O
the	O
conjugation	O
of	O
SUMO	O
-	O
1	O
(	O
small	O
ubiquitin	O
related	O
modifier	O
1	O
)	O
to	O
target	O
proteins	O
.	O

The	O
SUMO	O
-	O
1	O
conjugation	O
system	O
is	O
well	O
conserved	O
from	O
yeasts	O
to	O
higher	O
eukaryotes	O
,	O
but	O
many	O
SUMO	O
-	O
1	O
target	O
proteins	O
reported	O
recently	O
in	O
higher	O
eukaryotic	O
cells	O
,	O
including	O
IkappaBalpha	O
,	O
MDM2	O
,	O
p53	O
,	O
and	O
PML	O
,	O
are	O
not	O
present	O
in	O
yeasts	O
.	O

To	O
determine	O
the	O
physiological	O
roles	O
of	O
SUMO	O
-	O
1	O
conjugation	O
in	O
higher	O
eukaryotic	O
cells	O
,	O
we	O
constructed	O
a	O
conditional	O
UBC9	O
mutant	O
of	O
chicken	O
DT40	O
cells	O
containing	O
the	O
UBC9	O
transgene	O
under	O
control	O
of	O
a	O
tetracycline	O
-	O
repressible	O
promoter	O
and	O
characterized	O
their	O
loss	O
of	O
function	O
phenotypes	O
.	O

Ubc9	O
disappeared	O
3	O
days	O
after	O
the	O
addition	O
of	O
tetracycline	O
and	O
the	O
increase	O
in	O
viable	O
cell	O
number	O
stopped	O
4	O
days	O
after	O
the	O
addition	O
of	O
drug	O
.	O

In	O
contrast	O
to	O
the	O
cases	O
of	O
ubc9	O
mutants	O
of	O
budding	O
and	O
fission	O
yeasts	O
,	O
which	O
show	O
defects	O
in	O
progression	O
of	O
G2	O
or	O
early	O
M	O
phase	O
and	O
in	O
chromosome	O
segregation	O
,	O
respectively	O
,	O
we	O
did	O
not	O
observe	O
accumulation	O
of	O
cells	O
in	O
G2	O
/	O
M	O
phase	O
or	O
a	O
considerable	O
increase	O
in	O
the	O
frequency	O
of	O
chromosome	O
missegregation	O
upon	O
depletion	O
of	O
Ubc9	O
but	O
we	O
did	O
observe	O
an	O
increase	O
in	O
the	O
number	O
of	O
cells	O
containing	O
multiple	O
nuclei	O
,	O
indicating	O
defects	O
in	O
cytokinesis	O
.	O

A	O
considerable	O
portion	O
of	O
the	O
Ubc9	O
-	O
depleted	O
cell	O
population	O
was	O
committed	O
to	O
apoptosis	O
without	O
accumulating	O
in	O
a	O
specific	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
suggesting	O
that	O
chromosome	O
damages	O
are	O
accumulated	O
in	O
Ubc9	O
-	O
depleted	O
cells	O
,	O
and	O
apoptosis	O
is	O
triggered	O
without	O
activating	O
checkpoint	O
mechanisms	O
under	O
conditions	O
of	O
SUMO	O
-	O
1	O
conjugation	O
system	O
impairment	O
.	O

Involvement	O
of	O
Src	O
family	O
protein	O
tyrosine	O
kinases	O
in	O
Ca	O
(	O
2	O
+	O
)	O
sensitization	O
of	O
coronary	O
artery	O
contraction	O
mediated	O
by	O
a	O
sphingosylphosphorylcholine	O
-	O
Rho	O
-	O
kinase	O
pathway	O
.	O

We	O
recently	O
reported	O
that	O
sphingosylphosphorylcholine	O
(	O
SPC	O
)	O
is	O
a	O
novel	O
messenger	O
for	O
Rho	O
-	O
kinase	O
-	O
mediated	O
Ca	O
(	O
2	O
+	O
)	O
sensitization	O
of	O
vascular	O
smooth	O
muscle	O
(	O
VSM	O
)	O
contraction	O
.	O

Subcellular	O
localization	O
and	O
kinase	O
activity	O
of	O
Src	O
family	O
protein	O
kinases	O
(	O
SrcPTKs	O
)	O
,	O
except	O
for	O
c	O
-	O
Src	O
,	O
is	O
controlled	O
by	O
a	O
reversible	O
S	O
-	O
palmitoylation	O
,	O
an	O
event	O
inhibited	O
by	O
eicosapentaenoic	O
acid	O
(	O
EPA	O
)	O
.	O

We	O
examined	O
the	O
possible	O
involvement	O
of	O
SrcPTKs	O
in	O
SPC	O
-	O
induced	O
Ca	O
(	O
2	O
+	O
)	O
sensitization	O
and	O
effects	O
of	O
EPA	O
.	O

We	O
used	O
porcine	O
coronary	O
VSM	O
and	O
rat	O
aortic	O
VSM	O
cells	O
(	O
VSMCs	O
)	O
in	O
primary	O
culture	O
.	O

An	O
SrcPTKs	O
inhibitor	O
,	O
PP1	O
,	O
and	O
EPA	O
inhibited	O
SPC	O
-	O
induced	O
contraction	O
,	O
concentration	O
-	O
dependently	O
,	O
without	O
affecting	O
[	O
Ca	O
(	O
2	O
+	O
)	O
]	O
(	O
i	O
)	O
levels	O
and	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
contraction	O
induced	O
by	O
high	O
K	O
(	O
+	O
)	O
depolarization	O
.	O

A	O
digitized	O
immunocytochemical	O
analysis	O
in	O
VSMCs	O
revealed	O
that	O
SPC	O
induced	O
translocation	O
of	O
Fyn	O
,	O
but	O
not	O
of	O
c	O
-	O
Src	O
,	O
from	O
the	O
cytosol	O
to	O
the	O
cell	O
membrane	O
,	O
an	O
event	O
abolished	O
by	O
EPA	O
.	O

Translocation	O
of	O
Rho	O
-	O
kinase	O
from	O
the	O
cytosol	O
to	O
the	O
cell	O
membrane	O
by	O
SPC	O
was	O
also	O
inhibited	O
by	O
EPA	O
and	O
PP1	O
.	O

The	O
SPC	O
-	O
induced	O
activation	O
of	O
SrcPTKs	O
was	O
blocked	O
by	O
EPA	O
and	O
PP1	O
,	O
but	O
not	O
by	O
Y27632	O
,	O
an	O
Rho	O
-	O
kinase	O
inhibitor	O
.	O

Rho	O
-	O
kinase	O
-	O
dependent	O
phosphorylation	O
of	O
myosin	B-Complex
phosphatase	I-Complex
induced	O
by	O
SPC	O
was	O
inhibited	O
by	O
EPA	O
,	O
PP1	O
,	O
and	O
Y27632	O
.	O

Translocation	O
and	O
activation	O
of	O
SrcPTKs	O
,	O
including	O
Fyn	O
,	O
play	O
an	O
important	O
role	O
in	O
Ca	O
(	O
2	O
+	O
)	O
sensitization	O
of	O
VSM	O
contractions	O
mediated	O
by	O
a	O
SPC	O
-	O
Rho	O
-	O
kinase	O
pathway	O
.	O

Expression	O
and	O
characterization	O
of	O
recombinant	O
vitamin	O
K	O
-	O
dependent	O
gamma	O
-	O
glutamyl	O
carboxylase	O
from	O
an	O
invertebrate	O
,	O
Conus	O
textile	O
.	O

The	O
marine	O
snail	O
Conus	O
is	O
the	O
sole	O
invertebrate	O
wherein	O
both	O
the	O
vitamin	O
K	O
-	O
dependent	O
carboxylase	O
and	O
its	O
product	O
,	O
gamma	O
-	O
carboxyglutamic	O
acid	O
,	O
have	O
been	O
identified	O
.	O

To	O
examine	O
its	O
biosynthesis	O
of	O
gamma	O
-	O
carboxyglutamic	O
acid	O
,	O
we	O
studied	O
the	O
carboxylase	O
from	O
Conus	O
venom	O
ducts	O
.	O

The	O
carboxylase	O
cDNA	O
from	O
Conus	O
textile	O
has	O
an	O
ORF	O
that	O
encodes	O
a	O
811	O
-	O
amino	O
-	O
acid	O
protein	O
which	O
exhibits	O
sequence	O
similarity	O
to	O
the	O
vertebrate	O
carboxylases	O
,	O
with	O
41	O
%	O
identity	O
and	O
approximately	O
60	O
%	O
sequence	O
similarity	O
to	O
the	O
bovine	O
carboxylase	O
.	O

Expression	O
of	O
this	O
cDNA	O
in	O
COS	O
cells	O
or	O
insect	O
cells	O
yielded	O
vitamin	O
K	O
-	O
dependent	O
carboxylase	O
activity	O
and	O
vitamin	O
K	O
-	O
dependent	O
epoxidase	O
activity	O
.	O

The	O
recombinant	O
carboxylase	O
has	O
a	O
molecular	O
mass	O
of	O
approximately	O
130	O
kDa	O
.	O

The	O
recombinant	O
Conus	O
carboxylase	O
carboxylated	O
Phe	O
-	O
Leu	O
-	O
Glu	O
-	O
Glu	O
-	O
Leu	O
and	O
the	O
28	O
-	O
residue	O
peptides	O
based	O
on	O
residues	O
-	O
18	O
to	O
+	O
10	O
of	O
human	O
proprothrombin	O
and	O
proFactor	O
IX	O
with	O
Km	O
values	O
of	O
420	O
micro	O
m	O
,	O
1	O
.	O
7	O
micro	O
m	O
and	O
6	O
micro	O
m	O
,	O
respectively	O
;	O
the	O
Km	O
for	O
vitamin	O
K	O
is	O
52	O
micro	O
m	O
.	O

The	O
Km	O
values	O
for	O
peptides	O
based	O
on	O
the	O
sequence	O
of	O
the	O
conotoxin	O
epsilon	O
-	O
TxIX	O
and	O
two	O
precursor	O
analogs	O
containing	O
12	O
or	O
29	O
amino	O
acids	O
of	O
the	O
propeptide	O
region	O
are	O
565	O
micro	O
m	O
,	O
75	O
micro	O
m	O
and	O
74	O
micro	O
m	O
,	O
respectively	O
.	O

The	O
recombinant	O
Conus	O
carboxylase	O
,	O
in	O
the	O
absence	O
of	O
endogenous	O
substrates	O
,	O
is	O
stimulated	O
up	O
to	O
fivefold	O
by	O
vertebrate	O
propeptides	O
but	O
not	O
by	O
Conus	O
propeptides	O
.	O

These	O
results	O
suggest	O
two	O
propeptide	O
-	O
binding	O
sites	O
in	O
the	O
carboxylase	O
,	O
one	O
that	O
binds	O
the	O
Conus	O
and	O
vertebrate	O
propeptides	O
and	O
is	O
required	O
for	O
substrate	O
binding	O
,	O
and	O
the	O
other	O
that	O
binds	O
only	O
the	O
vertebrate	O
propeptide	O
and	O
is	O
required	O
for	O
enzyme	O
stimulation	O
.	O

The	O
marked	O
functional	O
and	O
structural	O
similarities	O
between	O
the	O
Conus	O
carboxylase	O
and	O
vertebrate	O
vitamin	O
K	O
-	O
dependent	O
gamma	O
-	O
carboxylases	O
argue	O
for	O
conservation	O
of	O
a	O
vitamin	O
K	O
-	O
dependent	O
carboxylase	O
across	O
animal	O
species	O
and	O
the	O
importance	O
of	O
gamma	O
-	O
carboxyglutamic	O
acid	O
synthesis	O
in	O
diverse	O
biological	O
systems	O
.	O

betaTrCP	O
-	O
mediated	O
proteolysis	O
of	O
NF	O
-	O
kappaB1	O
p105	O
requires	O
phosphorylation	O
of	O
p105	O
serines	O
927	O
and	O
932	O
.	O

NF	O
-	O
kappaB1	O
p105	O
functions	O
both	O
as	O
a	O
precursor	O
of	O
NF	O
-	O
kappaB1	O
p50	O
and	O
as	O
a	O
cytoplasmic	O
inhibitor	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
.	O

Following	O
the	O
stimulation	O
of	O
cells	O
with	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
,	O
the	O
IkappaB	B-Complex
kinase	I-Complex
(	O
IKK	B-Complex
)	O
complex	O
rapidly	O
phosphorylates	O
NF	O
-	O
kappaB1	O
p105	O
on	O
serine	O
927	O
in	O
the	O
PEST	O
region	O
.	O

This	O
phosphorylation	O
is	O
essential	O
for	O
TNF	O
-	O
alpha	O
to	O
trigger	O
p105	O
degradation	O
,	O
which	O
releases	O
the	O
associated	O
Rel	B-Complex
/	I-Complex
NF	I-Complex
-	I-Complex
kappaB	I-Complex
subunits	O
to	O
translocate	O
into	O
the	O
nucleus	O
and	O
regulate	O
target	O
gene	O
transcription	O
.	O

Serine	O
927	O
resides	O
in	O
a	O
conserved	O
motif	O
(	O
Asp	O
-	O
Ser	O
(	O
927	O
)	O
-	O
Gly	O
-	O
Val	O
-	O
Glu	O
-	O
Thr	O
-	O
Ser	O
(	O
932	O
)	O
)	O
homologous	O
to	O
the	O
IKK	B-Complex
target	O
sequence	O
in	O
IkappaBalpha	O
.	O

In	O
this	O
study	O
,	O
TNF	O
-	O
alpha	O
-	O
induced	O
p105	O
proteolysis	O
was	O
revealed	O
to	O
additionally	O
require	O
the	O
phosphorylation	O
of	O
serine	O
932	O
.	O

Experiments	O
with	O
IKK1	O
(	O
-	O
/	O
-	O
)	O
and	O
IKK2	O
(	O
-	O
/	O
-	O
)	O
double	O
knockout	O
embryonic	O
fibroblasts	O
demonstrate	O
that	O
the	O
IKK	B-Complex
complex	O
is	O
essential	O
for	O
TNF	O
-	O
alpha	O
to	O
stimulate	O
phosphorylation	O
on	O
p105	O
serines	O
927	O
and	O
932	O
.	O

Furthermore	O
,	O
purified	O
IKK1	O
and	O
IKK2	O
can	O
each	O
phosphorylate	O
a	O
glutathione	O
S	O
-	O
transferase	O
-	O
p105	O
(	O
758	O
-	O
967	O
)	O
fusion	O
protein	O
on	O
both	O
regulatory	O
serines	O
in	O
vitro	O
.	O

IKK	B-Complex
-	O
mediated	O
p105	O
phosphorylation	O
generates	O
a	O
binding	O
site	O
for	O
betaTrCP	O
,	O
the	O
receptor	O
subunit	O
of	O
an	O
SCF	B-Complex
-	I-Complex
type	I-Complex
ubiquitin	I-Complex
E3	I-Complex
ligase	I-Complex
,	O
and	O
depletion	O
of	O
betaTrCP	O
by	O
RNA	O
interference	O
blocks	O
TNF	O
-	O
alpha	O
-	O
induced	O
p105	O
ubiquitination	O
and	O
proteolysis	O
.	O

Phosphopeptide	O
competition	O
experiments	O
indicate	O
that	O
betaTrCP	O
binds	O
p105	O
more	O
effectively	O
when	O
both	O
serines	O
927	O
and	O
932	O
are	O
phosphorylated	O
.	O

Interestingly	O
,	O
however	O
,	O
betaTrCP	O
affinity	O
for	O
the	O
IKK	B-Complex
-	O
phosphorylated	O
sequence	O
on	O
p105	O
is	O
substantially	O
lower	O
than	O
that	O
on	O
IkappaBalpha	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
reduced	O
p105	O
recruitment	O
of	O
betaTrCP	O
and	O
subsequent	O
ubiquitination	O
may	O
contribute	O
to	O
delayed	O
p105	O
proteolysis	O
after	O
TNF	O
-	O
alpha	O
stimulation	O
relative	O
to	O
that	O
for	O
IkappaBalpha	O
.	O

Crosstalk	O
between	O
CARM1	O
methylation	O
and	O
CBP	O
acetylation	O
on	O
histone	O
H3	O
.	O

BACKGROUND	O
:	O
Dynamic	O
changes	O
in	O
the	O
modification	O
pattern	O
of	O
histones	O
,	O
such	O
as	O
acetylation	O
,	O
phosphorylation	O
,	O
methylation	O
,	O
and	O
ubiquitination	O
,	O
are	O
thought	O
to	O
provide	O
a	O
code	O
for	O
the	O
correct	O
regulation	O
of	O
gene	O
expression	O
mostly	O
by	O
affecting	O
chromatin	O
structure	O
and	O
interactions	O
of	O
non	O
-	O
histone	O
regulatory	O
factors	O
with	O
chromatin	O
.	O

Recent	O
studies	O
have	O
suggested	O
the	O
existence	O
of	O
an	O
interplay	O
between	O
histone	O
modifications	O
during	O
transcription	O
.	O

The	O
CBP	O
/	O
p300	O
acetylase	O
and	O
the	O
CARM1	O
methyltransferase	O
can	O
positively	O
regulate	O
the	O
expression	O
of	O
estrogen	O
-	O
responsive	O
genes	O
,	O
but	O
the	O
existence	O
of	O
a	O
crosstalk	O
between	O
lysine	O
acetylation	O
and	O
arginine	O
methylation	O
on	O
chromatin	O
has	O
not	O
yet	O
been	O
established	O
in	O
vivo	O
.	O

RESULTS	O
:	O
By	O
following	O
the	O
in	O
vivo	O
pattern	O
of	O
modifications	O
on	O
histone	O
H3	O
,	O
following	O
estrogen	O
stimulation	O
of	O
the	O
pS2	O
promoter	O
,	O
we	O
show	O
that	O
arginine	O
methylation	O
follows	O
prior	O
acetylation	O
of	O
H3	O
.	O

Within	O
15	O
min	O
after	O
estrogen	O
stimulation	O
,	O
CBP	O
is	O
bound	O
to	O
chromatin	O
,	O
and	O
acetylation	O
of	O
K18	O
takes	O
place	O
.	O

Following	O
these	O
events	O
,	O
K23	O
is	O
acetylated	O
,	O
CARM1	O
associates	O
with	O
chromatin	O
,	O
and	O
methylation	O
at	O
R17	O
takes	O
place	O
.	O

Exogenous	O
expression	O
of	O
CBP	O
is	O
sufficient	O
to	O
drive	O
the	O
association	O
of	O
CARM1	O
with	O
chromatin	O
and	O
methylation	O
of	O
R17	O
in	O
vivo	O
,	O
whereas	O
an	O
acetylase	O
-	O
deficient	O
CBP	O
mutant	O
is	O
unable	O
to	O
induce	O
these	O
events	O
.	O

A	O
mechanism	O
for	O
the	O
observed	O
cooperation	O
between	O
acetylation	O
and	O
arginine	O
methylation	O
comes	O
from	O
the	O
finding	O
that	O
acetylation	O
at	O
K18	O
and	O
K23	O
,	O
but	O
not	O
K14	O
,	O
tethers	O
recombinant	O
CARM1	O
to	O
the	O
H3	O
tail	O
and	O
allows	O
it	O
to	O
act	O
as	O
a	O
more	O
efficient	O
arginine	O
methyltransferase	O
.	O

CONCLUSION	O
:	O
These	O
results	O
reveal	O
an	O
ordered	O
and	O
interdependent	O
deposition	O
of	O
acetylation	O
and	O
arginine	O
methylation	O
during	O
estrogen	O
-	O
regulated	O
transcription	O
and	O
provide	O
support	O
for	O
a	O
combinatorial	O
role	O
of	O
histone	O
modifications	O
in	O
gene	O
expression	O
.	O

Assembly	O
of	O
the	O
SMRT	O
-	O
histone	O
deacetylase	O
3	O
repression	O
complex	O
requires	O
the	O
TCP	B-Complex
-	I-Complex
1	I-Complex
ring	I-Complex
complex	O
.	O

The	O
acetylation	O
of	O
histone	O
tails	O
is	O
a	O
primary	O
determinant	O
of	O
gene	O
activity	O
.	O

Histone	O
deacetylase	O
3	O
(	O
HDAC3	O
)	O
requires	O
the	O
nuclear	O
receptor	O
corepressor	O
SMRT	O
for	O
HDAC	O
enzyme	O
activity	O
.	O

Here	O
we	O
report	O
that	O
HDAC3	O
interacts	O
with	O
SMRT	O
only	O
after	O
priming	O
by	O
cellular	O
chaperones	O
including	O
the	O
TCP	B-Complex
-	I-Complex
1	I-Complex
ring	I-Complex
complex	O
(	O
TRiC	B-Complex
)	O
,	O
which	O
is	O
required	O
for	O
proper	O
folding	O
of	O
HDAC3	O
in	O
an	O
ATP	O
-	O
dependent	O
process	O
.	O

SMRT	O
displaces	O
TRiC	B-Complex
from	O
HDAC3	O
,	O
yielding	O
an	O
active	O
HDAC	O
enzyme	O
.	O

The	O
SMRT	O
-	O
HDAC3	O
repression	O
complex	O
thus	O
joins	O
the	O
VHL	O
-	O
elongin	O
BC	O
tumor	O
suppression	O
complex	O
and	O
the	O
cyclin	O
E	O
-	O
Cdk2	O
cell	O
cycle	O
regulation	O
complex	O
as	O
critical	O
cellular	O
machines	O
requiring	O
TRiC	B-Complex
for	O
proper	O
assembly	O
and	O
function	O
.	O

The	O
strict	O
control	O
of	O
HDAC3	O
activity	O
underscores	O
the	O
cellular	O
imperative	O
that	O
histone	O
deacetylation	O
occur	O
only	O
in	O
targeted	O
regions	O
of	O
the	O
genome	O
.	O

Mind	O
bomb	O
is	O
a	O
ubiquitin	O
ligase	O
that	O
is	O
essential	O
for	O
efficient	O
activation	O
of	O
Notch	O
signaling	O
by	O
Delta	O
.	O

Lateral	O
inhibition	O
,	O
mediated	O
by	O
Notch	O
signaling	O
,	O
leads	O
to	O
the	O
selection	O
of	O
cells	O
that	O
are	O
permitted	O
to	O
become	O
neurons	O
within	O
domains	O
defined	O
by	O
proneural	O
gene	O
expression	O
.	O

Reduced	O
lateral	O
inhibition	O
in	O
zebrafish	O
mib	O
mutant	O
embryos	O
permits	O
too	O
many	O
neural	O
progenitors	O
to	O
differentiate	O
as	O
neurons	O
.	O

Positional	O
cloning	O
of	O
mib	O
revealed	O
that	O
it	O
is	O
a	O
gene	O
in	O
the	O
Notch	O
pathway	O
that	O
encodes	O
a	O
RING	O
ubiquitin	O
ligase	O
.	O

Mib	O
interacts	O
with	O
the	O
intracellular	O
domain	O
of	O
Delta	O
to	O
promote	O
its	O
ubiquitylation	O
and	O
internalization	O
.	O

Cell	O
transplantation	O
studies	O
suggest	O
that	O
mib	O
function	O
is	O
essential	O
in	O
the	O
signaling	O
cell	O
for	O
efficient	O
activation	O
of	O
Notch	O
in	O
neighboring	O
cells	O
.	O

These	O
observations	O
support	O
a	O
model	O
for	O
Notch	O
activation	O
where	O
the	O
Delta	O
-	O
Notch	O
interaction	O
is	O
followed	O
by	O
endocytosis	O
of	O
Delta	O
and	O
transendocytosis	O
of	O
the	O
Notch	O
extracellular	O
domain	O
by	O
the	O
signaling	O
cell	O
.	O

This	O
facilitates	O
intramembranous	O
cleavage	O
of	O
the	O
remaining	O
Notch	O
receptor	O
,	O
release	O
of	O
the	O
Notch	O
intracellular	O
fragment	O
,	O
and	O
activation	O
of	O
target	O
genes	O
in	O
neighboring	O
cells	O
.	O

Growth	O
arrest	O
and	O
DNA	O
damage	O
-	O
inducible	O
protein	O
GADD34	O
targets	O
protein	O
phosphatase	O
1	O
alpha	O
to	O
the	O
endoplasmic	O
reticulum	O
and	O
promotes	O
dephosphorylation	O
of	O
the	O
alpha	O
subunit	O
of	O
eukaryotic	O
translation	O
initiation	O
factor	O
2	O
.	O

The	O
growth	O
arrest	O
and	O
DNA	O
damage	O
-	O
inducible	O
protein	O
,	O
GADD34	O
,	O
associates	O
with	O
protein	B-Complex
phosphatase	I-Complex
1	I-Complex
(	O
PP1	B-Complex
)	O
and	O
promotes	O
in	O
vitro	O
dephosphorylation	O
of	O
the	O
alpha	O
subunit	O
of	O
eukaryotic	O
translation	O
initiation	O
factor	O
2	O
,	O
(	O
eIF	O
-	O
2	O
alpha	O
)	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
the	O
expression	O
of	O
human	O
GADD34	O
in	O
cultured	O
cells	O
reversed	O
eIF	O
-	O
2	O
alpha	O
phosphorylation	O
induced	O
by	O
thapsigargin	O
and	O
tunicamycin	O
,	O
agents	O
that	O
promote	O
protein	O
unfolding	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
.	O

GADD34	O
expression	O
also	O
reversed	O
eIF	O
-	O
2	O
alpha	O
phosphorylation	O
induced	O
by	O
okadaic	O
acid	O
but	O
not	O
that	O
induced	O
by	O
another	O
phosphatase	O
inhibitor	O
,	O
calyculin	O
A	O
(	O
CA	O
)	O
,	O
which	O
is	O
a	O
result	O
consistent	O
with	O
PP1	B-Complex
being	O
a	O
component	O
of	O
the	O
GADD34	O
-	O
assembled	O
eIF	B-Complex
-	I-Complex
2	I-Complex
alpha	I-Complex
phosphatase	I-Complex
.	O

Structure	O
-	O
function	O
studies	O
identified	O
a	O
bipartite	O
C	O
-	O
terminal	O
domain	O
in	O
GADD34	O
that	O
encompassed	O
a	O
canonical	O
PP1	B-Complex
-	O
binding	O
motif	O
,	O
KVRF	O
,	O
and	O
a	O
novel	O
RARA	O
sequence	O
,	O
both	O
of	O
which	O
were	O
required	O
for	O
PP1	B-Complex
binding	O
.	O

N	O
-	O
terminal	O
deletions	O
of	O
GADD34	O
established	O
that	O
while	O
PP1	B-Complex
binding	O
was	O
necessary	O
,	O
it	O
was	O
not	O
sufficient	O
to	O
promote	O
eIF	O
-	O
2	O
alpha	O
dephosphorylation	O
in	O
cells	O
.	O

Imaging	O
of	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
-	O
GADD34	O
proteins	O
showed	O
that	O
the	O
N	O
-	O
terminal	O
180	O
residues	O
directed	O
the	O
localization	O
of	O
GADD34	O
at	O
the	O
ER	O
and	O
that	O
GADD34	O
targeted	O
the	O
alpha	O
isoform	O
of	O
PP1	B-Complex
to	O
the	O
ER	O
.	O

These	O
data	O
provide	O
new	O
insights	O
into	O
the	O
mode	O
of	O
action	O
of	O
GADD34	O
in	O
assembling	O
an	O
ER	O
-	O
associated	O
eIF	B-Complex
-	I-Complex
2	I-Complex
alpha	I-Complex
phosphatase	I-Complex
that	O
regulates	O
protein	O
translation	O
in	O
mammalian	O
cells	O
.	O

Attenuation	O
of	O
a	O
phosphorylation	O
-	O
dependent	O
activator	O
by	O
an	O
HDAC	O
-	O
PP1	B-Complex
complex	O
.	O

The	O
second	O
messenger	O
cAMP	O
stimulates	O
transcription	O
with	O
burst	O
-	O
attenuation	O
kinetics	O
that	O
mirror	O
the	O
PKA	O
-	O
dependent	O
phosphorylation	O
and	O
subsequent	O
protein	B-Complex
phosphatase	I-Complex
1	I-Complex
(	O
PP1	B-Complex
)	O
-	O
mediated	O
dephosphorylation	O
of	O
the	O
cAMP	O
responsive	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
at	O
Ser133	O
.	O

Phosphorylation	O
of	O
Ser133	O
promotes	O
recruitment	O
of	O
the	O
co	O
-	O
activator	O
histone	O
acetylase	O
(	O
HAT	O
)	O
paralogs	O
CBP	O
and	O
P300	O
,	O
which	O
in	O
turn	O
stimulate	O
acetylation	O
of	O
promoter	O
-	O
bound	O
histones	O
during	O
the	O
burst	O
phase	O
.	O

Remarkably	O
,	O
histone	O
deacetylase	O
(	O
HDAC	O
)	O
inhibitors	O
seem	O
to	O
potentiate	O
CREB	O
activity	O
by	O
prolonging	O
Ser133	O
phosphorylation	O
in	O
response	O
to	O
cAMP	O
stimulus	O
,	O
suggesting	O
a	O
potential	O
role	O
for	O
HDAC	O
complexes	O
in	O
silencing	O
CREB	O
activity	O
.	O

Here	O
we	O
show	O
that	O
HDAC1	O
associates	O
with	O
and	O
blocks	O
Ser133	O
phosphorylation	O
of	O
CREB	O
during	O
pre	O
-	O
stimulus	O
and	O
attenuation	O
phases	O
of	O
the	O
cAMP	O
response	O
.	O

HDAC1	O
promotes	O
Ser133	O
dephosphorylation	O
via	O
a	O
stable	O
interaction	O
with	O
PP1	B-Complex
,	O
which	O
we	O
detected	O
in	O
co	O
-	O
immunoprecipitation	O
and	O
co	O
-	O
purification	O
studies	O
.	O

These	O
results	O
illustrate	O
a	O
novel	O
mechanism	O
by	O
which	O
signaling	O
and	O
chromatin	O
-	O
modifying	O
activities	O
act	O
coordinately	O
to	O
repress	O
the	O
activity	O
of	O
a	O
phosphorylation	O
-	O
dependent	O
activator	O
.	O

Differential	O
interaction	O
of	O
the	O
tyrosine	O
phosphatases	O
PTP	O
-	O
SL	O
,	O
STEP	O
and	O
HePTP	O
with	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
ERK1	O
/	O
2	O
and	O
p38alpha	O
is	O
determined	O
by	O
a	O
kinase	O
specificity	O
sequence	O
and	O
influenced	O
by	O
reducing	O
agents	O
.	O

The	O
protein	O
tyrosine	O
phosphatases	O
(	O
PTPs	O
)	O
PTP	O
-	O
SL	O
,	O
STEP	O
and	O
HePTP	O
are	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
substrates	O
and	O
regulators	O
that	O
bind	O
to	O
MAPKs	O
through	O
a	O
kinase	O
-	O
interaction	O
motif	O
(	O
KIM	O
)	O
located	O
in	O
their	O
non	O
-	O
catalytic	O
regulatory	O
domains	O
.	O

We	O
have	O
found	O
that	O
the	O
binding	O
of	O
these	O
PTPs	O
to	O
the	O
MAPKs	O
extracellular	O
-	O
signal	O
-	O
regulated	O
kinase	O
1	O
and	O
2	O
(	O
ERK1	O
/	O
2	O
)	O
,	O
and	O
p38alpha	O
is	O
differentially	O
determined	O
by	O
the	O
KIM	O
-	O
adjacent	O
C	O
-	O
terminal	O
regions	O
of	O
the	O
PTPs	O
,	O
which	O
have	O
been	O
termed	O
kinase	O
-	O
specificity	O
sequences	O
,	O
and	O
is	O
influenced	O
by	O
reducing	O
agents	O
.	O

Under	O
control	O
conditions	O
,	O
PTP	O
-	O
SL	O
bound	O
preferentially	O
to	O
ERK1	O
/	O
2	O
,	O
whereas	O
STEP	O
and	O
HePTP	O
bound	O
preferentially	O
to	O
p38alpha	O
.	O

Under	O
reducing	O
conditions	O
,	O
the	O
association	O
of	O
p38alpha	O
with	O
STEP	O
or	O
HePTP	O
was	O
impaired	O
,	O
whereas	O
the	O
association	O
with	O
PTP	O
-	O
SL	O
was	O
unaffected	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
association	O
of	O
ERK1	O
/	O
2	O
with	O
HePTP	O
was	O
increased	O
under	O
reducing	O
conditions	O
,	O
whereas	O
the	O
association	O
with	O
STEP	O
or	O
PTP	O
-	O
SL	O
was	O
unaffected	O
.	O

In	O
intact	O
cells	O
,	O
PTP	O
-	O
SL	O
and	O
STEP	O
distinctively	O
regulated	O
the	O
kinase	O
activity	O
and	O
the	O
nuclear	O
translocation	O
of	O
ERK1	O
/	O
2	O
and	O
p38alpha	O
.	O

Our	O
results	O
suggest	O
that	O
intracellular	O
redox	O
conditions	O
could	O
modulate	O
the	O
activity	O
and	O
subcellular	O
location	O
of	O
ERK1	O
/	O
2	O
and	O
p38alpha	O
by	O
controlling	O
their	O
association	O
with	O
their	O
regulatory	O
PTPs	O
.	O

Transforming	O
growth	O
factor	O
-	O
beta	O
induces	O
secretion	O
of	O
activated	O
ADAMTS	O
-	O
2	O
.	O

A	O
procollagen	O
III	O
N	O
-	O
proteinase	O
.	O

The	O
metalloproteinase	O
ADAMTS	O
-	O
2	O
has	O
procollagen	O
I	O
N	O
-	O
proteinase	O
activity	O
capable	O
of	O
cleaving	O
procollagens	O
I	O
and	O
II	O
N	O
-	O
propeptides	O
in	O
vitro	O
,	O
whereas	O
mutations	O
in	O
the	O
ADAMTS	O
-	O
2	O
gene	O
in	O
dermatosparaxis	O
and	O
Ehlers	O
-	O
Danlos	O
syndrome	O
VIIC	O
show	O
this	O
enzyme	O
to	O
be	O
responsible	O
in	O
vivo	O
for	O
most	O
biosynthetic	O
processing	O
of	O
procollagen	O
I	O
N	O
-	O
propeptides	O
in	O
skin	O
.	O

Yet	O
despite	O
its	O
important	O
role	O
in	O
the	O
regulation	O
of	O
collagen	B-Complex
deposition	O
,	O
information	O
regarding	O
regulation	O
and	O
substrate	O
specificity	O
of	O
ADAMTS	O
-	O
2	O
has	O
remained	O
sparse	O
.	O

Here	O
we	O
demonstrate	O
that	O
ADAMTS	O
-	O
2	O
can	O
,	O
like	O
the	O
procollagen	O
C	O
-	O
proteinases	O
,	O
be	O
regulated	O
by	O
transforming	O
growth	O
factor	O
-	O
beta	O
1	O
(	O
TGF	O
-	O
beta	O
1	O
)	O
,	O
with	O
implications	O
for	O
mechanisms	O
whereby	O
this	O
growth	O
factor	O
effects	O
net	O
increases	O
in	O
formation	O
of	O
extracellular	O
matrix	O
.	O

TGF	O
-	O
beta	O
1	O
induced	O
ADAMTS	O
-	O
2	O
mRNA	O
approximately	O
8	O
-	O
fold	O
in	O
MG	O
-	O
63	O
osteosarcoma	O
cells	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
,	O
cycloheximide	O
-	O
inhibitable	O
manner	O
,	O
which	O
appeared	O
to	O
operate	O
at	O
the	O
transcriptional	O
level	O
.	O

Secreted	O
ADAMTS	O
-	O
2	O
protein	O
induced	O
by	O
TGF	O
-	O
beta	O
1	O
was	O
132	O
kDa	O
and	O
was	O
identical	O
in	O
size	O
to	O
the	O
fully	O
processed	O
,	O
active	O
form	O
of	O
the	O
protease	O
.	O

Biosynthetic	O
processing	O
of	O
ADAMTS	O
-	O
2	O
to	O
yield	O
the	O
132	O
-	O
kDa	O
form	O
is	O
shown	O
to	O
be	O
a	O
two	O
-	O
step	O
process	O
involving	O
sequential	O
cleavage	O
by	O
furin	O
-	O
like	O
convertases	O
at	O
two	O
sites	O
.	O

Surprisingly	O
,	O
purified	O
recombinant	O
ADAMTS	O
-	O
2	O
is	O
shown	O
to	O
cleave	O
procollagen	O
III	O
N	O
-	O
propeptides	O
as	O
effectively	O
as	O
those	O
of	O
procollagens	O
I	O
and	O
II	O
,	O
whereas	O
processing	O
of	O
procollagen	O
III	O
is	O
shown	O
to	O
be	O
decreased	O
in	O
Ehlers	O
-	O
Danlos	O
VIIC	O
.	O

Thus	O
,	O
the	O
dogma	O
that	O
procollagen	O
I	O
and	O
procollagen	O
III	O
N	O
-	O
proteinase	O
activities	O
are	O
provided	O
by	O
separate	O
enzymes	O
appears	O
to	O
be	O
false	O
,	O
whereas	O
the	O
phenotypes	O
of	O
dermatosparaxis	O
and	O
Ehlers	O
-	O
Danlos	O
VIIC	O
may	O
arise	O
from	O
defects	O
in	O
both	O
type	B-Complex
I	I-Complex
and	I-Complex
type	I-Complex
III	I-Complex
collagen	I-Complex
biosynthesis	O
.	O

Budding	O
yeast	O
mcm10	O
/	O
dna43	O
mutant	O
requires	O
a	O
novel	O
repair	O
pathway	O
for	O
viability	O
.	O

BACKGROUND	O
:	O
MCM10	O
is	O
essential	O
for	O
the	O
initiation	O
of	O
chromosomal	O
DNA	O
replication	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Mcm10p	O
functionally	O
interacts	O
with	O
components	O
of	O
the	O
pre	B-Complex
-	I-Complex
replicative	I-Complex
complex	O
(	O
Mcm2	O
-	O
Mcm7	O
complex	O
and	O
origin	B-Complex
recognition	I-Complex
complex	I-Complex
)	O
as	O
well	O
as	O
the	O
pre	B-Complex
-	I-Complex
initiation	I-Complex
complex	O
component	O
(	O
Cdc45p	O
)	O
suggesting	O
that	O
it	O
may	O
be	O
a	O
component	O
of	O
the	O
pre	B-Complex
-	I-Complex
RC	I-Complex
as	O
well	O
as	O
the	O
pre	B-Complex
-	I-Complex
IC	I-Complex
.	O

Two	O
-	O
dimensional	O
gel	O
electrophoresis	O
analysis	O
showed	O
that	O
Mcm10p	O
is	O
required	O
not	O
only	O
for	O
the	O
initiation	O
of	O
DNA	O
synthesis	O
at	O
replication	O
origins	O
but	O
also	O
for	O
the	O
smooth	O
passage	O
of	O
replication	O
forks	O
at	O
origins	O
.	O

Genetic	O
analysis	O
showed	O
that	O
MCM10	O
interacts	O
with	O
components	O
of	O
the	O
elongation	O
machinery	O
such	O
as	O
Pol	O
delta	O
and	O
Pol	O
epsilon	O
,	O
suggesting	O
that	O
it	O
may	O
play	O
a	O
role	O
in	O
elongation	O
replication	O
.	O

RESULTS	O
:	O
We	O
show	O
that	O
the	O
mcm10	O
mutation	O
causes	O
replication	O
fork	O
pausing	O
not	O
only	O
at	O
potentially	O
active	O
origins	O
but	O
also	O
at	O
silent	O
origins	O
.	O

We	O
screened	O
for	O
mutations	O
that	O
are	O
lethal	O
in	O
combination	O
with	O
mcm10	O
-	O
1	O
and	O
obtained	O
seven	O
mutants	O
named	O
slm1	O
-	O
slm6	O
for	O
synthetically	O
lethal	O
with	O
mcm10	O
.	O

These	O
mutants	O
comprised	O
six	O
complementation	O
groups	O
that	O
can	O
be	O
divided	O
into	O
three	O
classes	O
.	O

Class	O
1	O
includes	O
genes	O
that	O
encode	O
components	O
of	O
the	O
pre	B-Complex
-	I-Complex
RC	I-Complex
and	O
pre	B-Complex
-	I-Complex
IC	I-Complex
and	O
are	O
represented	O
by	O
SLM3	O
,	O
4	O
and	O
5	O
which	O
are	O
allelic	O
to	O
MCM7	O
,	O
MCM2	O
and	O
CDC45	O
,	O
respectively	O
.	O

Class	O
2	O
includes	O
genes	O
involved	O
in	O
the	O
processing	O
of	O
Okazaki	O
fragments	O
in	O
lagging	O
strand	O
synthesis	O
and	O
is	O
represented	O
by	O
SLM1	O
,	O
which	O
is	O
allelic	O
to	O
DNA2	O
.	O

Class	O
3	O
includes	O
novel	O
DNA	O
repair	O
genes	O
represented	O
by	O
SLM2	O
and	O
SLM6	O
.	O

CONCLUSIONS	O
:	O
The	O
viability	O
of	O
the	O
mcm10	O
-	O
1	O
mutant	O
is	O
dependent	O
on	O
a	O
novel	O
repair	O
pathway	O
that	O
may	O
participate	O
either	O
in	O
resolving	O
accumulated	O
replication	O
intermediates	O
or	O
the	O
damage	O
caused	O
by	O
blocked	O
replication	O
forks	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
Mcm10p	O
is	O
required	O
for	O
the	O
passage	O
of	O
replication	O
forks	O
through	O
obstacles	O
such	O
as	O
those	O
created	O
by	O
pre	B-Complex
-	I-Complex
RCs	I-Complex
assembled	O
at	O
active	O
or	O
inactive	O
replication	O
origins	O
.	O

The	O
COP9	B-Complex
signalosome	I-Complex
interacts	O
with	O
SCF	B-Complex
UFO	I-Complex
and	O
participates	O
in	O
Arabidopsis	O
flower	O
development	O
.	O

The	O
COP9	B-Complex
signalosome	I-Complex
(	O
CSN	B-Complex
)	O
is	O
involved	O
in	O
multiple	O
developmental	O
processes	O
.	O

It	O
interacts	O
with	O
SCF	B-Complex
ubiquitin	I-Complex
ligases	I-Complex
and	O
deconjugates	O
Nedd8	O
/	O
Rub1	O
from	O
cullins	O
(	O
deneddylation	O
)	O
.	O

CSN	B-Complex
is	O
highly	O
expressed	O
in	O
Arabidopsis	O
floral	O
tissues	O
.	O

To	O
investigate	O
the	O
role	O
of	O
CSN	B-Complex
in	O
flower	O
development	O
,	O
we	O
examined	O
the	O
expression	O
pattern	O
of	O
CSN	B-Complex
in	O
developing	O
flowers	O
.	O

We	O
report	O
here	O
that	O
two	O
csn1	O
partially	O
deficient	O
Arabidopsis	O
strains	O
exhibit	O
aberrant	O
development	O
of	O
floral	O
organs	O
,	O
decline	O
of	O
APETALA3	O
(	O
AP3	O
)	O
expression	O
,	O
and	O
low	O
fertility	O
in	O
addition	O
to	O
defects	O
in	O
shoot	O
and	O
inflorescence	O
meristems	O
.	O

We	O
show	O
that	O
UNUSUAL	O
FLORAL	O
ORGANS	O
(	O
UFO	O
)	O
forms	O
a	O
SCF	B-Complex
(	I-Complex
UFO	I-Complex
)	I-Complex
complex	O
,	O
which	O
is	O
associated	O
with	O
CSN	B-Complex
in	O
vivo	O
.	O

Genetic	O
interaction	O
analysis	O
indicates	O
that	O
CSN	B-Complex
is	O
necessary	O
for	O
the	O
gain	O
-	O
of	O
-	O
function	O
activity	O
of	O
the	O
F	O
-	O
box	O
protein	O
UFO	O
in	O
AP3	O
activation	O
and	O
in	O
floral	O
organ	O
transformation	O
.	O

Compared	O
with	O
the	O
previously	O
reported	O
csn5	O
antisense	O
and	O
csn1	O
null	O
mutants	O
,	O
partial	O
deficiency	O
of	O
CSN1	O
causes	O
a	O
reduction	O
in	O
the	O
level	O
of	O
CUL1	O
in	O
the	O
mutant	O
flowers	O
without	O
an	O
obvious	O
defect	O
in	O
CUL1	O
deneddylation	O
.	O

We	O
conclude	O
that	O
CSN	B-Complex
is	O
an	O
essential	O
regulator	O
of	O
Arabidopsis	O
flower	O
development	O
and	O
suggest	O
that	O
CSN	B-Complex
regulates	O
Arabidopsis	O
flower	O
development	O
in	O
part	O
by	O
modulating	O
SCF	B-Complex
(	I-Complex
UFO	I-Complex
)	I-Complex
-	O
mediated	O
AP3	O
activation	O
.	O

The	O
UCS	O
domain	O
protein	O
She4p	O
binds	O
to	O
myosin	O
motor	O
domains	O
and	O
is	O
essential	O
for	O
class	O
I	O
and	O
class	O
V	O
myosin	O
function	O
.	O

BACKGROUND	O
:	O
Myosins	O
are	O
motor	O
proteins	O
involved	O
in	O
processes	O
like	O
cell	O
motility	O
,	O
vesicle	O
transport	O
,	O
or	O
cytokinesis	O
.	O

In	O
a	O
variety	O
of	O
organisms	O
,	O
a	O
novel	O
group	O
of	O
proteins	O
forming	O
the	O
UCS	O
(	O
UNC	O
-	O
45	O
/	O
CRO1	O
/	O
SHE4	O
)	O
domain	O
-	O
containing	O
family	O
are	O
essential	O
for	O
proper	O
myosin	O
function	O
.	O

The	O
Saccharomyces	O
cerevisae	O
UCS	O
domain	O
protein	O
She4p	O
is	O
involved	O
in	O
two	O
myosin	O
-	O
requiring	O
events	O
,	O
endocytosis	O
and	O
mRNA	O
localization	O
.	O

RESULTS	O
:	O
In	O
contrast	O
to	O
UCS	O
domain	O
proteins	O
from	O
other	O
organisms	O
that	O
interact	O
with	O
class	O
II	O
myosins	O
,	O
we	O
demonstrate	O
that	O
She4p	O
associates	O
with	O
yeast	O
class	O
I	O
and	O
class	O
V	O
myosins	O
.	O

She4p	O
binds	O
to	O
motor	O
domains	O
of	O
class	O
V	O
myosin	O
Myo4p	O
and	O
class	O
I	O
myosin	O
Myo5p	O
,	O
and	O
this	O
binding	O
depends	O
on	O
She4p	O
'	O
s	O
UCS	O
domain	O
.	O

In	O
vivo	O
,	O
She4p	O
is	O
essential	O
for	O
the	O
function	O
and	O
localization	O
of	O
Myo3p	O
,	O
Myo4p	O
,	O
and	O
Myo5p	O
(	O
but	O
not	O
of	O
Myo2p	O
)	O
and	O
for	O
colocalization	O
of	O
class	O
I	O
myosins	O
with	O
cortical	O
actin	O
patches	O
.	O

In	O
vitro	O
,	O
She4p	O
stimulates	O
binding	O
of	O
Myo5p	O
to	O
filamentous	O
actin	O
.	O

Wild	O
-	O
type	O
She4p	O
,	O
but	O
not	O
a	O
mutant	O
lacking	O
the	O
UCS	O
domain	O
,	O
accumulates	O
in	O
a	O
cap	O
-	O
like	O
structure	O
at	O
the	O
bud	O
tip	O
.	O

This	O
localization	O
requires	O
Myo2p	O
and	O
actin	O
,	O
suggesting	O
a	O
Myo2	O
-	O
dependent	O
mechanism	O
by	O
which	O
She4p	O
is	O
targeted	O
to	O
the	O
bud	O
cap	O
.	O

Localization	O
of	O
She4p	O
is	O
essential	O
for	O
proper	O
positioning	O
and	O
myosin	O
-	O
actin	O
association	O
of	O
cortical	O
Myo5p	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
She4p	O
is	O
a	O
novel	O
myosin	O
motor	O
domain	O
binding	O
protein	O
and	O
operates	O
as	O
a	O
localized	O
regulator	O
of	O
myosin	O
function	O
of	O
class	O
I	O
and	O
likely	O
class	O
V	O
myosins	O
.	O

ATP	O
hydrolysis	O
on	O
actin	B-Complex
-	I-Complex
related	I-Complex
protein	I-Complex
2	I-Complex
/	I-Complex
3	I-Complex
complex	O
causes	O
debranching	O
of	O
dendritic	O
actin	O
arrays	O
.	O

Extension	O
of	O
lamellipodia	O
,	O
an	O
important	O
dissipative	O
process	O
in	O
cell	O
motility	O
,	O
is	O
driven	O
by	O
the	O
turnover	O
of	O
a	O
polarized	O
dendritic	O
array	O
of	O
actin	O
filaments	O
.	O

Motility	O
is	O
driven	O
by	O
catalytic	O
cycles	O
of	O
filament	O
attachment	O
to	O
Wiskott	O
-	O
Aldrich	O
syndrome	O
protein	O
(	O
WASP	O
)	O
-	O
activated	O
actin	B-Complex
-	I-Complex
related	I-Complex
protein	I-Complex
(	I-Complex
Arp	I-Complex
)	I-Complex
2	I-Complex
/	I-Complex
3	I-Complex
complex	O
at	O
the	O
leading	O
edge	O
,	O
branch	O
formation	O
,	O
and	O
detachment	O
,	O
allowing	O
subsequent	O
growth	O
of	O
branched	O
filaments	O
.	O

The	O
morphology	O
,	O
mechanical	O
strength	O
,	O
and	O
lifetime	O
of	O
the	O
array	O
are	O
determined	O
by	O
the	O
processes	O
of	O
filament	O
branching	O
,	O
debranching	O
,	O
and	O
treadmilling	O
.	O

All	O
three	O
processes	O
are	O
controlled	O
by	O
ATP	O
hydrolysis	O
.	O

ATP	O
hydrolysis	O
on	O
F	O
-	O
actin	O
is	O
known	O
to	O
be	O
at	O
the	O
origin	O
of	O
treadmilling	O
.	O

Here	O
,	O
by	O
using	O
radiolabeled	O
ATP	O
covalently	O
bound	O
to	O
Arp2	B-Complex
/	I-Complex
3	I-Complex
,	O
we	O
show	O
that	O
ATP	O
is	O
hydrolyzed	O
on	O
Arp2	O
,	O
not	O
on	O
Arp3	O
,	O
after	O
a	O
delay	O
following	O
filament	O
branching	O
.	O

Hydrolysis	O
of	O
ATP	O
on	O
Arp2	O
promotes	O
debranching	O
of	O
filaments	O
and	O
acts	O
as	O
a	O
clock	O
that	O
controls	O
the	O
stability	O
of	O
dendritic	O
actin	O
arrays	O
in	O
lamellipodia	O
.	O

Finally	O
,	O
we	O
propose	O
that	O
hydrolysis	O
of	O
ATP	O
on	O
G	O
-	O
actin	O
in	O
the	O
ternary	O
G	O
-	O
actin	O
-	O
WASP	O
-	O
Arp2	B-Complex
/	I-Complex
3	I-Complex
complex	O
on	O
branch	O
formation	O
destabilizes	O
the	O
WASP	O
-	O
actin	O
interface	O
and	O
energetically	O
facilitates	O
the	O
detachment	O
step	O
in	O
the	O
branching	O
reaction	O
.	O

The	O
kelch	O
repeat	O
protein	O
,	O
Tea1	O
,	O
is	O
a	O
potential	O
substrate	O
target	O
of	O
the	O
p21	O
-	O
activated	O
kinase	O
,	O
Shk1	O
,	O
in	O
the	O
fission	O
yeast	O
,	O
Schizosaccharomyces	O
pombe	O
.	O

The	O
p21	O
-	O
activated	O
kinase	O
(	O
PAK	O
)	O
homolog	O
,	O
Shk1	O
,	O
is	O
a	O
critical	O
component	O
of	O
a	O
multifunctional	O
Ras	O
/	O
Cdc42	O
/	O
PAK	O
complex	O
required	O
for	O
viability	O
,	O
polarized	O
growth	O
and	O
cell	O
shape	O
,	O
and	O
sexual	O
differentiation	O
in	O
the	O
fission	O
yeast	O
,	O
Schizosaccharomyces	O
pombe	O
.	O

Substrate	O
targets	O
of	O
the	O
Shk1	O
kinase	O
have	O
not	O
previously	O
been	O
described	O
.	O

Here	O
we	O
show	O
that	O
the	O
S	O
.	O
pombe	O
cell	O
polarity	O
factor	O
,	O
Tea1	O
,	O
is	O
directly	O
phosphorylated	O
by	O
Shk1	O
in	O
vitro	O
.	O

We	O
demonstrate	O
further	O
that	O
Tea1	O
is	O
phosphorylated	O
in	O
S	O
.	O
pombe	O
cells	O
and	O
that	O
its	O
level	O
of	O
phosphorylation	O
is	O
significantly	O
reduced	O
in	O
cells	O
defective	O
in	O
Shk1	O
function	O
.	O

Consistent	O
with	O
a	O
role	O
for	O
Tea1	O
as	O
a	O
potential	O
downstream	O
effector	O
of	O
Shk1	O
,	O
we	O
show	O
that	O
a	O
tea1	O
null	O
mutation	O
rescues	O
the	O
Shk1	O
hyperactivity	O
-	O
induced	O
lethal	O
phenotype	O
caused	O
by	O
loss	O
of	O
function	O
of	O
the	O
essential	O
Shk1	O
inhibitor	O
,	O
Skb15	O
.	O

All	O
phenotypes	O
associated	O
with	O
Skb15	O
loss	O
,	O
including	O
defects	O
in	O
actin	O
cytoskeletal	O
organization	O
,	O
chromosome	O
segregation	O
,	O
and	O
cytokinesis	O
,	O
are	O
suppressed	O
by	O
tea1	O
Delta	O
,	O
suggesting	O
that	O
Tea1	O
is	O
a	O
potential	O
mediator	O
of	O
multiple	O
Shk1	O
functions	O
.	O

S	O
.	O
pombe	O
cells	O
carrying	O
a	O
weak	O
hypomorphic	O
allele	O
of	O
shk1	O
together	O
with	O
a	O
tea1	O
Delta	O
mutation	O
exhibit	O
a	O
cytokinesis	O
defective	O
phenotype	O
that	O
is	O
significantly	O
more	O
severe	O
than	O
that	O
observed	O
in	O
the	O
respective	O
single	O
mutants	O
,	O
providing	O
evidence	O
that	O
Shk1	O
and	O
Tea1	O
cooperate	O
to	O
regulate	O
cytokinesis	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
S	O
.	O
pombe	O
cells	O
carrying	O
the	O
orb2	O
-	O
34	O
allele	O
of	O
shk1	O
exhibit	O
a	O
pattern	O
of	O
monopolar	O
growth	O
similar	O
to	O
that	O
observed	O
in	O
tea1	O
Delta	O
cells	O
,	O
suggesting	O
that	O
Shk1	O
and	O
Tea1	O
may	O
regulate	O
one	O
or	O
more	O
common	O
processes	O
involved	O
in	O
the	O
regulation	O
of	O
polarized	O
cell	O
growth	O
.	O

Taken	O
together	O
,	O
our	O
results	O
strongly	O
implicate	O
Tea1	O
as	O
a	O
potential	O
substrate	O
-	O
effector	O
of	O
the	O
Shk1	O
kinase	O
.	O

A	O
comparative	O
kinetic	O
study	O
on	O
the	O
singlet	O
molecular	O
oxygen	O
-	O
mediated	O
photoxidation	O
of	O
alpha	O
-	O
and	O
beta	O
-	O
chymotrypsins	O
.	O

Kinetic	O
aspects	O
of	O
the	O
sensitized	O
photooxidation	O
of	O
alpha	O
-	O
and	O
beta	O
-	O
chymotrypsins	O
have	O
been	O
studied	O
at	O
pH	O
6	O
and	O
8	O
.	O

The	O
sensitization	O
,	O
employing	O
classical	O
O2	O
(	O
1Deltag	O
)	O
-	O
photogenerators	O
,	O
such	O
as	O
xanthene	O
dyes	O
,	O
is	O
a	O
kinetically	O
intricate	O
process	O
because	O
of	O
the	O
presence	O
of	O
ground	O
state	O
dye	O
-	O
protein	O
associations	O
and	O
to	O
the	O
simultaneous	O
participation	O
of	O
superoxide	O
ion	O
and	O
singlet	O
molecular	O
oxygen	O
[	O
O2	O
(	O
1Deltag	O
)	O
]	O
.	O

Both	O
proteins	O
,	O
that	O
possess	O
the	O
same	O
distribution	O
pattern	O
of	O
photooxidizable	O
amino	O
acids	O
,	O
suffer	O
a	O
pure	O
O2	O
(	O
1Deltag	O
)	O
-	O
mediated	O
photodynamic	O
attack	O
,	O
using	O
the	O
carbonylic	O
sensitizer	O
Perinaphthenone	O
.	O

Overall	O
and	O
reactive	O
rate	O
constants	O
for	O
the	O
O2	O
(	O
1Deltag	O
)	O
-	O
quenching	O
(	O
in	O
the	O
order	O
of	O
108	O
and	O
107	O
/	O
M	O
/	O
s	O
,	O
respectively	O
)	O
,	O
and	O
rates	O
of	O
oxygen	O
consumption	O
determined	O
by	O
time	O
-	O
resolved	O
,	O
spectroscopic	O
and	O
polarographic	O
methods	O
indicate	O
that	O
alpha	O
-	O
and	O
beta	O
-	O
chymotrypsins	O
are	O
less	O
photooxidizable	O
at	O
pH	O
6	O
,	O
as	O
a	O
result	O
of	O
an	O
enhancement	O
of	O
the	O
O2	O
(	O
1Deltag	O
)	O
-	O
physical	O
quenching	O
component	O
.	O

In	O
general	O
terms	O
,	O
beta	O
-	O
chymotrypsin	O
exhibits	O
the	O
greater	O
overall	O
proclivity	O
to	O
interact	O
with	O
O2	O
(	O
1Deltag	O
)	O
,	O
whereas	O
structural	O
factors	O
,	O
possibly	O
evidenced	O
by	O
a	O
higher	O
exposure	O
of	O
the	O
reactive	O
tryptophan	O
residues	O
,	O
impart	O
an	O
increased	O
photooxidation	O
degree	O
to	O
the	O
proteins	O
at	O
pH	O
8	O
,	O
specially	O
to	O
the	O
alpha	O
-	O
chymotrypsin	O
.	O

Interaction	O
of	O
the	O
bullous	O
pemphigoid	O
antigen	O
1	O
(	O
BP230	O
)	O
and	O
desmoplakin	O
with	O
intermediate	O
filaments	O
is	O
mediated	O
by	O
distinct	O
sequences	O
within	O
their	O
COOH	O
terminus	O
.	O

The	O
bullous	O
pemphigoid	O
antigen	O
1	O
(	O
BP230	O
)	O
and	O
desmoplakin	O
(	O
DP	O
)	O
are	O
members	O
of	O
the	O
plakin	O
protein	O
family	O
of	O
cytolinkers	O
.	O

Despite	O
their	O
homology	O
,	O
their	O
COOH	O
termini	O
selectively	O
bind	O
distinct	O
intermediate	O
filaments	O
(	O
IFs	O
)	O
.	O

We	O
studied	O
sequences	O
within	O
their	O
COOH	O
termini	O
required	O
for	O
their	O
interaction	O
with	O
the	O
epidermal	O
keratins	O
K5	O
/	O
K14	O
,	O
the	O
simple	O
epithelial	O
keratins	O
K8	O
/	O
K18	O
,	O
and	O
type	O
III	O
IF	O
vimentin	O
by	O
yeast	O
three	O
-	O
hybrid	O
,	O
cell	O
transfection	O
,	O
and	O
overlay	O
assays	O
.	O

The	O
results	O
indicate	O
that	O
BP230	O
interacts	O
with	O
K5	O
/	O
K14	O
but	O
not	O
with	O
K8	O
/	O
K18	O
or	O
vimentin	O
via	O
a	O
region	O
encompassing	O
both	O
the	O
B	O
and	O
C	O
subdomains	O
and	O
the	O
COOH	O
extremity	O
,	O
including	O
a	O
COOH	O
-	O
terminal	O
eight	O
-	O
amino	O
-	O
acid	O
stretch	O
.	O

In	O
contrast	O
,	O
the	O
C	O
subdomain	O
with	O
the	O
COOH	O
-	O
terminal	O
extremity	O
of	O
DP	O
interacts	O
with	O
K5	O
/	O
K14	O
and	O
K8	O
/	O
K18	O
,	O
and	O
its	O
linker	O
region	O
is	O
able	O
to	O
associate	O
with	O
K8	O
/	O
K18	O
and	O
vimentin	O
.	O

Furthermore	O
,	O
the	O
potential	O
of	O
DP	O
to	O
interact	O
with	O
IF	O
proteins	O
in	O
yeast	O
seems	O
to	O
be	O
regulated	O
by	O
phosphorylation	O
of	O
Ser	O
2849	O
within	O
its	O
COOH	O
terminus	O
.	O

Strikingly	O
,	O
BP230	O
and	O
DP	O
interacted	O
with	O
cytokeratins	O
only	O
when	O
both	O
type	O
I	O
and	O
type	O
II	O
keratins	O
were	O
present	O
.	O

The	O
head	O
and	O
tail	O
domains	O
of	O
K5	O
/	O
K14	O
keratins	O
were	O
dispensable	O
for	O
their	O
interaction	O
with	O
BP230	O
or	O
DP	O
.	O

On	O
the	O
basis	O
of	O
our	O
findings	O
,	O
we	O
postulate	O
that	O
(	O
1	O
)	O
the	O
binding	O
specificity	O
of	O
plakins	O
for	O
various	O
IF	O
proteins	O
depends	O
on	O
their	O
linker	O
region	O
between	O
the	O
highly	O
homologous	O
B	O
and	O
C	O
subdomains	O
and	O
their	O
COOH	O
extremity	O
and	O
(	O
2	O
)	O
the	O
association	O
of	O
DP	O
and	O
BP230	O
with	O
both	O
epidermal	O
and	O
simple	O
keratins	O
is	O
critically	O
affected	O
by	O
the	O
tertiary	O
structure	O
induced	O
by	O
heterodimerization	O
and	O
involves	O
recognition	O
sites	O
located	O
primarily	O
in	O
the	O
rod	O
domain	O
of	O
these	O
keratins	O
.	O

Polyclonal	O
antibodies	O
to	O
p47	O
and	O
syntaxin5	O
were	O
prepared	O
as	O
described	O
.	O

A	O
rabbit	O
anti	O
-	O
p97	O
polyclonal	O
antibody	O
was	O
raised	O
using	O
His	O
-	O
p97	O
(	O
1	O
-	O
198	O
)	O
as	O
an	O
antigen	O
.	O

Monoclonal	O
anti	O
-	O
GalT	O
antibodies	O
and	O
polyclonal	O
anti	O
-	O
GM130	O
antibodies	O
were	O
gifts	O
from	O
Dr	O
.	O
Suganuma	O
(	O
Miyazaki	O
Medical	O
College	O
,	O
Miyazaki	O
,	O
Japan	O
)	O
and	O
Dr	O
.	O
Nakamura	O
(	O
Kanazawa	O
University	O
,	O
Kanazawa	O
,	O
Japan	O
)	O
,	O
respectively	O
.	O

mAb	O
to	O
p97	O
,	O
His	O
-	O
tag	O
,	O
and	O
GM130	O
were	O
purchased	O
from	O
Progen	O
,	O
QIAGEN	O
,	O
and	O
BD	O
Transduction	O
,	O
respectively	O
.	O

An	O
affinity	O
-	O
purified	O
antibody	O
(	O
Ab62	O
)	O
raised	O
against	O
a	O
delta	O
-	O
catenin	O
peptide	O
corresponding	O
to	O
aa	O
434	O
-	O
530	O
was	O
described	O
previously	O
,	O
and	O
monoclonal	O
delta	O
-	O
catenin	O
antibody	O
was	O
from	O
Transduction	O
Laboratories	O
,	O
Inc	O
.	O

Polyclonal	O
anticortactin	O
antibody	O
was	O
from	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
,	O
monoclonal	O
anti	O
-	O
MAP2	O
was	O
from	O
Chemicon	O
,	O
Inc	O
.	O
,	O
monoclonal	O
antitubulin	O
was	O
from	O
Sigma	O
-	O
Aldrich	O
.	O

Monoclonal	O
anti	O
-	O
HA	O
antibody	O
was	O
from	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O

Normal	O
mouse	O
IgG	B-Complex
was	O
from	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
,	O
and	O
Alexa	O
594	O
goat	O
anti	O
-	O
rabbit	O
IgG	B-Complex
,	O
Alexa	O
488	O
goat	O
anti	O
-	O
mouse	O
IgG	B-Complex
,	O
and	O
Phalloidin	O
594	O
were	O
from	O
Molecular	O
Probes	O
,	O
Inc	O
.	O

Rheb	O
binds	O
tuberous	O
sclerosis	O
complex	O
2	O
(	O
TSC2	O
)	O
and	O
promotes	O
S6	O
kinase	O
activation	O
in	O
a	O
rapamycin	O
-	O
and	O
farnesylation	O
-	O
dependent	O
manner	O
.	O

Recently	O
the	O
tuberous	O
sclerosis	O
complex	O
2	O
(	O
TSC2	O
)	O
tumor	O
suppressor	O
gene	O
product	O
has	O
been	O
identified	O
as	O
a	O
negative	O
regulator	O
of	O
protein	O
synthesis	O
upstream	O
of	O
the	O
mTOR	O
and	O
ribosomal	O
S6	O
kinases	O
.	O

Because	O
of	O
the	O
homology	O
of	O
TSC2	O
with	O
GTPase	O
-	O
activating	O
proteins	O
for	O
Rap1	O
,	O
we	O
examined	O
whether	O
a	O
Ras	O
/	O
Rap	O
-	O
related	O
GTPase	O
might	O
be	O
involved	O
in	O
this	O
process	O
.	O

TSC2	O
was	O
found	O
to	O
bind	O
to	O
Rheb	O
-	O
GTP	O
in	O
vitro	O
and	O
to	O
reduce	O
Rheb	O
GTP	O
levels	O
in	O
vivo	O
.	O

Over	O
-	O
expression	O
of	O
Rheb	O
but	O
not	O
Rap1	O
promoted	O
the	O
activation	O
of	O
S6	O
kinase	O
in	O
a	O
rapamycin	O
-	O
dependent	O
manner	O
,	O
suggesting	O
that	O
Rheb	O
acts	O
upstream	O
of	O
mTOR	O
.	O

The	O
ability	O
of	O
Rheb	O
to	O
induce	O
S6	O
phosphorylation	O
was	O
also	O
inhibited	O
by	O
a	O
farnesyl	B-Complex
transferase	I-Complex
inhibitor	O
,	O
suggesting	O
that	O
Rheb	O
may	O
be	O
responsible	O
for	O
the	O
Ras	O
-	O
independent	O
anti	O
-	O
neoplastic	O
properties	O
of	O
this	O
drug	O
.	O

Genome	O
-	O
wide	O
expression	O
analysis	O
of	O
mouse	O
liver	O
reveals	O
CLOCK	O
-	O
regulated	O
circadian	O
output	O
genes	O
.	O

CLOCK	O
is	O
a	O
positive	O
component	O
of	O
a	O
transcription	O
/	O
translation	O
-	O
based	O
negative	O
feedback	O
loop	O
of	O
the	O
central	O
circadian	O
oscillator	O
in	O
the	O
suprachiasmatic	O
nucleus	O
in	O
mammals	O
.	O

To	O
examine	O
CLOCK	O
-	O
regulated	O
circadian	O
transcription	O
in	O
peripheral	O
tissues	O
,	O
we	O
performed	O
microarray	O
analyses	O
using	O
liver	O
RNA	O
isolated	O
from	O
Clock	O
mutant	O
mice	O
.	O

We	O
also	O
compared	O
expression	O
profiles	O
with	O
those	O
of	O
Cryptochromes	O
(	O
Cry1	O
and	O
Cry2	O
)	O
double	O
knockout	O
mice	O
.	O

We	O
identified	O
more	O
than	O
100	O
genes	O
that	O
fluctuated	O
from	O
day	O
to	O
night	O
and	O
of	O
which	O
expression	O
levels	O
were	O
decreased	O
in	O
Clock	O
mutant	O
mice	O
.	O

In	O
Cry	O
-	O
deficient	O
mice	O
,	O
the	O
expression	O
levels	O
of	O
most	O
CLOCK	O
-	O
regulated	O
genes	O
were	O
elevated	O
to	O
the	O
upper	O
range	O
of	O
normal	O
oscillation	O
.	O

Most	O
of	O
the	O
screened	O
genes	O
had	O
a	O
CLOCK	O
/	O
BMAL1	O
binding	O
site	O
(	O
E	O
box	O
)	O
in	O
the	O
5	O
'	O
-	O
flanking	O
region	O
.	O

We	O
found	O
that	O
CLOCK	O
was	O
absolutely	O
concerned	O
with	O
the	O
circadian	O
transcription	O
of	O
one	O
type	O
of	O
liver	O
genes	O
(	O
such	O
as	O
DBP	O
,	O
TEF	O
,	O
and	O
Usp2	O
)	O
and	O
partially	O
with	O
another	O
(	O
such	O
as	O
mPer1	O
,	O
mPer2	O
,	O
mDec1	O
,	O
Nocturnin	O
,	O
P450	O
oxidoreductase	O
,	O
and	O
FKBP51	O
)	O
because	O
the	O
latter	O
were	O
damped	O
but	O
remained	O
rhythmic	O
in	O
the	O
mutant	O
mice	O
.	O

Our	O
results	O
showed	O
that	O
CLOCK	O
and	O
CRY	O
proteins	O
are	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
many	O
circadian	O
output	O
genes	O
in	O
the	O
mouse	O
liver	O
.	O

In	O
addition	O
to	O
being	O
a	O
core	O
component	O
of	O
the	O
negative	O
feedback	O
loop	O
that	O
drives	O
the	O
circadian	O
oscillator	O
,	O
CLOCK	O
also	O
appears	O
to	O
be	O
involved	O
in	O
various	O
physiological	O
functions	O
such	O
as	O
cell	O
cycle	O
,	O
lipid	O
metabolism	O
,	O
immune	O
functions	O
,	O
and	O
proteolysis	O
in	O
peripheral	O
tissues	O
.	O

High	O
affinity	O
for	O
farnesyltransferase	B-OOS
and	O
alternative	O
prenylation	O
contribute	O
individually	O
to	O
K	O
-	O
Ras4B	O
resistance	O
to	O
farnesyltransferase	B-OOS
inhibitors	O
.	O

Farnesyltransferase	B-OOS
inhibitors	O
(	O
FTIs	O
)	O
block	O
Ras	O
farnesylation	O
,	O
subcellular	O
localization	O
and	O
activity	O
,	O
and	O
inhibit	O
the	O
growth	O
of	O
Ras	O
-	O
transformed	O
cells	O
.	O

Although	O
FTIs	O
are	O
ineffective	O
against	O
K	O
-	O
Ras4B	O
,	O
the	O
Ras	O
isoform	O
most	O
commonly	O
mutated	O
in	O
human	O
cancers	O
,	O
they	O
can	O
inhibit	O
the	O
growth	O
of	O
tumors	O
containing	O
oncogenic	O
K	O
-	O
Ras4B	O
,	O
implicating	O
other	O
farnesylated	O
proteins	O
or	O
suggesting	O
distinct	O
functions	O
for	O
farnesylated	O
and	O
for	O
geranylgeranylated	O
K	O
-	O
Ras	O
,	O
which	O
is	O
generated	O
when	O
farnesyltransferase	B-OOS
is	O
inhibited	O
.	O

In	O
addition	O
to	O
bypassing	O
FTI	O
blockade	O
through	O
geranylgeranylation	O
,	O
K	O
-	O
Ras4B	O
resistance	O
to	O
FTIs	O
may	O
also	O
result	O
from	O
its	O
higher	O
affinity	O
for	O
farnesyltransferase	B-OOS
.	O

Using	O
chimeric	O
Ras	O
proteins	O
containing	O
all	O
combinations	O
of	O
Ras	O
background	O
,	O
CAAX	O
motif	O
,	O
and	O
K	O
-	O
Ras	O
polybasic	O
domain	O
,	O
we	O
show	O
that	O
either	O
a	O
polybasic	O
domain	O
or	O
an	O
alternatively	O
prenylated	O
CAAX	O
renders	O
Ras	O
prenylation	O
,	O
Ras	O
-	O
induced	O
Elk	O
-	O
1	O
activation	O
,	O
and	O
anchorage	O
-	O
independent	O
cell	O
growth	O
FTI	O
-	O
resistant	O
.	O

The	O
polybasic	O
domain	O
alone	O
increases	O
the	O
affinity	O
of	O
Ras	O
for	O
farnesyltransferase	B-OOS
,	O
implying	O
independent	O
roles	O
for	O
each	O
K	O
-	O
Ras4B	O
sequence	O
element	O
in	O
FTI	O
resistance	O
.	O

Using	O
microarray	O
analysis	O
and	O
colony	O
formation	O
assays	O
,	O
we	O
confirm	O
that	O
K	O
-	O
Ras	O
function	O
is	O
independent	O
of	O
the	O
identity	O
of	O
the	O
prenyl	O
group	O
and	O
,	O
therefore	O
,	O
that	O
FTI	O
inhibition	O
of	O
K	O
-	O
Ras	O
transformed	O
cells	O
is	O
likely	O
to	O
be	O
independent	O
of	O
K	O
-	O
Ras	O
inhibition	O
.	O

Our	O
results	O
imply	O
that	O
relevant	O
FTI	O
targets	O
will	O
lack	O
both	O
polybasic	O
and	O
potentially	O
geranylgeranylated	O
methionine	O
-	O
CAAX	O
motifs	O
.	O

Glutathione	O
peroxidase	O
1	O
is	O
regulated	O
by	O
the	O
c	O
-	O
Abl	O
and	O
Arg	O
tyrosine	O
kinases	O
.	O

The	O
c	O
-	O
Abl	O
and	O
Arg	O
tyrosine	O
kinases	O
are	O
activated	O
in	O
the	O
cellular	O
response	O
to	O
oxidative	O
stress	O
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
c	O
-	O
Abl	O
and	O
Arg	O
associate	O
with	O
glutathione	O
peroxidase	O
1	O
(	O
GPx1	O
)	O
and	O
that	O
this	O
interaction	O
is	O
regulated	O
by	O
intracellular	O
oxidant	O
levels	O
.	O

The	O
c	O
-	O
Abl	O
and	O
Arg	O
SH3	O
domains	O
bind	O
directly	O
to	O
a	O
proline	O
-	O
rich	O
site	O
in	O
GPx1	O
at	O
amino	O
acids	O
132	O
-	O
145	O
.	O

GPx1	O
also	O
functions	O
as	O
a	O
substrate	O
for	O
c	O
-	O
Abl	O
-	O
and	O
Arg	O
-	O
mediated	O
phosphorylation	O
on	O
Tyr	O
-	O
96	O
.	O

The	O
results	O
further	O
show	O
that	O
c	O
-	O
Abl	O
and	O
Arg	O
stimulate	O
GPx	O
activity	O
and	O
that	O
these	O
kinases	O
contribute	O
to	O
GPx	O
-	O
mediated	O
protection	O
of	O
cells	O
against	O
oxidative	O
stress	O
.	O

Our	O
findings	O
provide	O
the	O
first	O
evidence	O
that	O
GPx1	O
is	O
regulated	O
by	O
a	O
signaling	O
pathway	O
that	O
is	O
activated	O
in	O
the	O
oxidative	O
stress	O
response	O
.	O

Repression	O
of	O
Smad	O
transcriptional	O
activity	O
by	O
PIASy	O
,	O
an	O
inhibitor	O
of	O
activated	O
STAT	O
.	O

Smad	O
proteins	O
mediate	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
-	O
inducible	O
transcriptional	O
responses	O
.	O

Protein	O
inhibitor	O
of	O
activated	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
PIAS	O
)	O
represents	O
a	O
family	O
of	O
proteins	O
that	O
inhibits	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
and	O
also	O
regulates	O
other	O
transcriptional	O
responses	O
.	O

In	O
an	O
effort	O
to	O
identify	O
Smad	O
-	O
interacting	O
proteins	O
by	O
a	O
yeast	O
three	O
-	O
hybrid	O
screen	O
with	O
Smad3	O
and	O
Smad4	O
as	O
baits	O
,	O
we	O
identified	O
PIASy	O
,	O
a	O
member	O
of	O
the	O
PIAS	O
family	O
.	O

In	O
yeast	O
,	O
PIASy	O
interacts	O
strongly	O
with	O
Smad4	O
and	O
also	O
with	O
receptor	O
-	O
regulated	O
Smads	O
.	O

In	O
mammalian	O
cells	O
,	O
PIASy	O
binds	O
most	O
strongly	O
with	O
Smad3	O
and	O
also	O
associates	O
with	O
other	O
receptor	O
-	O
regulated	O
Smads	O
and	O
Smad4	O
.	O

The	O
interaction	O
between	O
Smad3	O
and	O
PIASy	O
is	O
increased	O
in	O
the	O
presence	O
of	O
TGF	O
-	O
beta	O
and	O
occurs	O
through	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
Smad3	O
.	O

Moreover	O
,	O
Smad3	O
,	O
Smad4	O
,	O
and	O
PIASy	O
can	O
form	O
a	O
ternary	O
complex	O
.	O

PIASy	O
does	O
not	O
inhibit	O
Smad	O
complex	O
binding	O
to	O
DNA	O
,	O
but	O
it	O
represses	O
Smad	O
transcriptional	O
activity	O
.	O

Interestingly	O
,	O
conditional	O
overexpression	O
of	O
PIASy	O
selectively	O
inhibits	O
a	O
subset	O
of	O
endogenous	O
TGF	O
-	O
beta	O
-	O
responsive	O
genes	O
,	O
which	O
includes	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p15	O
,	O
and	O
the	O
plasminogen	O
activator	O
inhibitor	O
1	O
.	O

We	O
further	O
show	O
that	O
PIASy	O
can	O
interact	O
constitutively	O
with	O
histone	O
deacetylase	O
1	O
(	O
HDAC1	O
)	O
and	O
that	O
addition	O
of	O
HDAC	O
inhibitor	O
trichostatin	O
A	O
(	O
TSA	O
)	O
can	O
prevent	O
the	O
inhibitory	O
function	O
of	O
PIASy	O
.	O

Taken	O
together	O
,	O
our	O
studies	O
indicate	O
that	O
PIASy	O
can	O
inhibit	O
TGF	O
-	O
beta	O
/	O
Smad	O
transcriptional	O
responses	O
through	O
interactions	O
with	O
Smad	O
proteins	O
and	O
HDAC	O
.	O

Protein	B-Complex
phosphatase	I-Complex
2A	I-Complex
positively	O
regulates	O
Ras	O
signaling	O
by	O
dephosphorylating	O
KSR1	O
and	O
Raf	O
-	O
1	O
on	O
critical	O
14	O
-	O
3	O
-	O
3	O
binding	O
sites	O
.	O

BACKGROUND	O
:	O
Kinase	O
Suppressor	O
of	O
Ras	O
(	O
KSR	O
)	O
is	O
a	O
conserved	O
component	O
of	O
the	O
Ras	O
pathway	O
that	O
acts	O
as	O
a	O
molecular	O
scaffold	O
to	O
facilitate	O
signal	O
transmission	O
through	O
the	O
MAPK	O
cascade	O
.	O

Although	O
recruitment	O
of	O
KSR1	O
from	O
the	O
cytosol	O
to	O
the	O
plasma	O
membrane	O
is	O
required	O
for	O
its	O
scaffolding	O
function	O
,	O
the	O
precise	O
mechanism	O
(	O
s	O
)	O
regulating	O
the	O
translocation	O
of	O
KSR1	O
have	O
not	O
been	O
fully	O
elucidated	O
.	O

RESULTS	O
:	O
Using	O
mass	O
spectrometry	O
to	O
analyze	O
the	O
KSR1	O
-	O
scaffolding	O
complex	O
,	O
we	O
identify	O
the	O
serine	O
/	O
threonine	O
protein	O
phosphatase	O
PP2A	B-Complex
as	O
a	O
KSR1	O
-	O
associated	O
protein	O
and	O
show	O
that	O
PP2A	B-Complex
is	O
a	O
critical	O
regulator	O
of	O
KSR1	O
activity	O
.	O

We	O
find	O
that	O
the	O
enzymatic	O
core	O
subunits	O
of	O
PP2A	B-Complex
(	O
PR65A	O
and	O
catalytic	O
C	O
)	O
constitutively	O
associate	O
with	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
KSR1	O
,	O
whereas	O
binding	O
of	O
the	O
regulatory	O
PR55B	O
subunit	O
is	O
induced	O
by	O
growth	O
factor	O
treatment	O
.	O

Specific	O
inhibition	O
of	O
PP2A	B-Complex
activity	O
prevents	O
the	O
growth	O
factor	O
-	O
induced	O
dephosphorylation	O
event	O
involved	O
in	O
the	O
membrane	O
recruitment	O
of	O
KSR1	O
and	O
blocks	O
the	O
activation	O
of	O
KSR1	O
-	O
associated	O
MEK	O
and	O
ERK	O
.	O

Moreover	O
,	O
we	O
find	O
that	O
PP2A	B-Complex
activity	O
is	O
required	O
for	O
activation	O
of	O
the	O
Raf	O
-	O
1	O
kinase	O
and	O
that	O
both	O
Raf	O
and	O
KSR1	O
must	O
be	O
dephosphorylated	O
by	O
PP2A	B-Complex
on	O
critical	O
regulatory	O
14	O
-	O
3	O
-	O
3	O
binding	O
sites	O
for	O
KSR1	O
to	O
promote	O
MAPK	O
pathway	O
activation	O
.	O

CONCLUSIONS	O
:	O
These	O
findings	O
identify	O
KSR1	O
as	O
novel	O
substrate	O
of	O
PP2A	B-Complex
and	O
demonstrate	O
the	O
inducible	O
dephosphorylation	O
of	O
KSR1	O
in	O
response	O
to	O
Ras	O
pathway	O
activation	O
.	O

Further	O
,	O
these	O
results	O
elucidate	O
a	O
common	O
regulatory	O
mechanism	O
for	O
KSR1	O
and	O
Raf	O
-	O
1	O
whereby	O
their	O
localization	O
and	O
activity	O
are	O
modulated	O
by	O
the	O
PP2A	B-Complex
-	O
mediated	O
dephosphorylation	O
of	O
critical	O
14	O
-	O
3	O
-	O
3	O
binding	O
sites	O
.	O

Studies	O
on	O
G	B-OOS
-	I-OOS
protein	I-OOS
alpha	I-OOS
.	I-OOS
betagamma	I-OOS
heterotrimer	O
formation	O
reveal	O
a	O
putative	O
S	O
-	O
prenyl	O
-	O
binding	O
site	O
in	O
the	O
alpha	O
subunit	O
.	O

The	O
alpha	O
and	O
betagamma	B-OOS
subunits	O
of	O
heterotrimeric	O
G	B-OOS
-	I-OOS
proteins	I-OOS
contain	O
specific	O
lipid	O
modifications	O
,	O
which	O
are	O
required	O
for	O
their	O
biological	O
function	O
.	O

However	O
,	O
the	O
relevance	O
of	O
these	O
modifications	O
to	O
the	O
interactions	O
within	O
the	O
heterotrimeric	O
G	B-OOS
-	I-OOS
protein	I-OOS
is	O
not	O
fully	O
understood	O
.	O

In	O
order	O
to	O
explore	O
the	O
role	O
of	O
the	O
S	O
-	O
prenyl	O
moiety	O
of	O
the	O
isoprenylated	O
betagamma	B-OOS
dimer	O
of	O
retinal	O
transducin	B-OOS
,	O
betagamma	B-OOS
(	O
t	O
)	O
,	O
in	O
the	O
formation	O
of	O
the	O
heterotrimeric	O
complex	O
with	O
the	O
corresponding	O
N	O
-	O
acylated	O
alpha	O
subunit	O
,	O
alpha	O
(	O
t	O
)	O
,	O
we	O
employed	O
purified	O
fully	O
processed	O
subunits	O
,	O
which	O
are	O
soluble	O
in	O
aqueous	O
solutions	O
without	O
detergents	O
.	O

Pertussis	O
-	O
toxin	O
-	O
mediated	O
[	O
(	O
32	O
)	O
P	O
]	O
ADP	O
-	O
ribosylation	O
of	O
alpha	O
(	O
t	O
)	O
is	O
strongly	O
stimulated	O
(	O
approximately	O
10	O
-	O
fold	O
)	O
in	O
the	O
presence	O
of	O
betagamma	B-OOS
(	O
t	O
)	O
and	O
can	O
thus	O
serve	O
as	O
a	O
measure	O
for	O
heterotrimer	O
formation	O
.	O

Using	O
this	O
assay	O
,	O
preincubation	O
of	O
alpha	O
(	O
t	O
)	O
with	O
S	O
-	O
prenyl	O
analogues	O
containing	O
farnesyl	O
or	O
geranylgeranyl	O
moieties	O
was	O
found	O
to	O
inhibit	O
heterotrimer	O
formation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
inhibition	O
was	O
competitive	O
and	O
reversible	O
,	O
as	O
indicated	O
by	O
its	O
reversal	O
upon	O
increase	O
of	O
the	O
betagamma	B-OOS
(	O
t	O
)	O
dimer	O
concentration	O
or	O
by	O
removal	O
of	O
the	O
S	O
-	O
prenyl	O
analogue	O
using	O
gel	O
filtration	O
.	O

The	O
competitive	O
nature	O
of	O
the	O
inhibition	O
is	O
supported	O
by	O
the	O
marked	O
attenuation	O
of	O
the	O
inhibition	O
when	O
the	O
S	O
-	O
prenyl	O
analogue	O
was	O
added	O
to	O
alpha	O
(	O
t	O
)	O
together	O
with	O
or	O
after	O
betagamma	B-OOS
(	O
t	O
)	O
.	O

The	O
inhibition	O
does	O
not	O
involve	O
interaction	O
with	O
the	O
alpha	O
(	O
t	O
)	O
acyl	O
group	O
,	O
since	O
an	O
S	O
-	O
prenyl	O
analogue	O
inhibited	O
the	O
[	O
(	O
32	O
)	O
P	O
]	O
ADP	O
-	O
ribosylation	O
of	O
an	O
unlipidated	O
alpha	O
(	O
t	O
)	O
mutant	O
.	O

These	O
data	O
suggest	O
the	O
existence	O
of	O
a	O
hitherto	O
unrecognized	O
S	O
-	O
prenyl	O
-	O
binding	O
site	O
in	O
alpha	O
(	O
t	O
)	O
,	O
which	O
is	O
critical	O
for	O
its	O
interaction	O
with	O
prenylated	O
betagamma	B-OOS
(	O
t	O
)	O
.	O

Sorting	O
nexin	O
9	O
participates	O
in	O
clathrin	B-Complex
-	O
mediated	O
endocytosis	O
through	O
interactions	O
with	O
the	O
core	O
components	O
.	O

Sorting	O
nexin	O
9	O
(	O
SNX9	O
)	O
belongs	O
to	O
a	O
family	O
of	O
proteins	O
,	O
the	O
sorting	O
nexins	O
,	O
that	O
are	O
characterized	O
by	O
the	O
presence	O
of	O
a	O
subclass	O
of	O
the	O
phosphoinositide	O
-	O
binding	O
phox	O
domain	O
.	O

SNX9	O
has	O
in	O
its	O
amino	O
terminus	O
a	O
Src	O
homology	O
3	O
domain	O
and	O
a	O
region	O
with	O
predicted	O
low	O
complexity	O
followed	O
by	O
a	O
carboxyl	O
-	O
terminal	O
part	O
containing	O
the	O
phox	O
domain	O
.	O

We	O
previously	O
found	O
that	O
SNX9	O
is	O
one	O
of	O
the	O
major	O
proteins	O
in	O
hematopoietic	O
cells	O
that	O
binds	O
to	O
the	O
alpha	O
and	O
beta2	O
-	O
appendages	O
of	O
adaptor	B-Complex
protein	I-Complex
complex	I-Complex
2	I-Complex
(	O
AP	B-Complex
-	I-Complex
2	I-Complex
)	O
,	O
a	O
protein	O
with	O
a	O
critical	O
role	O
in	O
the	O
formation	O
of	O
clathrin	B-Complex
-	O
coated	O
vesicles	O
at	O
the	O
plasma	O
membrane	O
.	O

In	O
the	O
present	O
study	O
we	O
show	O
that	O
clathrin	B-Complex
and	O
dynamin	O
-	O
2	O
,	O
two	O
other	O
essential	O
molecules	O
in	O
the	O
endocytic	O
process	O
,	O
also	O
interact	O
with	O
SNX9	O
.	O

We	O
found	O
that	O
both	O
AP	B-Complex
-	I-Complex
2	I-Complex
and	O
clathrin	B-Complex
bind	O
to	O
the	O
low	O
complexity	O
region	O
in	O
SNX9	O
in	O
a	O
cooperative	O
manner	O
,	O
whereas	O
dynamin	O
-	O
2	O
binds	O
to	O
the	O
Src	O
homology	O
3	O
domain	O
.	O

In	O
the	O
cytosol	O
,	O
SNX9	O
is	O
present	O
in	O
a	O
14	B-Complex
.	I-Complex
5	I-Complex
S	I-Complex
complex	O
containing	O
dynamin	O
-	O
2	O
and	O
an	O
unidentified	O
41	O
-	O
kDa	O
protein	O
.	O

In	O
HeLa	O
cells	O
,	O
SNX9	O
co	O
-	O
localized	O
with	O
both	O
AP	B-Complex
-	I-Complex
2	I-Complex
and	O
dynamin	O
-	O
2	O
at	O
the	O
plasma	O
membrane	O
or	O
on	O
vesicular	O
structures	O
derived	O
from	O
it	O
but	O
not	O
with	O
the	O
early	O
endosomal	O
marker	O
EEA1	O
or	O
with	O
AP	B-Complex
-	I-Complex
1	I-Complex
.	O

The	O
results	O
suggest	O
that	O
SNX9	O
may	O
be	O
recruited	O
together	O
with	O
dynamin	O
-	O
2	O
and	O
become	O
co	O
-	O
assembled	O
with	O
AP	B-Complex
-	I-Complex
2	I-Complex
and	O
clathrin	B-Complex
at	O
the	O
plasma	O
membrane	O
.	O

Overexpression	O
in	O
both	O
K562	O
and	O
HeLa	O
cells	O
of	O
truncated	O
forms	O
of	O
SNX9	O
interfered	O
with	O
the	O
uptake	O
of	O
transferrin	O
,	O
consistent	O
with	O
a	O
role	O
of	O
SNX9	O
in	O
endocytosis	O
.	O

Caenorhabditis	O
elegans	O
TAC	O
-	O
1	O
and	O
ZYG	O
-	O
9	O
form	O
a	O
complex	O
that	O
is	O
essential	O
for	O
long	O
astral	O
and	O
spindle	O
microtubules	O
.	O

TACC	O
(	O
transforming	O
acidic	O
coiled	O
-	O
coil	O
)	O
proteins	O
were	O
first	O
identified	O
by	O
their	O
ability	O
to	O
transform	O
cell	O
lines	O
[	O
1	O
]	O
,	O
and	O
links	O
between	O
human	O
cancer	O
and	O
the	O
overexpression	O
of	O
TACC	O
proteins	O
highlight	O
the	O
importance	O
of	O
understanding	O
the	O
biological	O
function	O
of	O
this	O
family	O
of	O
proteins	O
.	O

Herein	O
,	O
we	O
describe	O
the	O
characterization	O
of	O
a	O
new	O
member	O
of	O
the	O
TACC	O
family	O
of	O
proteins	O
in	O
Caenorhabditis	O
elegans	O
,	O
TAC	O
-	O
1	O
.	O

In	O
other	O
systems	O
,	O
TACC	O
proteins	O
associate	O
with	O
the	O
XMAP215	O
family	O
of	O
microtubule	O
-	O
stabilizing	O
proteins	O
;	O
however	O
,	O
it	O
is	O
unclear	O
whether	O
TACC	O
proteins	O
have	O
microtubule	O
-	O
based	O
functions	O
distinct	O
from	O
XMAP215	O
.	O

We	O
depleted	O
both	O
the	O
XMAP215	O
ortholog	O
ZYG	O
-	O
9	O
and	O
TAC	O
-	O
1	O
via	O
dsRNA	O
-	O
mediated	O
interference	O
(	O
RNAi	O
)	O
.	O

We	O
found	O
that	O
tac	O
-	O
1	O
(	O
RNAi	O
)	O
resulted	O
in	O
microtubule	O
-	O
based	O
defects	O
that	O
were	O
very	O
similar	O
to	O
zyg	O
-	O
9	O
(	O
RNAi	O
)	O
.	O

Furthermore	O
,	O
TAC	O
-	O
1	O
and	O
ZYG	O
-	O
9	O
are	O
required	O
for	O
long	O
astral	O
microtubules	O
in	O
general	O
and	O
long	O
spindle	O
microtubules	O
during	O
spindle	O
assembly	O
.	O

Loss	O
of	O
either	O
protein	O
did	O
not	O
affect	O
the	O
alpha	O
-	O
tubulin	O
immunofluorescence	O
intensity	O
near	O
centrosomes	O
;	O
this	O
finding	O
suggests	O
that	O
microtubule	O
nucleation	O
was	O
not	O
compromised	O
.	O

Both	O
proteins	O
localize	O
to	O
centrosomes	O
and	O
the	O
kinetochore	O
/	O
microtubule	O
region	O
of	O
chromosomes	O
in	O
metaphase	O
and	O
early	O
anaphase	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
ZYG	O
-	O
9	O
and	O
TAC	O
-	O
1	O
physically	O
interact	O
in	O
vivo	O
,	O
and	O
this	O
interaction	O
is	O
important	O
for	O
the	O
efficient	O
localization	O
of	O
the	O
ZYG	O
-	O
9	O
/	O
TAC	O
-	O
1	O
complex	O
to	O
centrosomes	O
.	O

Disruption	O
of	O
the	O
COP9	B-Complex
signalosome	I-Complex
Csn2	O
subunit	O
in	O
mice	O
causes	O
deficient	O
cell	O
proliferation	O
,	O
accumulation	O
of	O
p53	O
and	O
cyclin	O
E	O
,	O
and	O
early	O
embryonic	O
death	O
.	O

Csn2	O
(	O
Trip15	O
/	O
Cops2	O
/	O
Alien	O
)	O
encodes	O
the	O
second	O
subunit	O
of	O
the	O
COP9	B-Complex
signalosome	I-Complex
(	O
CSN	B-Complex
)	O
,	O
an	O
eight	O
-	O
subunit	O
heteromeric	O
complex	O
homologous	O
to	O
the	O
lid	O
subcomplex	O
of	O
the	O
26S	B-Complex
proteasome	I-Complex
.	O

CSN	B-Complex
is	O
a	O
regulator	O
of	O
SCF	B-Complex
(	O
Skp1	O
-	O
cullin	O
-	O
F	O
-	O
box	O
protein	O
)	O
ubiquitin	O
ligases	O
,	O
mostly	O
through	O
the	O
enzymatic	O
activity	O
that	O
deconjugates	O
the	O
ubiquitin	O
-	O
like	O
protein	O
Nedd8	O
from	O
the	O
SCF	B-Complex
Cul1	O
component	O
.	O

In	O
addition	O
,	O
CSN	B-Complex
associates	O
with	O
protein	O
kinase	O
activities	O
targeting	O
p53	O
,	O
c	O
-	O
Jun	O
,	O
and	O
IkappaB	B-Complex
for	O
phosphorylation	O
.	O

Csn2	O
also	O
interacts	O
with	O
and	O
regulates	O
a	O
subset	O
of	O
nuclear	O
hormone	O
receptors	O
and	O
is	O
considered	O
a	O
novel	O
corepressor	O
.	O

We	O
report	O
that	O
targeted	O
disruption	O
of	O
Csn2	O
in	O
mice	O
caused	O
arrest	O
of	O
embryo	O
development	O
at	O
the	O
peri	O
-	O
implantation	O
stage	O
.	O

Csn2	O
(	O
-	O
/	O
-	O
)	O
blastocysts	O
failed	O
to	O
outgrow	O
in	O
culture	O
and	O
exhibited	O
a	O
cell	O
proliferation	O
defect	O
in	O
inner	O
cell	O
mass	O
,	O
accompanied	O
by	O
a	O
slight	O
decrease	O
in	O
Oct4	O
.	O

In	O
addition	O
,	O
lack	O
of	O
Csn2	O
disrupted	O
the	O
CSN	B-Complex
complex	O
and	O
resulted	O
in	O
a	O
drastic	O
increase	O
in	O
cyclin	O
E	O
,	O
supporting	O
a	O
role	O
for	O
CSN	B-Complex
in	O
cooperating	O
with	O
the	O
SCF	B-Complex
-	O
ubiquitin	O
-	O
proteasome	B-Complex
system	O
to	O
regulate	O
protein	O
turnover	O
.	O

Furthermore	O
,	O
Csn2	O
(	O
-	O
/	O
-	O
)	O
embryos	O
contained	O
elevated	O
levels	O
of	O
p53	O
and	O
p21	O
,	O
which	O
may	O
contribute	O
to	O
premature	O
cell	O
cycle	O
arrest	O
of	O
the	O
mutant	O
.	O

Syndecan	O
-	O
4	O
as	O
a	O
molecule	O
involved	O
in	O
defense	O
mechanisms	O
.	O

Syndecan	O
-	O
4	O
is	O
a	O
transmembrane	O
heparan	O
sulfate	O
proteoglycan	O
belonging	O
to	O
the	O
syndecan	O
family	O
.	O

Syndecan	O
-	O
4	O
-	O
deficient	O
[	O
(	O
Synd4	O
(	O
-	O
/	O
-	O
)	O
]	O
mice	O
were	O
produced	O
to	O
clarify	O
the	O
in	O
vivo	O
role	O
of	O
syndecan	O
-	O
4	O
.	O

Synd4	O
(	O
-	O
/	O
-	O
)	O
mice	O
were	O
more	O
susceptible	O
to	O
kappa	O
-	O
carrageenan	O
-	O
induced	O
nephropathy	O
,	O
and	O
the	O
placental	O
labyrinth	O
from	O
the	O
deficient	O
embryos	O
exhibited	O
more	O
thrombi	O
than	O
wild	O
-	O
type	O
ones	O
.	O

Importantly	O
,	O
Synd4	O
(	O
-	O
/	O
-	O
)	O
mice	O
were	O
more	O
susceptible	O
to	O
endotoxin	O
shock	O
.	O

Further	O
analysis	O
revealed	O
that	O
the	O
mechanism	O
to	O
suppress	O
excessive	O
production	O
of	O
interleukin	O
-	O
1beta	O
(	O
1L	O
-	O
1beta	O
)	O
by	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
was	O
impaired	O
in	O
the	O
deficient	O
mice	O
.	O

TGF	O
-	O
beta	O
,	O
one	O
of	O
the	O
cytokines	O
involved	O
in	O
the	O
suppression	O
mechanism	O
,	O
bound	O
to	O
heparan	O
sulfate	O
chain	O
of	O
syndecan	O
-	O
4	O
,	O
which	O
was	O
induced	O
in	O
macrophages	O
and	O
the	O
microvasculature	O
after	O
administration	O
of	O
lipopolysaccharide	O
.	O

Therefore	O
,	O
augmentation	O
of	O
TGF	O
-	O
beta	O
function	O
by	O
induced	O
syndecan	O
-	O
4	O
was	O
suggested	O
as	O
a	O
mechanism	O
of	O
the	O
suppressive	O
action	O
of	O
syndecan	O
-	O
4	O
against	O
endotoxin	O
shock	O
.	O

A	O
lymphoid	O
cell	O
-	O
specific	O
nuclear	B-OOS
factor	I-OOS
containing	O
c	O
-	O
Rel	O
-	O
like	O
proteins	O
preferentially	O
interacts	O
with	O
interleukin	O
-	O
6	O
kappa	B-Complex
B	I-Complex
-	O
related	O
motifs	O
whose	O
activities	O
are	O
repressed	O
in	O
lymphoid	O
cells	O
.	O

The	O
proto	O
-	O
oncoprotein	O
c	O
-	O
Rel	O
is	O
a	O
member	O
of	O
the	O
nuclear	B-Complex
factor	I-Complex
kappa	I-Complex
B	I-Complex
transcription	I-Complex
factor	I-Complex
family	O
,	O
which	O
includes	O
the	O
p50	O
and	O
p65	O
subunits	O
of	O
nuclear	B-Complex
factor	I-Complex
kappa	I-Complex
B	I-Complex
.	O

We	O
show	O
here	O
that	O
c	O
-	O
Rel	O
binds	O
to	O
kappa	B-Complex
B	I-Complex
sites	O
as	O
homodimers	O
as	O
well	O
as	O
heterodimers	O
with	O
p50	O
.	O

These	O
homodimers	O
and	O
heterodimers	O
show	O
distinct	O
DNA	O
-	O
binding	O
specificities	O
and	O
affinities	O
for	O
various	O
kappa	B-Complex
B	I-Complex
motifs	O
.	O

In	O
particular	O
,	O
the	O
c	O
-	O
Rel	O
homodimer	O
has	O
a	O
high	O
affinity	O
for	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
and	O
beta	O
interferon	O
kappa	B-Complex
B	I-Complex
sites	O
.	O

In	O
spite	O
of	O
its	O
association	O
with	O
p50	O
in	O
vitro	O
,	O
however	O
,	O
we	O
found	O
a	O
lymphoid	O
cell	O
-	O
specific	O
nuclear	B-OOS
factor	I-OOS
in	O
vivo	O
that	O
contains	O
c	O
-	O
Rel	O
but	O
not	O
p50	O
epitopes	O
;	O
this	O
factor	O
,	O
termed	O
IL	O
-	O
6	O
kappa	O
B	O
binding	O
factor	O
II	O
,	O
appears	O
to	O
contain	O
the	O
c	O
-	O
Rel	O
homodimer	O
and	O
preferentially	O
recognizes	O
several	O
IL	O
-	O
6	O
kappa	B-Complex
B	I-Complex
-	O
related	O
kappa	B-Complex
B	I-Complex
motifs	O
.	O

Although	O
it	O
has	O
been	O
previously	O
shown	O
that	O
the	O
IL	O
-	O
6	O
kappa	B-Complex
B	I-Complex
motif	O
functions	O
as	O
a	O
potent	O
IL	O
-	O
1	O
/	O
tumor	O
necrosis	O
factor	O
-	O
responsive	O
element	O
in	O
nonlymphoid	O
cells	O
,	O
its	O
activity	O
was	O
found	O
to	O
be	O
repressed	O
in	O
lymphoid	O
cells	O
such	O
as	O
a	O
Jurkat	O
T	O
-	O
cell	O
line	O
.	O

We	O
also	O
present	O
evidence	O
that	O
IL	O
-	O
6	O
kappa	O
B	O
binding	O
factor	O
II	O
functions	O
as	O
a	O
repressor	O
specific	O
for	O
IL	O
-	O
6	O
kappa	B-Complex
B	I-Complex
-	O
related	O
kappa	B-Complex
B	I-Complex
motifs	O
in	O
lymphoid	O
cells	O
.	O

The	O
promoter	O
of	O
the	O
CD19	O
gene	O
is	O
a	O
target	O
for	O
the	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
BSAP	O
.	O

The	O
CD19	O
protein	O
is	O
expressed	O
on	O
the	O
surface	O
of	O
all	O
B	O
-	O
lymphoid	O
cells	O
with	O
the	O
exception	O
of	O
terminally	O
differentiated	O
plasma	O
cells	O
and	O
has	O
been	O
implicated	O
as	O
a	O
signal	O
-	O
transducing	O
receptor	O
in	O
the	O
control	O
of	O
proliferation	O
and	O
differentiation	O
.	O

Here	O
we	O
demonstrate	O
complete	O
correlation	O
between	O
the	O
expression	O
pattern	O
of	O
the	O
CD19	O
gene	O
and	O
the	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
BSAP	O
in	O
a	O
large	O
panel	O
of	O
B	O
-	O
lymphoid	O
cell	O
lines	O
.	O

The	O
human	O
CD19	O
gene	O
has	O
been	O
cloned	O
,	O
and	O
several	O
BSAP	O
-	O
binding	O
sites	O
have	O
been	O
mapped	O
by	O
in	O
vitro	O
protein	O
-	O
DNA	O
binding	O
studies	O
.	O

In	O
particular	O
,	O
a	O
high	O
-	O
affinity	O
BSAP	O
-	O
binding	O
site	O
instead	O
of	O
a	O
TATA	O
sequence	O
is	O
located	O
in	O
the	O
-	O
30	O
promoter	O
region	O
upstream	O
of	O
a	O
cluster	O
of	O
heterogeneous	O
transcription	O
start	O
sites	O
.	O

Moreover	O
,	O
this	O
site	O
is	O
occupied	O
by	O
BSAP	O
in	O
vivo	O
in	O
a	O
CD19	O
-	O
expressing	O
B	O
-	O
cell	O
line	O
but	O
not	O
in	O
plasma	O
or	O
HeLa	O
cells	O
.	O

This	O
high	O
-	O
affinity	O
site	O
has	O
been	O
conserved	O
in	O
the	O
promoters	O
of	O
both	O
human	O
and	O
mouse	O
CD19	O
genes	O
and	O
was	O
furthermore	O
shown	O
to	O
confer	O
B	O
-	O
cell	O
specificity	O
to	O
a	O
beta	O
-	O
globin	O
reporter	O
gene	O
in	O
transient	O
transfection	O
experiments	O
.	O

In	O
addition	O
,	O
BSAP	O
was	O
found	O
to	O
be	O
the	O
only	O
abundant	O
DNA	O
-	O
binding	O
activity	O
of	O
B	O
-	O
cell	O
nuclear	O
extracts	O
that	O
interacts	O
with	O
the	O
CD19	O
promoter	O
.	O

Together	O
,	O
this	O
evidence	O
strongly	O
implicates	O
BSAP	O
in	O
the	O
regulation	O
of	O
the	O
CD19	O
gene	O
.	O

For	O
these	O
experiments	O
,	O
lysis	O
was	O
performed	O
under	O
low	O
free	O
Ca2	O
+	O
conditions	O
(	O
5	O
mM	O
EGTA	O
)	O
.	O

This	O
was	O
because	O
there	O
is	O
evidence	O
that	O
interactions	O
of	O
Cdc31p	O
with	O
proteins	O
other	O
than	O
Kar1p	O
are	O
less	O
Ca2	O
+	O
sensitive	O
.	O

In	O
addition	O
,	O
interactions	O
of	O
spasmin	O
with	O
the	O
spasmoneme	O
,	O
and	O
centrin	O
with	O
a	O
350	O
-	O
kD	O
protein	O
in	O
the	O
Paramecium	O
infraciliary	O
lattice	O
,	O
are	O
stable	O
in	O
the	O
presence	O
of	O
EGTA	O
.	O

The	O
proteins	O
that	O
copurified	O
with	O
ZCdc31p	O
were	O
of	O
diverse	O
function	O
:	O
Vps13p	O
is	O
involved	O
membrane	O
traffic	O
,	O
Thp1p	O
is	O
involved	O
in	O
mitotic	O
recombination	O
,	O
and	O
Hem15p	O
is	O
ferrochelatase	O
.	O

One	O
protein	O
of	O
particular	O
interest	O
,	O
Sfi1p	O
,	O
was	O
initially	O
identified	O
as	O
a	O
suppressor	O
of	O
the	O
heat	O
sensitivity	O
associated	O
with	O
a	O
particular	O
mutation	O
in	O
adenyl	O
cyclase	O
.	O

When	O
Sfi1p	O
was	O
partly	O
characterized	O
,	O
it	O
was	O
found	O
not	O
to	O
be	O
involved	O
in	O
the	O
adenyl	O
cyclase	O
pathway	O
,	O
but	O
it	O
is	O
an	O
essential	O
protein	O
whose	O
depletion	O
causes	O
a	O
G2	O
/	O
M	O
arrest	O
with	O
failure	O
to	O
form	O
a	O
mitotic	O
spindle	O
.	O

This	O
is	O
similar	O
to	O
the	O
phenotype	O
of	O
cdc31	O
-	O
1	O
,	O
and	O
indicates	O
a	O
possible	O
function	O
at	O
the	O
SPB	O
.	O

The	O
comings	O
and	O
goings	O
of	O
nucleotide	O
excision	O
repair	O
factors	O
on	O
damaged	O
DNA	O
.	O

To	O
understand	O
the	O
mechanism	O
of	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
,	O
one	O
of	O
the	O
major	O
human	O
DNA	O
repair	O
pathways	O
,	O
we	O
have	O
set	O
up	O
a	O
DNA	O
repair	O
system	O
in	O
which	O
a	O
linear	O
damaged	O
DNA	O
substrate	O
is	O
immobilized	O
by	O
its	O
terminus	O
.	O

By	O
isolating	O
functionally	O
active	O
intermediate	O
complexes	O
,	O
our	O
data	O
dissect	O
the	O
ordered	O
arrival	O
and	O
displacement	O
of	O
NER	O
factors	O
in	O
the	O
progress	O
of	O
the	O
dual	O
incision	O
step	O
.	O

We	O
describe	O
(	O
i	O
)	O
the	O
role	O
of	O
ATP	O
in	O
remodelling	O
the	O
NER	O
-	O
initiating	O
complex	O
of	O
XPC	O
/	O
TFIIH	B-Complex
/	O
damaged	O
DNA	O
as	O
a	O
prerequisite	O
for	O
the	O
recruitment	O
of	O
the	O
next	O
NER	O
factors	O
;	O
(	O
ii	O
)	O
the	O
coordination	O
between	O
damage	O
removal	O
and	O
DNA	O
resynthesis	O
and	O
the	O
release	O
of	O
XPC	O
-	O
HR23B	O
,	O
TFIIH	B-Complex
and	O
XPA	O
upon	O
arrival	O
of	O
XPG	O
and	O
XPF	O
-	O
ERCC1	O
,	O
respectively	O
;	O
(	O
iii	O
)	O
how	O
RPA	O
remains	O
associated	O
with	O
the	O
excised	O
DNA	O
initiating	O
the	O
assembly	O
of	O
resynthesis	O
factors	O
such	O
as	O
PCNA	O
;	O
(	O
iv	O
)	O
the	O
recycling	O
of	O
XPC	O
-	O
HR23B	O
,	O
TFIIH	B-Complex
and	O
XPA	O
in	O
the	O
NER	O
;	O
and	O
the	O
shuttling	O
of	O
TFIIH	B-Complex
between	O
NER	O
and	O
transcription	O
.	O

Thus	O
,	O
our	O
findings	O
define	O
multiple	O
functions	O
of	O
NER	O
factors	O
to	O
explain	O
the	O
molecular	O
basis	O
of	O
human	O
NER	O
disorders	O
.	O

Retroviral	O
insertional	O
mutagenesis	O
identifies	O
a	O
small	O
protein	O
required	O
for	O
synthesis	O
of	O
diphthamide	O
,	O
the	O
target	O
of	O
bacterial	O
ADP	O
-	O
ribosylating	O
toxins	O
.	O

Retroviral	O
insertional	O
mutagenesis	O
was	O
used	O
to	O
produce	O
a	O
mutant	O
Chinese	O
hamster	O
ovary	O
cell	O
line	O
that	O
is	O
completely	O
resistant	O
to	O
several	O
different	O
bacterial	O
ADP	O
-	O
ribosylating	O
toxins	O
.	O

The	O
gene	O
responsible	O
for	O
toxin	O
resistance	O
,	O
termed	O
diphtheria	O
toxin	O
(	O
DT	O
)	O
and	O
Pseudomonas	O
exotoxin	O
A	O
(	O
ETA	O
)	O
sensitivity	O
required	O
gene	O
1	O
(	O
DESR1	O
)	O
,	O
encodes	O
two	O
small	O
protein	O
isoforms	O
of	O
82	O
and	O
57	O
residues	O
.	O

DESR1	O
is	O
evolutionally	O
conserved	O
and	O
ubiquitously	O
expressed	O
.	O

Only	O
the	O
longer	O
isoform	O
is	O
functional	O
because	O
the	O
mutant	O
cell	O
line	O
can	O
be	O
complemented	O
by	O
transfection	O
with	O
the	O
long	O
but	O
not	O
the	O
short	O
isoform	O
.	O

We	O
demonstrate	O
that	O
DESR1	O
is	O
required	O
for	O
the	O
first	O
step	O
in	O
the	O
posttranslational	O
modification	O
of	O
elongation	O
factor	O
-	O
2	O
at	O
His	O
(	O
715	O
)	O
that	O
yields	O
diphthamide	O
,	O
the	O
target	O
site	O
for	O
ADP	O
ribosylation	O
by	O
DT	O
and	O
ETA	O
.	O

KTI11	O
,	O
the	O
analog	O
of	O
DESR1	O
in	O
yeast	O
,	O
which	O
was	O
originally	O
identified	O
as	O
a	O
gene	O
regulating	O
the	O
sensitivity	O
of	O
yeast	O
to	O
zymocin	O
,	O
is	O
also	O
required	O
for	O
diphthamide	O
biosynthesis	O
,	O
implicating	O
DESR1	O
/	O
KTI11	O
in	O
multiple	O
biological	O
processes	O
.	O

HCF	O
-	O
1	O
functions	O
as	O
a	O
coactivator	O
for	O
the	O
zinc	O
finger	O
protein	O
Krox20	O
.	O

HCF	O
-	O
1	O
is	O
a	O
transcriptional	O
cofactor	O
required	O
for	O
activation	O
of	O
herpes	O
simplex	O
virus	O
immediate	O
-	O
early	O
genes	O
by	O
VP16	O
as	O
well	O
as	O
less	O
clearly	O
defined	O
roles	O
in	O
cell	O
proliferation	O
,	O
cytokinesis	O
,	O
and	O
spliceosome	B-Complex
formation	O
.	O

It	O
is	O
expressed	O
as	O
a	O
large	O
precursor	O
that	O
undergoes	O
proteolysis	O
to	O
yield	O
two	O
subunits	O
that	O
remain	O
stably	O
associated	O
.	O

VP16	O
uses	O
a	O
degenerate	O
4	O
-	O
amino	O
acid	O
sequence	O
,	O
known	O
as	O
the	O
HCF	O
-	O
binding	O
motif	O
,	O
to	O
bind	O
to	O
a	O
six	O
-	O
bladed	O
beta	O
-	O
propeller	O
domain	O
at	O
the	O
N	O
terminus	O
of	O
HCF	O
-	O
1	O
.	O

Functional	O
HCF	O
-	O
binding	O
motifs	O
are	O
also	O
found	O
in	O
LZIP	O
and	O
Zhangfei	O
,	O
two	O
cellular	O
bZIP	O
transcription	O
factors	O
of	O
unknown	O
function	O
.	O

Here	O
we	O
show	O
that	O
the	O
HCF	O
-	O
binding	O
motif	O
occurs	O
in	O
a	O
wide	O
spectrum	O
of	O
DNA	O
-	O
binding	O
proteins	O
and	O
transcriptional	O
cofactors	O
.	O

Three	O
well	O
characterized	O
examples	O
were	O
further	O
analyzed	O
for	O
their	O
ability	O
to	O
use	O
HCF	O
-	O
1	O
as	O
a	O
coactivator	O
.	O

Krox20	O
,	O
a	O
zinc	O
finger	O
transcription	O
factor	O
required	O
for	O
Schwann	O
cell	O
differentiation	O
,	O
and	O
E2F4	O
,	O
a	O
cell	O
cycle	O
regulator	O
,	O
showed	O
a	O
strong	O
requirement	O
for	O
functional	O
HCF	O
-	O
1	O
to	O
activate	O
transcription	O
.	O

In	O
contrast	O
,	O
activation	O
by	O
estrogen	O
receptor	O
-	O
alpha	O
did	O
not	O
display	O
HCF	O
dependence	O
.	O

In	O
Krox20	O
,	O
the	O
HCF	O
-	O
binding	O
motif	O
lies	O
within	O
the	O
N	O
-	O
terminal	O
activation	O
domain	O
and	O
mutation	O
of	O
this	O
sequence	O
diminishes	O
both	O
transactivation	O
and	O
association	O
with	O
the	O
HCF	O
-	O
1	O
beta	O
-	O
propeller	O
.	O

The	O
activation	O
domain	O
in	O
the	O
C	O
-	O
terminal	O
subunit	O
of	O
HCF	O
-	O
1	O
contributes	O
to	O
activation	O
by	O
Krox20	O
,	O
possibly	O
through	O
recruitment	O
of	O
p300	O
.	O

These	O
results	O
suggest	O
that	O
HCF	O
-	O
1	O
is	O
recruited	O
by	O
many	O
different	O
classes	O
of	O
cellular	O
transcription	O
factors	O
and	O
is	O
therefore	O
likely	O
to	O
be	O
required	O
for	O
a	O
variety	O
of	O
cellular	O
processes	O
including	O
cell	O
cycle	O
progression	O
and	O
development	O
.	O

The	O
human	O
SUMF1	O
gene	O
,	O
required	O
for	O
posttranslational	O
sulfatase	O
modification	O
,	O
defines	O
a	O
new	O
gene	O
family	O
which	O
is	O
conserved	O
from	O
pro	O
-	O
to	O
eukaryotes	O
.	O

Recently	O
,	O
the	O
human	O
C	O
(	O
alpha	O
)	O
-	O
formylglycine	O
(	O
FGly	O
)	O
-	O
generating	O
enzyme	O
(	O
FGE	O
)	O
,	O
whose	O
deficiency	O
causes	O
the	O
autosomal	O
-	O
recessively	O
transmitted	O
lysosomal	O
storage	O
disease	O
multiple	O
sulfatase	O
deficiency	O
(	O
MSD	O
)	O
,	O
has	O
been	O
identified	O
.	O

In	O
sulfatases	O
,	O
FGE	O
posttranslationally	O
converts	O
a	O
cysteine	O
residue	O
to	O
FGly	O
,	O
which	O
is	O
part	O
of	O
the	O
catalytic	O
site	O
and	O
is	O
essential	O
for	O
sulfatase	O
activity	O
.	O

FGE	O
is	O
encoded	O
by	O
the	O
sulfatase	O
modifying	O
factor	O
1	O
(	O
SUMF1	O
)	O
gene	O
,	O
which	O
defines	O
a	O
new	O
gene	O
family	O
comprising	O
orthologs	O
from	O
prokaryotes	O
to	O
higher	O
eukaryotes	O
.	O

The	O
genomes	O
of	O
E	O
.	O
coli	O
,	O
S	O
.	O
cerevisiae	O
and	O
C	O
.	O
elegans	O
lack	O
SUMF1	O
,	O
indicating	O
a	O
phylogenetic	O
gap	O
and	O
the	O
existence	O
of	O
an	O
alternative	O
FGly	O
-	O
generating	O
system	O
.	O

The	O
genomes	O
of	O
vertebrates	O
including	O
mouse	O
,	O
man	O
and	O
pufferfish	O
contain	O
a	O
sulfatase	O
modifying	O
factor	O
2	O
(	O
SUMF2	O
)	O
gene	O
encoding	O
an	O
FGE	O
paralog	O
of	O
unknown	O
function	O
.	O

SUMF2	O
evolved	O
from	O
a	O
single	O
exon	O
SUMF1	O
gene	O
as	O
found	O
in	O
diptera	O
prior	O
to	O
divergent	O
intron	O
acquisition	O
.	O

In	O
several	O
prokaryotic	O
genomes	O
,	O
the	O
SUMF1	O
gene	O
is	O
cotranscribed	O
with	O
genes	O
encoding	O
sulfatases	O
which	O
require	O
FGly	O
modification	O
.	O

The	O
FGE	O
protein	O
contains	O
a	O
single	O
domain	O
that	O
is	O
made	O
up	O
of	O
three	O
highly	O
conserved	O
subdomains	O
spaced	O
by	O
nonconserved	O
sequences	O
of	O
variable	O
lengths	O
.	O

The	O
similarity	O
among	O
the	O
eukaryotic	O
FGE	O
orthologs	O
varies	O
between	O
72	O
%	O
and	O
100	O
%	O
for	O
the	O
three	O
subdomains	O
and	O
is	O
highest	O
for	O
the	O
C	O
-	O
terminal	O
subdomain	O
,	O
which	O
is	O
a	O
hotspot	O
for	O
mutations	O
in	O
MSD	O
patients	O
.	O

Cytosolic	O
HSP90	O
associates	O
with	O
and	O
modulates	O
the	O
Arabidopsis	O
RPM1	O
disease	O
resistance	O
protein	O
.	O

The	O
Arabidopsis	O
protein	O
RPM1	O
activates	O
disease	O
resistance	O
in	O
response	O
to	O
Pseudomonas	O
syringae	O
proteins	O
targeted	O
to	O
the	O
inside	O
of	O
the	O
host	O
cell	O
via	O
the	O
bacterial	O
type	O
III	O
delivery	O
system	O
.	O

We	O
demonstrate	O
that	O
specific	O
mutations	O
in	O
the	O
ATP	O
-	O
binding	O
domain	O
of	O
a	O
single	O
Arabidopsis	O
cytosolic	O
HSP90	O
isoform	O
compromise	O
RPM1	O
function	O
.	O

These	O
mutations	O
do	O
not	O
affect	O
the	O
function	O
of	O
related	O
disease	O
resistance	O
proteins	O
.	O

RPM1	O
associates	O
with	O
HSP90	O
in	O
plant	O
cells	O
.	O

The	O
Arabidopsis	O
proteins	O
RAR1	O
and	O
SGT1	O
are	O
required	O
for	O
the	O
action	O
of	O
many	O
R	O
proteins	O
,	O
and	O
display	O
some	O
structural	O
similarity	O
to	O
HSP90	O
co	O
-	O
chaperones	O
.	O

Each	O
associates	O
with	O
HSP90	O
in	O
plant	O
cells	O
.	O

Our	O
data	O
suggest	O
that	O
(	O
i	O
)	O
RPM1	O
is	O
an	O
HSP90	O
client	O
protein	O
;	O
and	O
(	O
ii	O
)	O
RAR1	O
and	O
SGT1	O
may	O
function	O
independently	O
as	O
HSP90	O
cofactors	O
.	O

Dynamic	O
interactions	O
among	O
these	O
proteins	O
can	O
regulate	O
RPM1	O
stability	O
and	O
function	O
,	O
perhaps	O
similarly	O
to	O
the	O
formation	O
and	O
regulation	O
of	O
animal	O
steroid	O
receptor	O
complexes	O
.	O

Genomic	O
organization	O
and	O
transcription	O
of	O
the	O
human	O
retinol	O
dehydrogenase	O
10	O
(	O
RDH10	O
)	O
gene	O
.	O

A	O
cDNA	O
clone	O
up	O
-	O
regulated	O
in	O
hydraulic	O
lung	O
edema	O
in	O
rabbit	O
showed	O
high	O
similarity	O
with	O
human	O
RDH10	O
mRNA	O
,	O
which	O
encodes	O
a	O
protein	O
involved	O
in	O
retinoic	O
acid	O
metabolism	O
.	O

We	O
defined	O
the	O
organization	O
of	O
the	O
human	O
gene	O
,	O
which	O
includes	O
a	O
unique	O
transcriptional	O
start	O
site	O
,	O
a	O
coding	O
region	O
with	O
six	O
translated	O
exons	O
and	O
a	O
3	O
'	O
untranslated	O
region	O
containing	O
at	O
least	O
two	O
used	O
polyadenylation	O
sites	O
.	O

The	O
two	O
poly	O
(	O
A	O
)	O
signals	O
are	O
responsible	O
for	O
the	O
production	O
of	O
the	O
3	O
and	O
4	O
kb	O
RDH10	O
mRNA	O
isoforms	O
detected	O
in	O
several	O
human	O
tissues	O
and	O
cell	O
lines	O
.	O

Pannexins	O
,	O
a	O
family	O
of	O
gap	O
junction	O
proteins	O
expressed	O
in	O
brain	O
.	O

Database	O
search	O
has	O
led	O
to	O
the	O
identification	O
of	O
a	O
family	O
of	O
proteins	O
,	O
the	O
pannexins	O
,	O
which	O
share	O
some	O
structural	O
features	O
with	O
the	O
gap	O
junction	O
forming	O
proteins	O
of	O
invertebrates	O
and	O
vertebrates	O
.	O

The	O
function	O
of	O
these	O
proteins	O
has	O
remained	O
unclear	O
so	O
far	O
.	O

To	O
test	O
the	O
possibility	O
that	O
pannexins	O
underlie	O
electrical	O
communication	O
in	O
the	O
brain	O
,	O
we	O
have	O
investigated	O
their	O
tissue	O
distribution	O
and	O
functional	O
properties	O
.	O

Here	O
,	O
we	O
show	O
that	O
two	O
of	O
these	O
genes	O
,	O
pannexin	O
1	O
(	O
Px1	O
)	O
and	O
Px2	O
,	O
are	O
abundantly	O
expressed	O
in	O
the	O
CNS	O
.	O

In	O
many	O
neuronal	O
cell	O
populations	O
,	O
including	O
hippocampus	O
,	O
olfactory	O
bulb	O
,	O
cortex	O
and	O
cerebellum	O
,	O
there	O
is	O
coexpression	O
of	O
both	O
pannexins	O
,	O
whereas	O
in	O
other	O
brain	O
regions	O
,	O
e	O
.	O
g	O
.	O
,	O
white	O
matter	O
,	O
only	O
Px1	O
-	O
positive	O
cells	O
were	O
found	O
.	O

On	O
expression	O
in	O
Xenopus	O
oocytes	O
,	O
Px1	O
,	O
but	O
not	O
Px2	O
forms	O
functional	O
hemichannels	O
.	O

Coinjection	O
of	O
both	O
pannexin	O
RNAs	O
results	O
in	O
hemichannels	O
with	O
functional	O
properties	O
that	O
are	O
different	O
from	O
those	O
formed	O
by	O
Px1	O
only	O
.	O

In	O
paired	O
oocytes	O
,	O
Px1	O
,	O
alone	O
and	O
in	O
combination	O
with	O
Px2	O
,	O
induces	O
the	O
formation	O
of	O
intercellular	O
channels	O
.	O

The	O
functional	O
characteristics	O
of	O
homomeric	O
Px1	O
versus	O
heteromeric	O
Px1	O
/	O
Px2	O
channels	O
and	O
the	O
different	O
expression	O
patterns	O
of	O
Px1	O
and	O
Px2	O
in	O
the	O
brain	O
indicate	O
that	O
pannexins	O
form	O
cell	O
type	O
-	O
specific	O
gap	O
junctions	O
with	O
distinct	O
properties	O
that	O
may	O
subserve	O
different	O
functions	O
.	O

DU	O
145	O
and	O
Jurkat	O
cells	O
were	O
incubated	O
with	O
200	O
ng	O
ml	O
-	O
1	O
anti	O
-	O
Fas	O
IgM	B-Complex
for	O
4	O
and	O
24	O
h	O
as	O
indicated	O
.	O

The	O
cells	O
were	O
subsequently	O
harvested	O
,	O
washed	O
once	O
in	O
PBS	O
and	O
resuspended	O
in	O
200	O
mul	O
Annexin	O
V	O
binding	O
buffer	O
(	O
150	O
mM	O
NaCl	O
,	O
18	O
mM	O
CaCl2	O
,	O
10	O
mM	O
HEPES	O
,	O
5	O
mM	O
KCl	O
,	O
1	O
mM	O
MgCl2	O
)	O
.	O

A	O
measure	O
of	O
1	O
mug	O
ml	O
-	O
1	O
FITC	O
-	O
conjugated	O
Annexin	O
V	O
,	O
which	O
binds	O
specifically	O
to	O
external	O
phosphatidyl	O
serine	O
on	O
apoptotic	O
cells	O
,	O
was	O
added	O
to	O
each	O
sample	O
and	O
incubated	O
at	O
room	O
temperature	O
for	O
5	O
min	O
.	O

PI	O
(	O
50	O
mug	O
ml	O
-	O
1	O
)	O
was	O
added	O
immediately	O
prior	O
to	O
reading	O
the	O
samples	O
on	O
the	O
FACScan	O
.	O

Viable	O
cells	O
exclude	O
PI	O
and	O
stain	O
negative	O
on	O
FL	O
-	O
2	O
.	O

Apoptotic	O
cells	O
are	O
labelled	O
with	O
Annexin	O
V	O
and	O
stain	O
positive	O
on	O
FL	O
-	O
1	O
.	O

Analysis	O
was	O
carried	O
out	O
using	O
Cell	O
Quest	O
Software	O
.	O

Mechanism	O
of	O
5	O
'	O
-	O
directed	O
excision	O
in	O
human	O
mismatch	O
repair	O
.	O

We	O
have	O
developed	O
a	O
purified	O
system	O
that	O
supports	O
mismatch	O
-	O
dependent	O
5	O
'	O
-	O
-	O
>	O
3	O
'	O
excision	O
.	O

In	O
the	O
presence	O
of	O
RPA	O
,	O
ATP	O
,	O
and	O
a	O
mismatch	O
,	O
MutSalpha	B-Complex
activates	O
5	O
'	O
-	O
-	O
>	O
3	O
'	O
excision	O
by	O
EXOI	O
,	O
and	O
excision	O
terminates	O
after	O
removal	O
of	O
the	O
mispair	O
.	O

MutSalpha	B-Complex
confers	O
high	O
processivity	O
on	O
EXOI	O
,	O
and	O
termination	O
is	O
due	O
to	O
RPA	O
-	O
dependent	O
displacement	O
of	O
this	O
processive	O
complex	O
from	O
the	O
helix	O
and	O
a	O
weak	O
ability	O
of	O
EXOI	O
to	O
reload	O
at	O
the	O
RPA	O
-	O
bound	O
gap	O
in	O
the	O
product	O
,	O
as	O
well	O
as	O
MutSalpha	B-Complex
-	O
and	O
MutLalpha	B-Complex
-	O
dependent	O
suppression	O
of	O
EXOI	O
activity	O
in	O
the	O
absence	O
of	O
a	O
mismatch	O
cofactor	O
.	O

As	O
observed	O
in	O
the	O
purified	O
system	O
,	O
excision	O
directed	O
by	O
a	O
5	O
'	O
strand	O
break	O
in	O
HeLa	O
nuclear	O
extract	O
can	O
proceed	O
in	O
the	O
absence	O
of	O
MutLalpha	B-Complex
or	O
PCNA	O
,	O
although	O
3	O
'	O
excision	O
in	O
the	O
extract	O
system	O
requires	O
both	O
proteins	O
.	O

Regulation	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
signaling	O
by	O
Pin1	O
-	O
dependent	O
prolyl	O
isomerization	O
and	O
ubiquitin	O
-	O
mediated	O
proteolysis	O
of	O
p65	O
/	O
RelA	O
.	O

The	O
transcription	O
factor	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
is	O
activated	O
by	O
the	O
degradation	O
of	O
its	O
inhibitor	O
IkappaBalpha	O
,	O
resulting	O
in	O
its	O
nuclear	O
translocation	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
nuclear	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
is	O
subsequently	O
regulated	O
is	O
not	O
clear	O
.	O

Here	O
we	O
demonstrate	O
that	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
function	O
is	O
regulated	O
by	O
Pin1	O
-	O
mediated	O
prolyl	O
isomerization	O
and	O
ubiquitin	O
-	O
mediated	O
proteolysis	O
of	O
its	O
p65	O
/	O
RelA	O
subunit	O
.	O

Upon	O
cytokine	O
treatment	O
,	O
Pin1	O
binds	O
to	O
the	O
pThr254	O
-	O
Pro	O
motif	O
in	O
p65	O
and	O
inhibits	O
p65	O
binding	O
to	O
IkappaBalpha	O
,	O
resulting	O
in	O
increased	O
nuclear	O
accumulation	O
and	O
protein	O
stability	O
of	O
p65	O
and	O
enhanced	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activity	O
.	O

Significantly	O
,	O
Pin1	O
-	O
deficient	O
mice	O
and	O
cells	O
are	O
refractory	O
to	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
by	O
cytokine	O
signals	O
.	O

Moreover	O
,	O
the	O
stability	O
of	O
p65	O
is	O
controlled	O
by	O
ubiquitin	O
-	O
mediated	O
proteolysis	O
,	O
facilitated	O
by	O
a	O
cytokine	O
signal	O
inhibitor	O
,	O
SOCS	O
-	O
1	O
,	O
acting	O
as	O
a	O
ubiquitin	O
ligase	O
.	O

These	O
findings	O
uncover	O
two	O
important	O
mechanisms	O
of	O
regulating	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
signaling	O
and	O
offer	O
new	O
insight	O
into	O
the	O
pathogenesis	O
and	O
treatment	O
of	O
some	O
human	O
diseases	O
such	O
as	O
cancers	O
.	O

FBP11	O
regulates	O
nuclear	O
localization	O
of	O
N	O
-	O
WASP	O
and	O
inhibits	O
N	O
-	O
WASP	O
-	O
dependent	O
microspike	O
formation	O
.	O

WASP	O
family	O
proteins	O
are	O
involved	O
in	O
cortical	O
actin	O
cytoskeleton	O
reorganization	O
.	O

Neural	O
Wiskott	O
-	O
Aldrich	O
syndrome	O
protein	O
(	O
N	O
-	O
WASP	O
)	O
,	O
a	O
ubiquitously	O
expressed	O
WASP	O
homologous	O
protein	O
,	O
directly	O
binds	O
with	O
Cdc42	O
,	O
activating	O
Arp2	B-Complex
/	I-Complex
3	I-Complex
complex	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
N	O
-	O
WASP	O
-	O
dependent	O
microspike	O
formation	O
is	O
inhibited	O
by	O
formin	O
binding	O
protein	O
11	O
(	O
FBP11	O
)	O
.	O

Endogenous	O
FBP11	O
localizes	O
with	O
nuclear	O
-	O
speckles	O
,	O
and	O
co	O
-	O
localization	O
of	O
N	O
-	O
WASP	O
and	O
FBP11	O
was	O
observed	O
when	O
they	O
were	O
co	O
-	O
expressed	O
.	O

Epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
induced	O
actin	O
-	O
microspike	O
formation	O
in	O
COS7	O
cells	O
.	O

However	O
,	O
transient	O
expression	O
of	O
FBP11	O
suppressed	O
N	O
-	O
WASP	O
-	O
dependent	O
actin	O
-	O
microspike	O
formation	O
by	O
trapping	O
N	O
-	O
WASP	O
in	O
the	O
nucleus	O
.	O

These	O
results	O
indicate	O
that	O
FBP11	O
regulates	O
localization	O
of	O
N	O
-	O
WASP	O
,	O
thus	O
negatively	O
regulating	O
the	O
function	O
of	O
N	O
-	O
WASP	O
in	O
the	O
cytoplasm	O
.	O

CHIP	O
mediates	O
degradation	O
of	O
Smad	O
proteins	O
and	O
potentially	O
regulates	O
Smad	O
-	O
induced	O
transcription	O
.	O

Transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
/	O
bone	O
morphogenetic	O
protein	O
(	O
BMP	O
)	O
family	O
ligands	O
interact	O
with	O
specific	O
membrane	O
receptor	O
complexes	O
that	O
have	O
serine	O
/	O
threonine	O
kinase	O
activities	O
.	O

The	O
receptor	O
phosphorylation	O
and	O
activation	O
induced	O
by	O
the	O
ligands	O
leads	O
to	O
phosphorylation	O
of	O
the	O
Smad	O
proteins	O
,	O
which	O
translocate	O
to	O
the	O
nucleus	O
,	O
controlling	O
gene	O
expression	O
.	O

Thus	O
,	O
regulation	O
of	O
Smad	O
proteins	O
is	O
a	O
key	O
step	O
in	O
TGF	O
-	O
beta	O
/	O
BMP	O
-	O
induced	O
signal	O
transduction	O
.	O

Here	O
we	O
report	O
a	O
novel	O
mechanism	O
of	O
the	O
regulation	O
of	O
SMAD	O
-	O
mediated	O
signaling	O
,	O
by	O
which	O
the	O
Smad1	O
protein	O
level	O
is	O
controlled	O
through	O
expression	O
of	O
the	O
CHIP	O
protein	O
.	O

CHIP	O
is	O
a	O
U	O
-	O
box	O
-	O
dependent	O
E3	O
ubiquitin	O
ligase	O
,	O
previously	O
identified	O
as	O
a	O
cochaperon	O
protein	O
.	O

However	O
,	O
we	O
have	O
isolated	O
CHIP	O
as	O
a	O
Smad	O
-	O
interacting	O
protein	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
using	O
Smad1	O
as	O
bait	O
.	O

Furthermore	O
we	O
have	O
shown	O
CHIP	O
-	O
Smad	O
interaction	O
using	O
the	O
(	O
35	O
)	O
S	O
-	O
labeled	O
CHIP	O
protein	O
,	O
which	O
can	O
interact	O
with	O
glutathione	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
-	O
Smad1	O
and	O
GST	O
-	O
Smad4	O
in	O
an	O
in	O
vitro	O
protein	O
-	O
binding	O
assay	O
.	O

The	O
CHIP	O
-	O
Smad	O
interaction	O
has	O
been	O
confirmed	O
in	O
vivo	O
in	O
mammalian	O
cells	O
through	O
coimmunoprecipitation	O
.	O

Interestingly	O
,	O
we	O
demonstrate	O
that	O
the	O
coexpression	O
of	O
Smad1	O
and	O
Smad4	O
with	O
the	O
CHIP	O
protein	O
results	O
in	O
the	O
degradation	O
of	O
the	O
Smad	O
proteins	O
through	O
a	O
ubiquitin	O
-	O
mediated	O
process	O
.	O

Consistent	O
with	O
the	O
observation	O
that	O
CHIP	O
induces	O
Smad1	O
degradation	O
,	O
we	O
further	O
show	O
that	O
the	O
expression	O
of	O
CHIP	O
can	O
inhibit	O
the	O
transcriptional	O
activities	O
of	O
the	O
Smad1	O
/	O
Smad4	O
complex	O
induced	O
by	O
BMP	O
signals	O
.	O

Intriguingly	O
,	O
pBS	O
/	O
U6	O
/	O
CHIPi	O
,	O
which	O
diminishes	O
CHIP	O
expression	O
,	O
significantly	O
enhanced	O
Smad1	O
/	O
Smad4	O
-	O
or	O
BMPRIB	O
(	O
QD	O
)	O
-	O
induced	O
gene	O
transcription	O
.	O

These	O
results	O
suggest	O
that	O
CHIP	O
can	O
interact	O
with	O
the	O
Smad1	O
/	O
Smad4	O
proteins	O
and	O
block	O
BMP	O
signal	O
transduction	O
through	O
the	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
Smad	O
proteins	O
.	O

Identification	O
of	O
Ser	O
-	O
386	O
of	O
interferon	O
regulatory	O
factor	O
3	O
as	O
critical	O
target	O
for	O
inducible	O
phosphorylation	O
that	O
determines	O
activation	O
.	O

Interferon	O
regulatory	O
factor	O
(	O
IRF	O
)	O
-	O
3	O
is	O
a	O
critical	O
transcription	O
factor	O
regulating	O
innate	O
immune	O
responses	O
against	O
viral	O
and	O
bacterial	O
infections	O
.	O

Signals	O
activated	O
by	O
various	O
pathogens	O
are	O
integrated	O
by	O
IRF	O
-	O
3	O
kinase	O
,	O
resulting	O
in	O
the	O
specific	O
phosphorylation	O
of	O
IRF	O
-	O
3	O
in	O
the	O
cytoplasm	O
.	O

This	O
phosphorylation	O
induces	O
dimerization	O
and	O
association	O
with	O
the	O
coactivators	O
CREB	O
-	O
binding	O
protein	O
/	O
p300	O
,	O
and	O
the	O
resultant	O
complex	O
activates	O
the	O
target	O
genes	O
in	O
the	O
nucleus	O
.	O

However	O
,	O
the	O
phosphorylation	O
sites	O
that	O
determine	O
the	O
active	O
/	O
inactive	O
status	O
of	O
IRF	O
-	O
3	O
have	O
been	O
a	O
source	O
of	O
controversy	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
an	O
antibody	O
that	O
specifically	O
detects	O
the	O
phosphorylation	O
of	O
Ser	O
-	O
386	O
and	O
used	O
it	O
as	O
a	O
probe	O
.	O

We	O
found	O
:	O
1	O
)	O
viral	O
infection	O
specifically	O
induces	O
phosphorylation	O
of	O
the	O
Ser	O
-	O
386	O
;	O
2	O
)	O
recently	O
identified	O
IRF	O
-	O
3	O
kinases	O
(	O
IKK	O
-	O
i	O
/	O
epsilon	O
and	O
TBK	O
-	O
1	O
)	O
phosphorylate	O
Ser	O
-	O
386	O
and	O
induce	O
its	O
dimerization	O
;	O
3	O
)	O
phosphorylation	O
of	O
Ser	O
-	O
386	O
is	O
exclusively	O
observed	O
with	O
the	O
dimer	O
;	O
4	O
)	O
mutation	O
at	O
Ser	O
-	O
386	O
abolishes	O
the	O
dimerization	O
potential	O
;	O
5	O
)	O
a	O
constitutively	O
active	O
5D	O
mutant	O
designed	O
to	O
mimic	O
phosphorylation	O
of	O
Ser	O
/	O
Thr	O
residues	O
other	O
than	O
Ser	O
-	O
385	O
and	O
-	O
386	O
is	O
secondarily	O
phosphorylated	O
at	O
Ser	O
-	O
386	O
,	O
presumably	O
by	O
an	O
irrelevant	O
kinase	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
Ser	O
-	O
386	O
is	O
the	O
target	O
of	O
the	O
IRF	O
-	O
3	O
kinase	O
and	O
critical	O
determinant	O
for	O
the	O
activation	O
of	O
IRF	O
-	O
3	O
.	O

Targeted	O
degradation	O
of	O
c	O
-	O
Fos	O
,	O
but	O
not	O
v	O
-	O
Fos	O
,	O
by	O
a	O
phosphorylation	O
-	O
dependent	O
signal	O
on	O
c	O
-	O
Jun	O
.	O

The	O
proto	O
-	O
oncogene	O
products	O
c	O
-	O
Fos	O
and	O
c	O
-	O
Jun	O
heterodimerize	O
through	O
their	O
leucine	O
zippers	O
to	O
form	O
the	O
AP	B-Complex
-	I-Complex
1	I-Complex
transcription	O
factor	O
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
heterodimer	O
is	O
regulated	O
by	O
signal	O
-	O
dependent	O
phosphorylation	O
and	O
dephosphorylation	O
events	O
.	O

The	O
stability	O
of	O
c	O
-	O
Fos	O
was	O
found	O
to	O
also	O
be	O
controlled	O
by	O
intracellular	O
signal	O
transduction	O
.	O

In	O
transient	O
expression	O
and	O
in	O
vitro	O
degradation	O
experiments	O
,	O
the	O
stability	O
of	O
c	O
-	O
Fos	O
was	O
decreased	O
when	O
the	O
protein	O
was	O
dimerized	O
with	O
phosphorylated	O
c	O
-	O
Jun	O
.	O

c	O
-	O
Jun	O
protein	O
isolated	O
from	O
phorbol	O
ester	O
-	O
induced	O
cells	O
did	O
not	O
target	O
c	O
-	O
Fos	O
for	O
degradation	O
,	O
which	O
suggests	O
that	O
c	O
-	O
Fos	O
is	O
transiently	O
stabilized	O
after	O
stimulation	O
of	O
cell	O
growth	O
.	O

v	O
-	O
Fos	O
protein	O
,	O
the	O
retroviral	O
counterpart	O
of	O
c	O
-	O
Fos	O
,	O
was	O
not	O
susceptible	O
to	O
degradation	O
targeted	O
by	O
c	O
-	O
Jun	O
.	O

Dendrite	O
development	O
regulated	O
by	O
CREST	O
,	O
a	O
calcium	O
-	O
regulated	O
transcriptional	O
activator	O
.	O

The	O
lasting	O
effects	O
of	O
neuronal	O
activity	O
on	O
brain	O
development	O
involve	O
calcium	O
-	O
dependent	O
gene	O
expression	O
.	O

Using	O
a	O
strategy	O
called	O
transactivator	O
trap	O
,	O
we	O
cloned	O
a	O
calcium	O
-	O
responsive	O
transactivator	O
called	O
CREST	O
(	O
for	O
calcium	O
-	O
responsive	O
transactivator	O
)	O
.	O

CREST	O
is	O
a	O
SYT	O
-	O
related	O
nuclear	O
protein	O
that	O
interacts	O
with	O
adenosine	O
3	O
'	O
,	O
5	O
'	O
-	O
monophosphate	O
(	O
cAMP	O
)	O
response	O
element	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
-	O
binding	O
protein	O
(	O
CBP	O
)	O
and	O
is	O
expressed	O
in	O
the	O
developing	O
brain	O
.	O

Mice	O
that	O
have	O
a	O
targeted	O
disruption	O
of	O
the	O
crest	O
gene	O
are	O
viable	O
but	O
display	O
defects	O
in	O
cortical	O
and	O
hippocampal	O
dendrite	O
development	O
.	O

Cortical	O
neurons	O
from	O
crest	O
mutant	O
mice	O
are	O
compromised	O
in	O
calcium	O
-	O
dependent	O
dendritic	O
growth	O
.	O

Thus	O
,	O
calcium	O
activation	O
of	O
CREST	O
-	O
mediated	O
transcription	O
helps	O
regulate	O
neuronal	O
morphogenesis	O
.	O

GADD34	O
-	O
PP1c	O
recruited	O
by	O
Smad7	O
dephosphorylates	O
TGFbeta	O
type	O
I	O
receptor	O
.	O

The	O
cascade	O
of	O
phosphorylation	O
is	O
a	O
pivotal	O
event	O
in	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGFbeta	O
)	O
signaling	O
.	O

Reversible	O
phosphorylation	O
regulates	O
fundamental	O
aspects	O
of	O
cell	O
activity	O
.	O

TGFbeta	O
-	O
induced	O
Smad7	O
binds	O
to	O
type	O
I	O
receptor	O
(	O
TGFbeta	O
type	O
I	O
receptor	O
;	O
TbetaRI	O
)	O
functioning	O
as	O
a	O
receptor	O
kinase	O
antagonist	O
.	O

We	O
found	O
Smad7	O
interacts	O
with	O
growth	O
arrest	O
and	O
DNA	O
damage	O
protein	O
,	O
GADD34	O
,	O
a	O
regulatory	O
subunit	O
of	O
the	O
protein	B-Complex
phosphatase	I-Complex
1	I-Complex
(	O
PP1	B-Complex
)	O
holoenzyme	O
,	O
which	O
subsequently	O
recruits	O
catalytic	O
subunit	O
of	O
PP1	B-Complex
(	O
PP1c	O
)	O
to	O
dephosphorylate	O
TbetaRI	O
.	O

Blocking	O
Smad7	O
expression	O
by	O
RNA	O
interference	O
inhibits	O
association	O
of	O
GADD34	O
-	O
PP1c	O
complex	O
with	O
TbetaRI	O
,	O
indicating	O
Smad7	O
acts	O
as	O
an	O
adaptor	O
protein	O
in	O
the	O
formation	O
of	O
the	O
PP1	B-Complex
holoenzyme	O
that	O
targets	O
TbetaRI	O
for	O
dephosphorylation	O
.	O

SARA	O
(	O
Smad	O
anchor	O
for	O
receptor	O
activation	O
)	O
enhances	O
the	O
recruitment	O
PP1c	O
to	O
the	O
Smad7	O
-	O
GADD34	O
complex	O
by	O
controlling	O
the	O
specific	O
subcellular	O
localization	O
of	O
PP1c	O
.	O

Importantly	O
,	O
GADD34	O
-	O
PP1c	O
recruited	O
by	O
Smad7	O
inhibits	O
TGFbeta	O
-	O
induced	O
cell	O
cycle	O
arrest	O
and	O
mediates	O
TGFbeta	O
resistance	O
in	O
responding	O
to	O
UV	O
light	O
irradiation	O
.	O

The	O
dephosphorylation	O
of	O
TbetaRI	O
mediated	O
by	O
Smad7	O
is	O
an	O
effective	O
mechanism	O
for	O
governing	O
negative	O
feedback	O
in	O
TGFbeta	O
signaling	O
.	O

Glycolysis	O
mutants	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Mutants	O
have	O
been	O
isolated	O
in	O
S	O
.	O
cerevisiae	O
with	O
the	O
phenotype	O
of	O
growth	O
on	O
pyruvate	O
but	O
not	O
on	O
glucose	O
,	O
or	O
growth	O
on	O
rich	O
medium	O
with	O
pyruvate	O
but	O
inhibition	O
by	O
glucose	O
.	O

Screening	O
of	O
mutagenized	O
cultures	O
was	O
either	O
without	O
an	O
enrichment	O
step	O
,	O
or	O
after	O
enrichment	O
using	O
the	O
antibiotic	O
netropsin	O
(	O
Young	O
et	O
al	O
.	O
1976	O
)	O
or	O
inositol	O
starvation	O
(	O
Henry	O
,	O
Donahue	O
and	O
Culbertson	O
1975	O
)	O
.	O

One	O
class	O
of	O
mutants	O
lacked	O
pyruvate	O
kinase	O
(	O
pyk	O
)	O
,	O
another	O
class	O
had	O
all	O
the	O
enzymes	O
of	O
glycolysis	O
,	O
and	O
one	O
mutant	O
lacked	O
phosphoglucose	O
isomerase	O
(	O
pgi	O
,	O
Maitra	O
1971	O
)	O
.	O

Partial	O
reversion	O
of	O
pyruvate	O
kinase	O
mutants	O
on	O
rich	O
medium	O
containing	O
glucose	O
gave	O
double	O
mutants	O
now	O
also	O
lacking	O
hexokinase	O
(	O
hxk	O
)	O
,	O
phosphofructokinase	O
(	O
fk	O
)	O
,	O
or	O
several	O
enzymes	O
of	O
glycolysis	O
(	O
gcr	O
)	O
.	O

In	O
diploids	O
the	O
mutations	O
were	O
recessive	O
.	O
pyk	O
,	O
pgi	O
,	O
pfk	O
,	O
and	O
gcr	O
segregated	O
2	O
:	O
2	O
from	O
their	O
wild	O
-	O
type	O
alleles	O
.	O

PYK	O
hxk	O
,	O
PYK	O
pfk	O
,	O
and	O
PYK	O
gcr	O
segregrants	O
grew	O
on	O
glucose	O
.	O

Rabphilin	O
and	O
Noc2	O
are	O
recruited	O
to	O
dense	O
-	O
core	O
vesicles	O
through	O
specific	O
interaction	O
with	O
Rab27A	O
in	O
PC12	O
cells	O
.	O

Rabphilin	O
and	O
Noc2	O
were	O
originally	O
described	O
as	O
Rab3A	O
effector	O
proteins	O
involved	O
in	O
the	O
regulation	O
of	O
secretory	O
vesicle	O
exocytosis	O
,	O
however	O
,	O
recently	O
both	O
proteins	O
have	O
been	O
shown	O
to	O
bind	O
Rab27A	O
in	O
vitro	O
in	O
preference	O
to	O
Rab3A	O
(	O
Fukuda	O
,	O
M	O
.	O
(	O
2003	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
278	O
,	O
15373	O
-	O
15380	O
)	O
,	O
suggesting	O
that	O
Rab3A	O
is	O
not	O
their	O
major	O
ligand	O
in	O
vivo	O
.	O

In	O
the	O
present	O
study	O
we	O
showed	O
by	O
means	O
of	O
deletion	O
and	O
mutation	O
analyses	O
that	O
rabphilin	O
and	O
Noc2	O
are	O
recruited	O
to	O
dense	O
-	O
core	O
vesicles	O
through	O
specific	O
interaction	O
with	O
Rab27A	O
,	O
not	O
with	O
Rab3A	O
,	O
in	O
PC12	O
cells	O
.	O

Rab3A	O
binding	O
-	O
defective	O
mutants	O
of	O
rabphilin	O
(	O
E50A	O
)	O
and	O
Noc2	O
(	O
E51A	O
)	O
were	O
still	O
localized	O
in	O
the	O
distal	O
portion	O
of	O
the	O
neurites	O
(	O
where	O
dense	O
-	O
core	O
vesicles	O
had	O
accumulated	O
)	O
in	O
nerve	O
growth	O
factor	O
-	O
differentiated	O
PC12	O
cells	O
,	O
the	O
same	O
as	O
the	O
wild	O
-	O
type	O
proteins	O
,	O
whereas	O
Rab27A	O
binding	O
-	O
defective	O
mutants	O
of	O
rabphilin	O
(	O
E50A	O
/	O
I54A	O
)	O
and	O
Noc2	O
(	O
E51A	O
/	O
I55A	O
)	O
were	O
present	O
throughout	O
the	O
cytosol	O
.	O

We	O
further	O
showed	O
that	O
expression	O
of	O
the	O
wild	O
-	O
type	O
or	O
the	O
E50A	O
mutant	O
of	O
rabphilin	O
-	O
RBD	O
,	O
but	O
not	O
the	O
E50A	O
/	O
I54A	O
mutant	O
of	O
rabphilin	O
-	O
RBD	O
,	O
significantly	O
inhibited	O
high	O
KCl	O
-	O
dependent	O
neuropeptide	O
Y	O
secretion	O
by	O
PC12	O
cells	O
.	O

We	O
also	O
found	O
that	O
rabphilin	O
and	O
its	O
binding	O
partner	O
,	O
Rab27	O
have	O
been	O
highly	O
conserved	O
during	O
evolution	O
(	O
from	O
nematoda	O
to	O
humans	O
)	O
and	O
that	O
Caenorhabditis	O
elegans	O
and	O
Drosophila	O
rabphilin	O
(	O
ce	O
/	O
dm	O
-	O
rabphilin	O
)	O
specifically	O
interact	O
with	O
ce	O
/	O
dm	O
-	O
Rab27	O
,	O
but	O
not	O
with	O
ce	O
/	O
dm	O
-	O
Rab3	O
or	O
ce	O
/	O
dm	O
-	O
Rab8	O
,	O
suggesting	O
that	O
rabphilin	O
functions	O
as	O
a	O
Rab27	O
effector	O
across	O
phylogeny	O
.	O

Based	O
on	O
these	O
findings	O
,	O
we	O
propose	O
that	O
the	O
N	O
-	O
terminal	O
Rab	O
binding	O
domain	O
of	O
rabphilin	O
and	O
Noc2	O
be	O
referred	O
to	O
as	O
"	O
RBD27	O
(	O
Rab	O
binding	O
domain	O
for	O
Rab27	O
)	O
"	O
,	O
the	O
same	O
as	O
the	O
synaptotagmin	O
-	O
like	O
protein	O
homology	O
domain	O
(	O
SHD	O
)	O
of	O
Slac2	O
-	O
a	O
/	O
melanophilin	O
.	O

Activating	O
transcription	O
factor	O
3	O
is	O
integral	O
to	O
the	O
eukaryotic	O
initiation	O
factor	O
2	O
kinase	O
stress	O
response	O
.	O

In	O
response	O
to	O
environmental	O
stress	O
,	O
cells	O
induce	O
a	O
program	O
of	O
gene	O
expression	O
designed	O
to	O
remedy	O
cellular	O
damage	O
or	O
,	O
alternatively	O
,	O
induce	O
apoptosis	O
.	O

In	O
this	O
report	O
,	O
we	O
explore	O
the	O
role	O
of	O
a	O
family	O
of	O
protein	O
kinases	O
that	O
phosphorylate	O
eukaryotic	O
initiation	O
factor	O
2	O
(	O
eIF2	O
)	O
in	O
coordinating	O
stress	O
gene	O
responses	O
.	O

We	O
find	O
that	O
expression	O
of	O
activating	O
transcription	O
factor	O
3	O
(	O
ATF3	O
)	O
,	O
a	O
member	O
of	O
the	O
ATF	O
/	O
CREB	O
subfamily	O
of	O
basic	O
-	O
region	O
leucine	O
zipper	O
(	O
bZIP	O
)	O
proteins	O
,	O
is	O
induced	O
in	O
response	O
to	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
or	O
amino	O
acid	O
starvation	O
by	O
a	O
mechanism	O
requiring	O
eIF2	O
kinases	O
PEK	O
(	O
Perk	O
or	O
EIF2AK3	O
)	O
and	O
GCN2	O
(	O
EIF2AK4	O
)	O
,	O
respectively	O
.	O

Increased	O
expression	O
of	O
ATF3	O
protein	O
occurs	O
early	O
in	O
response	O
to	O
stress	O
by	O
a	O
mechanism	O
requiring	O
the	O
related	O
bZIP	O
transcriptional	O
regulator	O
ATF4	O
.	O

ATF3	O
contributes	O
to	O
induction	O
of	O
the	O
CHOP	O
transcriptional	O
factor	O
in	O
response	O
to	O
amino	O
acid	O
starvation	O
,	O
and	O
loss	O
of	O
ATF3	O
function	O
significantly	O
lowers	O
stress	O
-	O
induced	O
expression	O
of	O
GADD34	O
,	O
an	O
eIF2	B-Complex
protein	I-Complex
phosphatase	I-Complex
regulatory	O
subunit	O
implicated	O
in	O
feedback	O
control	O
of	O
the	O
eIF2	O
kinase	O
stress	O
response	O
.	O

Overexpression	O
of	O
ATF3	O
in	O
mouse	O
embryo	O
fibroblasts	O
partially	O
bypasses	O
the	O
requirement	O
for	O
PEK	O
for	O
induction	O
of	O
GADD34	O
in	O
response	O
to	O
ER	O
stress	O
,	O
further	O
supporting	O
the	O
idea	O
that	O
ATF3	O
functions	O
directly	O
or	O
indirectly	O
as	O
a	O
transcriptional	O
activator	O
of	O
genes	O
targeted	O
by	O
the	O
eIF2	O
kinase	O
stress	O
pathway	O
.	O

These	O
results	O
indicate	O
that	O
ATF3	O
has	O
an	O
integral	O
role	O
in	O
the	O
coordinate	O
gene	O
expression	O
induced	O
by	O
eIF2	O
kinases	O
.	O

Given	O
that	O
ATF3	O
is	O
induced	O
by	O
a	O
very	O
large	O
number	O
of	O
environmental	O
insults	O
,	O
this	O
study	O
supports	O
involvement	O
of	O
eIF2	O
kinases	O
in	O
the	O
coordination	O
of	O
gene	O
expression	O
in	O
response	O
to	O
a	O
more	O
diverse	O
set	O
of	O
stress	O
conditions	O
than	O
previously	O
proposed	O
.	O

The	O
conserved	O
kinetochore	O
protein	O
shugoshin	O
protects	O
centromeric	O
cohesion	O
during	O
meiosis	O
.	O

Meiosis	O
comprises	O
a	O
pair	O
of	O
specialized	O
nuclear	O
divisions	O
that	O
produce	O
haploid	O
germ	O
cells	O
.	O

To	O
accomplish	O
this	O
,	O
sister	O
chromatids	O
must	O
segregate	O
together	O
during	O
the	O
first	O
meiotic	O
division	O
(	O
meiosis	O
I	O
)	O
,	O
which	O
requires	O
that	O
sister	O
chromatid	O
cohesion	O
persists	O
at	O
centromeres	O
.	O

The	O
factors	O
that	O
protect	O
centromeric	O
cohesion	O
during	O
meiosis	O
I	O
have	O
remained	O
elusive	O
.	O

Here	O
we	O
identify	O
Sgo1	O
(	O
shugoshin	O
)	O
,	O
a	O
protector	O
of	O
the	O
centromeric	O
cohesin	O
Rec8	O
in	O
fission	O
yeast	O
.	O

We	O
also	O
identify	O
a	O
homologue	O
of	O
Sgo1	O
in	O
budding	O
yeast	O
.	O

We	O
provide	O
evidence	O
that	O
shugoshin	O
is	O
widely	O
conserved	O
among	O
eukaryotes	O
.	O

Moreover	O
,	O
we	O
identify	O
Sgo2	O
,	O
a	O
paralogue	O
of	O
shugoshin	O
in	O
fission	O
yeast	O
,	O
which	O
is	O
required	O
for	O
faithful	O
mitotic	O
chromosome	O
segregation	O
.	O

Localization	O
of	O
Sgo1	O
and	O
Sgo2	O
at	O
centromeres	O
requires	O
the	O
kinase	O
Bub1	O
,	O
identifying	O
shugoshin	O
as	O
a	O
crucial	O
target	O
for	O
the	O
kinetochore	O
function	O
of	O
Bub1	O
.	O

These	O
findings	O
provide	O
insights	O
into	O
the	O
evolution	O
of	O
meiosis	O
and	O
kinetochore	O
regulation	O
during	O
mitosis	O
and	O
meiosis	O
.	O

I	O
kappa	O
B	O
/	O
MAD	O
-	O
3	O
masks	O
the	O
nuclear	O
localization	O
signal	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p65	O
and	O
requires	O
the	O
transactivation	O
domain	O
to	O
inhibit	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p65	O
DNA	O
binding	O
.	O

The	O
active	O
nuclear	O
form	O
of	O
the	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
transcription	O
factor	O
complex	O
is	O
composed	O
of	O
two	O
DNA	O
binding	O
subunits	O
,	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p65	O
and	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p50	O
,	O
both	O
of	O
which	O
share	O
extensive	O
N	O
-	O
terminal	O
sequence	O
homology	O
with	O
the	O
v	O
-	O
rel	O
oncogene	O
product	O
.	O

The	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p65	O
subunit	O
provides	O
the	O
transactivation	O
activity	O
in	O
this	O
complex	O
and	O
serves	O
as	O
an	O
intracellular	O
receptor	O
for	O
a	O
cytoplasmic	O
inhibitor	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
,	O
termed	O
I	O
kappa	O
B	O
.	O

In	O
contrast	O
,	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p50	O
alone	O
fails	O
to	O
stimulate	O
kappa	B-Complex
B	I-Complex
-	O
directed	O
transcription	O
,	O
and	O
based	O
on	O
prior	O
in	O
vitro	O
studies	O
,	O
is	O
not	O
directly	O
regulated	O
by	O
I	O
kappa	O
B	O
.	O

To	O
investigate	O
the	O
molecular	O
basis	O
for	O
the	O
critical	O
regulatory	O
interaction	O
between	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
and	O
I	O
kappa	O
B	O
/	O
MAD	O
-	O
3	O
,	O
a	O
series	O
of	O
human	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p65	O
mutants	O
was	O
identified	O
that	O
functionally	O
segregated	O
DNA	O
binding	O
,	O
I	O
kappa	O
B	O
-	O
mediated	O
inhibition	O
,	O
and	O
I	O
kappa	O
B	O
-	O
induced	O
nuclear	O
exclusion	O
of	O
this	O
transcription	O
factor	O
.	O

Results	O
from	O
in	O
vivo	O
expression	O
studies	O
performed	O
with	O
these	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p65	O
mutants	O
revealed	O
the	O
following	O
:	O
1	O
)	O
I	O
kappa	O
B	O
/	O
MAD	O
-	O
3	O
completely	O
inhibits	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p65	O
-	O
dependent	O
transcriptional	O
activation	O
mediated	O
through	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
kappa	B-Complex
B	I-Complex
enhancer	O
in	O
human	O
T	O
lymphocytes	O
,	O
2	O
)	O
the	O
binding	O
of	O
I	O
kappa	O
B	O
/	O
MAD	O
-	O
3	O
to	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p65	O
is	O
sufficient	O
to	O
retarget	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p65	O
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
,	O
3	O
)	O
selective	O
deletion	O
of	O
the	O
functional	O
nuclear	O
localization	O
signal	O
present	O
in	O
the	O
Rel	O
homology	O
domain	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p65	O
disrupts	O
its	O
ability	O
to	O
engage	O
I	O
kappa	O
B	O
/	O
MAD	O
-	O
3	O
,	O
and	O
4	O
)	O
the	O
unique	O
C	O
-	O
terminus	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p65	O
attenuates	O
its	O
own	O
nuclear	O
localization	O
and	O
contains	O
sequences	O
that	O
are	O
required	O
for	O
I	O
kappa	O
B	O
-	O
mediated	O
inhibition	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p65	O
DNA	O
binding	O
activity	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
nuclear	O
localization	O
signal	O
and	O
transactivation	O
domain	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p65	O
constitute	O
a	O
bipartite	O
system	O
that	O
is	O
critically	O
involved	O
in	O
the	O
inhibitory	O
function	O
of	O
I	O
kappa	O
B	O
/	O
MAD	O
-	O
3	O
.	O

Unexpectedly	O
,	O
our	O
in	O
vivo	O
studies	O
also	O
demonstrate	O
that	O
I	O
kappa	O
B	O
/	O
MAD	O
-	O
3	O
binds	O
directly	O
to	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p50	O
.	O

This	O
interaction	O
is	O
functional	O
as	O
it	O
leads	O
to	O
retargeting	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p50	O
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

However	O
,	O
no	O
loss	O
of	O
DNA	O
binding	O
activity	O
is	O
observed	O
,	O
presumably	O
reflecting	O
the	O
unique	O
C	O
-	O
terminal	O
domain	O
that	O
is	O
distinct	O
from	O
that	O
present	O
in	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p65	O
.	O

Steroid	O
21	O
-	O
hydroxylase	O
deficiency	O
:	O
three	O
additional	O
mutated	O
alleles	O
and	O
establishment	O
of	O
phenotype	O
-	O
genotype	O
relationships	O
of	O
common	O
mutations	O
.	O

Lesions	O
in	O
the	O
gene	O
encoding	O
steroid	O
21	O
-	O
hydroxylase	O
[	O
steroid	O
hydrogen	O
-	O
donor	O
:	O
oxygen	O
oxidoreductase	O
(	O
21	O
-	O
hydroxylating	O
)	O
,	O
EC	O
1	O
.	O
14	O
.	O
99	O
.	O
10	O
]	O
result	O
in	O
defective	O
adrenal	O
steroid	O
synthesis	O
;	O
the	O
severe	O
forms	O
are	O
known	O
as	O
congenital	O
adrenal	O
hyperplasia	O
.	O

To	O
facilitate	O
complete	O
characterization	O
of	O
mutations	O
in	O
this	O
region	O
of	O
tandemly	O
repeated	O
genes	O
,	O
we	O
have	O
developed	O
selective	O
PCR	O
amplification	O
and	O
direct	O
sequencing	O
of	O
full	O
-	O
length	O
nonpseudogene	O
steroid	O
21	O
-	O
hydroxylase	O
genes	O
.	O

This	O
technique	O
identifies	O
known	O
mutations	O
,	O
characterizes	O
or	O
excludes	O
unknown	O
mutations	O
,	O
and	O
determines	O
the	O
gene	O
-	O
copy	O
number	O
.	O

Three	O
additional	O
defective	O
alleles	O
were	O
found	O
.	O

A	O
Gly	O
-	O
292	O
-	O
-	O
-	O
-	O
Ser	O
mutation	O
and	O
a	O
frameshift	O
mutation	O
at	O
Arg	O
-	O
484	O
(	O
GG	O
-	O
-	O
-	O
-	O
C	O
)	O
were	O
identified	O
in	O
patients	O
with	O
severe	O
steroid	O
21	O
-	O
hydroxylase	O
deficiency	O
.	O

An	O
allele	O
with	O
three	O
additional	O
sequence	O
variations	O
-	O
-	O
C	O
-	O
-	O
-	O
-	O
T	O
at	O
4	O
bases	O
upstream	O
of	O
translation	O
initiation	O
,	O
Pro	O
-	O
106	O
-	O
-	O
-	O
-	O
Leu	O
,	O
and	O
Pro	O
-	O
454	O
-	O
-	O
-	O
-	O
Ser	O
-	O
-	O
were	O
identified	O
in	O
two	O
siblings	O
with	O
late	O
-	O
onset	O
deficiency	O
.	O

Pro	O
-	O
454	O
is	O
conserved	O
in	O
four	O
species	O
,	O
indicating	O
its	O
importance	O
for	O
normal	O
enzyme	O
function	O
.	O

Functional	O
consequences	O
of	O
individual	O
alleles	O
have	O
been	O
determined	O
in	O
vivo	O
by	O
studying	O
individuals	O
with	O
only	O
one	O
steroid	O
21	O
-	O
hydroxylase	O
gene	O
.	O

Detailed	O
analyses	O
of	O
clinical	O
data	O
revealed	O
that	O
genotyping	O
could	O
predict	O
the	O
clinical	O
course	O
of	O
the	O
disease	O
.	O

The	O
locations	O
of	O
disease	O
-	O
causing	O
mutations	O
on	O
different	O
haplotypes	O
of	O
the	O
steroid	O
21	O
-	O
hydroxylase	O
gene	O
region	O
are	O
described	O
.	O

The	O
deubiquitinating	O
enzyme	O
Doa4p	O
protects	O
cells	O
from	O
DNA	O
topoisomerase	O
I	O
poisons	O
.	O

DNA	O
topoisomerase	O
I	O
(	O
Top1p	O
)	O
catalyzes	O
changes	O
in	O
DNA	O
topology	O
via	O
the	O
formation	O
of	O
an	O
enzyme	O
-	O
DNA	O
covalent	O
complex	O
that	O
is	O
reversibly	O
stabilized	O
by	O
the	O
antitumor	O
drug	O
,	O
camptothecin	O
(	O
CPT	O
)	O
.	O

During	O
S	O
-	O
phase	O
,	O
collisions	O
with	O
replication	O
forks	O
convert	O
these	O
complexes	O
into	O
cytotoxic	O
DNA	O
lesions	O
that	O
trigger	O
cell	O
cycle	O
arrest	O
and	O
cell	O
death	O
.	O

To	O
investigate	O
cellular	O
responses	O
to	O
CPT	O
-	O
induced	O
DNA	O
damage	O
,	O
a	O
yeast	O
genetic	O
screen	O
identified	O
conditional	O
tah	O
mutants	O
with	O
enhanced	O
sensitivity	O
to	O
self	O
-	O
poisoning	O
DNA	O
topoisomerase	O
I	O
mutant	O
(	O
Top1T722Ap	O
)	O
,	O
which	O
mimics	O
the	O
action	O
of	O
CPT	O
.	O

Mutant	O
alleles	O
of	O
three	O
genes	O
,	O
DOA4	O
,	O
SLA1	O
and	O
SLA2	O
,	O
were	O
recovered	O
.	O

A	O
nonsense	O
mutation	O
in	O
DOA4	O
eliminated	O
the	O
catalytic	O
residues	O
of	O
the	O
Doa4p	O
deubiquitinating	O
enzyme	O
,	O
yet	O
retained	O
the	O
rhodanase	O
domain	O
.	O

At	O
36	O
degrees	O
C	O
,	O
this	O
doa4	O
-	O
10	O
mutant	O
exhibited	O
increased	O
sensitivity	O
to	O
CPT	O
,	O
osmotic	O
stress	O
,	O
and	O
hydroxyurea	O
,	O
and	O
a	O
reversible	O
petite	O
phenotype	O
.	O

However	O
,	O
the	O
accumulation	O
of	O
pre	O
-	O
vacuolar	O
class	O
E	O
vesicles	O
that	O
was	O
observed	O
in	O
doa4Delta	O
cells	O
was	O
not	O
detected	O
in	O
the	O
doa4	O
-	O
10	O
mutant	O
.	O

Mutations	O
in	O
SLA1	O
or	O
SLA2	O
,	O
which	O
alter	O
actin	O
cytoskeleton	O
architecture	O
,	O
induced	O
a	O
conditional	O
synthetic	O
lethal	O
phenotype	O
in	O
combination	O
with	O
doa4	O
-	O
10	O
in	O
the	O
absence	O
of	O
DNA	O
damage	O
.	O

Here	O
actin	O
cytoskeleton	O
defects	O
coincided	O
with	O
the	O
enhanced	O
fragility	O
of	O
large	O
-	O
budded	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
enhanced	O
sensitivity	O
of	O
doa4	O
-	O
10	O
mutant	O
cells	O
to	O
Top1T722Ap	O
was	O
unrelated	O
to	O
alterations	O
in	O
endocytosis	O
and	O
was	O
selectively	O
suppressed	O
by	O
increased	O
dosage	O
of	O
the	O
ribonucleotide	O
reductase	O
inhibitor	O
Sml1p	O
.	O

Additional	O
studies	O
suggest	O
a	O
role	O
for	O
Doa4p	O
in	O
the	O
Rad9p	O
checkpoint	O
response	O
to	O
Top1p	O
poisons	O
.	O

These	O
findings	O
indicate	O
a	O
functional	O
link	O
between	O
ubiquitin	O
-	O
mediated	O
proteolysis	O
and	O
cellular	O
resistance	O
to	O
CPT	O
-	O
induced	O
DNA	O
damage	O
.	O

DEF6	O
,	O
a	O
novel	O
PH	O
-	O
DH	O
-	O
like	O
domain	O
protein	O
,	O
is	O
an	O
upstream	O
activator	O
of	O
the	O
Rho	O
GTPases	O
Rac1	O
,	O
Cdc42	O
,	O
and	O
RhoA	O
.	O

In	O
this	O
paper	O
,	O
we	O
describe	O
the	O
characterization	O
of	O
DEF6	O
,	O
a	O
novel	O
PH	O
-	O
DH	O
-	O
like	O
protein	O
related	O
to	O
SWAP	O
-	O
70	O
that	O
functions	O
as	O
an	O
upstream	O
activator	O
of	O
Rho	O
GTPases	O
.	O

In	O
NIH	O
3T3	O
cells	O
,	O
stimulation	O
of	O
the	O
PI	O
3	O
-	O
kinase	O
signaling	O
pathway	O
with	O
either	O
H2O2	O
or	O
platelet	O
-	O
derived	O
growth	O
factor	O
(	O
PDGF	O
)	O
resulted	O
in	O
the	O
translocation	O
of	O
an	O
overexpressed	O
DEF6	O
-	O
GFP	O
fusion	O
protein	O
to	O
the	O
cell	O
membrane	O
and	O
induced	O
the	O
formation	O
of	O
filopodia	O
and	O
lamellipodia	O
.	O

In	O
contrast	O
to	O
full	O
-	O
length	O
DEF6	O
,	O
expression	O
of	O
the	O
DH	O
-	O
like	O
(	O
DHL	O
)	O
domain	O
as	O
a	O
GFP	O
fusion	O
protein	O
potently	O
induced	O
actin	O
polymerization	O
,	O
including	O
stress	O
fiber	O
formation	O
in	O
COS	O
-	O
7	O
cells	O
,	O
in	O
the	O
absence	O
of	O
PI	O
3	O
-	O
kinase	O
signaling	O
,	O
indicating	O
that	O
it	O
was	O
constitutively	O
active	O
.	O

The	O
GTP	O
-	O
loading	O
of	O
Cdc42	O
was	O
strongly	O
enhanced	O
in	O
NIH	O
3T3	O
cells	O
expressing	O
the	O
DH	O
domain	O
while	O
filopodia	O
formation	O
,	O
membrane	O
ruffling	O
,	O
and	O
stress	O
fiber	O
formation	O
could	O
be	O
inhibited	O
by	O
the	O
co	O
-	O
expression	O
of	O
the	O
DH	O
domain	O
with	O
dominant	O
negative	O
mutants	O
of	O
either	O
N17Rac1	O
,	O
N17Cdc42	O
,	O
or	O
N19RhoA	O
,	O
respectively	O
.	O

This	O
indicated	O
that	O
DEF6	O
acts	O
upstream	O
of	O
the	O
Rho	O
GTPases	O
resulting	O
in	O
the	O
activation	O
of	O
the	O
Cdc42	O
,	O
Rac1	O
,	O
and	O
RhoA	O
signaling	O
pathways	O
.	O

In	O
vitro	O
,	O
DEF6	O
specifically	O
interacted	O
with	O
Rac1	O
,	O
Rac2	O
,	O
Cdc42	O
,	O
and	O
RhoA	O
,	O
suggesting	O
a	O
direct	O
role	O
for	O
DEF6	O
in	O
the	O
activation	O
of	O
Rho	O
GTPases	O
.	O

The	O
ability	O
of	O
DEF6	O
to	O
both	O
stimulate	O
actin	O
polymerization	O
and	O
bind	O
to	O
filamentous	O
actin	O
suggests	O
a	O
role	O
for	O
DEF6	O
in	O
regulating	O
cell	O
shape	O
,	O
polarity	O
,	O
and	O
movement	O
.	O

A	O
dominant	O
-	O
negative	O
isoform	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
alpha	O
specifically	O
expressed	O
in	O
human	O
testis	O
.	O

Spermatogenesis	O
in	O
the	O
seminiferous	O
tubuli	O
of	O
the	O
testis	O
occurs	O
under	O
a	O
high	O
proliferation	O
rate	O
,	O
suggesting	O
considerable	O
oxygen	O
consumption	O
.	O

Because	O
of	O
the	O
lack	O
of	O
blood	O
vessels	O
,	O
the	O
oxygen	O
partial	O
pressure	O
in	O
the	O
lumen	O
of	O
these	O
tubuli	O
is	O
very	O
low	O
.	O

We	O
previously	O
identified	O
a	O
testis	O
isoform	O
of	O
the	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
-	O
1alpha	O
in	O
the	O
mouse	O
,	O
termed	O
mHIF	O
-	O
1alphaI	O
.	O
1	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
expression	O
of	O
mHIF	O
-	O
1alphaI	O
.	O
1	O
increases	O
during	O
puberty	O
,	O
further	O
demonstrating	O
its	O
gene	O
induction	O
in	O
postmeiotic	O
germ	O
cells	O
.	O

Using	O
5	O
'	O
-	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
,	O
we	O
identified	O
a	O
novel	O
HIF	O
-	O
1alpha	O
isoform	O
in	O
the	O
human	O
testis	O
,	O
called	O
hHIF	O
-	O
1alphaTe	O
.	O

Like	O
mHIF	O
-	O
1alphaI	O
.	O
1	O
,	O
hHIF	O
-	O
1alphaTe	O
mRNA	O
is	O
derived	O
from	O
an	O
alternative	O
promoter	O
-	O
first	O
exon	O
combination	O
,	O
but	O
with	O
a	O
different	O
genomic	O
organization	O
and	O
a	O
different	O
nucleotide	O
sequence	O
.	O

Reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
analysis	O
confirmed	O
that	O
hHIF	O
-	O
1alphaTe	O
is	O
exclusively	O
expressed	O
in	O
the	O
testis	O
.	O

As	O
determined	O
by	O
immunofluorescence	O
of	O
ejaculated	O
sperm	O
cells	O
,	O
HIF	O
-	O
1alpha	O
protein	O
is	O
mainly	O
localized	O
in	O
the	O
postacrosomal	O
head	O
and	O
in	O
the	O
midpiece	O
of	O
spermatozoa	O
.	O

Though	O
overlapping	O
with	O
mitochondrial	O
localization	O
in	O
human	O
and	O
mouse	O
spermatozoa	O
,	O
neither	O
hHIF	O
-	O
1alphaTe	O
nor	O
hHIF	O
-	O
1alpha	O
associated	O
with	O
mitochondria	O
.	O

In	O
contrast	O
with	O
the	O
ubiquitously	O
expressed	O
HIF	O
-	O
1alpha	O
protein	O
and	O
the	O
mouse	O
testis	O
-	O
specific	O
mHIF	O
-	O
1alphaI	O
.	O
1	O
isoform	O
,	O
the	O
hHIF	O
-	O
1alphaTe	O
mRNA	O
sequence	O
predicts	O
a	O
protein	O
with	O
an	O
N	O
-	O
terminal	O
truncation	O
of	O
the	O
DNA	O
-	O
binding	O
domain	O
.	O

As	O
shown	O
by	O
yeast	O
two	O
-	O
hybrid	O
assays	O
,	O
hHIF	O
-	O
1alphaTe	O
still	O
formed	O
heterodimeric	O
complexes	O
with	O
HIF	O
-	O
1beta	O
.	O

However	O
,	O
hHIF	O
-	O
1alphaTe	O
was	O
incapable	O
of	O
forming	O
a	O
DNA	O
-	O
binding	O
HIF	O
-	O
1	O
complex	O
.	O

Overexpression	O
of	O
exogenous	O
hHIF	O
-	O
1alphaTe	O
resulted	O
in	O
the	O
inhibition	O
of	O
the	O
endogenous	O
HIF	O
-	O
1	O
transcriptional	O
activity	O
,	O
demonstrating	O
that	O
the	O
testis	O
-	O
specific	O
hHIF	O
-	O
1alphaTe	O
isoform	O
is	O
a	O
dominant	O
-	O
negative	O
regulator	O
of	O
normal	O
HIF	O
-	O
1	O
activity	O
.	O

CCAAT	O
/	O
enhancer	O
-	O
binding	O
protein	O
beta	O
(	O
nuclear	O
factor	O
for	O
interleukin	O
6	O
)	O
transactivates	O
the	O
human	O
MDR1	O
gene	O
by	O
interaction	O
with	O
an	O
inverted	O
CCAAT	O
box	O
in	O
human	O
cancer	O
cells	O
.	O

We	O
investigated	O
the	O
mechanisms	O
of	O
MDR1	O
gene	O
activation	O
by	O
CCAAT	O
/	O
enhancer	O
binding	O
protein	O
beta	O
(	O
C	O
/	O
EBPbeta	O
,	O
or	O
nuclear	O
factor	O
for	O
interleukin	O
6	O
)	O
in	O
human	O
cancer	O
cells	O
.	O

Transfection	O
of	O
the	O
breast	O
cancer	O
cell	O
line	O
MCF	O
-	O
7	O
and	O
its	O
doxorubicin	O
-	O
selected	O
variant	O
MCF	O
-	O
7	O
/	O
ADR	O
by	O
either	O
C	O
/	O
EBPbeta	O
or	O
C	O
/	O
EBPbeta	O
-	O
LIP	O
(	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
C	O
/	O
EBPbeta	O
)	O
confirmed	O
their	O
roles	O
in	O
the	O
activation	O
or	O
repression	O
of	O
the	O
endogenous	O
,	O
chromosomally	O
embedded	O
MDR1	O
gene	O
.	O

Cotransfection	O
experiments	O
with	O
promoter	O
constructs	O
revealed	O
a	O
C	O
/	O
EBPbeta	O
interaction	O
on	O
the	O
MDR1	O
promoter	O
via	O
the	O
region	O
within	O
-	O
128	O
to	O
-	O
75	O
.	O

Deletions	O
within	O
the	O
putative	O
AP	B-Complex
-	I-Complex
1	I-Complex
box	O
(	O
-	O
123	O
to	O
-	O
111	O
)	O
increased	O
MDR1	O
promoter	O
activity	O
when	O
stimulated	O
by	O
C	O
/	O
EBPbeta	O
,	O
suggesting	O
that	O
the	O
AP	B-Complex
-	I-Complex
1	I-Complex
site	O
negatively	O
regulates	O
MDR1	O
activation	O
by	O
C	O
/	O
EBPbeta	O
.	O

Mutations	O
within	O
the	O
inverted	O
CCAAT	O
box	O
(	O
Y	O
box	O
)	O
(	O
-	O
82	O
to	O
-	O
73	O
)	O
abolished	O
the	O
C	O
/	O
EBPbeta	O
-	O
stimulated	O
MDR1	O
promoter	O
activity	O
,	O
indicating	O
that	O
the	O
Y	O
box	O
is	O
required	O
for	O
MDR1	O
activation	O
by	O
C	O
/	O
EBPbeta	O
.	O

Chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
revealed	O
that	O
C	O
/	O
EBPbeta	O
precipitates	O
a	O
transcription	O
complex	O
containing	O
C	O
/	O
EBPbeta	O
,	O
the	O
MDR1	O
promoter	O
sequences	O
(	O
-	O
250	O
to	O
+	O
54	O
)	O
,	O
and	O
the	O
hBrm	O
protein	O
.	O

In	O
conclusion	O
,	O
alteration	O
of	O
expression	O
or	O
function	O
of	O
C	O
/	O
EBPbeta	O
plays	O
an	O
important	O
role	O
in	O
MDR1	O
gene	O
regulation	O
.	O

C	O
/	O
EBPbeta	O
activates	O
the	O
endogenous	O
MDR1	O
gene	O
of	O
MCF	O
-	O
7	O
cells	O
,	O
and	O
this	O
activation	O
was	O
associated	O
with	O
a	O
novel	O
C	O
/	O
EBPbeta	O
interaction	O
region	O
within	O
the	O
proximal	O
MDR1	O
promoter	O
(	O
-	O
128	O
to	O
-	O
75	O
)	O
.	O

The	O
mechanisms	O
of	O
MDR1	O
activation	O
by	O
C	O
/	O
EBPbeta	O
include	O
C	O
/	O
EBPbeta	O
binding	O
of	O
the	O
chromatin	O
of	O
the	O
MDR1	O
gene	O
and	O
interactions	O
of	O
C	O
/	O
EBPbeta	O
with	O
the	O
Y	O
box	O
and	O
Y	O
box	O
-	O
associated	O
proteins	O
.	O

pVHL	O
modification	O
by	O
NEDD8	O
is	O
required	O
for	O
fibronectin	O
matrix	O
assembly	O
and	O
suppression	O
of	O
tumor	O
development	O
.	O

Functional	O
inactivation	O
of	O
the	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
tumor	O
suppressor	O
gene	O
is	O
the	O
cause	O
of	O
the	O
familial	O
VHL	O
disease	O
and	O
most	O
sporadic	O
renal	O
clear	O
-	O
cell	O
carcinomas	O
(	O
RCC	O
)	O
.	O

pVHL	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
the	O
destruction	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
alpha	O
(	O
HIF	O
-	O
alpha	O
)	O
subunits	O
via	O
ubiquitin	O
-	O
mediated	O
proteolysis	O
and	O
in	O
the	O
regulation	O
of	O
fibronectin	O
matrix	O
assembly	O
.	O

Although	O
most	O
disease	O
-	O
causing	O
pVHL	O
mutations	O
hinder	O
the	O
regulation	O
of	O
the	O
HIF	O
pathway	O
,	O
every	O
disease	O
-	O
causing	O
pVHL	O
mutant	O
tested	O
to	O
date	O
has	O
failed	O
to	O
promote	O
the	O
assembly	O
of	O
the	O
fibronectin	O
matrix	O
,	O
underscoring	O
its	O
potential	O
importance	O
in	O
VHL	O
disease	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
ubiquitin	O
-	O
like	O
molecule	O
called	O
NEDD8	O
covalently	O
modifies	O
pVHL	O
.	O

A	O
nonneddylateable	O
pVHL	O
mutant	O
,	O
while	O
retaining	O
its	O
ability	O
to	O
ubiquitylate	O
HIF	O
,	O
failed	O
to	O
bind	O
to	O
and	O
promote	O
the	O
assembly	O
of	O
the	O
fibronectin	O
matrix	O
.	O

Expression	O
of	O
the	O
neddylation	O
-	O
defective	O
pVHL	O
in	O
RCC	O
cells	O
,	O
while	O
restoring	O
the	O
regulation	O
of	O
HIF	O
,	O
failed	O
to	O
promote	O
the	O
differentiated	O
morphology	O
in	O
a	O
three	O
-	O
dimensional	O
growth	O
assay	O
and	O
was	O
insufficient	O
to	O
suppress	O
the	O
formation	O
of	O
tumors	O
in	O
SCID	O
mice	O
.	O

These	O
results	O
suggest	O
that	O
NEDD8	O
modification	O
of	O
pVHL	O
plays	O
an	O
important	O
role	O
in	O
fibronectin	O
matrix	O
assembly	O
and	O
that	O
in	O
the	O
absence	O
of	O
such	O
regulation	O
,	O
an	O
intact	O
HIF	O
pathway	O
is	O
insufficient	O
to	O
prevent	O
VHL	O
-	O
associated	O
tumorigenesis	O
.	O

Tuberous	O
sclerosis	O
complex	O
2	O
gene	O
product	O
interacts	O
with	O
human	O
SMAD	O
proteins	O
.	O

A	O
molecular	O
link	O
of	O
two	O
tumor	O
suppressor	O
pathways	O
.	O

Tuberin	O
(	O
TSC2	O
)	O
is	O
a	O
tumor	O
suppressor	O
gene	O
.	O

At	O
the	O
cellular	O
level	O
,	O
tuberin	O
is	O
required	O
as	O
a	O
critical	O
regulator	O
of	O
cell	O
growth	O
,	O
neuronal	O
differentiation	O
,	O
and	O
tumor	O
suppression	O
.	O

Here	O
we	O
report	O
a	O
critical	O
role	O
for	O
tuberin	O
in	O
late	O
stage	O
myeloid	O
cell	O
differentiation	O
.	O

Tuberin	O
strongly	O
augments	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
beta1	O
signal	O
transduction	O
pathways	O
,	O
including	O
SMAD	O
activation	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
tuberin	O
interacts	O
specifically	O
with	O
the	O
MH2	O
domain	O
of	O
SMAD2	O
and	O
SMAD3	O
proteins	O
to	O
regulate	O
TGF	O
-	O
beta1	O
-	O
responsive	O
genes	O
such	O
as	O
p21	O
(	O
CIP	O
)	O
.	O

Inhibition	O
of	O
tuberin	O
expression	O
by	O
Tsc2	O
antisense	O
greatly	O
reduces	O
the	O
ability	O
of	O
TGF	O
-	O
beta	O
to	O
transcriptionally	O
regulate	O
p21	O
(	O
CIP	O
)	O
,	O
p27	O
(	O
KIP	O
)	O
,	O
and	O
cyclin	O
A	O
leading	O
to	O
an	O
abrogation	O
of	O
the	O
antiproliferative	O
effects	O
of	O
TGF	O
-	O
beta1	O
.	O

Also	O
,	O
inhibition	O
of	O
tuberin	O
expression	O
during	O
stimulation	O
of	O
monocytic	O
differentiation	O
with	O
vitamin	O
D	O
(	O
3	O
)	O
and	O
TGF	O
-	O
beta1	O
significantly	O
impaired	O
myeloid	O
cell	O
growth	O
inhibition	O
and	O
differentiation	O
.	O

Together	O
,	O
the	O
data	O
demonstrate	O
the	O
presence	O
of	O
a	O
novel	O
activation	O
process	O
following	O
TGF	O
-	O
beta1	O
stimulation	O
that	O
requires	O
tuberin	O
-	O
dependent	O
activity	O
.	O

Functional	O
variants	O
of	O
OCTN	O
cation	O
transporter	O
genes	O
are	O
associated	O
with	O
Crohn	O
disease	O
.	O

Crohn	O
disease	O
is	O
a	O
chronic	O
,	O
inflammatory	O
disease	O
of	O
the	O
gastrointestinal	O
tract	O
.	O

A	O
locus	O
of	O
approximately	O
250	O
kb	O
at	O
5q31	O
(	O
IBD5	O
)	O
was	O
previously	O
associated	O
with	O
susceptibility	O
to	O
Crohn	O
disease	O
,	O
as	O
indicated	O
by	O
increased	O
prevalence	O
of	O
a	O
risk	O
haplotype	O
of	O
11	O
single	O
-	O
nucleotide	O
polymorphisms	O
among	O
individuals	O
with	O
Crohn	O
disease	O
,	O
but	O
the	O
pathogenic	O
lesion	O
in	O
the	O
region	O
has	O
not	O
yet	O
been	O
identified	O
.	O

We	O
report	O
here	O
that	O
two	O
variants	O
in	O
the	O
organic	O
cation	O
transporter	O
cluster	O
at	O
5q31	O
(	O
a	O
missense	O
substitution	O
in	O
SLC22A4	O
and	O
a	O
G	O
-	O
-	O
>	O
C	O
transversion	O
in	O
the	O
SLC22A5	O
promoter	O
)	O
form	O
a	O
haplotype	O
associated	O
with	O
susceptibility	O
to	O
Crohn	O
disease	O
.	O

These	O
variants	O
alter	O
transcription	O
and	O
transporter	O
functions	O
of	O
the	O
organic	O
cation	O
transporters	O
and	O
interact	O
with	O
variants	O
in	O
another	O
gene	O
associated	O
with	O
Crohn	O
disease	O
,	O
CARD15	O
,	O
to	O
increase	O
risk	O
of	O
Crohn	O
disease	O
.	O

These	O
results	O
suggest	O
that	O
SLC22A4	O
,	O
SLC22A5	O
and	O
CARD15	O
act	O
in	O
a	O
common	O
pathogenic	O
pathway	O
to	O
cause	O
Crohn	O
disease	O
.	O

Transforming	O
growth	O
factor	O
-	O
beta	O
stimulates	O
p300	O
-	O
dependent	O
RUNX3	O
acetylation	O
,	O
which	O
inhibits	O
ubiquitination	O
-	O
mediated	O
degradation	O
.	O

The	O
Runt	O
domain	O
transcription	O
factors	O
(	O
RUNXs	O
)	O
play	O
essential	O
roles	O
in	O
normal	O
development	O
and	O
neoplasias	O
.	O

Genetic	O
analyses	O
of	O
animals	O
and	O
humans	O
have	O
revealed	O
the	O
involvement	O
of	O
RUNX1	O
in	O
hematopoiesis	O
and	O
leukemia	O
,	O
RUNX2	O
in	O
osteogenesis	O
and	O
cleidocranial	O
dysplasia	O
,	O
and	O
RUNX3	O
in	O
the	O
development	O
of	O
T	O
-	O
cells	O
and	O
dorsal	O
root	O
ganglion	O
neurons	O
and	O
in	O
the	O
genesis	O
of	O
gastric	O
cancer	O
.	O

Here	O
we	O
report	O
that	O
RUNX3	O
is	O
a	O
target	O
of	O
the	O
acetyltransferase	O
activity	O
of	O
p300	O
.	O

The	O
p300	O
-	O
dependent	O
acetylation	O
of	O
three	O
lysine	O
residues	O
protects	O
RUNX3	O
from	O
ubiquitin	O
ligase	O
Smurf	O
-	O
mediated	O
degradation	O
.	O

The	O
extent	O
of	O
the	O
acetylation	O
is	O
up	O
-	O
regulated	O
by	O
the	O
transforming	O
growth	O
factor	O
-	O
beta	O
signaling	O
pathway	O
and	O
down	O
-	O
regulated	O
by	O
histone	O
deacetylase	O
activities	O
.	O

Our	O
findings	O
demonstrate	O
that	O
the	O
level	O
of	O
RUNX3	O
protein	O
is	O
controlled	O
by	O
the	O
competitive	O
acetylation	O
and	O
deacetylation	O
of	O
the	O
three	O
lysine	O
residues	O
,	O
revealing	O
a	O
new	O
mechanism	O
for	O
the	O
posttranslational	O
regulation	O
of	O
RUNX3	O
expression	O
.	O

Atg21	O
is	O
a	O
phosphoinositide	O
binding	O
protein	O
required	O
for	O
efficient	O
lipidation	O
and	O
localization	O
of	O
Atg8	O
during	O
uptake	O
of	O
aminopeptidase	O
I	O
by	O
selective	O
autophagy	O
.	O

Delivery	O
of	O
proteins	O
and	O
organelles	O
to	O
the	O
vacuole	O
by	O
autophagy	O
and	O
the	O
cytoplasm	O
to	O
vacuole	O
targeting	O
(	O
Cvt	O
)	O
pathway	O
involves	O
novel	O
rearrangements	O
of	O
membrane	O
resulting	O
in	O
the	O
formation	O
of	O
vesicles	O
that	O
fuse	O
with	O
the	O
vacuole	O
.	O

The	O
mechanism	O
of	O
vesicle	O
formation	O
and	O
the	O
origin	O
of	O
the	O
membrane	O
are	O
complex	O
issues	O
still	O
to	O
be	O
resolved	O
.	O

Atg18	O
and	O
Atg21	O
are	O
proteins	O
essential	O
to	O
vesicle	O
formation	O
and	O
together	O
with	O
Ygr223c	O
form	O
a	O
novel	O
family	O
of	O
phosphoinositide	O
binding	O
proteins	O
that	O
are	O
associated	O
with	O
the	O
vacuole	O
and	O
perivacuolar	O
structures	O
.	O

Their	O
localization	O
requires	O
the	O
activity	O
of	O
Vps34	O
,	O
suggesting	O
that	O
phosphatidylinositol	O
(	O
3	O
)	O
phosphate	O
may	O
be	O
essential	O
for	O
their	O
function	O
.	O

The	O
activity	O
of	O
Atg18	O
is	O
vital	O
for	O
all	O
forms	O
of	O
autophagy	O
,	O
whereas	O
Atg21	O
is	O
required	O
for	O
the	O
Cvt	O
pathway	O
but	O
not	O
for	O
nitrogen	O
starvation	O
-	O
induced	O
autophagy	O
.	O

The	O
loss	O
of	O
Atg21	O
results	O
in	O
the	O
absence	O
of	O
Atg8	O
from	O
the	O
pre	O
-	O
autophagosomal	O
structure	O
(	O
PAS	O
)	O
,	O
which	O
may	O
be	O
ascribed	O
to	O
a	O
reduced	O
rate	O
of	O
conjugation	O
of	O
Atg8	O
to	O
phosphatidylethanolamine	O
.	O

A	O
similar	O
defect	O
in	O
localization	O
of	O
a	O
second	O
ubiquitin	O
-	O
like	O
conjugate	O
,	O
Atg12	O
-	O
Atg5	O
,	O
suggests	O
that	O
Atg21	O
may	O
be	O
involved	O
in	O
the	O
recruitment	O
of	O
membrane	O
to	O
the	O
PAS	O
.	O

The	O
Synechococcus	O
elongatus	O
P	O
signal	O
transduction	O
protein	O
controls	O
arginine	O
synthesis	O
by	O
complex	O
formation	O
with	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
glutamate	O
kinase	O
.	O

This	O
communication	O
identifies	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
receptor	O
protein	O
for	O
signal	O
perception	O
from	O
the	O
P	O
(	O
II	O
)	O
signal	O
transduction	O
protein	O
in	O
the	O
cyanobacterium	O
Synechococcus	O
elongatus	O
.	O

P	O
(	O
II	O
)	O
,	O
a	O
phosphoprotein	O
that	O
signals	O
the	O
carbon	O
/	O
nitrogen	O
status	O
of	O
the	O
cells	O
,	O
forms	O
a	O
tight	O
complex	O
with	O
the	O
key	O
enzyme	O
of	O
the	O
arginine	O
biosynthetic	O
pathway	O
,	O
N	O
-	O
acetylglutamate	O
(	O
NAG	O
)	O
kinase	O
.	O

In	O
complex	O
with	O
P	O
(	O
II	O
)	O
,	O
the	O
catalytic	O
activity	O
of	O
NAG	O
kinase	O
is	O
strongly	O
enhanced	O
.	O

Complex	O
formation	O
does	O
not	O
require	O
the	O
effector	O
molecules	O
of	O
P	O
(	O
II	O
)	O
,	O
2	O
-	O
oxoglutarate	O
and	O
ATP	O
,	O
but	O
it	O
is	O
highly	O
susceptible	O
to	O
modifications	O
at	O
the	O
phosphorylation	O
site	O
of	O
P	O
(	O
II	O
)	O
,	O
Ser	O
-	O
49	O
.	O

Stable	O
complexes	O
were	O
only	O
formed	O
with	O
the	O
non	O
-	O
phosphorylated	O
form	O
of	O
P	O
(	O
II	O
)	O
but	O
not	O
with	O
Ser	O
-	O
49	O
mutants	O
.	O

In	O
accordance	O
with	O
these	O
data	O
,	O
NAG	O
kinase	O
activity	O
in	O
S	O
.	O
elongatus	O
extracts	O
correlated	O
with	O
the	O
phosphorylation	O
state	O
of	O
P	O
(	O
II	O
)	O
,	O
with	O
high	O
NAG	O
kinase	O
activities	O
corresponding	O
to	O
non	O
-	O
phosphorylated	O
P	O
(	O
II	O
)	O
(	O
nitrogen	O
-	O
excess	O
conditions	O
)	O
and	O
low	O
activities	O
to	O
increased	O
levels	O
of	O
P	O
(	O
II	O
)	O
phosphorylation	O
(	O
nitrogen	O
-	O
poor	O
conditions	O
)	O
,	O
thus	O
subjecting	O
the	O
key	O
enzyme	O
of	O
arginine	O
biosynthesis	O
to	O
global	O
nitrogen	O
control	O
.	O

A	O
complex	O
of	O
the	O
Escherichia	O
coli	O
cell	O
division	O
proteins	O
FtsL	O
,	O
FtsB	O
and	O
FtsQ	O
forms	O
independently	O
of	O
its	O
localization	O
to	O
the	O
septal	O
region	O
.	O

Three	O
membrane	O
proteins	O
required	O
for	O
cell	O
division	O
in	O
Escherichia	O
coli	O
,	O
FtsQ	O
,	O
FtsL	O
and	O
FtsB	O
,	O
localize	O
to	O
the	O
cell	O
septum	O
.	O

FtsL	O
and	O
FtsB	O
,	O
which	O
each	O
contain	O
a	O
leucine	O
zipper	O
-	O
like	O
sequence	O
,	O
are	O
dependent	O
on	O
each	O
other	O
for	O
this	O
localization	O
,	O
and	O
each	O
of	O
them	O
is	O
dependent	O
on	O
FtsQ	O
.	O

However	O
,	O
FtsQ	O
is	O
found	O
at	O
the	O
cell	O
division	O
site	O
in	O
the	O
absence	O
of	O
FtsL	O
and	O
FtsB	O
.	O

FtsQ	O
,	O
in	O
turn	O
,	O
requires	O
FtsK	O
for	O
its	O
localization	O
.	O

Here	O
,	O
we	O
show	O
that	O
FtsL	O
,	O
FtsB	O
and	O
FtsQ	O
form	O
a	O
complex	O
in	O
vivo	O
.	O

Strikingly	O
,	O
this	O
complex	O
forms	O
in	O
the	O
absence	O
of	O
FtsK	O
,	O
which	O
is	O
required	O
for	O
the	O
localization	O
of	O
all	O
three	O
proteins	O
to	O
the	O
mid	O
-	O
cell	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
FtsL	O
,	O
FtsB	O
,	O
FtsQ	O
interactions	O
can	O
take	O
place	O
in	O
cells	O
before	O
movement	O
to	O
the	O
mid	O
-	O
cell	O
and	O
that	O
migration	O
to	O
this	O
position	O
might	O
occur	O
only	O
after	O
the	O
formation	O
of	O
the	O
complex	O
.	O

Evidence	O
indicating	O
the	O
regions	O
of	O
the	O
three	O
proteins	O
involved	O
in	O
complex	O
formation	O
is	O
presented	O
.	O

These	O
findings	O
provide	O
the	O
first	O
example	O
of	O
preassembly	O
of	O
a	O
subcomplex	O
of	O
cell	O
division	O
proteins	O
before	O
their	O
localization	O
to	O
the	O
septal	O
region	O
.	O

Suppressors	O
of	O
an	O
adenylate	O
cyclase	O
deletion	O
in	O
the	O
fission	O
yeast	O
Schizosaccharomyces	O
pombe	O
.	O

Schizosaccharomyces	O
pombe	O
utilizes	O
two	O
opposing	O
signaling	O
pathways	O
to	O
sense	O
and	O
respond	O
to	O
its	O
nutritional	O
environment	O
.	O

Glucose	O
detection	O
triggers	O
a	O
cyclic	O
AMP	O
signal	O
to	O
activate	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
,	O
while	O
glucose	O
or	O
nitrogen	O
starvation	O
activates	O
the	O
Spc1	O
/	O
Sty1	O
stress	O
-	O
activated	O
protein	O
kinase	O
(	O
SAPK	O
)	O
.	O

One	O
process	O
controlled	O
by	O
these	O
pathways	O
is	O
fbp1	O
+	O
transcription	O
,	O
which	O
is	O
glucose	O
repressed	O
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
strains	O
carrying	O
mutations	O
that	O
reduce	O
high	O
-	O
level	O
fbp1	O
+	O
transcription	O
conferred	O
by	O
the	O
loss	O
of	O
adenylate	O
cyclase	O
(	O
git2delta	O
)	O
,	O
including	O
both	O
wis1	O
-	O
(	O
SAPK	O
kinase	O
)	O
and	O
spc1	O
-	O
(	O
SAPK	O
)	O
mutants	O
.	O

While	O
characterizing	O
the	O
git2delta	O
suppressor	O
strains	O
,	O
we	O
found	O
that	O
the	O
git2delta	O
parental	O
strains	O
are	O
KCl	O
sensitive	O
,	O
though	O
not	O
osmotically	O
sensitive	O
.	O

Of	O
102	O
git2delta	O
suppressor	O
strains	O
,	O
17	O
strains	O
display	O
KCl	O
-	O
resistant	O
growth	O
and	O
comprise	O
a	O
single	O
linkage	O
group	O
,	O
carrying	O
mutations	O
in	O
the	O
cgs1	O
+	O
PKA	O
regulatory	O
subunit	O
gene	O
.	O

Surprisingly	O
,	O
some	O
of	O
these	O
mutants	O
are	O
mostly	O
wild	O
type	O
for	O
mating	O
and	O
stationary	O
-	O
phase	O
viability	O
,	O
unlike	O
the	O
previously	O
characterized	O
cgs1	O
-	O
1	O
mutant	O
,	O
while	O
showing	O
a	O
significant	O
defect	O
in	O
fbp1	O
-	O
lacZ	O
expression	O
.	O

Thus	O
,	O
certain	O
cgs1	O
-	O
mutant	O
alleles	O
dramatically	O
affect	O
some	O
PKA	O
-	O
regulated	O
processes	O
while	O
having	O
little	O
effect	O
on	O
others	O
.	O

We	O
demonstrate	O
that	O
the	O
PKA	O
and	O
SAPK	O
pathways	O
regulate	O
both	O
cgs1	O
+	O
and	O
pka1	O
+	O
transcription	O
,	O
providing	O
a	O
mechanism	O
for	O
cross	O
talk	O
between	O
these	O
two	O
antagonistically	O
acting	O
pathways	O
and	O
feedback	O
regulation	O
of	O
the	O
PKA	O
pathway	O
.	O

Finally	O
,	O
strains	O
defective	O
in	O
both	O
the	O
PKA	O
and	O
SAPK	O
pathways	O
display	O
transcriptional	O
regulation	O
of	O
cgs1	O
+	O
and	O
pka1	O
+	O
,	O
suggesting	O
the	O
presence	O
of	O
a	O
third	O
glucose	O
-	O
responsive	O
signaling	O
pathway	O
.	O

Silent	O
information	O
regulator	O
2	O
potentiates	O
Foxo1	O
-	O
mediated	O
transcription	O
through	O
its	O
deacetylase	O
activity	O
.	O

Longevity	O
regulatory	O
genes	O
include	O
the	O
Forkhead	O
transcription	O
factor	O
FOXO	O
and	O
the	O
NAD	O
-	O
dependent	O
histone	O
deacetylase	O
silent	O
information	O
regulator	O
2	O
(	O
Sir2	O
)	O
.	O

Genetic	O
studies	O
demonstrate	O
that	O
Sir2	O
acts	O
to	O
extend	O
lifespan	O
in	O
Caenorhabditis	O
elegans	O
upstream	O
of	O
DAF	O
-	O
16	O
,	O
a	O
member	O
of	O
the	O
FOXO	O
family	O
,	O
in	O
the	O
insulin	O
-	O
like	O
signaling	O
pathway	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
requirement	O
of	O
DAF	O
-	O
16	O
activity	O
in	O
Sir2	O
-	O
mediated	O
longevity	O
remain	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
reversible	O
acetylation	O
of	O
Foxo1	O
(	O
also	O
known	O
as	O
FKHR	O
)	O
,	O
the	O
mouse	O
DAF	O
-	O
16	O
ortholog	O
,	O
modulates	O
its	O
transactivation	O
function	O
.	O

cAMP	O
-	O
response	O
element	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
-	O
binding	O
protein	O
binds	O
and	O
acetylates	O
Foxo1	O
at	O
the	O
K242	O
,	O
K245	O
,	O
and	O
K262	O
residues	O
,	O
the	O
modification	O
of	O
which	O
is	O
involved	O
in	O
the	O
attenuation	O
of	O
Foxo1	O
as	O
a	O
transcription	O
factor	O
.	O

Conversely	O
,	O
Sir2	O
binds	O
and	O
deacetylates	O
Foxo1	O
at	O
residues	O
acetylated	O
by	O
cAMP	O
-	O
response	O
element	O
-	O
binding	O
protein	O
-	O
binding	O
protein	O
.	O

Sir2	O
is	O
recruited	O
to	O
insulin	O
response	O
sequence	O
-	O
containing	O
promoter	O
and	O
increases	O
the	O
expression	O
of	O
manganese	O
superoxide	O
dismutase	O
and	O
p27	O
(	O
kip1	O
)	O
in	O
a	O
deacetylase	O
-	O
activity	O
-	O
dependent	O
manner	O
.	O

Our	O
findings	O
establish	O
Foxo1	O
as	O
a	O
direct	O
and	O
functional	O
target	O
for	O
Sir2	O
in	O
mammalian	O
systems	O
.	O

N	O
-	O
Terminal	O
ubiquitination	O
of	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
3	O
and	O
p21	O
directs	O
their	O
degradation	O
by	O
the	O
proteasome	B-Complex
.	O

Extracellular	O
signal	O
-	O
regulated	O
kinase	O
3	O
(	O
ERK3	O
)	O
is	O
an	O
unstable	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
homologue	O
that	O
is	O
constitutively	O
degraded	O
by	O
the	O
ubiquitin	O
-	O
proteasome	B-Complex
pathway	O
in	O
proliferating	O
cells	O
.	O

Here	O
we	O
show	O
that	O
a	O
lysineless	O
mutant	O
of	O
ERK3	O
is	O
still	O
ubiquitinated	O
in	O
vivo	O
and	O
requires	O
a	O
functional	O
ubiquitin	O
conjugation	O
pathway	O
for	O
its	O
degradation	O
.	O

Addition	O
of	O
N	O
-	O
terminal	O
sequence	O
tags	O
of	O
increasing	O
size	O
stabilizes	O
ERK3	O
by	O
preventing	O
its	O
ubiquitination	O
.	O

Importantly	O
,	O
we	O
identified	O
a	O
fusion	O
peptide	O
between	O
the	O
N	O
-	O
terminal	O
methionine	O
of	O
ERK3	O
and	O
the	O
C	O
-	O
terminal	O
glycine	O
of	O
ubiquitin	O
in	O
vivo	O
by	O
tandem	O
mass	O
spectrometry	O
analysis	O
.	O

These	O
findings	O
demonstrate	O
that	O
ERK3	O
is	O
conjugated	O
to	O
ubiquitin	O
via	O
its	O
free	O
NH	O
(	O
2	O
)	O
terminus	O
.	O

We	O
found	O
that	O
large	O
N	O
-	O
terminal	O
tags	O
also	O
stabilize	O
the	O
expression	O
of	O
the	O
cell	O
cycle	O
inhibitor	O
p21	O
but	O
not	O
that	O
of	O
substrates	O
ubiquitinated	O
on	O
internal	O
lysine	O
residues	O
.	O

Consistent	O
with	O
this	O
observation	O
,	O
lysineless	O
p21	O
is	O
ubiquitinated	O
and	O
degraded	O
in	O
a	O
ubiquitin	O
-	O
dependent	O
manner	O
in	O
intact	O
cells	O
.	O

Our	O
results	O
suggests	O
that	O
N	O
-	O
terminal	O
ubiquitination	O
is	O
a	O
more	O
prevalent	O
modification	O
than	O
originally	O
recognized	O
.	O

Interactions	O
between	O
Fat	O
and	O
Dachsous	O
and	O
the	O
regulation	O
of	O
planar	O
cell	O
polarity	O
in	O
the	O
Drosophila	O
wing	O
.	O

It	O
was	O
recently	O
suggested	O
that	O
a	O
proximal	O
to	O
distal	O
gradient	O
of	O
the	O
protocadherin	O
Dachsous	O
(	O
Ds	O
)	O
acts	O
as	O
a	O
cue	O
for	O
planar	O
cell	O
polarity	O
(	O
PCP	O
)	O
in	O
the	O
Drosophila	O
wing	O
,	O
orienting	O
cell	O
-	O
cell	O
interactions	O
by	O
inhibiting	O
the	O
activity	O
of	O
the	O
protocadherin	O
Fat	O
(	O
Ft	O
)	O
.	O

This	O
Ft	O
-	O
Ds	O
signaling	O
model	O
is	O
based	O
on	O
mutant	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
,	O
leaving	O
open	O
the	O
question	O
of	O
whether	O
Ds	O
is	O
instructive	O
or	O
permissive	O
for	O
PCP	O
.	O

We	O
developed	O
tools	O
for	O
misexpressing	O
ds	O
and	O
ft	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
and	O
have	O
used	O
these	O
to	O
test	O
aspects	O
of	O
the	O
model	O
.	O

First	O
,	O
this	O
model	O
predicts	O
that	O
Ds	O
and	O
Ft	O
can	O
bind	O
.	O

We	O
show	O
that	O
Ft	O
and	O
Ds	O
mediate	O
preferentially	O
heterophilic	O
cell	O
adhesion	O
in	O
vitro	O
,	O
and	O
that	O
each	O
stabilizes	O
the	O
other	O
on	O
the	O
cell	O
surface	O
.	O

Second	O
,	O
the	O
model	O
predicts	O
that	O
artificial	O
gradients	O
of	O
Ds	O
are	O
sufficient	O
to	O
reorient	O
PCP	O
in	O
the	O
wing	O
;	O
our	O
data	O
confirms	O
this	O
prediction	O
.	O

Finally	O
,	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
suggest	O
that	O
the	O
gradient	O
of	O
ds	O
expression	O
is	O
necessary	O
for	O
correct	O
PCP	O
throughout	O
the	O
wing	O
.	O

Surprisingly	O
,	O
this	O
is	O
not	O
the	O
case	O
.	O

Uniform	O
levels	O
of	O
ds	O
drive	O
normally	O
oriented	O
PCP	O
and	O
,	O
in	O
all	O
but	O
the	O
most	O
proximal	O
regions	O
of	O
the	O
wing	O
,	O
uniform	O
ds	O
rescues	O
the	O
ds	O
mutant	O
PCP	O
phenotype	O
.	O

Nor	O
are	O
distal	O
PCP	O
defects	O
increased	O
by	O
the	O
loss	O
of	O
spatial	O
information	O
from	O
the	O
distally	O
expressed	O
four	O
-	O
jointed	O
(	O
fj	O
)	O
gene	O
,	O
which	O
encodes	O
putative	O
modulator	O
of	O
Ft	O
-	O
Ds	O
signaling	O
.	O

Thus	O
,	O
while	O
our	O
results	O
support	O
the	O
existence	O
of	O
Ft	O
-	O
Ds	O
binding	O
and	O
show	O
that	O
it	O
is	O
sufficient	O
to	O
alter	O
PCP	O
,	O
ds	O
expression	O
is	O
permissive	O
or	O
redundant	O
with	O
other	O
PCP	O
cues	O
in	O
much	O
of	O
the	O
wing	O
.	O

High	O
affinity	O
binding	O
of	O
Dab1	O
to	O
Reelin	O
receptors	O
promotes	O
normal	O
positioning	O
of	O
upper	O
layer	O
cortical	O
plate	O
neurons	O
.	O

The	O
positions	O
of	O
neurons	O
in	O
the	O
neocortex	O
,	O
hippocampus	O
,	O
cerebellum	O
and	O
various	O
other	O
laminated	O
brain	O
regions	O
are	O
regulated	O
by	O
a	O
signaling	O
pathway	O
initiated	O
by	O
the	O
secreted	O
protein	O
Reelin	O
and	O
requiring	O
the	O
intracellular	O
adaptor	O
protein	O
Dab1	O
.	O

Dab1	O
and	O
the	O
Reelin	O
receptors	O
VLDLR	O
and	O
ApoER2	O
are	O
expressed	O
by	O
neurons	O
whose	O
migrations	O
are	O
coordinated	O
by	O
Reelin	O
.	O

In	O
vitro	O
,	O
Dab1	O
binds	O
with	O
high	O
affinity	O
to	O
the	O
cytoplasmic	O
tails	O
of	O
VLDLR	O
and	O
ApoER2	O
via	O
its	O
PTB	O
domain	O
.	O

To	O
test	O
the	O
importance	O
of	O
Dab1	O
binding	O
to	O
VLDLR	O
and	O
ApoER2	O
,	O
we	O
replaced	O
the	O
Dab1	O
gene	O
with	O
a	O
cDNA	O
cassette	O
encoding	O
a	O
point	O
mutant	O
allele	O
,	O
Dab1	O
(	O
F158V	O
)	O
.	O

This	O
mutation	O
strongly	O
decreases	O
Dab1	O
binding	O
in	O
vitro	O
to	O
peptides	O
containing	O
the	O
ApoER2	O
or	O
VLDLR	O
cytoplasmic	O
regions	O
.	O

Surprisingly	O
,	O
Dab1	O
(	O
F158V	O
/	O
F158V	O
)	O
homozygotes	O
have	O
no	O
discernable	O
phenotype	O
.	O

However	O
,	O
Dab1	O
(	O
F158V	O
/	O
-	O
)	O
hemizygous	O
animals	O
have	O
a	O
subtle	O
phenotype	O
in	O
which	O
late	O
-	O
generated	O
cortical	O
plate	O
neurons	O
migrate	O
excessively	O
into	O
the	O
marginal	O
zone	O
.	O

Early	O
cortical	O
plate	O
neurons	O
,	O
subplate	O
neurons	O
,	O
hippocampal	O
pyramidal	O
cells	O
and	O
cerebellar	O
Purkinje	O
cells	O
are	O
positioned	O
normally	O
.	O

Thus	O
Dab	O
(	O
F158V	O
)	O
is	O
a	O
weak	O
loss	O
-	O
of	O
-	O
function	O
(	O
hypomorphic	O
)	O
allele	O
that	O
has	O
no	O
detectable	O
effect	O
when	O
homozygous	O
.	O

The	O
phenotype	O
of	O
Dab1	O
(	O
F158V	O
/	O
-	O
)	O
hemizygotes	O
shows	O
that	O
late	O
cortical	O
plate	O
neurons	O
of	O
layers	O
2	O
-	O
3	O
require	O
efficient	O
Reelin	O
-	O
Dab1	O
signaling	O
to	O
prevent	O
them	O
entering	O
the	O
marginal	O
zone	O
.	O

The	O
Dab1	O
(	O
F158V	O
)	O
allele	O
adds	O
to	O
a	O
series	O
of	O
Dab1	O
alleles	O
that	O
demonstrates	O
cell	O
type	O
-	O
specific	O
variation	O
in	O
the	O
Reelin	O
-	O
Dab1	O
pathway	O
.	O

Functional	O
characterization	O
of	O
the	O
yeast	O
Ppz1	O
phosphatase	O
inhibitory	O
subunit	O
Hal3	O
:	O
a	O
mutagenesis	O
study	O
.	O

Saccharomyces	O
cerevisiae	O
Hal3	O
is	O
a	O
conserved	O
protein	O
that	O
binds	O
the	O
carboxyl	O
-	O
terminal	O
catalytic	O
domain	O
of	O
the	O
PP1c	O
(	O
protein	B-Complex
phosphatase	I-Complex
1	I-Complex
)	O
-	O
related	O
phosphatase	O
Ppz1	O
and	O
potently	O
inhibits	O
its	O
activity	O
,	O
thus	O
modulating	O
all	O
of	O
the	O
characterized	O
functions	O
so	O
far	O
of	O
the	O
phosphatase	O
.	O

It	O
is	O
unknown	O
how	O
Hal3	O
binds	O
to	O
Ppz1	O
and	O
inhibits	O
its	O
activity	O
.	O

Although	O
it	O
contains	O
a	O
putative	O
protein	O
phosphatase	O
1c	O
binding	O
-	O
like	O
sequence	O
(	O
263KLHVLF268	O
)	O
,	O
mutagenesis	O
analysis	O
suggests	O
that	O
this	O
motif	O
is	O
not	O
required	O
for	O
Ppz1	O
binding	O
and	O
inhibition	O
.	O

The	O
mutation	O
of	O
the	O
conserved	O
His378	O
(	O
possibly	O
involved	O
in	O
dehydrogenase	O
catalytic	O
activity	O
)	O
did	O
not	O
impair	O
Hal3	O
functions	O
or	O
Ppz1	O
binding	O
.	O

Random	O
mutagenesis	O
of	O
the	O
228	O
residue	O
-	O
conserved	O
central	O
region	O
of	O
Hal3	O
followed	O
by	O
a	O
loss	O
-	O
of	O
-	O
function	O
screen	O
allowed	O
the	O
identification	O
of	O
nine	O
residues	O
important	O
for	O
Ppz1	O
-	O
related	O
Hal3	O
functions	O
.	O

Seven	O
of	O
these	O
residues	O
cluster	O
in	O
a	O
relatively	O
small	O
region	O
spanning	O
from	O
amino	O
acid	O
446	O
to	O
480	O
.	O

Several	O
mutations	O
affected	O
Ppz1	O
binding	O
and	O
inhibition	O
in	O
vitro	O
,	O
whereas	O
changes	O
in	O
Glu460	O
and	O
Val462	O
did	O
not	O
alter	O
binding	O
but	O
resulted	O
in	O
Hal3	O
versions	O
unable	O
to	O
inhibit	O
the	O
phosphatase	O
.	O

Therefore	O
,	O
there	O
are	O
independent	O
Hal3	O
structural	O
elements	O
required	O
for	O
Ppz1	O
binding	O
and	O
inhibition	O
.	O

S	O
.	O
cerevisiae	O
encodes	O
a	O
protein	O
(	O
Vhs3	O
)	O
structurally	O
related	O
to	O
Hal3	O
.	O

Recent	O
evidence	O
suggests	O
that	O
both	O
mutations	O
are	O
synthetically	O
lethal	O
.	O

Surprisingly	O
,	O
versions	O
of	O
Hal3	O
carrying	O
mutations	O
that	O
strongly	O
affected	O
Ppz1	O
binding	O
or	O
inhibitory	O
capacity	O
were	O
able	O
to	O
complement	O
lethality	O
.	O

In	O
contrast	O
,	O
the	O
mutation	O
of	O
His378	O
did	O
not	O
.	O

This	O
finding	O
suggests	O
that	O
Hal3	O
may	O
have	O
both	O
Ppz1	O
-	O
dependent	O
and	O
independent	O
functions	O
involving	O
different	O
structural	O
elements	O
.	O

A	O
novel	O
mitogen	O
-	O
inducible	O
gene	O
product	O
related	O
to	O
p50	O
/	O
p105	O
-	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
participates	O
in	O
transactivation	O
through	O
a	O
kappa	B-Complex
B	I-Complex
site	O
.	O

A	O
Rel	O
-	O
related	O
,	O
mitogen	O
-	O
inducible	O
,	O
kappa	B-Complex
B	I-Complex
-	O
binding	O
protein	O
has	O
been	O
cloned	O
as	O
an	O
immediate	O
-	O
early	O
activation	O
gene	O
of	O
human	O
peripheral	O
blood	O
T	O
cells	O
.	O

The	O
cDNA	O
has	O
an	O
open	O
reading	O
frame	O
of	O
900	O
amino	O
acids	O
capable	O
of	O
encoding	O
a	O
97	O
-	O
kDa	O
protein	O
.	O

This	O
protein	O
is	O
most	O
similar	O
to	O
the	O
105	O
-	O
kDa	O
precursor	O
polypeptide	O
of	O
p50	O
-	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O

Like	O
the	O
105	O
-	O
kDa	O
precursor	O
,	O
it	O
contains	O
an	O
amino	O
-	O
terminal	O
Rel	O
-	O
related	O
domain	O
of	O
about	O
300	O
amino	O
acids	O
and	O
a	O
carboxy	O
-	O
terminal	O
domain	O
containing	O
six	O
full	O
cell	O
cycle	O
or	O
ankyrin	O
repeats	O
.	O

In	O
vitro	O
-	O
translated	O
proteins	O
,	O
truncated	O
downstream	O
of	O
the	O
Rel	O
domain	O
and	O
excluding	O
the	O
repeats	O
,	O
bind	O
kappa	B-Complex
B	I-Complex
sites	O
.	O

We	O
refer	O
to	O
the	O
kappa	B-Complex
B	I-Complex
-	O
binding	O
,	O
truncated	O
protein	O
as	O
p50B	O
by	O
analogy	O
with	O
p50	O
-	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
and	O
to	O
the	O
full	O
-	O
length	O
protein	O
as	O
p97	O
.	O

p50B	O
is	O
able	O
to	O
form	O
heteromeric	O
kappa	B-Complex
B	I-Complex
-	O
binding	O
complexes	O
with	O
RelB	O
,	O
as	O
well	O
as	O
with	O
p65	O
and	O
p50	O
,	O
the	O
two	O
subunits	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O

Transient	O
-	O
transfection	O
experiments	O
in	O
embryonal	O
carcinoma	O
cells	O
demonstrate	O
a	O
functional	O
cooperation	O
between	O
p50B	O
and	O
RelB	O
or	O
p65	O
in	O
transactivation	O
of	O
a	O
reporter	O
plasmid	O
dependent	O
on	O
a	O
kappa	B-Complex
B	I-Complex
site	O
.	O

The	O
data	O
imply	O
the	O
existence	O
of	O
a	O
complex	O
family	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
-	O
like	O
transcription	O
factors	O
.	O

Effect	O
of	O
the	O
statin	O
atorvastatin	O
on	O
intracellular	O
signalling	O
by	O
the	O
prostacyclin	O
receptor	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Prostacyclin	O
plays	O
a	O
central	O
role	O
within	O
the	O
vasculature	O
.	O

We	O
have	O
previously	O
established	O
that	O
the	O
prostacyclin	O
receptor	O
(	O
IP	O
)	O
undergoes	O
isoprenylation	O
,	O
a	O
lipid	O
modification	O
obligate	O
for	O
its	O
function	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
the	O
hydroxy	O
methyl	O
glutaryl	O
co	O
-	O
enzyme	O
A	O
reductase	O
inhibitor	O
atorvastatin	O
on	O
signalling	O
and	O
function	O
of	O
the	O
IP	O
expressed	O
in	O
mammalian	O
whole	O
cells	O
and	O
in	O
platelets	O
isolated	O
from	O
patients	O
undergoing	O
therapeutic	O
intervention	O
with	O
atorvastatin	O
.	O

Initially	O
,	O
the	O
effect	O
of	O
atorvastatin	O
on	O
signalling	O
by	O
the	O
human	O
(	O
h	O
)	O
and	O
mouse	O
(	O
m	O
)	O
IP	O
overexpressed	O
in	O
human	O
embryonic	O
kidney	O
293	O
cells	O
and	O
the	O
hIP	O
endogenously	O
expressed	O
in	O
human	O
erythroleukaemic	O
92	O
.	O
1	O
.	O
7	O
cells	O
was	O
investigated	O
.	O

Atorvastatin	O
significantly	O
reduced	O
IP	O
-	O
mediated	O
cAMP	O
generation	O
(	O
IC	O
(	O
50	O
)	O
6	O
.	O
6	O
-	O
11	O
.	O
1	O
microm	O
)	O
and	O
[	O
Ca	O
(	O
2	O
+	O
)	O
]	O
(	O
i	O
)	O
mobilization	O
(	O
IC	O
(	O
50	O
)	O
7	O
.	O
2	O
-	O
16	O
.	O
4	O
microm	O
)	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
,	O
but	O
had	O
no	O
effect	O
on	O
signalling	O
by	O
the	O
nonisoprenylated	O
beta	O
(	O
2	O
)	O
adrenergic	O
receptor	O
or	O
the	O
alpha	O
or	O
beta	O
isoforms	O
of	O
the	O
human	O
thromboxane	O
A	O
(	O
2	O
)	O
receptor	O
(	O
TP	O
)	O
.	O

Moreover	O
,	O
atorvastatin	O
significantly	O
reduced	O
IP	O
-	O
mediated	O
crossdesensitization	O
of	O
signalling	O
by	O
TP	O
alpha	O
(	O
IC	O
(	O
50	O
)	O
10	O
.	O
4	O
microm	O
)	O
,	O
but	O
not	O
by	O
TP	O
beta	O
.	O

In	O
contrast	O
to	O
the	O
whole	O
-	O
cell	O
data	O
,	O
atorvastatin	O
therapy	O
did	O
not	O
interfere	O
with	O
IP	O
-	O
mediated	O
cAMP	O
generation	O
or	O
IP	O
-	O
induced	O
inhibition	O
of	O
TP	O
-	O
mediated	O
aggregation	O
of	O
platelets	O
isolated	O
from	O
human	O
volunteers	O
undergoing	O
therapeutic	O
intervention	O
with	O
atorvastatin	O
(	O
10	O
-	O
80	O
mg	O
per	O
daily	O
dose	O
)	O
.	O

In	O
conclusion	O
,	O
while	O
data	O
generated	O
in	O
whole	O
cells	O
indicated	O
that	O
atorvastatin	O
significantly	O
impairs	O
signalling	O
by	O
both	O
the	O
hIP	O
and	O
mP	O
,	O
the	O
in	O
vivo	O
clinical	O
data	O
indicated	O
that	O
,	O
at	O
the	O
administered	O
therapeutic	O
dose	O
,	O
atorvastatin	O
does	O
not	O
significantly	O
compromise	O
IP	O
signalling	O
and	O
function	O
in	O
humans	O
.	O

Sequestosome	O
1	O
/	O
p62	O
is	O
a	O
polyubiquitin	O
chain	O
binding	O
protein	O
involved	O
in	O
ubiquitin	O
proteasome	B-Complex
degradation	O
.	O

Herein	O
,	O
we	O
demonstrate	O
that	O
the	O
ubiquitin	O
-	O
associated	O
(	O
UBA	O
)	O
domain	O
of	O
sequestosome	O
1	O
/	O
p62	O
displays	O
a	O
preference	O
for	O
binding	O
K63	O
-	O
polyubiquitinated	O
substrates	O
.	O

Furthermore	O
,	O
the	O
UBA	O
domain	O
of	O
p62	O
was	O
necessary	O
for	O
aggregate	O
sequestration	O
and	O
cell	O
survival	O
.	O

However	O
,	O
the	O
inhibition	O
of	O
proteasome	B-Complex
function	O
compromised	O
survival	O
in	O
cells	O
with	O
aggregates	O
.	O

Mutational	O
analysis	O
of	O
the	O
UBA	O
domain	O
reveals	O
that	O
the	O
conserved	O
hydrophobic	O
patch	O
MGF	O
as	O
well	O
as	O
the	O
conserved	O
leucine	O
in	O
helix	O
2	O
are	O
necessary	O
for	O
binding	O
polyubiquitinated	O
proteins	O
and	O
for	O
sequestration	O
-	O
aggregate	O
formation	O
.	O

We	O
report	O
that	O
p62	O
interacts	O
with	O
the	O
proteasome	B-Complex
by	O
pull	O
-	O
down	O
assay	O
,	O
coimmunoprecipitation	O
,	O
and	O
colocalization	O
.	O

Depletion	O
of	O
p62	O
levels	O
results	O
in	O
an	O
inhibition	O
of	O
ubiquitin	O
proteasome	B-Complex
-	O
mediated	O
degradation	O
and	O
an	O
accumulation	O
of	O
ubiquitinated	O
proteins	O
.	O

Altogether	O
,	O
our	O
results	O
support	O
the	O
hypothesis	O
that	O
p62	O
may	O
act	O
as	O
a	O
critical	O
ubiquitin	O
chain	O
-	O
targeting	O
factor	O
that	O
shuttles	O
substrates	O
for	O
proteasomal	O
degradation	O
.	O

Identification	O
,	O
cloning	O
,	O
expression	O
,	O
and	O
purification	O
of	O
three	O
novel	O
human	O
calcium	O
-	O
independent	O
phospholipase	O
A2	O
family	O
members	O
possessing	O
triacylglycerol	O
lipase	O
and	O
acylglycerol	O
transacylase	O
activities	O
.	O

Genetic	O
knockout	O
of	O
hormone	O
-	O
sensitive	O
lipase	O
in	O
mice	O
has	O
implicated	O
the	O
presence	O
of	O
other	O
intracellular	O
triacylglycerol	O
(	O
TAG	O
)	O
lipases	O
mediating	O
TAG	O
hydrolysis	O
in	O
adipocytes	O
.	O

Despite	O
intense	O
interest	O
in	O
these	O
TAG	O
lipases	O
,	O
their	O
molecular	O
identities	O
thus	O
far	O
are	O
largely	O
unknown	O
.	O

Sequence	O
data	O
base	O
searches	O
for	O
proteins	O
containing	O
calcium	O
-	O
independent	O
phospholipase	O
A2	O
(	O
iPLA2	O
)	O
dual	O
signature	O
nucleotide	O
(	O
(	O
G	O
/	O
A	O
)	O
XGXXG	O
)	O
and	O
lipase	O
(	O
GXSXG	O
)	O
consensus	O
sequence	O
motifs	O
identified	O
a	O
novel	O
subfamily	O
of	O
three	O
putative	O
iPLA2	O
/	O
lipase	O
family	O
members	O
designated	O
iPLA2epsilon	O
,	O
iPLA2zeta	O
,	O
and	O
iPLA2eta	O
(	O
previously	O
named	O
adiponutrin	O
,	O
TTS	O
-	O
2	O
.	O
2	O
,	O
and	O
GS2	O
,	O
respectively	O
)	O
of	O
previously	O
unknown	O
catalytic	O
function	O
.	O

Herein	O
we	O
describe	O
the	O
cloning	O
,	O
heterologous	O
expression	O
,	O
and	O
affinity	O
purification	O
of	O
the	O
three	O
human	O
isoforms	O
of	O
this	O
iPLA2	O
subfamily	O
in	O
Sf9	O
cells	O
,	O
and	O
we	O
demonstrate	O
that	O
each	O
possesses	O
abundant	O
TAG	O
lipase	O
activity	O
.	O

Moreover	O
,	O
iPLA2epsilon	O
,	O
iPLA2zeta	O
,	O
and	O
iPLA2eta	O
also	O
possess	O
acylglycerol	O
transacylase	O
activity	O
utilizing	O
mono	O
-	O
olein	O
as	O
an	O
acyl	O
donor	O
which	O
,	O
in	O
the	O
presence	O
of	O
mono	O
-	O
olein	O
or	O
diolein	O
acceptors	O
,	O
results	O
in	O
the	O
synthesis	O
of	O
diolein	O
and	O
triolein	O
,	O
respectively	O
.	O

(	O
E	O
)	O
-	O
6	O
-	O
(	O
Bromomethylene	O
)	O
-	O
3	O
-	O
(	O
1	O
-	O
naphthalenyl	O
)	O
-	O
2H	O
-	O
tetrahydropyran	O
-	O
2	O
-	O
one	O
,	O
a	O
mechanism	O
-	O
based	O
suicide	O
substrate	O
inhibitor	O
of	O
all	O
known	O
iPLA2s	O
,	O
inhibits	O
the	O
triglyceride	O
lipase	O
activity	O
of	O
each	O
of	O
the	O
three	O
isoforms	O
similarly	O
(	O
IC50	O
=	O
0	O
.	O
1	O
-	O
0	O
.	O
5	O
microm	O
)	O
.	O

Quantitative	O
PCR	O
revealed	O
dramatically	O
increased	O
expression	O
of	O
iPLA2epsilon	O
and	O
iPLA2zeta	O
transcripts	O
during	O
the	O
hormone	O
-	O
induced	O
differentiation	O
of	O
3T3	O
-	O
L1	O
cells	O
into	O
adipocytes	O
and	O
identified	O
the	O
presence	O
of	O
all	O
three	O
iPLA2	O
isoforms	O
in	O
human	O
SW872	O
liposarcoma	O
cells	O
.	O

Collectively	O
,	O
these	O
results	O
identify	O
three	O
novel	O
TAG	O
lipases	O
/	O
acylglycerol	O
transacylases	O
that	O
likely	O
participate	O
in	O
TAG	O
hydrolysis	O
and	O
the	O
acyl	O
-	O
CoA	O
independent	O
transacylation	O
of	O
acylglycerols	O
,	O
thereby	O
facilitating	O
energy	O
mobilization	O
and	O
storage	O
in	O
adipocytes	O
.	O

To	O
confirm	O
this	O
observation	O
in	O
primary	O
T	O
cells	O
,	O
retroviral	O
gene	O
transfer	O
was	O
used	O
to	O
infect	O
activated	O
CD4	O
positive	O
lymph	O
node	O
/	O
spleen	O
cells	O
from	O
transgenic	O
DO11	O
.	O
10	O
mice	O
.	O

T	O
cells	O
from	O
this	O
mouse	O
expresses	O
a	O
TCR	B-Complex
for	O
chicken	O
OVA	O
peptide	O
(	O
residues	O
323	O
-	O
339	O
)	O
,	O
which	O
can	O
be	O
presented	O
by	O
A20	O
cells	O
.	O

Retroviral	O
gene	O
transfer	O
resulted	O
in	O
expression	O
of	O
GFP	O
,	O
ADAP	O
-	O
GFP	O
,	O
or	O
M12	O
-	O
GFP	O
in	O
18	O
-	O
27	O
%	O
of	O
cells	O
(	O
Fig	O
.	O
2	O
e	O
)	O
.	O

Conjugation	O
was	O
assessed	O
by	O
FACS	O
analysis	O
for	O
the	O
binding	O
of	O
GFP	O
-	O
expressing	O
cells	O
with	O
PKH26	O
labeled	O
A20	O
cells	O
.	O

Exposure	O
to	O
OVA	O
peptide	O
increased	O
conjugation	O
by	O
two	O
-	O
to	O
threefold	O
relative	O
to	O
vector	O
GFP	O
control	O
cells	O
(	O
i	O
.	O
e	O
.	O
,	O
2	O
-	O
3	O
to	O
7	O
-	O
8	O
%	O
;	O
Fig	O
.	O
2	O
c	O
)	O
.	O

Infection	O
with	O
ADAP	O
-	O
GFP	O
further	O
increased	O
conjugation	O
with	O
a	O
two	O
-	O
to	O
threefold	O
shift	O
in	O
binding	O
to	O
APCs	O
(	O
i	O
.	O
e	O
.	O
,	O
7	O
-	O
8	O
to	O
20	O
%	O
)	O
.	O

In	O
contrast	O
,	O
as	O
noted	O
with	O
the	O
T8	O
.	O
1	O
cells	O
,	O
the	O
expression	O
of	O
GFP	O
-	O
M12	O
failed	O
to	O
increase	O
conjugation	O
.	O

These	O
findings	O
indicate	O
that	O
ADAP	O
can	O
enhance	O
conjugate	O
formation	O
of	O
primary	O
murine	O
T	O
cells	O
in	O
a	O
manner	O
analogous	O
to	O
the	O
T8	O
.	O
1	O
system	O
,	O
and	O
that	O
the	O
loss	O
of	O
the	O
SLP	O
-	O
76	O
binding	O
sites	O
abrogates	O
this	O
effect	O
.	O

Western	O
blot	O
analyses	O
were	O
performed	O
as	O
described	O
in	O
.	O

Antibodies	O
used	O
were	O
antineogenin	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
;	O
antinetrin	O
-	O
3	O
(	O
provided	O
by	O
H	O
.	O
Cooper	O
,	O
Walter	O
and	O
Eliza	O
Hall	O
Institute	O
,	O
Victoria	O
,	O
Australia	O
)	O
;	O
anti	O
-	O
DCC	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
;	O
anti	O
-	O
NFATc3	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
;	O
anti	O
-	O
CDO	O
(	O
Zymed	O
Laboratories	O
)	O
;	O
antipan	O
cadherin	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
;	O
anti	O
-	O
MHC	O
(	O
MF20	O
;	O
Developmental	O
Studies	O
Hybridoma	O
Bank	O
)	O
;	O
anti	O
-	O
MyoD	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
;	O
antimyogenin	O
(	O
F5D	O
;	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Inc	O
.	O
)	O
;	O
and	O
anti	O
-	O
TnT	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
.	O

Regulation	O
of	O
HCN	O
channel	O
surface	O
expression	O
by	O
a	O
novel	O
C	O
-	O
terminal	O
protein	O
-	O
protein	O
interaction	O
.	O

Hyperpolarization	O
-	O
activated	O
cation	O
currents	O
(	O
I	O
(	O
h	O
)	O
)	O
are	O
carried	O
by	O
channels	O
encoded	O
by	O
a	O
family	O
of	O
four	O
genes	O
(	O
HCN1	O
-	O
4	O
)	O
that	O
are	O
differentially	O
expressed	O
within	O
the	O
brain	O
in	O
specific	O
cellular	O
and	O
subcellular	O
compartments	O
.	O

HCN1	O
shows	O
a	O
high	O
level	O
of	O
expression	O
in	O
apical	O
dendrites	O
of	O
cortical	O
pyramidal	O
neurons	O
and	O
in	O
presynaptic	O
terminals	O
of	O
cerebellar	O
basket	O
cells	O
,	O
structures	O
with	O
a	O
high	O
density	O
of	O
I	O
(	O
h	O
)	O
.	O

Expression	O
of	O
I	O
(	O
h	O
)	O
is	O
also	O
regulated	O
by	O
neuronal	O
activity	O
.	O

To	O
isolate	O
proteins	O
that	O
may	O
control	O
HCN	O
channel	O
expression	O
or	O
function	O
,	O
we	O
performed	O
yeast	O
two	O
-	O
hybrid	O
screens	O
using	O
the	O
C	O
-	O
terminal	O
cytoplasmic	O
tails	O
of	O
the	O
HCN	O
proteins	O
as	O
bait	O
.	O

We	O
identified	O
a	O
brain	O
-	O
specific	O
protein	O
,	O
which	O
has	O
been	O
previously	O
termed	O
TRIP8b	O
(	O
for	O
TPR	O
-	O
containing	O
Rab8b	O
interacting	O
protein	O
)	O
and	O
PEX5Rp	O
(	O
for	O
Pex5p	O
-	O
related	O
protein	O
)	O
,	O
that	O
specifically	O
interacts	O
with	O
all	O
four	O
HCN	O
channels	O
through	O
a	O
conserved	O
sequence	O
in	O
their	O
C	O
-	O
terminal	O
tails	O
.	O

In	O
situ	O
hybridization	O
and	O
immunohistochemistry	O
show	O
that	O
TRIP8b	O
and	O
HCN1	O
are	O
colocalized	O
,	O
particularly	O
within	O
dendritic	O
arbors	O
of	O
hippocampal	O
CA1	O
and	O
neocortical	O
layer	O
V	O
pyramidal	O
neurons	O
.	O

The	O
dendritic	O
expression	O
of	O
TRIP8b	O
in	O
layer	O
V	O
pyramidal	O
neurons	O
is	O
disrupted	O
after	O
deletion	O
of	O
HCN1	O
through	O
homologous	O
recombination	O
,	O
demonstrating	O
a	O
key	O
in	O
vivo	O
interaction	O
between	O
HCN1	O
and	O
TRIP8b	O
.	O

TRIP8b	O
dramatically	O
alters	O
the	O
trafficking	O
of	O
HCN	O
channels	O
heterologously	O
expressed	O
in	O
Xenopus	O
oocytes	O
and	O
human	O
embryonic	O
kidney	O
293	O
cells	O
,	O
causing	O
a	O
specific	O
decrease	O
in	O
surface	O
expression	O
of	O
HCN	O
protein	O
and	O
I	O
(	O
h	O
)	O
density	O
,	O
with	O
a	O
pronounced	O
intracellular	O
accumulation	O
of	O
HCN	O
protein	O
that	O
is	O
colocalized	O
in	O
discrete	O
cytoplasmic	O
clusters	O
with	O
TRIP8b	O
.	O

Finally	O
,	O
TRIP8b	O
expression	O
in	O
cultured	O
pyramidal	O
neurons	O
markedly	O
decreases	O
native	O
I	O
(	O
h	O
)	O
density	O
.	O

These	O
data	O
suggest	O
a	O
possible	O
role	O
for	O
TRIP8b	O
in	O
regulating	O
HCN	O
channel	O
density	O
in	O
the	O
plasma	O
membrane	O
.	O

BTB	O
protein	O
Keap1	O
targets	O
antioxidant	O
transcription	O
factor	O
Nrf2	O
for	O
ubiquitination	O
by	O
the	O
Cullin	O
3	O
-	O
Roc1	O
ligase	O
.	O

The	O
concentrations	O
and	O
functions	O
of	O
many	O
eukaryotic	O
proteins	O
are	O
regulated	O
by	O
the	O
ubiquitin	O
pathway	O
,	O
which	O
consists	O
of	O
ubiquitin	O
activation	O
(	O
E1	O
)	O
,	O
conjugation	O
(	O
E2	O
)	O
,	O
and	O
ligation	O
(	O
E3	O
)	O
.	O

Cullins	O
are	O
a	O
family	O
of	O
evolutionarily	O
conserved	O
proteins	O
that	O
assemble	O
by	O
far	O
the	O
largest	O
family	O
of	O
E3	O
ligase	O
complexes	O
.	O

Cullins	O
,	O
via	O
a	O
conserved	O
C	O
-	O
terminal	O
domain	O
,	O
bind	O
with	O
the	O
RING	O
finger	O
protein	O
Roc1	O
to	O
recruit	O
the	O
catalytic	O
function	O
of	O
E2	O
.	O

Via	O
a	O
distinct	O
N	O
-	O
terminal	O
domain	O
,	O
individual	O
cullins	O
bind	O
to	O
a	O
protein	O
motif	O
present	O
in	O
multiple	O
proteins	O
to	O
recruit	O
specific	O
substrates	O
.	O

Cullin	O
3	O
(	O
Cul3	O
)	O
,	O
but	O
not	O
other	O
cullins	O
,	O
binds	O
directly	O
with	O
BTB	O
domains	O
to	O
constitute	O
a	O
potentially	O
large	O
number	O
of	O
BTB	O
-	O
CUL3	O
-	O
ROC1	O
E3	O
ubiquitin	O
ligases	O
.	O

Here	O
we	O
report	O
that	O
the	O
human	O
BTB	O
-	O
Kelch	O
protein	O
Keap1	O
,	O
a	O
negative	O
regulator	O
of	O
the	O
antioxidative	O
transcription	O
factor	O
Nrf2	O
,	O
binds	O
to	O
CUL3	O
and	O
Nrf2	O
via	O
its	O
BTB	O
and	O
Kelch	O
domains	O
,	O
respectively	O
.	O

The	O
KEAP1	O
-	O
CUL3	O
-	O
ROC1	O
complex	O
promoted	O
NRF2	O
ubiquitination	O
in	O
vitro	O
and	O
knocking	O
down	O
Keap1	O
or	O
CUL3	O
by	O
short	O
interfering	O
RNA	O
resulted	O
in	O
NRF2	O
protein	O
accumulation	O
in	O
vivo	O
.	O

We	O
suggest	O
that	O
Keap1	O
negatively	O
regulates	O
Nrf2	O
function	O
in	O
part	O
by	O
targeting	O
Nrf2	O
for	O
ubiquitination	O
by	O
the	O
CUL3	O
-	O
ROC1	O
ligase	O
and	O
subsequent	O
degradation	O
by	O
the	O
proteasome	B-Complex
.	O

Blocking	O
NRF2	O
degradation	O
in	O
cells	O
expressing	O
both	O
KEAP1	O
and	O
NRF2	O
by	O
either	O
inhibiting	O
the	O
proteasome	B-Complex
activity	O
or	O
knocking	O
down	O
Cul3	O
,	O
resulted	O
in	O
NRF2	O
accumulation	O
in	O
the	O
cytoplasm	O
.	O

These	O
results	O
may	O
reconcile	O
previously	O
observed	O
cytoplasmic	O
sequestration	O
of	O
NRF2	O
by	O
KEAP1	O
and	O
suggest	O
a	O
possible	O
regulatory	O
step	O
between	O
KEAP1	O
-	O
NRF2	O
binding	O
and	O
NRF2	O
degradation	O
.	O

Functional	O
analysis	O
of	O
Rpn6p	O
,	O
a	O
lid	O
component	O
of	O
the	O
26	B-Complex
S	I-Complex
proteasome	I-Complex
,	O
using	O
temperature	O
-	O
sensitive	O
rpn6	O
mutants	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

Rpn6p	O
is	O
a	O
component	O
of	O
the	O
lid	O
of	O
the	O
26	B-Complex
S	I-Complex
proteasome	I-Complex
.	O

We	O
isolated	O
and	O
analyzed	O
two	O
temperature	O
-	O
sensitive	O
rpn6	O
mutants	O
in	O
the	O
yeast	O
,	O
Saccharomyces	O
cerevisiae	O
.	O

Both	O
mutants	O
showed	O
defects	O
in	O
protein	O
degradation	O
in	O
vivo	O
.	O

However	O
,	O
the	O
affinity	O
-	O
purified	O
26	B-Complex
S	I-Complex
proteasome	I-Complex
of	O
the	O
rpn6	O
mutants	O
grown	O
at	O
the	O
permissive	O
temperature	O
degraded	O
polyubiquitinated	O
Sic1p	O
efficiently	O
,	O
even	O
at	O
a	O
higher	O
temperature	O
.	O

Interestingly	O
,	O
their	O
enzyme	O
activity	O
was	O
even	O
higher	O
at	O
a	O
higher	O
temperature	O
,	O
indicating	O
that	O
once	O
made	O
mutant	O
proteasomes	B-Complex
are	O
stable	O
and	O
have	O
little	O
defect	O
in	O
the	O
proteolytic	O
function	O
.	O

These	O
results	O
suggest	O
that	O
the	O
deficiency	O
in	O
protein	O
degradation	O
observed	O
in	O
vivo	O
is	O
rather	O
due	O
to	O
a	O
defect	O
in	O
the	O
assembly	O
of	O
a	O
holoenzyme	O
at	O
the	O
restrictive	O
temperature	O
.	O

Indeed	O
,	O
both	O
rpn6	O
mutants	O
grown	O
at	O
the	O
restrictive	O
temperature	O
were	O
defective	O
in	O
assembling	O
the	O
26	B-Complex
S	I-Complex
proteasome	I-Complex
.	O

A	O
striking	O
feature	O
of	O
the	O
rpn6	O
mutants	O
at	O
the	O
restrictive	O
temperature	O
was	O
that	O
there	O
appeared	O
a	O
protein	O
complex	O
composed	O
of	O
only	O
four	O
of	O
the	O
nine	O
lid	O
components	O
,	O
Rpn5p	O
,	O
Rpn8p	O
,	O
Rpn9p	O
,	O
and	O
Rpn11p	O
.	O

Altogether	O
,	O
we	O
conclude	O
that	O
Rpn6p	O
is	O
essential	O
for	O
the	O
integrity	O
/	O
assembly	O
of	O
the	O
lid	O
in	O
the	O
sense	O
that	O
it	O
is	O
necessary	O
for	O
the	O
incorporation	O
of	O
Rpn3p	O
,	O
Rpn7p	O
,	O
Rpn12p	O
,	O
and	O
Sem1p	O
(	O
Rpn15p	O
)	O
into	O
the	O
lid	O
,	O
thereby	O
playing	O
an	O
essential	O
role	O
in	O
the	O
proper	O
function	O
of	O
the	O
26	B-Complex
S	I-Complex
proteasome	I-Complex
.	O

Downregulation	O
of	O
lipopolysaccharide	O
response	O
in	O
Drosophila	O
by	O
negative	O
crosstalk	O
between	O
the	O
AP1	B-Complex
and	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
signaling	O
modules	O
.	O

IkappaB	B-Complex
kinase	I-Complex
(	O
IKK	B-Complex
)	O
and	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
Jnk	O
)	O
signaling	O
modules	O
are	O
important	O
in	O
the	O
synthesis	O
of	O
immune	O
effector	O
molecules	O
during	O
innate	O
immune	O
responses	O
against	O
lipopolysaccharide	O
and	O
peptidoglycan	O
.	O

However	O
,	O
the	O
regulatory	O
mechanisms	O
required	O
for	O
specificity	O
and	O
termination	O
of	O
these	O
immune	O
responses	O
are	O
unclear	O
.	O

We	O
show	O
here	O
that	O
crosstalk	O
occurred	O
between	O
the	O
drosophila	O
Jnk	O
and	O
IKK	B-Complex
pathways	O
,	O
which	O
led	O
to	O
downregulation	O
of	O
each	O
other	O
'	O
s	O
activity	O
.	O

The	O
inhibitory	O
action	O
of	O
Jnk	O
was	O
mediated	O
by	O
binding	O
of	O
drosophila	O
activator	B-Complex
protein	I-Complex
1	I-Complex
(	O
AP1	B-Complex
)	O
to	O
promoters	O
activated	O
by	O
the	O
transcription	O
factor	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
.	O

This	O
binding	O
led	O
to	O
recruitment	O
of	O
the	O
histone	O
deacetylase	O
dHDAC1	O
to	O
the	O
promoter	O
of	O
the	O
gene	O
encoding	O
the	O
antibacterial	O
protein	O
Attacin	O
-	O
A	O
and	O
to	O
local	O
modification	O
of	O
histone	O
acetylation	O
content	O
.	O

Thus	O
,	O
AP1	B-Complex
acts	O
as	O
a	O
repressor	O
by	O
recruiting	O
the	O
deacetylase	O
complex	O
to	O
terminate	O
activation	O
of	O
a	O
group	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
target	O
genes	O
.	O

Cannabinoid	O
receptor	O
-	O
induced	O
neurite	O
outgrowth	O
is	O
mediated	O
by	O
Rap1	O
activation	O
through	O
G	O
(	O
alpha	O
)	O
o	O
/	O
i	O
-	O
triggered	O
proteasomal	O
degradation	O
of	O
Rap1GAPII	O
.	O

The	O
G	O
(	O
alpha	O
)	O
o	O
/	O
i	O
-	O
coupled	O
CB1	O
cannabionoid	O
receptor	O
induces	O
neurite	O
outgrowth	O
in	O
Neuro	O
-	O
2A	O
cells	O
.	O

The	O
mechanisms	O
of	O
signaling	O
through	O
G	O
(	O
alpha	O
)	O
o	O
/	O
i	O
to	O
induce	O
neurite	O
outgrowth	O
were	O
studied	O
.	O

The	O
expression	O
of	O
G	O
(	O
alpha	O
)	O
o	O
/	O
i	O
reduces	O
the	O
stability	O
of	O
its	O
direct	O
interactor	O
protein	O
,	O
Rap1GAPII	O
,	O
by	O
targeting	O
it	O
for	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
.	O

This	O
results	O
in	O
the	O
activation	O
of	O
Rap1	O
.	O

G	O
(	O
alpha	O
)	O
o	O
/	O
i	O
-	O
induced	O
activation	O
of	O
endogenous	O
Rap1	O
in	O
Neuro	O
-	O
2A	O
cells	O
is	O
blocked	O
by	O
the	O
proteasomal	O
inhibitor	O
lactacystin	O
.	O

G	O
(	O
alpha	O
)	O
o	O
/	O
i	O
stimulates	O
neurite	O
outgrowth	O
that	O
is	O
blocked	O
by	O
the	O
expression	O
of	O
dominant	O
negative	O
Rap1	O
.	O

Expression	O
of	O
Rap1GAPII	O
also	O
blocks	O
the	O
G	O
(	O
alpha	O
)	O
o	O
/	O
i	O
-	O
induced	O
neurite	O
outgrowth	O
and	O
treatment	O
with	O
proteasomal	O
inhibitors	O
potentiates	O
this	O
inhibition	O
.	O

The	O
endogenous	O
G	O
(	O
alpha	O
)	O
o	O
/	O
i	O
-	O
coupled	O
cannabinoid	O
(	O
CB1	O
)	O
receptor	O
in	O
Neuro	O
-	O
2A	O
cells	O
stimulates	O
the	O
degradation	O
of	O
Rap1GAPII	O
;	O
activation	O
of	O
Rap1	O
and	O
treatment	O
with	O
pertussis	O
toxin	O
or	O
lactacystin	O
blocks	O
these	O
effects	O
.	O

The	O
CB1	O
receptor	O
-	O
stimulated	O
neurite	O
outgrowth	O
is	O
blocked	O
by	O
treatment	O
with	O
pertussis	O
toxin	O
,	O
small	O
interfering	O
RNA	O
for	O
Rap	O
,	O
lactacystin	O
,	O
and	O
expression	O
of	O
Rap1GAPII	O
.	O

Thus	O
,	O
the	O
G	O
(	O
alpha	O
)	O
o	O
/	O
i	O
-	O
coupled	O
cannabinoid	O
receptor	O
,	O
by	O
regulating	O
the	O
proteasomal	O
degradation	O
of	O
Rap1GAPII	O
,	O
activates	O
Rap1	O
to	O
induce	O
neurite	O
outgrowth	O
.	O

SCF	B-Complex
(	I-Complex
Pof1	I-Complex
)	I-Complex
-	O
ubiquitin	O
and	O
its	O
target	O
Zip1	O
transcription	O
factor	O
mediate	O
cadmium	O
response	O
in	O
fission	O
yeast	O
.	O

Ubiquitin	O
-	O
dependent	O
proteolysis	O
regulates	O
gene	O
expression	O
in	O
many	O
eukaryotic	O
systems	O
.	O

Pof1	O
is	O
an	O
essential	O
fission	O
yeast	O
F	O
-	O
box	O
protein	O
that	O
is	O
homologous	O
to	O
budding	O
yeast	O
Met30	O
.	O

Temperature	O
-	O
sensitive	O
pof1	O
mutants	O
display	O
acute	O
growth	O
arrest	O
with	O
small	O
cell	O
size	O
.	O

Extragenic	O
suppressor	O
analysis	O
identified	O
Zip1	O
,	O
a	O
bZIP	O
(	O
basic	O
leucine	O
zipper	O
)	O
transcription	O
factor	O
,	O
as	O
a	O
target	O
for	O
Pof1	O
.	O

We	O
show	O
Zip1	O
is	O
stabilized	O
in	O
pof1	O
mutants	O
,	O
Pof1	O
binds	O
only	O
phosphorylated	O
forms	O
of	O
Zip1	O
,	O
and	O
Zip1	O
is	O
ubiquitylated	O
in	O
vivo	O
,	O
indicating	O
that	O
Zip1	O
is	O
a	O
substrate	O
of	O
SCF	B-Complex
(	I-Complex
Pof1	I-Complex
)	I-Complex
.	O

Genome	O
-	O
wide	O
DNA	O
microarray	O
assay	O
shows	O
that	O
many	O
cadmium	O
-	O
induced	O
genes	O
are	O
under	O
the	O
control	O
of	O
Zip1	O
,	O
suggesting	O
Zip1	O
plays	O
a	O
role	O
in	O
cadmium	O
response	O
.	O

Consistently	O
,	O
zip1	O
mutants	O
are	O
hypersensitive	O
to	O
cadmium	O
and	O
unlike	O
wild	O
type	O
,	O
lose	O
cell	O
viability	O
under	O
this	O
stress	O
.	O

Intriguingly	O
,	O
cadmium	O
exposure	O
results	O
in	O
upregulation	O
of	O
Zip1	O
levels	O
and	O
leads	O
wild	O
-	O
type	O
cells	O
to	O
growth	O
arrest	O
with	O
reduced	O
cell	O
size	O
,	O
reminiscent	O
of	O
pof1	O
phenotypes	O
.	O

Our	O
results	O
indicate	O
that	O
Zip1	O
mediates	O
growth	O
arrest	O
in	O
cadmium	O
response	O
,	O
which	O
is	O
essential	O
to	O
maintain	O
viability	O
.	O

Normally	O
growing	O
cells	O
prevent	O
this	O
response	O
through	O
constitutive	O
ubiquitylation	O
and	O
degradation	O
of	O
Zip1	O
via	O
SCF	B-Complex
(	I-Complex
Pof1	I-Complex
)	I-Complex
.	O

Functional	O
analysis	O
of	O
TbARL1	O
,	O
an	O
N	O
-	O
myristoylated	O
Golgi	O
protein	O
essential	O
for	O
viability	O
in	O
bloodstream	O
trypanosomes	O
.	O

Myristoyl	O
-	O
CoA	O
:	O
protein	O
N	O
-	O
myristoyltransferase	O
(	O
NMT	O
)	O
,	O
an	O
essential	O
protein	O
in	O
Trypanosoma	O
brucei	O
and	O
Leishmania	O
major	O
,	O
catalyses	O
the	O
covalent	O
attachment	O
of	O
the	O
fatty	O
acid	O
myristate	O
to	O
the	O
N	O
-	O
terminus	O
of	O
a	O
range	O
of	O
target	O
proteins	O
.	O

In	O
order	O
to	O
define	O
the	O
essential	O
targets	O
contributing	O
to	O
lethality	O
in	O
the	O
absence	O
of	O
NMT	O
activity	O
,	O
we	O
have	O
focused	O
on	O
the	O
ADP	O
-	O
ribosylation	O
factor	O
(	O
Arf	O
)	O
family	O
of	O
GTP	O
-	O
binding	O
proteins	O
,	O
as	O
growth	O
arrest	O
in	O
Saccharomyces	O
cerevisiae	O
mutants	O
with	O
reduced	O
NMT	O
activity	O
correlates	O
with	O
a	O
decrease	O
in	O
N	O
-	O
myristoylated	O
Arf	O
proteins	O
.	O

We	O
have	O
identified	O
nine	O
Arf	O
/	O
Arls	O
in	O
the	O
T	O
.	O
brucei	O
and	O
T	O
.	O
cruzi	O
genomes	O
and	O
ten	O
in	O
L	O
.	O
major	O
.	O

Characterization	O
of	O
the	O
T	O
.	O
brucei	O
ARL1	O
homologue	O
has	O
revealed	O
that	O
the	O
protein	O
is	O
localized	O
in	O
the	O
Golgi	O
apparatus	O
and	O
is	O
expressed	O
only	O
in	O
the	O
mammalian	O
bloodstream	O
form	O
of	O
the	O
parasite	O
and	O
not	O
in	O
the	O
insect	O
procyclic	O
stage	O
.	O

This	O
is	O
the	O
only	O
reported	O
example	O
to	O
date	O
of	O
a	O
differentially	O
expressed	O
ARL1	O
homologue	O
in	O
any	O
species	O
.	O

We	O
have	O
used	O
RNA	O
interference	O
to	O
demonstrate	O
that	O
ARL1	O
is	O
essential	O
for	O
viability	O
in	O
T	O
.	O
brucei	O
bloodstream	O
parasites	O
.	O

Prior	O
to	O
cell	O
death	O
,	O
depletion	O
of	O
ARL1	O
protein	O
in	O
bloodstream	O
parasites	O
results	O
in	O
abnormal	O
morphology	O
,	O
including	O
disintegration	O
of	O
the	O
Golgi	O
structure	O
,	O
multiple	O
flagella	O
and	O
nuclei	O
,	O
and	O
the	O
presence	O
of	O
large	O
numbers	O
of	O
vesicles	O
.	O

The	O
cells	O
have	O
only	O
a	O
minor	O
apparent	O
defect	O
in	O
endocytosis	O
but	O
exocytosis	O
of	O
variant	O
surface	O
glycoprotein	O
to	O
the	O
parasite	O
surface	O
is	O
significantly	O
delayed	O
.	O

RNA	O
interference	O
of	O
ARL1	O
in	O
procyclic	O
cells	O
has	O
no	O
effect	O
on	O
parasite	O
growth	O
or	O
morphology	O
.	O

Our	O
results	O
suggest	O
that	O
there	O
may	O
be	O
different	O
pathways	O
regulating	O
Golgi	O
structure	O
and	O
function	O
in	O
the	O
two	O
major	O
life	O
cycle	O
stages	O
of	O
T	O
.	O
brucei	O
.	O

Chaperone	O
activity	O
of	O
protein	O
O	O
-	O
fucosyltransferase	O
1	O
promotes	O
notch	O
receptor	O
folding	O
.	O

Notch	O
proteins	O
are	O
receptors	O
for	O
a	O
conserved	O
signaling	O
pathway	O
that	O
affects	O
numerous	O
cell	O
fate	O
decisions	O
.	O

We	O
found	O
that	O
in	O
Drosophila	O
,	O
Protein	O
O	O
-	O
fucosyltransferase	O
1	O
(	O
OFUT1	O
)	O
,	O
an	O
enzyme	O
that	O
glycosylates	O
epidermal	O
growth	O
factor	O
-	O
like	O
domains	O
of	O
Notch	O
,	O
also	O
has	O
a	O
distinct	O
Notch	O
chaperone	O
activity	O
.	O

OFUT1	O
is	O
an	O
endoplasmic	O
reticulum	O
protein	O
,	O
and	O
its	O
localization	O
was	O
essential	O
for	O
function	O
in	O
vivo	O
.	O

OFUT1	O
could	O
bind	O
to	O
Notch	O
,	O
was	O
required	O
for	O
the	O
trafficking	O
of	O
wild	O
-	O
type	O
Notch	O
out	O
of	O
the	O
endoplasmic	O
reticulum	O
,	O
and	O
could	O
partially	O
rescue	O
defects	O
in	O
secretion	O
and	O
ligand	O
binding	O
associated	O
with	O
Notch	O
point	O
mutations	O
.	O

This	O
ability	O
of	O
OFUT1	O
to	O
facilitate	O
folding	O
of	O
Notch	O
did	O
not	O
require	O
its	O
fucosyltransferase	O
activity	O
.	O

Thus	O
,	O
a	O
glycosyltransferase	O
can	O
bind	O
its	O
substrate	O
in	O
the	O
endoplasmic	O
reticulum	O
to	O
facilitate	O
normal	O
folding	O
.	O

Novel	O
role	O
of	O
ARF6	O
in	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
induced	O
signaling	O
and	O
angiogenesis	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
stimulates	O
endothelial	O
cell	O
(	O
EC	O
)	O
migration	O
and	O
proliferation	O
primarily	O
through	O
the	O
VEGF	O
receptor	O
-	O
2	O
(	O
VEGFR2	O
)	O
.	O

We	O
have	O
shown	O
that	O
VEGF	O
stimulates	O
a	O
Rac1	O
-	O
dependent	O
NAD	O
(	O
P	O
)	O
H	O
oxidase	O
to	O
produce	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
that	O
are	O
involved	O
in	O
VEGFR2	O
autophosphorylation	O
and	O
angiogenic	O
-	O
related	O
responses	O
in	O
ECs	O
.	O

The	O
small	O
GTPase	O
ARF6	O
is	O
involved	O
in	O
membrane	O
trafficking	O
and	O
cell	O
motility	O
;	O
however	O
,	O
its	O
roles	O
in	O
VEGF	O
signaling	O
and	O
physiological	O
responses	O
in	O
ECs	O
are	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
dominant	O
-	O
negative	O
ARF6	O
[	O
ARF6	O
(	O
T27N	O
)	O
]	O
almost	O
completely	O
inhibits	O
VEGF	O
-	O
induced	O
Rac1	O
activation	O
,	O
ROS	O
production	O
,	O
and	O
VEGFR2	O
autophosphorylation	O
in	O
ECs	O
.	O

Fractionation	O
of	O
caveolae	O
/	O
lipid	O
raft	O
membranes	O
demonstrates	O
that	O
ARF6	O
,	O
Rac1	O
,	O
and	O
VEGFR2	O
are	O
localized	O
in	O
caveolin	O
-	O
enriched	O
fractions	O
basally	O
.	O

VEGF	O
stimulation	O
results	O
in	O
the	O
release	O
of	O
VEGFR2	O
from	O
caveolae	O
/	O
lipid	O
rafts	O
and	O
caveolin	O
-	O
1	O
without	O
affecting	O
localization	O
of	O
ARF6	O
,	O
Rac1	O
,	O
or	O
caveolin	O
-	O
1	O
in	O
these	O
fractions	O
.	O

The	O
egress	O
of	O
VEGFR2	O
from	O
caveolae	O
/	O
lipid	O
rafts	O
is	O
contemporaneous	O
with	O
the	O
tyrosine	O
phosphorylation	O
of	O
caveolin	O
-	O
1	O
(	O
Tyr14	O
)	O
and	O
VEGFR2	O
and	O
with	O
their	O
association	O
with	O
each	O
other	O
.	O

ARF6	O
(	O
T27N	O
)	O
significantly	O
inhibits	O
both	O
VEGF	O
-	O
induced	O
responses	O
.	O

Immunofluorescence	O
studies	O
show	O
that	O
activated	O
VEGFR2	O
and	O
phosphocaveolin	O
colocalize	O
at	O
focal	O
complexes	O
/	O
adhesions	O
after	O
VEGF	O
stimulation	O
.	O

Both	O
overexpression	O
of	O
ARF6	O
(	O
T27N	O
)	O
and	O
mutant	O
caveolin	O
-	O
1	O
(	O
Y14F	O
)	O
,	O
which	O
cannot	O
be	O
phosphorylated	O
,	O
block	O
VEGF	O
-	O
stimulated	O
EC	O
migration	O
and	O
proliferation	O
.	O

Moreover	O
,	O
ARF6	O
expression	O
is	O
markedly	O
upregulated	O
in	O
association	O
with	O
an	O
increase	O
in	O
capillary	O
density	O
in	O
a	O
mouse	O
hindlimb	O
ischemia	O
model	O
of	O
angiogenesis	O
.	O

Thus	O
,	O
ARF6	O
is	O
involved	O
in	O
the	O
temporal	O
-	O
spatial	O
organization	O
of	O
caveolae	O
/	O
lipid	O
rafts	O
-	O
and	O
ROS	O
-	O
dependent	O
VEGF	O
signaling	O
in	O
ECs	O
as	O
well	O
as	O
in	O
angiogenesis	O
in	O
vivo	O
.	O

Effects	O
of	O
over	O
-	O
expression	O
of	O
the	O
regulatory	O
enzymes	O
DraT	O
and	O
DraG	O
on	O
the	O
ammonium	O
-	O
dependent	O
post	O
-	O
translational	O
regulation	O
of	O
nitrogenase	B-OOS
reductase	I-OOS
in	O
Azospirillum	O
brasilense	O
.	O

Nitrogen	O
fixation	O
in	O
Azospirillum	O
brasilense	O
is	O
regulated	O
at	O
transcriptional	O
and	O
post	O
-	O
translational	O
levels	O
.	O

Post	O
-	O
translational	O
control	O
occurs	O
through	O
the	O
reversible	O
ADP	O
-	O
ribosylation	O
of	O
dinitrogenase	B-OOS
reductase	I-OOS
(	O
Fe	B-OOS
Protein	I-OOS
)	O
,	O
mediated	O
by	O
the	O
dinitrogenase	O
reductase	O
ADP	O
-	O
ribosyltransferase	O
(	O
DraT	O
)	O
and	O
dinitrogenase	O
reductase	O
glycohydrolase	O
(	O
DraG	O
)	O
.	O

Although	O
the	O
DraT	O
and	O
DraG	O
activities	O
are	O
regulated	O
in	O
vivo	O
,	O
the	O
molecules	O
responsible	O
for	O
such	O
regulation	O
remain	O
unknown	O
.	O

We	O
have	O
constructed	O
broad	O
-	O
host	O
-	O
range	O
plasmids	O
capable	O
of	O
over	O
-	O
expressing	O
,	O
upon	O
IPTG	O
induction	O
,	O
the	O
regulatory	O
enzymes	O
DraT	O
and	O
DraG	O
as	O
six	O
-	O
histidine	O
-	O
N	O
-	O
terminal	O
fused	O
proteins	O
(	O
His	O
)	O
.	O

Both	O
DraT	O
-	O
His	O
and	O
DraG	O
-	O
His	O
are	O
functional	O
in	O
vivo	O
.	O

We	O
have	O
analyzed	O
the	O
effects	O
of	O
DraT	O
-	O
His	O
and	O
DraG	O
-	O
His	O
over	O
-	O
expression	O
on	O
the	O
post	O
-	O
translational	O
modification	O
of	O
Fe	B-OOS
Protein	I-OOS
.	O

The	O
DraT	O
-	O
His	O
over	O
-	O
expression	O
led	O
to	O
Fe	B-OOS
Protein	I-OOS
modification	O
in	O
the	O
absence	O
of	O
ammonium	O
addition	O
,	O
while	O
cells	O
over	O
-	O
expressing	O
DraG	O
-	O
His	O
showed	O
only	O
partial	O
ADP	O
-	O
ribosylation	O
of	O
Fe	B-OOS
Protein	I-OOS
by	O
adding	O
ammonium	O
.	O

These	O
results	O
suggest	O
that	O
both	O
DraT	O
-	O
His	O
and	O
DraG	O
-	O
His	O
lose	O
their	O
regulation	O
upon	O
over	O
-	O
expression	O
,	O
possible	O
by	O
titrating	O
out	O
negative	O
regulators	O
.	O

Synthesis	O
of	O
functionalized	O
rab	O
GTPases	O
by	O
a	O
combination	O
of	O
solution	O
-	O
or	O
solid	O
-	O
phase	O
lipopeptide	O
synthesis	O
with	O
expressed	O
protein	O
ligation	O
.	O

Prenylated	O
proteins	O
with	O
non	O
-	O
native	O
functionalities	O
are	O
generally	O
very	O
difficult	O
to	O
obtain	O
by	O
recombinant	O
or	O
enzymatic	O
means	O
.	O

The	O
semisynthesis	O
of	O
preparative	O
amounts	O
of	O
prenylated	O
Rab	O
guanosine	O
triphosphatases	O
(	O
GTPases	O
)	O
from	O
recombinant	O
proteins	O
and	O
synthetic	O
prenylated	O
peptides	O
depends	O
largely	O
on	O
the	O
availability	O
of	O
functionalised	O
prenylated	O
peptides	O
corresponding	O
to	O
the	O
proteins	O
'	O
native	O
structure	O
or	O
modifications	O
thereof	O
.	O

Here	O
,	O
we	O
describe	O
and	O
compare	O
solution	O
-	O
phase	O
and	O
solid	O
-	O
phase	O
strategies	O
for	O
the	O
generation	O
of	O
peptides	O
corresponding	O
to	O
the	O
prenylated	O
C	O
terminus	O
of	O
Rab7	O
GTPase	O
.	O

The	O
solid	O
-	O
phase	O
with	O
utilisation	O
of	O
a	O
hydrazide	O
linker	O
emerges	O
as	O
the	O
more	O
favourable	O
approach	O
.	O

It	O
allows	O
a	O
fast	O
and	O
practical	O
synthesis	O
of	O
pure	O
peptides	O
and	O
gives	O
a	O
high	O
degree	O
of	O
flexibility	O
in	O
their	O
modification	O
.	O

To	O
facilitate	O
the	O
analysis	O
of	O
semisynthetic	O
proteins	O
,	O
the	O
synthesised	O
peptides	O
were	O
equipped	O
with	O
a	O
fluorescent	O
group	O
.	O

Using	O
the	O
described	O
approach	O
,	O
we	O
introduced	O
fluorophores	O
at	O
several	O
different	O
positions	O
of	O
the	O
Rab7	O
C	O
terminus	O
.	O

The	O
position	O
of	O
the	O
incorporated	O
fluorescent	O
groups	O
in	O
the	O
peptides	O
did	O
not	O
influence	O
the	O
protein	O
-	O
ligation	O
reaction	O
,	O
as	O
the	O
generated	O
peptides	O
could	O
be	O
ligated	O
onto	O
thioester	O
-	O
tagged	O
Rab7	O
.	O

However	O
,	O
it	O
was	O
found	O
that	O
the	O
positioning	O
of	O
the	O
fluorescent	O
group	O
had	O
an	O
influence	O
on	O
the	O
functionality	O
of	O
the	O
Rab7	O
proteins	O
;	O
analysis	O
of	O
the	O
interaction	O
of	O
the	O
semisynthetic	O
Rab7	O
proteins	O
with	O
REP	O
(	O
Rab	O
escort	O
protein	O
)	O
and	O
GDI	O
(	O
guanosine	O
diphosphate	O
dissociation	O
inhibitor	O
)	O
molecules	O
revealed	O
that	O
modification	O
of	O
the	O
peptide	O
side	O
chains	O
or	O
of	O
the	O
C	O
-	O
terminal	O
isoprenoid	O
did	O
not	O
significantly	O
interfere	O
with	O
complex	O
formation	O
.	O

However	O
,	O
functionalisation	O
of	O
the	O
C	O
terminus	O
was	O
found	O
to	O
have	O
an	O
adverse	O
effect	O
on	O
complex	O
formation	O
and	O
stability	O
,	O
possibly	O
reflecting	O
low	O
structural	O
flexibility	O
of	O
the	O
Rab	O
GDI	O
/	O
REP	O
molecules	O
in	O
the	O
vicinity	O
of	O
the	O
lipid	O
-	O
binding	O
site	O
.	O

Disabled	O
-	O
2	O
(	O
Dab2	O
)	O
is	O
required	O
for	O
transforming	O
growth	O
factor	O
beta	O
-	O
induced	O
epithelial	O
to	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
.	O

Transforming	O
growth	O
factor	O
beta	O
(	O
TGFbeta	O
)	O
induces	O
an	O
epithelial	O
to	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
during	O
both	O
physiological	O
and	O
pathological	O
processes	O
;	O
however	O
,	O
the	O
mechanism	O
underlying	O
this	O
transition	O
is	O
not	O
fully	O
elucidated	O
.	O

Here	O
,	O
we	O
have	O
demonstrated	O
that	O
TGFbeta	O
induces	O
the	O
expression	O
of	O
the	O
adaptor	O
molecule	O
disabled	O
-	O
2	O
(	O
Dab2	O
)	O
concomitant	O
with	O
the	O
promotion	O
of	O
EMT	O
.	O

We	O
show	O
that	O
TGFbeta	O
induces	O
a	O
transient	O
accumulation	O
of	O
Dab2	O
to	O
the	O
membrane	O
and	O
increases	O
Dab2	O
binding	O
to	O
beta1	O
integrin	O
.	O

Furthermore	O
,	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
-	O
mediated	O
silencing	O
of	O
Dab2	O
expression	O
in	O
mouse	O
mammary	O
gland	O
epithelial	O
cells	O
results	O
in	O
inhibition	O
of	O
integrin	O
activation	O
,	O
shown	O
by	O
a	O
decrease	O
of	O
both	O
TGFbeta	O
-	O
induced	O
focal	O
adhesion	O
kinase	O
phosphorylation	O
and	O
cellular	O
adherence	O
,	O
leading	O
to	O
apoptosis	O
and	O
inhibition	O
of	O
EMT	O
.	O

Forced	O
re	O
-	O
expression	O
of	O
human	O
Dab2	O
,	O
not	O
targeted	O
by	O
the	O
mouse	O
siRNA	O
sequence	O
,	O
rescues	O
cells	O
from	O
apoptosis	O
and	O
restores	O
TGFbeta	O
-	O
mediated	O
integrin	O
activation	O
and	O
EMT	O
.	O

These	O
results	O
are	O
confirmed	O
in	O
the	O
F9	O
teratocarcinoma	O
cell	O
line	O
,	O
a	O
model	O
for	O
retinoic	O
acid	O
-	O
induced	O
visceral	O
endoderm	O
differentiation	O
in	O
which	O
we	O
demonstrate	O
that	O
ablation	O
of	O
retinoic	O
acid	O
-	O
induced	O
Dab2	O
expression	O
levels	O
,	O
by	O
stable	O
siRNA	O
silencing	O
of	O
Dab2	O
,	O
blocks	O
visceral	O
endoderm	O
differentiation	O
.	O

Our	O
findings	O
indicate	O
that	O
Dab2	O
plays	O
an	O
important	O
regulatory	O
role	O
during	O
cellular	O
differentiation	O
and	O
that	O
induction	O
of	O
differentiation	O
in	O
the	O
absence	O
of	O
Dab2	O
expression	O
commits	O
the	O
cell	O
to	O
apoptosis	O
.	O

Single	O
-	O
step	O
Strep	O
-	O
tag	O
purification	O
for	O
the	O
isolation	O
and	O
identification	O
of	O
protein	O
complexes	O
from	O
mammalian	O
cells	O
.	O

Identification	O
of	O
protein	O
complexes	O
is	O
the	O
key	O
to	O
understanding	O
cellular	O
functions	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
a	O
novel	O
method	O
for	O
the	O
identification	O
of	O
multiprotein	O
complexes	O
from	O
mammalian	O
cells	O
.	O

By	O
using	O
the	O
Strep	O
-	O
tag	O
affinity	O
chromatography	O
method	O
,	O
enabling	O
fast	O
and	O
simple	O
one	O
-	O
step	O
purification	O
,	O
coupled	O
with	O
competitive	O
elution	O
under	O
physiological	O
conditions	O
,	O
we	O
successfully	O
purified	O
a	O
PP2A	B-Complex
holoenzyme	O
protein	O
complex	O
from	O
a	O
cultured	O
mammalian	O
cancer	O
cell	O
line	O
.	O

We	O
identified	O
,	O
by	O
mass	O
spectrometry	O
,	O
both	O
known	O
and	O
novel	O
interacting	O
proteins	O
for	O
PP2A	B-Complex
,	O
and	O
demonstrate	O
that	O
the	O
purified	O
PP2A	B-Complex
complex	O
is	O
functional	O
.	O

The	O
benefits	O
and	O
potential	O
applications	O
of	O
the	O
Strep	O
-	O
tag	O
method	O
for	O
protein	O
complex	O
purification	O
are	O
discussed	O
.	O

Nep1	O
,	O
a	O
Schizosaccharomyces	O
pombe	O
deneddylating	O
enzyme	O
.	O

Nedd8	O
is	O
a	O
ubiquitin	O
-	O
like	O
modifier	O
that	O
is	O
attached	O
to	O
the	O
cullin	O
components	O
of	O
E3	O
ubiquitin	O
ligases	O
.	O

More	O
recently	O
,	O
p53	O
has	O
also	O
been	O
shown	O
to	O
be	O
Nedd8	O
-	O
modified	O
.	O

Nedd8	O
attachment	O
occurs	O
in	O
a	O
manner	O
similar	O
to	O
that	O
observed	O
for	O
other	O
ubiquitin	O
-	O
like	O
modifiers	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
on	O
the	O
characterization	O
of	O
Nep1	O
,	O
a	O
deneddylating	O
enzyme	O
in	O
fission	O
yeast	O
(	O
Schizosaccharomyces	O
pombe	O
)	O
.	O

Unlike	O
loss	O
of	O
ned8	O
,	O
deletion	O
of	O
the	O
nep1	O
gene	O
is	O
not	O
lethal	O
,	O
although	O
nep1	O
.	O
d	O
cells	O
are	O
heterogeneous	O
in	O
length	O
,	O
suggesting	O
a	O
defect	O
in	O
cell	O
-	O
cycle	O
progression	O
.	O

Viability	O
of	O
nep1	O
.	O
d	O
cells	O
is	O
dependent	O
on	O
a	O
functional	O
spindle	O
checkpoint	O
but	O
not	O
on	O
the	O
DNA	O
integrity	O
checkpoint	O
.	O

Deletion	O
of	O
a	O
related	O
gene	O
(	O
nep2	O
)	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
nep1	O
.	O
d	O
,	O
also	O
has	O
little	O
effect	O
on	O
cell	O
viability	O
.	O

We	O
show	O
that	O
Nep1	O
can	O
deneddylate	O
the	O
Pcu1	O
,	O
Pcu3	O
and	O
Pcu4	O
cullins	O
in	O
vitro	O
and	O
that	O
its	O
activity	O
is	O
sensitive	O
to	O
N	O
-	O
ethylmaleimide	O
,	O
consistent	O
with	O
the	O
idea	O
that	O
it	O
is	O
a	O
member	O
of	O
the	O
cysteine	O
protease	O
family	O
.	O

nep1	O
.	O
d	O
cells	O
accumulate	O
Nedd8	O
-	O
modified	O
proteins	O
,	O
although	O
these	O
do	O
not	O
correspond	O
to	O
modified	O
forms	O
of	O
the	O
cullins	O
,	O
suggesting	O
that	O
,	O
although	O
Nep1	O
can	O
deneddylate	O
cullins	O
in	O
vitro	O
,	O
this	O
is	O
not	O
its	O
main	O
function	O
in	O
vivo	O
.	O

Nep1	O
can	O
be	O
co	O
-	O
precipitated	O
with	O
the	O
signalosome	B-Complex
subunit	O
Csn5	O
.	O

Nep1	O
itself	O
is	O
present	O
in	O
a	O
high	O
-	O
molecular	O
-	O
mass	O
complex	O
,	O
but	O
the	O
presence	O
of	O
this	O
complex	O
is	O
not	O
dependent	O
on	O
the	O
production	O
of	O
intact	O
signalosomes	O
.	O

Our	O
results	O
suggest	O
that	O
,	O
in	O
vivo	O
,	O
Nep1	O
may	O
be	O
responsible	O
for	O
deneddylating	O
proteins	O
other	O
than	O
cullins	O
.	O

The	O
C2	O
domain	O
of	O
PKCdelta	O
is	O
a	O
phosphotyrosine	O
binding	O
domain	O
.	O

In	O
eukaryotic	O
cells	O
,	O
the	O
SH2	O
and	O
PTB	O
domains	O
mediate	O
protein	O
-	O
protein	O
interactions	O
by	O
recognizing	O
phosphotyrosine	O
residues	O
on	O
target	O
proteins	O
.	O

Here	O
we	O
make	O
the	O
unexpected	O
finding	O
that	O
the	O
C2	O
domain	O
of	O
PKCdelta	O
directly	O
binds	O
to	O
phosphotyrosine	O
peptides	O
in	O
a	O
sequence	O
-	O
specific	O
manner	O
.	O

We	O
provide	O
evidence	O
that	O
this	O
domain	O
mediates	O
PKCdelta	O
interaction	O
with	O
a	O
Src	O
binding	O
glycoprotein	O
,	O
CDCP1	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
PKCdelta	O
C2	O
domain	O
in	O
complex	O
with	O
an	O
optimal	O
phosphopeptide	O
reveals	O
a	O
new	O
mode	O
of	O
phosphotyrosine	O
binding	O
in	O
which	O
the	O
phosphotyrosine	O
moiety	O
forms	O
a	O
ring	O
-	O
stacking	O
interaction	O
with	O
a	O
histidine	O
residue	O
of	O
the	O
C2	O
domain	O
.	O

This	O
is	O
also	O
the	O
first	O
example	O
of	O
a	O
protein	O
Ser	O
/	O
Thr	O
kinase	O
containing	O
a	O
domain	O
that	O
binds	O
phosphotyrosine	O
.	O

POMT2	O
mutations	O
cause	O
alpha	O
-	O
dystroglycan	O
hypoglycosylation	O
and	O
Walker	O
-	O
Warburg	O
syndrome	O
.	O

BACKGROUND	O
:	O
Walker	O
-	O
Warburg	O
syndrome	O
(	O
WWS	O
)	O
is	O
an	O
autosomal	O
recessive	O
condition	O
characterised	O
by	O
congenital	O
muscular	O
dystrophy	O
,	O
structural	O
brain	O
defects	O
,	O
and	O
eye	O
malformations	O
.	O

Typical	O
brain	O
abnormalities	O
are	O
hydrocephalus	O
,	O
lissencephaly	O
,	O
agenesis	O
of	O
the	O
corpus	O
callosum	O
,	O
fusion	O
of	O
the	O
hemispheres	O
,	O
cerebellar	O
hypoplasia	O
,	O
and	O
neuronal	O
overmigration	O
,	O
which	O
causes	O
a	O
cobblestone	O
cortex	O
.	O

Ocular	O
abnormalities	O
include	O
cataract	O
,	O
microphthalmia	O
,	O
buphthalmos	O
,	O
and	O
Peters	O
anomaly	O
.	O

WWS	O
patients	O
show	O
defective	O
O	O
-	O
glycosylation	O
of	O
alpha	O
-	O
dystroglycan	O
(	O
alpha	O
-	O
DG	O
)	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
bridging	O
the	O
cytoskeleton	O
of	O
muscle	O
and	O
CNS	O
cells	O
with	O
extracellular	O
matrix	O
proteins	O
,	O
important	O
for	O
muscle	O
integrity	O
and	O
neuronal	O
migration	O
.	O

In	O
20	O
%	O
of	O
the	O
WWS	O
patients	O
,	O
hypoglycosylation	O
results	O
from	O
mutations	O
in	O
either	O
the	O
protein	O
O	O
-	O
mannosyltransferase	O
1	O
(	O
POMT1	O
)	O
,	O
fukutin	O
,	O
or	O
fukutin	O
related	O
protein	O
(	O
FKRP	O
)	O
genes	O
.	O

The	O
other	O
genes	O
for	O
this	O
highly	O
heterogeneous	O
disorder	O
remain	O
to	O
be	O
identified	O
.	O

OBJECTIVE	O
:	O
To	O
look	O
for	O
mutations	O
in	O
POMT2	O
as	O
a	O
cause	O
of	O
WWS	O
,	O
as	O
both	O
POMT1	O
and	O
POMT2	O
are	O
required	O
to	O
achieve	O
protein	O
O	O
-	O
mannosyltransferase	O
activity	O
.	O

METHODS	O
:	O
A	O
candidate	O
gene	O
approach	O
combined	O
with	O
homozygosity	O
mapping	O
.	O

RESULTS	O
:	O
Homozygosity	O
was	O
found	O
for	O
the	O
POMT2	O
locus	O
at	O
14q24	O
.	O
3	O
in	O
four	O
of	O
11	O
consanguineous	O
WWS	O
families	O
.	O

Homozygous	O
POMT2	O
mutations	O
were	O
present	O
in	O
two	O
of	O
these	O
families	O
as	O
well	O
as	O
in	O
one	O
patient	O
from	O
another	O
cohort	O
of	O
six	O
WWS	O
families	O
.	O

Immunohistochemistry	O
in	O
muscle	O
showed	O
severely	O
reduced	O
levels	O
of	O
glycosylated	O
alpha	O
-	O
DG	O
,	O
which	O
is	O
consistent	O
with	O
the	O
postulated	O
role	O
for	O
POMT2	O
in	O
the	O
O	O
-	O
mannosylation	O
pathway	O
.	O

CONCLUSIONS	O
:	O
A	O
fourth	O
causative	O
gene	O
for	O
WWS	O
was	O
uncovered	O
.	O

These	O
genes	O
account	O
for	O
approximately	O
one	O
third	O
of	O
the	O
WWS	O
cases	O
.	O

Several	O
more	O
genes	O
are	O
anticipated	O
,	O
which	O
are	O
likely	O
to	O
play	O
a	O
role	O
in	O
glycosylation	O
of	O
alpha	O
-	O
DG	O
.	O

The	O
multicopy	O
plasmid	O
YEp13	O
containing	O
the	O
INP1	O
gene	O
was	O
introduced	O
into	O
wild	O
-	O
type	O
cells	O
synthesizing	O
Pot1p	O
-	O
GFP	O
to	O
determine	O
the	O
effects	O
of	O
INP1	O
overexpression	O
on	O
the	O
peroxisome	O
phenotype	O
.	O

Overexpression	O
of	O
INP1	O
in	O
cells	O
incubated	O
in	O
oleic	O
acid	O
medium	O
led	O
to	O
the	O
preferential	O
localization	O
of	O
peroxisomes	O
to	O
the	O
cortical	O
regions	O
of	O
cells	O
(	O
Fig	O
.	O
2	O
C	O
)	O
,	O
as	O
shown	O
by	O
the	O
analysis	O
of	O
individual	O
optical	O
sections	O
in	O
a	O
z	O
-	O
stack	O
.	O

In	O
addition	O
,	O
overexpression	O
of	O
INP1	O
led	O
to	O
an	O
apparent	O
irregularity	O
in	O
the	O
distribution	O
of	O
peroxisomes	O
between	O
mother	O
cells	O
and	O
buds	O
,	O
with	O
a	O
significant	O
number	O
of	O
buds	O
not	O
containing	O
any	O
readily	O
evident	O
fluorescent	O
peroxisomes	O
.	O

Golgi	O
targeting	O
of	O
human	O
guanylate	O
-	O
binding	O
protein	O
-	O
1	O
requires	O
nucleotide	O
binding	O
,	O
isoprenylation	O
,	O
and	O
an	O
IFN	O
-	O
gamma	O
-	O
inducible	O
cofactor	O
.	O

Human	O
guanylate	O
-	O
binding	O
protein	O
-	O
1	O
(	O
hGBP	O
-	O
1	O
)	O
is	O
a	O
large	O
GTPase	O
,	O
similar	O
in	O
structure	O
to	O
the	O
dynamins	O
.	O

Like	O
many	O
smaller	O
GTPases	O
of	O
the	O
Ras	O
/	O
Rab	O
family	O
,	O
it	O
is	O
farnesylated	O
,	O
suggesting	O
it	O
may	O
dock	O
into	O
membranes	O
and	O
perhaps	O
play	O
a	O
role	O
in	O
intracellular	O
trafficking	O
.	O

To	O
date	O
,	O
however	O
,	O
hGBP	O
-	O
1	O
has	O
never	O
been	O
associated	O
with	O
a	O
specific	O
intracellular	O
compartment	O
.	O

Here	O
we	O
present	O
evidence	O
that	O
hGBP	O
-	O
1	O
can	O
associate	O
with	O
the	O
Golgi	O
apparatus	O
.	O

Redistribution	O
from	O
the	O
cytosol	O
to	O
the	O
Golgi	O
was	O
observed	O
by	O
immunofluorescence	O
and	O
subcellular	O
fractionation	O
after	O
aluminum	O
fluoride	O
treatment	O
,	O
suggesting	O
that	O
it	O
occurs	O
when	O
hGBP	O
-	O
1	O
is	O
in	O
its	O
GTP	O
-	O
bound	O
state	O
.	O

Relocalization	O
was	O
blocked	O
by	O
a	O
farnesyl	B-Complex
transferase	I-Complex
inhibitor	O
.	O

The	O
C589S	O
mutant	O
of	O
hGBP	O
-	O
1	O
,	O
which	O
cannot	O
be	O
farnesylated	O
,	O
and	O
the	O
previously	O
uncharacterized	O
R48P	O
mutant	O
,	O
which	O
cannot	O
bind	O
GTP	O
,	O
both	O
failed	O
to	O
localize	O
to	O
the	O
Golgi	O
.	O

These	O
two	O
mutants	O
had	O
a	O
dominant	O
-	O
negative	O
effect	O
,	O
preventing	O
endogenous	O
wild	O
-	O
type	O
hGBP	O
-	O
1	O
from	O
efficiently	O
redistributing	O
after	O
aluminum	O
fluoride	O
treatment	O
.	O

Furthermore	O
,	O
hGBP	O
-	O
1	O
requires	O
another	O
IFN	O
-	O
gamma	O
-	O
induced	O
factor	O
to	O
be	O
targeted	O
to	O
the	O
Golgi	O
,	O
because	O
constitutively	O
expressed	O
hGBP	O
-	O
1	O
remained	O
cytosolic	O
in	O
cells	O
treated	O
with	O
aluminum	O
fluoride	O
unless	O
the	O
cells	O
were	O
preincubated	O
with	O
IFN	O
-	O
gamma	O
.	O

Finally	O
,	O
two	O
nonhydrolyzing	O
mutants	O
of	O
hGBP	O
-	O
1	O
,	O
corresponding	O
to	O
active	O
mutants	O
of	O
Ras	O
family	O
proteins	O
,	O
failed	O
to	O
constitutively	O
associate	O
with	O
the	O
Golgi	O
;	O
we	O
propose	O
three	O
possible	O
explanations	O
for	O
this	O
surprising	O
result	O
.	O

Identification	O
of	O
LOV	O
KELCH	O
PROTEIN2	O
(	O
LKP2	O
)	O
-	O
interacting	O
factors	O
that	O
can	O
recruit	O
LKP2	O
to	O
nuclear	O
bodies	O
.	O

LOV	O
KELCH	O
PROTEIN2	O
(	O
LKP2	O
)	O
is	O
an	O
F	O
-	O
box	O
protein	O
that	O
has	O
been	O
postulated	O
to	O
function	O
centrally	O
,	O
or	O
near	O
to	O
the	O
circadian	O
clock	O
oscillator	O
.	O

As	O
a	O
first	O
step	O
to	O
determine	O
which	O
proteins	O
act	O
as	O
substrates	O
of	O
LKP2	O
,	O
yeast	O
two	O
-	O
hybrid	O
screening	O
was	O
performed	O
using	O
LKP2	O
as	O
bait	O
,	O
and	O
two	O
interaction	O
factors	O
,	O
Di19	O
and	O
COL1	O
,	O
were	O
isolated	O
.	O

The	O
transiently	O
expressed	O
Di19	O
-	O
GUS	O
fusion	O
protein	O
was	O
localized	O
in	O
the	O
nucleus	O
of	O
Arabidopsis	O
petiole	O
cells	O
.	O

COL1	O
and	O
other	O
CO	O
/	O
COL	O
family	O
proteins	O
could	O
also	O
interact	O
with	O
LKP1	O
/	O
ZTL	O
,	O
LKP2	O
or	O
FKF1	O
.	O

The	O
LKP2	O
-	O
binding	O
site	O
in	O
CO	O
or	O
COL1	O
was	O
near	O
the	O
center	O
of	O
each	O
protein	O
.	O

The	O
CCT	O
motif	O
in	O
CO	O
or	O
COL1	O
was	O
not	O
sufficient	O
for	O
interaction	O
with	O
LKP2	O
.	O

LKP2	O
recognized	O
CO	O
with	O
F	O
-	O
box	O
and	O
kelch	O
repeat	O
-	O
containing	O
regions	O
,	O
while	O
it	O
recognized	O
COL1	O
with	O
an	O
LOV	O
domain	O
.	O

When	O
LKP2	O
was	O
fused	O
with	O
cyan	O
fluorescent	O
proein	O
(	O
CFP	O
)	O
and	O
transiently	O
expressed	O
in	O
onion	O
epidermal	O
cells	O
,	O
CFP	O
-	O
LKP2	O
signals	O
were	O
localized	O
in	O
the	O
nucleus	O
and	O
cytosol	O
.	O

Both	O
yellow	O
fluorescent	O
protein	O
(	O
YFP	O
)	O
-	O
CO	O
and	O
YFP	O
-	O
COL1	O
were	O
located	O
in	O
the	O
nucleus	O
,	O
forming	O
nuclear	O
bodies	O
when	O
they	O
were	O
transiently	O
expressed	O
.	O

However	O
,	O
co	O
-	O
expression	O
of	O
CFP	O
-	O
LKP2	O
with	O
YFP	O
fused	O
to	O
either	O
CO	O
or	O
COL1	O
resulted	O
in	O
the	O
recruitment	O
of	O
CFP	O
-	O
LKP2	O
in	O
nuclear	O
bodies	O
.	O

Furthermore	O
,	O
the	O
CFP	O
-	O
LKP2	O
and	O
YFP	O
-	O
CO	O
signals	O
co	O
-	O
localized	O
with	O
signals	O
for	O
pU2B	O
'	O
'	O
-	O
mRFP	O
,	O
which	O
is	O
a	O
marker	O
for	O
Cajal	O
bodies	O
.	O

These	O
results	O
suggest	O
the	O
possibility	O
that	O
LKP2	O
functions	O
with	O
CO	O
/	O
COL	O
family	O
proteins	O
in	O
the	O
nuclear	O
bodies	O
.	O

Small	O
molecule	O
inhibitors	O
of	O
HDM2	O
ubiquitin	O
ligase	O
activity	O
stabilize	O
and	O
activate	O
p53	O
in	O
cells	O
.	O

The	O
p53	O
tumor	O
suppressor	O
protein	O
is	O
regulated	O
by	O
its	O
interaction	O
with	O
HDM2	O
,	O
which	O
serves	O
as	O
a	O
ubiquitin	O
ligase	O
(	O
E3	O
)	O
to	O
target	O
p53	O
for	O
degradation	O
.	O

We	O
have	O
identified	O
a	O
family	O
of	O
small	O
molecules	O
(	O
HLI98	O
)	O
that	O
inhibits	O
HDM2	O
'	O
s	O
E3	O
activity	O
.	O

These	O
compounds	O
show	O
some	O
specificity	O
for	O
HDM2	O
in	O
vitro	O
,	O
although	O
at	O
higher	O
concentrations	O
effects	O
on	O
unrelated	O
RING	O
and	O
HECT	O
domain	O
E3s	O
are	O
detectable	O
,	O
which	O
could	O
be	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
effects	O
on	O
E2	O
-	O
ubiquitin	O
thiol	O
-	O
ester	O
levels	O
.	O

In	O
cells	O
,	O
the	O
compounds	O
allow	O
the	O
stabilization	O
of	O
p53	O
and	O
HDM2	O
and	O
activation	O
of	O
p53	O
-	O
dependent	O
transcription	O
and	O
apoptosis	O
,	O
although	O
other	O
p53	O
-	O
independent	O
toxicity	O
was	O
also	O
observed	O
.	O

Loss	O
of	O
C	O
/	O
EBP	O
alpha	O
cell	O
cycle	O
control	O
increases	O
myeloid	O
progenitor	O
proliferation	O
and	O
transforms	O
the	O
neutrophil	O
granulocyte	O
lineage	O
.	O

CCAAT	O
/	O
enhancer	O
binding	O
protein	O
(	O
C	O
/	O
EBP	O
)	O
alpha	O
is	O
a	O
myeloid	O
-	O
specific	O
transcription	O
factor	O
that	O
couples	O
lineage	O
commitment	O
to	O
terminal	O
differentiation	O
and	O
cell	O
cycle	O
arrest	O
,	O
and	O
is	O
found	O
mutated	O
in	O
9	O
%	O
of	O
patients	O
who	O
have	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
.	O

We	O
previously	O
showed	O
that	O
mutations	O
which	O
dissociate	O
the	O
ability	O
of	O
C	O
/	O
EBP	O
alpha	O
to	O
block	O
cell	O
cycle	O
progression	O
through	O
E2F	O
inhibition	O
from	O
its	O
function	O
as	O
a	O
transcriptional	O
activator	O
impair	O
the	O
in	O
vivo	O
development	O
of	O
the	O
neutrophil	O
granulocyte	O
and	O
adipose	O
lineages	O
.	O

We	O
now	O
show	O
that	O
such	O
mutations	O
increase	O
the	O
capacity	O
of	O
bone	O
marrow	O
(	O
BM	O
)	O
myeloid	O
progenitors	O
to	O
proliferate	O
,	O
and	O
predispose	O
mice	O
to	O
a	O
granulocytic	O
myeloproliferative	O
disorder	O
and	O
transformation	O
of	O
the	O
myeloid	O
compartment	O
of	O
the	O
BM	O
.	O

Both	O
of	O
these	O
phenotypes	O
were	O
transplantable	O
into	O
lethally	O
irradiated	O
recipients	O
.	O

BM	O
transformation	O
was	O
characterized	O
by	O
a	O
block	O
in	O
granulocyte	O
differentiation	O
,	O
accumulation	O
of	O
myeloblasts	O
and	O
promyelocytes	O
,	O
and	O
expansion	O
of	O
myeloid	O
progenitor	O
populations	O
-	O
-	O
all	O
characteristics	O
of	O
AML	O
.	O

Circulating	O
myeloblasts	O
and	O
hepatic	O
leukocyte	O
infiltration	O
were	O
observed	O
,	O
but	O
thrombocytopenia	O
,	O
anemia	O
,	O
and	O
elevated	O
leukocyte	O
count	O
-	O
-	O
normally	O
associated	O
with	O
AML	O
-	O
were	O
absent	O
.	O

These	O
results	O
show	O
that	O
disrupting	O
the	O
cell	O
cycle	O
regulatory	O
function	O
of	O
C	O
/	O
EBP	O
alpha	O
is	O
sufficient	O
to	O
initiate	O
AML	O
-	O
like	O
transformation	O
of	O
the	O
granulocytic	O
lineage	O
,	O
but	O
only	O
partially	O
the	O
peripheral	O
pathology	O
of	O
AML	O
.	O

Phosphonocarboxylate	O
inhibitors	O
of	O
Rab	B-Complex
geranylgeranyl	I-Complex
transferase	I-Complex
disrupt	O
the	O
prenylation	O
and	O
membrane	O
localization	O
of	O
Rab	O
proteins	O
in	O
osteoclasts	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Nitrogen	O
-	O
containing	O
bisphosphonate	O
drugs	O
such	O
as	O
risedronate	O
act	O
by	O
inhibiting	O
farnesyl	O
diphosphate	O
synthase	O
,	O
thereby	O
disrupting	O
protein	O
prenylation	O
in	O
osteoclasts	O
.	O

We	O
recently	O
found	O
that	O
an	O
anti	O
-	O
resorptive	O
phosphonocarboxylate	O
analogue	O
of	O
risedronate	O
,	O
3	O
-	O
PEHPC	O
(	O
previously	O
referred	O
to	O
as	O
NE10790	O
)	O
,	O
selectively	O
prevents	O
prenylation	O
of	O
Rab	O
GTPases	O
in	O
vitro	O
by	O
specifically	O
inhibiting	O
Rab	B-Complex
geranylgeranyl	I-Complex
transferase	I-Complex
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
unprenylated	O
Rab6	O
could	O
be	O
detected	O
in	O
J774	O
cells	O
after	O
treatment	O
with	O
3	O
-	O
PEHPC	O
or	O
risedronate	O
for	O
as	O
little	O
as	O
4	O
h	O
,	O
and	O
reached	O
50	O
%	O
after	O
24	O
h	O
.	O

Furthermore	O
,	O
treatment	O
of	O
J774	O
cells	O
or	O
osteoclasts	O
with	O
either	O
3	O
-	O
PEHPC	O
or	O
risedronate	O
disrupted	O
membrane	O
association	O
of	O
several	O
Rab	O
family	O
proteins	O
.	O

Like	O
risedronate	O
,	O
the	O
effects	O
of	O
3	O
-	O
PEHPC	O
are	O
likely	O
to	O
be	O
restricted	O
to	O
osteoclasts	O
in	O
vivo	O
,	O
since	O
both	O
risedronate	O
and	O
3	O
-	O
PEHPC	O
inhibited	O
Rab	O
prenylation	O
in	O
osteoclasts	O
,	O
but	O
not	O
in	O
general	O
bone	O
marrow	O
cells	O
,	O
when	O
administered	O
to	O
rabbits	O
in	O
vivo	O
.	O

Analysis	O
of	O
two	O
new	O
phosphonocarboxylate	O
analogues	O
of	O
3	O
-	O
PEHPC	O
(	O
3	O
-	O
PEPC	O
and	O
2	O
-	O
PEPC	O
)	O
revealed	O
that	O
,	O
first	O
,	O
the	O
geminal	O
hydroxyl	O
group	O
is	O
not	O
essential	O
for	O
inhibition	O
of	O
Rab	O
prenylation	O
by	O
phosphonocarboxylates	O
,	O
but	O
does	O
contribute	O
to	O
their	O
anti	O
-	O
resorptive	O
potency	O
,	O
most	O
likely	O
by	O
enhancing	O
their	O
affinity	O
for	O
bone	O
mineral	O
.	O

Second	O
,	O
the	O
position	O
of	O
the	O
nitrogen	O
in	O
the	O
side	O
chain	O
of	O
phosphonocarboxylates	O
is	O
crucial	O
for	O
their	O
ability	O
to	O
inhibit	O
Rab	O
prenylation	O
and	O
hence	O
to	O
inhibit	O
bone	O
resorption	O
.	O

In	O
addition	O
,	O
there	O
is	O
a	O
good	O
correlation	O
between	O
the	O
ability	O
of	O
the	O
phosphonocarboxylates	O
to	O
inhibit	O
Rab	O
prenylation	O
and	O
to	O
inhibit	O
bone	O
resorption	O
in	O
vitro	O
,	O
indicating	O
that	O
these	O
compounds	O
are	O
a	O
new	O
class	O
of	O
pharmacological	O
agents	O
that	O
inhibit	O
bone	O
resorption	O
by	O
specifically	O
preventing	O
prenylation	O
of	O
Rab	O
proteins	O
.	O

Furthermore	O
,	O
although	O
phosphonocarboxylates	O
are	O
analogues	O
of	O
bisphosphonates	O
,	O
the	O
structure	O
-	O
activity	O
relationships	O
of	O
phosphonocarboxylates	O
for	O
inhibiting	O
Rab	B-Complex
geranylgeranyltransferase	I-Complex
appear	O
to	O
differ	O
from	O
the	O
structure	O
-	O
activity	O
relationships	O
of	O
bisphosphonates	O
for	O
inhibiting	O
farnesyl	O
diphosphate	O
synthase	O
.	O

Notch4	O
intracellular	O
domain	O
binding	O
to	O
Smad3	O
and	O
inhibition	O
of	O
the	O
TGF	O
-	O
beta	O
signaling	O
.	O

We	O
present	O
evidence	O
that	O
Notch4ICD	O
attenuates	O
TGF	O
-	O
beta	O
signaling	O
.	O

Cells	O
expressing	O
the	O
activated	O
form	O
of	O
the	O
Notch4	O
receptor	O
(	O
ICD4	O
)	O
were	O
resistant	O
to	O
the	O
growth	O
-	O
inhibitory	O
effects	O
of	O
TGF	O
-	O
beta	O
.	O

Notch4ICD	O
was	O
found	O
to	O
bind	O
to	O
Smad2	O
,	O
Smad3	O
and	O
Smad4	O
but	O
with	O
higher	O
affinity	O
to	O
Smad3	O
.	O

Deletion	O
analysis	O
showed	O
that	O
binding	O
of	O
Smad3	O
to	O
ICD4	O
was	O
mediated	O
by	O
its	O
MH2	O
domain	O
and	O
was	O
not	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
RAM23	O
region	O
in	O
ICD4	O
.	O

Using	O
two	O
TGF	O
-	O
beta	O
/	O
Activin	O
reporter	O
luciferase	O
assays	O
,	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
analysis	O
,	O
we	O
demonstrate	O
that	O
ICD4	O
and	O
ICD4	O
deltaRAM23	O
inhibit	O
Smad	O
-	O
binding	O
element	O
and	O
3TP	O
luciferase	O
reporter	O
activity	O
and	O
PAI	O
-	O
1	O
gene	O
expression	O
.	O

MCF	O
-	O
7	O
human	O
breast	O
cancer	O
cells	O
express	O
Notch4ICD	O
(	O
ICD4	O
)	O
and	O
are	O
resistant	O
to	O
the	O
growth	O
-	O
inhibitory	O
effects	O
of	O
TGF	O
-	O
beta	O
.	O

Blockage	O
of	O
Notch4	O
processing	O
to	O
ICD4	O
by	O
gamma	B-Complex
-	I-Complex
secretase	I-Complex
inhibitor	O
renders	O
MCF	O
-	O
7	O
cells	O
sensitive	O
to	O
growth	O
inhibition	O
by	O
TGF	O
-	O
beta	O
.	O

The	O
interplay	O
between	O
these	O
two	O
signaling	O
pathways	O
may	O
be	O
a	O
significant	O
determinant	O
during	O
mammary	O
tumorigenesis	O
.	O

CAND1	O
enhances	O
deneddylation	O
of	O
CUL1	O
by	O
COP9	B-Complex
signalosome	I-Complex
.	O

Cullin	O
-	O
RING	O
ligases	O
(	O
CRLs	O
)	O
regulate	O
diverse	O
cellular	O
functions	O
such	O
as	O
cell	O
cycle	O
progression	O
and	O
cytokine	O
signaling	O
by	O
ubiquitinating	O
key	O
regulatory	O
proteins	O
.	O

The	O
activity	O
of	O
CRLs	O
is	O
controlled	O
by	O
Nedd8	O
modification	O
of	O
the	O
cullin	O
subunits	O
.	O

Recent	O
reports	O
have	O
suggested	O
that	O
CAND1	O
,	O
which	O
specifically	O
binds	O
to	O
unmodified	O
CUL1	O
but	O
not	O
to	O
neddylated	O
one	O
,	O
is	O
required	O
for	O
the	O
in	O
vivo	O
function	O
of	O
SCFs	B-Complex
,	O
the	O
CUL1	O
-	O
containing	O
CRLs	O
.	O

We	O
show	O
here	O
that	O
CAND1	O
and	O
COP9	B-Complex
signalosome	I-Complex
(	O
CSN	B-Complex
)	O
,	O
the	O
major	O
deneddylase	O
of	O
cullins	O
,	O
bind	O
to	O
unneddylated	O
CUL1	O
in	O
a	O
mutually	O
exclusive	O
way	O
.	O

The	O
suppression	O
of	O
CAND1	O
expression	O
by	O
small	O
inhibitory	O
RNA	O
enhanced	O
the	O
interaction	O
between	O
CUL1	O
and	O
CSN	B-Complex
,	O
suggesting	O
that	O
CAND1	O
inhibited	O
the	O
binding	O
of	O
CSN	B-Complex
to	O
CUL1	O
.	O

We	O
found	O
that	O
the	O
binding	O
of	O
CSN	B-Complex
to	O
CUL1	O
required	O
the	O
four	O
helix	O
bundle	O
in	O
CUL1	O
C	O
-	O
terminal	O
domain	O
,	O
which	O
was	O
wrapped	O
around	O
by	O
CAND1	O
in	O
the	O
CAND1	O
-	O
CUL1	O
-	O
Rbx1	O
complex	O
.	O

CAND1	O
greatly	O
facilitated	O
CSN	B-Complex
-	O
mediated	O
deneddylation	O
of	O
CUL1	O
in	O
vitro	O
,	O
which	O
was	O
dependent	O
on	O
its	O
binding	O
to	O
CUL1	O
.	O

Our	O
data	O
suggest	O
that	O
enhancement	O
of	O
CSN	B-Complex
-	O
mediated	O
deneddylation	O
by	O
CAND1	O
may	O
contribute	O
to	O
its	O
function	O
as	O
a	O
positive	O
regulator	O
of	O
SCFs	B-Complex
in	O
vivo	O
.	O

Pc2	O
-	O
mediated	O
sumoylation	O
of	O
Smad	O
-	O
interacting	O
protein	O
1	O
attenuates	O
transcriptional	O
repression	O
of	O
E	O
-	O
cadherin	O
.	O

Epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
is	O
important	O
in	O
embryonic	O
development	O
and	O
tumorigenesis	O
.	O

Smad	O
-	O
interacting	O
protein	O
1	O
(	O
SIP1	O
)	O
can	O
induce	O
EMT	O
by	O
repressing	O
the	O
transcription	O
of	O
E	O
-	O
cadherin	O
through	O
recruitment	O
of	O
the	O
corepressor	O
C	O
-	O
terminal	O
-	O
binding	O
protein	O
(	O
CtBP	O
)	O
.	O

How	O
the	O
activity	O
of	O
SIP1	O
is	O
regulated	O
still	O
remains	O
unclear	O
.	O

Here	O
we	O
show	O
in	O
vivo	O
and	O
in	O
vitro	O
that	O
SIP1	O
is	O
covalently	O
modified	O
by	O
sumoylation	O
at	O
two	O
conserved	O
sites	O
,	O
Lys391	O
and	O
Lys866	O
.	O

The	O
polycomb	O
protein	O
Pc2	O
,	O
but	O
not	O
the	O
PIAS	O
(	O
protein	O
inhibitor	O
of	O
activated	O
STAT	O
)	O
family	O
proteins	O
,	O
acts	O
as	O
a	O
Small	O
ubiquitin	O
-	O
like	O
modifier	O
E3	O
ligase	O
for	O
SIP1	O
.	O

Sumoylation	O
of	O
SIP1	O
does	O
not	O
affect	O
its	O
subcellular	O
localization	O
,	O
but	O
regulates	O
its	O
transcriptional	O
activity	O
.	O

Compared	O
with	O
the	O
wild	O
-	O
type	O
,	O
a	O
SIP1	O
sumoylation	O
null	O
mutant	O
shows	O
more	O
potent	O
repression	O
on	O
E	O
-	O
cadherin	O
transcription	O
but	O
similar	O
repression	O
on	O
two	O
transforming	O
growth	O
factor	O
-	O
beta	O
-	O
responsive	O
reporter	O
genes	O
and	O
comparable	O
activation	O
on	O
vitamin	O
D3	O
receptor	O
transcription	O
.	O

Coexpression	O
of	O
SIP1	O
with	O
Pc2	O
can	O
partially	O
relieve	O
E	O
-	O
cadherin	O
repression	O
by	O
SIP1	O
.	O

We	O
further	O
show	O
that	O
SIP1	O
sumoylation	O
disrupts	O
the	O
recruitment	O
of	O
CtBP	O
.	O

Thus	O
SIP1	O
sumoylation	O
regulates	O
its	O
transcriptional	O
activity	O
in	O
a	O
promoter	O
context	O
-	O
dependent	O
manner	O
and	O
may	O
represent	O
an	O
important	O
intervention	O
target	O
to	O
modulate	O
EMT	O
in	O
tumorigenesis	O
.	O

Stem	O
cell	O
depletion	O
through	O
epidermal	O
deletion	O
of	O
Rac1	O
.	O

Mammalian	O
epidermis	O
is	O
maintained	O
by	O
self	O
-	O
renewal	O
of	O
stem	O
cells	O
,	O
but	O
the	O
underlying	O
mechanisms	O
are	O
unknown	O
.	O

Deletion	O
of	O
Rac1	O
,	O
a	O
Rho	O
guanosine	O
triphosphatase	O
,	O
in	O
adult	O
mouse	O
epidermis	O
stimulated	O
stem	O
cells	O
to	O
divide	O
and	O
undergo	O
terminal	O
differentiation	O
,	O
leading	O
to	O
failure	O
to	O
maintain	O
the	O
interfollicular	O
epidermis	O
,	O
hair	O
follicles	O
,	O
and	O
sebaceous	O
glands	O
.	O

Rac1	O
exerts	O
its	O
effects	O
in	O
the	O
epidermis	O
by	O
negatively	O
regulating	O
c	O
-	O
Myc	O
through	O
p21	O
-	O
activated	O
kinase	O
2	O
(	O
PAK2	O
)	O
phosphorylation	O
.	O

We	O
conclude	O
that	O
a	O
pleiotropic	O
regulator	O
of	O
cell	O
adhesion	O
and	O
the	O
cytoskeleton	O
plays	O
a	O
critical	O
role	O
in	O
controlling	O
exit	O
from	O
the	O
stem	O
cell	O
niche	O
and	O
propose	O
that	O
Rac	O
and	O
Myc	O
represent	O
a	O
global	O
stem	O
cell	O
regulatory	O
axis	O
.	O

From	O
the	O
Cover	O
:	O
Location	O
analysis	O
of	O
estrogen	O
receptor	O
alpha	O
target	O
promoters	O
reveals	O
that	O
FOXA1	O
defines	O
a	O
domain	O
of	O
the	O
estrogen	O
response	O
.	O

Nuclear	O
receptors	O
can	O
activate	O
diverse	O
biological	O
pathways	O
within	O
a	O
target	O
cell	O
in	O
response	O
to	O
their	O
cognate	O
ligands	O
,	O
but	O
how	O
this	O
compartmentalization	O
is	O
achieved	O
at	O
the	O
level	O
of	O
gene	O
regulation	O
is	O
poorly	O
understood	O
.	O

We	O
used	O
a	O
genome	O
-	O
wide	O
analysis	O
of	O
promoter	O
occupancy	O
by	O
the	O
estrogen	O
receptor	O
alpha	O
(	O
ERalpha	O
)	O
in	O
MCF	O
-	O
7	O
cells	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
action	O
of	O
17beta	O
-	O
estradiol	O
(	O
E2	O
)	O
in	O
controlling	O
the	O
growth	O
of	O
breast	O
cancer	O
cells	O
.	O

We	O
identified	O
153	O
promoters	O
bound	O
by	O
ERalpha	O
in	O
the	O
presence	O
of	O
E2	O
.	O

Motif	O
-	O
finding	O
algorithms	O
demonstrated	O
that	O
the	O
estrogen	O
response	O
element	O
(	O
ERE	O
)	O
is	O
the	O
most	O
common	O
motif	O
present	O
in	O
these	O
promoters	O
whereas	O
conventional	O
chromatin	O
immunoprecipitation	O
assays	O
showed	O
E2	O
-	O
modulated	O
recruitment	O
of	O
coactivator	O
AIB1	O
and	O
RNA	B-Complex
polymerase	I-Complex
II	I-Complex
at	O
these	O
loci	O
.	O

The	O
promoters	O
were	O
linked	O
to	O
known	O
ERalpha	O
targets	O
but	O
also	O
to	O
many	O
genes	O
not	O
directly	O
associated	O
with	O
the	O
estrogenic	O
response	O
,	O
including	O
the	O
transcriptional	O
factor	O
FOXA1	O
,	O
whose	O
expression	O
correlates	O
with	O
the	O
presence	O
of	O
ERalpha	O
in	O
breast	O
tumors	O
.	O

We	O
found	O
that	O
ablation	O
of	O
FOXA1	O
expression	O
in	O
MCF	O
-	O
7	O
cells	O
suppressed	O
ERalpha	O
binding	O
to	O
the	O
prototypic	O
TFF1	O
promoter	O
(	O
which	O
contains	O
a	O
FOXA1	O
binding	O
site	O
)	O
,	O
hindered	O
the	O
induction	O
of	O
TFF1	O
expression	O
by	O
E2	O
,	O
and	O
prevented	O
hormone	O
-	O
induced	O
reentry	O
into	O
the	O
cell	O
cycle	O
.	O

Taken	O
together	O
,	O
these	O
results	O
define	O
a	O
paradigm	O
for	O
estrogen	O
action	O
in	O
breast	O
cancer	O
cells	O
and	O
suggest	O
that	O
regulation	O
of	O
gene	O
expression	O
by	O
nuclear	O
receptors	O
can	O
be	O
compartmentalized	O
into	O
unique	O
transcriptional	O
domains	O
by	O
means	O
of	O
licensing	O
of	O
their	O
activity	O
to	O
cofactors	O
such	O
as	O
FOXA1	O
.	O

Regulation	O
of	O
MEF2	O
by	O
histone	O
deacetylase	O
4	O
-	O
and	O
SIRT1	O
deacetylase	O
-	O
mediated	O
lysine	O
modifications	O
.	O

The	O
class	O
II	O
deacetylase	O
histone	O
deacetylase	O
4	O
(	O
HDAC4	O
)	O
negatively	O
regulates	O
the	O
transcription	O
factor	O
MEF2	O
.	O

HDAC4	O
is	O
believed	O
to	O
repress	O
MEF2	O
transcriptional	O
activity	O
by	O
binding	O
to	O
MEF2	O
and	O
catalyzing	O
local	O
histone	O
deacetylation	O
.	O

Here	O
we	O
report	O
that	O
HDAC4	O
also	O
controls	O
MEF2	O
by	O
a	O
novel	O
SUMO	O
E3	O
ligase	O
activity	O
.	O

We	O
show	O
that	O
HDAC4	O
interacts	O
with	O
the	O
SUMO	O
E2	O
conjugating	O
enzyme	O
Ubc9	O
and	O
is	O
itself	O
sumoylated	O
.	O

The	O
overexpression	O
of	O
HDAC4	O
leads	O
to	O
prominent	O
MEF2	O
sumoylation	O
in	O
vivo	O
,	O
whereas	O
recombinant	O
HDAC4	O
stimulates	O
MEF2	O
sumoylation	O
in	O
a	O
reconstituted	O
system	O
in	O
vitro	O
.	O

Importantly	O
,	O
HDAC4	O
promotes	O
sumoylation	O
on	O
a	O
lysine	O
residue	O
that	O
is	O
also	O
subject	O
to	O
acetylation	O
by	O
a	O
MEF2	O
coactivator	O
,	O
the	O
acetyltransferase	O
CBP	O
,	O
suggesting	O
a	O
possible	O
interplay	O
between	O
acetylation	O
and	O
sumoylation	O
in	O
regulating	O
MEF2	O
activity	O
.	O

Indeed	O
,	O
MEF2	O
acetylation	O
is	O
correlated	O
with	O
MEF2	O
activation	O
and	O
dynamically	O
induced	O
upon	O
muscle	O
cell	O
differentiation	O
,	O
while	O
sumoylation	O
inhibits	O
MEF2	O
transcriptional	O
activity	O
.	O

Unexpectedly	O
,	O
we	O
found	O
that	O
HDAC4	O
does	O
not	O
function	O
as	O
a	O
MEF2	O
deacetylase	O
.	O

Instead	O
,	O
the	O
NAD	O
+	O
-	O
dependent	O
deacetylase	O
SIRT1	O
can	O
potently	O
induce	O
MEF2	O
deacetylation	O
.	O

Our	O
studies	O
reveal	O
a	O
novel	O
regulation	O
of	O
MEF2	O
transcriptional	O
activity	O
by	O
two	O
distinct	O
classes	O
of	O
deacetylases	O
that	O
affect	O
MEF2	O
sumoylation	O
and	O
acetylation	O
.	O

The	O
structure	O
of	O
the	O
follistatin	O
:	O
activin	O
complex	O
reveals	O
antagonism	O
of	O
both	O
type	O
I	O
and	O
type	O
II	O
receptor	O
binding	O
.	O

TGF	O
-	O
beta	O
ligands	O
stimulate	O
diverse	O
cellular	O
differentiation	O
and	O
growth	O
responses	O
by	O
signaling	O
through	O
type	O
I	O
and	O
II	O
receptors	O
.	O

Ligand	O
antagonists	O
,	O
such	O
as	O
follistatin	O
,	O
block	O
signaling	O
and	O
are	O
essential	O
regulators	O
of	O
physiological	O
responses	O
.	O

Here	O
we	O
report	O
the	O
structure	O
of	O
activin	O
A	O
,	O
a	O
TGF	O
-	O
beta	O
ligand	O
,	O
bound	O
to	O
the	O
high	O
-	O
affinity	O
antagonist	O
follistatin	O
.	O

Two	O
follistatin	O
molecules	O
encircle	O
activin	O
,	O
neutralizing	O
the	O
ligand	O
by	O
burying	O
one	O
-	O
third	O
of	O
its	O
residues	O
and	O
its	O
receptor	O
binding	O
sites	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
type	O
I	O
receptor	O
binding	O
would	O
not	O
be	O
blocked	O
by	O
follistatin	O
,	O
but	O
the	O
crystal	O
structure	O
reveals	O
that	O
the	O
follistatin	O
N	O
-	O
terminal	O
domain	O
has	O
an	O
unexpected	O
fold	O
that	O
mimics	O
a	O
universal	O
type	O
I	O
receptor	O
motif	O
and	O
occupies	O
this	O
receptor	O
binding	O
site	O
.	O

The	O
formation	O
of	O
follistatin	O
:	O
BMP	O
:	O
type	O
I	O
receptor	O
complexes	O
can	O
be	O
explained	O
by	O
the	O
stoichiometric	O
and	O
geometric	O
arrangement	O
of	O
the	O
activin	O
:	O
follistatin	O
complex	O
.	O

The	O
mode	O
of	O
ligand	O
binding	O
by	O
follistatin	O
has	O
important	O
implications	O
for	O
its	O
ability	O
to	O
neutralize	O
homo	O
-	O
and	O
heterodimeric	O
ligands	O
of	O
this	O
growth	O
factor	O
family	O
.	O

Mechanisms	O
of	O
protein	O
degradation	O
:	O
an	O
odyssey	O
with	O
ODC	O
.	O

Intracellular	O
proteolysis	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
fundamental	O
cellular	O
processes	O
such	O
as	O
cell	O
cycle	O
,	O
immune	O
and	O
inflammation	O
responses	O
,	O
development	O
,	O
differentiation	O
,	O
and	O
transformation	O
.	O

The	O
ubiquitin	O
-	O
proteasome	B-Complex
system	O
accounts	O
for	O
the	O
degradation	O
of	O
the	O
majority	O
of	O
cellular	O
short	O
-	O
lived	O
proteins	O
.	O

This	O
system	O
involves	O
the	O
conjugation	O
of	O
multiple	O
ubiquitin	O
residues	O
to	O
the	O
target	O
protein	O
and	O
its	O
recognition	O
by	O
the	O
26S	B-Complex
proteasome	I-Complex
through	O
the	O
poly	O
-	O
ubiquitin	O
chain	O
.	O

Studies	O
on	O
the	O
degradation	O
of	O
ornithine	O
decarboxylase	O
(	O
ODC	O
)	O
demonstrated	O
that	O
poly	O
-	O
ubiquitin	O
is	O
not	O
the	O
only	O
signal	O
recognized	O
by	O
the	O
26S	B-Complex
proteasome	I-Complex
.	O

The	O
recognition	O
of	O
ODC	O
by	O
the	O
26S	B-Complex
proteasome	I-Complex
is	O
mediated	O
by	O
interaction	O
with	O
a	O
polyamine	O
-	O
induced	O
protein	O
termed	O
,	O
antizyme	O
(	O
Az	O
)	O
.	O

While	O
the	O
degradation	O
of	O
ODC	O
is	O
ubiquitin	O
-	O
independent	O
,	O
the	O
degradation	O
of	O
its	O
regulator	O
Az	O
,	O
and	O
of	O
antizyme	O
-	O
inhibitor	O
(	O
AzI	O
)	O
,	O
an	O
ODC	O
homologous	O
protein	O
that	O
regulates	O
Az	O
availability	O
,	O
are	O
ubiquitin	O
dependent	O
.	O

Interestingly	O
,	O
ODC	O
undergoes	O
another	O
type	O
of	O
ubiquitin	O
-	O
independent	O
degradation	O
by	O
the	O
20S	B-Complex
proteasome	I-Complex
that	O
is	O
regulated	O
by	O
NAD	O
(	O
P	O
)	O
H	O
quinone	O
oxidoreductase	O
1	O
(	O
NQO1	O
)	O
.	O

Considering	O
the	O
prevalence	O
of	O
the	O
ubiquitin	O
system	O
in	O
the	O
process	O
of	O
cellular	O
protein	O
degradation	O
it	O
is	O
rather	O
remarkable	O
that	O
a	O
key	O
cellular	O
enzyme	O
is	O
subjected	O
to	O
two	O
different	O
proteolytic	O
pathways	O
that	O
are	O
different	O
from	O
the	O
ubiquitin	O
dependent	O
one	O
.	O

This	O
exceptional	O
behavior	O
of	O
ODC	O
provides	O
us	O
with	O
valuable	O
insights	O
regarding	O
protein	O
degradation	O
in	O
general	O
.	O

S	O
-	O
palmitoylation	O
modulates	O
estrogen	O
receptor	O
alpha	O
localization	O
and	O
functions	O
.	O

17beta	O
-	O
Estradiol	O
(	O
E2	O
)	O
acts	O
as	O
a	O
chemical	O
messenger	O
in	O
target	O
tissues	O
inducing	O
both	O
slow	O
nuclear	O
and	O
rapid	O
extra	O
-	O
nuclear	O
responses	O
.	O

E2	O
binds	O
to	O
its	O
cognate	O
nuclear	O
receptors	O
(	O
ER	O
)	O
resulting	O
in	O
the	O
activation	O
of	O
target	O
gene	O
transcription	O
in	O
the	O
nucleus	O
.	O

In	O
addition	O
to	O
these	O
genomic	O
effects	O
,	O
E2	O
modulates	O
cell	O
functions	O
through	O
rapid	O
non	O
-	O
genomic	O
actions	O
.	O

Stimulation	O
of	O
G	O
-	O
proteins	O
,	O
Ca	O
(	O
2	O
+	O
)	O
influx	O
,	O
inositol	O
phosphate	O
generation	O
as	O
well	O
as	O
phospholipase	O
C	O
,	O
ERK	O
/	O
MAPK	O
,	O
and	O
PI3K	O
/	O
AKT	O
activation	O
all	O
occur	O
within	O
seconds	O
to	O
minutes	O
after	O
E2	O
binding	O
to	O
a	O
small	O
population	O
of	O
ERalpha	O
located	O
at	O
the	O
plasma	O
membrane	O
.	O

The	O
great	O
impact	O
of	O
these	O
rapid	O
signals	O
on	O
cell	O
physiology	O
renders	O
central	O
the	O
knowledge	O
of	O
the	O
structural	O
bases	O
and	O
mechanisms	O
that	O
mediate	O
extra	O
-	O
nuclear	O
signaling	O
by	O
E2	O
.	O

Several	O
laboratories	O
,	O
including	O
our	O
own	O
,	O
have	O
recently	O
elucidated	O
the	O
structural	O
requirements	O
for	O
localization	O
and	O
function	O
of	O
plasma	O
membrane	O
ERalpha	O
.	O

This	O
review	O
summarizes	O
the	O
molecular	O
mechanisms	O
of	O
E2	O
-	O
induced	O
rapid	O
non	O
-	O
genomic	O
actions	O
relevant	O
for	O
cell	O
functions	O
,	O
highlighting	O
the	O
role	O
of	O
lipid	O
modification	O
(	O
i	O
.	O
e	O
.	O
,	O
palmitoylation	O
)	O
in	O
the	O
ERalpha	O
localization	O
to	O
and	O
residence	O
at	O
the	O
plasma	O
membrane	O
.	O

Mutation	O
and	O
polymorphism	O
spectrum	O
of	O
the	O
GALNS	O
gene	O
in	O
mucopolysaccharidosis	O
IVA	O
(	O
Morquio	O
A	O
)	O
.	O

Mucopolysaccharidosis	O
IVA	O
(	O
MPS	O
IVA	O
;	O
Morquio	O
A	O
disease	O
)	O
is	O
an	O
autosomal	O
-	O
recessive	O
disorder	O
caused	O
by	O
a	O
deficiency	O
of	O
lysosomal	O
N	O
-	O
acetylgalactosamine	O
-	O
6	O
-	O
sulfate	O
sulfatase	O
(	O
GALNS	O
;	O
E	O
.	O
C	O
.	O
3	O
.	O
1	O
.	O
6	O
.	O
4	O
)	O
.	O

GALNS	O
is	O
required	O
to	O
degrade	O
glycosaminoglycans	O
,	O
keratan	O
sulfate	O
(	O
KS	O
)	O
,	O
and	O
chondroitin	O
-	O
6	O
-	O
sulfate	O
.	O

Accumulation	O
of	O
undegraded	O
substrates	O
in	O
lysosomes	O
of	O
the	O
affected	O
tissues	O
leads	O
to	O
a	O
systemic	O
bone	O
dysplasia	O
.	O

We	O
summarize	O
information	O
on	O
148	O
unique	O
mutations	O
determined	O
to	O
date	O
in	O
the	O
GALNS	O
gene	O
,	O
including	O
26	O
novel	O
mutations	O
(	O
19	O
missense	O
,	O
four	O
small	O
deletions	O
,	O
one	O
splice	O
-	O
site	O
,	O
and	O
two	O
insertions	O
)	O
.	O

This	O
heterogeneity	O
in	O
GALNS	O
gene	O
mutations	O
accounts	O
for	O
an	O
extensive	O
clinical	O
variability	O
within	O
MPS	O
IVA	O
.	O

Seven	O
polymorphisms	O
that	O
cause	O
an	O
amino	O
acid	O
change	O
,	O
and	O
nine	O
silent	O
variants	O
in	O
the	O
coding	O
region	O
are	O
also	O
described	O
.	O

Of	O
the	O
analyzed	O
mutant	O
alleles	O
,	O
missense	O
mutations	O
accounted	O
for	O
78	O
.	O
4	O
%	O
;	O
small	O
deletions	O
,	O
9	O
.	O
2	O
%	O
;	O
nonsense	O
mutation	O
,	O
5	O
.	O
0	O
%	O
;	O
large	O
deletion	O
,	O
2	O
.	O
4	O
%	O
;	O
and	O
insertions	O
,	O
1	O
.	O
6	O
%	O
.	O

Transitional	O
mutations	O
at	O
CpG	O
dinucleotides	O
accounted	O
for	O
26	O
.	O
4	O
%	O
of	O
all	O
the	O
described	O
mutations	O
.	O

The	O
importance	O
of	O
the	O
relationship	O
between	O
methylation	O
status	O
and	O
distribution	O
of	O
transitional	O
mutations	O
at	O
CpG	O
sites	O
at	O
the	O
GALNS	O
gene	O
locus	O
was	O
elucidated	O
.	O

The	O
three	O
most	O
frequent	O
mutations	O
(	O
over	O
5	O
%	O
of	O
all	O
mutations	O
)	O
were	O
represented	O
by	O
missense	O
mutations	O
(	O
p	O
.	O
R386C	O
,	O
p	O
.	O
G301C	O
,	O
and	O
p	O
.	O
I113F	O
)	O
.	O

A	O
genotype	O
/	O
phenotype	O
correlation	O
was	O
defined	O
in	O
some	O
mutations	O
.	O

Missense	O
mutations	O
associated	O
with	O
a	O
certain	O
phenotype	O
were	O
studied	O
for	O
their	O
effects	O
on	O
enzyme	O
activity	O
and	O
stability	O
,	O
the	O
levels	O
of	O
blood	O
and	O
urine	O
KS	O
,	O
the	O
location	O
of	O
mutations	O
with	O
regard	O
to	O
the	O
tertiary	O
structure	O
,	O
and	O
the	O
loci	O
of	O
the	O
altered	O
amino	O
acid	O
residues	O
among	O
sulfatase	O
proteins	O
.	O

Characterization	O
of	O
the	O
N	O
-	O
deacetylase	O
domain	O
from	O
the	O
heparan	O
sulfate	O
N	O
-	O
deacetylase	O
/	O
N	O
-	O
sulfotransferase	O
2	O
.	O

Heparin	O
and	O
heparan	O
sulfate	O
are	O
linear	O
sulfated	O
polysaccharides	O
that	O
exert	O
a	O
multitude	O
of	O
biological	O
functions	O
.	O

Heparan	O
sulfate	O
glucosaminyl	O
N	O
-	O
deacetylase	O
/	O
N	O
-	O
sulfotransferase	O
isoform	O
2	O
(	O
NDST	O
-	O
2	O
)	O
,	O
a	O
key	O
enzyme	O
in	O
the	O
biosynthesis	O
of	O
heparin	O
,	O
contains	O
two	O
distinct	O
activities	O
.	O

This	O
bifunctional	O
enzyme	O
removes	O
the	O
acetyl	O
group	O
from	O
N	O
-	O
acetylated	O
glucosamine	O
(	O
N	O
-	O
deacetylase	O
activity	O
)	O
and	O
transfers	O
a	O
sulfuryl	O
group	O
to	O
the	O
unsubstituted	O
amino	O
position	O
(	O
N	O
-	O
sulfotransferase	O
activity	O
)	O
.	O

The	O
N	O
-	O
sulfotransferase	O
activity	O
of	O
NDST	O
has	O
been	O
unambiguously	O
localized	O
to	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
NDST	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
NDST	O
-	O
2	O
retains	O
N	O
-	O
deacetylase	O
activity	O
.	O

The	O
N	O
-	O
terminal	O
domain	O
(	O
A66	O
-	O
P604	O
)	O
of	O
human	O
NDST	O
-	O
2	O
,	O
designated	O
as	O
N	O
-	O
deacetylase	O
(	O
NDase	O
)	O
,	O
was	O
cloned	O
as	O
a	O
(	O
His	O
)	O
(	O
6	O
)	O
-	O
fusion	O
protein	O
,	O
and	O
protein	O
expression	O
was	O
carried	O
out	O
in	O
Escherichia	O
coli	O
.	O

Heparosan	O
treated	O
with	O
NDase	O
contains	O
N	O
-	O
unsubstituted	O
glucosamine	O
and	O
is	O
highly	O
susceptible	O
to	O
N	O
-	O
sulfation	O
by	O
N	O
-	O
sulfotransferase	O
.	O

Our	O
results	O
conclude	O
that	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
NDST	O
-	O
2	O
contains	O
functional	O
N	O
-	O
deacetylase	O
activity	O
.	O

This	O
finding	O
helps	O
further	O
elucidate	O
the	O
mechanism	O
of	O
action	O
of	O
heparan	O
sulfate	O
N	O
-	O
deacetylase	O
/	O
N	O
-	O
sulfotransferases	O
and	O
the	O
biosynthesis	O
of	O
heparan	O
sulfate	O
in	O
general	O
.	O

Histone	O
demethylation	O
by	O
a	O
family	O
of	O
JmjC	O
domain	O
-	O
containing	O
proteins	O
.	O

Covalent	O
modification	O
of	O
histones	O
has	O
an	O
important	O
role	O
in	O
regulating	O
chromatin	O
dynamics	O
and	O
transcription	O
.	O

Whereas	O
most	O
covalent	O
histone	O
modifications	O
are	O
reversible	O
,	O
until	O
recently	O
it	O
was	O
unknown	O
whether	O
methyl	O
groups	O
could	O
be	O
actively	O
removed	O
from	O
histones	O
.	O

Using	O
a	O
biochemical	O
assay	O
coupled	O
with	O
chromatography	O
,	O
we	O
have	O
purified	O
a	O
novel	O
JmjC	O
domain	O
-	O
containing	O
protein	O
,	O
JHDM1	O
(	O
JmjC	O
domain	O
-	O
containing	O
histone	O
demethylase	O
1	O
)	O
,	O
that	O
specifically	O
demethylates	O
histone	O
H3	O
at	O
lysine	O
36	O
(	O
H3	O
-	O
K36	O
)	O
.	O

In	O
the	O
presence	O
of	O
Fe	O
(	O
ii	O
)	O
and	O
alpha	O
-	O
ketoglutarate	O
,	O
JHDM1	O
demethylates	O
H3	O
-	O
methyl	O
-	O
K36	O
and	O
generates	O
formaldehyde	O
and	O
succinate	O
.	O

Overexpression	O
of	O
JHDM1	O
reduced	O
the	O
level	O
of	O
dimethyl	O
-	O
H3	O
-	O
K36	O
(	O
H3K36me2	O
)	O
in	O
vivo	O
.	O

The	O
demethylase	O
activity	O
of	O
the	O
JmjC	O
domain	O
-	O
containing	O
proteins	O
is	O
conserved	O
,	O
as	O
a	O
JHDM1	O
homologue	O
in	O
Saccharomyces	O
cerevisiae	O
also	O
has	O
H3	O
-	O
K36	O
demethylase	O
activity	O
.	O

Thus	O
,	O
we	O
identify	O
the	O
JmjC	O
domain	O
as	O
a	O
novel	O
demethylase	O
signature	O
motif	O
and	O
uncover	O
a	O
protein	O
demethylation	O
mechanism	O
that	O
is	O
conserved	O
from	O
yeast	O
to	O
human	O
.	O

In	O
addition	O
,	O
HDAC2	O
KD	O
did	O
not	O
affect	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
expression	O
,	O
nuclear	O
translocation	O
(	O
Fig	O
.	O
3	O
A	O
)	O
,	O
or	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
-	O
DNA	O
binding	O
(	O
Fig	O
.	O
3	O
B	O
)	O
.	O

We	O
confirmed	O
previous	O
data	O
showing	O
that	O
Dex	O
increased	O
GR	O
and	O
HDAC2	O
association	O
with	O
the	O
p65	O
-	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
complex	O
(	O
Fig	O
.	O
3	O
A	O
)	O
.	O

However	O
,	O
GR	O
was	O
not	O
recruited	O
to	O
the	O
p65	O
-	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
complex	O
after	O
HDAC2	O
KD	O
(	O
Fig	O
.	O
3	O
A	O
)	O
.	O

Chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
analysis	O
showed	O
that	O
Dex	O
failed	O
to	O
inhibit	O
histone	O
4	O
acetylation	O
at	O
the	O
p65	O
-	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
binding	O
site	O
in	O
the	O
GM	O
-	O
CSF	O
promoter	O
region	O
after	O
HDAC2	O
KD	O
(	O
Fig	O
.	O
3	O
C	O
)	O
.	O

Thus	O
,	O
HDAC2	O
KD	O
did	O
not	O
reduce	O
the	O
ability	O
of	O
GR	O
to	O
induce	O
GR	O
-	O
sensitive	O
gene	O
expression	O
but	O
had	O
a	O
preferential	O
effect	O
on	O
the	O
suppression	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
-	O
mediated	O
inflammatory	O
gene	O
expression	O
.	O

The	O
interaction	O
of	O
von	O
Willebrand	O
factor	O
-	O
A1	O
domain	O
with	O
collagen	B-Complex
:	O
mutation	O
G1324S	O
(	O
type	O
2M	O
von	O
Willebrand	O
disease	O
)	O
impairs	O
the	O
conformational	O
change	O
in	O
A1	O
domain	O
induced	O
by	O
collagen	B-Complex
.	O

BACKGROUND	O
:	O
It	O
is	O
established	O
that	O
the	O
A3	O
domain	O
in	O
von	O
Willebrand	O
factor	O
(	O
VWF	O
)	O
contains	O
the	O
major	O
collagen	B-Complex
-	O
binding	O
site	O
.	O

However	O
,	O
there	O
are	O
conflicting	O
reports	O
describing	O
the	O
capacity	O
of	O
the	O
A1	O
domain	O
to	O
interact	O
with	O
collagen	B-Complex
types	I-Complex
I	I-Complex
and	I-Complex
III	I-Complex
.	O

METHODS	O
:	O
In	O
this	O
study	O
,	O
we	O
have	O
used	O
recombinant	O
VWF	O
-	O
A1	O
polypeptides	O
,	O
as	O
well	O
as	O
conformation	O
-	O
specific	O
monoclonal	O
antibodies	O
(	O
mAb	O
)	O
,	O
to	O
analyze	O
the	O
A1	O
-	O
collagen	B-Complex
interaction	O
.	O

RESULTS	O
:	O
The	O
A1	O
domain	O
bound	O
to	O
collagen	B-Complex
with	O
K	O
(	O
d	O
)	O
approximately	O
8	O
.	O
0	O
nm	O
and	O
this	O
binding	O
was	O
blocked	O
by	O
the	O
mAb	O
6G1	O
,	O
which	O
blocks	O
the	O
interaction	O
between	O
ristocetin	O
and	O
VWF	O
.	O

In	O
addition	O
,	O
collagen	B-Complex
-	O
bound	O
A1	O
protein	O
was	O
able	O
to	O
support	O
flow	O
-	O
dependent	O
adhesion	O
of	O
platelets	O
,	O
demonstrating	O
that	O
the	O
binding	O
sites	O
for	O
collagen	B-Complex
and	O
glycoprotein	B-Complex
(	I-Complex
GP	I-Complex
)	I-Complex
Ib	I-Complex
are	O
different	O
.	O

Analysis	O
with	O
two	O
conformation	O
-	O
specific	O
mAb	O
demonstrated	O
that	O
the	O
structure	O
of	O
the	O
A1	O
domain	O
changed	O
as	O
a	O
result	O
of	O
the	O
binding	O
to	O
collagen	B-Complex
.	O

In	O
contrast	O
,	O
the	O
antibodies	O
failed	O
to	O
detect	O
conformational	O
change	O
in	O
the	O
G1324S	O
mutant	O
(	O
type	O
2M	O
von	O
Willebrand	O
disease	O
)	O
.	O

Thus	O
,	O
direct	O
binding	O
to	O
collagen	B-Complex
induces	O
a	O
change	O
in	O
the	O
structural	O
conformation	O
within	O
the	O
VWF	O
-	O
A1	O
domain	O
,	O
and	O
the	O
G1324S	O
substitution	O
prevents	O
this	O
conformational	O
change	O
.	O

CONCLUSION	O
:	O
This	O
study	O
has	O
shown	O
that	O
the	O
isolated	O
A1	O
domain	O
can	O
simultaneously	O
bind	O
to	O
collagen	B-Complex
and	O
platelet	O
GPIb	B-Complex
,	O
supporting	O
platelet	O
adhesion	O
under	O
high	O
-	O
flow	O
conditions	O
.	O

In	O
addition	O
,	O
this	O
study	O
has	O
used	O
mAb	O
to	O
demonstrate	O
that	O
the	O
binding	O
of	O
the	O
isolated	O
A1	O
domain	O
or	O
full	O
-	O
length	O
VWF	O
to	O
collagen	B-Complex
is	O
accompanied	O
by	O
a	O
conformational	O
change	O
in	O
A1	O
domain	O
.	O

Angiopoietin	O
2	O
induces	O
glioma	O
cell	O
invasion	O
by	O
stimulating	O
matrix	O
metalloprotease	O
2	O
expression	O
through	O
the	O
alphavbeta1	O
integrin	O
and	O
focal	O
adhesion	O
kinase	O
signaling	O
pathway	O
.	O

Accumulating	O
evidence	O
reveals	O
a	O
significant	O
correlation	O
between	O
angiopoietin	O
2	O
(	O
Ang2	O
)	O
expression	O
and	O
tumor	O
invasion	O
and	O
metastasis	O
in	O
various	O
human	O
cancers	O
,	O
but	O
the	O
major	O
focus	O
of	O
recent	O
studies	O
has	O
been	O
on	O
the	O
angiogenic	O
effects	O
of	O
Ang2	O
.	O

We	O
recently	O
reported	O
that	O
Ang2	O
-	O
stimulated	O
glioma	O
cell	O
invasion	O
results	O
from	O
the	O
up	O
-	O
regulation	O
and	O
activation	O
of	O
matrix	O
metalloprotease	O
2	O
(	O
MMP	O
-	O
2	O
)	O
in	O
tumor	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
identify	O
a	O
novel	O
mechanism	O
by	O
which	O
Ang2	O
stimulates	O
MMP	O
-	O
2	O
expression	O
leading	O
to	O
glioma	O
cell	O
invasion	O
.	O

We	O
show	O
that	O
Ang2	O
interacts	O
with	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
1	O
)	O
integrin	O
in	O
Tie2	O
-	O
deficient	O
human	O
glioma	O
cells	O
,	O
activating	O
focal	O
adhesion	O
kinase	O
(	O
FAK	O
)	O
,	O
p130	O
(	O
Cas	O
)	O
,	O
extracellular	O
signal	O
-	O
regulated	O
protein	O
kinase	O
(	O
ERK	O
)	O
1	O
/	O
2	O
,	O
and	O
c	O
-	O
jun	O
NH	O
(	O
2	O
)	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
and	O
substantially	O
enhancing	O
MMP	O
-	O
2	O
expression	O
and	O
secretion	O
.	O

The	O
Ang2	O
/	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
1	O
)	O
integrin	O
signaling	O
pathway	O
was	O
attenuated	O
by	O
functional	O
inhibition	O
of	O
beta	O
(	O
1	O
)	O
and	O
alpha	O
(	O
v	O
)	O
integrins	O
,	O
FAK	O
,	O
p130	O
(	O
Cas	O
)	O
,	O
ERK1	O
/	O
2	O
,	O
and	O
JNK	O
.	O

Furthermore	O
,	O
expression	O
of	O
a	O
negative	O
regulator	O
of	O
FAK	O
,	O
FAK	O
-	O
related	O
nonkinase	O
,	O
by	O
U87MG	O
/	O
Ang2	O
-	O
expressing	O
glioma	O
xenografts	O
suppressed	O
Ang2	O
-	O
induced	O
MMP	O
-	O
2	O
expression	O
and	O
glioma	O
cell	O
infiltration	O
in	O
the	O
murine	O
brain	O
.	O

These	O
data	O
establish	O
a	O
functional	O
link	O
between	O
Ang2	O
interaction	O
with	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
1	O
)	O
integrin	O
and	O
glioma	O
cell	O
invasion	O
through	O
the	O
FAK	O
/	O
p130	O
(	O
Cas	O
)	O
/	O
ERK1	O
/	O
2	O
and	O
JNK	O
-	O
mediated	O
signaling	O
pathway	O
.	O

Tax	O
ubiquitylation	O
and	O
sumoylation	O
control	O
critical	O
cytoplasmic	O
and	O
nuclear	O
steps	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
.	O

The	O
Tax	O
oncoprotein	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
proliferation	O
and	O
transformation	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
-	O
infected	O
T	O
lymphocytes	O
through	O
various	O
mechanisms	O
,	O
including	O
activation	O
of	O
the	O
nuclear	B-Complex
factor	I-Complex
(	I-Complex
NF	I-Complex
)	I-Complex
-	I-Complex
kappaB	I-Complex
pathway	O
.	O

We	O
found	O
that	O
cytoplasmic	O
ubiquitylation	O
of	O
Tax	O
C	O
-	O
terminal	O
lysines	O
is	O
critical	O
for	O
Tax	O
binding	O
to	O
the	O
IkappaB	B-Complex
kinase	I-Complex
complex	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
RelA	O
.	O

Conversely	O
,	O
we	O
demonstrate	O
that	O
the	O
same	O
lysines	O
are	O
sumoylated	O
in	O
the	O
nucleus	O
,	O
an	O
event	O
required	O
for	O
the	O
formation	O
of	O
RelA	O
/	O
p300	O
-	O
enriched	O
Tax	O
nuclear	O
bodies	O
and	O
full	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
transcriptional	O
activation	O
.	O

In	O
contrast	O
,	O
Tax	O
ubiquitylation	O
and	O
sumoylation	O
are	O
dispensable	O
for	O
its	O
activation	O
of	O
cyclic	O
adenosine	O
monophosphate	O
response	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
-	O
dependent	O
genes	O
.	O

Thus	O
,	O
ubiquitylation	O
and	O
sumoylation	O
of	O
the	O
same	O
residues	O
of	O
Tax	O
regulate	O
2	O
essential	O
steps	O
controlling	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
,	O
demonstrating	O
how	O
these	O
posttranslational	O
modifications	O
can	O
cooperate	O
to	O
promote	O
Tax	O
-	O
induced	O
transformation	O
.	O

Structure	O
of	O
glutamate	O
carboxypeptidase	O
II	O
,	O
a	O
drug	O
target	O
in	O
neuronal	O
damage	O
and	O
prostate	O
cancer	O
.	O

Membrane	O
-	O
bound	O
glutamate	O
carboxypeptidase	O
II	O
(	O
GCPII	O
)	O
is	O
a	O
zinc	O
metalloenzyme	O
that	O
catalyzes	O
the	O
hydrolysis	O
of	O
the	O
neurotransmitter	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
aspartyl	O
-	O
L	O
-	O
glutamate	O
(	O
NAAG	O
)	O
to	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
aspartate	O
and	O
L	O
-	O
glutamate	O
(	O
which	O
is	O
itself	O
a	O
neurotransmitter	O
)	O
.	O

Potent	O
and	O
selective	O
GCPII	O
inhibitors	O
have	O
been	O
shown	O
to	O
decrease	O
brain	O
glutamate	O
and	O
provide	O
neuroprotection	O
in	O
preclinical	O
models	O
of	O
stroke	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
and	O
neuropathic	O
pain	O
.	O

Here	O
,	O
we	O
report	O
crystal	O
structures	O
of	O
the	O
extracellular	O
part	O
of	O
GCPII	O
in	O
complex	O
with	O
both	O
potent	O
and	O
weak	O
inhibitors	O
and	O
with	O
glutamate	O
,	O
the	O
product	O
of	O
the	O
enzyme	O
'	O
s	O
hydrolysis	O
reaction	O
,	O
at	O
2	O
.	O
0	O
,	O
2	O
.	O
4	O
,	O
and	O
2	O
.	O
2	O
A	O
resolution	O
,	O
respectively	O
.	O

GCPII	O
folds	O
into	O
three	O
domains	O
:	O
protease	O
-	O
like	O
,	O
apical	O
,	O
and	O
C	O
-	O
terminal	O
.	O

All	O
three	O
participate	O
in	O
substrate	O
binding	O
,	O
with	O
two	O
of	O
them	O
directly	O
involved	O
in	O
C	O
-	O
terminal	O
glutamate	O
recognition	O
.	O

One	O
of	O
the	O
carbohydrate	O
moieties	O
of	O
the	O
enzyme	O
is	O
essential	O
for	O
homodimer	O
formation	O
of	O
GCPII	O
.	O

The	O
three	O
-	O
dimensional	O
structures	O
presented	O
here	O
reveal	O
an	O
induced	O
-	O
fit	O
substrate	O
-	O
binding	O
mode	O
of	O
this	O
key	O
enzyme	O
and	O
provide	O
essential	O
information	O
for	O
the	O
design	O
of	O
GCPII	O
inhibitors	O
useful	O
in	O
the	O
treatment	O
of	O
neuronal	O
diseases	O
and	O
prostate	O
cancer	O
.	O

Application	O
of	O
protein	O
semisynthesis	O
for	O
the	O
construction	O
of	O
functionalized	O
posttranslationally	O
modified	O
rab	O
GTPases	O
.	O

Rab	O
GTPases	O
represent	O
a	O
family	O
of	O
key	O
membrane	O
traffic	O
regulators	O
in	O
eukaryotic	O
cells	O
.	O

To	O
exert	O
their	O
function	O
,	O
Rab	O
proteins	O
must	O
be	O
modified	O
with	O
one	O
or	O
two	O
geranylgeranyl	O
moieties	O
.	O

This	O
modification	O
enables	O
them	O
to	O
reversibly	O
associate	O
with	O
intracellular	O
membranes	O
.	O

In	O
vivo	O
the	O
newly	O
synthesized	O
Rab	O
proteins	O
are	O
recruited	O
by	O
Rab	O
escort	O
protein	O
(	O
REP	O
)	O
that	O
presents	O
them	O
to	O
the	O
Rab	B-Complex
geranylgeranyl	I-Complex
transferase	I-Complex
(	O
Rab	B-Complex
GGTase	I-Complex
)	O
,	O
which	O
transfers	O
one	O
or	O
two	O
geranylgeranyl	O
moieties	O
to	O
the	O
C	O
-	O
terminal	O
cysteines	O
.	O

Detailed	O
understanding	O
of	O
the	O
mechanism	O
of	O
prenylation	O
reaction	O
and	O
subsequent	O
membrane	O
delivery	O
of	O
Rab	O
proteins	O
to	O
the	O
target	O
membranes	O
were	O
hampered	O
by	O
lack	O
of	O
efficient	O
technologies	O
for	O
the	O
generation	O
of	O
preparative	O
amounts	O
of	O
prenylated	O
Rab	O
GTPases	O
.	O

To	O
circumvent	O
this	O
problem	O
,	O
we	O
developed	O
an	O
approach	O
that	O
combines	O
recombinant	O
protein	O
production	O
,	O
chemical	O
synthesis	O
of	O
lipidated	O
peptides	O
with	O
precisely	O
designed	O
and	O
readily	O
alterable	O
structures	O
,	O
and	O
a	O
technique	O
for	O
peptide	O
-	O
to	O
-	O
protein	O
ligation	O
.	O

Using	O
this	O
approach	O
,	O
we	O
generated	O
a	O
number	O
of	O
semisynthetic	O
prenylated	O
Rab	O
GTPases	O
.	O

Some	O
of	O
the	O
proteins	O
were	O
also	O
supplemented	O
with	O
fluorophores	O
,	O
which	O
enabled	O
us	O
to	O
develop	O
a	O
fluorescence	O
-	O
based	O
in	O
vitro	O
prenylation	O
assay	O
.	O

The	O
approach	O
described	O
allows	O
production	O
of	O
preparative	O
amounts	O
of	O
prenylated	O
GTPases	O
,	O
which	O
was	O
demonstrated	O
by	O
generation	O
and	O
crystallization	O
of	O
a	O
monoprenylated	O
YPT1	O
:	O
Rab	O
GDI	O
complex	O
.	O

RNA	B-Complex
polymerase	I-Complex
II	I-Complex
subunit	O
Rpb9	O
is	O
important	O
for	O
transcriptional	O
fidelity	O
in	O
vivo	O
.	O

The	O
fidelity	O
of	O
yeast	O
RNA	B-Complex
polymerase	I-Complex
II	I-Complex
(	O
Pol	B-Complex
II	I-Complex
)	O
was	O
assessed	O
in	O
vivo	O
with	O
an	O
assay	O
in	O
which	O
errors	O
in	O
transcription	O
of	O
can1	O
-	O
100	O
,	O
a	O
nonsense	O
allele	O
of	O
CAN1	O
,	O
result	O
in	O
enhanced	O
sensitivity	O
to	O
the	O
toxic	O
arginine	O
analog	O
canavanine	O
.	O

The	O
Pol	B-Complex
II	I-Complex
accessory	O
factor	O
TFIIS	O
has	O
been	O
proposed	O
to	O
play	O
a	O
role	O
in	O
transcript	O
editing	O
by	O
stimulating	O
the	O
intrinsic	O
nuclease	O
activity	O
of	O
the	O
RNA	B-OOS
polymerase	I-OOS
.	O

However	O
,	O
deletion	O
of	O
DST1	O
,	O
the	O
gene	O
encoding	O
the	O
yeast	O
homolog	O
of	O
TFIIS	O
,	O
had	O
only	O
a	O
small	O
effect	O
on	O
transcriptional	O
fidelity	O
,	O
as	O
determined	O
by	O
this	O
assay	O
.	O

In	O
contrast	O
,	O
strains	O
containing	O
a	O
deletion	O
of	O
RPB9	O
,	O
which	O
encodes	O
a	O
small	O
core	O
subunit	O
of	O
Pol	B-Complex
II	I-Complex
,	O
were	O
found	O
to	O
engage	O
in	O
error	O
-	O
prone	O
transcription	O
.	O

rpb9Delta	O
strains	O
also	O
had	O
increased	O
steady	O
-	O
state	O
levels	O
of	O
can1	O
-	O
100	O
mRNA	O
,	O
consistent	O
with	O
transcriptional	O
errors	O
that	O
decrease	O
the	O
normal	O
sensitivity	O
of	O
the	O
can1	O
-	O
100	O
transcript	O
to	O
nonsense	O
-	O
mediated	O
decay	O
,	O
a	O
pathway	O
that	O
degrades	O
mRNAs	O
with	O
premature	O
stop	O
codons	O
.	O

Sequences	O
of	O
cDNAs	O
from	O
rpb9Delta	O
strains	O
confirmed	O
a	O
significantly	O
increased	O
occurrence	O
of	O
transcriptional	O
substitutions	O
and	O
insertions	O
.	O

These	O
results	O
suggest	O
that	O
Rpb9	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
transcriptional	O
fidelity	O
,	O
whereas	O
TFIIS	O
may	O
serve	O
a	O
different	O
primary	O
purpose	O
.	O

Histone	O
deacetylase	O
3	O
localizes	O
to	O
the	O
plasma	O
membrane	O
and	O
is	O
a	O
substrate	O
of	O
Src	O
.	O

Histone	O
deacetylases	O
(	O
HDACs	O
)	O
negatively	O
regulate	O
gene	O
expression	O
by	O
removing	O
acetyl	O
groups	O
from	O
lysine	O
residues	O
present	O
in	O
histones	O
and	O
other	O
proteins	O
.	O

Histone	O
deacetylase	O
3	O
is	O
unique	O
among	O
the	O
Class	O
I	O
family	O
of	O
HDACs	O
,	O
as	O
it	O
is	O
able	O
to	O
shuttle	O
between	O
the	O
nucleus	O
and	O
the	O
cytoplasm	O
,	O
whereas	O
the	O
other	O
family	O
members	O
remain	O
in	O
the	O
nucleus	O
.	O

Histone	O
deacetylase	O
3	O
often	O
forms	O
complexes	O
with	O
corepressor	O
proteins	O
that	O
do	O
not	O
associate	O
with	O
the	O
other	O
Class	O
I	O
HDACs	O
,	O
and	O
its	O
phosphorylation	O
correlates	O
with	O
increased	O
enzymatic	O
activity	O
.	O

Here	O
we	O
show	O
that	O
HDAC3	O
also	O
localizes	O
to	O
the	O
plasma	O
membrane	O
in	O
multiple	O
cell	O
types	O
.	O

Furthermore	O
,	O
c	O
-	O
Src	O
is	O
shown	O
to	O
form	O
a	O
complex	O
with	O
HDAC3	O
at	O
the	O
plasma	O
membrane	O
and	O
to	O
use	O
HDAC3	O
as	O
a	O
substrate	O
for	O
phosphorylation	O
.	O

Our	O
results	O
describe	O
a	O
novel	O
localization	O
and	O
binding	O
partner	O
for	O
the	O
HDAC3	O
protein	O
,	O
as	O
well	O
as	O
implicate	O
c	O
-	O
Src	O
in	O
HDAC3	O
regulation	O
.	O

TCF	O
-	O
4	O
isoforms	O
absent	O
in	O
TCF	O
-	O
4	O
mutated	O
MSI	O
-	O
H	O
colorectal	O
cancer	O
cells	O
colocalize	O
with	O
nuclear	O
CtBP	O
and	O
repress	O
TCF	O
-	O
4	O
-	O
mediated	O
transcription	O
.	O

TCF	O
-	O
4	O
is	O
the	O
main	O
effector	O
of	O
the	O
Wnt	O
/	O
Wingless	O
signalling	O
pathway	O
.	O

As	O
with	O
other	O
TCF	O
/	O
LEF	O
factors	O
,	O
numerous	O
alternative	O
splicings	O
at	O
its	O
3	O
'	O
end	O
affect	O
its	O
expression	O
.	O

Such	O
a	O
mechanism	O
leads	O
to	O
the	O
synthesis	O
of	O
numerous	O
TCF	O
-	O
4	O
isoforms	O
among	O
which	O
some	O
contain	O
binding	O
domains	O
for	O
CtBP	O
,	O
an	O
ubiquitous	O
transcriptional	O
corepressor	O
.	O

Of	O
interest	O
,	O
we	O
described	O
a	O
frequent	O
TCF	O
-	O
4	O
frameshift	O
mutation	O
in	O
mismatch	O
-	O
repair	O
deficient	O
colorectal	O
cancers	O
(	O
MSI	O
-	O
H	O
cancers	O
)	O
that	O
leads	O
to	O
the	O
selective	O
loss	O
of	O
TCF	O
-	O
4	O
isoforms	O
with	O
CtBP	O
binding	O
abilities	O
.	O

We	O
provide	O
here	O
data	O
that	O
argue	O
for	O
a	O
partial	O
colocalization	O
of	O
CtBP	O
with	O
TCF	O
-	O
4	O
isoforms	O
containing	O
CtBP	O
binding	O
domains	O
in	O
cellulo	O
,	O
and	O
for	O
a	O
functional	O
role	O
of	O
CtBP	O
in	O
repressing	O
TCF	O
-	O
4	O
mediated	O
transcription	O
.	O

We	O
also	O
demonstrate	O
that	O
such	O
a	O
colocalization	O
is	O
not	O
observed	O
in	O
MSI	O
-	O
H	O
colorectal	O
cancer	O
cells	O
that	O
harbour	O
the	O
TCF	O
-	O
4	O
frameshift	O
mutation	O
,	O
and	O
that	O
CtBP	O
is	O
not	O
able	O
to	O
repress	O
TCF	O
-	O
4	O
-	O
mediated	O
transcription	O
in	O
this	O
context	O
.	O

Taken	O
together	O
,	O
our	O
results	O
strongly	O
suggest	O
that	O
CtBP	O
would	O
play	O
a	O
role	O
in	O
regulating	O
TCF	O
-	O
4	O
mediated	O
transcription	O
upon	O
its	O
binding	O
with	O
some	O
TCF	O
-	O
4	O
isoforms	O
encoded	O
by	O
alternatively	O
spliced	O
mRNA	O
.	O

They	O
also	O
suggest	O
a	O
role	O
for	O
TCF	O
-	O
4	O
frameshift	O
mutation	O
during	O
MSI	O
-	O
H	O
colorectal	O
tumour	O
progression	O
,	O
by	O
regulating	O
the	O
relative	O
proportion	O
of	O
the	O
different	O
TCF	O
-	O
4	O
isoforms	O
.	O

Understanding	O
GFP	O
posttranslational	O
chemistry	O
:	O
structures	O
of	O
designed	O
variants	O
that	O
achieve	O
backbone	O
fragmentation	O
,	O
hydrolysis	O
,	O
and	O
decarboxylation	O
.	O

The	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
creates	O
a	O
fluorophore	O
out	O
of	O
three	O
sequential	O
amino	O
acids	O
by	O
promoting	O
spontaneous	O
posttranslational	O
modifications	O
.	O

Here	O
,	O
we	O
use	O
high	O
-	O
resolution	O
crystallography	O
to	O
characterize	O
GFP	O
variants	O
that	O
not	O
only	O
undergo	O
peptide	O
backbone	O
cyclization	O
but	O
additional	O
denaturation	O
-	O
induced	O
peptide	O
backbone	O
fragmentation	O
,	O
native	O
peptide	O
hydrolysis	O
,	O
and	O
decarboxylation	O
reactions	O
.	O

Our	O
analyses	O
indicate	O
that	O
architectural	O
features	O
that	O
favor	O
GFP	O
peptide	O
cyclization	O
also	O
drive	O
peptide	O
hydrolysis	O
.	O

These	O
results	O
are	O
relevant	O
for	O
the	O
maturation	O
pathways	O
of	O
GFP	O
homologues	O
,	O
such	O
as	O
the	O
kindling	O
fluorescent	O
protein	O
and	O
the	O
Kaede	B-OOS
protein	O
,	O
which	O
use	O
backbone	O
cleavage	O
to	O
red	O
-	O
shift	O
the	O
spectral	O
properties	O
of	O
their	O
chromophores	O
.	O

We	O
further	O
propose	O
a	O
photochemical	O
mechanism	O
for	O
the	O
decarboxylation	O
reaction	O
,	O
supporting	O
a	O
role	O
for	O
the	O
GFP	O
protein	O
environment	O
in	O
facilitating	O
radical	O
formation	O
and	O
one	O
-	O
electron	O
chemistry	O
,	O
which	O
may	O
be	O
important	O
in	O
activating	O
oxygen	O
for	O
the	O
oxidation	O
step	O
of	O
chromophore	O
biosynthesis	O
.	O

Together	O
,	O
our	O
results	O
characterize	O
GFP	O
posttranslational	O
modification	O
chemistry	O
with	O
implications	O
for	O
the	O
energetic	O
landscape	O
of	O
backbone	O
cyclization	O
and	O
subsequent	O
reactions	O
,	O
and	O
for	O
the	O
rational	O
design	O
of	O
predetermined	O
spontaneous	O
backbone	O
cyclization	O
and	O
cleavage	O
reactions	O
.	O

Gs	O
alpha	O
availability	O
to	O
cholera	B-Complex
toxin	I-Complex
-	O
catalysed	O
ADP	O
-	O
ribosylation	O
is	O
decreased	O
in	O
membranes	O
of	O
retinoic	O
acid	O
-	O
treated	O
leukemic	O
cell	O
lines	O
HL	O
-	O
60	O
and	O
THP	O
-	O
1	O
.	O

A	O
posttranslational	O
effect	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
induces	O
HL	O
-	O
60	O
and	O
THP	O
-	O
1	O
leukemic	O
cell	O
lines	O
to	O
differentiate	O
into	O
granulocyte	O
-	O
like	O
and	O
monocyte	O
-	O
like	O
cells	O
.	O

Limited	O
data	O
are	O
available	O
concerning	O
the	O
effects	O
of	O
RA	O
on	O
components	O
of	O
the	O
cyclic	O
AMP	O
pathway	O
in	O
human	O
myeloid	O
leukemic	O
cells	O
.	O

We	O
showed	O
previously	O
a	O
decrease	O
in	O
adenylate	O
cyclase	O
activity	O
in	O
the	O
presence	O
of	O
histamine	O
,	O
prostaglandin	O
E1	O
and	O
forskolin	O
in	O
RA	O
-	O
treated	O
HL	O
-	O
60	O
cells	O
as	O
compared	O
to	O
untreated	O
cells	O
.	O

We	O
examined	O
the	O
elements	O
of	O
the	O
signal	O
transduction	O
pathway	O
utilized	O
by	O
RA	O
in	O
the	O
human	O
myeloid	O
cell	O
line	O
HL	O
-	O
60	O
and	O
the	O
human	O
monocytic	O
cell	O
line	O
THP	O
-	O
1	O
.	O

We	O
therefore	O
studied	O
the	O
effect	O
of	O
RA	O
on	O
the	O
activity	O
of	O
the	O
stimulatory	B-OOS
G	I-OOS
-	I-OOS
protein	I-OOS
(	O
Gs	B-OOS
)	O
.	O

We	O
demonstrate	O
that	O
addition	O
of	O
RA	O
to	O
two	O
human	O
myeloid	O
leukemia	O
cell	O
lines	O
,	O
HL	O
-	O
60	O
and	O
THP	O
-	O
1	O
,	O
does	O
not	O
induce	O
a	O
reduction	O
of	O
the	O
2	O
subunit	O
of	O
Gs	B-OOS
(	O
Gs	O
alpha	O
)	O
RNA	O
or	O
Gs	O
alpha	O
protein	O
in	O
the	O
plasma	O
membrane	O
but	O
leads	O
to	O
a	O
rapid	O
decrease	O
in	O
the	O
cholera	B-Complex
toxin	I-Complex
(	O
CTX	B-Complex
)	O
-	O
catalysed	O
ADP	O
-	O
ribosylation	O
of	O
Gs	O
alpha	O
.	O

In	O
addition	O
,	O
this	O
effect	O
seems	O
to	O
be	O
specific	O
to	O
RA	O
,	O
since	O
there	O
was	O
no	O
modification	O
in	O
Gs	O
alpha	O
ADP	O
-	O
ribosylation	O
in	O
the	O
membranes	O
of	O
cells	O
treated	O
with	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
,	O
another	O
inducer	O
of	O
differentiation	O
in	O
HL	O
-	O
60	O
cells	O
.	O

It	O
is	O
anticipated	O
that	O
additional	O
genes	O
and	O
/	O
or	O
mechanisms	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
Rnr	O
activities	O
.	O

To	O
investigate	O
this	O
possibility	O
,	O
we	O
utilized	O
the	O
powerful	O
budding	O
yeast	O
genetic	O
system	O
to	O
identify	O
such	O
genes	O
,	O
and	O
report	O
here	O
the	O
identification	O
of	O
a	O
novel	O
gene	O
,	O
CRT10	O
,	O
whose	O
mutation	O
enhances	O
hydroxyurea	O
(	O
HU	O
)	O
resistance	O
.	O

Genetic	O
characterization	O
indicates	O
that	O
CRT10	O
is	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
RNR	O
genes	O
.	O

Physical	O
and	O
functional	O
interactions	O
of	O
Arabidopsis	O
ADA2	O
transcriptional	O
coactivator	O
proteins	O
with	O
the	O
acetyltransferase	O
GCN5	O
and	O
with	O
the	O
cold	O
-	O
induced	O
transcription	O
factor	O
CBF1	O
.	O

The	O
Arabidopsis	O
GCN5	O
,	O
ADA2a	O
and	O
ADA2b	O
proteins	O
are	O
homologs	O
of	O
components	O
of	O
several	O
yeast	O
and	O
animal	O
transcriptional	O
coactivator	O
complexes	O
.	O

Previous	O
work	O
has	O
implicated	O
these	O
plant	O
coactivator	O
proteins	O
in	O
the	O
stimulation	O
of	O
cold	O
-	O
regulated	O
gene	O
expression	O
by	O
the	O
transcriptional	O
activator	O
protein	O
CBF1	O
.	O

Surprisingly	O
,	O
protein	O
interaction	O
studies	O
demonstrate	O
that	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
CBF1	O
(	O
and	O
of	O
a	O
related	O
protein	O
,	O
TINY	O
)	O
,	O
rather	O
than	O
its	O
transcriptional	O
activation	O
domain	O
,	O
can	O
bind	O
directly	O
to	O
the	O
Arabidopsis	O
ADA2	O
proteins	O
.	O

The	O
ADA2a	O
and	O
ADA2b	O
proteins	O
can	O
also	O
bind	O
directly	O
to	O
GCN5	O
through	O
their	O
N	O
-	O
terminal	O
regions	O
(	O
comparable	O
to	O
a	O
region	O
previously	O
defined	O
in	O
yeast	O
Ada2	O
)	O
and	O
through	O
previously	O
unmapped	O
regions	O
in	O
the	O
middle	O
of	O
the	O
ADA2	O
proteins	O
,	O
which	O
bind	O
to	O
the	O
HAT	O
domain	O
of	O
GCN5	O
.	O

The	O
ADA2	O
proteins	O
enhance	O
the	O
ability	O
of	O
GCN5	O
to	O
acetylate	O
histones	O
in	O
vitro	O
and	O
enable	O
GCN5	O
to	O
acetylate	O
nucleosomal	O
histones	O
.	O

Moreover	O
,	O
GCN5	O
can	O
acetylate	O
the	O
ADA2	O
proteins	O
at	O
a	O
motif	O
unique	O
to	O
the	O
plant	O
homologs	O
and	O
absent	O
from	O
fungal	O
and	O
animal	O
homologs	O
.	O

We	O
speculate	O
that	O
this	O
modification	O
may	O
represent	O
a	O
novel	O
autoregulatory	O
mechanism	O
for	O
the	O
plant	O
SAGA	O
-	O
like	O
transcriptional	O
coactivator	O
complexes	O
.	O

Complementation	O
of	O
Saccharomyces	O
cerevisiae	O
coq7	O
mutants	O
by	O
mitochondrial	O
targeting	O
of	O
the	O
Escherichia	O
coli	O
UbiF	O
polypeptide	O
:	O
two	O
functions	O
of	O
yeast	O
Coq7	O
polypeptide	O
in	O
coenzyme	O
Q	O
biosynthesis	O
.	O

Coenzyme	O
Q	O
(	O
ubiquinone	O
or	O
Q	O
)	O
functions	O
in	O
the	O
respiratory	O
electron	O
transport	O
chain	O
and	O
serves	O
as	O
a	O
lipophilic	O
antioxidant	O
.	O

In	O
the	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
Q	O
biosynthesis	O
requires	O
nine	O
Coq	O
proteins	O
(	O
Coq1	O
-	O
Coq9	O
)	O
.	O

Previous	O
work	O
suggests	O
both	O
an	O
enzymatic	O
activity	O
and	O
a	O
structural	O
role	O
for	O
the	O
yeast	O
Coq7	O
protein	O
.	O

To	O
define	O
the	O
functional	O
roles	O
of	O
yeast	O
Coq7p	O
we	O
test	O
whether	O
Escherichia	O
coli	O
ubiF	O
can	O
functionally	O
substitute	O
for	O
yeast	O
COQ7	O
.	O

The	O
ubiF	O
gene	O
encodes	O
a	O
flavin	O
-	O
dependent	O
monooxygenase	O
that	O
shares	O
no	O
homology	O
to	O
the	O
Coq7	O
protein	O
and	O
is	O
required	O
for	O
the	O
final	O
monooxygenase	O
step	O
of	O
Q	O
biosynthesis	O
in	O
E	O
.	O
coli	O
.	O

The	O
ubiF	O
gene	O
expressed	O
at	O
low	O
copy	O
restores	O
growth	O
of	O
a	O
coq7	O
point	O
mutant	O
(	O
E194K	O
)	O
on	O
medium	O
containing	O
a	O
non	O
-	O
fermentable	O
carbon	O
source	O
,	O
but	O
fails	O
to	O
rescue	O
a	O
coq7	O
null	O
mutant	O
.	O

However	O
,	O
expression	O
of	O
ubiF	O
from	O
a	O
multicopy	O
vector	O
restores	O
growth	O
and	O
Q	O
synthesis	O
for	O
both	O
mutants	O
,	O
although	O
with	O
a	O
higher	O
efficiency	O
in	O
the	O
point	O
mutant	O
.	O

We	O
attribute	O
the	O
more	O
efficient	O
rescue	O
of	O
the	O
coq7	O
point	O
mutant	O
to	O
higher	O
steady	O
state	O
levels	O
of	O
the	O
Coq3	O
,	O
Coq4	O
,	O
and	O
Coq6	O
proteins	O
and	O
to	O
the	O
presence	O
of	O
demethoxyubiquinone	O
,	O
the	O
substrate	O
of	O
UbiF	O
.	O

Coq7p	O
co	O
-	O
migrates	O
with	O
the	O
Coq3	O
and	O
Coq4	O
polypeptides	O
as	O
a	O
high	O
molecular	O
mass	O
complex	O
.	O

Here	O
we	O
show	O
that	O
addition	O
of	O
Q	O
to	O
the	O
growth	O
media	O
also	O
stabilizes	O
the	O
Coq3	O
and	O
Coq4	O
polypeptides	O
in	O
the	O
coq7	O
null	O
mutant	O
.	O

The	O
data	O
suggest	O
that	O
Coq7p	O
,	O
and	O
the	O
lipid	O
quinones	O
(	O
demethoxyubiquinone	O
and	O
Q	O
)	O
function	O
to	O
stabilize	O
other	O
Coq	O
polypeptides	O
.	O

Unusual	O
splicing	O
events	O
result	O
in	O
distinct	O
Xin	O
isoforms	O
that	O
associate	O
differentially	O
with	O
filamin	O
c	O
and	O
Mena	O
/	O
VASP	O
.	O

Filamin	O
c	O
is	O
the	O
predominantly	O
expressed	O
filamin	O
isoform	O
in	O
striated	O
muscles	O
.	O

It	O
is	O
localized	O
in	O
myofibrillar	O
Z	O
-	O
discs	O
,	O
where	O
it	O
binds	O
FATZ	O
and	O
myotilin	O
,	O
and	O
in	O
myotendinous	O
junctions	O
and	O
intercalated	O
discs	O
.	O

Here	O
,	O
we	O
identify	O
Xin	O
,	O
the	O
protein	O
encoded	O
by	O
the	O
human	O
gene	O
'	O
cardiomyopathy	O
associated	O
1	O
'	O
(	O
CMYA1	O
)	O
as	O
filamin	O
c	O
binding	O
partner	O
at	O
these	O
specialized	O
structures	O
where	O
the	O
ends	O
of	O
myofibrils	O
are	O
attached	O
to	O
the	O
sarcolemma	O
.	O

Xin	O
directly	O
binds	O
the	O
EVH1	O
domain	O
proteins	O
Mena	O
and	O
VASP	O
.	O

In	O
the	O
adult	O
heart	O
,	O
Xin	O
and	O
Mena	O
/	O
VASP	O
colocalize	O
with	O
filamin	O
c	O
in	O
intercalated	O
discs	O
.	O

In	O
cultured	O
cardiomyocytes	O
,	O
the	O
proteins	O
also	O
localize	O
in	O
the	O
nonstriated	O
part	O
of	O
myofibrils	O
,	O
where	O
sarcomeres	O
are	O
assembled	O
and	O
an	O
extensive	O
reorganization	O
of	O
the	O
actin	O
cytoskeleton	O
occurs	O
.	O

Unusual	O
intraexonic	O
splicing	O
events	O
result	O
in	O
the	O
existence	O
of	O
three	O
Xin	O
isoforms	O
that	O
associate	O
differentially	O
with	O
its	O
ligands	O
.	O

The	O
identification	O
of	O
the	O
complex	O
filamin	O
c	O
-	O
Xin	O
-	O
Mena	O
/	O
VASP	O
provides	O
a	O
first	O
glance	O
on	O
the	O
role	O
of	O
Xin	O
in	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
developmental	O
and	O
adaptive	O
remodeling	O
of	O
the	O
actin	O
cytoskeleton	O
during	O
cardiac	O
morphogenesis	O
and	O
sarcomere	O
assembly	O
.	O

The	O
von	O
Hippel	O
-	O
Lindau	O
tumour	O
-	O
suppressor	O
protein	O
interaction	O
with	O
protein	O
kinase	O
Cdelta	O
.	O

The	O
VHL	O
(	O
von	O
Hippel	O
-	O
Lindau	O
)	O
tumour	O
-	O
suppressor	O
protein	O
forms	O
a	O
multi	O
-	O
protein	O
complex	O
[	O
VCB	O
(	O
pVHL	O
-	O
elongin	O
C	O
-	O
elongin	O
B	O
)	O
-	O
Cul	O
-	O
2	O
(	O
Cullin	O
-	O
2	O
)	O
]	O
with	O
elongin	O
C	O
,	O
elongin	O
B	O
,	O
Cul	O
-	O
2	O
and	O
Rbx1	O
,	O
acting	O
as	O
a	O
ubiquitin	O
-	O
ligase	O
(	O
E3	O
)	O
and	O
directing	O
proteasome	B-Complex
-	O
dependent	O
degradation	O
of	O
targeted	O
proteins	O
.	O

The	O
alpha	O
-	O
subunit	O
of	O
Hif1alpha	O
(	O
hypoxia	O
-	O
inducible	O
factor	O
1alpha	O
)	O
is	O
the	O
principal	O
substrate	O
for	O
the	O
VCB	O
-	O
Cul	O
-	O
2	O
complex	O
;	O
however	O
,	O
other	O
substrates	O
such	O
as	O
aPKC	O
(	O
atypical	O
protein	O
kinase	O
C	O
)	O
have	O
been	O
reported	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
show	O
with	O
FRET	O
(	O
fluorescence	O
resonance	O
energy	O
transfer	O
)	O
analysis	O
measured	O
by	O
FLIM	O
(	O
fluorescence	O
lifetime	O
imaging	O
microscopy	O
)	O
that	O
PKCdelta	O
and	O
pVHL	O
(	O
VHL	O
protein	O
)	O
interact	O
directly	O
in	O
cells	O
.	O

This	O
occurs	O
through	O
the	O
catalytic	O
domain	O
of	O
PKCdelta	O
(	O
residues	O
432	O
-	O
508	O
)	O
,	O
which	O
appears	O
to	O
interact	O
with	O
two	O
regions	O
of	O
pVHL	O
,	O
residues	O
113	O
-	O
122	O
and	O
130	O
-	O
154	O
.	O

Despite	O
this	O
robust	O
interaction	O
,	O
analysis	O
of	O
the	O
PMA	O
-	O
induced	O
proteasome	B-Complex
-	O
dependent	O
degradation	O
of	O
PKCdelta	O
in	O
different	O
RCC	O
(	O
renal	O
cell	O
carcinoma	O
)	O
lines	O
(	O
RCC4	O
,	O
UMRC2	O
and	O
786	O
O	O
)	O
shows	O
that	O
there	O
is	O
no	O
correlation	O
between	O
the	O
degradation	O
of	O
PKCdelta	O
and	O
the	O
presence	O
of	O
active	O
pVHL	O
.	O

Thus	O
,	O
in	O
contrast	O
with	O
aPKC	O
,	O
PKCdelta	O
is	O
not	O
a	O
conventional	O
substrate	O
of	O
the	O
ubiquitin	O
-	O
ligase	O
complex	O
,	O
VCB	O
-	O
Cul	O
-	O
2	O
,	O
and	O
the	O
observed	O
interaction	O
between	O
these	O
two	O
proteins	O
must	O
underlie	O
a	O
distinct	O
signalling	O
output	O
.	O

Histone	O
H3	O
and	O
H4	O
ubiquitylation	O
by	O
the	O
CUL4	O
-	O
DDB	O
-	O
ROC1	O
ubiquitin	O
ligase	O
facilitates	O
cellular	O
response	O
to	O
DNA	O
damage	O
.	O

Posttranslational	O
histone	O
modifications	O
play	O
important	O
roles	O
in	O
transcription	O
and	O
other	O
chromatin	O
-	O
based	O
processes	O
.	O

Compared	O
to	O
acetylation	O
,	O
methylation	O
,	O
and	O
phosphorylation	O
,	O
very	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
histone	O
ubiquitylation	O
.	O

Here	O
,	O
we	O
report	O
the	O
purification	O
and	O
functional	O
characterization	O
of	O
a	O
histone	O
H3	O
and	O
H4	O
ubiquitin	O
ligase	O
complex	O
,	O
CUL4	O
-	O
DDB	O
-	O
ROC1	O
.	O

We	O
demonstrate	O
that	O
CUL4	O
-	O
DDB	O
-	O
ROC1	O
-	O
mediated	O
H3	O
and	O
H4	O
ubiquitylation	O
occurs	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Importantly	O
,	O
CUL4	O
-	O
DDB	O
-	O
ROC1	O
-	O
mediated	O
H3	O
and	O
H4	O
ubiquitylation	O
is	O
regulated	O
by	O
UV	O
irradiation	O
.	O

Reduction	O
of	O
histone	O
H3	O
and	O
H4	O
ubiquitylation	O
by	O
knockdown	O
of	O
CUL4A	O
impairs	O
recruitment	O
of	O
the	O
repair	O
protein	O
XPC	O
to	O
the	O
damaged	O
foci	O
and	O
inhibits	O
the	O
repair	O
process	O
.	O

Biochemical	O
studies	O
indicate	O
that	O
CUL4	O
-	O
DDB	O
-	O
ROC1	O
-	O
mediated	O
histone	O
ubiquitylation	O
weakens	O
the	O
interaction	O
between	O
histones	O
and	O
DNA	O
and	O
facilitates	O
the	O
recruitment	O
of	O
repair	O
proteins	O
to	O
damaged	O
DNA	O
.	O

Thus	O
,	O
our	O
studies	O
uncover	O
CUL4	O
-	O
DDB	O
-	O
ROC1	O
as	O
a	O
histone	O
ubiquitin	O
ligase	O
and	O
demonstrate	O
that	O
histone	O
H3	O
and	O
H4	O
ubiquitylation	O
participates	O
in	O
the	O
cellular	O
response	O
to	O
DNA	O
damage	O
.	O

Multisite	O
protein	O
kinase	O
A	O
and	O
glycogen	O
synthase	O
kinase	O
3beta	O
phosphorylation	O
leads	O
to	O
Gli3	O
ubiquitination	O
by	O
SCFbetaTrCP	B-Complex
.	O

Gli3	O
is	O
a	O
zinc	O
finger	O
transcription	O
factor	O
proteolytically	O
processed	O
into	O
a	O
truncated	O
repressor	O
lacking	O
C	O
-	O
terminal	O
activation	O
domains	O
.	O

Gli3	O
processing	O
is	O
stimulated	O
by	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
and	O
inhibited	O
by	O
Hedgehog	O
signaling	O
,	O
a	O
major	O
signaling	O
pathway	O
in	O
vertebrate	O
development	O
and	O
disease	O
.	O

We	O
show	O
here	O
that	O
multisite	O
glycogen	O
synthase	O
kinase	O
3beta	O
(	O
GSK3beta	O
)	O
phosphorylation	O
and	O
ubiquitination	O
by	O
SCFbetaTrCP	B-Complex
are	O
required	O
for	O
Gli3	O
processing	O
.	O

We	O
identified	O
multiple	O
betaTrCP	O
-	O
binding	O
sites	O
related	O
to	O
the	O
DSGX2	O
-	O
4S	O
motif	O
in	O
Gli3	O
,	O
which	O
are	O
intertwined	O
with	O
PKA	O
and	O
GSK3beta	O
sites	O
,	O
and	O
SCFbetaTrCP	B-Complex
target	O
lysines	O
that	O
are	O
essential	O
for	O
processing	O
.	O

Our	O
results	O
support	O
a	O
simple	O
model	O
whereby	O
PKA	O
triggers	O
a	O
cascade	O
of	O
Gli3	O
phosphorylation	O
by	O
GSK3beta	O
and	O
CK1	O
that	O
leads	O
to	O
direct	O
betaTrCP	O
binding	O
and	O
ubiquitination	O
by	O
SCFbetaTrCP	B-Complex
.	O

Binding	O
of	O
betaTrCP	O
to	O
Gli3	O
N	O
-	O
and	O
C	O
-	O
terminal	O
domains	O
lacking	O
DSGX2	O
-	O
4S	O
-	O
related	O
motifs	O
was	O
also	O
observed	O
,	O
which	O
could	O
reflect	O
indirect	O
interaction	O
via	O
other	O
components	O
of	O
Hedgehog	O
signaling	O
,	O
such	O
as	O
the	O
tumor	O
suppressor	O
Sufu	O
.	O

Gli3	O
therefore	O
joins	O
a	O
small	O
set	O
of	O
transcription	O
factors	O
whose	O
processing	O
is	O
regulated	O
by	O
the	O
ubiquitin	O
-	O
proteasome	B-Complex
pathway	O
.	O

Our	O
study	O
sheds	O
light	O
on	O
the	O
role	O
of	O
PKA	O
phosphorylation	O
in	O
Gli3	O
processing	O
and	O
will	O
help	O
to	O
analyze	O
how	O
dose	O
-	O
dependent	O
tuning	O
of	O
Gli3	O
processing	O
is	O
achieved	O
by	O
Hedgehog	O
signaling	O
.	O

Molecular	O
basis	O
of	O
different	O
forms	O
of	O
metachromatic	O
leukodystrophy	O
.	O

BACKGROUND	O
:	O
Metachromatic	O
leukodystrophy	O
is	O
an	O
autosomal	O
recessive	O
inherited	O
lysosomal	O
storage	O
disorder	O
caused	O
by	O
a	O
deficiency	O
of	O
arylsulfatase	O
A	O
.	O

Three	O
forms	O
of	O
the	O
disease	O
can	O
be	O
distinguished	O
according	O
to	O
severity	O
and	O
the	O
age	O
at	O
onset	O
:	O
late	O
infantile	O
(	O
1	O
to	O
2	O
years	O
)	O
,	O
juvenile	O
(	O
3	O
to	O
16	O
)	O
,	O
and	O
adult	O
(	O
greater	O
than	O
16	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
To	O
understand	O
the	O
molecular	O
basis	O
of	O
the	O
different	O
forms	O
of	O
the	O
disease	O
,	O
we	O
analyzed	O
arylsulfatase	O
A	O
alleles	O
associated	O
with	O
metachromatic	O
leukodystrophy	O
.	O

Two	O
alleles	O
(	O
termed	O
I	O
and	O
A	O
)	O
were	O
identified	O
and	O
accounted	O
for	O
about	O
half	O
of	O
all	O
arylsulfatase	O
A	O
alleles	O
among	O
68	O
patients	O
with	O
metachromatic	O
leukodystrophy	O
whom	O
we	O
examined	O
.	O

Sufficient	O
information	O
was	O
available	O
for	O
66	O
of	O
the	O
patients	O
to	O
allow	O
classification	O
of	O
their	O
disease	O
.	O

Of	O
the	O
six	O
instances	O
of	O
homozygosity	O
for	O
allele	O
I	O
,	O
all	O
were	O
associated	O
with	O
the	O
late	O
-	O
infantile	O
form	O
of	O
the	O
disease	O
;	O
of	O
the	O
eight	O
instances	O
of	O
homozygosity	O
for	O
allele	O
A	O
,	O
five	O
were	O
associated	O
with	O
the	O
adult	O
form	O
and	O
three	O
with	O
the	O
juvenile	O
form	O
.	O

When	O
both	O
alleles	O
were	O
present	O
,	O
the	O
juvenile	O
form	O
resulted	O
(	O
seven	O
of	O
seven	O
instances	O
)	O
.	O

Heterozygosity	O
for	O
allele	O
I	O
(	O
with	O
the	O
other	O
allele	O
unknown	O
)	O
is	O
usually	O
associated	O
with	O
late	O
-	O
infantile	O
disease	O
,	O
and	O
heterozygosity	O
for	O
allele	O
A	O
with	O
a	O
later	O
onset	O
of	O
the	O
disease	O
.	O

The	O
clinical	O
variability	O
can	O
be	O
explained	O
by	O
the	O
different	O
levels	O
of	O
residual	O
arylsulfatase	O
A	O
activity	O
associated	O
with	O
these	O
genotypes	O
.	O

CONCLUSIONS	O
:	O
Like	O
many	O
lysosomal	O
storage	O
disorders	O
,	O
metachromatic	O
leukodystrophy	O
shows	O
clinical	O
heterogeneity	O
that	O
seems	O
to	O
reflect	O
genetic	O
heterogeneity	O
.	O

One	O
of	O
the	O
known	O
alleles	O
(	O
allele	O
I	O
)	O
is	O
associated	O
with	O
earlier	O
and	O
more	O
severe	O
disease	O
than	O
the	O
other	O
(	O
allele	O
A	O
)	O
.	O

The	O
frequency	O
of	O
neuroblast	O
telomeres	O
with	O
HOAP	O
staining	O
and	O
the	O
intensity	O
of	O
staining	O
at	O
those	O
telomeres	O
were	O
examined	O
in	O
wild	O
-	O
type	O
and	O
mutant	O
cells	O
(	O
Figure	O
4	O
,	O
Table	O
1	O
)	O
.	O

Measurements	O
of	O
fluorescence	O
intensity	O
can	O
be	O
used	O
to	O
demonstrate	O
that	O
HOAP	O
levels	O
at	O
individual	O
telomeres	O
are	O
reproducibly	O
increased	O
or	O
decreased	O
in	O
different	O
genotypes	O
.	O

(	O
However	O
,	O
we	O
note	O
that	O
there	O
may	O
not	O
be	O
a	O
linear	O
relationship	O
between	O
the	O
percent	O
change	O
of	O
fluorescence	O
observed	O
and	O
the	O
percent	O
change	O
of	O
telomeric	O
HOAP	O
protein	O
levels	O
.	O
)	O
Most	O
wild	O
-	O
type	O
,	O
tefu	O
,	O
or	O
mus304	O
mutant	O
metaphase	O
cells	O
are	O
HOAP	O
positive	O
;	O
between	O
77	O
%	O
and	O
94	O
%	O
of	O
these	O
cells	O
had	O
HOAP	O
signals	O
at	O
chromosome	O
ends	O
(	O
Figure	O
4	O
,	O
Table	O
1	O
)	O
.	O

Among	O
the	O
HOAP	O
positive	O
cells	O
,	O
between	O
66	O
%	O
and	O
72	O
%	O
of	O
telomeres	O
stained	O
for	O
HOAP	O
.	O

The	O
fluorescence	O
intensity	O
of	O
HOAP	O
staining	O
was	O
similar	O
at	O
the	O
telomeres	O
of	O
each	O
of	O
the	O
major	O
chromosome	O
arms	O
in	O
both	O
wild	O
-	O
type	O
and	O
mus304	O
mutant	O
cells	O
(	O
Figure	O
4G	O
and	O
4H	O
)	O
.	O

However	O
,	O
the	O
average	O
intensity	O
of	O
HOAP	O
staining	O
was	O
elevated	O
in	O
tefu	O
mutant	O
cells	O
(	O
Figure	O
4G	O
and	O
4H	O
)	O
,	O
indicating	O
that	O
although	O
HOAP	O
is	O
still	O
recruited	O
to	O
telomeres	O
,	O
the	O
mechanism	O
regulating	O
HOAP	O
levels	O
at	O
telomeres	O
may	O
be	O
perturbed	O
.	O

A	O
more	O
severe	O
effect	O
on	O
HOAP	O
localization	O
was	O
observed	O
in	O
nbs	O
mutant	O
metaphases	O
,	O
with	O
only	O
44	O
%	O
of	O
metaphases	O
displaying	O
HOAP	O
signals	O
and	O
only	O
30	O
%	O
of	O
the	O
telomeres	O
in	O
those	O
cells	O
staining	O
for	O
HOAP	O
(	O
Table	O
1	O
)	O
.	O

This	O
phenotype	O
is	O
similar	O
to	O
that	O
reported	O
for	O
mre11	O
and	O
rad50	O
mutant	O
neuroblasts	O
.	O

At	O
the	O
few	O
HOAP	O
-	O
positive	O
telomeres	O
that	O
are	O
present	O
in	O
nbs	O
mutant	O
cells	O
,	O
HOAP	O
fluorescence	O
staining	O
intensity	O
was	O
elevated	O
compared	O
to	O
wild	O
type	O
,	O
similar	O
to	O
the	O
HOAP	O
staining	O
at	O
tefu	O
mutant	O
telomeres	O
(	O
Figure	O
4H	O
)	O
.	O

Together	O
with	O
the	O
genetic	O
data	O
indicating	O
that	O
tefu	O
and	O
nbs	O
act	O
in	O
a	O
common	O
telomere	O
protection	O
pathway	O
,	O
these	O
results	O
suggest	O
that	O
an	O
alternative	O
pathway	O
can	O
maintain	O
HOAP	O
levels	O
at	O
telomeres	O
,	O
but	O
that	O
this	O
pathway	O
is	O
much	O
less	O
efficient	O
in	O
nbs	O
mutant	O
cells	O
.	O

Rap1	O
regulation	O
of	O
RIAM	O
and	O
cell	O
adhesion	O
.	O

The	O
small	O
GTPase	O
Rap1	O
has	O
been	O
involved	O
in	O
different	O
cellular	O
processes	O
.	O

Rap1	O
is	O
known	O
to	O
increase	O
cell	O
adhesion	O
by	O
means	O
of	O
integrin	O
activation	O
,	O
to	O
induce	O
cell	O
spreading	O
,	O
and	O
to	O
regulate	O
adherent	O
junctions	O
at	O
cell	O
-	O
cell	O
contacts	O
.	O

How	O
Rap1	O
mediates	O
these	O
cell	O
responses	O
is	O
poorly	O
known	O
,	O
but	O
currently	O
developing	O
evidence	O
points	O
to	O
the	O
involvement	O
of	O
different	O
effector	O
pathways	O
.	O

Recently	O
,	O
we	O
described	O
RIAM	O
,	O
a	O
Rap1	O
interacting	O
adaptor	O
protein	O
that	O
regulates	O
integrin	O
activation	O
and	O
hence	O
cell	O
adhesion	O
.	O

RIAM	O
is	O
required	O
for	O
Rap1	O
-	O
induced	O
adhesion	O
and	O
seems	O
to	O
control	O
Rap1	O
localization	O
at	O
the	O
plasma	O
membrane	O
,	O
where	O
Rap1	O
regulates	O
integrin	O
activation	O
.	O

In	O
this	O
chapter	O
,	O
we	O
focus	O
in	O
the	O
role	O
of	O
RIAM	O
in	O
regulating	O
Rap1	O
-	O
mediated	O
cell	O
adhesion	O
.	O

We	O
describe	O
the	O
method	O
for	O
studying	O
the	O
Rap1	O
-	O
RIAM	O
interaction	O
using	O
in	O
vitro	O
and	O
in	O
vivo	O
approaches	O
such	O
as	O
yeast	O
two	O
hybrids	O
,	O
pull	O
-	O
down	O
assays	O
.	O
and	O
coimmunoprecipitation	O
.	O

The	O
role	O
of	O
Rap1	O
and	O
RIAM	O
in	O
integrin	O
-	O
mediated	O
adhesion	O
is	O
studied	O
by	O
cell	O
adhesion	O
assays	O
to	O
immobilized	O
integrin	O
substrates	O
and	O
by	O
changes	O
in	O
integrin	O
activation	O
as	O
determined	O
by	O
activation	O
epitope	O
exposure	O
.	O

Finally	O
,	O
we	O
describe	O
an	O
approach	O
to	O
determine	O
the	O
role	O
of	O
RIAM	O
in	O
regulating	O
intracellular	O
localization	O
of	O
active	O
Rap1	O
.	O

To	O
investigate	O
protein	O
-	O
protein	O
interaction	O
sites	O
in	O
the	O
DNA	O
mismatch	O
repair	O
system	O
we	O
developed	O
a	O
crosslinking	O
/	O
mass	O
spectrometry	O
technique	O
employing	O
a	O
commercially	O
available	O
trifunctional	O
crosslinker	O
with	O
a	O
thiol	O
-	O
specific	O
methanethiosulfonate	O
group	O
,	O
a	O
photoactivatable	O
benzophenone	O
moiety	O
and	O
a	O
biotin	O
affinity	O
tag	O
.	O

The	O
XACM	O
approach	O
combines	O
photocrosslinking	O
(	O
X	O
)	O
,	O
in	O
-	O
solution	O
digestion	O
of	O
the	O
crosslinked	O
mixtures	O
,	O
affinity	O
purification	O
via	O
the	O
biotin	O
handle	O
(	O
A	O
)	O
,	O
chemical	O
coding	O
of	O
the	O
crosslinked	O
products	O
(	O
C	O
)	O
followed	O
by	O
MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
(	O
M	O
)	O
.	O

We	O
illustrate	O
the	O
feasibility	O
of	O
the	O
method	O
using	O
a	O
single	O
-	O
cysteine	O
variant	O
of	O
the	O
homodimeric	O
DNA	O
mismatch	O
repair	O
protein	O
MutL	O
.	O

Moreover	O
,	O
we	O
successfully	O
applied	O
this	O
method	O
to	O
identify	O
the	O
photocrosslink	O
formed	O
between	O
the	O
single	O
-	O
cysteine	O
MutH	O
variant	O
A223C	O
,	O
labeled	O
with	O
the	O
trifunctional	O
crosslinker	O
in	O
the	O
C	O
-	O
terminal	O
helix	O
and	O
its	O
activator	O
protein	O
MutL	O
.	O

The	O
identified	O
crosslinked	O
MutL	O
-	O
peptide	O
maps	O
to	O
a	O
conserved	O
surface	O
patch	O
of	O
the	O
MutL	O
C	O
-	O
terminal	O
dimerization	O
domain	O
.	O

These	O
observations	O
are	O
substantiated	O
by	O
additional	O
mutational	O
and	O
chemical	O
crosslinking	O
studies	O
.	O

Our	O
results	O
shed	O
light	O
on	O
the	O
potential	O
structures	O
of	O
the	O
MutL	O
holoenzyme	O
and	O
the	O
MutH	O
-	O
MutL	O
-	O
DNA	O
complex	O
.	O

Ribosome	O
biogenesis	O
in	O
yeast	O
involves	O
the	O
synthesis	O
of	O
a	O
35S	O
polycistronic	O
rRNA	O
precursor	O
(	O
pre	O
-	O
rRNA	O
)	O
that	O
is	O
processed	O
in	O
large	O
pre	O
-	O
ribosomal	O
particles	O
at	O
several	O
well	O
-	O
defined	O
sites	O
to	O
produce	O
the	O
mature	O
18S	O
,	O
5	O
.	O
8S	O
and	O
25S	O
rRNAs	O
[	O
for	O
a	O
recent	O
review	O
see	O
]	O
.	O

This	O
process	O
requires	O
over	O
200	O
proteins	O
and	O
hundreds	O
of	O
small	O
nucleolar	O
RNAs	O
(	O
snoRNAs	O
)	O
,	O
which	O
function	O
in	O
cleavage	O
and	O
chemical	O
modification	O
of	O
pre	O
-	O
rRNA	O
via	O
complementary	O
base	O
pairing	O
interactions	O
with	O
the	O
rRNA	O
.	O

A	O
total	O
of	O
18	O
putative	O
RNA	O
helicases	O
are	O
involved	O
in	O
pre	O
-	O
rRNA	O
processing	O
and	O
ribosome	B-OOS
assembly	O
.	O

Mutational	O
studies	O
of	O
RNA	O
helicases	O
involved	O
in	O
ribosome	B-OOS
biogenesis	O
revealed	O
that	O
conserved	O
amino	O
acids	O
predicted	O
to	O
be	O
involved	O
in	O
ATP	O
binding	O
and	O
hydrolysis	O
are	O
important	O
for	O
cell	O
viability	O
,	O
suggesting	O
that	O
they	O
may	O
indeed	O
function	O
as	O
RNA	O
helicases	O
.	O

Thus	O
far	O
,	O
only	O
four	O
of	O
the	O
18	O
proteins	O
(	O
Dbp4	O
,	O
Rok1	O
,	O
Dbp9	O
and	O
Has1	O
)	O
have	O
been	O
characterized	O
in	O
vitro	O
and	O
have	O
been	O
shown	O
to	O
harbor	O
ATPase	O
activity	O
.	O

Two	O
of	O
these	O
proteins	O
(	O
Dbp9	O
and	O
Has1	O
)	O
were	O
also	O
able	O
to	O
separate	O
artificial	O
nucleic	O
acid	O
duplexes	O
in	O
vitro	O
,	O
suggesting	O
that	O
they	O
are	O
indeed	O
helicases	O
.	O

However	O
,	O
biochemical	O
evidence	O
to	O
support	O
this	O
hypothesis	O
for	O
the	O
other	O
14	O
helicases	O
is	O
lacking	O
.	O

Association	O
between	O
SAP	O
and	O
FynT	O
:	O
Inducible	O
SH3	O
domain	O
-	O
mediated	O
interaction	O
controlled	O
by	O
engagement	O
of	O
the	O
SLAM	O
receptor	O
.	O

SAP	O
is	O
an	O
intracellular	O
adaptor	O
molecule	O
composed	O
almost	O
exclusively	O
of	O
an	O
SH2	O
domain	O
.	O

It	O
is	O
mutated	O
in	O
patients	O
with	O
X	O
-	O
linked	O
lymphoproliferative	O
disease	O
,	O
a	O
human	O
immunodeficiency	O
.	O

Several	O
immune	O
abnormalities	O
were	O
also	O
identified	O
in	O
SAP	O
-	O
deficient	O
mice	O
.	O

By	O
way	O
of	O
its	O
SH2	O
domain	O
,	O
SAP	O
interacts	O
with	O
tyrosine	O
-	O
based	O
motifs	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
SLAM	O
family	O
receptors	O
.	O

SAP	O
promotes	O
SLAM	O
family	O
receptor	O
-	O
induced	O
protein	O
tyrosine	O
phosphorylation	O
,	O
due	O
to	O
its	O
capacity	O
to	O
recruit	O
the	O
Src	O
-	O
related	O
kinase	O
FynT	O
.	O

This	O
unusual	O
property	O
relies	O
on	O
the	O
existence	O
of	O
a	O
second	O
binding	O
surface	O
in	O
the	O
SAP	O
SH2	O
domain	O
,	O
centered	O
on	O
arginine	O
78	O
of	O
SAP	O
,	O
that	O
binds	O
directly	O
to	O
the	O
FynT	O
SH3	O
domain	O
.	O

Herein	O
,	O
we	O
wanted	O
to	O
further	O
understand	O
the	O
mechanisms	O
controlling	O
the	O
interaction	O
between	O
SLAM	O
-	O
SAP	O
and	O
FynT	O
.	O

Our	O
experiments	O
showed	O
that	O
,	O
unlike	O
conventional	O
associations	O
mediated	O
by	O
SH3	O
domains	O
,	O
the	O
interaction	O
of	O
the	O
FynT	O
SH3	O
domain	O
with	O
SLAM	O
-	O
SAP	O
was	O
strictly	O
inducible	O
.	O

It	O
was	O
absolutely	O
dependent	O
on	O
engagement	O
of	O
SLAM	O
by	O
extracellular	O
ligands	O
.	O

We	O
obtained	O
evidence	O
that	O
this	O
inducibility	O
was	O
not	O
due	O
to	O
increased	O
binding	O
of	O
SLAM	O
to	O
SAP	O
following	O
SLAM	O
engagement	O
.	O

Furthermore	O
,	O
it	O
could	O
occur	O
independently	O
of	O
any	O
appreciable	O
SLAM	O
-	O
dependent	O
biochemical	O
signal	O
.	O

In	O
fact	O
,	O
our	O
data	O
indicated	O
that	O
the	O
induced	O
association	O
of	O
the	O
FynT	O
SH3	O
domain	O
with	O
SLAM	O
-	O
SAP	O
was	O
triggered	O
by	O
a	O
change	O
in	O
the	O
conformation	O
of	O
SLAM	O
-	O
associated	O
SAP	O
caused	O
by	O
SLAM	O
engagement	O
.	O

Together	O
,	O
these	O
data	O
elucidate	O
further	O
the	O
events	O
initiating	O
SLAM	O
-	O
SAP	O
signaling	O
in	O
immune	O
cells	O
.	O

Moreover	O
,	O
they	O
identify	O
a	O
strictly	O
inducible	O
interaction	O
mediated	O
by	O
an	O
SH3	O
domain	O
.	O

Proteasome	B-Complex
recruitment	O
and	O
activation	O
of	O
the	O
Uch37	O
deubiquitinating	O
enzyme	O
by	O
Adrm1	O
.	O

Uch37	O
is	O
one	O
of	O
the	O
three	O
principal	O
deubiquitinating	O
enzymes	O
(	O
DUBs	O
)	O
,	O
and	O
the	O
only	O
ubiquitin	O
carboxy	O
-	O
terminal	O
hydrolase	O
(	O
UCH	O
)	O
-	O
family	O
protease	O
,	O
that	O
is	O
associated	O
with	O
mammalian	O
proteasomes	B-Complex
.	O

We	O
show	O
that	O
Uch37	O
is	O
responsible	O
for	O
the	O
ubiquitin	O
isopeptidase	O
activity	O
in	O
the	O
PA700	B-Complex
(	I-Complex
19S	I-Complex
)	I-Complex
proteasome	I-Complex
regulatory	O
complex	O
.	O

PA700	B-Complex
isopeptidase	O
disassembles	O
Lys	O
48	O
-	O
linked	O
polyubiquitin	O
specifically	O
from	O
the	O
distal	O
end	O
of	O
the	O
chain	O
,	O
a	O
property	O
that	O
may	O
be	O
used	O
to	O
clear	O
poorly	O
ubiquitinated	O
or	O
unproductively	O
bound	O
substrates	O
from	O
the	O
proteasome	B-Complex
.	O

To	O
better	O
understand	O
Uch37	O
function	O
and	O
the	O
mechanism	O
responsible	O
for	O
its	O
specificity	O
,	O
we	O
investigated	O
how	O
Uch37	O
is	O
recruited	O
to	O
proteasomes	B-Complex
.	O

Uch37	O
binds	O
through	O
Adrm1	O
,	O
a	O
previously	O
unrecognized	O
orthologue	O
of	O
Saccharomyces	O
cerevisiae	O
Rpn13p	O
,	O
which	O
in	O
turn	O
is	O
bound	O
to	O
the	O
S1	O
(	O
also	O
known	O
as	O
Rpn2	O
)	O
subunit	O
of	O
the	O
19S	B-Complex
complex	O
.	O

Adrm1	O
(	O
human	O
Rpn13	O
,	O
hRpn13	O
)	O
binds	O
the	O
carboxy	O
-	O
terminal	O
tail	O
of	O
Uch37	O
,	O
a	O
region	O
that	O
is	O
distinct	O
from	O
the	O
UCH	O
catalytic	O
domain	O
,	O
which	O
we	O
show	O
inhibits	O
Uch37	O
activity	O
.	O

Following	O
binding	O
,	O
Adrm1	O
relieves	O
Uch37	O
autoinhibition	O
,	O
accelerating	O
the	O
hydrolysis	O
of	O
ubiquitin	O
-	O
7	O
-	O
amido	O
-	O
4	O
-	O
methylcoumarin	O
(	O
ubiquitin	O
-	O
AMC	O
)	O
.	O

However	O
,	O
neither	O
Uch37	O
alone	O
nor	O
the	O
Uch37	O
-	O
Adrm1	O
or	O
Uch37	O
-	O
Adrm1	O
-	O
S1	O
complexes	O
can	O
hydrolyse	O
di	O
-	O
ubiquitin	O
efficiently	O
;	O
rather	O
,	O
incorporation	O
into	O
the	O
19S	B-Complex
complex	O
is	O
required	O
to	O
enable	O
processing	O
of	O
polyubiquitin	O
chains	O
.	O

A	O
novel	O
Rad18	O
function	O
involved	O
in	O
protection	O
of	O
the	O
vertebrate	O
genome	O
after	O
exposure	O
to	O
camptothecin	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
Rad18	O
functions	O
in	O
post	O
-	O
replication	O
repair	O
pathways	O
,	O
such	O
as	O
error	O
-	O
free	O
damage	O
bypass	O
involving	O
Rad30	O
(	O
Poleta	B-OOS
)	O
and	O
error	O
-	O
prone	O
damage	O
bypass	O
involving	O
Rev3	O
/	O
7	O
(	O
Polzeta	B-Complex
)	O
.	O

Chicken	O
DT40	O
RAD18	O
(	O
-	O
/	O
-	O
)	O
cells	O
were	O
found	O
to	O
be	O
hypersensitive	O
to	O
camptothecin	O
(	O
CPT	O
)	O
,	O
while	O
RAD30	O
(	O
-	O
/	O
-	O
)	O
and	O
REV3	O
(	O
-	O
/	O
-	O
)	O
cells	O
,	O
which	O
are	O
defective	O
in	O
translesion	O
DNA	O
synthesis	O
,	O
were	O
not	O
.	O

RAD18	O
(	O
-	O
/	O
-	O
)	O
cells	O
also	O
showed	O
higher	O
levels	O
of	O
H2AX	O
phosphorylation	O
and	O
chromosomal	O
aberrations	O
,	O
particularly	O
chromosomal	O
gaps	O
and	O
breaks	O
,	O
upon	O
exposure	O
to	O
CPT	O
.	O

Detailed	O
analysis	O
by	O
alkaline	O
sucrose	O
density	O
gradient	O
centrifugation	O
revealed	O
that	O
RAD18	O
(	O
-	O
/	O
-	O
)	O
and	O
wild	O
type	O
cells	O
exhibited	O
similar	O
rates	O
of	O
elongation	O
of	O
newly	O
synthesized	O
DNA	O
in	O
the	O
presence	O
or	O
absence	O
of	O
low	O
concentrations	O
of	O
CPT	O
but	O
that	O
DNA	O
breaks	O
frequently	O
occurred	O
on	O
both	O
parental	O
and	O
nascent	O
strands	O
within	O
1h	O
after	O
a	O
brief	O
exposure	O
to	O
an	O
elevated	O
concentration	O
of	O
CPT	O
,	O
with	O
more	O
breaks	O
induced	O
in	O
RAD18	O
(	O
-	O
/	O
-	O
)	O
cells	O
than	O
in	O
wild	O
type	O
cells	O
.	O

These	O
data	O
suggest	O
a	O
previously	O
unanticipated	O
role	O
for	O
Rad18	O
in	O
dealing	O
with	O
replication	O
forks	O
upon	O
encountering	O
DNA	O
lesions	O
induced	O
by	O
CPT	O
.	O

Role	O
of	O
protein	O
phosphatases	O
2C	O
on	O
tolerance	O
to	O
lithium	O
toxicity	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

Protein	O
phosphatases	O
2C	O
are	O
a	O
family	O
of	O
conserved	O
enzymes	O
involved	O
in	O
many	O
aspects	O
of	O
the	O
cell	O
biology	O
.	O

We	O
reported	O
that	O
,	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
overexpression	O
of	O
the	O
Ptc3p	O
isoform	O
resulted	O
in	O
increased	O
lithium	O
tolerance	O
in	O
the	O
hypersensitive	O
hal3	O
background	O
.	O

We	O
have	O
found	O
that	O
the	O
tolerance	O
induced	O
by	O
PTC3	O
overexpression	O
is	O
also	O
observed	O
in	O
wild	O
-	O
type	O
cells	O
and	O
that	O
this	O
is	O
most	O
probably	O
the	O
result	O
of	O
increased	O
expression	O
of	O
the	O
ENA1	O
Na	O
(	O
+	O
)	O
-	O
ATPase	O
mediated	O
by	O
the	O
Hog1	O
MAP	O
kinase	O
pathway	O
.	O

This	O
effect	O
does	O
not	O
require	O
a	O
catalytically	O
active	O
protein	O
.	O

Surprisingly	O
,	O
deletion	O
of	O
PTC3	O
(	O
similarly	O
to	O
that	O
of	O
PTC2	O
,	O
PTC4	O
or	O
PTC5	O
)	O
does	O
not	O
confer	O
a	O
lithium	O
-	O
sensitive	O
phenotype	O
,	O
but	O
mutation	O
of	O
PTC1	O
does	O
.	O

Lack	O
of	O
PTC1	O
in	O
an	O
ena1	O
-	O
4	O
background	O
did	O
not	O
result	O
in	O
additive	O
lithium	O
sensitivity	O
and	O
the	O
ptc1	O
mutant	O
showed	O
a	O
decreased	O
expression	O
of	O
the	O
ENA1	O
gene	O
in	O
cells	O
stressed	O
with	O
LiCl	O
.	O

In	O
agreement	O
,	O
under	O
these	O
conditions	O
,	O
the	O
ptc1	O
mutant	O
was	O
less	O
effective	O
in	O
extruding	O
Li	O
(	O
+	O
)	O
and	O
accumulated	O
higher	O
concentrations	O
of	O
this	O
cation	O
.	O

Deletion	O
of	O
PTC1	O
in	O
a	O
hal3	O
background	O
did	O
not	O
exacerbate	O
the	O
halosensitive	O
phenotype	O
of	O
the	O
hal3	O
strain	O
.	O

In	O
addition	O
,	O
induction	O
from	O
the	O
ENA1	O
promoter	O
under	O
LiCl	O
stress	O
decreased	O
similarly	O
(	O
50	O
%	O
)	O
in	O
hal3	O
,	O
ptc1	O
and	O
ptc1	O
hal3	O
mutants	O
.	O

Finally	O
,	O
mutation	O
of	O
PTC1	O
virtually	O
abolishes	O
the	O
increased	O
tolerance	O
to	O
toxic	O
cations	O
provided	O
by	O
overexpression	O
of	O
Hal3p	O
.	O

These	O
results	O
indicate	O
that	O
Ptc1p	O
modulates	O
the	O
function	O
of	O
Ena1p	O
by	O
regulating	O
the	O
Hal3	O
/	O
Ppz1	O
,	O
2	O
pathway	O
.	O

In	O
conclusion	O
,	O
overexpression	O
of	O
PTC3	O
and	O
lack	O
of	O
PTC1	O
affect	O
lithium	O
tolerance	O
in	O
yeast	O
,	O
although	O
through	O
different	O
mechanisms	O
.	O

The	O
C	O
-	O
terminal	O
tail	O
of	O
the	O
Hedgehog	O
receptor	O
Patched	O
regulates	O
both	O
localization	O
and	O
turnover	O
.	O

Patched	O
(	O
Ptc	O
)	O
is	O
a	O
membrane	O
protein	O
whose	O
function	O
in	O
Hedgehog	O
(	O
Hh	O
)	O
signal	O
transduction	O
has	O
been	O
conserved	O
among	O
metazoans	O
and	O
whose	O
malfunction	O
has	O
been	O
implicated	O
in	O
human	O
cancers	O
.	O

Genetic	O
analysis	O
has	O
shown	O
that	O
Ptc	O
negatively	O
regulates	O
Hh	O
signal	O
transduction	O
,	O
but	O
its	O
activity	O
and	O
structure	O
are	O
not	O
known	O
.	O

We	O
investigated	O
the	O
functional	O
and	O
structural	O
properties	O
of	O
Drosophila	O
Ptc	O
and	O
its	O
C	O
-	O
terminal	O
domain	O
(	O
CTD	O
)	O
,	O
183	O
residues	O
that	O
are	O
predicted	O
to	O
reside	O
in	O
the	O
cytoplasm	O
.	O

Our	O
results	O
show	O
that	O
Ptc	O
,	O
as	O
well	O
as	O
truncated	O
Ptc	O
deleted	O
of	O
its	O
CTD	O
,	O
forms	O
a	O
stable	O
trimer	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
proposal	O
that	O
Ptc	O
is	O
structurally	O
similar	O
to	O
trimeric	O
transporters	O
.	O

The	O
CTD	O
itself	O
trimerizes	O
and	O
is	O
required	O
for	O
both	O
Ptc	O
internalization	O
and	O
turnover	O
.	O

Two	O
mutant	O
forms	O
of	O
the	O
CTD	O
,	O
one	O
that	O
disrupts	O
trimerization	O
and	O
the	O
other	O
that	O
mutates	O
the	O
target	O
sequence	O
of	O
the	O
Nedd4	O
ubiquitin	O
ligase	O
,	O
stabilize	O
Ptc	O
but	O
do	O
not	O
prevent	O
internalization	O
and	O
sequestration	O
of	O
Hh	O
.	O

Ptc	O
deleted	O
of	O
its	O
CTD	O
is	O
stable	O
and	O
localizes	O
to	O
the	O
plasma	O
membrane	O
.	O

These	O
data	O
show	O
that	O
degradation	O
of	O
Ptc	O
is	O
regulated	O
at	O
a	O
step	O
subsequent	O
to	O
endocytosis	O
,	O
although	O
endocytosis	O
is	O
a	O
likely	O
prerequisite	O
.	O

We	O
also	O
show	O
that	O
the	O
CTD	O
of	O
mouse	O
Ptc	O
regulates	O
turnover	O
.	O

Transport	O
and	O
assembly	O
of	O
gag	O
proteins	O
into	O
Moloney	O
murine	O
leukemia	O
virus	O
.	O

We	O
have	O
studied	O
the	O
process	O
of	O
Moloney	O
murine	O
leukemia	O
virus	O
(	O
M	O
-	O
MuLV	O
)	O
assembly	O
by	O
characterization	O
of	O
core	O
(	O
gag	O
)	O
protein	O
mutants	O
and	O
analysis	O
of	O
wild	O
-	O
type	O
(	O
wt	O
)	O
gag	O
proteins	O
produced	O
by	O
cells	O
in	O
the	O
presence	O
of	O
the	O
ionophore	O
monensin	O
.	O

Our	O
genetic	O
studies	O
involved	O
examination	O
of	O
linker	O
insertion	O
mutants	O
of	O
a	O
Gag	O
-	O
beta	O
-	O
galactosidase	O
(	O
Gag	O
-	O
beta	O
-	O
gal	O
)	O
fusion	O
protein	O
,	O
GBG2051	O
,	O
which	O
is	O
incorporated	O
into	O
virus	O
particles	O
when	O
expressed	O
in	O
the	O
presence	O
of	O
wt	O
viral	O
proteins	O
.	O

Analysis	O
indicated	O
that	O
the	O
amino	O
-	O
terminal	O
two	O
-	O
thirds	O
of	O
the	O
gag	O
matrix	O
domain	O
is	O
essential	O
for	O
targeting	O
of	O
proteins	O
to	O
the	O
plasma	O
membrane	O
;	O
mutant	O
proteins	O
localized	O
to	O
the	O
cytoplasm	O
or	O
were	O
trapped	O
on	O
intracellular	O
membranes	O
.	O

Mutations	O
through	O
most	O
of	O
the	O
coding	O
region	O
of	O
the	O
gag	O
capsid	O
domain	O
generated	O
proteins	O
which	O
were	O
released	O
from	O
cells	O
in	O
membrane	O
vesicles	O
but	O
not	O
in	O
virions	O
.	O

In	O
contrast	O
,	O
linker	O
insertions	O
into	O
p12gag	O
or	O
carboxy	O
-	O
terminal	O
portions	O
of	O
the	O
matrix	O
or	O
capsid	O
coding	O
regions	O
did	O
not	O
affect	O
assembly	O
of	O
fusion	O
proteins	O
into	O
virus	O
particles	O
.	O

Monensin	O
,	O
which	O
blocks	O
vesicular	O
transport	O
,	O
inhibited	O
gag	O
protein	O
intracellular	O
transport	O
and	O
release	O
from	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
a	O
significant	O
proportion	O
of	O
M	O
-	O
MuLV	O
myristylated	O
gag	O
proteins	O
travel	O
via	O
vesicles	O
to	O
the	O
cell	O
surface	O
.	O

Specific	O
matrix	O
protein	O
polypeptide	O
regions	O
and	O
myristic	O
acid	O
modification	O
are	O
both	O
necessary	O
for	O
appropriate	O
gag	O
protein	O
transport	O
,	O
while	O
capsid	O
protein	O
interactions	O
appear	O
to	O
mediate	O
the	O
final	O
phase	O
of	O
virion	O
formation	O
.	O

Triterpenoid	O
CDDO	O
-	O
Me	O
blocks	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
pathway	O
by	O
direct	O
inhibition	O
of	O
IKKbeta	O
on	O
Cys	O
-	O
179	O
.	O

The	O
novel	O
oleanane	O
triterpenoid	O
2	O
-	O
cyano	O
-	O
3	O
,	O
12	O
-	O
dioxooleana	O
-	O
1	O
,	O
9	O
,	O
-	O
dien	O
-	O
28	O
-	O
oic	O
acid	O
(	O
CDDO	O
)	O
and	O
the	O
C	O
-	O
28	O
methyl	O
ester	O
(	O
CDDO	O
-	O
Me	O
)	O
induce	O
apoptosis	O
of	O
human	O
tumor	O
cells	O
by	O
disruption	O
of	O
redox	O
balance	O
and	O
are	O
currently	O
in	O
clinical	O
trials	O
.	O

The	O
present	O
studies	O
show	O
that	O
CDDO	O
and	O
CDDO	O
-	O
Me	O
block	O
tumor	O
necrosis	O
factoralpha	O
-	O
induced	O
targeting	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
p65	O
to	O
the	O
nucleus	O
.	O

CDDO	O
-	O
Me	O
also	O
blocked	O
tumor	O
necrosis	O
factor	O
alpha	O
-	O
induced	O
phosphorylation	O
of	O
IkappaBalpha	O
.	O

In	O
concert	O
with	O
these	O
results	O
,	O
we	O
found	O
that	O
CDDO	O
-	O
Me	O
inhibits	O
IkappaBalpha	O
kinasebeta	O
(	O
IKKbeta	O
)	O
activity	O
in	O
cells	O
.	O

In	O
support	O
of	O
a	O
direct	O
mechanism	O
,	O
CDDO	O
-	O
Me	O
inhibited	O
recombinant	O
IKKbeta	O
activity	O
in	O
vitro	O
.	O

The	O
results	O
also	O
demonstrate	O
that	O
(	O
i	O
)	O
CDDO	O
and	O
CDDO	O
-	O
Me	O
form	O
adducts	O
with	O
IKKbeta	O
,	O
but	O
not	O
IKKbeta	O
with	O
mutation	O
of	O
Cys	O
-	O
179	O
to	O
Ala	O
,	O
and	O
(	O
ii	O
)	O
CDDO	O
-	O
Me	O
inhibits	O
IKKbeta	O
by	O
a	O
mechanism	O
dependent	O
on	O
oxidation	O
of	O
Cys	O
-	O
179	O
.	O

These	O
findings	O
indicate	O
that	O
CDDO	O
and	O
CDDO	O
-	O
Me	O
directly	O
block	O
IKKbeta	O
activity	O
and	O
thereby	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
pathway	O
by	O
interacting	O
with	O
Cys	O
-	O
179	O
in	O
the	O
IKKbeta	O
activation	O
loop	O
.	O

PIAS3	O
induction	O
of	O
PRB	O
sumoylation	O
represses	O
PRB	O
transactivation	O
by	O
destabilizing	O
its	O
retention	O
in	O
the	O
nucleus	O
.	O

Progesterone	O
receptor	O
(	O
PR	O
)	O
plays	O
a	O
critical	O
role	O
in	O
cell	O
proliferation	O
and	O
differentiation	O
,	O
and	O
its	O
transcriptional	O
activity	O
is	O
known	O
to	O
be	O
modulated	O
by	O
cofactor	O
proteins	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
in	O
the	O
presence	O
of	O
progesterone	O
,	O
protein	O
inhibitor	O
of	O
activated	O
STAT	O
-	O
3	O
(	O
PIAS3	O
)	O
significantly	O
inhibited	O
the	O
PR	O
transcriptional	O
activity	O
and	O
the	O
expression	O
of	O
progesterone	O
-	O
responsive	O
genes	O
.	O

Reduction	O
of	O
endogenous	O
PIAS3	O
by	O
PIAS3	O
small	O
-	O
interfering	O
RNA	O
enhanced	O
PR	O
transactivation	O
in	O
a	O
ligand	O
-	O
dependent	O
manner	O
.	O

PIAS3	O
interacted	O
with	O
PR	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
and	O
the	O
interaction	O
was	O
enhanced	O
by	O
progesterone	O
.	O

Furthermore	O
,	O
our	O
findings	O
suggested	O
that	O
PIAS3	O
strongly	O
induced	O
PRB	O
sumoylation	O
at	O
three	O
sites	O
,	O
Lys	O
-	O
7	O
,	O
Lys	O
-	O
388	O
and	O
Lys	O
-	O
531	O
.	O

In	O
addition	O
,	O
novel	O
roles	O
in	O
PRB	O
nuclear	O
retention	O
and	O
transactivation	O
were	O
identified	O
for	O
these	O
sites	O
.	O

Our	O
data	O
also	O
suggested	O
that	O
PIAS3	O
was	O
recruited	O
in	O
a	O
largely	O
hormone	O
-	O
dependent	O
manner	O
in	O
response	O
to	O
a	O
progesterone	O
-	O
responsive	O
promoter	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
PIAS3	O
inhibited	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
PR	O
and	O
influenced	O
its	O
nuclear	O
export	O
as	O
well	O
as	O
PR	O
transactivation	O
.	O

Taken	O
together	O
,	O
these	O
data	O
strongly	O
suggested	O
that	O
PIAS3	O
played	O
an	O
important	O
physiological	O
role	O
in	O
PR	O
function	O
.	O

Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
-	O
encoded	O
protein	O
kinase	O
and	O
its	O
interaction	O
with	O
K	O
-	O
bZIP	O
.	O

The	O
oncogenic	O
herpesvirus	O
,	O
Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
,	O
also	O
identified	O
as	O
human	O
herpesvirus	O
8	O
,	O
contains	O
genes	O
producing	O
proteins	O
that	O
control	O
transcription	O
and	O
influence	O
cell	O
signaling	O
.	O

Open	O
reading	O
frame	O
36	O
(	O
ORF36	O
)	O
of	O
this	O
virus	O
encodes	O
a	O
serine	O
/	O
threonine	O
protein	O
kinase	O
,	O
which	O
is	O
designated	O
the	O
viral	O
protein	O
kinase	O
(	O
vPK	O
)	O
.	O

Our	O
recent	O
efforts	O
to	O
elucidate	O
the	O
role	O
of	O
vPK	O
in	O
the	O
viral	O
life	O
cycle	O
have	O
focused	O
on	O
identifying	O
viral	O
protein	O
substrates	O
and	O
determining	O
the	O
effects	O
of	O
vPK	O
-	O
mediated	O
phosphorylation	O
on	O
specific	O
steps	O
in	O
viral	O
replication	O
.	O

The	O
vPK	O
gene	O
was	O
transcribed	O
into	O
4	O
.	O
2	O
-	O
kb	O
and	O
3	O
.	O
6	O
-	O
kb	O
mRNAs	O
during	O
the	O
early	O
and	O
late	O
phases	O
of	O
viral	O
reactivation	O
.	O

vPK	O
is	O
colocalized	O
with	O
viral	O
DNA	O
replication	O
/	O
transcription	O
compartments	O
as	O
marked	O
by	O
a	O
polymerase	O
processivity	O
factor	O
,	O
and	O
K	O
-	O
bZIP	O
,	O
a	O
protein	O
known	O
to	O
bind	O
the	O
viral	O
DNA	O
replication	O
origin	O
(	O
Ori	O
-	O
Lyt	O
)	O
and	O
to	O
regulate	O
viral	O
transcription	O
.	O

The	O
vPK	O
physically	O
associated	O
with	O
and	O
strongly	O
phosphorylated	O
K	O
-	O
bZIP	O
at	O
threonine	O
111	O
,	O
a	O
site	O
also	O
recognized	O
by	O
the	O
cyclin	O
-	O
dependent	O
kinase	O
Cdk2	O
.	O

Both	O
K	O
-	O
bZIP	O
and	O
vPK	O
were	O
corecruited	O
to	O
viral	O
promoters	O
targeted	O
by	O
K	O
-	O
bZIP	O
as	O
well	O
as	O
to	O
the	O
Ori	O
-	O
Lyt	O
region	O
.	O

Phosphorylation	O
of	O
K	O
-	O
bZIP	O
by	O
vPK	O
had	O
a	O
negative	O
impact	O
on	O
K	O
-	O
bZIP	O
transcription	O
repression	O
activity	O
.	O

The	O
extent	O
of	O
posttranslational	O
modification	O
of	O
K	O
-	O
bZIP	O
by	O
sumoylation	O
,	O
a	O
process	O
that	O
influences	O
its	O
repression	O
function	O
,	O
was	O
decreased	O
by	O
vPK	O
phosphorylation	O
at	O
threonine	O
111	O
.	O

Our	O
data	O
thus	O
identify	O
a	O
new	O
role	O
of	O
vPK	O
as	O
a	O
modulator	O
of	O
viral	O
transcription	O
.	O

Repression	O
of	O
p53	O
activity	O
by	O
Smyd2	O
-	O
mediated	O
methylation	O
.	O

Specific	O
sites	O
of	O
lysine	O
methylation	O
on	O
histones	O
correlate	O
with	O
either	O
activation	O
or	O
repression	O
of	O
transcription	O
.	O

The	O
tumour	O
suppressor	O
p53	O
(	O
refs	O
4	O
-	O
7	O
)	O
is	O
one	O
of	O
only	O
a	O
few	O
non	O
-	O
histone	O
proteins	O
known	O
to	O
be	O
regulated	O
by	O
lysine	O
methylation	O
.	O

Here	O
we	O
report	O
a	O
lysine	O
methyltransferase	O
,	O
Smyd2	O
,	O
that	O
methylates	O
a	O
previously	O
unidentified	O
site	O
,	O
Lys	O
370	O
,	O
in	O
p53	O
.	O

This	O
methylation	O
site	O
,	O
in	O
contrast	O
to	O
the	O
known	O
site	O
Lys	O
372	O
,	O
is	O
repressing	O
to	O
p53	O
-	O
mediated	O
transcriptional	O
regulation	O
.	O

Smyd2	O
helps	O
to	O
maintain	O
low	O
concentrations	O
of	O
promoter	O
-	O
associated	O
p53	O
.	O

We	O
show	O
that	O
reducing	O
Smyd2	O
concentrations	O
by	O
short	O
interfering	O
RNA	O
enhances	O
p53	O
-	O
mediated	O
apoptosis	O
.	O

We	O
find	O
that	O
Set9	O
-	O
mediated	O
methylation	O
of	O
Lys	O
372	O
inhibits	O
Smyd2	O
-	O
mediated	O
methylation	O
of	O
Lys	O
370	O
,	O
providing	O
regulatory	O
cross	O
-	O
talk	O
between	O
post	O
-	O
translational	O
modifications	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
the	O
inhibitory	O
effect	O
of	O
Lys	O
372	O
methylation	O
on	O
Lys	O
370	O
methylation	O
is	O
caused	O
,	O
in	O
part	O
,	O
by	O
blocking	O
the	O
interaction	O
between	O
p53	O
and	O
Smyd2	O
.	O

Thus	O
,	O
similar	O
to	O
histones	O
,	O
p53	O
is	O
subject	O
to	O
both	O
activating	O
and	O
repressing	O
lysine	O
methylation	O
.	O

Our	O
results	O
also	O
predict	O
that	O
Smyd2	O
may	O
function	O
as	O
a	O
putative	O
oncogene	O
by	O
methylating	O
p53	O
and	O
repressing	O
its	O
tumour	O
suppressive	O
function	O
.	O

The	O
BRCT	O
domain	O
of	O
mammalian	O
Pes1	O
is	O
crucial	O
for	O
nucleolar	O
localization	O
and	O
rRNA	O
processing	O
.	O

The	O
nucleolar	O
protein	O
Pes1	O
interacts	O
with	O
Bop1	O
and	O
WDR12	O
in	O
a	O
stable	O
complex	O
(	O
PeBoW	B-Complex
-	O
complex	O
)	O
and	O
its	O
expression	O
is	O
tightly	O
associated	O
with	O
cell	O
proliferation	O
.	O

The	O
yeast	O
homologue	O
Nop7p	O
(	O
Yph1p	O
)	O
functions	O
in	O
both	O
,	O
rRNA	O
processing	O
and	O
cell	O
cycle	O
progression	O
.	O

The	O
presence	O
of	O
a	O
BRCT	O
-	O
domain	O
(	O
BRCA1	O
C	O
-	O
terminal	O
)	O
within	O
Pes1	O
is	O
quite	O
unique	O
for	O
an	O
rRNA	O
processing	O
factor	O
,	O
as	O
this	O
domain	O
is	O
normally	O
found	O
in	O
factors	O
involved	O
in	O
DNA	O
-	O
damage	O
or	O
repair	O
pathways	O
.	O

Thus	O
,	O
the	O
function	O
of	O
the	O
BRCT	O
-	O
domain	O
in	O
Pes1	O
remains	O
elusive	O
.	O

We	O
established	O
a	O
conditional	O
siRNA	O
-	O
based	O
knock	O
-	O
down	O
-	O
knock	O
-	O
in	O
system	O
and	O
analysed	O
a	O
panel	O
of	O
Pes1	O
truncation	O
mutants	O
for	O
their	O
functionality	O
in	O
ribosome	B-OOS
synthesis	O
in	O
the	O
absence	O
of	O
endogenous	O
Pes1	O
.	O

Deletion	O
of	O
the	O
BRCT	O
-	O
domain	O
or	O
single	O
point	O
mutations	O
of	O
highly	O
conserved	O
residues	O
caused	O
diffuse	O
nucleoplasmic	O
distribution	O
and	O
failure	O
to	O
replace	O
endogenous	O
Pes1	O
in	O
rRNA	O
processing	O
.	O

Further	O
,	O
the	O
BRCT	O
-	O
mutants	O
of	O
Pes1	O
were	O
less	O
stable	O
and	O
not	O
incorporated	O
into	O
the	O
PeBoW	B-Complex
-	O
complex	O
.	O

Hence	O
,	O
the	O
integrity	O
of	O
the	O
BRCT	O
-	O
domain	O
of	O
Pes1	O
is	O
crucial	O
for	O
nucleolar	O
localization	O
and	O
its	O
function	O
in	O
rRNA	O
processing	O
.	O

Phospho	O
-	O
specific	O
antibody	O
against	O
Thr286	O
of	O
cyclin	O
D1	O
was	O
raised	O
using	O
KLH	O
-	O
conjugated	O
phospho	O
-	O
peptide	O
KDLAC	O
-	O
pT	O
-	O
PTDVR	O
as	O
an	O
antigen	O
in	O
collaboration	O
with	O
Zymed	O
Inc	O
.	O

Rabbits	O
were	O
immunized	O
three	O
times	O
with	O
the	O
peptides	O
and	O
serum	O
was	O
collected	O
after	O
3	O
months	O
,	O
and	O
subjected	O
to	O
affinity	O
-	O
purification	O
using	O
affinity	O
gel	O
coupled	O
with	O
phosphorylated	O
peptide	O
.	O

Anti	O
-	O
nonphosphorylated	O
cyclin	O
D1	O
antibodies	O
were	O
eliminated	O
by	O
affinity	O
-	O
absorption	O
using	O
gel	O
coupled	O
with	O
unphosphorylated	O
peptide	O
(	O
Zymed	O
)	O
.	O

Deficient	O
NER	O
in	O
tfb5	O
deletion	O
mutant	O
extracts	O
.	O

In	O
vitro	O
NER	O
was	O
performed	O
in	O
yeast	O
cell	O
-	O
free	O
extracts	O
(	O
250	O
mug	O
of	O
extract	O
protein	O
)	O
of	O
the	O
wild	O
-	O
type	O
strain	O
(	O
WT	O
)	O
(	O
lane	O
1	O
)	O
,	O
the	O
rad14	O
deletion	O
mutant	O
strain	O
(	O
lane	O
2	O
)	O
,	O
or	O
the	O
tfb5	O
deletion	O
mutant	O
strain	O
(	O
lane	O
3	O
)	O
.	O

Another	O
in	O
vitro	O
NER	O
assay	O
was	O
performed	O
in	O
a	O
mixture	O
of	O
the	O
rad14	O
and	O
tfb5	O
mutant	O
extracts	O
(	O
125	O
mug	O
each	O
)	O
(	O
lane	O
4	O
)	O
.	O

+	O
AAF	O
,	O
AAF	O
-	O
damaged	O
pUC18	O
DNA	O
;	O
-	O
AAF	O
,	O
undamaged	O
pGEM3Zf	O
DNA	O
as	O
the	O
internal	O
control	O
.	O

Upper	O
panel	O
,	O
ethidium	O
bromide	O
-	O
stained	O
gel	O
;	O
lower	O
panel	O
,	O
autoradiograph	O
of	O
the	O
gel	O
.	O

A	O
MAPK	O
docking	O
site	O
is	O
critical	O
for	O
downregulation	O
of	O
Capicua	O
by	O
Torso	O
and	O
EGFR	O
RTK	O
signaling	O
.	O

Early	O
Drosophila	O
development	O
requires	O
two	O
receptor	O
tyrosine	O
kinase	O
(	O
RTK	O
)	O
pathways	O
:	O
the	O
Torso	O
and	O
the	O
Epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
pathways	O
,	O
which	O
regulate	O
terminal	O
and	O
dorsal	O
-	O
ventral	O
patterning	O
,	O
respectively	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
these	O
pathways	O
,	O
either	O
directly	O
or	O
indirectly	O
,	O
lead	O
to	O
post	O
-	O
transcriptional	O
downregulation	O
of	O
the	O
Capicua	O
repressor	O
in	O
the	O
early	O
embryo	O
and	O
in	O
the	O
ovary	O
.	O

Here	O
,	O
we	O
show	O
that	O
both	O
regulatory	O
effects	O
are	O
direct	O
and	O
depend	O
on	O
a	O
MAPK	O
docking	O
site	O
in	O
Capicua	O
that	O
physically	O
interacts	O
with	O
the	O
MAPK	O
Rolled	O
.	O

Capicua	O
derivatives	O
lacking	O
this	O
docking	O
site	O
cause	O
dominant	O
phenotypes	O
similar	O
to	O
those	O
resulting	O
from	O
loss	O
of	O
Torso	O
and	O
EGFR	O
activities	O
.	O

Such	O
phenotypes	O
arise	O
from	O
inappropriate	O
repression	O
of	O
genes	O
normally	O
expressed	O
in	O
response	O
to	O
Torso	O
and	O
EGFR	O
signaling	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
a	O
model	O
whereby	O
Capicua	O
is	O
the	O
main	O
nuclear	O
effector	O
of	O
the	O
Torso	O
pathway	O
,	O
but	O
only	O
one	O
of	O
different	O
effectors	O
responding	O
to	O
EGFR	O
signaling	O
.	O

Finally	O
,	O
we	O
describe	O
differences	O
in	O
the	O
modes	O
of	O
Capicua	O
downregulation	O
by	O
Torso	O
and	O
EGFR	O
signaling	O
,	O
raising	O
the	O
possibility	O
that	O
such	O
differences	O
contribute	O
to	O
the	O
tissue	O
specificity	O
of	O
both	O
signals	O
.	O

Preventing	O
apoptotic	O
cell	O
death	O
by	O
a	O
novel	O
small	O
heat	O
shock	O
protein	O
.	O

NCBI	O
database	O
analysis	O
indicated	O
that	O
the	O
human	O
C1orf41	O
protein	O
(	O
small	O
heat	O
shock	O
-	O
like	O
protein	O
-	O
Hsp16	O
.	O
2	O
)	O
has	O
sequence	O
similarity	O
with	O
small	O
heat	O
shock	O
proteins	O
(	O
sHsps	O
)	O
.	O

Since	O
sHsps	O
have	O
chaperone	O
function	O
,	O
and	O
so	O
prevent	O
aggregation	O
of	O
denatured	O
proteins	O
,	O
we	O
determined	O
whether	O
Hsp16	O
.	O
2	O
could	O
prevent	O
the	O
heat	O
-	O
induced	O
aggregation	O
of	O
denatured	O
proteins	O
.	O

Under	O
our	O
experimental	O
conditions	O
,	O
recombinant	O
Hsp16	O
.	O
2	O
prevented	O
aggregation	O
of	O
aldolase	O
and	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
,	O
and	O
protected	O
Escherichia	O
coli	O
cells	O
from	O
heat	O
stress	O
indicating	O
its	O
chaperone	O
function	O
.	O

Hsp16	O
.	O
2	O
also	O
formed	O
oligomeric	O
complexes	O
in	O
aqueous	O
solution	O
.	O

Hsp16	O
.	O
2	O
was	O
found	O
to	O
be	O
expressed	O
at	O
different	O
levels	O
in	O
cell	O
lines	O
and	O
tissues	O
,	O
and	O
was	O
mainly	O
localized	O
to	O
the	O
nucleus	O
and	O
the	O
cytosol	O
,	O
but	O
to	O
a	O
smaller	O
extent	O
,	O
it	O
could	O
be	O
also	O
found	O
in	O
mitochondria	O
.	O

Hsp16	O
.	O
2	O
could	O
be	O
modified	O
covalently	O
by	O
poly	O
(	O
ADP	O
ribosylation	O
)	O
and	O
acetylation	O
.	O

Hsp16	O
.	O
2	O
over	O
-	O
expression	O
prevented	O
etoposide	O
-	O
induced	O
cell	O
death	O
as	O
well	O
as	O
the	O
release	O
of	O
mitochondrial	O
cytochrome	O
c	O
and	O
caspase	O
activation	O
.	O

These	O
data	O
suggest	O
that	O
Hsp16	O
.	O
2	O
can	O
prevent	O
the	O
destabilization	O
of	O
mitochondrial	O
membrane	O
systems	O
and	O
could	O
represent	O
a	O
suitable	O
target	O
for	O
modulating	O
cell	O
death	O
pathways	O
.	O

Histone	O
methylation	O
-	O
dependent	O
mechanisms	O
impose	O
ligand	O
dependency	O
for	O
gene	O
activation	O
by	O
nuclear	O
receptors	O
.	O

Nuclear	O
receptors	O
undergo	O
ligand	O
-	O
dependent	O
conformational	O
changes	O
that	O
are	O
required	O
for	O
corepressor	O
-	O
coactivator	O
exchange	O
,	O
but	O
whether	O
there	O
is	O
an	O
actual	O
requirement	O
for	O
specific	O
epigenetic	O
landmarks	O
to	O
impose	O
ligand	O
dependency	O
for	O
gene	O
activation	O
remains	O
unknown	O
.	O

Here	O
we	O
report	O
an	O
unexpected	O
and	O
general	O
strategy	O
that	O
is	O
based	O
on	O
the	O
requirement	O
for	O
specific	O
cohorts	O
of	O
inhibitory	O
histone	B-OOS
methyltransferases	I-OOS
(	O
HMTs	B-OOS
)	O
to	O
impose	O
gene	O
-	O
specific	O
gatekeeper	O
functions	O
that	O
prevent	O
unliganded	O
nuclear	O
receptors	O
and	O
other	O
classes	O
of	O
regulated	O
transcription	O
factors	O
from	O
binding	O
to	O
their	O
target	O
gene	O
promoters	O
and	O
causing	O
constitutive	O
gene	O
activation	O
in	O
the	O
absence	O
of	O
stimulating	O
signals	O
.	O

This	O
strategy	O
,	O
based	O
at	O
least	O
in	O
part	O
on	O
an	O
HMT	B-OOS
-	O
dependent	O
inhibitory	O
histone	O
code	O
,	O
imposes	O
a	O
requirement	O
for	O
specific	O
histone	O
demethylases	O
,	O
including	O
LSD1	O
,	O
to	O
permit	O
ligand	O
-	O
and	O
signal	O
-	O
dependent	O
activation	O
of	O
regulated	O
gene	O
expression	O
.	O

These	O
events	O
link	O
an	O
inhibitory	O
methylation	O
component	O
of	O
the	O
histone	O
code	O
to	O
a	O
broadly	O
used	O
strategy	O
that	O
circumvents	O
pathological	O
constitutive	O
gene	O
induction	O
by	O
physiologically	O
regulated	O
transcription	O
factors	O
.	O

The	O
deubiquitinating	O
enzyme	O
USP2a	O
regulates	O
the	O
p53	O
pathway	O
by	O
targeting	O
Mdm2	O
.	O

Mdm2	O
is	O
an	O
E3	O
ubiquitin	O
ligase	O
that	O
promotes	O
its	O
own	O
ubiquitination	O
and	O
also	O
ubiquitination	O
of	O
the	O
p53	O
tumour	O
suppressor	O
.	O

In	O
a	O
bacterial	O
two	O
-	O
hybrid	O
screen	O
,	O
using	O
Mdm2	O
as	O
bait	O
,	O
we	O
identified	O
an	O
Mdm2	O
-	O
interacting	O
peptide	O
that	O
bears	O
sequence	O
similarity	O
to	O
the	O
deubiquitinating	O
enzyme	O
USP2a	O
.	O

We	O
have	O
established	O
that	O
full	O
-	O
length	O
USP2a	O
associates	O
with	O
Mdm2	O
in	O
cells	O
where	O
it	O
can	O
deubiquitinate	O
Mdm2	O
while	O
demonstrating	O
no	O
deubiquitinating	O
activity	O
towards	O
p53	O
.	O

Ectopic	O
expression	O
of	O
USP2a	O
causes	O
accumulation	O
of	O
Mdm2	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
consequently	O
promotes	O
Mdm2	O
-	O
mediated	O
p53	O
degradation	O
.	O

This	O
differs	O
from	O
the	O
behaviour	O
of	O
HAUSP	O
,	O
which	O
deubiquitinates	O
p53	O
in	O
addition	O
to	O
Mdm2	O
and	O
thus	O
protects	O
p53	O
from	O
Mdm2	O
-	O
mediated	O
degradation	O
.	O

We	O
further	O
demonstrate	O
that	O
suppression	O
of	O
endogenous	O
USP2a	O
destabilises	O
Mdm2	O
and	O
causes	O
accumulation	O
of	O
p53	O
protein	O
and	O
activation	O
of	O
p53	O
.	O

Our	O
data	O
identify	O
the	O
deubiquitinating	O
enzyme	O
USP2a	O
as	O
a	O
novel	O
regulator	O
of	O
the	O
p53	O
pathway	O
that	O
acts	O
through	O
its	O
ability	O
to	O
selectively	O
target	O
Mdm2	O
.	O

Bypass	O
of	O
senescence	O
by	O
the	O
polycomb	O
group	O
protein	O
CBX8	O
through	O
direct	O
binding	O
to	O
the	O
INK4A	O
-	O
ARF	O
locus	O
.	O

The	O
Polycomb	O
group	O
(	O
PcG	O
)	O
proteins	O
are	O
essential	O
for	O
embryogenesis	O
,	O
and	O
their	O
expression	O
is	O
often	O
found	O
deregulated	O
in	O
human	O
cancer	O
.	O

The	O
PcGs	O
form	O
two	O
major	O
protein	O
complexes	O
,	O
called	O
polycomb	B-Complex
repressive	I-Complex
complexes	I-Complex
1	I-Complex
and	I-Complex
2	I-Complex
(	O
PRC1	B-Complex
and	O
PRC2	B-Complex
)	O
whose	O
function	O
is	O
to	O
maintain	O
transcriptional	O
repression	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
chromodomain	O
-	O
containing	O
protein	O
,	O
CBX8	O
,	O
which	O
is	O
part	O
of	O
one	O
of	O
the	O
PRC1	B-Complex
complexes	O
,	O
regulates	O
proliferation	O
of	O
diploid	O
human	O
and	O
mouse	O
fibroblasts	O
through	O
direct	O
binding	O
to	O
the	O
INK4A	O
-	O
ARF	O
locus	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
CBX8	O
is	O
limiting	O
for	O
the	O
regulation	O
of	O
INK4A	O
-	O
ARF	O
,	O
and	O
that	O
ectopic	O
expression	O
of	O
CBX8	O
leads	O
to	O
repression	O
of	O
the	O
Ink4a	O
-	O
Arf	O
locus	O
and	O
bypass	O
of	O
senescence	O
,	O
leading	O
to	O
cellular	O
immortalization	O
.	O

Gene	O
expression	O
and	O
location	O
analysis	O
demonstrate	O
that	O
besides	O
the	O
INK4A	O
-	O
ARF	O
locus	O
,	O
CBX8	O
also	O
regulates	O
a	O
number	O
of	O
other	O
genes	O
important	O
for	O
cell	O
growth	O
and	O
survival	O
.	O

On	O
the	O
basis	O
of	O
these	O
results	O
,	O
we	O
conclude	O
that	O
CBX8	O
is	O
an	O
essential	O
component	O
of	O
one	O
of	O
the	O
PRC1	B-Complex
complexes	O
,	O
which	O
directly	O
regulate	O
the	O
expression	O
of	O
numerous	O
target	O
genes	O
,	O
including	O
the	O
INK4A	O
-	O
ARF	O
locus	O
,	O
involved	O
in	O
cell	O
-	O
fate	O
decisions	O
.	O

Tyrosine	O
sulfation	O
of	O
statherin	O
.	O

Tyrosylprotein	O
sulfotransferase	O
(	O
TPST	O
)	O
,	O
responsible	O
for	O
the	O
sulfation	O
of	O
a	O
variety	O
of	O
secretory	O
and	O
membrane	O
proteins	O
,	O
has	O
been	O
identified	O
and	O
characterized	O
in	O
submandibular	O
salivary	O
glands	O
(	O
William	O
et	O
al	O
.	O
Arch	O
Biochem	O
Biophys	O
1997	O
;	O
338	O
:	O
90	O
-	O
96	O
)	O
.	O

In	O
the	O
present	O
study	O
we	O
demonstrate	O
the	O
sulfation	O
of	O
a	O
salivary	O
secretory	O
protein	O
,	O
statherin	O
,	O
by	O
the	O
tyrosylprotein	O
sulfotransferase	O
present	O
in	O
human	O
saliva	O
.	O

Optimum	O
statherin	O
sulfation	O
was	O
observed	O
at	O
pH	O
6	O
.	O
5	O
and	O
at	O
20	O
mm	O
MnCl	O
(	O
2	O
)	O
.	O

Increase	O
in	O
the	O
level	O
of	O
total	O
sulfation	O
was	O
observed	O
with	O
increasing	O
statherin	O
concentration	O
.	O

The	O
K	O
(	O
m	O
)	O
value	O
of	O
tyrosylprotein	O
sulfotransferase	O
for	O
statherin	O
was	O
40	O
microM	O
.	O

Analysis	O
of	O
the	O
sulfated	O
statherin	O
product	O
on	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
followed	O
by	O
autoradiography	O
revealed	O
(	O
35	O
)	O
S	O
-	O
labelling	O
of	O
a	O
5	O
kDa	O
statherin	O
.	O

Further	O
analysis	O
of	O
the	O
sulfated	O
statherin	O
revealed	O
the	O
sulfation	O
on	O
tyrosyl	O
residue	O
.	O

This	O
study	O
is	O
the	O
first	O
report	O
demonstrating	O
tyrosine	O
sulfation	O
of	O
a	O
salivary	O
secretory	O
protein	O
.	O

The	O
implications	O
of	O
this	O
sulfation	O
of	O
statherin	O
in	O
hydroxyapatite	O
binding	O
and	O
Actinomyces	O
viscosus	O
interactions	O
are	O
discussed	O
.	O

C1D	O
and	O
hMtr4p	O
co	O
-	O
localize	O
with	O
PM	O
/	O
Scl	O
-	O
100	O
in	O
the	O
nucleoli	O
of	O
HEp	O
-	O
2	O
cells	O
.	O

(	O
A	O
)	O
HEp	O
-	O
2	O
cells	O
were	O
transiently	O
transfected	O
with	O
cDNA	O
constructs	O
encoding	O
EGFP	O
alone	O
,	O
EGFP	O
-	O
PM	O
/	O
Scl	O
-	O
75	O
,	O
EGFP	O
-	O
MPP6	O
,	O
EGFP	O
-	O
C1D	O
or	O
EGFP	O
-	O
hMtr4p	O
.	O

Twenty	O
-	O
four	O
hours	O
after	O
transfection	O
,	O
the	O
cells	O
were	O
fixed	O
and	O
EGFP	O
or	O
EGFP	O
-	O
fusion	O
proteins	O
were	O
visualized	O
by	O
confocal	O
fluorescence	O
microscopy	O
.	O

(	O
B	O
)	O
HEp	O
-	O
2	O
cells	O
were	O
transfected	O
with	O
cDNA	O
constructs	O
encoding	O
C1D	O
and	O
hMtr4p	O
fused	O
to	O
the	O
C	O
-	O
terminus	O
of	O
EGFP	O
;	O
24	O
h	O
after	O
transfection	O
,	O
cells	O
were	O
fixed	O
and	O
incubated	O
with	O
rabbit	O
anti	O
-	O
PM	O
/	O
Scl	O
-	O
100	O
antibodies	O
,	O
which	O
were	O
visualized	O
by	O
Texas	O
-	O
Red	O
-	O
conjugated	O
secondary	O
antibodies	O
(	O
left	O
panels	O
)	O
.	O

The	O
localization	O
of	O
EGFP	O
-	O
tagged	O
C1D	O
and	O
hMtr4p	O
is	O
shown	O
in	O
the	O
middle	O
panels	O
,	O
and	O
the	O
corresponding	O
merged	O
images	O
are	O
shown	O
on	O
the	O
right	O
.	O

Polycomb	O
protein	O
Cbx4	O
promotes	O
SUMO	O
modification	O
of	O
de	O
novo	O
DNA	O
methyltransferase	O
Dnmt3a	O
.	O

The	O
'	O
de	O
novo	O
methyltransferase	O
'	O
Dnmt3a	O
(	O
DNA	O
methyltransferase	O
3a	O
)	O
has	O
been	O
shown	O
to	O
mediate	O
transcriptional	O
repression	O
.	O

Post	O
-	O
translational	O
modification	O
of	O
Dnmt3a	O
by	O
SUMOylation	O
affects	O
its	O
ability	O
to	O
transcriptionally	O
repress	O
.	O

However	O
,	O
very	O
little	O
is	O
known	O
about	O
how	O
the	O
SUMOylation	O
process	O
is	O
regulated	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
identified	O
a	O
PcG	O
(	O
Polycomb	O
group	O
)	O
protein	O
,	O
Cbx4	O
(	O
chromobox	O
4	O
)	O
,	O
as	O
a	O
specific	O
interaction	O
partner	O
of	O
Dnmt3a	O
.	O

Co	O
-	O
expression	O
of	O
Cbx4	O
and	O
SUMO	O
-	O
1	O
(	O
small	O
ubiquitin	O
-	O
related	O
modifier	O
-	O
1	O
)	O
along	O
with	O
Dnmt3a	O
in	O
transfected	O
cells	O
results	O
in	O
enhanced	O
modification	O
of	O
Dnmt3a	O
with	O
SUMO	O
-	O
1	O
.	O

Purified	O
Cbx4	O
also	O
promotes	O
SUMOylation	O
of	O
Dnmt3a	O
in	O
vitro	O
.	O

The	O
modification	O
occurs	O
in	O
the	O
N	O
-	O
terminal	O
regulatory	O
region	O
,	O
including	O
the	O
PWWP	O
(	O
Pro	O
-	O
Trp	O
-	O
Trp	O
-	O
Pro	O
)	O
domain	O
.	O

Our	O
results	O
suggest	O
that	O
Cbx4	O
functions	O
as	O
a	O
SUMO	O
E3	O
ligase	O
for	O
Dnmt3a	O
and	O
it	O
might	O
be	O
involved	O
in	O
the	O
functional	O
regulation	O
of	O
DNA	O
methyltransferases	O
by	O
promoting	O
their	O
SUMO	O
modification	O
.	O

Substrate	O
-	O
mediated	O
regulation	O
of	O
cullin	O
neddylation	O
.	O

Cullin	O
-	O
based	O
E3	O
ligases	O
are	O
a	O
large	O
family	O
of	O
multi	O
-	O
subunit	O
ubiquitin	O
ligases	O
with	O
diverse	O
cellular	O
functions	O
,	O
including	O
the	O
regulation	O
of	O
the	O
cell	O
cycle	O
,	O
of	O
the	O
DNA	O
damage	O
response	O
,	O
and	O
of	O
various	O
transcription	O
factors	O
.	O

These	O
ligases	O
are	O
composed	O
of	O
one	O
of	O
six	O
mammalian	O
cullin	O
homologs	O
(	O
Cul1	O
,	O
Cul2	O
,	O
Cul3	O
,	O
Cul4a	O
,	O
Cul4b	O
,	O
and	O
Cul5	O
)	O
,	O
the	O
Ring	O
finger	O
containing	O
protein	O
Roc1	O
/	O
Rbx1	O
,	O
and	O
cullin	O
homolog	O
-	O
specific	O
adaptor	O
and	O
substrate	O
recognition	O
subunits	O
.	O

To	O
be	O
active	O
,	O
cullin	O
-	O
based	O
ligases	O
require	O
the	O
covalent	O
modification	O
of	O
a	O
conserved	O
lysine	O
residue	O
in	O
the	O
cullin	O
protein	O
with	O
the	O
ubiquitin	O
-	O
like	O
protein	O
Nedd8	O
.	O

We	O
show	O
in	O
this	O
study	O
that	O
in	O
intact	O
cells	O
Cul1	O
neddylation	O
is	O
dependent	O
on	O
binding	O
to	O
adaptor	O
proteins	O
and	O
substrate	O
recognition	O
subunits	O
.	O

Mutant	O
Cul1	O
that	O
is	O
unable	O
to	O
recruit	O
adaptor	O
and	O
substrate	O
recognition	O
subunits	O
exhibits	O
markedly	O
reduced	O
neddylation	O
,	O
and	O
inhibiting	O
binding	O
of	O
adaptor	O
and	O
substrate	O
recognition	O
subunits	O
to	O
wild	O
type	O
Cul1	O
reduces	O
Nedd8	O
modification	O
.	O

This	O
regulatory	O
mechanism	O
also	O
extends	O
to	O
other	O
cullin	O
-	O
based	O
E3	O
ligases	O
,	O
including	O
Cul2	O
,	O
Cul3	O
,	O
and	O
Cul4a	O
.	O

The	O
regulation	O
of	O
cullin	O
neddylation	O
by	O
adaptor	O
proteins	O
and	O
substrate	O
recognition	O
subunits	O
in	O
cells	O
was	O
found	O
to	O
be	O
independent	O
of	O
both	O
CAND1	O
and	O
the	O
COP9	B-Complex
signalosome	I-Complex
,	O
two	O
negative	O
regulators	O
of	O
cullin	O
Nedd8	O
modification	O
.	O

Using	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1alpha	O
(	O
HIF	O
-	O
1alpha	O
)	O
,	O
a	O
substrate	O
of	O
the	O
Elongin	O
B	O
/	O
C	O
-	O
Cul2	O
-	O
VHL	O
ligase	O
,	O
we	O
demonstrate	O
the	O
critical	O
role	O
of	O
substrate	O
binding	O
to	O
promote	O
Cul2	O
neddylation	O
in	O
a	O
manner	O
that	O
does	O
not	O
require	O
substrate	O
ubiquitination	O
but	O
may	O
involve	O
a	O
conformational	O
change	O
.	O

These	O
findings	O
suggest	O
a	O
mechanism	O
through	O
which	O
availability	O
of	O
substrate	O
recognition	O
subunits	O
and	O
substrates	O
can	O
regulate	O
the	O
ubiquitin	O
ligase	O
activity	O
.	O

TREM	O
-	O
1	O
ligand	O
expression	O
on	O
platelets	O
enhances	O
neutrophil	O
activation	O
.	O

The	O
triggering	O
receptor	O
expressed	O
on	O
myeloid	O
cells	O
1	O
(	O
TREM	O
-	O
1	O
)	O
plays	O
an	O
important	O
role	O
in	O
the	O
innate	O
immune	O
response	O
related	O
to	O
severe	O
infections	O
and	O
sepsis	O
.	O

Modulation	O
of	O
TREM	O
-	O
1	O
-	O
associated	O
activation	O
improves	O
the	O
outcome	O
in	O
rodent	O
models	O
for	O
pneumonia	O
and	O
sepsis	O
.	O

However	O
,	O
the	O
identity	O
and	O
occurrence	O
of	O
the	O
natural	O
TREM	O
-	O
1	O
ligands	O
are	O
so	O
far	O
unknown	O
,	O
impairing	O
the	O
further	O
understanding	O
of	O
the	O
biology	O
of	O
this	O
receptor	O
.	O

Here	O
,	O
we	O
report	O
the	O
presence	O
of	O
a	O
ligand	O
for	O
TREM	O
-	O
1	O
on	O
human	O
platelets	O
.	O

Using	O
a	O
recombinant	O
TREM	O
-	O
1	O
fusion	O
protein	O
,	O
we	O
demonstrate	O
specific	O
binding	O
of	O
TREM	O
-	O
1	O
to	O
platelets	O
.	O

TREM	O
-	O
1	O
-	O
specific	O
signals	O
are	O
required	O
for	O
the	O
platelet	O
-	O
induced	O
augmentation	O
of	O
polymorphonuclear	O
leukocyte	O
(	O
PMN	O
)	O
effector	O
functions	O
(	O
provoked	O
by	O
LPS	O
)	O
.	O

However	O
,	O
TREM	O
-	O
1	O
interaction	O
with	O
its	O
ligand	O
is	O
not	O
required	O
for	O
platelet	O
/	O
PMN	O
complex	O
formation	O
,	O
which	O
is	O
dependent	O
on	O
integrins	O
and	O
selectins	O
.	O

Taken	O
together	O
,	O
the	O
results	O
indicate	O
that	O
the	O
TREM	O
-	O
1	O
ligand	O
is	O
expressed	O
by	O
platelets	O
,	O
and	O
the	O
TREM	O
-	O
1	O
/	O
ligand	O
interaction	O
contributes	O
to	O
the	O
amplification	O
of	O
LPS	O
-	O
induced	O
PMN	O
activation	O
.	O

Our	O
results	O
shed	O
new	O
light	O
on	O
our	O
understanding	O
of	O
TREM	O
-	O
1	O
and	O
its	O
role	O
in	O
the	O
innate	O
inflammatory	O
response	O
in	O
infections	O
and	O
might	O
contribute	O
to	O
the	O
development	O
of	O
future	O
concepts	O
to	O
treat	O
sepsis	O
.	O

Novel	O
c	O
-	O
CBL	O
and	O
CBL	O
-	O
b	O
ubiquitin	O
ligase	O
mutations	O
in	O
human	O
acute	O
myeloid	O
leukemia	O
.	O

The	O
CBL	O
ubiquitin	O
ligase	O
targets	O
a	O
variety	O
of	O
activated	O
tyrosine	O
kinases	O
(	O
TKs	O
)	O
for	O
degradation	O
.	O

Many	O
TKs	O
are	O
mutationally	O
or	O
autocrine	O
activated	O
and	O
/	O
or	O
often	O
overexpressed	O
at	O
the	O
mRNA	O
and	O
protein	O
levels	O
in	O
acute	O
leukemias	O
.	O

We	O
hypothesized	O
that	O
CBL	O
is	O
mutated	O
in	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
.	O

Four	O
of	O
12	O
patients	O
and	O
the	O
MOLM	O
-	O
13	O
cell	O
line	O
harbored	O
c	O
-	O
CBL	O
mutations	O
,	O
either	O
RNA	O
splicing	O
mutations	O
,	O
missense	O
mutations	O
,	O
or	O
a	O
nucleotide	O
insertion	O
.	O

Additionally	O
,	O
1	O
of	O
the	O
12	O
patients	O
harbored	O
a	O
missense	O
mutation	O
in	O
the	O
related	O
CBL	O
-	O
b	O
gene	O
.	O

Each	O
c	O
-	O
CBL	O
mutation	O
involves	O
the	O
structurally	O
important	O
alpha	O
-	O
helix	O
within	O
the	O
linker	O
region	O
,	O
while	O
the	O
mutation	O
in	O
CBL	O
-	O
b	O
was	O
located	O
in	O
the	O
Ub	O
-	O
E2	O
protein	O
-	O
binding	O
RING	O
finger	O
.	O

Short	O
-	O
interfering	O
RNA	O
knockdown	O
of	O
mutant	O
c	O
-	O
CBL	O
present	O
in	O
MOLM	O
-	O
13	O
cells	O
was	O
growth	O
inhibitory	O
.	O

In	O
summary	O
,	O
novel	O
mutations	O
in	O
c	O
-	O
CBL	O
and	O
CBL	O
-	O
b	O
have	O
been	O
identified	O
in	O
human	O
AML	O
and	O
may	O
represent	O
potential	O
targets	O
for	O
novel	O
therapeutics	O
.	O

Siglec	O
-	O
15	O
:	O
an	O
immune	O
system	O
Siglec	O
conserved	O
throughout	O
vertebrate	O
evolution	O
.	O

Siglecs	O
are	O
vertebrate	O
cell	O
-	O
surface	O
receptors	O
that	O
recognize	O
sialylated	O
glycans	O
.	O

Here	O
we	O
have	O
identified	O
and	O
characterized	O
a	O
novel	O
Siglec	O
,	O
named	O
Siglec	O
-	O
15	O
.	O

Siglec	O
-	O
15	O
is	O
a	O
type	O
-	O
I	O
transmembrane	O
protein	O
consisting	O
of	O
:	O
(	O
i	O
)	O
two	O
immunoglobulin	O
(	O
Ig	O
)	O
-	O
like	O
domains	O
,	O
(	O
ii	O
)	O
a	O
transmembrane	O
domain	O
containing	O
a	O
lysine	O
residue	O
,	O
and	O
(	O
iii	O
)	O
a	O
short	O
cytoplasmic	O
tail	O
.	O

Siglec	O
-	O
15	O
is	O
expressed	O
on	O
macrophages	O
and	O
/	O
or	O
dendritic	O
cells	O
of	O
human	O
spleen	O
and	O
lymph	O
nodes	O
.	O

We	O
show	O
that	O
the	O
extracellular	O
domain	O
of	O
Siglec	O
-	O
15	O
preferentially	O
recognizes	O
the	O
Neu5Acalpha2	O
-	O
6GalNAcalpha	O
-	O
structure	O
.	O

Siglec	O
-	O
15	O
associates	O
with	O
the	O
activating	O
adaptor	O
proteins	O
DNAX	O
activation	O
protein	O
(	O
DAP	O
)	O
12	O
and	O
DAP10	O
via	O
its	O
lysine	O
residue	O
in	O
the	O
transmembrane	O
domain	O
,	O
implying	O
that	O
it	O
functions	O
as	O
an	O
activating	O
signaling	O
molecule	O
.	O

Siglec	O
-	O
15	O
is	O
the	O
second	O
human	O
Siglec	O
identified	O
to	O
have	O
an	O
activating	O
signaling	O
potential	O
;	O
unlike	O
Siglec	O
-	O
14	O
,	O
however	O
,	O
it	O
does	O
not	O
have	O
an	O
inhibitory	O
counterpart	O
.	O

Orthologs	O
of	O
Siglec	O
-	O
15	O
are	O
present	O
not	O
only	O
in	O
mammals	O
but	O
also	O
in	O
other	O
branches	O
of	O
vertebrates	O
;	O
in	O
contrast	O
,	O
no	O
other	O
known	O
Siglec	O
expressed	O
in	O
the	O
immune	O
system	O
has	O
been	O
conserved	O
throughout	O
vertebrate	O
evolution	O
.	O

Thus	O
,	O
Siglec	O
-	O
15	O
probably	O
plays	O
a	O
conserved	O
,	O
regulatory	O
role	O
in	O
the	O
immune	O
system	O
of	O
vertebrates	O
.	O

Roles	O
for	O
negative	O
cell	O
regulator	O
14	O
-	O
3	O
-	O
3sigma	O
in	O
control	O
of	O
MDM2	O
activities	O
.	O

The	O
14	O
-	O
3	O
-	O
3sigma	O
,	O
upregulated	O
by	O
p53	O
in	O
response	O
to	O
DNA	O
damage	O
,	O
can	O
have	O
a	O
positive	O
-	O
feedback	O
impact	O
driving	O
p53	O
activities	O
and	O
is	O
a	O
human	O
cancer	O
epithelial	O
marker	O
downregulated	O
in	O
various	O
tumors	O
.	O

However	O
,	O
the	O
precise	O
roles	O
of	O
14	O
-	O
3	O
-	O
3sigma	O
during	O
tumorigenesis	O
are	O
not	O
well	O
characterized	O
.	O

Here	O
,	O
we	O
show	O
that	O
14	O
-	O
3	O
-	O
3sigma	O
is	O
a	O
critical	O
regulator	O
of	O
murine	O
double	O
minute	O
oncogene	O
(	O
MDM2	O
)	O
.	O

14	O
-	O
3	O
-	O
3sigma	O
interacts	O
with	O
MDM2	O
at	O
the	O
RING	O
domain	O
.	O

The	O
C	O
-	O
terminal	O
region	O
of	O
14	O
-	O
3	O
-	O
3sigma	O
binds	O
to	O
MDM2	O
very	O
efficiently	O
.	O

Importantly	O
,	O
14	O
-	O
3	O
-	O
3sigma	O
overexpression	O
leads	O
to	O
destabilization	O
of	O
MDM2	O
through	O
enhancing	O
MDM2	O
self	O
-	O
ubiquitination	O
and	O
accelerating	O
turnover	O
rate	O
.	O

Conversely	O
,	O
loss	O
of	O
14	O
-	O
3	O
-	O
3sigma	O
results	O
in	O
a	O
significant	O
increase	O
in	O
MDM2	O
protein	O
.	O

Moreover	O
,	O
live	O
-	O
cell	O
images	O
indicated	O
that	O
14	O
-	O
3	O
-	O
3sigma	O
can	O
affect	O
the	O
location	O
of	O
MDM2	O
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
,	O
and	O
that	O
MDM2	O
-	O
mediated	O
cytoplasmic	O
localization	O
of	O
p53	O
can	O
be	O
reversed	O
by	O
the	O
presence	O
of	O
14	O
-	O
3	O
-	O
3sigma	O
.	O

Significantly	O
,	O
we	O
further	O
showed	O
that	O
14	O
-	O
3	O
-	O
3sigma	O
causes	O
MDM2	O
downregulation	O
,	O
thereby	O
stabilizing	O
p53	O
and	O
inhibiting	O
tumor	O
growth	O
in	O
animal	O
tumors	O
.	O

Also	O
,	O
14	O
-	O
3	O
-	O
3sigma	O
blocks	O
MDM2	O
-	O
mediated	O
retinoblastoma	O
degradation	O
and	O
p53	O
NEDDylation	O
.	O

Our	O
results	O
provide	O
evidence	O
that	O
14	O
-	O
3	O
-	O
3sigma	O
is	O
a	O
pivotal	O
MDM2	O
regulator	O
involved	O
in	O
blocking	O
a	O
variety	O
of	O
activities	O
of	O
MDM2	O
.	O

Regulation	O
of	O
axon	O
guidance	O
by	O
slit	O
and	O
netrin	O
signaling	O
in	O
the	O
Drosophila	O
ventral	O
nerve	O
cord	O
.	O

Netrin	O
and	O
Slit	O
signaling	O
systems	O
play	O
opposing	O
roles	O
during	O
the	O
positioning	O
of	O
longitudinal	O
tracts	O
along	O
the	O
midline	O
in	O
the	O
ventral	O
nerve	O
cord	O
of	O
Drosophila	O
embryo	O
.	O

It	O
has	O
been	O
hypothesized	O
that	O
a	O
gradient	O
of	O
Slit	O
from	O
the	O
midline	O
interacts	O
with	O
three	O
different	O
Robo	O
receptors	O
to	O
specify	O
the	O
axon	O
tract	O
positioning	O
.	O

However	O
,	O
no	O
such	O
gradient	O
has	O
been	O
detected	O
.	O

Moreover	O
,	O
overexpression	O
of	O
Slit	O
at	O
the	O
midline	O
has	O
no	O
effect	O
on	O
the	O
positioning	O
of	O
these	O
lateral	O
tracts	O
.	O

In	O
this	O
article	O
,	O
we	O
show	O
that	O
Slit	O
is	O
present	O
outside	O
of	O
the	O
midline	O
along	O
the	O
longitudinal	O
and	O
commissural	O
tracts	O
.	O

Sli	O
from	O
the	O
midline	O
,	O
in	O
a	O
Robo	O
-	O
independent	O
manner	O
,	O
is	O
initially	O
taken	O
up	O
by	O
the	O
commissural	O
axon	O
tracts	O
when	O
they	O
cross	O
the	O
midline	O
and	O
is	O
transported	O
along	O
the	O
commissural	O
tracts	O
into	O
the	O
longitudinal	O
connectives	O
.	O

These	O
results	O
are	O
not	O
consistent	O
with	O
a	O
Sli	O
gradient	O
model	O
.	O

We	O
also	O
find	O
that	O
sli	O
mRNA	O
is	O
maternally	O
deposited	O
and	O
embryos	O
that	O
are	O
genetically	O
null	O
for	O
sli	O
can	O
have	O
weaker	O
guidance	O
defects	O
.	O

Moreover	O
,	O
in	O
robo	O
or	O
robo3	O
mutants	O
,	O
embryos	O
with	O
normal	O
axon	O
tracts	O
are	O
found	O
and	O
such	O
robo	O
embryos	O
reach	O
pupal	O
stages	O
and	O
die	O
,	O
while	O
robo3	O
mutant	O
embryos	O
develop	O
into	O
normal	O
individuals	O
and	O
produce	O
eggs	O
.	O

Interestingly	O
,	O
embryos	O
from	O
robo3	O
homozygous	O
individuals	O
fail	O
to	O
develop	O
but	O
have	O
axon	O
tracts	O
ranging	O
from	O
normal	O
to	O
various	O
defects	O
:	O
robo3	O
phenotype	O
,	O
robo	O
phenotype	O
,	O
and	O
slit	O
-	O
like	O
phenotype	O
,	O
suggesting	O
a	O
more	O
complex	O
functional	O
role	O
for	O
these	O
genes	O
than	O
what	O
has	O
been	O
proposed	O
.	O

Finally	O
,	O
our	O
previous	O
results	O
indicated	O
that	O
netrin	O
phenotype	O
is	O
epistatic	O
to	O
sli	O
or	O
robo	O
phenotypes	O
.	O

However	O
,	O
it	O
seems	O
likely	O
that	O
this	O
previously	O
reported	O
epistatic	O
relationship	O
might	O
be	O
due	O
to	O
the	O
partial	O
penetrance	O
of	O
the	O
sli	O
,	O
robo	O
,	O
robo3	O
(	O
or	O
robo2	O
)	O
phenotypes	O
.	O

Our	O
results	O
argue	O
that	O
double	O
mutant	O
epistasis	O
is	O
most	O
definitive	O
only	O
if	O
the	O
penetrance	O
of	O
the	O
phenotypes	O
of	O
the	O
mutants	O
involved	O
is	O
complete	O
.	O

Small	O
ubiquitin	O
-	O
related	O
modifier	O
(	O
SUMO	O
)	O
-	O
specific	O
proteases	O
:	O
profiling	O
the	O
specificities	O
and	O
activities	O
of	O
human	O
SENPs	O
.	O

SENPs	O
are	O
proteases	O
that	O
participate	O
in	O
the	O
regulation	O
of	O
SUMOylation	O
by	O
generating	O
mature	O
small	O
ubiquitin	O
-	O
related	O
modifiers	O
(	O
SUMO	O
)	O
for	O
protein	O
conjugation	O
(	O
endopeptidase	O
activity	O
)	O
and	O
removing	O
conjugated	O
SUMO	O
from	O
targets	O
(	O
isopeptidase	O
activity	O
)	O
.	O

Using	O
purified	O
recombinant	O
catalytic	O
domains	O
of	O
6	O
of	O
the	O
7	O
human	O
SENPs	O
,	O
we	O
demonstrate	O
the	O
specificity	O
of	O
their	O
respective	O
activities	O
on	O
SUMO	O
-	O
1	O
,	O
-	O
2	O
,	O
and	O
-	O
3	O
.	O

The	O
primary	O
mode	O
of	O
recognition	O
of	O
substrates	O
is	O
via	O
the	O
SUMO	O
domain	O
,	O
and	O
the	O
C	O
-	O
terminal	O
tails	O
direct	O
endopeptidase	O
specificity	O
.	O

Broadly	O
speaking	O
,	O
SENP1	O
is	O
the	O
most	O
efficient	O
endopeptidase	O
,	O
whereas	O
SENP2	O
and	O
-	O
5	O
-	O
7	O
have	O
substantially	O
higher	O
isopeptidase	O
than	O
endopeptidase	O
activities	O
.	O

We	O
developed	O
fluorogenic	O
tetrapeptide	O
substrates	O
that	O
are	O
cleaved	O
by	O
SENPs	O
,	O
enabling	O
us	O
to	O
characterize	O
the	O
environmental	O
profiles	O
of	O
each	O
enzyme	O
.	O

Using	O
these	O
synthetic	O
substrates	O
we	O
reveal	O
that	O
the	O
SUMO	O
domain	O
enhances	O
catalysis	O
of	O
SENP1	O
,	O
-	O
2	O
,	O
-	O
5	O
,	O
-	O
6	O
,	O
and	O
-	O
7	O
,	O
demonstrating	O
substrate	O
-	O
induced	O
activation	O
of	O
SENPs	O
by	O
SUMOs	O
.	O

The	O
serine	O
protease	O
HhoA	O
from	O
Synechocystis	O
sp	O
.	O
strain	O
PCC	O
6803	O
:	O
substrate	O
specificity	O
and	O
formation	O
of	O
a	O
hexameric	O
complex	O
are	O
regulated	O
by	O
the	O
PDZ	O
domain	O
.	O

Enzymes	O
of	O
the	O
ATP	O
-	O
independent	O
Deg	O
serine	O
endopeptidase	O
family	O
are	O
very	O
flexible	O
with	O
regard	O
to	O
their	O
substrate	O
specificity	O
.	O

Some	O
family	O
members	O
cleave	O
only	O
one	O
substrate	O
,	O
while	O
others	O
act	O
as	O
general	O
proteases	O
on	O
unfolded	O
substrates	O
.	O

The	O
proteolytic	O
activity	O
of	O
Deg	O
proteases	O
is	O
regulated	O
by	O
PDZ	O
protein	O
interaction	O
domains	O
.	O

Here	O
we	O
characterized	O
the	O
HhoA	O
protease	O
from	O
Synechocystis	O
sp	O
.	O
strain	O
PCC	O
6803	O
in	O
vitro	O
using	O
several	O
recombinant	O
protein	O
constructs	O
.	O

The	O
proteolytic	O
activity	O
of	O
HhoA	O
was	O
found	O
to	O
increase	O
with	O
temperature	O
and	O
basic	O
pH	O
and	O
was	O
stimulated	O
by	O
the	O
addition	O
of	O
Mg	O
(	O
2	O
+	O
)	O
or	O
Ca	O
(	O
2	O
+	O
)	O
.	O

We	O
found	O
that	O
the	O
single	O
PDZ	O
domain	O
of	O
HhoA	O
played	O
a	O
critical	O
role	O
in	O
regulating	O
protease	O
activity	O
and	O
in	O
the	O
assembly	O
of	O
a	O
hexameric	O
complex	O
.	O

Deletion	O
of	O
the	O
PDZ	O
domain	O
strongly	O
reduced	O
proteolysis	O
of	O
a	O
sterically	O
challenging	O
resorufin	O
-	O
labeled	O
casein	O
substrate	O
,	O
but	O
unlabeled	O
beta	O
-	O
casein	O
was	O
still	O
degraded	O
.	O

Reconstitution	O
of	O
the	O
purified	O
HhoA	O
with	O
total	O
membrane	O
proteins	O
isolated	O
from	O
Synechocystis	O
sp	O
.	O
wild	O
-	O
type	O
strain	O
PCC	O
6803	O
and	O
a	O
DeltahhoA	O
mutant	O
resulted	O
in	O
specific	O
degradation	O
of	O
selected	O
proteins	O
at	O
elevated	O
temperatures	O
.	O

We	O
concluded	O
that	O
a	O
single	O
PDZ	O
domain	O
of	O
HhoA	O
plays	O
a	O
critical	O
role	O
in	O
defining	O
the	O
protease	O
activity	O
and	O
oligomerization	O
state	O
,	O
combining	O
the	O
functions	O
that	O
are	O
attributed	O
to	O
two	O
PDZ	O
domains	O
in	O
the	O
homologous	O
DegP	O
protease	O
from	O
Escherichia	O
coli	O
.	O

Based	O
on	O
this	O
first	O
enzymatic	O
study	O
of	O
a	O
Deg	O
protease	O
from	O
cyanobacteria	O
,	O
we	O
propose	O
a	O
general	O
role	O
for	O
HhoA	O
in	O
the	O
quality	O
control	O
of	O
extracytoplasmic	O
proteins	O
,	O
including	O
membrane	O
proteins	O
,	O
in	O
Synechocystis	O
sp	O
.	O
strain	O
PCC	O
6803	O
.	O

Identification	O
of	O
differentially	O
expressed	O
genes	O
in	O
human	O
varicose	O
veins	O
:	O
involvement	O
of	O
matrix	O
gla	O
protein	O
in	O
extracellular	O
matrix	O
remodeling	O
.	O

This	O
study	O
was	O
designed	O
to	O
identify	O
the	O
global	O
pattern	O
of	O
differentially	O
expressed	O
genes	O
in	O
human	O
varicose	O
veins	O
.	O

Using	O
suppressive	O
subtractive	O
hybridization	O
,	O
we	O
identified	O
overexpression	O
of	O
genes	O
known	O
to	O
be	O
associated	O
with	O
extracellular	O
matrix	O
remodeling	O
,	O
including	O
collagen	B-Complex
III	I-Complex
,	O
tissue	O
inhibitor	O
of	O
metalloproteinases	O
I	O
,	O
dermatopontin	O
,	O
matrix	O
Gla	O
protein	O
(	O
MGP	O
)	O
and	O
tenascin	O
C	O
.	O

Real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
analysis	O
confirmed	O
the	O
differential	O
expression	O
of	O
these	O
genes	O
.	O

The	O
overexpression	O
of	O
MGP	O
transcript	O
was	O
associated	O
with	O
increased	O
MGP	O
level	O
in	O
varicose	O
veins	O
,	O
in	O
particular	O
the	O
undercarboxylated	O
form	O
of	O
the	O
protein	O
.	O

Smooth	O
muscle	O
cells	O
from	O
varicose	O
veins	O
showed	O
increased	O
proliferation	O
rate	O
and	O
enhanced	O
matrix	O
mineralization	O
.	O

This	O
observation	O
correlated	O
with	O
the	O
presence	O
of	O
ectopic	O
mineralization	O
areas	O
in	O
the	O
varicose	O
vein	O
walls	O
.	O

The	O
use	O
of	O
warfarin	O
,	O
to	O
inhibit	O
MGP	O
activity	O
,	O
or	O
siRNA	O
targeting	O
MGP	O
transcript	O
induced	O
a	O
reduction	O
in	O
the	O
exacerbated	O
proliferation	O
of	O
varicose	O
vein	O
smooth	O
muscle	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
high	O
expression	O
of	O
MGP	O
in	O
varicose	O
veins	O
may	O
contribute	O
to	O
venous	O
wall	O
remodeling	O
by	O
affecting	O
proliferation	O
and	O
mineralization	O
processes	O
probably	O
through	O
impaired	O
carboxylation	O
of	O
MGP	O
.	O

In	O
addition	O
,	O
suppressive	O
subtractive	O
hybridization	O
results	O
also	O
produce	O
a	O
profile	O
of	O
differentially	O
expressed	O
genes	O
in	O
varicose	O
veins	O
,	O
in	O
particular	O
extracellular	O
matrix	O
components	O
.	O

Further	O
study	O
of	O
these	O
genes	O
will	O
provide	O
insights	O
into	O
their	O
specific	O
roles	O
in	O
the	O
etiology	O
of	O
venous	O
disease	O
.	O

Functional	O
analysis	O
of	O
the	O
epidermal	O
-	O
specific	O
MYB	O
genes	O
CAPRICE	O
and	O
WEREWOLF	O
in	O
Arabidopsis	O
.	O

Epidermis	O
cell	O
differentiation	O
in	O
Arabidopsis	O
thaliana	O
is	O
a	O
model	O
system	O
for	O
understanding	O
the	O
developmental	O
end	O
state	O
of	O
plant	O
cells	O
.	O

Two	O
types	O
of	O
MYB	O
transcription	O
factors	O
,	O
R2R3	O
-	O
MYB	O
and	O
R3	O
-	O
MYB	O
,	O
are	O
involved	O
in	O
cell	O
fate	O
determination	O
.	O

To	O
examine	O
the	O
molecular	O
basis	O
of	O
this	O
process	O
,	O
we	O
analyzed	O
the	O
functional	O
relationship	O
of	O
the	O
R2R3	O
-	O
type	O
MYB	O
gene	O
WEREWOLF	O
(	O
WER	O
)	O
and	O
the	O
R3	O
-	O
type	O
MYB	O
gene	O
CAPRICE	O
(	O
CPC	O
)	O
.	O

Chimeric	O
constructs	O
made	O
from	O
the	O
R3	O
MYB	O
regions	O
of	O
WER	O
and	O
CPC	O
used	O
in	O
reciprocal	O
complementation	O
experiments	O
showed	O
that	O
the	O
CPC	O
R3	O
region	O
cannot	O
functionally	O
substitute	O
for	O
the	O
WER	O
R3	O
region	O
in	O
the	O
differentiation	O
of	O
hairless	O
cells	O
.	O

However	O
,	O
WER	O
R3	O
can	O
substantially	O
substitute	O
for	O
CPC	O
R3	O
.	O

There	O
are	O
no	O
differences	O
in	O
yeast	O
interaction	O
assays	O
of	O
WER	O
or	O
WER	O
chimera	O
proteins	O
with	O
GLABRA3	O
(	O
GL3	O
)	O
or	O
ENHANCER	O
OF	O
GLABRA3	O
(	O
EGL3	O
)	O
.	O

CPC	O
and	O
CPC	O
chimera	O
proteins	O
also	O
have	O
similar	O
activity	O
in	O
preventing	O
GL3	O
WER	O
and	O
EGL3	O
WER	O
interactions	O
.	O

Furthermore	O
,	O
we	O
showed	O
by	O
gel	O
mobility	O
shift	O
assays	O
that	O
WER	O
chimera	O
proteins	O
do	O
not	O
bind	O
to	O
the	O
GL2	O
promoter	O
region	O
.	O

However	O
,	O
a	O
CPC	O
chimera	O
protein	O
,	O
which	O
harbors	O
the	O
WER	O
R3	O
motif	O
,	O
still	O
binds	O
to	O
the	O
GL2	O
promoter	O
region	O
.	O

Single	O
A326G	O
mutation	O
converts	O
human	O
CYP24A1	O
from	O
25	O
-	O
OH	O
-	O
D3	O
-	O
24	O
-	O
hydroxylase	O
into	O
-	O
23	O
-	O
hydroxylase	O
,	O
generating	O
1alpha	O
,	O
25	O
-	O
(	O
OH	O
)	O
2D3	O
-	O
26	O
,	O
23	O
-	O
lactone	O
.	O

Studies	O
of	O
25	O
-	O
hydroxyvitamin	O
D	O
(	O
3	O
)	O
-	O
24	O
-	O
hydroxylase	O
(	O
CYP24A1	O
)	O
have	O
demonstrated	O
that	O
it	O
is	O
a	O
bifunctional	O
enzyme	O
capable	O
of	O
the	O
24	O
-	O
hydroxylation	O
of	O
1alpha	O
,	O
25	O
-	O
(	O
OH	O
)	O
(	O
2	O
)	O
D	O
(	O
3	O
)	O
,	O
leading	O
to	O
the	O
excretory	O
form	O
,	O
calcitroic	O
acid	O
,	O
and	O
23	O
-	O
hydroxylation	O
,	O
culminating	O
in	O
1alpha	O
,	O
25	O
-	O
(	O
OH	O
)	O
(	O
2	O
)	O
D	O
(	O
3	O
)	O
-	O
26	O
,	O
23	O
-	O
lactone	O
.	O

The	O
degree	O
to	O
which	O
CYP24A1	O
performs	O
either	O
23	O
-	O
or	O
24	O
-	O
hydroxylation	O
is	O
species	O
-	O
dependent	O
.	O

In	O
this	O
paper	O
,	O
we	O
show	O
that	O
the	O
human	O
enzyme	O
that	O
predominantly	O
24	O
-	O
hydroxylates	O
its	O
substrate	O
differs	O
from	O
the	O
opossum	O
enzyme	O
that	O
23	O
-	O
hydroxylates	O
it	O
at	O
only	O
a	O
limited	O
number	O
of	O
amino	O
acid	O
residues	O
.	O

Mutagenesis	O
of	O
the	O
human	O
form	O
at	O
a	O
single	O
substrate	O
-	O
binding	O
residue	O
(	O
A326G	O
)	O
dramatically	O
changes	O
the	O
regioselectivity	O
of	O
the	O
enzyme	O
from	O
a	O
24	O
-	O
hydroxylase	O
to	O
a	O
23	O
-	O
hydroxylase	O
,	O
whereas	O
other	O
modifications	O
have	O
no	O
effect	O
.	O

Ala	O
-	O
326	O
is	O
located	O
in	O
the	O
I	O
-	O
helix	O
,	O
close	O
to	O
the	O
terminus	O
of	O
the	O
docked	O
25	O
-	O
hydroxylated	O
side	O
chain	O
in	O
a	O
CYP24A1	O
homology	O
model	O
,	O
a	O
result	O
that	O
we	O
interpret	O
indicates	O
that	O
substitution	O
of	O
a	O
glycine	O
at	O
326	O
provides	O
extra	O
space	O
for	O
the	O
side	O
chain	O
of	O
the	O
substrate	O
to	O
move	O
deeper	O
into	O
the	O
pocket	O
and	O
place	O
it	O
in	O
a	O
optimal	O
stereochemical	O
position	O
for	O
23	O
-	O
hydroxylation	O
.	O

We	O
discuss	O
the	O
physiological	O
ramifications	O
of	O
these	O
results	O
for	O
species	O
possessing	O
the	O
A326G	O
substitution	O
,	O
as	O
well	O
as	O
implications	O
for	O
optimal	O
vitamin	O
D	O
analog	O
design	O
.	O

The	O
DNA	O
damage	O
response	O
mediator	O
MDC1	O
directly	O
interacts	O
with	O
the	O
anaphase	B-Complex
-	I-Complex
promoting	I-Complex
complex	I-Complex
/	I-Complex
cyclosome	I-Complex
.	O

MDC1	O
(	O
NFBD1	O
)	O
,	O
a	O
mediator	O
of	O
the	O
cellular	O
response	O
to	O
DNA	O
damage	O
,	O
plays	O
an	O
important	O
role	O
in	O
checkpoint	O
activation	O
and	O
DNA	O
repair	O
.	O

Here	O
we	O
identified	O
a	O
cross	O
-	O
talk	O
between	O
the	O
DNA	O
damage	O
response	O
and	O
cell	O
cycle	O
regulation	O
.	O

We	O
discovered	O
that	O
MDC1	O
binds	O
the	O
anaphase	B-Complex
-	I-Complex
promoting	I-Complex
complex	I-Complex
/	I-Complex
cyclosome	I-Complex
(	O
APC	B-Complex
/	I-Complex
C	I-Complex
)	O
,	O
an	O
E3	O
ubiquitin	O
ligase	O
that	O
controls	O
the	O
cell	O
cycle	O
.	O

The	O
interaction	O
is	O
direct	O
and	O
is	O
mediated	O
by	O
the	O
tandem	O
BRCA1	O
C	O
-	O
terminal	O
domains	O
of	O
MDC1	O
and	O
the	O
C	O
terminus	O
of	O
the	O
Cdc27	O
(	O
APC3	O
)	O
subunit	O
of	O
the	O
APC	B-Complex
/	I-Complex
C	I-Complex
.	O

It	O
requires	O
the	O
phosphorylation	O
of	O
Cdc27	O
and	O
is	O
enhanced	O
after	O
induction	O
of	O
DNA	O
damage	O
.	O

We	O
show	O
that	O
the	O
tandem	O
BRCA1	O
C	O
-	O
terminal	O
domains	O
of	O
MDC1	O
,	O
known	O
to	O
directly	O
bind	O
the	O
phosphorylated	O
form	O
of	O
histone	O
H2AX	O
(	O
gamma	O
-	O
H2AX	O
)	O
,	O
also	O
bind	O
the	O
APC	B-Complex
/	I-Complex
C	I-Complex
by	O
the	O
same	O
mechanism	O
,	O
as	O
phosphopeptides	O
that	O
correspond	O
to	O
the	O
C	O
termini	O
of	O
gamma	O
-	O
H2AX	O
and	O
Cdc27	O
competed	O
with	O
each	O
other	O
for	O
the	O
binding	O
to	O
MDC1	O
.	O

Our	O
results	O
reveal	O
a	O
link	O
between	O
the	O
cellular	O
response	O
to	O
DNA	O
damage	O
and	O
cell	O
cycle	O
regulation	O
,	O
suggesting	O
that	O
MDC1	O
,	O
known	O
to	O
have	O
a	O
role	O
in	O
checkpoint	O
regulation	O
,	O
executes	O
part	O
of	O
this	O
role	O
by	O
binding	O
the	O
APC	B-Complex
/	I-Complex
C	I-Complex
.	O

Fbw7	O
and	O
Usp28	O
regulate	O
myc	O
protein	O
stability	O
in	O
response	O
to	O
DNA	O
damage	O
.	O

The	O
cellular	O
levels	O
of	O
the	O
Myc	O
oncoprotein	O
are	O
critical	O
determinants	O
of	O
cell	O
proliferation	O
,	O
cell	O
growth	O
and	O
apoptosis	O
and	O
are	O
tightly	O
regulated	O
by	O
external	O
growth	O
factors	O
.	O

Levels	O
of	O
Myc	O
oncoprotein	O
also	O
decline	O
in	O
response	O
to	O
intracellular	O
stress	O
signals	O
such	O
as	O
DNA	O
damage	O
.	O

We	O
show	O
here	O
that	O
this	O
decline	O
is	O
in	O
part	O
due	O
to	O
proteasomal	O
degradation	O
and	O
that	O
it	O
is	O
mediated	O
by	O
the	O
Fbw7	O
ubiquitin	O
ligase	O
.	O

We	O
have	O
shown	O
previously	O
that	O
the	O
ubiquitin	O
-	O
specific	O
protease	O
Usp28	O
,	O
binds	O
to	O
the	O
nucleoplasmic	O
isoform	O
of	O
Fbw7	O
,	O
Fbw7alpha	O
,	O
and	O
counteracts	O
its	O
function	O
in	O
mammalian	O
cells	O
.	O

Usp28	O
dissociates	O
from	O
Fbw7alpha	O
in	O
response	O
to	O
UV	O
irradiation	O
,	O
providing	O
a	O
mechanism	O
how	O
Fbw7	O
-	O
mediated	O
degradation	O
of	O
Myc	O
is	O
enhanced	O
upon	O
DNA	O
damage	O
.	O

Our	O
data	O
extend	O
previous	O
observations	O
that	O
link	O
Myc	O
function	O
to	O
the	O
cellular	O
response	O
to	O
DNA	O
damage	O
.	O

To	O
gain	O
insight	O
into	O
the	O
mechanism	O
by	O
which	O
Rpb7p	O
functions	O
in	O
the	O
major	O
mRNA	O
decay	O
,	O
we	O
examined	O
what	O
step	O
(	O
s	O
)	O
in	O
mRNAs	O
turnover	O
is	O
/	O
are	O
stimulated	O
by	O
Rpb7p	O
.	O

Cells	O
were	O
shifted	O
to	O
42degreesC	O
to	O
inactivate	O
both	O
transcription	O
and	O
the	O
function	O
of	O
Rpb7p	O
ts	O
form	O
,	O
and	O
then	O
the	O
levels	O
and	O
poly	O
(	O
A	O
)	O
tail	O
lengths	O
of	O
RPL29	O
and	O
RPL25	O
mRNAs	O
were	O
monitored	O
using	O
the	O
polyacrylamide	O
gel	O
electrophoresis	O
Northern	O
(	O
PAGEN	O
)	O
technique	O
,	O
as	O
shown	O
in	O
Fig	O
.	O

3	O
.	O

These	O
mRNAs	O
were	O
chosen	O
because	O
their	O
short	O
length	O
enables	O
detection	O
of	O
small	O
differences	O
in	O
the	O
size	O
of	O
their	O
poly	O
(	O
A	O
)	O
tail	O
.	O

Three	O
conclusions	O
can	O
be	O
made	O
concerning	O
the	O
results	O
shown	O
in	O
Fig	O
.	O

3	O
.	O

First	O
,	O
the	O
decay	O
kinetics	O
of	O
these	O
mRNAs	O
is	O
fast	O
in	O
WT	O
cells	O
and	O
slower	O
in	O
mutant	O
cells	O
,	O
consistent	O
with	O
our	O
results	O
obtained	O
by	O
standard	O
Northern	O
analysis	O
shown	O
in	O
Fig	O
.	O

2	O
.	O

Second	O
,	O
deadenylation	O
is	O
abnormally	O
slow	O
in	O
the	O
mutant	O
cells	O
.	O

For	O
example	O
,	O
whereas	O
complete	O
deadenylation	O
of	O
RPL29	O
mRNA	O
is	O
observed	O
in	O
WT	O
after	O
45	O
min	O
(	O
Fig	O
.	O
3	O
,	O
lane	O
5	O
)	O
,	O
it	O
takes	O
70	O
min	O
for	O
this	O
to	O
occur	O
in	O
rpb7	O
-	O
28	O
(	O
Fig	O
.	O
3	O
,	O
lane	O
13	O
)	O
.	O

We	O
conclude	O
that	O
Rpb7	O
-	O
28p	O
is	O
defective	O
in	O
stimulating	O
rapid	O
deadenylation	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

3	O
,	O
after	O
its	O
complete	O
deadenylation	O
25	O
min	O
post	O
-	O
transcription	O
arrest	O
,	O
it	O
is	O
only	O
a	O
further	O
20	O
min	O
before	O
RPL25	O
mRNA	O
is	O
almost	O
completely	O
degraded	O
in	O
WT	O
(	O
between	O
25	O
to	O
45	O
min	O
post	O
-	O
transcription	O
arrest	O
;	O
see	O
lanes	O
4	O
and	O
5	O
)	O
.	O

In	O
contrast	O
,	O
to	O
degrade	O
comparably	O
the	O
deadenylated	O
RPL25	O
mRNA	O
in	O
rpb7	O
-	O
28	O
takes	O
75	O
min	O
(	O
lanes	O
12	O
-	O
14	O
)	O
.	O

A	O
third	O
conclusion	O
,	O
then	O
,	O
is	O
that	O
Rpb7p	O
stimulates	O
not	O
only	O
deadenylation	O
,	O
but	O
also	O
post	O
-	O
deadenylation	O
step	O
.	O

Refined	O
crystal	O
structures	O
of	O
red	O
and	O
green	O
fluorescent	O
proteins	O
from	O
the	O
button	O
polyp	O
Zoanthus	O
.	O

The	O
three	O
-	O
dimensional	O
structures	O
of	O
the	O
wild	O
-	O
type	O
red	O
(	O
zRFP574	O
)	O
and	O
green	O
(	O
zGFP506	O
)	O
fluorescent	O
proteins	O
(	O
FP	O
)	O
from	O
the	O
button	O
polyp	O
Zoanthus	O
have	O
been	O
determined	O
at	O
1	O
.	O
51	O
and	O
2	O
.	O
2	O
A	O
resolution	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
the	O
crystal	O
structures	O
of	O
a	O
zGFP506	O
variant	O
(	O
zGFP506	O
_	O
N66D	O
)	O
with	O
replacement	O
of	O
the	O
first	O
chromophore	O
-	O
forming	O
residue	O
(	O
Asn66	O
to	O
Asp	O
)	O
have	O
been	O
determined	O
in	O
the	O
transitional	O
'	O
green	O
'	O
and	O
mature	O
'	O
red	O
'	O
states	O
at	O
2	O
.	O
4	O
and	O
2	O
.	O
2	O
A	O
,	O
respectively	O
.	O

The	O
monomers	O
of	O
these	O
proteins	O
adopt	O
the	O
typical	O
fold	O
of	O
the	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
family	O
,	O
consisting	O
of	O
an	O
11	O
-	O
stranded	O
beta	O
-	O
barrel	O
with	O
a	O
chromophore	O
embedded	O
in	O
the	O
middle	O
of	O
an	O
internal	O
alpha	O
-	O
helix	O
directed	O
along	O
the	O
beta	O
-	O
barrel	O
axis	O
.	O

Post	O
-	O
translational	O
modification	O
of	O
the	O
chromophore	O
-	O
forming	O
sequence	O
Asn66	O
-	O
Tyr67	O
-	O
Gly68	O
within	O
zGFP506	O
results	O
in	O
a	O
typical	O
GFP	O
-	O
like	O
coplanar	O
two	O
-	O
ring	O
structure	O
consisting	O
of	O
a	O
five	O
-	O
membered	O
imidazolinone	O
heterocycle	O
with	O
the	O
phenolic	O
ring	O
of	O
Tyr67	O
in	O
a	O
cis	O
orientation	O
to	O
the	O
C	O
(	O
alpha	O
)	O
-	O
N	O
(	O
67	O
)	O
bond	O
.	O

A	O
novel	O
post	O
-	O
translational	O
modification	O
of	O
the	O
chromophore	O
-	O
forming	O
sequence	O
Asp66	O
-	O
Tyr67	O
-	O
Gly68	O
in	O
zRFP574	O
expands	O
the	O
protein	O
maturation	O
beyond	O
the	O
green	O
-	O
emitting	O
form	O
and	O
results	O
in	O
decarboxylation	O
of	O
the	O
Asp66	O
side	O
chain	O
.	O

It	O
is	O
suggested	O
that	O
electrostatic	O
conflict	O
between	O
the	O
closely	O
spaced	O
negatively	O
charged	O
side	O
chains	O
of	O
the	O
chromophore	O
Asp66	O
and	O
the	O
proximal	O
catalytic	O
Glu221	O
is	O
most	O
likely	O
to	O
be	O
the	O
trigger	O
for	O
the	O
chain	O
of	O
reactions	O
resulting	O
in	O
the	O
observed	O
decarboxylation	O
.	O

The	O
chromophore	O
structures	O
of	O
wild	O
-	O
type	O
zGFP506	O
and	O
of	O
its	O
mutant	O
zGFP506	O
_	O
N66D	O
in	O
the	O
'	O
green	O
'	O
and	O
'	O
red	O
'	O
states	O
support	O
this	O
suggestion	O
.	O

The	O
beta	O
-	O
barrel	O
frames	O
of	O
zRFP574	O
and	O
zGFP506	O
reveal	O
the	O
presence	O
of	O
a	O
water	O
-	O
filled	O
pore	O
leading	O
to	O
the	O
chromophore	O
Tyr67	O
,	O
similar	O
to	O
that	O
observed	O
previously	O
in	O
TurboGFP	O
.	O

An	O
analysis	O
of	O
the	O
residue	O
composition	O
at	O
two	O
inter	O
-	O
monomer	O
interfaces	O
in	O
the	O
tetrameric	O
biological	O
unit	O
of	O
zRFP574	O
and	O
zGFP506	O
,	O
as	O
well	O
as	O
of	O
zYFP538	O
from	O
the	O
same	O
species	O
,	O
has	O
revealed	O
a	O
group	O
of	O
highly	O
conserved	O
residues	O
that	O
are	O
apparently	O
responsible	O
for	O
oligomerization	O
.	O

These	O
residues	O
present	O
initial	O
useful	O
targets	O
for	O
rational	O
mutagenesis	O
aimed	O
at	O
designing	O
monomeric	O
forms	O
of	O
the	O
fluorescent	O
proteins	O
,	O
which	O
are	O
more	O
suitable	O
for	O
practical	O
applications	O
.	O

Methylation	O
of	O
histone	O
H3R2	O
by	O
PRMT6	O
and	O
H3K4	O
by	O
an	O
MLL	B-OOS
complex	O
are	O
mutually	O
exclusive	O
.	O

Eukaryotic	O
genomes	O
are	O
organized	O
into	O
active	O
(	O
euchromatic	O
)	O
and	O
inactive	O
(	O
heterochromatic	O
)	O
chromatin	O
domains	O
.	O

Post	O
-	O
translational	O
modifications	O
of	O
histones	O
(	O
or	O
'	O
marks	O
'	O
)	O
are	O
key	O
in	O
defining	O
these	O
functional	O
states	O
,	O
particularly	O
in	O
promoter	O
regions	O
.	O

Mutual	O
regulatory	O
interactions	O
between	O
these	O
marks	O
-	O
-	O
and	O
the	O
enzymes	O
that	O
catalyse	O
them	O
-	O
-	O
contribute	O
to	O
the	O
shaping	O
of	O
this	O
epigenetic	O
landscape	O
,	O
in	O
a	O
manner	O
that	O
remains	O
to	O
be	O
fully	O
elucidated	O
.	O

We	O
previously	O
observed	O
that	O
asymmetric	O
di	O
-	O
methylation	O
of	O
histone	O
H3	O
arginine	O
2	O
(	O
H3R2me2a	O
)	O
counter	O
-	O
correlates	O
with	O
di	O
-	O
and	O
tri	O
-	O
methylation	O
of	O
H3	O
lysine	O
4	O
(	O
H3K4me2	O
,	O
H3K4me3	O
)	O
on	O
human	O
promoters	O
.	O

Here	O
we	O
show	O
that	O
the	O
arginine	O
methyltransferase	O
PRMT6	O
catalyses	O
H3R2	O
di	O
-	O
methylation	O
in	O
vitro	O
and	O
controls	O
global	O
levels	O
of	O
H3R2me2a	O
in	O
vivo	O
.	O

H3R2	O
methylation	O
by	O
PRMT6	O
was	O
prevented	O
by	O
the	O
presence	O
of	O
H3K4me3	O
on	O
the	O
H3	O
tail	O
.	O

Conversely	O
,	O
the	O
H3R2me2a	O
mark	O
prevented	O
methylation	O
of	O
H3K4	O
as	O
well	O
as	O
binding	O
to	O
the	O
H3	O
tail	O
by	O
an	O
ASH2	O
/	O
WDR5	O
/	O
MLL	B-OOS
-	O
family	O
methyltransferase	O
complex	O
.	O

Chromatin	O
immunoprecipitation	O
showed	O
that	O
H3R2me2a	O
was	O
distributed	O
within	O
the	O
body	O
and	O
at	O
the	O
3	O
'	O
end	O
of	O
human	O
genes	O
,	O
regardless	O
of	O
their	O
transcriptional	O
state	O
,	O
whereas	O
it	O
was	O
selectively	O
and	O
locally	O
depleted	O
from	O
active	O
promoters	O
,	O
coincident	O
with	O
the	O
presence	O
of	O
H3K4me3	O
.	O

Hence	O
,	O
the	O
mutual	O
antagonism	O
between	O
H3R2	O
and	O
H3K4	O
methylation	O
,	O
together	O
with	O
the	O
association	O
of	O
MLL	B-OOS
-	O
family	O
complexes	O
with	O
the	O
basal	O
transcription	O
machinery	O
,	O
may	O
contribute	O
to	O
the	O
localized	O
patterns	O
of	O
H3K4	O
tri	O
-	O
methylation	O
characteristic	O
of	O
transcriptionally	O
poised	O
or	O
active	O
promoters	O
in	O
mammalian	O
genomes	O
.	O

Active	O
gamma	B-Complex
-	I-Complex
secretase	I-Complex
complexes	O
contain	O
only	O
one	O
of	O
each	O
component	O
.	O

Gamma	B-Complex
-	I-Complex
secretase	I-Complex
is	O
an	O
intramembrane	O
aspartyl	O
protease	O
complex	O
that	O
cleaves	O
type	O
I	O
integral	O
membrane	O
proteins	O
,	O
including	O
the	O
amyloid	O
beta	O
-	O
protein	O
precursor	O
and	O
the	O
Notch	O
receptor	O
,	O
and	O
is	O
composed	O
of	O
presenilin	O
,	O
Pen	O
-	O
2	O
,	O
nicastrin	O
,	O
and	O
Aph	O
-	O
1	O
.	O

Although	O
all	O
four	O
of	O
these	O
membrane	O
proteins	O
are	O
essential	O
for	O
assembly	O
and	O
activity	O
,	O
the	O
stoichiometry	O
of	O
the	O
complex	O
is	O
unknown	O
,	O
with	O
the	O
number	O
of	O
presenilin	O
molecules	O
present	O
being	O
especially	O
controversial	O
.	O

Here	O
we	O
analyze	O
functional	O
gamma	B-Complex
-	I-Complex
secretase	I-Complex
complexes	O
,	O
isolated	O
by	O
immunoprecipitation	O
from	O
solubilized	O
membrane	O
fractions	O
and	O
able	O
to	O
produce	O
amyloid	O
beta	O
-	O
peptides	O
and	O
amyloid	O
beta	O
-	O
protein	O
precursor	O
intracellular	O
domain	O
.	O

We	O
show	O
that	O
the	O
active	O
isolated	O
protease	O
contains	O
only	O
one	O
presenilin	O
per	O
complex	O
,	O
which	O
excludes	O
certain	O
models	O
of	O
the	O
active	O
site	O
that	O
require	O
aspartate	O
dyads	O
formed	O
between	O
two	O
presenilin	O
molecules	O
.	O

We	O
also	O
quantified	O
components	O
in	O
the	O
isolated	O
complexes	O
by	O
Western	O
blot	O
using	O
protein	O
standards	O
and	O
found	O
that	O
the	O
amounts	O
of	O
Pen	O
-	O
2	O
and	O
nicastrin	O
were	O
the	O
same	O
as	O
that	O
of	O
presenilin	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
one	O
Aph	O
-	O
1	O
was	O
not	O
co	O
-	O
immunoprecipitated	O
with	O
another	O
in	O
active	O
complexes	O
,	O
evidence	O
that	O
Aph	O
-	O
1	O
is	O
likewise	O
present	O
as	O
a	O
monomer	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
the	O
stoichiometry	O
of	O
gamma	B-Complex
-	O
components	O
presenilin	O
:	O
Pen	O
-	O
2	O
:	O
nicastrin	O
:	O
Aph	O
-	O
1	O
is	O
1	O
:	O
1	O
:	O
1	O
:	O
1	O
.	O

Mammalian	O
Sir2	O
homolog	O
SIRT3	O
regulates	O
global	O
mitochondrial	O
lysine	O
acetylation	O
.	O

Homologs	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
Sir2	O
protein	O
,	O
sirtuins	O
,	O
promote	O
longevity	O
in	O
many	O
organisms	O
.	O

Studies	O
of	O
the	O
sirtuin	O
SIRT3	O
have	O
so	O
far	O
been	O
limited	O
to	O
cell	O
culture	O
systems	O
.	O

Here	O
,	O
we	O
investigate	O
the	O
localization	O
and	O
function	O
of	O
SIRT3	O
in	O
vivo	O
.	O

We	O
show	O
that	O
endogenous	O
mouse	O
SIRT3	O
is	O
a	O
soluble	O
mitochondrial	O
protein	O
.	O

To	O
address	O
the	O
function	O
and	O
relevance	O
of	O
SIRT3	O
in	O
the	O
regulation	O
of	O
energy	O
metabolism	O
,	O
we	O
generated	O
and	O
phenotypically	O
characterized	O
SIRT3	O
knockout	O
mice	O
.	O

SIRT3	O
-	O
deficient	O
animals	O
exhibit	O
striking	O
mitochondrial	O
protein	O
hyperacetylation	O
,	O
suggesting	O
that	O
SIRT3	O
is	O
a	O
major	O
mitochondrial	O
deacetylase	O
.	O

In	O
contrast	O
,	O
no	O
mitochondrial	O
hyperacetylation	O
was	O
detectable	O
in	O
mice	O
lacking	O
the	O
two	O
other	O
mitochondrial	O
sirtuins	O
,	O
SIRT4	O
and	O
SIRT5	O
.	O

Surprisingly	O
,	O
despite	O
this	O
biochemical	O
phenotype	O
,	O
SIRT3	O
-	O
deficient	O
mice	O
are	O
metabolically	O
unremarkable	O
under	O
basal	O
conditions	O
and	O
show	O
normal	O
adaptive	O
thermogenesis	O
,	O
a	O
process	O
previously	O
suggested	O
to	O
involve	O
SIRT3	O
.	O

Overall	O
,	O
our	O
results	O
extend	O
the	O
recent	O
finding	O
of	O
lysine	O
acetylation	O
of	O
mitochondrial	O
proteins	O
and	O
demonstrate	O
that	O
SIRT3	O
has	O
evolved	O
to	O
control	O
reversible	O
lysine	O
acetylation	O
in	O
this	O
organelle	O
.	O

The	O
role	O
of	O
loop	O
and	O
beta	O
-	O
turn	O
residues	O
as	O
structural	O
and	O
functional	O
determinants	O
for	O
the	O
lipoyl	O
domain	O
from	O
the	O
Escherichia	O
coli	O
2	B-Complex
-	I-Complex
oxoglutarate	I-Complex
dehydrogenase	I-Complex
complex	O
.	O

The	O
lipoyl	O
domain	O
of	O
the	O
dihydrolipoyl	O
succinyltransferase	O
(	O
E2o	O
)	O
component	O
of	O
the	O
2OGDH	B-Complex
(	O
2	B-Complex
-	I-Complex
oxoglutarate	I-Complex
dehydrogenase	I-Complex
)	O
multienzyme	O
complex	O
houses	O
the	O
lipoic	O
acid	O
cofactor	O
through	O
covalent	O
attachment	O
to	O
a	O
specific	O
lysine	O
side	O
chain	O
residing	O
at	O
the	O
tip	O
of	O
a	O
beta	O
-	O
turn	O
.	O

Residues	O
within	O
the	O
lipoyl	O
-	O
lysine	O
beta	O
-	O
turn	O
and	O
a	O
nearby	O
prominent	O
loop	O
have	O
been	O
implicated	O
as	O
determinants	O
of	O
lipoyl	O
domain	O
structure	O
and	O
function	O
.	O

Protein	O
engineering	O
of	O
the	O
Escherichia	O
coli	O
E2o	O
lipoyl	O
domain	O
(	O
E2olip	O
)	O
revealed	O
that	O
removal	O
of	O
residues	O
from	O
the	O
loop	O
caused	O
a	O
major	O
structural	O
change	O
in	O
the	O
protein	O
,	O
which	O
rendered	O
the	O
domain	O
incapable	O
of	O
reductive	O
succinylation	O
by	O
2	O
-	O
oxoglutarate	O
decarboxylase	O
(	O
E1o	O
)	O
and	O
reduced	O
the	O
lipoylation	O
efficiency	O
.	O

Insertion	O
of	O
a	O
new	O
loop	O
corresponding	O
to	O
that	O
of	O
the	O
E	O
.	O
coli	O
pyruvate	B-Complex
dehydrogenase	I-Complex
lipoyl	O
domain	O
(	O
E2plip	O
)	O
restored	O
lipoylation	O
efficiency	O
and	O
the	O
capacity	O
to	O
undergo	O
reductive	O
succinylation	O
returned	O
,	O
albeit	O
at	O
a	O
lower	O
rate	O
.	O

Exchange	O
of	O
the	O
E2olip	O
loop	O
sequence	O
significantly	O
improved	O
the	O
ability	O
of	O
the	O
domain	O
to	O
be	O
reductively	O
acetylated	O
by	O
pyruvate	O
decarboxylase	O
(	O
E1p	O
)	O
,	O
retaining	O
approx	O
.	O
10	O
-	O
fold	O
more	O
acetyl	O
groups	O
after	O
25	O
min	O
than	O
wild	O
-	O
type	O
E2olip	O
.	O

Exchange	O
of	O
the	O
beta	O
-	O
turn	O
residue	O
on	O
the	O
N	O
-	O
terminal	O
side	O
of	O
the	O
E2o	O
lipoyl	O
-	O
lysine	O
DK	O
(	O
A	O
)	O
/	O
(	O
V	O
)	O
motif	O
to	O
the	O
equivalent	O
residue	O
in	O
E2plip	O
(	O
T42G	O
)	O
,	O
both	O
singly	O
and	O
in	O
conjunction	O
with	O
the	O
loop	O
exchange	O
,	O
reduced	O
the	O
ability	O
of	O
the	O
domain	O
to	O
be	O
reductively	O
succinylated	O
,	O
but	O
led	O
to	O
an	O
increased	O
capacity	O
to	O
be	O
reductively	O
acetylated	O
by	O
the	O
non	O
-	O
cognate	O
E1p	O
.	O

The	O
T42G	O
mutation	O
also	O
slightly	O
enhanced	O
the	O
lipoylation	O
rate	O
of	O
the	O
domain	O
.	O

The	O
surface	O
loop	O
is	O
important	O
to	O
the	O
structural	O
integrity	O
of	O
the	O
protein	O
and	O
together	O
with	O
Thr42	O
plays	O
an	O
important	O
role	O
in	O
specifying	O
the	O
interaction	O
of	O
the	O
lipoyl	O
domain	O
with	O
its	O
partner	O
E1o	O
in	O
the	O
E	O
.	O
coli	O
2OGDH	B-Complex
complex	O
.	O

The	O
Sam3	O
mutations	O
that	O
confer	O
sinefungin	O
-	O
resistance	O
also	O
result	O
in	O
loss	O
-	O
of	O
-	O
function	O
in	O
AdoMet	O
uptake	O
,	O
as	O
gauged	O
by	O
impaired	O
growth	O
on	O
AdoMet	O
-	O
containing	O
B	O
medium	O
.	O

Most	O
of	O
the	O
sfr	O
mutants	O
isolated	O
in	O
the	O
screen	O
are	O
functionally	O
null	O
for	O
Sam3	O
because	O
of	O
premature	O
translation	O
stops	O
that	O
remove	O
three	O
or	O
more	O
of	O
the	O
12	O
predicted	O
membrane	O
-	O
spanning	O
segments	O
.	O

The	O
Sam3	O
missense	O
mutations	O
that	O
confer	O
sinefungin	O
-	O
resistance	O
are	O
Q126P	O
,	O
S171R	O
,	O
E213K	O
,	O
and	O
S476F	O
.	O

Gln126	O
,	O
Ser171	O
and	O
Ser476	O
are	O
located	O
in	O
predicted	O
membrane	O
spanning	O
segments	O
2	O
,	O
3	O
and	O
11	O
,	O
respectively	O
.	O

Glu213	O
is	O
situated	O
between	O
the	O
third	O
and	O
fourth	O
membrane	O
-	O
spanning	O
segments	O
.	O

All	O
four	O
of	O
these	O
Sam3	O
side	O
chains	O
are	O
conserved	O
in	O
the	O
yeast	O
Mmp1	O
permease	O
that	O
transports	O
S	O
-	O
methylmethionine	O
.	O

Antagonistic	O
roles	O
of	O
Wnt5	O
and	O
the	O
Drl	O
receptor	O
in	O
patterning	O
the	O
Drosophila	O
antennal	O
lobe	O
.	O

Numerous	O
studies	O
have	O
shown	O
that	O
ingrowing	O
olfactory	O
axons	O
exert	O
powerful	O
inductive	O
influences	O
on	O
olfactory	O
map	O
development	O
.	O

From	O
an	O
overexpression	O
screen	O
,	O
we	O
have	O
identified	O
wnt5	O
as	O
a	O
potent	O
organizer	O
of	O
the	O
olfactory	O
map	O
in	O
Drosophila	O
melanogaster	O
.	O

Loss	O
of	O
wnt5	O
resulted	O
in	O
severe	O
derangement	O
of	O
the	O
glomerular	O
pattern	O
,	O
whereas	O
overexpression	O
of	O
wnt5	O
resulted	O
in	O
the	O
formation	O
of	O
ectopic	O
midline	O
glomeruli	O
.	O

Cell	O
type	O
-	O
specific	O
cDNA	O
rescue	O
and	O
mosaic	O
experiments	O
showed	O
that	O
wnt5	O
functions	O
in	O
olfactory	O
neurons	O
.	O

Mutation	O
of	O
the	O
derailed	O
(	O
drl	O
)	O
gene	O
,	O
encoding	O
a	O
receptor	O
for	O
Wnt5	O
,	O
resulted	O
in	O
derangement	O
of	O
the	O
glomerular	O
map	O
,	O
ectopic	O
midline	O
glomeruli	O
and	O
the	O
accumulation	O
of	O
Wnt5	O
at	O
the	O
midline	O
.	O

We	O
show	O
here	O
that	O
drl	O
functions	O
in	O
glial	O
cells	O
,	O
where	O
it	O
acts	O
upstream	O
of	O
wnt5	O
to	O
modulate	O
its	O
function	O
in	O
glomerular	O
patterning	O
.	O

Our	O
findings	O
establish	O
wnt5	O
as	O
an	O
anterograde	O
signal	O
that	O
is	O
expressed	O
by	O
olfactory	O
axons	O
and	O
demonstrate	O
a	O
previously	O
unappreciated	O
,	O
yet	O
powerful	O
,	O
role	O
for	O
glia	O
in	O
patterning	O
the	O
Drosophila	O
olfactory	O
map	O
.	O

Malt1	O
ubiquitination	O
triggers	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
signaling	O
upon	O
T	O
-	O
cell	O
activation	O
.	O

Triggering	O
of	O
antigen	O
receptors	O
on	O
lymphocytes	O
is	O
critical	O
for	O
initiating	O
adaptive	O
immune	O
response	O
against	O
pathogens	O
.	O

T	B-Complex
-	I-Complex
cell	I-Complex
receptor	I-Complex
(	O
TCR	B-Complex
)	O
engagement	O
induces	O
the	O
formation	O
of	O
the	O
Carma1	O
-	O
Bcl10	O
-	O
Malt1	O
(	O
CBM	B-Complex
)	O
complex	O
that	O
is	O
essential	O
for	O
activation	O
of	O
the	O
IkappaB	B-Complex
kinase	I-Complex
(	O
IKK	B-Complex
)	O
/	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
pathway	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
that	O
link	O
CBM	B-Complex
complex	O
formation	O
to	O
IKK	B-Complex
activation	O
remain	O
unclear	O
.	O

Here	O
we	O
report	O
that	O
Malt1	O
is	O
polyubiquitinated	O
upon	O
T	O
-	O
cell	O
activation	O
.	O

Ubiquitin	O
chains	O
on	O
Malt1	O
provide	O
a	O
docking	O
surface	O
for	O
the	O
recruitment	O
of	O
the	O
IKK	B-Complex
regulatory	O
subunit	O
NEMO	O
/	O
IKKgamma	O
.	O

TRAF6	O
associates	O
with	O
Malt1	O
in	O
response	O
to	O
T	O
-	O
cell	O
activation	O
and	O
can	O
function	O
as	O
an	O
E3	O
ligase	O
for	O
Malt1	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
mediating	O
lysine	O
63	O
-	O
linked	O
ubiquitination	O
of	O
Malt1	O
.	O

Multiple	O
lysine	O
residues	O
in	O
the	O
C	O
-	O
terminus	O
of	O
Malt1	O
serve	O
as	O
acceptor	O
sites	O
for	O
the	O
assembly	O
of	O
polyubiquitin	O
chains	O
.	O

Malt1	O
mutants	O
that	O
lack	O
C	O
-	O
terminal	O
ubiquitin	O
acceptor	O
lysines	O
are	O
impaired	O
in	O
rescuing	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
signaling	O
and	O
IL	O
-	O
2	O
production	O
in	O
Malt1	O
-	O
/	O
-	O
T	O
cells	O
.	O

Thus	O
,	O
our	O
data	O
demonstrate	O
that	O
induced	O
Malt1	O
ubiquitination	O
is	O
critical	O
for	O
the	O
engagement	O
of	O
CBM	B-Complex
and	O
IKK	B-Complex
complexes	O
,	O
thereby	O
directing	O
TCR	B-Complex
signals	O
to	O
the	O
canonical	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
pathway	O
.	O

MAPK	O
p38	O
regulates	O
transcriptional	O
activity	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
in	O
primary	O
human	O
astrocytes	O
via	O
acetylation	O
of	O
p65	O
.	O

MAPK	O
-	O
p38	O
plays	O
an	O
important	O
role	O
in	O
inflammation	O
.	O

Several	O
studies	O
have	O
shown	O
that	O
blocking	O
p38	O
activity	O
attenuates	O
the	O
transcriptional	O
activity	O
of	O
the	O
proinflammatory	O
transcription	O
factor	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
without	O
altering	O
its	O
DNA	O
-	O
binding	O
activity	O
.	O

We	O
have	O
also	O
observed	O
that	O
blocking	O
p38	O
in	O
human	O
primary	O
astrocytes	O
suppresses	O
the	O
transcriptional	O
but	O
not	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
and	O
down	O
-	O
regulates	O
the	O
expression	O
of	O
an	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
-	O
dependent	O
gene	O
,	O
inducible	O
NO	O
synthase	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
of	O
p38	O
-	O
mediated	O
regulation	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
remains	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
delineate	O
that	O
p38	O
controls	O
the	O
transcriptional	O
activity	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
by	O
regulating	O
acetylation	O
of	O
p65	O
,	O
but	O
not	O
its	O
phosphorylation	O
.	O

The	O
combination	O
of	O
IL	O
-	O
1beta	O
and	O
IFN	O
-	O
gamma	O
,	O
previously	O
shown	O
to	O
strongly	O
induce	O
inducible	O
NO	O
synthase	O
in	O
human	O
primary	O
astrocytes	O
,	O
induced	O
p38	O
-	O
dependent	O
phosphorylation	O
of	O
acetyltransferase	O
coactivator	O
p300	O
,	O
but	O
not	O
p65	O
,	O
and	O
subsequent	O
association	O
of	O
p300	O
with	O
p65	O
.	O

Furthermore	O
,	O
immunocomplex	O
-	O
histone	O
acetyltransferase	O
assays	O
demonstrated	O
that	O
cytokine	O
-	O
induced	O
association	O
of	O
p65	O
with	O
biologically	O
active	O
immunocomplex	O
-	O
histone	O
acetyltransferase	O
assay	O
was	O
dependent	O
on	O
p38	O
.	O

It	O
has	O
been	O
previously	O
reported	O
that	O
acetylation	O
of	O
p65	O
at	O
K310	O
residue	O
is	O
important	O
for	O
transcriptional	O
activity	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
.	O

Accordingly	O
,	O
we	O
found	O
that	O
cytokine	O
-	O
induced	O
association	O
of	O
p65	O
with	O
p300	O
led	O
to	O
acetylation	O
of	O
p65	O
at	O
K310	O
.	O

Because	O
p38	O
regulated	O
the	O
association	O
between	O
p65	O
and	O
p300	O
,	O
blocking	O
p38	O
activity	O
also	O
led	O
to	O
attenuation	O
of	O
p65	O
-	O
K310	O
acetylation	O
in	O
cytokine	O
-	O
stimulated	O
astrocytes	O
.	O

Taken	O
together	O
,	O
this	O
study	O
illuminates	O
a	O
novel	O
regulatory	O
role	O
of	O
p38	O
during	O
neuroinflammation	O
where	O
this	O
MAP	O
kinase	O
controls	O
acetylation	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
p65	O
by	O
regulating	O
acetyltransferase	O
activity	O
of	O
coactivator	O
p300	O
.	O

Defining	O
targets	O
for	O
complement	O
components	O
C4b	O
and	O
C3b	O
on	O
the	O
pathogenic	O
neisseriae	O
.	O

Complement	O
is	O
a	O
key	O
arm	O
of	O
the	O
innate	O
immune	O
defenses	O
against	O
the	O
pathogenic	O
neisseriae	O
.	O

We	O
previously	O
identified	O
lipooligosaccharide	O
on	O
Neisseria	O
meningitidis	O
as	O
an	O
acceptor	O
for	O
complement	O
C4b	O
.	O

Little	O
is	O
known	O
about	O
other	O
neisserial	O
targets	O
for	O
complement	O
proteins	O
C3	O
and	O
C4	O
,	O
which	O
covalently	O
attach	O
to	O
bacterial	O
surfaces	O
and	O
initiate	O
opsonization	O
and	O
killing	O
.	O

In	O
this	O
study	O
we	O
demonstrate	O
that	O
Neisseria	O
gonorrhoeae	O
porin	O
(	O
Por	O
)	O
1B	O
selectively	O
binds	O
C4b	O
via	O
amide	O
linkages	O
and	O
C3b	O
via	O
ester	O
linkages	O
.	O

Using	O
strains	O
expressing	O
hybrid	O
Por1A	O
/	O
1B	O
molecules	O
,	O
a	O
region	O
spanned	O
by	O
loops	O
4	O
and	O
5	O
of	O
Por1B	O
was	O
identified	O
as	O
the	O
preferred	O
binding	O
site	O
for	O
C4b	O
.	O

We	O
also	O
identified	O
the	O
opacity	O
protein	O
(	O
Opa	O
)	O
,	O
a	O
major	O
adhesin	O
of	O
pathogenic	O
neisseriae	O
,	O
as	O
a	O
target	O
for	O
C4b	O
and	O
C3b	O
on	O
both	O
N	O
.	O
meningitidis	O
and	O
N	O
.	O
gonorrhoeae	O
.	O

Using	O
N	O
.	O
gonorrhoeae	O
variants	O
that	O
predominantly	O
expressed	O
individual	O
Opa	O
proteins	O
,	O
we	O
found	O
that	O
all	O
Opa	O
proteins	O
tested	O
(	O
A	O
,	O
B	O
,	O
C	O
,	O
D	O
,	O
E	O
,	O
F	O
,	O
and	O
I	O
)	O
bound	O
C4b	O
and	O
C3b	O
via	O
amide	O
and	O
ester	O
linkages	O
,	O
respectively	O
.	O

Amide	O
linkages	O
with	O
Por1B	O
and	O
Opa	O
were	O
confirmed	O
using	O
serum	O
containing	O
only	O
the	O
C4A	O
isoform	O
,	O
which	O
exclusively	O
forms	O
amide	O
linkages	O
with	O
targets	O
.	O

While	O
monomers	O
and	O
heterodimers	O
of	O
C4Ab	O
were	O
detected	O
on	O
bacterial	O
targets	O
,	O
C4Bb	O
appeared	O
to	O
preferentially	O
participate	O
in	O
heterodimer	O
(	O
C5	O
convertase	O
)	O
formation	O
.	O

Our	O
data	O
provide	O
another	O
explanation	O
for	O
the	O
enhanced	O
serum	O
sensitivity	O
of	O
Por1B	O
-	O
bearing	O
gonococci	O
.	O

The	O
binding	O
of	O
C3b	O
and	O
C4b	O
to	O
Opa	O
provides	O
a	O
rationale	O
for	O
the	O
recovery	O
of	O
predominantly	O
"	O
transparent	O
"	O
(	O
Opa	O
-	O
negative	O
)	O
neisserial	O
isolates	O
from	O
persons	O
with	O
invasive	O
disease	O
,	O
where	O
the	O
bacteria	O
encounter	O
high	O
levels	O
of	O
complement	O
.	O

Protein	B-Complex
phosphatase	I-Complex
2A	I-Complex
subunit	O
PR70	O
interacts	O
with	O
pRb	O
and	O
mediates	O
its	O
dephosphorylation	O
.	O

The	O
retinoblastoma	O
tumor	O
suppressor	O
protein	O
(	O
pRb	O
)	O
regulates	O
cell	O
proliferation	O
and	O
differentiation	O
via	O
phosphorylation	O
-	O
sensitive	O
interactions	O
with	O
specific	O
targets	O
.	O

While	O
the	O
role	O
of	O
cyclin	O
/	O
cyclin	O
-	O
dependent	O
kinase	O
complexes	O
in	O
the	O
modulation	O
of	O
pRb	O
phosphorylation	O
has	O
been	O
extensively	O
studied	O
,	O
relatively	O
little	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
regulating	O
phosphate	O
removal	O
by	O
phosphatases	O
.	O

Protein	B-Complex
phosphatase	I-Complex
2A	I-Complex
(	O
PP2A	B-Complex
)	O
is	O
constituted	O
by	O
a	O
core	O
dimer	O
bearing	O
catalytic	O
activity	O
and	O
one	O
variable	O
B	O
regulatory	O
subunit	O
conferring	O
target	O
specificity	O
and	O
subcellular	O
localization	O
.	O

We	O
previously	O
demonstrated	O
that	O
PP2A	B-Complex
core	O
dimer	O
binds	O
pRb	O
and	O
dephosphorylates	O
pRb	O
upon	O
oxidative	O
stress	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
identified	O
a	O
specific	O
PP2A	B-OOS
-	O
B	O
subunit	O
,	O
PR70	O
,	O
that	O
was	O
associated	O
with	O
pRb	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

PR70	O
overexpression	O
caused	O
pRb	O
dephosphorylation	O
;	O
conversely	O
,	O
PR70	O
knockdown	O
prevented	O
both	O
pRb	O
dephosphorylation	O
and	O
DNA	O
synthesis	O
inhibition	O
induced	O
by	O
oxidative	O
stress	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
intracellular	O
Ca	O
(	O
2	O
+	O
)	O
mobilization	O
was	O
necessary	O
and	O
sufficient	O
to	O
trigger	O
pRb	O
dephosphorylation	O
and	O
PP2A	B-Complex
phosphatase	O
activity	O
of	O
PR70	O
was	O
Ca	O
(	O
2	O
+	O
)	O
induced	O
.	O

These	O
data	O
underline	O
the	O
importance	O
of	O
PR70	O
-	O
Ca	O
(	O
2	O
+	O
)	O
interaction	O
in	O
the	O
signal	O
transduction	O
mechanisms	O
triggered	O
by	O
redox	O
imbalance	O
and	O
leading	O
to	O
pRb	O
dephosphorylation	O
.	O

Molecular	O
characterization	O
of	O
a	O
novel	O
type	O
of	O
prostamide	O
/	O
prostaglandin	O
F	O
synthase	O
,	O
belonging	O
to	O
the	O
thioredoxin	O
-	O
like	O
superfamily	O
.	O

Prostaglandin	O
F	O
(	O
PGF	O
)	O
ethanolamide	O
(	O
prostamide	O
F	O
)	O
synthase	O
,	O
which	O
catalyzed	O
the	O
reduction	O
of	O
prostamide	O
H	O
(	O
2	O
)	O
to	O
prostamide	O
F	O
(	O
2alpha	O
)	O
,	O
was	O
found	O
in	O
mouse	O
and	O
swine	O
brain	O
.	O

The	O
enzyme	O
was	O
purified	O
from	O
swine	O
brain	O
,	O
and	O
its	O
amino	O
acid	O
sequence	O
was	O
defined	O
.	O

The	O
mouse	O
enzyme	O
consisted	O
of	O
a	O
603	O
-	O
bp	O
open	O
reading	O
frame	O
coding	O
for	O
a	O
201	O
-	O
amino	O
acid	O
polypeptide	O
with	O
a	O
molecular	O
weight	O
of	O
21	O
,	O
669	O
.	O

The	O
amino	O
acid	O
sequence	O
placed	O
the	O
enzyme	O
in	O
the	O
thioredoxin	O
-	O
like	O
superfamily	O
with	O
Cys	O
(	O
44	O
)	O
being	O
the	O
active	O
site	O
.	O

The	O
enzyme	O
expressed	O
in	O
Escherichia	O
coli	O
as	O
well	O
as	O
the	O
native	O
enzyme	O
catalyzed	O
not	O
only	O
the	O
reduction	O
of	O
prostamide	O
H	O
(	O
2	O
)	O
to	O
prostamide	O
F	O
(	O
2alpha	O
)	O
but	O
also	O
that	O
of	O
PGH	O
(	O
2	O
)	O
to	O
PGF	O
(	O
2alpha	O
)	O
.	O

The	O
V	O
(	O
max	O
)	O
and	O
K	O
(	O
m	O
)	O
values	O
for	O
prostamide	O
H	O
(	O
2	O
)	O
were	O
about	O
0	O
.	O
25	O
micromol	O
/	O
min	O
.	O
mg	O
of	O
protein	O
and	O
7	O
.	O
6	O
microm	O
,	O
respectively	O
,	O
and	O
those	O
for	O
PGH	O
(	O
2	O
)	O
were	O
about	O
0	O
.	O
69	O
micromol	O
/	O
min	O
.	O
mg	O
of	O
protein	O
and	O
6	O
.	O
9	O
microm	O
,	O
respectively	O
.	O

Neither	O
PGE	O
(	O
2	O
)	O
nor	O
PGD	O
(	O
2	O
)	O
served	O
as	O
a	O
substrate	O
for	O
this	O
synthase	O
.	O

Based	O
on	O
these	O
data	O
,	O
we	O
named	O
the	O
enzyme	O
prostamide	O
/	O
PGF	O
synthase	O
.	O

Although	O
the	O
enzyme	O
showed	O
a	O
broad	O
specificity	O
for	O
reductants	O
,	O
reduced	O
thioredoxin	O
preferentially	O
served	O
as	O
a	O
reducing	O
equivalent	O
donor	O
for	O
this	O
enzyme	O
.	O

Moreover	O
,	O
Northern	O
and	O
Western	O
blot	O
analyses	O
in	O
addition	O
to	O
the	O
prostamide	O
F	O
synthase	O
activity	O
showed	O
that	O
the	O
enzyme	O
was	O
mainly	O
distributed	O
in	O
the	O
brain	O
and	O
spinal	O
cord	O
,	O
and	O
the	O
immunohistochemical	O
study	O
in	O
the	O
spinal	O
cord	O
showed	O
that	O
the	O
enzyme	O
was	O
found	O
mainly	O
in	O
the	O
cytosol	O
.	O

These	O
results	O
suggest	O
that	O
prostamide	O
/	O
PGF	O
synthase	O
may	O
play	O
an	O
important	O
functional	O
role	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Daxx	O
mediates	O
SUMO	O
-	O
dependent	O
transcriptional	O
control	O
and	O
subnuclear	O
compartmentalization	O
.	O

SUMO	O
(	O
small	O
ubiquitin	O
-	O
related	O
modifier	O
)	O
modification	O
is	O
emerging	O
as	O
an	O
important	O
post	O
-	O
translational	O
control	O
in	O
transcription	O
.	O

In	O
general	O
,	O
SUMO	O
modification	O
is	O
associated	O
with	O
transcriptional	O
repression	O
.	O

Although	O
many	O
SUMO	O
-	O
modified	O
transcription	O
factors	O
and	O
co	O
-	O
activators	O
have	O
been	O
identified	O
,	O
little	O
is	O
known	O
about	O
the	O
mechanism	O
underlying	O
SUMOylation	O
-	O
elicited	O
transcriptional	O
repression	O
.	O

Here	O
,	O
we	O
summarize	O
that	O
SUMO	O
modification	O
of	O
transcription	O
factors	O
such	O
as	O
androgen	O
receptor	O
,	O
glucocorticoid	O
receptor	O
,	O
Smad4	O
and	O
CBP	O
[	O
CREB	O
(	O
cAMP	O
-	O
response	O
-	O
element	O
-	O
binding	O
protein	O
)	O
-	O
binding	O
protein	O
]	O
co	O
-	O
activator	O
results	O
in	O
the	O
recruitment	O
of	O
a	O
transcriptional	O
co	O
-	O
repressor	O
Daxx	O
,	O
thereby	O
causing	O
transcriptional	O
repression	O
.	O

Such	O
a	O
SUMO	O
-	O
dependent	O
recruitment	O
of	O
Daxx	O
is	O
mediated	O
by	O
the	O
interaction	O
between	O
the	O
SUMO	O
moiety	O
of	O
SUMOylated	O
factors	O
and	O
Daxx	O
SUMO	O
-	O
interacting	O
motif	O
.	O

Interestingly	O
,	O
the	O
transrepression	O
effect	O
of	O
Daxx	O
on	O
these	O
SUMOylated	O
transcription	O
factors	O
can	O
be	O
relieved	O
by	O
SUMOylated	O
PML	O
(	O
promyelocytic	O
leukaemia	O
)	O
via	O
altering	O
Daxx	O
partition	O
from	O
the	O
targeted	O
gene	O
promoter	O
to	O
PML	B-OOS
nuclear	I-OOS
bodies	I-OOS
.	O

Because	O
Daxx	O
SUMO	O
-	O
interacting	O
motif	O
is	O
a	O
common	O
binding	O
site	O
for	O
SUMOylated	O
factors	O
,	O
a	O
model	O
of	O
competition	O
for	O
Daxx	O
recruitment	O
between	O
SUMOylated	O
PML	O
and	O
SUMOylated	O
transcription	O
factors	O
was	O
proposed	O
.	O

Together	O
,	O
our	O
findings	O
strongly	O
suggest	O
that	O
Daxx	O
functions	O
as	O
a	O
SUMO	O
reader	O
in	O
the	O
SUMO	O
-	O
dependent	O
regulation	O
of	O
transcription	O
and	O
subnuclear	O
compartmentalization	O
.	O

We	O
asked	O
whether	O
the	O
two	O
peripheral	O
SAM	B-Complex
proteins	O
Sam35	O
and	O
Sam37	O
,	O
which	O
expose	O
domains	O
at	O
the	O
cytosolic	O
side	O
,	O
also	O
affect	O
the	O
biogenesis	O
pathway	O
of	O
Tom22	O
.	O

The	O
essential	O
protein	O
Sam35	O
was	O
addressed	O
through	O
use	O
of	O
the	O
temperature	O
-	O
sensitive	O
yeast	O
mutant	O
sam35	O
-	O
2	O
.	O

The	O
cells	O
were	O
exposed	O
to	O
an	O
in	O
vivo	O
heat	O
shock	O
at	O
37degreesC	O
for	O
10	O
h	O
,	O
and	O
mitochondria	O
were	O
isolated	O
and	O
analyzed	O
for	O
steady	O
-	O
state	O
protein	O
levels	O
.	O

Remarkably	O
,	O
the	O
level	O
of	O
Tom22	O
in	O
the	O
sam35	O
-	O
2	O
mutant	O
mitochondria	O
was	O
reduced	O
to	O
a	O
greater	O
extent	O
than	O
that	O
of	O
Tom40	O
,	O
whereas	O
further	O
proteins	O
analyzed	O
were	O
present	O
in	O
similar	O
amounts	O
as	O
in	O
wild	O
-	O
type	O
mitochondria	O
(	O
Fig	O
.	O
2	O
A	O
)	O
.	O

For	O
protein	O
import	O
experiments	O
,	O
we	O
used	O
sam35	O
-	O
2	O
mitochondria	O
that	O
were	O
isolated	O
from	O
cells	O
grown	O
at	O
permissive	O
conditions	O
.	O

Before	O
incubation	O
with	O
radiolabeled	O
precursor	O
proteins	O
,	O
the	O
isolated	O
mitochondria	O
were	O
subjected	O
to	O
a	O
short	O
-	O
term	O
shift	O
to	O
nonpermissive	O
conditions	O
(	O
37degreesC	O
)	O
.	O

Similar	O
to	O
the	O
situation	O
with	O
sam50	O
-	O
1	O
mitochondria	O
,	O
the	O
sam35	O
-	O
2	O
mitochondria	O
retain	O
wild	O
-	O
type	O
levels	O
of	O
the	O
TOM	B-Complex
complex	O
in	O
addition	O
to	O
all	O
of	O
the	O
mitochondrial	O
marker	O
proteins	O
analyzed	O
and	O
efficiently	O
import	O
precursor	O
proteins	O
to	O
internal	O
mitochondrial	O
compartments	O
.	O

However	O
,	O
the	O
assembly	O
of	O
Tom22	O
was	O
strongly	O
inhibited	O
in	O
sam35	O
-	O
2	O
mitochondria	O
(	O
Fig	O
.	O
2	O
B	O
)	O
.	O

As	O
controls	O
,	O
the	O
import	O
of	O
Tom40	O
displayed	O
the	O
classic	O
defect	O
in	O
beta	O
-	O
barrel	O
protein	O
assembly	O
,	O
whereas	O
the	O
import	O
of	O
Tom20	O
and	O
Tom70	O
remained	O
unaffected	O
(	O
Fig	O
.	O
2	O
,	O
C	O
and	O
D	O
)	O
.	O

Thus	O
,	O
the	O
second	O
essential	O
SAM	B-Complex
protein	O
,	O
Sam35	O
,	O
also	O
affects	O
the	O
assembly	O
pathway	O
of	O
the	O
precursor	O
of	O
Tom22	O
.	O

Flag	O
-	O
tagged	O
IFNAR1	O
proteins	O
(	O
wild	O
type	O
or	O
KR	O
mutant	O
)	O
were	O
expressed	O
in	O
293T	O
cells	O
and	O
purified	O
using	O
M2	O
agarose	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
followed	O
by	O
sequential	O
stringent	O
washes	O
with	O
buffers	O
containing	O
1	O
%	O
Nonidet	O
P	O
-	O
40	O
,	O
1	O
M	O
NaCl	O
,	O
and	O
0	O
.	O
1	O
%	O
SDS	O
.	O

Subsequent	O
washes	O
were	O
performed	O
with	O
the	O
same	O
buffer	O
containing	O
200	O
mM	O
NaCl	O
,	O
100	O
mM	O
NaCl	O
,	O
and	O
,	O
finally	O
,	O
TBS	O
.	O

These	O
washes	O
were	O
stringent	O
enough	O
to	O
remove	O
any	O
detectable	O
Tyk2	O
from	O
immunoprecipitated	O
IFNAR1	O
.	O

The	O
precipitated	O
proteins	O
were	O
eluted	O
with	O
0	O
.	O
1	O
M	O
glycine	O
,	O
pH	O
3	O
.	O
0	O
and	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
.	O

Approximately	O
1	O
%	O
of	O
the	O
eluate	O
was	O
analyzed	O
by	O
immunoblotting	O
with	O
antiubiquitin	O
antibody	O
(	O
FK2	O
;	O
BIOMOL	O
International	O
,	O
L	O
.	O
P	O
.	O
)	O
to	O
determine	O
the	O
apparent	O
molecular	O
weight	O
of	O
ubiquitinated	O
receptor	O
and	O
anti	O
-	O
FLAG	O
M2	O
antibody	O
.	O

80	O
%	O
of	O
eluate	O
was	O
analyzed	O
by	O
SDS	O
-	O
PAGE	O
followed	O
by	O
colloidal	O
Coomassie	O
(	O
Invitrogen	O
)	O
staining	O
.	O

Competitive	O
inhibition	O
of	O
histone	O
deacetylase	O
activity	O
by	O
trichostatin	O
A	O
and	O
butyrate	O
.	O

Histone	O
deacetylases	O
(	O
HDACs	O
)	O
play	O
a	O
pivotal	O
role	O
in	O
gene	O
expression	O
through	O
their	O
involvement	O
in	O
chromatin	O
remodeling	O
.	O

The	O
abnormal	O
targeting	O
or	O
retention	O
of	O
HDACs	O
to	O
DNA	O
regulatory	O
regions	O
is	O
observed	O
in	O
many	O
cancers	O
,	O
and	O
hence	O
HDAC	O
inhibitors	O
are	O
being	O
tested	O
as	O
promising	O
anti	O
-	O
tumor	O
agents	O
.	O

The	O
results	O
of	O
previous	O
kinetic	O
studies	O
,	O
characterizing	O
trichostatin	O
A	O
(	O
TSA	O
)	O
,	O
as	O
well	O
as	O
butyrate	O
,	O
as	O
HDAC	O
noncompetitive	O
inhibitors	O
,	O
conflict	O
with	O
crystallographic	O
and	O
homology	O
modeling	O
data	O
suggesting	O
that	O
TSA	O
should	O
act	O
as	O
a	O
competitive	O
inhibitor	O
.	O

Our	O
results	O
demonstrate	O
that	O
each	O
of	O
the	O
HDAC	O
inhibitors	O
TSA	O
and	O
butyrate	O
inhibits	O
HDAC	O
activity	O
in	O
a	O
competitive	O
fashion	O
.	O

Co	O
-	O
immunoprecipitation	O
studies	O
show	O
that	O
the	O
inhibition	O
of	O
HDAC1	O
and	O
HDAC2	O
activity	O
by	O
TSA	O
does	O
not	O
disturb	O
the	O
extensive	O
level	O
of	O
their	O
association	O
in	O
the	O
human	O
breast	O
cancer	O
cell	O
line	O
MCF	O
-	O
7	O
.	O

Moreover	O
,	O
the	O
inhibition	O
of	O
HDAC	O
activity	O
by	O
TSA	O
does	O
not	O
interfere	O
with	O
the	O
interaction	O
of	O
HDAC1	O
and	O
HDAC2	O
with	O
Sin3A	O
,	O
a	O
core	O
component	O
of	O
the	O
Sin3	B-Complex
complex	O
.	O

Thus	O
,	O
repressor	O
complexes	O
such	O
as	O
Sin3	B-Complex
,	O
appear	O
to	O
be	O
stable	O
in	O
the	O
presence	O
of	O
TSA	O
.	O

The	O
association	O
of	O
HDAC2	O
with	O
transcription	O
factor	O
Sp1	O
is	O
also	O
not	O
affected	O
by	O
TSA	O
.	O

NMD	O
factors	O
UPF2	O
and	O
UPF3	O
bridge	O
UPF1	O
to	O
the	O
exon	B-Complex
junction	I-Complex
complex	I-Complex
and	O
stimulate	O
its	O
RNA	O
helicase	O
activity	O
.	O

Nonsense	O
-	O
mediated	O
mRNA	O
decay	O
(	O
NMD	O
)	O
eliminates	O
mRNAs	O
containing	O
a	O
premature	O
translation	O
termination	O
codon	O
through	O
the	O
recruitment	O
of	O
the	O
conserved	O
NMD	O
factors	O
UPF1	O
,	O
UPF2	O
and	O
UPF3	O
.	O

In	O
humans	O
,	O
a	O
dynamic	O
assembly	O
pathway	O
allows	O
UPF1	O
to	O
join	O
UPF2	O
and	O
UPF3	O
recruited	O
to	O
the	O
mRNA	O
by	O
the	O
exon	B-Complex
-	I-Complex
junction	I-Complex
complex	I-Complex
(	O
EJC	B-Complex
)	O
.	O

Here	O
we	O
show	O
that	O
the	O
recombinant	O
EJC	B-Complex
core	O
is	O
sufficient	O
to	O
reconstitute	O
,	O
with	O
the	O
three	O
UPF	B-Complex
proteins	O
,	O
a	O
stable	O
heptameric	O
complex	O
on	O
RNA	O
.	O

The	O
EJC	B-Complex
proteins	O
MAGOH	O
,	O
Y14	O
and	O
eIF4AIII	O
provide	O
a	O
composite	O
binding	O
site	O
for	O
UPF3b	O
that	O
serves	O
as	O
a	O
bridge	O
to	O
UPF2	O
and	O
UPF1	O
.	O

In	O
the	O
UPF	B-Complex
trimeric	O
complex	O
,	O
UPF2	O
and	O
UPF3b	O
cooperatively	O
stimulate	O
both	O
ATPase	O
and	O
RNA	O
helicase	O
activities	O
of	O
UPF1	O
.	O

This	O
work	O
demonstrates	O
that	O
the	O
EJC	B-Complex
core	O
is	O
sufficient	O
to	O
stably	O
anchor	O
the	O
UPF	B-Complex
proteins	O
to	O
mRNA	O
and	O
provides	O
insights	O
into	O
the	O
regulation	O
of	O
its	O
central	O
effector	O
,	O
UPF1	O
.	O

Our	O
SPR	O
data	O
have	O
established	O
the	O
stoichiometry	O
of	O
the	O
Dr	O
adhesin	O
/	O
N	O
-	O
CEA	O
complex	O
to	O
be	O
1	O
:	O
1	O
.	O

Based	O
on	O
the	O
chemical	O
shift	O
perturbation	O
data	O
combined	O
with	O
available	O
mutagenesis	O
data	O
,	O
an	O
initial	O
model	O
of	O
a	O
1	O
:	O
1	O
complex	O
was	O
constructed	O
by	O
the	O
HADDOCK	O
approach	O
using	O
the	O
solution	O
structure	O
of	O
AfaE	O
-	O
dsc	O
and	O
the	O
crystal	O
structure	O
of	O
N	O
-	O
CEA	O
(	O
this	O
study	O
)	O
.	O

Using	O
this	O
model	O
,	O
N	O
-	O
CEA	O
residue	O
positions	O
were	O
chosen	O
for	O
mutation	O
to	O
cysteine	O
and	O
subsequent	O
coupling	O
to	O
either	O
a	O
paramagnetic	O
or	O
diamagnetic	O
label	O
.	O

NMR	O
PRE	O
data	O
were	O
recorded	O
for	O
each	O
mutant	O
separately	O
,	O
yielding	O
a	O
total	O
of	O
46	O
resonances	O
demonstrating	O
significant	O
paramagnetic	O
effects	O
in	O
AfaE	O
-	O
dsc	O
.	O

PRE	O
effects	O
were	O
introduced	O
into	O
the	O
structure	O
calculation	O
as	O
distance	O
restraints	O
with	O
+	O
/	O
-	O
4	O
Aa	O
error	O
.	O

To	O
check	O
for	O
non	O
-	O
specific	O
binding	O
effects	O
,	O
a	O
control	O
mutant	O
(	O
V20C	O
)	O
was	O
chosen	O
that	O
was	O
located	O
over	O
25	O
Aa	O
from	O
the	O
predicted	O
binding	O
surface	O
.	O

No	O
paramagnetic	O
effects	O
were	O
observed	O
in	O
the	O
V20C	O
complex	O
.	O

Interestingly	O
,	O
a	O
further	O
mutant	O
,	O
L95C	O
,	O
displayed	O
severely	O
reduced	O
affinity	O
for	O
N	O
-	O
CEA	O
(	O
Table	O
II	O
)	O
and	O
yielded	O
a	O
complex	O
undergoing	O
exchange	O
in	O
the	O
fast	O
limit	O
.	O

Distances	O
from	O
this	O
mutant	O
were	O
not	O
included	O
in	O
the	O
structure	O
calculation	O
as	O
this	O
residue	O
was	O
presumed	O
to	O
form	O
part	O
of	O
the	O
interaction	O
surface	O
of	O
CEA	O
,	O
but	O
it	O
served	O
to	O
support	O
the	O
resulting	O
structural	O
ensemble	O
.	O

Drugs	O
affecting	O
prelamin	O
A	O
processing	O
:	O
effects	O
on	O
heterochromatin	O
organization	O
.	O

Increasing	O
interest	O
in	O
drugs	O
acting	O
on	O
prelamin	O
A	O
has	O
derived	O
from	O
the	O
finding	O
of	O
prelamin	O
A	O
involvement	O
in	O
severe	O
laminopathies	O
.	O

Amelioration	O
of	O
the	O
nuclear	O
morphology	O
by	O
inhibitors	O
of	O
prelamin	O
A	O
farnesylation	O
has	O
been	O
widely	O
reported	O
in	O
progeroid	O
laminopathies	O
.	O

We	O
investigated	O
the	O
effects	O
on	O
chromatin	O
organization	O
of	O
two	O
drugs	O
inhibiting	O
prelamin	O
A	O
processing	O
by	O
an	O
ultrastructural	O
and	O
biochemical	O
approach	O
.	O

The	O
farnesyltransferase	B-OOS
inhibitor	O
FTI	O
-	O
277	O
and	O
the	O
non	O
-	O
peptidomimetic	O
drug	O
N	O
-	O
acetyl	O
-	O
S	O
-	O
farnesyl	O
-	O
l	O
-	O
cysteine	O
methylester	O
(	O
AFCMe	O
)	O
were	O
administered	O
to	O
cultured	O
control	O
human	O
fibroblasts	O
for	O
6	O
or	O
18	O
h	O
.	O

FTI	O
-	O
277	O
interferes	O
with	O
protein	O
farnesylation	O
causing	O
accumulation	O
of	O
non	O
-	O
farnesylated	O
prelamin	O
A	O
,	O
while	O
AFCMe	O
impairs	O
the	O
last	O
cleavage	O
of	O
the	O
lamin	O
A	O
precursor	O
and	O
is	O
expected	O
to	O
accumulate	O
farnesylated	O
prelamin	O
A	O
.	O

FTI	O
-	O
277	O
caused	O
redistribution	O
of	O
heterochromatin	O
domains	O
at	O
the	O
nuclear	O
interior	O
,	O
while	O
AFCMe	O
caused	O
loss	O
of	O
heterochromatin	O
domains	O
,	O
increase	O
of	O
nuclear	O
size	O
and	O
nuclear	O
lamina	O
thickening	O
.	O

At	O
the	O
biochemical	O
level	O
,	O
heterochromatin	O
-	O
associated	O
proteins	O
and	O
LAP2	O
alpha	O
were	O
clustered	O
at	O
the	O
nuclear	O
interior	O
following	O
FTI	O
-	O
277	O
treatment	O
,	O
while	O
they	O
were	O
unevenly	O
distributed	O
or	O
absent	O
in	O
AFCMe	O
-	O
treated	O
nuclei	O
.	O

The	O
reported	O
effects	O
show	O
that	O
chromatin	O
is	O
an	O
immediate	O
target	O
of	O
FTI	O
-	O
277	O
and	O
AFCMe	O
and	O
that	O
dramatic	O
remodeling	O
of	O
chromatin	O
domains	O
occurs	O
following	O
treatment	O
with	O
the	O
drugs	O
.	O

These	O
effects	O
appear	O
to	O
depend	O
,	O
at	O
least	O
in	O
part	O
,	O
on	O
the	O
accumulation	O
of	O
prelamin	O
A	O
forms	O
,	O
since	O
impairment	O
of	O
prelamin	O
A	O
accumulation	O
,	O
here	O
obtained	O
by	O
5	O
-	O
azadeoxycytidine	O
treatment	O
,	O
abolishes	O
the	O
chromatin	O
effects	O
.	O

These	O
results	O
may	O
be	O
used	O
to	O
evaluate	O
downstream	O
effects	O
of	O
FTIs	O
or	O
other	O
prelamin	O
A	O
inhibitors	O
potentially	O
useful	O
for	O
the	O
therapy	O
of	O
laminopathies	O
.	O

Fbx8	O
makes	O
Arf6	O
refractory	O
to	O
function	O
via	O
ubiquitination	O
.	O

The	O
small	O
GTP	O
-	O
binding	O
protein	O
Arf6	O
regulates	O
membrane	O
remodeling	O
at	O
cell	O
peripheries	O
and	O
plays	O
crucial	O
roles	O
in	O
higher	O
orders	O
of	O
cellular	O
functions	O
including	O
tumor	O
invasion	O
.	O

Here	O
we	O
show	O
that	O
Fbx8	O
,	O
an	O
F	O
-	O
box	O
protein	O
bearing	O
the	O
Sec7	O
domain	O
,	O
mediates	O
ubiquitination	O
of	O
Arf6	O
.	O

This	O
ubiquitination	O
did	O
not	O
appear	O
to	O
be	O
linked	O
to	O
immediate	O
proteasomal	O
degradation	O
of	O
Arf6	O
,	O
whereas	O
Fbx8	O
knockdown	O
caused	O
hyperactivation	O
of	O
Arf6	O
.	O

Expression	O
of	O
Fbx8	O
protein	O
was	O
substantially	O
lost	O
in	O
several	O
breast	O
tumor	O
cell	O
lines	O
,	O
in	O
which	O
Arf6	O
activity	O
is	O
pivotal	O
for	O
their	O
invasion	O
.	O

Forced	O
expression	O
of	O
Fbx8	O
in	O
these	O
cells	O
suppressed	O
their	O
Arf6	O
activities	O
and	O
invasive	O
activities	O
,	O
in	O
which	O
the	O
F	O
-	O
box	O
and	O
Sec7	O
domains	O
of	O
Fbx8	O
are	O
required	O
.	O

Together	O
with	O
the	O
possible	O
mechanism	O
as	O
to	O
how	O
Fbx8	O
-	O
mediated	O
ubiquitination	O
interferes	O
with	O
the	O
functions	O
of	O
Arf6	O
,	O
we	O
propose	O
that	O
Fbx8	O
provides	O
a	O
novel	O
suppressive	O
control	O
of	O
Arf6	O
activity	O
through	O
noncanonical	O
ubiquitination	O
.	O

Our	O
results	O
indicate	O
that	O
dysfunction	O
of	O
Fbx8	O
expression	O
may	O
contribute	O
to	O
the	O
invasiveness	O
of	O
some	O
breast	O
cancer	O
cells	O
.	O

Wnt	O
signaling	O
requires	O
retromer	B-Complex
-	O
dependent	O
recycling	O
of	O
MIG	O
-	O
14	O
/	O
Wntless	O
in	O
Wnt	O
-	O
producing	O
cells	O
.	O

Wnt	O
proteins	O
are	O
secreted	O
signaling	O
molecules	O
that	O
play	O
a	O
central	O
role	O
in	O
development	O
and	O
adult	O
tissue	O
homeostasis	O
.	O

We	O
have	O
previously	O
shown	O
that	O
Wnt	O
signaling	O
requires	O
retromer	B-Complex
function	O
in	O
Wnt	O
-	O
producing	O
cells	O
.	O

The	O
retromer	B-Complex
is	O
a	O
multiprotein	O
complex	O
that	O
mediates	O
endosome	O
-	O
to	O
-	O
Golgi	O
transport	O
of	O
specific	O
sorting	O
receptors	O
.	O

MIG	O
-	O
14	O
/	O
Wls	O
is	O
a	O
conserved	O
transmembrane	O
protein	O
that	O
binds	O
Wnt	O
and	O
is	O
required	O
in	O
Wnt	O
-	O
producing	O
cells	O
for	O
Wnt	O
secretion	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
in	O
the	O
absence	O
of	O
retromer	B-Complex
function	O
,	O
MIG	O
-	O
14	O
/	O
Wls	O
is	O
degraded	O
in	O
lysosomes	O
and	O
becomes	O
limiting	O
for	O
Wnt	O
signaling	O
.	O

We	O
show	O
that	O
retromer	B-Complex
-	O
dependent	O
recycling	O
of	O
MIG	O
-	O
14	O
/	O
Wls	O
is	O
part	O
of	O
a	O
trafficking	O
pathway	O
that	O
retrieves	O
MIG	O
-	O
14	O
/	O
Wls	O
from	O
the	O
plasma	O
membrane	O
.	O

We	O
propose	O
that	O
MIG	O
-	O
14	O
/	O
Wls	O
cycles	O
between	O
the	O
Golgi	O
and	O
the	O
plasma	O
membrane	O
to	O
mediate	O
Wnt	O
secretion	O
.	O

Regulation	O
of	O
this	O
transport	O
pathway	O
may	O
enable	O
Wnt	O
-	O
producing	O
cells	O
to	O
control	O
the	O
range	O
of	O
Wnt	O
signaling	O
in	O
the	O
tissue	O
.	O

These	O
studies	O
raise	O
an	O
interesting	O
question	O
of	O
whether	O
the	O
two	O
paxillin	O
-	O
binding	O
sites	O
of	O
FAK	O
are	O
simply	O
redundant	O
interaction	O
surfaces	O
that	O
strengthen	O
the	O
association	O
between	O
these	O
two	O
proteins	O
,	O
or	O
alternatively	O
,	O
whether	O
paxillin	O
binding	O
to	O
each	O
site	O
might	O
mediate	O
a	O
distinct	O
function	O
.	O

To	O
address	O
these	O
important	O
questions	O
,	O
site	O
-	O
directed	O
mutagenesis	O
was	O
used	O
to	O
disrupt	O
binding	O
to	O
the	O
alpha	O
-	O
helix	O
2	O
/	O
3	O
paxillin	O
-	O
binding	O
site	O
(	O
E949A	O
/	O
K956A	O
/	O
R963A	O
or	O
EKR	O
)	O
or	O
to	O
the	O
alpha	O
-	O
helix	O
1	O
/	O
4	O
paxillin	O
-	O
binding	O
site	O
(	O
I937A	O
)	O
.	O

Combining	O
these	O
mutations	O
together	O
(	O
E949A	O
/	O
K956A	O
/	O
R963A	O
/	O
I937A	O
or	O
EKR	O
/	O
I937A	O
)	O
completely	O
abolished	O
paxillin	O
binding	O
as	O
demonstrated	O
in	O
vitro	O
by	O
GST	O
pulldown	O
and	O
in	O
vivo	O
by	O
co	O
-	O
immunoprecipitation	O
as	O
previously	O
reported	O
.	O

These	O
mutants	O
have	O
been	O
characterized	O
to	O
determine	O
the	O
role	O
of	O
paxillin	O
binding	O
to	O
each	O
site	O
individually	O
in	O
the	O
regulation	O
of	O
FAK	O
.	O

Trafficking	O
and	O
postsecretory	O
events	O
responsible	O
for	O
the	O
formation	O
of	O
secreted	O
human	O
salivary	O
peptides	O
:	O
a	O
proteomics	O
approach	O
.	O

To	O
elucidate	O
the	O
localization	O
of	O
post	O
-	O
translational	O
modifications	O
of	O
different	O
classes	O
of	O
human	O
salivary	O
proteins	O
and	O
peptides	O
(	O
acidic	O
and	O
basic	O
proline	O
-	O
rich	O
proteins	O
(	O
PRPs	O
)	O
,	O
Histatins	O
,	O
Statherin	O
,	O
P	O
-	O
B	O
peptide	O
,	O
and	O
"	O
S	O
type	O
"	O
Cystatins	O
)	O
a	O
comparative	O
reversed	O
phase	O
HPLC	O
-	O
ESI	O
-	O
MS	O
analysis	O
on	O
intact	O
proteins	O
of	O
enriched	O
granule	O
preparations	O
from	O
parotid	O
and	O
submandibular	O
glands	O
as	O
well	O
as	O
parotid	O
,	O
submandibular	O
/	O
sublingual	O
(	O
Sm	O
/	O
Sl	O
)	O
,	O
and	O
whole	O
saliva	O
was	O
performed	O
.	O

The	O
main	O
results	O
of	O
this	O
study	O
indicate	O
the	O
following	O
.	O

(	O
i	O
)	O
Phosphorylation	O
of	O
all	O
salivary	O
peptides	O
,	O
sulfation	O
of	O
Histatin	O
1	O
,	O
proteolytic	O
cleavages	O
of	O
acidic	O
and	O
precursor	O
basic	O
PRPs	O
occur	O
before	O
granule	O
storage	O
.	O

(	O
ii	O
)	O
In	O
agreement	O
with	O
previous	O
studies	O
,	O
basic	O
PRPs	O
are	O
secreted	O
by	O
the	O
parotid	O
gland	O
only	O
,	O
whereas	O
all	O
isoforms	O
of	O
acidic	O
PRPs	O
(	O
aPRPs	O
)	O
are	O
secreted	O
by	O
both	O
parotid	O
and	O
Sm	O
/	O
Sl	O
glands	O
.	O

(	O
iii	O
)	O
Phosphorylation	O
levels	O
of	O
aPRPs	O
,	O
Histatin	O
1	O
,	O
and	O
Statherin	O
are	O
higher	O
in	O
the	O
parotid	O
gland	O
,	O
whereas	O
the	O
extent	O
of	O
cleavage	O
of	O
aPRP	O
is	O
higher	O
in	O
Sm	O
/	O
Sl	O
glands	O
.	O

(	O
iv	O
)	O
O	O
-	O
Sulfation	O
of	O
tyrosines	O
of	O
Histatin	O
1	O
is	O
a	O
post	O
-	O
translational	O
modification	O
specific	O
for	O
the	O
submandibular	O
gland	O
.	O

(	O
v	O
)	O
The	O
concentration	O
of	O
Histatin	O
3	O
,	O
Histatin	O
5	O
,	O
and	O
Histatin	O
6	O
,	O
but	O
not	O
Histatin	O
1	O
,	O
is	O
higher	O
in	O
parotid	O
saliva	O
.	O

(	O
vi	O
)	O
Histatin	O
3	O
is	O
submitted	O
to	O
the	O
first	O
proteolytic	O
cleavage	O
(	O
generating	O
Histatins	O
6	O
and	O
5	O
)	O
during	O
granule	O
maturation	O
,	O
and	O
it	O
occurs	O
to	O
the	O
same	O
relative	O
extent	O
in	O
both	O
glands	O
.	O

(	O
vii	O
)	O
The	O
proteolytic	O
cleavages	O
of	O
Histatin	O
5	O
and	O
6	O
,	O
generating	O
a	O
cascade	O
of	O
Histatin	O
3	O
fragments	O
,	O
take	O
place	O
after	O
granule	O
secretion	O
and	O
are	O
more	O
extensive	O
in	O
parotid	O
secretion	O
.	O

(	O
viii	O
)	O
Basic	O
PRPs	O
are	O
cleaved	O
in	O
the	O
oral	O
cavity	O
by	O
unknown	O
peptidases	O
,	O
generating	O
various	O
small	O
proline	O
-	O
rich	O
peptides	O
.	O

(	O
ix	O
)	O
C	O
-	O
terminal	O
removal	O
from	O
Statherin	O
is	O
more	O
extensive	O
in	O
parotid	O
saliva	O
.	O

(	O
x	O
)	O
P	O
-	O
B	O
peptide	O
is	O
secreted	O
by	O
both	O
glands	O
,	O
and	O
its	O
relative	O
quantity	O
is	O
higher	O
in	O
submandibular	O
/	O
sublingual	O
secretion	O
.	O

(	O
xi	O
)	O
In	O
agreement	O
with	O
previous	O
studies	O
,	O
S	O
type	O
Cystatins	O
are	O
mainly	O
the	O
product	O
of	O
Sm	O
/	O
Sl	O
glands	O
.	O

Distinct	O
chromatin	O
modulators	O
regulate	O
the	O
formation	O
of	O
accessible	O
and	O
repressive	O
chromatin	O
at	O
the	O
fission	O
yeast	O
recombination	O
hotspot	O
ade6	O
-	O
M26	O
.	O

Histone	O
acetyltransferases	O
(	O
HATs	O
)	O
and	O
ATP	O
-	O
dependent	O
chromatin	O
remodeling	O
factors	O
(	O
ADCRs	O
)	O
regulate	O
transcription	O
and	O
recombination	O
via	O
alteration	O
of	O
local	O
chromatin	O
configuration	O
.	O

The	O
ade6	O
-	O
M26	O
allele	O
of	O
Schizosaccharomyces	O
pombe	O
creates	O
a	O
meiotic	O
recombination	O
hotspot	O
that	O
requires	O
a	O
cAMP	O
-	O
responsive	O
element	O
(	O
CRE	O
)	O
-	O
like	O
sequence	O
M26	O
,	O
the	O
Atf1	O
/	O
Pcr1	O
heterodimeric	O
ATF	O
/	O
CREB	O
transcription	O
factor	O
,	O
the	O
Gcn5	O
HAT	O
,	O
and	O
the	O
Snf22	O
SWI2	B-OOS
/	I-OOS
SNF2	I-OOS
family	O
ADCR	O
.	O

Chromatin	O
alteration	O
occurs	O
meiotically	O
around	O
M26	O
,	O
leading	O
to	O
the	O
activation	O
of	O
meiotic	O
recombination	O
.	O

We	O
newly	O
report	O
the	O
roles	O
of	O
other	O
chromatin	O
remodeling	O
factors	O
that	O
function	O
positively	O
and	O
negatively	O
in	O
chromatin	O
alteration	O
at	O
M26	O
:	O
two	O
CHD	O
-	O
1	O
family	O
ADCRs	O
(	O
Hrp1	O
and	O
Hrp3	O
)	O
,	O
a	O
Spt	O
-	O
Ada	O
-	O
Gcn5	O
acetyltransferase	O
component	O
(	O
Ada2	O
)	O
,	O
and	O
a	O
member	O
of	O
Moz	O
-	O
Ybf2	O
/	O
Sas3	O
-	O
Sas2	O
-	O
Tip60	O
family	O
(	O
Mst2	O
)	O
.	O

Ada2	O
,	O
Mst2	O
,	O
and	O
Hrp3	O
are	O
required	O
for	O
the	O
full	O
activation	O
of	O
chromatin	O
changes	O
around	O
M26	O
and	O
meiotic	O
recombination	O
.	O

Acetylation	O
of	O
histone	O
H3	O
around	O
M26	O
is	O
remarkably	O
reduced	O
in	O
gcn5Delta	O
,	O
ada2Delta	O
and	O
snf22Delta	O
,	O
suggesting	O
cooperative	O
functions	O
of	O
these	O
HAT	O
complexes	O
and	O
Snf22	O
.	O

Conversely	O
,	O
Hrp1	O
,	O
another	O
CHD	O
-	O
1	O
family	O
ADCR	O
,	O
maintains	O
repressive	O
chromatin	O
configuration	O
at	O
ade6	O
-	O
M26	O
.	O

Interestingly	O
,	O
transcriptional	O
initiation	O
site	O
is	O
shifted	O
to	O
a	O
site	O
around	O
M26	O
from	O
the	O
original	O
initiation	O
sites	O
,	O
in	O
couple	O
with	O
the	O
histone	O
acetylation	O
and	O
meiotic	O
chromatin	O
alteration	O
induced	O
around	O
3	O
'	O
region	O
of	O
M26	O
,	O
suggesting	O
a	O
collaboration	O
between	O
these	O
chromatin	O
modulators	O
and	O
the	O
transcriptional	O
machinery	O
to	O
form	O
accessible	O
chromatin	O
.	O

These	O
HATs	O
and	O
ADCRs	O
are	O
also	O
required	O
for	O
the	O
regulation	O
of	O
transcription	O
and	O
chromatin	O
structure	O
around	O
M26	O
in	O
response	O
to	O
osmotic	O
stress	O
.	O

Thus	O
,	O
we	O
propose	O
that	O
multiple	O
chromatin	O
modulators	O
regulate	O
chromatin	O
structure	O
reversibly	O
and	O
participate	O
in	O
the	O
regulation	O
of	O
both	O
meiotic	O
recombination	O
and	O
stress	O
-	O
induced	O
transcription	O
around	O
CRE	O
-	O
like	O
sequences	O
.	O

Functional	O
and	O
structural	O
roles	O
of	O
conserved	O
cysteine	O
residues	O
in	O
the	O
carboxyl	O
-	O
terminal	O
domain	O
of	O
the	O
follicle	O
-	O
stimulating	O
hormone	O
receptor	O
in	O
human	O
embryonic	O
kidney	O
293	O
cells	O
.	O

The	O
carboxyl	O
-	O
terminal	O
segment	O
of	O
G	O
protein	O
-	O
coupled	O
receptors	O
has	O
one	O
or	O
more	O
conserved	O
cysteine	O
residues	O
that	O
are	O
potential	O
sites	O
for	O
palmitoylation	O
.	O

This	O
posttranslational	O
modification	O
contributes	O
to	O
membrane	O
association	O
,	O
internalization	O
,	O
and	O
membrane	O
targeting	O
of	O
proteins	O
.	O

In	O
contrast	O
to	O
other	O
members	O
of	O
the	O
glycoprotein	O
hormone	O
receptor	O
family	O
(	O
the	O
LH	O
and	O
thyroid	O
-	O
stimulating	O
hormone	O
receptors	O
)	O
,	O
it	O
is	O
not	O
known	O
whether	O
the	O
follicle	O
-	O
stimulating	O
hormone	O
receptor	O
(	O
FSHR	O
)	O
is	O
palmitoylated	O
and	O
what	O
are	O
the	O
effects	O
of	O
abolishing	O
its	O
potential	O
palmitoylation	O
sites	O
.	O

In	O
the	O
present	O
study	O
,	O
a	O
functional	O
analysis	O
of	O
the	O
FSHR	O
carboxyl	O
-	O
terminal	O
segment	O
cysteine	O
residues	O
was	O
carried	O
out	O
.	O

We	O
constructed	O
a	O
series	O
of	O
mutant	O
FSHRs	O
by	O
substituting	O
cysteine	O
residues	O
with	O
alanine	O
,	O
serine	O
,	O
or	O
threonine	O
individually	O
and	O
together	O
at	O
positions	O
629	O
and	O
655	O
(	O
conserved	O
cysteines	O
)	O
and	O
627	O
(	O
nonconserved	O
)	O
.	O

The	O
results	O
showed	O
that	O
all	O
three	O
cysteine	O
residues	O
are	O
palmitoylated	O
but	O
that	O
only	O
modification	O
at	O
Cys629	O
is	O
functionally	O
relevant	O
.	O

The	O
lack	O
of	O
palmitoylation	O
does	O
not	O
appear	O
to	O
greatly	O
impair	O
coupling	O
to	O
G	O
(	O
s	O
)	O
but	O
,	O
when	O
absent	O
at	O
position	O
629	O
,	O
does	O
significantly	O
impair	O
cell	O
surface	O
membrane	O
expression	O
of	O
the	O
partially	O
palmitoylated	O
receptor	O
.	O

All	O
FSHR	O
Cys	O
mutants	O
were	O
capable	O
of	O
binding	O
agonist	O
with	O
the	O
same	O
affinity	O
as	O
the	O
wild	O
-	O
type	O
receptor	O
and	O
internalizing	O
on	O
agonist	O
stimulation	O
.	O

Molecular	O
dynamics	O
simulations	O
at	O
a	O
time	O
scale	O
of	O
approximately	O
100	O
nsec	O
revealed	O
that	O
replacement	O
of	O
Cys629	O
resulted	O
in	O
structures	O
that	O
differed	O
significantly	O
from	O
that	O
of	O
the	O
wild	O
-	O
type	O
receptor	O
.	O

Thus	O
,	O
deviations	O
from	O
wild	O
-	O
type	O
conformation	O
may	O
potentially	O
contribute	O
to	O
the	O
severe	O
impairment	O
in	O
plasma	O
membrane	O
expression	O
and	O
the	O
modest	O
effects	O
on	O
signaling	O
exhibited	O
by	O
the	O
receptors	O
modified	O
in	O
this	O
particular	O
position	O
.	O

Specific	O
ion	O
influences	O
on	O
self	O
-	O
association	O
of	O
pyruvate	O
dehydrogenase	O
kinase	O
isoform	O
2	O
(	O
PDHK2	O
)	O
,	O
binding	O
of	O
PDHK2	O
to	O
the	O
L2	O
lipoyl	O
domain	O
,	O
and	O
effects	O
of	O
the	O
lipoyl	O
group	O
-	O
binding	O
site	O
inhibitor	O
,	O
Nov3r	O
.	O

Association	O
of	O
the	O
PDHK2	O
and	O
GST	O
-	O
L2	O
(	O
glutathione	O
-	O
S	O
-	O
transferase	O
fused	O
to	O
the	O
inner	O
lipoyl	O
domain	O
(	O
L2	O
)	O
of	O
dihydrolipoyl	B-OOS
acetyltransferase	I-OOS
(	O
E2	B-OOS
)	O
)	O
dimers	O
was	O
enhanced	O
by	O
K	O
+	O
with	O
higher	O
affinity	O
K	O
+	O
binding	O
than	O
occurs	O
at	O
the	O
PDHK2	O
active	O
site	O
.	O

Supporting	O
a	O
distinct	O
K	O
+	O
binding	O
site	O
,	O
the	O
NH4	O
+	O
ion	O
did	O
not	O
effectively	O
replace	O
K	O
+	O
in	O
aiding	O
GST	O
-	O
L2	O
binding	O
.	O

With	O
50	O
mM	O
K	O
+	O
,	O
Pi	O
enhanced	O
interference	O
by	O
ADP	O
,	O
ATP	O
,	O
or	O
pyruvate	O
of	O
PDHK2	O
binding	O
to	O
GST	O
-	O
L2	O
.	O

The	O
inclusion	O
of	O
Pi	O
with	O
ADP	O
or	O
ATP	O
plus	O
pyruvate	O
greatly	O
hindered	O
PDHK2	O
binding	O
to	O
GST	O
-	O
L2	O
and	O
promoted	O
PDHK2	O
forming	O
a	O
tetramer	O
.	O

Reciprocally	O
,	O
GST	O
-	O
L2	O
interference	O
with	O
ATP	O
/	O
ADP	O
binding	O
also	O
required	O
elevated	O
K	O
+	O
and	O
was	O
increased	O
by	O
Pi	O
.	O

Potent	O
inhibition	O
by	O
Nov3r	O
of	O
E2	B-OOS
-	O
activated	O
PDHK2	O
activity	O
(	O
IC50	O
of	O
approximately	O
7	O
.	O
8	O
nM	O
)	O
required	O
elevated	O
K	O
+	O
and	O
Pi	O
.	O

Nov3r	O
only	O
modestly	O
inhibited	O
the	O
low	O
activity	O
of	O
PDHK2	O
without	O
E2	B-OOS
.	O

By	O
binding	O
at	O
the	O
lipoyl	O
group	O
binding	O
site	O
,	O
Nov3r	O
prevented	O
PDHK2	O
binding	O
to	O
E2	B-OOS
and	O
GST	O
-	O
L2	O
.	O

Nov3r	O
interfered	O
with	O
high	O
-	O
affinity	O
binding	O
of	O
ADP	O
and	O
pyruvate	O
via	O
a	O
Pi	O
-	O
dependent	O
mechanism	O
.	O

Thus	O
,	O
GST	O
-	O
L2	O
binding	O
to	O
PDHK2	O
is	O
supported	O
by	O
K	O
+	O
binding	O
at	O
a	O
site	O
distinct	O
from	O
the	O
active	O
site	O
.	O

Pi	O
makes	O
major	O
contributions	O
to	O
ligands	O
interfering	O
with	O
PDHK2	O
binding	O
to	O
GST	O
-	O
L2	O
,	O
the	O
conversion	O
of	O
PDHK2	O
dimer	O
to	O
a	O
tetramer	O
,	O
and	O
Nov3r	O
(	O
an	O
acetyl	O
-	O
lipoate	O
analog	O
)	O
interfering	O
with	O
binding	O
of	O
ADP	O
and	O
pyruvate	O
.	O

Pi	O
is	O
suggested	O
to	O
facilitate	O
transmission	O
within	O
PDHK2	O
of	O
the	O
stimulatory	O
signal	O
of	O
acetylation	O
from	O
the	O
distal	O
lipoyl	O
-	O
group	O
binding	O
site	O
to	O
the	O
active	O
site	O
.	O

Our	O
study	O
on	O
the	O
growth	O
-	O
promoting	O
function	O
of	O
bunA	O
in	O
Drosophila	O
may	O
influence	O
the	O
perspective	O
on	O
the	O
mammalian	O
homologs	O
of	O
Bun	O
,	O
especially	O
on	O
TSC	O
-	O
22	O
(	O
TSC22D1	O
)	O
.	O

Whereas	O
the	O
longer	O
isoform	O
of	O
TSC	O
-	O
22	O
(	O
TSC22D1	O
.	O
1	O
)	O
is	O
similar	O
to	O
BunA	O
(	O
and	O
BunF	O
)	O
,	O
the	O
shorter	O
isoform	O
(	O
TSC22D1	O
.	O
2	O
)	O
resembles	O
BunB	O
,	O
BunD	O
,	O
and	O
BunE	O
.	O

Data	O
from	O
numerous	O
studies	O
suggest	O
that	O
TSC22D1	O
.	O
2	O
acts	O
as	O
a	O
tumor	O
suppressor	O
,	O
which	O
is	O
at	O
odds	O
with	O
the	O
fact	O
that	O
only	O
bunA	O
is	O
involved	O
in	O
growth	O
regulation	O
in	O
Drosophila	O
,	O
and	O
that	O
BunA	O
behaves	O
rather	O
opposite	O
to	O
a	O
tumor	O
suppressor	O
.	O

The	O
results	O
from	O
our	O
in	O
vivo	O
analysis	O
may	O
be	O
of	O
special	O
interest	O
in	O
this	O
context	O
,	O
since	O
the	O
relative	O
balance	O
of	O
bun	O
transcripts	O
is	O
important	O
(	O
allelic	O
series	O
)	O
and	O
overexpression	O
of	O
bunC	O
(	O
and	O
also	O
bunB	O
)	O
interferes	O
with	O
bunA	O
function	O
in	O
a	O
dominant	O
negative	O
manner	O
.	O

If	O
this	O
interaction	O
is	O
conserved	O
in	O
mammals	O
,	O
we	O
can	O
envision	O
the	O
following	O
scenario	O
for	O
how	O
the	O
TSC	O
-	O
22	O
locus	O
may	O
be	O
involved	O
in	O
tumor	O
suppression	O
.	O

Whereas	O
the	O
long	O
TSC	O
-	O
22	O
isoform	O
,	O
TSC22D1	O
.	O
1	O
,	O
positively	O
regulates	O
cellular	O
growth	O
(	O
as	O
does	O
BunA	O
)	O
,	O
the	O
short	O
isoform	O
,	O
TSC22D1	O
.	O
2	O
,	O
inhibits	O
growth	O
by	O
competing	O
with	O
TSC22D1	O
.	O
1	O
.	O

The	O
antagonism	O
between	O
the	O
long	O
and	O
the	O
short	O
isoforms	O
can	O
be	O
achieved	O
at	O
several	O
levels	O
.	O

An	O
excess	O
of	O
the	O
short	O
isoform	O
could	O
lead	O
to	O
the	O
formation	O
of	O
non	O
-	O
functional	O
heterodimers	O
,	O
or	O
the	O
two	O
isoforms	O
could	O
compete	O
for	O
another	O
dimerization	O
partner	O
.	O

Provided	O
that	O
TSC	O
-	O
22	O
functions	O
in	O
transcriptional	O
regulation	O
,	O
the	O
two	O
isoforms	O
might	O
also	O
contribute	O
to	O
differential	O
regulation	O
of	O
target	O
genes	O
.	O

In	O
either	O
case	O
,	O
the	O
long	O
TSC	O
-	O
22	O
isoform	O
could	O
be	O
hyperactivated	O
as	O
a	O
consequence	O
of	O
the	O
loss	O
of	O
the	O
short	O
isoform	O
.	O

Thus	O
,	O
the	O
short	O
isoform	O
could	O
act	O
as	O
a	O
tumor	O
suppressor	O
by	O
keeping	O
the	O
long	O
isoform	O
in	O
check	O
.	O

Our	O
findings	O
should	O
encourage	O
further	O
studies	O
in	O
mammals	O
that	O
distinguish	O
between	O
the	O
TSC	O
-	O
22	O
isoforms	O
and	O
that	O
primarily	O
focus	O
on	O
the	O
function	O
of	O
the	O
long	O
TSC	O
-	O
22	O
protein	O
,	O
TSC22D1	O
.	O
1	O
.	O

Galectin	O
-	O
1	O
is	O
a	O
novel	O
structural	O
component	O
and	O
a	O
major	O
regulator	O
of	O
h	O
-	O
ras	O
nanoclusters	O
.	O

The	O
organization	O
of	O
Ras	O
proteins	O
into	O
nanoclusters	O
on	O
the	O
inner	O
plasma	O
membrane	O
is	O
essential	O
for	O
Ras	O
signal	O
transduction	O
,	O
but	O
the	O
mechanisms	O
that	O
drive	O
nanoclustering	O
are	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
epidermal	O
growth	O
factor	O
receptor	O
activation	O
stimulates	O
the	O
formation	O
of	O
H	O
-	O
Ras	O
.	O
GTP	O
-	O
Galectin	O
-	O
1	O
(	O
Gal	O
-	O
1	O
)	O
complexes	O
on	O
the	O
plasma	O
membrane	O
that	O
are	O
then	O
assembled	O
into	O
transient	O
nanoclusters	O
.	O

Gal	O
-	O
1	O
is	O
therefore	O
an	O
integral	O
structural	O
component	O
of	O
the	O
H	O
-	O
Ras	O
-	O
signaling	O
nanocluster	O
.	O

Increasing	O
Gal	O
-	O
1	O
levels	O
increases	O
the	O
stability	O
of	O
H	O
-	O
Ras	O
nanoclusters	O
,	O
leading	O
to	O
enhanced	O
effector	O
recruitment	O
and	O
signal	O
output	O
.	O

Elements	O
in	O
the	O
H	O
-	O
Ras	O
C	O
-	O
terminal	O
hypervariable	O
region	O
and	O
an	O
activated	O
G	O
-	O
domain	O
are	O
required	O
for	O
H	O
-	O
Ras	O
-	O
Gal	O
-	O
1	O
interaction	O
.	O

Palmitoylation	O
is	O
not	O
required	O
for	O
H	O
-	O
Ras	O
-	O
Gal	O
-	O
1	O
complex	O
formation	O
,	O
but	O
is	O
required	O
to	O
anchor	O
H	O
-	O
Ras	O
-	O
Gal	O
-	O
1	O
complexes	O
to	O
the	O
plasma	O
membrane	O
.	O

Our	O
data	O
suggest	O
a	O
mechanism	O
for	O
H	O
-	O
Ras	O
nanoclustering	O
that	O
involves	O
a	O
dual	O
role	O
for	O
Gal	O
-	O
1	O
as	O
a	O
critical	O
scaffolding	O
protein	O
and	O
a	O
molecular	O
chaperone	O
that	O
contributes	O
to	O
H	O
-	O
Ras	O
trafficking	O
by	O
returning	O
depalmitoylated	O
H	O
-	O
Ras	O
to	O
the	O
Golgi	O
complex	O
for	O
repalmitoylation	O
.	O

Heterozygous	O
screen	O
in	O
Saccharomyces	O
cerevisiae	O
identifies	O
dosage	O
-	O
sensitive	O
genes	O
that	O
affect	O
chromosome	O
stability	O
.	O

Current	O
techniques	O
for	O
identifying	O
mutations	O
that	O
convey	O
a	O
small	O
increased	O
cancer	O
risk	O
or	O
those	O
that	O
modify	O
cancer	O
risk	O
in	O
carriers	O
of	O
highly	O
penetrant	O
mutations	O
are	O
limited	O
by	O
the	O
statistical	O
power	O
of	O
epidemiologic	O
studies	O
,	O
which	O
require	O
screening	O
of	O
large	O
populations	O
and	O
candidate	O
genes	O
.	O

To	O
identify	O
dosage	O
-	O
sensitive	O
genes	O
that	O
mediate	O
genomic	O
stability	O
,	O
we	O
performed	O
a	O
genomewide	O
screen	O
in	O
Saccharomyces	O
cerevisiae	O
for	O
heterozygous	O
mutations	O
that	O
increase	O
chromosome	O
instability	O
in	O
a	O
checkpoint	O
-	O
deficient	O
diploid	O
strain	O
.	O

We	O
used	O
two	O
genome	O
stability	O
assays	O
sensitive	O
enough	O
to	O
detect	O
the	O
impact	O
of	O
heterozygous	O
mutations	O
and	O
identified	O
172	O
heterozygous	O
gene	O
disruptions	O
that	O
affected	O
chromosome	O
fragment	O
(	O
CF	O
)	O
loss	O
,	O
45	O
%	O
of	O
which	O
also	O
conferred	O
modest	O
but	O
statistically	O
significant	O
instability	O
of	O
endogenous	O
chromosomes	O
.	O

Analysis	O
of	O
heterozygous	O
deletion	O
of	O
65	O
of	O
these	O
genes	O
demonstrated	O
that	O
the	O
majority	O
increased	O
genomic	O
instability	O
in	O
both	O
checkpoint	O
-	O
deficient	O
and	O
wild	O
-	O
type	O
backgrounds	O
.	O

Strains	O
heterozygous	O
for	O
COMA	B-Complex
kinetochore	O
complex	O
genes	O
were	O
particularly	O
unstable	O
.	O

Over	O
50	O
%	O
of	O
the	O
genes	O
identified	O
in	O
this	O
screen	O
have	O
putative	O
human	O
homologs	O
,	O
including	O
CHEK2	O
,	O
ERCC4	O
,	O
and	O
TOPBP1	O
,	O
which	O
are	O
already	O
associated	O
with	O
inherited	O
cancer	O
susceptibility	O
.	O

These	O
findings	O
encourage	O
the	O
incorporation	O
of	O
this	O
orthologous	O
gene	O
list	O
into	O
cancer	O
epidemiology	O
studies	O
and	O
suggest	O
further	O
analysis	O
of	O
heterozygous	O
phenotypes	O
in	O
yeast	O
as	O
models	O
of	O
human	O
disease	O
resulting	O
from	O
haplo	O
-	O
insufficiency	O
.	O

Inhibition	O
of	O
endoplasmic	O
reticulum	O
stress	O
-	O
induced	O
apoptosis	O
of	O
melanoma	O
cells	O
by	O
the	O
ARC	O
protein	O
.	O

We	O
have	O
shown	O
previously	O
that	O
most	O
melanoma	O
cell	O
lines	O
are	O
insensitive	O
to	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
-	O
induced	O
apoptosis	O
,	O
but	O
resistance	O
can	O
be	O
reversed	O
through	O
activation	O
of	O
caspase	O
-	O
4	O
by	O
inhibition	O
of	O
the	O
MEK	O
/	O
ERK	O
pathway	O
.	O

We	O
report	O
in	O
this	O
study	O
that	O
apoptosis	O
was	O
induced	O
by	O
the	O
ER	O
stress	O
inducer	O
thapsigargin	O
or	O
tunicamycin	O
via	O
a	O
caspase	O
-	O
8	O
-	O
mediated	O
pathway	O
in	O
the	O
melanoma	O
cell	O
line	O
Me1007	O
,	O
although	O
the	O
MEK	O
/	O
ERK	O
pathway	O
was	O
activated	O
in	O
this	O
cell	O
line	O
.	O

The	O
high	O
sensitivity	O
of	O
Me1007	O
to	O
ER	O
stress	O
-	O
induced	O
apoptosis	O
was	O
associated	O
with	O
low	O
expression	O
levels	O
of	O
the	O
apoptosis	O
repressor	O
with	O
caspase	O
recruitment	O
domain	O
(	O
ARC	O
)	O
protein	O
that	O
was	O
expressed	O
at	O
relatively	O
high	O
levels	O
in	O
the	O
resistant	O
melanoma	O
cell	O
lines	O
.	O

Transfection	O
of	O
cDNA	O
encoding	O
ARC	O
into	O
Me1007	O
cells	O
inhibited	O
both	O
caspase	O
-	O
8	O
activation	O
and	O
apoptosis	O
induced	O
by	O
thapsigargin	O
or	O
tunicamycin	O
.	O

In	O
contrast	O
,	O
inhibition	O
of	O
ARC	O
by	O
small	O
interfering	O
RNA	O
knockdown	O
sensitized	O
the	O
resistant	O
melanoma	O
cell	O
lines	O
to	O
ER	O
stress	O
-	O
induced	O
apoptosis	O
,	O
which	O
was	O
inhibitable	O
by	O
blockage	O
of	O
caspase	O
-	O
8	O
activation	O
.	O

Both	O
exogenous	O
and	O
endogenous	O
ARC	O
seemed	O
to	O
predominantly	O
locate	O
to	O
the	O
cytoplasm	O
and	O
mitochondria	O
and	O
could	O
be	O
coimmunoprecipitated	O
with	O
caspase	O
-	O
8	O
.	O

Taken	O
together	O
,	O
ER	O
stress	O
can	O
potentially	O
activate	O
multiple	O
apoptosis	O
signaling	O
pathways	O
in	O
melanoma	O
cells	O
in	O
a	O
context	O
-	O
dependent	O
manner	O
.	O

Whereas	O
the	O
MEK	O
/	O
ERK	O
signaling	O
pathway	O
plays	O
an	O
important	O
role	O
in	O
inhibiting	O
ER	O
stress	O
-	O
induced	O
caspase	O
-	O
4	O
activation	O
,	O
ARC	O
seems	O
to	O
be	O
critical	O
in	O
blocking	O
activation	O
of	O
caspase	O
-	O
8	O
in	O
melanoma	O
cells	O
subjected	O
to	O
ER	O
stress	O
.	O

A	O
targeted	O
proteomic	O
analysis	O
of	O
the	O
ubiquitin	O
-	O
like	O
modifier	O
nedd8	O
and	O
associated	O
proteins	O
.	O

Nedd8	O
is	O
a	O
small	O
ubiquitin	O
-	O
like	O
protein	O
that	O
can	O
be	O
conjugated	O
to	O
substrate	O
-	O
proteins	O
in	O
a	O
process	O
known	O
as	O
neddylation	O
.	O

Although	O
neddylation	O
plays	O
a	O
critical	O
regulatory	O
role	O
in	O
cell	O
proliferation	O
and	O
development	O
,	O
the	O
spectrum	O
of	O
Nedd8	O
substrates	O
and	O
its	O
interaction	O
network	O
remain	O
poorly	O
understood	O
.	O

To	O
explore	O
the	O
neddylation	O
pathway	O
at	O
the	O
proteome	O
level	O
,	O
we	O
have	O
affinity	O
purified	O
Nedd8	O
modified	O
and	O
associated	O
proteins	O
from	O
HEK293	O
cells	O
stably	O
expressing	O
GST	O
-	O
Nedd8	O
and	O
employed	O
LC	O
-	O
MS	O
/	O
MS	O
for	O
subsequent	O
protein	O
identification	O
.	O

A	O
total	O
of	O
496	O
GST	O
-	O
Nedd8	O
modified	O
and	O
associated	O
proteins	O
have	O
been	O
identified	O
,	O
including	O
all	O
of	O
the	O
eight	O
cullin	O
family	O
members	O
(	O
i	O
.	O
e	O
.	O
,	O
Cul	O
-	O
1	O
,	O
-	O
2	O
,	O
-	O
3	O
,	O
-	O
4A	O
,	O
-	O
4B	O
,	O
-	O
5	O
,	O
-	O
7	O
,	O
and	O
Parc	O
)	O
that	O
are	O
involved	O
in	O
the	O
neddylation	O
and	O
ubiquitin	O
-	O
proteasome	B-Complex
degradation	O
pathway	O
.	O

In	O
addition	O
,	O
a	O
group	O
of	O
proteins	O
involved	O
in	O
transcription	O
,	O
DNA	O
repair	O
and	O
replication	O
,	O
cell	O
cycle	O
regulation	O
and	O
chromatin	O
organization	O
,	O
and	O
remodeling	O
have	O
been	O
copurified	O
and	O
identified	O
.	O

Apart	O
from	O
protein	O
identification	O
,	O
the	O
neddylation	O
sites	O
of	O
cullins	O
were	O
determined	O
by	O
MS	O
/	O
MS	O
analysis	O
,	O
which	O
agree	O
well	O
with	O
previous	O
mutagenesis	O
studies	O
.	O

Furthermore	O
,	O
MS	O
analyses	O
revealed	O
that	O
Nedd8	O
K11	O
,	O
K22	O
,	O
K48	O
,	O
and	O
K60	O
can	O
form	O
chains	O
in	O
vivo	O
,	O
whereas	O
Nedd8	O
K22	O
and	O
K48	O
can	O
be	O
neddylated	O
in	O
vitro	O
.	O

These	O
results	O
present	O
the	O
first	O
molecular	O
evidence	O
for	O
in	O
vitro	O
and	O
in	O
vivo	O
polyneddylation	O
,	O
suggesting	O
that	O
chain	O
formation	O
of	O
ubiquitin	O
and	O
ubiquitin	O
-	O
like	O
proteins	O
may	O
be	O
a	O
general	O
phenomenon	O
for	O
these	O
modifications	O
.	O

Although	O
much	O
remains	O
to	O
be	O
explored	O
for	O
the	O
biological	O
significance	O
of	O
the	O
observations	O
,	O
this	O
work	O
provides	O
critically	O
important	O
information	O
regarding	O
Nedd8	O
chain	O
assembly	O
and	O
its	O
interaction	O
network	O
.	O

The	O
vast	O
amount	O
of	O
proteomic	O
information	O
obtained	O
here	O
can	O
provide	O
clues	O
on	O
the	O
biological	O
role	O
of	O
Nedd8	O
and	O
lay	O
the	O
foundation	O
for	O
an	O
in	O
-	O
depth	O
analysis	O
of	O
the	O
regulation	O
of	O
the	O
Nedd8	O
pathway	O
.	O

The	O
Ser	O
(	O
186	O
)	O
phospho	O
-	O
acceptor	O
site	O
within	O
ERK4	O
is	O
essential	O
for	O
its	O
ability	O
to	O
interact	O
with	O
and	O
activate	O
PRAK	O
/	O
MK5	O
.	O

ERK	O
(	O
extracellular	O
-	O
signal	O
-	O
regulated	O
kinase	O
)	O
4	O
[	O
MAPK	O
(	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
)	O
4	O
]	O
and	O
ERK3	O
(	O
MAPK6	O
)	O
are	O
atypical	O
MAPKs	O
.	O

One	O
major	O
difference	O
between	O
these	O
proteins	O
and	O
the	O
classical	O
MAPKs	O
is	O
substitution	O
of	O
the	O
conserved	O
T	O
-	O
X	O
-	O
Y	O
motif	O
within	O
the	O
activation	O
loop	O
by	O
a	O
single	O
phospho	O
-	O
acceptor	O
site	O
within	O
an	O
S	O
-	O
E	O
-	O
G	O
motif	O
.	O

In	O
the	O
present	O
study	O
we	O
report	O
that	O
Ser	O
(	O
186	O
)	O
of	O
the	O
S	O
-	O
E	O
-	O
G	O
motif	O
in	O
ERK4	O
is	O
phosphorylated	O
in	O
vivo	O
.	O

Kinase	O
-	O
dead	O
ERK4	O
is	O
also	O
phosphorylated	O
on	O
Ser	O
(	O
186	O
)	O
,	O
indicating	O
that	O
an	O
ERK4	O
kinase	O
,	O
rather	O
than	O
autophosphorylation	O
,	O
is	O
responsible	O
.	O

Co	O
-	O
expression	O
of	O
MK5	O
[	O
MAPK	O
-	O
activated	O
protein	O
kinase	O
5	O
;	O
also	O
known	O
as	O
PRAK	O
(	O
p38	O
-	O
regulated	O
/	O
activated	O
kinase	O
)	O
]	O
,	O
a	O
physiological	O
target	O
of	O
ERK4	O
,	O
increases	O
phosphorylation	O
of	O
Ser	O
(	O
186	O
)	O
.	O

This	O
is	O
not	O
dependent	O
on	O
MK5	O
activity	O
,	O
but	O
does	O
require	O
interaction	O
between	O
ERK4	O
and	O
MK5	O
suggesting	O
that	O
MK5	O
binding	O
either	O
prevents	O
ERK4	O
dephosphorylation	O
or	O
facilitates	O
ERK4	O
kinase	O
activity	O
.	O

ERK4	O
mutants	O
in	O
which	O
Ser	O
(	O
186	O
)	O
is	O
replaced	O
with	O
either	O
an	O
alanine	O
residue	O
or	O
a	O
phospho	O
-	O
mimetic	O
residue	O
(	O
glutamate	O
)	O
are	O
unable	O
to	O
activate	O
MK5	O
and	O
Ser	O
(	O
186	O
)	O
is	O
also	O
required	O
for	O
cytoplasmic	O
anchoring	O
of	O
MK5	O
.	O

Both	O
defects	O
seem	O
to	O
reflect	O
an	O
impaired	O
ability	O
of	O
the	O
ERK4	O
mutants	O
to	O
interact	O
with	O
MK5	O
.	O

We	O
find	O
that	O
there	O
are	O
at	O
least	O
two	O
endogenous	O
pools	O
of	O
wild	O
-	O
type	O
ERK4	O
.	O

One	O
form	O
exhibits	O
reduced	O
mobility	O
when	O
analysed	O
using	O
SDS	O
/	O
PAGE	O
.	O

This	O
is	O
due	O
to	O
MK5	O
-	O
dependent	O
phosphorylation	O
and	O
only	O
this	O
retarded	O
ERK4	O
species	O
is	O
both	O
phosphorylated	O
on	O
Ser	O
(	O
186	O
)	O
and	O
co	O
-	O
immunoprecipitates	O
with	O
wild	O
-	O
type	O
MK5	O
.	O

We	O
conclude	O
that	O
binding	O
between	O
ERK4	O
and	O
MK5	O
facilitates	O
phosphorylation	O
of	O
Ser	O
(	O
186	O
)	O
and	O
stabilization	O
of	O
the	O
ERK4	O
-	O
MK5	O
complex	O
.	O

This	O
results	O
in	O
phosphorylation	O
and	O
activation	O
of	O
MK5	O
,	O
which	O
in	O
turn	O
phosphorylates	O
ERK4	O
on	O
sites	O
other	O
than	O
Ser	O
(	O
186	O
)	O
resulting	O
in	O
the	O
observed	O
mobility	O
shift	O
.	O

Fine	O
mapping	O
of	O
posttranslational	O
modifications	O
of	O
the	O
linker	O
histone	O
H1	O
from	O
Drosophila	O
melanogaster	O
.	O

The	O
linker	O
histone	O
H1	O
binds	O
to	O
the	O
DNA	O
in	O
between	O
adjacent	O
nucleosomes	O
and	O
contributes	O
to	O
chromatin	O
organization	O
and	O
transcriptional	O
control	O
.	O

It	O
is	O
known	O
that	O
H1	O
carries	O
diverse	O
posttranslational	O
modifications	O
(	O
PTMs	O
)	O
,	O
including	O
phosphorylation	O
,	O
lysine	O
methylation	O
and	O
ADP	O
-	O
ribosylation	O
.	O

Their	O
biological	O
functions	O
,	O
however	O
,	O
remain	O
largely	O
unclear	O
.	O

This	O
is	O
in	O
part	O
due	O
to	O
the	O
fact	O
that	O
most	O
of	O
the	O
studies	O
have	O
been	O
performed	O
in	O
organisms	O
that	O
have	O
several	O
H1	O
variants	O
,	O
which	O
complicates	O
the	O
analyses	O
.	O

We	O
have	O
chosen	O
Drosophila	O
melanogaster	O
,	O
a	O
model	O
organism	O
,	O
which	O
has	O
a	O
single	O
H1	O
variant	O
,	O
to	O
approach	O
the	O
study	O
of	O
the	O
role	O
of	O
H1	O
PTMs	O
during	O
embryonic	O
development	O
.	O

Mass	O
spectrometry	O
mapping	O
of	O
the	O
entire	O
sequence	O
of	O
the	O
protein	O
showed	O
phosphorylation	O
only	O
in	O
the	O
ten	O
N	O
-	O
terminal	O
amino	O
acids	O
,	O
mostly	O
at	O
S10	O
.	O

For	O
the	O
first	O
time	O
,	O
changes	O
in	O
the	O
PTMs	O
of	O
a	O
linker	O
H1	O
during	O
the	O
development	O
of	O
a	O
multicellular	O
organism	O
are	O
reported	O
.	O

The	O
abundance	O
of	O
H1	O
monophosphorylated	O
at	O
S10	O
decreases	O
as	O
the	O
embryos	O
age	O
,	O
which	O
suggests	O
that	O
this	O
PTM	O
is	O
related	O
to	O
cell	O
cycle	O
progression	O
and	O
/	O
or	O
cell	O
differentiation	O
.	O

Additionally	O
,	O
we	O
have	O
found	O
a	O
polymorphism	O
in	O
the	O
protein	O
sequence	O
that	O
can	O
be	O
mistaken	O
with	O
lysine	O
methylation	O
if	O
the	O
analysis	O
is	O
not	O
rigorous	O
.	O

Bioinformatic	O
analyses	O
indicated	O
that	O
B14	O
is	O
a	O
member	O
of	O
a	O
family	O
of	O
poxvirus	O
proteins	O
that	O
include	O
B14	O
,	O
K7	O
,	O
C6	O
,	O
and	O
A52	O
.	O

Subsequently	O
,	O
the	O
A46	O
protein	O
was	O
shown	O
to	O
be	O
related	O
to	O
A52	O
and	O
was	O
added	O
to	O
this	O
family	O
.	O

Given	O
that	O
proteins	O
A46	O
and	O
A52	O
are	O
intracellular	O
inhibitors	O
of	O
TLR	O
signaling	O
pathways	O
,	O
the	O
presence	O
of	O
B14	O
in	O
the	O
same	O
family	O
suggested	O
that	O
B14	O
might	O
also	O
act	O
to	O
regulate	O
signaling	O
pathways	O
leading	O
to	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
.	O

A	O
novel	O
mutant	O
of	O
the	O
Sup35	O
protein	O
of	O
Saccharomyces	O
cerevisiae	O
defective	O
in	O
translation	O
termination	O
and	O
in	O
GTPase	O
activity	O
still	O
supports	O
cell	O
viability	O
.	O

BACKGROUND	O
:	O
When	O
a	O
stop	O
codon	O
is	O
located	O
in	O
the	O
ribosomal	O
A	O
-	O
site	O
,	O
the	O
termination	O
complex	O
promotes	O
release	O
of	O
the	O
polypeptide	O
and	O
dissociation	O
of	O
the	O
80S	B-OOS
ribosome	I-OOS
.	O

In	O
eukaryotes	O
two	O
proteins	O
eRF1	O
and	O
eRF3	O
play	O
a	O
crucial	O
function	O
in	O
the	O
termination	O
process	O
.	O

The	O
essential	O
GTPase	O
Sup35p	O
,	O
the	O
eRF3	O
release	O
factor	O
of	O
Saccharomyces	O
cerevisiae	O
is	O
highly	O
conserved	O
.	O

In	O
particular	O
,	O
we	O
observed	O
that	O
all	O
eRF3	O
homologs	O
share	O
a	O
potential	O
phosphorylation	O
site	O
at	O
threonine	O
341	O
,	O
suggesting	O
a	O
functional	O
role	O
for	O
this	O
residue	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
this	O
residue	O
is	O
actually	O
phosphorylated	O
in	O
yeast	O
and	O
if	O
it	O
is	O
involved	O
in	O
the	O
termination	O
activity	O
of	O
the	O
protein	O
.	O

RESULTS	O
:	O
We	O
detected	O
no	O
phosphorylation	O
of	O
the	O
Sup35	O
protein	O
in	O
vivo	O
.	O

However	O
,	O
we	O
show	O
that	O
it	O
is	O
phosphorylated	O
by	O
the	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
A	O
on	O
T341	O
in	O
vitro	O
.	O

T341	O
was	O
mutated	O
to	O
either	O
alanine	O
or	O
to	O
aspartic	O
acid	O
to	O
assess	O
the	O
role	O
of	O
this	O
residue	O
in	O
the	O
activity	O
of	O
the	O
protein	O
.	O

Both	O
mutant	O
proteins	O
showed	O
a	O
large	O
decrease	O
of	O
GTPase	O
activity	O
and	O
a	O
reduced	O
interaction	O
with	O
eRF1	O
/	O
Sup45p	O
.	O

This	O
was	O
correlated	O
with	O
an	O
increase	O
of	O
translational	O
readthrough	O
in	O
cells	O
carrying	O
the	O
mutant	O
alleles	O
.	O

We	O
also	O
show	O
that	O
this	O
residue	O
is	O
involved	O
in	O
functional	O
interaction	O
between	O
the	O
N	O
-	O
and	O
C	O
-	O
domains	O
of	O
the	O
protein	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
point	O
to	O
a	O
new	O
critical	O
residue	O
involved	O
in	O
the	O
translation	O
termination	O
activity	O
of	O
Sup35	O
and	O
in	O
functional	O
interaction	O
between	O
the	O
N	O
-	O
and	O
C	O
-	O
domains	O
of	O
the	O
protein	O
.	O

They	O
also	O
raise	O
interesting	O
questions	O
about	O
the	O
relation	O
between	O
GTPase	O
activity	O
of	O
Sup35	O
and	O
its	O
essential	O
function	O
in	O
yeast	O
.	O

The	O
full	O
-	O
length	O
cDNA	O
of	O
CG4454	O
(	O
borr	O
)	O
and	O
CG17009	O
(	O
aust	O
)	O
was	O
amplified	O
by	O
PCR	O
using	O
primers	O
that	O
include	O
BamHI	O
and	O
HindIII	O
restriction	O
enzyme	O
sites	O
at	O
the	O
5	O
'	O
and	O
3	O
'	O
ends	O
,	O
respectively	O
.	O

cDNAs	O
were	O
cloned	O
into	O
pGEM	O
-	O
T	O
,	O
sequenced	O
to	O
confirm	O
the	O
identity	O
of	O
the	O
products	O
,	O
and	O
subsequently	O
subcloned	O
into	O
the	O
bacterial	O
expression	O
vector	O
pMAL	O
-	O
c2x	O
using	O
the	O
BamHI	O
and	O
HindIII	O
restriction	O
sites	O
.	O

The	O
MBP	O
-	O
tagged	O
proteins	O
were	O
purified	O
as	O
described	O
previously	O
.	O

To	O
express	O
genes	O
in	O
mammalian	O
tissue	O
culture	O
cells	O
,	O
full	O
-	O
length	O
INCENP	O
and	O
aurora	O
B	O
were	O
amplified	O
and	O
cloned	O
into	O
a	O
pGEM	O
-	O
T	O
vector	O
and	O
fully	O
sequenced	O
before	O
subcloning	O
into	O
either	O
HA	O
-	O
tagged	O
pCDEF3	O
or	O
FLAG	O
-	O
tagged	O
pCDEF3	O
using	O
NdeI	O
and	O
NotI	O
restriction	O
sites	O
.	O

The	O
expression	O
of	O
transgenes	O
in	O
mammalian	O
cells	O
was	O
performed	O
as	O
described	O
previously	O
.	O

Trabid	O
,	O
a	O
new	O
positive	O
regulator	O
of	O
Wnt	O
-	O
induced	O
transcription	O
with	O
preference	O
for	O
binding	O
and	O
cleaving	O
K63	O
-	O
linked	O
ubiquitin	O
chains	O
.	O

A	O
key	O
effector	O
of	O
the	O
canonical	O
Wnt	O
pathway	O
is	O
beta	O
-	O
catenin	O
,	O
which	O
binds	O
to	O
TCF	O
/	O
LEF	O
factors	O
to	O
promote	O
the	O
transcription	O
of	O
Wnt	O
target	O
genes	O
.	O

In	O
the	O
absence	O
of	O
Wnt	O
stimulation	O
,	O
beta	O
-	O
catenin	O
is	O
phosphorylated	O
constitutively	O
,	O
and	O
modified	O
with	O
K48	O
-	O
linked	O
ubiquitin	O
for	O
subsequent	O
proteasomal	O
degradation	O
.	O

Here	O
,	O
we	O
identify	O
Trabid	O
as	O
a	O
new	O
positive	O
regulator	O
of	O
Wnt	O
signaling	O
in	O
mammalian	O
and	O
Drosophila	O
cells	O
.	O

Trabid	O
show	O
a	O
remarkable	O
preference	O
for	O
binding	O
to	O
K63	O
-	O
linked	O
ubiquitin	O
chains	O
with	O
its	O
three	O
tandem	O
NZF	O
fingers	O
(	O
Npl4	O
zinc	O
finger	O
)	O
,	O
and	O
it	O
cleaves	O
these	O
chains	O
with	O
its	O
OTU	O
(	O
ovarian	O
tumor	O
)	O
domain	O
.	O

These	O
activities	O
of	O
Trabid	O
are	O
required	O
for	O
efficient	O
TCF	O
-	O
mediated	O
transcription	O
in	O
cells	O
with	O
high	O
Wnt	O
pathway	O
activity	O
,	O
including	O
colorectal	O
cancer	O
cell	O
lines	O
.	O

We	O
further	O
show	O
that	O
Trabid	O
can	O
bind	O
to	O
and	O
deubiquitylate	O
the	O
APC	O
tumor	O
suppressor	O
protein	O
,	O
a	O
negative	O
regulator	O
of	O
Wnt	O
-	O
mediated	O
transcription	O
.	O

Epistasis	O
experiments	O
indicate	O
that	O
Trabid	O
acts	O
below	O
the	O
stabilization	O
of	O
beta	O
-	O
catenin	O
,	O
and	O
that	O
it	O
may	O
affect	O
the	O
association	O
or	O
activity	O
of	O
the	O
TCF	O
-	O
beta	O
-	O
catenin	O
transcription	O
complex	O
.	O

Our	O
results	O
indicate	O
a	O
role	O
of	O
K63	O
-	O
linked	O
ubiquitin	O
chains	O
during	O
Wnt	O
-	O
induced	O
transcription	O
.	O

IKAP	O
localizes	O
to	O
membrane	O
ruffles	O
with	O
filamin	O
A	O
and	O
regulates	O
actin	O
cytoskeleton	O
organization	O
and	O
cell	O
migration	O
.	O

Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
IKBKAP	O
gene	O
,	O
which	O
encodes	O
IKAP	O
(	O
ELP1	O
)	O
,	O
cause	O
familial	O
dysautonomia	O
(	O
FD	O
)	O
,	O
with	O
defective	O
neuronal	O
development	O
and	O
maintenance	O
.	O

Molecular	O
mechanisms	O
leading	O
to	O
FD	O
are	O
poorly	O
understood	O
.	O

We	O
demonstrate	O
that	O
various	O
RNA	O
-	O
interference	O
-	O
based	O
depletions	O
of	O
IKAP	O
lead	O
to	O
defective	O
adhesion	O
and	O
migration	O
in	O
several	O
cell	O
types	O
,	O
including	O
rat	O
primary	O
neurons	O
.	O

The	O
defects	O
could	O
be	O
rescued	O
by	O
reintroduction	O
of	O
wild	O
-	O
type	O
IKAP	O
but	O
not	O
by	O
FD	O
-	O
IKAP	O
,	O
a	O
truncated	O
form	O
of	O
IKAP	O
constructed	O
according	O
to	O
the	O
mutation	O
found	O
in	O
the	O
majority	O
of	O
FD	O
patients	O
.	O

Cytosolic	O
IKAP	O
co	O
-	O
purified	O
with	O
proteins	O
involved	O
in	O
cell	O
migration	O
,	O
including	O
filamin	O
A	O
,	O
which	O
is	O
also	O
involved	O
in	O
neuronal	O
migration	O
.	O

Immunostaining	O
of	O
IKAP	O
and	O
filamin	O
A	O
revealed	O
a	O
distinct	O
co	O
-	O
localization	O
of	O
these	O
two	O
proteins	O
in	O
membrane	O
ruffles	O
.	O

Depletion	O
of	O
IKAP	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
filamin	O
A	O
localization	O
in	O
membrane	O
ruffles	O
and	O
defective	O
actin	O
cytoskeleton	O
organization	O
,	O
which	O
both	O
could	O
be	O
rescued	O
by	O
the	O
expression	O
of	O
wild	O
-	O
type	O
IKAP	O
but	O
not	O
by	O
FD	O
-	O
IKAP	O
.	O

No	O
downregulation	O
in	O
the	O
protein	O
levels	O
of	O
paxillin	O
or	O
beclin	O
1	O
,	O
which	O
were	O
recently	O
described	O
as	O
specific	O
transcriptional	O
targets	O
of	O
IKAP	O
,	O
was	O
detected	O
.	O

These	O
results	O
provide	O
evidence	O
for	O
the	O
role	O
of	O
the	O
cytosolic	O
interactions	O
of	O
IKAP	O
in	O
cell	O
adhesion	O
and	O
migration	O
,	O
and	O
support	O
the	O
notion	O
that	O
cell	O
-	O
motility	O
deficiencies	O
could	O
contribute	O
to	O
FD	O
.	O

An	O
important	O
unresolved	O
issue	O
is	O
the	O
identification	O
of	O
physiological	O
substrates	O
of	O
SCFFbh1	B-Complex
that	O
presumably	O
regulate	O
the	O
HR	O
pathway	O
.	O

A	O
recent	O
study	O
has	O
shown	O
that	O
hFBH1	O
has	O
a	O
short	O
half	O
-	O
life	O
when	O
it	O
is	O
expressed	O
in	O
S	O
.	O
cerevisiae	O
,	O
and	O
its	O
degradation	O
depends	O
on	O
the	O
presence	O
of	O
a	O
functional	O
F	O
-	O
box	O
and	O
yeast	O
SCF	B-Complex
components	O
,	O
suggesting	O
that	O
one	O
candidate	O
for	O
a	O
SCFhFBH1	B-Complex
substrate	O
is	O
hFBH1	O
itself	O
.	O

The	O
rapid	O
turnover	O
of	O
hFBH1	O
might	O
contribute	O
to	O
the	O
tight	O
regulation	O
of	O
hFBH1	O
helicase	O
activity	O
.	O

However	O
,	O
if	O
SCFhFBH1	B-Complex
complex	O
formation	O
is	O
also	O
necessary	O
for	O
its	O
nuclear	O
transport	O
and	O
recruitment	O
to	O
DNA	O
damage	O
sites	O
,	O
the	O
alteration	O
in	O
subcellular	O
localization	O
caused	O
by	O
the	O
F	O
-	O
box	O
mutation	O
might	O
affect	O
hFBH1	O
stability	O
in	O
budding	O
yeast	O
cells	O
.	O

In	O
addition	O
,	O
many	O
F	O
-	O
box	O
proteins	O
identified	O
to	O
date	O
target	O
more	O
than	O
one	O
substrate	O
for	O
degradation	O
.	O

Since	O
our	O
present	O
data	O
suggest	O
that	O
Fbh1	O
functions	O
as	O
an	O
SCFFbh1	B-Complex
ubiquitin	O
ligase	O
complex	O
for	O
HR	O
repair	O
,	O
the	O
most	O
plausible	O
candidates	O
as	O
SCFFbh1	B-Complex
substrates	O
are	O
HR	O
proteins	O
,	O
including	O
Rhp51	O
.	O

For	O
example	O
,	O
SCFFbh1	B-Complex
might	O
contribute	O
to	O
regulate	O
Rhp51	O
-	O
dependent	O
HR	O
by	O
promoting	O
the	O
ubiquitination	O
of	O
Rhp51	O
or	O
other	O
recombination	O
proteins	O
.	O

Future	O
studies	O
will	O
be	O
needed	O
to	O
determine	O
whether	O
Fbh1	O
is	O
a	O
physiological	O
SCFFbh1	B-Complex
substrate	O
and	O
to	O
identify	O
other	O
SCFFbh1	B-Complex
substrates	O
,	O
which	O
would	O
provide	O
a	O
means	O
to	O
conduct	O
a	O
more	O
detailed	O
analysis	O
of	O
its	O
function	O
in	O
HR	O
repair	O
.	O

The	O
Glc7	O
phosphatase	O
subunit	O
of	O
the	O
cleavage	B-Complex
and	I-Complex
polyadenylation	I-Complex
factor	I-Complex
is	O
essential	O
for	O
transcription	O
termination	O
on	O
snoRNA	O
genes	O
.	O

Glc7	O
,	O
the	O
yeast	O
protein	B-Complex
phosphatase	I-Complex
1	I-Complex
,	O
is	O
a	O
component	O
of	O
the	O
cleavage	B-Complex
and	I-Complex
polyadenylation	I-Complex
factor	I-Complex
(	O
CPF	B-Complex
)	O
.	O

Here	O
we	O
show	O
that	O
downregulation	O
of	O
Glc7	O
,	O
or	O
its	O
dissociation	O
from	O
CPF	B-Complex
in	O
the	O
absence	O
of	O
CPF	B-Complex
subunits	O
Ref2	O
or	O
Swd2	O
,	O
results	O
in	O
similar	O
snoRNA	O
termination	O
defects	O
.	O

Overexpressing	O
a	O
C	O
-	O
terminal	O
fragment	O
of	O
Sen1	O
,	O
a	O
superfamily	O
I	O
helicase	O
required	O
for	O
snoRNA	O
termination	O
,	O
suppresses	O
the	O
growth	O
and	O
termination	O
defects	O
associated	O
with	O
loss	O
of	O
Swd2	O
or	O
Ref2	O
,	O
but	O
not	O
Glc7	O
.	O

Suppression	O
by	O
Sen1	O
requires	O
nuclear	O
localization	O
and	O
direct	O
interaction	O
with	O
Glc7	O
,	O
which	O
can	O
dephosphorylate	O
Sen1	O
in	O
vitro	O
.	O

The	O
suppressing	O
fragment	O
,	O
and	O
in	O
a	O
similar	O
manner	O
full	O
-	O
length	O
Sen1	O
,	O
copurifies	O
with	O
the	O
snoRNA	O
termination	O
factors	O
Nrd1	O
and	O
Nab3	O
,	O
suggesting	O
loss	O
of	O
Glc7	O
from	O
CPF	B-Complex
can	O
be	O
compensated	O
by	O
recruiting	O
Glc7	O
to	O
Nrd1	O
-	O
Nab3	O
through	O
Sen1	O
.	O

Swd2	O
is	O
also	O
a	O
subunit	O
of	O
the	O
Set1c	B-Complex
histone	I-Complex
H3K4	I-Complex
methyltransferase	I-Complex
complex	O
and	O
is	O
required	O
for	O
its	O
stability	O
and	O
optimal	O
methyltransferase	O
activity	O
.	O

Synaptic	O
NMDA	O
receptor	O
activity	O
boosts	O
intrinsic	O
antioxidant	O
defenses	O
.	O

Intrinsic	O
antioxidant	O
defenses	O
are	O
important	O
for	O
neuronal	O
longevity	O
.	O

We	O
found	O
that	O
in	O
rat	O
neurons	O
,	O
synaptic	O
activity	O
,	O
acting	O
via	O
NMDA	O
receptor	O
(	O
NMDAR	O
)	O
signaling	O
,	O
boosted	O
antioxidant	O
defenses	O
by	O
making	O
changes	O
to	O
the	O
thioredoxin	O
-	O
peroxiredoxin	O
(	O
Prx	O
)	O
system	O
.	O

Synaptic	O
activity	O
enhanced	O
thioredoxin	O
activity	O
,	O
facilitated	O
the	O
reduction	O
of	O
overoxidized	O
Prxs	O
and	O
promoted	O
resistance	O
to	O
oxidative	O
stress	O
.	O

Resistance	O
was	O
mediated	O
by	O
coordinated	O
transcriptional	O
changes	O
;	O
synaptic	O
NMDAR	O
activity	O
inactivated	O
a	O
previously	O
unknown	O
Forkhead	O
box	O
O	O
target	O
gene	O
,	O
the	O
thioredoxin	O
inhibitor	O
Txnip	O
.	O

Conversely	O
,	O
NMDAR	O
blockade	O
upregulated	O
Txnip	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
where	O
it	O
bound	O
thioredoxin	O
and	O
promoted	O
vulnerability	O
to	O
oxidative	O
damage	O
.	O

Synaptic	O
activity	O
also	O
upregulated	O
the	O
Prx	O
reactivating	O
genes	O
Sesn2	O
(	O
sestrin	O
2	O
)	O
and	O
Srxn1	O
(	O
sulfiredoxin	O
)	O
,	O
via	O
C	O
/	O
EBPbeta	O
and	O
AP	B-Complex
-	I-Complex
1	I-Complex
,	O
respectively	O
.	O

Mimicking	O
these	O
expression	O
changes	O
was	O
sufficient	O
to	O
strengthen	O
antioxidant	O
defenses	O
.	O

Trans	O
-	O
synaptic	O
stimulation	O
of	O
synaptic	O
NMDARs	O
was	O
crucial	O
for	O
boosting	O
antioxidant	O
defenses	O
;	O
chronic	O
bath	O
activation	O
of	O
all	O
(	O
synaptic	O
and	O
extrasynaptic	O
)	O
NMDARs	O
induced	O
no	O
antioxidative	O
effects	O
.	O

Thus	O
,	O
synaptic	O
NMDAR	O
activity	O
may	O
influence	O
the	O
progression	O
of	O
pathological	O
processes	O
associated	O
with	O
oxidative	O
damage	O
.	O

Polyunsaturated	O
fatty	O
acids	O
block	O
platelet	O
-	O
activating	O
factor	O
-	O
induced	O
phosphatidylinositol	O
3	O
kinase	O
/	O
Akt	O
-	O
mediated	O
apoptosis	O
in	O
intestinal	O
epithelial	O
cells	O
.	O

We	O
have	O
shown	O
earlier	O
that	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
causes	O
apoptosis	O
in	O
enterocytes	O
via	O
a	O
mechanism	O
that	O
involves	O
Bax	O
translocation	O
to	O
mitochondria	O
,	O
followed	O
by	O
caspase	O
activation	O
and	O
DNA	O
fragmentation	O
.	O

Herein	O
we	O
report	O
that	O
,	O
in	O
rat	O
small	O
intestinal	O
epithelial	O
cells	O
(	O
IEC	O
-	O
6	O
)	O
,	O
these	O
downstream	O
apoptotic	O
effects	O
are	O
mediated	O
by	O
a	O
PAF	O
-	O
induced	O
inhibition	O
of	O
the	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI	O
3	O
-	O
kinase	O
)	O
/	O
protein	O
kinase	O
B	O
(	O
Akt	O
)	O
signaling	O
pathway	O
.	O

Treatment	O
with	O
PAF	O
results	O
in	O
rapid	O
dephosphorylation	O
of	O
Akt	O
,	O
phosphoinositide	O
-	O
dependent	O
kinase	O
-	O
1	O
,	O
and	O
the	O
YXXM	O
p85	O
binding	O
motif	O
of	O
several	O
proteins	O
and	O
redistribution	O
of	O
Akt	O
-	O
pleckstrin	O
homology	O
domain	O
-	O
green	O
fluorescent	O
protein	O
,	O
i	O
.	O
e	O
.	O
,	O
an	O
in	O
vivo	O
phosphatidylinositol	O
(	O
3	O
,	O
4	O
,	O
5	O
)	O
-	O
trisphosphate	O
sensor	O
,	O
from	O
membrane	O
to	O
cytosol	O
.	O

The	O
proapoptotic	O
effects	O
of	O
PAF	O
were	O
inhibited	O
by	O
both	O
n	O
-	O
3	O
and	O
n	O
-	O
6	O
polyunsaturated	O
fatty	O
acids	O
but	O
not	O
by	O
a	O
saturated	O
fatty	O
acid	O
palmitate	O
.	O

Indomethacin	O
,	O
an	O
inhibitor	O
of	O
prostaglandin	O
biosynthesis	O
,	O
did	O
not	O
influence	O
the	O
baseline	O
or	O
PAF	O
-	O
induced	O
apoptosis	O
,	O
but	O
2	O
-	O
bromopalmitate	O
,	O
an	O
inhibitor	O
of	O
protein	O
palmitoylation	O
,	O
inhibited	O
all	O
of	O
the	O
proapoptotic	O
effects	O
of	O
PAF	O
.	O

Our	O
data	O
strongly	O
suggest	O
that	O
an	O
inhibition	O
of	O
the	O
PI	O
3	O
-	O
kinase	O
/	O
Akt	O
signaling	O
pathway	O
is	O
the	O
main	O
mechanism	O
of	O
PAF	O
-	O
induced	O
apoptosis	O
in	O
enterocytes	O
and	O
that	O
polyunsaturated	O
fatty	O
acids	O
block	O
this	O
mechanism	O
very	O
early	O
in	O
the	O
signaling	O
cascade	O
independently	O
of	O
any	O
effect	O
on	O
prostaglandin	O
synthesis	O
,	O
and	O
probably	O
directly	O
via	O
an	O
effect	O
on	O
protein	O
palmitoylation	O
.	O

Expression	O
pattern	O
diversity	O
and	O
functional	O
conservation	O
between	O
retroposed	O
PRAT	O
genes	O
from	O
Drosophila	O
melanogaster	O
and	O
Drosophila	O
virilis	O
.	O

Gene	O
duplication	O
by	O
retrotransposition	O
duplicates	O
only	O
the	O
coding	O
and	O
untranslated	O
regions	O
of	O
a	O
gene	O
and	O
,	O
thus	O
,	O
biases	O
retroduplicated	O
genes	O
toward	O
having	O
different	O
expression	O
patterns	O
from	O
their	O
parental	O
genes	O
.	O

As	O
such	O
,	O
genes	O
duplicated	O
by	O
retrotransposition	O
are	O
more	O
likely	O
to	O
develop	O
novel	O
expression	O
domains	O
.	O

To	O
explore	O
this	O
idea	O
further	O
,	O
we	O
used	O
the	O
Prat	O
/	O
Prat2	O
gene	O
duplication	O
in	O
Drosophila	O
as	O
a	O
case	O
study	O
to	O
examine	O
the	O
aftermath	O
of	O
a	O
retrotransposition	O
event	O
that	O
resulted	O
in	O
both	O
the	O
parent	O
and	O
the	O
child	O
gene	O
becoming	O
essential	O
for	O
survival	O
.	O

We	O
used	O
the	O
Gal4	O
-	O
UAS	O
transgene	O
system	O
with	O
EGFP	O
as	O
a	O
reporter	O
to	O
determine	O
the	O
developmental	O
expression	O
patterns	O
of	O
Prat	O
and	O
Prat2	O
from	O
D	O
.	O
melanogaster	O
(	O
DmPrat	O
and	O
DmPrat2	O
)	O
and	O
Prat	O
from	O
D	O
.	O
virilis	O
(	O
DvPrat	O
)	O
.	O

We	O
also	O
tested	O
the	O
functional	O
equivalence	O
of	O
the	O
protein	O
products	O
of	O
DmPrat	O
and	O
DmPrat2	O
.	O

We	O
found	O
that	O
each	O
of	O
the	O
proteins	O
could	O
rescue	O
DmPrat	O
mutations	O
,	O
showing	O
that	O
the	O
requirement	O
for	O
both	O
Prat	O
and	O
Prat2	O
in	O
Drosophila	O
is	O
not	O
simply	O
due	O
to	O
differences	O
in	O
protein	O
function	O
.	O

In	O
contrast	O
,	O
we	O
found	O
that	O
the	O
DmPrat	O
and	O
DmPrat2	O
genes	O
have	O
developed	O
nonoverlapping	O
patterns	O
of	O
expression	O
,	O
which	O
correlate	O
with	O
their	O
respective	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
.	O

We	O
further	O
found	O
that	O
DvPrat	O
expression	O
is	O
similar	O
to	O
DmPrat	O
during	O
development	O
but	O
differs	O
in	O
adult	O
gonads	O
.	O

Thus	O
,	O
the	O
function	O
of	O
the	O
Prat	O
retrogene	O
has	O
not	O
diverged	O
in	O
the	O
D	O
.	O
melanogaster	O
and	O
D	O
.	O
virilis	O
lineages	O
,	O
while	O
some	O
aspects	O
of	O
its	O
expression	O
pattern	O
have	O
evolved	O
.	O

Finally	O
,	O
we	O
have	O
identified	O
promoter	O
elements	O
,	O
conserved	O
upstream	O
of	O
DmPrat	O
and	O
DvPrat	O
,	O
that	O
this	O
retrogene	O
has	O
acquired	O
to	O
drive	O
its	O
expression	O
.	O

The	O
histone	O
-	O
binding	O
protein	O
COPR5	O
is	O
required	O
for	O
nuclear	O
functions	O
of	O
the	O
protein	O
arginine	O
methyltransferase	O
PRMT5	O
.	O

Protein	O
arginine	O
methyltransferase	O
5	O
(	O
PRMT5	O
)	O
targets	O
nuclear	O
and	O
cytoplasmic	O
proteins	O
.	O

Here	O
,	O
we	O
identified	O
a	O
nuclear	O
protein	O
,	O
called	O
cooperator	O
of	O
PRMT5	O
(	O
COPR5	O
)	O
,	O
involved	O
in	O
the	O
nuclear	O
functions	O
of	O
PRMT5	O
.	O

COPR5	O
tightly	O
binds	O
to	O
PRMT5	O
,	O
both	O
in	O
vitro	O
and	O
in	O
living	O
cells	O
,	O
but	O
not	O
to	O
other	O
members	O
of	O
the	O
PRMT	O
family	O
.	O

PRMT5	O
bound	O
to	O
COPR5	O
methylates	O
histone	O
H4	O
(	O
R3	O
)	O
preferentially	O
when	O
compared	O
with	O
histone	O
H3	O
(	O
R8	O
)	O
,	O
suggesting	O
that	O
COPR5	O
modulates	O
the	O
substrate	O
specificity	O
of	O
nuclear	O
PRMT5	O
-	O
containing	O
complexes	O
,	O
at	O
least	O
towards	O
histones	O
.	O

Markedly	O
,	O
recombinant	O
COPR5	O
binds	O
to	O
the	O
amino	O
terminus	O
of	O
histone	O
H4	O
and	O
is	O
required	O
to	O
recruit	O
PRMT5	O
to	O
reconstituted	O
nucleosomes	O
in	O
vitro	O
.	O

Consistently	O
,	O
COPR5	O
depletion	O
in	O
cells	O
strongly	O
reduces	O
PRMT5	O
recruitment	O
on	O
chromatin	O
at	O
the	O
PRMT5	O
target	O
gene	O
cyclin	O
E1	O
(	O
CCNE1	O
)	O
in	O
vivo	O
.	O

Moreover	O
,	O
both	O
COPR5	O
depletion	O
and	O
overexpression	O
affect	O
CCNE1	O
promoter	O
expression	O
.	O

We	O
propose	O
that	O
COPR5	O
is	O
an	O
important	O
chromatin	O
adaptor	O
for	O
PRMT5	O
to	O
function	O
on	O
a	O
subset	O
of	O
its	O
target	O
genes	O
.	O

Characterization	O
of	O
Dnmt3b	O
:	O
thymine	O
-	O
DNA	O
glycosylase	O
interaction	O
and	O
stimulation	O
of	O
thymine	O
glycosylase	O
-	O
mediated	O
repair	O
by	O
DNA	O
methyltransferase	O
(	O
s	O
)	O
and	O
RNA	O
.	O

Methylation	O
of	O
cytosine	O
residues	O
in	O
CpG	O
dinucleotides	O
plays	O
an	O
important	O
role	O
in	O
epigenetic	O
regulation	O
of	O
gene	O
expression	O
and	O
chromatin	O
structure	O
/	O
stability	O
in	O
higher	O
eukaryotes	O
.	O

DNA	O
methylation	O
patterns	O
are	O
established	O
and	O
maintained	O
at	O
CpG	O
dinucleotides	O
by	O
DNA	O
methyltransferases	O
(	O
Dnmt1	O
,	O
Dnmt3a	O
,	O
and	O
Dnmt3b	O
)	O
.	O

In	O
mammals	O
and	O
many	O
other	O
eukaryotes	O
,	O
the	O
CpG	O
dinucleotide	O
is	O
underrepresented	O
in	O
the	O
genome	O
.	O

This	O
loss	O
is	O
postulated	O
to	O
be	O
the	O
result	O
of	O
unrepaired	O
deamination	O
of	O
cytosine	O
and	O
5	O
-	O
methylcytosine	O
to	O
uracil	O
and	O
thymine	O
,	O
respectively	O
.	O

Two	O
thymine	O
glycosylases	O
are	O
believed	O
to	O
reduce	O
the	O
impact	O
of	O
5	O
-	O
methylcytosine	O
deamination	O
.	O

G	O
/	O
T	O
mismatch	O
-	O
specific	O
thymine	O
-	O
DNA	O
glycosylase	O
(	O
Tdg	O
)	O
and	O
methyl	O
-	O
CpG	O
binding	O
domain	O
protein	O
4	O
can	O
both	O
excise	O
uracil	O
or	O
thymine	O
at	O
U	O
.	O
G	O
and	O
T	O
.	O
G	O
mismatches	O
to	O
initiate	O
base	O
excision	O
repair	O
.	O

Here	O
,	O
we	O
report	O
the	O
characterization	O
of	O
interactions	O
between	O
Dnmt3b	O
and	O
both	O
Tdg	O
and	O
methyl	O
-	O
CpG	O
binding	O
domain	O
protein	O
4	O
.	O

Our	O
results	O
demonstrate	O
(	O
1	O
)	O
that	O
both	O
Tdg	O
and	O
Dnmt3b	O
are	O
colocalized	O
to	O
heterochromatin	O
and	O
(	O
2	O
)	O
reduction	O
of	O
T	O
.	O
G	O
mismatch	O
repair	O
efficiency	O
upon	O
loss	O
of	O
DNA	O
methyltransferase	O
expression	O
,	O
as	O
well	O
as	O
a	O
requirement	O
for	O
an	O
RNA	O
component	O
for	O
correct	O
T	O
.	O
G	O
mismatch	O
repair	O
.	O

Human	O
betaine	O
-	O
homocysteine	O
methyltransferase	O
(	O
BHMT	O
)	O
and	O
BHMT2	O
:	O
common	O
gene	O
sequence	O
variation	O
and	O
functional	O
characterization	O
.	O

Betaine	O
-	O
homocysteine	O
methyltransferase	O
(	O
BHMT	O
)	O
catalyzes	O
the	O
remethylation	O
of	O
homocysteine	O
.	O

BHMT2	O
encodes	O
a	O
protein	O
73	O
%	O
identical	O
in	O
amino	O
acid	O
sequence	O
to	O
BHMT	O
,	O
but	O
the	O
function	O
of	O
BHMT2	O
remains	O
unclear	O
.	O

We	O
set	O
out	O
to	O
identify	O
and	O
functionally	O
characterize	O
common	O
genetic	O
variation	O
in	O
BHMT	O
and	O
BHMT2	O
.	O

Specifically	O
,	O
we	O
sequenced	O
exons	O
,	O
exon	O
-	O
intron	O
splice	O
junctions	O
and	O
the	O
5	O
'	O
-	O
flanking	O
regions	O
(	O
5	O
'	O
-	O
FRs	O
)	O
of	O
BHMT	O
and	O
BHMT2	O
using	O
240	O
DNA	O
samples	O
from	O
four	O
ethnic	O
groups	O
.	O

Twenty	O
-	O
five	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
,	O
including	O
4	O
nonsynonymous	O
SNPs	O
,	O
and	O
39	O
SNPs	O
,	O
including	O
4	O
nonsynonymous	O
,	O
were	O
observed	O
in	O
BHMT	O
and	O
BHMT2	O
,	O
respectively	O
.	O

BHMT	O
wild	O
type	O
(	O
WT	O
)	O
and	O
variant	O
allozymes	O
were	O
expressed	O
in	O
COS	O
-	O
1	O
cells	O
.	O

Variant	O
allozymes	O
showed	O
no	O
significant	O
differences	O
from	O
WT	O
in	O
levels	O
of	O
enzyme	O
activity	O
or	O
immunoreactive	O
protein	O
,	O
but	O
there	O
were	O
statistically	O
significant	O
differences	O
in	O
apparent	O
K	O
(	O
m	O
)	O
values	O
.	O

Luciferase	O
reporter	O
gene	O
constructs	O
were	O
created	O
for	O
the	O
three	O
most	O
common	O
BHMT	O
5	O
'	O
-	O
FR	O
haplotypes	O
,	O
and	O
significant	O
variation	O
was	O
observed	O
in	O
the	O
ability	O
of	O
these	O
constructs	O
to	O
drive	O
transcription	O
.	O

Although	O
BHMT2	O
mRNA	O
has	O
been	O
observed	O
in	O
human	O
liver	O
and	O
kidney	O
,	O
expression	O
of	O
the	O
protein	O
has	O
not	O
been	O
reported	O
.	O

We	O
were	O
unable	O
to	O
express	O
BHMT2	O
in	O
mammalian	O
cells	O
,	O
and	O
the	O
protein	O
aggregated	O
after	O
bacterial	O
expression	O
.	O

Furthermore	O
,	O
BHMT2	O
was	O
rapidly	O
degraded	O
in	O
a	O
rabbit	O
reticulocyte	O
lysate	O
,	O
but	O
it	O
could	O
be	O
stabilized	O
by	O
cotransfection	O
of	O
COS	O
-	O
1	O
cells	O
with	O
BHMT	O
and	O
,	O
after	O
cotransfection	O
,	O
it	O
coprecipitated	O
with	O
BHMT	O
.	O

These	O
studies	O
have	O
defined	O
common	O
genetic	O
variation	O
in	O
BHMT	O
and	O
BHMT2	O
and	O
functionally	O
characterized	O
BHMT	O
SNPs	O
.	O

They	O
may	O
also	O
help	O
to	O
explain	O
why	O
BHMT2	O
has	O
not	O
previously	O
been	O
defined	O
functionally	O
.	O

S	O
.	O
cerevisiae	O
Vts1p	O
induces	O
deadenylation	O
-	O
dependent	O
transcript	O
degradation	O
and	O
interacts	O
with	O
the	O
Ccr4p	O
-	O
Pop2p	O
-	O
Not	O
deadenylase	O
complex	O
.	O

The	O
Smaug	O
family	O
of	O
sequence	O
-	O
specific	O
RNA	O
binding	O
proteins	O
regulates	O
mRNA	O
translation	O
and	O
degradation	O
by	O
binding	O
to	O
consensus	O
stem	O
-	O
loop	O
structures	O
in	O
target	O
mRNAs	O
.	O

Vts1p	O
is	O
a	O
member	O
of	O
the	O
Smaug	O
protein	O
family	O
that	O
regulates	O
the	O
stability	O
of	O
target	O
transcripts	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Here	O
we	O
focus	O
on	O
the	O
mechanism	O
of	O
Vts1p	O
-	O
mediated	O
mRNA	O
decay	O
.	O

Using	O
RNA	O
reporters	O
that	O
recapitulate	O
Vts1p	O
-	O
mediated	O
decay	O
in	O
vivo	O
,	O
we	O
demonstrate	O
that	O
Vts1p	O
stimulates	O
mRNA	O
degradation	O
through	O
deadenylation	O
mediated	O
by	O
the	O
Ccr4p	O
-	O
Pop2p	O
-	O
Not	O
deadenylase	O
complex	O
.	O

We	O
also	O
show	O
that	O
Vts1p	O
interacts	O
with	O
the	O
Ccr4p	O
-	O
Pop2p	O
-	O
Not	O
complex	O
suggesting	O
that	O
Vts1p	O
recruits	O
the	O
Ccr4p	O
-	O
Pop2p	O
-	O
Not	O
deadenylase	O
complex	O
to	O
target	O
mRNAs	O
,	O
resulting	O
in	O
transcript	O
decay	O
.	O

Following	O
deadenylation	O
Vts1p	O
target	O
transcripts	O
are	O
decapped	O
and	O
subsequently	O
degraded	O
by	O
the	O
5	O
'	O
-	O
to	O
-	O
3	O
'	O
exonuclease	O
Xrn1p	O
.	O

Decapping	O
and	O
5	O
'	O
-	O
to	O
-	O
3	O
'	O
decay	O
is	O
thought	O
to	O
occur	O
in	O
foci	O
known	O
as	O
P	O
-	O
bodies	O
,	O
and	O
we	O
provide	O
evidence	O
that	O
Vts1p	O
function	O
may	O
involve	O
P	O
-	O
bodies	O
.	O

Taken	O
together	O
with	O
previous	O
work	O
,	O
these	O
data	O
suggest	O
that	O
Smaug	O
family	O
members	O
employ	O
a	O
conserved	O
mechanism	O
to	O
induce	O
transcript	O
degradation	O
that	O
involves	O
recruitment	O
of	O
the	O
Ccr4	O
-	O
Pop2	O
-	O
Not	O
deadenylase	O
to	O
target	O
mRNAs	O
.	O

Structural	O
basis	O
for	O
tropomyosin	O
overlap	O
in	O
thin	O
(	O
actin	O
)	O
filaments	O
and	O
the	O
generation	O
of	O
a	O
molecular	O
swivel	O
by	O
troponin	O
-	O
T	O
.	O

Head	O
-	O
to	O
-	O
tail	O
polymerization	O
of	O
tropomyosin	O
is	O
crucial	O
for	O
its	O
actin	O
binding	O
,	O
function	O
in	O
actin	O
filament	O
assembly	O
,	O
and	O
the	O
regulation	O
of	O
actin	O
-	O
myosin	O
contraction	O
.	O

Here	O
,	O
we	O
describe	O
the	O
2	O
.	O
1	O
A	O
resolution	O
structure	O
of	O
crystals	O
containing	O
overlapping	O
tropomyosin	O
N	O
and	O
C	O
termini	O
(	O
TM	O
-	O
N	O
and	O
TM	O
-	O
C	O
)	O
and	O
the	O
2	O
.	O
9	O
A	O
resolution	O
structure	O
of	O
crystals	O
containing	O
TM	O
-	O
N	O
and	O
TM	O
-	O
C	O
together	O
with	O
a	O
fragment	O
of	O
troponin	O
-	O
T	O
(	O
TnT	O
)	O
.	O

At	O
each	O
junction	O
,	O
the	O
N	O
-	O
terminal	O
helices	O
of	O
TM	O
-	O
N	O
were	O
splayed	O
,	O
with	O
only	O
one	O
of	O
them	O
packing	O
against	O
TM	O
-	O
C	O
.	O

In	O
the	O
C	O
-	O
terminal	O
region	O
of	O
TM	O
-	O
C	O
,	O
a	O
crucial	O
water	O
in	O
the	O
coiled	O
-	O
coil	O
core	O
broke	O
the	O
local	O
2	O
-	O
fold	O
symmetry	O
and	O
helps	O
generate	O
a	O
kink	O
on	O
one	O
helix	O
.	O

In	O
the	O
presence	O
of	O
a	O
TnT	O
fragment	O
,	O
the	O
asymmetry	O
in	O
TM	O
-	O
C	O
facilitates	O
formation	O
of	O
a	O
4	O
-	O
helix	O
bundle	O
containing	O
two	O
TM	O
-	O
C	O
chains	O
and	O
one	O
chain	O
each	O
of	O
TM	O
-	O
N	O
and	O
TnT	O
.	O

Mutating	O
the	O
residues	O
that	O
generate	O
the	O
asymmetry	O
in	O
TM	O
-	O
C	O
caused	O
a	O
marked	O
decrease	O
in	O
the	O
affinity	O
of	O
troponin	O
for	O
actin	O
-	O
tropomyosin	O
filaments	O
.	O

The	O
highly	O
conserved	O
region	O
of	O
TnT	O
,	O
in	O
which	O
most	O
cardiomyopathy	O
mutations	O
reside	O
,	O
is	O
crucial	O
for	O
interacting	O
with	O
tropomyosin	O
.	O

The	O
structure	O
of	O
the	O
ternary	O
complex	O
also	O
explains	O
why	O
the	O
skeletal	O
-	O
and	O
cardiac	O
-	O
muscle	O
specific	O
C	O
-	O
terminal	O
region	O
is	O
required	O
to	O
bind	O
TnT	O
and	O
why	O
tropomyosin	O
homodimers	O
bind	O
only	O
a	O
single	O
TnT	O
.	O

On	O
actin	O
filaments	O
,	O
the	O
head	O
-	O
to	O
-	O
tail	O
junction	O
can	O
function	O
as	O
a	O
molecular	O
swivel	O
to	O
accommodate	O
irregularities	O
in	O
the	O
coiled	O
-	O
coil	O
path	O
between	O
successive	O
tropomyosins	O
enabling	O
each	O
to	O
interact	O
equivalently	O
with	O
the	O
actin	O
helix	O
.	O

Structure	O
of	O
the	O
Hsp110	O
:	O
Hsc70	O
nucleotide	O
exchange	O
machine	O
.	O

Hsp70s	O
mediate	O
protein	O
folding	O
,	O
translocation	O
,	O
and	O
macromolecular	O
complex	O
remodeling	O
reactions	O
.	O

Their	O
activities	O
are	O
regulated	O
by	O
proteins	O
that	O
exchange	O
ADP	O
for	O
ATP	O
from	O
the	O
nucleotide	O
-	O
binding	O
domain	O
(	O
NBD	O
)	O
of	O
the	O
Hsp70	O
.	O

These	O
nucleotide	O
exchange	O
factors	O
(	O
NEFs	O
)	O
include	O
the	O
Hsp110s	O
,	O
which	O
are	O
themselves	O
members	O
of	O
the	O
Hsp70	O
family	O
.	O

We	O
report	O
the	O
structure	O
of	O
an	O
Hsp110	O
:	O
Hsc70	O
nucleotide	O
exchange	O
complex	O
.	O

The	O
complex	O
is	O
characterized	O
by	O
extensive	O
protein	O
:	O
protein	O
interactions	O
and	O
symmetric	O
bridging	O
interactions	O
between	O
the	O
nucleotides	O
bound	O
in	O
each	O
partner	O
protein	O
'	O
s	O
NBD	O
.	O

An	O
electropositive	O
pore	O
allows	O
nucleotides	O
to	O
enter	O
and	O
exit	O
the	O
complex	O
.	O

The	O
role	O
of	O
nucleotides	O
in	O
complex	O
formation	O
and	O
dissociation	O
,	O
and	O
the	O
effects	O
of	O
the	O
protein	O
:	O
protein	O
interactions	O
on	O
nucleotide	O
exchange	O
,	O
can	O
be	O
understood	O
in	O
terms	O
of	O
the	O
coupled	O
effects	O
of	O
the	O
nucleotides	O
and	O
protein	O
:	O
protein	O
interactions	O
on	O
the	O
open	O
-	O
closed	O
isomerization	O
of	O
the	O
NBDs	O
.	O

The	O
symmetrical	O
interactions	O
in	O
the	O
complex	O
may	O
model	O
other	O
Hsp70	O
family	O
heterodimers	O
in	O
which	O
two	O
Hsp70s	O
reciprocally	O
act	O
as	O
NEFs	O
.	O

TSG	O
-	O
6	O
is	O
an	O
inflammation	O
-	O
induced	O
protein	O
that	O
is	O
produced	O
at	O
pathological	O
sites	O
,	O
including	O
arthritic	O
joints	O
.	O

In	O
animal	O
models	O
of	O
arthritis	O
,	O
TSG	O
-	O
6	O
protects	O
against	O
joint	O
damage	O
;	O
this	O
has	O
been	O
attributed	O
to	O
its	O
inhibitory	O
effects	O
on	O
neutrophil	O
migration	O
and	O
plasmin	O
activity	O
.	O

Here	O
we	O
investigated	O
whether	O
TSG	O
-	O
6	O
can	O
directly	O
influence	O
bone	O
erosion	O
.	O

Our	O
data	O
reveal	O
that	O
TSG	O
-	O
6	O
inhibits	O
RANKL	O
-	O
induced	O
osteoclast	O
differentiation	O
/	O
activation	O
from	O
human	O
and	O
murine	O
precursor	O
cells	O
,	O
where	O
elevated	O
dentine	O
erosion	O
by	O
osteoclasts	O
derived	O
from	O
TSG	O
-	O
6	O
(	O
-	O
/	O
-	O
)	O
mice	O
is	O
consistent	O
with	O
the	O
very	O
severe	O
arthritis	O
seen	O
in	O
these	O
animals	O
.	O

However	O
,	O
the	O
long	O
bones	O
from	O
unchallenged	O
TSG	O
-	O
6	O
(	O
-	O
/	O
-	O
)	O
mice	O
were	O
found	O
to	O
have	O
higher	O
trabecular	O
mass	O
than	O
controls	O
,	O
suggesting	O
that	O
in	O
the	O
absence	O
of	O
inflammation	O
TSG	O
-	O
6	O
has	O
a	O
role	O
in	O
bone	O
homeostasis	O
;	O
we	O
have	O
detected	O
expression	O
of	O
the	O
TSG	O
-	O
6	O
protein	O
in	O
the	O
bone	O
marrow	O
of	O
unchallenged	O
wild	O
type	O
mice	O
.	O

Furthermore	O
,	O
we	O
have	O
observed	O
that	O
TSG	O
-	O
6	O
can	O
inhibit	O
bone	O
morphogenetic	O
protein	O
-	O
2	O
(	O
BMP	O
-	O
2	O
)	O
-	O
mediated	O
osteoblast	O
differentiation	O
.	O

Interaction	O
analysis	O
revealed	O
that	O
TSG	O
-	O
6	O
binds	O
directly	O
to	O
RANKL	O
and	O
to	O
BMP	O
-	O
2	O
(	O
as	O
well	O
as	O
other	O
osteogenic	O
BMPs	O
but	O
not	O
BMP	O
-	O
3	O
)	O
via	O
composite	O
surfaces	O
involving	O
its	O
Link	O
and	O
CUB	O
modules	O
.	O

Consistent	O
with	O
this	O
,	O
the	O
full	O
-	O
length	O
protein	O
is	O
required	O
for	O
maximal	O
inhibition	O
of	O
osteoblast	O
differentiation	O
and	O
osteoclast	O
activation	O
,	O
although	O
the	O
isolated	O
Link	O
module	O
retains	O
significant	O
activity	O
in	O
the	O
latter	O
case	O
.	O

We	O
hypothesize	O
that	O
TSG	O
-	O
6	O
has	O
dual	O
roles	O
in	O
bone	O
remodeling	O
;	O
one	O
protective	O
,	O
where	O
it	O
inhibits	O
RANKL	O
-	O
induced	O
bone	O
erosion	O
in	O
inflammatory	O
diseases	O
such	O
as	O
arthritis	O
,	O
and	O
the	O
other	O
homeostatic	O
,	O
where	O
its	O
interactions	O
with	O
BMP	O
-	O
2	O
and	O
RANKL	O
help	O
to	O
balance	O
mineralization	O
by	O
osteoblasts	O
and	O
bone	O
resorption	O
by	O
osteoclasts	O
.	O

Palmitoylation	O
and	O
membrane	O
interactions	O
of	O
the	O
neuroprotective	O
chaperone	O
cysteine	O
-	O
string	O
protein	O
.	O

Cysteine	O
-	O
string	O
protein	O
(	O
CSP	O
)	O
is	O
an	O
extensively	O
palmitoylated	O
DnaJ	O
-	O
family	O
chaperone	O
,	O
which	O
exerts	O
an	O
important	O
neuroprotective	O
function	O
.	O

Palmitoylation	O
is	O
required	O
for	O
the	O
intracellular	O
sorting	O
and	O
function	O
of	O
CSP	O
,	O
and	O
thus	O
it	O
is	O
important	O
to	O
understand	O
how	O
this	O
essential	O
modification	O
of	O
CSP	O
is	O
regulated	O
.	O

Recent	O
work	O
identified	O
23	O
putative	O
palmitoyl	O
transferases	O
containing	O
a	O
conserved	O
DHHC	O
domain	O
in	O
mammalian	O
cells	O
,	O
and	O
here	O
we	O
show	O
that	O
palmitoylation	O
of	O
CSP	O
is	O
enhanced	O
specifically	O
by	O
co	O
-	O
expression	O
of	O
the	O
Golgi	O
-	O
localized	O
palmitoyl	O
transferases	O
DHHC3	O
,	O
DHHC7	O
,	O
DHHC15	O
,	O
or	O
DHHC17	O
.	O

Indeed	O
,	O
these	O
DHHC	O
proteins	O
promote	O
stable	O
membrane	O
attachment	O
of	O
CSP	O
,	O
which	O
is	O
otherwise	O
cytosolic	O
.	O

An	O
inverse	O
correlation	O
was	O
identified	O
between	O
membrane	O
affinity	O
of	O
unpalmitoylated	O
CSP	O
mutants	O
and	O
subsequent	O
palmitoylation	O
:	O
mutants	O
with	O
an	O
increased	O
membrane	O
affinity	O
localize	O
to	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
are	O
physically	O
separated	O
from	O
the	O
Golgi	O
-	O
localized	O
DHHC	O
proteins	O
.	O

Palmitoylation	O
of	O
an	O
ER	O
-	O
localized	O
mutant	O
could	O
be	O
rescued	O
by	O
brefeldin	O
A	O
treatment	O
,	O
which	O
promotes	O
the	O
mixing	O
of	O
ER	O
and	O
Golgi	O
membranes	O
.	O

Interestingly	O
though	O
,	O
the	O
palmitoylated	O
mutant	O
remained	O
at	O
the	O
ER	O
following	O
brefeldin	O
A	O
washout	O
and	O
did	O
not	O
traffic	O
to	O
more	O
distal	O
membrane	O
compartments	O
.	O

We	O
propose	O
that	O
CSP	O
has	O
a	O
weak	O
membrane	O
affinity	O
that	O
allows	O
the	O
protein	O
to	O
locate	O
its	O
partner	O
Golgi	O
-	O
localized	O
DHHC	O
proteins	O
directly	O
by	O
membrane	O
"	O
sampling	O
.	O
"	O
Mutations	O
that	O
enhance	O
membrane	O
association	O
prevent	O
sampling	O
and	O
lead	O
to	O
accumulation	O
of	O
CSP	O
on	O
cellular	O
membranes	O
such	O
as	O
the	O
ER	O
.	O

The	O
coupling	O
of	O
CSP	O
palmitoylation	O
to	O
Golgi	O
membranes	O
may	O
thus	O
be	O
an	O
important	O
requirement	O
for	O
subsequent	O
sorting	O
.	O

Involvement	O
of	O
heat	O
shock	O
factor	O
1	O
in	O
statin	O
-	O
induced	O
transcriptional	O
upregulation	O
of	O
endothelial	O
thrombomodulin	O
.	O

Statins	O
upregulate	O
endothelial	O
thrombomodulin	O
(	O
TM	O
)	O
by	O
mechanisms	O
that	O
involve	O
members	O
of	O
the	O
Kruppel	O
-	O
like	O
factor	O
family	O
.	O

Although	O
Kruppel	O
-	O
like	O
factors	O
are	O
unequivocally	O
implicated	O
in	O
this	O
process	O
,	O
experimental	O
evidence	O
points	O
to	O
additional	O
mechanisms	O
.	O

Deletion	O
/	O
mutation	O
analysis	O
of	O
reporter	O
constructs	O
was	O
used	O
to	O
demonstrate	O
that	O
mutation	O
of	O
the	O
SP1	O
/	O
Kruppel	O
-	O
like	O
factor	O
element	O
in	O
the	O
TM	O
promoter	O
only	O
partially	O
abolishes	O
statin	O
-	O
induced	O
TM	O
upregulation	O
,	O
whereas	O
simultaneous	O
mutation	O
of	O
relevant	O
heat	O
shock	O
elements	O
and	O
SP1	O
/	O
Kruppel	O
-	O
like	O
factor	O
element	O
completely	O
prevents	O
statin	O
-	O
induced	O
TM	O
upregulation	O
,	O
thus	O
demonstrating	O
a	O
role	O
for	O
heat	O
shock	O
factors	O
(	O
HSFs	O
)	O
.	O

We	O
further	O
identified	O
the	O
pathway	O
by	O
which	O
statins	O
increase	O
binding	O
of	O
HSF1	O
to	O
heat	O
shock	O
elements	O
in	O
the	O
TM	O
promoter	O
.	O

Specifically	O
,	O
statins	O
caused	O
NO	O
-	O
dependent	O
dissociation	O
of	O
HSF1	O
from	O
heat	O
shock	O
protein	O
90	O
,	O
nuclear	O
translocation	O
of	O
HSF1	O
,	O
and	O
binding	O
to	O
heat	O
shock	O
elements	O
in	O
the	O
TM	O
promoter	O
.	O

Statins	O
also	O
decreased	O
nuclear	O
content	O
of	O
the	O
HSF1	O
chaperone	O
14	O
-	O
3	O
-	O
3beta	O
.	O

In	O
addition	O
to	O
reducing	O
TM	O
upregulation	O
,	O
inhibition	O
of	O
HSF1	O
reduced	O
statin	O
-	O
induced	O
upregulation	O
of	O
tissue	O
plasminogen	O
activator	O
,	O
whereas	O
downregulation	O
of	O
thrombomospondin	O
,	O
plasminogen	O
activator	O
inhibitor	O
1	O
,	O
or	O
connective	O
tissue	O
growth	O
factor	O
was	O
unaffected	O
.	O

Knockdown	O
of	O
14	O
-	O
3	O
-	O
3beta	O
or	O
inhibition	O
of	O
HSF1	O
phosphorylation	O
enhanced	O
the	O
effect	O
of	O
statins	O
on	O
TM	O
and	O
tissue	O
plasminogen	O
activator	O
,	O
but	O
did	O
not	O
influence	O
thrombomospondin	O
,	O
plasminogen	O
activator	O
inhibitor	O
1	O
,	O
or	O
connective	O
tissue	O
growth	O
factor	O
.	O

These	O
data	O
demonstrate	O
that	O
HSF1	O
is	O
involved	O
in	O
statin	O
-	O
induced	O
regulation	O
of	O
TM	O
.	O

They	O
also	O
suggest	O
that	O
analogous	O
mechanisms	O
may	O
apply	O
to	O
genes	O
that	O
are	O
upregulated	O
by	O
statins	O
,	O
but	O
not	O
to	O
downregulated	O
genes	O
.	O

These	O
results	O
may	O
have	O
broad	O
implications	O
and	O
suggest	O
the	O
use	O
of	O
heat	O
shock	O
protein	O
modulators	O
to	O
selectively	O
regulate	O
pleiotropic	O
statin	O
effects	O
.	O

The	O
Ecdysone	O
-	O
inducible	O
zinc	O
-	O
finger	O
transcription	O
factor	O
Crol	O
regulates	O
Wg	O
transcription	O
and	O
cell	O
cycle	O
progression	O
in	O
Drosophila	O
.	O

The	O
steroid	O
hormone	O
Ecdysone	O
is	O
crucial	O
for	O
developmental	O
cell	O
death	O
,	O
proliferation	O
and	O
morphogenesis	O
in	O
Drosophila	O
.	O

Herein	O
,	O
we	O
delineate	O
a	O
molecular	O
pathway	O
linking	O
Ecdysone	O
signalling	O
to	O
cell	O
cycle	O
regulation	O
in	O
the	O
Drosophila	O
developing	O
wing	O
.	O

We	O
present	O
evidence	O
that	O
the	O
Ecdysone	O
-	O
inducible	O
zinc	O
-	O
finger	O
transcription	O
factor	O
Crol	O
provides	O
a	O
crucial	O
link	O
between	O
the	O
Ecdysone	O
steroid	O
hormone	O
pathway	O
and	O
the	O
Wingless	O
(	O
Wg	O
)	O
signalling	O
pathway	O
in	O
Drosophila	O
.	O

We	O
identified	O
Crol	O
as	O
a	O
strong	O
enhancer	O
of	O
a	O
wing	O
phenotype	O
generated	O
by	O
overexpression	O
of	O
the	O
Wg	O
-	O
inducible	O
cell	O
cycle	O
inhibitor	O
Hfp	O
.	O

We	O
demonstrate	O
that	O
Crol	O
is	O
required	O
for	O
cell	O
cycle	O
progression	O
:	O
crol	O
mutant	O
clones	O
have	O
reduced	O
cell	O
cycles	O
and	O
are	O
removed	O
by	O
apoptosis	O
,	O
while	O
upregulation	O
of	O
Crol	O
overrides	O
the	O
Wg	O
-	O
mediated	O
developmental	O
cell	O
cycle	O
arrest	O
in	O
the	O
zone	O
of	O
non	O
-	O
proliferating	O
cells	O
in	O
the	O
wing	O
disc	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
Crol	O
acts	O
to	O
repress	O
wg	O
transcription	O
.	O

We	O
also	O
show	O
that	O
overexpression	O
of	O
crol	O
results	O
in	O
downregulation	O
of	O
Hfp	O
,	O
consistent	O
with	O
the	O
identification	O
of	O
the	O
crol	O
mutant	O
as	O
a	O
dominant	O
enhancer	O
of	O
the	O
Hfp	O
overexpression	O
phenotype	O
.	O

Taken	O
together	O
,	O
our	O
studies	O
have	O
revealed	O
a	O
novel	O
mechanism	O
for	O
cell	O
cycle	O
regulation	O
,	O
whereby	O
Crol	O
links	O
steroid	O
hormone	O
signals	O
to	O
Wg	O
signalling	O
and	O
the	O
regulation	O
of	O
crucial	O
cell	O
cycle	O
targets	O
.	O

In	O
Drosophila	O
,	O
the	O
expression	O
of	O
particular	O
Or	O
genes	O
,	O
and	O
hence	O
the	O
odor	O
-	O
specificity	O
of	O
the	O
ORN	O
,	O
has	O
recently	O
been	O
found	O
to	O
depend	O
on	O
a	O
regulatory	O
code	O
of	O
cis	O
-	O
acting	O
elements	O
.	O

Transcription	O
factors	O
that	O
act	O
in	O
the	O
process	O
of	O
receptor	O
gene	O
expression	O
include	O
Acj6	O
(	O
Abnormal	O
chemosensory	O
jump	O
6	O
)	O
,	O
a	O
POU	O
transcription	O
factor	O
.	O

The	O
acj6	O
gene	O
was	O
identified	O
by	O
a	O
defect	O
in	O
olfactory	O
behavior	O
.	O

In	O
a	O
null	O
mutant	O
of	O
acj6	O
,	O
some	O
maxillary	O
palp	O
ORNs	O
respond	O
normally	O
to	O
odors	O
,	O
some	O
are	O
present	O
but	O
have	O
lost	O
response	O
to	O
all	O
odors	O
,	O
and	O
some	O
undergo	O
changes	O
in	O
odor	O
specificity	O
.	O

Correspondingly	O
,	O
acj6	O
is	O
required	O
for	O
the	O
expression	O
of	O
a	O
subset	O
of	O
Or	O
genes	O
.	O

Betacellulin	O
stimulates	O
growth	O
of	O
the	O
mouse	O
intestinal	O
epithelium	O
and	O
increases	O
adenoma	O
multiplicity	O
in	O
Apc	O
+	O
/	O
Min	O
mice	O
.	O

We	O
employed	O
transgenic	O
mice	O
overexpressing	O
betacellulin	O
(	O
BTC	O
)	O
to	O
study	O
its	O
effects	O
in	O
the	O
gut	O
.	O

BTC	O
stimulated	O
crypt	O
cell	O
proliferation	O
and	O
markedly	O
increased	O
intestinal	O
size	O
,	O
while	O
the	O
crypt	O
-	O
villus	O
architecture	O
was	O
preserved	O
.	O

Introduction	O
of	O
a	O
dominant	O
negative	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
completely	O
abolished	O
the	O
intestinal	O
hyperplasia	O
.	O

BTC	O
increased	O
polyp	O
multiplicity	O
but	O
did	O
not	O
change	O
the	O
mean	O
size	O
or	O
the	O
histological	O
quality	O
of	O
intestinal	O
polyps	O
in	O
Apc	O
(	O
+	O
/	O
Min	O
)	O
mice	O
.	O

Analysis	O
of	O
intact	O
and	O
cleaved	O
caspase	O
-	O
3	O
levels	O
indicated	O
that	O
BTC	O
has	O
anti	O
-	O
apoptotic	O
effects	O
in	O
the	O
intestinal	O
epithelium	O
.	O

We	O
conclude	O
that	O
increased	O
BTC	O
levels	O
support	O
the	O
survival	O
of	O
nascent	O
adenomas	O
in	O
Apc	O
(	O
+	O
/	O
Min	O
)	O
mice	O
,	O
resulting	O
in	O
a	O
larger	O
total	O
polyp	O
number	O
at	O
later	O
stages	O
.	O

Ubiquitylation	O
is	O
required	O
for	O
degradation	O
of	O
transmembrane	O
surface	O
proteins	O
in	O
trypanosomes	O
.	O

The	O
surface	O
of	O
Trypanosoma	O
brucei	O
is	O
dominated	O
by	O
glycosyl	O
-	O
phosphatidylinositol	O
(	O
GPI	O
)	O
-	O
anchored	O
proteins	O
,	O
and	O
endocytosis	O
is	O
clathrin	B-Complex
dependent	O
.	O

The	O
vast	O
majority	O
of	O
internalized	O
GPI	O
-	O
anchored	O
protein	O
is	O
efficiently	O
recycled	O
,	O
while	O
the	O
processes	O
by	O
which	O
transmembrane	O
domain	O
(	O
TMD	O
)	O
proteins	O
are	O
internalized	O
and	O
sorted	O
are	O
unknown	O
.	O

We	O
demonstrate	O
that	O
internalization	O
of	O
invariant	O
surface	O
glycoprotein	O
(	O
ISG	O
)	O
65	O
,	O
a	O
trypanosome	O
TMD	O
protein	O
,	O
involves	O
ubiquitylation	O
and	O
also	O
requires	O
clathrin	B-Complex
.	O

We	O
find	O
a	O
hierarchical	O
requirement	O
for	O
cytoplasmic	O
lysine	O
residues	O
in	O
internalization	O
and	O
turnover	O
,	O
and	O
a	O
single	O
position	O
-	O
specific	O
lysine	O
is	O
sufficient	O
for	O
degradation	O
,	O
surface	O
removal	O
and	O
attachment	O
of	O
oligoubiquitin	O
chains	O
.	O

Ubiquitylation	O
is	O
context	O
dependent	O
as	O
provision	O
of	O
additional	O
lysine	O
residues	O
by	O
C	O
-	O
terminal	O
fusion	O
of	O
neuronal	O
precursor	O
cell	O
-	O
expressed	O
developmentally	O
downregulated	O
protein	O
(	O
NEDD	O
)	O
8	O
fails	O
to	O
support	O
ubiquitylation	O
.	O

Attachment	O
of	O
NEDD8	O
leads	O
to	O
degradation	O
by	O
a	O
second	O
ubiquitin	O
-	O
independent	O
pathway	O
.	O

Moreover	O
,	O
degradation	O
of	O
ubiquitylated	O
or	O
NEDDylated	O
substrate	O
takes	O
place	O
in	O
an	O
acidic	O
compartment	O
and	O
is	O
proteosome	B-Complex
independent	O
.	O

Significantly	O
,	O
in	O
non	O
-	O
opisthokont	O
lineages	O
,	O
Rsp5p	O
or	O
c	O
-	O
Cbl	O
,	O
the	O
E3	O
ubiquitin	O
ligases	O
acting	O
on	O
endocytic	O
cargo	O
,	O
are	O
absent	O
but	O
Uba1	O
class	O
genes	O
are	O
present	O
and	O
are	O
required	O
for	O
cell	O
viability	O
and	O
ISG65	O
ubiquitylation	O
.	O

Hence	O
,	O
ubiquitylation	O
is	O
an	O
evolutionarily	O
conserved	O
mechanism	O
for	O
internalization	O
of	O
surface	O
proteins	O
,	O
but	O
aspects	O
of	O
the	O
machinery	O
differ	O
substantially	O
between	O
the	O
major	O
eukaryotic	O
lineages	O
.	O

Given	O
the	O
the	O
in	O
vitro	O
interactions	O
of	O
Rbf1N	O
with	O
ORC	B-Complex
and	O
colocalization	O
of	O
Rbf1N	O
and	O
Orc2	O
,	O
we	O
hypothesized	O
that	O
the	O
Rbf1N	O
domain	O
may	O
function	O
to	O
regulate	O
cell	O
cycle	O
progression	O
in	O
general	O
and	O
DNA	O
replication	O
in	O
particular	O
.	O

To	O
test	O
this	O
hypothesis	O
we	O
overexpressed	O
the	O
Rbf1N	O
protein	O
in	O
tissues	O
of	O
transgenic	O
Drosophila	O
.	O

First	O
,	O
actin	O
>	O
GAL4	O
driving	O
expression	O
of	O
the	O
UAS	O
>	O
Rbf1N	O
-	O
RFP	O
was	O
examined	O
in	O
the	O
ovarian	O
follicle	O
cells	O
.	O

We	O
observed	O
robust	O
expression	O
and	O
nuclear	O
localization	O
of	O
the	O
Rbf1N	O
-	O
RFP	O
in	O
follicle	O
cells	O
,	O
however	O
BrdU	O
labeling	O
of	O
follicle	O
cells	O
did	O
not	O
reveal	O
any	O
detectable	O
changes	O
in	O
DNA	O
replication	O
patterns	O
during	O
endoreplication	O
or	O
chorion	O
gene	O
amplification	O
(	O
data	O
not	O
shown	O
)	O
.	O

Flow	O
cytometry	O
analysis	O
of	O
follicle	O
cell	O
nuclei	O
also	O
did	O
not	O
reveal	O
any	O
significant	O
differences	O
in	O
ploidy	O
content	O
(	O
Table	O
S1	O
)	O
,	O
proportion	O
of	O
follicle	O
cells	O
in	O
S	O
phase	O
(	O
Table	O
S2	O
)	O
or	O
nuclear	O
size	O
(	O
Table	O
S3	O
)	O
versus	O
controls	O
.	O

In	O
addition	O
,	O
overexpression	O
of	O
Rbf1N	O
-	O
RFP	O
in	O
diploid	O
proliferating	O
neuroblasts	O
similarly	O
did	O
not	O
cause	O
any	O
cell	O
cycle	O
pertubation	O
,	O
as	O
assayed	O
by	O
flow	O
cytometry	O
(	O
data	O
not	O
shown	O
)	O
.	O

Lastly	O
,	O
overexpression	O
of	O
different	O
independent	O
insertion	O
lines	O
of	O
UAS	O
>	O
Rbf1N	O
-	O
RFP	O
in	O
the	O
developing	O
eye	O
by	O
GMR	O
>	O
GAL4	O
or	O
ey	O
>	O
GAL4	O
did	O
not	O
yield	O
any	O
obvious	O
adult	O
eye	O
phenotypes	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
data	O
suggest	O
that	O
although	O
Rbf1N	O
is	O
sufficient	O
for	O
chromatin	O
localization	O
and	O
its	O
interaction	O
with	O
Orc2	O
,	O
the	O
Rbf1N	O
(	O
1	O
-	O
345	O
)	O
domain	O
alone	O
is	O
not	O
sufficient	O
for	O
significantly	O
altering	O
the	O
cell	O
cycle	O
in	O
vivo	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
third	O
PHD	O
finger	O
of	O
MLL	O
interacts	O
with	O
Cyp33	O
/	O
PPIE	O
,	O
an	O
RNA	O
binding	O
nuclear	O
cyclophilin	O
.	O

Cyp33	O
enhances	O
the	O
recruitment	O
of	O
HDAC1	O
to	O
the	O
MLL	O
repression	O
domain	O
and	O
down	O
-	O
regulates	O
expression	O
of	O
the	O
HOXC8	O
gene	O
in	O
an	O
MLL	O
dependent	O
manner	O
.	O

This	O
indicates	O
that	O
Cyp33	O
may	O
contribute	O
to	O
the	O
intrinsic	O
repression	O
potential	O
of	O
MLL	O
.	O

The	O
MLL	O
repression	O
domain	O
,	O
Cyp33	O
,	O
and	O
the	O
PHD	O
finger	O
domain	O
form	O
a	O
repression	O
unit	O
that	O
contributes	O
to	O
the	O
repression	O
potential	O
of	O
MLL	O
-	O
N	O
and	O
balances	O
the	O
activation	O
potential	O
of	O
MLL	O
-	O
C	O
.	O

In	O
MLL	O
-	O
ENL	O
,	O
the	O
loss	O
of	O
the	O
PHD	O
fingers	O
disrupts	O
this	O
repression	O
unit	O
.	O

Therefore	O
,	O
the	O
intrinsic	O
repression	O
potential	O
is	O
compromised	O
,	O
and	O
in	O
the	O
presence	O
of	O
an	O
activation	O
domain	O
on	O
the	O
partner	O
protein	O
,	O
the	O
MLL	O
-	O
ENL	O
fusion	O
functions	O
as	O
a	O
dominant	O
constitutive	O
activator	O
of	O
MLL	O
target	O
HOX	O
genes	O
.	O

The	O
HOOK	O
-	O
domain	O
between	O
the	O
SH3	O
and	O
the	O
GK	O
domains	O
of	O
Cavbeta	O
subunits	O
contains	O
key	O
determinants	O
controlling	O
calcium	O
channel	O
inactivation	O
.	O

Ca	O
(	O
v	O
)	O
beta	O
subunits	O
of	O
voltage	O
-	O
gated	O
calcium	O
channels	O
contain	O
two	O
conserved	O
domains	O
,	O
a	O
src	O
-	O
homology	O
-	O
3	O
(	O
SH3	O
)	O
-	O
domain	O
and	O
a	O
guanylate	O
kinase	O
-	O
like	O
(	O
GK	O
)	O
-	O
domain	O
.	O

The	O
SH3	O
-	O
domain	O
is	O
split	O
,	O
with	O
its	O
final	O
(	O
fifth	O
)	O
beta	O
-	O
strand	O
separated	O
from	O
the	O
rest	O
of	O
the	O
domain	O
by	O
an	O
intervening	O
sequence	O
termed	O
the	O
HOOK	O
-	O
domain	O
,	O
whose	O
sequence	O
varies	O
between	O
Ca	O
(	O
v	O
)	O
beta	O
subunits	O
.	O

Here	O
we	O
have	O
been	O
guided	O
by	O
the	O
recent	O
structural	O
studies	O
of	O
Ca	O
(	O
v	O
)	O
beta	O
subunits	O
in	O
the	O
design	O
of	O
specific	O
truncated	O
constructs	O
,	O
with	O
the	O
goal	O
of	O
investigating	O
the	O
role	O
of	O
the	O
HOOK	O
-	O
domain	O
of	O
Ca	O
(	O
v	O
)	O
beta	O
subunits	O
in	O
the	O
modulation	O
of	O
inactivation	O
of	O
N	O
-	O
type	O
calcium	O
channels	O
.	O

We	O
have	O
coexpressed	O
the	O
beta	O
subunit	O
constructs	O
with	O
Ca	O
(	O
v	O
)	O
2	O
.	O
2	O
and	O
alpha	O
(	O
2	O
)	O
delta	O
-	O
2	O
,	O
using	O
the	O
N	O
-	O
terminally	O
palmitoylated	O
beta	O
(	O
2a	O
)	O
subunit	O
,	O
because	O
it	O
supports	O
very	O
little	O
voltage	O
-	O
dependent	O
inactivation	O
,	O
and	O
made	O
comparisons	O
with	O
beta	O
(	O
1b	O
)	O
domains	O
.	O

Deletion	O
of	O
the	O
variable	O
region	O
of	O
the	O
beta	O
(	O
2a	O
)	O
HOOK	O
-	O
domain	O
resulted	O
in	O
currents	O
with	O
a	O
rapidly	O
inactivating	O
component	O
,	O
and	O
additional	O
mutation	O
of	O
the	O
beta	O
(	O
2a	O
)	O
palmitoylation	O
motif	O
further	O
enhanced	O
inactivation	O
.	O

The	O
isolated	O
GK	O
-	O
domain	O
of	O
beta	O
(	O
2a	O
)	O
alone	O
enhanced	O
current	O
amplitude	O
,	O
but	O
the	O
currents	O
were	O
rapidly	O
and	O
completely	O
inactivating	O
.	O

When	O
the	O
beta	O
(	O
2a	O
)	O
-	O
GK	O
-	O
domain	O
construct	O
was	O
extended	O
proximally	O
,	O
by	O
including	O
the	O
HOOK	O
-	O
domain	O
and	O
the	O
epsilon	O
-	O
strand	O
of	O
the	O
SH3	O
-	O
domain	O
,	O
inactivation	O
was	O
about	O
four	O
-	O
fold	O
slower	O
than	O
in	O
the	O
absence	O
of	O
the	O
HOOK	O
domain	O
.	O

When	O
the	O
SH3	O
-	O
domain	O
of	O
beta	O
(	O
2a	O
)	O
truncated	O
prior	O
to	O
the	O
HOOK	O
-	O
domain	O
was	O
coexpressed	O
with	O
the	O
(	O
HOOK	O
+	O
epsilonSH3	O
+	O
GK	O
)	O
-	O
domain	O
of	O
beta	O
(	O
2a	O
)	O
,	O
all	O
the	O
properties	O
of	O
beta	O
(	O
2a	O
)	O
were	O
restored	O
,	O
in	O
terms	O
of	O
loss	O
of	O
inactivation	O
.	O

Furthermore	O
,	O
removal	O
of	O
the	O
HOOK	O
sequence	O
from	O
the	O
(	O
HOOK	O
+	O
epsilonSH3	O
+	O
GK	O
)	O
-	O
beta	O
(	O
2a	O
)	O
construct	O
increased	O
inactivation	O
.	O

Together	O
,	O
these	O
results	O
provide	O
evidence	O
that	O
the	O
HOOK	O
domain	O
is	O
an	O
important	O
determinant	O
of	O
inactivation	O
.	O

Polyubiquitination	O
of	O
proliferating	B-OOS
cell	I-OOS
nuclear	I-OOS
antigen	I-OOS
by	O
HLTF	O
and	O
SHPRH	O
prevents	O
genomic	O
instability	O
from	O
stalled	O
replication	O
forks	O
.	O

Chronic	O
stalling	O
of	O
DNA	O
replication	O
forks	O
caused	O
by	O
DNA	O
damage	O
can	O
lead	O
to	O
genomic	O
instability	O
.	O

Cells	O
have	O
evolved	O
lesion	O
bypass	O
pathways	O
such	O
as	O
postreplication	O
repair	O
(	O
PRR	O
)	O
to	O
resolve	O
these	O
arrested	O
forks	O
.	O

In	O
yeast	O
,	O
one	O
branch	O
of	O
PRR	O
involves	O
proliferating	B-OOS
cell	I-OOS
nuclear	I-OOS
antigen	I-OOS
(	O
PCNA	B-OOS
)	O
polyubiquitination	O
mediated	O
by	O
the	O
Rad5	O
-	O
Ubc13	O
-	O
Mms2	O
complex	O
that	O
allows	O
bypass	O
of	O
DNA	O
lesion	O
by	O
a	O
template	O
-	O
switching	O
mechanism	O
.	O

Previously	O
,	O
we	O
identified	O
human	O
SHPRH	O
as	O
a	O
functional	O
homologue	O
of	O
yeast	O
Rad5	O
and	O
revealed	O
the	O
existence	O
of	O
RAD5	O
-	O
like	O
pathway	O
in	O
human	O
cells	O
.	O

Here	O
we	O
report	O
the	O
identification	O
of	O
HLTF	O
as	O
a	O
second	O
RAD5	O
homologue	O
in	O
human	O
cells	O
.	O

HLTF	O
,	O
like	O
SHPRH	O
,	O
shares	O
a	O
unique	O
domain	O
architecture	O
with	O
Rad5	O
and	O
promotes	O
lysine	O
63	O
-	O
linked	O
polyubiquitination	O
of	O
PCNA	B-OOS
.	O

Similar	O
to	O
yeast	O
Rad5	O
,	O
HLTF	O
is	O
able	O
to	O
interact	O
with	O
UBC13	O
and	O
PCNA	B-OOS
,	O
as	O
well	O
as	O
SHPRH	O
;	O
and	O
the	O
reduction	O
of	O
either	O
SHPRH	O
or	O
HLTF	O
expression	O
enhances	O
spontaneous	O
mutagenesis	O
.	O

Moreover	O
,	O
Hltf	O
-	O
deficient	O
mouse	O
embryonic	O
fibroblasts	O
show	O
elevated	O
chromosome	O
breaks	O
and	O
fusions	O
after	O
methyl	O
methane	O
sulfonate	O
treatment	O
.	O

Our	O
results	O
suggest	O
that	O
HLTF	O
and	O
SHPRH	O
are	O
functional	O
homologues	O
of	O
yeast	O
Rad5	O
that	O
cooperatively	O
mediate	O
PCNA	B-OOS
polyubiquitination	O
and	O
maintain	O
genomic	O
stability	O
.	O

Structural	O
basis	O
for	O
recognition	O
of	O
hemi	O
-	O
methylated	O
DNA	O
by	O
the	O
SRA	O
domain	O
of	O
human	O
UHRF1	O
.	O

Epigenetic	O
inheritance	O
in	O
mammals	O
is	O
characterized	O
by	O
high	O
-	O
fidelity	O
replication	O
of	O
CpG	O
methylation	O
patterns	O
during	O
development	O
.	O

UHRF1	O
(	O
also	O
known	O
as	O
ICBP90	O
in	O
humans	O
and	O
Np95	O
in	O
mouse	O
)	O
is	O
an	O
E3	O
ligase	O
important	O
for	O
the	O
maintenance	O
of	O
global	O
and	O
local	O
DNA	O
methylation	O
in	O
vivo	O
.	O

The	O
preferential	O
affinity	O
of	O
UHRF1	O
for	O
hemi	O
-	O
methylated	O
DNA	O
over	O
symmetrically	O
methylated	O
DNA	O
by	O
means	O
of	O
its	O
SET	O
and	O
RING	O
-	O
associated	O
(	O
SRA	O
)	O
domain	O
and	O
its	O
association	O
with	O
the	O
maintenance	O
DNA	O
methyltransferase	O
1	O
(	O
DNMT1	O
)	O
suggests	O
a	O
role	O
in	O
replication	O
of	O
the	O
epigenetic	O
code	O
.	O

Here	O
we	O
report	O
the	O
1	O
.	O
7	O
A	O
crystal	O
structure	O
of	O
the	O
apo	O
SRA	O
domain	O
of	O
human	O
UHRF1	O
and	O
a	O
2	O
.	O
2	O
A	O
structure	O
of	O
its	O
complex	O
with	O
hemi	O
-	O
methylated	O
DNA	O
,	O
revealing	O
a	O
previously	O
unknown	O
reading	O
mechanism	O
for	O
methylated	O
CpG	O
sites	O
(	O
mCpG	O
)	O
.	O

The	O
SRA	O
-	O
DNA	O
complex	O
has	O
several	O
notable	O
structural	O
features	O
including	O
a	O
binding	O
pocket	O
that	O
accommodates	O
the	O
5	O
-	O
methylcytosine	O
that	O
is	O
flipped	O
out	O
of	O
the	O
duplex	O
DNA	O
.	O

Two	O
specialized	O
loops	O
reach	O
through	O
the	O
resulting	O
gap	O
in	O
the	O
DNA	O
from	O
both	O
the	O
major	O
and	O
the	O
minor	O
grooves	O
to	O
read	O
the	O
other	O
three	O
bases	O
of	O
the	O
CpG	O
duplex	O
.	O

The	O
major	O
groove	O
loop	O
confers	O
both	O
specificity	O
for	O
the	O
CpG	O
dinucleotide	O
and	O
discrimination	O
against	O
methylation	O
of	O
deoxycytidine	O
of	O
the	O
complementary	O
strand	O
.	O

The	O
structure	O
,	O
along	O
with	O
mutagenesis	O
data	O
,	O
suggests	O
how	O
UHRF1	O
acts	O
as	O
a	O
key	O
factor	O
for	O
DNMT1	O
maintenance	O
methylation	O
through	O
recognition	O
of	O
a	O
fundamental	O
unit	O
of	O
epigenetic	O
inheritance	O
,	O
mCpG	O
.	O

The	O
CCT	B-Complex
/	I-Complex
TRiC	I-Complex
chaperonin	I-Complex
is	O
required	O
for	O
maturation	O
of	O
sphingosine	O
kinase	O
1	O
.	O

Sphingosine	O
kinase	O
1	O
(	O
SK1	O
)	O
catalyses	O
the	O
generation	O
of	O
sphingosine	O
1	O
-	O
phosphate	O
(	O
S1P	O
)	O
,	O
a	O
bioactive	O
phospholipid	O
that	O
influences	O
a	O
diverse	O
range	O
of	O
cellular	O
processes	O
,	O
including	O
proliferation	O
,	O
survival	O
,	O
adhesion	O
,	O
migration	O
,	O
morphogenesis	O
and	O
differentiation	O
.	O

SK1	O
is	O
controlled	O
by	O
various	O
mechanisms	O
,	O
including	O
transcriptional	O
regulation	O
,	O
and	O
post	O
-	O
translational	O
activation	O
by	O
phosphorylation	O
and	O
protein	O
-	O
protein	O
interactions	O
which	O
can	O
regulate	O
both	O
the	O
activity	O
and	O
localisation	O
of	O
this	O
enzyme	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
regulatory	O
mechanisms	O
controlling	O
SK1	O
activity	O
and	O
function	O
we	O
performed	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
to	O
identify	O
SK1	O
-	O
interacting	O
proteins	O
.	O

Using	O
this	O
approach	O
we	O
identified	O
that	O
SK1	O
interacts	O
with	O
subunit	O
7	O
(	O
eta	O
)	O
of	O
cytosolic	B-Complex
chaperonin	I-Complex
CCT	I-Complex
(	O
chaperonin	B-Complex
containing	I-Complex
t	I-Complex
-	I-Complex
complex	I-Complex
polypeptide	I-Complex
,	O
also	O
called	O
TRiC	B-Complex
for	O
TCP	B-Complex
-	I-Complex
1	I-Complex
ring	I-Complex
complex	O
)	O
,	O
a	O
hexadecameric	O
chaperonin	O
that	O
binds	O
unfolded	O
polypeptides	O
and	O
mediates	O
their	O
folding	O
and	O
release	O
in	O
an	O
ATP	O
-	O
dependent	O
manner	O
.	O

Further	O
analysis	O
of	O
the	O
SK1	O
-	O
CCTeta	O
interaction	O
demonstrated	O
that	O
other	O
CCT	B-Complex
/	I-Complex
TRiC	I-Complex
subunits	O
also	O
associated	O
with	O
SK1	O
in	O
HEK293T	O
cell	O
lysates	O
in	O
an	O
ATP	O
-	O
sensitive	O
manner	O
,	O
suggesting	O
that	O
the	O
intact	O
,	O
functional	O
,	O
multimeric	O
CCT	B-Complex
/	I-Complex
TRiC	I-Complex
complex	O
associated	O
with	O
SK1	O
.	O

Furthermore	O
,	O
pulse	O
-	O
chase	O
studies	O
indicated	O
that	O
CCT	B-Complex
/	I-Complex
TRiC	I-Complex
binds	O
specifically	O
to	O
newly	O
translated	O
SK1	O
.	O

Finally	O
,	O
depletion	O
of	O
functional	O
CCT	B-Complex
/	I-Complex
TRiC	I-Complex
through	O
the	O
use	O
of	O
RNA	O
interference	O
in	O
HeLa	O
cells	O
or	O
temperature	O
sensitive	O
CCT	B-Complex
yeast	O
mutants	O
reduced	O
cellular	O
SK1	O
activity	O
.	O

Thus	O
,	O
combined	O
this	O
data	O
suggests	O
that	O
SK1	O
is	O
a	O
CCT	B-Complex
/	I-Complex
TRiC	I-Complex
substrate	O
,	O
and	O
that	O
this	O
chaperonin	O
facilitates	O
folding	O
of	O
newly	O
translated	O
SK1	O
into	O
its	O
mature	O
active	O
form	O
.	O

Effect	O
of	O
metal	O
binding	O
and	O
posttranslational	O
lysine	O
carboxylation	O
on	O
the	O
activity	O
of	O
recombinant	O
hydantoinase	O
.	O

Bacterial	O
hydantoinase	O
possesses	O
a	O
binuclear	O
metal	O
center	O
in	O
which	O
two	O
metal	O
ions	O
are	O
bridged	O
by	O
a	O
posttranslationally	O
carboxylated	O
lysine	O
.	O

How	O
the	O
carboxylated	O
lysine	O
and	O
metal	O
binding	O
affect	O
the	O
activity	O
of	O
hydantoinase	O
was	O
investigated	O
.	O

A	O
significant	O
amount	O
of	O
iron	O
was	O
always	O
found	O
in	O
Agrobacterium	O
radiobacter	O
hydantoinase	O
purified	O
from	O
unsupplemented	O
cobalt	O
-	O
,	O
manganese	O
-	O
,	O
or	O
zinc	O
-	O
amended	O
Escherichia	O
coli	O
cell	O
cultures	O
.	O

A	O
titration	O
curve	O
for	O
the	O
reactivation	O
of	O
apohydantoinase	O
with	O
cobalt	O
indicates	O
that	O
the	O
first	O
metal	O
was	O
preferentially	O
bound	O
but	O
did	O
not	O
give	O
any	O
enzyme	O
activity	O
until	O
the	O
second	O
metal	O
was	O
also	O
attached	O
to	O
the	O
hydantoinase	O
.	O

The	O
pH	O
profiles	O
of	O
the	O
metal	O
-	O
reconstituted	O
hydantoinase	O
were	O
dependent	O
on	O
the	O
specific	O
metal	O
ion	O
bound	O
to	O
the	O
active	O
site	O
,	O
indicating	O
a	O
direct	O
involvement	O
of	O
metal	O
in	O
catalysis	O
.	O

Mutation	O
of	O
the	O
metal	O
binding	O
site	O
residues	O
,	O
H57A	O
,	O
H59A	O
,	O
K148A	O
,	O
H181A	O
,	O
H237A	O
,	O
and	O
D313A	O
,	O
completely	O
abolished	O
hydantoinase	O
activity	O
but	O
preserved	O
about	O
half	O
of	O
the	O
metal	O
content	O
,	O
except	O
for	O
K148A	O
,	O
which	O
lost	O
both	O
metals	O
in	O
its	O
active	O
site	O
.	O

However	O
,	O
the	O
activity	O
of	O
K148A	O
could	O
be	O
chemically	O
rescued	O
by	O
short	O
-	O
chain	O
carboxylic	O
acids	O
in	O
the	O
presence	O
of	O
cobalt	O
,	O
indicating	O
that	O
the	O
carboxylated	O
lysine	O
was	O
needed	O
to	O
coordinate	O
the	O
binuclear	O
ion	O
within	O
the	O
active	O
site	O
of	O
hydantoinase	O
.	O

The	O
mutant	O
D313E	O
enzyme	O
was	O
also	O
active	O
but	O
resulted	O
in	O
a	O
pH	O
profile	O
different	O
from	O
that	O
of	O
wild	O
-	O
type	O
hydantoinase	O
.	O

A	O
mechanism	O
for	O
hydantoinase	O
involving	O
metal	O
,	O
carboxylated	O
K148	O
,	O
and	O
D313	O
was	O
proposed	O
.	O

For	O
tubulin	O
,	O
we	O
created	O
an	O
S	O
.	O
pombe	O
strain	O
mmsp174	O
(	O
h	O
-	O
ura4	O
.	O
d18	O
arg3	O
.	O
D4	O
atb2	O
-	O
:	O
:	O
nda2	O
+	O
)	O
containing	O
only	O
alpha1	O
-	O
and	O
beta	O
-	O
tubulin	O
protein	O
isoforms	O
by	O
replacing	O
the	O
atb2	O
(	O
alpha2	O
)	O
gene	O
protein	O
-	O
encoding	O
region	O
with	O
the	O
protein	O
-	O
coding	O
region	O
of	O
the	O
alpha1	O
gene	O
nda2	O
using	O
a	O
DNA	O
fragment	O
that	O
was	O
PCR	O
-	O
amplified	O
from	O
genomic	O
DNA	O
using	O
a	O
previously	O
described	O
method	O
.	O

Single	O
isoform	O
S	O
.	O
pombe	O
alpha1	O
-	O
and	O
beta	O
-	O
tubulin	O
was	O
prepared	O
by	O
a	O
modification	O
of	O
a	O
previously	O
described	O
method	O
to	O
be	O
described	O
in	O
detail	O
elsewhere	O
.	O

Purified	O
tubulins	O
were	O
desalted	O
into	O
K	O
-	O
PEM	O
buffer	O
(	O
100	O
mM	O
PIPES	O
,	O
1	O
mM	O
MgSO4	O
and	O
2	O
mM	O
EGTA	O
adjusted	O
to	O
pH	O
6	O
.	O
9	O
with	O
KOH	O
)	O
containing	O
20	O
muM	O
GDP	O
before	O
storage	O
in	O
liquid	O
nitrogen	O
.	O

Protein	O
concentrations	O
were	O
determined	O
by	O
UV	O
-	O
absorption	O
scan	O
of	O
protein	O
samples	O
dissolved	O
in	O
6	O
M	O
guanidine	O
hydrochloride	O
,	O
assuming	O
full	O
nucleotide	O
occupancy	O
and	O
epsilon	O
of	O
108	O
,	O
390	O
M	O
-	O
1	O
cm	O
-	O
1	O
.	O

To	O
determine	O
if	O
these	O
large	O
PopZ	O
complexes	O
exist	O
in	O
C	O
.	O
crescentus	O
,	O
we	O
compared	O
the	O
mobility	O
of	O
PopZ	O
in	O
whole	O
cell	O
lysates	O
of	O
C	O
.	O
crescentus	O
and	O
E	O
.	O
coli	O
cultures	O
(	O
expressing	O
PopZ	O
)	O
with	O
purified	O
protein	O
(	O
Figure	O
6C	O
)	O
.	O

We	O
found	O
that	O
the	O
majority	O
of	O
PopZ	O
in	O
C	O
.	O
crescentus	O
cells	O
is	O
the	O
same	O
size	O
as	O
the	O
major	O
band	O
in	O
E	O
.	O
coli	O
,	O
indicating	O
that	O
the	O
high	O
molecular	O
weight	O
PopZ	O
complex	O
is	O
a	O
physiologically	O
relevant	O
form	O
.	O

In	O
the	O
whole	O
cell	O
lysates	O
,	O
we	O
observed	O
an	O
additional	O
band	O
(	O
excluded	O
from	O
our	O
preparations	O
of	O
purified	O
PopZ	O
during	O
size	O
exclusion	O
chromatography	O
)	O
that	O
is	O
approximately	O
half	O
the	O
size	O
of	O
the	O
major	O
band	O
,	O
suggesting	O
that	O
PopZ	O
complex	O
assembly	O
has	O
at	O
least	O
one	O
stable	O
alternate	O
or	O
intermediate	O
form	O
.	O

Since	O
we	O
were	O
unable	O
to	O
detect	O
monomeric	O
PopZ	O
in	O
whole	O
cell	O
lysates	O
,	O
we	O
propose	O
that	O
PopZ	O
is	O
synthesized	O
and	O
assembled	O
into	O
small	O
oligomers	O
(	O
approximately	O
325	O
kDa	O
and	O
650	O
kDa	O
)	O
in	O
the	O
cytoplasm	O
.	O

We	O
examined	O
the	O
effects	O
of	O
inhibiting	O
MreB	O
activity	O
on	O
the	O
formation	O
of	O
PopZ	O
oligomers	O
,	O
and	O
found	O
that	O
the	O
depletion	O
of	O
MreB	O
from	O
C	O
.	O
crescentus	O
(	O
Fig	O
6C	O
,	O
compare	O
lanes	O
4	O
and	O
5	O
)	O
and	O
the	O
addition	O
of	O
A22	O
to	O
E	O
.	O
coli	O
(	O
compare	O
lanes	O
2	O
and	O
3	O
)	O
did	O
not	O
affect	O
the	O
PopZ	O
oligomerization	O
state	O
in	O
whole	O
cell	O
lysates	O
,	O
suggesting	O
that	O
PopZ	O
oligomerization	O
is	O
independent	O
of	O
polar	O
accumulation	O
.	O

In	O
yeast	O
,	O
the	O
cytosolic	O
kinase	O
Sky1	O
phosphorylates	O
the	O
SP	O
motif	O
closest	O
to	O
the	O
C	O
-	O
terminus	O
of	O
Npl3	O
(	O
S411	O
)	O
.	O

Phosphorylation	O
of	O
Npl3	O
at	O
S411	O
in	O
a	O
sky1	O
deletion	O
strain	O
is	O
reduced	O
,	O
but	O
not	O
abolished	O
(	O
data	O
not	O
shown	O
)	O
,	O
raising	O
the	O
possibility	O
that	O
another	O
Npl3	O
-	O
specific	O
kinase	O
remained	O
to	O
be	O
identified	O
,	O
and	O
that	O
other	O
phosphorylation	O
sites	O
in	O
Npl3	O
might	O
exist	O
.	O

To	O
ascertain	O
the	O
later	O
possibility	O
,	O
endogenous	O
Npl3	O
was	O
immunoprecipitated	O
from	O
whole	O
cell	O
extracts	O
and	O
phosphorylation	O
sites	O
were	O
analyzed	O
by	O
mass	O
spectrometry	O
.	O

Multiple	O
phosphorylation	O
sites	O
were	O
identified	O
in	O
the	O
endogenous	O
Npl3	O
(	O
Table	O
1	O
)	O
.	O

Our	O
results	O
confirmed	O
phosphorylation	O
of	O
serine	O
224	O
,	O
349	O
and	O
356	O
,	O
which	O
where	O
identified	O
previously	O
in	O
two	O
large	O
-	O
scale	O
phosphorylation	O
analyses	O
.	O

One	O
new	O
additional	O
site	O
was	O
shown	O
to	O
be	O
phosphorylated	O
,	O
serine	O
212	O
.	O

This	O
data	O
is	O
summarized	O
in	O
Table	O
1	O
.	O

In	O
a	O
separate	O
study	O
,	O
our	O
laboratory	O
has	O
carried	O
out	O
a	O
genome	O
-	O
wide	O
screen	O
that	O
has	O
identified	O
more	O
than	O
240	O
gene	O
deletions	O
that	O
suppress	O
the	O
temperature	O
sensitivity	O
of	O
cdc13	O
-	O
1	O
strains	O
and	O
,	O
thus	O
,	O
may	O
play	O
specific	O
roles	O
in	O
telomere	O
capping	O
.	O

With	O
the	O
aim	O
of	O
identifying	O
differentially	O
expressed	O
genes	O
with	O
novel	O
telomeric	O
roles	O
,	O
we	O
compared	O
the	O
list	O
of	O
cdc13	O
-	O
1	O
suppressors	O
to	O
genes	O
differentially	O
expressed	O
in	O
the	O
cdc13	O
-	O
1	O
microarrays	O
,	O
and	O
found	O
that	O
22	O
genes	O
were	O
common	O
to	O
both	O
(	O
Figure	O
6a	O
and	O
Table	O
3	O
)	O
.	O

In	O
order	O
to	O
extend	O
the	O
comparison	O
between	O
the	O
two	O
data	O
sets	O
,	O
we	O
used	O
Biogrid	O
and	O
Osprey	O
to	O
identify	O
and	O
visualize	O
functional	O
relationships	O
between	O
differentially	O
expressed	O
genes	O
and	O
those	O
whose	O
deletion	O
suppresses	O
cdc13	O
-	O
1	O
temperature	O
sensitivity	O
.	O

These	O
functional	O
relationships	O
are	O
based	O
upon	O
protein	O
-	O
protein	O
interactions	O
,	O
co	O
-	O
lethality	O
,	O
co	O
-	O
expression	O
across	O
large	O
numbers	O
of	O
microarray	O
experiments	O
and	O
co	O
-	O
citation	O
in	O
the	O
literature	O
.	O

We	O
were	O
particularly	O
interested	O
in	O
a	O
gene	O
called	O
BNA2	O
,	O
because	O
it	O
was	O
highly	O
and	O
significantly	O
up	O
-	O
regulated	O
in	O
cdc13	O
-	O
1	O
strains	O
(	O
Figure	O
6b	O
)	O
.	O

Differential	O
expression	O
of	O
BNA2	O
was	O
not	O
observed	O
in	O
the	O
absence	O
of	O
telomerase	B-Complex
,	O
although	O
it	O
is	O
expressed	O
in	O
response	O
to	O
environmental	O
stress	O
.	O

Biogrid	O
analysis	O
revealed	O
that	O
BNA2	O
interacts	O
genetically	O
with	O
a	O
cdc13	O
-	O
1	O
suppressor	O
,	O
NPT1	O
,	O
as	O
co	O
-	O
deletion	O
of	O
these	O
genes	O
is	O
synthetically	O
lethal	O
(	O
Figure	O
6c	O
)	O
.	O

NPT1	O
is	O
not	O
differentially	O
expressed	O
when	O
telomeres	O
are	O
uncapped	O
in	O
cdc3	O
-	O
1	O
strains	O
.	O

BNA2	O
encodes	O
a	O
tryptophan	O
2	O
,	O
3	O
-	O
dioxygenase	O
required	O
for	O
biosynthesis	O
of	O
nicotinic	O
acid	O
(	O
an	O
NAD	O
+	O
precursor	O
)	O
from	O
tryptophan	O
via	O
the	O
kynurenine	O
pathway	O
,	O
while	O
NPT1	O
encodes	O
a	O
nicotinate	O
phosphoribosyltransferase	O
that	O
acts	O
in	O
the	O
salvage	O
pathway	O
of	O
NAD	O
+	O
biosynthesis	O
and	O
is	O
required	O
for	O
telomeric	O
silencing	O
.	O

Several	O
studies	O
have	O
shown	O
that	O
ET	O
-	O
1	O
-	O
injection	O
induced	O
hypoxia	O
to	O
the	O
optic	O
nerve	O
,	O
astrogliosis	O
and	O
axonal	O
loss	O
.	O

Therefore	O
,	O
the	O
effect	O
of	O
intravitreal	O
injection	O
of	O
ET	O
-	O
1	O
on	O
AQP4	O
expression	O
in	O
retina	O
was	O
tested	O
.	O

As	O
shown	O
in	O
Figure	O
2A	O
,	O
ET	O
-	O
1	O
injection	O
resulted	O
in	O
a	O
decrease	O
in	O
AQP4	O
mRNA	O
as	O
determined	O
by	O
Q	O
-	O
PCR	O
.	O

Five	O
out	O
of	O
7	O
rats	O
(	O
71	O
%	O
)	O
showed	O
a	O
significant	O
reduction	O
in	O
mRNA	O
(	O
54	O
+	O
/	O
-	O
11	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
versus	O
HEPES	O
-	O
injected	O
or	O
control	O
,	O
Figure	O
2A	O
)	O
,	O
and	O
there	O
was	O
a	O
similar	O
reduction	O
in	O
AQP4	O
mRNA	O
upon	O
elevation	O
of	O
IOP	O
in	O
six	O
out	O
nine	O
rats	O
(	O
67	O
%	O
,	O
62	O
+	O
/	O
-	O
12	O
,	O
p	O
=	O
0	O
.	O
001	O
,	O
Figure	O
2B	O
)	O
.	O

A	O
similar	O
reduction	O
was	O
observed	O
in	O
AQP4	O
protein	O
levels	O
in	O
ET	O
-	O
1	O
injected	O
and	O
IOP	O
-	O
elevated	O
eyes	O
.	O

As	O
shown	O
in	O
Figure	O
3A	O
,	O
nine	O
out	O
of	O
11	O
rats	O
(	O
82	O
%	O
,	O
Figure	O
3A	O
)	O
showed	O
a	O
decrease	O
in	O
AQP4	O
protein	O
levels	O
in	O
ET	O
-	O
1	O
injected	O
eyes	O
(	O
70	O
+	O
/	O
-	O
10	O
%	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
AQP4	O
protein	O
levels	O
decreased	O
in	O
five	O
out	O
seven	O
rats	O
following	O
elevation	O
of	O
IOP	O
(	O
71	O
%	O
;	O
72	O
+	O
/	O
-	O
12	O
%	O
p	O
<	O
0	O
.	O
001	O
,	O
3C	O
)	O
.	O

Multimodal	O
activation	O
of	O
the	O
ubiquitin	O
ligase	O
SCF	B-Complex
by	O
Nedd8	O
conjugation	O
.	O

Conjugation	O
of	O
ubiquitin	O
-	O
like	O
protein	O
Nedd8	O
to	O
cullins	O
(	O
neddylation	O
)	O
is	O
essential	O
for	O
the	O
function	O
of	O
cullin	O
-	O
RING	O
ubiquitin	O
ligases	O
(	O
CRLs	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
neddylation	O
stimulates	O
CRL	O
activity	O
by	O
multiple	O
mechanisms	O
.	O

For	O
the	O
initiator	O
ubiquitin	O
,	O
the	O
major	O
effect	O
is	O
to	O
bridge	O
the	O
approximately	O
50	O
A	O
gap	O
between	O
naked	O
substrate	O
and	O
E2	O
approximately	O
Ub	O
bound	O
to	O
SCF	B-Complex
.	O

The	O
gap	O
between	O
the	O
acceptor	O
lysine	O
of	O
ubiquitinated	O
substrate	O
and	O
E2	O
approximately	O
Ub	O
is	O
much	O
smaller	O
,	O
and	O
,	O
consequentially	O
,	O
the	O
impact	O
of	O
neddylation	O
on	O
transfer	O
of	O
subsequent	O
ubiquitins	O
by	O
Cdc34	O
arises	O
primarily	O
from	O
improved	O
E2	O
recruitment	O
and	O
enhanced	O
amide	O
bond	O
formation	O
in	O
the	O
E2	O
active	O
site	O
.	O

The	O
combined	O
effects	O
of	O
neddylation	O
greatly	O
enhance	O
the	O
probability	O
that	O
a	O
substrate	O
molecule	O
acquires	O
>	O
or	O
=	O
4	O
ubiquitins	O
in	O
a	O
single	O
encounter	O
with	O
a	O
CRL	O
.	O

The	O
surprisingly	O
diverse	O
effects	O
of	O
Nedd8	O
conjugation	O
underscore	O
the	O
complexity	O
of	O
CRL	O
regulation	O
and	O
suggest	O
that	O
modification	O
of	O
other	O
ubiquitin	O
ligases	O
with	O
ubiquitin	O
or	O
ubiquitin	O
-	O
like	O
proteins	O
may	O
likewise	O
have	O
major	O
functional	O
consequences	O
.	O

Rad51	O
gain	O
-	O
of	O
-	O
function	O
mutants	O
that	O
exhibit	O
high	O
affinity	O
DNA	O
binding	O
cause	O
DNA	O
damage	O
sensitivity	O
in	O
the	O
absence	O
of	O
Srs2	O
.	O

We	O
previously	O
identified	O
several	O
rad51	O
gain	O
-	O
of	O
-	O
function	O
alleles	O
that	O
partially	O
suppress	O
the	O
requirement	O
for	O
RAD55	O
and	O
RAD57	O
in	O
DNA	O
repair	O
.	O

To	O
gain	O
further	O
insight	O
into	O
the	O
mechanism	O
of	O
action	O
of	O
these	O
alleles	O
,	O
we	O
compared	O
the	O
activities	O
of	O
Rad51	O
-	O
V328A	O
,	O
Rad51	O
-	O
P339S	O
and	O
Rad51	O
-	O
I345T	O
with	O
wild	O
-	O
type	O
Rad51	O
,	O
for	O
DNA	O
binding	O
,	O
filament	O
stability	O
,	O
strand	O
exchange	O
and	O
interaction	O
with	O
the	O
antirecombinase	O
helicase	O
,	O
Srs2	O
.	O

These	O
alleles	O
were	O
chosen	O
because	O
they	O
show	O
the	O
highest	O
activity	O
in	O
suppression	O
of	O
ionizing	O
radiation	O
sensitivity	O
of	O
the	O
rad57	O
mutant	O
,	O
and	O
Val	O
328	O
and	O
Ile	O
345	O
are	O
conserved	O
in	O
the	O
human	O
Rad51	O
protein	O
.	O

All	O
three	O
mutant	O
proteins	O
exhibited	O
higher	O
affinity	O
for	O
single	O
-	O
stranded	O
DNA	O
(	O
ssDNA	O
)	O
and	O
showed	O
more	O
robust	O
strand	O
exchange	O
activity	O
with	O
oligonucleotide	O
substrates	O
than	O
wild	O
-	O
type	O
Rad51	O
,	O
with	O
the	O
Rad51	O
-	O
I345T	O
and	O
Rad51	O
-	O
V328A	O
proteins	O
displaying	O
higher	O
activity	O
than	O
Rad51	O
-	O
P339S	O
.	O

However	O
,	O
the	O
Srs2	O
antirecombinase	O
was	O
able	O
to	O
disrupt	O
Rad51	O
-	O
ssDNA	O
complexes	O
formed	O
with	O
all	O
the	O
mutant	O
proteins	O
.	O

In	O
vivo	O
,	O
the	O
rad51	O
-	O
I345T	O
mutant	O
strain	O
exhibited	O
high	O
resistance	O
to	O
methyl	O
methane	O
sulfonate	O
that	O
was	O
dependent	O
on	O
functional	O
SRS2	O
.	O

These	O
results	O
suggest	O
the	O
Srs2	O
translocase	O
is	O
able	O
to	O
disrupt	O
Rad51	O
-	O
ssDNA	O
complexes	O
at	O
stalled	O
replication	O
forks	O
,	O
but	O
in	O
the	O
absence	O
of	O
Srs2	O
the	O
enhanced	O
DNA	O
binding	O
of	O
the	O
Rad51	O
-	O
I345T	O
protein	O
is	O
detrimental	O
to	O
cell	O
survival	O
.	O

Characterization	O
of	O
the	O
35	O
-	O
kilodalton	O
Treponema	O
pallidum	O
subsp	O
.	O
pallidum	O
recombinant	O
lipoprotein	O
TmpC	O
and	O
antibody	O
response	O
to	O
lipidated	O
and	O
nonlipidated	O
T	O
.	O
pallidum	O
antigens	O
.	O

The	O
gene	O
encoding	O
the	O
35	O
-	O
kDa	O
immunogenic	O
Treponema	O
pallidium	O
subsp	O
.	O
pallidum	O
(	O
T	O
.	O
pallidum	O
)	O
membrane	O
protein	O
C	O
,	O
TmpC	O
,	O
was	O
cloned	O
,	O
sequenced	O
,	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
carries	O
on	O
N	O
-	O
terminal	O
signal	O
sequence	O
with	O
a	O
four	O
-	O
amino	O
-	O
acid	O
motif	O
,	O
which	O
is	O
characteristic	O
for	O
bacterial	O
lipoproteins	O
.	O

Metabolic	O
labeling	O
with	O
radioactive	O
palmitic	O
acid	O
of	O
E	O
.	O
coli	O
expressing	O
TmpC	O
revealed	O
incorporation	O
of	O
the	O
fatty	O
acid	O
into	O
the	O
antigen	O
.	O

The	O
antigen	O
was	O
overproduced	O
,	O
purified	O
to	O
near	O
homogeneity	O
and	O
used	O
in	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
to	O
evaluate	O
its	O
potential	O
for	O
the	O
serodiagnosis	O
of	O
syphilis	O
.	O

Although	O
all	O
sera	O
from	O
untreated	O
secondary	O
syphilis	O
patients	O
were	O
reactive	O
in	O
this	O
TmpC	O
ELISA	O
,	O
only	O
a	O
minority	O
of	O
the	O
serum	O
samples	O
from	O
untreated	O
patients	O
in	O
the	O
primary	O
or	O
early	O
latent	O
stage	O
of	O
the	O
disease	O
contained	O
significant	O
anti	O
-	O
TmpC	O
antibodies	O
.	O

To	O
study	O
the	O
influence	O
of	O
the	O
lipid	O
moiety	O
on	O
the	O
antigenic	O
properties	O
of	O
the	O
TmpC	O
,	O
TmpA	O
,	O
and	O
TpD	O
lipoproteins	O
,	O
plasmids	O
encoding	O
nonlipidated	O
forms	O
of	O
these	O
antigens	O
were	O
constructed	O
.	O

In	O
addition	O
,	O
a	O
plasmid	O
expressing	O
a	O
lipidated	O
form	O
of	O
the	O
otherwise	O
non	O
-	O
lipid	O
-	O
modified	O
antigen	O
TmpB	O
was	O
constructed	O
.	O

Immunization	O
and	O
absorption	O
experiments	O
with	O
these	O
lipidated	O
and	O
nonlipidated	O
antigens	O
showed	O
that	O
antibodies	O
against	O
the	O
lipid	O
moiety	O
of	O
lipoproteins	O
could	O
not	O
be	O
detected	O
on	O
immunoblots	O
,	O
neither	O
in	O
sera	O
from	O
infected	O
rabbits	O
nor	O
in	O
sera	O
from	O
animals	O
immunized	O
with	O
the	O
lipoproteins	O
.	O

In	O
addition	O
,	O
we	O
were	O
unable	O
to	O
demonstrate	O
cross	O
-	O
reactivity	O
between	O
antibodies	O
against	O
the	O
T	O
.	O
pallidum	O
lipoproteins	O
and	O
those	O
reactive	O
to	O
the	O
Venereal	O
Diseases	O
Research	O
Laboratories	O
test	O
,	O
suggesting	O
that	O
antibodies	O
reactive	O
to	O
the	O
Venereal	O
Diseases	O
Research	O
Laboratories	O
test	O
are	O
unrelated	O
to	O
antilipoprotein	O
antibodies	O
.	O

RanBP2	O
and	O
SENP3	O
function	O
in	O
a	O
mitotic	O
SUMO2	O
/	O
3	O
conjugation	O
-	O
deconjugation	O
cycle	O
on	O
Borealin	O
.	O

The	O
ubiquitin	O
-	O
like	O
SUMO	O
system	O
controls	O
cellular	O
key	O
functions	O
,	O
and	O
several	O
lines	O
of	O
evidence	O
point	O
to	O
a	O
critical	O
role	O
of	O
SUMO	O
for	O
mitotic	O
progression	O
.	O

However	O
,	O
in	O
mammalian	O
cells	O
mitotic	O
substrates	O
of	O
sumoylation	O
and	O
the	O
regulatory	O
components	O
involved	O
are	O
not	O
well	O
defined	O
.	O

Here	O
,	O
we	O
identify	O
Borealin	O
,	O
a	O
component	O
of	O
the	O
chromosomal	B-Complex
passenger	I-Complex
complex	I-Complex
(	O
CPC	B-Complex
)	O
,	O
as	O
a	O
mitotic	O
target	O
of	O
SUMO	O
.	O

The	O
CPC	B-Complex
,	O
which	O
additionally	O
comprises	O
INCENP	O
,	O
Survivin	O
,	O
and	O
Aurora	O
B	O
,	O
regulates	O
key	O
mitotic	O
events	O
,	O
including	O
chromosome	O
congression	O
,	O
the	O
spindle	O
assembly	O
checkpoint	O
,	O
and	O
cytokinesis	O
.	O

We	O
show	O
that	O
Borealin	O
is	O
preferentially	O
modified	O
by	O
SUMO2	O
/	O
3	O
and	O
demonstrate	O
that	O
the	O
modification	O
is	O
dynamically	O
regulated	O
during	O
mitotic	O
progression	O
,	O
peaking	O
in	O
early	O
mitosis	O
.	O

Intriguingly	O
,	O
the	O
SUMO	O
ligase	O
RanBP2	O
interacts	O
with	O
the	O
CPC	B-Complex
,	O
stimulates	O
SUMO	O
modification	O
of	O
Borealin	O
in	O
vitro	O
,	O
and	O
is	O
required	O
for	O
its	O
modification	O
in	O
vivo	O
.	O

Moreover	O
,	O
the	O
SUMO	O
isopeptidase	O
SENP3	O
is	O
a	O
specific	O
interaction	O
partner	O
of	O
Borealin	O
and	O
catalyzes	O
the	O
removal	O
of	O
SUMO2	O
/	O
3	O
from	O
Borealin	O
.	O

These	O
data	O
thus	O
delineate	O
a	O
mitotic	O
SUMO2	O
/	O
3	O
conjugation	O
-	O
deconjugation	O
cycle	O
of	O
Borealin	O
and	O
further	O
assign	O
a	O
regulatory	O
function	O
of	O
RanBP2	O
and	O
SENP3	O
in	O
the	O
mitotic	O
SUMO	O
pathway	O
.	O

Molecular	O
characterization	O
of	O
transgenic	O
AtGRP8	O
-	O
RQ	O
ox	O
lines	O
.	O

(	O
A	O
)	O
WT	O
,	O
AtGRP8	O
-	O
ox	O
and	O
AtGRP8	O
-	O
RQ	O
-	O
ox	O
plants	O
were	O
harvested	O
at	O
zt3	O
and	O
zt11	O
.	O

The	O
RNA	O
gel	O
blot	O
was	O
hybridized	O
with	O
the	O
AtGRP8	O
cDNA	O
to	O
determine	O
the	O
total	O
transcript	O
level	O
(	O
top	O
)	O
and	O
with	O
the	O
gene	O
-	O
specific	O
probe	O
to	O
monitor	O
the	O
endogenous	O
AtGRP8	O
transcript	O
(	O
middle	O
)	O
.	O

The	O
position	O
of	O
the	O
pre	O
-	O
mRNA	O
,	O
as	O
_	O
AtGRP8	O
retaining	O
the	O
first	O
half	O
of	O
the	O
intron	O
and	O
the	O
mRNA	O
are	O
indicated	O
.	O

Boxes	O
represent	O
exons	O
,	O
lines	O
represent	O
the	O
first	O
and	O
the	O
second	O
half	O
of	O
the	O
intron	O
,	O
respectively	O
.	O

The	O
ethidium	O
-	O
bromide	O
stained	O
gel	O
shows	O
equal	O
loading	O
(	O
bottom	O
)	O
.	O

(	O
B	O
)	O
The	O
immunoblot	O
with	O
total	O
protein	O
of	O
WT	O
plants	O
,	O
the	O
AtGRP8	O
-	O
ox	O
lines	O
5	O
and	O
21	O
,	O
and	O
the	O
AtGRP8	O
-	O
RQ	O
-	O
ox	O
lines	O
1	O
,	O
4	O
and	O
5	O
,	O
harvested	O
at	O
zt11	O
,	O
was	O
probed	O
with	O
the	O
AtGRP8	O
antibody	O
(	O
top	O
)	O
and	O
an	O
antibody	O
against	O
LHCP	O
as	O
loading	O
control	O
(	O
bottom	O
)	O
.	O

(	O
C	O
)	O
The	O
RNA	O
gel	O
blot	O
shown	O
in	O
(	O
A	O
)	O
was	O
stripped	O
and	O
rehybridized	O
with	O
the	O
AtGRP7	O
probe	O
.	O

(	O
D	O
)	O
The	O
immunoblot	O
with	O
the	O
same	O
protein	O
extracts	O
as	O
shown	O
in	O
(	O
B	O
)	O
was	O
probed	O
with	O
the	O
AtGRP7	O
antibody	O
(	O
top	O
)	O
and	O
the	O
LHCP	O
antibody	O
(	O
bottom	O
)	O
.	O

O	O
-	O
linked	O
GlcNAc	O
modification	O
of	O
cardiac	O
myofilament	O
proteins	O
:	O
a	O
novel	O
regulator	O
of	O
myocardial	O
contractile	O
function	O
.	O

In	O
addition	O
to	O
O	O
-	O
phosphorylation	O
,	O
O	O
-	O
linked	O
modifications	O
of	O
serine	O
and	O
threonine	O
by	O
beta	O
-	O
N	O
-	O
acetyl	O
-	O
D	O
-	O
glucosamine	O
(	O
GlcNAc	O
)	O
may	O
regulate	O
muscle	O
contractile	O
function	O
.	O

This	O
study	O
assessed	O
the	O
potential	O
role	O
of	O
O	O
-	O
GlcNAcylation	O
in	O
cardiac	O
muscle	O
contractile	O
activation	O
.	O

To	O
identify	O
specific	O
sites	O
of	O
O	O
-	O
GlcNAcylation	O
in	O
cardiac	O
myofilament	O
proteins	O
,	O
a	O
recently	O
developed	O
methodology	O
based	O
on	O
GalNAz	O
-	O
biotin	O
labeling	O
followed	O
by	O
dithiothreitol	O
replacement	O
and	O
light	O
chromatography	O
/	O
tandem	O
mass	O
spectrometry	O
site	O
mapping	O
was	O
adopted	O
.	O

Thirty	O
-	O
two	O
O	O
-	O
GlcNAcylated	O
peptides	O
from	O
cardiac	O
myofilaments	O
were	O
identified	O
on	O
cardiac	O
myosin	O
heavy	O
chain	O
,	O
actin	O
,	O
myosin	O
light	O
chains	O
,	O
and	O
troponin	O
I	O
.	O

To	O
assess	O
the	O
potential	O
physiological	O
role	O
of	O
the	O
GlcNAc	O
,	O
force	O
-	O
[	O
Ca	O
(	O
2	O
+	O
)	O
]	O
relationships	O
were	O
studied	O
in	O
skinned	O
rat	O
trabeculae	O
.	O

Exposure	O
to	O
GlcNAc	O
significantly	O
decreased	O
calcium	O
sensitivity	O
(	O
pCa50	O
)	O
,	O
whereas	O
maximal	O
force	O
(	O
F	O
(	O
max	O
)	O
)	O
and	O
Hill	O
coefficient	O
(	O
n	O
)	O
were	O
not	O
modified	O
.	O

Using	O
a	O
pan	O
-	O
specific	O
O	O
-	O
GlcNAc	O
antibody	O
,	O
it	O
was	O
determined	O
that	O
acute	O
exposure	O
of	O
myofilaments	O
to	O
GlcNAc	O
induced	O
a	O
significant	O
increase	O
in	O
actin	O
O	O
-	O
GlcNAcylation	O
.	O

This	O
study	O
provides	O
the	O
first	O
identification	O
of	O
O	O
-	O
GlcNAcylation	O
sites	O
in	O
cardiac	O
myofilament	O
proteins	O
and	O
demonstrates	O
their	O
potential	O
role	O
in	O
regulating	O
myocardial	O
contractile	O
function	O
.	O

Identification	O
of	O
G	O
protein	O
alpha	O
subunit	O
-	O
palmitoylating	O
enzyme	O
.	O

The	O
heterotrimeric	O
G	O
protein	O
alpha	O
subunit	O
(	O
Galpha	O
)	O
is	O
targeted	O
to	O
the	O
cytoplasmic	O
face	O
of	O
the	O
plasma	O
membrane	O
through	O
reversible	O
lipid	O
palmitoylation	O
and	O
relays	O
signals	O
from	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
to	O
its	O
effectors	O
.	O

By	O
screening	O
23	O
DHHC	O
motif	O
(	O
Asp	O
-	O
His	O
-	O
His	O
-	O
Cys	O
)	O
palmitoyl	O
acyl	O
-	O
transferases	O
,	O
we	O
identified	O
DHHC3	O
and	O
DHHC7	O
as	O
Galpha	O
palmitoylating	O
enzymes	O
.	O

DHHC3	O
and	O
DHHC7	O
robustly	O
palmitoylated	O
Galpha	O
(	O
q	O
)	O
,	O
Galpha	O
(	O
s	O
)	O
,	O
and	O
Galpha	O
(	O
i2	O
)	O
in	O
HEK293T	O
cells	O
.	O

Knockdown	O
of	O
DHHC3	O
and	O
DHHC7	O
decreased	O
Galpha	O
(	O
q	O
/	O
11	O
)	O
palmitoylation	O
and	O
relocalized	O
it	O
from	O
the	O
plasma	O
membrane	O
into	O
the	O
cytoplasm	O
.	O

Photoconversion	O
analysis	O
revealed	O
that	O
Galpha	O
(	O
q	O
)	O
rapidly	O
shuttles	O
between	O
the	O
plasma	O
membrane	O
and	O
the	O
Golgi	O
apparatus	O
,	O
where	O
DHHC3	O
specifically	O
localizes	O
.	O

Fluorescence	O
recovery	O
after	O
photobleaching	O
studies	O
showed	O
that	O
DHHC3	O
and	O
DHHC7	O
are	O
necessary	O
for	O
this	O
continuous	O
Galpha	O
(	O
q	O
)	O
shuttling	O
.	O

Furthermore	O
,	O
DHHC3	O
and	O
DHHC7	O
knockdown	O
blocked	O
the	O
alpha	O
(	O
1A	O
)	O
-	O
adrenergic	O
receptor	O
/	O
Galpha	O
(	O
q	O
/	O
11	O
)	O
-	O
mediated	O
signaling	O
pathway	O
.	O

Together	O
,	O
our	O
findings	O
revealed	O
that	O
DHHC3	O
and	O
DHHC7	O
regulate	O
GPCR	O
-	O
mediated	O
signal	O
transduction	O
by	O
controlling	O
Galpha	O
localization	O
to	O
the	O
plasma	O
membrane	O
.	O

Xenobiotic	O
incorporation	O
into	O
pyruvate	B-Complex
dehydrogenase	I-Complex
complex	O
can	O
occur	O
via	O
the	O
exogenous	O
lipoylation	O
pathway	O
.	O

Lipoylated	O
enzymes	O
such	O
as	O
the	O
E2	B-OOS
component	O
of	O
pyruvate	B-Complex
dehydrogenase	I-Complex
complex	O
(	O
PDC	B-OOS
-	I-OOS
E2	I-OOS
)	O
are	O
targets	O
for	O
autoreactive	O
immune	O
responses	O
in	O
primary	O
biliary	O
cirrhosis	O
,	O
with	O
lipoic	O
acid	O
itself	O
forming	O
a	O
component	O
of	O
the	O
dominant	O
auto	O
-	O
epitopes	O
.	O

A	O
candidate	O
mechanism	O
for	O
the	O
initiation	O
of	O
tolerance	O
breakdown	O
in	O
this	O
disease	O
is	O
immune	O
recognition	O
of	O
neo	O
-	O
antigens	O
formed	O
by	O
xenobiotic	O
substitution	O
of	O
normal	O
proteins	O
.	O

Importantly	O
,	O
sensitization	O
with	O
proteins	O
artificially	O
substituted	O
with	O
the	O
lipoic	O
acid	O
analogue	O
xenobiotic	O
6	O
-	O
bromohexanoic	O
acid	O
(	O
6BH	O
)	O
can	O
induce	O
an	O
immune	O
response	O
that	O
cross	O
-	O
reacts	O
with	O
PDC	O
-	O
E2	O
.	O

This	O
study	O
investigated	O
the	O
potential	O
of	O
recombinant	O
lipoylation	O
enzymes	O
lipoate	O
activating	O
enzyme	O
and	O
lipoyl	O
-	O
AMP	O
(	O
GMP	O
)	O
:	O
N	O
-	O
lysine	O
lipoyl	O
transferase	O
to	O
aberrantly	O
incorporate	O
xenobiotics	O
into	O
PDC	B-OOS
-	I-OOS
E2	I-OOS
.	O

It	O
was	O
found	O
that	O
these	O
enzymes	O
could	O
incorporate	O
lipoic	O
acid	O
analogues	O
including	O
octanoic	O
and	O
hexanoic	O
acids	O
and	O
the	O
xenobiotic	O
6BH	O
into	O
PDC	B-OOS
-	I-OOS
E2	I-OOS
.	O

The	O
efficiency	O
of	O
incorporation	O
of	O
these	O
analogues	O
showed	O
a	O
variable	O
dependence	O
on	O
activation	O
by	O
adenosine	O
triphosphate	O
(	O
ATP	O
)	O
or	O
guanosine	O
triphosphate	O
(	O
GTP	O
)	O
,	O
with	O
ATP	O
favoring	O
the	O
incorporation	O
of	O
hexanoic	O
acid	O
and	O
6BH	O
whereas	O
GTP	O
enhanced	O
substitution	O
by	O
octanoic	O
acid	O
.	O

Importantly	O
,	O
competition	O
studies	O
showed	O
that	O
the	O
relative	O
incorporation	O
of	O
both	O
6BH	O
and	O
lipoic	O
acid	O
could	O
be	O
regulated	O
by	O
the	O
balance	O
between	O
ATP	O
and	O
GTP	O
,	O
with	O
the	O
formation	O
of	O
6BH	O
-	O
substituted	O
PDC	B-OOS
-	I-OOS
E2	I-OOS
predominating	O
in	O
an	O
ATP	O
-	O
rich	O
environment	O
.	O

Conclusion	O
:	O
Using	O
a	O
well	O
-	O
defined	O
system	O
in	O
vitro	O
we	O
have	O
shown	O
that	O
an	O
important	O
xenobiotic	O
can	O
be	O
incorporated	O
into	O
PDC	B-Complex
in	O
place	O
of	O
lipoic	O
acid	O
by	O
the	O
exogenous	O
lipoylation	O
system	O
;	O
the	O
relative	O
levels	O
of	O
lipoic	O
acid	O
and	O
xenobiotic	O
incorporation	O
may	O
be	O
determined	O
by	O
the	O
balance	O
between	O
ATP	O
and	O
GTP	O
.	O

These	O
observations	O
suggest	O
a	O
clear	O
mechanism	O
for	O
the	O
generation	O
of	O
an	O
auto	O
-	O
immunogenic	O
neo	O
-	O
antigen	O
of	O
relevance	O
for	O
the	O
pathogenesis	O
of	O
primary	O
biliary	O
cirrhosis	O
.	O

Structural	O
and	O
functional	O
roles	O
of	O
the	O
conserved	O
cysteine	O
residues	O
of	O
the	O
redox	O
-	O
regulated	O
import	O
receptor	O
Mia40	O
in	O
the	O
intermembrane	O
space	O
of	O
mitochondria	O
.	O

Oxidative	O
folding	O
drives	O
the	O
import	O
of	O
proteins	O
containing	O
twin	O
CXnC	O
motifs	O
into	O
the	O
intermembrane	O
space	O
of	O
mitochondria	O
.	O

This	O
import	O
pathway	O
employs	O
a	O
disulfide	O
relay	O
system	O
whose	O
key	O
components	O
are	O
the	O
redox	O
-	O
regulated	O
import	O
receptor	O
Mia40	O
and	O
the	O
thiol	O
oxidase	O
Erv1	O
.	O

Mia40	O
contains	O
six	O
cysteine	O
residues	O
in	O
a	O
CPC	O
-	O
CX9C	O
-	O
CX9C	O
arrangement	O
in	O
a	O
highly	O
conserved	O
domain	O
.	O

We	O
show	O
that	O
this	O
domain	O
is	O
sufficient	O
for	O
the	O
function	O
of	O
Mia40	O
.	O

By	O
analysis	O
of	O
Mia40	O
cysteine	O
mutants	O
we	O
demonstrate	O
that	O
the	O
cysteine	O
residues	O
have	O
distinct	O
roles	O
and	O
are	O
not	O
equally	O
important	O
for	O
Mia40	O
function	O
.	O

The	O
second	O
cysteine	O
residue	O
is	O
essential	O
for	O
viability	O
of	O
yeast	O
cells	O
.	O

It	O
is	O
required	O
for	O
the	O
interaction	O
of	O
Mia40	O
with	O
Erv1	O
in	O
a	O
disulfide	O
intermediate	O
and	O
forms	O
a	O
redox	O
-	O
sensitive	O
disulfide	O
bond	O
with	O
the	O
first	O
cysteine	O
residue	O
.	O

Both	O
cysteine	O
residues	O
are	O
required	O
for	O
the	O
oxidation	O
of	O
the	O
substrate	O
,	O
Tim10	O
,	O
in	O
a	O
reconstituted	O
system	O
comprised	O
of	O
Mia40	O
and	O
Erv1	O
.	O

Mutants	O
with	O
amino	O
acid	O
exchanges	O
in	O
the	O
third	O
and	O
sixth	O
cysteine	O
residues	O
have	O
severe	O
defects	O
in	O
growth	O
and	O
in	O
the	O
import	O
of	O
intermembrane	O
space	O
proteins	O
.	O

These	O
Mia40	O
variants	O
are	O
not	O
tightly	O
folded	O
.	O

We	O
conclude	O
that	O
the	O
cysteine	O
residues	O
of	O
the	O
twin	O
CX9C	O
motif	O
have	O
a	O
structural	O
role	O
and	O
stabilize	O
Mia40	O
.	O

In	O
particular	O
,	O
the	O
disulfide	O
bond	O
formed	O
by	O
the	O
third	O
and	O
sixth	O
cysteine	O
residues	O
apparently	O
supports	O
a	O
conformation	O
crucial	O
for	O
the	O
function	O
of	O
Mia40	O
.	O

Furthermore	O
,	O
the	O
disulfide	O
bond	O
in	O
the	O
CPC	O
segment	O
mediates	O
the	O
redox	O
reactions	O
with	O
the	O
thiol	O
oxidase	O
Erv1	O
and	O
substrate	O
proteins	O
in	O
mitochondria	O
.	O

Two	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
/	O
ER	O
Golgi	O
intermediate	O
compartment	O
-	O
based	O
lysine	O
acetyltransferases	O
post	O
-	O
translationally	O
regulate	O
BACE1	O
levels	O
.	O

We	O
have	O
recently	O
identified	O
a	O
novel	O
form	O
of	O
post	O
-	O
translational	O
regulation	O
of	O
BACE1	O
(	O
beta	O
-	O
site	O
amyloid	O
precursor	O
protein	O
-	O
cleaving	O
enzyme	O
1	O
)	O
,	O
a	O
membrane	O
protein	O
that	O
acts	O
as	O
the	O
rate	O
-	O
limiting	O
enzyme	O
in	O
the	O
generation	O
of	O
the	O
Alzheimer	O
disease	O
amyloid	O
beta	O
-	O
peptide	O
.	O

Specifically	O
,	O
nascent	O
BACE1	O
is	O
transiently	O
acetylated	O
in	O
seven	O
lysine	O
residues	O
clustered	O
in	O
a	O
highly	O
disordered	O
region	O
of	O
the	O
protein	O
that	O
faces	O
the	O
lumen	O
of	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
/	O
ER	O
Golgi	O
intermediate	O
compartment	O
(	O
ER	O
/	O
ERGIC	O
)	O
.	O

The	O
acetylation	O
protects	O
the	O
nascent	O
protein	O
from	O
degradation	O
by	O
PCSK9	O
/	O
NARC	O
-	O
1	O
in	O
the	O
ERGIC	O
and	O
allows	O
it	O
to	O
reach	O
the	O
Golgi	O
apparatus	O
.	O

Here	O
we	O
report	O
the	O
identification	O
of	O
two	O
ER	O
/	O
ERGIC	O
-	O
based	O
acetyltransferases	O
,	O
ATase1	O
and	O
ATase2	O
.	O

Both	O
proteins	O
display	O
acetyl	O
-	O
CoA	O
:	O
lysine	O
acetyltransferase	O
activity	O
,	O
can	O
interact	O
with	O
and	O
acetylate	O
BACE1	O
,	O
and	O
display	O
an	O
ER	O
/	O
ERGIC	O
localization	O
with	O
the	O
catalytic	O
site	O
facing	O
the	O
lumen	O
of	O
the	O
organelle	O
.	O

Both	O
ATase1	O
and	O
ATase2	O
regulate	O
the	O
steady	O
-	O
state	O
levels	O
of	O
BACE1	O
and	O
the	O
rate	O
of	O
amyloid	O
beta	O
-	O
peptide	O
generation	O
.	O

Finally	O
,	O
their	O
transcripts	O
are	O
up	O
-	O
regulated	O
by	O
ceramide	O
treatment	O
.	O

In	O
conclusion	O
,	O
our	O
studies	O
have	O
identified	O
two	O
new	O
enzymes	O
that	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
late	O
-	O
onset	O
Alzheimer	O
disease	O
.	O

The	O
biochemical	O
characterization	O
of	O
the	O
above	O
events	O
could	O
lead	O
to	O
the	O
identification	O
of	O
novel	O
pharmacological	O
strategies	O
for	O
the	O
prevention	O
of	O
this	O
form	O
of	O
dementia	O
.	O

SUMOylation	O
inhibits	O
SF	O
-	O
1	O
activity	O
by	O
reducing	O
CDK7	O
-	O
mediated	O
serine	O
203	O
phosphorylation	O
.	O

Steroidogenic	O
factor	O
1	O
(	O
SF	O
-	O
1	O
)	O
is	O
an	O
orphan	O
nuclear	O
receptor	O
selectively	O
expressed	O
in	O
the	O
adrenal	O
cortex	O
and	O
gonads	O
,	O
where	O
it	O
mediates	O
the	O
hormonal	O
stimulation	O
of	O
multiple	O
genes	O
involved	O
in	O
steroid	O
hormone	O
biosynthesis	O
.	O

SF	O
-	O
1	O
is	O
the	O
target	O
of	O
both	O
phosphorylation	O
and	O
SUMOylation	O
,	O
but	O
how	O
these	O
modifications	O
interact	O
or	O
contribute	O
to	O
SF	O
-	O
1	O
regulation	O
of	O
endogenous	O
genes	O
remains	O
poorly	O
defined	O
.	O

We	O
found	O
that	O
SF	O
-	O
1	O
is	O
selectively	O
SUMOylated	O
at	O
K194	O
in	O
Y1	O
adrenocarcinoma	O
cells	O
and	O
that	O
although	O
SUMOylation	O
does	O
not	O
alter	O
the	O
subcellular	O
localization	O
of	O
SF	O
-	O
1	O
,	O
the	O
modification	O
inhibits	O
the	O
ability	O
of	O
SF	O
-	O
1	O
to	O
activate	O
target	O
genes	O
.	O

Notably	O
,	O
whereas	O
SF	O
-	O
1	O
SUMOylation	O
is	O
independent	O
of	O
S203	O
phosphorylation	O
and	O
is	O
unaffected	O
by	O
adrenocorticotropin	O
(	O
ACTH	O
)	O
treatment	O
,	O
loss	O
of	O
SUMOylation	O
leads	O
to	O
enhanced	O
SF	O
-	O
1	O
phosphorylation	O
at	O
serine	O
203	O
.	O

Furthermore	O
,	O
preventing	O
SF	O
-	O
1	O
SUMOylation	O
increases	O
the	O
mRNA	O
and	O
protein	O
levels	O
of	O
multiple	O
steroidogenic	O
enzyme	O
genes	O
.	O

Analysis	O
of	O
the	O
StAR	O
promoter	O
indicates	O
that	O
blockade	O
of	O
SF	O
-	O
1	O
SUMOylation	O
leads	O
to	O
an	O
increase	O
in	O
overall	O
promoter	O
occupancy	O
but	O
does	O
not	O
alter	O
the	O
oscillatory	O
recruitment	O
dynamics	O
in	O
response	O
to	O
ACTH	O
.	O

Notably	O
,	O
we	O
find	O
that	O
CDK7	O
binds	O
preferentially	O
to	O
the	O
SUMOylation	O
-	O
deficient	O
form	O
of	O
SF	O
-	O
1	O
and	O
that	O
CDK7	O
inhibition	O
reduces	O
phosphorylation	O
of	O
SF	O
-	O
1	O
.	O

Based	O
on	O
these	O
observations	O
,	O
we	O
propose	O
a	O
coordinated	O
modification	O
model	O
in	O
which	O
inhibition	O
of	O
SF	O
-	O
1	O
-	O
mediated	O
transcription	O
by	O
SUMOylation	O
in	O
adrenocortical	O
cancer	O
cells	O
is	O
mediated	O
through	O
reduced	O
CDK7	O
-	O
induced	O
phosphorylation	O
of	O
SF	O
-	O
1	O
.	O

Site	O
-	O
specific	O
mutagenesis	O
identifies	O
three	O
cysteine	O
residues	O
in	O
the	O
cytoplasmic	O
tail	O
as	O
acylation	O
sites	O
of	O
influenza	O
virus	O
hemagglutinin	O
.	O

The	O
hemagglutinin	O
(	O
HA	O
)	O
of	O
influenza	O
virus	O
is	O
a	O
type	O
I	O
transmembrane	O
glycoprotein	O
which	O
is	O
acylated	O
with	O
long	O
-	O
chain	O
fatty	O
acids	O
.	O

In	O
this	O
study	O
we	O
have	O
used	O
oligonucleotide	O
-	O
directed	O
mutagenesis	O
of	O
cloned	O
cDNA	O
and	O
a	O
simian	O
virus	O
40	O
expression	O
system	O
to	O
determine	O
the	O
fatty	O
acid	O
binding	O
site	O
in	O
HA	O
and	O
to	O
examine	O
possible	O
functions	O
of	O
covalently	O
linked	O
fatty	O
acids	O
.	O

The	O
results	O
show	O
that	O
the	O
HA	O
is	O
acylated	O
through	O
thioester	O
linkages	O
at	O
three	O
highly	O
conserved	O
cysteine	O
residues	O
located	O
in	O
the	O
cytoplasmic	O
domain	O
and	O
at	O
the	O
carboxy	O
-	O
terminal	O
end	O
of	O
the	O
transmembrane	O
region	O
,	O
whereas	O
a	O
cysteine	O
located	O
in	O
the	O
middle	O
of	O
the	O
membrane	O
-	O
spanning	O
domain	O
is	O
not	O
acylated	O
.	O

Mutants	O
lacking	O
fatty	O
acids	O
at	O
individual	O
or	O
all	O
three	O
attachment	O
sites	O
acquire	O
endoglycosidase	O
H	O
-	O
resistant	O
oligosaccharide	O
side	O
chains	O
,	O
are	O
cleaved	O
into	O
HA1	O
and	O
HA2	O
subunits	O
,	O
and	O
are	O
transported	O
to	O
the	O
plasma	O
membrane	O
at	O
rates	O
similar	O
to	O
that	O
of	O
wild	O
-	O
type	O
HA	O
.	O

All	O
mutants	O
are	O
membrane	O
bound	O
and	O
not	O
secreted	O
into	O
the	O
medium	O
.	O

These	O
results	O
exclude	O
transport	O
signal	O
and	O
membrane	O
-	O
anchoring	O
functions	O
of	O
covalently	O
linked	O
fatty	O
acids	O
for	O
this	O
integral	O
membrane	O
glycoprotein	O
.	O

Furthermore	O
,	O
lack	O
of	O
acylation	O
has	O
no	O
obvious	O
influence	O
on	O
the	O
biological	O
activities	O
of	O
HA	O
:	O
cells	O
expressing	O
fatty	O
acid	O
-	O
free	O
HA	O
bind	O
to	O
and	O
,	O
after	O
brief	O
exposure	O
to	O
mildly	O
acidic	O
pH	O
,	O
fuse	O
with	O
erythrocytes	O
;	O
the	O
HA	O
-	O
induced	O
polykaryon	O
formation	O
is	O
not	O
impaired	O
,	O
either	O
.	O

Other	O
possible	O
functions	O
of	O
covalently	O
linked	O
fatty	O
acids	O
in	O
integral	O
membrane	O
glycoproteins	O
which	O
cannot	O
be	O
examined	O
in	O
conventional	O
cDNA	O
expression	O
systems	O
are	O
discussed	O
.	O

Calcium	O
-	O
bound	O
structure	O
of	O
calpain	O
and	O
its	O
mechanism	O
of	O
inhibition	O
by	O
calpastatin	O
.	O

Calpains	O
are	O
non	O
-	O
lysosomal	O
calcium	O
-	O
dependent	O
cysteine	O
proteinases	O
that	O
selectively	O
cleave	O
proteins	O
in	O
response	O
to	O
calcium	O
signals	O
and	O
thereby	O
control	O
cellular	O
functions	O
such	O
as	O
cytoskeletal	O
remodelling	O
,	O
cell	O
cycle	O
progression	O
,	O
gene	O
expression	O
and	O
apoptotic	O
cell	O
death	O
.	O

In	O
mammals	O
,	O
the	O
two	O
best	O
-	O
characterized	O
members	O
of	O
the	O
calpain	O
family	O
,	O
calpain	O
1	O
and	O
calpain	O
2	O
(	O
micro	O
-	O
calpain	O
and	O
m	O
-	O
calpain	O
,	O
respectively	O
)	O
,	O
are	O
ubiquitously	O
expressed	O
.	O

The	O
activity	O
of	O
calpains	O
is	O
tightly	O
controlled	O
by	O
the	O
endogenous	O
inhibitor	O
calpastatin	O
,	O
which	O
is	O
an	O
intrinsically	O
unstructured	O
protein	O
capable	O
of	O
reversibly	O
binding	O
and	O
inhibiting	O
four	O
molecules	O
of	O
calpain	O
,	O
but	O
only	O
in	O
the	O
presence	O
of	O
calcium	O
.	O

To	O
date	O
,	O
the	O
mechanism	O
of	O
inhibition	O
by	O
calpastatin	O
and	O
the	O
basis	O
for	O
its	O
absolute	O
specificity	O
have	O
remained	O
speculative	O
.	O

It	O
was	O
not	O
clear	O
how	O
this	O
unstructured	O
protein	O
inhibits	O
calpains	O
without	O
being	O
cleaved	O
itself	O
,	O
nor	O
was	O
it	O
known	O
how	O
calcium	O
induced	O
changes	O
that	O
facilitated	O
the	O
binding	O
of	O
calpastatin	O
to	O
calpain	O
.	O

Here	O
we	O
report	O
the	O
2	O
.	O
4	O
-	O
A	O
-	O
resolution	O
crystal	O
structure	O
of	O
the	O
calcium	O
-	O
bound	O
calpain	O
2	O
heterodimer	O
bound	O
by	O
one	O
of	O
the	O
four	O
inhibitory	O
domains	O
of	O
calpastatin	O
.	O

Calpastatin	O
is	O
seen	O
to	O
inhibit	O
calpain	O
by	O
occupying	O
both	O
sides	O
of	O
the	O
active	O
site	O
cleft	O
.	O

Although	O
the	O
inhibitor	O
passes	O
through	O
the	O
active	O
site	O
cleft	O
it	O
escapes	O
cleavage	O
in	O
a	O
novel	O
manner	O
by	O
looping	O
out	O
and	O
around	O
the	O
active	O
site	O
cysteine	O
.	O

The	O
inhibitory	O
domain	O
of	O
calpastatin	O
recognizes	O
multiple	O
lower	O
affinity	O
sites	O
present	O
only	O
in	O
the	O
calcium	O
-	O
bound	O
form	O
of	O
the	O
enzyme	O
,	O
resulting	O
in	O
an	O
interaction	O
that	O
is	O
tight	O
,	O
specific	O
and	O
calcium	O
dependent	O
.	O

This	O
crystal	O
structure	O
,	O
and	O
that	O
of	O
a	O
related	O
complex	O
,	O
also	O
reveal	O
the	O
conformational	O
changes	O
that	O
calpain	O
undergoes	O
on	O
binding	O
calcium	O
,	O
which	O
include	O
opening	O
of	O
the	O
active	O
site	O
cleft	O
and	O
movement	O
of	O
the	O
domains	O
relative	O
to	O
each	O
other	O
to	O
produce	O
a	O
more	O
compact	O
enzyme	O
.	O

The	O
ATPase	O
activity	O
of	O
wild	O
-	O
type	O
Rad51	O
becomes	O
significant	O
after	O
the	O
addition	O
of	O
poly	O
(	O
dT	O
)	O
as	O
DNA	O
substrate	O
,	O
displaying	O
saturation	O
at	O
a	O
stoichiometry	O
above	O
12	O
nt	O
per	O
monomer	O
Rad51	O
protein	O
(	O
Figure	O
2C	O
)	O
,	O
again	O
in	O
agreement	O
with	O
previous	O
analyses	O
.	O

The	O
ATPase	O
activity	O
of	O
Rad51	O
-	O
K342E	O
protein	O
was	O
stimulated	O
by	O
the	O
addition	O
of	O
poly	O
(	O
dT	O
)	O
by	O
about	O
30	O
%	O
,	O
saturating	O
with	O
a	O
similar	O
stoichiometry	O
as	O
wild	O
-	O
type	O
protein	O
(	O
Figure	O
2C	O
)	O
.	O

A	O
BBSome	B-Complex
subunit	O
links	O
ciliogenesis	O
,	O
microtubule	O
stability	O
,	O
and	O
acetylation	O
.	O

Primary	O
cilium	O
dysfunction	O
affects	O
the	O
development	O
and	O
homeostasis	O
of	O
many	O
organs	O
in	O
Bardet	O
-	O
Biedl	O
syndrome	O
(	O
BBS	O
)	O
.	O

We	O
recently	O
showed	O
that	O
seven	O
highly	O
conserved	O
BBS	O
proteins	O
form	O
a	O
stable	O
complex	O
,	O
the	O
BBSome	B-Complex
,	O
that	O
functions	O
in	O
membrane	O
trafficking	O
to	O
and	O
inside	O
the	O
primary	O
cilium	O
.	O

We	O
have	O
now	O
discovered	O
a	O
BBSome	B-Complex
subunit	O
that	O
we	O
named	O
BBIP10	O
.	O

Similar	O
to	O
other	O
BBSome	B-Complex
subunits	O
,	O
BBIP10	O
localizes	O
to	O
the	O
primary	O
cilium	O
,	O
BBIP10	O
is	O
present	O
exclusively	O
in	O
ciliated	O
organisms	O
,	O
and	O
depletion	O
of	O
BBIP10	O
yields	O
characteristic	O
BBS	O
phenotypes	O
in	O
zebrafish	O
.	O

Unexpectedly	O
,	O
BBIP10	O
is	O
required	O
for	O
cytoplasmic	O
microtubule	O
polymerization	O
and	O
acetylation	O
,	O
two	O
functions	O
not	O
shared	O
with	O
any	O
other	O
BBSome	B-Complex
subunits	O
.	O

Strikingly	O
,	O
inhibition	O
of	O
the	O
tubulin	O
deacetylase	O
HDAC6	O
restores	O
microtubule	O
acetylation	O
in	O
BBIP10	O
-	O
depleted	O
cells	O
,	O
and	O
BBIP10	O
physically	O
interacts	O
with	O
HDAC6	O
.	O

BBSome	B-Complex
-	O
bound	O
BBIP10	O
may	O
therefore	O
function	O
to	O
couple	O
acetylation	O
of	O
axonemal	O
microtubules	O
and	O
ciliary	O
membrane	O
growth	O
.	O

A	O
calcium	O
-	O
dependent	O
switch	O
in	O
a	O
CREST	O
-	O
BRG1	O
complex	O
regulates	O
activity	O
-	O
dependent	O
gene	O
expression	O
.	O

CREST	O
plays	O
a	O
critical	O
role	O
in	O
activity	O
-	O
dependent	O
development	O
,	O
but	O
its	O
mechanism	O
of	O
action	O
is	O
not	O
well	O
understood	O
.	O

Here	O
,	O
we	O
show	O
that	O
a	O
CREST	O
-	O
BRG1	O
complex	O
regulates	O
promoter	O
activation	O
by	O
orchestrating	O
a	O
calcium	O
-	O
dependent	O
release	O
of	O
a	O
repressor	O
complex	O
and	O
a	O
recruitment	O
of	O
an	O
activator	O
complex	O
.	O

In	O
resting	O
neurons	O
,	O
transcription	O
of	O
the	O
c	O
-	O
fos	O
promoter	O
is	O
inhibited	O
by	O
BRG1	O
-	O
dependent	O
recruitment	O
of	O
a	O
phospho	O
-	O
Rb	O
-	O
HDAC	O
repressor	O
complex	O
.	O

Upon	O
calcium	O
influx	O
,	O
Rb	O
becomes	O
dephosphorylated	O
at	O
serine	O
795	O
by	O
calcineurin	B-Complex
,	O
which	O
leads	O
to	O
release	O
of	O
the	O
repressor	O
complex	O
.	O

At	O
the	O
same	O
time	O
,	O
there	O
is	O
increased	O
recruitment	O
of	O
CBP	O
to	O
the	O
promoter	O
by	O
a	O
CREST	O
-	O
dependent	O
mechanism	O
,	O
which	O
leads	O
to	O
transcriptional	O
activation	O
.	O

The	O
CREST	O
-	O
BRG1	O
also	O
binds	O
to	O
the	O
NR2B	O
promoter	O
,	O
and	O
activity	O
-	O
dependent	O
induction	O
of	O
NR2B	O
expression	O
involves	O
a	O
release	O
of	O
HDAC1	O
and	O
recruitment	O
of	O
CBP	O
,	O
suggesting	O
that	O
this	O
mechanism	O
may	O
be	O
generally	O
involved	O
in	O
regulating	O
calcium	O
-	O
dependent	O
transcription	O
of	O
neuronal	O
genes	O
.	O

TRAF6	O
autoubiquitination	O
-	O
independent	O
activation	O
of	O
the	O
NFkappaB	B-Complex
and	O
MAPK	O
pathways	O
in	O
response	O
to	O
IL	O
-	O
1	O
and	O
RANKL	O
.	O

The	O
adapter	O
protein	O
TRAF6	O
is	O
critical	O
for	O
mediating	O
signal	O
transduction	O
from	O
members	O
of	O
the	O
IL	O
-	O
1R	O
/	O
TLR	O
and	O
TNFR	O
superfamilies	O
.	O

The	O
TRAF6	O
RING	O
finger	O
domain	O
functions	O
as	O
an	O
ubiquitin	O
E3	O
ligase	O
capable	O
of	O
generating	O
non	O
-	O
degradative	O
K63	O
-	O
linked	O
ubiquitin	O
chains	O
.	O

It	O
is	O
believed	O
that	O
these	O
chains	O
serve	O
as	O
docking	O
sites	O
for	O
formation	O
of	O
signaling	O
complexes	O
,	O
and	O
that	O
K63	O
-	O
linked	O
autoubiquitination	O
of	O
TRAF6	O
is	O
essential	O
for	O
formation	O
and	O
activation	O
of	O
a	O
complex	O
involving	O
the	O
kinase	O
TAK1	O
and	O
its	O
adapters	O
,	O
TAB1	O
and	O
TAB2	O
.	O

In	O
order	O
to	O
assess	O
independently	O
the	O
E3	O
ligase	O
and	O
ubiquitin	O
substrate	O
functions	O
of	O
TRAF6	O
,	O
we	O
generated	O
,	O
respectively	O
,	O
RING	O
domain	O
and	O
complete	O
lysine	O
-	O
deficient	O
TRAF6	O
mutants	O
.	O

We	O
found	O
that	O
while	O
the	O
TRAF6	O
RING	O
domain	O
is	O
required	O
for	O
activation	O
of	O
TAK1	O
,	O
it	O
is	O
dispensable	O
for	O
interaction	O
between	O
TRAF6	O
and	O
the	O
TAK1	O
-	O
TAB1	O
-	O
TAB2	O
complex	O
.	O

Likewise	O
,	O
lysine	O
-	O
deficient	O
TRAF6	O
was	O
found	O
to	O
interact	O
with	O
the	O
TAK1	O
-	O
TAB1	O
-	O
TAB2	O
complex	O
,	O
but	O
surprisingly	O
was	O
also	O
found	O
to	O
be	O
fully	O
competent	O
to	O
activate	O
TAK1	O
,	O
as	O
well	O
as	O
NFkappaB	B-Complex
and	O
AP	B-Complex
-	I-Complex
1	I-Complex
reporters	O
.	O

Furthermore	O
,	O
lysine	O
-	O
deficient	O
TRAF6	O
rescued	O
IL	O
-	O
1	O
-	O
mediated	O
NFkappaB	B-Complex
and	O
MAPK	O
activation	O
,	O
as	O
well	O
as	O
IL	O
-	O
6	O
elaboration	O
in	O
retrovirally	O
-	O
rescued	O
TRAF6	O
-	O
deficient	O
fibroblasts	O
.	O

Lysine	O
-	O
deficient	O
TRAF6	O
also	O
rescued	O
RANKL	O
-	O
mediated	O
NFkappaB	B-Complex
and	O
MAPK	O
activation	O
,	O
and	O
osteoclastogenesis	O
in	O
retrovirally	O
-	O
rescued	O
TRAF6	O
-	O
deficient	O
bone	O
marrow	O
macrophages	O
.	O

While	O
incapable	O
of	O
being	O
ubiquitinated	O
itself	O
,	O
we	O
demonstrate	O
that	O
lysine	O
-	O
deficient	O
TRAF6	O
remains	O
competent	O
to	O
induce	O
ubiquitination	O
of	O
IKKgamma	O
/	O
NEMO	O
.	O

Further	O
,	O
this	O
NEMO	O
modification	O
contributes	O
to	O
TRAF6	O
-	O
mediated	O
activation	O
of	O
NFkappaB	B-Complex
.	O

Collectively	O
,	O
our	O
results	O
suggest	O
that	O
while	O
TRAF6	O
autoubiquitination	O
may	O
serve	O
as	O
a	O
marker	O
of	O
activation	O
,	O
it	O
is	O
unlikely	O
to	O
underpin	O
RING	O
finger	O
-	O
dependent	O
TRAF6	O
function	O
.	O

A	O
nuclear	O
factor	O
NF	B-Complex
-	I-Complex
GM2	I-Complex
that	O
interacts	O
with	O
a	O
regulatory	O
region	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
essential	O
for	O
its	O
induction	O
in	O
responses	O
to	O
T	O
-	O
cell	O
activation	O
:	O
purification	O
from	O
human	O
T	O
-	O
cell	O
leukemia	O
line	O
Jurkat	O
cells	O
and	O
similarity	O
to	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O

Activation	O
of	O
T	O
cells	O
by	O
antigen	O
,	O
lectin	O
,	O
or	O
a	O
combination	O
of	O
phorbol	O
-	O
12	O
-	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
leads	O
to	O
the	O
induction	O
of	O
genes	O
for	O
a	O
set	O
of	O
lymphokines	O
,	O
including	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
.	O

We	O
demonstrated	O
in	O
earlier	O
studies	O
that	O
the	O
upstream	O
region	O
of	O
the	O
mouse	O
GM	O
-	O
CSF	O
promoter	O
at	O
positions	O
between	O
-	O
95	O
and	O
-	O
73	O
is	O
essential	O
for	O
transcriptional	O
activation	O
in	O
response	O
to	O
PMA	O
/	O
A23187	O
.	O

This	O
region	O
contains	O
two	O
DNA	O
-	O
binding	O
motifs	O
,	O
GM2	O
and	O
GC	O
-	O
box	O
.	O

The	O
GM2	O
sequence	O
(	O
GGTAGTTCCC	O
)	O
is	O
recognized	O
by	O
an	O
inducible	O
factor	O
NF	B-Complex
-	I-Complex
GM2	I-Complex
;	O
the	O
other	O
(	O
CCGCCC	O
)	O
by	O
constitutive	O
factors	O
A1	O
,	O
A2	O
,	O
and	O
B	O
.	O

To	O
elucidate	O
the	O
mechanism	O
of	O
GM	O
-	O
CSF	O
gene	O
activation	O
,	O
we	O
have	O
purified	O
the	O
inducible	O
factor	O
NF	B-Complex
-	I-Complex
GM2	I-Complex
from	O
the	O
nuclear	O
extract	O
of	O
stimulated	O
Jurkat	O
cells	O
on	O
the	O
basis	O
of	O
specific	O
DNA	O
-	O
binding	O
activity	O
.	O

The	O
purified	O
NF	B-Complex
-	I-Complex
GM2	I-Complex
consists	O
of	O
50	O
(	O
p50	O
)	O
and	O
65	O
kDa	O
(	O
p65	O
)	O
polypeptides	O
and	O
has	O
a	O
binding	O
activity	O
specific	O
for	O
both	O
the	O
GM	O
-	O
CSF	O
and	O
immunoglobulin	O
kappa	O
(	O
GGAAAGTCCC	O
)	O
enhancers	O
.	O

Electrophoretically	O
purified	O
p50	O
alone	O
can	O
form	O
a	O
protein	O
-	O
DNA	O
complex	O
,	O
but	O
in	O
the	O
mixture	O
,	O
p50	O
associates	O
preferentially	O
with	O
p65	O
to	O
form	O
the	O
NF	B-Complex
-	I-Complex
GM2	I-Complex
complex	O
.	O

In	O
addition	O
,	O
p65	O
gave	O
per	O
se	O
,	O
with	O
low	O
affinity	O
,	O
a	O
protein	O
-	O
DNA	O
complex	O
that	O
migrated	O
more	O
slowly	O
than	O
native	O
NF	B-Complex
-	I-Complex
GM2	I-Complex
complex	O
.	O

Furthermore	O
,	O
an	O
antiserum	O
against	O
KBF1	O
(	O
identical	O
to	O
50	O
kDa	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
protein	O
)	O
reacted	O
with	O
the	O
p50	O
of	O
NF	B-Complex
-	I-Complex
GM2	I-Complex
,	O
indicating	O
that	O
the	O
NF	B-Complex
-	I-Complex
GM2	I-Complex
polypeptide	O
cannot	O
be	O
immunologically	O
differentiated	O
from	O
the	O
50	O
kDa	O
subunit	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O

The	O
purified	O
NF	B-Complex
-	I-Complex
GM2	I-Complex
activated	O
in	O
vitro	O
transcription	O
from	O
the	O
kappa	B-Complex
B	I-Complex
enhancer	O
,	O
while	O
it	O
failed	O
to	O
stimulate	O
transcription	O
from	O
the	O
GM	O
-	O
CSF	O
promoter	O
harboring	O
the	O
GM2	O
sequence	O
.	O

This	O
suggests	O
that	O
the	O
activation	O
mechanism	O
of	O
the	O
GM	O
-	O
CSF	O
gene	O
through	O
the	O
GM2	O
/	O
GC	O
-	O
box	O
sequence	O
is	O
different	O
from	O
that	O
of	O
genes	O
carrying	O
the	O
kappa	B-Complex
B	I-Complex
enhancer	O
alone	O
.	O

Loss	O
-	O
of	O
-	O
function	O
analysis	O
suggests	O
that	O
Omi	O
/	O
HtrA2	O
is	O
not	O
an	O
essential	O
component	O
of	O
the	O
PINK1	O
/	O
PARKIN	O
pathway	O
in	O
vivo	O
.	O

Recently	O
,	O
a	O
mutation	O
in	O
the	O
mitochondrial	O
protease	O
Omi	O
/	O
HtrA2	O
,	O
G399S	O
,	O
was	O
found	O
in	O
sporadic	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
patients	O
,	O
leading	O
to	O
the	O
designation	O
of	O
Omi	O
/	O
HtrA2	O
as	O
PD	O
locus	O
13	O
(	O
PARK13	O
)	O
.	O

G399S	O
reportedly	O
results	O
in	O
reduced	O
Omi	O
protease	O
activity	O
.	O

In	O
vitro	O
studies	O
have	O
suggested	O
that	O
Omi	O
/	O
HtrA2	O
acts	O
downstream	O
of	O
PINK1	O
,	O
mutations	O
in	O
which	O
mediate	O
recessive	O
forms	O
of	O
PD	O
.	O

We	O
,	O
as	O
well	O
as	O
other	O
,	O
have	O
previously	O
shown	O
that	O
the	O
Drosophila	O
homologs	O
of	O
the	O
familial	O
PD	O
genes	O
,	O
PINK1	O
(	O
PARK6	O
)	O
and	O
PARKIN	O
(	O
PARK2	O
)	O
,	O
function	O
in	O
a	O
common	O
genetic	O
pathway	O
to	O
regulate	O
mitochondrial	O
integrity	O
and	O
dynamics	O
.	O

Whether	O
Omi	O
/	O
HtrA2	O
regulates	O
mitochondrial	O
integrity	O
and	O
whether	O
it	O
acts	O
downstream	O
of	O
PINK1	O
in	O
vivo	O
remain	O
to	O
be	O
explored	O
.	O

Here	O
,	O
we	O
show	O
that	O
Omi	O
/	O
HtrA2	O
null	O
mutants	O
in	O
Drosophila	O
,	O
in	O
contrast	O
to	O
pink1	O
or	O
parkin	O
null	O
mutants	O
,	O
do	O
not	O
show	O
mitochondrial	O
morphological	O
defects	O
.	O

Extensive	O
genetic	O
interaction	O
studies	O
do	O
not	O
provide	O
support	O
for	O
models	O
in	O
which	O
Omi	O
/	O
HtrA2	O
functions	O
in	O
the	O
same	O
genetic	O
pathway	O
as	O
pink1	O
,	O
or	O
carries	O
out	O
partially	O
redundant	O
functions	O
with	O
pink1	O
,	O
at	O
least	O
with	O
respect	O
to	O
regulation	O
of	O
mitochondrial	O
integrity	O
and	O
dynamics	O
.	O

Furthermore	O
,	O
Omi	O
/	O
HtrA2	O
G399S	O
retains	O
significant	O
,	O
if	O
not	O
full	O
,	O
function	O
of	O
Omi	O
/	O
HtrA2	O
,	O
compared	O
with	O
expression	O
of	O
protease	O
-	O
compromised	O
versions	O
of	O
the	O
protein	O
.	O

In	O
light	O
of	O
recent	O
findings	O
showing	O
that	O
G399S	O
can	O
be	O
found	O
at	O
comparable	O
frequencies	O
in	O
PD	O
patients	O
and	O
healthy	O
controls	O
,	O
we	O
do	O
not	O
favor	O
a	O
hypothesis	O
in	O
which	O
Omi	O
/	O
HtrA2	O
plays	O
an	O
essential	O
role	O
in	O
PD	O
pathogenesis	O
,	O
at	O
least	O
with	O
respect	O
to	O
regulation	O
of	O
mitochondrial	O
integrity	O
in	O
the	O
pink1	O
/	O
parkin	O
pathway	O
.	O

Palmitoylation	O
modification	O
of	O
Galpha	O
(	O
o	O
)	O
depresses	O
its	O
susceptibility	O
to	O
GAP	O
-	O
43	O
activation	O
.	O

Interaction	O
between	O
GAP	O
-	O
43	O
(	O
growth	O
associated	O
protein	O
-	O
43	O
)	O
and	O
Galpha	O
(	O
o	O
)	O
(	O
alpha	O
subunit	O
of	O
Go	O
protein	O
)	O
influences	O
the	O
signal	O
transduction	O
pathways	O
leading	O
to	O
differentiation	O
of	O
neural	O
cells	O
.	O

GAP	O
-	O
43	O
is	O
known	O
to	O
increase	O
guanine	O
nucleotide	O
exchange	O
by	O
Galpha	O
(	O
o	O
)	O
,	O
which	O
is	O
a	O
major	O
component	O
of	O
neuronal	O
growth	O
cone	O
membranes	O
.	O

However	O
,	O
it	O
is	O
not	O
clear	O
whether	O
GAP	O
-	O
43	O
stimulation	O
is	O
related	O
to	O
the	O
Galpha	O
(	O
o	O
)	O
palmitoylation	O
or	O
the	O
conversion	O
of	O
Galpha	O
(	O
o	O
)	O
from	O
oligmers	O
to	O
monomers	O
,	O
which	O
was	O
shown	O
to	O
be	O
a	O
necessary	O
regulatory	O
factor	O
in	O
GDP	O
/	O
GTP	O
exchange	O
of	O
Galpha	O
(	O
o	O
)	O
.	O

Here	O
we	O
expressed	O
and	O
purified	O
GAP	O
-	O
43	O
,	O
GST	O
-	O
GAP	O
-	O
43	O
and	O
Galpha	O
(	O
o	O
)	O
proteins	O
,	O
detected	O
their	O
stimulatory	O
effect	O
on	O
[	O
(	O
35	O
)	O
S	O
]	O
-	O
GTPgammaS	O
binding	O
of	O
Galpha	O
(	O
o	O
)	O
.	O

It	O
was	O
found	O
that	O
the	O
EC	O
(	O
50	O
)	O
of	O
both	O
GAP	O
-	O
43	O
and	O
GST	O
-	O
GAP	O
-	O
43	O
activation	O
were	O
tenfold	O
lower	O
in	O
case	O
of	O
depalmitoylated	O
Galpha	O
(	O
o	O
)	O
than	O
palmitoylated	O
Galpha	O
(	O
o	O
)	O
.	O

Non	O
-	O
denaturing	O
gel	O
electrophoresis	O
and	O
p	O
-	O
PDM	O
cross	O
-	O
linking	O
analysis	O
revealed	O
that	O
addition	O
of	O
GST	O
-	O
GAP	O
-	O
43	O
induced	O
disassociation	O
of	O
depalmitoylated	O
Galpha	O
(	O
o	O
)	O
from	O
oligomers	O
to	O
monomers	O
,	O
but	O
did	O
not	O
influence	O
the	O
oligomeric	O
state	O
of	O
palmitoylated	O
Galpha	O
(	O
o	O
)	O
,	O
which	O
suggests	O
that	O
palmitoylation	O
is	O
a	O
key	O
regulatory	O
factor	O
in	O
GAP	O
-	O
43	O
stimulation	O
on	O
Galpha	O
(	O
o	O
)	O
.	O

These	O
results	O
indicated	O
the	O
interaction	O
of	O
GAP	O
-	O
43	O
and	O
Galpha	O
(	O
o	O
)	O
could	O
accelerate	O
conversion	O
of	O
depalmitoylated	O
Galpha	O
(	O
o	O
)	O
but	O
not	O
palmitoylated	O
Galpha	O
(	O
o	O
)	O
from	O
oligomers	O
to	O
monomers	O
,	O
so	O
as	O
to	O
increase	O
the	O
GTPgammaS	O
binding	O
activity	O
of	O
Galpha	O
(	O
o	O
)	O
.	O

Results	O
here	O
provide	O
new	O
evidence	O
about	O
how	O
signaling	O
protein	O
palmitoylation	O
is	O
involved	O
in	O
the	O
G	O
-	O
protein	O
-	O
coupled	O
signal	O
transduction	O
cascade	O
,	O
and	O
give	O
a	O
useful	O
clue	O
on	O
the	O
participation	O
of	O
GAP	O
-	O
43	O
in	O
G	O
-	O
protein	O
cycle	O
by	O
its	O
preferential	O
activation	O
of	O
depalmitoylated	O
Galpha	O
(	O
o	O
)	O
.	O

The	O
consistent	O
observation	O
of	O
a	O
2	O
:	O
1	O
stoichiometry	O
for	O
PNK	O
-	O
FHA	O
-	O
binding	O
to	O
all	O
the	O
peptides	O
tested	O
,	O
other	O
than	O
that	O
phosphorylated	O
on	O
Thr523	O
only	O
,	O
was	O
surprising	O
.	O

To	O
determine	O
if	O
this	O
was	O
related	O
to	O
the	O
use	O
of	O
the	O
isolated	O
FHA	O
domain	O
,	O
we	O
repeated	O
the	O
titrations	O
with	O
full	O
-	O
length	O
human	O
PNK	O
,	O
against	O
the	O
pSer518	O
/	O
pThr519	O
,	O
and	O
pSer518	O
/	O
pThr519	O
/	O
pThr523	O
/	O
pSer525	O
peptides	O
.	O

The	O
measured	O
affinities	O
for	O
these	O
peptides	O
(	O
Kd	O
=	O
1	O
.	O
57	O
microM	O
and	O
0	O
.	O
10	O
microM	O
,	O
respectively	O
)	O
were	O
comparable	O
to	O
those	O
obtained	O
with	O
the	O
isolated	O
FHA	O
domains	O
,	O
and	O
the	O
stoichiometries	O
obtained	O
for	O
the	O
full	O
-	O
length	O
proteins	O
(	O
N	O
=	O
0	O
.	O
61	O
and	O
0	O
.	O
49	O
)	O
were	O
similarly	O
consistent	O
with	O
formation	O
of	O
2	O
:	O
1	O
complexes	O
with	O
the	O
peptide	O
in	O
both	O
cases	O
(	O
Figure	O
2C	O
)	O
.	O

Finally	O
we	O
inverted	O
the	O
ITC	O
experiment	O
from	O
the	O
normal	O
arrangement	O
with	O
the	O
protein	O
in	O
the	O
cell	O
and	O
the	O
peptide	O
injected	O
.	O

When	O
PNK	O
-	O
FHA	O
was	O
injected	O
into	O
the	O
cell	O
containing	O
the	O
pSer518	O
/	O
pThr519	O
peptide	O
,	O
the	O
measured	O
affinity	O
(	O
Kd	O
=	O
2	O
.	O
23	O
microM	O
)	O
was	O
comparable	O
to	O
that	O
obtained	O
in	O
the	O
inverted	O
experiment	O
,	O
with	O
the	O
measured	O
stoichiometry	O
(	O
N	O
=	O
1	O
.	O
76	O
)	O
inverted	O
,	O
but	O
fully	O
consistent	O
with	O
formation	O
of	O
a	O
2	O
:	O
1	O
protein	O
-	O
peptide	O
complex	O
(	O
Figure	O
2D	O
)	O
.	O

These	O
results	O
,	O
together	O
with	O
the	O
substrate	O
activities	O
of	O
the	O
acyl	O
-	O
CoAs	O
reported	O
in	O
the	O
previous	O
section	O
,	O
suggest	O
that	O
hTHEM2	O
requires	O
CoA	O
as	O
the	O
substrate	O
thiol	O
unit	O
,	O
which	O
in	O
turn	O
demands	O
that	O
hTHEM2	O
has	O
a	O
CoA	O
binding	O
site	O
.	O

We	O
tested	O
this	O
prediction	O
by	O
measuring	O
the	O
inhibition	O
constant	O
of	O
the	O
CoA	O
analog	O
desulfoCoA	O
,	O
in	O
which	O
the	O
CH2SH	O
is	O
replaced	O
with	O
CH3	O
.	O

Because	O
the	O
activity	O
assay	O
is	O
based	O
on	O
measuring	O
CoA	O
formation	O
using	O
DTNB	O
,	O
CoA	O
itself	O
could	O
not	O
be	O
tested	O
.	O

The	O
desulfoCoA	O
was	O
shown	O
to	O
be	O
tight	O
binding	O
competitive	O
inhibitor	O
of	O
hTHEM2	O
catalysis	O
(	O
Ki	O
=	O
9	O
muM	O
;	O
Table	O
2	O
)	O
.	O

For	O
evaluating	O
the	O
effect	O
of	O
WIF1	O
,	O
DN	O
-	O
LEF1	O
,	O
and	O
TCF4shRNA	O
expression	O
on	O
cell	O
proliferation	O
,	O
T24	O
and	O
TSU	O
-	O
PR1	O
cells	O
stably	O
transfected	O
with	O
WIF1	O
,	O
DN	O
-	O
LEF1	O
,	O
TCF4shRNA	O
,	O
or	O
control	O
pRK5	O
were	O
cultured	O
for	O
1	O
,	O
3	O
,	O
and	O
5	O
days	O
in	O
24	O
-	O
well	O
plates	O
.	O

For	O
studying	O
the	O
effects	O
of	O
recombinant	O
WD	O
protein	O
on	O
cell	O
proliferation	O
,	O
T24	O
cells	O
were	O
treated	O
with	O
different	O
concentrations	O
of	O
recombinant	O
WD	O
protein	O
in	O
24	O
-	O
well	O
plates	O
for	O
2	O
days	O
.	O

The	O
3	O
-	O
(	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)	O
-	O
2	O
,	O
5	O
-	O
diphenyltetrazolium	O
bromide	O
(	O
Sigma	O
)	O
was	O
added	O
to	O
a	O
final	O
concentration	O
of	O
1	O
mg	O
/	O
mL	O
.	O

The	O
reaction	O
mixture	O
was	O
incubated	O
for	O
3	O
h	O
at	O
37degreesC	O
and	O
the	O
absorbance	O
was	O
measured	O
at	O
570	O
nm	O
.	O

To	O
test	O
whether	O
UvrB	O
and	O
Mfd	O
proteins	O
influence	O
UvrA	O
degradation	O
we	O
performed	O
pulse	O
-	O
chase	O
experiments	O
in	O
uvrB	O
and	O
mfd	O
mutant	O
cells	O
and	O
determined	O
the	O
rate	O
of	O
UvrA	O
degradation	O
at	O
40	O
min	O
post	O
-	O
UV	O
treatment	O
.	O

Deletion	O
of	O
either	O
mfd	O
or	O
uvrB	O
increased	O
UvrA	O
half	O
-	O
life	O
from	O
~	O
70	O
min	O
in	O
wild	O
-	O
type	O
cells	O
to	O
~	O
150	O
min	O
in	O
the	O
mfd	O
mutant	O
and	O
to	O
~	O
290	O
min	O
in	O
the	O
uvrB	O
mutant	O
cells	O
(	O
Fig	O
.	O
5B	O
)	O
.	O

The	O
absence	O
of	O
Mfd	O
or	O
UvrB	O
from	O
the	O
cells	O
is	O
expected	O
to	O
affect	O
the	O
kinetics	O
of	O
DNA	O
repair	O
and	O
may	O
also	O
influence	O
UvrA	O
stability	O
more	O
directly	O
,	O
as	O
both	O
proteins	O
are	O
known	O
to	O
interact	O
with	O
UvrA	O
.	O

Motor	O
-	O
and	O
tail	O
-	O
dependent	O
targeting	O
of	O
dynein	B-Complex
to	O
microtubule	O
plus	O
ends	O
and	O
the	O
cell	O
cortex	O
.	O

BACKGROUND	O
:	O
Cytoplasmic	O
dynein	B-Complex
mediates	O
spindle	O
positioning	O
in	O
budding	O
yeast	O
by	O
powering	O
sliding	O
of	O
microtubules	O
along	O
the	O
cell	O
cortex	O
.	O

Although	O
previous	O
studies	O
have	O
demonstrated	O
cortical	O
and	O
plus	O
-	O
end	O
targeting	O
of	O
dynein	O
heavy	O
chain	O
(	O
Dyn1	O
/	O
HC	O
)	O
,	O
the	O
regulation	O
of	O
its	O
recruitment	O
to	O
these	O
sites	O
remains	O
elusive	O
.	O

RESULTS	O
:	O
Here	O
we	O
show	O
that	O
separate	O
domains	O
of	O
Dyn1	O
/	O
HC	O
confer	O
differential	O
localization	O
to	O
the	O
dynein	B-Complex
complex	O
.	O

The	O
N	O
-	O
terminal	O
tail	O
domain	O
targets	O
Dyn1	O
/	O
HC	O
to	O
cortical	O
Num1	O
receptor	O
sites	O
,	O
whereas	O
the	O
C	O
-	O
terminal	O
motor	O
domain	O
targets	O
Dyn1	O
/	O
HC	O
to	O
microtubule	O
plus	O
ends	O
in	O
a	O
Bik1	O
/	O
CLIP	O
-	O
170	O
-	O
and	O
Pac1	O
/	O
LIS1	O
-	O
dependent	O
manner	O
.	O

Surprisingly	O
,	O
the	O
isolated	O
motor	O
domain	O
blocks	O
plus	O
-	O
end	O
targeting	O
of	O
Dyn1	O
/	O
HC	O
,	O
leading	O
to	O
a	O
dominant	O
-	O
negative	O
effect	O
on	O
dynein	B-Complex
function	O
.	O

Overexpression	O
of	O
Pac1	O
/	O
LIS1	O
,	O
but	O
not	O
Bik1	O
/	O
CLIP	O
-	O
170	O
,	O
rescues	O
the	O
dominant	O
negativity	O
by	O
restoring	O
Dyn1	O
/	O
HC	O
to	O
plus	O
ends	O
.	O

In	O
contrast	O
,	O
the	O
isolated	O
tail	O
domain	O
has	O
no	O
inhibitory	O
effect	O
on	O
Dyn1	O
/	O
HC	O
targeting	O
and	O
function	O
.	O

However	O
,	O
cortical	O
targeting	O
of	O
the	O
tail	O
construct	O
is	O
more	O
robust	O
than	O
full	O
-	O
length	O
Dyn1	O
/	O
HC	O
and	O
occurs	O
independently	O
of	O
Bik1	O
/	O
CLIP	O
-	O
170	O
or	O
Pac1	O
/	O
LIS1	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
cortical	O
association	O
domain	O
is	O
normally	O
masked	O
in	O
the	O
full	O
-	O
length	O
dynein	B-Complex
molecule	O
.	O

We	O
propose	O
that	O
targeting	O
of	O
dynein	B-Complex
to	O
plus	O
ends	O
unmasks	O
the	O
tail	O
,	O
priming	O
the	O
motor	O
for	O
off	O
-	O
loading	O
to	O
cortical	O
Num1	O
sites	O
.	O

Rai1	O
is	O
bound	O
about	O
30	O
Aa	O
away	O
and	O
on	O
the	O
opposite	O
face	O
from	O
the	O
active	O
site	O
of	O
Rat1	O
(	O
Fig	O
.	O
1b	O
)	O
.	O

The	O
primary	O
interactions	O
involve	O
the	O
poorly	O
conserved	O
C	O
-	O
terminal	O
segment	O
of	O
Rat1	O
and	O
the	O
beta8	O
-	O
alphaE	O
segment	O
and	O
strand	O
beta4	O
of	O
Rai1	O
(	O
Fig	O
.	O
1d	O
,	O
Supplemental	O
Fig	O
.	O
6	O
)	O
.	O

Approximately	O
800	O
Aa2	O
of	O
the	O
surface	O
area	O
of	O
Rat1	O
and	O
Rai1	O
are	O
buried	O
in	O
this	O
interface	O
,	O
and	O
the	O
two	O
surfaces	O
at	O
the	O
interface	O
are	O
highly	O
complementary	O
to	O
each	O
other	O
,	O
with	O
a	O
shape	O
correlation	O
score	O
of	O
0	O
.	O
76	O
,	O
consistent	O
with	O
the	O
stability	O
of	O
the	O
Rat1	O
-	O
Rai1	O
complex	O
(	O
see	O
below	O
)	O
.	O

Both	O
the	O
RGS	O
domain	O
and	O
the	O
six	O
C	O
-	O
terminal	O
amino	O
acids	O
of	O
mouse	O
Axin	O
are	O
required	O
for	O
normal	O
embryogenesis	O
.	O

Axin	O
is	O
a	O
negative	O
regulator	O
of	O
canonical	O
Wnt	O
signaling	O
,	O
which	O
promotes	O
the	O
degradation	O
of	O
beta	O
-	O
catenin	O
,	O
the	O
major	O
effector	O
in	O
this	O
signaling	O
cascade	O
.	O

While	O
many	O
protein	O
-	O
binding	O
domains	O
of	O
Axin	O
have	O
been	O
identified	O
,	O
their	O
significance	O
has	O
not	O
been	O
evaluated	O
in	O
vivo	O
.	O

Here	O
,	O
we	O
report	O
the	O
generation	O
and	O
analysis	O
of	O
mice	O
carrying	O
modified	O
Axin	O
alleles	O
in	O
which	O
either	O
the	O
RGS	O
domain	O
or	O
the	O
six	O
C	O
-	O
terminal	O
amino	O
acids	O
(	O
C6	O
motif	O
)	O
were	O
deleted	O
.	O

The	O
RGS	O
domain	O
is	O
required	O
for	O
APC	O
-	O
binding	O
,	O
while	O
the	O
C6	O
motif	O
has	O
been	O
implicated	O
in	O
the	O
activation	O
of	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
,	O
but	O
is	O
not	O
required	O
for	O
the	O
effects	O
of	O
Axin	O
on	O
the	O
Wnt	O
/	O
beta	O
-	O
catenin	O
pathway	O
,	O
in	O
vitro	O
.	O

Both	O
mutant	O
Axin	O
alleles	O
caused	O
recessive	O
embryonic	O
lethality	O
at	O
E9	O
.	O
5	O
-	O
E10	O
.	O
5	O
,	O
with	O
defects	O
indistinguishable	O
from	O
those	O
caused	O
by	O
a	O
null	O
allele	O
.	O

As	O
Axin	O
-	O
DeltaRGS	O
protein	O
was	O
produced	O
at	O
normal	O
levels	O
,	O
its	O
inability	O
to	O
support	O
embryogenesis	O
confirms	O
the	O
importance	O
of	O
interactions	O
between	O
Axin	O
and	O
APC	O
.	O

In	O
contrast	O
,	O
Axin	O
-	O
DeltaC6	O
protein	O
was	O
expressed	O
at	O
only	O
25	O
-	O
30	O
%	O
of	O
the	O
normal	O
level	O
,	O
which	O
may	O
account	O
for	O
the	O
recessive	O
lethality	O
of	O
this	O
allele	O
.	O

Furthermore	O
,	O
many	O
Axin	O
(	O
DeltaC6	O
/	O
DeltaC6	O
)	O
embryos	O
that	O
were	O
heterozygous	O
for	O
a	O
beta	O
-	O
catenin	O
null	O
mutation	O
survived	O
to	O
term	O
,	O
demonstrating	O
that	O
early	O
lethality	O
was	O
due	O
to	O
failure	O
to	O
negatively	O
regulate	O
beta	O
-	O
catenin	O
.	O

Recent	O
comparative	O
analysis	O
of	O
insect	O
genomes	O
have	O
identified	O
putative	O
SBP2	O
proteins	O
.	O

In	O
this	O
work	O
we	O
set	O
out	O
to	O
clone	O
and	O
characterize	O
dSBP2	O
and	O
compare	O
it	O
to	O
hSBP2	O
.	O

tBlastn	O
searches	O
were	O
performed	O
at	O
NCBI	O
using	O
the	O
hSBP2	O
amino	O
acid	O
sequence	O
and	O
one	O
significant	O
hit	O
(	O
AI062219	O
)	O
was	O
obtained	O
with	O
a	O
D	O
.	O
melanogaster	O
sequence	O
predicted	O
to	O
encode	O
a	O
313	O
amino	O
-	O
acid	O
protein	O
.	O

Figure	O
1	O
shows	O
a	O
multiple	O
sequence	O
alignment	O
of	O
this	O
protein	O
as	O
well	O
as	O
other	O
putative	O
SBP2	O
from	O
D	O
.	O
pseudoobscura	O
and	O
D	O
.	O
sechelia	O
with	O
the	O
characterized	O
rat	O
and	O
human	O
SBP2	O
and	O
the	O
annotated	O
chicken	O
and	O
Sus	O
scrofa	O
SBP2s	O
.	O

Strikingly	O
,	O
the	O
three	O
putative	O
Drosophila	O
SBP2s	O
lack	O
homology	O
to	O
the	O
vertebrate	O
SBP2	O
N	O
-	O
terminal	O
region	O
.	O

Homologies	O
to	O
vertebrate	O
SBP2s	O
were	O
found	O
throughout	O
the	O
rest	O
of	O
the	O
sequence	O
,	O
starting	O
from	O
hSBP2	O
residue	O
427	O
.	O

Two	O
blocks	O
of	O
high	O
sequence	O
identity	O
were	O
detected	O
,	O
one	O
extending	O
from	O
K517	O
to	O
K544	O
,	O
the	O
other	O
from	O
I624	O
to	O
K774	O
(	O
hSBP2	O
numbering	O
)	O
,	O
with	O
50	O
%	O
and	O
36	O
%	O
identity	O
,	O
respectively	O
.	O

The	O
latter	O
block	O
contains	O
the	O
previously	O
identified	O
L7Ae	O
RNA	O
-	O
binding	O
module	O
spanning	O
residues	O
R672	O
to	O
I749	O
.	O

Interaction	O
between	O
SARS	O
-	O
CoV	O
helicase	O
and	O
a	O
multifunctional	O
cellular	O
protein	O
(	O
Ddx5	O
)	O
revealed	O
by	O
yeast	O
and	O
mammalian	O
cell	O
two	O
-	O
hybrid	O
systems	O
.	O

To	O
reveal	O
the	O
putative	O
cellular	O
factors	O
involved	O
in	O
SARS	O
coronavirus	O
replication	O
,	O
the	O
helicase	O
(	O
Hel	O
,	O
nsp13	O
)	O
of	O
SARS	O
coronavirus	O
was	O
used	O
to	O
screen	O
the	O
cDNA	O
library	O
of	O
rat	O
pulmonary	O
epithelial	O
cells	O
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
.	O

Positively	O
interacting	O
proteins	O
were	O
further	O
tested	O
using	O
a	O
mammalian	O
cell	O
hybrid	O
system	O
and	O
co	O
-	O
immunoprecipitation	O
in	O
the	O
human	O
A549	O
cell	O
line	O
,	O
which	O
has	O
been	O
shown	O
to	O
support	O
SARS	O
coronavirus	O
replication	O
.	O

Out	O
of	O
the	O
seven	O
positive	O
clones	O
observed	O
by	O
yeast	O
two	O
-	O
hybrid	O
assay	O
,	O
only	O
the	O
Ddx5	O
(	O
Asp	O
-	O
Glu	O
-	O
Ala	O
-	O
Asp	O
box	O
polypeptide	O
5	O
)	O
protein	O
showed	O
specific	O
interaction	O
with	O
SARS	O
-	O
CoV	O
helicase	O
.	O

When	O
expression	O
of	O
DdX5	O
was	O
knocked	O
down	O
by	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
,	O
SARS	O
coronavirus	O
replication	O
was	O
significantly	O
inhibited	O
in	O
fetal	O
rhesus	O
kidney	O
(	O
FRhK	O
-	O
4	O
)	O
cells	O
.	O

Since	O
Ddx5	O
is	O
a	O
multifunctional	O
protein	O
that	O
plays	O
important	O
roles	O
in	O
transcriptional	O
regulation	O
,	O
its	O
interaction	O
with	O
SARS	O
coronavirus	O
helicase	O
provides	O
interesting	O
clues	O
for	O
studying	O
virus	O
-	O
host	O
cell	O
interactions	O
in	O
SARS	O
-	O
CoV	O
infections	O
.	O

Evidence	O
for	O
an	O
active	O
role	O
of	O
IF3mt	O
in	O
the	O
initiation	O
of	O
translation	O
in	O
mammalian	O
mitochondria	O
.	O

Mitochondrial	O
translational	O
initiation	O
factor	O
3	O
(	O
IF3	O
(	O
mt	O
)	O
)	O
is	O
a	O
29	O
kDa	O
protein	O
that	O
has	O
N	O
-	O
and	O
C	O
-	O
terminal	O
domains	O
,	O
homologous	O
to	O
prokaryotic	O
IF3	O
,	O
connected	O
by	O
a	O
linker	O
region	O
.	O

The	O
homology	O
domains	O
are	O
preceded	O
and	O
followed	O
by	O
short	O
extensions	O
.	O

No	O
information	O
is	O
currently	O
available	O
on	O
the	O
specific	O
residues	O
in	O
IF3	O
(	O
mt	O
)	O
important	O
for	O
its	O
activity	O
.	O

On	O
the	O
basis	O
of	O
homology	O
models	O
of	O
IF3	O
(	O
mt	O
)	O
,	O
mutations	O
were	O
designed	O
in	O
the	O
N	O
-	O
terminal	O
,	O
C	O
-	O
terminal	O
,	O
and	O
linker	O
domains	O
to	O
identify	O
the	O
functionally	O
important	O
regions	O
.	O

Mutation	O
of	O
residues	O
170	O
-	O
171	O
,	O
and	O
175	O
in	O
the	O
C	O
-	O
terminal	O
domain	O
to	O
alanine	O
resulted	O
in	O
a	O
nearly	O
complete	O
loss	O
of	O
activity	O
in	O
initiation	B-OOS
complex	I-OOS
formation	O
and	O
in	O
the	O
dissociation	O
of	O
mitochondrial	B-OOS
55S	I-OOS
ribosomes	I-OOS
.	O

However	O
,	O
these	O
mutated	O
proteins	O
bind	O
to	O
the	O
small	O
(	O
28S	B-Complex
)	O
subunit	O
of	O
the	O
mammalian	B-OOS
mitochondrial	I-OOS
ribosome	I-OOS
with	O
K	O
(	O
d	O
)	O
values	O
similar	O
to	O
that	O
of	O
the	O
wild	O
-	O
type	O
factor	O
.	O

These	O
mutations	O
appear	O
to	O
lead	O
to	O
a	O
factor	O
defective	O
in	O
the	O
ability	O
to	O
displace	O
the	O
large	O
(	O
39S	B-Complex
)	O
subunit	O
of	O
the	O
ribosome	B-OOS
from	O
the	O
55S	B-OOS
monosomes	I-OOS
in	O
an	O
active	O
process	O
.	O

Other	O
mutations	O
in	O
the	O
N	O
-	O
terminal	O
domain	O
,	O
the	O
linker	O
region	O
,	O
and	O
the	O
C	O
-	O
terminal	O
domain	O
had	O
little	O
or	O
no	O
effect	O
on	O
the	O
ability	O
of	O
IF3	O
(	O
mt	O
)	O
to	O
promote	O
initiation	B-OOS
complex	I-OOS
formation	O
on	O
mitochondrial	B-OOS
55S	I-OOS
ribosomes	I-OOS
.	O

Mutation	O
of	O
residues	O
247	O
and	O
248	O
in	O
the	O
C	O
-	O
terminal	O
extension	O
abolished	O
the	O
ability	O
of	O
IF3	O
(	O
mt	O
)	O
to	O
reduce	O
the	O
level	O
of	O
binding	O
of	O
fMet	O
-	O
tRNA	O
to	O
the	O
ribosome	B-OOS
in	O
the	O
absence	O
of	O
mRNA	O
.	O

Our	O
results	O
suggest	O
that	O
IF3	O
(	O
mt	O
)	O
plays	O
an	O
active	O
role	O
in	O
initiation	O
of	O
translation	O
.	O

Structural	O
basis	O
of	O
tRNA	O
modification	O
with	O
CO2	O
fixation	O
and	O
methylation	O
by	O
wybutosine	O
synthesizing	O
enzyme	O
TYW4	O
.	O

Wybutosine	O
(	O
yW	O
)	O
,	O
one	O
of	O
the	O
most	O
complicated	O
modified	O
nucleosides	O
,	O
is	O
found	O
in	O
the	O
anticodon	O
loop	O
of	O
eukaryotic	O
phenylalanine	O
tRNA	O
.	O

This	O
hypermodified	O
nucleoside	O
ensures	O
correct	O
codon	O
recognition	O
by	O
stabilizing	O
codon	O
-	O
anticodon	O
pairings	O
during	O
the	O
decoding	O
process	O
in	O
the	O
ribosome	B-OOS
.	O

TYW4	O
is	O
an	O
S	O
-	O
adenosylmethionine	O
(	O
SAM	O
)	O
-	O
dependent	O
enzyme	O
that	O
catalyzes	O
the	O
final	O
step	O
of	O
yW	O
biosynthesis	O
,	O
methylation	O
and	O
methoxycarbonylation	O
.	O

However	O
,	O
the	O
structural	O
basis	O
for	O
the	O
catalytic	O
mechanism	O
by	O
TYW4	O
,	O
and	O
especially	O
that	O
for	O
the	O
methoxycarbonylation	O
,	O
have	O
remained	O
elusive	O
.	O

Here	O
we	O
report	O
the	O
apo	O
and	O
cofactor	O
-	O
bound	O
crystal	O
structures	O
of	O
yeast	O
TYW4	O
.	O

The	O
structures	O
revealed	O
that	O
the	O
C	O
-	O
terminal	O
domain	O
folds	O
into	O
a	O
beta	O
-	O
propeller	O
structure	O
,	O
forming	O
part	O
of	O
the	O
binding	O
pocket	O
for	O
the	O
target	O
nucleoside	O
.	O

A	O
comparison	O
of	O
the	O
apo	O
,	O
SAM	O
-	O
bound	O
,	O
and	O
S	O
-	O
adenosylhomocysteine	O
-	O
bound	O
structures	O
of	O
TYW4	O
revealed	O
a	O
drastic	O
structural	O
change	O
upon	O
cofactor	O
binding	O
,	O
which	O
may	O
sequester	O
solvent	O
from	O
the	O
catalytic	O
site	O
during	O
the	O
reaction	O
and	O
facilitate	O
product	O
release	O
after	O
the	O
reaction	O
.	O

In	O
conjunction	O
with	O
the	O
functional	O
analysis	O
,	O
our	O
results	O
suggest	O
that	O
TYW4	O
catalyzes	O
both	O
methylation	O
and	O
methoxycarbonylation	O
at	O
a	O
single	O
catalytic	O
site	O
,	O
and	O
in	O
the	O
latter	O
reaction	O
,	O
the	O
methoxycarbonyl	O
group	O
is	O
formed	O
through	O
the	O
fixation	O
of	O
carbon	O
dioxide	O
.	O

The	O
export	O
of	O
mRNA	O
to	O
the	O
cytoplasm	O
through	O
NPCs	B-Complex
is	O
mediated	O
by	O
the	O
Mex67	O
:	O
Mtr2	O
heterodimer	O
in	O
yeast	O
and	O
NXF1	O
:	O
NXT1	O
(	O
TAP	O
:	O
P15	O
)	O
in	O
metazoans	O
.	O

Mex67	O
:	O
Mtr2	O
is	O
recruited	O
to	O
mRNA	O
during	O
transcription	O
and	O
processing	O
via	O
proteins	O
,	O
including	O
Yra1	O
and	O
Sub2	O
.	O

Once	O
associated	O
with	O
the	O
mRNP	O
,	O
Mex67	O
:	O
Mtr2	O
interacts	O
with	O
the	O
phenylalanine	O
-	O
glycine	O
(	O
FG	O
)	O
repeats	O
present	O
in	O
many	O
nuclear	O
pore	O
proteins	O
(	O
nucleoporins	O
)	O
to	O
facilitate	O
transport	O
through	O
NPCs	B-Complex
.	O

Studies	O
in	O
yeast	O
and	O
mammals	O
show	O
that	O
Yra1	O
and	O
Sub2	O
are	O
part	O
of	O
the	O
multisubunit	O
TREX	B-Complex
(	O
TRanscription	B-Complex
and	I-Complex
EXport	I-Complex
)	O
complex	O
,	O
which	O
also	O
contains	O
components	O
(	O
THO	O
)	O
involved	O
in	O
transcription	O
elongation	O
.	O

Mutation	O
of	O
juxtamembrane	O
cysteines	O
in	O
the	O
tetraspanin	O
CD81	O
affects	O
palmitoylation	O
and	O
alters	O
interaction	O
with	O
other	O
proteins	O
at	O
the	O
cell	O
surface	O
.	O

Palmitoylation	O
of	O
tetraspanins	O
affects	O
protein	O
-	O
protein	O
interactions	O
,	O
suggesting	O
a	O
key	O
role	O
in	O
the	O
assembly	O
of	O
the	O
tetraspanin	O
web	O
.	O

Since	O
palmitoylation	O
occurs	O
on	O
intracellular	O
cysteine	O
residues	O
,	O
we	O
examined	O
whether	O
mutating	O
these	O
residues	O
in	O
the	O
human	O
tetraspanin	O
CD81	O
would	O
affect	O
the	O
association	O
of	O
CD81	O
with	O
other	O
surface	O
membrane	O
proteins	O
.	O

Mutation	O
of	O
at	O
least	O
six	O
of	O
the	O
eight	O
juxtamembrane	O
cysteines	O
was	O
required	O
to	O
completely	O
eliminate	O
detectable	O
CD81	O
palmitoylation	O
,	O
indicating	O
that	O
several	O
sites	O
can	O
be	O
palmitoylated	O
.	O

Interestingly	O
,	O
these	O
mutated	O
proteins	O
exhibited	O
reduced	O
cell	O
surface	O
detection	O
by	O
antibody	O
compared	O
to	O
wild	O
-	O
type	O
CD81	O
,	O
but	O
this	O
was	O
not	O
due	O
to	O
differences	O
in	O
the	O
level	O
of	O
protein	O
expression	O
,	O
trafficking	O
to	O
the	O
cell	O
surface	O
,	O
protein	O
stability	O
,	O
or	O
anti	O
-	O
CD81	O
antibody	O
binding	O
affinity	O
.	O

Instead	O
,	O
the	O
mutant	O
CD81	O
proteins	O
appeared	O
to	O
be	O
partially	O
hidden	O
from	O
detection	O
by	O
anti	O
-	O
CD81	O
antibody	O
,	O
presumably	O
due	O
to	O
altered	O
interactions	O
with	O
other	O
proteins	O
at	O
the	O
cell	O
surface	O
.	O

Associations	O
with	O
the	O
known	O
CD81	O
-	O
interacting	O
proteins	O
CD9	O
and	O
EWI	O
-	O
2	O
were	O
also	O
impaired	O
with	O
the	O
mutant	O
CD81	O
proteins	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
mutation	O
of	O
juxtamembrane	O
cysteines	O
alters	O
the	O
interaction	O
of	O
CD81	O
with	O
other	O
proteins	O
,	O
either	O
because	O
of	O
reduced	O
palmitoylation	O
,	O
structural	O
alterations	O
in	O
the	O
mutant	O
proteins	O
,	O
or	O
a	O
combination	O
of	O
both	O
factors	O
,	O
and	O
this	O
affects	O
the	O
CD81	O
microenvironment	O
on	O
the	O
cell	O
surface	O
.	O

A	O
Mutant	O
-	O
p53	O
/	O
Smad	O
complex	O
opposes	O
p63	O
to	O
empower	O
TGFbeta	O
-	O
induced	O
metastasis	O
.	O

TGFbeta	O
ligands	O
act	O
as	O
tumor	O
suppressors	O
in	O
early	O
stage	O
tumors	O
but	O
are	O
paradoxically	O
diverted	O
into	O
potent	O
prometastatic	O
factors	O
in	O
advanced	O
cancers	O
.	O

The	O
molecular	O
nature	O
of	O
this	O
switch	O
remains	O
enigmatic	O
.	O

Here	O
,	O
we	O
show	O
that	O
TGFbeta	O
-	O
dependent	O
cell	O
migration	O
,	O
invasion	O
and	O
metastasis	O
are	O
empowered	O
by	O
mutant	O
-	O
p53	O
and	O
opposed	O
by	O
p63	O
.	O

Mechanistically	O
,	O
TGFbeta	O
acts	O
in	O
concert	O
with	O
oncogenic	O
Ras	O
and	O
mutant	O
-	O
p53	O
to	O
induce	O
the	O
assembly	O
of	O
a	O
mutant	O
-	O
p53	O
/	O
p63	O
protein	O
complex	O
in	O
which	O
Smads	O
serve	O
as	O
essential	O
platforms	O
.	O

Within	O
this	O
ternary	O
complex	O
,	O
p63	O
functions	O
are	O
antagonized	O
.	O

Downstream	O
of	O
p63	O
,	O
we	O
identified	O
two	O
candidate	O
metastasis	O
suppressor	O
genes	O
associated	O
with	O
metastasis	O
risk	O
in	O
a	O
large	O
cohort	O
of	O
breast	O
cancer	O
patients	O
.	O

Thus	O
,	O
two	O
common	O
oncogenic	O
lesions	O
,	O
mutant	O
-	O
p53	O
and	O
Ras	O
,	O
selected	O
in	O
early	O
neoplasms	O
to	O
promote	O
growth	O
and	O
survival	O
,	O
also	O
prefigure	O
a	O
cellular	O
set	O
-	O
up	O
with	O
particular	O
metastasis	O
proclivity	O
by	O
TGFbeta	O
-	O
dependent	O
inhibition	O
of	O
p63	O
function	O
.	O

A	O
point	O
mutation	O
in	O
TRPC3	O
causes	O
abnormal	O
Purkinje	O
cell	O
development	O
and	O
cerebellar	O
ataxia	O
in	O
moonwalker	O
mice	O
.	O

The	O
hereditary	O
ataxias	O
are	O
a	O
complex	O
group	O
of	O
neurological	O
disorders	O
characterized	O
by	O
the	O
degeneration	O
of	O
the	O
cerebellum	O
and	O
its	O
associated	O
connections	O
.	O

The	O
molecular	O
mechanisms	O
that	O
trigger	O
the	O
loss	O
of	O
Purkinje	O
cells	O
in	O
this	O
group	O
of	O
diseases	O
remain	O
incompletely	O
understood	O
.	O

Here	O
,	O
we	O
report	O
a	O
previously	O
undescribed	O
dominant	O
mouse	O
model	O
of	O
cerebellar	O
ataxia	O
,	O
moonwalker	O
(	O
Mwk	O
)	O
,	O
that	O
displays	O
motor	O
and	O
coordination	O
defects	O
and	O
loss	O
of	O
cerebellar	O
Purkinje	O
cells	O
.	O

Mwk	O
mice	O
harbor	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
(	O
T635A	O
)	O
in	O
the	O
Trpc3	O
gene	O
encoding	O
the	O
nonselective	O
transient	O
receptor	O
potential	O
cation	O
channel	O
,	O
type	O
C3	O
(	O
TRPC3	O
)	O
,	O
resulting	O
in	O
altered	O
TRPC3	O
channel	O
gating	O
.	O

TRPC3	O
is	O
highly	O
expressed	O
in	O
Purkinje	O
cells	O
during	O
the	O
phase	O
of	O
dendritogenesis	O
.	O

Interestingly	O
,	O
growth	O
and	O
differentiation	O
of	O
Purkinje	O
cell	O
dendritic	O
arbors	O
are	O
profoundly	O
impaired	O
in	O
Mwk	O
mice	O
.	O

Our	O
findings	O
define	O
a	O
previously	O
unknown	O
role	O
for	O
TRPC3	O
in	O
both	O
dendritic	O
development	O
and	O
survival	O
of	O
Purkinje	O
cells	O
,	O
and	O
provide	O
a	O
unique	O
mechanism	O
underlying	O
cerebellar	O
ataxia	O
.	O

Execution	O
of	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
:	O
what	O
defines	O
a	O
substrate	O
?	O

The	O
nonsense	O
-	O
mediated	O
mRNA	O
decay	O
(	O
NMD	O
)	O
pathway	O
targets	O
mRNAs	O
with	O
premature	O
termination	O
codons	O
as	O
well	O
as	O
a	O
subset	O
of	O
normal	O
mRNAs	O
for	O
rapid	O
decay	O
.	O

Emerging	O
evidence	O
suggests	O
that	O
mRNAs	O
become	O
NMD	O
substrates	O
based	O
on	O
the	O
composition	O
of	O
the	O
mRNP	O
downstream	O
of	O
the	O
translation	O
termination	O
event	O
,	O
which	O
either	O
stimulates	O
or	O
antagonizes	O
recruitment	O
of	O
the	O
NMD	O
machinery	O
.	O

The	O
NMD	O
mRNP	O
subsequently	O
undergoes	O
several	O
remodeling	O
events	O
,	O
which	O
involve	O
hydrolysis	O
of	O
ATP	O
by	O
the	O
NMD	O
factor	O
Upf1	O
and	O
in	O
metazoans	O
,	O
a	O
phosphorylation	O
/	O
dephosphorylation	O
cycle	O
of	O
Upf1	O
mediated	O
by	O
Smg	O
proteins	O
.	O

This	O
leads	O
to	O
mRNA	O
decay	O
following	O
translational	O
repression	O
.	O

Recent	O
evidence	O
suggests	O
that	O
in	O
Drosophila	O
and	O
human	O
cells	O
,	O
decay	O
is	O
initiated	O
by	O
the	O
endonuclease	O
Smg6	O
.	O

Since	O
Cdk5	O
is	O
essential	O
for	O
neuronal	O
migration	O
,	O
the	O
physiological	O
role	O
of	O
Cdk5	O
-	O
mediated	O
talin	O
phosphorylation	O
was	O
assessed	O
in	O
neuroblastoma	O
SH	O
-	O
SY5Y	O
cells	O
.	O

We	O
transfected	O
these	O
cells	O
with	O
EGFP	O
-	O
talin	O
,	O
-	O
talS425A	O
or	O
-	O
talS425D	O
,	O
and	O
cell	O
migration	O
was	O
measured	O
using	O
transwell	O
assays	O
.	O

Whereas	O
the	O
migration	O
of	O
cells	O
expressing	O
EGFP	O
-	O
talin	O
was	O
stimulated	O
by	O
PDGF	O
,	O
expression	O
of	O
EGFP	O
-	O
talS425A	O
or	O
EGFP	O
-	O
talS425D	O
markedly	O
retarded	O
PDGF	O
-	O
induced	O
cell	O
migration	O
(	O
Fig	O
.	O
2a	O
;	O
Supplementary	O
Information	O
,	O
Fig	O
.	O
S2a	O
)	O
.	O

Moreover	O
,	O
roscovitine	O
inhibited	O
PDGF	O
-	O
induced	O
migration	O
of	O
SH	O
-	O
SY5Y	O
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Supplementary	O
Information	O
,	O
Fig	O
.	O
S2b	O
)	O
,	O
and	O
reducing	O
Cdk5	O
expression	O
by	O
shRNA	O
knockdown	O
also	O
significantly	O
inhibited	O
neuroblastoma	O
cell	O
migration	O
(	O
Supplementary	O
Information	O
,	O
Fig	O
.	O
S2c	O
)	O
.	O

INF2	O
is	O
an	O
endoplasmic	O
reticulum	O
-	O
associated	O
formin	O
protein	O
.	O

In	O
addition	O
to	O
its	O
ability	O
to	O
accelerate	O
filament	O
assembly	O
,	O
which	O
is	O
common	O
to	O
formins	O
,	O
INF2	O
is	O
a	O
formin	O
protein	O
with	O
the	O
unique	O
biochemical	O
ability	O
to	O
accelerate	O
actin	O
filament	O
depolymerization	O
.	O

The	O
depolymerization	O
activity	O
of	O
INF2	O
requires	O
its	O
actin	O
monomer	O
-	O
binding	O
WASP	O
homology	O
2	O
(	O
WH2	O
)	O
motif	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
INF2	O
is	O
peripherally	O
bound	O
to	O
the	O
cytoplasmic	O
face	O
of	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
in	O
Swiss	O
3T3	O
cells	O
.	O

Both	O
endogenous	O
INF2	O
and	O
GFP	O
-	O
fusion	O
constructs	O
display	O
ER	O
localization	O
.	O

INF2	O
is	O
post	O
-	O
translationally	O
modified	O
by	O
a	O
C	O
-	O
terminal	O
farnesyl	O
group	O
,	O
and	O
this	O
modification	O
is	O
required	O
for	O
ER	O
interaction	O
.	O

However	O
,	O
farnesylation	O
is	O
not	O
sufficient	O
for	O
ER	O
association	O
,	O
and	O
membrane	O
extraction	O
experiments	O
suggest	O
that	O
ionic	O
interactions	O
are	O
also	O
important	O
.	O

The	O
WH2	O
motif	O
also	O
serves	O
as	O
a	O
diaphanous	O
autoregulatory	O
domain	O
(	O
DAD	O
)	O
,	O
which	O
binds	O
to	O
the	O
N	O
-	O
terminal	O
diaphanous	O
inhibitory	O
domain	O
(	O
DID	O
)	O
,	O
with	O
an	O
apparent	O
dissociation	O
constant	O
of	O
1	O
.	O
1	O
muM	O
.	O

Surprisingly	O
,	O
the	O
DID	O
-	O
DAD	O
interaction	O
does	O
not	O
inhibit	O
the	O
actin	O
nucleation	O
activity	O
of	O
INF2	O
;	O
however	O
,	O
it	O
does	O
inhibit	O
the	O
depolymerization	O
activity	O
.	O

Point	O
mutations	O
to	O
the	O
DAD	O
/	O
WH2	O
inhibit	O
both	O
the	O
DID	O
-	O
DAD	O
interaction	O
and	O
depolymerization	O
activity	O
.	O

Expression	O
of	O
GFP	O
-	O
INF2	O
containing	O
these	O
DAD	O
/	O
WH2	O
mutations	O
causes	O
the	O
ER	O
to	O
collapse	O
around	O
the	O
nucleus	O
,	O
with	O
accumulation	O
of	O
actin	O
filaments	O
around	O
the	O
collapsed	O
ER	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
show	O
the	O
association	O
of	O
an	O
actin	O
-	O
assembly	O
factor	O
with	O
the	O
ER	O
.	O

The	O
cataract	O
-	O
associated	O
R14C	O
mutant	O
of	O
human	O
gamma	O
D	O
-	O
crystallin	O
shows	O
a	O
variety	O
of	O
intermolecular	O
disulfide	O
cross	O
-	O
links	O
:	O
a	O
Raman	O
spectroscopic	O
study	O
.	O

The	O
Arg14	O
to	O
Cys	O
(	O
R14C	O
)	O
mutation	O
in	O
the	O
human	O
gammaD	O
-	O
crystallin	O
(	O
HGD	O
)	O
gene	O
has	O
been	O
associated	O
with	O
a	O
juvenile	O
-	O
onset	O
hereditary	O
cataract	O
.	O

We	O
showed	O
previously	O
[	O
Pande	O
,	O
A	O
.	O
,	O
et	O
al	O
.	O
(	O
2000	O
)	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
U	O
.	O
S	O
.	O
A	O
.	O
97	O
,	O
1993	O
-	O
1998	O
]	O
that	O
rapid	O
oxidation	O
of	O
Cys14	O
in	O
the	O
mutant	O
leads	O
to	O
the	O
formation	O
of	O
intermolecular	O
,	O
disulfide	O
-	O
cross	O
-	O
linked	O
aggregates	O
at	O
physiological	O
pH	O
.	O

Here	O
we	O
present	O
a	O
Raman	O
spectroscopic	O
analysis	O
of	O
R14C	O
and	O
HGD	O
and	O
show	O
that	O
R14C	O
forms	O
such	O
aggregates	O
even	O
at	O
pH	O
4	O
.	O
5	O
.	O

The	O
lower	O
pH	O
enabled	O
us	O
to	O
monitor	O
the	O
evolution	O
of	O
a	O
variety	O
of	O
disulfide	O
cross	O
-	O
links	O
with	O
distinct	O
conformations	O
around	O
the	O
CC	O
-	O
SS	O
-	O
CC	O
dihedral	O
angles	O
.	O

At	O
least	O
three	O
cysteine	O
residues	O
are	O
involved	O
,	O
forming	O
protein	O
-	O
protein	O
cross	O
-	O
links	O
through	O
disulfide	O
-	O
exchange	O
reactions	O
.	O

From	O
the	O
pattern	O
of	O
the	O
S	O
-	O
S	O
and	O
Trp	O
Raman	O
bands	O
,	O
we	O
infer	O
that	O
Cys32	O
is	O
likely	O
to	O
be	O
involved	O
in	O
the	O
cross	O
-	O
linking	O
.	O

The	O
data	O
suggest	O
that	O
protein	O
precipitation	O
in	O
the	O
mutant	O
may	O
not	O
be	O
the	O
direct	O
result	O
of	O
disulfide	O
cross	O
-	O
linking	O
,	O
although	O
such	O
cross	O
-	O
linking	O
is	O
the	O
initiating	O
event	O
.	O

Thus	O
,	O
our	O
Raman	O
data	O
not	O
only	O
enhance	O
the	O
understanding	O
of	O
the	O
reactivity	O
of	O
Cys14	O
in	O
the	O
R14C	O
mutant	O
and	O
the	O
mechanism	O
of	O
opacity	O
,	O
but	O
also	O
shed	O
light	O
on	O
the	O
mechanism	O
of	O
oxidative	O
degradation	O
during	O
long	O
-	O
term	O
storage	O
of	O
thiol	O
-	O
containing	O
pharmaceuticals	O
.	O

Extracellular	O
proteases	O
regulate	O
enterococcal	O
fratricide	O
.	O

A	O
.	O

Detection	O
of	O
GFP	O
immunoreactivity	O
in	O
stationary	O
phase	O
predator	O
-	O
prey	O
co	O
-	O
culture	O
supernatants	O
.	O

Predator	O
(	O
V583	O
,	O
GelE	O
+	O
SprE	O
+	O
;	O
VT01	O
,	O
GelE	O
-	O
SprE	O
+	O
;	O
VT02	O
,	O
GelE	O
+	O
SprE	O
-	O
;	O
and	O
VT03	O
,	O
GelE	O
-	O
SprE	O
-	O
)	O
and	O
prey	O
(	O
VT12	O
,	O
GelE	O
-	O
SprE	O
-	O
GFP	O
+	O
)	O
were	O
co	O
-	O
inoculated	O
at	O
a	O
20	O
:	O
1	O
ratio	O
of	O
prey	O
:	O
predator	O
and	O
grown	O
overnight	O
at	O
37degreesC	O
prior	O
to	O
immunodetection	O
of	O
GFP	O
.	O

B	O
.	O

Effect	O
of	O
extracellular	O
proteases	O
on	O
lysis	O
of	O
VT03	O
(	O
GelE	O
-	O
SprE	O
-	O
)	O
.	O

Differences	O
in	O
lysis	O
rates	O
of	O
VT03	O
in	O
the	O
absence	O
or	O
presence	O
of	O
extracellular	O
proteases	O
(	O
GelE	O
and	O
SprE	O
)	O
are	O
exhibited	O
as	O
percent	O
values	O
of	O
initial	O
optical	O
density	O
at	O
600	O
nm	O
.	O

VT03	O
was	O
incubated	O
alone	O
(	O
*	O
)	O
or	O
in	O
the	O
presence	O
of	O
100	O
ng	O
of	O
GelE	O
(	O
*	O
)	O
,	O
SprE	O
(	O
^	O
)	O
or	O
GelE	O
and	O
SprE	O
(	O
v	O
;	O
)	O
together	O
over	O
a	O
period	O
of	O
12	O
hours	O
at	O
37degreesC	O
.	O

Data	O
are	O
mean	O
+	O
/	O
-	O
SE	O
of	O
three	O
independent	O
trials	O
with	O
each	O
performed	O
in	O
triplicate	O
.	O

Negative	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
in	O
monocytes	O
:	O
role	O
of	O
the	O
65	O
-	O
kDa	O
plus	O
50	O
-	O
kDa	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
dimer	O
.	O

Although	O
monocytic	O
cells	O
can	O
provide	O
a	O
reservoir	O
for	O
viral	O
production	O
in	O
vivo	O
,	O
their	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
transcription	O
can	O
be	O
either	O
latent	O
,	O
restricted	O
,	O
or	O
productive	O
.	O

These	O
differences	O
in	O
gene	O
expression	O
have	O
not	O
been	O
molecularly	O
defined	O
.	O

In	O
THP	O
-	O
1	O
cells	O
with	O
restricted	O
HIV	O
expression	O
,	O
there	O
is	O
an	O
absence	O
of	O
DNA	O
-	O
protein	O
binding	O
complex	O
formation	O
with	O
the	O
HIV	O
-	O
1	O
promoter	O
-	O
enhancer	O
associated	O
with	O
markedly	O
less	O
viral	O
RNA	O
production	O
.	O

This	O
absence	O
of	O
binding	O
was	O
localized	O
to	O
the	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
region	O
of	O
the	O
HIV	O
-	O
1	O
enhancer	O
;	O
the	O
65	O
-	O
kDa	O
plus	O
50	O
-	O
kDa	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
heterodimer	O
was	O
preferentially	O
lost	O
.	O

Adding	O
purified	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
protein	O
to	O
nuclear	O
extracts	O
from	O
cells	O
with	O
restricted	O
expression	O
overcomes	O
this	O
lack	O
of	O
binding	O
.	O

In	O
addition	O
,	O
treatment	O
of	O
these	O
nuclear	O
extracts	O
with	O
sodium	O
deoxycholate	O
restored	O
their	O
ability	O
to	O
form	O
the	O
heterodimer	O
,	O
suggesting	O
the	O
presence	O
of	O
an	O
inhibitor	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
activity	O
.	O

Furthermore	O
,	O
treatment	O
of	O
nuclear	O
extracts	O
from	O
these	O
cells	O
that	O
had	O
restricted	O
expression	O
with	O
lipopolysaccharide	O
increased	O
viral	O
production	O
and	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
activity	O
.	O

Antiserum	O
specific	O
for	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
binding	O
proteins	O
,	O
but	O
not	O
c	O
-	O
rel	O
-	O
specific	O
antiserum	O
,	O
disrupted	O
heterodimer	O
complex	O
formation	O
.	O

Thus	O
,	O
both	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
-	O
binding	O
complexes	O
are	O
needed	O
for	O
optimal	O
viral	O
transcription	O
.	O

Binding	O
of	O
the	O
65	O
-	O
kDa	O
plus	O
50	O
-	O
kDa	O
heterodimer	O
to	O
the	O
HIV	O
-	O
1	O
enhancer	O
can	O
be	O
negatively	O
regulated	O
in	O
monocytes	O
,	O
providing	O
one	O
mechanism	O
restricting	O
HIV	O
-	O
1	O
gene	O
expression	O
.	O

A	O
functional	O
screen	O
implicates	O
microRNA	O
-	O
138	O
-	O
dependent	O
regulation	O
of	O
the	O
depalmitoylation	O
enzyme	O
APT1	O
in	O
dendritic	O
spine	O
morphogenesis	O
.	O

The	O
microRNA	O
pathway	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
synaptic	O
protein	O
synthesis	O
and	O
ultimately	O
in	O
dendritic	O
spine	O
morphogenesis	O
,	O
a	O
phenomenon	O
associated	O
with	O
long	O
-	O
lasting	O
forms	O
of	O
memory	O
.	O

However	O
,	O
the	O
particular	O
microRNAs	O
(	O
miRNAs	O
)	O
involved	O
are	O
largely	O
unknown	O
.	O

Here	O
we	O
identify	O
specific	O
miRNAs	O
that	O
function	O
at	O
synapses	O
to	O
control	O
dendritic	O
spine	O
structure	O
by	O
performing	O
a	O
functional	O
screen	O
.	O

One	O
of	O
the	O
identified	O
miRNAs	O
,	O
miR	O
-	O
138	O
,	O
is	O
highly	O
enriched	O
in	O
the	O
brain	O
,	O
localized	O
within	O
dendrites	O
and	O
negatively	O
regulates	O
the	O
size	O
of	O
dendritic	O
spines	O
in	O
rat	O
hippocampal	O
neurons	O
.	O

miR	O
-	O
138	O
controls	O
the	O
expression	O
of	O
acyl	O
protein	O
thioesterase	O
1	O
(	O
APT1	O
)	O
,	O
an	O
enzyme	O
regulating	O
the	O
palmitoylation	O
status	O
of	O
proteins	O
that	O
are	O
known	O
to	O
function	O
at	O
the	O
synapse	O
,	O
including	O
the	O
alpha	O
(	O
13	O
)	O
subunits	O
of	O
G	O
proteins	O
(	O
Galpha	O
(	O
13	O
)	O
)	O
.	O

RNA	O
-	O
interference	O
-	O
mediated	O
knockdown	O
of	O
APT1	O
and	O
the	O
expression	O
of	O
membrane	O
-	O
localized	O
Galpha	O
(	O
13	O
)	O
both	O
suppress	O
spine	O
enlargement	O
caused	O
by	O
inhibition	O
of	O
miR	O
-	O
138	O
,	O
suggesting	O
that	O
APT1	O
-	O
regulated	O
depalmitoylation	O
of	O
Galpha	O
(	O
13	O
)	O
might	O
be	O
an	O
important	O
downstream	O
event	O
of	O
miR	O
-	O
138	O
function	O
.	O

Our	O
results	O
uncover	O
a	O
previously	O
unknown	O
miRNA	O
-	O
dependent	O
mechanism	O
in	O
neurons	O
and	O
demonstrate	O
a	O
previously	O
unrecognized	O
complexity	O
of	O
miRNA	O
-	O
dependent	O
control	O
of	O
dendritic	O
spine	O
morphogenesis	O
.	O

The	O
involvement	O
of	O
the	O
Schizosaccharomyces	O
pombe	O
sep9	O
/	O
spt8	O
gene	O
in	O
the	O
regulation	O
of	O
septum	O
cleavage	O
.	O

Schizosaccharomyces	O
cells	O
divide	O
by	O
medial	O
septation	O
,	O
followed	O
by	O
enzymatic	O
degradation	O
of	O
parts	O
of	O
the	O
septum	O
(	O
septum	O
cleavage	O
)	O
to	O
allow	O
the	O
sister	O
cells	O
to	O
separate	O
from	O
each	O
other	O
.	O

In	O
a	O
previous	O
study	O
we	O
found	O
that	O
the	O
cell	O
separation	O
mutant	O
sep9	O
-	O
307	O
was	O
defective	O
in	O
a	O
gene	O
that	O
encodes	O
a	O
protein	O
highly	O
similar	O
in	O
sequence	O
to	O
the	O
Saccharomyces	O
cerevisiae	O
protein	O
Spt8	O
,	O
a	O
subunit	O
of	O
the	O
SAGA	B-Complex
complex	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
sep9	O
-	O
307	O
mutation	O
causes	O
a	O
frameshift	O
in	O
translation	O
.	O

The	O
deletion	O
of	O
sep9	O
(	O
+	O
)	O
is	O
not	O
lethal	O
but	O
abolishes	O
normal	O
septum	O
cleavage	O
by	O
reducing	O
the	O
activity	O
of	O
ace2	O
(	O
+	O
)	O
,	O
a	O
gene	O
coding	O
for	O
a	O
transcription	O
factor	O
of	O
numerous	O
genes	O
producing	O
proteins	O
for	O
septum	O
cleavage	O
.	O

Indirect	O
evidence	O
indicates	O
that	O
Sep9	O
might	O
also	O
act	O
directly	O
in	O
the	O
transcription	O
of	O
certain	O
target	O
genes	O
(	O
e	O
.	O
g	O
.	O
eng1	O
(	O
+	O
)	O
)	O
of	O
this	O
regulator	O
.	O

sep9	O
-	O
307	O
is	O
synthetically	O
lethal	O
with	O
mutations	O
in	O
the	O
cell	O
separation	O
genes	O
sep11	O
/	O
med18	O
(	O
+	O
)	O
and	O
sep15	O
/	O
med8	O
(	O
+	O
)	O
,	O
which	O
encode	O
subunits	O
of	O
the	O
general	O
transcription	O
factor	O
mediator	O
.	O

Heterologous	O
expression	O
of	O
SPT8	O
and	O
the	O
putative	O
Schizosaccharomyces	O
japonicus	O
sep9	O
(	O
+	O
)	O
orthologue	O
cannot	O
substitute	O
for	O
sep9	O
(	O
+	O
)	O
.	O

Both	O
Spt8	O
and	O
the	O
fission	O
yeast	O
proteins	O
have	O
highly	O
acidic	O
(	O
74	O
-	O
76	O
amino	O
-	O
acid	O
long	O
)	O
N	O
-	O
terminal	O
regions	O
with	O
no	O
sequence	O
conservation	O
.	O

Rho	O
GTPases	O
are	O
key	O
regulators	O
of	O
the	O
actin	O
-	O
based	O
cytoskeleton	O
and	O
thus	O
control	O
most	O
aspects	O
of	O
cell	O
dynamics	O
,	O
including	O
migration	O
,	O
division	O
,	O
and	O
morphogenesis	O
.	O

There	O
are	O
at	O
least	O
20	O
members	O
of	O
this	O
subfamily	O
of	O
Ras	O
-	O
like	O
GTPases	O
in	O
humans	O
,	O
and	O
although	O
many	O
have	O
been	O
studied	O
in	O
great	O
detail	O
,	O
the	O
so	O
-	O
called	O
atypical	O
Rho	O
GTPase	O
subset	O
are	O
much	O
less	O
well	O
understood	O
.	O

Three	O
atypical	O
Rho	O
GTPases	O
,	O
RhoBTB1	O
,	O
2	O
and	O
3	O
,	O
are	O
much	O
larger	O
(	O
67	O
-	O
83kD	O
)	O
than	O
conventional	O
Rho	O
proteins	O
and	O
are	O
comprised	O
of	O
N	O
-	O
terminal	O
,	O
Rho	O
-	O
related	O
domains	O
followed	O
by	O
one	O
or	O
more	O
BTB	O
(	O
Bric	O
-	O
a	O
-	O
brac	O
,	O
Tramtrack	O
,	O
Broad	O
-	O
complex	O
)	O
domains	O
(	O
Fig	O
.	O
1	O
)	O
.	O

BTB	O
domains	O
are	O
found	O
in	O
about	O
200	O
proteins	O
and	O
are	O
thought	O
to	O
mediate	O
protein	O
:	O
protein	O
interactions	O
.	O

Palmitoylation	O
of	O
the	O
synaptic	O
vesicle	O
fusion	O
machinery	O
.	O

The	O
fusion	O
of	O
synaptic	O
vesicles	O
with	O
the	O
pre	O
-	O
synaptic	O
plasma	O
membrane	O
mediates	O
the	O
secretion	O
of	O
neurotransmitters	O
at	O
nerve	O
terminals	O
.	O

This	O
pathway	O
is	O
regulated	O
by	O
an	O
array	O
of	O
protein	O
-	O
protein	O
interactions	O
.	O

Of	O
central	O
importance	O
are	O
the	O
soluble	B-Complex
NSF	I-Complex
(	I-Complex
N	I-Complex
-	I-Complex
ethylmaleimide	I-Complex
-	I-Complex
sensitive	I-Complex
factor	I-Complex
)	I-Complex
attachment	I-Complex
protein	I-Complex
receptor	I-Complex
(	O
SNARE	B-Complex
)	O
proteins	O
syntaxin	O
1	O
and	O
SNAP25	O
,	O
which	O
are	O
associated	O
with	O
the	O
pre	O
-	O
synaptic	O
plasma	O
membrane	O
and	O
vesicle	O
-	O
associated	O
membrane	O
protein	O
(	O
VAMP2	O
)	O
,	O
a	O
synaptic	O
vesicle	O
SNARE	B-Complex
.	O

Syntaxin	O
1	O
,	O
SNAP25	O
and	O
VAMP2	O
interact	O
to	O
form	O
a	O
tight	O
complex	O
bridging	O
the	O
vesicle	O
and	O
plasma	O
membranes	O
,	O
which	O
has	O
been	O
suggested	O
to	O
represent	O
the	O
minimal	O
membrane	O
fusion	O
machinery	O
.	O

Synaptic	O
vesicle	O
fusion	O
is	O
stimulated	O
by	O
a	O
rise	O
in	O
intraterminal	O
Ca2	O
+	O
levels	O
,	O
and	O
a	O
major	O
Ca2	O
+	O
sensor	O
for	O
vesicle	O
fusion	O
is	O
synaptotagmin	O
I	O
.	O

Synaptotagmin	O
is	O
likely	O
to	O
couple	O
Ca2	O
+	O
entry	O
to	O
vesicle	O
fusion	O
via	O
Ca2	O
+	O
-	O
dependent	O
and	O
independent	O
interactions	O
with	O
membrane	O
phospholipids	O
and	O
the	O
SNARE	B-Complex
proteins	O
.	O

Intriguingly	O
,	O
syntaxin	O
1	O
,	O
SNAP25	O
,	O
VAMP2	O
and	O
synaptotagmin	O
I	O
have	O
all	O
been	O
reported	O
to	O
be	O
modified	O
by	O
palmitoylation	O
in	O
neurons	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
mechanisms	O
and	O
dynamics	O
of	O
palmitoylation	O
of	O
these	O
proteins	O
and	O
speculate	O
on	O
how	O
palmitoylation	O
might	O
contribute	O
to	O
the	O
regulation	O
of	O
synaptic	O
vesicle	O
fusion	O
.	O

Here	O
we	O
demonstrate	O
that	O
DNase	O
II	O
is	O
required	O
for	O
the	O
cell	O
-	O
autonomous	O
degradation	O
of	O
DNA	O
in	O
dying	O
NCs	O
during	O
developmental	O
PCD	O
.	O

Further	O
,	O
we	O
find	O
that	O
both	O
dCAD	O
and	O
DNase	O
II	O
are	O
required	O
for	O
distinct	O
steps	O
of	O
NC	O
nuclear	O
breakdown	O
during	O
mid	O
-	O
oogenesis	O
.	O

Cell	O
death	O
in	O
mid	O
-	O
oogenesis	O
has	O
characteristics	O
of	O
both	O
apoptosis	O
and	O
autophagy	O
,	O
whereas	O
developmental	O
NC	O
PCD	O
appears	O
to	O
involve	O
a	O
distinct	O
mechanism	O
.	O

We	O
find	O
that	O
NCs	O
become	O
acidified	O
during	O
the	O
final	O
stages	O
of	O
PCD	O
,	O
and	O
lysosomal	O
genes	O
are	O
required	O
for	O
this	O
process	O
,	O
suggesting	O
that	O
developmental	O
NC	O
PCD	O
shows	O
characteristics	O
of	O
programmed	O
necrosis	O
.	O

These	O
findings	O
indicate	O
that	O
DNase	O
II	O
can	O
act	O
cell	O
-	O
autonomously	O
to	O
degrade	O
DNA	O
during	O
non	O
-	O
apoptotic	O
cell	O
death	O
.	O

The	O
HSPs	O
(	O
hereditary	O
spastic	O
paraplegias	O
)	O
are	O
genetic	O
conditions	O
in	O
which	O
there	O
is	O
distal	O
degeneration	O
of	O
the	O
longest	O
axons	O
of	O
the	O
corticospinal	O
tract	O
,	O
resulting	O
in	O
spastic	O
paralysis	O
of	O
the	O
legs	O
.	O

The	O
gene	O
encoding	O
spartin	O
is	O
mutated	O
in	O
Troyer	O
syndrome	O
,	O
an	O
HSP	O
in	O
which	O
paralysis	O
is	O
accompanied	O
by	O
additional	O
clinical	O
features	O
.	O

There	O
has	O
been	O
controversy	O
over	O
the	O
subcellular	O
distribution	O
of	O
spartin	O
.	O

We	O
show	O
here	O
that	O
,	O
at	O
steady	O
state	O
,	O
endogenous	O
spartin	O
exists	O
in	O
a	O
cytosolic	O
pool	O
that	O
can	O
be	O
recruited	O
to	O
endosomes	O
and	O
to	O
lipid	O
droplets	O
.	O

Cytosolic	O
endogenous	O
spartin	O
is	O
mono	O
-	O
ubiquitinated	O
and	O
we	O
demonstrate	O
that	O
it	O
interacts	O
via	O
a	O
PPXY	O
motif	O
with	O
the	O
ubiquitin	O
E3	O
ligases	O
AIP4	O
[	O
atrophin	O
-	O
interacting	O
protein	O
4	O
;	O
ITCH	O
(	O
itchy	O
E3	O
ubiquitin	O
protein	O
ligase	O
homologue	O
]	O
[	O
corrected	O
]	O
and	O
AIP5	O
(	O
WWP1	O
)	O
.	O

Surprisingly	O
,	O
the	O
PPXY	O
motif	O
,	O
AIP4	O
and	O
AIP5	O
are	O
not	O
required	O
for	O
spartin	O
'	O
s	O
ubiquitination	O
,	O
and	O
so	O
we	O
propose	O
that	O
spartin	O
acts	O
as	O
an	O
adaptor	O
for	O
these	O
proteins	O
.	O

Our	O
results	O
suggest	O
that	O
spartin	O
is	O
involved	O
in	O
diverse	O
cellular	O
functions	O
,	O
which	O
may	O
be	O
of	O
relevance	O
to	O
the	O
complex	O
phenotype	O
seen	O
in	O
Troyer	O
syndrome	O
.	O

TGF	O
-	O
beta3	O
plays	O
a	O
role	O
as	O
an	O
inhibitor	O
of	O
MEE	O
proliferation	O
during	O
palatal	O
fusion	O
and	O
an	O
inducer	O
of	O
apoptosis	O
.	O

Using	O
Ki67	O
as	O
a	O
marker	O
for	O
proliferation	O
we	O
did	O
not	O
observe	O
increased	O
proliferation	O
in	O
E14	O
.	O
5	O
and	O
E15	O
.	O
5	O
palates	O
of	O
the	O
Jeff	O
homozygote	O
MEE	O
.	O

However	O
,	O
we	O
also	O
stained	O
for	O
apoptotic	O
cells	O
using	O
a	O
caspase	O
-	O
3	O
antibody	O
and	O
found	O
many	O
fewer	O
positive	O
cells	O
in	O
Jeff	O
homozygote	O
E15	O
.	O
5	O
palates	O
.	O

It	O
appears	O
that	O
in	O
the	O
presence	O
of	O
a	O
mutation	O
in	O
Fbxo11	O
,	O
palatal	O
fusion	O
is	O
inhibited	O
and	O
MEE	O
cells	O
are	O
not	O
able	O
to	O
progress	O
to	O
epithelial	O
programmed	O
cell	O
death	O
or	O
epithelial	O
-	O
mesenchymal	O
transformation	O
.	O

Coexpression	O
of	O
the	O
type	O
2	O
diabetes	O
susceptibility	O
gene	O
variants	O
KCNJ11	O
E23K	O
and	O
ABCC8	O
S1369A	O
alter	O
the	O
ATP	O
and	O
sulfonylurea	O
sensitivities	O
of	O
the	O
ATP	O
-	O
sensitive	O
K	O
(	O
+	O
)	O
channel	O
.	O

In	O
the	O
pancreatic	O
beta	O
-	O
cell	O
,	O
ATP	O
-	O
sensitive	O
K	O
(	O
+	O
)	O
(	O
K	O
(	O
ATP	O
)	O
)	O
channels	O
couple	O
metabolism	O
with	O
excitability	O
and	O
consist	O
of	O
Kir6	O
.	O
2	O
and	O
SUR1	O
subunits	O
encoded	O
by	O
KCNJ11	O
and	O
ABCC8	O
,	O
respectively	O
.	O

Sulfonylureas	O
,	O
which	O
inhibit	O
the	O
K	O
(	O
ATP	O
)	O
channel	O
,	O
are	O
used	O
to	O
treat	O
type	O
2	O
diabetes	O
.	O

Rare	O
activating	O
mutations	O
cause	O
neonatal	O
diabetes	O
,	O
whereas	O
the	O
common	O
variants	O
,	O
E23K	O
in	O
KCNJ11	O
and	O
S1369A	O
in	O
ABCC8	O
,	O
are	O
in	O
strong	O
linkage	O
disequilibrium	O
,	O
constituting	O
a	O
haplotype	O
that	O
predisposes	O
to	O
type	O
2	O
diabetes	O
.	O

To	O
date	O
it	O
has	O
not	O
been	O
possible	O
to	O
establish	O
which	O
of	O
these	O
represents	O
the	O
etiological	O
variant	O
,	O
and	O
functional	O
studies	O
are	O
inconsistent	O
.	O

Furthermore	O
,	O
there	O
have	O
been	O
no	O
studies	O
of	O
the	O
S1369A	O
variant	O
or	O
the	O
combined	O
effect	O
of	O
the	O
two	O
on	O
K	O
(	O
ATP	O
)	O
channel	O
function	O
.	O

The	O
patch	O
-	O
clamp	O
technique	O
was	O
used	O
to	O
study	O
the	O
nucleotide	O
sensitivity	O
and	O
sulfonylurea	O
inhibition	O
of	O
recombinant	O
human	O
K	O
(	O
ATP	O
)	O
channels	O
containing	O
either	O
the	O
K23	O
/	O
A1369	O
or	O
E23	O
/	O
S1369	O
variants	O
.	O

ATP	O
sensitivity	O
of	O
the	O
K	O
(	O
ATP	O
)	O
channel	O
was	O
decreased	O
in	O
the	O
K23	O
/	O
A1369	O
variant	O
(	O
half	O
-	O
maximal	O
inhibitory	O
concentration	O
[	O
IC	O
(	O
50	O
)	O
]	O
=	O
8	O
.	O
0	O
vs	O
.	O
2	O
.	O
5	O
mumol	O
/	O
l	O
for	O
the	O
E23	O
/	O
S1369	O
variant	O
)	O
,	O
although	O
there	O
was	O
no	O
difference	O
in	O
ADP	O
sensitivity	O
.	O

The	O
K23	O
/	O
A1369	O
variant	O
also	O
displayed	O
increased	O
inhibition	O
by	O
gliclazide	O
,	O
an	O
A	O
-	O
site	O
sulfonylurea	O
drug	O
(	O
IC	O
(	O
50	O
)	O
=	O
52	O
.	O
7	O
vs	O
.	O
188	O
.	O
7	O
nmol	O
/	O
l	O
for	O
the	O
E23	O
/	O
S1369	O
variant	O
)	O
,	O
but	O
not	O
by	O
glibenclamide	O
(	O
AB	O
site	O
)	O
or	O
repaglinide	O
(	O
B	O
site	O
)	O
.	O

Our	O
findings	O
indicate	O
that	O
the	O
common	O
K23	O
/	O
A1369	O
variant	O
K	O
(	O
ATP	O
)	O
channel	O
displays	O
decreased	O
ATP	O
inhibition	O
that	O
may	O
contribute	O
to	O
the	O
observed	O
increased	O
risk	O
for	O
type	O
2	O
diabetes	O
.	O

Moreover	O
,	O
the	O
increased	O
sensitivity	O
of	O
the	O
K23	O
/	O
A1369	O
variant	O
to	O
the	O
A	O
-	O
site	O
sulfonylurea	O
drug	O
gliclazide	O
may	O
provide	O
a	O
pharmacogenomic	O
therapeutic	O
approach	O
for	O
patients	O
with	O
type	O
2	O
diabetes	O
who	O
are	O
homozygous	O
for	O
both	O
risk	O
alleles	O
.	O

Epidithiodiketopiperazines	O
block	O
the	O
interaction	O
between	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1alpha	O
(	O
HIF	O
-	O
1alpha	O
)	O
and	O
p300	O
by	O
a	O
zinc	O
ejection	O
mechanism	O
.	O

The	O
hypoxic	O
response	O
in	O
humans	O
is	O
regulated	O
by	O
the	O
hypoxia	O
-	O
inducible	O
transcription	O
factor	O
system	O
;	O
inhibition	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
activity	O
has	O
potential	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

Chetomin	O
,	O
a	O
member	O
of	O
the	O
epidithiodiketopiperazine	O
(	O
ETP	O
)	O
family	O
of	O
natural	O
products	O
,	O
inhibits	O
the	O
interaction	O
between	O
HIF	O
-	O
alpha	O
and	O
the	O
transcriptional	O
coactivator	O
p300	O
.	O

Structure	O
-	O
activity	O
studies	O
employing	O
both	O
natural	O
and	O
synthetic	O
ETP	O
derivatives	O
reveal	O
that	O
only	O
the	O
structurally	O
unique	O
ETP	O
core	O
is	O
required	O
and	O
sufficient	O
to	O
block	O
the	O
interaction	O
of	O
HIF	O
-	O
1alpha	O
and	O
p300	O
.	O

In	O
support	O
of	O
both	O
cell	O
-	O
based	O
and	O
animal	O
work	O
showing	O
that	O
the	O
cytotoxic	O
effect	O
of	O
ETPs	O
is	O
reduced	O
by	O
the	O
addition	O
of	O
Zn	O
(	O
2	O
+	O
)	O
through	O
an	O
unknown	O
mechanism	O
,	O
our	O
mechanistic	O
studies	O
reveal	O
that	O
ETPs	O
react	O
with	O
p300	O
,	O
causing	O
zinc	O
ion	O
ejection	O
.	O

Cell	O
studies	O
with	O
both	O
natural	O
and	O
synthetic	O
ETPs	O
demonstrated	O
a	O
decrease	O
in	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
antiproliferative	O
effects	O
that	O
were	O
abrogated	O
by	O
zinc	O
supplementation	O
.	O

The	O
results	O
have	O
implications	O
for	O
the	O
design	O
of	O
selective	O
ETPs	O
and	O
for	O
the	O
interaction	O
of	O
ETPs	O
with	O
other	O
zinc	O
ion	O
-	O
binding	O
protein	O
targets	O
involved	O
in	O
gene	O
expression	O
.	O

Palmitoylation	O
-	O
dependent	O
plasma	O
membrane	O
transport	O
but	O
lipid	O
raft	O
-	O
independent	O
signaling	O
by	O
linker	O
for	O
activation	O
of	O
T	O
cells	O
.	O

Linker	O
for	O
activation	O
of	O
T	O
cells	O
(	O
LAT	O
)	O
is	O
a	O
dually	O
palmitoylated	O
transmembrane	O
adaptor	O
protein	O
essential	O
for	O
T	O
cell	O
development	O
and	O
activation	O
.	O

However	O
,	O
whether	O
LAT	O
palmitoylation	O
and	O
/	O
or	O
lipid	O
raft	O
localization	O
are	O
required	O
for	O
its	O
function	O
is	O
controversial	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
used	O
a	O
combination	O
of	O
biochemical	O
,	O
imaging	O
,	O
and	O
genetic	O
approaches	O
,	O
including	O
LAT	O
retrovirus	O
-	O
transduced	O
mouse	O
T	O
cells	O
and	O
bone	O
marrow	O
chimeric	O
mice	O
.	O

A	O
nonpalmitoylated	O
,	O
non	O
-	O
lipid	O
raft	O
-	O
residing	O
mutant	O
of	O
transmembrane	O
LAT	O
could	O
not	O
reconstitute	O
T	O
cell	O
development	O
in	O
bone	O
marrow	O
chimeric	O
mice	O
.	O

This	O
mutant	O
was	O
absent	O
from	O
the	O
plasma	O
membrane	O
(	O
PM	O
)	O
and	O
was	O
restricted	O
mainly	O
to	O
the	O
Golgi	O
apparatus	O
.	O

A	O
chimeric	O
,	O
nonpalmitoylated	O
LAT	O
protein	O
consisting	O
of	O
the	O
PM	O
-	O
targeting	O
N	O
-	O
terminal	O
sequence	O
of	O
Src	O
kinase	O
and	O
the	O
LAT	O
cytoplasmic	O
domain	O
(	O
Src	O
-	O
LAT	O
)	O
localized	O
as	O
a	O
peripheral	O
membrane	O
protein	O
in	O
the	O
PM	O
,	O
but	O
outside	O
lipid	O
rafts	O
.	O

Nevertheless	O
,	O
Src	O
-	O
LAT	O
restored	O
T	O
cell	O
development	O
and	O
activation	O
.	O

Lastly	O
,	O
monopalmitoylation	O
of	O
LAT	O
on	O
Cys	O
(	O
26	O
)	O
(	O
but	O
not	O
Cys	O
(	O
29	O
)	O
)	O
was	O
required	O
and	O
sufficient	O
for	O
its	O
PM	O
transport	O
and	O
function	O
.	O

Thus	O
,	O
the	O
function	O
of	O
LAT	O
in	O
T	O
cells	O
requires	O
its	O
PM	O
,	O
but	O
not	O
raft	O
,	O
localization	O
,	O
even	O
when	O
expressed	O
as	O
a	O
peripheral	O
membrane	O
protein	O
.	O

Furthermore	O
,	O
LAT	O
palmitoylation	O
functions	O
primarily	O
as	O
a	O
sorting	O
signal	O
required	O
for	O
its	O
PM	O
transport	O
.	O

Mobile	O
DHHC	O
palmitoylating	O
enzyme	O
mediates	O
activity	O
-	O
sensitive	O
synaptic	O
targeting	O
of	O
PSD	O
-	O
95	O
.	O

Protein	O
palmitoylation	O
is	O
the	O
most	O
common	O
posttranslational	O
lipid	O
modification	O
;	O
its	O
reversibility	O
mediates	O
protein	O
shuttling	O
between	O
intracellular	O
compartments	O
.	O

A	O
large	O
family	O
of	O
DHHC	O
(	O
Asp	O
-	O
His	O
-	O
His	O
-	O
Cys	O
)	O
proteins	O
has	O
emerged	O
as	O
protein	O
palmitoyl	O
acyltransferases	O
(	O
PATs	O
)	O
.	O

However	O
,	O
mechanisms	O
that	O
regulate	O
these	O
PATs	O
in	O
a	O
physiological	O
context	O
remain	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
efficiently	O
monitored	O
the	O
dynamic	O
palmitate	O
cycling	O
on	O
synaptic	O
scaffold	O
PSD	O
-	O
95	O
.	O

We	O
found	O
that	O
blocking	O
synaptic	O
activity	O
rapidly	O
induces	O
PSD	O
-	O
95	O
palmitoylation	O
and	O
mediates	O
synaptic	O
clustering	O
of	O
PSD	O
-	O
95	O
and	O
associated	O
AMPA	O
(	O
alpha	O
-	O
amino	O
-	O
3	O
-	O
hydroxy	O
-	O
5	O
-	O
methyl	O
-	O
4	O
-	O
isoxazole	O
propionic	O
acid	O
)	O
-	O
type	O
glutamate	O
receptors	O
.	O

A	O
dendritically	O
localized	O
DHHC2	O
but	O
not	O
the	O
Golgi	O
-	O
resident	O
DHHC3	O
mediates	O
this	O
activity	O
-	O
sensitive	O
palmitoylation	O
.	O

Upon	O
activity	O
blockade	O
,	O
DHHC2	O
translocates	O
to	O
the	O
postsynaptic	O
density	O
to	O
transduce	O
this	O
effect	O
.	O

These	O
data	O
demonstrate	O
that	O
individual	O
DHHC	O
members	O
are	O
differentially	O
regulated	O
and	O
that	O
dynamic	O
recruitment	O
of	O
protein	O
palmitoylation	O
machinery	O
enables	O
compartmentalized	O
regulation	O
of	O
protein	O
trafficking	O
in	O
response	O
to	O
extracellular	O
signals	O
.	O

The	O
trafficking	O
/	O
interaction	O
of	O
eNOS	O
and	O
caveolin	O
-	O
1	O
induced	O
by	O
insulin	O
modulates	O
endothelial	O
nitric	O
oxide	O
production	O
.	O

Endothelial	O
nitric	O
oxide	O
synthase	O
(	O
eNOS	O
)	O
activity	O
is	O
tightly	O
regulated	O
by	O
posttranscriptional	O
modification	O
and	O
its	O
subcellular	O
localization	O
.	O

Here	O
we	O
examined	O
whether	O
insulin	O
modulates	O
nitric	O
oxide	O
(	O
NO	O
)	O
production	O
by	O
regulating	O
eNOS	O
subcellular	O
localization	O
.	O

We	O
used	O
confocal	O
microscopy	O
and	O
immunoblots	O
to	O
examine	O
the	O
time	O
course	O
for	O
1	O
)	O
subcellular	O
targeting	O
/	O
association	O
of	O
eNOS	O
and	O
caveolin	O
-	O
1	O
(	O
CAV	O
-	O
1	O
)	O
;	O
2	O
)	O
eNOS	O
Ser	O
(	O
1179	O
)	O
phosphorylation	O
;	O
and	O
3	O
)	O
NO	O
production	O
in	O
cultured	O
bovine	O
aorta	O
endothelial	O
cells	O
.	O

Serum	O
starvation	O
increased	O
eNOS	O
/	O
CAV	O
-	O
1	O
localization	O
to	O
the	O
perinuclear	O
region	O
.	O

Adding	O
insulin	O
provoked	O
their	O
prompt	O
translocation	O
to	O
and	O
association	O
at	O
the	O
plasma	O
membrane	O
(	O
PM	O
)	O
.	O

Specific	O
monoclonal	O
antibodies	O
against	O
either	O
CAV	O
-	O
1	O
or	O
eNOS	O
coimmunoprecipitated	O
the	O
other	O
from	O
bovine	O
aorta	O
endothelial	O
cell	O
membrane	O
extracts	O
,	O
and	O
insulin	O
increased	O
this	O
interaction	O
.	O

Insulin	O
stimulated	O
NO	O
production	O
transiently	O
despite	O
a	O
persistent	O
eNOS	O
Ser	O
(	O
1179	O
)	O
phosphorylation	O
.	O

The	O
decline	O
of	O
NO	O
production	O
correlated	O
temporally	O
to	O
insulin	O
-	O
induced	O
translocation	O
of	O
eNOS	O
and	O
CAV	O
-	O
1	O
to	O
PM	O
.	O

Knockdown	O
of	O
CAV	O
-	O
1	O
expression	O
with	O
a	O
specific	O
small	O
interfering	O
RNA	O
duplex	O
resulted	O
in	O
eNOS	O
redistributing	O
to	O
the	O
perinuclear	O
region	O
and	O
nearly	O
doubled	O
insulin	O
-	O
induced	O
NO	O
production	O
.	O

Inhibition	O
of	O
phosphatidylinositol	O
3	O
-	O
kinase	O
activity	O
with	O
wortmannin	O
not	O
only	O
significantly	O
inhibited	O
insulin	O
-	O
induced	O
translocation	O
of	O
eNOS	O
and	O
CAV	O
-	O
1	O
to	O
PM	O
but	O
also	O
blocked	O
insulin	O
-	O
induced	O
interaction	O
of	O
CAV	O
-	O
1	O
with	O
eNOS	O
at	O
PM	O
.	O

Insulin	O
increased	O
incorporation	O
of	O
[	O
(	O
3	O
)	O
H	O
]	O
palmitic	O
acid	O
into	O
eNOS	O
immunoprecipitates	O
by	O
approximately	O
140	O
%	O
.	O

Insulin	O
-	O
induced	O
translocation	O
of	O
eNOS	O
and	O
CAV	O
-	O
1	O
to	O
PM	O
was	O
palmitoylation	O
dependent	O
.	O

Inhibiting	O
eNOS	O
and	O
CAV	O
-	O
1	O
palmitoylation	O
enhanced	O
the	O
NO	O
production	O
while	O
blocking	O
the	O
translocation	O
of	O
eNOS	O
and	O
CAV	O
-	O
1	O
to	O
PM	O
induced	O
by	O
insulin	O
.	O

These	O
data	O
show	O
that	O
insulin	O
acutely	O
regulates	O
eNOS	O
and	O
CAV	O
-	O
1	O
trafficking	O
to	O
PM	O
of	O
vascular	O
endothelial	O
cells	O
where	O
their	O
interaction	O
can	O
regulate	O
eNOS	O
activity	O
.	O

Specific	O
pathways	O
prevent	O
duplication	O
-	O
mediated	O
genome	O
rearrangements	O
.	O

We	O
have	O
investigated	O
the	O
ability	O
of	O
different	O
regions	O
of	O
the	O
left	O
arm	O
of	O
Saccharomyces	O
cerevisiae	O
chromosome	O
V	O
to	O
participate	O
in	O
the	O
formation	O
of	O
gross	O
chromosomal	O
rearrangements	O
(	O
GCRs	O
)	O
.	O

We	O
found	O
that	O
the	O
4	O
.	O
2	O
-	O
kilobase	O
HXT13	O
-	O
DSF1	O
region	O
sharing	O
divergent	O
homology	O
with	O
chromosomes	O
IV	O
,	O
X	O
and	O
XIV	O
,	O
similar	O
to	O
mammalian	O
segmental	O
duplications	O
,	O
was	O
'	O
at	O
risk	O
'	O
for	O
participating	O
in	O
duplication	O
-	O
mediated	O
GCRs	O
generated	O
by	O
homologous	O
recombination	O
.	O

Numerous	O
genes	O
and	O
pathways	O
,	O
including	O
SGS1	O
,	O
TOP3	O
,	O
RMI1	O
,	O
SRS2	O
,	O
RAD6	O
,	O
SLX1	O
,	O
SLX4	O
,	O
SLX5	O
,	O
MSH2	O
,	O
MSH6	O
,	O
RAD10	O
and	O
the	O
DNA	O
replication	O
stress	O
checkpoint	O
requiring	O
MRC1	O
and	O
TOF1	O
,	O
were	O
highly	O
specific	O
for	O
suppressing	O
these	O
GCRs	O
compared	O
to	O
GCRs	O
mediated	O
by	O
single	O
-	O
copy	O
sequences	O
.	O

These	O
results	O
indicate	O
that	O
the	O
mechanisms	O
for	O
formation	O
and	O
suppression	O
of	O
rearrangements	O
occurring	O
in	O
regions	O
containing	O
at	O
-	O
risk	O
sequences	O
differ	O
from	O
those	O
occurring	O
in	O
regions	O
of	O
single	O
-	O
copy	O
sequence	O
.	O

This	O
explains	O
how	O
extensive	O
genome	O
instability	O
is	O
prevented	O
in	O
eukaryotic	O
cells	O
whose	O
genomes	O
contain	O
numerous	O
divergent	O
repeated	O
sequences	O
.	O

The	O
structural	O
basis	O
of	O
Arf	O
effector	O
specificity	O
:	O
the	O
crystal	O
structure	O
of	O
ARF6	O
in	O
a	O
complex	O
with	O
JIP4	O
.	O

The	O
JNK	O
-	O
interacting	O
proteins	O
,	O
JIP3	O
and	O
JIP4	O
,	O
are	O
specific	O
effectors	O
of	O
the	O
small	O
GTP	O
-	O
binding	O
protein	O
ARF6	O
.	O

The	O
interaction	O
of	O
ARF6	O
-	O
GTP	O
with	O
the	O
second	O
leucine	O
zipper	O
(	O
LZII	O
)	O
domains	O
of	O
JIP3	O
/	O
JIP4	O
regulates	O
the	O
binding	O
of	O
JIPs	O
to	O
kinesin	O
-	O
1	O
and	O
dynactin	B-Complex
.	O

Here	O
,	O
we	O
report	O
the	O
crystal	O
structure	O
of	O
ARF6	O
-	O
GTP	O
bound	O
to	O
the	O
JIP4	O
-	O
LZII	O
at	O
1	O
.	O
9	O
A	O
resolution	O
.	O

The	O
complex	O
is	O
a	O
heterotetramer	O
with	O
dyad	O
symmetry	O
arranged	O
in	O
an	O
ARF6	O
-	O
(	O
JIP4	O
)	O
(	O
2	O
)	O
-	O
ARF6	O
configuration	O
.	O

Comparison	O
of	O
the	O
ARF6	O
-	O
JIP4	O
interface	O
with	O
the	O
equivalent	O
region	O
of	O
ARF1	O
shows	O
the	O
structural	O
basis	O
of	O
JIP4	O
'	O
s	O
specificity	O
for	O
ARF6	O
.	O

Using	O
site	O
-	O
directed	O
mutagenesis	O
and	O
surface	O
plasmon	O
resonance	O
,	O
we	O
further	O
show	O
that	O
non	O
-	O
conserved	O
residues	O
at	O
the	O
switch	O
region	O
borders	O
are	O
the	O
key	O
structural	O
determinants	O
of	O
JIP4	O
specificity	O
.	O

A	O
structure	O
-	O
derived	O
model	O
of	O
the	O
association	O
of	O
the	O
ARF6	O
-	O
JIP3	O
/	O
JIP4	O
complex	O
with	O
membranes	O
shows	O
that	O
the	O
JIP4	O
-	O
LZII	O
coiled	O
-	O
coil	O
should	O
lie	O
along	O
the	O
membrane	O
to	O
prevent	O
steric	O
hindrances	O
,	O
resulting	O
in	O
only	O
one	O
ARF6	O
molecule	O
bound	O
.	O

Such	O
a	O
heterotrimeric	O
complex	O
gives	O
insights	O
to	O
better	O
understand	O
the	O
ARF6	O
-	O
mediated	O
motor	O
switch	O
regulatory	O
function	O
.	O

Crosstalk	O
between	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activating	O
IKK	B-Complex
-	O
complex	O
and	O
the	O
CSN	B-Complex
signalosome	I-Complex
.	O

A	O
great	O
variety	O
of	O
signalling	O
pathways	O
regulating	O
inflammation	O
,	O
cell	O
development	O
and	O
cell	O
survival	O
require	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
transcription	O
factors	O
,	O
which	O
are	O
normally	O
inactive	O
due	O
to	O
binding	O
to	O
inhibitors	O
,	O
such	O
as	O
IkappaBalpha	O
.	O

The	O
canonical	O
activation	O
pathway	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
is	O
initiated	O
by	O
phosphorylation	O
of	O
the	O
inhibitor	O
by	O
an	O
IkappaB	B-Complex
kinase	I-Complex
(	O
IKK	B-Complex
)	O
complex	O
triggering	O
ubiquitination	O
of	O
IkappaB	B-Complex
molecules	O
by	O
SCF	B-Complex
-	I-Complex
type	I-Complex
E3	I-Complex
-	I-Complex
ligase	I-Complex
complexes	O
and	O
rapid	O
degradation	O
by	O
26S	B-Complex
-	I-Complex
proteasomes	I-Complex
.	O

The	O
ubiquitination	O
machinery	O
is	O
regulated	O
by	O
the	O
COP9	B-Complex
signalosome	I-Complex
(	O
CSN	B-Complex
)	O
.	O

We	O
show	O
that	O
IkappaB	O
kinases	O
interact	O
with	O
the	O
CSN	B-Complex
-	O
complex	O
,	O
as	O
well	O
as	O
the	O
SCF	B-Complex
-	O
ubiquitination	O
machinery	O
,	O
providing	O
an	O
explanation	O
for	O
the	O
rapid	O
signalling	O
-	O
induced	O
ubiquitination	O
and	O
degradation	O
of	O
IkappaBalpha	O
.	O

Furthermore	O
,	O
we	O
reveal	O
that	O
IKK	B-Complex
'	O
s	O
phosphorylate	O
not	O
only	O
IkappaBalpha	O
,	O
but	O
also	O
the	O
CSN	B-Complex
-	O
subunit	O
Csn5	O
/	O
JAB1	O
(	O
c	O
-	O
Jun	O
activation	O
domain	O
binding	O
protein	O
-	O
1	O
)	O
and	O
that	O
IKK2	O
influences	O
ubiquitination	O
of	O
Csn5	O
/	O
JAB1	O
.	O

Our	O
observations	O
imply	O
that	O
the	O
CSN	B-Complex
complex	O
acts	O
as	O
an	O
inhibitor	O
of	O
constitutive	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activity	O
in	O
non	O
-	O
activated	O
cells	O
.	O

Knock	O
-	O
down	O
of	O
Csn5	O
/	O
JAB1	O
clearly	O
enhanced	O
basal	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activity	O
and	O
improved	O
cell	O
survival	O
under	O
stress	O
.	O

The	O
inhibitory	O
effect	O
of	O
Csn5	O
/	O
JAB1	O
requires	O
a	O
functional	O
MPN	O
(	O
+	O
)	O
metalloprotease	O
domain	O
,	O
which	O
is	O
responsible	O
for	O
cleaving	O
ubiquitin	O
-	O
like	O
Nedd8	O
-	O
modifications	O
.	O

Upon	O
activation	O
of	O
cells	O
with	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
,	O
the	O
CSN	B-Complex
complex	O
dissociates	O
from	O
IKK	B-Complex
'	O
s	O
allowing	O
full	O
and	O
rapid	O
activation	O
of	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
pathway	O
by	O
the	O
concerted	O
action	O
of	O
interacting	O
protein	O
complexes	O
.	O

The	O
selectivity	O
of	O
receptor	O
tyrosine	O
kinase	O
signaling	O
is	O
controlled	O
by	O
a	O
secondary	O
SH2	O
domain	O
binding	O
site	O
.	O

SH2	O
domain	O
-	O
mediated	O
interactions	O
represent	O
a	O
crucial	O
step	O
in	O
transmembrane	O
signaling	O
by	O
receptor	O
tyrosine	O
kinases	O
.	O

SH2	O
domains	O
recognize	O
phosphotyrosine	O
(	O
pY	O
)	O
in	O
the	O
context	O
of	O
particular	O
sequence	O
motifs	O
in	O
receptor	O
phosphorylation	O
sites	O
.	O

However	O
,	O
the	O
modest	O
binding	O
affinity	O
of	O
SH2	O
domains	O
to	O
pY	O
containing	O
peptides	O
may	O
not	O
account	O
for	O
and	O
likely	O
represents	O
an	O
oversimplified	O
mechanism	O
for	O
regulation	O
of	O
selectivity	O
of	O
signaling	O
pathways	O
in	O
living	O
cells	O
.	O

Here	O
we	O
describe	O
the	O
crystal	O
structure	O
of	O
the	O
activated	O
tyrosine	O
kinase	O
domain	O
of	O
FGFR1	O
in	O
complex	O
with	O
a	O
phospholipase	O
Cgamma	O
fragment	O
.	O

The	O
structural	O
and	O
biochemical	O
data	O
and	O
experiments	O
with	O
cultured	O
cells	O
show	O
that	O
the	O
selectivity	O
of	O
phospholipase	O
Cgamma	O
binding	O
and	O
signaling	O
via	O
activated	O
FGFR1	O
are	O
determined	O
by	O
interactions	O
between	O
a	O
secondary	O
binding	O
site	O
on	O
an	O
SH2	O
domain	O
and	O
a	O
region	O
in	O
FGFR1	O
kinase	O
domain	O
in	O
a	O
phosphorylation	O
independent	O
manner	O
.	O

These	O
experiments	O
reveal	O
a	O
mechanism	O
for	O
how	O
SH2	O
domain	O
selectivity	O
is	O
regulated	O
in	O
vivo	O
to	O
mediate	O
a	O
specific	O
cellular	O
process	O
.	O

Global	O
analysis	O
of	O
H3K4	O
methylation	O
defines	O
MLL	O
family	O
member	O
targets	O
and	O
points	O
to	O
a	O
role	O
for	O
MLL1	O
-	O
mediated	O
H3K4	O
methylation	O
in	O
the	O
regulation	O
of	O
transcriptional	O
initiation	O
by	O
RNA	B-Complex
polymerase	I-Complex
II	I-Complex
.	O

A	O
common	O
landmark	O
of	O
activated	O
genes	O
is	O
the	O
presence	O
of	O
trimethylation	O
on	O
lysine	O
4	O
of	O
histone	O
H3	O
(	O
H3K4	O
)	O
at	O
promoter	O
regions	O
.	O

Set1	B-Complex
/	I-Complex
COMPASS	I-Complex
was	O
the	O
founding	O
member	O
and	O
is	O
the	O
only	O
H3K4	O
methylase	O
in	O
Saccharomyces	O
cerevisiae	O
;	O
however	O
,	O
in	O
mammals	O
,	O
at	O
least	O
six	O
H3K4	O
methylases	O
,	O
Set1A	O
and	O
Set1B	O
and	O
MLL1	O
to	O
MLL4	O
,	O
are	O
found	O
in	O
COMPASS	B-Complex
-	O
like	O
complexes	O
capable	O
of	O
methylating	O
H3K4	O
.	O

To	O
gain	O
further	O
insight	O
into	O
the	O
different	O
roles	O
and	O
functional	O
targets	O
for	O
the	O
H3K4	O
methylases	O
,	O
we	O
have	O
undertaken	O
a	O
genome	O
-	O
wide	O
analysis	O
of	O
H3K4	O
methylation	O
patterns	O
in	O
wild	O
-	O
type	O
Mll1	O
(	O
+	O
/	O
+	O
)	O
and	O
Mll1	O
(	O
-	O
)	O
(	O
/	O
)	O
(	O
-	O
)	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
.	O

We	O
found	O
that	O
Mll1	O
is	O
required	O
for	O
the	O
H3K4	O
trimethylation	O
of	O
less	O
than	O
5	O
%	O
of	O
promoters	O
carrying	O
this	O
modification	O
.	O

Many	O
of	O
these	O
genes	O
,	O
which	O
include	O
developmental	O
regulators	O
such	O
as	O
Hox	O
genes	O
,	O
show	O
decreased	O
levels	O
of	O
RNA	B-Complex
polymerase	I-Complex
II	I-Complex
recruitment	O
and	O
expression	O
concomitant	O
with	O
the	O
loss	O
of	O
H3K4	O
methylation	O
.	O

Although	O
Mll1	O
is	O
only	O
required	O
for	O
the	O
methylation	O
of	O
a	O
subset	O
of	O
Hox	O
genes	O
,	O
menin	O
,	O
a	O
component	O
of	O
the	O
Mll1	O
and	O
Mll2	O
complexes	O
,	O
is	O
required	O
for	O
the	O
overwhelming	O
majority	O
of	O
H3K4	O
methylation	O
at	O
Hox	O
loci	O
.	O

However	O
,	O
the	O
loss	O
of	O
MLL3	O
/	O
MLL4	O
and	O
/	O
or	O
the	O
Set1	B-Complex
complexes	O
has	O
little	O
to	O
no	O
effect	O
on	O
the	O
H3K4	O
methylation	O
of	O
Hox	O
loci	O
or	O
their	O
expression	O
levels	O
in	O
these	O
MEFs	O
.	O

Together	O
these	O
data	O
provide	O
insight	O
into	O
the	O
redundancy	O
and	O
specialization	O
of	O
COMPASS	B-Complex
-	O
like	O
complexes	O
in	O
mammals	O
and	O
provide	O
evidence	O
for	O
a	O
possible	O
role	O
for	O
Mll1	O
-	O
mediated	O
H3K4	O
methylation	O
in	O
the	O
regulation	O
of	O
transcriptional	O
initiation	O
.	O

Phosphorylation	O
of	O
CARMA1	O
by	O
HPK1	O
is	O
critical	O
for	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
in	O
T	O
cells	O
.	O

Activation	O
of	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
pathway	O
in	O
T	O
cells	O
is	O
required	O
for	O
induction	O
of	O
an	O
adaptive	O
immune	O
response	O
.	O

Hematopoietic	O
progenitor	O
kinase	O
(	O
HPK1	O
)	O
is	O
an	O
important	O
proximal	O
mediator	O
of	O
T	B-Complex
-	I-Complex
cell	I-Complex
receptor	I-Complex
(	O
TCR	B-Complex
)	O
-	O
induced	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
.	O

Knock	O
-	O
down	O
of	O
HPK1	O
abrogates	O
TCR	B-Complex
-	O
induced	O
IKKbeta	O
and	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
,	O
whereas	O
active	O
HPK1	O
leads	O
to	O
increased	O
IKKbeta	O
activity	O
in	O
T	O
cells	O
.	O

Yet	O
,	O
the	O
precise	O
molecular	O
mechanism	O
of	O
this	O
process	O
remains	O
elusive	O
.	O

Here	O
,	O
we	O
show	O
that	O
HPK1	O
-	O
mediated	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
is	O
dependent	O
on	O
the	O
adaptor	O
protein	O
CARMA1	O
.	O

HPK1	O
interacts	O
with	O
CARMA1	O
in	O
a	O
TCR	B-Complex
stimulation	O
-	O
dependent	O
manner	O
and	O
phosphorylates	O
the	O
linker	O
region	O
of	O
CARMA1	O
.	O

Interestingly	O
,	O
the	O
putative	O
HPK1	O
phosphorylation	O
sites	O
in	O
CARMA1	O
are	O
different	O
from	O
known	O
PKC	O
consensus	O
sites	O
.	O

Mutations	O
of	O
residues	O
S549	O
,	O
S551	O
,	O
and	O
S552	O
in	O
CARMA1	O
abrogated	O
phosphorylation	O
of	O
a	O
CARMA1	O
-	O
linker	O
construct	O
by	O
HPK1	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
CARMA1	O
S551A	O
or	O
S5549A	O
/	O
S551A	O
point	O
mutants	O
failed	O
to	O
restore	O
HPK1	O
-	O
mediated	O
and	O
TCR	B-Complex
-	O
mediated	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
and	O
IL	O
-	O
2	O
expression	O
in	O
CARMA1	O
-	O
deficient	O
T	O
cells	O
.	O

Thus	O
,	O
we	O
identify	O
HPK1	O
as	O
a	O
kinase	O
specific	O
for	O
CARMA1	O
and	O
suggest	O
HPK1	O
-	O
mediated	O
phosphorylation	O
of	O
CARMA1	O
as	O
an	O
additional	O
regulatory	O
mechanism	O
tuning	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
response	O
upon	O
TCR	B-Complex
stimulation	O
.	O

Deubiquitinating	O
enzyme	O
USP33	O
/	O
VDU1	O
is	O
required	O
for	O
Slit	O
signaling	O
in	O
inhibiting	O
breast	O
cancer	O
cell	O
migration	O
.	O

Slit	O
regulates	O
migration	O
of	O
not	O
only	O
neurons	O
,	O
but	O
also	O
nonneuronal	O
cells	O
,	O
such	O
as	O
leukocytes	O
and	O
cancer	O
cells	O
.	O

Slit	O
effect	O
on	O
cancer	O
cell	O
migration	O
has	O
not	O
been	O
well	O
-	O
characterized	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
several	O
different	O
assays	O
to	O
examine	O
Slit	O
effect	O
on	O
breast	O
cancer	O
cell	O
migration	O
in	O
vitro	O
.	O

We	O
show	O
that	O
ubiquitin	O
-	O
specific	O
protease	O
33	O
(	O
USP33	O
)	O
/	O
VDU1	O
,	O
originally	O
identified	O
as	O
a	O
von	O
Hippel	O
-	O
Lindau	O
tumor	O
suppressor	O
(	O
VHL	O
)	O
protein	O
-	O
interacting	O
deubiquitinating	O
enzyme	O
,	O
binds	O
to	O
the	O
Robo1	O
receptor	O
,	O
and	O
that	O
USP33	O
is	O
required	O
for	O
Slit	O
responsiveness	O
in	O
breast	O
cancer	O
cells	O
.	O

Slit	O
induces	O
redistribution	O
of	O
Robo1	O
from	O
intracellular	O
compartments	O
to	O
the	O
plasma	O
membrane	O
in	O
a	O
USP33	O
-	O
dependent	O
manner	O
.	O

Slit	O
impairs	O
directional	O
migration	O
of	O
breast	O
cancer	O
cells	O
without	O
affecting	O
their	O
migration	O
speed	O
.	O

This	O
inhibitory	O
effect	O
is	O
Robo	O
-	O
mediated	O
and	O
USP33	O
-	O
dependent	O
.	O

These	O
data	O
uncover	O
a	O
previously	O
unknown	O
function	O
of	O
USP33	O
and	O
reveal	O
a	O
new	O
player	O
in	O
Slit	O
-	O
Robo	O
signaling	O
in	O
cancer	O
cell	O
migration	O
.	O

SUMO	O
-	O
dependent	O
regulation	O
of	O
centrin	O
-	O
2	O
.	O

Centrins	O
are	O
multifunctional	O
Ca	O
(	O
2	O
+	O
)	O
-	O
binding	O
proteins	O
that	O
are	O
highly	O
conserved	O
from	O
yeast	O
to	O
humans	O
.	O

Centrin	O
-	O
2	O
is	O
a	O
core	O
component	O
of	O
the	O
centrosome	O
of	O
higher	O
eukaryotes	O
.	O

In	O
addition	O
,	O
it	O
is	O
present	O
within	O
the	O
nucleus	O
,	O
in	O
which	O
it	O
is	O
part	O
of	O
the	O
xeroderma	O
pigmentosum	O
group	O
C	O
(	O
XPC	O
)	O
complex	O
,	O
which	O
controls	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
.	O

Regulation	O
of	O
the	O
subcellular	O
distribution	O
of	O
centrin	O
-	O
2	O
has	O
so	O
far	O
remained	O
elusive	O
.	O

Here	O
we	O
show	O
that	O
centrin	O
-	O
2	O
is	O
a	O
substrate	O
of	O
SUMOylation	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
and	O
that	O
it	O
is	O
preferentially	O
modified	O
by	O
SUMO2	O
/	O
3	O
.	O

Moreover	O
,	O
we	O
identify	O
the	O
SUMO	O
E3	O
-	O
like	O
ligase	O
human	O
polycomb	O
protein	O
2	O
(	O
PC2	O
;	O
also	O
known	O
as	O
hPC2	O
)	O
as	O
essential	O
for	O
centrin	O
-	O
2	O
modification	O
.	O

Interference	O
with	O
the	O
SUMOylation	O
pathway	O
leads	O
to	O
a	O
striking	O
defect	O
in	O
nuclear	O
localization	O
of	O
centrin	O
-	O
2	O
and	O
accumulation	O
in	O
the	O
cytoplasm	O
,	O
whereas	O
centrosomal	O
recruitment	O
of	O
centrin	O
-	O
2	O
is	O
unaffected	O
.	O

Depletion	O
of	O
the	O
XPC	O
protein	O
mimics	O
this	O
situation	O
and	O
we	O
provide	O
evidence	O
that	O
SUMO	O
conjugation	O
of	O
centrin	O
-	O
2	O
enhances	O
its	O
binding	O
to	O
the	O
XPC	O
protein	O
.	O

These	O
data	O
show	O
that	O
the	O
nucleocytoplasmic	O
shuttling	O
of	O
centrin	O
-	O
2	O
depends	O
on	O
the	O
SUMO	O
system	O
and	O
indicates	O
that	O
localization	O
of	O
centrin	O
-	O
2	O
within	O
the	O
nucleus	O
depends	O
on	O
its	O
ability	O
to	O
bind	O
to	O
the	O
XPC	O
protein	O
.	O

Vinculin	O
nucleates	O
actin	O
polymerization	O
and	O
modifies	O
actin	O
filament	O
structure	O
.	O

Vinculin	O
links	O
integrins	O
to	O
the	O
actin	O
cytoskeleton	O
by	O
binding	O
F	O
-	O
actin	O
.	O

Little	O
is	O
known	O
with	O
respect	O
to	O
how	O
this	O
interaction	O
occurs	O
or	O
affects	O
actin	O
dynamics	O
.	O

Here	O
we	O
assess	O
the	O
consequence	O
of	O
the	O
vinculin	O
tail	O
(	O
VT	O
)	O
on	O
actin	O
dynamics	O
by	O
examining	O
its	O
binding	O
to	O
monomeric	O
and	O
filamentous	O
yeast	O
actins	O
.	O

VT	O
causes	O
pyrene	O
-	O
labeled	O
G	O
-	O
actin	O
to	O
polymerize	O
in	O
low	O
ionic	O
strength	O
buffer	O
(	O
G	O
-	O
buffer	O
)	O
,	O
conditions	O
that	O
normally	O
do	O
not	O
promote	O
actin	O
polymerization	O
.	O

Analysis	O
by	O
electron	O
microscopy	O
shows	O
that	O
,	O
under	O
these	O
conditions	O
,	O
the	O
filaments	O
form	O
small	O
bundles	O
at	O
low	O
VT	O
concentrations	O
,	O
which	O
gradually	O
increase	O
in	O
size	O
until	O
saturation	O
occurs	O
at	O
a	O
ratio	O
of	O
2	O
VT	O
:	O
1	O
actin	O
.	O

Addition	O
of	O
VT	O
to	O
pyrene	O
-	O
labeled	O
mutant	O
yeast	O
G	O
-	O
actin	O
(	O
S265C	O
)	O
produced	O
a	O
fluorescence	O
excimer	O
band	O
,	O
which	O
requires	O
a	O
relatively	O
normal	O
filament	O
geometry	O
.	O

In	O
higher	O
ionic	O
strength	O
polymerization	O
-	O
promoting	O
F	O
-	O
buffer	O
,	O
substoichiometric	O
amounts	O
of	O
VT	O
accelerate	O
the	O
polymerization	O
of	O
pyrene	O
-	O
labeled	O
WT	O
actin	O
.	O

However	O
,	O
the	O
amplitude	O
of	O
the	O
pyrene	O
fluorescence	O
caused	O
by	O
actin	O
polymerization	O
is	O
quenched	O
as	O
the	O
VT	O
concentration	O
increases	O
without	O
an	O
effect	O
on	O
net	O
actin	O
polymerization	O
as	O
determined	O
by	O
centrifugation	O
assays	O
.	O

Finally	O
,	O
addition	O
of	O
VT	O
to	O
preformed	O
pyrene	O
-	O
labeled	O
S265C	O
F	O
-	O
actin	O
causes	O
a	O
concentration	O
-	O
dependent	O
decrease	O
in	O
the	O
maximum	O
amplitude	O
of	O
the	O
pyrene	O
fluorescence	O
band	O
demonstrating	O
the	O
ability	O
of	O
VT	O
to	O
remodel	O
the	O
conformation	O
of	O
the	O
actin	O
filament	O
.	O

These	O
observations	O
support	O
the	O
idea	O
that	O
vinculin	O
can	O
link	O
adhesion	O
plaques	O
to	O
the	O
cytoskeleton	O
by	O
initiating	O
the	O
formation	O
of	O
bundled	O
actin	O
filaments	O
or	O
by	O
remodeling	O
existing	O
filaments	O
.	O

Fission	O
yeast	O
strains	O
used	O
in	O
this	O
study	O
are	O
listed	O
in	O
Table	O
S1	O
.	O

Strains	O
not	O
created	O
in	O
this	O
study	O
were	O
provided	O
by	O
J	O
.	O

Jimenez	O
(	O
Centro	O
Andaluz	O
de	O
Biologia	O
del	O
Desarrollo	O
,	O
Sevilla	O
,	O
Spain	O
)	O
and	O
M	O
.	O

Balasubramanian	O
(	O
The	O
National	O
University	O
of	O
Singapore	O
,	O
Singapore	O
,	O
Republic	O
of	O
Singapore	O
)	O
.	O

Genetic	O
crosses	O
and	O
general	O
yeast	O
techniques	O
were	O
performed	O
as	O
described	O
previously	O
.	O

S	O
.	O
pombe	O
strains	O
were	O
grown	O
in	O
rich	O
medium	O
(	O
yeast	O
extract	O
[	O
YE	O
]	O
)	O
or	O
Edinburgh	O
minimal	O
medium	O
(	O
EMM	O
)	O
with	O
appropriate	O
supplements	O
.	O

EMM	O
with	O
5	O
microg	O
/	O
ml	O
thiamine	O
or	O
YE	O
was	O
used	O
to	O
repress	O
expression	O
from	O
the	O
nmt1	O
promoter	O
.	O

For	O
expression	O
of	O
GFP	O
-	O
Etd1	O
,	O
cells	O
were	O
grown	O
for	O
2	O
d	O
in	O
EMM	O
solid	O
without	O
thiamine	O
at	O
25degreesC	O
and	O
then	O
grown	O
in	O
EMM	O
liquid	O
without	O
thiamine	O
for	O
an	O
additional	O
20	O
h	O
.	O

YE	O
containing	O
100	O
mg	O
Geneticin	O
(	O
G	O
-	O
418	O
;	O
Sigma	O
-	O
Aldrich	O
)	O
per	O
liter	O
was	O
used	O
for	O
selecting	O
KanR	O
cells	O
.	O

For	O
serial	O
dilution	O
drop	O
tests	O
for	O
growth	O
,	O
four	O
serial	O
10	O
-	O
fold	O
dilutions	O
were	O
made	O
,	O
and	O
5	O
microl	O
of	O
each	O
dilution	O
was	O
spotted	O
on	O
plates	O
with	O
the	O
starting	O
cell	O
number	O
of	O
104	O
.	O

Cells	O
were	O
grown	O
in	O
liquid	O
YE	O
or	O
EMM	O
at	O
25degreesC	O
and	O
then	O
spotted	O
onto	O
YE	O
or	O
EMM	O
plates	O
at	O
the	O
indicated	O
temperatures	O
and	O
incubated	O
for	O
3	O
-	O
5	O
d	O
before	O
photography	O
.	O

All	O
strains	O
with	O
an	O
etd1Delta	O
genotype	O
were	O
built	O
by	O
genetic	O
crosses	O
with	O
the	O
strain	O
DM3547	O
.	O

After	O
tetrad	O
dissection	O
,	O
the	O
YE	O
plates	O
containing	O
single	O
spores	O
were	O
incubated	O
at	O
36degreesC	O
,	O
and	O
the	O
final	O
ura	O
+	O
clones	O
were	O
screened	O
for	O
the	O
etd1Delta	O
phenotype	O
at	O
25degreesC	O
and	O
for	O
the	O
absence	O
or	O
presence	O
of	O
the	O
plasmid	O
-	O
containing	O
etd1	O
+	O
gene	O
through	O
the	O
leucine	O
marker	O
.	O

GFP	O
fluorescence	O
or	O
G	O
-	O
418	O
resistance	O
was	O
used	O
to	O
screen	O
for	O
other	O
markers	O
in	O
the	O
strains	O
of	O
interest	O
.	O

For	O
treatment	O
with	O
MBC	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
,	O
log	O
-	O
phase	O
cells	O
were	O
treated	O
for	O
10	O
min	O
with	O
MBC	O
used	O
at	O
the	O
final	O
concentration	O
of	O
25	O
microg	O
/	O
ml	O
from	O
a	O
10	O
mg	O
/	O
ml	O
stock	O
and	O
then	O
centrifuged	O
in	O
a	O
microfuge	O
(	O
model	O
5415C	O
;	O
Eppendorf	O
)	O
to	O
concentrate	O
the	O
cells	O
and	O
imaged	O
in	O
the	O
presence	O
of	O
25	O
microg	O
/	O
ml	O
MBC	O
.	O

Completing	O
the	O
hypusine	O
pathway	O
in	O
Plasmodium	O
.	O

In	O
searching	O
for	O
new	O
targets	O
for	O
antimalarials	O
we	O
investigated	O
the	O
biosynthesis	O
of	O
hypusine	O
present	O
in	O
eukaryotic	O
initiation	O
factor	O
-	O
5A	O
(	O
eIF	O
-	O
5A	O
)	O
in	O
Plasmodium	O
.	O

Here	O
,	O
we	O
describe	O
the	O
cloning	O
and	O
expression	O
of	O
deoxyhypusine	O
hydroxylase	O
(	O
DOHH	O
)	O
,	O
which	O
completes	O
the	O
modification	O
of	O
eIF	O
-	O
5A	O
through	O
hydroxylation	O
of	O
deoxyhypusine	O
.	O

The	O
dohh	O
cDNA	O
sequence	O
revealed	O
an	O
ORF	O
of	O
1236	O
bp	O
encoding	O
a	O
protein	O
of	O
412	O
amino	O
acids	O
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
46	O
.	O
45	O
kDa	O
and	O
an	O
isoelectric	O
point	O
of	O
4	O
.	O
96	O
.	O

Interestingly	O
,	O
DOHH	O
from	O
Plasmodium	O
has	O
a	O
FASTA	O
SCORE	O
of	O
only	O
27	O
compared	O
with	O
its	O
human	O
ortholog	O
and	O
contains	O
several	O
matches	O
similar	O
to	O
E	O
-	O
Z	O
-	O
type	O
HEAT	O
-	O
like	O
repeat	O
proteins	O
(	O
IPR004155	O
(	O
InterPro	O
)	O
,	O
PF03130	O
(	O
Pfam	O
)	O
,	O
SM00567	O
(	O
SMART	O
)	O
present	O
in	O
the	O
phycocyanin	O
lyase	O
subunits	O
of	O
cyanobacteria	O
.	O

Purified	O
DOHH	O
protein	O
displayed	O
hydroxylase	O
activity	O
in	O
a	O
novel	O
in	O
vitro	O
DOHH	O
assay	O
,	O
but	O
phycocyanin	O
lyase	O
activity	O
was	O
absent	O
.	O
dohh	O
is	O
present	O
as	O
a	O
single	O
-	O
copy	O
gene	O
and	O
is	O
transcribed	O
in	O
the	O
asexual	O
blood	O
stages	O
of	O
the	O
parasite	O
.	O

A	O
signal	O
peptide	O
at	O
the	O
N	O
-	O
terminus	O
might	O
direct	O
the	O
protein	O
to	O
a	O
different	O
cellular	O
compartment	O
.	O

During	O
evolution	O
,	O
Plasmodium	O
falciparum	O
acquired	O
an	O
apicoplast	O
that	O
lost	O
its	O
photosynthetic	O
function	O
.	O

It	O
is	O
possible	O
that	O
plasmodial	O
DOHH	O
arose	O
from	O
an	O
E	O
/	O
F	O
-	O
type	O
phycobilin	O
lyase	O
that	O
gained	O
a	O
new	O
role	O
in	O
hydroxylation	O
.	O

Structured	O
digital	O
abstract	O
:	O
*	O
MINT	O
-	O
7255047	O
:	O
DHS	O
(	O
uniprotkb	O
:	O
P49366	O
)	O
enzymaticly	O
reacts	O
(	O
MI	O
:	O
0414	O
)	O
with	O
eIF	O
-	O
5A	O
(	O
uniprotkb	O
:	O
Q710D1	O
)	O
by	O
enzymatic	O
studies	O
(	O
MI	O
:	O
0415	O
)	O
*	O
MINT	O
-	O
7255326	O
:	O
DOHH	O
(	O
uniprotkb	O
:	O
Q8I701	O
)	O
enzymaticly	O
reacts	O
(	O
MI	O
:	O
0414	O
)	O
with	O
eIF	O
-	O
5A	O
(	O
uniprotkb	O
:	O
Q710D1	O
)	O
by	O
enzymatic	O
studies	O
(	O
MI	O
:	O
0415	O
)	O
.	O

To	O
examine	O
whether	O
coordinated	O
ATP	O
hydrolysis	O
is	O
conserved	O
in	O
human	O
m	O
-	O
AAA	O
proteases	O
,	O
we	O
expressed	O
paraplegin	O
and	O
AFG3L2	O
or	O
variants	O
thereof	O
harboring	O
mutations	O
in	O
the	O
AAA	O
domain	O
in	O
Deltayta10Deltayta12	O
cells	O
.	O

In	O
this	O
experimental	O
setting	O
,	O
respiratory	O
growth	O
depends	O
on	O
paraplegin	O
subunits	O
within	O
the	O
hetero	O
-	O
oligomeric	O
m	O
-	O
AAA	O
isoenzyme	O
when	O
inactive	O
AFG3L2	O
variants	O
are	O
expressed	O
.	O

This	O
allowed	O
us	O
to	O
monitor	O
effects	O
of	O
specific	O
mutations	O
within	O
the	O
AAA	O
domain	O
of	O
AFG3L2	O
on	O
paraplegin	O
activity	O
in	O
vivo	O
.	O

Coexpression	O
of	O
C	O
-	O
terminally	O
hexahistadine	O
tagged	O
paraplegin	O
with	O
the	O
Walker	O
A	O
AFG3L2	O
mutant	O
partially	O
restored	O
respiratory	O
growth	O
of	O
Deltayta10Deltayta12	O
cells	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

In	O
contrast	O
,	O
respiratory	O
growth	O
was	O
completely	O
abolished	O
when	O
paraplegin	O
was	O
coexpressed	O
with	O
AFG3L2	O
harboring	O
a	O
mutation	O
in	O
the	O
Walker	O
B	O
motif	O
(	O
Fig	O
.	O
2A	O
)	O
.	O

Mutations	O
in	O
Walker	O
B	O
but	O
not	O
Walker	O
A	O
motifs	O
of	O
AFG3L2	O
inhibited	O
almost	O
completely	O
the	O
ATPase	O
activity	O
of	O
purified	O
hetero	O
-	O
oligomeric	O
m	O
-	O
AAA	O
complexes	O
in	O
vitro	O
(	O
Fig	O
.	O
2B	O
)	O
.	O

Similar	O
effects	O
were	O
observed	O
when	O
m	O
-	O
AAA	O
proteases	O
with	O
analogous	O
mutant	O
subunits	O
of	O
paraplegin	O
were	O
analyzed	O
(	O
Fig	O
.	O
2B	O
)	O
.	O

Thus	O
,	O
only	O
mutations	O
in	O
the	O
Walker	O
B	O
motif	O
inhibited	O
ATP	O
hydrolysis	O
in	O
hetero	O
-	O
oligomeric	O
human	O
protease	O
complexes	O
,	O
consistent	O
with	O
an	O
inhibitory	O
effect	O
of	O
ATP	O
binding	O
on	O
adjacent	O
subunits	O
.	O

PARP	O
-	O
1	O
transcriptional	O
activity	O
is	O
regulated	O
by	O
sumoylation	O
upon	O
heat	O
shock	O
.	O

Heat	O
shock	O
and	O
other	O
environmental	O
stresses	O
rapidly	O
induce	O
transcriptional	O
responses	O
subject	O
to	O
regulation	O
by	O
a	O
variety	O
of	O
post	O
-	O
translational	O
modifications	O
.	O

Among	O
these	O
,	O
poly	O
(	O
ADP	O
-	O
ribosyl	O
)	O
ation	O
and	O
sumoylation	O
have	O
received	O
growing	O
attention	O
.	O

Here	O
we	O
show	O
that	O
the	O
SUMO	O
E3	O
ligase	O
PIASy	O
interacts	O
with	O
the	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
PARP	O
-	O
1	O
,	O
and	O
that	O
PIASy	O
mediates	O
heat	O
shock	O
-	O
induced	O
poly	O
-	O
sumoylation	O
of	O
PARP	O
-	O
1	O
.	O

Furthermore	O
,	O
PIASy	O
,	O
and	O
hence	O
sumoylation	O
,	O
appears	O
indispensable	O
for	O
full	O
activation	O
of	O
the	O
inducible	O
HSP70	O
.	O
1	O
gene	O
.	O

Chromatin	O
immunoprecipitation	O
experiments	O
show	O
that	O
PIASy	O
,	O
SUMO	O
and	O
the	O
SUMO	O
-	O
conjugating	O
enzyme	O
Ubc9	O
are	O
rapidly	O
recruited	O
to	O
the	O
HSP70	O
.	O
1	O
promoter	O
upon	O
heat	O
shock	O
,	O
and	O
that	O
they	O
are	O
subsequently	O
released	O
with	O
kinetics	O
similar	O
to	O
PARP	O
-	O
1	O
.	O

Finally	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
SUMO	O
-	O
targeted	O
ubiquitin	O
ligase	O
RNF4	O
mediates	O
heat	O
-	O
shock	O
-	O
inducible	O
ubiquitination	O
of	O
PARP	O
-	O
1	O
,	O
regulates	O
the	O
stability	O
of	O
PARP	O
-	O
1	O
,	O
and	O
,	O
like	O
PIASy	O
,	O
is	O
a	O
positive	O
regulator	O
of	O
HSP70	O
.	O
1	O
gene	O
activity	O
.	O

These	O
results	O
,	O
thus	O
,	O
point	O
to	O
a	O
novel	O
mechanism	O
for	O
regulating	O
PARP	O
-	O
1	O
transcription	O
function	O
,	O
and	O
suggest	O
crosstalk	O
between	O
sumoylation	O
and	O
RNF4	O
-	O
mediated	O
ubiquitination	O
in	O
regulating	O
gene	O
expression	O
in	O
response	O
to	O
heat	O
shock	O
.	O

Dnmt3	O
/	O
transcription	O
factor	O
interactions	O
as	O
crucial	O
players	O
in	O
targeted	O
DNA	O
methylation	O
.	O

Epigenetic	O
gene	O
inactivation	O
in	O
mammalian	O
cells	O
involves	O
many	O
silencing	O
mechanisms	O
.	O

One	O
of	O
these	O
mechanisms	O
is	O
the	O
transcriptional	O
repression	O
by	O
targeted	O
promoter	O
hypermethylation	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
site	O
-	O
specific	O
DNA	O
(	O
hyper	O
)	O
methylation	O
are	O
not	O
fully	O
elucidate	O
.	O

By	O
using	O
the	O
Dnmt3a	O
/	O
c	O
-	O
myc	O
interaction	O
as	O
an	O
example	O
,	O
we	O
here	O
showed	O
that	O
this	O
interaction	O
promotes	O
the	O
site	O
-	O
specific	O
methylation	O
of	O
CG	O
dinucleotides	O
localized	O
in	O
c	O
-	O
myc	O
boxes	O
of	O
promoter	O
regions	O
of	O
CDKN2a	O
,	O
CCND1	O
and	O
TIMP2	O
genes	O
.	O

Indeed	O
,	O
the	O
invalidation	O
of	O
c	O
-	O
myc	O
reveals	O
that	O
c	O
-	O
myc	O
allows	O
the	O
Dnmt3a	O
recruitment	O
on	O
c	O
-	O
myc	O
box	O
of	O
c	O
-	O
myc	O
-	O
regulated	O
genes	O
.	O

Acellular	O
experiments	O
corroborated	O
and	O
complemented	O
these	O
results	O
by	O
revealing	O
that	O
the	O
specificity	O
of	O
consensus	O
sequence	O
for	O
DNA	O
methylation	O
of	O
Dnmt3a	O
is	O
increased	O
in	O
presence	O
of	O
c	O
-	O
myc	O
.	O

Indeed	O
,	O
our	O
work	O
indicates	O
that	O
Dnmt3a	O
and	O
Dnmt3b	O
have	O
consensus	O
sequences	O
to	O
methylate	O
DNA	O
(	O
T	O
/	O
A	O
/	O
C	O
)	O
(	O
A	O
/	O
T	O
)	O
(	O
T	O
/	O
G	O
/	O
A	O
)	O
CG	O
(	O
T	O
/	O
G	O
/	O
C	O
)	O
G	O
(	O
G	O
/	O
C	O
/	O
A	O
)	O
and	O
(	O
A	O
/	O
C	O
)	O
(	O
C	O
/	O
G	O
/	O
A	O
)	O
(	O
A	O
/	O
G	O
)	O
CGT	O
(	O
C	O
/	O
G	O
)	O
(	O
A	O
/	O
G	O
)	O
.	O

Thus	O
,	O
the	O
low	O
specificity	O
of	O
these	O
sequences	O
(	O
consensual	O
for	O
162	O
and	O
48	O
possibilities	O
,	O
respectively	O
)	O
does	O
not	O
support	O
the	O
idea	O
of	O
targeted	O
DNA	O
methylation	O
.	O

By	O
monitoring	O
transcription	O
factor	O
arrays	O
spotted	O
with	O
103	O
transcription	O
factors	O
,	O
we	O
next	O
identified	O
42	O
transcription	O
factors	O
interacting	O
with	O
Dnmt3a	O
and	O
Dnmt3b	O
(	O
such	O
as	O
CREB	O
and	O
FOS	O
)	O
,	O
27	O
transcription	O
factors	O
interacting	O
with	O
Dnmt3a	O
(	O
such	O
as	O
AP2alpha	O
and	O
p53	O
)	O
,	O
10	O
transcription	O
factors	O
interacting	O
with	O
Dnmt3b	O
(	O
such	O
as	O
SP1	O
and	O
SP4	O
)	O
and	O
24	O
transcription	O
factors	O
devoid	O
of	O
direct	O
interaction	O
with	O
Dnm3a	O
and	O
Dnmt3b	O
(	O
such	O
as	O
C	O
/	O
EBPalpha	O
and	O
NFkappaB	B-Complex
-	O
p65	O
)	O
.	O

Thus	O
,	O
The	O
description	O
of	O
direct	O
interaction	O
between	O
Dnmt3a	O
and	O
/	O
or	O
Dnmt3b	O
and	O
transcription	O
factors	O
provides	O
rational	O
molecular	O
explanation	O
to	O
the	O
mechanisms	O
of	O
targeted	O
DNA	O
(	O
hyper	O
)	O
methylation	O
,	O
and	O
to	O
the	O
mechanisms	O
by	O
which	O
transcription	O
factors	O
repress	O
genes	O
expression	O
.	O

Hyou1	O
heterozygosity	O
aggravates	O
ER	O
stress	O
in	O
Sil1	O
-	O
/	O
-	O
Purkinje	O
cells	O
.	O

BiP	O
upregulation	O
in	O
lobule	O
II	O
(	O
A	O
-	O
D	O
)	O
or	O
lobule	O
X	O
(	O
E	O
-	O
H	O
)	O
of	O
cerebella	O
from	O
6	O
-	O
week	O
-	O
old	O
Sil1	O
-	O
/	O
-	O
(	O
A	O
,	O
B	O
,	O
E	O
,	O
F	O
)	O
and	O
Sil1	O
-	O
/	O
-	O
;	O
Hyou1	O
+	O
/	O
-	O
mice	O
(	O
C	O
,	O
D	O
,	O
G	O
,	O
H	O
)	O
.	O

Sections	O
were	O
subjected	O
to	O
immunostaining	O
with	O
antibodies	O
against	O
BiP	O
and	O
calbindin	O
-	O
D28	O
(	O
Calb	O
)	O
.	O

Camera	O
exposure	O
times	O
are	O
equal	O
for	O
images	O
of	O
the	O
same	O
channel	O
.	O

Scale	O
bar	O
=	O
100	O
microm	O
.	O

(	O
A	O
)	O
Mean	O
length	O
of	O
primary	O
and	O
secondary	O
neurites	O
of	O
neurons	O
transfected	O
with	O
control	O
shRNA	O
/	O
pEGFP	O
,	O
Capzb2	O
shRNA	O
/	O
pEGFP	O
,	O
or	O
Capzb2	O
shRNA	O
/	O
RNAi	O
resistant	O
(	O
Res	O
)	O
Capzb2	O
-	O
EGFP	O
(	O
ratio	O
4	O
:	O
1	O
)	O
were	O
analyzed	O
72	O
h	O
posttransfection	O
and	O
4	O
%	O
paraformaldehyde	O
fixation	O
.	O

Capzb2	O
shRNA	O
transfection	O
results	O
in	O
reduced	O
length	O
of	O
both	O
primary	O
and	O
secondary	O
neurites	O
;	O
concomitant	O
transfection	O
of	O
RNAi	O
Res	O
Capzb2	O
-	O
EGFP	O
reverses	O
the	O
effect	O
of	O
Capzb2	O
RNAi	O
.	O

Mean	O
values	O
+	O
/	O
-	O
s	O
.	O
e	O
.	O
m	O
.	O

(	O
n	O
=	O
100	O
neurons	O
in	O
each	O
category	O
)	O
are	O
depicted	O
;	O
*	O
*	O
*	O
=	O
p	O
<	O
0	O
.	O
001	O
.	O

(	O
B	O
and	O
C	O
)	O
Representative	O
shRNA	O
/	O
pEGFP	O
transfected	O
neurons	O
:	O
(	O
B	O
)	O
control	O
shRNA	O
/	O
pEGFP	O
and	O
(	O
C	O
)	O
Capzb2	O
shRNA	O
/	O
pEGFP	O
;	O
GFP	O
(	O
green	O
)	O
,	O
F	O
-	O
actin	O
(	O
red	O
)	O
,	O
and	O
betaIII	O
-	O
tubulin	O
(	O
purple	O
)	O
;	O
scale	O
bar	O
indicates	O
10	O
microm	O
.	O

(	O
D	O
)	O
Higher	O
magnification	O
of	O
a	O
normal	O
growth	O
cone	O
delineated	O
by	O
the	O
white	O
box	O
in	O
(	O
B	O
)	O
,	O
characterized	O
by	O
an	O
F	O
-	O
actin	O
-	O
rich	O
periphery	O
(	O
red	O
)	O
and	O
a	O
betaIII	O
-	O
tubulin	O
-	O
rich	O
C	O
-	O
zone	O
(	O
purple	O
)	O
;	O
scale	O
bar	O
indicates	O
5	O
microm	O
.	O

(	O
E	O
)	O
Higher	O
magnification	O
of	O
a	O
growth	O
cone	O
delineated	O
by	O
the	O
white	O
box	O
in	O
(	O
C	O
)	O
in	O
which	O
there	O
is	O
overlap	O
of	O
F	O
-	O
actin	O
(	O
red	O
)	O
and	O
betaIII	O
-	O
tubulin	O
(	O
purple	O
)	O
signal	O
;	O
scale	O
bar	O
indicates	O
5	O
microm	O
.	O

Note	O
the	O
altered	O
morphology	O
as	O
characterized	O
by	O
the	O
absence	O
of	O
lamellipodia	O
,	O
resulting	O
in	O
a	O
fork	O
-	O
like	O
appearance	O
.	O

(	O
F	O
)	O
Representative	O
images	O
of	O
betaIII	O
-	O
tubulin	O
(	O
purple	O
)	O
and	O
F	O
-	O
actin	O
(	O
red	O
)	O
in	O
normal	O
,	O
fork	O
-	O
like	O
,	O
and	O
unclassified	O
growth	O
cones	O
/	O
actin	O
-	O
rich	O
neuritic	O
endings	O
(	O
scale	O
bar	O
indicates	O
5	O
microm	O
)	O
,	O
and	O
quantification	O
of	O
each	O
of	O
these	O
categories	O
in	O
neurons	O
transfected	O
with	O
control	O
shRNA	O
/	O
pEGFP	O
,	O
Capzb2	O
shRNA	O
/	O
pEGFP	O
,	O
and	O
Capzb2	O
shRNA	O
+	O
RNAi	O
Res	O
Capzb2	O
-	O
EGFP	O
(	O
rescue	O
transfection	O
)	O
.	O

The	O
neurons	O
were	O
fixed	O
in	O
PHEM	O
buffer	O
48	O
h	O
posttransfection	O
.	O

The	O
neuritic	O
ending	O
morphology	O
classified	O
as	O
fork	O
-	O
like	O
lacked	O
lamellipodia	O
,	O
and	O
the	O
betaIII	O
-	O
tubulin	O
signal	O
(	O
purple	O
)	O
extended	O
into	O
the	O
periphery	O
and	O
overlapped	O
with	O
F	O
-	O
actin	O
(	O
red	O
)	O
rather	O
than	O
being	O
confined	O
centrally	O
as	O
in	O
normal	O
growth	O
cones	O
.	O

Fork	O
-	O
like	O
"	O
growth	O
cones	O
"	O
dominated	O
in	O
neurons	O
transfected	O
with	O
Capzb2	O
shRNA	O
,	O
whereas	O
normal	O
growth	O
cones	O
were	O
significantly	O
more	O
common	O
in	O
control	O
and	O
rescue	O
conditions	O
.	O

The	O
third	O
category	O
,	O
unclassified	O
,	O
represents	O
neuritic	O
endings	O
that	O
could	O
not	O
be	O
classified	O
as	O
either	O
normal	O
or	O
fork	O
-	O
like	O
.	O

These	O
neuritic	O
endings	O
had	O
uniform	O
appearance	O
and	O
were	O
found	O
in	O
similar	O
frequencies	O
across	O
the	O
experimental	O
conditions	O
.	O
more	O
than	O
230	O
growth	O
cones	O
/	O
actin	O
-	O
rich	O
neuritic	O
endings	O
from	O
neurons	O
belonging	O
to	O
each	O
category	O
were	O
analyzed	O
;	O
mean	O
values	O
+	O
/	O
-	O
s	O
.	O
e	O
.	O
m	O
.	O
are	O
depicted	O
;	O
*	O
*	O
*	O
=	O
p	O
<	O
0	O
.	O
001	O
.	O

(	O
G	O
)	O
EGFP	O
-	O
Capzb2	O
is	O
present	O
in	O
the	O
neuronal	O
soma	O
and	O
processes	O
including	O
the	O
growth	O
cones	O
where	O
it	O
colocalizes	O
with	O
betaIII	O
-	O
tubulin	O
.	O

The	O
lower	O
panels	O
are	O
higher	O
magnifications	O
of	O
the	O
area	O
delineated	O
by	O
the	O
white	O
box	O
in	O
the	O
upper	O
right	O
-	O
hand	O
panel	O
.	O

Identification	O
of	O
FGFR4	O
-	O
activating	O
mutations	O
in	O
human	O
rhabdomyosarcomas	O
that	O
promote	O
metastasis	O
in	O
xenotransplanted	O
models	O
.	O

Rhabdomyosarcoma	O
(	O
RMS	O
)	O
is	O
a	O
childhood	O
cancer	O
originating	O
from	O
skeletal	O
muscle	O
,	O
and	O
patient	O
survival	O
is	O
poor	O
in	O
the	O
presence	O
of	O
metastatic	O
disease	O
.	O

Few	O
determinants	O
that	O
regulate	O
metastasis	O
development	O
have	O
been	O
identified	O
.	O

The	O
receptor	O
tyrosine	O
kinase	O
FGFR4	O
is	O
highly	O
expressed	O
in	O
RMS	O
tissue	O
,	O
suggesting	O
a	O
role	O
in	O
tumorigenesis	O
,	O
although	O
its	O
functional	O
importance	O
has	O
not	O
been	O
defined	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
mutations	O
in	O
FGFR4	O
in	O
human	O
RMS	O
tumors	O
that	O
lead	O
to	O
its	O
activation	O
and	O
present	O
evidence	O
that	O
it	O
functions	O
as	O
an	O
oncogene	O
in	O
RMS	O
.	O

Higher	O
FGFR4	O
expression	O
in	O
RMS	O
tumors	O
was	O
associated	O
with	O
advanced	O
-	O
stage	O
cancer	O
and	O
poor	O
survival	O
,	O
while	O
FGFR4	O
knockdown	O
in	O
a	O
human	O
RMS	O
cell	O
line	O
reduced	O
tumor	O
growth	O
and	O
experimental	O
lung	O
metastases	O
when	O
the	O
cells	O
were	O
transplanted	O
into	O
mice	O
.	O

Moreover	O
,	O
6	O
FGFR4	O
tyrosine	O
kinase	O
domain	O
mutations	O
were	O
found	O
among	O
7	O
of	O
94	O
(	O
7	O
.	O
5	O
%	O
)	O
primary	O
human	O
RMS	O
tumors	O
.	O

The	O
mutants	O
K535	O
and	O
E550	O
increased	O
autophosphorylation	O
,	O
Stat3	O
signaling	O
,	O
tumor	O
proliferation	O
,	O
and	O
metastatic	O
potential	O
when	O
expressed	O
in	O
a	O
murine	O
RMS	O
cell	O
line	O
.	O

These	O
mutants	O
also	O
transformed	O
NIH	O
3T3	O
cells	O
and	O
led	O
to	O
an	O
enhanced	O
metastatic	O
phenotype	O
.	O

Finally	O
,	O
murine	O
RMS	O
cell	O
lines	O
expressing	O
the	O
K535	O
and	O
E550	O
FGFR4	O
mutants	O
were	O
substantially	O
more	O
susceptible	O
to	O
apoptosis	O
in	O
the	O
presence	O
of	O
a	O
pharmacologic	O
FGFR	O
inhibitor	O
than	O
the	O
control	O
cell	O
lines	O
expressing	O
the	O
empty	O
vector	O
or	O
wild	O
-	O
type	O
FGFR4	O
.	O

Together	O
,	O
our	O
results	O
demonstrate	O
that	O
mutationally	O
activated	O
FGFR4	O
acts	O
as	O
an	O
oncogene	O
,	O
and	O
these	O
are	O
what	O
we	O
believe	O
to	O
be	O
the	O
first	O
known	O
mutations	O
in	O
a	O
receptor	O
tyrosine	O
kinase	O
in	O
RMS	O
.	O

These	O
findings	O
support	O
the	O
potential	O
therapeutic	O
targeting	O
of	O
FGFR4	O
in	O
RMS	O
.	O

The	O
zmm	O
mutants	O
have	O
similar	O
defects	O
in	O
crossover	O
frequencies	O
,	O
however	O
,	O
msh4	O
and	O
msh5	O
display	O
improved	O
chromosome	O
segregation	O
at	O
33degreesC	O
.	O

At	O
least	O
two	O
observations	O
suggest	O
that	O
temperature	O
modulates	O
chromosome	O
segregation	O
independently	O
of	O
increasing	O
crossover	O
frequencies	O
.	O

First	O
,	O
crossover	O
frequencies	O
on	O
chromosome	O
III	O
were	O
similar	O
at	O
23	O
and	O
33degreesC	O
(	O
Table	O
3	O
)	O
.	O

Second	O
,	O
missegregation	O
of	O
the	O
non	O
-	O
exchange	O
homeolog	O
chromosome	O
pair	O
was	O
also	O
improved	O
at	O
33degreesC	O
in	O
msh4	O
cells	O
.	O

SUMOylation	O
attenuates	O
the	O
aggregation	O
propensity	O
and	O
cellular	O
toxicity	O
of	O
the	O
polyglutamine	O
expanded	O
ataxin	O
-	O
7	O
.	O

Post	O
-	O
translational	O
modification	O
by	O
SUMO	O
(	O
small	O
ubiquitin	O
-	O
like	O
modifier	O
)	O
was	O
proposed	O
to	O
modulate	O
the	O
pathogenesis	O
of	O
several	O
neurodegenerative	O
diseases	O
.	O

Spinocerebellar	O
ataxia	O
type	O
7	O
(	O
SCA7	O
)	O
is	O
a	O
neurodegenerative	O
disorder	O
,	O
whose	O
pathology	O
is	O
caused	O
by	O
an	O
expansion	O
of	O
a	O
polyglutamine	O
stretch	O
in	O
the	O
protein	O
ataxin	O
-	O
7	O
(	O
ATXN7	O
)	O
.	O

Here	O
,	O
we	O
identified	O
ATXN7	O
as	O
new	O
target	O
for	O
SUMOylation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
major	O
SUMO	O
acceptor	O
site	O
was	O
mapped	O
to	O
lysine	O
257	O
,	O
which	O
is	O
part	O
of	O
an	O
evolutionarily	O
conserved	O
consensus	O
SUMOylation	O
motif	O
.	O

SUMOylation	O
did	O
not	O
influence	O
the	O
subcellular	O
localization	O
of	O
ATXN7	O
nor	O
its	O
interaction	O
with	O
components	O
of	O
the	O
TFTC	O
/	O
STAGA	B-Complex
complex	O
.	O

Expansion	O
of	O
the	O
polyglutamine	O
stretch	O
did	O
not	O
impair	O
the	O
SUMOylation	O
of	O
ATXN7	O
.	O

Furthermore	O
,	O
SUMO1	O
and	O
SUMO2	O
colocalized	O
with	O
ATXN7	O
in	O
a	O
subset	O
of	O
neuronal	O
intranuclear	O
inclusions	O
in	O
the	O
brain	O
of	O
SCA7	O
patients	O
and	O
SCA7	O
knock	O
-	O
in	O
mice	O
.	O

In	O
a	O
COS	O
-	O
7	O
cellular	O
model	O
of	O
SCA7	O
,	O
in	O
addition	O
to	O
diffuse	O
nucleoplasmic	O
staining	O
we	O
identified	O
two	O
populations	O
of	O
nuclear	O
inclusions	O
:	O
homogenous	O
or	O
non	O
-	O
homogenous	O
.	O

Non	O
-	O
homogenous	O
inclusions	O
showed	O
significantly	O
reduced	O
colocalization	O
with	O
SUMO1	O
and	O
SUMO2	O
,	O
but	O
were	O
highly	O
enriched	O
in	O
Hsp70	O
,	O
19S	B-Complex
proteasome	I-Complex
and	O
ubiquitin	O
.	O

Interestingly	O
,	O
they	O
were	O
characterized	O
by	O
increased	O
staining	O
with	O
the	O
apoptotic	O
marker	O
caspase	O
-	O
3	O
and	O
by	O
disruption	O
of	O
PML	B-OOS
nuclear	I-OOS
bodies	I-OOS
.	O

Importantly	O
,	O
preventing	O
the	O
SUMOylation	O
of	O
expanded	O
ATXN7	O
by	O
mutating	O
the	O
SUMO	O
site	O
increased	O
both	O
the	O
amount	O
of	O
SDS	O
-	O
insoluble	O
aggregates	O
and	O
of	O
caspase	O
-	O
3	O
positive	O
non	O
-	O
homogenous	O
inclusions	O
,	O
which	O
act	O
toxic	O
to	O
the	O
cells	O
.	O

Our	O
results	O
demonstrate	O
an	O
influence	O
of	O
SUMOylation	O
on	O
the	O
multistep	O
aggregation	O
process	O
of	O
ATXN7	O
and	O
implicate	O
a	O
role	O
for	O
ATXN7	O
SUMOylation	O
in	O
SCA7	O
pathogenesis	O
.	O

Consortin	O
,	O
a	O
trans	O
-	O
Golgi	O
network	O
cargo	O
receptor	O
for	O
the	O
plasma	O
membrane	O
targeting	O
and	O
recycling	O
of	O
connexins	O
.	O

Targeting	O
of	O
numerous	O
transmembrane	O
proteins	O
to	O
the	O
cell	O
surface	O
is	O
thought	O
to	O
depend	O
on	O
their	O
recognition	O
by	O
cargo	O
receptors	O
that	O
interact	O
with	O
the	O
adaptor	O
machinery	O
for	O
anterograde	O
traffic	O
at	O
the	O
distal	O
end	O
of	O
the	O
Golgi	O
complex	O
.	O

We	O
report	O
here	O
on	O
consortin	O
,	O
a	O
novel	O
integral	O
membrane	O
protein	O
that	O
is	O
predicted	O
to	O
be	O
intrinsically	O
disordered	O
,	O
i	O
.	O
e	O
.	O
that	O
contains	O
large	O
segments	O
whose	O
native	O
state	O
is	O
unstructured	O
.	O

We	O
identified	O
consortin	O
as	O
a	O
binding	O
partner	O
of	O
connexins	O
,	O
the	O
building	O
blocks	O
of	O
gap	O
junctions	O
.	O

Consortin	O
is	O
located	O
at	O
the	O
trans	O
-	O
Golgi	O
network	O
(	O
TGN	O
)	O
,	O
in	O
tubulovesicular	O
transport	O
organelles	O
,	O
and	O
at	O
the	O
plasma	O
membrane	O
.	O

It	O
directly	O
interacts	O
with	O
the	O
TGN	O
clathrin	B-Complex
adaptors	O
GGA1	O
and	O
GGA2	O
,	O
and	O
disruption	O
of	O
this	O
interaction	O
by	O
expression	O
of	O
a	O
consortin	O
mutant	O
lacking	O
the	O
acidic	O
cluster	O
-	O
dileucine	O
(	O
DXXLL	O
)	O
GGA	O
interaction	O
motif	O
causes	O
an	O
intracellular	O
accumulation	O
of	O
several	O
connexins	O
.	O

RNA	O
interference	O
-	O
mediated	O
silencing	O
of	O
consortin	O
expression	O
in	O
HeLa	O
cells	O
blocks	O
the	O
cell	O
surface	O
targeting	O
of	O
these	O
connexins	O
,	O
which	O
accumulate	O
intracellularly	O
,	O
whereas	O
partial	O
depletion	O
and	O
redistribution	O
of	O
the	O
consortin	O
pool	O
slows	O
down	O
the	O
intracellular	O
degradation	O
of	O
gap	O
junction	O
plaques	O
.	O

Altogether	O
,	O
our	O
results	O
show	O
that	O
,	O
by	O
studying	O
connexin	O
trafficking	O
,	O
we	O
have	O
identified	O
the	O
first	O
TGN	O
cargo	O
receptor	O
for	O
the	O
targeting	O
of	O
transmembrane	O
proteins	O
to	O
the	O
plasma	O
membrane	O
.	O

The	O
identification	O
of	O
consortin	O
provides	O
in	O
addition	O
a	O
potential	O
target	O
for	O
therapies	O
aimed	O
at	O
diseases	O
in	O
which	O
connexin	O
traffic	O
is	O
altered	O
,	O
including	O
cardiac	O
ischemia	O
,	O
peripheral	O
neuropathies	O
,	O
cataracts	O
and	O
hearing	O
impairment	O
.	O

Sequence	O
accession	O
numbers	O
.	O

GenBank	O
:	O
Human	O
CNST	O
cDNA	O
,	O
NM	O
_	O
152609	O
;	O
mouse	O
Cnst	O
cDNA	O
,	O
NM	O
_	O
146105	O
.	O

The	O
E3	O
ubiquitin	O
ligase	O
Triad3A	O
negatively	O
regulates	O
the	O
RIG	O
-	O
I	O
/	O
MAVS	O
signaling	O
pathway	O
by	O
targeting	O
TRAF3	O
for	O
degradation	O
.	O

The	O
primary	O
role	O
of	O
the	O
innate	O
immune	O
response	O
is	O
to	O
limit	O
the	O
spread	O
of	O
infectious	O
pathogens	O
,	O
with	O
activation	O
of	O
Toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
and	O
RIG	O
-	O
like	O
receptor	O
(	O
RLR	O
)	O
pathways	O
resulting	O
in	O
a	O
pro	O
-	O
inflammatory	O
response	O
required	O
to	O
combat	O
infection	O
.	O

Limiting	O
the	O
activation	O
of	O
these	O
signaling	O
pathways	O
is	O
likewise	O
essential	O
to	O
prevent	O
tissue	O
injury	O
in	O
the	O
host	O
.	O

Triad3A	O
is	O
an	O
E3	O
ubiquitin	O
ligase	O
that	O
interacts	O
with	O
several	O
components	O
of	O
TLR	O
signaling	O
and	O
modulates	O
TLR	O
activity	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
Triad3A	O
negatively	O
regulates	O
the	O
RIG	O
-	O
I	O
RNA	O
sensing	O
pathway	O
through	O
Lys48	O
-	O
linked	O
,	O
ubiquitin	O
-	O
mediated	O
degradation	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
factor	O
3	O
(	O
TRAF3	O
)	O
adapter	O
.	O

Triad3A	O
was	O
induced	O
following	O
dsRNA	O
exposure	O
or	O
virus	O
infection	O
and	O
decreased	O
TRAF3	O
levels	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
;	O
moreover	O
,	O
Triad3A	O
expression	O
blocked	O
IRF	O
-	O
3	O
activation	O
by	O
Ser	O
-	O
396	O
phosphorylation	O
and	O
inhibited	O
the	O
expression	O
of	O
type	O
1	O
interferon	O
and	O
antiviral	O
genes	O
.	O

Lys48	O
-	O
linked	O
ubiquitination	O
of	O
TRAF3	O
by	O
Triad3A	O
increased	O
TRAF3	O
turnover	O
,	O
whereas	O
reduction	O
of	O
Triad3A	O
expression	O
by	O
stable	O
shRNA	O
expression	O
correlated	O
with	O
an	O
increase	O
in	O
TRAF3	O
protein	O
expression	O
and	O
enhancement	O
of	O
the	O
antiviral	O
response	O
following	O
VSV	O
or	O
Sendai	O
virus	O
infection	O
.	O

Triad3A	O
and	O
TRAF3	O
physically	O
interacted	O
together	O
,	O
and	O
TRAF3	O
residues	O
Y440	O
and	O
Q442	O
-	O
-	O
previously	O
shown	O
to	O
be	O
important	O
for	O
association	O
with	O
the	O
MAVS	O
adapter	O
-	O
-	O
were	O
also	O
critical	O
for	O
Triad3A	O
.	O

Point	O
mutation	O
of	O
the	O
TRAF	O
-	O
Interacting	O
-	O
Motif	O
(	O
TIM	O
)	O
of	O
Triad3A	O
abrogated	O
its	O
ability	O
to	O
interact	O
with	O
TRAF3	O
and	O
modulate	O
RIG	O
-	O
I	O
signaling	O
.	O

TRAF3	O
appears	O
to	O
undergo	O
sequential	O
ubiquitin	O
"	O
immuno	O
-	O
editing	O
"	O
following	O
virus	O
infection	O
that	O
is	O
crucial	O
for	O
regulation	O
of	O
RIG	O
-	O
I	O
-	O
dependent	O
signaling	O
to	O
the	O
antiviral	O
response	O
.	O

Thus	O
,	O
Triad3A	O
represents	O
a	O
versatile	O
E3	O
ubiquitin	O
ligase	O
that	O
negatively	O
regulates	O
RIG	O
-	O
like	O
receptor	O
signaling	O
by	O
targeting	O
TRAF3	O
for	O
degradation	O
following	O
RNA	O
virus	O
infection	O
.	O

Side	O
chain	O
specificity	O
of	O
ADP	O
-	O
ribosylation	O
by	O
a	O
sirtuin	O
.	O

Endogenous	O
mono	O
-	O
ADP	O
-	O
ribosylation	O
in	O
eukaryotes	O
is	O
involved	O
in	O
regulating	O
protein	O
synthesis	O
,	O
signal	O
transduction	O
,	O
cytoskeletal	O
integrity	O
,	O
and	O
cell	O
proliferation	O
,	O
although	O
few	O
cellular	O
ADP	O
-	O
ribosyltransferases	O
have	O
been	O
identified	O
.	O

The	O
sirtuins	O
constitute	O
a	O
highly	O
conserved	O
family	O
of	O
protein	O
deacetylases	O
,	O
and	O
several	O
family	O
members	O
have	O
also	O
been	O
reported	O
to	O
perform	O
protein	O
ADP	O
-	O
ribosylation	O
.	O

We	O
characterized	O
the	O
ADP	O
-	O
ribosylation	O
reaction	O
of	O
the	O
nuclear	O
sirtuin	O
homolog	O
Trypanosoma	O
brucei	O
SIR2	O
-	O
related	O
protein	O
1	O
(	O
TbSIR2RP1	O
)	O
on	O
both	O
acetylated	O
and	O
unacetylated	O
substrates	O
.	O

We	O
demonstrated	O
that	O
an	O
acetylated	O
substrate	O
is	O
not	O
required	O
for	O
ADP	O
-	O
ribosylation	O
to	O
occur	O
,	O
indicating	O
that	O
the	O
reaction	O
performed	O
by	O
TbSIR2RP1	O
is	O
a	O
genuine	O
enzymatic	O
reaction	O
and	O
not	O
a	O
side	O
reaction	O
of	O
deacetylation	O
.	O

Biochemical	O
and	O
MS	O
data	O
showed	O
that	O
arginine	O
is	O
the	O
major	O
ADP	O
-	O
ribose	O
acceptor	O
for	O
unacetylated	O
substrates	O
,	O
whereas	O
arginine	O
does	O
not	O
appear	O
to	O
be	O
the	O
major	O
ADP	O
-	O
ribose	O
acceptor	O
in	O
reactions	O
with	O
acetylated	O
histone	O
H1	O
.	O
1	O
.	O

We	O
performed	O
combined	O
ab	O
initio	O
quantum	O
mechanical	O
/	O
molecular	O
mechanical	O
molecular	O
dynamics	O
simulations	O
,	O
which	O
indicated	O
that	O
sirtuin	O
ADP	O
-	O
ribosylation	O
at	O
arginine	O
is	O
energetically	O
feasible	O
,	O
and	O
involves	O
a	O
concerted	O
mechanism	O
with	O
a	O
highly	O
dissociative	O
transition	O
state	O
.	O

In	O
comparison	O
with	O
the	O
corresponding	O
nicotinamide	O
cleavage	O
in	O
the	O
deacetylation	O
reaction	O
,	O
the	O
simulations	O
suggest	O
that	O
sirtuin	O
ADP	O
-	O
ribosylation	O
would	O
be	O
several	O
orders	O
slower	O
but	O
less	O
sensitive	O
to	O
nicotinamide	O
inhibition	O
,	O
which	O
is	O
consistent	O
with	O
experimental	O
results	O
.	O

These	O
results	O
suggest	O
that	O
TbSIR2RP1	O
can	O
perform	O
ADP	O
-	O
ribosylation	O
using	O
two	O
distinct	O
mechanisms	O
,	O
depending	O
on	O
whether	O
or	O
not	O
the	O
substrate	O
is	O
acetylated	O
.	O

Cohesin	B-Complex
promotes	O
the	O
repair	O
of	O
ionizing	O
radiation	O
-	O
induced	O
DNA	O
double	O
-	O
strand	O
breaks	O
in	O
replicated	O
chromatin	O
.	O

The	O
cohesin	B-Complex
protein	O
complex	O
holds	O
sister	O
chromatids	O
together	O
after	O
synthesis	O
until	O
mitosis	O
.	O

It	O
also	O
contributes	O
to	O
post	O
-	O
replicative	O
DNA	O
repair	O
in	O
yeast	O
and	O
higher	O
eukaryotes	O
and	O
accumulates	O
at	O
sites	O
of	O
laser	O
-	O
induced	O
damage	O
in	O
human	O
cells	O
.	O

Our	O
goal	O
was	O
to	O
determine	O
whether	O
the	O
cohesin	B-Complex
subunits	O
SMC1	O
and	O
Rad21	O
contribute	O
to	O
DNA	O
double	O
-	O
strand	O
break	O
repair	O
in	O
X	O
-	O
irradiated	O
human	O
cells	O
in	O
the	O
G2	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

RNA	O
interference	O
-	O
mediated	O
depletion	O
of	O
SMC1	O
sensitized	O
HeLa	O
cells	O
to	O
X	O
-	O
rays	O
.	O

Repair	O
of	O
radiation	O
-	O
induced	O
DNA	O
double	O
-	O
strand	O
breaks	O
,	O
measured	O
by	O
gammaH2AX	O
/	O
53BP1	O
foci	O
analysis	O
,	O
was	O
slower	O
in	O
SMC1	O
-	O
or	O
Rad21	O
-	O
depleted	O
cells	O
than	O
in	O
controls	O
in	O
G2	O
but	O
not	O
in	O
G1	O
.	O

Inhibition	O
of	O
the	O
DNA	O
damage	O
kinase	O
DNA	B-OOS
-	I-OOS
PK	I-OOS
,	O
but	O
not	O
ATM	O
,	O
further	O
inhibited	O
foci	O
loss	O
in	O
cohesin	B-Complex
-	O
depleted	O
cells	O
in	O
G2	O
.	O

SMC1	O
depletion	O
had	O
no	O
effect	O
on	O
DNA	O
single	O
-	O
strand	O
break	O
repair	O
in	O
either	O
G1	O
or	O
late	O
S	O
/	O
G2	O
.	O

Rad21	O
and	O
SMC1	O
were	O
recruited	O
to	O
sites	O
of	O
X	O
-	O
ray	O
-	O
induced	O
DNA	O
damage	O
in	O
G2	O
-	O
phase	O
cells	O
,	O
but	O
not	O
in	O
G1	O
,	O
and	O
only	O
when	O
DNA	O
damage	O
was	O
concentrated	O
in	O
subnuclear	O
stripes	O
,	O
generated	O
by	O
partially	O
shielded	O
ultrasoft	O
X	O
-	O
rays	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
cohesin	B-Complex
complex	O
contributes	O
to	O
cell	O
survival	O
by	O
promoting	O
the	O
repair	O
of	O
radiation	O
-	O
induced	O
DNA	O
double	O
-	O
strand	O
breaks	O
in	O
G2	O
-	O
phase	O
cells	O
in	O
an	O
ATM	O
-	O
dependent	O
pathway	O
.	O

The	O
Drosophila	O
PGC	O
-	O
1	O
homologue	O
Spargel	O
coordinates	O
mitochondrial	O
activity	O
to	O
insulin	O
signalling	O
.	O

Mitochondrial	O
mass	O
and	O
activity	O
must	O
be	O
adapted	O
to	O
tissue	O
function	O
,	O
cellular	O
growth	O
and	O
nutrient	O
availability	O
.	O

In	O
mammals	O
,	O
the	O
related	O
transcriptional	O
coactivators	O
PGC	O
-	O
1alpha	O
,	O
PGC	O
-	O
1beta	O
and	O
PRC	O
regulate	O
multiple	O
metabolic	O
functions	O
,	O
including	O
mitochondrial	O
biogenesis	O
.	O

However	O
,	O
we	O
know	O
relatively	O
little	O
about	O
their	O
respective	O
roles	O
in	O
vivo	O
.	O

Here	O
we	O
show	O
that	O
the	O
Drosophila	O
PGC	O
-	O
1	O
family	O
homologue	O
,	O
Spargel	O
,	O
is	O
required	O
for	O
the	O
expression	O
of	O
multiple	O
genes	O
encoding	O
mitochondrial	O
proteins	O
.	O

Accordingly	O
,	O
spargel	O
mutants	O
showed	O
mitochondrial	O
respiration	O
defects	O
when	O
complex	B-Complex
II	I-Complex
of	O
the	O
electron	O
transport	O
chain	O
was	O
stimulated	O
.	O

Spargel	O
,	O
however	O
,	O
was	O
not	O
limiting	O
for	O
mitochondrial	O
mass	O
,	O
but	O
functioned	O
in	O
this	O
respect	O
redundantly	O
with	O
Delg	O
,	O
the	O
fly	O
NRF	O
-	O
2alpha	O
/	O
GABPalpha	O
homologue	O
.	O

More	O
importantly	O
,	O
in	O
the	O
larval	O
fat	O
body	O
,	O
Spargel	O
mediated	O
mitochondrial	O
activity	O
,	O
cell	O
growth	O
and	O
transcription	O
of	O
target	O
genes	O
in	O
response	O
to	O
insulin	O
signalling	O
.	O

In	O
this	O
process	O
,	O
Spargel	O
functioned	O
in	O
parallel	O
to	O
the	O
insulin	O
-	O
responsive	O
transcription	O
factor	O
,	O
dFoxo	O
,	O
and	O
provided	O
a	O
negative	O
feedback	O
loop	O
to	O
fine	O
-	O
tune	O
insulin	O
signalling	O
.	O

Taken	O
together	O
,	O
our	O
data	O
place	O
Spargel	O
at	O
a	O
nodal	O
point	O
for	O
the	O
integration	O
of	O
mitochondrial	O
activity	O
to	O
tissue	O
and	O
organismal	O
metabolism	O
and	O
growth	O
.	O

c	O
-	O
Abl	O
tyrosine	O
kinase	O
interacts	O
with	O
MAVS	O
and	O
regulates	O
innate	O
immune	O
response	O
.	O

The	O
tyrosine	O
kinase	O
,	O
c	O
-	O
Abl	O
,	O
plays	O
important	O
roles	O
in	O
many	O
aspects	O
of	O
cellular	O
function	O
.	O

Previous	O
reports	O
showed	O
that	O
c	O
-	O
Abl	O
is	O
involved	O
in	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
signaling	O
.	O

However	O
,	O
the	O
functions	O
of	O
c	O
-	O
Abl	O
in	O
innate	O
immunity	O
are	O
still	O
unknown	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
mitochondrial	O
antiviral	O
signaling	O
(	O
MAVS	O
)	O
protein	O
can	O
be	O
physically	O
associated	O
with	O
c	O
-	O
Abl	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

MAVS	O
interacted	O
with	O
c	O
-	O
Abl	O
through	O
its	O
Card	O
and	O
TM	O
domain	O
.	O

A	O
phosphotyrosine	O
-	O
specific	O
antibody	O
indicated	O
that	O
MAVS	O
was	O
phosphorylated	O
by	O
c	O
-	O
Abl	O
.	O

Functional	O
impairment	O
of	O
c	O
-	O
Abl	O
attenuated	O
MAVS	O
or	O
VSV	O
induced	O
type	O
-	O
I	O
IFN	O
production	O
.	O

Importantly	O
,	O
c	O
-	O
Abl	O
knockdown	O
in	O
MCF7	O
cells	O
displayed	O
impaired	O
MAVS	O
-	O
mediated	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
and	O
IRF3	O
activation	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
c	O
-	O
Abl	O
modulates	O
innate	O
immune	O
response	O
through	O
MAVS	O
.	O

The	O
chromosomal	O
association	O
of	O
condensin	O
II	O
is	O
regulated	O
by	O
a	O
noncatalytic	O
function	O
of	O
PP2A	B-Complex
.	O

Mitotic	O
chromosomal	O
assembly	O
in	O
vertebrates	O
is	O
regulated	O
by	O
condensin	O
I	O
and	O
condensin	O
II	O
,	O
which	O
work	O
cooperatively	O
but	O
have	O
different	O
chromosomal	O
localization	O
profiles	O
and	O
make	O
distinct	O
mechanistic	O
contributions	O
to	O
this	O
process	O
.	O

We	O
show	O
here	O
that	O
protein	B-Complex
phosphatase	I-Complex
2A	I-Complex
(	O
PP2A	B-Complex
)	O
,	O
which	O
interacts	O
with	O
condensin	O
II	O
but	O
not	O
condensin	O
I	O
,	O
plays	O
an	O
essential	O
role	O
in	O
targeting	O
condensin	O
II	O
to	O
chromosomes	O
.	O

Unexpectedly	O
,	O
our	O
data	O
indicate	O
that	O
PP2A	B-Complex
acts	O
as	O
a	O
recruiter	O
protein	O
rather	O
than	O
a	O
catalytic	O
enzyme	O
to	O
target	O
condensin	O
II	O
to	O
chromosomes	O
.	O

This	O
recruiting	O
activity	O
of	O
PP2A	B-Complex
was	O
inhibited	O
by	O
okadaic	O
acid	O
,	O
but	O
not	O
by	O
fostriecin	O
,	O
even	O
though	O
both	O
molecules	O
strongly	O
inhibited	O
the	O
catalytic	O
activity	O
of	O
PP2A	B-Complex
.	O

Additionally	O
,	O
we	O
found	O
that	O
the	O
chromokinesin	O
KIF4a	O
is	O
also	O
targeted	O
to	O
chromosomes	O
via	O
the	O
noncatalytic	O
activity	O
of	O
PP2A	B-Complex
.	O

Thus	O
,	O
our	O
studies	O
reveal	O
a	O
previously	O
unknown	O
contribution	O
of	O
PP2A	B-Complex
to	O
chromosome	O
assembly	O
.	O

Phosphorylation	O
of	O
VACM	O
-	O
1	O
/	O
Cul5	O
by	O
protein	O
kinase	O
A	O
regulates	O
its	O
neddylation	O
and	O
antiproliferative	O
effect	O
.	O

Expression	O
of	O
the	O
VACM	O
-	O
1	O
/	O
cul5	O
gene	O
in	O
endothelial	O
and	O
in	O
cancer	O
cell	O
lines	O
in	O
vitro	O
inhibits	O
cellular	O
proliferation	O
and	O
decreases	O
phosphorylation	O
of	O
MAPK	O
.	O

Structure	O
-	O
function	O
analysis	O
of	O
the	O
VACM	O
-	O
1	O
protein	O
sequence	O
identified	O
consensus	O
sites	O
specific	O
for	O
phosphorylation	O
by	O
protein	O
kinases	O
A	O
and	O
C	O
(	O
PKA	O
and	O
PKC	O
)	O
and	O
a	O
Nedd8	O
protein	O
modification	O
site	O
.	O

Mutations	O
at	O
the	O
PKA	O
-	O
specific	O
site	O
in	O
VACM	O
-	O
1	O
/	O
Cul5	O
(	O
(	O
S730A	O
)	O
VACM	O
-	O
1	O
)	O
sequence	O
resulted	O
in	O
increased	O
cellular	O
growth	O
and	O
the	O
appearance	O
of	O
a	O
Nedd8	O
-	O
modified	O
VACM	O
-	O
1	O
/	O
Cul5	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
if	O
PKA	O
-	O
dependent	O
phosphorylation	O
of	O
VACM	O
-	O
1	O
/	O
Cul5	O
controls	O
its	O
neddylation	O
status	O
,	O
phosphorylation	O
by	O
PKC	O
,	O
and	O
ultimately	O
growth	O
.	O

Our	O
results	O
indicate	O
that	O
in	O
vitro	O
transfection	O
of	O
rat	O
adrenal	O
medullary	O
endothelial	O
cells	O
with	O
anti	O
-	O
VACM	O
-	O
1	O
-	O
specific	O
small	O
interfering	O
RNA	O
oligonucleotides	O
decreases	O
endogenous	O
VACM	O
-	O
1	O
protein	O
concentration	O
and	O
increases	O
cell	O
growth	O
.	O

Western	O
blot	O
analysis	O
of	O
cell	O
lysates	O
immunoprecipitated	O
with	O
an	O
antibody	O
directed	O
against	O
a	O
PKA	O
-	O
specific	O
phosphorylation	O
site	O
and	O
probed	O
with	O
anti	O
-	O
VACM	O
-	O
1	O
-	O
specific	O
antibody	O
showed	O
that	O
PKA	O
-	O
dependent	O
phosphorylation	O
of	O
VACM	O
-	O
1	O
protein	O
was	O
decreased	O
in	O
cells	O
transfected	O
with	O
(	O
S730A	O
)	O
VACM	O
-	O
1	O
cDNA	O
when	O
compared	O
with	O
the	O
cytomegalovirus	O
-	O
transfected	O
cells	O
.	O

This	O
change	O
was	O
associated	O
with	O
increased	O
modification	O
of	O
VACM	O
-	O
1	O
protein	O
by	O
Nedd8	O
.	O

Induction	O
of	O
PKA	O
activity	O
with	O
forskolin	O
reduced	O
modification	O
of	O
VACM	O
-	O
1	O
protein	O
by	O
Nedd8	O
.	O

Finally	O
,	O
rat	O
adrenal	O
medullary	O
endothelial	O
cells	O
transfected	O
with	O
(	O
S730A	O
)	O
VACM	O
-	O
1	O
/	O
cul5	O
cDNA	O
and	O
treated	O
with	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
10	O
and	O
100	O
nm	O
)	O
to	O
induce	O
PKC	O
activity	O
grew	O
significantly	O
faster	O
than	O
the	O
control	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
antiproliferative	O
effect	O
of	O
VACM	O
-	O
1	O
/	O
Cul5	O
is	O
dependent	O
on	O
its	O
posttranslational	O
modifications	O
and	O
will	O
help	O
in	O
the	O
design	O
of	O
new	O
anticancer	O
therapeutics	O
that	O
target	O
the	O
Nedd8	O
pathway	O
.	O

SUMOylation	O
of	O
human	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
alpha	O
inhibits	O
its	O
trans	O
-	O
activity	O
through	O
the	O
recruitment	O
of	O
the	O
nuclear	O
corepressor	O
NCoR	O
.	O

The	O
nuclear	O
receptor	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
alpha	O
(	O
PPARalpha	O
)	O
is	O
a	O
key	O
regulator	O
of	O
genes	O
implicated	O
in	O
lipid	O
homeostasis	O
and	O
inflammation	O
.	O

PPARalpha	O
trans	O
-	O
activity	O
is	O
enhanced	O
by	O
recruitment	O
of	O
coactivators	O
such	O
as	O
SRC1	O
and	O
CBP	O
/	O
p300	O
and	O
is	O
inhibited	O
by	O
binding	O
of	O
corepressors	O
such	O
as	O
NCoR	O
and	O
SMRT	O
.	O

In	O
addition	O
to	O
ligand	O
binding	O
,	O
PPARalpha	O
activity	O
is	O
regulated	O
by	O
post	O
-	O
translational	O
modifications	O
such	O
as	O
phosphorylation	O
and	O
ubiquitination	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
hPPARalpha	O
is	O
SUMOylated	O
by	O
SUMO	O
-	O
1	O
on	O
lysine	O
185	O
in	O
the	O
hinge	O
region	O
.	O

The	O
E2	O
-	O
conjugating	O
enzyme	O
Ubc9	O
and	O
the	O
SUMO	O
E3	O
-	O
ligase	O
PIASy	O
are	O
implicated	O
in	O
this	O
process	O
.	O

In	O
addition	O
,	O
ligand	O
treatment	O
decreases	O
the	O
SUMOylation	O
rate	O
of	O
hPPARalpha	O
.	O

Finally	O
,	O
our	O
results	O
demonstrate	O
that	O
SUMO	O
-	O
1	O
modification	O
of	O
hPPARalpha	O
down	O
-	O
regulates	O
its	O
trans	O
-	O
activity	O
through	O
the	O
specific	O
recruitment	O
of	O
corepressor	O
NCoR	O
but	O
not	O
SMRT	O
leading	O
to	O
the	O
differential	O
expression	O
of	O
a	O
subset	O
of	O
PPARalpha	O
target	O
genes	O
.	O

In	O
conclusion	O
,	O
hPPARalpha	O
SUMOylation	O
on	O
lysine	O
185	O
down	O
-	O
regulates	O
its	O
trans	O
-	O
activity	O
through	O
the	O
selective	O
recruitment	O
of	O
NCoR	O
.	O

Multiple	O
Ser	O
/	O
Thr	O
-	O
rich	O
degrons	O
mediate	O
the	O
degradation	O
of	O
Ci	O
/	O
Gli	O
by	O
the	O
Cul3	O
-	O
HIB	O
/	O
SPOP	O
E3	O
ubiquitin	O
ligase	O
.	O

The	O
Cul3	O
-	O
based	O
E3	O
ubiquitin	O
ligases	O
regulate	O
many	O
cellular	O
processes	O
using	O
a	O
large	O
family	O
of	O
BTB	O
domain	O
-	O
containing	O
proteins	O
as	O
their	O
target	O
recognition	O
components	O
,	O
but	O
how	O
they	O
recognize	O
targets	O
remains	O
unknown	O
.	O

Here	O
we	O
identify	O
and	O
characterize	O
degrons	O
that	O
mediate	O
the	O
degradation	O
of	O
the	O
Hedgehog	O
pathway	O
transcription	O
factor	O
cubitus	O
interruptus	O
(	O
Ci	O
)	O
/	O
Gli	O
by	O
Cul3	O
-	O
Hedghog	O
-	O
induced	O
MATH	O
and	O
BTB	O
domain	O
-	O
containing	O
protein	O
(	O
HIB	O
)	O
/	O
SPOP	O
.	O

Ci	O
uses	O
multiple	O
Ser	O
/	O
Thr	O
(	O
S	O
/	O
T	O
)	O
-	O
rich	O
motifs	O
that	O
bind	O
HIB	O
cooperatively	O
to	O
mediate	O
its	O
degradation	O
.	O

We	O
provide	O
evidence	O
that	O
both	O
HIB	O
and	O
Ci	O
form	O
dimers	O
/	O
oligomers	O
and	O
engage	O
in	O
multivalent	O
interactions	O
,	O
which	O
underlies	O
the	O
in	O
vivo	O
cooperativity	O
among	O
individual	O
HIB	O
-	O
binding	O
sites	O
.	O

We	O
find	O
that	O
similar	O
S	O
/	O
T	O
-	O
rich	O
motifs	O
are	O
present	O
in	O
Gli	O
proteins	O
as	O
well	O
as	O
in	O
numerous	O
HIB	O
-	O
interacting	O
proteins	O
and	O
mediate	O
Gli	O
degradation	O
by	O
SPOP	O
.	O

Our	O
results	O
provide	O
a	O
mechanistic	O
insight	O
into	O
how	O
HIB	O
/	O
SPOP	O
recognizes	O
its	O
substrates	O
and	O
have	O
important	O
implications	O
for	O
the	O
genome	O
-	O
wide	O
prediction	O
of	O
substrates	O
for	O
Cul3	O
-	O
based	O
E3	O
ligases	O
.	O

Collagen	O
-	O
related	O
peptides	O
(	O
GPO	O
)	O
10	O
,	O
GCO	O
-	O
(	O
GPO	O
)	O
10	O
-	O
GCOG	O
-	O
NH2	O
that	O
recognizes	O
collagen	B-Complex
binding	O
site	O
for	O
GPVI	O
,	O
and	O
the	O
GFOGER	O
peptide	O
,	O
GPC	O
(	O
GPP	O
)	O
5GFOGER	O
(	O
GPP	O
)	O
5GPC	O
that	O
recognizes	O
the	O
integrin	O
alpha2beta1	O
binding	O
site	O
were	O
synthesized	O
by	O
Synbiosci	O
Co	O
.	O

(	O
Livermore	O
,	O
CA	O
)	O
.	O

The	O
RGQOGVMGF	O
peptide	O
,	O
GPC	O
-	O
(	O
GPP	O
)	O
5	O
-	O
GPOGPSGPRGQOGVMGFOGPKGNDGAO	O
-	O
(	O
GPP	O
)	O
5	O
-	O
GPC	O
-	O
NH2	O
that	O
recognizes	O
the	O
vWF	O
binding	O
site	O
in	O
collagen	B-Complex
was	O
synthesized	O
by	O
Biosynthesis	O
,	O
Inc	O
.	O

(	O
Lewisville	O
,	O
TX	O
)	O
.	O

RGQOGVMGF	O
peptide	O
was	O
also	O
obtained	O
without	O
hydroxyproline	O
and	O
referred	O
as	O
RGQPGVMGF	O
peptide	O
.	O

For	O
some	O
control	O
experiments	O
RGQPGVMGF	O
peptide	O
was	O
scrambled	O
(	O
http	O
:	O
/	O
/	O
users	O
.	O
umassmed	O
.	O
edu	O
)	O
and	O
the	O
resulting	O
peptide	O
PGGPDGGF	O
(	O
P	O
)	O
10GPGGKPPNGQGPPSPPGPAGGPGPGMPPGPPGGVPGCGGPGRPPC	O
-	O
NH2	O
synthesized	O
by	O
Biosynthesis	O
Inc	O
(	O
Lewisville	O
,	O
TX	O
)	O
(	O
Supplemental	O
data	O
,	O
Figure	O
S3E	O
)	O
.	O

All	O
peptides	O
were	O
purified	O
by	O
HPLC	O
and	O
the	O
molecular	O
mass	O
estimated	O
by	O
mass	O
spectrometry	O
:	O
(	O
GPO	O
)	O
10	O
(	O
mass	O
spectrum	O
,	O
3294	O
.	O
7	O
da	O
;	O
theoretical	O
,	O
3293	O
.	O
6	O
da	O
)	O
;	O
GFOGER	O
(	O
mass	O
spectrum	O
,	O
3705	O
.	O
3	O
da	O
;	O
theoretical	O
,	O
3704	O
.	O
2	O
da	O
)	O
;	O
RGQOGVMGF	O
(	O
mass	O
spectrum	O
,	O
5573	O
.	O
2	O
da	O
;	O
theoretical	O
,	O
5571	O
.	O
27	O
da	O
)	O
and	O
scrambled	O
RGQPGVMGF	O
(	O
mass	O
spectrum	O
,	O
5511	O
.	O
36	O
;	O
theoretical	O
5511	O
.	O
3	O
da	O
)	O
.	O

For	O
cross	O
-	O
linking	O
,	O
the	O
peptides	O
were	O
re	O
-	O
suspended	O
in	O
PBS	O
and	O
incubated	O
at	O
4degreesC	O
for	O
48	O
hours	O
,	O
or	O
incubated	O
with	O
SPDP	O
(	O
N	O
-	O
succinimimidyl	O
-	O
3	O
-	O
[	O
2	O
-	O
Pyridyldithiol	O
]	O
propionate	O
)	O
reagent	O
from	O
Pierce	O
Co	O
.	O

(	O
Rockford	O
,	O
IL	O
)	O
,	O
as	O
described	O
.	O

Control	O
experiments	O
show	O
that	O
RGQOGVMGF	O
supports	O
vWF	O
binding	O
(	O
Figure	O
3F	O
)	O
,	O
(	O
GPO	O
)	O
10	O
induces	O
platelet	O
aggregation	O
(	O
Figure	O
4C	O
)	O
,	O
and	O
GFOGER	O
supports	O
platelet	O
adhesion	O
in	O
a	O
Ca2	O
+	O
-	O
dependent	O
manner	O
(	O
Figure	O
4D	O
)	O
,	O
indicating	O
that	O
all	O
peptides	O
were	O
biologically	O
active	O
according	O
to	O
appropriate	O
in	O
vitro	O
assays	O
.	O

Interestingly	O
a	O
different	O
Rac	O
GEF	O
,	O
Kalirin	O
,	O
has	O
been	O
reported	O
to	O
promote	O
ARF6	O
-	O
dependent	O
Rac	O
activation	O
downstream	O
of	O
EFA6	O
,	O
another	O
ARF6	O
-	O
GEF	O
.	O

Therefore	O
different	O
ARF	O
-	O
GEFs	O
might	O
not	O
only	O
regulate	O
ARFs	O
at	O
different	O
subcellular	O
locations	O
,	O
they	O
might	O
also	O
couple	O
ARF	O
to	O
different	O
signaling	O
pathways	O
to	O
achieve	O
similar	O
outputs	O
.	O

Clearly	O
much	O
work	O
remains	O
to	O
delineate	O
signaling	O
networks	O
involving	O
ARF6	O
.	O

Noc1p	O
,	O
Noc3p	O
and	O
Noc4p	O
are	O
eukaryotic	O
proteins	O
which	O
play	O
essential	O
roles	O
in	O
yeast	O
ribosome	B-OOS
biogenesis	O
and	O
contain	O
a	O
homologous	O
stretch	O
of	O
about	O
45	O
aminoacids	O
(	O
Noc	O
-	O
domain	O
)	O
of	O
unknown	O
function	O
.	O

Yeast	O
Noc4p	O
is	O
a	O
component	O
of	O
the	O
small	B-Complex
ribosomal	I-Complex
subunit	I-Complex
(	I-Complex
SSU	I-Complex
)	I-Complex
processome	I-Complex
,	O
can	O
be	O
isolated	O
as	O
a	O
stable	O
Noc4p	O
-	O
Nop14p	O
SSU	B-Complex
-	I-Complex
processome	I-Complex
submodule	O
from	O
yeast	O
cells	O
,	O
and	O
is	O
required	O
for	O
nuclear	O
steps	O
of	O
small	B-Complex
ribosomal	I-Complex
subunit	I-Complex
rRNA	O
maturation	O
.	O

We	O
expressed	O
a	O
series	O
of	O
mutated	O
alleles	O
of	O
NOC4	O
in	O
yeast	O
cells	O
and	O
analysed	O
whether	O
the	O
corresponding	O
protein	O
variants	O
support	O
vegetative	O
growth	O
,	O
interact	O
with	O
Nop14p	O
,	O
and	O
are	O
incorporated	O
into	O
the	O
SSU	B-Complex
-	I-Complex
processome	I-Complex
.	O

The	O
data	O
reveal	O
that	O
the	O
essential	O
C	O
-	O
terminus	O
of	O
Noc4p	O
which	O
contains	O
237	O
aminoacids	O
including	O
the	O
Noc	O
-	O
domain	O
represents	O
a	O
protein	O
-	O
protein	O
interaction	O
module	O
.	O

It	O
is	O
required	O
and	O
sufficient	O
for	O
its	O
association	O
with	O
Nop14p	O
and	O
several	O
nuclear	O
precursors	O
of	O
the	O
small	B-Complex
ribosomal	I-Complex
subunit	I-Complex
.	O

The	O
N	O
-	O
terminal	O
Noc4	O
-	O
part	O
seems	O
to	O
be	O
targeted	O
to	O
pre	B-Complex
-	I-Complex
ribosomes	I-Complex
via	O
the	O
C	O
-	O
terminus	O
of	O
Noc4p	O
and	O
plays	O
there	O
an	O
essential	O
role	O
in	O
SSU	B-Complex
-	I-Complex
processome	I-Complex
function	O
.	O

Replacement	O
of	O
the	O
Noc4p	O
-	O
Noc	O
-	O
domain	O
by	O
its	O
homologues	O
Noc1p	O
-	O
counterpart	O
results	O
in	O
a	O
hybrid	O
Noc4p	O
variant	O
which	O
fails	O
to	O
associate	O
with	O
Nop14p	O
and	O
pre	B-Complex
-	I-Complex
ribosomes	I-Complex
.	O

On	O
the	O
other	O
hand	O
,	O
exchange	O
of	O
6	O
amino	O
acids	O
in	O
the	O
Noc1	O
-	O
Noc	O
-	O
domain	O
of	O
this	O
hybrid	O
Noc4p	O
protein	O
is	O
sufficient	O
to	O
restore	O
its	O
essential	O
in	O
vivo	O
functions	O
.	O

These	O
data	O
suggest	O
that	O
Noc	O
-	O
domains	O
of	O
Noc1p	O
and	O
Noc4p	O
share	O
a	O
common	O
structural	O
backbone	O
in	O
which	O
diverging	O
amino	O
acids	O
play	O
crucial	O
roles	O
in	O
mediating	O
specific	O
regulated	O
interactions	O
.	O

Our	O
analysis	O
allows	O
us	O
to	O
distinguish	O
between	O
different	O
functions	O
of	O
certain	O
domains	O
within	O
Noc4p	O
and	O
contribute	O
to	O
the	O
understanding	O
of	O
how	O
incorporation	O
of	O
Noc4p	O
into	O
ribosomal	O
precursors	O
is	O
coupled	O
to	O
rRNA	O
processing	O
and	O
maturation	O
of	O
the	O
small	B-Complex
ribosomal	I-Complex
subunit	I-Complex
.	O

In	O
ChIP	O
assays	O
,	O
the	O
wild	O
-	O
type	O
Txnip	O
promoter	O
was	O
precipitated	O
by	O
both	O
NF	O
-	O
YA	O
and	O
NF	O
-	O
YB	O
antibodies	O
;	O
Txnip	O
promoters	O
with	O
single	O
mutation	O
at	O
the	O
CCAAT	O
box	O
or	O
the	O
inverted	O
CCAAT	O
box	O
were	O
also	O
precipitated	O
by	O
NF	O
-	O
Y	O
antibodies	O
although	O
the	O
signals	O
were	O
reduced	O
;	O
however	O
,	O
the	O
Txnip	O
promoter	O
with	O
mutations	O
at	O
both	O
CCAAT	O
boxes	O
was	O
not	O
pulled	O
-	O
down	O
by	O
NF	O
-	O
Y	O
antibodies	O
(	O
Figure	O
8C	O
)	O
.	O

This	O
confirms	O
that	O
both	O
CCAAT	O
boxes	O
on	O
Txnip	O
promoter	O
are	O
targets	O
of	O
NF	O
-	O
Y	O
,	O
and	O
both	O
sites	O
are	O
required	O
for	O
optimal	O
recruitment	O
of	O
NF	O
-	O
Y	O
onto	O
Txnip	O
promoter	O
.	O

StarD7	O
mediates	O
the	O
intracellular	O
trafficking	O
of	O
phosphatidylcholine	O
to	O
mitochondria	O
.	O

Steroidogenic	O
acute	O
regulatory	O
protein	O
-	O
related	O
lipid	O
transfer	O
(	O
START	O
)	O
domains	O
,	O
found	O
in	O
15	O
mammalian	O
proteins	O
termed	O
StarD1	O
-	O
StarD15	O
,	O
are	O
lipid	O
-	O
binding	O
domains	O
implicated	O
in	O
the	O
intracellular	O
lipid	O
transport	O
systems	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
lipid	O
ligand	O
and	O
function	O
of	O
StarD7	O
.	O

We	O
found	O
two	O
variable	O
forms	O
of	O
mammalian	O
StarD7	O
,	O
termed	O
StarD7	O
-	O
I	O
and	O
StarD7	O
-	O
II	O
.	O

Unlike	O
StarD7	O
-	O
II	O
,	O
StarD7	O
-	O
I	O
contained	O
a	O
mitochondrial	O
-	O
targeting	O
sequence	O
in	O
its	O
N	O
terminus	O
.	O

Overexpressed	O
StarD7	O
-	O
I	O
tagged	O
with	O
V5	O
/	O
His	O
in	O
HEPA	O
-	O
1	O
cells	O
was	O
mainly	O
observed	O
in	O
the	O
mitochondria	O
of	O
cells	O
prepared	O
at	O
low	O
cellular	O
density	O
,	O
but	O
it	O
was	O
distributed	O
in	O
the	O
cytoplasm	O
of	O
high	O
density	O
cells	O
.	O

StarD7	O
-	O
II	O
was	O
constantly	O
distributed	O
in	O
the	O
cytoplasm	O
at	O
any	O
cellular	O
density	O
.	O

Endogenous	O
StarD7	O
in	O
HEPA	O
-	O
1	O
cells	O
and	O
rat	O
liver	O
was	O
also	O
distributed	O
in	O
both	O
the	O
cytoplasm	O
and	O
the	O
mitochondria	O
.	O

A	O
protease	O
K	O
protection	O
assay	O
indicated	O
that	O
the	O
mitochondrial	O
StarD7	O
was	O
associated	O
with	O
the	O
outer	O
mitochondrial	O
membrane	O
.	O

The	O
purified	O
recombinant	O
StarD7	O
specifically	O
catalyzed	O
the	O
transfer	O
of	O
PC	O
between	O
lipid	O
vesicles	O
in	O
vitro	O
.	O

Furthermore	O
,	O
the	O
intracellular	O
transport	O
of	O
fluorescent	O
PC	O
that	O
was	O
exogenously	O
incorporated	O
into	O
the	O
mitochondria	O
was	O
increased	O
in	O
cells	O
that	O
overexpressed	O
StarD7	O
-	O
I	O
.	O

These	O
results	O
suggest	O
that	O
StarD7	O
facilitates	O
the	O
delivery	O
of	O
PC	O
to	O
mitochondria	O
in	O
non	O
-	O
vesicular	O
system	O
.	O

Direct	O
binding	O
of	O
TRAF2	O
and	O
TRAF6	O
to	O
TICAM	O
-	O
1	O
/	O
TRIF	O
adaptor	O
participates	O
in	O
activation	O
of	O
the	O
Toll	O
-	O
like	O
receptor	O
3	O
/	O
4	O
pathway	O
.	O

Using	O
yeast	O
two	O
-	O
hybrid	O
screening	O
,	O
we	O
found	O
three	O
TRAF	O
proteins	O
TRAF1	O
,	O
2	O
and	O
6	O
,	O
bound	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
TLR3	O
/	O
4	O
adaptor	O
TICAM	O
-	O
1	O
(	O
TRIF	O
)	O
.	O

TRAF2	O
,	O
a	O
newly	O
identified	O
TICAM	O
-	O
1	O
-	O
binding	O
protein	O
,	O
bound	O
the	O
PxQxS	O
motif	O
(	O
aa	O
333	O
-	O
338	O
)	O
of	O
TICAM	O
-	O
1	O
using	O
mutagenesis	O
by	O
alanine	O
substitutions	O
.	O

TICAM	O
-	O
1	O
is	O
known	O
to	O
induce	O
the	O
activation	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
and	O
IRF	O
-	O
3	O
,	O
which	O
leads	O
to	O
activation	O
of	O
the	O
interferon	O
(	O
IFN	O
)	O
-	O
beta	O
promoter	O
,	O
an	O
activity	O
that	O
is	O
conserved	O
in	O
the	O
N	O
+	O
TIR	O
fragment	O
(	O
aa	O
1	O
-	O
533	O
)	O
.	O

By	O
mutation	O
of	O
the	O
two	O
distinct	O
binding	O
sites	O
for	O
TRAF2	O
and	O
TRAF6	O
in	O
N	O
+	O
TIR	O
TICAM	O
-	O
1	O
,	O
the	O
induction	O
of	O
IFN	O
-	O
beta	O
was	O
completely	O
abrogated	O
.	O

Although	O
the	O
TRAF2	O
site	O
single	O
mutation	O
only	O
marginally	O
affected	O
TICAM	O
-	O
1	O
-	O
mediated	O
type	O
I	O
IFN	O
induction	O
,	O
it	O
further	O
impaired	O
the	O
function	O
of	O
the	O
TRAF6	O
site	O
mutant	O
.	O

Moreover	O
,	O
double	O
point	O
mutations	O
of	O
the	O
TRAF2	O
and	O
TRAF6	O
binding	O
motifs	O
in	O
TICAM	O
-	O
1	O
N	O
+	O
TIR	O
reduced	O
the	O
activation	O
of	O
IRF	O
-	O
3	O
and	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
,	O
the	O
critical	O
transcription	O
factors	O
for	O
IFN	O
-	O
beta	O
expression	O
.	O

Furthermore	O
,	O
TRAF2	O
/	O
6	O
functioned	O
as	O
an	O
E3	O
ligase	O
to	O
induce	O
K63	O
-	O
mediated	O
ubiquitination	O
on	O
N	O
+	O
TIR	O
which	O
was	O
abrogated	O
in	O
the	O
mutant	O
lacking	O
the	O
TRAF2	O
/	O
6	O
sites	O
in	O
parallel	O
with	O
IFN	O
-	O
inducing	O
activity	O
.	O

Confocal	O
microscopy	O
analysis	O
indicated	O
that	O
TRAF2	O
and	O
TRAF6	O
merged	O
with	O
oligomerized	O
(	O
i	O
.	O
e	O
.	O
activated	O
)	O
TICAM	O
-	O
1	O
N	O
+	O
TIR	O
.	O

However	O
,	O
TRAF3	O
,	O
which	O
is	O
another	O
TRAF	O
family	O
member	O
essential	O
for	O
TLR3	O
-	O
mediated	O
type	O
-	O
I	O
IFN	O
signaling	O
,	O
still	O
assembled	O
in	O
the	O
mutant	O
lacking	O
the	O
TRAF2	O
/	O
6	O
sites	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
binding	O
of	O
TRAF2	O
and	O
TRAF6	O
to	O
TICAM	O
-	O
1	O
cooperatively	O
activates	O
the	O
IFN	O
-	O
inducing	O
pathway	O
through	O
ubiquitination	O
of	O
TICAM	O
-	O
1	O
,	O
a	O
modification	O
which	O
occurs	O
unrelated	O
to	O
TRAF3	O
recruitment	O
in	O
the	O
TICAM	O
-	O
1	O
signaling	O
complex	O
.	O

TRAF2	O
/	O
6	O
may	O
participate	O
in	O
TICAM	O
-	O
1	O
-	O
mediated	O
IFN	O
-	O
beta	O
induction	O
besides	O
TRAF3	O
.	O

Mechanism	O
of	O
action	O
of	O
oral	O
fingolimod	O
(	O
FTY720	O
)	O
in	O
multiple	O
sclerosis	O
.	O

Fingolimod	O
(	O
FTY720	O
)	O
is	O
a	O
first	O
-	O
in	O
-	O
class	O
orally	O
bioavailable	O
compound	O
that	O
has	O
shown	O
efficacy	O
in	O
advanced	O
clinical	O
trials	O
for	O
the	O
treatment	O
of	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
.	O

In	O
vivo	O
,	O
fingolimod	O
is	O
phosphorylated	O
to	O
form	O
fingolimod	O
-	O
phosphate	O
,	O
which	O
resembles	O
naturally	O
occurring	O
sphingosine	O
1	O
-	O
phosphate	O
(	O
S1P	O
)	O
,	O
an	O
extracellular	O
lipid	O
mediator	O
whose	O
major	O
effects	O
are	O
mediated	O
by	O
cognate	O
G	O
protein	O
-	O
coupled	O
receptors	O
.	O

There	O
are	O
at	O
least	O
5	O
S1P	O
receptor	O
subtypes	O
,	O
known	O
as	O
S1P	O
subtypes	O
1	O
-	O
5	O
(	O
S1P1	O
-	O
5	O
)	O
,	O
4	O
of	O
which	O
bind	O
fingolimod	O
-	O
phosphate	O
.	O

These	O
receptors	O
are	O
expressed	O
on	O
a	O
wide	O
range	O
of	O
cells	O
that	O
are	O
involved	O
in	O
many	O
biological	O
processes	O
relevant	O
to	O
MS	O
.	O

S1P1	O
plays	O
a	O
key	O
role	O
in	O
the	O
immune	O
system	O
,	O
regulating	O
lymphocyte	O
egress	O
from	O
lymphoid	O
tissues	O
into	O
the	O
circulation	O
.	O

Fingolimod	O
-	O
phosphate	O
initially	O
activates	O
lymphocyte	O
S1P1	O
via	O
high	O
-	O
affinity	O
receptor	O
binding	O
yet	O
subsequently	O
induces	O
S1P1	O
down	O
-	O
regulation	O
that	O
prevents	O
lymphocyte	O
egress	O
from	O
lymphoid	O
tissues	O
,	O
thereby	O
reducing	O
autoaggressive	O
lymphocyte	O
infiltration	O
into	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

S1P	O
receptors	O
are	O
also	O
expressed	O
by	O
many	O
CNS	O
cell	O
types	O
and	O
have	O
been	O
shown	O
to	O
influence	O
cell	O
proliferation	O
,	O
morphology	O
,	O
and	O
migration	O
.	O

Fingolimod	O
crosses	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
may	O
therefore	O
have	O
direct	O
CNS	O
effects	O
,	O
distinguishing	O
it	O
from	O
immunologically	O
targeted	O
MS	O
therapies	O
.	O

Prophylactic	O
administration	O
of	O
fingolimod	O
to	O
animals	O
with	O
experimental	O
autoimmune	O
encephalitis	O
(	O
EAE	O
)	O
,	O
a	O
model	O
of	O
MS	O
,	O
completely	O
prevents	O
development	O
of	O
EAE	O
features	O
,	O
whereas	O
therapeutic	O
administration	O
significantly	O
reduces	O
clinical	O
severity	O
of	O
EAE	O
.	O

Therapeutic	O
efficacy	O
observed	O
in	O
animal	O
studies	O
has	O
been	O
substantiated	O
in	O
phase	O
2	O
and	O
3	O
trials	O
involving	O
patients	O
with	O
relapsing	O
or	O
relapsing	O
-	O
remitting	O
MS	O
.	O

Regulation	O
of	O
SNAP	O
-	O
25	O
trafficking	O
and	O
function	O
by	O
palmitoylation	O
.	O

The	O
SNARE	B-Complex
(	O
soluble	B-Complex
N	I-Complex
-	I-Complex
ethylmaleimide	I-Complex
-	I-Complex
sensitive	I-Complex
fusion	I-Complex
protein	I-Complex
-	I-Complex
attachment	I-Complex
protein	I-Complex
receptor	I-Complex
)	I-Complex
protein	O
SNAP	O
-	O
25	O
(	O
25	O
kDa	O
synaptosome	O
-	O
associated	O
protein	O
)	O
is	O
essential	O
for	O
regulated	O
exocytosis	O
in	O
neuronal	O
and	O
neuroendocrine	O
cells	O
.	O

Whereas	O
the	O
majority	O
of	O
SNARE	B-Complex
proteins	O
contain	O
transmembrane	O
domains	O
,	O
SNAP	O
-	O
25	O
is	O
instead	O
anchored	O
to	O
membranes	O
by	O
the	O
palmitoylation	O
of	O
a	O
central	O
cysteine	O
-	O
rich	O
region	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
mechanisms	O
of	O
SNAP	O
-	O
25	O
palmitoylation	O
and	O
how	O
this	O
modification	O
regulates	O
the	O
intracellular	O
trafficking	O
and	O
exocytotic	O
function	O
of	O
this	O
essential	O
protein	O
.	O

UBR2	O
mediates	O
transcriptional	O
silencing	O
during	O
spermatogenesis	O
via	O
histone	O
ubiquitination	O
.	O

Ubiquitination	O
of	O
histones	O
provides	O
an	O
important	O
mechanism	O
regulating	O
chromatin	O
remodeling	O
and	O
gene	O
expression	O
.	O

Recent	O
studies	O
have	O
revealed	O
ubiquitin	O
ligases	O
involved	O
in	O
histone	O
ubiquitination	O
,	O
yet	O
the	O
responsible	O
enzymes	O
and	O
the	O
function	O
of	O
histone	O
ubiquitination	O
in	O
spermatogenesis	O
remain	O
unclear	O
.	O

We	O
have	O
previously	O
shown	O
that	O
mice	O
lacking	O
the	O
ubiquitin	O
ligase	O
UBR2	O
,	O
one	O
of	O
the	O
recognition	O
E3	O
components	O
of	O
the	O
N	O
-	O
end	O
rule	O
proteolytic	O
pathway	O
,	O
are	O
infertile	O
associated	O
with	O
meiotic	O
arrest	O
at	O
prophase	O
I	O
.	O

We	O
here	O
show	O
that	O
UBR2	O
localizes	O
to	O
meiotic	O
chromatin	O
regions	O
,	O
including	O
unsynapsed	O
axial	O
elements	O
linked	O
to	O
chromatin	O
inactivation	O
,	O
and	O
mediates	O
transcriptional	O
silencing	O
via	O
the	O
ubiquitination	O
of	O
histone	O
H2A	O
.	O

UBR2	O
interacts	O
with	O
the	O
ubiquitin	O
conjugating	O
enzyme	O
HR6B	O
and	O
its	O
substrate	O
H2A	O
and	O
promotes	O
the	O
HR6B	O
-	O
H2A	O
interaction	O
and	O
the	O
HR6B	O
-	O
to	O
-	O
H2A	O
transfer	O
of	O
ubiquitin	O
.	O

UBR2	O
and	O
ubiquitinated	O
H2A	O
(	O
uH2A	O
)	O
spatiotemporally	O
mark	O
meiotic	O
chromatin	O
regions	O
subject	O
to	O
transcriptional	O
silencing	O
,	O
and	O
UBR2	O
-	O
deficient	O
spermatocytes	O
fail	O
to	O
induce	O
the	O
ubiquitination	O
of	O
H2A	O
during	O
meiosis	O
.	O

UBR2	O
-	O
deficient	O
spermatocytes	O
are	O
profoundly	O
impaired	O
in	O
chromosome	O
-	O
wide	O
transcriptional	O
silencing	O
of	O
genes	O
linked	O
to	O
unsynapsed	O
axes	O
of	O
the	O
X	O
and	O
Y	O
chromosomes	O
.	O

Our	O
findings	O
suggest	O
that	O
insufficiency	O
in	O
UBR2	O
-	O
dependent	O
histone	O
ubiquitination	O
triggers	O
a	O
pachytene	O
checkpoint	O
system	O
,	O
providing	O
a	O
new	O
insight	O
into	O
chromatin	O
remodeling	O
and	O
gene	O
expression	O
regulation	O
.	O

Dual	O
-	O
specificity	O
histone	O
demethylase	O
KIAA1718	O
(	O
KDM7A	O
)	O
regulates	O
neural	O
differentiation	O
through	O
FGF4	O
.	O

Dimethylations	O
of	O
histone	O
H3	O
lysine	O
9	O
and	O
lysine	O
27	O
are	O
important	O
epigenetic	O
marks	O
associated	O
with	O
transcription	O
repression	O
.	O

Here	O
,	O
we	O
identified	O
KIAA1718	O
(	O
KDM7A	O
)	O
as	O
a	O
novel	O
histone	O
demethylase	O
specific	O
for	O
these	O
two	O
repressing	O
marks	O
.	O

Using	O
mouse	O
embryonic	O
stem	O
cells	O
,	O
we	O
demonstrated	O
that	O
KIAA1718	O
expression	O
increased	O
at	O
the	O
early	O
phase	O
of	O
neural	O
differentiation	O
.	O

Knockdown	O
of	O
the	O
gene	O
blocked	O
neural	O
differentiation	O
and	O
the	O
effect	O
was	O
rescued	O
by	O
the	O
wild	O
-	O
type	O
human	O
gene	O
,	O
and	O
not	O
by	O
a	O
catalytically	O
inactive	O
mutant	O
.	O

In	O
addition	O
,	O
overexpression	O
of	O
KIAA1718	O
accelerated	O
neural	O
differentiation	O
.	O

We	O
provide	O
the	O
evidence	O
that	O
the	O
pro	O
-	O
neural	O
differentiation	O
effect	O
of	O
KDM7A	O
is	O
mediated	O
through	O
direct	O
transcriptional	O
activation	O
of	O
FGF4	O
,	O
a	O
signal	O
molecule	O
implicated	O
in	O
neural	O
differentiation	O
.	O

Thus	O
,	O
our	O
study	O
identified	O
a	O
dual	O
-	O
specificity	O
histone	O
demethylase	O
that	O
regulates	O
neural	O
differentiation	O
through	O
FGF4	O
.	O

A	O
role	O
for	O
non	O
-	O
covalent	O
SUMO	O
interaction	O
motifs	O
in	O
Pc2	O
/	O
CBX4	O
E3	O
activity	O
.	O

BACKGROUND	O
:	O
Modification	O
of	O
proteins	O
by	O
the	O
small	O
ubiquitin	O
like	O
modifier	O
(	O
SUMO	O
)	O
is	O
an	O
essential	O
process	O
in	O
mammalian	O
cells	O
.	O

SUMO	O
is	O
covalently	O
attached	O
to	O
lysines	O
in	O
target	O
proteins	O
via	O
an	O
enzymatic	O
cascade	O
which	O
consists	O
of	O
E1	O
and	O
E2	O
,	O
SUMO	O
activating	O
and	O
conjugating	O
enzymes	O
.	O

There	O
is	O
also	O
a	O
variable	O
requirement	O
for	O
non	O
-	O
enzymatic	O
E3	O
adapter	O
like	O
proteins	O
,	O
which	O
can	O
increase	O
the	O
efficiency	O
and	O
specificity	O
of	O
the	O
sumoylation	O
process	O
.	O

In	O
addition	O
to	O
covalent	O
attachment	O
of	O
SUMO	O
to	O
target	O
proteins	O
,	O
specific	O
non	O
-	O
covalent	O
SUMO	O
interaction	O
motifs	O
(	O
SIMs	O
)	O
that	O
are	O
generally	O
short	O
hydrophobic	O
peptide	O
motifs	O
have	O
been	O
identified	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
Intriguingly	O
,	O
consensus	O
SIMs	O
are	O
present	O
in	O
most	O
SUMO	O
E3s	O
,	O
including	O
the	O
polycomb	O
protein	O
,	O
Pc2	O
/	O
Cbx4	O
.	O

However	O
,	O
a	O
role	O
for	O
SIMs	O
in	O
SUMO	O
E3	O
activity	O
remains	O
to	O
be	O
shown	O
.	O

We	O
show	O
that	O
Pc2	O
contains	O
two	O
functional	O
SIMs	O
,	O
both	O
of	O
which	O
contribute	O
to	O
full	O
E3	O
activity	O
in	O
mammalian	O
cells	O
,	O
and	O
are	O
also	O
required	O
for	O
sumoylation	O
of	O
Pc2	O
itself	O
.	O

Pc2	O
forms	O
distinct	O
sub	O
-	O
nuclear	O
foci	O
,	O
termed	O
polycomb	O
bodies	O
,	O
and	O
can	O
recruit	O
partner	O
proteins	O
,	O
such	O
as	O
the	O
corepressor	O
CtBP	O
.	O

We	O
demonstrate	O
that	O
mutation	O
of	O
the	O
SIMs	O
in	O
Pc2	O
prevents	O
Pc2	O
-	O
dependent	O
CtBP	O
sumoylation	O
,	O
and	O
decreases	O
enrichment	O
of	O
SUMO1	O
and	O
SUMO2	O
at	O
polycomb	O
foci	O
.	O

Furthermore	O
,	O
mutational	O
analysis	O
of	O
both	O
SUMO1	O
and	O
SUMO2	O
reveals	O
that	O
the	O
SIM	O
-	O
interacting	O
residues	O
of	O
both	O
SUMO	O
isoforms	O
are	O
required	O
for	O
Pc2	O
-	O
mediated	O
sumoylation	O
and	O
localization	O
to	O
polycomb	O
foci	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
This	O
work	O
provides	O
the	O
first	O
clear	O
evidence	O
for	O
a	O
role	O
for	O
SIMs	O
in	O
SUMO	O
E3	O
activity	O
.	O

NUB1	O
promotes	O
cytoplasmic	O
localization	O
of	O
p53	O
through	O
cooperation	O
of	O
the	O
NEDD8	O
and	O
ubiquitin	O
pathways	O
.	O

Non	O
-	O
covalent	O
recognition	O
of	O
ubiquitin	O
(	O
Ub	O
)	O
and	O
ubiquitin	O
-	O
like	O
molecules	O
(	O
Ubls	O
)	O
by	O
interacting	O
proteins	O
has	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
protein	O
function	O
and	O
initiation	O
of	O
signalling	O
events	O
.	O

In	O
addition	O
,	O
growing	O
evidence	O
suggests	O
that	O
regulation	O
of	O
p53	O
subcellular	O
localization	O
contributes	O
to	O
the	O
biological	O
outcome	O
of	O
the	O
p53	O
response	O
.	O

Cytoplasmic	O
p53	O
is	O
shown	O
to	O
promote	O
apoptosis	O
and	O
inhibit	O
the	O
induction	O
of	O
autophagy	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
NEDD8	O
ultimate	O
buster	O
1	O
(	O
NUB1	O
)	O
,	O
a	O
non	O
-	O
covalent	O
interactor	O
of	O
the	O
Ubl	O
NEDD8	O
(	O
neural	O
precursor	O
cell	O
expressed	O
,	O
developmentally	O
downregulated	O
8	O
)	O
,	O
controls	O
the	O
localization	O
of	O
p53	O
.	O

Expression	O
of	O
NUB1	O
leads	O
to	O
decreased	O
modification	O
of	O
p53	O
with	O
NEDD8	O
and	O
stimulation	O
of	O
p53	O
ubiquitination	O
.	O

The	O
biological	O
outcome	O
is	O
the	O
cytoplasmic	O
localization	O
and	O
inhibition	O
of	O
the	O
transcriptional	O
activity	O
of	O
p53	O
.	O

Although	O
the	O
effects	O
of	O
NUB1	O
on	O
p53	O
depend	O
on	O
NEDDylation	O
and	O
the	O
murine	O
double	O
minute	O
2	O
(	O
Mdm2	O
)	O
E3	O
-	O
ligase	O
,	O
the	O
cooperation	O
of	O
NEDD8	O
with	O
ubiquitin	O
is	O
required	O
.	O

The	O
data	O
identify	O
a	O
role	O
for	O
NEDD8	O
in	O
controlling	O
p53	O
localization	O
and	O
suggest	O
that	O
NEDD8	O
can	O
control	O
protein	O
function	O
through	O
its	O
non	O
-	O
covalent	O
recognition	O
by	O
interacting	O
proteins	O
.	O

The	O
molecular	O
chaperone	O
Hsp90	O
regulates	O
accumulation	O
of	O
DNA	O
polymerase	O
eta	O
at	O
replication	O
stalling	O
sites	O
in	O
UV	O
-	O
irradiated	O
cells	O
.	O

DNA	O
polymerase	O
eta	O
(	O
Pol	O
eta	O
)	O
is	O
a	O
member	O
of	O
the	O
mammalian	O
Y	O
family	O
polymerases	O
and	O
performs	O
error	O
-	O
free	O
translesion	O
synthesis	O
across	O
UV	O
-	O
damaged	O
DNA	O
.	O

For	O
this	O
function	O
,	O
Pol	O
eta	O
accumulates	O
in	O
nuclear	O
foci	O
at	O
replication	O
stalling	O
sites	O
via	O
its	O
interaction	O
with	O
monoubiquitinated	O
PCNA	B-OOS
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
posttranslational	O
control	O
mechanisms	O
of	O
Pol	O
eta	O
,	O
which	O
regulate	O
its	O
accumulation	O
in	O
replication	O
foci	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
molecular	O
chaperone	O
Hsp90	O
promotes	O
UV	O
irradiation	O
-	O
induced	O
nuclear	O
focus	O
formation	O
of	O
Pol	O
eta	O
through	O
control	O
of	O
its	O
stability	O
and	O
binding	O
to	O
monoubiquitinated	O
PCNA	B-OOS
.	O

Our	O
data	O
indicate	O
that	O
Hsp90	O
facilitates	O
the	O
folding	O
of	O
Pol	O
eta	O
into	O
an	O
active	O
form	O
in	O
which	O
PCNA	B-OOS
-	O
and	O
ubiquitin	O
-	O
binding	O
regions	O
are	O
functional	O
.	O

Furthermore	O
,	O
Hsp90	O
inhibition	O
potentiates	O
UV	O
-	O
induced	O
cytotoxicity	O
and	O
mutagenesis	O
in	O
a	O
Pol	O
eta	O
-	O
dependent	O
manner	O
.	O

Our	O
studies	O
identify	O
Hsp90	O
as	O
an	O
essential	O
regulator	O
of	O
Pol	O
eta	O
-	O
mediated	O
translesion	O
synthesis	O
.	O

Fission	O
yeast	O
TORC1	B-Complex
regulates	O
phosphorylation	O
of	O
ribosomal	O
S6	O
proteins	O
in	O
response	O
to	O
nutrients	O
and	O
its	O
activity	O
is	O
inhibited	O
by	O
rapamycin	O
.	O

Cellular	O
activities	O
are	O
regulated	O
by	O
environmental	O
stimuli	O
through	O
protein	O
phosphorylation	O
.	O

Target	O
of	O
rapamycin	O
(	O
TOR	O
)	O
,	O
a	O
serine	O
/	O
threonine	O
kinase	O
,	O
plays	O
pivotal	O
roles	O
in	O
cell	O
proliferation	O
and	O
cell	O
growth	O
in	O
response	O
to	O
nutrient	O
status	O
.	O

In	O
Schizosaccharomyces	O
pombe	O
,	O
TORC1	B-Complex
,	O
which	O
contains	O
Tor2	O
,	O
plays	O
crucial	O
roles	O
in	O
nutrient	O
response	O
.	O

Here	O
we	O
find	O
a	O
nitrogen	O
-	O
regulated	O
phosphoprotein	O
,	O
p27	O
,	O
in	O
S	O
.	O
pombe	O
using	O
the	O
phospho	O
-	O
Akt	O
substrate	O
antibody	O
.	O

Response	O
of	O
p27	O
phosphorylation	O
to	O
nitrogen	O
availability	O
is	O
mediated	O
by	O
TORC1	B-Complex
and	O
the	O
TSC	O
-	O
Rhb1	O
signaling	O
,	O
but	O
not	O
by	O
TORC2	B-Complex
or	O
other	O
nutrient	O
stress	O
-	O
related	O
pathways	O
.	O

Database	O
and	O
biochemical	O
analyses	O
indicate	O
that	O
p27	O
is	O
identical	O
to	O
ribosomal	O
protein	O
S6	O
(	O
Rps6	O
)	O
.	O

Ser235	O
and	O
Ser236	O
in	O
Rps6	O
are	O
necessary	O
for	O
Rps6	O
phosphorylation	O
by	O
TORC1	B-Complex
.	O

These	O
Rps6	O
phosphorylations	O
are	O
dispensable	O
for	O
cell	O
viability	O
.	O

Rps6	O
phosphorylation	O
by	O
TORC1	B-Complex
also	O
responds	O
to	O
availability	O
of	O
glucose	O
and	O
is	O
inhibited	O
by	O
osmotic	O
and	O
oxidative	O
stresses	O
.	O

Rapamycin	O
inhibits	O
the	O
ability	O
of	O
TORC1	B-Complex
to	O
phosphorylate	O
Rps6	O
,	O
owing	O
to	O
interaction	O
of	O
the	O
rapamycin	O
-	O
FKBP12	O
complex	O
with	O
the	O
FRB	O
domain	O
in	O
Tor2	O
.	O

Rapamycin	O
also	O
leads	O
to	O
a	O
decrease	O
in	O
cell	O
size	O
in	O
a	O
TORC1	B-Complex
-	O
dependent	O
manner	O
.	O

Our	O
findings	O
demonstrate	O
that	O
the	O
nutrient	O
-	O
responsive	O
and	O
rapamycin	O
-	O
sensitive	O
TORC1	B-Complex
-	O
S6	O
signaling	O
exists	O
in	O
S	O
.	O
pombe	O
,	O
and	O
that	O
this	O
pathway	O
plays	O
a	O
role	O
in	O
cell	O
size	O
control	O
.	O

The	O
27	O
-	O
amino	O
acid	O
region	O
from	O
the	O
D	O
-	O
AKAP2	O
AKB	O
(	O
residues	O
623	O
-	O
650	O
)	O
was	O
synthesized	O
and	O
purified	O
to	O
greater	O
than	O
95	O
%	O
purity	O
by	O
HPLC	O
(	O
Peptron	O
,	O
Inc	O
)	O
.	O

The	O
last	O
residue	O
was	O
changed	O
to	O
Cys	O
for	O
fluorescent	O
labeling	O
.	O

0	O
.	O
5	O
mg	O
of	O
protein	O
was	O
incubated	O
overnight	O
with	O
a	O
2	O
-	O
fold	O
molar	O
excess	O
of	O
fluorescin	O
-	O
5	O
-	O
maleimide	O
or	O
tetramethylrhodamine	O
-	O
5	O
-	O
maleimide	O
(	O
Molecular	O
Probes	O
,	O
Inc	O
.	O
)	O
.	O

The	O
labeled	O
peptides	O
were	O
purified	O
by	O
HPLC	O
and	O
excess	O
organic	O
solvent	O
was	O
evaporated	O
on	O
a	O
Speed	O
Vac	O
(	O
Savant	O
,	O
Inc	O
.	O
)	O
.	O

Concentrations	O
were	O
determined	O
using	O
absorbance	O
at	O
485	O
nm	O
(	O
epsilon485nm	O
=	O
90000	O
M	O
-	O
1	O
cm	O
-	O
1	O
)	O
and	O
541	O
nm	O
(	O
epsilon541nm	O
=	O
91000	O
M	O
-	O
1	O
cm	O
-	O
1	O
)	O
for	O
the	O
fluorescein	O
-	O
and	O
rhodamine	O
-	O
labeled	O
peptides	O
,	O
respectively	O
.	O

Binding	O
studies	O
with	O
full	O
-	O
length	O
and	O
mutant	O
proteins	O
were	O
carried	O
out	O
as	O
previously	O
described	O
.	O

To	O
further	O
prove	O
that	O
HES1	O
negatively	O
regulates	O
DTX1	O
expression	O
,	O
we	O
made	O
a	O
dominant	O
negative	O
human	O
HES1	O
(	O
dnHES1	O
)	O
by	O
mutating	O
three	O
amino	O
acids	O
critical	O
for	O
DNA	O
binding	O
while	O
leaving	O
dimerization	O
motifs	O
intact	O
.	O

HES1	O
binds	O
to	O
and	O
inhibits	O
the	O
activity	O
of	O
its	O
own	O
promoter	O
,	O
which	O
can	O
be	O
shown	O
with	O
reporter	O
construct	O
HES1	O
-	O
AB	O
.	O

In	O
293T	O
cells	O
,	O
expression	O
of	O
HES1	O
suppressed	O
HES1	O
-	O
AB	O
promoter	O
activity	O
,	O
but	O
adding	O
dnHES1	O
reversed	O
HES1	O
-	O
mediated	O
inhibition	O
of	O
Hes1	O
-	O
AB	O
(	O
Figure	O
4A	O
)	O
.	O

Similar	O
results	O
were	O
found	O
in	O
OS187	O
cells	O
(	O
data	O
not	O
shown	O
)	O
,	O
confirming	O
that	O
dnHES1	O
blocks	O
HES1	O
function	O
.	O

Then	O
,	O
we	O
tested	O
whether	O
dnHES1	O
could	O
block	O
HES1	O
-	O
mediated	O
inhibition	O
of	O
DTX1	O
transcription	O
in	O
osteosarcoma	O
.	O

Transduction	O
with	O
dnHES1	O
upregulated	O
DTX1	O
transcription	O
in	O
three	O
osteosarcoma	O
cell	O
lines	O
(	O
Figure	O
4B	O
)	O
,	O
indicating	O
that	O
HES1	O
suppressed	O
DTX1	O
expression	O
in	O
osteosarcoma	O
.	O

Expression	O
of	O
HASH1	O
,	O
a	O
known	O
HES1	O
target	O
,	O
also	O
was	O
upregulated	O
by	O
dnHES1	O
(	O
Figure	O
4B	O
and	O
4C	O
)	O
in	O
parallel	O
with	O
DTX1	O
.	O

The	O
interaction	O
between	O
full	O
-	O
length	O
MOR	O
and	O
GPR177	O
was	O
verified	O
in	O
co	O
-	O
immunoprecipitation	O
(	O
CoIP	O
)	O
experiments	O
.	O

To	O
demonstrate	O
interaction	O
,	O
we	O
tested	O
the	O
ability	O
of	O
an	O
anti	O
-	O
MOR	O
antibody	O
to	O
coimmunoprecipitate	O
GPR177	O
from	O
lysates	O
prepared	O
from	O
HEK293	O
cells	O
stably	O
expressing	O
FLAG	O
-	O
tagged	O
MORs	O
(	O
293	O
-	O
MOR	O
cells	O
)	O
and	O
transiently	O
transfected	O
with	O
a	O
FLAG	O
/	O
6x	O
His	O
-	O
tagged	O
GPR177	O
construct	O
.	O

293	O
-	O
MOR	O
cells	O
were	O
a	O
generous	O
gift	O
from	O
Dr	O
.	O
Mark	O
von	O
Zastrow	O
(	O
UCSF	O
)	O
.	O

Preliminary	O
Western	O
blot	O
analysis	O
(	O
Additional	O
file	O
1	O
,	O
Figure	O
S1A	O
)	O
revealed	O
that	O
the	O
anti	O
-	O
MOR	O
antibody	O
specifically	O
immunoprecipitated	O
(	O
IP	O
)	O
the	O
mu	O
-	O
opioid	O
receptor	O
from	O
293	O
-	O
MOR	O
cells	O
.	O

Lysates	O
from	O
transfected	O
cells	O
were	O
immunoprecipitated	O
using	O
the	O
anti	O
-	O
MOR	O
antibody	O
,	O
and	O
immunocomplexes	O
probed	O
with	O
chicken	O
anti	O
-	O
GPR177	O
antibodies	O
.	O

As	O
shown	O
in	O
Figure	O
2B	O
,	O
an	O
immunoreactive	O
band	O
of	O
~	O
50	O
kDA	O
,	O
the	O
predicted	O
size	O
of	O
GPR177	O
,	O
was	O
detected	O
in	O
lysates	O
prepared	O
from	O
transfected	O
cells	O
with	O
the	O
anti	O
-	O
GPR177	O
antibody	O
.	O

A	O
band	O
migrating	O
with	O
the	O
identical	O
molecular	O
mass	O
was	O
detected	O
in	O
the	O
IP	O
lane	O
,	O
but	O
not	O
in	O
IPs	O
from	O
cells	O
lacking	O
MOR	O
expression	O
(	O
-	O
MOR	O
lane	O
)	O
,	O
IPs	O
from	O
293	O
-	O
MOR	O
cells	O
not	O
transfected	O
with	O
GPR177	O
(	O
-	O
GPR	O
lane	O
)	O
,	O
or	O
mock	O
IPs	O
(	O
mock	O
lane	O
)	O
.	O

The	O
specificity	O
of	O
the	O
anti	O
-	O
GPR177	O
antisera	O
was	O
ascertained	O
by	O
transfecting	O
a	O
FLAG	O
/	O
6x	O
His	O
-	O
tagged	O
GPR177	O
cDNA	O
into	O
HEK293	O
cells	O
.	O

A	O
Western	O
blot	O
containing	O
lysate	O
prepared	O
from	O
transfected	O
cells	O
was	O
first	O
probed	O
with	O
anti	O
-	O
FLAG	O
antibodies	O
,	O
then	O
stripped	O
and	O
reprobed	O
with	O
anti	O
-	O
GPR177	O
antibodies	O
.	O

A	O
band	O
migrating	O
with	O
the	O
identical	O
molecular	O
mass	O
was	O
detected	O
with	O
anti	O
-	O
FLAG	O
and	O
anti	O
-	O
GPR177	O
antibodies	O
(	O
Additional	O
file	O
1	O
,	O
Figure	O
S1B	O
)	O
,	O
indicating	O
that	O
the	O
GPR177	O
antibodies	O
react	O
specifically	O
with	O
GPR177	O
.	O

Using	O
BRET	O
to	O
study	O
chemical	O
compound	O
-	O
induced	O
disruptions	O
of	O
the	O
p53	O
-	O
HDM2	O
interactions	O
in	O
live	O
cells	O
.	O

Modification	O
of	O
protein	O
-	O
protein	O
interactions	O
(	O
PPIs	O
)	O
holds	O
promise	O
for	O
novel	O
rational	O
drug	O
design	O
.	O

Disrupting	O
or	O
modifying	O
protein	O
interactions	O
offers	O
new	O
challenges	O
in	O
terms	O
of	O
chemical	O
compound	O
libraries	O
and	O
techniques	O
for	O
compound	O
validation	O
.	O

As	O
proteins	O
interact	O
with	O
several	O
partners	O
in	O
different	O
allosteric	O
conformation	O
in	O
a	O
pathological	O
and	O
tissue	O
-	O
specific	O
fashion	O
,	O
it	O
is	O
difficult	O
to	O
predict	O
the	O
in	O
vivo	O
effect	O
of	O
PPI	O
acting	O
compounds	O
identified	O
by	O
in	O
vitro	O
screening	O
assays	O
.	O

It	O
is	O
therefore	O
desirable	O
to	O
develop	O
techniques	O
that	O
rapidly	O
allow	O
cell	O
-	O
based	O
validation	O
of	O
protein	O
interacting	O
compounds	O
.	O

The	O
binding	O
of	O
the	O
p53	O
tumor	O
suppressor	O
to	O
the	O
HDM2	O
E3	O
ubiquitin	O
ligase	O
is	O
important	O
for	O
controlling	O
p53	O
activity	O
,	O
and	O
several	O
compounds	O
,	O
such	O
as	O
Nutlin	O
-	O
3	O
,	O
have	O
been	O
designed	O
to	O
bind	O
a	O
hydrophobic	O
pocket	O
in	O
the	O
N	O
-	O
terminus	O
of	O
HDM2	O
to	O
prevent	O
the	O
interaction	O
with	O
p53	O
to	O
stabilize	O
and	O
activate	O
downstream	O
p53	O
pathways	O
.	O

We	O
have	O
used	O
the	O
p53	O
-	O
HDM2	O
interaction	O
as	O
a	O
model	O
system	O
to	O
explore	O
the	O
bioluminescence	O
resonance	O
energy	O
transfer	O
(	O
BRET	O
)	O
technique	O
for	O
validating	O
compounds	O
that	O
disrupt	O
PPIs	O
in	O
living	O
cells	O
.	O

The	O
structure	O
of	O
dopamine	O
induced	O
alpha	O
-	O
synuclein	O
oligomers	O
.	O

Inclusions	O
of	O
aggregated	O
alpha	O
-	O
synuclein	O
(	O
alpha	O
-	O
syn	O
)	O
in	O
dopaminergic	O
neurons	O
are	O
a	O
characteristic	O
histological	O
marker	O
of	O
Parkinson	O
'	O
s	O
disease	O
(	O
PD	O
)	O
.	O

In	O
vitro	O
,	O
alpha	O
-	O
syn	O
in	O
the	O
presence	O
of	O
dopamine	O
(	O
DA	O
)	O
at	O
physiological	O
pH	O
forms	O
SDS	O
-	O
resistant	O
non	O
-	O
amyloidogenic	O
oligomers	O
.	O

We	O
used	O
a	O
combination	O
of	O
biophysical	O
techniques	O
,	O
including	O
sedimentation	O
velocity	O
analysis	O
,	O
small	O
angle	O
X	O
-	O
ray	O
scattering	O
(	O
SAXS	O
)	O
and	O
circular	O
dichroism	O
spectroscopy	O
to	O
study	O
the	O
characteristics	O
of	O
alpha	O
-	O
syn	O
oligomers	O
formed	O
in	O
the	O
presence	O
of	O
DA	O
.	O

Our	O
SAXS	O
data	O
show	O
that	O
the	O
trimers	O
formed	O
by	O
the	O
action	O
of	O
DA	O
on	O
alpha	O
-	O
syn	O
consist	O
of	O
overlapping	O
worm	O
-	O
like	O
monomers	O
,	O
with	O
no	O
end	O
-	O
to	O
-	O
end	O
associations	O
.	O

This	O
lack	O
of	O
structure	O
contrasts	O
with	O
the	O
well	O
-	O
established	O
,	O
extensive	O
beta	O
-	O
sheet	O
structure	O
of	O
the	O
amyloid	O
fibril	O
form	O
of	O
the	O
protein	O
and	O
its	O
pre	O
-	O
fibrillar	O
oligomers	O
.	O

We	O
propose	O
on	O
the	O
basis	O
of	O
these	O
and	O
earlier	O
data	O
that	O
oxidation	O
of	O
the	O
four	O
methionine	O
residues	O
at	O
the	O
C	O
-	O
and	O
N	O
-	O
terminal	O
ends	O
of	O
alpha	O
-	O
syn	O
molecules	O
prevents	O
their	O
end	O
-	O
to	O
-	O
end	O
association	O
and	O
stabilises	O
oligomers	O
formed	O
by	O
cross	O
linking	O
with	O
DA	O
-	O
quinone	O
/	O
DA	O
-	O
melanin	O
,	O
which	O
are	O
formed	O
as	O
a	O
result	O
of	O
the	O
redox	O
process	O
,	O
thus	O
inhibiting	O
formation	O
of	O
the	O
beta	O
-	O
sheet	O
structure	O
found	O
in	O
other	O
pre	O
-	O
fibrillar	O
forms	O
of	O
alpha	O
-	O
syn	O
.	O

Gravid	O
adults	O
were	O
allowed	O
to	O
lay	O
eggs	O
on	O
plates	O
containing	O
tunicamycin	O
.	O

Analysis	O
of	O
developmental	O
stages	O
was	O
performed	O
72	O
h	O
later	O
.	O

At	O
least	O
three	O
independent	O
experiments	O
were	O
performed	O
for	O
each	O
tunicamycin	O
concentration	O
(	O
0	O
-	O
7	O
.	O
5	O
or	O
0	O
-	O
5	O
mug	O
/	O
ml	O
)	O
,	O
and	O
three	O
plates	O
for	O
each	O
treatment	O
were	O
analyzed	O
in	O
each	O
experiment	O
;	O
n	O
values	O
above	O
the	O
bars	O
are	O
the	O
total	O
number	O
of	O
embryos	O
.	O

To	O
examine	O
tunicamycin	O
sensitivity	O
of	O
worms	O
treated	O
with	O
RNAi	O
,	O
embryos	O
were	O
transferred	O
to	O
duplicated	O
RNAi	O
feeding	O
plates	O
seeded	O
with	O
rnf	O
-	O
121	O
dsRNA	O
-	O
producing	O
bacteria	O
or	O
with	O
bacteria	O
containing	O
the	O
empty	O
feeding	O
vector	O
L4440	O
as	O
a	O
control	O
.	O

Plates	O
were	O
maintained	O
in	O
20degreesC	O
,	O
and	O
four	O
P0	O
larvae	O
were	O
transferred	O
to	O
fresh	O
RNAi	O
plates	O
every	O
day	O
.	O

F1s	O
gravid	O
adults	O
were	O
transferred	O
to	O
RNAi	O
plates	O
containing	O
different	O
amount	O
of	O
tunicamycin	O
.	O

The	O
rnf	O
-	O
121	O
(	O
ok848	O
)	O
worms	O
exhibit	O
higher	O
sensitivity	O
to	O
2	O
mug	O
/	O
ml	O
tunicamycin	O
compared	O
with	O
rnf	O
-	O
121	O
(	O
RNAi	O
)	O
-	O
treated	O
worms	O
suggesting	O
incomplete	O
silencing	O
of	O
this	O
gene	O
by	O
RNAi	O
(	O
compare	O
Figure	O
2A	O
to	O
Figure	O
3A	O
,	O
top	O
,	O
at	O
2	O
mug	O
/	O
ml	O
tunicamycin	O
)	O
.	O

Chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
was	O
performed	O
as	O
described	O
previously	O
.	O

The	O
antibodies	O
used	O
in	O
this	O
study	O
include	O
mouse	O
monoclonal	O
antibodies	O
to	O
the	O
HA	O
and	O
Myc	O
epitopes	O
(	O
F7	O
and	O
9E10	O
,	O
Santa	O
Cruz	O
Biotechnology	O
)	O
,	O
and	O
rabbit	O
polyclonal	O
antibodies	O
to	O
Met28	O
and	O
Met32	O
(	O
kindly	O
provided	O
by	O
Mike	O
Tyers	O
,	O
Samuel	O
Lunenfeld	O
Research	O
Institute	O
)	O
.	O

DNA	O
was	O
quantified	O
by	O
real	O
time	O
PCR	O
using	O
the	O
LightCycler	O
480	O
instrument	O
,	O
and	O
reaction	O
kits	O
containing	O
SYBR	O
Green	O
I	O
(	O
Roche	O
)	O
.	O

A	O
typical	O
run	O
included	O
duplicates	O
of	O
each	O
IP	O
and	O
input	O
DNA	O
,	O
and	O
serial	O
dilutions	O
of	O
one	O
input	O
DNA	O
to	O
create	O
a	O
standard	O
curve	O
and	O
determine	O
the	O
efficiency	O
of	O
the	O
amplification	O
.	O

Data	O
was	O
analyzed	O
with	O
the	O
LightCycler	O
480	O
software	O
using	O
the	O
'	O
second	O
derivative	O
maximum	O
'	O
method	O
for	O
quantification	O
.	O

Occupancy	O
at	O
a	O
genomic	O
location	O
was	O
calculated	O
by	O
dividing	O
the	O
immunoprecipitated	O
(	O
IP	O
)	O
over	O
input	O
DNA	O
ratio	O
for	O
a	O
fragment	O
encompassing	O
the	O
location	O
by	O
the	O
IP	O
over	O
input	O
DNA	O
ratio	O
of	O
a	O
fragment	O
of	O
reference	O
(	O
typically	O
,	O
a	O
sequence	O
within	O
the	O
open	O
reading	O
frame	O
of	O
the	O
meiotic	O
gene	O
IME2	O
)	O
.	O

The	O
75	O
kDa	O
human	O
BCRP	O
is	O
a	O
polytopic	O
plasma	O
membrane	O
transport	O
protein	O
which	O
has	O
been	O
detected	O
in	O
many	O
drug	O
-	O
resistant	O
cell	O
lines	O
,	O
solid	O
tumors	O
,	O
and	O
hematological	O
malignancies	O
.	O

Transport	O
studies	O
using	O
BCRP	O
-	O
overexpressing	O
intact	O
cells	O
or	O
BCRP	O
-	O
enriched	O
plasma	O
membrane	O
vesicles	O
have	O
established	O
that	O
BCRP	O
can	O
actively	O
transport	O
a	O
broad	O
spectrum	O
of	O
substrates	O
,	O
ranging	O
from	O
hydrophobic	O
chemotherapeutics	O
to	O
hydrophilic	O
anionic	O
conjugated	O
endo	O
-	O
and	O
xenobiotics	O
.	O

BCRP	O
is	O
highly	O
expressed	O
in	O
organs	O
important	O
for	O
the	O
absorption	O
(	O
the	O
small	O
intestine	O
)	O
,	O
distribution	O
(	O
e	O
.	O
g	O
.	O
,	O
the	O
blood	O
-	O
brain	O
and	O
placental	O
barriers	O
)	O
,	O
and	O
elimination	O
(	O
e	O
.	O
g	O
.	O
,	O
the	O
liver	O
and	O
kidney	O
)	O
of	O
drugs	O
,	O
and	O
plays	O
an	O
important	O
role	O
in	O
drug	O
disposition	O
.	O

The	O
SAXS	O
measurements	O
were	O
carried	O
out	O
using	O
an	O
Anton	O
Paar	O
SAXSess	O
camera	O
equipped	O
with	O
a	O
PANalytical	O
PW3830	O
X	O
-	O
ray	O
generator	O
and	O
a	O
Princeton	O
CCD	O
detector	O
.	O

The	O
beam	O
length	O
was	O
set	O
to	O
18	O
mm	O
and	O
the	O
beam	O
profile	O
was	O
recorded	O
using	O
an	O
image	O
plate	O
for	O
subsequent	O
desmearing	O
.	O

Data	O
for	O
the	O
IscS	O
-	O
IscU	O
complex	O
were	O
collected	O
at	O
4degreesC	O
with	O
protein	O
concentrations	O
of	O
4	O
.	O
5	O
mg	O
/	O
ml	O
(	O
10	O
h	O
)	O
,	O
10	O
mg	O
/	O
ml	O
(	O
2	O
h	O
)	O
,	O
and	O
21	O
mg	O
/	O
ml	O
(	O
2	O
h	O
)	O
.	O

For	O
the	O
IscS	O
-	O
TusA	O
complex	O
,	O
a	O
data	O
set	O
was	O
recorded	O
at	O
4degreesC	O
for	O
30	O
min	O
at	O
22	O
mg	O
/	O
ml	O
.	O

Dark	O
current	O
correction	O
,	O
scaling	O
,	O
buffer	O
subtraction	O
,	O
and	O
desmearing	O
were	O
performed	O
using	O
the	O
Anton	O
Paar	O
software	O
SAXSquant	O
3	O
.	O
0	O
.	O

Data	O
sets	O
recorded	O
at	O
different	O
concentrations	O
for	O
IscS	O
-	O
IscU	O
were	O
merged	O
in	O
Primus	O
after	O
removal	O
of	O
the	O
lowest	O
resolution	O
shell	O
(	O
0	O
.	O
012	O
-	O
0	O
.	O
12	O
Aa	O
-	O
1	O
)	O
for	O
the	O
10	O
and	O
21	O
mg	O
/	O
ml	O
data	O
sets	O
,	O
for	O
which	O
Guinier	O
plots	O
showed	O
larger	O
Rg	O
values	O
(	O
~	O
39	O
Aa	O
)	O
indicating	O
concentration	O
-	O
dependent	O
oligomerization	O
.	O

The	O
data	O
sets	O
were	O
binned	O
(	O
5	O
:	O
1	O
)	O
in	O
the	O
range	O
of	O
0	O
.	O
012	O
-	O
0	O
.	O
35	O
Aa	O
-	O
1	O
and	O
fitted	O
directly	O
against	O
predicted	O
scattering	O
calculated	O
from	O
atomic	O
coordinates	O
using	O
the	O
program	O
CRYSOL	O
(	O
http	O
:	O
/	O
/	O
www	O
.	O
embl	O
-	O
hamburg	O
.	O
de	O
/	O
ExternalInfo	O
/	O
Research	O
/	O
Sax	O
/	O
crysol	O
.	O
html	O
)	O
.	O

Experimental	O
Rg	O
values	O
were	O
estimated	O
from	O
Guinier	O
plots	O
,	O
while	O
calculated	O
Rg	O
values	O
were	O
determined	O
using	O
CRYSOL	O
.	O

In	O
vitro	O
reconstitution	O
of	O
SARS	O
-	O
coronavirus	O
mRNA	O
cap	O
methylation	O
.	O

SARS	O
-	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
genome	O
expression	O
depends	O
on	O
the	O
synthesis	O
of	O
a	O
set	O
of	O
mRNAs	O
,	O
which	O
presumably	O
are	O
capped	O
at	O
their	O
5	O
'	O
end	O
and	O
direct	O
the	O
synthesis	O
of	O
all	O
viral	O
proteins	O
in	O
the	O
infected	O
cell	O
.	O

Sixteen	O
viral	O
non	O
-	O
structural	O
proteins	O
(	O
nsp1	O
to	O
nsp16	O
)	O
constitute	O
an	O
unusually	O
large	O
replicase	B-OOS
complex	O
,	O
which	O
includes	O
two	O
methyltransferases	O
putatively	O
involved	O
in	O
viral	O
mRNA	O
cap	O
formation	O
.	O

The	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
methionine	O
(	O
AdoMet	O
)	O
-	O
dependent	O
(	O
guanine	O
-	O
N7	O
)	O
-	O
methyltransferase	O
(	O
N7	O
-	O
MTase	O
)	O
activity	O
was	O
recently	O
attributed	O
to	O
nsp14	O
,	O
whereas	O
nsp16	O
has	O
been	O
predicted	O
to	O
be	O
the	O
AdoMet	O
-	O
dependent	O
(	O
nucleoside	O
-	O
2	O
'	O
O	O
)	O
-	O
methyltransferase	O
.	O

Here	O
,	O
we	O
have	O
reconstituted	O
complete	O
SARS	O
-	O
CoV	O
mRNA	O
cap	O
methylation	O
in	O
vitro	O
.	O

We	O
show	O
that	O
mRNA	O
cap	O
methylation	O
requires	O
a	O
third	O
viral	O
protein	O
,	O
nsp10	O
,	O
which	O
acts	O
as	O
an	O
essential	O
trigger	O
to	O
complete	O
RNA	O
cap	O
-	O
1	O
formation	O
.	O

The	O
obligate	O
sequence	O
of	O
methylation	O
events	O
is	O
initiated	O
by	O
nsp14	O
,	O
which	O
first	O
methylates	O
capped	O
RNA	O
transcripts	O
to	O
generate	O
cap	O
-	O
0	O
(	O
7Me	O
)	O
GpppA	O
-	O
RNAs	O
.	O

The	O
latter	O
are	O
then	O
selectively	O
2	O
'	O
O	O
-	O
methylated	O
by	O
the	O
2	O
'	O
O	O
-	O
MTase	O
nsp16	O
in	O
complex	O
with	O
its	O
activator	O
nsp10	O
to	O
give	O
rise	O
to	O
cap	O
-	O
1	O
(	O
7Me	O
)	O
GpppA	O
(	O
2	O
'	O
OMe	O
)	O
-	O
RNAs	O
.	O

Furthermore	O
,	O
sensitive	O
in	O
vitro	O
inhibition	O
assays	O
of	O
both	O
activities	O
show	O
that	O
aurintricarboxylic	O
acid	O
,	O
active	O
in	O
SARS	O
-	O
CoV	O
infected	O
cells	O
,	O
targets	O
both	O
MTases	O
with	O
IC	O
(	O
50	O
)	O
values	O
in	O
the	O
micromolar	O
range	O
,	O
providing	O
a	O
validated	O
basis	O
for	O
anti	O
-	O
coronavirus	O
drug	O
design	O
.	O

Histone	O
H2A	O
deubiquitinase	O
activity	O
of	O
the	O
Polycomb	B-Complex
repressive	I-Complex
complex	O
PR	B-Complex
-	I-Complex
DUB	I-Complex
.	O

Polycomb	O
group	O
(	O
PcG	O
)	O
proteins	O
are	O
transcriptional	O
repressors	O
that	O
control	O
processes	O
ranging	O
from	O
the	O
maintenance	O
of	O
cell	O
fate	O
decisions	O
and	O
stem	O
cell	O
pluripotency	O
in	O
animals	O
to	O
the	O
control	O
of	O
flowering	O
time	O
in	O
plants	O
.	O

In	O
Drosophila	O
,	O
genetic	O
studies	O
identified	O
more	O
than	O
15	O
different	O
PcG	O
proteins	O
that	O
are	O
required	O
to	O
repress	O
homeotic	O
(	O
HOX	O
)	O
and	O
other	O
developmental	O
regulator	O
genes	O
in	O
cells	O
where	O
they	O
must	O
stay	O
inactive	O
.	O

Biochemical	O
analyses	O
established	O
that	O
these	O
PcG	O
proteins	O
exist	O
in	O
distinct	O
multiprotein	O
complexes	O
that	O
bind	O
to	O
and	O
modify	O
chromatin	O
of	O
target	O
genes	O
.	O

Among	O
those	O
,	O
Polycomb	B-Complex
repressive	I-Complex
complex	I-Complex
1	I-Complex
(	O
PRC1	B-Complex
)	O
and	O
the	O
related	O
dRing	B-Complex
-	I-Complex
associated	I-Complex
factors	I-Complex
(	O
dRAF	B-Complex
)	O
complex	O
contain	O
an	O
E3	O
ligase	O
activity	O
for	O
monoubiquitination	O
of	O
histone	O
H2A	O
(	O
refs	O
1	O
-	O
4	O
)	O
.	O

Here	O
we	O
show	O
that	O
the	O
uncharacterized	O
Drosophila	O
PcG	O
gene	O
calypso	O
encodes	O
the	O
ubiquitin	O
carboxy	O
-	O
terminal	O
hydrolase	O
BAP1	O
.	O

Biochemically	O
purified	O
Calypso	O
exists	O
in	O
a	O
complex	O
with	O
the	O
PcG	O
protein	O
ASX	O
,	O
and	O
this	O
complex	O
,	O
named	O
Polycomb	B-Complex
repressive	I-Complex
deubiquitinase	I-Complex
(	O
PR	B-Complex
-	I-Complex
DUB	I-Complex
)	O
,	O
is	O
bound	O
at	O
PcG	O
target	O
genes	O
in	O
Drosophila	O
.	O

Reconstituted	O
recombinant	O
Drosophila	O
and	O
human	O
PR	B-Complex
-	I-Complex
DUB	I-Complex
complexes	O
remove	O
monoubiquitin	O
from	O
H2A	O
but	O
not	O
from	O
H2B	O
in	O
nucleosomes	O
.	O

Drosophila	O
mutants	O
lacking	O
PR	B-Complex
-	I-Complex
DUB	I-Complex
show	O
a	O
strong	O
increase	O
in	O
the	O
levels	O
of	O
monoubiquitinated	O
H2A	O
.	O

A	O
mutation	O
that	O
disrupts	O
the	O
catalytic	O
activity	O
of	O
Calypso	O
,	O
or	O
absence	O
of	O
the	O
ASX	O
subunit	O
abolishes	O
H2A	O
deubiquitination	O
in	O
vitro	O
and	O
HOX	O
gene	O
repression	O
in	O
vivo	O
.	O

Polycomb	O
gene	O
silencing	O
may	O
thus	O
entail	O
a	O
dynamic	O
balance	O
between	O
H2A	O
ubiquitination	O
by	O
PRC1	B-Complex
and	O
dRAF	B-Complex
,	O
and	O
H2A	O
deubiquitination	O
by	O
PR	B-Complex
-	I-Complex
DUB	I-Complex
.	O

Ubiquitin	O
-	O
dependent	O
DNA	O
damage	O
bypass	O
is	O
separable	O
from	O
genome	O
replication	O
.	O

Post	O
-	O
replication	O
repair	O
(	O
PRR	O
)	O
is	O
a	O
pathway	O
that	O
allows	O
cells	O
to	O
bypass	O
or	O
overcome	O
lesions	O
during	O
DNA	O
replication	O
.	O

In	O
eukaryotes	O
,	O
damage	O
bypass	O
is	O
activated	O
by	O
ubiquitylation	O
of	O
the	O
replication	O
clamp	O
PCNA	O
through	O
components	O
of	O
the	O
RAD6	O
pathway	O
.	O

Whereas	O
monoubiquitylation	O
of	O
PCNA	O
allows	O
mutagenic	O
translesion	O
synthesis	O
by	O
damage	O
-	O
tolerant	O
DNA	B-OOS
polymerases	I-OOS
,	O
polyubiquitylation	O
is	O
required	O
for	O
an	O
error	O
-	O
free	O
pathway	O
that	O
probably	O
involves	O
a	O
template	O
switch	O
to	O
the	O
undamaged	O
sister	O
chromatid	O
.	O

Both	O
the	O
timing	O
of	O
PRR	O
events	O
during	O
the	O
cell	O
cycle	O
and	O
their	O
location	O
relative	O
to	O
replication	O
forks	O
,	O
as	O
well	O
as	O
the	O
factors	O
required	O
downstream	O
of	O
PCNA	O
ubiquitylation	O
,	O
have	O
remained	O
poorly	O
characterized	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
RAD6	O
pathway	O
normally	O
operates	O
during	O
S	O
phase	O
.	O

However	O
,	O
using	O
an	O
inducible	O
system	O
of	O
DNA	O
damage	O
bypass	O
in	O
budding	O
yeast	O
(	O
Saccharomyces	O
cerevisiae	O
)	O
,	O
we	O
show	O
that	O
the	O
process	O
is	O
separable	O
in	O
time	O
and	O
space	O
from	O
genome	O
replication	O
,	O
thus	O
allowing	O
direct	O
visualization	O
and	O
quantification	O
of	O
productive	O
PRR	O
tracts	O
.	O

We	O
found	O
that	O
both	O
during	O
and	O
after	O
S	O
phase	O
ultraviolet	O
-	O
radiation	O
-	O
induced	O
lesions	O
are	O
bypassed	O
predominantly	O
via	O
translesion	O
synthesis	O
,	O
whereas	O
the	O
error	O
-	O
free	O
pathway	O
functions	O
as	O
a	O
backup	O
system	O
.	O

Our	O
approach	O
has	O
revealed	O
the	O
distribution	O
of	O
PRR	O
tracts	O
in	O
a	O
synchronized	O
cell	O
population	O
.	O

It	O
will	O
allow	O
an	O
in	O
-	O
depth	O
mechanistic	O
analysis	O
of	O
how	O
cells	O
manage	O
the	O
processing	O
of	O
lesions	O
to	O
their	O
genomes	O
during	O
and	O
after	O
replication	O
.	O

Mds3	O
regulates	O
morphogenesis	O
in	O
Candida	O
albicans	O
through	O
the	O
TOR	O
pathway	O
.	O

The	O
success	O
of	O
Candida	O
albicans	O
as	O
a	O
major	O
human	O
fungal	O
pathogen	O
is	O
dependent	O
on	O
its	O
ability	O
to	O
colonize	O
and	O
survive	O
as	O
a	O
commensal	O
on	O
diverse	O
mucosal	O
surfaces	O
.	O

One	O
trait	O
required	O
for	O
survival	O
and	O
virulence	O
in	O
the	O
host	O
is	O
the	O
morphogenetic	O
yeast	O
-	O
to	O
-	O
hypha	O
transition	O
.	O

Mds3	O
was	O
identified	O
as	O
a	O
regulator	O
of	O
pH	O
-	O
dependent	O
morphogenesis	O
that	O
functions	O
in	O
parallel	O
with	O
the	O
classic	O
Rim101	O
pH	O
-	O
sensing	O
pathway	O
.	O

Microarray	O
analyses	O
revealed	O
that	O
mds3	O
Delta	O
/	O
Delta	O
cells	O
had	O
an	O
expression	O
profile	O
indicative	O
of	O
a	O
hyperactive	O
TOR	O
pathway	O
,	O
including	O
the	O
preferential	O
expression	O
of	O
genes	O
encoding	O
ribosomal	O
proteins	O
and	O
a	O
decreased	O
expression	O
of	O
genes	O
involved	O
in	O
nitrogen	O
source	O
utilization	O
.	O

The	O
transcriptional	O
and	O
morphological	O
defects	O
of	O
the	O
mds3	O
Delta	O
/	O
Delta	O
mutant	O
were	O
rescued	O
by	O
rapamycin	O
,	O
an	O
inhibitor	O
of	O
TOR	O
,	O
and	O
this	O
rescue	O
was	O
lost	O
in	O
strains	O
carrying	O
the	O
rapamycin	O
-	O
resistant	O
TOR1	O
-	O
1	O
allele	O
or	O
an	O
rbp1	O
Delta	O
/	O
Delta	O
deletion	O
.	O

Rapamycin	O
also	O
rescued	O
the	O
transcriptional	O
and	O
morphological	O
defects	O
associated	O
with	O
the	O
loss	O
of	O
Sit4	O
,	O
a	O
TOR	O
pathway	O
effector	O
,	O
but	O
not	O
the	O
loss	O
of	O
Rim101	O
or	O
Ras1	O
.	O

The	O
sit4	O
Delta	O
/	O
Delta	O
and	O
mds3	O
Delta	O
/	O
Delta	O
mutants	O
had	O
additional	O
phenotypic	O
similarities	O
,	O
suggesting	O
that	O
Sit4	O
and	O
Mds3	O
function	O
similarly	O
in	O
the	O
TOR	O
pathway	O
.	O

Finally	O
,	O
we	O
found	O
that	O
Mds3	O
and	O
Sit4	O
coimmunoprecipitate	O
.	O

Thus	O
,	O
Mds3	O
is	O
a	O
new	O
member	O
of	O
the	O
TOR	O
pathway	O
that	O
contributes	O
to	O
morphogenesis	O
in	O
C	O
.	O
albicans	O
as	O
a	O
regulator	O
of	O
this	O
key	O
morphogenetic	O
pathway	O
.	O

Protein	O
was	O
isolated	O
by	O
vigorously	O
vortexing	O
protoplasts	O
pellets	O
in	O
100	O
mul	O
LUC	O
extraction	O
buffer	O
(	O
100	O
mM	O
potassium	O
phosphate	O
,	O
1	O
mM	O
DTT	O
,	O
pH7	O
.	O
5	O
)	O
for	O
30	O
s	O
.	O

After	O
centrifugation	O
(	O
10	O
min	O
,	O
13	O
,	O
000g	O
,	O
4degreesC	O
)	O
,	O
the	O
supernatant	O
was	O
pipetted	O
into	O
a	O
new	O
1	O
.	O
5	O
ml	O
Eppendorf	O
tube	O
and	O
used	O
for	O
determination	O
of	O
LUC	O
activity	O
and	O
protein	O
concentrations	O
.	O

At	O
room	O
temperature	O
,	O
after	O
adding	O
100	O
mul	O
filter	O
-	O
sterilized	O
LUC	O
assay	O
buffer	O
(	O
20	O
mM	O
tricine	O
,	O
1	O
.	O
07	O
mM	O
(	O
MgCO3	O
)	O
4Mg	O
(	O
OH	O
)	O
2	O
x	O
5H2O	O
,	O
2	O
.	O
67	O
mM	O
MgSO4	O
,	O
0	O
.	O
1	O
mM	O
EDTA	O
,	O
33	O
mM	O
DTT	O
,	O
0	O
.	O
27	O
mM	O
CoA	O
,	O
0	O
.	O
47	O
mM	O
D	O
-	O
luciferin	O
,	O
0	O
.	O
53	O
mM	O
ATP	O
,	O
pH	O
7	O
.	O
8	O
)	O
to	O
10	O
mul	O
of	O
extract	O
LUC	O
activity	O
was	O
determined	O
by	O
Luminometer	O
Lumat	O
LB9501	O
with	O
an	O
interval	O
of	O
10	O
s	O
.	O

Specific	O
LUC	O
activity	O
is	O
given	O
as	O
relative	O
light	O
units	O
(	O
RLUs	O
)	O
mug	O
protein	O
-	O
1	O
s	O
-	O
1	O
.	O

Bimodal	O
expression	O
of	O
Sprouty2	O
during	O
the	O
cell	O
cycle	O
is	O
mediated	O
by	O
phase	O
-	O
specific	O
Ras	O
/	O
MAPK	O
and	O
c	O
-	O
Cbl	O
activities	O
.	O

Sprouty2	O
is	O
an	O
important	O
inhibitor	O
of	O
cell	O
proliferation	O
and	O
signal	O
transduction	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
a	O
bimodal	O
expression	O
of	O
Sprouty2	O
protein	O
during	O
cell	O
cycle	O
progression	O
after	O
exit	O
from	O
quiescence	O
,	O
whereas	O
elevated	O
Sprouty4	O
expression	O
in	O
the	O
G1	O
phase	O
stayed	O
high	O
throughout	O
the	O
rest	O
of	O
the	O
cell	O
cycle	O
.	O

Induction	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
via	O
activated	O
Ras	O
was	O
crucial	O
for	O
increased	O
Sprouty2	O
expression	O
at	O
the	O
G0	O
/	O
G1	O
transition	O
.	O

Following	O
the	O
first	O
peak	O
,	O
accelerated	O
proteasomal	O
protein	O
degradation	O
caused	O
a	O
transient	O
attenuation	O
of	O
Sprouty2	O
abundance	O
during	O
late	O
G1	O
.	O

Since	O
the	O
decline	O
in	O
its	O
expression	O
was	O
abolished	O
by	O
dominant	O
negative	O
c	O
-	O
Cbl	O
and	O
the	O
timely	O
restricted	O
interaction	O
between	O
Sprouty2	O
and	O
c	O
-	O
Cbl	O
disappeared	O
at	O
the	O
second	O
peak	O
of	O
Sprouty2	O
expression	O
,	O
we	O
conclude	O
that	O
the	O
second	O
phase	O
in	O
the	O
cell	O
cycle	O
-	O
specific	O
expression	O
profile	O
of	O
Sprouty2	O
is	O
solely	O
dependent	O
on	O
ubiquitination	O
by	O
c	O
-	O
Cbl	O
.	O

Our	O
results	O
suggest	O
that	O
Sprouty2	O
abundance	O
is	O
the	O
result	O
of	O
strictly	O
coordinated	O
activities	O
of	O
Ras	O
and	O
c	O
-	O
Cbl	O
.	O

Analysis	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
demonstrated	O
that	O
HR1	O
as	O
well	O
as	O
TR2	O
possess	O
high	O
dsRNA	O
binding	O
affinity	O
,	O
which	O
is	O
greatly	O
reduced	O
in	O
HR2	O
.	O

Consistent	O
with	O
the	O
EMSA	O
results	O
,	O
domain	O
swapping	O
experiments	O
showed	O
that	O
TR2	O
is	O
capable	O
of	O
replacing	O
HR1	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
:	O
TR2	O
+	O
HR2	O
chimeric	O
protein	O
has	O
similar	O
pri	O
-	O
miRNA	O
binding	O
affinity	O
in	O
vitro	O
compared	O
with	O
HR1	O
+	O
2	O
and	O
the	O
TR2	O
+	O
HR2	O
chimeric	O
protein	O
is	O
able	O
to	O
rescue	O
the	O
hyl1	O
-	O
2	O
mutant	O
phenotype	O
in	O
vivo	O
.	O

Notably	O
,	O
from	O
the	O
crystal	O
structure	O
we	O
found	O
HR2	O
harbors	O
a	O
putative	O
dimerization	O
interface	O
.	O

The	O
dimerization	O
of	O
HYL1	O
was	O
further	O
confirmed	O
by	O
in	O
vitro	O
pull	O
-	O
down	O
,	O
coimmunoprecipitation	O
,	O
and	O
analytical	O
gel	O
filtration	O
assays	O
.	O

The	O
dual	O
-	O
specificity	O
MAP	O
kinase	O
phosphatases	O
:	O
critical	O
roles	O
in	O
development	O
and	O
cancer	O
.	O

Intracellular	O
signaling	O
by	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
(	O
MAPK	O
)	O
is	O
involved	O
in	O
many	O
cellular	O
responses	O
and	O
in	O
the	O
regulation	O
of	O
various	O
physiological	O
and	O
pathological	O
conditions	O
.	O

Tight	O
control	O
of	O
the	O
localization	O
and	O
duration	O
of	O
extracellular	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
,	O
c	O
-	O
Jun	O
NH	O
(	O
2	O
)	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
,	O
or	O
p38	O
MAPK	O
activity	O
is	O
thus	O
a	O
fundamental	O
aspect	O
of	O
cell	O
biology	O
.	O

Several	O
members	O
of	O
the	O
dual	O
-	O
specificity	O
phosphatase	O
(	O
DUSPs	O
)	O
family	O
are	O
able	O
to	O
dephosphorylate	O
MAPK	O
isoforms	O
with	O
different	O
specificity	O
,	O
cellular	O
,	O
and	O
tissue	O
localization	O
.	O

Understanding	O
how	O
these	O
phosphatases	O
are	O
themselves	O
regulated	O
during	O
development	O
or	O
in	O
physiological	O
and	O
pathological	O
conditions	O
is	O
therefore	O
fundamental	O
.	O

Over	O
the	O
years	O
,	O
gene	O
deletion	O
and	O
knockdown	O
studies	O
have	O
completed	O
initial	O
in	O
vitro	O
studies	O
and	O
shed	O
a	O
new	O
light	O
on	O
the	O
global	O
and	O
specific	O
roles	O
of	O
DUSPs	O
in	O
vivo	O
.	O

Whereas	O
DUSP1	O
,	O
DUSP2	O
,	O
and	O
DUSP10	O
appear	O
as	O
crucial	O
players	O
in	O
the	O
regulation	O
of	O
immune	O
responses	O
,	O
other	O
members	O
of	O
the	O
family	O
,	O
like	O
the	O
ERK	O
-	O
specific	O
DUSP6	O
,	O
were	O
shown	O
to	O
play	O
a	O
major	O
role	O
in	O
development	O
.	O

Recent	O
findings	O
on	O
the	O
involvement	O
of	O
DUSPs	O
in	O
cancer	O
progression	O
and	O
resistance	O
will	O
also	O
be	O
discussed	O
.	O

Ch	O
organ	O
SOP	O
cells	O
activate	O
rho	O
in	O
a	O
region	O
-	O
specific	O
manner	O
to	O
differentially	O
pattern	O
the	O
Drosophila	O
embryo	O
.	O

In	O
abdominal	O
segments	O
,	O
for	O
example	O
,	O
a	O
set	O
of	O
five	O
Ato	O
-	O
positive	O
primary	O
(	O
1degrees	O
)	O
SOP	O
cells	O
(	O
C1	O
-	O
C5	O
)	O
activate	O
rho	O
,	O
secrete	O
Spi	O
,	O
and	O
thereby	O
induce	O
three	O
secondary	O
(	O
2degrees	O
)	O
SOP	O
cells	O
and	O
a	O
cluster	O
of	O
oenocytes	O
.	O

In	O
contrast	O
,	O
even	O
though	O
a	O
similar	O
set	O
of	O
Ato	O
-	O
positive	O
1degrees	O
SOP	O
cells	O
forms	O
within	O
thoracic	O
segments	O
,	O
these	O
cells	O
fail	O
to	O
up	O
-	O
regulate	O
rho	O
and	O
2degrees	O
SOP	O
cells	O
and	O
oenocytes	O
do	O
not	O
form	O
within	O
the	O
thorax	O
.	O

The	O
differential	O
ability	O
of	O
abdominal	O
and	O
thoracic	O
SOP	O
cells	O
to	O
activate	O
rho	O
is	O
linked	O
to	O
the	O
expression	O
of	O
a	O
specific	O
Hox	O
factor	O
,	O
Abdominal	O
-	O
A	O
(	O
Abd	O
-	O
A	O
)	O
.	O

In	O
the	O
absence	O
of	O
Abd	O
-	O
A	O
,	O
the	O
abdominal	O
ch	O
organ	O
SOP	O
cells	O
fail	O
to	O
stimulate	O
rho	O
and	O
lack	O
Spi	O
secretion	O
,	O
thereby	O
preventing	O
the	O
induction	O
of	O
2degrees	O
SOP	O
cells	O
and	O
oenocytes	O
.	O

What	O
remains	O
unclear	O
is	O
how	O
the	O
Ato	O
proneural	O
and	O
Abd	O
-	O
A	O
Hox	O
pathways	O
are	O
integrated	O
to	O
stimulate	O
gene	O
expression	O
within	O
specific	O
abdominal	O
SOP	O
cells	O
.	O

These	O
findings	O
leave	O
open	O
the	O
possibility	O
that	O
HLA	O
-	O
F	O
binds	O
to	O
a	O
specific	O
receptor	O
(	O
s	O
)	O
or	O
even	O
that	O
HLA	O
-	O
F	O
and	O
MHC	B-Complex
-	I-Complex
I	I-Complex
HC	O
interactions	O
can	O
occur	O
in	O
trans	O
between	O
cells	O
.	O

Addressing	O
the	O
former	O
possibility	O
,	O
while	O
our	O
immunoprecipitations	O
with	O
3D11	O
and	O
4A11	O
did	O
not	O
co	O
-	O
precipitate	O
equimolar	O
amounts	O
of	O
MHC	B-Complex
-	I-Complex
I	I-Complex
as	O
did	O
4B4	O
,	O
it	O
is	O
unlikely	O
that	O
this	O
evidence	O
argues	O
against	O
an	O
interaction	O
of	O
HLA	O
-	O
F	O
and	O
MHC	B-Complex
-	I-Complex
I	I-Complex
HC	O
on	O
the	O
surface	O
.	O

Subequimolar	O
amounts	O
were	O
detected	O
with	O
both	O
antibodies	O
and	O
it	O
is	O
not	O
clear	O
that	O
this	O
was	O
due	O
to	O
experimental	O
conditions	O
(	O
e	O
.	O
g	O
.	O
the	O
detergent	O
used	O
)	O
and	O
possibly	O
compounded	O
by	O
antibody	O
specificities	O
.	O

In	O
fact	O
,	O
there	O
is	O
a	O
strong	O
correlation	O
with	O
binding	O
of	O
HLA	O
-	O
F	O
tetramer	O
and	O
the	O
presence	O
of	O
surface	O
MHC	B-Complex
-	I-Complex
I	I-Complex
HC	O
(	O
Fig	O
.	O
3	O
)	O
.	O

In	O
addition	O
,	O
surface	O
HLA	O
-	O
F	O
is	O
internalized	O
upon	O
addition	O
of	O
free	O
HC	O
antibodies	O
,	O
which	O
could	O
implicate	O
an	O
interaction	O
between	O
the	O
two	O
molecules	O
prior	O
to	O
the	O
addition	O
of	O
HC	O
antibody	O
.	O

If	O
heterodimers	O
of	O
MHC	B-Complex
-	I-Complex
I	I-Complex
HC	O
and	O
HLA	O
-	O
F	O
or	O
similar	O
complexes	O
of	O
homodimers	O
of	O
each	O
species	O
do	O
exist	O
on	O
the	O
surface	O
.	O

it	O
would	O
suggest	O
the	O
possibility	O
for	O
interaction	O
with	O
a	O
unique	O
receptor	O
in	O
trans	O
,	O
perhaps	O
another	O
polymorphic	O
locus	O
or	O
group	O
of	O
genes	O
.	O

One	O
SUMO	O
is	O
sufficient	O
to	O
silence	O
the	O
dimeric	O
potassium	O
channel	O
K2P1	O
.	O

Small	O
ubiquitin	O
modifier	O
1	O
(	O
SUMO1	O
)	O
is	O
shown	O
to	O
regulate	O
K2P1	O
background	O
channels	O
in	O
the	O
plasma	O
membrane	O
(	O
PM	O
)	O
of	O
live	O
mammalian	O
cells	O
.	O

Confocal	O
microscopy	O
reveals	O
native	O
SUMO1	O
,	O
SAE1	O
,	O
and	O
Ubc9	O
(	O
the	O
enzymes	O
that	O
activate	O
and	O
conjugate	O
SUMO1	O
)	O
at	O
PM	O
where	O
SUMO1	O
and	O
expressed	O
human	O
K2P1	O
are	O
demonstrated	O
to	O
colocalize	O
.	O

Silent	O
K2P1	O
channels	O
in	O
excised	O
PM	O
patches	O
are	O
activated	O
by	O
SUMO	O
isopeptidase	O
(	O
SENP1	O
)	O
and	O
resilenced	O
by	O
SUMO1	O
.	O

K2P1	O
-	O
Lys274	O
is	O
crucial	O
:	O
when	O
mutated	O
to	O
Gln	O
,	O
Arg	O
,	O
Glu	O
,	O
Asp	O
,	O
Cys	O
,	O
or	O
Ala	O
,	O
the	O
channels	O
are	O
constitutively	O
active	O
and	O
insensitive	O
to	O
SUMO1	O
and	O
SENP1	O
.	O

Tandem	O
mass	O
spectrometry	O
confirms	O
conjugation	O
of	O
SUMO1	O
to	O
the	O
epsilon	O
-	O
amino	O
group	O
of	O
Lys274	O
in	O
vitro	O
.	O

FRET	O
microscopy	O
shows	O
that	O
assembly	O
of	O
K2P1	O
and	O
SUMO1	O
requires	O
Lys274	O
.	O

Single	O
-	O
particle	O
TIRF	O
microscopy	O
shows	O
that	O
wild	O
-	O
type	O
channels	O
in	O
PM	O
have	O
two	O
K2P1	O
subunits	O
and	O
assemble	O
with	O
two	O
SUMO1	O
monomers	O
.	O

Although	O
channels	O
engineered	O
with	O
one	O
Lys274	O
site	O
carry	O
just	O
one	O
SUMO1	O
they	O
are	O
activated	O
and	O
silenced	O
by	O
SENP1	O
and	O
SUMO1	O
like	O
wild	O
-	O
type	O
channels	O
.	O

Chicken	O
TLR21	O
is	O
an	O
innate	O
CpG	O
DNA	O
receptor	O
distinct	O
from	O
mammalian	O
TLR9	O
.	O

TLRs	O
comprise	O
a	O
family	O
of	O
evolutionary	O
conserved	O
sensory	O
receptors	O
that	O
respond	O
to	O
distinct	O
classes	O
of	O
ligands	O
.	O

For	O
one	O
major	O
evolutionary	O
branch	O
of	O
TLRs	O
,	O
the	O
ligands	O
are	O
still	O
largely	O
unknown	O
.	O

Here	O
we	O
report	O
the	O
cloning	O
and	O
function	O
of	O
one	O
member	O
of	O
this	O
group	O
,	O
chicken	O
TLR21	O
(	O
chTLR21	O
)	O
.	O

This	O
TLR	O
is	O
absent	O
in	O
the	O
human	O
species	O
but	O
has	O
homologs	O
in	O
fish	O
and	O
frog	O
and	O
displays	O
similarity	O
with	O
mouse	O
TLR13	O
.	O

Expression	O
of	O
chTLR21	O
in	O
HEK293	O
cells	O
resulted	O
in	O
activation	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
in	O
response	O
to	O
unmethylated	O
CpG	O
DNA	O
,	O
typically	O
recognized	O
by	O
mammalian	O
TLR9	O
.	O

Silencing	O
of	O
chTLR21	O
(	O
but	O
not	O
chTLR4	O
)	O
in	O
chicken	O
macrophages	O
inhibited	O
the	O
response	O
to	O
CpG	O
-	O
DNA	O
(	O
but	O
not	O
to	O
LPS	O
)	O
,	O
indicating	O
similar	O
functionality	O
of	O
the	O
endogenous	O
receptor	O
.	O

ChTLR21	O
responded	O
to	O
human	O
-	O
and	O
murine	O
-	O
specific	O
TLR9	O
ligands	O
,	O
as	O
well	O
as	O
to	O
bacterial	O
genomic	O
DNA	O
isolated	O
from	O
Salmonella	O
enterica	O
serovar	O
Enteritidis	O
.	O

Confocal	O
microscopy	O
located	O
chTLR21	O
in	O
the	O
same	O
intracellular	O
compartments	O
as	O
human	O
TLR9	O
.	O

Inhibition	O
of	O
the	O
chTLR21	O
response	O
by	O
the	O
endosomal	O
maturation	O
inhibitor	O
chloroquine	O
suggested	O
that	O
the	O
receptor	O
is	O
functional	O
in	O
endolysosomes	O
,	O
as	O
known	O
for	O
TLR9	O
.	O

The	O
analogous	O
localization	O
and	O
function	O
of	O
the	O
phylogenetically	O
only	O
distantly	O
related	O
chTLR21	O
and	O
mammalian	O
TLR9	O
suggest	O
that	O
during	O
evolution	O
different	O
classes	O
of	O
TLRs	O
have	O
emerged	O
that	O
recognize	O
the	O
same	O
type	O
of	O
ligands	O
.	O

Transcriptional	O
repression	O
by	O
sumoylation	O
of	O
Epstein	O
-	O
Barr	O
virus	O
BZLF1	O
protein	O
correlates	O
with	O
association	O
of	O
histone	O
deacetylase	O
.	O

The	O
transition	O
from	O
latent	O
to	O
lytic	O
phases	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
life	O
cycle	O
is	O
triggered	O
by	O
expression	O
of	O
a	O
viral	O
transactivator	O
,	O
BZLF1	O
,	O
that	O
then	O
induces	O
expression	O
of	O
the	O
viral	O
immediate	O
-	O
early	O
and	O
early	O
genes	O
.	O

The	O
BZLF1	O
protein	O
is	O
post	O
-	O
translationally	O
modified	O
by	O
a	O
small	O
ubiquitin	O
-	O
related	O
modifier	O
-	O
1	O
(	O
SUMO	O
-	O
1	O
)	O
.	O

Here	O
we	O
found	O
that	O
BZLF1	O
is	O
conjugated	O
at	O
lysine	O
12	O
not	O
only	O
by	O
SUMO	O
-	O
1	O
but	O
also	O
by	O
SUMO	O
-	O
2	O
and	O
3	O
.	O

The	O
K12R	O
mutant	O
of	O
BZLF1	O
,	O
which	O
no	O
longer	O
becomes	O
sumoylated	O
,	O
exhibits	O
stronger	O
transactivation	O
than	O
the	O
wild	O
-	O
type	O
BZLF1	O
in	O
a	O
reporter	O
assay	O
system	O
as	O
well	O
as	O
in	O
the	O
context	O
of	O
virus	O
genome	O
with	O
nucleosomal	O
structures	O
.	O

Furthermore	O
,	O
exogenous	O
supply	O
of	O
a	O
SUMO	O
-	O
specific	O
protease	O
,	O
SENP	O
,	O
caused	O
de	O
-	O
sumoylation	O
of	O
BZLF1	O
and	O
enhanced	O
BZLF1	O
-	O
mediated	O
transactivation	O
.	O

Immunoprecipitation	O
experiments	O
proved	O
that	O
histone	O
deacetylase	O
3	O
preferentially	O
associated	O
with	O
the	O
sumoylated	O
form	O
of	O
BZLF1	O
.	O

Levels	O
of	O
the	O
sumoylated	O
BZLF1	O
increased	O
as	O
lytic	O
replication	O
progressed	O
.	O

Based	O
on	O
these	O
observations	O
,	O
we	O
conclude	O
that	O
sumoylation	O
of	O
BZLF1	O
regulates	O
its	O
transcriptional	O
activity	O
through	O
histone	O
modification	O
during	O
Epstein	O
-	O
Barr	O
virus	O
productive	O
replication	O
.	O

The	O
small	O
GTPases	O
ARL	O
-	O
13	O
and	O
ARL	O
-	O
3	O
coordinate	O
intraflagellar	O
transport	O
and	O
ciliogenesis	O
.	O

Intraflagellar	O
transport	O
(	O
IFT	O
)	O
machinery	O
mediates	O
the	O
bidirectional	O
movement	O
of	O
cargos	O
that	O
are	O
required	O
for	O
the	O
assembly	O
and	O
maintenance	O
of	O
cilia	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
how	O
IFT	O
is	O
regulated	O
in	O
vivo	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
the	O
small	O
guanosine	O
triphosphatase	O
(	O
GTPase	O
)	O
adenosine	O
diphosphate	O
ribosylation	O
factor	O
-	O
like	O
protein	O
13	O
(	O
ARL	O
-	O
13	O
)	O
encoded	O
by	O
the	O
Caenorhabditis	O
elegans	O
homologue	O
of	O
the	O
human	O
Joubert	O
syndrome	O
causal	O
gene	O
ARL13B	O
,	O
localizes	O
exclusively	O
to	O
the	O
doublet	O
segment	O
of	O
the	O
cilium	O
.	O

arl	O
-	O
13	O
mutants	O
have	O
shortened	O
cilia	O
with	O
various	O
ultrastructural	O
deformities	O
and	O
a	O
disrupted	O
association	O
between	O
IFT	O
subcomplexes	O
A	O
and	O
B	O
.	O

Intriguingly	O
,	O
depletion	O
of	O
ARL	O
-	O
3	O
,	O
another	O
ciliary	O
small	O
GTPase	O
,	O
partially	O
suppresses	O
ciliogenesis	O
defects	O
in	O
arl	O
-	O
13	O
mutants	O
by	O
indirectly	O
restoring	O
binding	O
between	O
IFT	O
subcomplexes	O
A	O
and	O
B	O
.	O

Rescue	O
of	O
arl	O
-	O
13	O
mutants	O
by	O
ARL	O
-	O
3	O
depletion	O
is	O
mediated	O
by	O
an	O
HDAC6	O
deacetylase	O
-	O
dependent	O
pathway	O
.	O

Thus	O
,	O
we	O
propose	O
that	O
two	O
conserved	O
small	O
GTPases	O
,	O
ARL	O
-	O
13	O
and	O
ARL	O
-	O
3	O
,	O
coordinate	O
to	O
regulate	O
IFT	O
and	O
that	O
perturbing	O
this	O
balance	O
results	O
in	O
cilia	O
deformation	O
.	O

Sequential	O
and	O
gamma	B-Complex
-	I-Complex
secretase	I-Complex
-	O
dependent	O
processing	O
of	O
the	O
betacellulin	O
precursor	O
generates	O
a	O
palmitoylated	O
intracellular	O
-	O
domain	O
fragment	O
that	O
inhibits	O
cell	O
growth	O
.	O

Betacellulin	O
(	O
BTC	O
)	O
belongs	O
to	O
the	O
family	O
of	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
-	O
like	O
growth	O
factors	O
that	O
are	O
expressed	O
as	O
transmembrane	O
precursors	O
and	O
undergo	O
proteolytic	O
ectodomain	O
shedding	O
to	O
release	O
soluble	O
mature	O
ligands	O
.	O

BTC	O
is	O
a	O
dual	O
-	O
specificity	O
ligand	O
for	O
ErbB1	O
and	O
ErbB4	O
receptors	O
,	O
and	O
can	O
activate	O
unique	O
signal	O
-	O
transduction	O
pathways	O
that	O
are	O
beneficial	O
for	O
the	O
function	O
,	O
survival	O
and	O
regeneration	O
of	O
pancreatic	O
beta	O
-	O
cells	O
.	O

We	O
have	O
previously	O
shown	O
that	O
BTC	O
precursor	O
(	O
proBTC	O
)	O
is	O
cleaved	O
by	O
ADAM10	O
to	O
generate	O
soluble	O
ligand	O
and	O
a	O
stable	O
,	O
transmembrane	O
remnant	O
(	O
BTC	O
-	O
CTF	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
fate	O
of	O
the	O
BTC	O
-	O
CTF	O
in	O
greater	O
detail	O
.	O

We	O
demonstrated	O
that	O
proBTC	O
is	O
cleaved	O
by	O
ADAM10	O
to	O
produce	O
BTC	O
-	O
CTF	O
,	O
which	O
then	O
undergoes	O
intramembrane	O
processing	O
by	O
presenilin	O
-	O
1	O
-	O
and	O
/	O
or	O
presenilin	O
-	O
2	O
-	O
dependent	O
gamma	B-Complex
-	I-Complex
secretase	I-Complex
to	O
generate	O
an	O
intracellular	O
-	O
domain	O
fragment	O
(	O
BTC	O
-	O
ICD	O
)	O
.	O

We	O
found	O
that	O
the	O
proBTC	O
cytoplasmic	O
domain	O
is	O
palmitoylated	O
and	O
that	O
palmitoylation	O
is	O
not	O
required	O
for	O
ADAM10	O
-	O
dependent	O
cleavage	O
but	O
is	O
necessary	O
for	O
the	O
stability	O
and	O
gamma	B-Complex
-	I-Complex
secretase	I-Complex
-	O
dependent	O
processing	O
of	O
BTC	O
-	O
CTF	O
to	O
generate	O
BTC	O
-	O
ICD	O
.	O

Additionally	O
,	O
palmitoylation	O
is	O
required	O
for	O
nuclear	O
-	O
membrane	O
localization	O
of	O
BTC	O
-	O
ICD	O
,	O
as	O
demonstrated	O
by	O
the	O
redistribution	O
of	O
non	O
-	O
palmitoylated	O
BTC	O
-	O
ICD	O
mutant	O
to	O
the	O
nucleoplasm	O
.	O

Importantly	O
,	O
a	O
novel	O
receptor	O
-	O
independent	O
role	O
for	O
BTC	O
-	O
ICD	O
signaling	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
BTC	O
-	O
ICD	O
to	O
inhibit	O
cell	O
growth	O
in	O
vitro	O
.	O

The	O
lipoatrophic	O
caveolin	O
-	O
1	O
deficient	O
mouse	O
model	O
reveals	O
autophagy	O
in	O
mature	O
adipocytes	O
.	O

Adipose	O
tissue	O
lipoatrophy	O
caused	O
by	O
caveolin	O
gene	O
deletion	O
in	O
mice	O
is	O
not	O
linked	O
to	O
defective	O
adipocyte	O
differentiation	O
.	O

We	O
show	O
that	O
adipose	O
tissue	O
development	O
cannot	O
be	O
rescued	O
by	O
endothelial	O
specific	O
caveolin	O
-	O
1	O
re	O
-	O
expression	O
,	O
indicating	O
primordial	O
role	O
of	O
caveolin	O
in	O
mature	O
adipocytes	O
.	O

Partial	O
or	O
total	O
caveolin	O
deficiency	O
in	O
adipocytes	O
induced	O
broad	O
protein	O
expression	O
defects	O
,	O
including	O
but	O
not	O
limited	O
to	O
previously	O
described	O
downregulation	O
of	O
insulin	O
receptor	O
.	O

Global	O
alterations	O
in	O
protein	O
turnover	O
,	O
and	O
accelerated	O
degradation	O
of	O
long	O
-	O
lived	O
proteins	O
were	O
found	O
in	O
caveolin	O
-	O
deficient	O
adipocytes	O
.	O

Lipidation	O
of	O
endogenous	O
LC3	O
autophagy	O
marker	O
and	O
distribution	O
of	O
GFP	O
-	O
LC3	O
into	O
aggregates	O
demonstrated	O
activated	O
autophagy	O
in	O
the	O
absence	O
of	O
caveolin	O
-	O
1	O
in	O
adipocytes	O
.	O

Furthermore	O
,	O
electron	O
microscopy	O
revealed	O
autophagic	O
vacuoles	O
in	O
caveolin	O
-	O
1	O
deficient	O
but	O
not	O
control	O
adipocytes	O
.	O

Surprisingly	O
,	O
significant	O
levels	O
of	O
lipidated	O
LC3	O
-	O
II	O
were	O
found	O
around	O
lipid	O
droplets	O
of	O
normal	O
adipocytes	O
,	O
maintained	O
in	O
nutrient	O
-	O
rich	O
conditions	O
or	O
isolated	O
from	O
fed	O
mice	O
,	O
which	O
do	O
not	O
display	O
autophagy	O
.	O

Altogether	O
,	O
these	O
data	O
indicate	O
that	O
caveolin	O
deficiency	O
induce	O
autophagy	O
in	O
adipocytes	O
,	O
a	O
feature	O
that	O
is	O
not	O
a	O
physiological	O
response	O
to	O
fasting	O
in	O
normal	O
fat	O
cells	O
.	O

This	O
likely	O
resulted	O
from	O
defective	O
insulin	O
and	O
lipolytic	O
responses	O
that	O
converge	O
in	O
chronic	O
nutrient	O
shortage	O
in	O
adipocytes	O
lacking	O
caveolin	O
-	O
1	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
pathological	O
situation	O
with	O
autophagy	O
as	O
an	O
adaptative	O
response	O
to	O
adipocyte	O
failure	O
.	O

Palmitoylation	O
of	O
SARS	O
-	O
CoV	O
S	O
protein	O
is	O
necessary	O
for	O
partitioning	O
into	O
detergent	O
-	O
resistant	O
membranes	O
and	O
cell	O
-	O
cell	O
fusion	O
but	O
not	O
interaction	O
with	O
M	O
protein	O
.	O

Coronaviruses	O
are	O
enveloped	O
RNA	O
viruses	O
that	O
generally	O
cause	O
mild	O
disease	O
in	O
humans	O
.	O

However	O
,	O
the	O
recently	O
emerged	O
coronavirus	O
that	O
caused	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
-	O
CoV	O
)	O
is	O
the	O
most	O
pathogenic	O
human	O
coronavirus	O
discovered	O
to	O
date	O
.	O

The	O
SARS	O
-	O
CoV	O
spike	O
(	O
S	O
)	O
protein	O
mediates	O
virus	O
entry	O
by	O
binding	O
cellular	O
receptors	O
and	O
inducing	O
fusion	O
between	O
the	O
viral	O
envelope	O
and	O
the	O
host	O
cell	O
membrane	O
.	O

Coronavirus	O
S	O
proteins	O
are	O
palmitoylated	O
,	O
which	O
may	O
affect	O
function	O
.	O

Here	O
,	O
we	O
created	O
a	O
non	O
-	O
palmitoylated	O
SARS	O
-	O
CoV	O
S	O
protein	O
by	O
mutating	O
all	O
nine	O
cytoplasmic	O
cysteine	O
residues	O
.	O

Palmitoylation	O
of	O
SARS	O
-	O
CoV	O
S	O
was	O
required	O
for	O
partitioning	O
into	O
detergent	O
-	O
resistant	O
membranes	O
and	O
for	O
cell	O
-	O
cell	O
fusion	O
.	O

Surprisingly	O
,	O
however	O
,	O
palmitoylation	O
of	O
S	O
was	O
not	O
required	O
for	O
interaction	O
with	O
SARS	O
-	O
CoV	O
M	O
protein	O
.	O

This	O
contrasts	O
with	O
the	O
requirement	O
for	O
palmitoylation	O
of	O
mouse	O
hepatitis	O
virus	O
S	O
protein	O
for	O
interaction	O
with	O
M	O
protein	O
and	O
may	O
point	O
to	O
important	O
differences	O
in	O
assembly	O
and	O
infectivity	O
of	O
these	O
two	O
coronaviruses	O
.	O

Interplay	O
between	O
Cdh1	O
and	O
JNK	O
activity	O
during	O
the	O
cell	O
cycle	O
.	O

The	O
ubiquitin	O
ligase	O
APC	B-Complex
/	I-Complex
C	I-Complex
(	O
Cdh1	O
)	O
coordinates	O
degradation	O
of	O
key	O
cell	O
cycle	O
regulators	O
.	O

We	O
report	O
here	O
that	O
a	O
nuclear	O
-	O
localized	O
portion	O
of	O
the	O
stress	O
-	O
activated	O
kinase	O
JNK	O
is	O
degraded	O
by	O
the	O
APC	B-Complex
/	I-Complex
C	I-Complex
(	O
Cdh1	O
)	O
during	O
exit	O
from	O
mitosis	O
and	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Expression	O
of	O
a	O
non	O
-	O
degradable	O
JNK	O
induces	O
prometaphase	O
-	O
like	O
arrest	O
and	O
aberrant	O
mitotic	O
spindle	O
dynamics	O
.	O

Moreover	O
,	O
JNK	O
phosphorylates	O
Cdh1	O
directly	O
,	O
during	O
G2	O
and	O
early	O
mitosis	O
,	O
changing	O
its	O
subcellular	O
localization	O
and	O
attenuating	O
its	O
ability	O
to	O
activate	O
the	O
APC	B-Complex
/	I-Complex
C	I-Complex
during	O
G2	O
/	O
M	O
.	O

This	O
regulatory	O
mechanism	O
between	O
JNK	O
and	O
Cdh1	O
reveals	O
an	O
important	O
function	O
for	O
JNK	O
during	O
the	O
cell	O
cycle	O
.	O

Elucidation	O
of	O
XA21	O
-	O
mediated	O
innate	O
immunity	O
.	O

In	O
the	O
early	O
1970s	O
,	O
the	O
Xa21	O
gene	O
from	O
the	O
wild	O
rice	O
species	O
Oryza	O
longistaminata	O
drew	O
attention	O
of	O
rice	O
breeders	O
because	O
of	O
its	O
broad	O
-	O
spectrum	O
resistance	O
to	O
diverse	O
strains	O
of	O
a	O
serious	O
bacterial	O
disease	O
of	O
rice	O
in	O
Asia	O
and	O
Africa	O
,	O
called	O
'	O
bacterial	O
blight	O
disease	O
'	O
,	O
caused	O
by	O
the	O
Gram	O
-	O
negative	O
bacterium	O
,	O
Xanthomonas	O
oryzae	O
pv	O
.	O
oryzae	O
(	O
Xoo	O
)	O
.	O

In	O
1995	O
,	O
we	O
isolated	O
the	O
gene	O
controlling	O
this	O
resistance	O
and	O
in	O
2009	O
demonstrated	O
that	O
XA21	O
recognizes	O
a	O
highly	O
conserved	O
peptide	O
,	O
called	O
'	O
Ax21	O
'	O
(	O
activator	O
of	O
XA21	O
-	O
mediated	O
immunity	O
)	O
.	O

Tyrosine	O
sulfation	O
of	O
Ax21	O
is	O
required	O
for	O
recognition	O
by	O
rice	O
XA21	O
.	O

A	O
decade	O
of	O
genetic	O
,	O
molecular	O
and	O
biochemical	O
studies	O
have	O
uncovered	O
key	O
components	O
of	O
the	O
XA21	O
-	O
mediated	O
signalling	O
cascade	O
.	O

Ax21	O
recognition	O
by	O
XA21	O
at	O
the	O
cell	O
surface	O
induces	O
phosphorylation	O
-	O
mediated	O
events	O
,	O
which	O
are	O
predicted	O
to	O
alter	O
subcellular	O
localization	O
and	O
/	O
or	O
DNA	O
-	O
binding	O
activity	O
of	O
a	O
WRKY	O
family	O
of	O
transcription	O
factors	O
.	O

Because	O
XA21	O
is	O
representative	O
of	O
the	O
large	O
number	O
of	O
predicted	O
pattern	O
recognition	O
receptors	O
(	O
PRRs	O
)	O
in	O
rice	O
(	O
n	O
=	O
328	O
)	O
,	O
Arabidopsis	O
(	O
n	O
=	O
35	O
)	O
and	O
other	O
plant	O
species	O
,	O
further	O
characterization	O
of	O
XA21	O
-	O
mediated	O
signalling	O
pathways	O
will	O
contribute	O
to	O
elucidation	O
of	O
these	O
important	O
defence	O
responses	O
.	O

GFP	O
-	O
zip	O
/	O
MyoII	O
in	O
a	O
zipper	O
heterozygous	O
background	O
resulted	O
in	O
a	O
mild	O
rescue	O
of	O
the	O
crossvein	O
phenotypes	O
(	O
Table	O
1	O
)	O
.	O

Possible	O
reasons	O
for	O
these	O
observations	O
are	O
discussed	O
later	O
.	O

GFP	O
-	O
zip	O
/	O
MyoII	O
-	O
Neck	O
-	O
Rod	O
,	O
zip	O
/	O
MyoII	O
-	O
Rod	O
and	O
GFP	O
-	O
zip	O
/	O
MyoII	O
-	O
Rod	O
(	O
DeltaNterm58	O
)	O
expressing	O
wings	O
often	O
exhibited	O
similar	O
vein	O
and	O
crossvein	O
phenotypes	O
to	O
those	O
induced	O
by	O
zip	O
/	O
MyoII	O
-	O
HMM	O
(	O
DeltaCterm407	O
)	O
-	O
GFP	O
.	O

Due	O
to	O
the	O
severity	O
of	O
these	O
other	O
phenotypes	O
the	O
vein	O
and	O
crossvein	O
phenotypes	O
were	O
difficult	O
to	O
document	O
and	O
quantify	O
.	O

Regulation	O
of	O
the	O
p53	O
pathway	O
by	O
ubiquitin	O
and	O
related	O
proteins	O
.	O

The	O
p53	O
tumour	O
suppressor	O
protein	O
is	O
subject	O
to	O
many	O
levels	O
of	O
control	O
,	O
including	O
modification	O
with	O
ubiquitin	O
and	O
related	O
proteins	O
such	O
as	O
SUMO	O
and	O
NEDD8	O
.	O

These	O
modifications	O
regulate	O
p53	O
at	O
a	O
number	O
of	O
levels	O
,	O
including	O
control	O
of	O
protein	O
turnover	O
,	O
alterations	O
in	O
sub	O
-	O
cellular	O
localization	O
and	O
changes	O
in	O
the	O
ability	O
to	O
regulate	O
gene	O
expression	O
.	O

Numerous	O
E3	O
ligases	O
that	O
can	O
mediate	O
these	O
modifications	O
of	O
p53	O
have	O
been	O
described	O
,	O
some	O
of	O
which	O
promote	O
conjugation	O
with	O
more	O
than	O
one	O
ubiquitin	O
-	O
like	O
protein	O
.	O

Understanding	O
the	O
complexity	O
of	O
this	O
mechanism	O
of	O
p53	O
regulation	O
will	O
help	O
in	O
the	O
development	O
of	O
therapeutic	O
drugs	O
that	O
function	O
to	O
modulate	O
these	O
events	O
.	O

Preferential	O
selection	O
of	O
the	O
5	O
'	O
-	O
terminal	O
start	O
codon	O
on	O
leaderless	O
mRNAs	O
by	O
mammalian	O
mitochondrial	O
ribosomes	B-OOS
.	O

Mammalian	O
mitochondrial	O
mRNAs	O
are	O
basically	O
leaderless	O
,	O
having	O
few	O
or	O
no	O
untranslated	O
nucleotides	O
prior	O
to	O
the	O
5	O
'	O
-	O
start	O
codon	O
.	O

We	O
demonstrate	O
here	O
that	O
mammalian	O
mitochondrial	B-OOS
55	I-OOS
S	I-OOS
ribosomes	I-OOS
preferentially	O
form	O
initiation	B-OOS
complexes	I-OOS
at	O
a	O
5	O
'	O
-	O
terminal	O
AUG	O
codon	O
over	O
an	O
internal	O
AUG	O
.	O

The	O
preferential	O
use	O
of	O
the	O
5	O
'	O
-	O
start	O
codon	O
is	O
also	O
seen	O
on	O
mitochondrial	O
28	B-Complex
S	I-Complex
small	O
subunits	O
,	O
which	O
suggests	O
that	O
mitochondrial	O
translation	O
initiation	O
on	O
leaderless	O
mRNAs	O
does	O
not	O
require	O
the	O
large	B-Complex
ribosomal	I-Complex
subunit	I-Complex
.	O

The	O
selection	O
of	O
the	O
5	O
'	O
-	O
AUG	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
fMet	O
-	O
tRNA	O
and	O
is	O
enhanced	O
by	O
the	O
presence	O
of	O
the	O
mitochondrial	O
initiation	O
factor	O
IF2	O
(	O
mt	O
)	O
.	O

In	O
prokaryotes	O
,	O
IF3	O
is	O
believed	O
to	O
antagonize	O
initiation	O
on	O
leaderless	O
mRNAs	O
.	O

However	O
,	O
IF3	O
(	O
mt	O
)	O
stimulates	O
initiation	B-OOS
complex	I-OOS
formation	O
on	O
leaderless	O
mRNAs	O
when	O
tested	O
with	O
55	B-OOS
S	I-OOS
ribosomes	I-OOS
.	O

The	O
addition	O
of	O
even	O
a	O
few	O
nucleotides	O
5	O
'	O
to	O
the	O
AUG	O
codon	O
significantly	O
reduces	O
the	O
efficiency	O
of	O
initiation	O
,	O
highlighting	O
the	O
importance	O
of	O
the	O
leaderless	O
or	O
nearly	O
leaderless	O
nature	O
of	O
mitochondrial	O
mRNAs	O
.	O

In	O
addition	O
,	O
very	O
few	O
initiation	B-OOS
complexes	I-OOS
could	O
form	O
on	O
a	O
hybrid	O
mRNA	O
construct	O
consisting	O
of	O
tRNA	O
(	O
Met	O
)	O
attached	O
at	O
the	O
5	O
'	O
-	O
end	O
of	O
a	O
mitochondrial	O
protein	O
-	O
coding	O
sequence	O
.	O

This	O
observation	O
demonstrates	O
that	O
post	O
-	O
transcriptional	O
processing	O
must	O
occur	O
prior	O
to	O
translation	O
in	O
mammalian	O
mitochondria	O
.	O

Dynamics	O
of	O
cohesin	B-Complex
proteins	O
REC8	O
,	O
STAG3	O
,	O
SMC1	O
beta	O
and	O
SMC3	O
are	O
consistent	O
with	O
a	O
role	O
in	O
sister	O
chromatid	O
cohesion	O
during	O
meiosis	O
in	O
human	O
oocytes	O
.	O

BACKGROUND	O
:	O
Sister	O
chromatid	O
cohesion	O
is	O
essential	O
for	O
ordered	O
chromosome	O
segregation	O
at	O
mitosis	O
and	O
meiosis	O
.	O

This	O
is	O
carried	O
out	O
by	O
cohesin	B-Complex
complexes	O
,	O
comprising	O
four	O
proteins	O
,	O
which	O
seem	O
to	O
form	O
a	O
ring	O
-	O
like	O
complex	O
.	O

Data	O
from	O
animal	O
models	O
suggest	O
that	O
loss	O
of	O
sister	O
chromatid	O
cohesion	O
may	O
be	O
involved	O
in	O
age	O
-	O
related	O
non	O
-	O
disjunction	O
in	O
human	O
oocytes	O
.	O

Here	O
,	O
we	O
describe	O
the	O
distribution	O
of	O
cohesins	B-Complex
throughout	O
meiosis	O
in	O
human	O
oocytes	O
.	O

METHODS	O
:	O
We	O
used	O
immunofluorescence	O
in	O
human	O
oocytes	O
at	O
different	O
meiotic	O
stages	O
to	O
detect	O
cohesin	B-Complex
subunits	O
REC8	O
,	O
STAG3	O
,	O
SMC1	O
beta	O
and	O
SMC3	O
,	O
[	O
also	O
synaptonemal	O
complex	O
(	O
SC	O
)	O
protein	O
3	O
and	O
shugoshin	O
1	O
]	O
.	O

Samples	O
from	O
euploid	O
fetuses	O
and	O
adult	O
women	O
were	O
collected	O
,	O
and	O
51	O
metaphase	O
I	O
(	O
MI	O
)	O
and	O
113	O
metaphase	O
II	O
(	O
MII	O
)	O
oocytes	O
analyzed	O
.	O

SMC1	O
beta	O
transcript	O
levels	O
were	O
quantified	O
in	O
85	O
maturing	O
germinal	O
vesicle	O
(	O
GV	O
)	O
oocytes	O
from	O
34	O
women	O
aged	O
19	O
-	O
43	O
years	O
by	O
real	O
-	O
time	O
PCR	O
.	O

RESULTS	O
:	O
At	O
prophase	O
I	O
,	O
cohesin	B-Complex
subunits	O
REC8	O
,	O
STAG3	O
,	O
SMC1	O
beta	O
and	O
SMC3	O
overlapped	O
with	O
the	O
lateral	O
element	O
of	O
the	O
SC	B-Complex
.	O

Short	O
cohesin	B-Complex
fibers	O
are	O
observed	O
in	O
the	O
oocyte	O
nucleus	O
during	O
dictyate	O
arrest	O
.	O

All	O
four	O
subunits	O
are	O
observed	O
at	O
centromeres	O
and	O
along	O
chromosomal	O
arms	O
,	O
except	O
at	O
chiasmata	O
,	O
at	O
MI	O
and	O
are	O
present	O
at	O
centromeric	O
domains	O
from	O
anaphase	O
I	O
to	O
MII	O
.	O

SMC1	O
beta	O
transcripts	O
were	O
detected	O
(	O
with	O
high	O
inter	O
-	O
sample	O
variability	O
)	O
in	O
GV	O
oocytes	O
but	O
no	O
correlation	O
between	O
SMC1	O
beta	O
mRNA	O
levels	O
and	O
age	O
was	O
found	O
.	O

CONCLUSIONS	O
:	O
The	O
dynamics	O
of	O
cohesins	B-Complex
REC8	O
,	O
STAG3	O
,	O
SMC1	O
beta	O
and	O
SMC3	O
suggest	O
their	O
participation	O
in	O
sister	O
chromatid	O
cohesion	O
throughout	O
the	O
whole	O
meiotic	O
process	O
in	O
human	O
oocytes	O
.	O

Our	O
data	O
do	O
not	O
support	O
the	O
view	O
that	O
decreased	O
levels	O
of	O
SMC1	O
beta	O
gene	O
expression	O
in	O
older	O
women	O
are	O
involved	O
in	O
age	O
-	O
related	O
non	O
-	O
disjunction	O
.	O

C	O
.	O
elegans	O
CAND	O
-	O
1	O
regulates	O
cullin	O
neddylation	O
,	O
cell	O
proliferation	O
and	O
morphogenesis	O
in	O
specific	O
tissues	O
.	O

Cullin	O
-	O
RING	O
ubiquitin	O
ligases	O
(	O
CRLs	O
)	O
are	O
critical	O
regulators	O
of	O
multiple	O
developmental	O
and	O
cellular	O
processes	O
in	O
eukaryotes	O
.	O

CAND1	O
is	O
a	O
biochemical	O
inhibitor	O
of	O
CRLs	O
,	O
yet	O
has	O
been	O
shown	O
to	O
promote	O
CRL	O
activity	O
in	O
plant	O
and	O
mammalian	O
cells	O
.	O

Here	O
we	O
analyze	O
CAND1	O
function	O
in	O
the	O
context	O
of	O
a	O
developing	O
metazoan	O
organism	O
.	O

Caenorhabditis	O
elegans	O
CAND	O
-	O
1	O
is	O
capable	O
of	O
binding	O
to	O
all	O
of	O
the	O
cullins	O
,	O
and	O
we	O
show	O
that	O
it	O
physically	O
interacts	O
with	O
CUL	O
-	O
2	O
and	O
CUL	O
-	O
4	O
in	O
vivo	O
.	O

The	O
covalent	O
attachment	O
of	O
the	O
ubiquitin	O
-	O
like	O
protein	O
Nedd8	O
is	O
required	O
for	O
cullin	O
activity	O
in	O
animals	O
and	O
plants	O
.	O

In	O
cand	O
-	O
1	O
mutants	O
,	O
the	O
levels	O
of	O
the	O
neddylated	O
isoforms	O
of	O
CUL	O
-	O
2	O
and	O
CUL	O
-	O
4	O
are	O
increased	O
,	O
indicating	O
that	O
CAND	O
-	O
1	O
is	O
a	O
negative	O
regulator	O
of	O
cullin	O
neddylation	O
.	O

cand	O
-	O
1	O
mutants	O
are	O
hypersensitive	O
to	O
the	O
partial	O
loss	O
of	O
cullin	O
activity	O
,	O
suggesting	O
that	O
CAND	O
-	O
1	O
facilitates	O
CRL	O
functions	O
.	O

cand	O
-	O
1	O
mutants	O
exhibit	O
impenetrant	O
phenotypes	O
,	O
including	O
developmental	O
arrest	O
,	O
morphological	O
defects	O
of	O
the	O
vulva	O
and	O
tail	O
,	O
and	O
reduced	O
fecundity	O
.	O

cand	O
-	O
1	O
mutants	O
share	O
with	O
cul	O
-	O
1	O
and	O
lin	O
-	O
23	O
mutants	O
the	O
phenotypes	O
of	O
supernumerary	O
seam	O
cell	O
divisions	O
,	O
defective	O
alae	O
formation	O
,	O
and	O
the	O
accumulation	O
of	O
the	O
SCF	B-Complex
(	I-Complex
LIN	I-Complex
-	I-Complex
23	I-Complex
)	I-Complex
target	O
the	O
glutamate	O
receptor	O
GLR	O
-	O
1	O
.	O

The	O
observation	O
that	O
cand	O
-	O
1	O
mutants	O
have	O
phenotypes	O
associated	O
with	O
the	O
loss	O
of	O
the	O
SCF	B-Complex
(	I-Complex
LIN	I-Complex
-	I-Complex
23	I-Complex
)	I-Complex
complex	O
,	O
but	O
lack	O
phenotypes	O
associated	O
with	O
other	O
specific	O
CRL	O
complexes	O
,	O
suggests	O
that	O
CAND	O
-	O
1	O
is	O
differentially	O
required	O
for	O
the	O
activity	O
of	O
distinct	O
CRL	O
complexes	O
.	O

A	O
striking	O
feature	O
of	O
KPNA7	O
is	O
its	O
localization	O
to	O
the	O
nucleus	O
under	O
steady	O
state	O
conditions	O
,	O
while	O
KPNA2	O
is	O
predominantly	O
cytoplasmic	O
.	O

This	O
nuclear	O
localization	O
suggests	O
that	O
nucleocytoplasmic	O
shuttling	O
of	O
KPNA7	O
differs	O
from	O
that	O
of	O
the	O
other	O
members	O
of	O
the	O
importin	O
alpha	O
family	O
.	O

There	O
are	O
three	O
possibilities	O
for	O
the	O
altered	O
subcellular	O
distribution	O
;	O
1	O
)	O
enhanced	O
nuclear	O
import	O
by	O
importin	O
beta	O
;	O
2	O
)	O
decreased	O
nuclear	O
export	O
by	O
CAS	O
;	O
and	O
3	O
)	O
inefficient	O
release	O
of	O
KPNA7	O
from	O
target	O
NLS	O
,	O
resulting	O
in	O
nuclear	O
retention	O
.	O

The	O
most	O
likely	O
of	O
these	O
situations	O
,	O
given	O
our	O
evidence	O
that	O
KPNA7	O
binds	O
importin	O
beta	O
with	O
much	O
higher	O
affinity	O
than	O
other	O
a	O
family	O
members	O
is	O
that	O
this	O
enhanced	O
binding	O
results	O
in	O
increased	O
nuclear	O
import	O
of	O
KPNA7	O
.	O

Similarly	O
,	O
the	O
different	O
Galpha	O
-	O
subunits	O
possess	O
a	O
similar	O
affinity	O
towards	O
the	O
interaction	O
with	O
the	O
Gbetagamma	B-OOS
heterodimer	O
,	O
not	O
providing	O
an	O
explanation	O
for	O
a	O
specific	O
ability	O
of	O
Galphao	O
to	O
antagonize	O
the	O
Gs	B-OOS
-	O
mediated	O
post	O
-	O
eclosion	O
pathway	O
.	O

We	O
are	O
thus	O
tempted	O
to	O
propose	O
that	O
a	O
previously	O
uncharacterized	O
biochemical	O
mechanism	O
may	O
allow	O
for	O
a	O
specific	O
antagonism	O
physiologically	O
existing	O
between	O
the	O
Gs	B-OOS
-	O
and	O
Go	B-OOS
-	O
mediated	O
signaling	O
pathways	O
.	O

As	O
liberation	O
of	O
high	O
amounts	O
of	O
GDP	O
-	O
loaded	O
Galphao	O
is	O
predicted	O
to	O
be	O
a	O
consequence	O
of	O
activation	O
of	O
multiple	O
Go	B-OOS
-	O
coupled	O
GPCRs	O
,	O
and	O
as	O
Go	B-OOS
is	O
a	O
heavily	O
expressed	O
G	B-OOS
protein	I-OOS
representing	O
the	O
major	O
G	B-OOS
protein	I-OOS
species	O
e	O
.	O
g	O
.	O
in	O
the	O
brain	O
of	O
flies	O
and	O
mammals	O
,	O
this	O
specific	O
ability	O
of	O
Galphao	O
to	O
antagonize	O
the	O
Gs	B-OOS
-	O
mediated	O
signaling	O
may	O
have	O
physiological	O
implications	O
in	O
other	O
tissues	O
and	O
organisms	O
than	O
Drosophila	O
wing	O
.	O

However	O
,	O
we	O
would	O
like	O
to	O
add	O
that	O
these	O
speculations	O
are	O
based	O
on	O
the	O
analysis	O
of	O
the	O
overexpression	O
data	O
and	O
must	O
be	O
treated	O
with	O
caution	O
when	O
translating	O
them	O
into	O
physiological	O
situations	O
.	O

Purification	O
of	O
TCF	O
-	O
1	O
alpha	O
,	O
a	O
T	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
that	O
activates	O
the	O
T	O
-	O
cell	O
receptor	O
C	O
alpha	O
gene	O
enhancer	O
in	O
a	O
context	O
-	O
dependent	O
manner	O
.	O

The	O
differentiation	O
of	O
T	O
cells	O
into	O
functionally	O
diverse	O
subpopulations	O
is	O
controlled	O
in	O
part	O
,	O
by	O
transcriptional	O
activation	O
and	O
silencing	O
;	O
however	O
,	O
little	O
is	O
known	O
in	O
detail	O
about	O
the	O
proteins	O
that	O
influence	O
this	O
developmental	O
process	O
.	O

We	O
have	O
purified	O
a	O
new	O
T	O
-	O
cell	O
-	O
specific	O
factor	O
,	O
TCF	O
-	O
1	O
alpha	O
,	O
that	O
is	O
implicated	O
in	O
the	O
activation	O
of	O
genes	O
encoding	O
a	O
major	O
component	O
of	O
the	O
human	O
T	B-Complex
-	I-Complex
cell	I-Complex
receptor	I-Complex
(	O
TCR	B-Complex
)	O
.	O

TCF	O
-	O
1	O
alpha	O
,	O
originally	O
identified	O
and	O
purified	O
through	O
its	O
binding	O
sites	O
on	O
the	O
HIV	O
-	O
1	O
promoter	O
,	O
was	O
found	O
to	O
bind	O
to	O
the	O
TCR	O
alpha	O
enhancer	O
and	O
to	O
promoters	O
for	O
several	O
genes	O
expressed	O
at	O
significantly	O
earlier	O
stages	O
of	O
T	O
-	O
cell	O
development	O
than	O
the	O
TCR	O
alpha	O
gene	O
(	O
e	O
.	O
g	O
.	O
,	O
p56lck	O
and	O
CD3	O
delta	O
)	O
.	O

Sequences	O
related	O
to	O
the	O
TCF	O
-	O
1	O
alpha	O
binding	O
motif	O
(	O
5	O
'	O
-	O
GGCACCCTTTGA	O
-	O
3	O
'	O
)	O
are	O
also	O
found	O
in	O
the	O
human	O
TCR	O
delta	O
(	O
and	O
possibly	O
TCR	O
beta	O
)	O
enhancers	O
.	O

Southwestern	O
and	O
gel	O
renaturation	O
experiments	O
with	O
the	O
use	O
of	O
purified	O
protein	O
fractions	O
revealed	O
that	O
TCF	O
-	O
1	O
alpha	O
activity	O
is	O
derived	O
from	O
a	O
family	O
of	O
57	O
-	O
to	O
53	O
-	O
kD	O
proteins	O
that	O
are	O
abundantly	O
expressed	O
in	O
mature	O
and	O
immature	O
T	O
-	O
cell	O
lines	O
(	O
Jurkat	O
,	O
CCRF	O
-	O
CEM	O
)	O
and	O
not	O
in	O
mature	O
B	O
cells	O
(	O
JY	O
,	O
Namalwa	O
)	O
or	O
nonlymphoid	O
(	O
HeLa	O
)	O
cell	O
lines	O
.	O

A	O
small	O
95	O
-	O
bp	O
fragment	O
of	O
the	O
TCR	O
alpha	O
control	O
region	O
that	O
contains	O
the	O
TCF	O
-	O
1	O
alpha	O
binding	O
site	O
juxtaposed	O
between	O
a	O
cAMP	O
-	O
response	O
element	O
(	O
the	O
CRE	O
or	O
T	O
alpha	O
1	O
motif	O
)	O
and	O
the	O
binding	O
site	O
for	O
a	O
distinct	O
lymphoid	O
-	O
specific	O
protein	O
(	O
TCF	O
-	O
2	O
alpha	O
)	O
behaved	O
as	O
a	O
potent	O
T	O
-	O
cell	O
-	O
specific	O
enhancer	O
in	O
vivo	O
.	O

Tandem	O
copies	O
of	O
this	O
enhancer	O
functioned	O
synergistically	O
in	O
mature	O
(	O
Jurkat	O
)	O
T	O
-	O
cell	O
lines	O
as	O
well	O
as	O
resting	O
and	O
activated	O
immature	O
(	O
CCRF	O
-	O
CEM	O
)	O
T	O
-	O
cell	O
lines	O
.	O

Mutation	O
of	O
the	O
TCF	O
-	O
1	O
alpha	O
binding	O
site	O
diminished	O
enhancer	O
activity	O
and	O
disrupted	O
the	O
synergism	O
observed	O
in	O
vivo	O
between	O
tandem	O
enhancer	O
repeats	O
.	O

The	O
TCF	O
-	O
1	O
alpha	O
binding	O
site	O
was	O
also	O
required	O
for	O
TCR	O
alpha	O
enhancer	O
activity	O
in	O
transcriptionally	O
active	O
extracts	O
from	O
Jurkat	O
but	O
not	O
HeLa	O
cells	O
,	O
confirming	O
that	O
TCF	O
-	O
1	O
alpha	O
is	O
a	O
T	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
.	O

Curiously	O
,	O
the	O
TCF	O
-	O
1	O
alpha	O
binding	O
element	O
was	O
inactive	O
in	O
vivo	O
when	O
removed	O
from	O
its	O
neighboring	O
elements	O
on	O
the	O
TCR	O
alpha	O
enhancer	O
and	O
positioned	O
in	O
one	O
or	O
more	O
copies	O
upstream	O
of	O
a	O
heterologous	O
promoter	O
.	O

Thus	O
,	O
the	O
transcriptional	O
activity	O
of	O
TCF	O
-	O
1	O
alpha	O
appears	O
to	O
depend	O
on	O
the	O
TCF	O
-	O
2	O
alpha	O
and	O
T	O
alpha	O
1	O
(	O
CREB	O
)	O
transcription	O
factors	O
and	O
the	O
context	O
of	O
its	O
binding	O
site	O
within	O
the	O
TCR	O
alpha	O
enhancer	O
.	O

To	O
examine	O
if	O
any	O
of	O
these	O
decapping	O
activators	O
directly	O
affected	O
translation	O
,	O
we	O
examined	O
the	O
affect	O
of	O
recombinant	O
Scd6	O
,	O
and	O
different	O
domains	O
of	O
Edc3	O
and	O
Pat1	O
on	O
translation	O
in	O
vitro	O
.	O

Purification	O
of	O
sufficient	O
full	O
length	O
Edc3	O
and	O
Pat1	O
protein	O
for	O
measuring	O
their	O
effects	O
on	O
translation	O
was	O
not	O
possible	O
due	O
to	O
solubility	O
issues	O
.	O

Critical	O
role	O
of	O
endoglin	O
in	O
tumor	O
cell	O
plasticity	O
of	O
Ewing	O
sarcoma	O
and	O
melanoma	O
.	O

Tumor	O
cell	O
plasticity	O
enables	O
certain	O
types	O
of	O
highly	O
malignant	O
tumor	O
cells	O
to	O
dedifferentiate	O
and	O
engage	O
a	O
plastic	O
multipotent	O
embryonic	O
-	O
like	O
phenotype	O
,	O
which	O
enables	O
them	O
to	O
'	O
adapt	O
'	O
during	O
tumor	O
progression	O
and	O
escape	O
conventional	O
therapeutic	O
strategies	O
.	O

This	O
plastic	O
phenotype	O
of	O
aggressive	O
cancer	O
cells	O
enables	O
them	O
to	O
express	O
endothelial	O
cell	O
-	O
specific	O
markers	O
and	O
form	O
tube	O
-	O
like	O
structures	O
,	O
a	O
phenotype	O
that	O
has	O
been	O
linked	O
to	O
aggressive	O
behavior	O
and	O
poor	O
prognosis	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
beta	O
co	O
-	O
receptor	O
endoglin	O
,	O
an	O
endothelial	O
cell	O
marker	O
,	O
is	O
expressed	O
by	O
tumor	O
cells	O
and	O
its	O
expression	O
correlates	O
with	O
tumor	O
cell	O
plasticity	O
in	O
two	O
types	O
of	O
human	O
cancer	O
,	O
Ewing	O
sarcoma	O
and	O
melanoma	O
.	O

Moreover	O
,	O
endoglin	O
expression	O
was	O
significantly	O
associated	O
with	O
worse	O
survival	O
of	O
Ewing	O
sarcoma	O
patients	O
.	O

Endoglin	O
knockdown	O
in	O
tumor	O
cells	O
interferes	O
with	O
tumor	O
cell	O
plasticity	O
and	O
reduces	O
invasiveness	O
and	O
anchorage	O
-	O
independent	O
growth	O
in	O
vitro	O
.	O

Ewing	O
sarcoma	O
and	O
melanoma	O
cells	O
with	O
reduced	O
endoglin	O
levels	O
showed	O
reduced	O
tumor	O
growth	O
in	O
vivo	O
.	O

Mechanistically	O
,	O
we	O
provide	O
evidence	O
that	O
endoglin	O
,	O
while	O
interfering	O
with	O
TGF	O
-	O
beta	O
signaling	O
,	O
is	O
required	O
for	O
efficient	O
bone	O
morphogenetic	O
protein	O
,	O
integrin	O
,	O
focal	O
adhesion	O
kinase	O
and	O
phosphoinositide	O
-	O
3	O
-	O
kinase	O
signaling	O
in	O
order	O
to	O
maintain	O
tumor	O
cell	O
plasticity	O
.	O

The	O
present	O
study	O
delineates	O
an	O
important	O
role	O
of	O
endoglin	O
in	O
tumor	O
cell	O
plasticity	O
and	O
progression	O
of	O
aggressive	O
tumors	O
.	O

RA	O
promotes	O
epigenetic	O
changes	O
.	O

RA	O
treatment	O
of	O
ES	O
cells	O
decreases	O
H3k27me3	O
and	O
increases	O
H3k4me3	O
marks	O
.	O

Moreover	O
,	O
RA	O
displaces	O
Suz12	O
from	O
some	O
of	O
RA	O
response	O
elements	O
(	O
RAREs	O
)	O
in	O
F9	O
cells	O
.	O

Suz12	O
,	O
a	O
member	O
of	O
Polycomb	B-Complex
Repressive	I-Complex
Complex	I-Complex
-	I-Complex
2	I-Complex
(	O
PRC2	B-Complex
)	O
involved	O
in	O
H3K27me3	O
methylation	O
and	O
in	O
maintaining	O
ES	O
cell	O
self	O
-	O
renewal	O
,	O
is	O
a	O
powerful	O
repressor	O
of	O
homeobox	O
(	O
Hox	O
)	O
gene	O
expression	O
.	O

Hox	O
gene	O
clusters	O
are	O
expressed	O
during	O
ES	O
cell	O
differentiation	O
and	O
transcriptionally	O
activated	O
by	O
RA	O
.	O

Our	O
data	O
indicates	O
that	O
the	O
Rbf1	O
IE	O
region	O
influences	O
Rbf1	O
instability	O
and	O
contributes	O
to	O
Rbf1	O
repression	O
potency	O
,	O
providing	O
a	O
link	O
between	O
these	O
two	O
activities	O
.	O

However	O
,	O
during	O
these	O
analyses	O
we	O
additionally	O
observed	O
that	O
Rbf1	O
(	O
6KA	O
)	O
,	O
harboring	O
substitutions	O
of	O
all	O
lysine	O
residues	O
within	O
the	O
IE	O
was	O
reproducibly	O
a	O
more	O
potent	O
repressor	O
than	O
Rbf1	O
(	O
4KA	O
)	O
,	O
harboring	O
substitutions	O
of	O
only	O
the	O
four	O
most	O
N	O
-	O
terminal	O
lysine	O
residues	O
within	O
the	O
IE	O
.	O

This	O
observation	O
raised	O
the	O
possibility	O
that	O
while	O
most	O
of	O
the	O
lysines	O
play	O
a	O
positive	O
role	O
in	O
Rbf1	O
repression	O
,	O
one	O
or	O
both	O
of	O
the	O
C	O
-	O
terminal	O
-	O
most	O
lysine	O
residues	O
(	O
K774	O
,	O
K782	O
)	O
play	O
a	O
negative	O
role	O
,	O
restricting	O
Rbf1	O
activity	O
.	O

Therefore	O
,	O
to	O
determine	O
whether	O
the	O
lysine	O
residues	O
within	O
the	O
IE	O
contribute	O
to	O
both	O
positive	O
and	O
negative	O
regulation	O
of	O
Rbf1	O
function	O
,	O
we	O
tested	O
the	O
repression	O
activities	O
of	O
Rbf1	O
proteins	O
with	O
individual	O
alanine	O
substitutions	O
of	O
each	O
lysine	O
residue	O
within	O
the	O
IE	O
.	O

A	O
subset	O
of	O
these	O
results	O
is	O
shown	O
in	O
Figure	O
6A	O
,	O
revealing	O
three	O
outcomes	O
.	O

In	O
one	O
case	O
(	O
K732	O
)	O
,	O
alanine	O
substitution	O
did	O
not	O
affect	O
repressor	O
potency	O
and	O
was	O
indistinguishable	O
from	O
wild	O
-	O
type	O
Rbf1	O
.	O

The	O
second	O
class	O
of	O
mutants	O
were	O
hypomorphic	O
(	O
K739	O
,	O
K740	O
,	O
K754	O
)	O
,	O
exhibiting	O
modest	O
but	O
reproducible	O
inhibitory	O
effects	O
on	O
repression	O
,	O
consistent	O
with	O
these	O
residues	O
contributing	O
a	O
positive	O
influence	O
on	O
repressor	O
potency	O
(	O
Figure	O
6	O
,	O
A	O
and	O
B	O
)	O
.	O

In	O
contrast	O
,	O
three	O
mutants	O
,	O
K774A	O
,	O
K774R	O
,	O
and	O
K782A	O
exhibited	O
hypermorphic	O
phenotypes	O
with	O
modest	O
but	O
reproducibly	O
higher	O
repression	O
activity	O
than	O
the	O
wild	O
-	O
type	O
Rbf1	O
protein	O
,	O
suggesting	O
that	O
these	O
residues	O
are	O
involved	O
in	O
a	O
negative	O
control	O
of	O
repressor	O
activity	O
(	O
Figure	O
6	O
,	O
A	O
and	O
B	O
)	O
.	O

In	O
cases	O
where	O
lysine	O
to	O
arginine	O
substitution	O
did	O
not	O
moderate	O
activity	O
to	O
wild	O
-	O
type	O
levels	O
,	O
such	O
as	O
with	O
K754	O
and	O
K774	O
,	O
it	O
is	O
possible	O
that	O
the	O
lysine	O
in	O
question	O
is	O
a	O
target	O
of	O
modification	O
,	O
as	O
a	O
positive	O
charge	O
is	O
not	O
the	O
sole	O
important	O
feature	O
.	O

However	O
,	O
for	O
mutants	O
with	O
only	O
single	O
point	O
mutations	O
,	O
we	O
did	O
not	O
observe	O
the	O
robust	O
stabilization	O
of	O
mutant	O
proteins	O
compared	O
with	O
the	O
wild	O
-	O
type	O
protein	O
(	O
not	O
shown	O
)	O
.	O

Together	O
,	O
these	O
data	O
also	O
indicate	O
that	O
the	O
IE	O
exerts	O
both	O
positive	O
and	O
negative	O
influences	O
on	O
transcriptional	O
activity	O
.	O

Those	O
mutant	O
forms	O
of	O
Rbf1	O
lacking	O
all	O
lysines	O
exhibited	O
intermediate	O
repression	O
phenotypes	O
because	O
of	O
two	O
distinct	O
and	O
opposite	O
effects	O
,	O
with	O
decreased	O
activity	O
caused	O
by	O
mutations	O
in	O
K739	O
,	O
740	O
,	O
and	O
754	O
partially	O
offset	O
by	O
increased	O
activity	O
mediated	O
by	O
the	O
mutation	O
of	O
K774	O
and	O
K782	O
.	O

At	O
Pol	B-Complex
II	I-Complex
promoters	O
,	O
RSC	B-Complex
activity	O
generally	O
involves	O
single	O
nucleosome	O
events	O
that	O
help	O
to	O
form	O
and	O
maintain	O
the	O
NFR	O
.	O

These	O
data	O
were	O
generated	O
from	O
studies	O
using	O
a	O
temperature	O
sensitive	O
mutant	O
of	O
the	O
Sth1	O
catalytic	O
subunit	O
,	O
which	O
is	O
common	O
to	O
both	O
the	O
RSC1	O
and	O
RSC2	O
complexes	O
.	O

We	O
found	O
that	O
only	O
the	O
RSC1	O
complex	O
affects	O
genome	O
-	O
wide	O
5	O
'	O
acetylated	O
H4	O
levels	O
,	O
and	O
that	O
the	O
small	O
STE11	O
cryptic	O
transcript	O
is	O
sensitive	O
to	O
RSC1	O
deletion	O
.	O

It	O
is	O
possible	O
that	O
in	O
the	O
absence	O
of	O
the	O
RSC1	O
complex	O
,	O
certain	O
promoters	O
are	O
not	O
able	O
to	O
maintain	O
an	O
NFR	O
and	O
therefore	O
have	O
greater	O
histone	O
density	O
at	O
the	O
promoter	O
region	O
.	O

Future	O
studies	O
could	O
examine	O
the	O
role	O
of	O
RSC1	O
complex	O
versus	O
RSC2	O
complex	O
in	O
the	O
establishment	O
and	O
maintenance	O
of	O
Pol	B-Complex
II	I-Complex
promoter	O
NFRs	O
.	O

Translational	O
defects	O
in	O
a	O
mutant	O
deficient	O
in	O
YajL	O
,	O
the	O
bacterial	O
homolog	O
of	O
the	O
parkinsonism	O
-	O
associated	O
protein	O
DJ	O
-	O
1	O
.	O

We	O
report	O
here	O
that	O
YajL	O
is	O
associated	O
with	O
ribosomes	B-OOS
and	O
interacts	O
with	O
many	O
ribosomal	O
proteins	O
and	O
that	O
a	O
yajL	O
mutant	O
of	O
Escherichia	O
coli	O
displays	O
decreased	O
translation	O
accuracy	O
,	O
as	O
well	O
as	O
increased	O
dissociation	O
of	O
70S	B-OOS
ribosomes	I-OOS
into	O
50S	B-Complex
and	O
30S	B-Complex
subunits	O
after	O
oxidative	O
stress	O
.	O

We	O
also	O
tested	O
the	O
influence	O
of	O
a	O
set	O
of	O
mutations	O
in	O
the	O
DEP	O
domain	O
on	O
its	O
association	O
of	O
Dvl2	O
(	O
417	O
-	O
588	O
)	O
with	O
mu2C	O
and	O
with	O
intact	O
AP	B-Complex
-	I-Complex
2	I-Complex
,	O
purified	O
from	O
bovine	O
brain	O
(	O
Fig	O
.	O
6	O
)	O
.	O

Because	O
the	O
DEP	O
-	O
mu2	O
contact	O
is	O
weak	O
,	O
we	O
chose	O
to	O
use	O
as	O
bait	O
in	O
the	O
pull	O
-	O
down	O
assay	O
the	O
Dvl2	O
fragment	O
(	O
417	O
-	O
588	O
)	O
containing	O
both	O
the	O
DEP	O
domain	O
and	O
the	O
tyrosine	O
motif	O
.	O

We	O
therefore	O
were	O
testing	O
for	O
modulations	O
in	O
apparent	O
affinity	O
,	O
rather	O
than	O
all	O
-	O
or	O
-	O
none	O
effects	O
.	O

Mutating	O
the	O
tyrosine	O
residue	O
of	O
YHEL	O
results	O
in	O
a	O
substantial	O
loss	O
of	O
binding	O
as	O
expected	O
.	O

Single	O
polar	O
amino	O
-	O
acid	O
changes	O
(	O
Asp441Lys	O
,	O
Asn451Ala	O
,	O
Arg489Ala	O
)	O
reduced	O
affinity	O
;	O
double	O
or	O
triple	O
mutation	O
did	O
not	O
produce	O
a	O
further	O
decrease	O
(	O
Fig	O
.	O
6	O
)	O
.	O

We	O
conclude	O
that	O
even	O
the	O
single	O
substitutions	O
in	O
the	O
DEP	O
domain	O
fully	O
destabilize	O
the	O
DEP	O
:	O
mu2	O
interface	O
,	O
and	O
further	O
changes	O
do	O
not	O
affect	O
the	O
basal	O
affinity	O
determined	O
by	O
the	O
tyrosine	O
motif	O
.	O

Many	O
intrinsically	O
disordered	O
eukaryotic	O
proteins	O
have	O
been	O
found	O
to	O
adopt	O
folded	O
structures	O
upon	O
binding	O
to	O
their	O
biological	O
targets	O
.	O

The	O
"	O
fly	O
-	O
casting	O
"	O
mechanism	O
was	O
proposed	O
to	O
explain	O
the	O
widespread	O
occurrence	O
of	O
unfolded	O
domains	O
in	O
eukaryotic	O
proteins	O
.	O

This	O
mechanism	O
might	O
also	O
be	O
applicable	O
to	O
the	O
Pup	O
-	O
proteasome	B-Complex
system	O
.	O

Full	O
-	O
length	O
Pup	O
alone	O
is	O
randomly	O
coiled	O
and	O
extended	O
under	O
physiologically	O
relevant	O
conditions	O
in	O
vitro	O
.	O

The	O
randomly	O
coiled	O
state	O
of	O
Pup	O
may	O
increase	O
its	O
target	O
capture	O
radius	O
,	O
allowing	O
it	O
to	O
find	O
the	O
proteasomal	O
ATPase	O
more	O
easily	O
.	O

Once	O
the	O
C	O
-	O
terminal	O
part	O
of	O
Pup	O
contacts	O
the	O
Mpa	O
coiled	O
-	O
coil	O
,	O
the	O
pupylated	O
substrate	O
is	O
"	O
reeled	O
"	O
into	O
the	O
proteasomal	O
ATPase	O
,	O
and	O
the	O
Pup	O
N	O
-	O
terminus	O
is	O
gradually	O
forced	O
towards	O
the	O
OB	O
channel	O
in	O
Mpa	O
.	O

The	O
pulling	O
of	O
Pup	O
'	O
s	O
N	O
-	O
terminus	O
into	O
the	O
OB	O
channel	O
might	O
subsequently	O
pull	O
the	O
Pup	O
helix	O
away	O
from	O
the	O
Mpa	O
coiled	O
-	O
coil	O
,	O
causing	O
Pup	O
to	O
unfold	O
and	O
thread	O
further	O
into	O
the	O
channel	O
to	O
reach	O
the	O
Mpa	O
AAA	O
region	O
.	O

This	O
notion	O
is	O
supported	O
by	O
our	O
structure	O
demonstrating	O
the	O
displacement	O
of	O
the	O
N	O
-	O
terminal	O
half	O
of	O
the	O
Pup	O
helix	O
(	O
residues	O
21	O
-	O
30	O
)	O
from	O
the	O
Mpa	O
coiled	O
-	O
coil	O
(	O
Fig	O
.	O
2a	O
-	O
b	O
)	O
,	O
and	O
by	O
the	O
observation	O
that	O
this	O
region	O
of	O
Pup	O
interacts	O
more	O
weakly	O
with	O
Mpa	O
than	O
the	O
C	O
-	O
terminal	O
half	O
.	O

Human	O
stanniocalcin	O
-	O
1	O
interacts	O
with	O
nuclear	O
and	O
cytoplasmic	O
proteins	O
and	O
acts	O
as	O
a	O
SUMO	O
E3	O
ligase	O
.	O

Human	O
stanniocalcin	O
-	O
1	O
(	O
STC1	O
)	O
is	O
a	O
glycoprotein	O
that	O
has	O
been	O
implicated	O
in	O
different	O
physiological	O
process	O
,	O
including	O
angiogenesis	O
,	O
apoptosis	O
and	O
carcinogenesis	O
.	O

Here	O
we	O
identified	O
STC1	O
as	O
a	O
putative	O
molecular	O
marker	O
for	O
the	O
leukemic	O
bone	O
marrow	O
microenvironment	O
and	O
identified	O
new	O
interacting	O
protein	O
partners	O
for	O
STC1	O
.	O

Seven	O
selected	O
interactions	O
retrieved	O
from	O
yeast	O
two	O
-	O
hybrid	O
screens	O
were	O
confirmed	O
by	O
GST	O
-	O
pull	O
down	O
assays	O
in	O
vitro	O
.	O

The	O
N	O
-	O
terminal	O
region	O
was	O
mapped	O
to	O
be	O
the	O
region	O
that	O
mediates	O
the	O
interaction	O
with	O
cytoplasmic	O
,	O
mitochondrial	O
and	O
nuclear	O
proteins	O
.	O

STC1	O
interacts	O
with	O
SUMO	O
-	O
1	O
and	O
several	O
proteins	O
that	O
have	O
been	O
shown	O
to	O
be	O
SUMOylated	O
and	O
localized	O
to	O
SUMOylation	O
related	O
nuclear	O
bodies	O
.	O

Although	O
STC1	O
interacts	O
with	O
SUMO	O
-	O
1	O
and	O
has	O
a	O
high	O
theoretical	O
prediction	O
score	O
for	O
a	O
SUMOylation	O
site	O
,	O
endogenous	O
co	O
-	O
immunoprecipitation	O
and	O
in	O
vitro	O
SUMOylation	O
assays	O
with	O
the	O
purified	O
recombinant	O
protein	O
could	O
not	O
detect	O
STC1	O
SUMOylation	O
.	O

However	O
,	O
when	O
we	O
tested	O
STC1	O
for	O
SUMO	O
E3	O
ligase	O
activity	O
,	O
we	O
found	O
in	O
an	O
in	O
vitro	O
assay	O
,	O
that	O
it	O
significantly	O
increases	O
the	O
SUMOylation	O
of	O
two	O
other	O
proteins	O
.	O

Confocal	O
microscopic	O
subcellular	O
localization	O
studies	O
using	O
both	O
transfected	O
cells	O
and	O
specific	O
antibodies	O
for	O
endogenous	O
STC1	O
revealed	O
a	O
cytoplasmic	O
and	O
nuclear	O
deposition	O
,	O
the	O
latter	O
in	O
the	O
form	O
of	O
some	O
specific	O
dot	O
-	O
like	O
substructure	O
resembling	O
SUMOylation	O
related	O
nuclear	O
bodies	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
a	O
new	O
role	O
for	O
STC1	O
in	O
SUMOylation	O
pathways	O
,	O
in	O
nuclear	O
bodies	O
.	O

Two	O
distinct	O
transcription	O
factors	O
that	O
bind	O
the	O
immunoglobulin	B-OOS
enhancer	O
microE5	O
/	O
kappa	O
2	O
motif	O
.	O

Activity	O
of	O
the	O
immunoglobulin	O
heavy	O
and	O
kappa	O
light	O
chain	O
gene	O
enhancers	O
depends	O
on	O
a	O
complex	O
interplay	O
of	O
ubiquitous	O
and	O
developmentally	O
regulated	O
proteins	O
.	O

Two	O
complementary	O
DNAs	O
were	O
isolated	O
that	O
encode	O
proteins	O
,	O
denoted	O
ITF	O
-	O
1	O
and	O
ITF	O
-	O
2	O
,	O
that	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
cell	O
types	O
and	O
bind	O
the	O
microE5	O
/	O
kappa	O
2	O
motif	O
found	O
in	O
both	O
heavy	O
and	O
kappa	O
light	O
chain	O
enhancers	O
.	O

The	O
complementary	O
DNAs	O
are	O
the	O
products	O
of	O
distinct	O
genes	O
,	O
yet	O
both	O
ITF	O
-	O
1	O
and	O
ITF	O
-	O
2	O
are	O
structurally	O
and	O
functionally	O
similar	O
.	O

The	O
two	O
proteins	O
interact	O
with	O
one	O
another	O
through	O
their	O
putative	O
helix	O
-	O
loop	O
-	O
helix	O
motifs	O
and	O
each	O
possesses	O
a	O
distinct	O
domain	O
that	O
dictates	O
transcription	O
activation	O
.	O

Phosphorylation	O
of	O
RUNX1	O
by	O
cyclin	O
-	O
dependent	O
kinase	O
reduces	O
direct	O
interaction	O
with	O
HDAC1	O
and	O
HDAC3	O
.	O

RUNX1	O
regulates	O
formation	O
of	O
the	O
definitive	O
hematopoietic	O
stem	O
cell	O
and	O
its	O
subsequent	O
lineage	O
maturation	O
,	O
and	O
mutations	O
of	O
RUNX1	O
contribute	O
to	O
leukemic	O
transformation	O
.	O

Phosphorylation	O
of	O
Ser	O
-	O
48	O
,	O
Ser	O
-	O
303	O
,	O
and	O
Ser	O
-	O
424	O
by	O
cyclin	O
-	O
dependent	O
kinases	O
(	O
cdks	O
)	O
increases	O
RUNX1	O
trans	O
-	O
activation	O
activity	O
without	O
perturbing	O
p300	O
interaction	O
.	O

We	O
now	O
find	O
that	O
endogenous	O
RUNX1	O
interacts	O
with	O
endogenous	O
HDAC1	O
or	O
HDAC3	O
.	O

Mutation	O
of	O
the	O
three	O
RUNX1	O
serines	O
to	O
aspartic	O
acid	O
reduces	O
co	O
-	O
immunoprecipitation	O
with	O
HDAC1	O
or	O
HDAC3	O
when	O
expressed	O
in	O
293T	O
cells	O
;	O
mutation	O
of	O
these	O
three	O
serines	O
to	O
alanine	O
increases	O
HDAC	O
interaction	O
,	O
and	O
mutation	O
of	O
each	O
serine	O
individually	O
to	O
aspartic	O
acid	O
also	O
reduces	O
these	O
interactions	O
.	O

GST	O
-	O
RUNX1	O
isolated	O
from	O
bacterial	O
extracts	O
bound	O
in	O
vitro	O
translated	O
HDAC1	O
or	O
HDAC3	O
,	O
and	O
these	O
interactions	O
were	O
weakened	O
by	O
mutation	O
of	O
Ser	O
-	O
48	O
,	O
Ser	O
-	O
303	O
,	O
and	O
Ser	O
-	O
424	O
to	O
aspartic	O
acid	O
.	O

The	O
ability	O
of	O
RUNX1	O
phosphorylation	O
and	O
not	O
only	O
serine	O
to	O
aspartic	O
acid	O
conversion	O
to	O
reduce	O
HDAC1	O
binding	O
was	O
demonstrated	O
using	O
wild	O
-	O
type	O
GST	O
-	O
RUNX1	O
phosphorylated	O
in	O
vitro	O
using	O
cdk1	O
/	O
cyclinB	O
and	O
by	O
exposure	O
of	O
293T	O
cells	O
transduced	O
with	O
RUNX1	O
and	O
HDAC1	O
to	O
roscovitine	O
,	O
a	O
cdk	O
inhibitor	O
.	O

Finally	O
,	O
RUNX1	O
or	O
RUNX1	O
(	O
tripleD	O
)	O
,	O
in	O
which	O
Ser	O
-	O
48	O
,	O
Ser	O
-	O
303	O
,	O
and	O
Ser	O
-	O
424	O
are	O
mutated	O
to	O
aspartic	O
acid	O
,	O
stimulated	O
proliferation	O
of	O
transduced	O
,	O
lineage	O
-	O
negative	O
murine	O
marrow	O
progenitors	O
more	O
potently	O
than	O
did	O
RUNX1	O
(	O
tripleA	O
)	O
,	O
in	O
which	O
these	O
serines	O
are	O
mutated	O
to	O
alanine	O
,	O
suggesting	O
that	O
stimulation	O
of	O
RUNX1	O
trans	O
-	O
activation	O
by	O
cdk	O
-	O
mediated	O
reduction	O
in	O
HDAC	O
interaction	O
increases	O
marrow	O
progenitor	O
cell	O
proliferation	O
.	O

A	O
transmembrane	O
serine	O
protease	O
is	O
linked	O
to	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
coronavirus	O
receptor	O
and	O
activates	O
virus	O
entry	O
.	O

Spike	O
(	O
S	O
)	O
proteins	O
,	O
the	O
defining	O
projections	O
of	O
the	O
enveloped	O
coronaviruses	O
(	O
CoVs	O
)	O
,	O
mediate	O
cell	O
entry	O
by	O
connecting	O
viruses	O
to	O
plasma	O
membrane	O
receptors	O
and	O
by	O
catalyzing	O
subsequent	O
virus	O
-	O
cell	O
membrane	O
fusions	O
.	O

The	O
latter	O
membrane	O
fusion	O
requires	O
an	O
S	O
protein	O
conformational	O
flexibility	O
that	O
is	O
facilitated	O
by	O
proteolytic	O
cleavages	O
.	O

We	O
hypothesized	O
that	O
the	O
most	O
relevant	O
cellular	O
proteases	O
in	O
this	O
process	O
are	O
those	O
closely	O
linked	O
to	O
host	O
cell	O
receptors	O
.	O

The	O
primary	O
receptor	O
for	O
the	O
human	O
severe	O
acute	O
respiratory	O
syndrome	O
CoV	O
(	O
SARS	O
)	O
CoV	O
is	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
(	O
ACE2	O
)	O
.	O

ACE2	O
immunoprecipitation	O
captured	O
transmembrane	O
protease	O
/	O
serine	O
subfamily	O
member	O
2	O
(	O
TMPRSS2	O
)	O
,	O
a	O
known	O
human	O
airway	O
and	O
alveolar	O
protease	O
.	O

ACE2	O
and	O
TMPRSS2	O
colocalized	O
on	O
cell	O
surfaces	O
and	O
enhanced	O
the	O
cell	O
entry	O
of	O
both	O
SARS	O
S	O
-	O
pseudotyped	O
HIV	O
and	O
authentic	O
SARS	O
-	O
CoV	O
.	O

Enhanced	O
entry	O
correlated	O
with	O
TMPRSS2	O
-	O
mediated	O
proteolysis	O
of	O
both	O
S	O
and	O
ACE2	O
.	O

These	O
findings	O
indicate	O
that	O
a	O
cell	O
surface	O
complex	O
comprising	O
a	O
primary	O
receptor	O
and	O
a	O
separate	O
endoprotease	O
operates	O
as	O
a	O
portal	O
for	O
activation	O
of	O
SARS	O
-	O
CoV	O
cell	O
entry	O
.	O

In	O
the	O
past	O
twenty	O
years	O
,	O
numerous	O
elements	O
of	O
ABA	O
signaling	O
have	O
been	O
identified	O
,	O
culminating	O
with	O
the	O
recent	O
establishment	O
of	O
a	O
core	O
ABA	O
signaling	O
pathway	O
.	O

Based	O
on	O
genetic	O
studies	O
,	O
it	O
was	O
previously	O
established	O
that	O
clade	O
A	O
Ser	O
/	O
Thr	O
Protein	O
Phosphatase	O
2Cs	O
(	O
PP2C	O
)	O
,	O
including	O
ABI1	O
,	O
ABI2	O
and	O
HAB1	O
are	O
major	O
negative	O
regulators	O
of	O
ABA	O
signaling	O
.	O

In	O
contrast	O
,	O
the	O
identification	O
of	O
the	O
drought	O
-	O
sensitive	O
Arabidopsis	O
mutant	O
ost1	O
,	O
also	O
called	O
srk2e	O
,	O
which	O
does	O
not	O
close	O
its	O
stomata	O
in	O
response	O
to	O
ABA	O
indicates	O
that	O
the	O
ABA	O
-	O
activated	O
Ser	O
/	O
Thr	O
Snf1	O
-	O
Related	O
Kinase	O
2	O
OST1	O
/	O
SRK2E	O
/	O
SnRK2	O
.	O
6	O
(	O
hereafter	O
called	O
OST1	O
)	O
,	O
a	O
homologue	O
of	O
Vicia	O
faba	O
AAPK	O
,	O
acts	O
as	O
positive	O
regulator	O
of	O
ABA	O
signaling	O
in	O
guard	O
cells	O
.	O

In	O
addition	O
to	O
OST1	O
,	O
the	O
Arabidopsis	O
genome	O
encodes	O
two	O
other	O
SnRK2s	O
strongly	O
activated	O
by	O
ABA	O
,	O
SnRK2	O
.	O
2	O
and	O
SnRK2	O
.	O
3	O
.	O

While	O
single	O
mutants	O
are	O
not	O
distinguishable	O
from	O
the	O
wild	O
type	O
,	O
the	O
double	O
mutant	O
snrk2	O
.	O
2	O
snrk2	O
.	O
3	O
is	O
insensitive	O
to	O
ABA	O
inhibition	O
of	O
seed	O
germination	O
,	O
root	O
growth	O
,	O
and	O
marker	O
gene	O
expression	O
,	O
but	O
is	O
not	O
significantly	O
affected	O
in	O
transpiration	O
.	O

This	O
genetic	O
analysis	O
indicated	O
that	O
SnRK2	O
.	O
2	O
and	O
SnRK2	O
.	O
3	O
are	O
redundant	O
positive	O
regulator	O
of	O
ABA	O
signaling	O
principally	O
acting	O
outside	O
of	O
guard	O
cells	O
.	O

Overall	O
structure	O
of	O
Nep1	O
and	O
dimer	O
interface	O
.	O

(	O
A	O
)	O
Sequence	O
alignment	O
from	O
of	O
Nep1	O
from	O
S	O
.	O
cerevisiae	O
(	O
NEP1	O
_	O
YEAST	O
)	O
,	O
Homo	O
sapiens	O
(	O
NEP1	O
_	O
HUMAN	O
)	O
,	O
Drosophila	O
melanogaster	O
(	O
NEP1	O
_	O
DROME	O
)	O
and	O
A	O
.	O
fulgidus	O
(	O
NEP1	O
_	O
ARCFU	O
)	O
.	O

Yellow	O
,	O
red	O
and	O
blue	O
dots	O
indicate	O
residues	O
involved	O
in	O
dimerization	O
,	O
RNA	O
binding	O
and	O
SAM	B-OOS
binding	O
respectively	O
.	O

Secondary	O
structure	O
for	O
yeast	O
(	O
top	O
)	O
and	O
A	O
.	O
fulgidus	O
(	O
bottom	O
)	O
shown	O
as	O
open	O
bars	O
for	O
alpha	O
-	O
helices	O
and	O
arrows	O
for	O
beta	O
-	O
strands	O
and	O
numbered	O
according	O
to	O
Leulliot	O
et	O
al	O
.	O
for	O
yeast	O
,	O
and	O
Taylor	O
et	O
al	O
.	O
for	O
A	O
.	O
fulgidus	O
.	O

(	O
B	O
)	O
The	O
scNep1	O
dimer	O
.	O

RNA	O
binding	O
and	O
catalytic	O
regions	O
of	O
the	O
molecules	O
are	O
colored	O
red	O
and	O
dark	O
blue	O
respectively	O
.	O

The	O
molecules	O
of	O
SAH	O
are	O
shown	O
in	O
sticks	O
.	O

Secondary	O
structure	O
elements	O
are	O
labeled	O
according	O
to	O
Leulliot	O
et	O
al	O
.	O
.	O

(	O
C	O
)	O
Front	O
view	O
of	O
the	O
dimerization	O
interface	O
of	O
Nep1	O
.	O

Residues	O
are	O
labeled	O
with	O
chain	O
names	O
and	O
residue	O
numbers	O
.	O

(	O
D	O
)	O
Top	O
view	O
of	O
the	O
interface	O
showing	O
the	O
interaction	O
of	O
the	O
C	O
-	O
terminus	O
in	O
the	O
interface	O
.	O

Residues	O
that	O
are	O
identical	O
in	O
eukaryotic	O
sequences	O
are	O
labeled	O
in	O
red	O
text	O
.	O

All	O
3D	O
structure	O
figures	O
were	O
generated	O
in	O
PyMOL	O
(	O
www	O
.	O
pymol	O
.	O
org	O
)	O
.	O

Our	O
data	O
showed	O
that	O
over	O
-	O
expressed	O
KIF5B	O
-	O
YFP	O
transported	O
dendritic	O
Kv3	O
.	O
1aHA	O
into	O
axons	O
.	O

We	O
wondered	O
what	O
is	O
the	O
determinant	O
in	O
this	O
process	O
.	O

In	O
our	O
previous	O
study	O
,	O
we	O
generated	O
Kv3	O
.	O
1b	O
mutants	O
with	O
altered	O
ATM	O
in	O
the	O
C	O
-	O
terminal	O
region	O
.	O

These	O
mutants	O
are	O
restricted	O
in	O
somatodendritic	O
regions	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
made	O
Kv3	O
.	O
1	O
mutants	O
with	O
disrupted	O
Zn2	O
+	O
-	O
binding	O
site	O
in	O
T1	O
and	O
these	O
mutants	O
also	O
failed	O
to	O
enter	O
axons	O
(	O
Fig	O
.	O
6	O
)	O
.	O

These	O
mutants	O
were	O
co	O
-	O
transfected	O
with	O
KIF5B	O
-	O
YFP	O
into	O
neurons	O
.	O

Remarkably	O
,	O
over	O
-	O
expressed	O
KIF5B	O
-	O
YFP	O
brought	O
all	O
the	O
Kv3	O
.	O
1	O
C	O
-	O
terminal	O
mutants	O
with	O
an	O
impaired	O
ATM	O
to	O
penetrate	O
the	O
AIS	O
and	O
enter	O
distal	O
axons	O
,	O
but	O
failed	O
to	O
affect	O
any	O
of	O
the	O
T1	O
mutants	O
(	O
Fig	O
.	O
8E	O
,	O
F	O
)	O
.	O

Expression	O
of	O
KIF5B	O
-	O
YFP	O
further	O
increased	O
Kv3	O
.	O
1bHA	O
axonal	O
levels	O
(	O
Fig	O
.	O
8F	O
)	O
.	O

Therefore	O
,	O
over	O
-	O
expressed	O
KIF5B	O
-	O
YFP	O
assisted	O
dendritic	O
Kv3	O
.	O
1aHA	O
and	O
even	O
Kv3	O
.	O
1	O
mutants	O
with	O
a	O
faulty	O
ATM	O
to	O
penetrate	O
the	O
AIS	O
and	O
enter	O
the	O
axon	O
.	O

Interestingly	O
,	O
this	O
effect	O
apparently	O
requires	O
properly	O
assembled	O
T1	O
domains	O
,	O
consistent	O
with	O
the	O
hypothesis	O
that	O
T1	O
tetramerization	O
is	O
essential	O
for	O
binding	O
to	O
KIF5	O
and	O
hence	O
Kv3	O
.	O
1	O
targeting	O
in	O
axons	O
(	O
Figs	O
.	O
5	O
,	O
6	O
)	O
.	O

Tissue	O
-	O
specific	O
human	O
beta	O
-	O
defensins	O
(	O
HBD	O
)	O
1	O
,	O
HBD2	O
,	O
and	O
HBD3	O
secretion	O
from	O
human	O
extra	O
-	O
placental	O
membranes	O
stimulated	O
with	O
Escherichia	O
coli	O
.	O

During	O
an	O
ascending	O
infection	O
along	O
the	O
reproductive	O
tract	O
,	O
the	O
extra	O
-	O
placental	O
membranes	O
must	O
act	O
as	O
a	O
selective	O
and	O
competent	O
barrier	O
against	O
pathogens	O
.	O

Human	O
beta	O
defensins	O
(	O
HBD	O
)	O
1	O
,	O
HBD2	O
,	O
and	O
HBD3	O
are	O
key	O
elements	O
of	O
innate	O
immunity	O
that	O
are	O
secreted	O
to	O
neutralize	O
/	O
control	O
the	O
progression	O
of	O
infection	O
.	O

Full	O
-	O
thickness	O
membranes	O
were	O
mounted	O
on	O
a	O
Transwell	O
device	O
,	O
constituted	O
by	O
two	O
independent	O
chambers	O
,	O
1	O
x	O
10	O
(	O
6	O
)	O
CFU	O
/	O
ml	O
of	O
Escherichia	O
coli	O
were	O
added	O
to	O
either	O
the	O
amnion	O
(	O
AMN	O
)	O
or	O
the	O
choriodecidual	O
(	O
CHD	O
)	O
face	O
or	O
to	O
both	O
.	O

Secretion	O
profiles	O
of	O
HBD1	O
,	O
HBD2	O
,	O
and	O
HBD3	O
to	O
the	O
culture	O
medium	O
were	O
quantified	O
by	O
ELISA	O
.	O

In	O
comparison	O
with	O
basal	O
conditions	O
,	O
the	O
secretion	O
profile	O
of	O
HBD1	O
remained	O
without	O
significant	O
changes	O
;	O
HBD2	O
level	O
in	O
CHD	O
and	O
AMN	O
increased	O
1	O
.	O
9	O
-	O
and	O
1	O
.	O
4	O
-	O
times	O
,	O
respectively	O
,	O
after	O
stimulation	O
with	O
bacteria	O
.	O

HBD3	O
secretion	O
level	O
increased	O
significantly	O
(	O
7	O
.	O
8	O
+	O
/	O
-	O
1	O
.	O
9	O
pg	O
/	O
micrograms	O
)	O
in	O
the	O
CHD	O
but	O
only	O
if	O
the	O
stimulus	O
was	O
applied	O
on	O
the	O
AMN	O
side	O
.	O

Selective	O
stimulation	O
of	O
extra	O
-	O
placental	O
membranes	O
with	O
E	O
.	O
coli	O
,	O
results	O
in	O
a	O
tissue	O
specific	O
secretion	O
of	O
HBD1	O
,	O
HBD2	O
,	O
and	O
HBD3	O
mainly	O
in	O
the	O
CHD	O
,	O
which	O
is	O
the	O
first	O
infected	O
region	O
during	O
an	O
ascending	O
infection	O
.	O

Lysine	O
methylation	O
of	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
subunit	O
RelA	O
by	O
SETD6	O
couples	O
activity	O
of	O
the	O
histone	B-OOS
methyltransferase	I-OOS
GLP	O
at	O
chromatin	O
to	O
tonic	O
repression	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
signaling	O
.	O

Signaling	O
via	O
the	O
methylation	O
of	O
lysine	O
residues	O
in	O
proteins	O
has	O
been	O
linked	O
to	O
diverse	O
biological	O
and	O
disease	O
processes	O
,	O
yet	O
the	O
catalytic	O
activity	O
and	O
substrate	O
specificity	O
of	O
many	O
human	O
protein	O
lysine	O
methyltransferases	O
(	O
PKMTs	O
)	O
are	O
unknown	O
.	O

We	O
screened	O
over	O
40	O
candidate	O
PKMTs	O
and	O
identified	O
SETD6	O
as	O
a	O
methyltransferase	O
that	O
monomethylated	O
chromatin	O
-	O
associated	O
transcription	O
factor	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
subunit	O
RelA	O
at	O
Lys310	O
(	O
RelAK310me1	O
)	O
.	O

SETD6	O
-	O
mediated	O
methylation	O
rendered	O
RelA	O
inert	O
and	O
attenuated	O
RelA	O
-	O
driven	O
transcriptional	O
programs	O
,	O
including	O
inflammatory	O
responses	O
in	O
primary	O
immune	O
cells	O
.	O

RelAK310me1	O
was	O
recognized	O
by	O
the	O
ankryin	O
repeat	O
of	O
the	O
histone	B-OOS
methyltransferase	I-OOS
GLP	O
,	O
which	O
under	O
basal	O
conditions	O
promoted	O
a	O
repressed	O
chromatin	O
state	O
at	O
RelA	O
target	O
genes	O
through	O
GLP	O
-	O
mediated	O
methylation	O
of	O
histone	O
H3	O
Lys9	O
(	O
H3K9	O
)	O
.	O

NF	B-Complex
-	I-Complex
kappaB	I-Complex
-	O
activation	O
-	O
linked	O
phosphorylation	O
of	O
RelA	O
at	O
Ser311	O
by	O
protein	O
kinase	O
C	O
-	O
zeta	O
(	O
PKC	O
-	O
zeta	O
)	O
blocked	O
the	O
binding	O
of	O
GLP	O
to	O
RelAK310me1	O
and	O
relieved	O
repression	O
of	O
the	O
target	O
gene	O
.	O

Our	O
findings	O
establish	O
a	O
previously	O
uncharacterized	O
mechanism	O
by	O
which	O
chromatin	O
signaling	O
regulates	O
inflammation	O
programs	O
.	O

New	O
insights	O
into	O
the	O
Lpt	B-Complex
machinery	O
for	O
lipopolysaccharide	O
transport	O
to	O
the	O
cell	O
surface	O
:	O
LptA	O
-	O
LptC	O
interaction	O
and	O
LptA	O
stability	O
as	O
sensors	O
of	O
a	O
properly	O
assembled	O
transenvelope	O
complex	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
a	O
major	O
glycolipid	O
present	O
in	O
the	O
outer	O
membrane	O
(	O
OM	O
)	O
of	O
Gram	O
-	O
negative	O
bacteria	O
.	O

The	O
peculiar	O
permeability	O
barrier	O
of	O
the	O
OM	O
is	O
due	O
to	O
the	O
presence	O
of	O
LPS	O
at	O
the	O
outer	O
leaflet	O
of	O
this	O
membrane	O
that	O
prevents	O
many	O
toxic	O
compounds	O
from	O
entering	O
the	O
cell	O
.	O

In	O
Escherichia	O
coli	O
LPS	O
synthesized	O
inside	O
the	O
cell	O
is	O
first	O
translocated	O
over	O
the	O
inner	O
membrane	O
(	O
IM	O
)	O
by	O
the	O
essential	O
MsbA	O
flippase	O
;	O
then	O
,	O
seven	O
essential	O
Lpt	B-Complex
proteins	O
located	O
in	O
the	O
IM	O
(	O
LptBCDF	O
)	O
,	O
in	O
the	O
periplasm	O
(	O
LptA	O
)	O
,	O
and	O
in	O
the	O
OM	O
(	O
LptDE	O
)	O
are	O
responsible	O
for	O
LPS	O
transport	O
across	O
the	O
periplasmic	O
space	O
and	O
its	O
assembly	O
at	O
the	O
cell	O
surface	O
.	O

The	O
Lpt	B-Complex
proteins	O
constitute	O
a	O
transenvelope	O
complex	O
spanning	O
IM	O
and	O
OM	O
that	O
appears	O
to	O
operate	O
as	O
a	O
single	O
device	O
.	O

We	O
show	O
here	O
that	O
in	O
vivo	O
LptA	O
and	O
LptC	O
physically	O
interact	O
,	O
forming	O
a	O
stable	O
complex	O
and	O
,	O
based	O
on	O
the	O
analysis	O
of	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
LptC	O
,	O
we	O
suggest	O
that	O
the	O
C	O
-	O
terminal	O
region	O
of	O
LptC	O
is	O
implicated	O
in	O
LptA	O
binding	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
defects	O
in	O
Lpt	B-Complex
components	O
of	O
either	O
IM	O
or	O
OM	O
result	O
in	O
LptA	O
degradation	O
;	O
thus	O
,	O
LptA	O
abundance	O
in	O
the	O
cell	O
appears	O
to	O
be	O
a	O
marker	O
of	O
properly	O
bridged	O
IM	O
and	O
OM	O
.	O

Collectively	O
,	O
our	O
data	O
support	O
the	O
recently	O
proposed	O
transenvelope	O
model	O
for	O
LPS	O
transport	O
.	O

The	O
steady	O
-	O
state	O
repertoire	O
of	O
human	O
SCF	B-Complex
Ubiquitin	O
ligase	O
complexes	O
does	O
not	O
require	O
ongoing	O
Nedd8	O
conjugation	O
.	O

The	O
human	O
genome	O
encodes	O
69	O
different	O
F	O
-	O
box	O
proteins	O
(	O
FBPs	O
)	O
,	O
each	O
of	O
which	O
can	O
potentially	O
assemble	O
with	O
Skp1	O
-	O
Cul1	O
-	O
RING	O
to	O
serve	O
as	O
the	O
substrate	O
specificity	O
subunit	O
of	O
an	O
SCF	B-Complex
ubiquitin	O
ligase	O
complex	O
.	O

SCF	B-Complex
activity	O
is	O
switched	O
on	O
by	O
conjugation	O
of	O
the	O
ubiquitin	O
-	O
like	O
protein	O
Nedd8	O
to	O
Cul1	O
.	O

Cycles	O
of	O
Nedd8	O
conjugation	O
and	O
deconjugation	O
acting	O
in	O
conjunction	O
with	O
the	O
Cul1	O
-	O
sequestering	O
factor	O
Cand1	O
are	O
thought	O
to	O
control	O
dynamic	O
cycles	O
of	O
SCF	B-Complex
assembly	O
and	O
disassembly	O
,	O
which	O
would	O
enable	O
a	O
dynamic	O
equilibrium	O
between	O
the	O
Cul1	O
-	O
RING	O
catalytic	O
core	O
of	O
SCF	B-Complex
and	O
the	O
cellular	O
repertoire	O
of	O
FBPs	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
determined	O
the	O
cellular	O
composition	O
of	O
SCF	B-Complex
complexes	O
and	O
evaluated	O
the	O
impact	O
of	O
Nedd8	O
conjugation	O
on	O
this	O
steady	O
-	O
state	O
.	O

At	O
least	O
42	O
FBPs	O
assembled	O
with	O
Cul1	O
in	O
HEK	O
293	O
cells	O
,	O
and	O
the	O
levels	O
of	O
Cul1	O
-	O
bound	O
FBPs	O
varied	O
by	O
over	O
two	O
orders	O
of	O
magnitude	O
.	O

Unexpectedly	O
,	O
quantitative	O
mass	O
spectrometry	O
revealed	O
that	O
blockade	O
of	O
Nedd8	O
conjugation	O
led	O
to	O
a	O
modest	O
increase	O
,	O
rather	O
than	O
a	O
decrease	O
,	O
in	O
the	O
overall	O
level	O
of	O
most	O
SCF	B-Complex
complexes	O
.	O

We	O
suggest	O
that	O
multiple	O
mechanisms	O
including	O
FBP	O
dissociation	O
and	O
turnover	O
cooperate	O
to	O
maintain	O
the	O
cellular	O
pool	O
of	O
SCF	B-Complex
ubiquitin	O
ligases	O
.	O

Role	O
for	O
cohesin	B-Complex
in	O
the	O
formation	O
of	O
a	O
heterochromatic	O
domain	O
at	O
fission	O
yeast	O
subtelomeres	O
.	O

Increasing	O
evidence	O
implicates	O
cohesin	B-Complex
in	O
the	O
control	O
of	O
gene	O
expression	O
.	O

Here	O
we	O
report	O
the	O
first	O
analysis	O
of	O
cohesin	B-Complex
-	O
dependent	O
gene	O
regulation	O
in	O
fission	O
yeast	O
.	O

Global	O
expression	O
profiling	O
of	O
the	O
mis4	O
-	O
367	O
cohesin	B-Complex
loader	O
mutant	O
identified	O
a	O
small	O
number	O
of	O
upregulated	O
and	O
downregulated	O
genes	O
within	O
subtelomeric	O
domains	O
(	O
SD	O
)	O
.	O

These	O
20	O
-	O
to	O
40	O
-	O
kb	O
regions	O
between	O
chromosome	O
arm	O
euchromatin	O
and	O
telomere	O
-	O
proximal	O
heterochromatin	O
are	O
characterized	O
by	O
a	O
combination	O
of	O
euchromatin	O
(	O
methylated	O
lysine	O
4	O
on	O
histone	O
H3	O
/	O
methylated	O
Tysine	O
9	O
on	O
histone	O
H3	O
[	O
H3K4me	O
]	O
)	O
and	O
heterochromatin	O
(	O
H3K9me	O
)	O
marks	O
.	O

We	O
focused	O
our	O
analysis	O
on	O
the	O
chromosome	O
1	O
right	O
SD	O
,	O
which	O
contains	O
several	O
upregulated	O
genes	O
and	O
is	O
bordered	O
on	O
the	O
telomere	O
-	O
distal	O
side	O
by	O
a	O
pair	O
of	O
downregulated	O
genes	O
.	O

We	O
find	O
that	O
the	O
expression	O
changes	O
in	O
the	O
SD	O
also	O
occur	O
in	O
a	O
mutant	O
of	O
the	O
cohesin	B-Complex
core	O
component	O
Rad21	O
.	O

Remarkably	O
,	O
mutation	O
of	O
Rad21	O
results	O
in	O
the	O
depletion	O
of	O
Swi6	O
binding	O
in	O
the	O
SD	O
.	O

In	O
fact	O
,	O
the	O
Rad21	O
mutation	O
phenocopied	O
Swi6	O
loss	O
of	O
function	O
:	O
both	O
mutations	O
led	O
to	O
reduced	O
cohesin	B-Complex
binding	O
,	O
reduced	O
H3K9me	O
,	O
and	O
similar	O
gene	O
expression	O
changes	O
in	O
the	O
SD	O
.	O

In	O
particular	O
,	O
expression	O
of	O
the	O
gene	O
pair	O
bordering	O
the	O
SD	O
was	O
dependent	O
both	O
on	O
cohesin	B-Complex
and	O
on	O
Swi6	O
.	O

Our	O
data	O
indicate	O
that	O
cohesin	B-Complex
participates	O
in	O
the	O
setup	O
of	O
a	O
subtelomeric	O
heterochromatin	O
domain	O
and	O
controls	O
the	O
expression	O
of	O
the	O
genes	O
residing	O
in	O
that	O
domain	O
.	O

Partitioning	O
of	O
chromosomes	O
into	O
euchromatic	O
and	O
heterochromatic	O
domains	O
requires	O
mechanisms	O
that	O
specify	O
boundaries	O
.	O

The	O
S	O
.	O
pombe	O
JmjC	O
family	O
protein	O
Epe1	O
prevents	O
the	O
ectopic	O
spread	O
of	O
heterochromatin	O
and	O
is	O
itself	O
concentrated	O
at	O
boundaries	O
.	O

Paradoxically	O
,	O
Epe1	O
is	O
recruited	O
to	O
heterochromatin	O
by	O
HP1	O
silencing	O
factors	O
that	O
are	O
distributed	O
throughout	O
heterochromatin	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
selective	O
enrichment	O
of	O
Epe1	O
at	O
boundaries	O
requires	O
its	O
regulation	O
by	O
the	O
conserved	O
Cul4	O
-	O
Ddb1	O
(	O
Cdt	O
)	O
^	O
2	O
ubiquitin	O
ligase	O
,	O
which	O
directly	O
recognizes	O
Epe1	O
and	O
promotes	O
its	O
polyubiquitylation	O
and	O
degradation	O
.	O

Strikingly	O
,	O
in	O
cells	O
lacking	O
the	O
ligase	O
,	O
Epe1	O
persists	O
in	O
the	O
body	O
of	O
heterochromatin	O
thereby	O
inducing	O
a	O
defect	O
in	O
gene	O
silencing	O
.	O

Epe1	O
is	O
the	O
sole	O
target	O
of	O
the	O
Cul4	O
-	O
Ddb1	O
(	O
Cdt	O
)	O
^	O
2	O
complex	O
whose	O
destruction	O
is	O
necessary	O
for	O
the	O
preservation	O
of	O
heterochromatin	O
.	O

This	O
mechanism	O
acts	O
parallel	O
with	O
phosphorylation	O
of	O
HP1	O
/	O
Swi6	O
by	O
CK2	B-Complex
to	O
restrict	O
Epe1	O
.	O

We	O
conclude	O
that	O
the	O
ubiquitin	O
-	O
dependent	O
sculpting	O
of	O
the	O
chromosomal	O
distribution	O
of	O
an	O
antisilencing	O
factor	O
is	O
critical	O
for	O
heterochromatin	O
boundaries	O
to	O
form	O
correctly	O
.	O

Protein	O
-	O
tyrosine	O
phosphatase	O
DEP	O
-	O
1	O
controls	O
receptor	O
tyrosine	O
kinase	O
FLT3	O
signaling	O
.	O

Fms	O
-	O
like	O
tyrosine	O
kinase	O
3	O
(	O
FLT3	O
)	O
plays	O
an	O
important	O
role	O
in	O
hematopoietic	O
differentiation	O
,	O
and	O
constitutively	O
active	O
FLT3	O
mutant	O
proteins	O
contribute	O
to	O
the	O
development	O
of	O
acute	O
myeloid	O
leukemia	O
.	O

Little	O
is	O
known	O
about	O
the	O
protein	O
-	O
tyrosine	O
phosphatases	O
(	O
PTP	O
)	O
affecting	O
the	O
signaling	O
activity	O
of	O
FLT3	O
.	O

To	O
identify	O
such	O
PTP	O
,	O
myeloid	O
cells	O
expressing	O
wild	O
type	O
FLT3	O
were	O
infected	O
with	O
a	O
panel	O
of	O
lentiviral	O
pseudotypes	O
carrying	O
shRNA	O
expression	O
cassettes	O
targeting	O
different	O
PTP	O
.	O

Out	O
of	O
20	O
PTP	O
tested	O
,	O
expressed	O
in	O
hematopoietic	O
cells	O
,	O
or	O
presumed	O
to	O
be	O
involved	O
in	O
oncogenesis	O
or	O
tumor	O
suppression	O
,	O
DEP	O
-	O
1	O
(	O
PTPRJ	O
)	O
was	O
identified	O
as	O
a	O
PTP	O
negatively	O
regulating	O
FLT3	O
phosphorylation	O
and	O
signaling	O
.	O

Stable	O
32D	O
myeloid	O
cell	O
lines	O
with	O
strongly	O
reduced	O
DEP	O
-	O
1	O
levels	O
showed	O
site	O
-	O
selective	O
hyperphosphorylation	O
of	O
FLT3	O
.	O

In	O
particular	O
,	O
the	O
sites	O
pTyr	O
-	O
589	O
,	O
pTyr	O
-	O
591	O
,	O
and	O
pTyr	O
-	O
842	O
involved	O
in	O
the	O
FLT3	O
ligand	O
(	O
FL	O
)	O
-	O
mediated	O
activation	O
of	O
FLT3	O
were	O
hyperphosphorylated	O
the	O
most	O
.	O

Similarly	O
,	O
acute	O
depletion	O
of	O
DEP	O
-	O
1	O
in	O
the	O
human	O
AML	O
cell	O
line	O
THP	O
-	O
1	O
caused	O
elevated	O
FLT3	O
phosphorylation	O
.	O

Direct	O
interaction	O
of	O
DEP	O
-	O
1	O
and	O
FLT3	O
was	O
demonstrated	O
by	O
"	O
substrate	O
trapping	O
"	O
experiments	O
showing	O
association	O
of	O
DEP	O
-	O
1	O
D1205A	O
or	O
C1239S	O
mutant	O
proteins	O
with	O
FLT3	O
by	O
co	O
-	O
immunoprecipitation	O
.	O

Moreover	O
,	O
activated	O
FLT3	O
could	O
be	O
dephosphorylated	O
by	O
recombinant	O
DEP	O
-	O
1	O
in	O
vitro	O
.	O

Enhanced	O
FLT3	O
phosphorylation	O
in	O
DEP	O
-	O
1	O
-	O
depleted	O
cells	O
was	O
accompanied	O
by	O
enhanced	O
FLT3	O
-	O
dependent	O
activation	O
of	O
ERK	O
and	O
cell	O
proliferation	O
.	O

Stable	O
overexpression	O
of	O
DEP	O
-	O
1	O
in	O
32D	O
cells	O
and	O
transient	O
overexpression	O
with	O
FLT3	O
in	O
HEK293	O
cells	O
resulted	O
in	O
reduction	O
of	O
FL	O
-	O
mediated	O
FLT3	O
signaling	O
activity	O
.	O

Furthermore	O
,	O
FL	O
-	O
stimulated	O
colony	O
formation	O
of	O
32D	O
cells	O
expressing	O
FLT3	O
in	O
methylcellulose	O
was	O
induced	O
in	O
response	O
to	O
shRNA	O
-	O
mediated	O
DEP	O
-	O
1	O
knockdown	O
.	O

This	O
transforming	O
effect	O
of	O
DEP	O
-	O
1	O
knockdown	O
was	O
consistent	O
with	O
a	O
moderately	O
increased	O
activation	O
of	O
STAT5	O
upon	O
FL	O
stimulation	O
but	O
did	O
not	O
translate	O
into	O
myeloproliferative	O
disease	O
formation	O
in	O
the	O
32D	O
-	O
C3H	O
/	O
HeJ	O
mouse	O
model	O
.	O

The	O
data	O
indicate	O
that	O
DEP	O
-	O
1	O
is	O
negatively	O
regulating	O
FLT3	O
signaling	O
activity	O
and	O
that	O
its	O
loss	O
may	O
contribute	O
to	O
but	O
is	O
not	O
sufficient	O
for	O
leukemogenic	O
cell	O
transformation	O
.	O

Given	O
that	O
GLR	O
-	O
1	O
:	O
:	O
GFP	O
levels	O
decrease	O
in	O
both	O
the	O
VNC	O
and	O
in	O
interneuron	O
cell	O
bodies	O
of	O
usp	O
-	O
46	O
mutants	O
,	O
we	O
tested	O
whether	O
USP	O
-	O
46	O
affects	O
transcription	O
of	O
glr	O
-	O
1	O
.	O

If	O
USP	O
-	O
46	O
controls	O
GLR	O
-	O
1	O
:	O
:	O
GFP	O
abundance	O
by	O
regulating	O
glr	O
-	O
1	O
transcription	O
,	O
we	O
would	O
expect	O
glr	O
-	O
1	O
transcript	O
levels	O
to	O
be	O
decreased	O
in	O
usp	O
-	O
46	O
mutants	O
.	O

We	O
performed	O
real	O
-	O
time	O
PCR	O
analysis	O
of	O
total	O
mRNA	O
isolated	O
from	O
wild	O
type	O
and	O
usp	O
-	O
46	O
mutant	O
animals	O
and	O
quantified	O
the	O
ratio	O
of	O
glr	O
-	O
1	O
to	O
act	O
-	O
1	O
(	O
actin	O
)	O
mRNA	O
.	O

We	O
observed	O
a	O
2	O
.	O
6	O
-	O
fold	O
increase	O
in	O
glr	O
-	O
1	O
mRNA	O
in	O
usp	O
-	O
46	O
mutants	O
(	O
Fig	O
.	O
2B	O
)	O
,	O
indicating	O
that	O
the	O
decrease	O
in	O
GLR	O
-	O
1	O
:	O
:	O
GFP	O
in	O
the	O
VNCs	O
of	O
these	O
animals	O
is	O
not	O
due	O
to	O
a	O
decrease	O
in	O
glr	O
-	O
1	O
transcription	O
.	O

The	O
increase	O
in	O
glr	O
-	O
1	O
transcription	O
is	O
suggestive	O
of	O
a	O
potential	O
negative	O
feedback	O
loop	O
in	O
which	O
decreased	O
GLR	O
-	O
1	O
at	O
synapses	O
in	O
usp	O
-	O
46	O
loss	O
-	O
of	O
-	O
function	O
animals	O
leads	O
to	O
increased	O
transcription	O
of	O
the	O
receptor	O
,	O
however	O
further	O
experiments	O
will	O
be	O
necessary	O
to	O
test	O
this	O
hypothesis	O
.	O

This	O
putative	O
transcriptional	O
compensation	O
suggests	O
that	O
we	O
may	O
underestimate	O
the	O
decrease	O
in	O
GLR	O
-	O
1	O
protein	O
abundance	O
in	O
usp	O
-	O
46	O
mutants	O
.	O

Histone	O
H4	O
Lys	O
20	O
monomethylation	O
by	O
histone	O
methylase	O
SET8	O
mediates	O
Wnt	O
target	O
gene	O
activation	O
.	O

Histone	O
methylation	O
has	O
an	O
important	O
role	O
in	O
transcriptional	O
regulation	O
.	O

However	O
,	O
unlike	O
H3K4	O
and	O
H3K9	O
methylation	O
,	O
the	O
role	O
of	O
H4K20	O
monomethylation	O
(	O
H4K20me	O
-	O
1	O
)	O
in	O
transcriptional	O
regulation	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
that	O
Wnt3a	O
specifically	O
stimulates	O
H4K20	O
monomethylation	O
at	O
the	O
T	O
cell	O
factor	O
(	O
TCF	O
)	O
-	O
binding	O
element	O
through	O
the	O
histone	O
methylase	O
SET8	O
.	O

Additionally	O
,	O
SET8	O
is	O
crucial	O
for	O
activation	O
of	O
the	O
Wnt	O
reporter	O
gene	O
and	O
target	O
genes	O
in	O
both	O
mammalian	O
cells	O
and	O
zebrafish	O
.	O

Furthermore	O
,	O
SET8	O
interacts	O
with	O
lymphoid	O
enhancing	O
factor	O
-	O
1	O
(	O
LEF1	O
)	O
/	O
TCF4	O
directly	O
,	O
and	O
this	O
interaction	O
is	O
regulated	O
by	O
Wnt3a	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
SET8	O
is	O
a	O
Wnt	O
signaling	O
mediator	O
and	O
is	O
recruited	O
by	O
LEF1	O
/	O
TCF4	O
to	O
regulate	O
the	O
transcription	O
of	O
Wnt	O
-	O
activated	O
genes	O
,	O
possibly	O
through	O
H4K20	O
monomethylation	O
at	O
the	O
target	O
gene	O
promoters	O
.	O

Our	O
findings	O
also	O
indicate	O
that	O
H4K20me	O
-	O
1	O
is	O
a	O
marker	O
for	O
gene	O
transcription	O
activation	O
,	O
at	O
least	O
in	O
canonical	O
Wnt	O
signaling	O
.	O

Steady	O
state	O
levels	O
of	O
Coq9p	O
mirrored	O
those	O
of	O
Coq7p	O
,	O
and	O
thus	O
it	O
is	O
tempting	O
to	O
speculate	O
that	O
Coq8	O
may	O
also	O
phosphorylate	O
Coq9p	O
.	O

In	O
fact	O
,	O
Coq9p	O
has	O
been	O
detected	O
in	O
a	O
yeast	O
phosphoproteome	O
analysis	O
and	O
is	O
phosphorylated	O
at	O
T34	O
.	O

Currently	O
,	O
this	O
is	O
the	O
only	O
reported	O
phosphorylation	O
site	O
in	O
any	O
yeast	O
Coq	O
polypeptide	O
.	O

The	O
amino	O
terminal	O
sequence	O
of	O
Coq9	O
residue	O
is	O
not	O
conserved	O
in	O
metazoan	O
Coq9	O
sequences	O
,	O
and	O
it	O
is	O
interesting	O
that	O
T34	O
may	O
be	O
located	O
within	O
the	O
predicted	O
mitochondrial	O
leader	O
sequence	O
of	O
yeast	O
Coq9p	O
(	O
Table	O
1S	O
)	O
.	O

Overexpression	O
of	O
COQ8	O
is	O
known	O
to	O
suppress	O
a	O
nonsense	O
(	O
Q151STOP	O
)	O
coq9	O
mutant	O
,	O
and	O
was	O
attributed	O
to	O
a	O
detectable	O
presence	O
of	O
Coq9p	O
due	O
to	O
read	O
-	O
through	O
.	O

Overexpression	O
of	O
COQ8	O
restores	O
the	O
steady	O
state	O
level	O
of	O
Coq4p	O
in	O
several	O
coq	O
null	O
mutants	O
,	O
but	O
not	O
in	O
the	O
coq9	O
null	O
mutant	O
.	O

While	O
experiments	O
have	O
not	O
revealed	O
a	O
complex	O
between	O
Coq8p	O
and	O
Coq9p	O
,	O
it	O
is	O
certainly	O
possible	O
that	O
phosphorylation	O
of	O
Coq9p	O
by	O
Coq8p	O
might	O
be	O
necessary	O
to	O
form	O
a	O
Q	O
biosynthetic	O
complex	O
and	O
so	O
preserve	O
the	O
otherwise	O
unstable	O
Coq	O
polypeptides	O
known	O
to	O
interact	O
with	O
Coq9	O
,	O
including	O
Coq4p	O
,	O
Coq6p	O
,	O
and	O
Coq7p	O
.	O

It	O
is	O
likely	O
that	O
such	O
Coq8	O
-	O
mediated	O
phosphorylation	O
of	O
Coq	O
polypeptides	O
might	O
function	O
to	O
regulate	O
Q6	O
synthesis	O
,	O
and	O
thus	O
also	O
account	O
for	O
the	O
COQ8	O
multicopy	O
suppression	O
of	O
the	O
coq10	O
mutant	O
.	O

The	O
TrkH	O
/	O
TrkG	O
/	O
KtrB	O
proteins	O
mediate	O
K	O
(	O
+	O
)	O
uptake	O
in	O
bacteria	O
and	O
probably	O
evolved	O
from	O
simple	O
K	O
(	O
+	O
)	O
channels	O
by	O
multiple	O
gene	O
duplications	O
or	O
fusions	O
.	O

Here	O
we	O
present	O
the	O
crystal	O
structure	O
of	O
a	O
TrkH	O
from	O
Vibrio	O
parahaemolyticus	O
.	O

TrkH	O
is	O
a	O
homodimer	O
,	O
and	O
each	O
protomer	O
contains	O
an	O
ion	O
permeation	O
pathway	O
.	O

A	O
selectivity	O
filter	O
,	O
similar	O
in	O
architecture	O
to	O
those	O
of	O
K	O
(	O
+	O
)	O
channels	O
but	O
significantly	O
shorter	O
,	O
is	O
lined	O
by	O
backbone	O
and	O
side	O
-	O
chain	O
oxygen	O
atoms	O
.	O

Functional	O
studies	O
showed	O
that	O
TrkH	O
is	O
selective	O
for	O
permeation	O
of	O
K	O
(	O
+	O
)	O
and	O
Rb	O
(	O
+	O
)	O
over	O
smaller	O
ions	O
such	O
as	O
Na	O
(	O
+	O
)	O
or	O
Li	O
(	O
+	O
)	O
.	O

Immediately	O
intracellular	O
to	O
the	O
selectivity	O
filter	O
are	O
an	O
intramembrane	O
loop	O
and	O
an	O
arginine	O
residue	O
,	O
both	O
highly	O
conserved	O
,	O
which	O
constrict	O
the	O
permeation	O
pathway	O
.	O

Substituting	O
the	O
arginine	O
with	O
an	O
alanine	O
significantly	O
increases	O
the	O
rate	O
of	O
K	O
(	O
+	O
)	O
flux	O
.	O

These	O
results	O
reveal	O
the	O
molecular	O
basis	O
of	O
K	O
(	O
+	O
)	O
selectivity	O
and	O
suggest	O
a	O
novel	O
gating	O
mechanism	O
for	O
this	O
large	O
and	O
important	O
family	O
of	O
membrane	O
transport	O
proteins	O
.	O

Joppich	O
et	O
al	O
.	O
have	O
reported	O
that	O
similar	O
to	O
LHR	O
,	O
HP4	O
(	O
Hip	O
)	O
binds	O
to	O
HP1	O
and	O
HP6	O
(	O
Umbrea	O
)	O
in	O
vitro	O
,	O
and	O
that	O
these	O
proteins	O
colocalize	O
at	O
pericentric	O
heterochromatin	O
and	O
form	O
a	O
complex	O
in	O
vivo	O
.	O

These	O
authors	O
further	O
proposed	O
that	O
the	O
association	O
between	O
HP1	O
and	O
HP6	O
is	O
mediated	O
by	O
heterodimerization	O
of	O
the	O
chromo	O
-	O
shadow	O
domain	O
(	O
CSD	O
)	O
in	O
each	O
protein	O
,	O
similar	O
to	O
the	O
known	O
homodimerization	O
of	O
the	O
CSD	O
in	O
HP1	O
.	O

Structural	O
investigation	O
suggests	O
that	O
CSD	O
dimerization	O
results	O
in	O
formation	O
of	O
a	O
protein	O
-	O
protein	O
interaction	O
pit	O
that	O
is	O
predicted	O
to	O
bind	O
one	O
peptide	O
per	O
CSD	O
dimer	O
.	O

LHR	O
,	O
HP4	O
,	O
and	O
HP5	O
each	O
interact	O
with	O
both	O
HP1	O
and	O
HP6	O
,	O
but	O
do	O
not	O
interact	O
with	O
each	O
other	O
.	O

These	O
interaction	O
results	O
combined	O
with	O
the	O
limitation	O
of	O
CSD	O
dimers	O
to	O
only	O
bind	O
one	O
peptide	O
,	O
suggest	O
that	O
LHR	O
,	O
HP4	O
and	O
HP5	O
are	O
unlikely	O
to	O
simultaneously	O
bind	O
to	O
HP1	O
or	O
HP6	O
CSD	O
dimers	O
or	O
to	O
HP1	O
/	O
HP6	O
heterodimers	O
.	O

Instead	O
,	O
LHR	O
,	O
HP4	O
,	O
and	O
HP5	O
likely	O
interact	O
separately	O
with	O
HP1	O
in	O
distinct	O
complexes	O
.	O

Pivotal	O
role	O
of	O
the	O
C2	O
domain	O
of	O
the	O
Smurf1	O
ubiquitin	O
ligase	O
in	O
substrate	O
selection	O
.	O

The	O
C2	O
-	O
WW	O
-	O
HECT	O
-	O
type	O
ubiquitin	O
ligases	O
Smurf1	O
and	O
Smurf2	O
play	O
a	O
critical	O
role	O
in	O
embryogenesis	O
and	O
adult	O
bone	O
homeostasis	O
via	O
regulation	O
of	O
bone	O
morphogenetic	O
protein	O
,	O
Wnt	O
,	O
and	O
RhoA	O
signaling	O
pathways	O
.	O

The	O
intramolecular	O
interaction	O
between	O
C2	O
and	O
HECT	O
domains	O
autoinhibits	O
the	O
ligase	O
activity	O
of	O
Smurf2	O
.	O

However	O
,	O
the	O
role	O
of	O
the	O
Smurf1	O
C2	O
domain	O
remains	O
elusive	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
C2	O
-	O
HECT	O
autoinhibition	O
mechanism	O
is	O
not	O
observed	O
in	O
Smurf1	O
,	O
and	O
instead	O
its	O
C2	O
domain	O
functions	O
in	O
substrate	O
selection	O
.	O

The	O
Smurf1	O
C2	O
domain	O
exerts	O
a	O
key	O
role	O
in	O
localization	O
to	O
the	O
plasma	O
membrane	O
and	O
endows	O
Smurf1	O
with	O
differential	O
activity	O
toward	O
RhoA	O
versus	O
Smad5	O
and	O
Runx2	O
.	O

Crystal	O
structure	O
analysis	O
reveals	O
that	O
the	O
Smurf1	O
C2	O
domain	O
possesses	O
a	O
typical	O
anti	O
-	O
parallel	O
beta	O
-	O
sandwich	O
fold	O
.	O

Examination	O
of	O
the	O
sulfate	O
-	O
binding	O
site	O
analysis	O
reveals	O
two	O
key	O
lysine	O
residues	O
,	O
Lys	O
-	O
28	O
and	O
Lys	O
-	O
85	O
,	O
within	O
the	O
C2	O
domain	O
that	O
are	O
important	O
for	O
Smurf1	O
localization	O
at	O
the	O
plasma	O
membrane	O
,	O
regulation	O
on	O
cell	O
migration	O
,	O
and	O
robust	O
ligase	O
activity	O
toward	O
RhoA	O
,	O
which	O
further	O
supports	O
a	O
Ca	O
(	O
2	O
+	O
)	O
-	O
independent	O
localization	O
mechanism	O
for	O
Smurf1	O
.	O

These	O
findings	O
demonstrate	O
a	O
previously	O
unidentified	O
role	O
of	O
the	O
Smurf1	O
C2	O
domain	O
in	O
substrate	O
selection	O
and	O
cellular	O
localization	O
.	O

The	O
melanoma	O
(	O
A375	O
-	O
TetOn	O
and	O
BLM	O
-	O
TetOn	O
)	O
cells	O
were	O
generated	O
using	O
the	O
Tet	O
-	O
On	O
expression	O
system	O
(	O
Clontech	O
,	O
Inc	O
.	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
as	O
described	O
previously	O
.	O

Briefly	O
,	O
the	O
melanoma	O
cell	O
lines	O
(	O
A375	O
and	O
BLM	O
)	O
were	O
transfected	O
with	O
pTet	O
-	O
On	O
plasmid	O
.	O

Twenty	O
-	O
four	O
hours	O
later	O
,	O
the	O
transfected	O
cells	O
were	O
challenged	O
with	O
G418	O
(	O
600	O
mug	O
/	O
ml	O
)	O
for	O
selection	O
.	O

After	O
6	O
weeks	O
,	O
single	O
clones	O
were	O
picked	O
up	O
and	O
expanded	O
.	O

The	O
induction	O
level	O
was	O
examined	O
by	O
the	O
transfection	O
of	O
pTRE2hyg	O
-	O
Luciferase	O
vector	O
and	O
subsequent	O
induction	O
of	O
luciferase	O
expression	O
by	O
the	O
addition	O
of	O
Dox	O
(	O
10	O
ng	O
/	O
ml	O
)	O
for	O
24	O
hrs	O
.	O

The	O
induction	O
levels	O
of	O
each	O
clone	O
were	O
determined	O
using	O
luciferase	O
assay	O
as	O
described	O
.	O

Clones	O
with	O
high	O
induction	O
level	O
and	O
low	O
background	O
were	O
chosen	O
for	O
the	O
transfection	O
with	O
pTRE2	O
hyg	O
-	O
APR	O
-	O
1	O
.	O

Cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
both	O
G418	O
(	O
600	O
mug	O
/	O
ml	O
)	O
and	O
Hygromycine	O
(	O
300	O
mug	O
/	O
ml	O
)	O
.	O

Single	O
clones	O
were	O
picked	O
up	O
and	O
expanded	O
for	O
further	O
examination	O
using	O
qRT	O
-	O
PCR	O
and	O
luciferase	O
assay	O
.	O

Clones	O
with	O
high	O
induction	O
levels	O
were	O
chosen	O
for	O
functional	O
analysis	O
of	O
APR	O
-	O
1	O
protein	O
.	O

In	O
the	O
complex	O
,	O
12	O
NKp30	O
residues	O
contact	O
11	O
B7	O
-	O
H6	O
residues	O
through	O
predominantly	O
hydrophobic	O
interactions	O
,	O
with	O
no	O
bound	O
water	O
molecules	O
in	O
the	O
interface	O
(	O
Fig	O
.	O
5	O
A	O
;	O
Table	O
II	O
)	O
.	O

The	O
three	O
potential	O
N	O
-	O
linked	O
glycosylation	O
sites	O
of	O
NKp30	O
are	O
located	O
outside	O
the	O
interface	O
with	O
B7	O
-	O
H6	O
and	O
so	O
should	O
not	O
interfere	O
with	O
binding	O
.	O

The	O
NKp30	O
-	O
B7	O
-	O
H6	O
complex	O
buries	O
a	O
total	O
solvent	O
-	O
accessible	O
surface	O
of	O
only	O
1	O
,	O
130	O
Aa2	O
,	O
of	O
which	O
578	O
Aa2	O
is	O
contributed	O
by	O
NKp30	O
and	O
552	O
Aa2	O
by	O
B7	O
-	O
H6	O
.	O

This	O
small	O
interface	O
,	O
which	O
is	O
similar	O
in	O
size	O
to	O
that	O
of	O
the	O
CTLA	O
-	O
4	O
-	O
B7	O
-	O
1	O
complex	O
(	O
1	O
,	O
250	O
Aa2	O
)	O
but	O
substantially	O
less	O
than	O
the	O
interface	O
of	O
the	O
PD	O
-	O
1	O
-	O
PDL1	O
complex	O
(	O
1	O
,	O
900	O
Aa2	O
)	O
,	O
is	O
at	O
the	O
lower	O
limit	O
of	O
the	O
mean	O
value	O
of	O
1	O
,	O
600	O
(	O
+	O
/	O
-	O
400	O
)	O
Aa2	O
for	O
stable	O
protein	O
-	O
protein	O
complexes	O
.	O

However	O
,	O
the	O
interface	O
is	O
characterized	O
by	O
high	O
shape	O
complementarity	O
,	O
based	O
on	O
a	O
calculated	O
shape	O
correlation	O
statistic	O
(	O
Sc	O
)	O
of	O
0	O
.	O
77	O
(	O
Sc	O
=	O
1	O
.	O
0	O
for	O
interfaces	O
with	O
geometrically	O
perfect	O
fits	O
)	O
,	O
which	O
is	O
at	O
the	O
upper	O
end	O
of	O
the	O
range	O
for	O
protein	O
-	O
protein	O
complexes	O
.	O

This	O
high	O
Sc	O
value	O
is	O
readily	O
explained	O
by	O
the	O
topologies	O
of	O
the	O
contacting	O
surfaces	O
,	O
whereby	O
the	O
FG	O
loop	O
of	O
B7	O
-	O
H6	O
forms	O
a	O
prominent	O
bulge	O
on	O
the	O
surface	O
of	O
the	O
ligand	O
which	O
fits	O
snugly	O
into	O
a	O
deep	O
groove	O
between	O
strands	O
FG	O
and	O
helix	O
alpha2	O
of	O
the	O
NKp30	O
receptor	O
that	O
is	O
unique	O
to	O
this	O
CD28	O
family	O
receptor	O
(	O
Fig	O
.	O
5	O
B	O
)	O
.	O

The	O
high	O
shape	O
complementarity	O
of	O
the	O
NKp30	O
-	O
B7	O
-	O
H6	O
interface	O
,	O
which	O
is	O
also	O
characterized	O
by	O
the	O
complete	O
exclusion	O
of	O
bulk	O
solvent	O
,	O
probably	O
compensates	O
for	O
its	O
small	O
size	O
to	O
achieve	O
sufficient	O
affinity	O
for	O
NK	O
cell	O
activation	O
.	O

To	O
confirm	O
the	O
frequent	O
bipolar	O
attachment	O
of	O
sister	O
chromatids	O
in	O
achiasmate	O
cells	O
,	O
we	O
depleted	O
Sgo1	O
,	O
which	O
inhibits	O
the	O
removal	O
of	O
centromeric	O
cohesin	B-Complex
during	O
anaphase	O
I	O
.	O

We	O
hypothesized	O
that	O
although	O
sister	O
chromatids	O
are	O
frequently	O
attached	O
to	O
both	O
poles	O
and	O
are	O
pulled	O
from	O
opposite	O
directions	O
,	O
the	O
centromere	O
cohesion	O
that	O
persists	O
until	O
meiosis	O
II	O
should	O
provide	O
resistance	O
against	O
this	O
force	O
and	O
prevent	O
their	O
separation	O
during	O
anaphase	O
I	O
in	O
achiasmate	O
cells	O
.	O

If	O
so	O
,	O
depletion	O
of	O
Sgo1	O
,	O
which	O
eliminates	O
centromere	O
cohesion	O
during	O
anaphase	O
I	O
,	O
should	O
lead	O
to	O
frequent	O
equational	O
segregation	O
of	O
sister	O
chromatids	O
.	O

The	O
most	O
common	O
mutation	O
in	O
human	O
melanoma	O
,	O
BRAF	O
(	O
V600E	O
)	O
,	O
activates	O
the	O
serine	O
/	O
threonine	O
kinase	O
BRAF	O
and	O
causes	O
excessive	O
activity	O
in	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
pathway	O
.	O

BRAF	O
(	O
V600E	O
)	O
mutations	O
are	O
also	O
present	O
in	O
benign	O
melanocytic	O
naevi	O
,	O
highlighting	O
the	O
importance	O
of	O
additional	O
genetic	O
alterations	O
in	O
the	O
genesis	O
of	O
malignant	O
tumours	O
.	O

Such	O
changes	O
include	O
recurrent	O
copy	O
number	O
variations	O
that	O
result	O
in	O
the	O
amplification	O
of	O
oncogenes	O
.	O

For	O
certain	O
amplifications	O
,	O
the	O
large	O
number	O
of	O
genes	O
in	O
the	O
interval	O
has	O
precluded	O
an	O
understanding	O
of	O
the	O
cooperating	O
oncogenic	O
events	O
.	O

Here	O
we	O
have	O
used	O
a	O
zebrafish	O
melanoma	O
model	O
to	O
test	O
genes	O
in	O
a	O
recurrently	O
amplified	O
region	O
of	O
chromosome	O
1	O
for	O
the	O
ability	O
to	O
cooperate	O
with	O
BRAF	O
(	O
V600E	O
)	O
and	O
accelerate	O
melanoma	O
.	O

SETDB1	O
,	O
an	O
enzyme	O
that	O
methylates	O
histone	O
H3	O
on	O
lysine	O
9	O
(	O
H3K9	O
)	O
,	O
was	O
found	O
to	O
accelerate	O
melanoma	O
formation	O
significantly	O
in	O
zebrafish	O
.	O

Chromatin	O
immunoprecipitation	O
coupled	O
with	O
massively	O
parallel	O
DNA	O
sequencing	O
and	O
gene	O
expression	O
analyses	O
uncovered	O
genes	O
,	O
including	O
HOX	O
genes	O
,	O
that	O
are	O
transcriptionally	O
dysregulated	O
in	O
response	O
to	O
increased	O
levels	O
of	O
SETDB1	O
.	O

Our	O
studies	O
establish	O
SETDB1	O
as	O
an	O
oncogene	O
in	O
melanoma	O
and	O
underscore	O
the	O
role	O
of	O
chromatin	O
factors	O
in	O
regulating	O
tumorigenesis	O
.	O

Interaction	O
with	O
the	O
histone	O
chaperone	O
Vps75	O
promotes	O
nuclear	O
localization	O
and	O
HAT	O
activity	O
of	O
Rtt109	O
in	O
vivo	O
.	O

Modification	O
of	O
histones	O
is	O
critical	O
for	O
the	O
regulation	O
of	O
all	O
chromatin	O
-	O
templated	O
processes	O
.	O

Yeast	O
Rtt109	O
is	O
a	O
histone	O
acetyltransferase	O
(	O
HAT	O
)	O
that	O
acetylates	O
H3	O
lysines	O
9	O
,	O
27	O
and	O
56	O
.	O

Rtt109	O
associates	O
with	O
and	O
is	O
stabilized	O
by	O
Nap1	O
family	O
histone	O
chaperone	O
Vps75	O
.	O

Our	O
data	O
suggest	O
Vps75	O
and	O
Nap1	O
have	O
some	O
overlapping	O
functions	O
despite	O
their	O
different	O
cellular	O
localization	O
and	O
histone	O
binding	O
specificity	O
.	O

We	O
determined	O
that	O
Vps75	O
contains	O
a	O
classical	O
nuclear	O
localization	O
signal	O
and	O
is	O
imported	O
by	O
Kap60	O
-	O
Kap95	O
.	O

Rtt109	O
nuclear	O
localization	O
depends	O
on	O
Vps75	O
,	O
and	O
nuclear	O
localization	O
of	O
the	O
Vps75	O
-	O
Rtt109	O
complex	O
is	O
not	O
critical	O
for	O
Rtt109	O
-	O
dependent	O
functions	O
,	O
suggesting	O
Rtt109	O
may	O
be	O
able	O
to	O
acetylate	O
nascent	O
histones	O
before	O
nuclear	O
import	O
.	O

To	O
date	O
,	O
the	O
effects	O
of	O
VPS75	O
deletion	O
on	O
Rtt109	O
function	O
had	O
not	O
been	O
separated	O
from	O
the	O
resulting	O
Rtt109	O
degradation	O
;	O
thus	O
,	O
we	O
used	O
an	O
Rtt109	O
mutant	O
lacking	O
the	O
Vps75	O
-	O
interaction	O
domain	O
that	O
is	O
stable	O
without	O
Vps75	O
.	O

Our	O
data	O
show	O
that	O
in	O
addition	O
to	O
promoting	O
Rtt109	O
stability	O
,	O
Vps75	O
binding	O
is	O
necessary	O
for	O
Rtt109	O
acetylation	O
of	O
the	O
H3	O
tail	O
.	O

Direct	O
interaction	O
of	O
Vps75	O
with	O
H3	O
likely	O
allows	O
Rtt109	O
access	O
to	O
the	O
histone	O
tail	O
.	O

Furthermore	O
,	O
our	O
genetic	O
interaction	O
data	O
support	O
the	O
idea	O
of	O
Rtt109	O
-	O
independent	O
functions	O
of	O
Vps75	O
.	O

In	O
summary	O
,	O
our	O
data	O
suggest	O
that	O
Vps75	O
influences	O
chromatin	O
structure	O
by	O
regulating	O
histone	O
modification	O
and	O
through	O
its	O
histone	O
chaperone	O
functions	O
.	O

To	O
investigate	O
whether	O
Angiomotin	O
is	O
required	O
for	O
tumor	O
development	O
in	O
vivo	O
,	O
we	O
employed	O
a	O
mouse	O
model	O
of	O
NF2	O
in	O
which	O
conditional	O
deletion	O
of	O
Nf2	O
in	O
mouse	O
Schwann	O
cells	O
(	O
P0	O
-	O
Cre	O
:	O
Nf2flox	O
/	O
flox	O
)	O
leads	O
to	O
schwannoma	O
development	O
,	O
within	O
a	O
lag	O
time	O
of	O
several	O
months	O
.	O

To	O
assess	O
the	O
requirement	O
for	O
Angiomotin	O
in	O
this	O
model	O
,	O
we	O
crossed	O
the	O
P0	O
-	O
Cre	O
and	O
P0	O
-	O
Cre	O
:	O
Nf2flox	O
/	O
flox	O
to	O
Amotflox	O
/	O
flox	O
mice	O
.	O

While	O
P0	O
-	O
Cre	O
:	O
Amotflox	O
/	O
flox	O
mice	O
are	O
born	O
at	O
the	O
expected	O
Mendelian	O
ratios	O
and	O
develop	O
normally	O
,	O
the	O
P0	O
-	O
Cre	O
:	O
Nf2flox	O
/	O
flox	O
:	O
Amotflox	O
/	O
flox	O
mice	O
die	O
shortly	O
after	O
birth	O
due	O
to	O
neurological	O
defects	O
(	O
Yi	O
and	O
Kissil	O
,	O
unpublished	O
results	O
)	O
,	O
precluding	O
the	O
use	O
of	O
this	O
model	O
.	O

Quantification	O
of	O
receptor	O
tyrosine	O
kinase	O
transactivation	O
through	O
direct	O
dimerization	O
and	O
surface	O
density	O
measurements	O
in	O
single	O
cells	O
.	O

Cell	O
signaling	O
involves	O
dynamic	O
changes	O
in	O
protein	O
oligomerization	O
leading	O
to	O
the	O
formation	O
of	O
different	O
signaling	O
complexes	O
and	O
modulation	O
of	O
activity	O
.	O

Spatial	O
intensity	O
distribution	O
analysis	O
(	O
SpIDA	O
)	O
is	O
an	O
image	O
analysis	O
method	O
that	O
can	O
directly	O
measure	O
oligomerization	O
and	O
trafficking	O
of	O
endogenous	O
proteins	O
in	O
single	O
cells	O
.	O

Here	O
,	O
we	O
show	O
the	O
use	O
of	O
SpIDA	O
to	O
quantify	O
dimerization	O
/	O
activation	O
and	O
surface	O
transport	O
of	O
receptor	O
protein	O
kinases	O
-	O
-	O
EGF	O
receptor	O
and	O
TrkB	O
-	O
-	O
at	O
early	O
stages	O
of	O
their	O
transactivation	O
by	O
several	O
G	O
protein	O
-	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
.	O

Transactivation	O
occurred	O
on	O
the	O
same	O
timescale	O
and	O
was	O
directly	O
limited	O
by	O
GPCR	O
activation	O
but	O
independent	O
of	O
G	O
-	O
protein	O
coupling	O
types	O
.	O

Early	O
receptor	O
protein	O
kinase	O
transactivation	O
and	O
internalization	O
were	O
not	O
interdependent	O
for	O
all	O
receptor	O
pairs	O
tested	O
,	O
revealing	O
heterogeneity	O
between	O
groups	O
of	O
GPCRs	O
.	O

SpIDA	O
also	O
detected	O
transactivation	O
of	O
TrkB	O
by	O
dopamine	O
receptors	O
in	O
intact	O
neurons	O
.	O

By	O
allowing	O
for	O
time	O
and	O
space	O
resolved	O
quantification	O
of	O
protein	O
populations	O
with	O
heterogeneous	O
oligomeric	O
states	O
,	O
SpIDA	O
provides	O
a	O
unique	O
approach	O
to	O
undertake	O
single	O
cell	O
multivariate	O
quantification	O
of	O
signaling	O
processes	O
involving	O
changes	O
in	O
protein	O
interactions	O
,	O
trafficking	O
,	O
and	O
activity	O
.	O

To	O
understand	O
the	O
mechanisms	O
of	O
aggregation	O
and	O
cellular	O
toxicity	O
caused	O
by	O
expansion	O
of	O
polyA	O
tracts	O
in	O
yeast	O
,	O
we	O
chose	O
Pab1	O
as	O
an	O
initial	O
example	O
to	O
expand	O
its	O
native	O
polyA	O
tract	O
.	O

Pab1	O
is	O
a	O
nuclear	O
-	O
cytoplasmic	O
poly	O
(	O
Ade	O
)	O
-	O
binding	O
protein	O
that	O
is	O
a	O
component	O
of	O
the	O
3	O
'	O
-	O
end	O
mRNA	O
-	O
processing	O
complex	O
.	O

Pab1	O
mediates	O
interactions	O
between	O
the	O
5	O
'	O
cap	O
structure	O
and	O
the	O
3	O
'	O
poly	O
(	O
Ade	O
)	O
tail	O
of	O
mRNA	O
.	O

We	O
focused	O
on	O
Pab1	O
because	O
it	O
is	O
similar	O
to	O
the	O
human	O
nuclear	O
poly	O
(	O
Ade	O
)	O
-	O
binding	O
protein	O
PABPN1	O
,	O
which	O
possesses	O
a	O
polyA	O
tract	O
that	O
when	O
expanded	O
results	O
in	O
OPMD	O
,	O
and	O
is	O
a	O
homologue	O
of	O
PABPC1	O
,	O
which	O
also	O
possesses	O
a	O
polyA	O
tract	O
(	O
Figure	O
1A	O
)	O
.	O

Expansion	O
of	O
PABPN1	O
'	O
s	O
polyA	O
tract	O
causes	O
the	O
protein	O
to	O
form	O
aggregates	O
in	O
muscle	O
cells	O
and	O
confers	O
dominant	O
-	O
negative	O
toxicity	O
in	O
the	O
affected	O
cells	O
.	O

Therefore	O
we	O
tested	O
whether	O
expansion	O
of	O
the	O
yeast	O
Pab1	O
polyA	O
tract	O
would	O
cause	O
aggregation	O
and	O
cellular	O
dysfunction	O
.	O

To	O
perform	O
siRNA	O
studies	O
in	O
erythroid	O
cells	O
,	O
they	O
were	O
transfected	O
on	O
day	O
11	O
using	O
the	O
CD34	O
+	O
-	O
Nucleofector	O
kit	O
(	O
Amaxa	O
)	O
.	O

Briefly	O
,	O
3	O
x	O
106	O
cells	O
were	O
incubated	O
in	O
100	O
mul	O
of	O
Nucleofector	O
solution	O
with	O
si	O
-	O
KLF4	O
[	O
100	O
and	O
300	O
nmol	O
/	O
l	O
]	O
or	O
Scr	O
[	O
100	O
nmol	O
/	O
l	O
]	O
control	O
;	O
all	O
samples	O
were	O
also	O
treated	O
with	O
2	O
mug	O
of	O
the	O
pMAxGFP	O
reporter	O
(	O
Amaxa	O
)	O
to	O
monitor	O
transfection	O
efficiency	O
.	O

Cells	O
were	O
electroporated	O
on	O
the	O
U	O
-	O
08	O
setting	O
for	O
erythroid	O
progenitors	O
and	O
incubated	O
for	O
72	O
h	O
.	O

The	O
same	O
experimental	O
conditions	O
were	O
employed	O
to	O
perform	O
enforced	O
expression	O
studies	O
.	O

Primary	O
cells	O
(	O
5	O
x	O
106	O
)	O
were	O
electroporated	O
with	O
5	O
or	O
10	O
mug	O
of	O
pMT3	O
or	O
pMT3	O
-	O
KLF4	O
expression	O
vector	O
and	O
2	O
mug	O
of	O
pMAxGFP	O
.	O

The	O
pMT3	O
-	O
KLF4	O
expression	O
vector	O
carried	O
a	O
full	O
-	O
length	O
cDNA	O
for	O
the	O
human	O
KLF4	O
gene	O
,	O
a	O
kind	O
gift	O
from	O
Dr	O
Vincent	O
Yang	O
,	O
Emory	O
University	O
School	O
of	O
Medicine	O
.	O

Chromatin	O
-	O
modifying	O
complex	O
component	O
Nurf55	O
/	O
p55	O
associates	O
with	O
histones	O
H3	O
and	O
H4	O
and	O
polycomb	B-Complex
repressive	I-Complex
complex	I-Complex
2	I-Complex
subunit	O
Su	O
(	O
z	O
)	O
12	O
through	O
partially	O
overlapping	O
binding	O
sites	O
.	O

Drosophila	O
Nurf55	O
is	O
a	O
component	O
of	O
different	O
chromatin	O
-	O
modifying	O
complexes	O
,	O
including	O
the	O
PRC2	B-Complex
(	O
Polycomb	B-Complex
repressive	I-Complex
complex	I-Complex
2	I-Complex
)	O
.	O

Based	O
on	O
the	O
1	O
.	O
75	O
-	O
Aa	O
crystal	O
structure	O
of	O
Nurf55	O
bound	O
to	O
histone	O
H4	O
helix	O
1	O
,	O
we	O
analyzed	O
interactions	O
of	O
Nurf55	O
(	O
Nurf55	O
or	O
p55	O
in	O
fly	O
and	O
RbAp48	O
/	O
46	O
in	O
human	O
)	O
with	O
the	O
N	O
-	O
terminal	O
tail	O
of	O
histone	O
H3	O
,	O
the	O
first	O
helix	O
of	O
histone	O
H4	O
,	O
and	O
an	O
N	O
-	O
terminal	O
fragment	O
of	O
the	O
PRC2	B-Complex
subunit	O
Su	O
(	O
z	O
)	O
12	O
using	O
isothermal	O
calorimetry	O
and	O
pulldown	O
experiments	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
identified	O
the	O
binding	O
site	O
of	O
histone	O
H3	O
at	O
the	O
top	O
of	O
the	O
Nurf55	O
WD40	O
propeller	O
.	O

Unmodified	O
or	O
K9me3	O
-	O
or	O
K27me3	O
-	O
containing	O
H3	O
peptides	O
were	O
bound	O
with	O
similar	O
affinities	O
,	O
whereas	O
the	O
affinity	O
for	O
K4me3	O
-	O
containing	O
H3	O
peptides	O
was	O
reduced	O
.	O

Helix	O
1	O
of	O
histone	O
H4	O
and	O
Su	O
(	O
z	O
)	O
12	O
bound	O
to	O
the	O
edge	O
of	O
the	O
beta	O
-	O
propeller	O
using	O
overlapping	O
binding	O
sites	O
.	O

Our	O
results	O
show	O
similarities	O
in	O
the	O
recognition	O
of	O
histone	O
H4	O
and	O
Su	O
(	O
z	O
)	O
12	O
and	O
identify	O
Nurf55	O
as	O
a	O
versatile	O
interactor	O
that	O
simultaneously	O
contacts	O
multiple	O
partners	O
.	O

Mitotic	O
kinase	O
Aurora	O
-	O
B	O
is	O
regulated	O
by	O
SUMO	O
-	O
2	O
/	O
3	O
conjugation	O
/	O
deconjugation	O
during	O
mitosis	O
.	O

The	O
small	O
ubiquitin	O
-	O
related	O
modifier	O
(	O
SUMO	O
)	O
system	O
of	O
higher	O
eukaryotes	O
plays	O
important	O
roles	O
in	O
normal	O
cell	O
division	O
,	O
especially	O
in	O
chromosome	O
segregation	O
.	O

However	O
,	O
only	O
a	O
few	O
mitotic	O
SUMO	O
substrates	O
have	O
been	O
identified	O
in	O
mammals	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
mitotic	O
kinase	O
Aurora	O
-	O
B	O
can	O
be	O
modified	O
by	O
SUMO	O
.	O

The	O
E3	O
SUMO	O
-	O
protein	O
ligase	O
PIAS3	O
[	O
protein	O
inhibitor	O
of	O
activated	O
STAT	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
)	O
]	O
dramatically	O
enhanced	O
poly	O
-	O
SUMO	O
-	O
2	O
/	O
3	O
conjugation	O
of	O
Aurora	O
-	O
B	O
,	O
whereas	O
the	O
SUMO	O
-	O
specific	O
isopeptidase	O
SENP2	O
(	O
Sentrin	O
/	O
SUMO	O
-	O
specific	O
protease	O
)	O
specifically	O
deconjugated	O
SUMO	O
from	O
Aurora	O
-	O
B	O
.	O

The	O
Lys	O
-	O
202	O
residue	O
on	O
human	O
Aurora	O
-	O
B	O
was	O
preferentially	O
modified	O
by	O
SUMO	O
,	O
and	O
enhancement	O
of	O
SUMOylation	O
in	O
cells	O
facilitated	O
Aurora	O
-	O
B	O
autophosphorylation	O
,	O
which	O
is	O
essential	O
for	O
its	O
activation	O
.	O

Conversely	O
,	O
SENP2	O
-	O
mediated	O
deSUMOylation	O
of	O
Aurora	O
-	O
B	O
down	O
-	O
regulated	O
its	O
autophosphorylation	O
in	O
cells	O
and	O
also	O
impaired	O
its	O
re	O
-	O
activation	O
in	O
Aurora	O
inhibitor	O
VX	O
-	O
680	O
-	O
treated	O
mitotic	O
cells	O
.	O

Poly	O
-	O
SUMO	O
-	O
2	O
conjugation	O
of	O
Aurora	O
-	O
B	O
occurred	O
during	O
the	O
M	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
both	O
SUMO	O
-	O
2	O
and	O
PIAS3	O
were	O
localized	O
adjacent	O
to	O
Aurora	O
-	O
B	O
in	O
the	O
kinetochores	O
in	O
early	O
mitosis	O
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
propose	O
that	O
Aurora	O
-	O
B	O
is	O
a	O
novel	O
mitotic	O
SUMO	O
substrate	O
and	O
that	O
its	O
kinase	O
activity	O
is	O
fine	O
-	O
tuned	O
by	O
the	O
SUMO	O
system	O
.	O

In	O
budding	O
yeast	O
genetic	O
screens	O
identified	O
SPC97	O
(	O
spindle	O
pole	O
body	O
component	O
of	O
97	O
kDa	O
)	O
and	O
SPC98	O
as	O
interacting	O
partners	O
of	O
the	O
gamma	O
-	O
tubulin	O
TUB4	O
.	O

Spc97	O
,	O
Spc98	O
and	O
Tub4	B-Complex
constitute	O
the	O
core	O
set	O
of	O
the	O
yeast	O
gamma	B-Complex
-	I-Complex
TuSC	I-Complex
(	O
known	O
as	O
the	O
Tub4	B-Complex
complex	O
)	O
.	O

The	O
Tub4	B-Complex
complex	O
was	O
later	O
found	O
to	O
be	O
a	O
Y	O
-	O
shaped	O
heterotetramer	O
composed	O
of	O
one	O
molecule	O
of	O
Spc97	O
and	O
Spc98	O
and	O
two	O
molecules	O
of	O
Tub4	B-Complex
.	O

Subsequently	O
,	O
homologues	O
of	O
Spc97	O
and	O
Spc98	O
were	O
identified	O
in	O
various	O
organisms	O
such	O
as	O
fission	O
yeast	O
,	O
insects	O
,	O
humans	O
and	O
plants	O
.	O

DU145	O
,	O
PC	O
-	O
3	O
and	O
PPC	O
-	O
1	O
cells	O
were	O
seeded	O
into	O
6	O
-	O
well	O
tissue	O
culture	O
plates	O
.	O

Cells	O
were	O
transfected	O
with	O
non	O
-	O
targeting	O
siRNA	O
or	O
siRNA	O
specific	O
for	O
Siah2	O
or	O
POSH	O
.	O

48	O
hours	O
after	O
siRNA	O
transfection	O
,	O
RNA	O
was	O
harvested	O
using	O
the	O
RNeasy	O
kit	O
(	O
Qiagen	O
,	O
Valencia	O
,	O
CA	O
)	O
.	O

cDNA	O
was	O
generated	O
using	O
SuperScript	O
II	O
Reverse	O
Transcriptase	O
(	O
Invitrogen	O
)	O
.	O

qRT	O
-	O
PCR	O
was	O
carried	O
out	O
using	O
primer	O
sets	O
for	O
18S	O
,	O
Siah2	O
or	O
POSH	O
in	O
the	O
presence	O
of	O
FastStart	O
Universal	O
SYBR	O
Green	O
Master	O
Mix	O
(	O
Roche	O
,	O
Nutley	O
,	O
NJ	O
)	O
.	O

PCR	O
was	O
performed	O
and	O
analyzed	O
using	O
a	O
4300	O
Real	O
Time	O
PCR	O
System	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
.	O

Percent	O
mRNA	O
remaining	O
was	O
determined	O
by	O
the	O
comparative	O
CT	O
method	O
(	O
DeltaCT	O
)	O
for	O
relative	O
quantification	O
.	O

Here	O
we	O
report	O
the	O
identification	O
of	O
a	O
human	O
complex	O
comprising	O
the	O
MBT	O
-	O
domain	O
containing	O
protein	O
L3MBTL2	O
along	O
with	O
well	O
-	O
characterized	O
PcG	O
proteins	O
.	O

We	O
describe	O
the	O
multiple	O
activities	O
exhibited	O
by	O
this	O
complex	O
that	O
promote	O
repressive	O
chromatin	O
architecture	O
.	O

We	O
also	O
found	O
that	O
the	O
methyl	O
-	O
lysine	O
binding	O
capability	O
of	O
L3MBTL2	O
was	O
not	O
required	O
for	O
its	O
transcriptional	O
repressor	O
function	O
,	O
yet	O
the	O
ability	O
of	O
the	O
complex	O
to	O
compact	O
chromatin	O
and	O
independently	O
mediate	O
H2AK119ub1	O
was	O
important	O
for	O
maintaining	O
repression	O
of	O
target	O
genes	O
.	O

To	O
probe	O
further	O
whether	O
up	O
-	O
regulation	O
of	O
mitochondrial	O
respiration	O
in	O
puf3Delta	O
strains	O
was	O
independent	O
of	O
mitochondrial	O
biogenesis	O
pathways	O
,	O
we	O
over	O
-	O
expressed	O
Hap4p	O
,	O
a	O
known	O
transcriptional	O
regulator	O
of	O
mitochondrial	O
biogenesis	O
,	O
and	O
Gsm1p	O
,	O
another	O
transcription	O
factor	O
implicated	O
in	O
regulating	O
the	O
expression	O
of	O
OXPHOS	O
proteins	O
,	O
in	O
wild	O
-	O
type	O
and	O
puf3Delta	O
strains	O
.	O

Simultaneous	O
over	O
-	O
expression	O
of	O
these	O
two	O
transcription	O
factors	O
caused	O
similar	O
increases	O
in	O
respiration	O
in	O
both	O
wild	O
-	O
type	O
and	O
puf3Delta	O
strains	O
(	O
Figure	O
2A	O
)	O
and	O
,	O
further	O
increases	O
in	O
the	O
already	O
heightened	O
steady	O
-	O
state	O
levels	O
of	O
Cox2p	O
and	O
Cox4p	O
in	O
the	O
puf3Delta	O
strain	O
(	O
Figure	O
2B	O
)	O
.	O

Finally	O
,	O
we	O
assayed	O
the	O
steady	O
-	O
state	O
levels	O
of	O
COX17	O
transcripts	O
,	O
a	O
canonical	O
Puf3	O
target	O
,	O
and	O
two	O
non	O
-	O
P3E	O
-	O
target	O
transcripts	O
,	O
RIP1	O
and	O
COX12	O
,	O
by	O
quantitative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
.	O

As	O
expected	O
,	O
deletion	O
of	O
PUF3	O
leads	O
to	O
a	O
dramatic	O
increase	O
in	O
COX17	O
transcripts	O
,	O
but	O
had	O
little	O
or	O
no	O
effect	O
on	O
the	O
non	O
-	O
P3E	O
targets	O
,	O
while	O
over	O
-	O
expression	O
of	O
HAP4	O
and	O
GSM1	O
in	O
a	O
wild	O
-	O
type	O
strain	O
led	O
to	O
an	O
increase	O
in	O
COX12	O
and	O
RIP1	O
mRNA	O
(	O
Figure	O
2C	O
)	O
.	O

Importantly	O
,	O
Hap4p	O
/	O
Gsm1p	O
over	O
-	O
expression	O
increased	O
all	O
of	O
these	O
transcripts	O
to	O
a	O
similar	O
degree	O
in	O
the	O
puf3Delta	O
strain	O
(	O
Figure	O
2C	O
)	O
,	O
bolstering	O
our	O
conclusion	O
that	O
up	O
-	O
regulation	O
of	O
respiration	O
in	O
the	O
absence	O
of	O
Puf3p	O
is	O
largely	O
independent	O
of	O
pathways	O
that	O
increase	O
mitochondrial	O
biogenesis	O
.	O

Altering	O
the	O
stability	O
of	O
the	O
Cdc8	O
overlap	O
region	O
modulates	O
the	O
ability	O
of	O
this	O
tropomyosin	O
to	O
bind	O
co	O
-	O
operatively	O
to	O
actin	O
and	O
regulate	O
myosin	O
.	O

Tm	O
(	O
tropomyosin	O
)	O
is	O
an	O
evolutionarily	O
conserved	O
alpha	O
-	O
helical	O
coiled	O
-	O
coil	O
protein	O
,	O
dimers	O
of	O
which	O
form	O
end	O
-	O
to	O
-	O
end	O
polymers	O
capable	O
of	O
associating	O
with	O
and	O
stabilizing	O
actin	O
filaments	O
,	O
and	O
regulating	O
myosin	O
function	O
.	O

The	O
fission	O
yeast	O
Schizosaccharomyces	O
pombe	O
possesses	O
a	O
single	O
essential	O
Tm	O
,	O
Cdc8	O
,	O
which	O
can	O
be	O
acetylated	O
on	O
its	O
N	O
-	O
terminal	O
methionine	O
residue	O
to	O
increase	O
its	O
affinity	O
for	O
actin	O
and	O
enhance	O
its	O
ability	O
to	O
regulate	O
myosin	O
function	O
.	O

We	O
have	O
designed	O
and	O
generated	O
a	O
number	O
of	O
novel	O
Cdc8	O
mutant	O
proteins	O
with	O
N	O
-	O
terminal	O
substitutions	O
to	O
explore	O
how	O
stability	O
of	O
the	O
Cdc8	O
overlap	O
region	O
affects	O
the	O
regulatory	O
function	O
of	O
this	O
Tm	O
.	O

By	O
correlating	O
the	O
stability	O
of	O
each	O
protein	O
,	O
its	O
propensity	O
to	O
form	O
stable	O
polymers	O
,	O
its	O
ability	O
to	O
associate	O
with	O
actin	O
and	O
to	O
regulate	O
myosin	O
,	O
we	O
have	O
shown	O
that	O
the	O
stability	O
of	O
the	O
N	O
-	O
terminal	O
of	O
the	O
Cdc8	O
alpha	O
-	O
helix	O
is	O
crucial	O
for	O
Tm	O
function	O
.	O

In	O
addition	O
we	O
have	O
identified	O
a	O
novel	O
Cdc8	O
mutant	O
with	O
increased	O
N	O
-	O
terminal	O
stability	O
,	O
dimers	O
of	O
which	O
are	O
capable	O
of	O
forming	O
Tm	O
polymers	O
significantly	O
longer	O
than	O
the	O
wild	O
-	O
type	O
protein	O
.	O

This	O
protein	O
had	O
a	O
reduced	O
affinity	O
for	O
actin	O
with	O
respect	O
to	O
wild	O
-	O
type	O
,	O
and	O
was	O
unable	O
to	O
regulate	O
actomyosin	B-Complex
interactions	O
.	O

The	O
results	O
of	O
the	O
present	O
paper	O
are	O
consistent	O
with	O
acetylation	O
providing	O
a	O
mechanism	O
for	O
modulating	O
the	O
formation	O
and	O
stability	O
of	O
Cdc8	O
polymers	O
within	O
the	O
fission	O
yeast	O
cell	O
.	O

The	O
data	O
also	O
provide	O
evidence	O
for	O
a	O
mechanism	O
in	O
which	O
Tm	O
dimers	O
form	O
end	O
-	O
to	O
-	O
end	O
polymers	O
on	O
the	O
actin	O
filament	O
,	O
consistent	O
with	O
a	O
co	O
-	O
operative	O
model	O
for	O
Tm	O
binding	O
to	O
actin	O
.	O

All	O
GPI	O
-	O
anchored	O
proteins	O
seem	O
to	O
share	O
two	O
conserved	O
motifs	O
that	O
could	O
potentially	O
function	O
as	O
a	O
recognition	O
motif	O
for	O
the	O
p24	B-Complex
complex	O
:	O
the	O
GPI	O
anchor	O
and	O
a	O
serine	O
/	O
threonine	O
(	O
S	O
/	O
T	O
)	O
region	O
.	O

The	O
GPI	O
-	O
anchor	O
is	O
covalently	O
attached	O
to	O
a	O
newly	O
generated	O
COOH	O
-	O
terminal	O
residue	O
(	O
omega	O
site	O
)	O
after	O
cleavage	O
of	O
the	O
GPI	O
-	O
attachment	O
signal	O
in	O
the	O
ER	O
.	O

The	O
S	O
/	O
T	O
region	O
upstream	O
of	O
the	O
omega	O
site	O
is	O
a	O
site	O
for	O
O	O
-	O
mannosylation	O
,	O
which	O
begins	O
in	O
the	O
ER	O
in	O
yeast	O
.	O

To	O
identify	O
the	O
region	O
of	O
GPI	O
-	O
anchored	O
protein	O
binding	O
to	O
Emp24p	O
,	O
we	O
used	O
three	O
different	O
mutant	O
constructs	O
of	O
the	O
Gas1p	O
.	O

In	O
one	O
construct	O
Gas1p	O
is	O
devoid	O
of	O
its	O
GPI	O
anchor	O
and	O
instead	O
contains	O
an	O
artificial	O
transmembrane	O
domain	O
(	O
TMD	O
)	O
consisting	O
of	O
19	O
leucine	O
residues	O
and	O
two	O
flanking	O
arginine	O
and	O
serine	O
residues	O
(	O
Gas1TMD	O
)	O
.	O

In	O
a	O
second	O
construct	O
Gas1p	O
is	O
deleted	O
of	O
its	O
S	O
/	O
T	O
region	O
[	O
Gas1	O
(	O
-	O
S	O
/	O
T	O
)	O
]	O
.	O

In	O
the	O
third	O
construct	O
Gas1p	O
is	O
mutated	O
at	O
the	O
omega	O
site	O
to	O
prevent	O
GPI	O
anchoring	O
(	O
Gas1Q	O
)	O
.	O

We	O
observed	O
that	O
only	O
wild	O
-	O
type	O
Gas1p	O
and	O
Gas1	O
(	O
-	O
S	O
/	O
T	O
)	O
can	O
be	O
cross	O
-	O
linked	O
to	O
Emp24p	O
(	O
Figure	O
1	O
,	O
D	O
and	O
E	O
)	O
.	O

Therefore	O
these	O
results	O
show	O
that	O
Emp24p	O
recognizes	O
and	O
binds	O
to	O
the	O
GPI	O
-	O
anchored	O
proteins	O
via	O
the	O
GPI	O
anchor	O
prior	O
to	O
and	O
/	O
or	O
during	O
ER	O
exit	O
.	O

The	O
increase	O
in	O
Pho2	O
and	O
Pho4	O
binding	O
after	O
Pi	O
starvation	O
(	O
recruitment	O
)	O
is	O
calculated	O
using	O
the	O
following	O
equation	O
:	O
taking	O
Pho4	O
as	O
an	O
example	O
,	O
EnrichmentNo	O
/	O
High	O
=	O
(	O
Pho4ChIP	O
No	O
/	O
Pho4Input	O
No	O
)	O
/	O
(	O
Pho4ChIP	O
High	O
/	O
Pho4Input	O
High	O
)	O
.	O

To	O
estimate	O
a	O
threshold	O
to	O
define	O
transcription	O
factor	O
recruitment	O
,	O
we	O
calculated	O
the	O
mean	O
and	O
standard	O
deviation	O
of	O
Pho2	O
and	O
Pho4	O
recruitment	O
at	O
all	O
consensus	O
'	O
CACGTG	O
'	O
sites	O
,	O
excluding	O
the	O
sites	O
at	O
regulatory	O
regions	O
of	O
Pho4	O
regulated	O
genes	O
(	O
functional	O
binding	O
sites	O
)	O
.	O

We	O
used	O
mean	O
+	O
2	O
standard	O
deviations	O
(	O
s	O
.	O
d	O
.	O
)	O
as	O
the	O
threshold	O
to	O
identify	O
the	O
sites	O
showing	O
the	O
most	O
significant	O
recruitment	O
(	O
Figure	O
4B	O
)	O
.	O

23	O
of	O
28	O
sites	O
showing	O
recruitment	O
of	O
both	O
Pho2	O
and	O
Pho4	O
are	O
regulated	O
by	O
both	O
factors	O
(	O
p	O
=	O
8	O
.	O
1	O
x	O
10	O
-	O
16	O
,	O
Fisher	O
'	O
s	O
exact	O
test	O
)	O
,	O
and	O
none	O
of	O
the	O
Pho4	O
-	O
only	O
recruited	O
sites	O
is	O
regulated	O
by	O
Pho4	O
(	O
p	O
=	O
0	O
.	O
003	O
,	O
Fisher	O
'	O
s	O
exact	O
test	O
)	O
.	O

We	O
used	O
a	O
structural	O
genomics	O
approach	O
to	O
human	O
START	O
domain	O
containing	O
proteins	O
.	O

Based	O
on	O
previously	O
published	O
crystal	O
structures	O
multiple	O
expression	O
constructs	O
were	O
designed	O
for	O
STARD1	O
,	O
STARD5	O
,	O
STARD7	O
-	O
11	O
,	O
STARD13	O
and	O
STARD14	O
.	O

Following	O
recombinant	O
protein	O
production	O
in	O
E	O
.	O
coli	O
,	O
well	O
-	O
diffracting	O
crystals	O
were	O
obtained	O
for	O
the	O
START	O
domains	O
of	O
STARD1	O
,	O
STARD5	O
,	O
STARD13	O
and	O
STARD14	O
(	O
Table	O
2	O
)	O
.	O

Their	O
crystal	O
structures	O
were	O
solved	O
and	O
refined	O
to	O
between	O
2	O
.	O
0	O
and	O
3	O
.	O
4	O
Aa	O
resolution	O
(	O
Table	O
3	O
)	O
.	O

Complex	O
formation	O
was	O
carried	O
out	O
in	O
column	O
buffer	O
[	O
50	O
mM	O
KHEPES	O
(	O
pH	O
7	O
.	O
5	O
)	O
,	O
200	O
mM	O
NaCl	O
,	O
2	O
mM	O
Mg	O
(	O
OAc	O
)	O
2	O
,	O
2	O
mM	O
DTT	O
]	O
.	O

10	O
muM	O
of	O
cpSRP54	O
was	O
mixed	O
with	O
10	O
muM	O
wildtype	O
or	O
mutant	O
cpFtsY	O
in	O
the	O
presence	O
of	O
450	O
muM	O
GMPPNP	O
and	O
incubated	O
on	O
ice	O
for	O
10	O
minutes	O
before	O
loading	O
onto	O
Superdex	O
200	O
(	O
GE	O
Healthcare	O
)	O
.	O

Reference	O
runs	O
of	O
the	O
individual	O
proteins	O
confirmed	O
the	O
identities	O
of	O
the	O
peaks	O
.	O

Detection	O
of	O
antigen	O
interactions	O
ex	O
vivo	O
by	O
proximity	O
ligation	O
assay	O
:	O
endogenous	O
dopamine	O
D2	O
-	O
adenosine	O
A2A	O
receptor	O
complexes	O
in	O
the	O
striatum	O
.	O

The	O
existence	O
of	O
G	O
protein	O
-	O
coupled	O
receptor	O
(	O
GPCR	O
)	O
dimers	O
and	O
/	O
or	O
oligomers	O
has	O
been	O
demonstrated	O
in	O
heterologous	O
systems	O
using	O
a	O
variety	O
of	O
biochemical	O
and	O
biophysical	O
assays	O
.	O

While	O
these	O
interactions	O
are	O
the	O
subject	O
of	O
intense	O
research	O
because	O
of	O
their	O
potential	O
role	O
in	O
modulating	O
signaling	O
and	O
altering	O
pharmacology	O
,	O
evidence	O
for	O
the	O
existence	O
of	O
receptor	O
interactions	O
in	O
vivo	O
is	O
still	O
elusive	O
because	O
of	O
a	O
lack	O
of	O
appropriate	O
methods	O
to	O
detect	O
them	O
.	O

Here	O
,	O
we	O
adapted	O
and	O
optimized	O
a	O
proximity	O
ligation	O
assay	O
(	O
PLA	O
)	O
for	O
the	O
detection	O
in	O
brain	O
slices	O
of	O
molecular	O
proximity	O
of	O
two	O
antigens	O
located	O
on	O
either	O
the	O
same	O
or	O
two	O
different	O
GPCRs	O
.	O

Using	O
this	O
approach	O
,	O
we	O
were	O
able	O
to	O
confirm	O
the	O
existence	O
of	O
dopamine	O
D2	O
and	O
adenosine	O
A2A	O
receptor	O
complexes	O
in	O
the	O
striatum	O
of	O
mice	O
ex	O
vivo	O
.	O

The	O
cytosolic	O
domains	O
of	O
Tom70	O
and	O
Tom20	O
(	O
Tom70CD	O
and	O
Tom20CD	O
)	O
were	O
recombinantly	O
expressed	O
and	O
purified	O
as	O
previously	O
described	O
.	O

For	O
binding	O
studies	O
,	O
Tom70CD	O
and	O
Tom20CD	O
were	O
bound	O
to	O
Ni	O
-	O
NTA	O
agarose	O
and	O
incubated	O
with	O
35S	O
-	O
Ugo1	O
precursor	O
in	O
import	O
buffer	O
containing	O
0	O
.	O
2	O
%	O
BSA	O
for	O
40	O
min	O
at	O
4degreesC	O
.	O

After	O
excessive	O
washing	O
,	O
bound	O
proteins	O
were	O
eluted	O
with	O
500	O
mM	O
imidazole	O
in	O
lysis	O
buffer	O
and	O
subjected	O
to	O
SDS	O
-	O
PAGE	O
.	O

Bound	O
proteins	O
were	O
detected	O
by	O
Coomassie	O
staining	O
and	O
autoradiography	O
.	O

As	O
piRNA	O
clusters	O
are	O
the	O
primary	O
source	O
of	O
transposon	O
-	O
targeting	O
piRNAs	O
,	O
we	O
analyzed	O
changes	O
in	O
piRNAs	O
mapping	O
uniquely	O
to	O
the	O
genome	O
,	O
ensuring	O
that	O
they	O
were	O
in	O
fact	O
derived	O
from	O
the	O
corresponding	O
cluster	O
(	O
Fig	O
.	O
6B	O
,	O
C	O
)	O
.	O

We	O
found	O
that	O
piRNAs	O
from	O
germline	O
(	O
42AB	O
and	O
Cluster	O
3	O
)	O
and	O
soma	O
(	O
flam	O
and	O
traffic	O
jam	O
)	O
as	O
well	O
as	O
clusters	O
expressed	O
in	O
both	O
tissues	O
(	O
Cluster	O
2	O
)	O
were	O
dramatically	O
reduced	O
in	O
the	O
absence	O
of	O
vret	O
(	O
Fig	O
.	O
6B	O
,	O
C	O
)	O
.	O

MEMO	O
associated	O
with	O
an	O
ErbB2	O
receptor	O
phosphopeptide	O
reveals	O
a	O
new	O
phosphotyrosine	O
motif	O
.	O

Tyrosine	O
phosphorylations	O
are	O
essential	O
in	O
signal	O
transduction	O
.	O

Recently	O
,	O
a	O
new	O
type	O
of	O
phosphotyrosine	O
binding	O
protein	O
,	O
MEMO	O
(	O
Mediator	O
of	O
ErbB2	O
-	O
driven	O
cell	O
motility	O
)	O
,	O
has	O
been	O
reported	O
to	O
bind	O
specifically	O
to	O
an	O
ErbB2	O
-	O
derived	O
phosphorylated	O
peptide	O
encompassing	O
Tyr	O
-	O
1227	O
(	O
PYD	O
)	O
.	O

Structural	O
and	O
functional	O
analyses	O
of	O
variants	O
of	O
this	O
peptide	O
revealed	O
the	O
minimum	O
sequence	O
required	O
for	O
MEMO	O
recognition	O
.	O

Using	O
a	O
docking	O
approach	O
we	O
have	O
generated	O
a	O
structural	O
model	O
for	O
MEMO	O
/	O
PYD	O
complex	O
and	O
compare	O
this	O
new	O
phosphotyrosine	O
motif	O
to	O
SH2	O
and	O
PTB	O
phosphotyrosine	O
motives	O
.	O

RNA	O
processing	O
in	O
human	O
mitochondria	O
.	O

Mammalian	O
mitochondrial	O
DNA	O
is	O
transcribed	O
as	O
precursor	O
polycistronic	O
transcripts	O
containing	O
13	O
mRNAs	O
,	O
2	O
rRNAs	O
,	O
punctuated	O
by	O
22	O
tRNAs	O
.	O

The	O
mechanisms	O
involved	O
in	O
the	O
excision	O
of	O
mitochondrial	O
tRNAs	O
from	O
these	O
polycistronic	O
transcripts	O
have	O
remained	O
largely	O
unknown	O
.	O

We	O
have	O
investigated	O
the	O
roles	O
of	O
ELAC2	O
,	O
mitochondrial	O
RNase	O
P	O
proteins	O
1	O
and	O
3	O
,	O
and	O
pentatricopeptide	O
repeat	O
domain	O
protein	O
1	O
in	O
the	O
processing	O
of	O
mitochondrial	O
polycistronic	O
transcripts	O
.	O

We	O
used	O
a	O
deep	O
sequencing	O
approach	O
to	O
characterize	O
the	O
5	O
'	O
and	O
3	O
'	O
ends	O
of	O
processed	O
mitochondrial	O
transcripts	O
and	O
provide	O
a	O
detailed	O
map	O
of	O
mitochondrial	O
tRNA	O
processing	O
sites	O
affected	O
by	O
these	O
proteins	O
.	O

We	O
show	O
that	O
MRPP1	O
and	O
MRPP3	O
process	O
the	O
5	O
'	O
ends	O
of	O
tRNAs	O
and	O
the	O
5	O
'	O
unconventional	O
,	O
non	O
tRNA	O
containing	O
site	O
of	O
the	O
CO1	O
transcript	O
.	O

By	O
contrast	O
,	O
we	O
find	O
that	O
ELAC2	O
and	O
PTCD1	O
affect	O
the	O
3	O
'	O
end	O
processing	O
of	O
tRNAs	O
.	O

Finally	O
,	O
we	O
found	O
that	O
MRPP1	O
is	O
essential	O
for	O
transcript	O
processing	O
,	O
RNA	O
modification	O
,	O
translation	O
and	O
mitochondrial	O
respiration	O
.	O

(	O
A	O
-	O
I	O
)	O
Cuticles	O
of	O
dechorionated	O
and	O
devitellinized	O
embryos	O
were	O
prepared	O
to	O
visualize	O
exoskeletons	O
and	O
segmentation	O
phenotypes	O
.	O

The	O
cuticle	O
phenotypes	O
in	O
the	O
original	O
Ten	O
-	O
m	O
mutant	O
stock	O
and	O
odd	O
paired	O
alleles	O
are	O
shown	O
.	O

The	O
new	O
Ten	O
-	O
m	O
N1	O
allele	O
and	O
rebalanced	O
reference	O
alleles	O
fail	O
to	O
reproduce	O
a	O
pair	O
-	O
rule	O
phenotype	O
.	O

Embryos	O
shown	O
are	O
derived	O
from	O
the	O
original	O
:	O
5309	O
(	O
A	O
and	O
D	O
)	O
;	O
Df	O
(	O
3L	O
)	O
Ten	O
-	O
mAL1	O
(	O
B	O
and	O
E	O
)	O
;	O
and	O
Df	O
(	O
3L	O
)	O
Ten	O
-	O
mAL29	O
(	O
C	O
and	O
F	O
)	O
stocks	O
.	O

(	O
G	O
)	O
N1	O
,	O
(	O
H	O
)	O
odd	O
paired1	O
,	O
and	O
(	O
I	O
)	O
odd	O
paired2	O
.	O

Embryos	O
are	O
oriented	O
:	O
anterior	O
-	O
left	O
.	O

We	O
examined	O
the	O
expression	O
of	O
Set7	O
in	O
different	O
adult	O
mouse	O
tissues	O
.	O

RT	O
-	O
PCR	O
analysis	O
showed	O
that	O
Set7	O
is	O
expressed	O
in	O
all	O
tissues	O
tested	O
,	O
including	O
skeletal	O
muscle	O
(	O
Fig	O
.	O
1	O
A	O
)	O
.	O

We	O
next	O
investigated	O
the	O
potential	O
change	O
of	O
Set7	O
expression	O
during	O
muscle	O
differentiation	O
.	O

C2C12	O
myoblasts	O
are	O
a	O
well	O
-	O
established	O
cell	O
line	O
that	O
can	O
faithfully	O
mimic	O
skeletal	O
muscle	O
differentiation	O
in	O
vitro	O
,	O
as	O
indicated	O
by	O
the	O
terminal	O
differentiation	O
and	O
expression	O
of	O
muscle	O
differentiation	O
marker	O
genes	O
,	O
upon	O
serum	O
withdrawal	O
.	O

RT	O
-	O
PCR	O
and	O
Western	O
blot	O
analyses	O
demonstrate	O
that	O
the	O
expression	O
level	O
of	O
both	O
Set7	O
transcript	O
and	O
protein	O
increases	O
during	O
C2C12	O
differentiation	O
(	O
Fig	O
.	O
1	O
,	O
B	O
and	O
C	O
)	O
,	O
occurring	O
in	O
parallel	O
with	O
increased	O
expression	O
of	O
the	O
muscle	O
differentiation	O
markers	O
myogenin	O
and	O
myosin	O
heavy	O
chain	O
(	O
MHC	O
;	O
Fig	O
.	O
1	O
,	O
B	O
and	O
C	O
)	O
.	O

Together	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
expression	O
of	O
Set7	O
is	O
dynamically	O
regulated	O
during	O
normal	O
skeletal	O
muscle	O
differentiation	O
,	O
suggesting	O
a	O
role	O
in	O
skeletal	O
muscle	O
development	O
.	O

Bulk	O
polymerization	O
was	O
measured	O
using	O
the	O
pyrene	O
-	O
actin	O
assay	O
.	O

While	O
the	O
polymerization	O
activity	O
of	O
Spire	O
was	O
mapped	O
to	O
its	O
four	O
-	O
W	O
domain	O
repeat	O
,	O
VopL	O
construct	O
3W	O
,	O
comprising	O
the	O
three	O
W	O
domains	O
,	O
had	O
negligible	O
activity	O
compared	O
to	O
the	O
spontaneous	O
polymerization	O
of	O
actin	O
alone	O
(	O
Fig	O
.	O
1b	O
)	O
.	O

In	O
contrast	O
,	O
3W	O
-	O
VCD	O
,	O
comprising	O
in	O
addition	O
the	O
VCD	O
,	O
had	O
very	O
strong	O
activity	O
(	O
Fig	O
.	O
1b	O
)	O
,	O
which	O
increased	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Fig	O
.	O
1c	O
and	O
Supplementary	O
Fig	O
.	O
2a	O
)	O
.	O

This	O
construct	O
had	O
even	O
stronger	O
activity	O
than	O
the	O
Arp2	B-Complex
/	I-Complex
3	I-Complex
complex	O
analyzed	O
at	O
the	O
same	O
concentration	O
(	O
25	O
nM	O
)	O
with	O
activation	O
by	O
250	O
nM	O
N	O
-	O
WASP	O
WCA	O
(	O
Supplementary	O
Fig	O
.	O
3	O
)	O
.	O

A	O
fragment	O
corresponding	O
to	O
the	O
four	O
W	O
domain	O
repeat	O
of	O
Drosophila	O
Spire	O
(	O
residues	O
366	O
-	O
482	O
)	O
had	O
negligible	O
activity	O
at	O
this	O
concentration	O
(	O
Supplementary	O
Fig	O
.	O
3	O
)	O
,	O
which	O
is	O
consistent	O
with	O
previous	O
reports	O
(	O
analyzed	O
further	O
below	O
)	O
.	O

At	O
24	O
h	O
before	O
transfection	O
,	O
cells	O
(	O
2	O
x	O
105	O
-	O
aliquots	O
)	O
were	O
plated	O
in	O
6	O
-	O
well	O
plates	O
and	O
transfected	O
with	O
increasing	O
amounts	O
of	O
B7	O
.	O
1	O
-	O
YPet	O
-	O
,	O
B7	O
-	O
H1	O
-	O
YPet	O
-	O
or	O
IR	O
-	O
YPet	O
-	O
expressing	O
plasmids	O
(	O
10	O
to	O
500	O
ng	O
/	O
well	O
)	O
,	O
and	O
constant	O
amounts	O
(	O
10	O
ng	O
-	O
aliquots	O
)	O
of	O
plasmid	O
expressing	O
B7	O
-	O
H1	O
-	O
Rluc8	O
or	O
B7	O
.	O
1	O
-	O
Rluc8	O
fusion	O
protein	O
.	O

48	O
h	O
later	O
,	O
cells	O
were	O
collected	O
and	O
washed	O
twice	O
with	O
PBS	O
,	O
and	O
aliquots	O
were	O
placed	O
in	O
384	O
-	O
well	O
plates	O
.	O

Coelenterazine	O
H	O
substrate	O
was	O
added	O
at	O
a	O
final	O
molarity	O
of	O
5	O
muM	O
,	O
and	O
BRET	O
was	O
measured	O
immediately	O
.	O

To	O
analyze	O
the	O
effect	O
of	O
the	O
penton	O
,	O
cells	O
were	O
incubated	O
for	O
5	O
min	O
without	O
or	O
with	O
penton	O
protein	O
solution	O
at	O
0	O
.	O
33	O
,	O
0	O
.	O
66	O
or	O
132	O
ng	O
/	O
muL	O
,	O
followed	O
by	O
Coelenterazine	O
H	O
addition	O
and	O
BRET	O
measurement	O
.	O

BRET	O
was	O
monitored	O
using	O
a	O
lumino	O
/	O
fluorometer	O
(	O
Mithras	O
;	O
Berthold	O
Technologies	O
,	O
France	O
)	O
,	O
allowing	O
for	O
the	O
sequential	O
integration	O
of	O
luminescence	O
with	O
two	O
filter	O
settings	O
(	O
Rluc	O
filter	O
,	O
485	O
+	O
/	O
-	O
10	O
nm	O
;	O
YFP	O
filter	O
,	O
530	O
+	O
/	O
-	O
12	O
.	O
5	O
nm	O
)	O
.	O

The	O
emission	O
signal	O
values	O
obtained	O
at	O
530	O
nm	O
were	O
divided	O
by	O
the	O
emission	O
signal	O
values	O
obtained	O
at	O
485	O
nm	O
.	O

The	O
BRET	O
ratio	O
was	O
calculated	O
by	O
dividing	O
the	O
emission	O
signal	O
value	O
obtained	O
with	O
coexpressed	O
donor	O
and	O
acceptor	O
by	O
that	O
obtained	O
with	O
the	O
donor	O
protein	O
expressed	O
alone	O
.	O

Data	O
from	O
at	O
least	O
three	O
independent	O
experiments	O
were	O
averaged	O
,	O
and	O
results	O
expressed	O
as	O
milliBRET	O
(	O
mBRET	O
)	O
,	O
corresponding	O
to	O
the	O
BRET	O
ratio	O
multiplied	O
by	O
1	O
,	O
000	O
.	O

Donor	O
saturation	O
curves	O
were	O
determined	O
as	O
previously	O
described	O
.	O

N	O
-	O
terminal	O
acetylation	O
acts	O
as	O
an	O
avidity	O
enhancer	O
within	O
an	O
interconnected	O
multiprotein	O
complex	O
.	O

Although	O
many	O
eukaryotic	O
proteins	O
are	O
amino	O
(	O
N	O
)	O
-	O
terminally	O
acetylated	O
,	O
structural	O
mechanisms	O
by	O
which	O
N	O
-	O
terminal	O
acetylation	O
mediates	O
protein	O
interactions	O
are	O
largely	O
unknown	O
.	O

Here	O
,	O
we	O
found	O
that	O
N	O
-	O
terminal	O
acetylation	O
of	O
the	O
E2	O
enzyme	O
,	O
Ubc12	O
,	O
dictates	O
distinctive	O
E3	O
-	O
dependent	O
ligation	O
of	O
the	O
ubiquitin	O
-	O
like	O
protein	O
Nedd8	O
to	O
Cul1	O
.	O

Structural	O
,	O
biochemical	O
,	O
biophysical	O
,	O
and	O
genetic	O
analyses	O
revealed	O
how	O
complete	O
burial	O
of	O
Ubc12	O
'	O
s	O
N	O
-	O
acetyl	O
-	O
methionine	O
in	O
a	O
hydrophobic	O
pocket	O
in	O
the	O
E3	O
,	O
Dcn1	O
,	O
promotes	O
cullin	O
neddylation	O
.	O

The	O
results	O
suggest	O
that	O
the	O
N	O
-	O
terminal	O
acetyl	O
both	O
directs	O
Ubc12	O
'	O
s	O
interactions	O
with	O
Dcn1	O
and	O
prevents	O
repulsion	O
of	O
a	O
charged	O
N	O
terminus	O
.	O

Our	O
data	O
provide	O
a	O
link	O
between	O
acetylation	O
and	O
ubiquitin	O
-	O
like	O
protein	O
conjugation	O
and	O
define	O
a	O
mechanism	O
for	O
N	O
-	O
terminal	O
acetylation	O
-	O
dependent	O
recognition	O
.	O

Inducible	O
nuclear	O
factor	O
binding	O
to	O
the	O
kappa	B-Complex
B	I-Complex
elements	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
enhancer	O
in	O
T	O
cells	O
can	O
be	O
blocked	O
by	O
cyclosporin	O
A	O
in	O
a	O
signal	O
-	O
dependent	O
manner	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
is	O
thought	O
to	O
exert	O
its	O
immunosuppressive	O
effects	O
by	O
inhibiting	O
the	O
expression	O
of	O
a	O
distinct	O
set	O
of	O
lymphokine	O
genes	O
which	O
are	O
induced	O
upon	O
T	O
-	O
cell	O
activation	O
,	O
among	O
them	O
the	O
gene	O
coding	O
for	O
interleukin	O
-	O
2	O
.	O

In	O
addition	O
,	O
the	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
partially	O
suppressed	O
.	O

To	O
better	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
suppression	O
by	O
CsA	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
this	O
drug	O
on	O
transcription	O
factors	O
in	O
T	O
cells	O
.	O

Here	O
we	O
report	O
that	O
the	O
formation	O
of	O
two	O
distinct	O
mitogen	O
-	O
inducible	O
DNA	O
-	O
binding	O
complexes	O
,	O
the	O
kappa	B-Complex
B	I-Complex
complex	O
within	O
the	O
HIV	O
enhancer	O
and	O
the	O
NFAT	B-OOS
-	I-OOS
1	I-OOS
complex	O
within	O
the	O
interleukin	O
-	O
2	O
enhancer	O
,	O
is	O
inhibited	O
in	O
the	O
presence	O
of	O
CsA	O
.	O

The	O
kappa	B-Complex
B	I-Complex
-	O
binding	O
activity	O
with	O
the	O
HIV	O
enhancer	O
is	O
inhibited	O
only	O
if	O
it	O
is	O
activated	O
via	O
the	O
mitogen	O
phytohemagglutinin	O
whereas	O
phorbol	O
myristate	O
acetate	O
-	O
mediated	O
activation	O
is	O
completely	O
insensitive	O
to	O
the	O
drug	O
.	O

This	O
suggests	O
a	O
model	O
in	O
which	O
functionally	O
indistinguishable	O
kappa	B-Complex
B	I-Complex
complexes	O
can	O
be	O
activated	O
via	O
two	O
separate	O
pathways	O
of	O
signal	O
transduction	O
distinguishable	O
by	O
CsA	O
.	O

To	O
determine	O
whether	O
the	O
response	O
to	O
fasting	O
is	O
conserved	O
across	O
mammals	O
,	O
we	O
measured	O
Arrdc3	O
expression	O
levels	O
in	O
multiple	O
tissues	O
of	O
mice	O
fed	O
ad	O
libitum	O
or	O
fasted	O
14	O
h	O
.	O

Real	O
-	O
time	O
PCR	O
analysis	O
showed	O
that	O
fasting	O
induced	O
Arrdc3	O
expression	O
most	O
prominently	O
in	O
visceral	O
(	O
epididymal	O
)	O
fat	O
(	O
5	O
.	O
6	O
-	O
fold	O
)	O
,	O
with	O
significant	O
induction	O
in	O
brown	O
fat	O
(	O
2	O
.	O
3	O
-	O
fold	O
)	O
and	O
skeletal	O
muscle	O
(	O
3	O
.	O
9	O
-	O
fold	O
)	O
as	O
well	O
(	O
Figure	O
3D	O
)	O
.	O

We	O
then	O
performed	O
northern	O
analysis	O
and	O
confirmed	O
a	O
striking	O
induction	O
of	O
Arrdc3	O
by	O
fasting	O
in	O
visceral	O
fat	O
and	O
skeletal	O
muscle	O
(	O
Figure	O
3E	O
)	O
.	O

Farnesyl	O
cysteine	O
C	O
-	O
terminal	O
methyltransferase	O
activity	O
is	O
dependent	O
upon	O
the	O
STE14	O
gene	O
product	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

Membrane	O
extracts	O
of	O
sterile	O
Saccharomyces	O
cerevisiae	O
strains	O
containing	O
the	O
a	O
-	O
specific	O
ste14	O
mutation	O
lack	O
a	O
farnesyl	O
cysteine	O
C	O
-	O
terminal	O
carboxyl	O
methyltransferase	O
activity	O
that	O
is	O
present	O
in	O
wild	O
-	O
type	O
a	O
and	O
alpha	O
cells	O
.	O

Other	O
a	O
-	O
specific	O
sterile	O
strains	O
with	O
ste6	O
and	O
ste16	O
mutations	O
also	O
have	O
wild	O
-	O
type	O
levels	O
of	O
the	O
farnesyl	O
cysteine	O
carboxyl	O
methyltransferase	O
activity	O
.	O

This	O
enzyme	O
activity	O
,	O
detected	O
by	O
using	O
a	O
synthetic	O
peptide	O
sequence	O
based	O
on	O
the	O
C	O
-	O
terminus	O
of	O
a	O
ras	O
protein	O
,	O
may	O
be	O
responsible	O
not	O
only	O
for	O
the	O
essential	O
methylation	O
of	O
the	O
farnesyl	O
cysteine	O
residue	O
of	O
a	O
mating	O
factor	O
,	O
but	O
also	O
for	O
the	O
methylation	O
of	O
yeast	O
RAS1	O
and	O
RAS2	O
proteins	O
and	O
possibly	O
other	O
polypeptides	O
with	O
similar	O
C	O
-	O
terminal	O
structures	O
.	O

We	O
demonstrate	O
that	O
the	O
farnesylation	O
of	O
the	O
cysteine	O
residue	O
in	O
the	O
peptide	O
is	O
required	O
for	O
the	O
methyltransferase	O
activity	O
,	O
suggesting	O
that	O
methyl	O
esterification	O
follows	O
the	O
lipidation	O
reaction	O
in	O
the	O
cell	O
.	O

To	O
show	O
that	O
the	O
loss	O
of	O
methyltransferase	O
activity	O
is	O
a	O
direct	O
result	O
of	O
the	O
ste14	O
mutation	O
,	O
we	O
transformed	O
ste14	O
mutant	O
cells	O
with	O
a	O
plasmid	O
complementing	O
the	O
mating	O
defect	O
of	O
this	O
strain	O
and	O
found	O
that	O
active	O
enzyme	O
was	O
produced	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
a	O
similar	O
transformation	O
of	O
cells	O
possessing	O
the	O
wild	O
-	O
type	O
STE14	O
gene	O
resulted	O
in	O
sixfold	O
overproduction	O
of	O
the	O
enzyme	O
.	O

Although	O
more	O
complicated	O
possibilities	O
cannot	O
be	O
ruled	O
out	O
,	O
these	O
results	O
suggest	O
that	O
STE14	O
is	O
a	O
candidate	O
for	O
the	O
structural	O
gene	O
for	O
a	O
methyltransferase	O
involved	O
in	O
the	O
formation	O
of	O
isoprenylated	O
cysteine	O
alpha	O
-	O
methyl	O
ester	O
C	O
-	O
terminal	O
structures	O
.	O

RNF34	O
is	O
a	O
cold	O
-	O
regulated	O
E3	O
ubiquitin	O
ligase	O
for	O
PGC	O
-	O
1alpha	O
and	O
modulates	O
brown	O
fat	O
cell	O
metabolism	O
.	O

The	O
transcriptional	O
coactivator	O
PGC	O
-	O
1alpha	O
is	O
a	O
master	O
regulator	O
of	O
energy	O
metabolism	O
and	O
adaptive	O
thermogenesis	O
in	O
the	O
brown	O
fat	O
cell	O
.	O

PGC	O
-	O
1alpha	O
is	O
a	O
short	O
-	O
lived	O
protein	O
,	O
and	O
the	O
molecular	O
components	O
that	O
control	O
PGC	O
-	O
1alpha	O
turnover	O
and	O
their	O
functional	O
importance	O
in	O
energy	O
metabolism	O
are	O
largely	O
unknown	O
.	O

Here	O
we	O
performed	O
a	O
luciferase	O
-	O
based	O
overexpression	O
screen	O
and	O
identified	O
a	O
Ring	O
-	O
finger	O
-	O
containing	O
protein	O
,	O
RNF34	O
,	O
as	O
a	O
specific	O
E3	O
ubiquitin	O
ligase	O
for	O
PGC	O
-	O
1alpha	O
.	O

RNF34	O
is	O
a	O
nuclear	O
protein	O
that	O
interacts	O
with	O
and	O
ubiquitinates	O
PGC	O
-	O
1alpha	O
to	O
promote	O
its	O
turnover	O
.	O

Interestingly	O
,	O
RNF34	O
binds	O
to	O
the	O
C	O
-	O
terminal	O
half	O
of	O
PGC	O
-	O
1alpha	O
and	O
targets	O
it	O
for	O
degradation	O
independently	O
of	O
the	O
previously	O
identified	O
N	O
-	O
terminal	O
phosphodegron	O
motif	O
.	O

In	O
brown	O
fat	O
cells	O
,	O
knockdown	O
of	O
RNF34	O
increases	O
the	O
endogenous	O
PGC	O
-	O
1alpha	O
protein	O
level	O
,	O
uncoupling	O
protein	O
1	O
(	O
UCP1	O
)	O
expression	O
,	O
and	O
oxygen	O
consumption	O
,	O
while	O
the	O
opposite	O
effects	O
are	O
observed	O
in	O
brown	O
fat	O
cells	O
ectopically	O
expressing	O
wild	O
-	O
type	O
RNF34	O
but	O
not	O
in	O
cells	O
expressing	O
the	O
ligase	O
activity	O
-	O
defective	O
mutant	O
.	O

Moreover	O
,	O
cold	O
exposure	O
and	O
beta3	O
-	O
adrenergic	O
receptor	O
signaling	O
,	O
conditions	O
that	O
induce	O
PGC	O
-	O
1alpha	O
expression	O
,	O
suppress	O
RNF34	O
expression	O
in	O
the	O
brown	O
fat	O
cell	O
,	O
indicating	O
a	O
physiological	O
relevance	O
of	O
this	O
E3	O
ligase	O
in	O
thermogenesis	O
.	O

Our	O
results	O
reveal	O
that	O
RNF34	O
is	O
a	O
bona	O
fide	O
E3	O
ubiquitin	O
ligase	O
for	O
PGC	O
-	O
1alpha	O
and	O
negatively	O
regulates	O
brown	O
fat	O
cell	O
metabolism	O
.	O

Lipoic	O
acid	O
synthetase	O
deficiency	O
causes	O
neonatal	O
-	O
onset	O
epilepsy	O
,	O
defective	O
mitochondrial	O
energy	O
metabolism	O
,	O
and	O
glycine	O
elevation	O
.	O

Lipoic	O
acid	O
is	O
an	O
essential	O
prosthetic	O
group	O
of	O
four	O
mitochondrial	O
enzymes	O
involved	O
in	O
the	O
oxidative	O
decarboxylation	O
of	O
pyruvate	O
,	O
alpha	O
-	O
ketoglutarate	O
,	O
and	O
branched	O
chain	O
amino	O
acids	O
and	O
in	O
the	O
glycine	O
cleavage	O
.	O

Lipoic	O
acid	O
is	O
synthesized	O
stepwise	O
within	O
mitochondria	O
through	O
a	O
process	O
that	O
includes	O
lipoic	O
acid	O
synthetase	O
.	O

We	O
identified	O
the	O
homozygous	O
mutation	O
c	O
.	O
746G	O
>	O
A	O
(	O
p	O
.	O
Arg249His	O
)	O
in	O
LIAS	O
in	O
an	O
individual	O
with	O
neonatal	O
-	O
onset	O
epilepsy	O
,	O
muscular	O
hypotonia	O
,	O
lactic	O
acidosis	O
,	O
and	O
elevated	O
glycine	O
concentration	O
in	O
plasma	O
and	O
urine	O
.	O

Investigation	O
of	O
the	O
mitochondrial	O
energy	O
metabolism	O
showed	O
reduced	O
oxidation	O
of	O
pyruvate	O
and	O
decreased	O
pyruvate	B-Complex
dehydrogenase	I-Complex
complex	O
activity	O
.	O

A	O
pronounced	O
reduction	O
of	O
the	O
prosthetic	O
group	O
lipoamide	O
was	O
found	O
in	O
lipoylated	O
proteins	O
.	O

Sec22b	O
regulates	O
phagosomal	O
maturation	O
and	O
antigen	O
crosspresentation	O
by	O
dendritic	O
cells	O
.	O

Antigen	O
(	O
Ag	O
)	O
crosspresentation	O
by	O
dendritic	O
cells	O
(	O
DCs	O
)	O
involves	O
the	O
presentation	O
of	O
internalized	O
Ags	O
on	O
MHC	B-Complex
class	I-Complex
I	I-Complex
molecules	O
to	O
initiate	O
CD8	O
+	O
T	O
cell	O
-	O
mediated	O
immunity	O
in	O
response	O
to	O
certain	O
pathogens	O
and	O
tumor	O
cells	O
.	O

Here	O
,	O
we	O
identify	O
the	O
SNARE	B-Complex
Sec22b	O
as	O
a	O
specific	O
regulator	O
of	O
Ag	O
crosspresentation	O
.	O

Sec22b	O
localizes	O
to	O
the	O
ER	O
-	O
Golgi	O
intermediate	O
compartment	O
(	O
ERGIC	O
)	O
and	O
pairs	O
to	O
the	O
plasma	O
membrane	O
SNARE	B-Complex
syntaxin	O
4	O
,	O
which	O
is	O
present	O
in	O
phagosomes	O
(	O
Phgs	O
)	O
.	O

Depletion	O
of	O
Sec22b	O
inhibits	O
the	O
recruitment	O
of	O
ER	O
-	O
resident	O
proteins	O
to	O
Phgs	O
and	O
to	O
the	O
vacuole	O
containing	O
the	O
Toxoplasma	O
gondii	O
parasite	O
.	O

In	O
Sec22b	O
-	O
deficient	O
DCs	O
,	O
crosspresentation	O
is	O
compromised	O
after	O
Ag	O
phagocytosis	O
or	O
endocytosis	O
and	O
after	O
invasion	O
by	O
T	O
.	O
gondii	O
.	O

Sec22b	O
silencing	O
inhibited	O
Ag	O
export	O
to	O
the	O
cytosol	O
and	O
increased	O
phagosomal	O
degradation	O
by	O
accelerating	O
lysosomal	O
recruitment	O
.	O

Our	O
findings	O
provide	O
insight	O
into	O
an	O
intracellular	O
traffic	O
pathway	O
required	O
for	O
crosspresentation	O
and	O
show	O
that	O
Sec22b	O
-	O
dependent	O
recruitment	O
of	O
ER	O
proteins	O
to	O
Phgs	O
critically	O
influences	O
phagosomal	O
functions	O
in	O
DCs	O
.	O

A	O
recent	O
structural	O
study	O
of	O
mCSF	O
-	O
1	O
in	O
complex	O
with	O
the	O
first	O
three	O
extracellular	O
domains	O
of	O
mCSF	O
-	O
1R	O
(	O
mCSF	O
-	O
1RD1	O
-	O
D3	O
)	O
revealed	O
unexpected	O
monovalent	O
binding	O
of	O
mCSF	O
-	O
1	O
to	O
one	O
mCSF	O
-	O
1RD1	O
-	O
D3	O
molecule	O
leading	O
to	O
a	O
binary	O
complex	O
,	O
in	O
contrast	O
to	O
predictions	O
based	O
on	O
earlier	O
studies	O
of	O
the	O
homologous	O
murine	O
and	O
human	O
c	O
-	O
kit	O
receptors	O
in	O
complex	O
with	O
Stem	O
Cell	O
Factor	O
(	O
SCF	O
)	O
.	O

While	O
this	O
first	O
structural	O
snapshot	O
of	O
a	O
partial	O
mCSF	O
-	O
1R	O
complex	O
is	O
informative	O
in	O
its	O
own	O
right	O
,	O
it	O
cannot	O
be	O
readily	O
extrapolated	O
to	O
represent	O
CSF	O
-	O
1R	O
activation	O
in	O
general	O
,	O
given	O
the	O
complexity	O
of	O
species	O
cross	O
-	O
reactivity	O
in	O
CSF	O
-	O
1R	O
signaling	O
.	O

Furthermore	O
,	O
the	O
reported	O
binary	O
mCSF	O
-	O
1RD1	O
-	O
D3	O
:	O
mCSF	O
-	O
1	O
complex	O
does	O
not	O
offer	O
realistic	O
insights	O
into	O
possible	O
homotypic	O
receptor	O
interactions	O
,	O
a	O
likely	O
critical	O
element	O
of	O
receptor	O
activation	O
.	O

The	O
Brucella	O
TIR	O
-	O
like	O
protein	O
TcpB	O
interacts	O
with	O
the	O
death	O
domain	O
of	O
MyD88	O
.	O

The	O
pathogen	O
Brucella	O
melitensis	O
secretes	O
a	O
Toll	O
/	O
interleukin	O
-	O
1	O
receptor	O
(	O
TIR	O
)	O
domain	O
containing	O
protein	O
that	O
abrogates	O
host	O
innate	O
immune	O
responses	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
characterized	O
the	O
biochemical	O
interactions	O
of	O
Brucella	O
TIR	O
-	O
like	O
protein	O
TcpB	O
with	O
host	O
innate	O
immune	O
adaptor	O
proteins	O
.	O

Using	O
protein	O
-	O
fragment	O
complementation	O
assays	O
based	O
on	O
Gaussia	O
luciferase	O
and	O
green	O
fluorescent	O
protein	O
,	O
we	O
find	O
that	O
TcpB	O
interacts	O
directly	O
with	O
MyD88	O
and	O
that	O
this	O
interaction	O
is	O
significantly	O
stronger	O
than	O
the	O
interaction	O
of	O
TcpB	O
with	O
TIRAP	O
,	O
the	O
only	O
other	O
adaptor	O
protein	O
that	O
detectably	O
interacts	O
with	O
TcpB	O
.	O

Surprisingly	O
,	O
the	O
TcpB	O
-	O
MyD88	O
interaction	O
depends	O
on	O
the	O
death	O
domain	O
(	O
DD	O
)	O
of	O
MyD88	O
,	O
and	O
TcpB	O
does	O
not	O
interact	O
with	O
the	O
isolated	O
TIR	O
domain	O
of	O
MyD88	O
.	O

TcpB	O
disrupts	O
MyD88	O
(	O
DD	O
)	O
-	O
MyD88	O
(	O
DD	O
)	O
,	O
MyD88	O
(	O
DD	O
)	O
-	O
MyD88	O
(	O
TIR	O
)	O
and	O
MyD88	O
(	O
DD	O
)	O
-	O
MyD88	O
interactions	O
but	O
not	O
MyD88	O
-	O
MyD88	O
or	O
MyD88	O
(	O
TIR	O
)	O
-	O
MyD88	O
(	O
TIR	O
)	O
interactions	O
.	O

Structural	O
models	O
consistent	O
with	O
these	O
results	O
suggest	O
how	O
TcpB	O
might	O
inhibit	O
TLR	O
signaling	O
by	O
targeting	O
MyD88	O
via	O
a	O
DD	O
-	O
TIR	O
domain	O
interface	O
.	O

Earlier	O
studies	O
have	O
identified	O
typically	O
one	O
or	O
two	O
spontaneous	O
TIFs	O
in	O
senescent	O
interphase	O
nuclei	O
,	O
which	O
seems	O
inconsistent	O
with	O
our	O
calculation	O
of	O
4	O
-	O
5	O
G1	O
-	O
TIFs	O
per	O
senescent	O
cell	O
.	O

When	O
we	O
stained	O
interphase	O
senescent	O
cells	O
,	O
we	O
also	O
commonly	O
found	O
one	O
or	O
two	O
large	O
gamma	O
-	O
H2AX	O
foci	O
per	O
nucleus	O
that	O
colocalized	O
with	O
the	O
DDR	O
proteins	O
MRE11	O
and	O
NBS1	O
(	O
Fig	O
3A	O
)	O
.	O

However	O
,	O
deconvolved	O
images	O
showed	O
that	O
71	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
3	O
%	O
of	O
senescent	O
nuclei	O
(	O
mean	O
+	O
/	O
-	O
s	O
.	O
d	O
.	O
,	O
n	O
=	O
3	O
experiments	O
,	O
each	O
examining	O
25	O
nuclei	O
)	O
had	O
multiple	O
telomeres	O
colocalized	O
within	O
individual	O
gamma	O
-	O
H2AX	O
foci	O
,	O
suggesting	O
that	O
dysfunctional	O
telomeres	O
aggregate	O
in	O
senescent	O
cells	O
(	O
Fig	O
3B	O
)	O
.	O

To	O
test	O
this	O
further	O
,	O
we	O
measured	O
the	O
mean	O
telomeric	O
fluorescence	O
intensity	O
in	O
gamma	O
-	O
H2AX	O
foci	O
of	O
11	O
senescent	O
nuclei	O
and	O
compared	O
this	O
with	O
that	O
of	O
the	O
10	O
brightest	O
and	O
10	O
faintest	O
telomere	O
signals	O
in	O
the	O
same	O
nuclei	O
.	O

The	O
telomeric	O
signal	O
within	O
the	O
gamma	O
-	O
H2AX	O
focus	O
was	O
always	O
brighter	O
than	O
the	O
faintest	O
telomeres	O
and	O
often	O
brighter	O
than	O
the	O
brightest	O
individual	O
telomeres	O
within	O
the	O
cell	O
,	O
consistent	O
with	O
the	O
conclusion	O
that	O
a	O
single	O
gamma	O
-	O
H2AX	O
focus	O
might	O
contain	O
aggregates	O
of	O
dysfunctional	O
telomeres	O
(	O
Fig	O
3C	O
)	O
.	O

ARL4A	O
acts	O
with	O
GCC185	O
to	O
modulate	O
Golgi	O
complex	O
organization	O
.	O

ADP	O
-	O
ribosylation	O
factor	O
-	O
like	O
protein	O
4A	O
(	O
ARL4A	O
)	O
is	O
a	O
developmentally	O
regulated	O
member	O
of	O
the	O
ARF	O
/	O
ARL	O
GTPase	O
family	O
.	O

The	O
primary	O
structure	O
of	O
ARL4A	O
is	O
very	O
similar	O
to	O
that	O
of	O
other	O
ARF	O
/	O
ARL	O
molecules	O
,	O
but	O
its	O
function	O
remains	O
unclear	O
.	O

The	O
trans	O
-	O
Golgi	O
network	O
golgin	O
GCC185	O
is	O
required	O
for	O
maintenance	O
of	O
Golgi	O
structure	O
and	O
distinct	O
endosome	O
-	O
to	O
-	O
Golgi	O
transport	O
.	O

We	O
show	O
here	O
that	O
GCC185	O
acts	O
as	O
a	O
new	O
effector	O
for	O
ARL4	O
to	O
modulate	O
Golgi	O
organization	O
.	O

ARL4A	O
directly	O
interacts	O
with	O
GCC185	O
in	O
a	O
GTP	O
-	O
dependent	O
manner	O
.	O

Sub	O
-	O
coiled	O
-	O
coil	O
regions	O
of	O
the	O
CC2	O
domain	O
of	O
GCC185	O
are	O
required	O
for	O
the	O
interaction	O
between	O
GCC185	O
and	O
ARL4A	O
.	O

Depletion	O
of	O
ARL4A	O
reproduces	O
the	O
GCC185	O
-	O
depleted	O
phenotype	O
,	O
causing	O
fragmentation	O
of	O
the	O
Golgi	O
compartment	O
and	O
defects	O
in	O
endosome	O
-	O
to	O
-	O
Golgi	O
transport	O
.	O

GCC185	O
and	O
ARL4A	O
localize	O
to	O
the	O
Golgi	O
independently	O
of	O
each	O
other	O
.	O

Deletion	O
of	O
the	O
ARL4A	O
-	O
interacting	O
region	O
of	O
GCC185	O
results	O
in	O
inability	O
to	O
maintain	O
Golgi	O
structure	O
.	O

Depletion	O
of	O
ARL4A	O
impairs	O
the	O
interaction	O
between	O
GCC185	O
and	O
cytoplasmic	O
linker	O
-	O
associated	O
proteins	O
1	O
and	O
2	O
(	O
CLASP1	O
and	O
CLASP2	O
,	O
hereafter	O
CLASPs	O
)	O
in	O
vivo	O
,	O
and	O
abolishes	O
the	O
GCC185	O
-	O
mediated	O
Golgi	O
recruitment	O
of	O
these	O
CLASPs	O
,	O
which	O
is	O
crucial	O
for	O
the	O
maintenance	O
of	O
Golgi	O
structure	O
.	O

In	O
summary	O
,	O
we	O
suggest	O
that	O
ARL4A	O
alters	O
the	O
integrity	O
of	O
the	O
Golgi	O
structure	O
by	O
facilitating	O
the	O
interaction	O
of	O
GCC185	O
with	O
CLASPs	O
.	O

Nucleotide	O
-	O
sensing	O
TLRs	O
are	O
divided	O
into	O
two	O
groups	O
based	O
on	O
their	O
distribution	O
profiles	O
in	O
DCs	O
.	O

In	O
humans	O
,	O
TLR3	O
and	O
TLR8	O
are	O
expressed	O
in	O
myeloid	O
DCs	O
,	O
while	O
TLR7	O
and	O
TLR9	O
are	O
expressed	O
in	O
plasmacytoid	O
DCs	O
.	O

Although	O
TLR8	O
belongs	O
to	O
the	O
TLR7	O
/	O
8	O
/	O
9	O
subfamily	O
,	O
the	O
present	O
study	O
demonstrated	O
that	O
TLR8	O
possesses	O
properties	O
distinct	O
from	O
those	O
of	O
TLR7	O
and	O
TLR9	O
.	O

First	O
,	O
TLR8	O
,	O
like	O
TLR3	O
,	O
is	O
localized	O
to	O
the	O
early	O
endosome	O
but	O
not	O
in	O
the	O
late	O
endosome	O
/	O
lysosome	O
,	O
where	O
TLR7	O
and	O
TLR9	O
reside	O
.	O

Second	O
,	O
although	O
TLR8	O
requires	O
UNC93B1	O
to	O
exit	O
from	O
the	O
ER	O
,	O
the	O
TIR	O
domain	O
determines	O
the	O
endosomal	O
targeting	O
of	O
TLR8	O
.	O

MEK1	O
/	O
2	O
dual	O
-	O
specificity	O
protein	O
kinases	O
:	O
structure	O
and	O
regulation	O
.	O

MEK1	O
and	O
MEK2	O
are	O
related	O
protein	O
kinases	O
that	O
participate	O
in	O
the	O
RAS	O
-	O
RAF	O
-	O
MEK	O
-	O
ERK	O
signal	O
transduction	O
cascade	O
.	O

This	O
cascade	O
participates	O
in	O
the	O
regulation	O
of	O
a	O
large	O
variety	O
of	O
processes	O
including	O
apoptosis	O
,	O
cell	O
cycle	O
progression	O
,	O
cell	O
migration	O
,	O
differentiation	O
,	O
metabolism	O
,	O
and	O
proliferation	O
.	O

Moreover	O
,	O
oncogenic	O
mutations	O
in	O
RAS	O
or	O
B	O
-	O
RAF	O
are	O
responsible	O
for	O
a	O
large	O
proportion	O
of	O
human	O
cancers	O
.	O

MEK1	O
is	O
activated	O
by	O
phosphorylation	O
of	O
S218	O
and	O
S222	O
in	O
its	O
activation	O
segment	O
as	O
catalyzed	O
by	O
RAF	O
kinases	O
in	O
an	O
intricate	O
process	O
that	O
involves	O
a	O
KSR	B-OOS
scaffold	O
.	O

Besides	O
functioning	O
as	O
a	O
scaffold	O
,	O
the	O
kinase	O
activity	O
of	O
KSR	B-OOS
is	O
also	O
required	O
for	O
MEK	O
activation	O
.	O

MEK1	O
regulation	O
is	O
unusual	O
in	O
that	O
S212	O
phosphorylation	O
in	O
its	O
activation	O
segment	O
is	O
inhibitory	O
.	O

Moreover	O
,	O
active	O
ERK	O
catalyzes	O
a	O
feedback	O
inhibitory	O
phosphorylation	O
of	O
MEK1	O
T292	O
that	O
serves	O
to	O
downregulate	O
the	O
pathway	O
.	O

A	O
poised	O
chromatin	O
platform	O
for	O
TGF	O
-	O
beta	O
access	O
to	O
master	O
regulators	O
.	O

Specific	O
chromatin	O
marks	O
keep	O
master	O
regulators	O
of	O
differentiation	O
silent	O
yet	O
poised	O
for	O
activation	O
by	O
extracellular	O
signals	O
.	O

We	O
report	O
that	O
nodal	O
TGF	O
-	O
beta	O
signals	O
use	O
the	O
poised	O
histone	O
mark	O
H3K9me3	O
to	O
trigger	O
differentiation	O
of	O
mammalian	O
embryonic	O
stem	O
cells	O
.	O

Nodal	O
receptors	O
induce	O
the	O
formation	O
of	O
companion	O
Smad4	O
-	O
Smad2	O
/	O
3	O
and	O
TRIM33	O
-	O
Smad2	O
/	O
3	O
complexes	O
.	O

The	O
PHD	O
-	O
Bromo	O
cassette	O
of	O
TRIM33	O
facilitates	O
binding	O
of	O
TRIM33	O
-	O
Smad2	O
/	O
3	O
to	O
H3K9me3	O
and	O
H3K18ac	O
on	O
the	O
promoters	O
of	O
mesendoderm	O
regulators	O
Gsc	O
and	O
Mixl1	O
.	O

The	O
crystal	O
structure	O
of	O
this	O
cassette	O
,	O
bound	O
to	O
histone	O
H3	O
peptides	O
,	O
illustrates	O
that	O
PHD	O
recognizes	O
K9me3	O
,	O
and	O
Bromo	O
binds	O
an	O
adjacent	O
K18ac	O
.	O

The	O
interaction	O
between	O
TRIM33	O
-	O
Smad2	O
/	O
3	O
and	O
H3K9me3	O
displaces	O
the	O
chromatin	O
-	O
compacting	O
factor	O
HP1gamma	O
,	O
making	O
nodal	O
response	O
elements	O
accessible	O
to	O
Smad4	O
-	O
Smad2	O
/	O
3	O
for	O
Pol	B-Complex
II	I-Complex
recruitment	O
.	O

In	O
turn	O
,	O
Smad4	O
increases	O
K18	O
acetylation	O
to	O
augment	O
TRIM33	O
-	O
Smad2	O
/	O
3	O
binding	O
.	O

Thus	O
,	O
nodal	O
effectors	O
use	O
the	O
H3K9me3	O
mark	O
as	O
a	O
platform	O
to	O
switch	O
master	O
regulators	O
of	O
stem	O
cell	O
differentiation	O
from	O
the	O
poised	O
to	O
the	O
active	O
state	O
.	O

Dissection	O
of	O
the	O
NUP107	B-OOS
nuclear	B-Complex
pore	I-Complex
subcomplex	I-Complex
reveals	O
a	O
novel	O
interaction	O
with	O
spindle	O
assembly	O
checkpoint	O
protein	O
MAD1	O
in	O
Caenorhabditis	O
elegans	O
.	O

Nuclear	B-Complex
pore	I-Complex
complexes	I-Complex
consist	O
of	O
several	O
subcomplexes	O
.	O

The	O
NUP107	B-OOS
complex	O
is	O
important	O
for	O
nucleocytoplasmic	O
transport	O
,	O
nuclear	O
envelope	O
assembly	O
,	O
and	O
kinetochore	O
function	O
.	O

However	O
,	O
the	O
underlying	O
molecular	O
mechanisms	O
and	O
the	O
roles	O
of	O
individual	O
complex	O
members	O
remain	O
elusive	O
.	O

We	O
report	O
the	O
first	O
description	O
of	O
a	O
genetic	O
disruption	O
of	O
NUP107	B-OOS
in	O
a	O
metazoan	O
.	O

Caenorhabditis	O
elegans	O
NUP107	B-OOS
/	O
npp	O
-	O
5	O
mutants	O
display	O
temperature	O
-	O
dependent	O
lethality	O
.	O

Surprisingly	O
,	O
NPP	O
-	O
5	O
is	O
dispensable	O
for	O
incorporation	O
of	O
most	O
nucleoporins	O
into	O
nuclear	O
pores	O
and	O
for	O
nuclear	O
protein	O
import	O
.	O

In	O
contrast	O
,	O
NPP	O
-	O
5	O
is	O
essential	O
for	O
proper	O
kinetochore	O
localization	O
of	O
NUP133	O
/	O
NPP	O
-	O
15	O
,	O
another	O
NUP107	B-OOS
complex	O
member	O
,	O
whereas	O
recruitment	O
of	O
NUP96	O
/	O
NPP	O
-	O
10C	O
and	O
ELYS	O
/	O
MEL	O
-	O
28	O
is	O
NPP	O
-	O
5	O
independent	O
.	O

We	O
found	O
that	O
kinetochore	O
protein	O
NUF2	O
/	O
HIM	O
-	O
10	O
and	O
Aurora	O
B	O
/	O
AIR	O
-	O
2	O
kinase	O
are	O
less	O
abundant	O
on	O
mitotic	O
chromatin	O
upon	O
NPP	O
-	O
5	O
depletion	O
.	O

npp	O
-	O
5	O
mutants	O
are	O
hypersensitive	O
to	O
anoxia	O
,	O
suggesting	O
that	O
the	O
spindle	O
assembly	O
checkpoint	O
(	O
SAC	O
)	O
is	O
compromised	O
.	O

Indeed	O
,	O
NPP	O
-	O
5	O
interacts	O
genetically	O
and	O
physically	O
with	O
SAC	O
protein	O
MAD1	O
/	O
MDF	O
-	O
1	O
,	O
whose	O
nuclear	O
envelope	O
accumulation	O
requires	O
NPP	O
-	O
5	O
.	O

Thus	O
our	O
results	O
strengthen	O
the	O
emerging	O
connection	O
between	O
nuclear	O
pore	O
proteins	O
and	O
chromosome	O
segregation	O
.	O

Oxidative	O
stress	O
induces	O
mitochondrial	O
fragmentation	O
in	O
frataxin	O
-	O
deficient	O
cells	O
.	O

Friedreich	O
ataxia	O
(	O
FA	O
)	O
is	O
the	O
most	O
common	O
recessive	O
neurodegenerative	O
disease	O
.	O

It	O
is	O
caused	O
by	O
deficiency	O
in	O
mitochondrial	O
frataxin	O
,	O
which	O
participates	O
in	O
iron	O
-	O
sulfur	O
cluster	O
assembly	O
.	O

Yeast	O
cells	O
lacking	O
frataxin	O
(	O
Deltayfh1	O
mutant	O
)	O
showed	O
an	O
increased	O
proportion	O
of	O
fragmented	O
mitochondria	O
compared	O
to	O
wild	O
-	O
type	O
.	O

In	O
addition	O
,	O
oxidative	O
stress	O
induced	O
complete	O
fragmentation	O
of	O
mitochondria	O
in	O
Deltayfh1	O
cells	O
.	O

Genetically	O
controlled	O
inhibition	O
of	O
mitochondrial	O
fission	O
in	O
these	O
cells	O
led	O
to	O
increased	O
resistance	O
to	O
oxidative	O
stress	O
.	O

Here	O
we	O
present	O
evidence	O
that	O
in	O
yeast	O
frataxin	O
-	O
deficiency	O
interferes	O
with	O
mitochondrial	O
dynamics	O
,	O
which	O
might	O
therefore	O
be	O
relevant	O
for	O
the	O
pathophysiology	O
of	O
FA	O
.	O

That	O
mutations	O
in	O
amino	O
acids	O
6	O
-	O
11	O
at	O
the	O
N	O
terminus	O
and	O
mutations	O
at	O
the	O
C	O
terminus	O
of	O
ICP27	O
both	O
affect	O
the	O
interaction	O
in	O
vitro	O
with	O
bacterially	O
purified	O
Nup62	O
suggests	O
that	O
both	O
regions	O
of	O
ICP27	O
may	O
act	O
together	O
for	O
Nup62	O
binding	O
.	O

However	O
,	O
N	O
-	O
terminal	O
mutant	O
10	O
-	O
512	O
,	O
which	O
deletes	O
part	O
(	O
aa	O
6	O
-	O
9	O
)	O
of	O
the	O
ICP27	O
NES	O
(	O
aa	O
6	O
-	O
19	O
)	O
when	O
used	O
in	O
the	O
transport	O
assay	O
,	O
in	O
70	O
%	O
of	O
cells	O
showed	O
a	O
phenotype	O
similar	O
to	O
full	O
-	O
length	O
WT	O
protein	O
.	O

In	O
fewer	O
cells	O
,	O
nuclear	O
retention	O
of	O
the	O
reporter	O
protein	O
was	O
also	O
observed	O
.	O

Our	O
observations	O
are	O
similar	O
to	O
those	O
reported	O
earlier	O
that	O
mutant	O
d1	O
-	O
2	O
(	O
which	O
deletes	O
aa	O
12	O
-	O
63	O
,	O
including	O
part	O
of	O
NES	O
aa	O
6	O
-	O
19	O
)	O
showed	O
reduced	O
shuttling	O
,	O
and	O
in	O
the	O
dleu	O
mutant	O
,	O
deletion	O
of	O
NES	O
(	O
aa	O
6	O
-	O
19	O
)	O
of	O
ICP27	O
weakened	O
but	O
did	O
not	O
abrogate	O
shuttling	O
.	O

Mutant	O
ICP27	O
dleu	O
virus	O
is	O
replication	O
-	O
deficient	O
but	O
not	O
replication	O
-	O
defective	O
.	O

Hence	O
,	O
for	O
these	O
N	O
-	O
terminal	O
mutants	O
,	O
alternative	O
routes	O
for	O
nuclear	O
egress	O
appear	O
to	O
exist	O
when	O
other	O
regions	O
of	O
the	O
protein	O
,	O
especially	O
the	O
C	O
terminus	O
,	O
are	O
intact	O
.	O

Our	O
observations	O
are	O
not	O
quantitative	O
in	O
nature	O
but	O
help	O
us	O
to	O
understand	O
the	O
role	O
(	O
s	O
)	O
played	O
by	O
various	O
segments	O
of	O
ICP27	O
.	O

From	O
the	O
ICP27	O
-	O
Nup62	O
interaction	O
even	O
in	O
the	O
presence	O
of	O
LMB	O
(	O
supplemental	O
Fig	O
.	O
S2	O
)	O
and	O
from	O
transport	O
assays	O
utilizing	O
various	O
N	O
-	O
and	O
C	O
-	O
terminal	O
ICP27	O
plasmid	O
mutations	O
,	O
it	O
becomes	O
clear	O
that	O
,	O
although	O
the	O
N	O
-	O
terminal	O
region	O
of	O
ICP27	O
affects	O
its	O
ability	O
to	O
bind	O
Nup62	O
in	O
vitro	O
,	O
functionally	O
it	O
appears	O
to	O
be	O
the	O
C	O
terminus	O
of	O
ICP27	O
that	O
acts	O
as	O
the	O
major	O
region	O
of	O
importance	O
for	O
shuttling	O
of	O
viral	O
protein	O
.	O

These	O
data	O
revealed	O
that	O
mutants	O
that	O
reduce	O
protein	O
-	O
protein	O
interactions	O
with	O
Nup62	O
at	O
the	O
C	O
terminus	O
alter	O
and	O
dramatically	O
decrease	O
the	O
ability	O
of	O
ICP27	O
to	O
shuttle	O
and	O
also	O
inhibit	O
multiple	O
host	O
cell	O
nucleo	O
-	O
cytoplasmic	O
transport	O
pathways	O
.	O

The	O
ICP27	O
M15	O
mutant	O
protein	O
appears	O
to	O
be	O
able	O
to	O
enter	O
the	O
nucleus	O
after	O
synthesis	O
in	O
the	O
cytoplasm	O
via	O
alternative	O
routes	O
;	O
however	O
,	O
its	O
ability	O
to	O
export	O
out	O
of	O
the	O
nucleus	O
seems	O
to	O
be	O
defective	O
.	O

Loss	O
of	O
Nup62	O
interaction	O
correlates	O
with	O
the	O
inability	O
of	O
M15	O
to	O
re	O
-	O
export	O
and	O
shuttle	O
continuously	O
,	O
and	O
it	O
appears	O
that	O
as	O
a	O
result	O
of	O
the	O
loss	O
of	O
this	O
crucial	O
function	O
,	O
M15	O
is	O
replication	O
-	O
defective	O
.	O

With	O
regard	O
to	O
cellular	O
and	O
viral	O
mRNA	O
processing	O
,	O
HeLa	O
cells	O
infected	O
with	O
M15	O
mutant	O
virus	O
failed	O
to	O
accumulate	O
cellular	O
unspliced	O
alpha	O
-	O
globin	O
pre	O
-	O
mRNA	O
,	O
and	O
mutation	O
in	O
the	O
M15	O
virus	O
greatly	O
increased	O
the	O
length	O
and	O
heterogeneity	O
of	O
the	O
poly	O
(	O
A	O
)	O
tail	O
of	O
spliced	O
alpha	O
-	O
globin	O
mRNA	O
.	O

Additionally	O
,	O
ICP0	O
is	O
one	O
of	O
the	O
few	O
intron	O
-	O
containing	O
viral	O
genes	O
,	O
and	O
it	O
yielded	O
no	O
detectable	O
intron	O
1	O
-	O
containing	O
transcripts	O
in	O
M15	O
infections	O
.	O

M15	O
protein	O
has	O
been	O
reported	O
to	O
have	O
an	O
exclusively	O
nuclear	O
distribution	O
,	O
and	O
in	O
contrast	O
to	O
the	O
WT	O
ICP27	O
protein	O
,	O
the	O
M15	O
mutant	O
protein	O
was	O
absent	O
from	O
the	O
polyribosome	O
fractions	O
.	O

It	O
remains	O
possible	O
,	O
however	O
,	O
that	O
the	O
M15	O
mutation	O
might	O
affect	O
activities	O
of	O
ICP27	O
other	O
than	O
NPC	B-Complex
interaction	O
.	O

In	O
S	O
.	O
cerevisiae	O
,	O
Pex11p	O
was	O
shown	O
to	O
homodimerize	O
via	O
the	O
Cys	O
-	O
3	O
residue	O
,	O
and	O
mutation	O
of	O
this	O
residue	O
to	O
alanine	O
inhibited	O
dimerization	O
,	O
causing	O
numerous	O
and	O
small	O
peroxisomes	O
.	O

The	O
study	O
suggested	O
the	O
monomeric	O
form	O
to	O
be	O
the	O
active	O
species	O
.	O

However	O
,	O
P	O
.	O
pastoris	O
Pex11p	O
lacks	O
cysteine	O
residues	O
in	O
its	O
protein	O
sequence	O
.	O

Therefore	O
,	O
an	O
alternate	O
mechanism	O
for	O
activation	O
of	O
Pex11p	O
to	O
induce	O
division	O
is	O
necessary	O
.	O

Here	O
we	O
suggest	O
a	O
phosphorylation	O
-	O
mediated	O
activation	O
of	O
Pex11p	O
for	O
division	O
.	O

The	O
involvement	O
of	O
RPD3	O
-	O
type	O
HDAs	O
,	O
HDA6	O
and	O
HDA19	O
,	O
in	O
ABA	O
and	O
abiotic	O
stress	O
has	O
been	O
reported	O
.	O

It	O
was	O
found	O
that	O
hda6	O
mutant	O
and	O
HDA6	O
RNA	O
-	O
interference	O
(	O
HDA6	O
-	O
RNAi	O
)	O
plants	O
displayed	O
a	O
phenotype	O
that	O
is	O
more	O
sensitive	O
to	O
ABA	O
and	O
salt	O
stress	O
.	O

Compared	O
with	O
wild	O
-	O
type	O
plants	O
,	O
the	O
expression	O
of	O
ABA	O
and	O
abiotic	O
stress	O
-	O
responsive	O
genes	O
was	O
decreased	O
in	O
hda6	O
and	O
HDA6	O
-	O
RNAi	O
plants	O
.	O

Similarly	O
,	O
the	O
Arabidopsis	O
HDA19	O
T	O
-	O
DNA	O
insertion	O
mutant	O
,	O
hda19	O
-	O
1	O
,	O
was	O
hypersensitive	O
to	O
ABA	O
and	O
salt	O
stress	O
,	O
and	O
the	O
expression	O
of	O
ABA	O
-	O
responsive	O
genes	O
was	O
decreased	O
in	O
hda19	O
-	O
1	O
plants	O
.	O

Arabidopsis	O
HDA19	O
may	O
act	O
in	O
a	O
protein	O
complex	O
of	O
AtERF7	O
,	O
a	O
transcription	O
repressor	O
,	O
to	O
regulate	O
the	O
abiotic	O
stress	O
response	O
genes	O
.	O

Furthermore	O
,	O
AtERF7	O
interacts	O
with	O
the	O
Arabidopsis	O
homologue	O
of	O
a	O
human	O
global	O
corepressor	O
of	O
transcription	O
,	O
AtSin3	O
,	O
which	O
,	O
in	O
turn	O
,	O
may	O
interact	O
with	O
HDA19	O
.	O

It	O
was	O
proposed	O
that	O
AtERF7	O
,	O
AtSin3	O
,	O
and	O
HDA19	O
can	O
form	O
a	O
transcriptional	O
repressor	O
complex	O
to	O
regulate	O
ABA	O
and	O
drought	O
response	O
in	O
Arabidopsis	O
.	O

RNF8	O
-	O
and	O
RNF168	O
-	O
dependent	O
degradation	O
of	O
KDM4A	O
/	O
JMJD2A	O
triggers	O
53BP1	O
recruitment	O
to	O
DNA	O
damage	O
sites	O
.	O

In	O
response	O
to	O
DNA	O
damage	O
,	O
cells	O
initiate	O
complex	O
signalling	O
cascades	O
leading	O
to	O
growth	O
arrest	O
and	O
DNA	O
repair	O
.	O

The	O
recruitment	O
of	O
53BP1	O
to	O
damaged	O
sites	O
requires	O
the	O
activation	O
of	O
the	O
ubiquitination	O
cascade	O
controlled	O
by	O
the	O
E3	O
ubiquitin	O
ligases	O
RNF8	O
and	O
RNF168	O
,	O
and	O
methylation	O
of	O
histone	O
H4	O
on	O
lysine	O
20	O
.	O

However	O
,	O
molecular	O
events	O
that	O
regulate	O
the	O
accessibility	O
of	O
methylated	O
histones	O
,	O
to	O
allow	O
the	O
recruitment	O
of	O
53BP1	O
to	O
DNA	O
breaks	O
,	O
are	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
that	O
like	O
53BP1	O
,	O
the	O
JMJD2A	O
(	O
also	O
known	O
as	O
KDM4A	O
)	O
tandem	O
tudor	O
domain	O
binds	O
dimethylated	O
histone	O
H4K20	O
;	O
however	O
,	O
JMJD2A	O
is	O
degraded	O
by	O
the	O
proteasome	B-Complex
following	O
the	O
DNA	O
damage	O
in	O
an	O
RNF8	O
-	O
dependent	O
manner	O
.	O

We	O
demonstrate	O
that	O
JMJD2A	O
is	O
ubiquitinated	O
by	O
RNF8	O
and	O
RNF168	O
.	O

Moreover	O
,	O
ectopic	O
expression	O
of	O
JMJD2A	O
abrogates	O
53BP1	O
recruitment	O
to	O
DNA	O
damage	O
sites	O
,	O
indicating	O
a	O
role	O
in	O
antagonizing	O
53BP1	O
for	O
methylated	O
histone	O
marks	O
.	O

The	O
combined	O
knockdown	O
of	O
JMJD2A	O
and	O
JMJD2B	O
significantly	O
rescued	O
the	O
ability	O
of	O
RNF8	O
-	O
and	O
RNF168	O
-	O
deficient	O
cells	O
to	O
form	O
53BP1	O
foci	O
.	O

We	O
propose	O
that	O
the	O
RNF8	O
-	O
dependent	O
degradation	O
of	O
JMJD2A	O
regulates	O
DNA	O
repair	O
by	O
controlling	O
the	O
recruitment	O
of	O
53BP1	O
at	O
DNA	O
damage	O
sites	O
.	O

MMP	O
mediated	O
type	B-Complex
V	I-Complex
collagen	I-Complex
degradation	O
(	O
C5M	O
)	O
is	O
elevated	O
in	O
ankylosing	O
spondylitis	O
.	O

OBJECTIVES	O
:	O
Type	B-Complex
V	I-Complex
collagen	I-Complex
has	O
been	O
demonstrated	O
to	O
control	O
fibril	O
formation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
an	O
ELISA	O
capable	O
of	O
detecting	O
a	O
fragment	O
of	O
type	B-Complex
V	I-Complex
collagen	I-Complex
generated	O
by	O
MMP	O
-	O
2	O
/	O
9	O
and	O
to	O
evaluate	O
the	O
assay	O
as	O
biomarker	O
for	O
ankylosing	O
spondylitis	O
(	O
AS	O
)	O
.	O

DESIGN	O
AND	O
METHODS	O
:	O
A	O
fragment	O
unique	O
to	O
type	B-Complex
V	I-Complex
collagen	I-Complex
and	O
generated	O
by	O
both	O
MMP	O
-	O
2	O
/	O
9	O
cleaved	O
at	O
the	O
amino	O
acid	O
position	O
1317	O
(	O
C5M	O
)	O
was	O
selected	O
for	O
ELISA	O
development	O
.	O

40	O
AS	O
patients	O
and	O
40	O
age	O
-	O
matched	O
controls	O
were	O
evaluated	O
.	O

RESULTS	O
:	O
An	O
ELISA	O
detecting	O
C5M	O
with	O
inter	O
-	O
and	O
intra	O
-	O
assay	O
variations	O
of	O
9	O
.	O
1	O
%	O
and	O
4	O
.	O
4	O
%	O
was	O
developed	O
.	O

C5M	O
levels	O
were	O
significantly	O
higher	O
in	O
AS	O
patients	O
compared	O
to	O
controls	O
,	O
229	O
%	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

The	O
diagnostic	O
AUC	O
was	O
83	O
%	O
.	O

CONCLUSIONS	O
:	O
This	O
ELISA	O
is	O
the	O
first	O
for	O
detecting	O
type	B-Complex
V	I-Complex
collagen	I-Complex
degradation	O
.	O

AS	O
patients	O
had	O
highly	O
elevated	O
levels	O
of	O
MMP	O
mediated	O
type	B-Complex
V	I-Complex
collagen	I-Complex
degradation	O
.	O

The	O
prognostic	O
and	O
diagnostic	O
values	O
need	O
to	O
be	O
further	O
investigated	O
in	O
additional	O
clinical	O
settings	O
.	O

Role	O
for	O
two	O
conserved	O
intermembrane	O
space	O
proteins	O
,	O
Ups1p	O
and	O
Ups2p	O
,	O
[	O
corrected	O
]	O
in	O
intra	O
-	O
mitochondrial	O
phospholipid	O
trafficking	O
.	O

Mitochondrial	O
membranes	O
maintain	O
a	O
specific	O
phospholipid	O
composition	O
.	O

Most	O
phospholipids	O
are	O
synthesized	O
in	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
transported	O
to	O
mitochondria	O
,	O
but	O
cardiolipin	O
and	O
phosphatidylethanolamine	O
are	O
produced	O
in	O
mitochondria	O
.	O

In	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
phospholipid	O
exchange	O
between	O
the	O
ER	O
and	O
mitochondria	O
relies	O
on	O
the	O
ER	B-Complex
-	I-Complex
mitochondria	I-Complex
encounter	I-Complex
structure	I-Complex
(	O
ERMES	B-Complex
)	O
complex	O
,	O
which	O
physically	O
connects	O
the	O
ER	O
and	O
mitochondrial	O
outer	O
membrane	O
.	O

However	O
,	O
the	O
proteins	O
and	O
mechanisms	O
involved	O
in	O
phospholipid	O
transport	O
within	O
mitochondria	O
remain	O
elusive	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
role	O
of	O
the	O
conserved	O
intermembrane	O
space	O
proteins	O
,	O
Ups1p	O
and	O
Ups2p	O
,	O
and	O
an	O
inner	O
membrane	O
protein	O
,	O
Mdm31p	O
,	O
in	O
phospholipid	O
metabolism	O
.	O

Our	O
data	O
show	O
that	O
loss	O
of	O
the	O
ERMES	B-Complex
complex	O
,	O
Ups1p	O
,	O
and	O
Mdm31p	O
causes	O
similar	O
defects	O
in	O
mitochondrial	O
phospholipid	O
metabolism	O
,	O
mitochondrial	O
morphology	O
,	O
and	O
cell	O
growth	O
.	O

Defects	O
in	O
cells	O
lacking	O
the	O
ERMES	B-Complex
complex	O
or	O
Ups1p	O
are	O
suppressed	O
by	O
Mdm31p	O
overexpression	O
as	O
well	O
as	O
additional	O
loss	O
of	O
Ups2p	O
,	O
which	O
antagonizes	O
Ups1p	O
.	O

Combined	O
loss	O
of	O
the	O
ERMES	B-Complex
complex	O
and	O
Ups1p	O
exacerbates	O
phospholipid	O
defects	O
.	O

Finally	O
,	O
pulse	O
-	O
chase	O
experiments	O
using	O
[	O
(	O
14	O
)	O
C	O
]	O
serine	O
revealed	O
that	O
Ups1p	O
and	O
Ups2p	O
antagonistically	O
regulate	O
conversion	O
of	O
phosphatidylethanolamine	O
to	O
phosphatidylcholine	O
.	O

Our	O
results	O
suggest	O
that	O
Ups	O
proteins	O
and	O
Mdm31p	O
play	O
important	O
roles	O
in	O
phospholipid	O
biosynthesis	O
in	O
mitochondria	O
.	O

Ups	O
proteins	O
may	O
function	O
in	O
phospholipid	O
trafficking	O
between	O
the	O
outer	O
and	O
inner	O
mitochondrial	O
membranes	O
.	O

Similar	O
to	O
Cand1	O
,	O
Glmn	O
binds	O
to	O
a	O
broad	O
range	O
of	O
CRLs	O
although	O
in	O
a	O
completely	O
different	O
manner	O
.	O

Cand1	O
associates	O
with	O
un	O
-	O
neddylated	O
cullins	O
not	O
bound	O
to	O
SRs	O
.	O

In	O
contrast	O
,	O
Glmn	O
can	O
bind	O
to	O
cullins	O
independent	O
of	O
their	O
neddylation	O
status	O
or	O
association	O
with	O
SRs	O
.	O

However	O
,	O
the	O
specific	O
role	O
of	O
Cand1	O
in	O
regulating	O
CRL	O
activity	O
remains	O
largely	O
unknown	O
.	O

Depletion	O
of	O
Cand1	O
had	O
little	O
effect	O
on	O
the	O
abundance	O
of	O
cullins	O
and	O
Cand1	O
only	O
associates	O
with	O
a	O
small	O
fraction	O
of	O
un	O
-	O
neddylated	O
cullins	O
.	O

Inhibition	O
of	O
neddylation	O
with	O
MLN4924	O
led	O
to	O
small	O
increases	O
in	O
the	O
fraction	O
of	O
cullins	O
bound	O
to	O
Cand1	O
and	O
little	O
changes	O
in	O
cullin	O
binding	O
to	O
SRs	O
.	O

Interestingly	O
,	O
loss	O
of	O
Cand1	O
function	O
in	O
C	O
.	O
elegans	O
results	O
in	O
reduction	O
of	O
specific	O
CRL	O
functions	O
while	O
leaving	O
others	O
unaffected	O
.	O

Therefore	O
,	O
although	O
Cand1	O
can	O
bind	O
to	O
the	O
broad	O
class	O
of	O
unmodified	O
Rbx1	O
-	O
Cullins	O
,	O
its	O
impact	O
on	O
CRL	O
activity	O
is	O
quite	O
limited	O
.	O

To	O
analyze	O
the	O
biogenesis	O
of	O
Tom40	O
,	O
we	O
incubated	O
the	O
35S	O
-	O
labeled	O
precursor	O
with	O
isolated	O
mitochondria	O
.	O

We	O
used	O
the	O
wild	O
-	O
type	O
precursor	O
of	O
Tom40	O
and	O
two	O
mutant	O
forms	O
of	O
Ser	O
-	O
54	O
.	O

When	O
serine	O
was	O
replaced	O
by	O
alanine	O
,	O
the	O
binding	O
of	O
Tom40	O
to	O
mitochondria	O
was	O
only	O
mildly	O
affected	O
compared	O
with	O
the	O
wild	O
-	O
type	O
precursor	O
(	O
Figure	O
3A	O
,	O
lanes	O
4	O
-	O
9	O
)	O
.	O

When	O
serine	O
was	O
replaced	O
by	O
the	O
phosphomimetic	O
residue	O
glutamate	O
,	O
however	O
,	O
binding	O
of	O
Tom40	O
to	O
mitochondria	O
was	O
reduced	O
(	O
Figure	O
3A	O
,	O
lanes	O
1	O
-	O
3	O
)	O
.	O

Treatment	O
of	O
mitochondria	O
with	O
sodium	O
carbonate	O
at	O
alkaline	O
pH	O
leads	O
to	O
the	O
extraction	O
of	O
soluble	O
and	O
peripheral	O
membrane	O
proteins	O
,	O
whereas	O
integral	O
membrane	O
proteins	O
remain	O
in	O
the	O
membrane	O
sheets	O
.	O

Mitochondria	O
were	O
incubated	O
with	O
[	O
35S	O
]	O
Tom40	O
and	O
then	O
treated	O
at	O
alkaline	O
pH	O
,	O
demonstrating	O
that	O
the	O
replacement	O
of	O
Ser	O
-	O
54	O
by	O
glutamate	O
considerably	O
reduced	O
the	O
membrane	O
integration	O
of	O
Tom40	O
(	O
Figure	O
3B	O
,	O
lanes	O
1	O
-	O
3	O
)	O
.	O

Likewise	O
,	O
a	O
mild	O
effect	O
of	O
hypertubulation	O
on	O
recycling	O
was	O
observed	O
for	O
the	O
three	O
cargoes	O
:	O
on	O
cPLA2alpha	O
depletion	O
,	O
recycling	O
of	O
Tac	O
-	O
GPI	O
,	O
CD59	O
(	O
unpublished	O
data	O
)	O
,	O
and	O
Tac	O
(	O
both	O
believed	O
to	O
reside	O
within	O
cholesterol	O
-	O
containing	O
endosomes	O
)	O
was	O
moderately	O
delayed	O
,	O
whereas	O
Tac	O
-	O
LL	O
recycling	O
remained	O
unaffected	O
(	O
Figure	O
4	O
)	O
.	O

This	O
delay	O
was	O
more	O
evident	O
for	O
Tac	O
-	O
GPI	O
at	O
short	O
treatments	O
with	O
MAFP	O
and	O
BAPTA	O
-	O
AM	O
,	O
compared	O
with	O
the	O
other	O
two	O
Tac	O
cargoes	O
.	O

Whereas	O
activation	O
of	O
cPLA2alpha	O
with	O
melittin	O
resulted	O
in	O
vast	O
vesicular	O
distribution	O
of	O
CD59	O
,	O
it	O
did	O
not	O
alter	O
its	O
transport	O
back	O
to	O
the	O
plasma	O
membrane	O
,	O
nor	O
did	O
it	O
do	O
so	O
for	O
the	O
other	O
two	O
Tac	O
cargoes	O
.	O

Although	O
vesicles	O
laden	O
with	O
cargo	O
might	O
conceivably	O
be	O
more	O
easily	O
transported	O
along	O
microtubules	O
to	O
the	O
cell	O
surface	O
compared	O
with	O
cargo	O
associated	O
with	O
tubular	O
membranes	O
,	O
motor	O
proteins	O
may	O
be	O
the	O
limiting	O
step	O
,	O
controlling	O
the	O
rate	O
of	O
vesicles	O
that	O
recycle	O
.	O

We	O
speculate	O
that	O
the	O
modest	O
inhibition	O
observed	O
in	O
recycling	O
under	O
conditions	O
of	O
hypertubulation	O
could	O
result	O
from	O
cargo	O
shunting	O
to	O
an	O
alternative	O
route	O
of	O
recycling	O
(	O
fast	O
recycling	O
)	O
,	O
occurring	O
directly	O
from	O
peripheral	O
endosomes	O
partly	O
bypassing	O
the	O
tubular	O
recycling	O
compartment	O
.	O

The	O
data	O
presented	O
in	O
the	O
current	O
study	O
also	O
show	O
that	O
prostratin	O
,	O
a	O
non	O
-	O
tumorigenic	O
phorbol	O
ester	O
,	O
and	O
HMBA	O
,	O
a	O
hybrid	O
bipolar	O
compound	O
,	O
are	O
both	O
able	O
to	O
enhance	O
ELL2	O
accumulation	O
and	O
SECs	B-Complex
formation	O
despite	O
their	O
completely	O
different	O
structures	O
and	O
presumably	O
distinct	O
mechanisms	O
of	O
action	O
.	O

The	O
enhancement	O
correlates	O
well	O
with	O
their	O
abilities	O
to	O
decrease	O
Siah1	O
expression	O
and	O
ELL2	O
polyubiquitination	O
,	O
although	O
additional	O
mechanisms	O
may	O
be	O
used	O
to	O
further	O
enhance	O
ELL2	O
expression	O
.	O

For	O
example	O
,	O
the	O
ELL2	O
mRNA	O
level	O
was	O
found	O
to	O
increase	O
by	O
about	O
2	O
-	O
fold	O
upon	O
the	O
treatment	O
with	O
prostratin	O
but	O
not	O
HMBA	O
(	O
data	O
not	O
shown	O
)	O
.	O

Purification	O
and	O
characterization	O
of	O
extracellular	O
matrix	O
-	O
degrading	O
metalloproteinase	O
,	O
matrin	O
(	O
pump	O
-	O
1	O
)	O
,	O
secreted	O
from	O
human	O
rectal	O
carcinoma	O
cell	O
line	O
.	O

A	O
metalloproteinase	O
with	O
Mr	O
29	O
,	O
000	O
was	O
purified	O
to	O
homogeneity	O
as	O
a	O
latent	O
proenzyme	O
from	O
the	O
conditioned	O
medium	O
of	O
a	O
human	O
rectal	O
carcinoma	O
cell	O
line	O
CaR	O
-	O
1	O
.	O

This	O
enzyme	O
hydrolyzed	O
casein	O
more	O
potently	O
than	O
gelatin	O
embedded	O
in	O
polyacrylamide	O
gels	O
in	O
zymography	O
assay	O
.	O

Calcium	O
ion	O
was	O
essential	O
for	O
the	O
activity	O
.	O

It	O
exerted	O
the	O
maximum	O
activity	O
at	O
pH	O
7	O
-	O
9	O
.	O

Its	O
activity	O
was	O
stimulated	O
by	O
organomercurials	O
,	O
such	O
as	O
p	O
-	O
amino	O
-	O
phenyl	O
mercuric	O
acetate	O
and	O
p	O
-	O
chloromercuric	O
benzoic	O
acid	O
,	O
and	O
was	O
inhibited	O
by	O
1	O
,	O
10	O
-	O
phenanthroline	O
but	O
was	O
hardly	O
affected	O
by	O
diisopropyl	O
fluorophosphate	O
and	O
pepstatin	O
.	O

When	O
the	O
purified	O
proenzyme	O
was	O
activated	O
by	O
the	O
organomercurials	O
,	O
it	O
effectively	O
hydrolyzed	O
fibronectin	O
,	O
laminin	O
,	O
type	B-Complex
IV	I-Complex
basement	I-Complex
membrane	I-Complex
collagen	I-Complex
,	O
and	O
several	O
types	O
of	O
gelatins	O
but	O
not	O
interstitial	O
type	B-Complex
I	I-Complex
and	I-Complex
III	I-Complex
collagens	I-Complex
.	O

The	O
treatment	O
of	O
the	O
purified	O
proenzyme	O
with	O
p	O
-	O
aminophenyl	O
mercuric	O
acetate	O
or	O
trypsin	O
formed	O
an	O
active	O
peptide	O
with	O
Mr	O
20	O
,	O
000	O
.	O

The	O
structural	O
analysis	O
indicated	O
that	O
it	O
was	O
most	O
likely	O
identical	O
to	O
putative	O
metalloproteinase	O
-	O
1	O
,	O
the	O
complementary	O
DNA	O
of	O
which	O
had	O
been	O
cloned	O
from	O
human	O
tumor	O
mRNAs	O
capable	O
of	O
hybridizing	O
to	O
a	O
rat	O
transin	O
complementary	O
DNA	O
.	O

Based	O
on	O
the	O
fact	O
that	O
this	O
enzyme	O
is	O
secreted	O
extracellularly	O
and	O
degrades	O
the	O
matrix	O
proteins	O
,	O
we	O
propose	O
the	O
name	O
"	O
matrin	O
"	O
for	O
this	O
newly	O
identified	O
enzyme	O
.	O

The	O
DFz2C	O
granules	O
within	O
the	O
INM	O
invaginations	O
appeared	O
to	O
be	O
bounded	O
by	O
membrane	O
(	O
Fig	O
.	O
3D	O
;	O
arrow	O
)	O
.	O

If	O
these	O
granules	O
are	O
enveloped	O
by	O
the	O
INM	O
,	O
then	O
Lamin	O
immunoreactivity	O
could	O
surround	O
the	O
dense	O
granules	O
.	O

Indeed	O
,	O
LamC	O
immunoreactivity	O
lined	O
the	O
outer	O
edge	O
of	O
the	O
DFz2C	O
granules	O
(	O
Fig	O
.	O
3E	O
,	O
G	O
;	O
SF3B	O
;	O
N	O
=	O
29	O
animals	O
;	O
93	O
foci	O
)	O
,	O
which	O
correlates	O
well	O
with	O
our	O
observations	O
of	O
DFz2C	O
/	O
LamC	O
foci	O
at	O
the	O
light	O
level	O
.	O

A	O
fast	O
and	O
accurate	O
method	O
is	O
reported	O
to	O
generate	O
distance	O
constraints	O
between	O
juxtaposited	O
amino	O
acids	O
and	O
to	O
validate	O
molecular	O
models	O
of	O
halophilic	O
protein	O
complexes	O
.	O

Proteasomal	B-Complex
20S	I-Complex
core	I-Complex
particles	I-Complex
(	O
CPs	B-Complex
)	O
from	O
the	O
haloarchaeon	O
Haloferax	O
volcanii	O
were	O
used	O
to	O
investigate	O
the	O
quaternary	O
structure	O
of	O
halophilic	O
proteins	O
based	O
on	O
their	O
symmetrical	O
,	O
yet	O
distinct	O
subunit	O
composition	O
.	O

Proteasomal	B-Complex
CPs	I-Complex
are	O
cylindrical	O
barrel	O
-	O
like	O
structures	O
of	O
four	O
-	O
stacked	O
homoheptameric	O
rings	O
of	O
Alfa	O
-	O
and	O
Beta	O
-	O
type	O
subunits	O
organized	O
in	O
Alfa	O
(	O
7	O
)	O
Beta	O
(	O
7	O
)	O
Beta	O
(	O
7	O
)	O
Alfa	O
(	O
7	O
)	O
stoichiometry	O
.	O

The	O
CPs	B-Complex
of	O
H	O
.	O
volcanii	O
are	O
formed	O
from	O
a	O
single	O
type	O
of	O
Beta	O
subunit	O
associated	O
with	O
Alfa1	O
and	O
/	O
or	O
Alfa2	O
subunits	O
.	O

Tandem	O
affinity	O
chromatography	O
and	O
new	O
genetic	O
constructs	O
were	O
used	O
to	O
separately	O
isolate	O
Alfa1	O
(	O
7	O
)	O
Beta	O
(	O
7	O
)	O
Beta	O
(	O
7	O
)	O
Alfa1	O
(	O
7	O
)	O
and	O
Alfa2	O
(	O
7	O
)	O
Beta	O
(	O
7	O
)	O
Beta	O
(	O
7	O
)	O
Alfa2	O
(	O
7	O
)	O
CPs	B-Complex
from	O
H	O
.	O
volcanii	O
.	O

Chemically	O
cross	O
-	O
linked	O
peptides	O
of	O
the	O
H	O
.	O
volcanii	O
CPs	B-Complex
were	O
analyzed	O
by	O
high	O
-	O
performance	O
mass	O
spectrometry	O
and	O
an	O
open	O
modification	O
search	O
strategy	O
to	O
first	O
generate	O
and	O
then	O
to	O
interpret	O
the	O
resulting	O
tandem	O
mass	O
spectrometric	O
data	O
.	O

Distance	O
constraints	O
obtained	O
by	O
chemical	O
cross	O
-	O
linking	O
mass	O
spectrometry	O
,	O
together	O
with	O
the	O
available	O
structural	O
data	O
of	O
nonhalophilic	O
CPs	B-Complex
,	O
facilitated	O
the	O
selection	O
of	O
accurate	O
models	O
of	O
H	O
.	O
volcanii	O
proteasomal	B-Complex
CPs	I-Complex
composed	O
of	O
Alfa1	O
-	O
,	O
Alfa2	O
-	O
,	O
and	O
Beta	O
-	O
homoheptameric	O
rings	O
from	O
several	O
different	O
possible	O
structures	O
from	O
Protein	O
Data	O
Bank	O
.	O

Post	O
-	O
translational	O
modification	O
of	O
bovine	O
pro	O
-	O
opiomelanocortin	O
.	O

Tyrosine	O
sulfation	O
and	O
pyroglutamate	O
formation	O
,	O
a	O
mass	O
spectrometric	O
study	O
.	O

The	O
amino	O
-	O
terminal	O
fragment	O
of	O
beta	O
-	O
lipotropin	O
(	O
i	O
.	O
e	O
.	O
beta	O
-	O
lipotropin	O
(	O
1	O
-	O
40	O
)	O
)	O
and	O
joining	O
peptide	O
portions	O
of	O
pro	O
-	O
opiomelanocortin	O
have	O
been	O
purified	O
from	O
extracts	O
of	O
bovine	O
posterior	O
pituitaries	O
.	O

Peptides	O
were	O
purified	O
using	O
a	O
combination	O
of	O
reversed	O
-	O
phase	O
and	O
ion	O
-	O
exchange	O
batch	O
extraction	O
procedures	O
followed	O
by	O
reversed	O
-	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
.	O

beta	O
-	O
Lipotropin	O
(	O
1	O
-	O
40	O
)	O
was	O
found	O
to	O
consist	O
of	O
four	O
major	O
components	O
while	O
joining	O
peptide	O
was	O
found	O
to	O
consist	O
of	O
two	O
major	O
components	O
.	O

Fast	O
atom	O
bombardment	O
-	O
mass	O
spectrometric	O
analysis	O
of	O
the	O
tryptic	O
fragments	O
of	O
both	O
peptides	O
revealed	O
that	O
the	O
observed	O
heterogeneity	O
could	O
be	O
explained	O
in	O
terms	O
of	O
post	O
-	O
translational	O
modifications	O
.	O

beta	O
-	O
Lipotropin	O
(	O
1	O
-	O
40	O
)	O
was	O
found	O
to	O
be	O
sulfated	O
at	O
tyrosine	O
residue	O
28	O
to	O
an	O
extent	O
of	O
about	O
50	O
%	O
.	O

The	O
tyrosine	O
residue	O
in	O
beta	O
-	O
lipotropin	O
(	O
1	O
-	O
40	O
)	O
is	O
situated	O
within	O
an	O
amino	O
acid	O
sequence	O
with	O
a	O
preponderance	O
of	O
glutamate	O
residues	O
.	O

Sulfation	O
of	O
this	O
amino	O
acid	O
residue	O
is	O
entirely	O
compatible	O
with	O
the	O
known	O
primary	O
structure	O
requirements	O
of	O
the	O
sulfotransferase	O
enzyme	O
located	O
in	O
the	O
trans	O
-	O
Golgi	O
fraction	O
.	O

Both	O
beta	O
-	O
lipotropin	O
(	O
1	O
-	O
40	O
)	O
and	O
joining	O
peptide	O
were	O
found	O
to	O
have	O
pyroglutamate	O
at	O
their	O
amino	O
termini	O
to	O
an	O
extent	O
of	O
about	O
50	O
%	O
.	O

The	O
cDNA	O
sequence	O
for	O
bovine	O
pro	O
-	O
opiomelanocortin	O
predicts	O
the	O
presence	O
of	O
glutamic	O
acid	O
at	O
position	O
1	O
of	O
both	O
peptides	O
.	O

Pyroglutamate	O
is	O
normally	O
formed	O
through	O
the	O
cyclization	O
of	O
glutamine	O
.	O

This	O
reaction	O
is	O
thought	O
to	O
be	O
catalyzed	O
by	O
a	O
pyroglutamate	O
forming	O
enzyme	O
located	O
within	O
the	O
secretory	O
granule	O
fraction	O
.	O

Under	O
certain	O
circumstances	O
peptides	O
with	O
glutamate	O
at	O
their	O
amino	O
termini	O
may	O
act	O
as	O
substrates	O
for	O
this	O
enzyme	O
.	O

Replication	O
of	O
the	O
2	O
,	O
6	O
-	O
diamino	O
-	O
4	O
-	O
hydroxy	O
-	O
N	O
(	O
5	O
)	O
-	O
(	O
methyl	O
)	O
-	O
formamidopyrimidine	O
(	O
MeFapy	O
-	O
dGuo	O
)	O
adduct	O
by	O
eukaryotic	O
DNA	B-OOS
polymerases	I-OOS
.	O

N	O
(	O
6	O
)	O
-	O
(	O
2	O
-	O
Deoxy	O
-	O
d	O
-	O
erythro	O
-	O
pentofuranosyl	O
)	O
-	O
2	O
,	O
6	O
-	O
diamino	O
-	O
3	O
,	O
4	O
-	O
dihydro	O
-	O
4	O
-	O
oxo	O
-	O
5	O
-	O
N	O
-	O
methylformamidopyrimidine	O
(	O
MeFapy	O
-	O
dGuo	O
)	O
has	O
been	O
identified	O
as	O
a	O
stable	O
DNA	O
adduct	O
that	O
arises	O
from	O
the	O
reaction	O
of	O
DNA	O
with	O
a	O
variety	O
of	O
methylating	O
agents	O
.	O

Since	O
this	O
lesion	O
persists	O
in	O
DNA	O
and	O
may	O
contribute	O
to	O
the	O
overall	O
mutagenesis	O
from	O
electrophilic	O
methylating	O
agents	O
,	O
the	O
MeFapy	O
-	O
dGuo	O
lesion	O
was	O
incorporated	O
into	O
oligonucleotides	O
,	O
and	O
its	O
replication	O
bypass	O
was	O
examined	O
in	O
vitro	O
with	O
a	O
panel	O
of	O
eukaryotic	O
high	O
fidelity	O
(	O
hPols	O
Alfa	O
,	O
Beta	O
,	O
and	O
Delta	O
/	O
PCNA	O
)	O
and	O
translesion	O
(	O
hPols	O
n	O
,	O
K	O
,	O
l	O
,	O
Rev1	O
,	O
nu	O
,	O
and	O
yPol	O
Zeta	O
)	O
polymerases	O
to	O
address	O
its	O
miscoding	O
potential	O
.	O

The	O
MeFapy	O
-	O
dGuo	O
was	O
found	O
to	O
be	O
a	O
strong	O
block	O
to	O
the	O
high	O
fidelity	O
polymerases	O
at	O
either	O
the	O
insertion	O
or	O
the	O
extension	O
step	O
.	O

Efficient	O
translesion	O
synthesis	O
was	O
observed	O
for	O
hPols	O
n	O
and	O
K	O
,	O
and	O
the	O
combined	O
activities	O
of	O
hRev1	O
and	O
yPol	O
Zeta	O
.	O

The	O
nucleotide	O
sequences	O
of	O
the	O
extension	O
products	O
were	O
determined	O
by	O
mass	O
spectrometry	O
.	O

The	O
error	O
-	O
free	O
extension	O
product	O
was	O
the	O
most	O
abundant	O
product	O
observed	O
for	O
each	O
polymerase	O
.	O

Misreplication	O
products	O
,	O
which	O
included	O
misinsertion	O
of	O
Thy	O
,	O
Gua	O
,	O
and	O
Ade	O
opposite	O
the	O
MeFapy	O
-	O
dGuo	O
lesion	O
,	O
as	O
well	O
as	O
an	O
interesting	O
one	O
-	O
nucleotide	O
deletion	O
product	O
,	O
were	O
observed	O
when	O
hPols	O
n	O
and	O
K	O
were	O
employed	O
;	O
these	O
events	O
accounted	O
for	O
8	O
-	O
29	O
%	O
of	O
the	O
total	O
extension	O
products	O
observed	O
.	O

The	O
distribution	O
and	O
abundance	O
of	O
the	O
misreplication	O
products	O
were	O
dependent	O
on	O
the	O
polymerases	O
and	O
local	O
sequence	O
context	O
of	O
the	O
lesion	O
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
although	O
MeFapy	O
-	O
dGuo	O
adducts	O
represent	O
a	O
relatively	O
minor	O
proportion	O
of	O
the	O
total	O
alkylated	O
lesions	O
,	O
their	O
miscoding	O
potentials	O
could	O
significantly	O
contribute	O
to	O
genomic	O
instability	O
.	O

Given	O
the	O
role	O
of	O
Ubp9	O
,	O
Ubp13	O
and	O
Duf1	O
for	O
normal	O
mitochondria	O
function	O
,	O
we	O
first	O
checked	O
the	O
localization	O
of	O
these	O
three	O
proteins	O
.	O

We	O
found	O
that	O
these	O
three	O
proteins	O
had	O
similar	O
distributions	O
:	O
GFP	O
-	O
tagged	O
proteins	O
were	O
found	O
mostly	O
in	O
the	O
cytoplasm	O
,	O
in	O
various	O
growth	O
conditions	O
(	O
data	O
not	O
shown	O
)	O
,	O
as	O
described	O
in	O
databases	O
for	O
Ubp9	O
and	O
Duf1	O
.	O

Biochemical	O
fractionation	O
of	O
chromosomal	O
-	O
encoded	O
HA	O
-	O
tagged	O
proteins	O
indicated	O
that	O
,	O
in	O
addition	O
to	O
the	O
cytoplasmic	O
soluble	O
fraction	O
,	O
these	O
proteins	O
also	O
display	O
a	O
membrane	O
-	O
bound	O
fraction	O
,	O
possibly	O
associated	O
with	O
mitochondria	O
(	O
Supplemental	O
Fig	O
.	O
S2	O
B	O
-	O
C	O
)	O
.	O

HEK	O
-	O
293	O
,	O
HT	O
-	O
22	O
cells	O
and	O
N2A	O
cells	O
were	O
grown	O
in	O
a	O
humid	O
atmosphere	O
of	O
5	O
%	O
CO2	O
at	O
37degreesC	O
in	O
DMEM	O
supplemented	O
with	O
10	O
%	O
FBS	O
,	O
L	O
-	O
glutamine	O
(	O
2mM	O
)	O
,	O
penicillin	O
(	O
100units	O
/	O
ml	O
)	O
,	O
and	O
streptomycin	O
(	O
100	O
microg	O
/	O
ml	O
)	O
.	O

Primary	O
astrocytes	O
were	O
grown	O
in	O
DMEM	O
supplemented	O
with	O
10	O
%	O
FBS	O
,	O
L	O
-	O
glutamine	O
(	O
2	O
mM	O
)	O
,	O
penicillin	O
(	O
100	O
units	O
/	O
ml	O
)	O
,	O
streptomycin	O
(	O
100	O
microg	O
/	O
ml	O
)	O
and	O
sodium	O
pyruvate	O
(	O
1	O
mM	O
)	O
.	O

Primary	O
astrocytes	O
were	O
prepared	O
from	O
mouse	O
cortex	O
as	O
described	O
.	O

The	O
purity	O
of	O
the	O
culture	O
was	O
assessed	O
by	O
immunofluorescence	O
using	O
GFAP	O
as	O
an	O
astrocyte	O
marker	O
and	O
85	O
-	O
95	O
%	O
of	O
the	O
cells	O
are	O
GFAP	O
positive	O
.	O

Dissociated	O
cortical	O
neurons	O
were	O
prepared	O
from	O
E18	O
mice	O
as	O
described	O
.	O

HEK	O
-	O
293	O
cells	O
were	O
transfected	O
with	O
polyfect	O
(	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
and	O
HT	O
-	O
22	O
and	O
N2A	O
cells	O
were	O
transfected	O
with	O
lipofectamine	O
(	O
Invitrogen	O
,	O
Grand	O
Island	O
,	O
NY	O
)	O
.	O

VeA	O
bridges	O
VelB	O
and	O
LaeA	O
in	O
the	O
trimeric	O
VelB	O
-	O
VeA	O
-	O
LaeA	O
complex	O
.	O

We	O
addressed	O
whether	O
AnFus3	O
activity	O
affects	O
complex	O
formation	O
.	O

VeA	O
protein	O
levels	O
(	O
Figure	O
2C	O
)	O
were	O
similar	O
in	O
wild	O
type	O
and	O
mpkB	O
mutant	O
strains	O
.	O

velB	O
RNA	O
was	O
unchanged	O
whereas	O
laeA	O
transcripts	O
were	O
downregulated	O
as	O
previously	O
reported	O
(	O
Figure	O
S2A	O
)	O
.	O

TAP	O
purification	O
of	O
natively	O
expressed	O
VeA	O
:	O
:	O
cTAP	O
revealed	O
that	O
under	O
conditions	O
where	O
sexual	O
development	O
was	O
normally	O
promoted	O
,	O
only	O
significantly	O
reduced	O
amounts	O
of	O
VelB	O
and	O
LaeA	O
proteins	O
were	O
enriched	O
by	O
tagged	O
VeA	O
in	O
the	O
absence	O
of	O
MpkB	O
(	O
Figure	O
2D	O
,	O
Tables	O
S2	O
and	O
S3	O
)	O
.	O

The	O
MAP	O
kinase	O
does	O
not	O
affect	O
VeA	O
nuclear	O
import	O
,	O
because	O
the	O
interaction	O
of	O
VeA	O
with	O
the	O
importin	O
KapA	O
was	O
not	O
significantly	O
affected	O
in	O
mpkB	O
mutant	O
.	O

Consistently	O
,	O
nuclear	O
import	O
of	O
the	O
subunits	O
of	O
the	O
trimeric	O
VelB	O
-	O
VeA	O
-	O
LaeA	O
complex	O
was	O
not	O
affected	O
in	O
a	O
mkkB	O
mutant	O
lacking	O
the	O
upstream	O
MAP2K	O
AnSte7	O
(	O
Figure	O
S2B	O
)	O
.	O

Lack	O
of	O
laeA	O
normally	O
causes	O
enhanced	O
VeA	O
and	O
VelB	O
expression	O
as	O
well	O
as	O
enhanced	O
complex	O
formation	O
.	O

This	O
suggests	O
that	O
decreased	O
VeA	O
-	O
VelB	O
association	O
is	O
not	O
a	O
result	O
of	O
the	O
reduced	O
levels	O
of	O
LaeA	O
in	O
mpkB	O
mutants	O
.	O

Seg1	O
controls	O
eisosome	O
assembly	O
and	O
shape	O
.	O

Eisosomes	O
are	O
stable	O
domains	O
at	O
the	O
plasma	O
membrane	O
of	O
the	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
and	O
have	O
been	O
proposed	O
to	O
function	O
in	O
endocytosis	O
.	O

Eisosomes	O
are	O
composed	O
of	O
two	O
main	O
cytoplasmic	O
proteins	O
,	O
Pil1	O
and	O
Lsp1	O
,	O
that	O
form	O
a	O
scaffold	O
around	O
furrow	O
-	O
like	O
plasma	O
membrane	O
invaginations	O
.	O

We	O
show	O
here	O
that	O
the	O
poorly	O
characterized	O
eisosome	O
protein	O
Seg1	O
/	O
Ymr086w	O
is	O
important	O
for	O
eisosome	O
biogenesis	O
and	O
architecture	O
.	O

Seg1	O
was	O
required	O
for	O
efficient	O
incorporation	O
of	O
Pil1	O
into	O
eisosomes	O
and	O
the	O
generation	O
of	O
normal	O
plasma	O
membrane	O
furrows	O
.	O

Seg1	O
preceded	O
Pil1	O
during	O
eisosome	O
formation	O
and	O
established	O
a	O
platform	O
for	O
the	O
assembly	O
of	O
other	O
eisosome	O
components	O
.	O

This	O
platform	O
was	O
further	O
shaped	O
and	O
stabilized	O
upon	O
the	O
arrival	O
of	O
Pil1	O
and	O
Lsp1	O
.	O

Moreover	O
,	O
Seg1	O
abundance	O
controlled	O
the	O
shape	O
of	O
eisosomes	O
by	O
determining	O
their	O
length	O
.	O

Similarly	O
,	O
the	O
Schizosaccharomyces	O
pombe	O
Seg1	O
-	O
like	O
protein	O
Sle1	O
was	O
necessary	O
to	O
generate	O
the	O
filamentous	O
eisosomes	O
present	O
in	O
fission	O
yeast	O
.	O

The	O
function	O
of	O
Seg1	O
in	O
the	O
stepwise	O
biogenesis	O
of	O
eisosomes	O
reveals	O
striking	O
architectural	O
similarities	O
between	O
eisosomes	O
in	O
yeast	O
and	O
caveolae	O
in	O
mammals	O
.	O

Structural	O
flexibility	O
regulates	O
phosphopeptide	O
-	O
binding	O
activity	O
of	O
the	O
tyrosine	O
kinase	O
binding	O
domain	O
of	O
Cbl	O
-	O
c	O
.	O

Through	O
their	O
ubiquitin	O
ligase	O
activity	O
,	O
Cbl	O
-	O
family	O
proteins	O
suppress	O
signalling	O
mediated	O
by	O
protein	O
-	O
tyrosine	O
kinases	O
(	O
PTKs	O
)	O
,	O
but	O
can	O
also	O
function	O
as	O
adaptor	O
proteins	O
to	O
positively	O
regulate	O
signalling	O
.	O

The	O
tyrosine	O
kinase	O
binding	O
(	O
TKB	O
)	O
domain	O
of	O
this	O
family	O
is	O
critical	O
for	O
binding	O
with	O
tyrosine	O
-	O
phosphorylated	O
target	O
proteins	O
.	O

Here	O
,	O
we	O
analysed	O
the	O
crystal	O
structure	O
of	O
the	O
TKB	O
domain	O
of	O
Cbl	O
-	O
c	O
/	O
Cbl	O
-	O
3	O
(	O
Cbl	O
-	O
c	O
TKB	O
)	O
,	O
which	O
is	O
a	O
distinct	O
member	O
of	O
the	O
mammalian	O
Cbl	O
-	O
family	O
.	O

In	O
comparison	O
with	O
Cbl	O
TKB	O
,	O
Cbl	O
-	O
c	O
TKB	O
showed	O
restricted	O
structural	O
flexibility	O
upon	O
phosphopeptide	O
binding	O
.	O

A	O
mutation	O
in	O
Cbl	O
-	O
c	O
TKB	O
augmenting	O
this	O
flexibility	O
enhanced	O
its	O
binding	O
to	O
target	O
phosphoproteins	O
.	O

These	O
results	O
suggest	O
that	O
proteins	O
,	O
post	O
-	O
translational	O
modifications	O
or	O
mutations	O
that	O
alter	O
structural	O
flexibility	O
of	O
the	O
TKB	O
domain	O
of	O
Cbl	O
-	O
family	O
proteins	O
could	O
regulate	O
their	O
binding	O
to	O
target	O
phosphoproteins	O
and	O
thereby	O
,	O
affect	O
PTK	O
-	O
mediated	O
signalling	O
.	O

We	O
are	O
particularly	O
interested	O
in	O
understanding	O
how	O
proteins	O
with	O
well	O
-	O
known	O
roles	O
for	O
RNA	O
processing	O
contribute	O
to	O
maintaining	O
telomere	O
integrity	O
.	O

Mammalian	O
heterogeneous	O
ribonucleoprotein	O
(	O
hnRNP	O
)	O
A1	O
regulates	O
splicing	O
and	O
exports	O
mRNA	O
(	O
reviewed	O
in	O
)	O
,	O
and	O
several	O
studies	O
have	O
shown	O
its	O
role	O
in	O
telomere	O
maintenance	O
.	O

Deletion	O
in	O
hnRNP	O
A1	O
causes	O
significantly	O
short	O
telomeres	O
.	O

hnRNP	O
A1	O
also	O
interacts	O
with	O
telomeric	O
DNA	O
and	O
telomerase	B-Complex
as	O
well	O
as	O
stimulates	O
telomerase	O
-	O
dependent	O
telomere	O
maintenance	O
in	O
vivo	O
.	O

hnRNP	O
A1	O
likely	O
has	O
protective	O
roles	O
at	O
the	O
telomeres	O
.	O

The	O
Drosophila	O
MI	O
-	O
2	O
chromatin	O
-	O
remodeling	O
factor	O
regulates	O
higher	O
-	O
order	O
chromatin	O
structure	O
and	O
cohesin	B-Complex
dynamics	O
in	O
vivo	O
.	O

dMi	O
-	O
2	O
is	O
a	O
highly	O
conserved	O
ATP	O
-	O
dependent	O
chromatin	O
-	O
remodeling	O
factor	O
that	O
regulates	O
transcription	O
and	O
cell	O
fates	O
by	O
altering	O
the	O
structure	O
or	O
positioning	O
of	O
nucleosomes	O
.	O

Here	O
we	O
report	O
an	O
unanticipated	O
role	O
for	O
dMi	O
-	O
2	O
in	O
the	O
regulation	O
of	O
higher	O
-	O
order	O
chromatin	O
structure	O
in	O
Drosophila	O
.	O

Loss	O
of	O
dMi	O
-	O
2	O
function	O
causes	O
salivary	O
gland	O
polytene	O
chromosomes	O
to	O
lose	O
their	O
characteristic	O
banding	O
pattern	O
and	O
appear	O
more	O
condensed	O
than	O
normal	O
.	O

Conversely	O
,	O
increased	O
expression	O
of	O
dMi	O
-	O
2	O
triggers	O
decondensation	O
of	O
polytene	O
chromosomes	O
accompanied	O
by	O
a	O
significant	O
increase	O
in	O
nuclear	O
volume	O
;	O
this	O
effect	O
is	O
relatively	O
rapid	O
and	O
is	O
dependent	O
on	O
the	O
ATPase	O
activity	O
of	O
dMi	O
-	O
2	O
.	O

Live	O
analysis	O
revealed	O
that	O
dMi	O
-	O
2	O
disrupts	O
interactions	O
between	O
the	O
aligned	O
chromatids	O
of	O
salivary	O
gland	O
polytene	O
chromosomes	O
.	O

dMi	O
-	O
2	O
and	O
the	O
cohesin	B-Complex
complex	O
are	O
enriched	O
at	O
sites	O
of	O
active	O
transcription	O
;	O
fluorescence	O
-	O
recovery	O
after	O
photobleaching	O
(	O
FRAP	O
)	O
assays	O
showed	O
that	O
dMi	O
-	O
2	O
decreases	O
stable	O
association	O
of	O
cohesin	B-Complex
with	O
polytene	O
chromosomes	O
.	O

These	O
findings	O
demonstrate	O
that	O
dMi	O
-	O
2	O
is	O
an	O
important	O
regulator	O
of	O
both	O
chromosome	O
condensation	O
and	O
cohesin	B-Complex
binding	O
in	O
interphase	O
cells	O
.	O

NOL11	O
,	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
North	O
American	O
Indian	O
childhood	O
cirrhosis	O
,	O
is	O
required	O
for	O
pre	O
-	O
rRNA	O
transcription	O
and	O
processing	O
.	O

The	O
fundamental	O
process	O
of	O
ribosome	B-OOS
biogenesis	O
requires	O
hundreds	O
of	O
factors	O
and	O
takes	O
place	O
in	O
the	O
nucleolus	O
.	O

This	O
process	O
has	O
been	O
most	O
thoroughly	O
characterized	O
in	O
baker	O
'	O
s	O
yeast	O
and	O
is	O
generally	O
well	O
conserved	O
from	O
yeast	O
to	O
humans	O
.	O

However	O
,	O
some	O
of	O
the	O
required	O
proteins	O
in	O
yeast	O
are	O
not	O
found	O
in	O
humans	O
,	O
raising	O
the	O
possibility	O
that	O
they	O
have	O
been	O
replaced	O
by	O
functional	O
analogs	O
.	O

Our	O
objective	O
was	O
to	O
identify	O
non	O
-	O
conserved	O
interaction	O
partners	O
for	O
the	O
human	O
ribosome	B-OOS
biogenesis	O
factor	O
,	O
hUTP4	O
/	O
Cirhin	O
,	O
since	O
the	O
R565W	O
mutation	O
in	O
the	O
C	O
-	O
terminus	O
of	O
hUTP4	O
/	O
Cirhin	O
was	O
reported	O
to	O
cause	O
North	O
American	O
Indian	O
childhood	O
cirrhosis	O
(	O
NAIC	O
)	O
.	O

By	O
screening	O
a	O
yeast	O
two	O
-	O
hybrid	O
cDNA	O
library	O
derived	O
from	O
human	O
liver	O
,	O
and	O
through	O
affinity	O
purification	O
followed	O
by	O
mass	O
spectrometry	O
,	O
we	O
identified	O
an	O
uncharacterized	O
nucleolar	O
protein	O
,	O
NOL11	O
,	O
as	O
an	O
interaction	O
partner	O
for	O
hUTP4	O
/	O
Cirhin	O
.	O

Bioinformatic	O
analysis	O
revealed	O
that	O
NOL11	O
is	O
conserved	O
throughout	O
metazoans	O
and	O
their	O
immediate	O
ancestors	O
but	O
is	O
not	O
found	O
in	O
any	O
other	O
phylogenetic	O
groups	O
.	O

Co	O
-	O
immunoprecipitation	O
experiments	O
show	O
that	O
NOL11	O
is	O
a	O
component	O
of	O
the	O
human	O
ribosomal	B-Complex
small	I-Complex
subunit	I-Complex
(	I-Complex
SSU	I-Complex
)	I-Complex
processome	I-Complex
.	O

siRNA	O
knockdown	O
of	O
NOL11	O
revealed	O
that	O
it	O
is	O
involved	O
in	O
the	O
cleavage	O
steps	O
required	O
to	O
generate	O
the	O
mature	O
18S	O
rRNA	O
and	O
is	O
required	O
for	O
optimal	O
rDNA	O
transcription	O
.	O

Furthermore	O
,	O
abnormal	O
nucleolar	O
morphology	O
results	O
from	O
the	O
absence	O
of	O
NOL11	O
.	O

Finally	O
,	O
yeast	O
two	O
-	O
hybrid	O
analysis	O
shows	O
that	O
NOL11	O
interacts	O
with	O
the	O
C	O
-	O
terminus	O
of	O
hUTP4	O
/	O
Cirhin	O
and	O
that	O
the	O
R565W	O
mutation	O
partially	O
disrupts	O
this	O
interaction	O
.	O

We	O
have	O
therefore	O
identified	O
NOL11	O
as	O
a	O
novel	O
protein	O
required	O
for	O
the	O
early	O
stages	O
of	O
ribosome	B-OOS
biogenesis	O
in	O
humans	O
.	O

Our	O
results	O
further	O
implicate	O
a	O
role	O
for	O
NOL11	O
in	O
the	O
pathogenesis	O
of	O
NAIC	O
.	O

Similar	O
to	O
the	O
pathogen	O
protein	O
EspFU	O
,	O
the	O
identified	O
cellular	O
ligands	O
of	O
IRTKS	O
/	O
IRSp53	O
SH3	O
,	O
namely	O
Shank	O
1	O
-	O
3	O
and	O
Eps8	O
also	O
contain	O
a	O
tandem	O
PxxP	O
motif	O
.	O

However	O
,	O
a	O
pathogen	O
protein	O
would	O
be	O
expected	O
to	O
have	O
a	O
higher	O
SH3	O
binding	O
affinity	O
to	O
displace	O
cellular	O
ligands	O
in	O
order	O
to	O
hijack	O
IRTKS	O
/	O
IRSp53	O
-	O
mediated	O
signaling	O
pathways	O
of	O
the	O
host	O
cell	O
.	O

To	O
test	O
this	O
assumption	O
we	O
compared	O
the	O
binding	O
affinities	O
obtained	O
using	O
NMR	O
CSP	O
(	O
chemical	O
shift	O
perturbation	O
)	O
mapping	O
and	O
ITC	O
of	O
EspFU	O
R475	O
and	O
a	O
20	O
-	O
residue	O
peptide	O
derived	O
from	O
Eps8	O
containing	O
the	O
tandem	O
PxxP	O
IRTKS	O
recognition	O
motif	O
(	O
see	O
Table	O
3	O
)	O
.	O

The	O
CSP	O
mapping	O
showed	O
that	O
these	O
peptides	O
bound	O
to	O
the	O
same	O
binding	O
site	O
on	O
IRTKS	O
SH3	O
as	O
peptide	O
addition	O
induced	O
chemical	O
shift	O
changes	O
for	O
the	O
same	O
set	O
of	O
NH	O
correlations	O
in	O
the	O
15N	O
-	O
HSQC	O
spectrum	O
of	O
15N	O
-	O
labeled	O
IRTKS	O
SH3	O
(	O
Fig	O
.	O
3	O
,	O
upper	O
panels	O
)	O
.	O

However	O
,	O
the	O
binding	O
affinities	O
were	O
different	O
.	O

EspFU	O
was	O
clearly	O
a	O
strong	O
binder	O
as	O
two	O
sets	O
of	O
peaks	O
were	O
observed	O
in	O
subequimolar	O
concentrations	O
,	O
while	O
CSPs	O
observed	O
for	O
the	O
Eps8	O
peptide	O
were	O
in	O
the	O
regime	O
of	O
intermediate	O
exchange	O
in	O
the	O
NMR	O
timescale	O
,	O
indicating	O
lower	O
affinity	O
.	O

In	O
agreement	O
with	O
CSP	O
,	O
we	O
obtained	O
dissociation	O
constants	O
Kd	O
(	O
EspFU	O
)	O
=	O
0	O
.	O
5	O
muM	O
vs	O
.	O
Kd	O
(	O
Eps8	O
)	O
=	O
30	O
.	O
5	O
muM	O
,	O
using	O
ITC	O
.	O

These	O
data	O
showed	O
that	O
the	O
pathogenic	O
EspFU	O
is	O
able	O
to	O
usurp	O
this	O
host	O
cell	O
signaling	O
pathway	O
by	O
superseding	O
the	O
cellular	O
ligand	O
with	O
approximately	O
60	O
times	O
higher	O
affinity	O
against	O
its	O
target	O
.	O

Our	O
experiments	O
suggest	O
a	O
major	O
function	O
for	O
MSP	O
-	O
300	O
both	O
in	O
promoting	O
nuclear	O
spacing	O
(	O
cooperatively	O
with	O
Klar	O
)	O
and	O
in	O
mediating	O
anchoring	O
of	O
the	O
nuclei	O
as	O
well	O
as	O
other	O
organelles	O
to	O
the	O
muscle	O
core	O
myofibrillar	O
domain	O
.	O

The	O
spectrin	O
repeats	O
domain	O
is	O
critical	O
for	O
this	O
latter	O
function	O
,	O
as	O
most	O
of	O
it	O
is	O
eliminated	O
in	O
msp	O
-	O
300Delta3	O
'	O
.	O

Similarly	O
to	O
other	O
proteins	O
containing	O
the	O
spectrin	O
repeats	O
domain	O
,	O
the	O
multiple	O
(	O
52	O
)	O
spectrin	O
repeats	O
are	O
likely	O
to	O
promote	O
formation	O
of	O
MSP	O
-	O
300	O
dimers	O
that	O
form	O
elongated	O
filaments	O
capable	O
of	O
connecting	O
between	O
different	O
organelles	O
and	O
the	O
cytoskeleton	O
.	O

In	O
striated	O
muscle	O
,	O
we	O
suggest	O
that	O
such	O
filaments	O
connect	O
between	O
the	O
various	O
organelles	O
and	O
the	O
Z	O
-	O
discs	O
.	O

The	O
association	O
of	O
these	O
filaments	O
with	O
the	O
Z	O
-	O
discs	O
requires	O
the	O
activity	O
of	O
d	O
-	O
Titin	O
/	O
Sallimus	O
,	O
another	O
large	O
protein	O
that	O
associates	O
with	O
the	O
Z	O
-	O
discs	O
.	O

The	O
function	O
of	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
MSP	O
-	O
300	O
containing	O
the	O
calponin	O
-	O
homology	O
(	O
CH	O
)	O
actin	O
-	O
binding	O
motifs	O
is	O
still	O
elusive	O
because	O
of	O
the	O
early	O
lethality	O
of	O
the	O
homozygous	O
mutants	O
.	O

Intracellular	O
calcium	O
(	O
Ca2	O
+	O
)	O
homeostasis	O
plays	O
a	O
crucial	O
role	O
in	O
neuron	O
survival	O
and	O
function	O
.	O

Neuronal	O
Ca2	O
+	O
influx	O
is	O
mediated	O
through	O
voltage	O
-	O
gated	O
channels	O
and	O
/	O
or	O
receptor	O
-	O
operated	O
channels	O
activated	O
by	O
neurotransmitters	O
.	O

Intracellular	O
Ca2	O
+	O
release	O
occurs	O
via	O
ryanodine	O
receptors	O
(	O
RyRs	O
)	O
and	O
inositol	O
(	O
1	O
,	O
4	O
,	O
5	O
)	O
-	O
trisphosphate	O
receptors	O
(	O
IP3Rs	O
)	O
on	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
.	O

There	O
are	O
three	O
isoforms	O
of	O
RyR	O
in	O
the	O
brain	O
.	O

RyR1	O
and	O
RyR2	O
are	O
both	O
expressed	O
in	O
the	O
hippocampus	O
.	O

RyR2	O
expression	O
is	O
up	O
-	O
regulated	O
in	O
rat	O
hippocampus	O
following	O
intensive	O
training	O
tasks	O
.	O

RyR2	O
knock	O
-	O
down	O
impairs	O
performance	O
of	O
mice	O
in	O
passive	O
avoidance	O
tests	O
whereas	O
RyR1	O
knock	O
-	O
down	O
did	O
not	O
.	O

Anchored	O
phosphatases	O
modulate	O
glucose	O
homeostasis	O
.	O

Endocrine	O
release	O
of	O
insulin	O
principally	O
controls	O
glucose	O
homeostasis	O
.	O

Nutrient	O
-	O
induced	O
exocytosis	O
of	O
insulin	O
granules	O
from	O
pancreatic	O
beta	O
-	O
cells	O
involves	O
ion	O
channels	O
and	O
mobilization	O
of	O
Ca	O
(	O
2	O
+	O
)	O
and	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
signalling	O
pathways	O
.	O

Whole	O
-	O
animal	O
physiology	O
,	O
islet	O
studies	O
and	O
live	O
-	O
beta	O
-	O
cell	O
imaging	O
approaches	O
reveal	O
that	O
ablation	O
of	O
the	O
kinase	O
/	O
phosphatase	O
anchoring	O
protein	O
AKAP150	O
impairs	O
insulin	O
secretion	O
in	O
mice	O
.	O

Loss	O
of	O
AKAP150	O
impacts	O
L	O
-	O
type	O
Ca	O
(	O
2	O
+	O
)	O
currents	O
,	O
and	O
attenuates	O
cytoplasmic	O
accumulation	O
of	O
Ca	O
(	O
2	O
+	O
)	O
and	O
cAMP	O
in	O
beta	O
-	O
cells	O
.	O

Yet	O
surprisingly	O
AKAP150	O
null	O
animals	O
display	O
improved	O
glucose	O
handling	O
and	O
heightened	O
insulin	O
sensitivity	O
in	O
skeletal	O
muscle	O
.	O

More	O
refined	O
analyses	O
of	O
AKAP150	O
knock	O
-	O
in	O
mice	O
unable	O
to	O
anchor	O
protein	O
kinase	O
A	O
or	O
protein	O
phosphatase	O
2B	O
uncover	O
an	O
unexpected	O
observation	O
that	O
tethering	O
of	O
phosphatases	O
to	O
a	O
seven	O
-	O
residue	O
sequence	O
of	O
the	O
anchoring	O
protein	O
is	O
the	O
predominant	O
molecular	O
event	O
underlying	O
these	O
metabolic	O
phenotypes	O
.	O

Thus	O
anchored	O
signalling	O
events	O
that	O
facilitate	O
insulin	O
secretion	O
and	O
glucose	O
homeostasis	O
may	O
be	O
set	O
by	O
AKAP150	O
associated	O
phosphatase	O
activity	O
.	O

Small	O
-	O
subunit	O
(	O
40S	B-Complex
)	O
18S	O
rRNA	O
in	O
Saccharomyces	O
cerevisiae	O
contains	O
only	O
three	O
base	O
methylations	O
.	O

Two	O
of	O
these	O
,	O
at	O
positions	O
A1781	O
and	O
A1782	O
,	O
are	O
catalyzed	O
by	O
Dim1	O
.	O

Dim1	O
is	O
essential	O
for	O
viability	O
,	O
but	O
the	O
methylations	O
catalyzed	O
by	O
it	O
are	O
not	O
.	O

The	O
third	O
base	O
methylation	O
,	O
at	O
position	O
G1575	O
,	O
is	O
catalyzed	O
by	O
Bud23	O
.	O

The	O
methylated	O
guanosine	O
is	O
located	O
in	O
the	O
P	O
-	O
site	O
of	O
the	O
small	O
subunit	O
,	O
and	O
its	O
methylation	O
is	O
conserved	O
throughout	O
eukaryotes	O
.	O

However	O
,	O
similar	O
to	O
Dim1	O
and	O
despite	O
its	O
seemingly	O
important	O
location	O
,	O
methylation	O
of	O
G1575	O
is	O
also	O
not	O
essential	O
.	O

Large	O
-	O
subunit	O
(	O
60S	B-Complex
)	O
25S	O
rRNA	O
contains	O
at	O
least	O
six	O
base	O
methylations	O
,	O
but	O
none	O
of	O
the	O
methyltransferases	O
responsible	O
for	O
these	O
modifications	O
has	O
been	O
characterized	O
.	O

RhoJ	O
regulates	O
melanoma	O
chemoresistance	O
by	O
suppressing	O
pathways	O
that	O
sense	O
DNA	O
damage	O
.	O

Melanomas	O
resist	O
conventional	O
chemotherapeutics	O
,	O
in	O
part	O
,	O
through	O
intrinsic	O
disrespect	O
of	O
apoptotic	O
checkpoint	O
activation	O
.	O

In	O
this	O
study	O
,	O
using	O
an	O
unbiased	O
genome	O
-	O
wide	O
RNA	O
interference	O
screen	O
,	O
we	O
identified	O
RhoJ	O
and	O
its	O
effector	O
PAK1	O
,	O
as	O
key	O
modulators	O
of	O
melanoma	O
cell	O
sensitivity	O
to	O
DNA	O
damage	O
.	O

We	O
find	O
that	O
RhoJ	O
activates	O
PAK1	O
in	O
response	O
to	O
drug	O
-	O
induced	O
DNA	O
damage	O
,	O
which	O
then	O
uncouples	O
ATR	O
from	O
its	O
downstream	O
effectors	O
,	O
ultimately	O
resulting	O
in	O
a	O
blunted	O
DNA	O
damage	O
response	O
(	O
DDR	O
)	O
.	O

In	O
addition	O
,	O
ATR	O
suppression	O
leads	O
to	O
the	O
decreased	O
phosphorylation	O
of	O
ATF2	O
and	O
consequent	O
increased	O
expression	O
of	O
the	O
melanocyte	O
survival	O
gene	O
Sox10	O
resulting	O
in	O
a	O
higher	O
DDR	O
threshold	O
required	O
to	O
engage	O
melanoma	O
cell	O
death	O
.	O

In	O
the	O
setting	O
of	O
normal	O
melanocyte	O
behavior	O
,	O
this	O
regulatory	O
relationship	O
may	O
facilitate	O
appropriate	O
epidermal	O
melanization	O
in	O
response	O
to	O
UV	O
-	O
induced	O
DNA	O
damage	O
.	O

However	O
,	O
pathologic	O
pathway	O
activation	O
during	O
oncogenic	O
transformation	O
produces	O
a	O
tumor	O
that	O
is	O
intrinsically	O
resistant	O
to	O
chemotherapy	O
and	O
has	O
the	O
propensity	O
to	O
accumulate	O
additional	O
mutations	O
.	O

These	O
findings	O
identify	O
DNA	O
damage	O
agents	O
and	O
pharmacologic	O
inhibitors	O
of	O
RhoJ	O
/	O
PAK1	O
as	O
novel	O
synergistic	O
agents	O
that	O
can	O
be	O
used	O
to	O
treat	O
melanomas	O
that	O
are	O
resistant	O
to	O
conventional	O
chemotherapies	O
.	O

We	O
also	O
tested	O
the	O
de	O
novo	O
folding	O
of	O
the	O
individual	O
mtHsp70	O
domains	O
.	O

To	O
mimic	O
the	O
two	O
-	O
domain	O
structure	O
of	O
full	O
-	O
length	O
mtHsp70	O
,	O
the	O
individual	O
domains	O
were	O
analyzed	O
in	O
the	O
context	O
of	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
fusion	O
proteins	O
,	O
from	O
now	O
on	O
referred	O
to	O
as	O
PBD	O
-	O
DHFR	O
and	O
ATPase	O
-	O
DHFR	O
,	O
respectively	O
,	O
in	O
which	O
the	O
PBD	O
and	O
the	O
ATPase	O
domain	O
were	O
each	O
fused	O
with	O
an	O
80	O
-	O
aa	O
-	O
residue	O
-	O
long	O
spacer	O
to	O
the	O
mouse	O
DHFR	O
.	O

Trypsin	O
treatment	O
of	O
imported	O
PBD	O
-	O
DHFR	O
generated	O
two	O
protease	O
-	O
resistant	O
fragments	O
,	O
corresponding	O
to	O
the	O
PBD	O
and	O
the	O
DHFR	O
domain	O
(	O
Fig	O
.	O
1	O
B	O
)	O
.	O

The	O
kinetics	O
of	O
import	O
of	O
PBD	O
-	O
DHFR	O
and	O
of	O
the	O
formation	O
of	O
the	O
protease	O
-	O
resistant	O
fragments	O
were	O
very	O
similar	O
,	O
indicating	O
that	O
the	O
PBD	O
-	O
DHFR	O
folds	O
immediately	O
after	O
its	O
import	O
into	O
the	O
mitochondrial	O
matrix	O
.	O

In	O
the	O
case	O
of	O
the	O
ATPase	O
-	O
DHFR	O
construct	O
,	O
the	O
DHFR	O
domain	O
was	O
protease	O
resistant	O
,	O
but	O
the	O
ATPase	O
domain	O
was	O
almost	O
completely	O
protease	O
sensitive	O
(	O
Fig	O
.	O
1	O
C	O
)	O
.	O

Thus	O
,	O
the	O
ATPase	O
domain	O
does	O
not	O
fold	O
properly	O
in	O
the	O
context	O
of	O
the	O
DHFR	O
fusion	O
protein	O
.	O

On	O
the	O
contrary	O
,	O
the	O
PBD	O
folds	O
independently	O
of	O
the	O
ATPase	O
domain	O
.	O

Characterization	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
-	O
binding	O
proteins	O
from	O
the	O
human	O
T	O
-	O
cell	O
line	O
Jurkat	O
.	O

The	O
transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
is	O
under	O
the	O
control	O
of	O
cellular	O
proteins	O
that	O
bind	O
to	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

Among	O
the	O
protein	O
-	O
binding	O
regions	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
is	O
the	O
transcription	O
-	O
enhancer	O
region	O
.	O

We	O
show	O
that	O
at	O
least	O
one	O
inducible	O
,	O
C1	O
,	O
and	O
one	O
constitutive	O
,	O
C2	O
,	O
protein	O
can	O
bind	O
to	O
the	O
HIV	O
enhancer	O
in	O
Jurkat	O
cells	O
.	O

The	O
two	O
proteins	O
differ	O
in	O
their	O
surface	O
charge	O
,	O
since	O
they	O
are	O
separable	O
by	O
anion	O
-	O
exchange	O
chromatography	O
.	O

Bivalent	O
cations	O
such	O
as	O
Mg2	O
+	O
and	O
Zn2	O
+	O
differentially	O
affect	O
their	O
binding	O
to	O
oligonucleotides	O
which	O
contain	O
the	O
HIV	O
-	O
enhancer	O
domain	O
.	O

Both	O
C1	O
and	O
C2	O
proteins	O
also	O
bind	O
to	O
a	O
similar	O
sequence	O
found	O
in	O
the	O
interleukin	O
-	O
2	O
-	O
receptor	O
alpha	O
-	O
subunit	O
enhancer	O
.	O

The	O
inducible	O
C1	O
protein	O
was	O
partially	O
purified	O
by	O
three	O
chromatographic	O
steps	O
and	O
characterized	O
by	O
u	O
.	O
v	O
.	O
cross	O
-	O
linking	O
as	O
a	O
47	O
kDa	O
protein	O
.	O

Rif2	O
promotes	O
a	O
telomere	O
fold	O
-	O
back	O
structure	O
through	O
Rpd3L	B-Complex
recruitment	O
in	O
budding	O
yeast	O
.	O

Using	O
a	O
genome	O
-	O
wide	O
screening	O
approach	O
,	O
we	O
have	O
established	O
the	O
genetic	O
requirements	O
for	O
proper	O
telomere	O
structure	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

We	O
uncovered	O
112	O
genes	O
,	O
many	O
of	O
which	O
have	O
not	O
previously	O
been	O
implicated	O
in	O
telomere	O
function	O
,	O
that	O
are	O
required	O
to	O
form	O
a	O
fold	O
-	O
back	O
structure	O
at	O
chromosome	O
ends	O
.	O

Among	O
other	O
biological	O
processes	O
,	O
lysine	O
deacetylation	O
,	O
through	O
the	O
Rpd3L	B-Complex
,	O
Rpd3S	B-Complex
,	O
and	O
Hda1	B-Complex
complexes	O
,	O
emerged	O
as	O
being	O
a	O
critical	O
regulator	O
of	O
telomere	O
structure	O
.	O

The	O
telomeric	O
-	O
bound	O
protein	O
,	O
Rif2	O
,	O
was	O
also	O
found	O
to	O
promote	O
a	O
telomere	O
fold	O
-	O
back	O
through	O
the	O
recruitment	O
of	O
Rpd3L	B-Complex
to	O
telomeres	O
.	O

In	O
the	O
absence	O
of	O
Rpd3	O
function	O
,	O
telomeres	O
have	O
an	O
increased	O
susceptibility	O
to	O
nucleolytic	O
degradation	O
,	O
telomere	O
loss	O
,	O
and	O
the	O
initiation	O
of	O
premature	O
senescence	O
,	O
suggesting	O
that	O
an	O
Rpd3	O
-	O
mediated	O
structure	O
may	O
have	O
protective	O
functions	O
.	O

Together	O
these	O
data	O
reveal	O
that	O
multiple	O
genetic	O
pathways	O
may	O
directly	O
or	O
indirectly	O
impinge	O
on	O
telomere	O
structure	O
,	O
thus	O
broadening	O
the	O
potential	O
targets	O
available	O
to	O
manipulate	O
telomere	O
function	O
.	O

A	O
)	O
Western	O
blot	O
analyses	O
of	O
TIP	O
-	O
1	O
expression	O
in	O
D54	O
,	O
U87	O
and	O
T98G	O
cells	O
in	O
which	O
TIP	O
-	O
1	O
protein	O
expression	O
was	O
genetically	O
manipulated	O
with	O
recombinant	O
plasmids	O
or	O
shRNA	O
respectively	O
.	O

Two	O
independent	O
shRNA	O
sequences	O
were	O
used	O
for	O
TIP	O
-	O
1	O
knockdown	O
.	O

B	O
)	O
Survival	O
fractions	O
of	O
D54	O
,	O
U87	O
and	O
T98G	O
cells	O
after	O
single	O
dose	O
X	O
-	O
ray	O
radiation	O
treatment	O
were	O
determined	O
with	O
clonogenic	O
assays	O
.	O

Vector	O
control	O
and	O
parental	O
cells	O
were	O
included	O
in	O
the	O
assays	O
.	O

Shown	O
are	O
representative	O
data	O
from	O
at	O
least	O
three	O
independent	O
experiments	O
performed	O
in	O
triplicate	O
.	O

To	O
determine	O
whether	O
TBC1D3	O
interacts	O
with	O
Fbw8	O
in	O
a	O
phosphorylation	O
-	O
dependent	O
manner	O
,	O
an	O
in	O
vitro	O
pull	O
-	O
down	O
experiment	O
was	O
carried	O
out	O
with	O
TBC1D3	O
bound	O
to	O
Protein	O
-	O
G	O
beads	O
(	O
TBC1D3	O
-	O
beads	O
)	O
and	O
a	O
cytosol	O
preparation	O
obtained	O
from	O
a	O
separate	O
set	O
of	O
cells	O
overexpressing	O
Fbw8	O
(	O
Fbw8	O
-	O
cytosol	O
)	O
(	O
Figure	O
6A	O
)	O
.	O

The	O
TBC1D3	O
-	O
beads	O
were	O
prepared	O
from	O
HeLa	O
cells	O
transfected	O
with	O
GFP	O
-	O
TBC1D3	O
.	O

After	O
starvation	O
,	O
the	O
cells	O
were	O
stimulated	O
with	O
or	O
without	O
FCS	O
,	O
lysed	O
and	O
TBC1D3	O
was	O
immunoprecipitated	O
with	O
anti	O
-	O
GFP	O
antibody	O
.	O

TBC1D3	O
-	O
beads	O
were	O
pre	O
-	O
incubated	O
with	O
or	O
without	O
alkaline	O
phosphatase	O
(	O
AP	O
)	O
(	O
37degreesC	O
;	O
60	O
min	O
)	O
.	O

To	O
test	O
the	O
recruitment	O
of	O
Fbw8	O
by	O
TBC1D3	O
,	O
Fbw8	O
-	O
cytosol	O
was	O
added	O
to	O
each	O
immunoprecipitate	O
.	O

The	O
TBC1D3	O
-	O
beads	O
were	O
then	O
washed	O
and	O
eluted	O
with	O
Laemmli	O
sample	O
buffer	O
.	O

Proteins	O
associated	O
with	O
the	O
anti	O
-	O
GFP	O
pull	O
-	O
downs	O
were	O
then	O
separated	O
by	O
SDS	O
-	O
PAGE	O
and	O
immunoblotted	O
for	O
Fbw8	O
.	O

Figure	O
6A	O
shows	O
that	O
in	O
the	O
absence	O
of	O
FCS	O
stimulation	O
,	O
there	O
was	O
little	O
recruitment	O
of	O
Fbw8	O
by	O
the	O
TBC1D3	O
-	O
beads	O
.	O

However	O
,	O
TBC1D3	O
-	O
Fbw8	O
binding	O
was	O
detected	O
following	O
FCS	O
stimulation	O
,	O
suggesting	O
a	O
GF	O
-	O
dependent	O
interaction	O
between	O
TBC1D3	O
and	O
Fbw8	O
.	O

Moreover	O
,	O
treatment	O
of	O
TBC1D3	O
-	O
beads	O
with	O
AP	O
abolished	O
the	O
ability	O
of	O
Fbw8	O
to	O
bind	O
to	O
TBC1D3	O
.	O

These	O
findings	O
suggested	O
that	O
FCS	O
-	O
induced	O
binding	O
of	O
Fbw8	O
to	O
TBC1D3	O
is	O
phosphorylation	O
-	O
dependent	O
.	O

Structural	O
and	O
functional	O
integration	O
of	O
the	O
PLCgamma	O
interaction	O
domains	O
critical	O
for	O
regulatory	O
mechanisms	O
and	O
signaling	O
deregulation	O
.	O

Multidomain	O
proteins	O
incorporating	O
interaction	O
domains	O
are	O
central	O
to	O
regulation	O
of	O
cellular	O
processes	O
.	O

The	O
elucidation	O
of	O
structural	O
organization	O
and	O
mechanistic	O
insights	O
into	O
many	O
of	O
these	O
proteins	O
,	O
however	O
,	O
remain	O
challenging	O
due	O
to	O
their	O
inherent	O
flexibility	O
.	O

Here	O
,	O
we	O
describe	O
the	O
organization	O
and	O
function	O
of	O
four	O
interaction	O
domains	O
in	O
PLCgamma1	O
using	O
a	O
combination	O
of	O
structural	O
biology	O
and	O
biochemical	O
approaches	O
.	O

Intramolecular	O
interactions	O
within	O
the	O
regulatory	O
region	O
center	O
on	O
the	O
cSH2	O
domain	O
,	O
the	O
only	O
domain	O
that	O
also	O
interacts	O
with	O
the	O
PLC	O
-	O
core	O
.	O

In	O
the	O
context	O
of	O
fibroblast	O
growth	O
-	O
factor	O
receptor	O
signaling	O
,	O
the	O
coordinated	O
involvement	O
of	O
nSH2	O
and	O
cSH2	O
domains	O
mediates	O
efficient	O
phosphorylation	O
of	O
PLCgamma1	O
resulting	O
in	O
the	O
interruption	O
of	O
an	O
autoinhibitory	O
interface	O
by	O
direct	O
competition	O
and	O
,	O
independently	O
,	O
dissociation	O
of	O
PLCgamma1	O
from	O
the	O
receptor	O
.	O

Further	O
structural	O
insights	O
into	O
the	O
autoinhibitory	O
surfaces	O
provide	O
a	O
framework	O
to	O
interpret	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
PLCgamma	O
isoforms	O
linked	O
to	O
immune	O
disorders	O
and	O
illustrate	O
a	O
distinct	O
mechanism	O
for	O
regulation	O
of	O
PLC	O
activity	O
by	O
common	O
interaction	O
domains	O
.	O

The	O
principal	O
forms	O
for	O
DNA	O
damage	O
induced	O
by	O
UVB	O
and	O
UVA	O
are	O
cyclobutane	O
pyrimidine	O
dimers	O
and	O
6	O
,	O
4	O
-	O
pyrimidine	O
-	O
pyrimidone	O
photoproducts	O
,	O
while	O
UVC	O
mostly	O
forms	O
dipyrimidines	O
that	O
contain	O
5	O
-	O
methylcytosine	O
.	O

These	O
photoproducts	O
are	O
mutagenic	O
and	O
block	O
DNA	O
replication	O
by	O
the	O
replicative	O
DNA	B-OOS
polymerases	I-OOS
.	O

The	O
swi7	O
-	O
1	O
mutant	O
cells	O
were	O
only	O
mildly	O
sensitive	O
to	O
UV	O
irradiation	O
(	O
Figure	O
1A	O
)	O
.	O

Cell	O
growth	O
began	O
to	O
decline	O
slightly	O
only	O
when	O
yeast	O
cells	O
were	O
subjected	O
to	O
a	O
150	O
J	O
/	O
m2	O
dose	O
of	O
UV	O
.	O

These	O
results	O
indicate	O
that	O
the	O
swi7	O
-	O
1	O
mutation	O
affects	O
the	O
ability	O
of	O
Pol	O
alpha	O
to	O
respond	O
to	O
alkylation	O
and	O
HU	O
-	O
induced	O
DNA	O
damage	O
.	O

MRI	O
analysis	O
of	O
embryos	O
15	O
.	O
5	O
days	O
post	O
coitum	O
(	O
dpc	O
)	O
.	O

Genotypes	O
are	O
indicated	O
as	O
shown	O
.	O

Sagittal	O
sections	O
through	O
the	O
left	O
kidney	O
(	O
A	O
-	O
E	O
)	O
are	O
shown	O
to	O
indicate	O
the	O
left	O
adrenal	O
gland	O
where	O
present	O
(	O
arrows	O
)	O
,	O
and	O
absent	O
(	O
arrowhead	O
)	O
.	O

Transverse	O
sections	O
through	O
the	O
thorax	O
(	O
F	O
-	O
J	O
)	O
and	O
3D	O
reconstructions	O
(	O
K	O
-	O
O	O
)	O
are	O
shown	O
to	O
demonstrate	O
cardiac	O
anatomy	O
.	O

Loss	O
of	O
Cited2	O
leads	O
to	O
adrenal	O
agenesis	O
(	O
B	O
,	O
arrowhead	O
)	O
,	O
right	O
atrial	O
isomerism	O
,	O
ventricular	O
septal	O
defect	O
(	O
VSD	O
)	O
and	O
common	O
atrium	O
(	O
G	O
)	O
,	O
and	O
abnormal	O
ventricular	O
topology	O
(	O
L	O
)	O
.	O

Embryos	O
expressing	O
only	O
the	O
T166N	O
variant	O
,	O
the	O
MRG1	O
isoform	O
,	O
or	O
full	O
length	O
human	O
CITED2	O
have	O
normal	O
adrenal	O
glands	O
and	O
hearts	O
.	O

RA	O
,	O
Right	O
Atria	O
;	O
RV	O
,	O
Right	O
Ventricle	O
;	O
LV	O
,	O
Left	O
Ventricle	O
;	O
IVS	O
,	O
Interventricular	O
Septum	O
;	O
IAS	O
,	O
Intra	O
-	O
atrial	O
Septum	O
;	O
AAo	O
,	O
Aorta	O
;	O
AoA	O
,	O
Aortic	O
Arch	O
;	O
Tr	O
,	O
Trachea	O
;	O
DAo	O
,	O
Dorsal	O
Aorta	O
;	O
LSVS	O
and	O
RSVS	O
,	O
Left	O
and	O
Right	O
Systemic	O
Venous	O
Sinus	O
.	O

Axis	O
:	O
A	O
,	O
Anterior	O
;	O
P	O
,	O
Posterior	O
;	O
V	O
,	O
Ventral	O
;	O
D	O
,	O
Dorsal	O
;	O
L	O
,	O
Left	O
;	O
R	O
,	O
Right	O
.	O

Scale	O
bars	O
:	O
0	O
.	O
5	O
mm	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
the	O
double	O
mutants	O
between	O
npr1	O
-	O
1	O
and	O
NahG	O
(	O
a	O
transgenic	O
plant	O
that	O
degrades	O
SA	O
,	O
)	O
,	O
eds5	O
(	O
a	O
mutant	O
in	O
SA	O
transport	O
,	O
)	O
,	O
and	O
sid2	O
(	O
a	O
mutant	O
in	O
SA	O
biosynthesis	O
,	O
)	O
,	O
were	O
constructed	O
and	O
tested	O
for	O
RIM	O
.	O

npr1	O
-	O
1	O
did	O
not	O
respond	O
to	O
MeJA	O
even	O
if	O
the	O
levels	O
of	O
SA	O
were	O
low	O
(	O
Figure	O
3c	O
)	O
,	O
so	O
the	O
hypothesis	O
of	O
a	O
reinforcement	O
of	O
the	O
negative	O
crosstalk	O
was	O
not	O
supported	O
.	O

Recent	O
findings	O
have	O
demonstrated	O
a	O
possible	O
role	O
of	O
the	O
TMD	O
in	O
TLR	O
activation	O
.	O

First	O
,	O
it	O
has	O
been	O
shown	O
that	O
by	O
forcing	O
the	O
TMD	O
and	O
TIR	O
domains	O
of	O
TLRs	O
to	O
be	O
in	O
a	O
dimeric	O
complex	O
using	O
constitutively	O
dimeric	O
extracellular	O
domains	O
,	O
it	O
is	O
possible	O
to	O
activate	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
pathway	O
as	O
well	O
as	O
other	O
known	O
TLR	O
gene	O
promoters	O
in	O
the	O
absence	O
of	O
ligands	O
.	O

Second	O
,	O
FRET	O
studies	O
demonstrated	O
that	O
TLR9	O
existed	O
as	O
preformed	O
dimers	O
in	O
the	O
cell	O
membrane	O
and	O
underwent	O
small	O
conformational	O
changes	O
upon	O
ligand	O
addition	O
.	O

Third	O
,	O
structural	O
modeling	O
using	O
the	O
TLR3	O
extracellular	O
domain	O
and	O
TLR10	O
TIR	O
domain	O
suggested	O
a	O
close	O
proximity	O
between	O
TMD	O
domains	O
in	O
the	O
dimeric	O
complex	O
that	O
could	O
allow	O
for	O
the	O
TMD	O
region	O
to	O
associate	O
.	O

Last	O
,	O
recent	O
studies	O
on	O
TLR4	O
have	O
demonstrated	O
the	O
importance	O
of	O
the	O
tight	O
coupling	O
of	O
the	O
extracellular	O
domain	O
and	O
TIR	O
domain	O
to	O
the	O
TMD	O
as	O
a	O
requirement	O
for	O
signaling	O
,	O
and	O
that	O
the	O
TLR4	O
extracellular	O
domain	O
prevents	O
constitutive	O
dimeric	O
activation	O
of	O
TLR4	O
in	O
the	O
absence	O
of	O
ligand	O
.	O

Based	O
on	O
these	O
findings	O
and	O
the	O
fact	O
that	O
the	O
TLRs	O
are	O
single	O
pass	O
membrane	O
proteins	O
that	O
are	O
known	O
to	O
form	O
functional	O
homo	O
-	O
and	O
heterodimers	O
we	O
asked	O
the	O
question	O
if	O
TLR	O
TMDs	O
are	O
capable	O
of	O
oligomerization	O
in	O
a	O
manner	O
analogous	O
to	O
the	O
native	O
TLRs	O
.	O

Interestingly	O
,	O
such	O
a	O
hypothesis	O
is	O
also	O
supported	O
by	O
the	O
fact	O
that	O
for	O
the	O
two	O
pairs	O
of	O
heterodimeric	O
TLRs	O
(	O
TLR2	O
/	O
1	O
,	O
TLR2	O
/	O
6	O
)	O
,	O
the	O
transmembrane	O
domain	O
sequences	O
of	O
TLR1	O
and	O
TLR6	O
are	O
almost	O
identical	O
(	O
Table	O
1	O
)	O
due	O
to	O
recent	O
evolutionary	O
divergence	O
,	O
suggesting	O
that	O
their	O
TMD	O
regions	O
possibly	O
contribute	O
to	O
their	O
association	O
with	O
TLR2	O
.	O

Our	O
results	O
demonstrate	O
that	O
isolated	O
TLR	O
TMDs	O
are	O
indeed	O
capable	O
of	O
oligomerizing	O
and	O
have	O
higher	O
propensity	O
for	O
TLR	O
interactions	O
previously	O
identified	O
.	O

Studies	O
of	O
whether	O
such	O
findings	O
apply	O
to	O
the	O
full	O
length	O
TLRs	O
are	O
currently	O
ongoing	O
.	O

Nonetheless	O
,	O
good	O
correlations	O
with	O
existing	O
structural	O
and	O
functional	O
data	O
has	O
been	O
observed	O
,	O
implying	O
that	O
such	O
interactions	O
between	O
TLR	O
TMDs	O
may	O
be	O
biologically	O
relevant	O
.	O

As	O
such	O
,	O
our	O
findings	O
may	O
provide	O
new	O
targets	O
for	O
the	O
development	O
of	O
chemotherapeutics	O
for	O
diseases	O
wherein	O
dysregulated	O
TLR	O
signaling	O
is	O
implicated	O
.	O

The	O
Duolink	O
in	O
situ	O
Proximity	O
Ligation	O
Assay	O
(	O
DPLA	O
,	O
Olink	O
Bioscience	O
,	O
Uppsala	O
,	O
Sweden	O
)	O
was	O
used	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
(	O
www	O
.	O
olink	O
.	O
com	O
/	O
products	O
-	O
services	O
/	O
duolink	O
)	O
to	O
detect	O
the	O
interaction	O
between	O
Prdx6	O
and	O
piGST	O
in	O
intact	O
cells	O
.	O

PMVEC	O
from	O
Prdx6	O
null	O
mice	O
were	O
grown	O
to	O
70	O
%	O
confluence	O
on	O
glass	O
coverslips	O
and	O
transfected	O
with	O
constructs	O
expressing	O
wild	O
type	O
or	O
mutated	O
Prdx6	O
ZsGreen	O
vector	O
using	O
the	O
Amaxa	O
Nucleofector	O
system	O
(	O
program	O
T	O
-	O
023	O
)	O
and	O
the	O
Basic	O
Endothelial	O
Nucleofector	O
Kit	O
(	O
Lonza	O
Group	O
,	O
Basel	O
,	O
Switzerland	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

MCF7	O
cells	O
were	O
transfected	O
with	O
human	O
piGST	O
using	O
the	O
GenJet	O
transfection	O
reagent	O
.	O

Cells	O
were	O
cultured	O
for	O
an	O
additional	O
48	O
h	O
after	O
transfection	O
.	O

Get3	O
-	O
GFP	O
-	O
positive	O
foci	O
are	O
protein	O
-	O
rich	O
,	O
membrane	O
-	O
and	O
ribosome	B-OOS
-	O
free	O
deposits	O
.	O

(	O
A	O
-	O
C	O
)	O
Examples	O
of	O
cryosections	O
from	O
glucose	O
-	O
starved	O
and	O
chemically	O
fixed	O
Deltaget1get2	O
double	O
-	O
deletion	O
cells	O
expressing	O
Get3	O
-	O
GFP	O
from	O
its	O
endogenous	O
promoter	O
.	O

Cells	O
were	O
fixed	O
after	O
60	O
minutes	O
of	O
glucose	O
withdrawal	O
as	O
described	O
for	O
Fig	O
.	O

1	O
.	O

The	O
sections	O
were	O
immunolabeled	O
with	O
anti	O
-	O
GFP	O
antibody	O
and	O
10	O
nm	O
gold	O
particles	O
conjugated	O
to	O
protein	O
A	O
.	O

(	O
D	O
,	O
E	O
)	O
Sections	O
obtained	O
after	O
high	O
-	O
pressure	O
freezing	O
of	O
glucose	O
-	O
starved	O
(	O
60	O
minutes	O
)	O
wild	O
-	O
type	O
cells	O
(	O
wt	O
-	O
D	O
)	O
expressing	O
Get3	O
-	O
GFP	O
from	O
the	O
endogenous	O
promoter	O
.	O

(	O
F	O
)	O
Example	O
of	O
sections	O
obtained	O
after	O
high	O
-	O
pressure	O
freezing	O
of	O
Deltaget2	O
deletion	O
cells	O
expressing	O
Get3	O
-	O
GFP	O
from	O
its	O
endogenous	O
promoter	O
without	O
exposing	O
them	O
to	O
glucose	O
starvation	O
.	O

ER	O
,	O
endoplasmic	O
reticulum	O
;	O
pnER	O
,	O
perinuclear	O
ER	O
;	O
N	O
,	O
nucleus	O
;	O
M	O
,	O
mitochondria	O
;	O
V	O
,	O
vacuole	O
;	O
LD	O
,	O
lipid	O
droplet	O
;	O
PM	O
,	O
plasma	O
membrane	O
;	O
CW	O
,	O
cell	O
wall	O
.	O

White	O
scale	O
bars	O
:	O
200	O
nm	O
;	O
black	O
scale	O
bar	O
:	O
500	O
nm	O
.	O

Arrows	O
indicate	O
anti	O
-	O
GFP	O
immuno	O
-	O
label	O
to	O
mark	O
Get3	O
-	O
GFP	O
.	O

In	O
cardiomyocytes	O
,	O
binding	O
of	O
unzipping	O
peptide	O
activates	O
ryanodine	O
receptor	O
2	O
and	O
reciprocally	O
inhibits	O
calmodulin	O
binding	O
.	O

RATIONALE	O
:	O
One	O
hypothesis	O
for	O
elevated	O
Ca	O
(	O
2	O
+	O
)	O
leak	O
through	O
cardiac	O
ryanodine	O
receptors	O
(	O
ryanodine	O
receptor	O
2	O
[	O
RyR2	O
]	O
)	O
in	O
heart	O
failure	O
is	O
interdomain	O
unzipping	O
that	O
can	O
enhance	O
aberrant	O
channel	O
activation	O
.	O

A	O
peptide	O
(	O
domain	O
peptide	O
corresponding	O
to	O
RyR2	O
residues	O
2460	O
-	O
2495	O
[	O
DPc10	O
]	O
)	O
corresponding	O
to	O
RyR2	O
central	O
domain	O
residues	O
2460	O
-	O
2495	O
recapitulates	O
this	O
arrhythmogenic	O
RyR2	O
leakiness	O
by	O
unzipping	O
N	O
-	O
terminal	O
and	O
central	O
domains	O
.	O

Calmodulin	O
(	O
CaM	O
)	O
and	O
FK506	O
-	O
binding	O
protein	O
(	O
FKBP12	O
.	O
6	O
)	O
bind	O
to	O
RyR2	O
and	O
stabilize	O
the	O
closed	O
channel	O
.	O

Little	O
is	O
known	O
about	O
DPc10	O
binding	O
to	O
the	O
RyR2	O
and	O
how	O
that	O
may	O
interact	O
with	O
binding	O
(	O
and	O
effects	O
)	O
of	O
CaM	O
and	O
FKBP12	O
.	O
6	O
to	O
RyR2	O
.	O

OBJECTIVE	O
:	O
To	O
measure	O
,	O
directly	O
in	O
cardiac	O
myocytes	O
,	O
the	O
kinetics	O
and	O
binding	O
affinity	O
of	O
DPc10	O
to	O
RyR2	O
and	O
how	O
that	O
affects	O
RyR2	O
interaction	O
with	O
FKBP12	O
.	O
6	O
and	O
CaM	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
used	O
permeabilized	O
rat	O
ventricular	O
myocytes	O
and	O
fluorescently	O
labeled	O
DPc10	O
,	O
FKBP12	O
.	O
6	O
,	O
and	O
CaM	O
.	O

DPc10	O
access	O
to	O
its	O
binding	O
site	O
is	O
extremely	O
slow	O
in	O
resting	O
RyR2	O
but	O
is	O
accelerated	O
by	O
promoting	O
RyR	O
opening	O
or	O
unzipping	O
(	O
by	O
unlabeled	O
DPc10	O
)	O
.	O

RyR2	O
-	O
bound	O
CaM	O
(	O
but	O
not	O
FKBP12	O
.	O
6	O
)	O
drastically	O
slowed	O
DPc10	O
binding	O
.	O

Conversely	O
,	O
DPc10	O
binding	O
significantly	O
reduced	O
CaM	O
(	O
but	O
not	O
FKBP12	O
.	O
6	O
)	O
binding	O
to	O
the	O
RyR2	O
.	O

Fluorescence	O
resonance	O
energy	O
transfer	O
measurements	O
indicate	O
that	O
DPc10	O
-	O
binding	O
and	O
CaM	O
-	O
binding	O
sites	O
are	O
separate	O
and	O
allow	O
triangulation	O
of	O
the	O
structural	O
DPc10	O
binding	O
locus	O
on	O
RyR2	O
vs	O
FKBP12	O
.	O
6	O
-	O
binding	O
and	O
CaM	O
-	O
binding	O
sites	O
.	O

CONCLUSIONS	O
:	O
DPc10	O
-	O
RyR2	O
binding	O
is	O
sterically	O
limited	O
by	O
the	O
resting	O
zipped	O
RyR2	O
state	O
.	O

CaM	O
binding	O
to	O
RyR2	O
stabilizes	O
this	O
zipped	O
state	O
,	O
whereas	O
RyR2	O
activation	O
or	O
prebound	O
DPc10	O
enhances	O
DPc10	O
access	O
.	O

DPc10	O
-	O
binding	O
and	O
CaM	O
-	O
binding	O
sites	O
are	O
distinct	O
but	O
are	O
allosterically	O
interacting	O
RyR2	O
sites	O
.	O

Neither	O
DPc10	O
nor	O
FKBP12	O
.	O
6	O
influences	O
RyR2	O
binding	O
of	O
the	O
other	O
.	O

To	O
simultaneously	O
inhibit	O
all	O
HIF	O
complexes	O
,	O
we	O
considered	O
targeting	O
interactions	O
between	O
the	O
ARNT	O
subunit	O
,	O
shared	O
among	O
these	O
complexes	O
,	O
with	O
transcriptional	O
coactivators	O
.	O

This	O
strategy	O
is	O
predicated	O
on	O
the	O
ARNT	O
PAS	O
-	O
B	O
domain	O
(	O
Fig	O
.	O
1	O
)	O
directly	O
recruiting	O
coiled	O
coil	O
coactivators	O
(	O
CCCs	O
)	O
to	O
HIF	O
for	O
proper	O
transcriptional	O
regulation	O
.	O

By	O
depleting	O
endogenous	O
proteins	O
or	O
overexpressing	O
mutants	O
,	O
we	O
found	O
that	O
HIF	O
complexes	O
differentially	O
utilize	O
several	O
CCC	O
proteins	O
including	O
thyroid	O
hormone	O
receptor	O
interacting	O
protein	O
230	O
(	O
TRIP230	O
)	O
,	O
Coiled	O
-	O
Coil	O
Coactivator	O
(	O
CoCoA	O
)	O
and	O
transforming	O
acidic	O
coiled	O
-	O
coil	O
3	O
(	O
TACC3	O
)	O
at	O
different	O
promoters	O
.	O

Combining	O
biophysical	O
and	O
mutagenesis	O
data	O
,	O
we	O
generated	O
a	O
structural	O
model	O
of	O
the	O
ARNT	O
/	O
TACC3	O
complex	O
,	O
showing	O
that	O
CCC	O
proteins	O
use	O
a	O
coiled	O
coil	O
to	O
bind	O
a	O
helical	O
surface	O
on	O
ARNT	O
PAS	O
-	O
B	O
(	O
Fig	O
.	O
1b	O
)	O
.	O

Notably	O
,	O
the	O
CCC	O
-	O
binding	O
surface	O
on	O
ARNT	O
is	O
near	O
where	O
other	O
PAS	O
domains	O
bind	O
cofactors	O
that	O
modulate	O
their	O
protein	O
/	O
protein	O
interactions	O
,	O
leading	O
us	O
to	O
hypothesize	O
that	O
artificial	O
ARNT	O
-	O
binding	O
compounds	O
might	O
similarly	O
control	O
ARNT	O
PAS	O
-	O
B	O
/	O
CCC	O
interactions	O
to	O
regulate	O
HIF	O
activity	O
.	O

ADP	O
-	O
ribosylation	O
of	O
proteins	O
in	O
brain	O
regions	O
of	O
rats	O
during	O
postnatal	O
development	O
.	O

Post	O
-	O
translational	O
modifications	O
of	O
chromatin	O
-	O
bound	O
proteins	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
eukaryotic	O
gene	O
expression	O
.	O

Processes	O
such	O
as	O
acetylation	O
,	O
methylation	O
,	O
phosphorylation	O
and	O
ADP	O
-	O
ribosylation	O
may	O
alter	O
the	O
interaction	O
of	O
these	O
proteins	O
with	O
DNA	O
and	O
consequently	O
affect	O
chromatin	O
conformation	O
and	O
the	O
binding	O
of	O
enzymes	O
and	O
other	O
molecules	O
involved	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
.	O

In	O
the	O
present	O
study	O
the	O
process	O
of	O
ADP	O
-	O
ribosylation	O
of	O
chromosomal	O
proteins	O
(	O
histone	O
and	O
non	O
-	O
histone	O
proteins	O
)	O
in	O
some	O
rat	O
brain	O
regions	O
during	O
postnatal	O
development	O
was	O
investigated	O
;	O
also	O
the	O
effect	O
of	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
on	O
this	O
process	O
in	O
fetal	O
brain	O
slices	O
was	O
studied	O
.	O

It	O
has	O
been	O
found	O
that	O
the	O
process	O
of	O
ADP	O
-	O
ribosylation	O
of	O
total	O
histones	O
extracted	O
from	O
rat	O
cerebral	O
cortex	O
and	O
cerebellum	O
at	O
1	O
,	O
10	O
and	O
30	O
days	O
of	O
age	O
,	O
increases	O
from	O
1	O
to	O
10	O
days	O
of	O
age	O
(	O
i	O
.	O
e	O
.	O
the	O
period	O
of	O
maximal	O
cell	O
proliferation	O
)	O
and	O
decreases	O
thereafter	O
,	O
while	O
the	O
process	O
of	O
ADP	O
-	O
ribosylation	O
of	O
non	O
-	O
histone	O
proteins	O
(	O
NHPs	O
)	O
sharply	O
decreases	O
during	O
the	O
same	O
developmental	O
period	O
.	O

The	O
addition	O
of	O
EGF	O
to	O
fetal	O
brain	O
slices	O
causes	O
a	O
significant	O
increase	O
of	O
ADP	O
-	O
ribosylation	O
of	O
total	O
histones	O
(	O
particularly	O
of	O
the	O
histone	O
H1	O
fraction	O
)	O
and	O
also	O
of	O
NHPs	O
and	O
microsomal	O
proteins	O
.	O

This	O
result	O
is	O
in	O
agreement	O
with	O
the	O
effect	O
of	O
EGF	O
as	O
a	O
mitogen	O
factor	O
,	O
previously	O
shown	O
in	O
astroglial	O
cell	O
cultures	O
.	O

To	O
address	O
the	O
formation	O
of	O
UNC	O
-	O
45	O
chains	O
,	O
we	O
generated	O
three	O
distinct	O
mutants	O
affecting	O
the	O
two	O
faces	O
of	O
the	O
UNC	O
-	O
45	O
multimerization	O
site	O
formed	O
by	O
helices	O
of	O
the	O
TPR	O
domain	O
(	O
motif	O
-	O
1	O
)	O
and	O
the	O
neck	O
domain	O
(	O
motif	O
-	O
2	O
)	O
.	O

Two	O
mutants	O
comprise	O
site	O
-	O
specific	O
exchanges	O
in	O
motif	O
-	O
1	O
(	O
L121W	O
)	O
and	O
motif	O
-	O
2	O
(	O
V480R	O
/	O
V484R	O
)	O
,	O
respectively	O
,	O
whereas	O
the	O
DeltaTPR	O
mutant	O
lacks	O
the	O
entire	O
motif	O
-	O
1	O
.	O

Though	O
all	O
three	O
interface	O
mutants	O
blocked	O
chain	O
formation	O
in	O
vitro	O
,	O
the	O
structural	O
data	O
suggest	O
that	O
the	O
DeltaTPR	O
mutant	O
should	O
show	O
the	O
strongest	O
effect	O
in	O
impairing	O
UNC	O
-	O
45	O
oligomer	O
function	O
in	O
vivo	O
.	O

It	O
is	O
thus	O
surprising	O
that	O
the	O
double	O
arginine	O
mutant	O
V480R	O
/	O
V484R	O
exhibits	O
the	O
most	O
pronounced	O
defects	O
and	O
could	O
not	O
rescue	O
the	O
temperature	O
-	O
dependent	O
locomotion	O
phenotype	O
of	O
unc	O
-	O
45	O
(	O
m94	O
)	O
ts	O
mutants	O
,	O
whereas	O
expression	O
of	O
the	O
two	O
TPR	O
transgenes	O
(	O
L121W	O
and	O
DeltaTPR	O
)	O
rescued	O
motility	O
at	O
least	O
partially	O
.	O

Est1p	O
undergoes	O
cell	O
cycle	O
-	O
regulated	O
degradation	O
during	O
G1	O
phase	O
,	O
thereby	O
preventing	O
Est3p	O
recruitment	O
and	O
telomerase	B-Complex
complex	O
assembly	O
.	O

Here	O
we	O
present	O
evidence	O
that	O
Est1	O
protein	O
levels	O
oscillate	O
during	O
the	O
cell	O
cycle	O
through	O
an	O
APC	B-Complex
-	O
dependent	O
mechanism	O
in	O
vivo	O
.	O

Degradation	O
requires	O
three	O
sequences	O
in	O
Est1p	O
that	O
match	O
the	O
D	O
-	O
box	O
consensus	O
,	O
consistent	O
with	O
direct	O
recognition	O
of	O
Est1p	O
by	O
the	O
APC	B-Complex
.	O

However	O
,	O
recombinant	O
Est1	O
protein	O
is	O
not	O
degraded	O
or	O
ubiquitinated	O
by	O
the	O
APC	B-Complex
in	O
vitro	O
,	O
suggesting	O
that	O
Est1p	O
either	O
lacks	O
the	O
necessary	O
structure	O
or	O
modification	O
(	O
s	O
)	O
that	O
influence	O
APC	B-Complex
recognition	O
in	O
vivo	O
or	O
is	O
an	O
indirect	O
target	O
of	O
the	O
APC	B-Complex
.	O

Because	O
Est1p	O
stimulates	O
association	O
of	O
Est3p	O
with	O
the	O
telomerase	B-Complex
complex	O
,	O
these	O
results	O
shed	O
light	O
on	O
the	O
regulation	O
of	O
yeast	O
telomerase	B-Complex
biogenesis	O
and	O
demonstrate	O
an	O
additional	O
connection	O
between	O
telomere	O
maintenance	O
and	O
cell	O
cycle	O
regulation	O
pathways	O
.	O

The	O
limited	O
degree	O
of	O
flexibility	O
seen	O
in	O
exomer	B-Complex
stands	O
in	O
contrast	O
to	O
the	O
dichotomy	O
between	O
rigid	O
structures	O
and	O
complete	O
flexibility	O
seen	O
in	O
other	O
cargo	O
adaptors	O
.	O

The	O
Sec23	O
/	O
24	O
COPII	B-Complex
cargo	O
adaptor	O
forms	O
a	O
seemingly	O
rigid	O
"	O
pre	O
-	O
budding	O
complex	O
"	O
with	O
its	O
cognate	O
GTPase	O
Sar1	O
.	O

The	O
clathrin	B-Complex
adaptor	I-Complex
AP	I-Complex
complexes	O
,	O
while	O
exhibiting	O
a	O
significant	O
conformational	O
rearrangement	O
upon	O
membrane	O
and	O
cargo	O
binding	O
,	O
appear	O
to	O
exist	O
in	O
a	O
single	O
,	O
stable	O
conformation	O
when	O
membrane	O
bound	O
.	O

We	O
note	O
that	O
both	O
Sec23	O
/	O
Sec24	O
and	O
the	O
AP	B-Complex
complexes	O
bind	O
to	O
vesicle	O
cage	O
and	O
accessory	O
proteins	O
via	O
flexible	O
linkers	O
.	O

Exomer	B-Complex
,	O
however	O
,	O
employs	O
a	O
hinge	O
domain	O
as	O
a	O
primary	O
source	O
of	O
flexibility	O
,	O
implying	O
that	O
constrained	O
flexibility	O
,	O
rather	O
than	O
the	O
complete	O
conformational	O
freedom	O
allowed	O
by	O
a	O
flexible	O
linker	O
,	O
is	O
critical	O
for	O
its	O
function	O
at	O
the	O
TGN	O
.	O

UHRF2	O
,	O
a	O
ubiquitin	O
E3	O
ligase	O
,	O
acts	O
as	O
a	O
small	O
ubiquitin	O
-	O
like	O
modifier	O
E3	O
ligase	O
for	O
zinc	O
finger	O
protein	O
131	O
.	O

Small	O
ubiquitin	O
-	O
like	O
modifier	O
(	O
SUMO	O
)	O
,	O
a	O
member	O
of	O
the	O
ubiquitin	O
-	O
related	O
protein	O
family	O
,	O
is	O
covalently	O
conjugated	O
to	O
lysine	O
residues	O
of	O
its	O
substrates	O
in	O
a	O
process	O
referred	O
to	O
as	O
SUMOylation	O
.	O

SUMOylation	O
occurs	O
through	O
a	O
series	O
of	O
enzymatic	O
reactions	O
analogous	O
to	O
that	O
of	O
the	O
ubiquitination	O
pathway	O
,	O
resulting	O
in	O
modification	O
of	O
the	O
biochemical	O
and	O
functional	O
properties	O
of	O
substrates	O
.	O

To	O
date	O
,	O
four	O
mammalian	O
SUMO	O
isoforms	O
,	O
a	O
single	O
heterodimeric	O
SUMO	O
-	O
activating	O
E1	O
enzyme	O
SAE1	O
/	O
SAE2	O
,	O
a	O
single	O
SUMO	O
-	O
conjugating	O
E2	O
enzyme	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
E2I	O
(	O
UBC9	O
)	O
,	O
and	O
a	O
few	O
subgroups	O
of	O
SUMO	O
E3	O
ligases	O
have	O
been	O
identified	O
.	O

Several	O
SUMO	O
E3	O
ligases	O
such	O
as	O
topoisomerase	O
I	O
binding	O
,	O
arginine	O
/	O
serine	O
-	O
rich	O
(	O
TOPORS	O
)	O
,	O
TNF	O
receptor	O
-	O
associated	O
factor	O
7	O
(	O
TRAF7	O
)	O
,	O
and	O
tripartite	O
motif	O
containing	O
27	O
(	O
TRIM27	O
)	O
have	O
dual	O
functions	O
as	O
ubiquitin	O
E3	O
ligases	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
ubiquitin	O
E3	O
ligase	O
UHRF2	O
also	O
acts	O
as	O
a	O
SUMO	O
E3	O
ligase	O
.	O

UHRF2	O
effectively	O
enhances	O
zinc	O
finger	O
protein	O
131	O
(	O
ZNF131	O
)	O
SUMOylation	O
but	O
does	O
not	O
enhance	O
ZNF131	O
ubiquitination	O
.	O

In	O
addition	O
,	O
the	O
SUMO	O
E3	O
activity	O
of	O
UHRF2	O
on	O
ZNF131	O
depends	O
on	O
the	O
presence	O
of	O
SET	O
and	O
RING	O
finger	O
-	O
associated	O
and	O
nuclear	O
localization	O
signal	O
-	O
containing	O
region	O
domains	O
,	O
whereas	O
the	O
critical	O
ubiquitin	O
E3	O
activity	O
RING	O
domain	O
is	O
dispensable	O
.	O

Our	O
findings	O
suggest	O
that	O
UHRF2	O
has	O
independent	O
functional	O
domains	O
and	O
regulatory	O
mechanisms	O
for	O
these	O
two	O
distinct	O
enzymatic	O
activities	O
.	O

Our	O
previous	O
study	O
showed	O
that	O
the	O
major	O
role	O
of	O
the	O
loop	O
lies	O
in	O
the	O
recruitment	O
of	O
the	O
microtubule	O
-	O
associated	O
protein	O
Dis1	O
,	O
a	O
founding	O
member	O
of	O
the	O
TOG	O
/	O
XMAP215	O
microtubule	O
-	O
associated	O
protein	O
family	O
,	O
and	O
in	O
the	O
ndc80	O
-	O
21	O
mutant	O
(	O
L405P	O
)	O
,	O
Dis1	O
delocalized	O
from	O
the	O
mitotic	O
kinetochore	O
.	O

Accordingly	O
,	O
we	O
examined	O
Dis1	O
localization	O
in	O
the	O
ndc80	O
-	O
NH12	O
mutant	O
and	O
quantified	O
its	O
intensity	O
.	O

Intriguingly	O
,	O
the	O
signal	O
intensities	O
of	O
Dis1	O
at	O
the	O
mitotic	O
kinetochore	O
were	O
indistinguishable	O
from	O
those	O
of	O
wild	O
-	O
type	O
cells	O
(	O
Figure	O
4A	O
)	O
.	O

The	O
WD40	O
protein	O
Morg1	O
facilitates	O
Par6	O
-	O
aPKC	O
binding	O
to	O
Crb3	O
for	O
apical	O
identity	O
in	O
epithelial	O
cells	O
.	O

Formation	O
of	O
apico	O
-	O
basal	O
polarity	O
in	O
epithelial	O
cells	O
is	O
crucial	O
for	O
both	O
morphogenesis	O
(	O
e	O
.	O
g	O
.	O
,	O
cyst	O
formation	O
)	O
and	O
function	O
(	O
e	O
.	O
g	O
.	O
,	O
tight	O
junction	O
development	O
)	O
.	O

Atypical	O
protein	O
kinase	O
C	O
(	O
aPKC	O
)	O
,	O
complexed	O
with	O
Par6	O
,	O
is	O
considered	O
to	O
translocate	O
to	O
the	O
apical	O
membrane	O
and	O
function	O
in	O
epithelial	O
cell	O
polarization	O
.	O

However	O
,	O
the	O
mechanism	O
for	O
translocation	O
of	O
the	O
Par6	O
-	O
aPKC	O
complex	O
has	O
remained	O
largely	O
unknown	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
WD40	O
protein	O
Morg1	O
(	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
organizer	O
1	O
)	O
directly	O
binds	O
to	O
Par6	O
and	O
thus	O
facilitates	O
apical	O
targeting	O
of	O
Par6	O
-	O
aPKC	O
in	O
Madin	O
-	O
Darby	O
canine	O
kidney	O
epithelial	O
cells	O
.	O

Morg1	O
also	O
interacts	O
with	O
the	O
apical	O
transmembrane	O
protein	O
Crumbs3	O
to	O
promote	O
Par6	O
-	O
aPKC	O
binding	O
to	O
Crumbs3	O
,	O
which	O
is	O
reinforced	O
with	O
the	O
apically	O
localized	O
small	O
GTPase	O
Cdc42	O
.	O

Depletion	O
of	O
Morg1	O
disrupted	O
both	O
tight	O
junction	O
development	O
in	O
monolayer	O
culture	O
and	O
cyst	O
formation	O
in	O
three	O
-	O
dimensional	O
culture	O
;	O
apico	O
-	O
basal	O
polarity	O
was	O
notably	O
restored	O
by	O
forced	O
targeting	O
of	O
aPKC	O
to	O
the	O
apical	O
surface	O
.	O

Thus	O
,	O
Par6	O
-	O
aPKC	O
recruitment	O
to	O
the	O
premature	O
apical	O
membrane	O
appears	O
to	O
be	O
required	O
for	O
definition	O
of	O
apical	O
identity	O
of	O
epithelial	O
cells	O
.	O

Gradual	O
processing	O
of	O
the	O
ITS1	O
from	O
the	O
nucleolus	O
to	O
the	O
cytoplasm	O
during	O
synthesis	O
of	O
the	O
human	O
18S	O
rRNA	O
.	O

Defects	O
in	O
ribosome	B-OOS
biogenesis	O
trigger	O
stress	O
response	O
pathways	O
,	O
which	O
perturb	O
cell	O
proliferation	O
and	O
differentiation	O
in	O
several	O
genetic	O
diseases	O
.	O

In	O
Diamond	O
-	O
Blackfan	O
anemia	O
(	O
DBA	O
)	O
,	O
a	O
congenital	O
erythroblastopenia	O
,	O
mutations	O
in	O
ribosomal	O
protein	O
genes	O
often	O
interfere	O
with	O
the	O
processing	O
of	O
the	O
internal	O
transcribed	O
spacer	O
1	O
(	O
ITS1	O
)	O
,	O
the	O
mechanism	O
of	O
which	O
remains	O
elusive	O
in	O
human	O
cells	O
.	O

Using	O
loss	O
-	O
of	O
-	O
function	O
experiments	O
and	O
extensive	O
RNA	O
analysis	O
,	O
we	O
have	O
defined	O
the	O
precise	O
position	O
of	O
the	O
endonucleolytic	O
cleavage	O
E	O
in	O
the	O
ITS1	O
,	O
which	O
generates	O
the	O
18S	O
-	O
E	O
intermediate	O
,	O
the	O
last	O
precursor	O
to	O
the	O
18S	O
rRNA	O
.	O

Unexpectedly	O
,	O
this	O
cleavage	O
is	O
followed	O
by	O
3	O
'	O
-	O
5	O
'	O
exonucleolytic	O
trimming	O
of	O
the	O
18S	O
-	O
E	O
precursor	O
during	O
nuclear	O
export	O
of	O
the	O
pre	O
-	O
40S	B-Complex
particle	O
,	O
which	O
sets	O
a	O
new	O
mechanism	O
for	O
18S	O
rRNA	O
formation	O
clearly	O
different	O
from	O
that	O
established	O
in	O
yeast	O
.	O

In	O
addition	O
,	O
cleavage	O
at	O
site	O
E	O
is	O
also	O
followed	O
by	O
5	O
'	O
-	O
3	O
'	O
exonucleolytic	O
trimming	O
of	O
the	O
ITS1	O
by	O
exonuclease	O
XRN2	O
.	O

Perturbation	O
of	O
this	O
step	O
on	O
knockdown	O
of	O
the	O
large	O
subunit	O
ribosomal	O
protein	O
RPL26	O
,	O
which	O
was	O
recently	O
associated	O
to	O
DBA	O
,	O
reveals	O
the	O
putative	O
role	O
of	O
a	O
highly	O
conserved	O
cis	O
-	O
acting	O
sequence	O
in	O
ITS1	O
processing	O
.	O

These	O
data	O
cast	O
new	O
light	O
on	O
the	O
original	O
mechanism	O
of	O
ITS1	O
elimination	O
in	O
human	O
cells	O
and	O
provide	O
a	O
mechanistic	O
framework	O
to	O
further	O
study	O
the	O
interplay	O
of	O
DBA	O
-	O
linked	O
ribosomal	O
proteins	O
in	O
this	O
process	O
.	O

A	O
.	O

Schematic	O
depiction	O
of	O
domain	O
organization	O
of	O
human	O
guanylate	O
cyclase	O
.	O

The	O
native	O
enzyme	O
is	O
a	O
heterodimer	O
of	O
alpha	O
and	O
beta	O
subunits	O
(	O
encoded	O
by	O
GUCY1A3	O
and	O
GUCY1B3	O
,	O
respectively	O
)	O
,	O
with	O
interaction	O
interfaces	O
spread	O
across	O
the	O
PAS	O
,	O
CC	O
and	O
cyclase	O
catalytic	O
domains	O
.	O

The	O
catalytic	O
domains	O
associate	O
in	O
a	O
head	O
to	O
tail	O
orientation	O
;	O
conserved	O
residues	O
involved	O
in	O
substrate	O
binding	O
and	O
catalysis	O
are	O
distributed	O
between	O
the	O
two	O
subunits	O
.	O

B	O
.	O

A	O
list	O
of	O
conserved	O
active	O
-	O
site	O
residues	O
in	O
guanylate	O
cyclase	O
(	O
sGCalpha	O
and	O
beta	O
)	O
and	O
in	O
the	O
chimeric	O
adenylate	O
cyclase	O
(	O
AC	O
-	O
V	O
C1	O
domain	O
and	O
AC	O
-	O
II	O
C2	O
domain	O
)	O
.	O

A	O
full	O
alignment	O
of	O
adenylate	O
and	O
guanylate	O
cyclases	O
is	O
shown	O
in	O
Supporting	O
Fig	O
.	O

S1	O
.	O

To	O
determine	O
the	O
ability	O
of	O
wild	O
-	O
type	O
and	O
chimeric	O
SIVcpz	O
and	O
SIVgor	O
Vpus	O
to	O
promote	O
virus	O
release	O
in	O
the	O
presence	O
of	O
tetherin	O
,	O
we	O
co	O
-	O
transfected	O
293T	O
cells	O
with	O
a	O
vpu	O
defective	O
HIV	O
-	O
1	O
NL4	O
-	O
3	O
construct	O
,	O
pCGCG	O
vectors	O
expressing	O
AU1	O
-	O
tagged	O
versions	O
of	O
Vpu	O
and	O
different	O
doses	O
of	O
human	O
tetherin	O
.	O

In	O
contrast	O
to	O
the	O
parental	O
SIVcpz	O
and	O
SIVgor	O
proteins	O
,	O
all	O
chimeras	O
were	O
capable	O
of	O
promoting	O
infectious	O
virus	O
release	O
(	O
Figures	O
3A	O
)	O
.	O

The	O
chimera	O
between	O
the	O
HIV	O
-	O
1	O
TMD	O
and	O
the	O
SIVgor	O
BQ664	O
CP	O
(	O
NL	O
-	O
BQ	O
)	O
increased	O
infectious	O
virus	O
release	O
in	O
both	O
293T	O
and	O
HeLa	O
cells	O
almost	O
as	O
efficiently	O
as	O
the	O
control	O
NL4	O
-	O
3	O
Vpu	O
and	O
was	O
substantially	O
more	O
effective	O
than	O
the	O
chimeras	O
between	O
HIV	O
-	O
1	O
and	O
SIVcpzPtt	O
Vpus	O
(	O
NL	O
-	O
MB	O
,	O
NL	O
-	O
EK	O
)	O
(	O
Figures	O
3A	O
,	O
3B	O
)	O
.	O

This	O
was	O
surprising	O
because	O
in	O
contrast	O
to	O
the	O
SIVcpzPtt	O
MB897	O
and	O
EK505	O
Vpus	O
,	O
the	O
cytoplasmic	O
part	O
of	O
the	O
SIVgor	O
BQ664	O
Vpu	O
contains	O
substitutions	O
in	O
the	O
DSGxxS	O
motif	O
(	O
DEGYES	O
)	O
and	O
lacks	O
a	O
putative	O
Yxxphi	O
motif	O
(	O
Figure	O
1B	O
)	O
.	O

These	O
results	O
were	O
confirmed	O
by	O
measuring	O
the	O
quantity	O
of	O
fectious	O
virus	O
and	O
p24	B-Complex
release	O
in	O
the	O
culture	O
supernatant	O
of	O
HeLa	O
cells	O
co	O
-	O
transfected	O
with	O
proviral	O
HIV	O
-	O
1	O
and	O
Vpu	O
expression	O
constructs	O
(	O
Figures	O
3C	O
to	O
E	O
)	O
.	O

All	O
Vpus	O
that	O
promoted	O
infectious	O
virus	O
release	O
in	O
transiently	O
transfected	O
293T	O
cells	O
were	O
also	O
active	O
in	O
HeLa	O
cells	O
(	O
Figure	O
3F	O
)	O
and	O
most	O
Vpu	O
proteins	O
that	O
reduced	O
tetherin	O
surface	O
expression	O
also	O
enhanced	O
virion	O
release	O
(	O
Figure	O
3G	O
,	O
3H	O
)	O
.	O

SENP3	O
-	O
mediated	O
deSUMOylation	O
of	O
dynamin	O
-	O
related	O
protein	O
1	O
promotes	O
cell	O
death	O
following	O
ischaemia	O
.	O

Global	O
increases	O
in	O
small	O
ubiquitin	O
-	O
like	O
modifier	O
(	O
SUMO	O
)	O
-	O
2	O
/	O
3	O
conjugation	O
are	O
a	O
neuroprotective	O
response	O
to	O
severe	O
stress	O
but	O
the	O
mechanisms	O
and	O
specific	O
target	O
proteins	O
that	O
determine	O
cell	O
survival	O
have	O
not	O
been	O
identified	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
SUMO	O
-	O
2	O
/	O
3	O
-	O
specific	O
protease	O
SENP3	O
is	O
degraded	O
during	O
oxygen	O
/	O
glucose	O
deprivation	O
(	O
OGD	O
)	O
,	O
an	O
in	O
vitro	O
model	O
of	O
ischaemia	O
,	O
via	O
a	O
pathway	O
involving	O
the	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
kinase	O
PERK	O
and	O
the	O
lysosomal	O
enzyme	O
cathepsin	O
B	O
.	O

A	O
key	O
target	O
for	O
SENP3	O
-	O
mediated	O
deSUMOylation	O
is	O
the	O
GTPase	O
Drp1	O
,	O
which	O
plays	O
a	O
major	O
role	O
in	O
regulating	O
mitochondrial	O
fission	O
.	O

We	O
show	O
that	O
depletion	O
of	O
SENP3	O
prolongs	O
Drp1	O
SUMOylation	O
,	O
which	O
suppresses	O
Drp1	O
-	O
mediated	O
cytochrome	O
c	O
release	O
and	O
caspase	O
-	O
mediated	O
cell	O
death	O
.	O

SENP3	O
levels	O
recover	O
following	O
reoxygenation	O
after	O
OGD	O
allowing	O
deSUMOylation	O
of	O
Drp1	O
,	O
which	O
facilitates	O
Drp1	O
localization	O
at	O
mitochondria	O
and	O
promotes	O
fragmentation	O
and	O
cytochrome	O
c	O
release	O
.	O

RNAi	O
knockdown	O
of	O
SENP3	O
protects	O
cells	O
from	O
reoxygenation	O
-	O
induced	O
cell	O
death	O
via	O
a	O
mechanism	O
that	O
requires	O
Drp1	O
SUMOylation	O
.	O

Thus	O
,	O
we	O
identify	O
a	O
novel	O
adaptive	O
pathway	O
to	O
extreme	O
cell	O
stress	O
in	O
which	O
dynamic	O
changes	O
in	O
SENP3	O
stability	O
and	O
regulation	O
of	O
Drp1	O
SUMOylation	O
are	O
crucial	O
determinants	O
of	O
cell	O
fate	O
.	O

Ubiquitin	O
C	O
-	O
terminal	O
hydrolase	O
L1	O
(	O
UCH	O
-	O
L1	O
)	O
acts	O
as	O
a	O
novel	O
potentiator	O
of	O
cyclin	O
-	O
dependent	O
kinases	O
to	O
enhance	O
cell	O
proliferation	O
independently	O
of	O
its	O
hydrolase	O
activity	O
.	O

Dysregulation	O
of	O
cell	O
proliferation	O
and	O
the	O
cell	O
cycle	O
are	O
associated	O
with	O
various	O
diseases	O
,	O
such	O
as	O
cancer	O
.	O

Cyclin	O
-	O
dependent	O
kinases	O
(	O
CDKs	O
)	O
play	O
central	O
roles	O
in	O
cell	O
proliferation	O
and	O
the	O
cell	O
cycle	O
.	O

Ubiquitin	O
C	O
-	O
terminal	O
hydrolase	O
L1	O
(	O
UCH	O
-	O
L1	O
)	O
is	O
expressed	O
in	O
a	O
restricted	O
range	O
of	O
tissues	O
,	O
including	O
the	O
brain	O
and	O
numerous	O
types	O
of	O
cancer	O
.	O

However	O
,	O
the	O
molecular	O
functions	O
of	O
UCH	O
-	O
L1	O
remain	O
elusive	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
UCH	O
-	O
L1	O
physically	O
interacts	O
with	O
CDK1	O
,	O
CDK4	O
,	O
and	O
CDK5	O
,	O
enhancing	O
their	O
kinase	O
activity	O
.	O

Using	O
several	O
mutants	O
of	O
UCH	O
-	O
L1	O
,	O
we	O
showed	O
that	O
this	O
enhancement	O
is	O
dependent	O
upon	O
interaction	O
levels	O
between	O
UCH	O
-	O
L1	O
and	O
CDKs	O
but	O
is	O
independent	O
of	O
the	O
known	O
ubiquitin	O
-	O
related	O
functions	O
of	O
UCH	O
-	O
L1	O
.	O

Gain	O
-	O
and	O
loss	O
-	O
of	O
-	O
function	O
studies	O
revealed	O
that	O
UCH	O
-	O
L1	O
enhances	O
proliferation	O
of	O
multiple	O
cell	O
types	O
,	O
including	O
human	O
cancer	O
cells	O
.	O

Inhibition	O
of	O
the	O
interaction	O
between	O
UCH	O
-	O
L1	O
and	O
cell	O
cycle	O
-	O
associated	O
CDK	O
resulted	O
in	O
the	O
abolishment	O
of	O
UCH	O
-	O
L1	O
-	O
induced	O
enhancement	O
of	O
cell	O
proliferation	O
.	O

RNA	O
interference	O
of	O
UCH	O
-	O
L1	O
reduced	O
the	O
growth	O
of	O
human	O
xenograft	O
tumors	O
in	O
mice	O
.	O

We	O
concluded	O
that	O
UCH	O
-	O
L1	O
is	O
a	O
novel	O
regulator	O
of	O
the	O
kinase	O
activities	O
of	O
CDKs	O
.	O

We	O
believe	O
that	O
our	O
findings	O
from	O
this	O
study	O
will	O
significantly	O
contribute	O
to	O
our	O
understanding	O
of	O
cell	O
cycle	O
-	O
associated	O
diseases	O
.	O

The	O
Biotinidase	O
Gene	O
Variants	O
Registry	O
:	O
A	O
Paradigm	O
Public	O
Database	O
.	O

The	O
BTD	O
gene	O
codes	O
for	O
production	O
of	O
biotinidase	O
,	O
the	O
enzyme	O
responsible	O
for	O
helping	O
the	O
body	O
reuse	O
and	O
recycle	O
the	O
biotin	O
found	O
in	O
foods	O
.	O

Biotinidase	O
deficiency	O
is	O
an	O
autosomal	O
recessively	O
inherited	O
disorder	O
resulting	O
in	O
the	O
inability	O
to	O
recycle	O
the	O
vitamin	O
biotin	O
and	O
affects	O
approximately	O
1	O
in	O
60	O
,	O
000	O
newborns	O
.	O

If	O
untreated	O
,	O
the	O
depletion	O
of	O
intracellular	O
biotin	O
leads	O
to	O
impaired	O
activities	O
of	O
the	O
biotin	O
-	O
dependent	O
carboxylases	O
and	O
can	O
result	O
in	O
cutaneous	O
and	O
neurological	O
abnormalities	O
in	O
individuals	O
with	O
the	O
disorder	O
.	O

Mutations	O
in	O
the	O
biotinidase	O
gene	O
(	O
BTD	O
)	O
alter	O
enzymatic	O
function	O
.	O

To	O
date	O
,	O
more	O
than	O
165	O
mutations	O
in	O
BTD	O
have	O
been	O
reported	O
.	O

Our	O
group	O
has	O
developed	O
a	O
database	O
that	O
characterizes	O
the	O
known	O
mutations	O
and	O
sequence	O
variants	O
in	O
BTD	O
(	O
http	O
:	O
/	O
/	O
arup	O
.	O
utah	O
.	O
edu	O
/	O
database	O
/	O
BTD	O
/	O
BTD	O
_	O
welcome	O
.	O
php	O
)	O
.	O

All	O
sequence	O
variants	O
have	O
been	O
verified	O
for	O
their	O
positions	O
within	O
the	O
BTD	O
gene	O
and	O
designated	O
according	O
to	O
standard	O
nomenclature	O
suggested	O
by	O
Human	O
Genome	O
Variation	O
Society	O
(	O
HGVS	O
)	O
.	O

In	O
addition	O
,	O
we	O
describe	O
the	O
change	O
in	O
the	O
protein	O
,	O
indicate	O
whether	O
the	O
variant	O
is	O
a	O
known	O
or	O
likely	O
mutation	O
vs	O
.	O
a	O
benign	O
polymorphism	O
,	O
and	O
include	O
the	O
reference	O
that	O
first	O
described	O
the	O
alteration	O
.	O

We	O
also	O
indicate	O
whether	O
the	O
alteration	O
is	O
known	O
to	O
be	O
clinically	O
pathological	O
based	O
on	O
an	O
observation	O
of	O
a	O
known	O
symptomatic	O
individual	O
or	O
predicted	O
to	O
be	O
pathological	O
based	O
on	O
enzymatic	O
activity	O
or	O
putative	O
disruption	O
of	O
the	O
protein	O
structure	O
.	O

We	O
incorporated	O
the	O
published	O
phenotype	O
to	O
help	O
establish	O
genotype	O
-	O
phenotype	O
correlations	O
and	O
facilitate	O
this	O
process	O
for	O
those	O
performing	O
mutation	O
analysis	O
and	O
/	O
or	O
interpreting	O
results	O
.	O

Other	O
features	O
of	O
this	O
database	O
include	O
disease	O
information	O
,	O
relevant	O
links	O
about	O
biotinidase	O
deficiency	O
,	O
reference	O
sequences	O
,	O
ability	O
to	O
query	O
by	O
various	O
criteria	O
,	O
and	O
the	O
process	O
for	O
submitting	O
novel	O
variations	O
.	O

This	O
database	O
is	O
free	O
to	O
the	O
public	O
and	O
will	O
be	O
updated	O
quarterly	O
.	O

This	O
database	O
is	O
a	O
paradigm	O
for	O
formulating	O
databases	O
for	O
other	O
inherited	O
metabolic	O
disorders	O
.	O

In	O
budding	O
yeast	O
,	O
mutational	O
analyses	O
have	O
shown	O
that	O
all	O
five	O
KEOPS	B-Complex
subunits	O
contribute	O
to	O
telomere	O
homeostasis	O
and	O
t6A	O
formation	O
.	O

Of	O
the	O
five	O
KEOPS	B-Complex
subunits	O
,	O
Kae1	O
is	O
the	O
sole	O
subunit	O
universally	O
conserved	O
across	O
all	O
three	O
domains	O
of	O
life	O
.	O

Hence	O
,	O
we	O
reasoned	O
that	O
Kae1	O
contributed	O
an	O
essential	O
core	O
function	O
within	O
KEOPS	B-Complex
and	O
that	O
Bud32	O
,	O
Cgi121	O
,	O
Pcc1	O
and	O
Gon7	O
evolved	O
to	O
augment	O
or	O
regulate	O
Kae1	O
.	O

Interestingly	O
,	O
eukaryotic	O
cells	O
harbor	O
a	O
Kae1	O
paralog	O
,	O
Qri7	O
,	O
which	O
is	O
targeted	O
to	O
mitochondria	O
.	O

Consistent	O
with	O
the	O
predicted	O
paralogous	O
relationship	O
,	O
redirection	O
of	O
Qri7	O
from	O
the	O
mitochondria	O
to	O
the	O
cytoplasm	O
via	O
deletion	O
of	O
the	O
mitochondrial	O
targeting	O
sequence	O
enabled	O
rescue	O
of	O
the	O
slow	O
growth	O
phenotype	O
of	O
a	O
kae1Delta	O
yeast	O
strain	O
.	O

Intriguingly	O
,	O
GFP	O
-	O
tagged	O
Bud32	O
,	O
Gon7	O
,	O
Cgi121	O
and	O
Pcc1	O
proteins	O
do	O
not	O
localize	O
to	O
the	O
mitochondria	O
and	O
the	O
yeast	O
genome	O
does	O
not	O
appear	O
to	O
encode	O
mitochondria	O
-	O
targeted	O
paralogues	O
of	O
Bud32	O
,	O
Gon7	O
,	O
Cgi121	O
and	O
Pcc1	O
.	O

Taken	O
together	O
,	O
these	O
results	O
raised	O
the	O
possibility	O
that	O
Qri7	O
and	O
Kae1	O
share	O
a	O
common	O
essential	O
function	O
,	O
but	O
that	O
Qri7	O
operates	O
in	O
mitochondria	O
in	O
the	O
absence	O
of	O
additional	O
regulatory	O
KEOPS	B-Complex
subunits	O
.	O

Search	O
for	O
putative	O
new	O
Siah2	O
substrates	O
was	O
performed	O
using	O
LC	O
-	O
MS	O
/	O
MS	O
analysis	O
of	O
proteins	O
bound	O
to	O
a	O
ligase	O
-	O
deficient	O
Siah2	O
RING	O
mutant	O
(	O
Siah2RM	O
)	O
.	O

Among	O
Siah2	O
-	O
bound	O
proteins	O
this	O
analysis	O
confirmed	O
three	O
known	O
Siah	O
-	O
interacting	O
proteins	O
,	O
OGDH	B-Complex
(	O
2	B-Complex
-	I-Complex
oxoglutarate	I-Complex
dehydrogenase	I-Complex
)	O
,	O
GAPDH	O
(	O
glyceraldehyde	O
-	O
3	O
-	O
phosphate	O
dehydrogenase	O
)	O
,	O
and	O
TPX2	O
(	O
microtubule	O
-	O
associated	O
protein	O
homolog	O
)	O
(	O
supplementary	O
Figure	O
S1a	O
)	O
.	O

Notably	O
,	O
this	O
analysis	O
also	O
identified	O
high	O
number	O
of	O
peptides	O
for	O
two	O
members	O
of	O
the	O
ASPP	O
proteins	O
,	O
ASPP1	O
and	O
ASPP2	O
.	O

Initial	O
support	O
for	O
the	O
possibility	O
that	O
ASPPs	O
may	O
be	O
Siah2	O
substrates	O
was	O
the	O
finding	O
that	O
both	O
proteins	O
contained	O
Siah2	O
degrons	O
(	O
supplementary	O
Figure	O
S1a	O
)	O
and	O
that	O
bands	O
corresponding	O
to	O
the	O
expected	O
molecular	O
weight	O
of	O
ASPP	O
proteins	O
were	O
detected	O
in	O
the	O
silver	O
staining	O
analysis	O
of	O
Siah2	O
interacting	O
proteins	O
(	O
supplementary	O
Figure	O
S1b	O
)	O
.	O

These	O
initial	O
observations	O
were	O
corroborated	O
by	O
a	O
series	O
of	O
Siah1	O
/	O
2	O
-	O
ASPP1	O
/	O
2	O
biochemical	O
studies	O
.	O

First	O
,	O
we	O
observed	O
a	O
specific	O
interaction	O
between	O
ASPP1	O
/	O
2	O
and	O
Siah1	O
/	O
2	O
using	O
ectopically	O
expressed	O
proteins	O
(	O
Figure	O
1a	O
;	O
supplementary	O
Figure	O
S1c	O
)	O
.	O

Of	O
interest	O
,	O
the	O
in	O
vitro	O
analysis	O
for	O
ASPP1	O
/	O
2	O
-	O
Siah1	O
/	O
2	O
interaction	O
was	O
higher	O
using	O
immunoprecipitated	O
ASPP1	O
and	O
ASPP2	O
,	O
(	O
Figure	O
1b	O
;	O
supplementary	O
Figure	O
S1d	O
and	O
S1e	O
)	O
,	O
suggesting	O
that	O
ASPP1	O
/	O
2	O
may	O
be	O
subject	O
to	O
post	O
-	O
translational	O
modification	O
required	O
for	O
efficient	O
interaction	O
with	O
Siah2	O
.	O

Notably	O
,	O
specific	O
interaction	O
between	O
endogenous	O
ASPP1	O
/	O
2	O
and	O
Siah2	O
was	O
also	O
detected	O
,	O
albeit	O
,	O
in	O
the	O
presence	O
of	O
the	O
proteasome	B-Complex
inhibitor	O
,	O
implying	O
that	O
inhibition	O
of	O
proteasome	B-Complex
-	O
dependent	O
degradation	O
of	O
ASPP1	O
/	O
2	O
upon	O
association	O
with	O
Siah2	O
increases	O
the	O
available	O
pool	O
of	O
ASPP1	O
/	O
2	O
for	O
interacting	O
with	O
Siah2	O
(	O
Figure	O
1c	O
;	O
supplementary	O
Figure	O
S1f	O
)	O
.	O

That	O
input	O
level	O
of	O
ASPP2	O
was	O
not	O
increased	O
in	O
cells	O
treated	O
with	O
MG132	O
is	O
consistent	O
with	O
the	O
notion	O
that	O
ASPP2	O
requires	O
post	O
-	O
translational	O
modification	O
for	O
efficient	O
recognition	O
by	O
Siah2	O
,	O
enriched	O
upon	O
IP	O
.	O

Among	O
the	O
two	O
ubiquitin	O
ligases	O
,	O
endogenous	O
Siah2	O
,	O
but	O
not	O
Siah1	O
,	O
was	O
found	O
to	O
interact	O
with	O
ASPPs	O
,	O
implying	O
physiological	O
relevant	O
regulation	O
of	O
these	O
substrates	O
by	O
Siah2	O
.	O

Aprataxin	O
possesses	O
both	O
a	O
zinc	O
finger	O
domain	O
and	O
a	O
forkhead	O
-	O
associated	O
domain	O
(	O
major	O
splice	O
variant	O
only	O
)	O
in	O
addition	O
to	O
the	O
HIT	O
domain	O
.	O

An	O
enzyme	O
that	O
is	O
specific	O
to	O
the	O
nucleus	O
and	O
nucleolus	O
,	O
Aprataxin	O
hydrolyzes	O
both	O
dinucleotide	O
polyphosphates	O
and	O
phophoramidates	O
,	O
and	O
may	O
play	O
a	O
role	O
in	O
repairing	O
5	O
'	O
AMP	O
overhangs	O
resulting	O
from	O
the	O
repair	O
of	O
single	O
-	O
strand	O
DNA	O
breaks	O
by	O
DNA	O
ligase	O
.	O

Mutations	O
in	O
the	O
Aprataxin	O
-	O
encoding	O
gene	O
(	O
APTX	O
)	O
cause	O
ataxia	O
oculomotor	O
apraxia	O
-	O
1	O
,	O
a	O
neurodegenerative	O
disorder	O
characterized	O
by	O
the	O
inability	O
to	O
control	O
eye	O
and	O
other	O
facial	O
musculature	O
.	O

We	O
hypothesized	O
that	O
the	O
delay	O
in	O
karyogamy	O
might	O
exacerbate	O
the	O
extra	O
-	O
spore	O
phenotype	O
of	O
mal3Delta	O
cells	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
constructed	O
a	O
mutant	O
strain	O
with	O
deletions	O
of	O
both	O
mal3	O
and	O
dhc1	O
,	O
which	O
encodes	O
the	O
dynein	O
heavy	O
chain	O
,	O
and	O
a	O
mutant	O
strain	O
with	O
deletions	O
of	O
both	O
mal3	O
and	O
ssm4	O
,	O
which	O
encodes	O
the	O
p150	O
glued	O
subunit	O
of	O
the	O
dynactin	B-Complex
complex	O
,	O
since	O
nuclear	O
fusion	O
is	O
reportedly	O
delayed	O
in	O
mutants	O
lacking	O
the	O
dynein	O
heavy	O
chain	O
.	O

These	O
double	O
mutant	O
strains	O
showed	O
the	O
exaggerated	O
phenotype	O
,	O
as	O
expected	O
(	O
79	O
%	O
in	O
mal3Delta	O
dhc1Delta	O
and	O
71	O
%	O
in	O
mal3Delta	O
ssm4Delta	O
versus	O
21	O
%	O
in	O
mal3Delta	O
,	O
Fig	O
.	O
1B	O
)	O
.	O

The	O
intrinsically	O
disordered	O
C	O
-	O
terminal	O
region	O
of	O
Arabidopsis	O
thaliana	O
TCP8	O
transcription	O
factor	O
acts	O
both	O
as	O
a	O
transactivation	O
and	O
self	O
-	O
assembly	O
domain	O
.	O

TCPs	O
are	O
plant	O
specific	O
transcription	O
factors	O
with	O
non	O
-	O
canonical	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
domains	O
.	O

While	O
Arabidopsis	O
thaliana	O
has	O
24	O
TCPs	O
involved	O
in	O
cell	O
proliferation	O
and	O
differentiation	O
,	O
their	O
mode	O
of	O
action	O
has	O
not	O
been	O
fully	O
elucidated	O
.	O

Using	O
bioinformatic	O
tools	O
,	O
we	O
demonstrate	O
that	O
TCP	O
transcription	O
factors	O
belong	O
to	O
the	O
intrinsically	O
disordered	O
proteins	O
(	O
IDP	O
)	O
family	O
and	O
that	O
disorder	O
is	O
higher	O
in	O
class	O
I	O
TCPs	O
than	O
in	O
class	O
II	O
TCPs	O
.	O

In	O
particular	O
,	O
using	O
bioinformatic	O
and	O
biochemical	O
approaches	O
,	O
we	O
have	O
characterized	O
TCP8	O
,	O
a	O
class	O
I	O
TCP	O
.	O

TCP8	O
exhibits	O
three	O
intrinsically	O
disordered	O
regions	O
(	O
IDR	O
)	O
made	O
of	O
more	O
than	O
50	O
consecutive	O
residues	O
,	O
in	O
which	O
phosphorylable	O
Ser	O
residues	O
are	O
mainly	O
clustered	O
.	O

Phosphorylation	O
of	O
Ser	O
-	O
211	O
that	O
belongs	O
to	O
the	O
central	O
IDR	O
was	O
confirmed	O
by	O
mass	O
spectrometry	O
.	O

Yeast	O
two	O
-	O
hybrid	O
assays	O
also	O
showed	O
that	O
the	O
C	O
-	O
terminal	O
IDR	O
corresponds	O
to	O
a	O
transactivation	O
domain	O
.	O

Moreover	O
,	O
biochemical	O
experiments	O
demonstrated	O
that	O
TCP8	O
tends	O
to	O
oligomerize	O
in	O
dimers	O
,	O
trimers	O
and	O
higher	O
-	O
order	O
multimers	O
.	O

Bimolecular	O
fluorescence	O
complementation	O
(	O
BiFC	O
)	O
experiments	O
carried	O
out	O
on	O
a	O
truncated	O
form	O
of	O
TCP8	O
lacking	O
the	O
C	O
-	O
terminal	O
IDR	O
indicated	O
that	O
it	O
is	O
effectively	O
required	O
for	O
the	O
pronounced	O
self	O
-	O
assembly	O
of	O
TCP8	O
.	O

These	O
data	O
were	O
reinforced	O
by	O
the	O
prediction	O
of	O
a	O
coiled	O
coil	O
domain	O
in	O
this	O
IDR	O
.	O

The	O
C	O
-	O
terminal	O
IDR	O
acts	O
thus	O
as	O
an	O
oligomerization	O
domain	O
and	O
also	O
a	O
transactivation	O
domain	O
.	O

Moreover	O
,	O
many	O
Molecular	O
Recognition	O
Features	O
(	O
MoRFs	O
)	O
were	O
predicted	O
,	O
indicating	O
that	O
TCP8	O
could	O
interact	O
with	O
several	O
partners	O
to	O
fulfill	O
a	O
fine	O
regulation	O
of	O
transcription	O
in	O
response	O
to	O
various	O
stimuli	O
.	O

Interaction	O
between	O
NBS1	O
and	O
the	O
mTOR	O
/	O
Rictor	O
/	O
SIN1	O
complex	O
through	O
specific	O
domains	O
.	O

Nijmegen	O
breakage	O
syndrome	O
(	O
NBS	O
)	O
is	O
a	O
chromosomal	O
-	O
instability	O
syndrome	O
.	O

The	O
NBS	O
gene	O
product	O
,	O
NBS1	O
(	O
p95	O
or	O
nibrin	O
)	O
,	O
is	O
a	O
part	O
of	O
the	O
Mre11	O
-	O
Rad50	O
-	O
NBS1	O
complex	O
.	O

SIN1	O
is	O
a	O
component	O
of	O
the	O
mTOR	O
/	O
Rictor	O
/	O
SIN1	O
complex	O
mediating	O
the	O
activation	O
of	O
Akt	O
.	O

Here	O
we	O
show	O
that	O
NBS1	O
interacted	O
with	O
mTOR	O
,	O
Rictor	O
,	O
and	O
SIN1	O
.	O

The	O
specific	O
domains	O
of	O
mTOR	O
,	O
Rictor	O
,	O
or	O
SIN1	O
interacted	O
with	O
the	O
internal	O
domain	O
(	O
a	O
.	O
a	O
.	O
221	O
-	O
402	O
)	O
of	O
NBS1	O
.	O

Sucrose	O
density	O
gradient	O
showed	O
that	O
NBS1	O
was	O
located	O
in	O
the	O
same	O
fractions	O
as	O
the	O
mTOR	O
/	O
Rictor	O
/	O
SIN1	O
complex	O
.	O

Knockdown	O
of	O
NBS1	O
decreased	O
the	O
levels	O
of	O
phosphorylated	O
Akt	O
and	O
its	O
downstream	O
targets	O
.	O

Ionizing	O
radiation	O
(	O
IR	O
)	O
increased	O
the	O
NBS1	O
levels	O
and	O
activated	O
Akt	O
activity	O
.	O

These	O
results	O
demonstrate	O
that	O
NBS1	O
interacts	O
with	O
the	O
mTOR	O
/	O
Rictor	O
/	O
SIN1	O
complex	O
through	O
the	O
a	O
.	O
a	O
.	O

221	O
-	O
402	O
domain	O
and	O
contributes	O
to	O
the	O
activation	O
of	O
Akt	O
activity	O
.	O

Development	O
of	O
a	O
high	O
-	O
throughput	O
screen	O
to	O
detect	O
inhibitors	O
of	O
TRPS1	O
sumoylation	O
.	O

Small	O
ubiquitin	O
-	O
like	O
modifier	O
(	O
SUMO	O
)	O
belongs	O
to	O
the	O
family	O
of	O
ubiquitin	O
-	O
like	O
proteins	O
(	O
Ubls	O
)	O
that	O
can	O
be	O
reversibly	O
conjugated	O
to	O
target	O
-	O
specific	O
lysines	O
on	O
substrate	O
proteins	O
.	O

Although	O
covalently	O
sumoylated	O
products	O
are	O
readily	O
detectible	O
in	O
gel	O
-	O
based	O
assays	O
,	O
there	O
has	O
been	O
little	O
progress	O
toward	O
the	O
development	O
of	O
robust	O
quantitative	O
sumoylation	O
assay	O
formats	O
for	O
the	O
evaluation	O
of	O
large	O
compound	O
libraries	O
.	O

In	O
an	O
effort	O
to	O
identify	O
inhibitors	O
of	O
ubiquitin	O
carrier	O
protein	O
9	O
(	O
Ubc9	O
)	O
-	O
dependent	O
sumoylation	O
,	O
a	O
high	O
-	O
throughput	O
fluorescence	O
polarization	O
assay	O
was	O
developed	O
,	O
which	O
allows	O
detection	O
of	O
Lys	O
-	O
1201	O
sumoylation	O
,	O
corresponding	O
to	O
the	O
major	O
site	O
of	O
functional	O
sumoylation	O
within	O
the	O
transcriptional	O
repressor	O
trichorhino	O
-	O
phalangeal	O
syndrome	O
type	O
I	O
protein	O
(	O
TRPS1	O
)	O
.	O

A	O
minimal	O
hexapeptide	O
substrate	O
peptide	O
,	O
TMR	O
-	O
VVK1201TEK	O
,	O
was	O
used	O
in	O
this	O
assay	O
format	O
to	O
afford	O
high	O
-	O
throughput	O
screening	O
of	O
the	O
GlaxoSmithKline	O
diversity	O
compound	O
collection	O
.	O

A	O
total	O
of	O
728	O
hits	O
were	O
confirmed	O
but	O
no	O
specific	O
noncovalent	O
inhibitors	O
of	O
Ubc9	O
dependent	O
trans	O
-	O
sumoylation	O
were	O
found	O
.	O

However	O
,	O
several	O
diaminopyrimidine	O
compounds	O
were	O
identified	O
as	O
inhibitors	O
in	O
the	O
assay	O
with	O
IC50	O
values	O
of	O
12	O
.	O
5	O
muM	O
.	O

These	O
were	O
further	O
characterized	O
to	O
be	O
competent	O
substrates	O
which	O
were	O
subject	O
to	O
sumoylation	O
by	O
SUMO	O
-	O
Ubc9	O
and	O
which	O
were	O
competitive	O
with	O
the	O
sumoylation	O
of	O
the	O
TRPS1	O
peptide	O
substrates	O
.	O

IM	O
-	O
MS	O
measurements	O
for	O
the	O
ASB9	O
-	O
EloBC	O
-	O
Cul5NTD	O
protein	O
complex	O
were	O
performed	O
with	O
the	O
Synapt	O
HDMS	O
.	O

N2	O
gas	O
was	O
used	O
in	O
the	O
ion	O
-	O
mobility	O
cell	O
at	O
0	O
.	O
5	O
mbar	O
pressure	O
,	O
whereas	O
the	O
traveling	O
wave	O
velocity	O
was	O
250	O
ms	O
-	O
1	O
.	O

To	O
optimize	O
the	O
IM	O
separation	O
for	O
the	O
ASB9	O
-	O
EloBC	O
-	O
Cul5NTD	O
complex	O
,	O
measurements	O
were	O
taken	O
at	O
six	O
wave	O
heights	O
(	O
7	O
.	O
0	O
,	O
7	O
.	O
5	O
,	O
8	O
.	O
0	O
,	O
8	O
.	O
5	O
,	O
9	O
.	O
0	O
,	O
and	O
9	O
.	O
5	O
V	O
)	O
.	O

The	O
reported	O
collision	O
cross	O
section	O
(	O
CCS	O
)	O
values	O
are	O
an	O
average	O
of	O
the	O
data	O
recorded	O
over	O
all	O
of	O
the	O
wave	O
heights	O
.	O

The	O
CCS	O
calibration	O
procedure	O
used	O
was	O
described	O
previously	O
and	O
involved	O
validation	O
through	O
the	O
use	O
of	O
CCS	O
data	O
from	O
other	O
known	O
protein	O
ions	O
.	O

The	O
drift	O
times	O
for	O
all	O
charge	O
states	O
were	O
obtained	O
using	O
MassLynx	O
and	O
DriftScope	O
(	O
Waters	O
)	O
.	O

Direct	O
comparison	O
of	O
PRDC	O
and	O
SOST	O
monomers	O
reveals	O
an	O
RMSD	O
of	O
3	O
.	O
3	O
Aa	O
when	O
aligning	O
their	O
cystine	O
knot	O
motifs	O
,	O
including	O
F1	O
and	O
F2	O
of	O
their	O
DAN	O
domains	O
.	O

However	O
,	O
PRDC	O
shows	O
a	O
number	O
of	O
significant	O
structural	O
differences	O
in	O
the	O
N	O
-	O
terminus	O
and	O
Wrist	O
region	O
,	O
accounting	O
for	O
an	O
overall	O
RMSD	O
of	O
8	O
.	O
7	O
Aa	O
(	O
Figure	O
6B	O
)	O
.	O

Interestingly	O
,	O
these	O
same	O
regions	O
form	O
important	O
contacts	O
at	O
the	O
dimer	O
interface	O
of	O
PRDC	O
,	O
providing	O
an	O
explanation	O
of	O
the	O
assembly	O
differences	O
of	O
PRDC	O
and	O
SOST	O
(	O
dimer	O
vs	O
.	O
monomer	O
)	O
.	O

In	O
terms	O
of	O
BMP	O
inhibition	O
,	O
there	O
is	O
limited	O
conservation	O
between	O
PRDC	O
and	O
SOST	O
for	O
the	O
hydrophobic	O
residues	O
defining	O
the	O
BMP	O
-	O
binding	O
epitope	O
(	O
Figure	O
6A	O
)	O
.	O

Without	O
these	O
residues	O
,	O
it	O
would	O
be	O
expected	O
that	O
SOST	O
would	O
be	O
limited	O
in	O
terms	O
of	O
BMP	O
-	O
binding	O
affinity	O
or	O
bind	O
BMP	O
utilizing	O
a	O
different	O
epitope	O
than	O
PRDC	O
.	O

Certainly	O
a	O
key	O
structural	O
difference	O
between	O
the	O
two	O
DAN	O
family	O
members	O
is	O
dimerization	O
.	O

Therefore	O
,	O
a	O
dimer	O
with	O
two	O
BMP	O
binding	O
epitopes	O
would	O
offer	O
an	O
advantage	O
to	O
affinity	O
when	O
binding	O
to	O
BMP	O
ligands	O
,	O
much	O
like	O
the	O
Noggin	O
dimer	O
.	O

Furthermore	O
,	O
lack	O
of	O
dimer	O
formation	O
might	O
allow	O
SOST	O
to	O
function	O
as	O
a	O
more	O
effective	O
Wnt	O
inhibitor	O
.	O

Recent	O
studies	O
have	O
pinpointed	O
the	O
interaction	O
of	O
SOST	O
with	O
LRP5	O
/	O
6	O
to	O
a	O
linear	O
stretch	O
of	O
residues	O
within	O
the	O
wrist	O
region	O
of	O
SOST	O
.	O

Besides	O
a	O
lack	O
of	O
conservation	O
with	O
PRDC	O
,	O
these	O
residues	O
are	O
packed	O
at	O
the	O
dimer	O
interface	O
and	O
would	O
not	O
be	O
solvent	O
accessible	O
as	O
in	O
SOST	O
.	O

Therefore	O
,	O
differences	O
in	O
specific	O
residues	O
and	O
overall	O
oligimerization	O
could	O
differentiate	O
BMP	O
or	O
Wnt	O
antagonism	O
.	O

In	O
the	O
future	O
,	O
it	O
will	O
be	O
interesting	O
to	O
see	O
if	O
those	O
DAN	O
family	O
antagonists	O
that	O
exist	O
as	O
dimers	O
solely	O
exhibit	O
anti	O
-	O
BMP	O
functionality	O
.	O

In	O
support	O
of	O
this	O
notion	O
,	O
we	O
have	O
previously	O
characterized	O
Dan	O
,	O
which	O
is	O
very	O
different	O
than	O
PRDC	O
and	O
SOST	O
,	O
to	O
exist	O
as	O
a	O
non	O
-	O
covalent	O
dimer	O
capable	O
of	O
inhibiting	O
BMP	O
signaling	O
.	O

In	O
sight	O
of	O
this	O
,	O
it	O
can	O
be	O
expected	O
that	O
Gremlin	O
,	O
a	O
potent	O
inhibitor	O
of	O
BMP	O
signaling	O
,	O
also	O
exists	O
as	O
a	O
dimer	O
.	O

Protein	B-Complex
kinase	I-Complex
CK2	I-Complex
holoenzyme	O
promotes	O
start	O
-	O
specific	O
transcription	O
in	O
Saccharomyces	O
cerevisiae	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
the	O
entrance	O
into	O
S	O
phase	O
requires	O
the	O
activation	O
of	O
a	O
specific	O
burst	O
of	O
transcription	O
,	O
which	O
depends	O
on	O
SBF	B-Complex
(	O
SCB	B-Complex
binding	I-Complex
factor	I-Complex
,	O
Swi4	O
/	O
Swi6	O
)	O
and	O
MBF	B-Complex
(	O
MCB	B-Complex
binding	I-Complex
factor	I-Complex
,	O
Mbp1	O
/	O
Swi6	O
)	O
complexes	O
.	O

CK2	B-Complex
is	O
a	O
pleiotropic	O
kinase	O
involved	O
in	O
several	O
cellular	O
processes	O
,	O
including	O
the	O
regulation	O
of	O
the	O
cell	O
cycle	O
.	O

CK2	B-Complex
is	O
composed	O
of	O
two	O
catalytic	O
subunits	O
(	O
alpha	O
and	O
alpha	O
'	O
)	O
and	O
two	O
regulatory	O
subunits	O
(	O
beta	O
and	O
beta	O
'	O
)	O
,	O
both	O
of	O
which	O
are	O
required	O
to	O
form	O
the	O
active	O
holoenzyme	O
.	O

Here	O
we	O
investigate	O
the	O
function	O
of	O
the	O
CK2	B-Complex
holoenzyme	O
in	O
Start	O
-	O
specific	O
transcription	O
.	O

The	O
ckb1Delta	O
ckb2Delta	O
mutant	O
strain	O
,	O
bearing	O
deletions	O
of	O
both	O
genes	O
encoding	O
CK2	B-Complex
regulatory	O
subunits	O
,	O
shows	O
a	O
delay	O
of	O
S	O
-	O
phase	O
entrance	O
due	O
to	O
a	O
severe	O
reduction	O
of	O
the	O
expression	O
of	O
SBF	B-Complex
-	O
and	O
MBF	B-Complex
-	O
dependent	O
genes	O
.	O

This	O
transcriptional	O
defect	O
is	O
caused	O
by	O
an	O
impaired	O
recruitment	O
of	O
Swi6	O
and	O
Swi4	O
to	O
G1	O
gene	O
promoters	O
.	O

Moreover	O
,	O
CK2	O
alpha	O
and	O
beta	O
'	O
subunits	O
interact	O
with	O
RNA	B-Complex
polymerase	I-Complex
II	I-Complex
,	O
whose	O
binding	O
to	O
G1	O
promoters	O
is	O
positively	O
regulated	O
by	O
the	O
CK2	B-Complex
holoenzyme	O
.	O

Collectively	O
,	O
these	O
findings	O
suggest	O
a	O
novel	O
role	O
for	O
the	O
CK2	B-Complex
holoenzyme	O
in	O
the	O
activation	O
of	O
G1	O
transcription	O
.	O

Temporal	O
analysis	O
of	O
recruitment	O
of	O
mammalian	O
ATG	O
proteins	O
to	O
the	O
autophagosome	O
formation	O
site	O
.	O

Autophagosome	O
formation	O
is	O
governed	O
by	O
sequential	O
functions	O
of	O
autophagy	O
-	O
related	O
(	O
ATG	O
)	O
proteins	O
.	O

Although	O
their	O
genetic	O
hierarchy	O
in	O
terms	O
of	O
localization	O
to	O
the	O
autophagosome	O
formation	O
site	O
has	O
been	O
determined	O
,	O
their	O
temporal	O
relationships	O
remain	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
comprehensively	O
analyzed	O
the	O
recruitment	O
of	O
mammalian	O
ATG	O
proteins	O
to	O
the	O
autophagosome	O
formation	O
site	O
by	O
live	O
-	O
cell	O
imaging	O
,	O
and	O
determined	O
their	O
temporal	O
relationships	O
.	O

Although	O
ULK1	O
and	O
ATG5	O
are	O
separated	O
in	O
the	O
genetic	O
hierarchy	O
,	O
they	O
synchronously	O
accumulate	O
at	O
pre	O
-	O
existing	O
VMP1	O
-	O
positive	O
punctate	O
structures	O
,	O
followed	O
by	O
recruitment	O
of	O
ATG14	O
,	O
ZFYVE1	O
,	O
and	O
WIPI1	O
.	O

Only	O
a	O
small	O
number	O
of	O
ATG9	O
vesicles	O
appear	O
to	O
be	O
associated	O
with	O
these	O
structures	O
.	O

Finally	O
,	O
LC3	O
and	O
SQSTM1	O
/	O
p62	O
accumulate	O
synchronously	O
,	O
while	O
the	O
other	O
ATG	O
proteins	O
dissociate	O
from	O
the	O
autophagic	O
structures	O
.	O

These	O
results	O
suggest	O
that	O
autophagosome	O
formation	O
takes	O
place	O
on	O
the	O
VMP1	O
-	O
containing	O
domain	O
of	O
the	O
endoplasmic	O
reticulum	O
or	O
a	O
closely	O
related	O
structure	O
,	O
where	O
ULK1	O
and	O
ATG5	O
complexes	O
are	O
synchronously	O
recruited	O
.	O

Myc	O
-	O
driven	O
overgrowth	O
requires	O
unfolded	O
protein	O
response	O
-	O
mediated	O
induction	O
of	O
autophagy	O
and	O
antioxidant	O
responses	O
in	O
Drosophila	O
melanogaster	O
.	O

Autophagy	O
,	O
a	O
lysosomal	O
self	O
-	O
degradation	O
and	O
recycling	O
pathway	O
,	O
plays	O
dual	O
roles	O
in	O
tumorigenesis	O
.	O

Autophagy	O
deficiency	O
predisposes	O
to	O
cancer	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
accumulation	O
of	O
the	O
selective	O
autophagy	O
cargo	O
p62	O
,	O
leading	O
to	O
activation	O
of	O
antioxidant	O
responses	O
and	O
tumor	O
formation	O
.	O

While	O
cell	O
growth	O
and	O
autophagy	O
are	O
inversely	O
regulated	O
in	O
most	O
cells	O
,	O
elevated	O
levels	O
of	O
autophagy	O
are	O
observed	O
in	O
many	O
established	O
tumors	O
,	O
presumably	O
mediating	O
survival	O
of	O
cancer	O
cells	O
.	O

Still	O
,	O
the	O
relationship	O
of	O
autophagy	O
and	O
oncogenic	O
signaling	O
is	O
poorly	O
characterized	O
.	O

Here	O
we	O
show	O
that	O
the	O
evolutionarily	O
conserved	O
transcription	O
factor	O
Myc	O
(	O
dm	O
)	O
,	O
a	O
proto	O
-	O
oncogene	O
involved	O
in	O
cell	O
growth	O
and	O
proliferation	O
,	O
is	O
also	O
a	O
physiological	O
regulator	O
of	O
autophagy	O
in	O
Drosophila	O
melanogaster	O
.	O

Loss	O
of	O
Myc	O
activity	O
in	O
null	O
mutants	O
or	O
in	O
somatic	O
clones	O
of	O
cells	O
inhibits	O
autophagy	O
.	O

Forced	O
expression	O
of	O
Myc	O
results	O
in	O
cell	O
-	O
autonomous	O
increases	O
in	O
cell	O
growth	O
,	O
autophagy	O
induction	O
,	O
and	O
p62	O
(	O
Ref2P	O
)	O
-	O
mediated	O
activation	O
of	O
Nrf2	O
(	O
cnc	O
)	O
,	O
a	O
transcription	O
factor	O
promoting	O
antioxidant	O
responses	O
.	O

Mechanistically	O
,	O
Myc	O
overexpression	O
increases	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
,	O
which	O
leads	O
to	O
PERK	O
-	O
dependent	O
autophagy	O
induction	O
and	O
may	O
be	O
responsible	O
for	O
p62	O
accumulation	O
.	O

Genetic	O
or	O
pharmacological	O
inhibition	O
of	O
UPR	O
,	O
autophagy	O
or	O
p62	O
/	O
Nrf2	O
signaling	O
prevents	O
Myc	O
-	O
induced	O
overgrowth	O
,	O
while	O
these	O
pathways	O
are	O
dispensable	O
for	O
proper	O
growth	O
of	O
control	O
cells	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
the	O
autophagy	O
and	O
antioxidant	O
pathways	O
are	O
required	O
in	O
parallel	O
for	O
excess	O
cell	O
growth	O
driven	O
by	O
Myc	O
.	O

Deregulated	O
expression	O
of	O
Myc	O
drives	O
tumor	O
progression	O
in	O
most	O
human	O
cancers	O
,	O
and	O
UPR	O
and	O
autophagy	O
have	O
been	O
implicated	O
in	O
the	O
survival	O
of	O
Myc	O
-	O
dependent	O
cancer	O
cells	O
.	O

Our	O
data	O
obtained	O
in	O
a	O
complete	O
animal	O
show	O
that	O
UPR	O
,	O
autophagy	O
and	O
p62	O
/	O
Nrf2	O
signaling	O
are	O
required	O
for	O
Myc	O
-	O
dependent	O
cell	O
growth	O
.	O

These	O
novel	O
results	O
give	O
additional	O
support	O
for	O
finding	O
future	O
approaches	O
to	O
specifically	O
inhibit	O
the	O
growth	O
of	O
cancer	O
cells	O
addicted	O
to	O
oncogenic	O
Myc	O
.	O

Previously	O
,	O
we	O
have	O
genetically	O
and	O
molecularly	O
characterized	O
the	O
functions	O
of	O
PCFS4	O
in	O
flowering	O
time	O
control	O
.	O

We	O
found	O
that	O
the	O
flowering	O
delay	O
of	O
the	O
pcfs4	O
mutants	O
could	O
be	O
partially	O
explained	O
by	O
the	O
effects	O
of	O
PCFS4	O
on	O
the	O
alternative	O
processing	O
of	O
FCA	O
pre	O
-	O
mRNA	O
.	O

In	O
addition	O
to	O
its	O
delayed	O
flowering	O
,	O
pcfs4	O
mutants	O
also	O
showed	O
other	O
phenotypes	O
including	O
reduced	O
vigor	O
of	O
their	O
seedlings	O
,	O
altered	O
leaf	O
shape	O
and	O
inflorescence	O
phyllotaxy	O
(	O
Figure	O
1	O
)	O
.	O

In	O
the	O
early	O
seedling	O
stage	O
,	O
mutant	O
plants	O
were	O
significantly	O
smaller	O
than	O
the	O
wild	O
type	O
(	O
Figure	O
1A	O
)	O
.	O

Leaf	O
edges	O
of	O
pcfs4	O
-	O
1	O
were	O
more	O
curved	O
down	O
towards	O
its	O
abaxial	O
side	O
(	O
Figure	O
1B	O
)	O
.	O

The	O
siliques	O
of	O
pcfs4	O
-	O
1	O
mutants	O
formed	O
a	O
larger	O
angle	O
with	O
its	O
stem	O
in	O
contrast	O
to	O
that	O
in	O
wild	O
type	O
Col	O
(	O
Figure	O
1C	O
)	O
.	O

Albeit	O
all	O
these	O
defects	O
,	O
the	O
mutant	O
remained	O
quite	O
healthy	O
throughout	O
its	O
whole	O
life	O
cycle	O
in	O
the	O
standard	O
growth	O
conditions	O
,	O
suggesting	O
that	O
PCFS4	O
is	O
not	O
essential	O
for	O
the	O
viability	O
of	O
the	O
plants	O
.	O

Supporting	O
this	O
conclusion	O
is	O
that	O
the	O
expression	O
of	O
PCFS4	O
is	O
not	O
ubiquitous	O
,	O
but	O
instead	O
,	O
tissue	O
-	O
specific	O
and	O
developmentally	O
regulated	O
.	O

The	O
non	O
-	O
essential	O
nature	O
of	O
PCFS4	O
for	O
plant	O
viability	O
and	O
specific	O
developmental	O
defects	O
of	O
pcfs4	O
mutants	O
support	O
a	O
hypothesis	O
that	O
PCFS4	O
might	O
specifically	O
target	O
on	O
a	O
subset	O
of	O
genes	O
.	O

The	O
EBAX	O
-	O
type	O
Cullin	O
-	O
RING	O
E3	O
ligase	O
and	O
Hsp90	O
guard	O
the	O
protein	O
quality	O
of	O
the	O
SAX	O
-	O
3	O
/	O
Robo	O
receptor	O
in	O
developing	O
neurons	O
.	O

Although	O
protein	O
quality	O
control	O
(	O
PQC	O
)	O
is	O
generally	O
perceived	O
as	O
important	O
for	O
the	O
development	O
of	O
the	O
nervous	O
system	O
,	O
the	O
specific	O
mechanisms	O
of	O
neuronal	O
PQC	O
have	O
remained	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
report	O
that	O
C	O
.	O
elegans	O
Elongin	O
BC	O
-	O
binding	O
axon	O
regulator	O
(	O
EBAX	O
-	O
1	O
)	O
,	O
a	O
conserved	O
BC	O
-	O
box	O
protein	O
,	O
regulates	O
axon	O
guidance	O
through	O
PQC	O
of	O
the	O
SAX	O
-	O
3	O
/	O
Robo	O
receptor	O
.	O

EBAX	O
-	O
1	O
buffers	O
guidance	O
errors	O
against	O
temperature	O
variations	O
.	O

As	O
a	O
substrate	O
-	O
recognition	O
subunit	O
in	O
the	O
Elongin	O
BC	O
-	O
containing	O
Cullin	O
-	O
RING	O
ubiquitin	O
ligase	O
(	O
CRL	O
)	O
,	O
EBAX	O
-	O
1	O
also	O
binds	O
to	O
DAF	O
-	O
21	O
,	O
a	O
cytosolic	O
Hsp90	O
chaperone	O
.	O

The	O
EBAX	O
-	O
type	O
CRL	O
and	O
DAF	O
-	O
21	O
collaboratively	O
regulate	O
SAX	O
-	O
3	O
-	O
mediated	O
axon	O
pathfinding	O
.	O

Biochemical	O
and	O
imaging	O
assays	O
indicate	O
that	O
EBAX	O
-	O
1	O
specifically	O
recognizes	O
misfolded	O
SAX	O
-	O
3	O
and	O
promotes	O
its	O
degradation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Importantly	O
,	O
vertebrate	O
EBAX	O
also	O
shows	O
substrate	O
preference	O
toward	O
aberrant	O
Robo3	O
implicated	O
in	O
horizontal	O
gaze	O
palsy	O
with	O
progressive	O
scoliosis	O
(	O
HGPPS	O
)	O
.	O

Together	O
,	O
our	O
findings	O
demonstrate	O
a	O
triage	O
PQC	O
mechanism	O
mediated	O
by	O
the	O
EBAX	O
-	O
type	O
CRL	O
and	O
DAF	O
-	O
21	O
/	O
Hsp90	O
that	O
maintains	O
the	O
accuracy	O
of	O
neuronal	O
wiring	O
.	O

RNF185	O
is	O
a	O
novel	O
E3	O
ligase	O
of	O
endoplasmic	O
reticulum	O
-	O
associated	O
degradation	O
(	O
ERAD	O
)	O
that	O
targets	O
cystic	O
fibrosis	O
transmembrane	O
conductance	O
regulator	O
(	O
CFTR	O
)	O
.	O

In	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
,	O
misfolded	O
or	O
improperly	O
assembled	O
proteins	O
are	O
exported	O
to	O
the	O
cytoplasm	O
and	O
degraded	O
by	O
the	O
ubiquitin	O
-	O
proteasome	B-Complex
pathway	O
through	O
a	O
process	O
called	O
ER	O
-	O
associated	O
degradation	O
(	O
ERAD	O
)	O
.	O

ER	O
-	O
associated	O
E3	O
ligases	O
,	O
which	O
coordinate	O
substrate	O
recognition	O
,	O
export	O
,	O
and	O
proteasome	B-Complex
targeting	O
,	O
are	O
key	O
components	O
of	O
ERAD	O
.	O

Cystic	O
fibrosis	O
transmembrane	O
conductance	O
regulator	O
(	O
CFTR	O
)	O
is	O
one	O
ERAD	O
substrate	O
targeted	O
to	O
co	O
-	O
translational	O
degradation	O
by	O
the	O
E3	O
ligase	O
RNF5	O
/	O
RMA1	O
.	O

RNF185	O
is	O
a	O
RING	O
domain	O
-	O
containing	O
polypeptide	O
homologous	O
to	O
RNF5	O
.	O

We	O
show	O
that	O
RNF185	O
controls	O
the	O
stability	O
of	O
CFTR	O
and	O
of	O
the	O
CFTRDeltaF508	O
mutant	O
in	O
a	O
RING	O
-	O
and	O
proteasome	B-Complex
-	O
dependent	O
manner	O
but	O
does	O
not	O
control	O
that	O
of	O
other	O
classical	O
ERAD	O
model	O
substrates	O
.	O

Reciprocally	O
,	O
its	O
silencing	O
stabilizes	O
CFTR	O
proteins	O
.	O

Turnover	O
analyses	O
indicate	O
that	O
,	O
as	O
RNF5	O
,	O
RNF185	O
targets	O
CFTR	O
to	O
co	O
-	O
translational	O
degradation	O
.	O

Importantly	O
,	O
however	O
,	O
simultaneous	O
depletion	O
of	O
RNF5	O
and	O
RNF185	O
profoundly	O
blocks	O
CFTRDeltaF508	O
degradation	O
not	O
only	O
during	O
translation	O
but	O
also	O
after	O
synthesis	O
is	O
complete	O
.	O

Our	O
data	O
thus	O
identify	O
RNF185	O
and	O
RNF5	O
as	O
a	O
novel	O
E3	O
ligase	O
module	O
that	O
is	O
central	O
to	O
the	O
control	O
of	O
CFTR	O
degradation	O
.	O

Three	O
overlapping	O
AbG	O
sets	O
were	O
defined	O
to	O
include	O
AbGs	O
-	O
5	O
kb	O
,	O
-	O
1	O
kb	O
and	O
-	O
0	O
.	O
5	O
kb	O
,	O
which	O
consist	O
of	O
genes	O
with	O
at	O
least	O
one	O
Ago1	O
peak	O
within	O
+	O
/	O
-	O
5	O
,	O
+	O
/	O
-	O
1	O
,	O
and	O
+	O
/	O
-	O
0	O
.	O
5	O
kb	O
away	O
from	O
TSSs	O
,	O
respectively	O
.	O

AbGs	O
-	O
5	O
kb	O
,	O
-	O
1	O
kb	O
and	O
-	O
0	O
.	O
5	O
kb	O
respectively	O
contain	O
15503	O
,	O
10074	O
,	O
and	O
8057	O
unique	O
genes	O
encompassing	O
27	O
.	O
5	O
%	O
,	O
17	O
.	O
9	O
%	O
,	O
and	O
14	O
.	O
3	O
%	O
of	O
all	O
annotated	O
genes	O
in	O
Ensembl	O
human	O
genome	O
database	O
(	O
Table	O
S10	O
,	O
S11	O
,	O
S12	O
)	O
.	O

Interestingly	O
,	O
clustering	O
AbGs	O
-	O
5	O
kb	O
,	O
-	O
1	O
kb	O
or	O
-	O
0	O
.	O
5	O
kb	O
genes	O
by	O
their	O
chromosomal	O
location	O
reveal	O
several	O
cytobands	O
implicated	O
in	O
different	O
human	O
cancers	O
that	O
are	O
highly	O
overrepresented	O
(	O
Figure	O
S9	O
,	O
Table	O
S13	O
,	O
S14	O
)	O
.	O

For	O
example	O
,	O
the	O
top	O
-	O
enriched	O
cytobands	O
19p13	O
.	O
3	O
and	O
16p13	O
.	O
3	O
have	O
been	O
established	O
by	O
numerous	O
studies	O
to	O
be	O
susceptibility	O
loci	O
for	O
several	O
types	O
of	O
cancers	O
including	O
prostate	O
,	O
breast	O
,	O
thyroid	O
,	O
and	O
lymphoma	O
.	O

NEDD4	O
E3	O
ligase	O
inhibits	O
the	O
activity	O
of	O
the	O
Hippo	O
pathway	O
by	O
targeting	O
LATS1	O
for	O
degradation	O
.	O

Proper	O
regulation	O
of	O
cell	O
proliferation	O
,	O
cell	O
apoptosis	O
,	O
and	O
cell	O
death	O
are	O
vital	O
for	O
the	O
development	O
and	O
survival	O
of	O
living	O
organisms	O
.	O

Failure	O
or	O
dysfunction	O
of	O
any	O
of	O
these	O
processes	O
can	O
have	O
devastating	O
effects	O
,	O
including	O
cancer	O
.	O

The	O
Hippo	O
pathway	O
,	O
first	O
discovered	O
in	O
Drosophila	O
,	O
has	O
been	O
found	O
to	O
be	O
a	O
major	O
growth	O
-	O
regulatory	O
signaling	O
pathway	O
that	O
controls	O
these	O
crucial	O
processes	O
and	O
has	O
been	O
implicated	O
in	O
cell	O
-	O
progress	O
regulation	O
and	O
organ	O
size	O
determination	O
.	O

Abnormal	O
regulation	O
of	O
this	O
pathway	O
has	O
been	O
found	O
in	O
several	O
cancer	O
types	O
.	O

However	O
,	O
the	O
mechanisms	O
that	O
regulate	O
the	O
pathway	O
and	O
its	O
core	O
members	O
yet	O
have	O
to	O
be	O
elucidated	O
.	O

One	O
of	O
the	O
main	O
core	O
components	O
of	O
this	O
pathway	O
is	O
LATS1	O
,	O
a	O
serine	O
/	O
threonine	O
kinase	O
.	O

Therefore	O
,	O
understanding	O
how	O
LATS1	O
activity	O
is	O
regulated	O
is	O
expected	O
to	O
shed	O
light	O
on	O
new	O
mechanisms	O
that	O
regulate	O
the	O
Hippo	O
pathway	O
.	O

In	O
the	O
current	O
work	O
,	O
we	O
identified	O
several	O
potential	O
LATS1	O
regulators	O
and	O
proved	O
that	O
NEDD4	O
E3	O
ubiquitin	O
ligase	O
controls	O
LATS1	O
stability	O
.	O

We	O
demonstrate	O
that	O
NEDD4	O
directly	O
interacts	O
with	O
LATS1	O
,	O
leading	O
to	O
ubiquitination	O
and	O
decreased	O
levels	O
of	O
LATS1	O
and	O
,	O
thus	O
,	O
increased	O
YAP	O
localization	O
in	O
the	O
nucleus	O
,	O
which	O
subsequently	O
increases	O
the	O
transcriptional	O
activity	O
of	O
YAP	O
.	O

As	O
such	O
,	O
we	O
show	O
that	O
NEDD4	O
acts	O
as	O
an	O
additional	O
regulator	O
of	O
the	O
Hippo	O
pathway	O
on	O
the	O
protein	O
level	O
via	O
interactions	O
between	O
WW	O
domain	O
-	O
containing	O
and	O
PPxY	O
motif	O
-	O
containing	O
proteins	O
.	O

These	O
findings	O
might	O
be	O
applied	O
in	O
the	O
development	O
of	O
new	O
therapeutic	O
approaches	O
through	O
the	O
activation	O
of	O
LATS1	O
.	O

Counteracting	O
neuronal	O
nitric	O
oxide	O
synthase	O
proteasomal	O
degradation	O
improves	O
glucose	O
transport	O
in	O
insulin	O
-	O
resistant	O
skeletal	O
muscle	O
from	O
Zucker	O
fa	O
/	O
fa	O
rats	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O
Insulin	O
-	O
mediated	O
glucose	O
transport	O
and	O
utilisation	O
are	O
decreased	O
in	O
skeletal	O
muscle	O
from	O
type	O
2	O
diabetic	O
and	O
glucose	O
-	O
intolerant	O
individuals	O
because	O
of	O
alterations	O
in	O
insulin	O
receptor	O
signalling	O
,	O
GLUT4	O
translocation	O
to	O
the	O
plasma	O
membrane	O
and	O
microvascular	O
blood	O
flow	O
.	O

Catalytic	O
activity	O
of	O
the	O
muscle	O
-	O
specific	O
isoform	O
of	O
neuronal	O
nitric	O
oxide	O
synthase	O
(	O
nNOS	O
)	O
also	O
participates	O
in	O
the	O
regulation	O
of	O
glucose	O
transport	O
and	O
appears	O
to	O
be	O
decreased	O
in	O
a	O
relevant	O
animal	O
model	O
of	O
drastic	O
insulin	O
resistance	O
,	O
the	O
obese	O
Zucker	O
fa	O
/	O
fa	O
rat	O
.	O

Our	O
objective	O
was	O
to	O
determine	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
this	O
defect	O
.	O

METHODS	O
:	O
Isolated	O
rat	O
muscles	O
and	O
primary	O
cultures	O
of	O
myocytes	O
were	O
used	O
for	O
western	O
blot	O
analysis	O
of	O
protein	O
expression	O
,	O
immunohistochemistry	O
,	O
glucose	O
uptake	O
measurements	O
and	O
GLUT4	O
translocation	O
assays	O
.	O

RESULTS	O
:	O
nNOS	O
expression	O
was	O
reduced	O
in	O
skeletal	O
muscle	O
from	O
fa	O
/	O
fa	O
rats	O
.	O

This	O
was	O
caused	O
by	O
increased	O
ubiquitination	O
of	O
the	O
enzyme	O
and	O
subsequent	O
degradation	O
by	O
the	O
ubiquitin	O
proteasome	B-Complex
pathway	O
.	O

The	O
degradation	O
occurred	O
through	O
a	O
greater	O
interaction	O
of	O
nNOS	O
with	O
the	O
chaperone	O
heat	O
-	O
shock	O
protein	O
70	O
and	O
the	O
co	O
-	O
chaperone	O
,	O
carboxyl	O
terminus	O
of	O
Hsc70	O
-	O
interacting	O
protein	O
(	O
CHIP	O
)	O
.	O

In	O
addition	O
,	O
an	O
alteration	O
in	O
nNOS	O
sarcolemmal	O
localisation	O
was	O
observed	O
.	O

We	O
confirmed	O
the	O
implication	O
of	O
nNOS	O
breakdown	O
in	O
defective	O
insulin	O
-	O
induced	O
glucose	O
transport	O
by	O
demonstrating	O
that	O
blockade	O
of	O
proteasomal	O
degradation	O
or	O
overexpression	O
of	O
nNOS	O
improved	O
basal	O
and	O
/	O
or	O
insulin	O
-	O
stimulated	O
glucose	O
uptake	O
and	O
GLUT4	O
translocation	O
in	O
primary	O
cultures	O
of	O
insulin	O
-	O
resistant	O
myocytes	O
.	O

CONCLUSIONS	O
/	O
INTERPRETATION	O
:	O
Recovery	O
of	O
nNOS	O
in	O
insulin	O
-	O
resistant	O
muscles	O
should	O
be	O
considered	O
a	O
potential	O
new	O
approach	O
to	O
address	O
insulin	O
resistance	O
.	O

At	O
the	O
molecular	O
level	O
,	O
some	O
Hoxa2	O
transcriptional	O
targets	O
such	O
as	O
Lmo1	O
,	O
Meox1	O
,	O
Lhx6	O
,	O
Ptx1	O
,	O
Robo2	O
or	O
Six2	O
have	O
been	O
reported	O
.	O

However	O
,	O
only	O
Six2	O
,	O
Robo2	O
and	O
Hoxa2	O
itself	O
,	O
have	O
been	O
characterized	O
so	O
far	O
as	O
direct	O
Hoxa2	O
target	O
genes	O
.	O

A	O
genome	O
-	O
wide	O
survey	O
of	O
Hoxa2	O
-	O
bound	O
sequences	O
in	O
the	O
second	O
branchial	O
arch	O
correlated	O
to	O
transcriptomic	O
analyses	O
allowed	O
identifying	O
large	O
sets	O
of	O
candidate	O
genes	O
under	O
the	O
immediate	O
control	O
of	O
Hoxa2	O
.	O

As	O
interaction	O
partners	O
,	O
only	O
TALE	O
proteins	O
could	O
be	O
directly	O
related	O
to	O
Hoxa2	O
molecular	O
function	O
and	O
a	O
few	O
candidate	O
Hoxa2	O
-	O
interacting	O
proteins	O
have	O
been	O
identified	O
mainly	O
in	O
the	O
context	O
of	O
high	O
-	O
throughput	O
experiments	O
.	O

Phosphatidylserine	O
exposure	O
on	O
the	O
outer	O
leaflet	O
of	O
the	O
plasma	O
membrane	O
was	O
detected	O
by	O
the	O
Annexin	O
V	O
-	O
FITC	O
apoptosis	O
detection	O
Kit	O
(	O
Cayman	O
Chemical	O
,	O
Ann	O
Arbor	O
,	O
MI	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Briefly	O
,	O
1	O
x	O
106	O
cells	O
were	O
pelleted	O
following	O
treatment	O
and	O
washed	O
in	O
PBS	O
.	O

Cells	O
were	O
then	O
resuspended	O
in	O
500	O
mul	O
of	O
binding	O
buffer	O
,	O
mixed	O
with	O
Annexin	O
V	O
-	O
FITC	O
and	O
propidium	O
iodide	O
(	O
PI	O
)	O
and	O
incubated	O
at	O
room	O
temperature	O
for	O
10	O
min	O
in	O
the	O
dark	O
.	O

The	O
Annexin	O
V	O
-	O
positive	O
cells	O
were	O
analyzed	O
by	O
flow	O
cytometry	O
using	O
BD	O
FACSCalibur	O
flow	O
cytometer	O
(	O
BD	O
,	O
Franklin	O
Lakes	O
,	O
NJ	O
)	O

Plasma	O
membrane	O
translocation	O
of	O
trimerized	O
MLKL	O
protein	O
is	O
required	O
for	O
TNF	O
-	O
induced	O
necroptosis	O
.	O

The	O
mixed	O
lineage	O
kinase	O
domain	O
-	O
like	O
protein	O
(	O
MLKL	O
)	O
has	O
recently	O
been	O
identified	O
as	O
a	O
key	O
RIP3	O
(	O
receptor	O
interacting	O
protein	O
3	O
)	O
downstream	O
component	O
of	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
induced	O
necroptosis	O
.	O

MLKL	O
is	O
phosphorylated	O
by	O
RIP3	O
and	O
is	O
recruited	O
to	O
the	O
necrosome	O
through	O
its	O
interaction	O
with	O
RIP3	O
.	O

However	O
,	O
it	O
is	O
still	O
unknown	O
how	O
MLKL	O
mediates	O
TNF	O
-	O
induced	O
necroptosis	O
.	O

Here	O
,	O
we	O
report	O
that	O
MLKL	O
forms	O
a	O
homotrimer	O
through	O
its	O
amino	O
-	O
terminal	O
coiled	O
-	O
coil	O
domain	O
and	O
locates	O
to	O
the	O
cell	O
plasma	O
membrane	O
during	O
TNF	O
-	O
induced	O
necroptosis	O
.	O

By	O
generating	O
different	O
MLKL	O
mutants	O
,	O
we	O
demonstrated	O
that	O
the	O
plasma	O
membrane	O
localization	O
of	O
trimerized	O
MLKL	O
is	O
critical	O
for	O
mediating	O
necroptosis	O
.	O

Importantly	O
,	O
we	O
found	O
that	O
the	O
membrane	O
localization	O
of	O
MLKL	O
is	O
essential	O
for	O
Ca	O
(	O
2	O
+	O
)	O
influx	O
,	O
which	O
is	O
an	O
early	O
event	O
of	O
TNF	O
-	O
induced	O
necroptosis	O
.	O

Furthermore	O
,	O
we	O
identified	O
that	O
TRPM7	O
(	O
transient	O
receptor	O
potential	O
melastatin	O
related	O
7	O
)	O
is	O
a	O
MLKL	O
downstream	O
target	O
for	O
the	O
mediation	O
of	O
Ca	O
(	O
2	O
+	O
)	O
influx	O
and	O
TNF	O
-	O
induced	O
necroptosis	O
.	O

Hence	O
,	O
our	O
study	O
reveals	O
a	O
crucial	O
mechanism	O
of	O
MLKL	O
-	O
mediated	O
TNF	O
-	O
induced	O
necroptosis	O
.	O

Spectroscopic	O
analysis	O
of	O
acylated	O
and	O
deacylated	O
myelin	O
proteolipid	O
protein	O
.	O

The	O
effect	O
of	O
covalently	O
bound	O
fatty	O
acid	O
on	O
the	O
conformation	O
of	O
the	O
myelin	O
proteolipid	O
protein	O
has	O
been	O
studied	O
by	O
ultraviolet	O
and	O
intrinsic	O
fluorescence	O
spectroscopy	O
.	O

With	O
dimethyl	O
sulfoxide	O
used	O
as	O
a	O
perturbant	O
,	O
the	O
exposure	O
of	O
Trp	O
and	O
Tyr	O
residues	O
in	O
various	O
mixtures	O
of	O
chloroform	O
-	O
methanol	O
was	O
evaluated	O
by	O
difference	O
spectroscopy	O
of	O
the	O
proteolipid	O
protein	O
(	O
APL	O
)	O
and	O
its	O
chemically	O
deacylated	O
form	O
(	O
d	O
-	O
APL	O
)	O
.	O

The	O
fraction	O
of	O
chromophoric	O
groups	O
exposed	O
increased	O
with	O
the	O
proportion	O
of	O
chloroform	O
with	O
25	O
%	O
of	O
the	O
groups	O
exposed	O
in	O
1	O
:	O
2	O
chloroform	O
-	O
methanol	O
and	O
98	O
%	O
in	O
3	O
:	O
1	O
chloroform	O
-	O
methanol	O
.	O

These	O
conformational	O
changes	O
correlate	O
well	O
with	O
changes	O
in	O
intrinsic	O
viscosity	O
.	O

Values	O
for	O
the	O
deacylated	O
form	O
were	O
indistinguishable	O
from	O
those	O
of	O
the	O
acylated	O
protein	O
,	O
suggesting	O
that	O
fatty	O
acids	O
do	O
not	O
affect	O
protein	O
conformation	O
in	O
organic	O
solvents	O
.	O

In	O
water	O
,	O
UV	O
difference	O
spectroscopy	O
indicated	O
that	O
the	O
number	O
of	O
Tyr	O
and	O
Trp	O
groups	O
exposed	O
in	O
both	O
APL	O
and	O
d	O
-	O
APL	O
was	O
relatively	O
small	O
and	O
was	O
independent	O
of	O
the	O
molecular	O
size	O
of	O
the	O
perturbant	O
.	O

However	O
,	O
differences	O
in	O
the	O
environment	O
of	O
the	O
Trp	O
groups	O
in	O
the	O
two	O
forms	O
of	O
the	O
protein	O
could	O
be	O
demonstrated	O
by	O
intrinsic	O
fluorescence	O
.	O

When	O
the	O
protein	O
was	O
excited	O
at	O
295	O
nm	O
,	O
the	O
maximum	O
emission	O
wavelength	O
for	O
the	O
acylated	O
protein	O
was	O
330	O
nm	O
,	O
whereas	O
it	O
was	O
335	O
nm	O
for	O
the	O
deacylated	O
form	O
.	O

Furthermore	O
,	O
the	O
Trp	O
groups	O
in	O
d	O
-	O
APL	O
were	O
more	O
easily	O
quenched	O
by	O
acrylamide	O
than	O
in	O
APL	O
,	O
indicating	O
that	O
they	O
were	O
more	O
exposed	O
,	O
or	O
in	O
a	O
more	O
hydrophilic	O
environment	O
,	O
following	O
deacylation	O
.	O

Protein	O
aggregation	O
appears	O
to	O
be	O
independent	O
of	O
the	O
presence	O
of	O
fatty	O
acids	O
,	O
suggesting	O
that	O
the	O
fluorescence	O
differences	O
between	O
APL	O
and	O
d	O
-	O
APL	O
are	O
related	O
to	O
factors	O
other	O
than	O
aggregation	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

First	O
,	O
we	O
verified	O
the	O
degradation	O
of	O
MED19a	O
in	O
the	O
presence	O
of	O
HaRxL44	O
in	O
Arabidopsis	O
,	O
by	O
generating	O
a	O
transgenic	O
line	O
expressing	O
both	O
GFP	O
-	O
MED19a	O
and	O
3HA	O
-	O
Strep2	O
-	O
HaRxL44	O
(	O
or	O
3HA	O
-	O
Strep2	O
-	O
GUS	O
as	O
control	O
)	O
.	O

We	O
showed	O
that	O
,	O
as	O
we	O
observed	O
in	O
N	O
.	O
benthamiana	O
,	O
MED19a	O
is	O
degraded	O
in	O
the	O
presence	O
of	O
HaRxL44	O
in	O
Arabidopsis	O
and	O
the	O
addition	O
of	O
MG132	O
blocks	O
the	O
effect	O
of	O
HaRxL44	O
on	O
MED19a	O
stability	O
(	O
Figure	O
S5D	O
)	O
.	O

We	O
then	O
investigated	O
whether	O
the	O
presence	O
of	O
HaRxL44	O
affects	O
the	O
interaction	O
between	O
MED19a	O
and	O
the	O
Mediator	B-Complex
complex	O
.	O

We	O
found	O
that	O
,	O
even	O
in	O
the	O
presence	O
of	O
3HA	O
-	O
HaRxL44	O
,	O
MED6	O
co	O
-	O
immunoprecipitates	O
with	O
GFP	O
-	O
MED19a	O
in	O
Arabidopsis	O
(	O
Figure	O
S5E	O
)	O
,	O
suggesting	O
that	O
MED6	O
and	O
GFP	O
-	O
MED19a	O
also	O
associate	O
in	O
the	O
nucleolus	O
.	O

However	O
,	O
overproduction	O
of	O
MED19a	O
and	O
HaRxL44	O
in	O
Arabidopsis	O
may	O
affect	O
the	O
stoichiometry	O
or	O
nuclear	O
/	O
nucleolar	O
distribution	O
of	O
interactions	O
between	O
MED19a	O
and	O
the	O
Mediator	B-Complex
complex	O
,	O
or	O
Mediator	B-Complex
subcomplexes	O
,	O
obscuring	O
potential	O
effects	O
of	O
HaRxL44	O
on	O
the	O
integration	O
or	O
stability	O
of	O
MED19a	O
subunits	O
in	O
the	O
Mediator	B-Complex
complex	O
.	O

Substrate	O
specificity	O
of	O
the	O
MUS81	O
-	O
EME2	O
structure	O
selective	O
endonuclease	O
.	O

MUS81	O
plays	O
important	O
cellular	O
roles	O
in	O
the	O
restart	O
of	O
stalled	O
replication	O
forks	O
,	O
the	O
resolution	O
of	O
recombination	O
intermediates	O
and	O
in	O
telomere	O
length	O
maintenance	O
.	O

Although	O
the	O
actions	O
of	O
MUS81	O
-	O
EME1	O
have	O
been	O
extensively	O
investigated	O
,	O
MUS81	O
is	O
the	O
catalytic	O
subunit	O
of	O
two	O
human	O
structure	O
-	O
selective	O
endonucleases	O
,	O
MUS81	O
-	O
EME1	O
and	O
MUS81	O
-	O
EME2	O
.	O

Little	O
is	O
presently	O
known	O
about	O
the	O
activities	O
of	O
MUS81	O
-	O
EME2	O
.	O

Here	O
,	O
we	O
have	O
purified	O
MUS81	O
-	O
EME2	O
and	O
compared	O
its	O
activities	O
with	O
MUS81	O
-	O
EME1	O
.	O

We	O
find	O
that	O
MUS81	O
-	O
EME2	O
is	O
a	O
more	O
active	O
endonuclease	O
than	O
MUS81	O
-	O
EME1	O
and	O
exhibits	O
broader	O
substrate	O
specificity	O
.	O

Like	O
MUS81	O
-	O
EME1	O
,	O
MUS81	O
-	O
EME2	O
cleaves	O
3	O
'	O
-	O
flaps	O
,	O
replication	O
forks	O
and	O
nicked	O
Holliday	O
junctions	O
,	O
and	O
exhibits	O
limited	O
endonuclease	O
activity	O
with	O
intact	O
Holliday	O
junctions	O
.	O

In	O
contrast	O
to	O
MUS81	O
-	O
EME1	O
,	O
however	O
,	O
MUS81	O
-	O
EME2	O
cuts	O
D	O
-	O
loop	O
recombination	O
intermediates	O
and	O
in	O
so	O
doing	O
disengages	O
the	O
D	O
-	O
loop	O
structure	O
by	O
cleaving	O
the	O
3	O
'	O
-	O
invading	O
strand	O
.	O

Additionally	O
,	O
MUS81	O
-	O
EME2	O
acts	O
on	O
5	O
'	O
-	O
flap	O
structures	O
to	O
cleave	O
off	O
a	O
duplex	O
arm	O
,	O
in	O
reactions	O
that	O
cannot	O
be	O
promoted	O
by	O
MUS81	O
-	O
EME1	O
.	O

These	O
studies	O
suggest	O
that	O
MUS81	O
-	O
EME1	O
and	O
MUS81	O
-	O
EME2	O
exhibit	O
similar	O
and	O
yet	O
distinct	O
DNA	O
structure	O
selectivity	O
,	O
indicating	O
that	O
the	O
two	O
MUS81	O
complexes	O
may	O
promote	O
different	O
nucleolytic	O
cleavage	O
reactions	O
in	O
vivo	O
.	O

Smc5	O
/	O
6	O
coordinates	O
formation	O
and	O
resolution	O
of	O
joint	O
molecules	O
with	O
chromosome	O
morphology	O
to	O
ensure	O
meiotic	O
divisions	O
.	O

During	O
meiosis	O
,	O
Structural	B-OOS
Maintenance	I-OOS
of	I-OOS
Chromosome	I-OOS
(	O
SMC	B-OOS
)	O
complexes	O
underpin	O
two	O
fundamental	O
features	O
of	O
meiosis	O
:	O
homologous	O
recombination	O
and	O
chromosome	O
segregation	O
.	O

While	O
meiotic	O
functions	O
of	O
the	O
cohesin	B-Complex
and	O
condensin	B-Complex
complexes	O
have	O
been	O
delineated	O
,	O
the	O
role	O
of	O
the	O
third	O
SMC	B-OOS
complex	O
,	O
Smc5	O
/	O
6	O
,	O
remains	O
enigmatic	O
.	O

Here	O
we	O
identify	O
specific	O
,	O
essential	O
meiotic	O
functions	O
for	O
the	O
Smc5	O
/	O
6	O
complex	O
in	O
homologous	O
recombination	O
and	O
the	O
regulation	O
of	O
cohesin	B-Complex
.	O

We	O
show	O
that	O
Smc5	O
/	O
6	O
is	O
enriched	O
at	O
centromeres	O
and	O
cohesin	B-Complex
-	O
association	O
sites	O
where	O
it	O
regulates	O
sister	O
-	O
chromatid	O
cohesion	O
and	O
the	O
timely	O
removal	O
of	O
cohesin	B-Complex
from	O
chromosomal	O
arms	O
,	O
respectively	O
.	O

Smc5	O
/	O
6	O
also	O
localizes	O
to	O
recombination	O
hotspots	O
,	O
where	O
it	O
promotes	O
normal	O
formation	O
and	O
resolution	O
of	O
a	O
subset	O
of	O
joint	O
-	O
molecule	O
intermediates	O
.	O

In	O
this	O
regard	O
,	O
Smc5	O
/	O
6	O
functions	O
independently	O
of	O
the	O
major	O
crossover	O
pathway	O
defined	O
by	O
the	O
MutLgamma	O
complex	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
Smc5	O
/	O
6	O
is	O
required	O
for	O
stable	O
chromosomal	O
localization	O
of	O
the	O
XPF	O
-	O
family	O
endonuclease	O
,	O
Mus81	O
-	O
Mms4	O
(	O
Eme1	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
Smc5	O
/	O
6	O
complex	O
is	O
required	O
for	O
specific	O
recombination	O
and	O
chromosomal	O
processes	O
throughout	O
meiosis	O
and	O
that	O
in	O
its	O
absence	O
,	O
attempts	O
at	O
cell	O
division	O
with	O
unresolved	O
joint	O
molecules	O
and	O
residual	O
cohesin	B-Complex
lead	O
to	O
severe	O
recombination	O
-	O
induced	O
meiotic	O
catastrophe	O
.	O

The	O
discovery	O
that	O
Dph3	O
is	O
an	O
electron	O
donor	O
in	O
diphthamide	O
biosynthesis	O
is	O
the	O
first	O
time	O
that	O
the	O
physiological	O
role	O
of	O
a	O
member	O
from	O
the	O
CSL	O
zinc	O
finger	O
family	O
is	O
convincingly	O
demonstrated	O
,	O
paving	O
the	O
road	O
for	O
understanding	O
the	O
function	O
of	O
this	O
protein	O
family	O
.	O

In	O
the	O
Pfam	O
database	O
,	O
the	O
CSL	O
type	O
zinc	O
finger	O
family	O
(	O
PF05207	O
)	O
is	O
listed	O
with	O
560	O
sequences	O
from	O
303	O
species	O
,	O
but	O
no	O
definite	O
function	O
has	O
been	O
assigned	O
to	O
CSL	O
zinc	O
fingers	O
.	O

In	O
the	O
560	O
sequences	O
,	O
307	O
sequences	O
have	O
only	O
the	O
CSL	O
zinc	O
finger	O
domain	O
like	O
Dph3	O
.	O

Among	O
the	O
303	O
species	O
that	O
contain	O
CSL	O
zinc	O
finger	O
proteins	O
,	O
there	O
are	O
296	O
eukaryotes	O
and	O
7	O
bacteria	O
.	O

As	O
diphthamide	O
modification	O
only	O
exits	O
in	O
archaea	O
and	O
eukaryotes	O
,	O
proteins	O
in	O
this	O
family	O
must	O
have	O
functions	O
other	O
than	O
diphthamide	O
biosynthesis	O
.	O

Knowing	O
the	O
electron	O
-	O
donor	O
activity	O
of	O
Dph3	O
will	O
help	O
to	O
understand	O
the	O
functions	O
of	O
other	O
CSL	O
zinc	O
finger	O
proteins	O
.	O

Mid2	O
cytoplasmic	O
tail	O
interacts	O
directly	O
with	O
the	O
Apm4	O
mu	O
homology	O
region	O
.	O

A	O
)	O
GST	O
alone	O
;	O
GST	O
tagged	O
wild	O
type	O
Apm4	O
and	O
GST	O
tagged	O
Apm4	O
mutants	O
were	O
prepared	O
as	O
described	O
and	O
incubated	O
with	O
His	O
-	O
tagged	O
cytoplasmic	O
tail	O
of	O
Mid2	O
.	O

Their	O
binding	O
interaction	O
was	O
tested	O
using	O
pull	O
down	O
assays	O
on	O
beads	O
at	O
two	O
different	O
concentrations	O
of	O
Mid2	O
.	O

Mid2	O
binding	O
was	O
detected	O
using	O
anti	O
-	O
His	O
tag	O
antibodies	O
after	O
western	O
blotting	O
.	O

Input	O
lane	O
is	O
35	O
microm	O
Mid2	O
.	O

B	O
)	O
Mid2	O
-	O
GFP	O
was	O
transformed	O
into	O
cells	O
expressing	O
wild	O
type	O
,	O
mutant	O
or	O
no	O
Apm4	O
.	O

Localization	O
to	O
the	O
bud	O
neck	O
following	O
150	O
microg	O
/	O
mL	O
CF	O
was	O
analysed	O
.	O

Scale	O
bar	O
=	O
5	O
microm	O
.	O

As	O
part	O
of	O
an	O
effort	O
to	O
understand	O
the	O
structure	O
of	O
UTPB	B-Complex
,	O
we	O
have	O
determined	O
the	O
crystal	O
structure	O
of	O
the	O
tandem	O
WD	O
domain	O
of	O
Utp21	O
,	O
the	O
first	O
structure	O
of	O
a	O
UTPB	B-Complex
component	O
.	O

We	O
further	O
identified	O
a	O
region	O
of	O
Utp18	O
that	O
mediates	O
the	O
interaction	O
with	O
Utp21	O
.	O

The	O
structure	O
allows	O
us	O
to	O
integrate	O
available	O
crosslinking	O
and	O
interaction	O
data	O
to	O
obtain	O
a	O
better	O
understanding	O
of	O
the	O
organization	O
of	O
UTPB	B-Complex
.	O

HDAC6	O
is	O
highly	O
expressed	O
in	O
human	O
pancreatic	O
cancer	O
.	O

(	O
A	O
)	O
Immunohistochemistry	O
of	O
HDAC6	O
expression	O
in	O
normal	O
pancreas	O
,	O
pancreatic	O
cancer	O
,	O
and	O
adjacent	O
tissue	O
samples	O
.	O

Representative	O
images	O
of	O
samples	O
with	O
low	O
and	O
high	O
expression	O
of	O
HDAC6	O
are	O
shown	O
.	O

(	O
B	O
)	O
Quantification	O
of	O
normal	O
pancreas	O
,	O
pancreatic	O
cancer	O
,	O
and	O
adjacent	O
tissue	O
samples	O
with	O
low	O
or	O
high	O
expression	O
of	O
HDAC6	O
.	O

(	O
C	O
)	O
Quantitative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
analysis	O
of	O
HDAC6	O
mRNA	O
levels	O
in	O
normal	O
pancreas	O
,	O
pancreatic	O
cancer	O
,	O
and	O
adjacent	O
tissue	O
samples	O

Role	O
of	O
caspase	O
-	O
1	O
in	O
nuclear	O
translocation	O
of	O
IL	O
-	O
37	O
,	O
release	O
of	O
the	O
cytokine	O
,	O
and	O
IL	O
-	O
37	O
inhibition	O
of	O
innate	O
immune	O
responses	O
.	O

IL	O
-	O
37	O
is	O
a	O
fundamental	O
inhibitor	O
of	O
innate	O
immunity	O
.	O

Human	O
IL	O
-	O
37	O
has	O
a	O
caspase	O
-	O
1	O
cleavage	O
site	O
and	O
translocates	O
to	O
the	O
nucleus	O
upon	O
LPS	O
stimulation	O
.	O

Here	O
,	O
we	O
investigated	O
whether	O
caspase	O
-	O
1	O
processing	O
affects	O
IL	O
-	O
37	O
-	O
mediated	O
suppression	O
of	O
LPS	O
-	O
induced	O
cytokines	O
and	O
the	O
release	O
from	O
cells	O
by	O
analyzing	O
a	O
caspase	O
-	O
1	O
cleavage	O
site	O
mutant	O
IL	O
-	O
37	O
(	O
IL	O
-	O
37D20A	O
)	O
.	O

Nuclear	O
translocation	O
of	O
IL	O
-	O
37D20A	O
is	O
significantly	O
impaired	O
compared	O
with	O
WT	O
IL	O
-	O
37	O
in	O
transfected	O
cells	O
.	O

LPS	O
-	O
induced	O
IL	O
-	O
6	O
was	O
decreased	O
in	O
cells	O
expressing	O
WT	O
IL	O
-	O
37	O
but	O
not	O
IL	O
-	O
37D20A	O
.	O

The	O
function	O
of	O
IL	O
-	O
37	O
in	O
transfected	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
is	O
nucleotide	O
-	O
binding	O
oligomerization	O
domain	O
-	O
like	O
receptor	O
family	O
,	O
pyrin	O
domain	O
containing	O
3	O
(	O
NLRP3	O
)	O
inflammasome	B-Complex
-	O
dependent	O
,	O
because	O
IL	O
-	O
37	O
transfection	O
in	O
apoptosis	O
-	O
associated	O
speck	O
-	O
like	O
protein	O
containing	O
a	O
carboxyl	O
-	O
terminal	O
caspase	O
recruitment	O
domain	O
-	O
and	O
NLRP3	O
-	O
deficient	O
cells	O
does	O
not	O
reduce	O
levels	O
of	O
IL	O
-	O
6	O
and	O
IL	O
-	O
1beta	O
upon	O
LPS	O
stimulation	O
.	O

IL	O
-	O
37	O
-	O
expressing	O
macrophages	O
release	O
both	O
precursor	O
and	O
mature	O
IL	O
-	O
37	O
,	O
but	O
only	O
the	O
externalization	O
of	O
mature	O
IL	O
-	O
37	O
was	O
dependent	O
on	O
ATP	O
.	O

Precursor	O
and	O
mature	O
IL	O
-	O
37	O
was	O
also	O
secreted	O
from	O
human	O
dendritic	O
cells	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

To	O
determine	O
whether	O
IL	O
-	O
37	O
is	O
active	O
in	O
the	O
extracellular	O
compartment	O
,	O
we	O
pretreated	O
IL	O
-	O
37	O
transgenic	O
mice	O
with	O
IL	O
-	O
37	O
-	O
neutralizing	O
antibodies	O
before	O
LPS	O
challenge	O
.	O

In	O
IL	O
-	O
37	O
-	O
expressing	O
mice	O
,	O
neutralizing	O
IL	O
-	O
37	O
antibodies	O
reversed	O
the	O
suppression	O
of	O
LPS	O
-	O
induced	O
serum	O
IL	O
-	O
6	O
.	O

In	O
contrast	O
,	O
the	O
addition	O
of	O
neutralizing	O
antibody	O
did	O
not	O
reverse	O
suppression	O
of	O
LPS	O
-	O
induced	O
IL	O
-	O
6	O
in	O
mouse	O
macrophages	O
transfected	O
with	O
IL	O
-	O
37	O
.	O

Although	O
caspase	O
-	O
1	O
is	O
required	O
for	O
nuclear	O
translocation	O
of	O
intracellular	O
IL	O
-	O
37	O
and	O
for	O
secretion	O
of	O
mature	O
IL	O
-	O
37	O
,	O
the	O
release	O
of	O
the	O
IL	O
-	O
37	O
precursor	O
is	O
independent	O
of	O
caspase	O
-	O
1	O
activation	O
.	O

IL	O
-	O
37	O
now	O
emerges	O
as	O
a	O
dual	O
-	O
function	O
cytokine	O
with	O
intra	O
-	O
and	O
extracellular	O
properties	O
for	O
suppressing	O
innate	O
inflammation	O
.	O

The	O
intermediate	O
truncation	O
allele	O
YHC1	O
-	O
(	O
1	O
-	O
189	O
)	O
displayed	O
a	O
spectrum	O
of	O
mutational	O
synergies	O
in	O
different	O
genetic	O
backgrounds	O
.	O

Because	O
YHC1	O
-	O
(	O
1	O
-	O
189	O
)	O
mud1Delta	O
cells	O
grew	O
about	O
as	O
well	O
as	O
YHC1	O
mud1Delta	O
cells	O
at	O
all	O
temperatures	O
tested	O
(	O
Figure	O
11	O
,	O
bottom	O
panel	O
)	O
,	O
whereas	O
YHC1	O
-	O
(	O
1	O
-	O
170	O
)	O
mud1Delta	O
cells	O
were	O
inviable	O
,	O
we	O
surmise	O
that	O
the	O
Yhc1	O
segment	O
from	O
aa	O
171	O
to	O
189	O
is	O
genetically	O
redundant	O
with	O
the	O
Mud1	O
subunit	O
of	O
the	O
U1	B-Complex
snRNP	I-Complex
.	O

We	O
found	O
that	O
YHC1	O
-	O
(	O
1	O
-	O
189	O
)	O
mud2Delta	O
cells	O
grew	O
well	O
at	O
lower	O
temperatures	O
(	O
18	O
-	O
25degreesC	O
)	O
but	O
were	O
tightly	O
ts	O
and	O
failed	O
to	O
thrive	O
at	O
34	O
-	O
37degreesC	O
(	O
Figure	O
11	O
,	O
bottom	O
panel	O
)	O
.	O

In	O
comparison	O
with	O
the	O
lethality	O
of	O
mud2Delta	O
to	O
YHC1	O
-	O
(	O
170	O
)	O
and	O
the	O
normal	O
growth	O
of	O
YHC1	O
mud2Delta	O
cells	O
,	O
this	O
result	O
signifies	O
that	O
the	O
Yhc1	O
segment	O
from	O
aa	O
171	O
to	O
189	O
compensates	O
for	O
the	O
absence	O
of	O
Mud2	O
at	O
low	O
temperatures	O
,	O
whereas	O
the	O
Yhc1	O
segment	O
from	O
aa	O
190	O
to	O
212	O
is	O
required	O
to	O
buffer	O
Mud2	O
loss	O
at	O
high	O
temperatures	O
.	O

The	O
YHC1	O
-	O
(	O
1	O
-	O
189	O
)	O
tgs1Delta	O
strain	O
displayed	O
a	O
mild	O
synthetic	O
defect	O
compared	O
with	O
the	O
YHC1	O
tgs1Delta	O
,	O
seen	O
as	O
smaller	O
colony	O
size	O
at	O
34	O
-	O
37degreesC	O
(	O
not	O
shown	O
)	O
and	O
scored	O
as	O
+	O
+	O
growth	O
(	O
Figure	O
11	O
)	O
.	O

Given	O
that	O
tgs1Delta	O
was	O
lethal	O
with	O
YHC1	O
-	O
(	O
1	O
-	O
170	O
)	O
,	O
we	O
invoke	O
genetic	O
redundancy	O
of	O
Yhc1	O
-	O
(	O
171	O
-	O
189	O
)	O
with	O
the	O
TMG	O
cap	O
.	O

Rab8	O
binding	O
to	O
immune	O
cell	O
-	O
specific	O
adaptor	O
LAX	O
facilitates	O
formation	O
of	O
trans	O
-	O
Golgi	O
network	O
-	O
proximal	O
CTLA	O
-	O
4	O
vesicles	O
for	O
surface	O
expression	O
.	O

Despite	O
playing	O
a	O
central	O
role	O
in	O
tolerance	O
,	O
little	O
is	O
known	O
regarding	O
the	O
mechanism	O
by	O
which	O
intracellular	O
CTLA	O
-	O
4	O
is	O
shuttled	O
from	O
the	O
trans	O
-	O
Golgi	O
network	O
to	O
the	O
surfaces	O
of	O
T	O
cells	O
.	O

In	O
this	O
context	O
,	O
Ras	O
-	O
related	O
GTPase	O
Rab8	O
plays	O
an	O
important	O
role	O
in	O
the	O
intracellular	O
transport	O
,	O
while	O
we	O
have	O
previously	O
shown	O
that	O
CTLA	O
-	O
4	O
binds	O
to	O
the	O
immune	O
cell	O
adaptor	O
TRIM	O
in	O
T	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
CTLA	O
-	O
4	O
forms	O
a	O
multimeric	O
complex	O
comprised	O
of	O
TRIM	O
and	O
related	O
LAX	O
that	O
in	O
turn	O
binds	O
to	O
GTP	O
bound	O
Rab8	O
for	O
post	O
-	O
Golgi	O
transport	O
to	O
the	O
cell	O
surface	O
.	O

LAX	O
bound	O
via	O
its	O
N	O
terminus	O
to	O
active	O
GTP	O
-	O
Rab8	O
,	O
as	O
well	O
as	O
the	O
cytoplasmic	O
tail	O
of	O
CTLA	O
-	O
4	O
.	O

TRIM	O
required	O
LAX	O
for	O
binding	O
to	O
Rab8	O
in	O
a	O
complex	O
.	O

Wild	O
-	O
type	O
LAX	O
or	O
its	O
N	O
terminus	O
(	O
residues	O
1	O
to	O
77	O
)	O
increased	O
CTLA	O
-	O
4	O
surface	O
expression	O
,	O
whereas	O
small	O
interfering	O
RNAs	O
of	O
Rab8	O
or	O
LAX	O
or	O
disruption	O
of	O
LAX	O
/	O
Rab8	O
binding	O
reduced	O
numbers	O
of	O
CTLA	O
-	O
4	O
-	O
containing	O
vesicles	O
and	O
its	O
coreceptor	O
surface	O
expression	O
.	O

LAX	O
also	O
promoted	O
the	O
polarization	O
of	O
CTLA	O
-	O
4	O
and	O
the	O
reorientation	O
of	O
the	O
microtubule	O
-	O
organizing	O
center	O
to	O
the	O
site	O
of	O
T	B-Complex
-	I-Complex
cell	I-Complex
receptor	I-Complex
engagement	O
.	O

Our	O
results	O
identify	O
a	O
novel	O
CTLA	O
-	O
4	O
/	O
TRIM	O
/	O
LAX	O
/	O
Rab8	O
effector	O
complex	O
in	O
the	O
transport	O
of	O
CTLA	O
-	O
4	O
to	O
the	O
surfaces	O
of	O
T	O
cells	O
.	O

The	O
roles	O
of	O
SSU	B-Complex
processome	I-Complex
components	O
and	O
surveillance	O
factors	O
in	O
the	O
initial	O
processing	O
of	O
human	O
ribosomal	O
RNA	O
.	O

During	O
eukaryotic	O
ribosome	B-OOS
biogenesis	O
,	O
three	O
of	O
the	O
mature	O
ribosomal	O
(	O
r	O
)	O
RNAs	O
are	O
released	O
from	O
a	O
single	O
precursor	O
transcript	O
(	O
pre	O
-	O
rRNA	O
)	O
by	O
an	O
ordered	O
series	O
of	O
endonucleolytic	O
cleavages	O
and	O
exonucleolytic	O
processing	O
steps	O
.	O

Production	O
of	O
the	O
18S	O
rRNA	O
requires	O
the	O
removal	O
of	O
the	O
5	O
'	O
external	O
transcribed	O
spacer	O
(	O
5	O
'	O
ETS	O
)	O
by	O
endonucleolytic	O
cleavages	O
at	O
sites	O
A0	O
and	O
A1	O
/	O
site	O
1	O
.	O

In	O
metazoans	O
,	O
an	O
additional	O
cleavage	O
in	O
the	O
5	O
'	O
ETS	O
,	O
at	O
site	O
A	O
'	O
,	O
upstream	O
of	O
A0	O
,	O
has	O
also	O
been	O
reported	O
.	O

Here	O
,	O
we	O
have	O
investigated	O
how	O
A	O
'	O
processing	O
is	O
coordinated	O
with	O
assembly	O
of	O
the	O
early	O
preribosomal	O
complex	O
.	O

We	O
find	O
that	O
only	O
the	O
tUTP	O
(	O
UTP	O
-	O
A	O
)	O
complex	O
is	O
critical	O
for	O
A	O
'	O
cleavage	O
,	O
while	O
components	O
of	O
the	O
bUTP	O
(	O
UTP	O
-	O
B	O
)	O
and	O
U3	B-Complex
snoRNP	I-Complex
are	O
important	O
,	O
but	O
not	O
essential	O
,	O
for	O
efficient	O
processing	O
at	O
this	O
site	O
.	O

All	O
other	O
factors	O
involved	O
in	O
the	O
early	O
stages	O
of	O
18S	O
rRNA	O
processing	O
that	O
were	O
tested	O
here	O
function	O
downstream	O
from	O
this	O
processing	O
step	O
.	O

Interestingly	O
,	O
we	O
show	O
that	O
the	O
RNA	O
surveillance	O
factors	O
XRN2	O
and	O
MTR4	O
are	O
also	O
involved	O
in	O
A	O
'	O
cleavage	O
in	O
humans	O
.	O

A	O
'	O
cleavage	O
is	O
largely	O
bypassed	O
when	O
XRN2	O
is	O
depleted	O
,	O
and	O
we	O
also	O
discover	O
that	O
A	O
'	O
cleavage	O
is	O
not	O
always	O
the	O
initial	O
processing	O
event	O
in	O
all	O
cell	O
types	O
.	O

Together	O
,	O
our	O
data	O
suggest	O
that	O
A	O
'	O
cleavage	O
is	O
not	O
a	O
prerequisite	O
for	O
downstream	O
pre	O
-	O
rRNA	O
processing	O
steps	O
and	O
may	O
,	O
in	O
fact	O
,	O
represent	O
a	O
quality	O
control	O
step	O
for	O
initial	O
pre	O
-	O
rRNA	O
transcripts	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
components	O
of	O
the	O
RNA	O
surveillance	O
machinery	O
,	O
including	O
the	O
exosome	B-Complex
and	O
TRAMP	B-Complex
complexes	O
,	O
also	O
play	O
key	O
roles	O
in	O
the	O
recycling	O
of	O
excised	O
spacer	O
fragments	O
and	O
degradation	O
of	O
aberrant	O
pre	O
-	O
rRNAs	O
in	O
human	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
zfh1	O
is	O
sufficient	O
to	O
promote	O
transcription	O
of	O
some	O
of	O
the	O
dMN	O
guidance	O
molecules	O
in	O
EWs	O
but	O
grn	O
is	O
not	O
.	O

However	O
,	O
both	O
zfh1	O
and	O
grn	O
can	O
work	O
together	O
with	O
eve	O
to	O
transcriptionally	O
reprogram	O
EWs	O
and	O
regulate	O
guidance	O
receptors	O
and	O
CAMs	O
normally	O
expressed	O
in	O
dMNs	O
.	O

Additionally	O
,	O
the	O
combinatorial	O
expression	O
of	O
eve	O
with	O
zfh1	O
or	O
grn	O
induces	O
a	O
more	O
robust	O
transcriptional	O
reprograming	O
of	O
EWs	O
than	O
each	O
of	O
them	O
alone	O
(	O
Figure	O
6Q	O
)	O
.	O

To	O
gain	O
insight	O
to	O
the	O
specificity	O
of	O
acetyltransferases	O
in	O
the	O
YopJ	O
effector	O
family	O
,	O
we	O
determined	O
if	O
HopZ1a	O
could	O
acetylate	O
AvrBsT	O
'	O
s	O
substrate	O
ACIP1	O
.	O

Conversely	O
,	O
we	O
determined	O
if	O
AvrBsT	O
could	O
acetylate	O
HopZ1a	O
'	O
s	O
substrate	O
tubulin	O
.	O

Incubation	O
of	O
GST	O
-	O
HopZ1a	O
with	O
GST	O
-	O
ACIP1	O
did	O
not	O
result	O
in	O
detectable	O
acetylation	O
of	O
ACIP1	O
(	O
Figure	O
2C	O
)	O
.	O

Moreover	O
,	O
neither	O
HopZ1a	O
nor	O
other	O
members	O
of	O
the	O
HopZ	O
family	O
could	O
physically	O
associate	O
with	O
ACIP1	O
in	O
targeted	O
yeast	O
two	O
-	O
hybrid	O
screens	O
(	O
Figure	O
S5A	O
,	O
B	O
)	O
.	O

Similarly	O
,	O
we	O
could	O
not	O
detect	O
AvrBsT	O
-	O
dependent	O
acetylation	O
of	O
tubulin	O
in	O
vitro	O
(	O
Figure	O
S5C	O
)	O
or	O
direct	O
physical	O
interaction	O
between	O
AvrBsT	O
and	O
tubulin	O
in	O
yeast	O
(	O
Figure	O
S5A	O
,	O
B	O
)	O
.	O

These	O
data	O
suggest	O
that	O
AvrBsT	O
and	O
HopZ1a	O
possess	O
distinct	O
substrate	O
specificity	O
.	O

A	O
)	O
TB	O
stem	O
cells	O
(	O
TBSCs	O
)	O
were	O
isolated	O
from	O
wild	O
-	O
type	O
and	O
Asb4	O
-	O
/	O
-	O
extraembryonic	O
ectoderm	O
at	O
E7	O
.	O
5	O
.	O

Cells	O
isolated	O
from	O
each	O
conceptus	O
were	O
cultured	O
in	O
isolation	O
,	O
and	O
these	O
data	O
represent	O
4	O
unique	O
populations	O
of	O
cells	O
for	O
each	O
genotype	O
.	O

Serum	O
withdrawal	O
induces	O
the	O
formation	O
of	O
large	O
,	O
multinucleated	O
trophoblast	O
giant	O
cells	O
(	O
TGCs	O
,	O
arrows	O
)	O
that	O
differentiate	O
from	O
TBSCs	O
(	O
asterisks	O
)	O
.	O

As	O
shown	O
,	O
wild	O
-	O
type	O
TBSCs	O
largely	O
differentiate	O
into	O
TGCs	O
(	O
left	O
panel	O
)	O
while	O
Asb4	O
-	O
/	O
-	O
cells	O
remain	O
in	O
undifferentiated	O
embryoid	O
bodies	O
(	O
right	O
panel	O
)	O
.	O

MEF	O
-	O
feeder	O
cells	O
are	O
indicated	O
by	O
filled	O
arrows	O
.	O

Dashed	O
outlines	O
indicate	O
the	O
border	O
of	O
non	O
-	O
MEF	O
cell	O
clusters	O
.	O

B	O
)	O
JAR	O
cells	O
were	O
transfected	O
to	O
express	O
vector	O
,	O
Asb4	O
,	O
or	O
Asb4	O
co	O
-	O
transfected	O
with	O
vector	O
,	O
wild	O
-	O
type	O
Id2	O
,	O
or	O
degradation	O
-	O
resistant	O
Id2	O
(	O
DR	O
-	O
Id2	O
)	O
.	O

ASB4	O
induced	O
hCG	O
secretion	O
,	O
and	O
co	O
-	O
expression	O
of	O
wild	O
-	O
type	O
ID2	O
with	O
ASB4	O
did	O
not	O
change	O
hCG	O
secretion	O
compared	O
to	O
ASB4	O
expression	O
alone	O
.	O

DR	O
-	O
ID2	O
prevented	O
dcbAMP	O
-	O
induced	O
hGC	O
section	O
,	O
with	O
concentrations	O
of	O
hCG	O
no	O
different	O
than	O
vector	O
/	O
vector	O
transfected	O
cells	O
.	O

*	O
p	O
<	O
0	O
.	O
01	O
compared	O
with	O
vector	O
/	O
vector	O
.	O

MCF7	O
cells	O
were	O
grown	O
in	O
10	O
cm	O
plates	O
to	O
40	O
%	O
confluency	O
and	O
transfected	O
(	O
Roche	O
Xtreme	O
Gene	O
9	O
)	O
with	O
HA	O
-	O
DBC2	O
or	O
pcDNA3	O
-	O
empty	O
vector	O
for	O
16	O
hours	O
.	O

Cells	O
were	O
washed	O
twice	O
with	O
cold	O
PBS	O
supplemented	O
with	O
20	O
mM	O
sodium	O
molybdate	O
and	O
then	O
lysed	O
with	O
HNET	O
buffer	O
(	O
20	O
mM	O
Hepes	O
pH	O
7	O
.	O
7	O
with	O
KOH	O
,	O
100	O
mM	O
NaCl	O
,	O
2	O
mM	O
EGTA	O
,	O
0	O
.	O
5	O
%	O
NP	O
-	O
40	O
,	O
5	O
%	O
glycerol	O
,	O
20	O
mM	O
sodium	O
molybdate	O
and	O
Roche	O
protease	O
inhibitor	O
cocktail	O
)	O
.	O

Lysates	O
were	O
centrifuged	O
at	O
maximum	O
speed	O
in	O
a	O
bench	O
top	O
centrifuge	O
at	O
4degreesC	O
for	O
15	O
minutes	O
.	O

Supernatants	O
were	O
then	O
added	O
to	O
40	O
microl	O
of	O
anti	O
-	O
HA	O
beads	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
A2095	O
)	O
and	O
mixed	O
at	O
4degreesC	O
for	O
3	O
hours	O
.	O

Following	O
washing	O
of	O
the	O
pull	O
-	O
down	O
beads	O
3	O
times	O
with	O
HNET	O
buffer	O
,	O
adsorbed	O
proteins	O
were	O
eluted	O
with	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
sample	O
buffer	O
.	O

Samples	O
were	O
subsequently	O
analyzed	O
by	O
SDS	O
-	O
PAGE	O
and	O
Western	O
blotting	O
for	O
Hsp90	O
[	O
OSUb2	O
,	O
]	O
and	O
HA	O
(	O
Covance	O
,	O
MMS	O
-	O
101P	O
)	O
]	O
.	O

SPAK	O
mediates	O
KCC3	O
-	O
enhanced	O
cervical	O
cancer	O
tumorigenesis	O
.	O

Ste20	O
-	O
related	O
proline	O
/	O
alanine	O
-	O
rich	O
kinase	O
(	O
SPAK	O
)	O
plays	O
a	O
role	O
in	O
regulating	O
many	O
biological	O
activities	O
,	O
and	O
interacts	O
with	O
K	O
-	O
Cl	O
co	O
-	O
transporter	O
3	O
(	O
KCC3	O
)	O
;	O
however	O
,	O
the	O
importance	O
of	O
SPAK	O
for	O
KCC3	O
function	O
has	O
not	O
been	O
demonstrated	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
role	O
of	O
SPAK	O
in	O
KCC3	O
-	O
regulated	O
cell	O
invasiveness	O
and	O
tumor	O
formation	O
.	O

We	O
show	O
that	O
induction	O
of	O
KCC3	O
expression	O
triggers	O
activation	O
of	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
and	O
SPAK	O
signaling	O
cascades	O
,	O
leading	O
to	O
activation	O
of	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
and	O
matrix	O
metalloproteinase	O
-	O
2	O
(	O
MMP2	O
)	O
.	O

A	O
small	O
interference	O
RNA	O
-	O
mediated	O
reduction	O
in	O
SPAK	O
protein	O
levels	O
suppressed	O
the	O
invasive	O
ability	O
and	O
oncogenic	O
potential	O
of	O
cervical	O
cancer	O
cells	O
,	O
and	O
decreased	O
tumor	O
formation	O
in	O
mouse	O
xenografts	O
.	O

A	O
combination	O
of	O
experimental	O
approaches	O
,	O
including	O
RT	O
-	O
PCR	O
and	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
,	O
gelatin	O
zymography	O
,	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
luciferase	O
activity	O
and	O
chromatin	O
immunoprecipitation	O
assays	O
,	O
showed	O
that	O
the	O
induction	O
of	O
KCC3	O
over	O
-	O
expression	O
increased	O
MMP2	O
expression	O
and	O
augmented	O
binding	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
to	O
its	O
putative	O
SPAK	O
promoter	O
binding	O
site	O
,	O
suggesting	O
that	O
the	O
SPAK	O
/	O
MMP2	O
axis	O
is	O
up	O
-	O
regulated	O
by	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
.	O

Pharmacological	O
inhibition	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
or	O
MMP2	O
abrogated	O
KCC3	O
-	O
triggered	O
,	O
SPAK	O
-	O
dependent	O
cell	O
invasiveness	O
.	O

Furthermore	O
,	O
p38	O
MAPK	O
was	O
identified	O
as	O
the	O
upstream	O
regulator	O
of	O
KCC3	O
-	O
dependent	O
MMP2	O
activation	O
.	O

We	O
conclude	O
that	O
SPAK	O
may	O
promote	O
KCC3	O
-	O
mediated	O
tumor	O
aggressiveness	O
via	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
/	O
p38	O
MAPK	O
/	O
MMP2	O
axis	O
.	O

Distinct	O
modes	O
of	O
ubiquitination	O
of	O
peroxisome	O
-	O
targeting	O
signal	O
type	O
1	O
(	O
PTS1	O
)	O
receptor	O
Pex5p	O
regulate	O
PTS1	O
protein	O
import	O
.	O

Peroxisome	O
targeting	O
signal	O
type	O
-	O
1	O
(	O
PTS1	O
)	O
receptor	O
,	O
Pex5p	O
,	O
is	O
a	O
key	O
player	O
in	O
peroxisomal	O
matrix	O
protein	O
import	O
.	O

Pex5p	O
recognizes	O
PTS1	O
cargoes	O
in	O
the	O
cytosol	O
,	O
targets	O
peroxisomes	O
,	O
translocates	O
across	O
the	O
membrane	O
,	O
unloads	O
the	O
cargoes	O
,	O
and	O
shuttles	O
back	O
to	O
the	O
cytosol	O
.	O

Ubiquitination	O
of	O
Pex5p	O
at	O
a	O
conserved	O
cysteine	O
is	O
required	O
for	O
the	O
exit	O
from	O
peroxisomes	O
.	O

However	O
,	O
any	O
potential	O
ubiquitin	O
ligase	O
(	O
E3	O
)	O
remains	O
unidentified	O
in	O
mammals	O
.	O

Here	O
,	O
we	O
establish	O
an	O
in	O
vitro	O
ubiquitination	O
assay	O
system	O
and	O
demonstrate	O
that	O
RING	O
finger	O
Pex10p	O
functions	O
as	O
an	O
E3	O
with	O
an	O
E2	O
,	O
UbcH5C	O
.	O

The	O
E3	O
activity	O
of	O
Pex10p	O
is	O
essential	O
for	O
its	O
peroxisome	O
-	O
restoring	O
activity	O
,	O
being	O
enhanced	O
by	O
another	O
RING	O
peroxin	O
,	O
Pex12p	O
.	O

The	O
Pex10p	O
.	O
Pex12p	O
complex	O
catalyzes	O
monoubiquitination	O
of	O
Pex5p	O
at	O
one	O
of	O
multiple	O
lysine	O
residues	O
in	O
vitro	O
,	O
following	O
the	O
dissociation	O
of	O
Pex5p	O
from	O
Pex14p	O
and	O
the	O
PTS1	O
cargo	O
.	O

Several	O
lines	O
of	O
evidence	O
with	O
lysine	O
-	O
to	O
-	O
arginine	O
mutants	O
of	O
Pex5p	O
demonstrate	O
that	O
Pex10p	O
RING	O
E3	O
-	O
mediated	O
ubiquitination	O
of	O
Pex5p	O
is	O
required	O
for	O
its	O
efficient	O
export	O
from	O
peroxisomes	O
to	O
the	O
cytosol	O
and	O
peroxisomal	O
matrix	O
protein	O
import	O
.	O

RING	O
peroxins	O
are	O
required	O
for	O
both	O
modes	O
of	O
Pex5p	O
ubiquitination	O
,	O
thus	O
playing	O
a	O
pivotal	O
role	O
in	O
Pex5p	O
shuttling	O
.	O

We	O
analyzed	O
the	O
mitotic	O
defects	O
of	O
the	O
ensc	O
mutants	O
in	O
detail	O
by	O
fully	O
depolymerizing	O
mitotic	O
spindles	O
from	O
WT	O
and	O
ensc	O
Nbs	O
by	O
cold	O
treatment	O
and	O
monitoring	O
Mt	O
regrowth	O
at	O
25degreesC	O
(	O
Fig	O
.	O
3	O
A	O
)	O
.	O

In	O
control	O
tests	O
,	O
we	O
observed	O
large	O
centrosomal	O
asters	O
30	O
s	O
after	O
the	O
return	O
to	O
25degreesC	O
conditions	O
(	O
Fig	O
.	O
3	O
B	O
,	O
left	O
,	O
red	O
arrows	O
;	O
n	O
=	O
19	O
)	O
.	O

We	O
also	O
detected	O
asters	O
around	O
the	O
main	O
chromosome	O
mass	O
and	O
discrete	O
Kt	O
fibers	O
(	O
Fig	O
.	O
3	O
B	O
,	O
white	O
arrows	O
)	O
.	O

At	O
90	O
s	O
,	O
the	O
WT	O
spindles	O
had	O
a	O
normal	O
,	O
bipolar	O
shape	O
(	O
n	O
=	O
25	O
)	O
.	O

The	O
ensc	O
mutant	O
Nbs	O
displayed	O
weak	O
aster	O
formation	O
around	O
the	O
chromosomes	O
and	O
no	O
obvious	O
Kt	O
fibers	O
after	O
30	O
s	O
(	O
n	O
>	O
30	O
;	O
Fig	O
.	O
3	O
B	O
,	O
right	O
)	O
.	O

After	O
90	O
s	O
,	O
only	O
short	O
spindles	O
with	O
weak	O
,	O
disorganized	O
Mt	O
arrays	O
were	O
present	O
(	O
n	O
=	O
24	O
)	O
.	O

Overall	O
,	O
our	O
results	O
suggest	O
that	O
Ensconsin	O
contributes	O
to	O
the	O
polymerization	O
of	O
spindle	O
Mts	O
.	O

For	O
confirmation	O
of	O
this	O
role	O
,	O
we	O
quantified	O
Mt	O
growth	O
directly	O
by	O
tracking	O
EB1	O
-	O
GFP	O
comets	O
at	O
Mt	O
plus	O
ends	O
in	O
WT	O
and	O
ensc	O
Nbs	O
(	O
Fig	O
.	O
3	O
C	O
and	O
Video	O
8	O
)	O
.	O

Measurements	O
of	O
Mt	O
dynamic	O
parameters	O
revealed	O
that	O
the	O
mean	O
rate	O
of	O
Mt	O
polymerization	O
was	O
significantly	O
lower	O
(	O
reduced	O
by	O
12	O
%	O
)	O
in	O
the	O
ensc	O
mutant	O
than	O
in	O
WT	O
Nbs	O
(	O
Fig	O
.	O
3	O
D	O
)	O
,	O
a	O
difference	O
sufficient	O
to	O
account	O
for	O
the	O
short	O
spindles	O
observed	O
in	O
ensc	O
mutants	O
.	O

Using	O
pull	O
-	O
down	O
assays	O
performed	O
under	O
stringent	O
conditions	O
,	O
we	O
further	O
characterized	O
the	O
homophilic	O
and	O
heterophilic	O
interactions	O
mediated	O
by	O
PCDH24	O
.	O

We	O
generated	O
6xHis	O
and	O
FLAG	O
-	O
tagged	O
EDs	O
from	O
PCDH24	O
and	O
both	O
isoforms	O
of	O
MLPCDH	O
(	O
Fig	O
.	O
4A	O
)	O
.	O
.	O

Co	O
-	O
incubation	O
of	O
differentially	O
tagged	O
versions	O
of	O
PCDH24	O
did	O
not	O
reveal	O
homophilic	O
interactions	O
by	O
pull	O
-	O
down	O
analysis	O
,	O
most	O
likely	O
because	O
the	O
interaction	O
is	O
too	O
weak	O
to	O
be	O
detected	O
by	O
this	O
method	O
(	O
Fig	O
.	O
4D	O
)	O
.	O

PCDH24	O
was	O
found	O
,	O
however	O
,	O
to	O
interact	O
strongly	O
with	O
both	O
isoforms	O
of	O
MLPCDH	O
(	O
Fig	O
.	O
4D	O
)	O
.	O

This	O
interaction	O
was	O
again	O
specific	O
to	O
the	O
PCDH24	O
N	O
-	O
terminus	O
,	O
as	O
deletion	O
of	O
the	O
first	O
EC	O
domain	O
abolished	O
binding	O
.	O

Thus	O
,	O
PCDH24	O
and	O
MLPCDH	O
interact	O
in	O
trans	O
to	O
form	O
Ca2	O
+	O
-	O
dependent	O
adhesion	O
complexes	O
.	O

Yeast	O
cells	O
expressing	O
tetracystein	O
-	O
tagged	O
Gln1	O
were	O
incubated	O
over	O
night	O
with	O
FIAsH	O
-	O
EDT2	O
to	O
label	O
Gln1	O
.	O

The	O
cells	O
were	O
washed	O
twice	O
with	O
water	O
and	O
resuspended	O
in	O
a	O
phosphate	O
-	O
citrate	O
buffer	O
to	O
induce	O
starvation	O
(	O
pH	O
6	O
)	O
.	O

Images	O
were	O
taken	O
4	O
hr	O
after	O
onset	O
of	O
starvation	O
.	O

White	O
lines	O
denote	O
the	O
cell	O
boundaries	O
.	O

The	O
scale	O
bar	O
is	O
5	O
mum	O
.	O

Deletion	O
of	O
Cul9	O
in	O
mice	O
resulted	O
in	O
spontaneous	O
tumor	O
development	O
in	O
multiple	O
organ	O
tissues	O
,	O
including	O
lymphoma	O
,	O
sarcoma	O
and	O
tumors	O
in	O
pituitary	O
,	O
lung	O
,	O
liver	O
and	O
ovary	O
,	O
accelerated	O
Emicro	O
-	O
Myc	O
-	O
induced	O
lymphomagenesis	O
and	O
rendered	O
mice	O
susceptible	O
to	O
carcinogenesis	O
.	O

The	O
cellular	O
and	O
molecular	O
basis	O
for	O
CUL9	O
function	O
in	O
tumor	O
suppression	O
is	O
unclear	O
.	O

Prompted	O
by	O
the	O
function	O
of	O
the	O
3M	B-Complex
complex	O
in	O
maintaining	O
microtubule	O
integrity	O
(	O
Yan	O
et	O
al	O
.	O
accompanying	O
paper	O
)	O
and	O
the	O
previous	O
report	O
that	O
CUL7	O
forms	O
a	O
heterodimer	O
with	O
CUL9	O
,	O
we	O
investigated	O
the	O
function	O
of	O
CUL9	O
in	O
maintaining	O
genome	O
stability	O
and	O
its	O
functional	O
relationship	O
with	O
CUL7	O
and	O
the	O
3M	B-Complex
complex	O
.	O

These	O
studies	O
led	O
to	O
the	O
discovery	O
that	O
CUL9	O
is	O
a	O
critical	O
downstream	O
effector	O
of	O
the	O
3M	B-Complex
complex	O
in	O
the	O
maintenance	O
of	O
microtubules	O
and	O
genome	O
integrity	O
and	O
that	O
survivin	O
is	O
a	O
substrate	O
of	O
CUL9	O
.	O

A	O
high	O
-	O
coverage	O
shRNA	O
screen	O
identifies	O
TMEM129	O
as	O
an	O
E3	O
ligase	O
involved	O
in	O
ER	O
-	O
associated	O
protein	O
degradation	O
.	O

Misfolded	O
ER	O
proteins	O
are	O
retrotranslocated	O
into	O
the	O
cytosol	O
for	O
degradation	O
via	O
the	O
ubiquitin	O
-	O
proteasome	B-Complex
system	O
.	O

The	O
human	O
cytomegalovirus	O
protein	O
US11	O
exploits	O
this	O
ER	O
-	O
associated	O
protein	O
degradation	O
(	O
ERAD	O
)	O
pathway	O
to	O
downregulate	O
HLA	B-Complex
class	I-Complex
I	I-Complex
molecules	O
in	O
virus	O
-	O
infected	O
cells	O
,	O
thereby	O
evading	O
elimination	O
by	O
cytotoxic	O
T	O
-	O
lymphocytes	O
.	O

US11	O
-	O
mediated	O
degradation	O
of	O
HLA	B-Complex
class	I-Complex
I	I-Complex
has	O
been	O
instrumental	O
in	O
the	O
identification	O
of	O
key	O
components	O
of	O
mammalian	O
ERAD	O
,	O
including	O
Derlin	O
-	O
1	O
,	O
p97	O
,	O
VIMP	O
and	O
SEL1L	O
.	O

Despite	O
this	O
,	O
the	O
process	O
governing	O
retrotranslocation	O
of	O
the	O
substrate	O
is	O
still	O
poorly	O
understood	O
.	O

Here	O
using	O
a	O
high	O
-	O
coverage	O
genome	O
-	O
wide	O
shRNA	O
library	O
,	O
we	O
identify	O
the	O
uncharacterized	O
protein	O
TMEM129	O
and	O
the	O
ubiquitin	O
-	O
conjugating	O
E2	O
enzyme	O
UBE2J2	O
to	O
be	O
essential	O
for	O
US11	O
-	O
mediated	O
HLA	B-Complex
class	I-Complex
I	I-Complex
downregulation	O
.	O

TMEM129	O
is	O
an	O
unconventional	O
C4C4	O
-	O
type	O
RING	O
finger	O
E3	O
ubiquitin	O
ligase	O
that	O
resides	O
within	O
a	O
complex	O
containing	O
various	O
other	O
ERAD	O
components	O
,	O
including	O
Derlin	O
-	O
1	O
,	O
Derlin	O
-	O
2	O
,	O
VIMP	O
and	O
p97	O
,	O
indicating	O
that	O
TMEM129	O
is	O
an	O
integral	O
part	O
of	O
the	O
ER	O
-	O
resident	O
dislocation	O
complex	O
mediating	O
US11	O
-	O
induced	O
HLA	B-Complex
class	I-Complex
I	I-Complex
degradation	O
.	O

This	O
study	O
suggests	O
that	O
while	O
the	O
general	O
pathways	O
and	O
enzymes	O
for	O
genome	O
stability	O
are	O
similar	O
across	O
eukaryotes	O
,	O
the	O
activities	O
of	O
specific	O
DNA	O
regulators	O
have	O
diverged	O
within	O
those	O
modules	O
.	O

Among	O
the	O
SNF2	O
-	O
specific	O
helicases	O
,	O
for	O
example	O
,	O
metazoans	O
have	O
significantly	O
expanded	O
the	O
family	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
helicase	O
function	O
of	O
S	O
.	O
pombe	O
Rad8	O
is	O
potentially	O
required	O
under	O
specialized	O
circumstances	O
,	O
as	O
a	O
minor	O
redundant	O
pathway	O
with	O
the	O
HR	O
proteins	O
most	O
notably	O
in	O
the	O
restart	O
of	O
replication	O
forks	O
in	O
HU	O
,	O
or	O
in	O
the	O
absence	O
of	O
ubiquitin	O
-	O
PCNA	B-OOS
.	O

The	O
primary	O
function	O
of	O
this	O
enzyme	O
in	O
fission	O
yeast	O
in	O
the	O
maintenance	O
of	O
genome	O
stability	O
appears	O
to	O
be	O
due	O
to	O
its	O
E3	O
ubiquitin	O
ligase	O
activity	O
and	O
the	O
HIRAN	O
domain	O
,	O
indicating	O
a	O
fundamental	O
role	O
for	O
PCNA	B-OOS
modification	O
in	O
preserving	O
genomic	O
integrity	O
.	O

There	O
are	O
two	O
key	O
features	O
in	O
the	O
pattern	O
of	O
subunit	O
arrangement	O
.	O

First	O
,	O
pseudo	O
-	O
symmetry	O
mismatch	O
is	O
present	O
between	O
the	O
extracellular	O
region	O
and	O
the	O
TMD	O
.	O

The	O
GluN1a	O
and	O
GluN2B	O
subunits	O
are	O
arranged	O
in	O
a	O
1	O
-	O
2	O
-	O
1	O
-	O
2	O
orientation	O
with	O
two	O
-	O
fold	O
symmetry	O
between	O
the	O
two	O
GluN1a	O
/	O
GluN2B	O
heterodimers	O
in	O
the	O
ATD	O
and	O
LBD	O
,	O
but	O
with	O
pseudo	O
-	O
four	O
-	O
fold	O
symmetry	O
in	O
the	O
TMD	O
(	O
Fig	O
.	O
2	O
)	O
.	O

A	O
similar	O
subunit	O
arrangement	O
is	O
observed	O
in	O
the	O
GluA2	O
homotetrameric	O
structure	O
that	O
has	O
two	O
-	O
fold	O
symmetries	O
within	O
and	O
between	O
homodimers	O
of	O
the	O
ATD	O
and	O
LBD	O
and	O
fourfold	O
symmetry	O
in	O
the	O
TMD	O
indicating	O
that	O
symmetry	O
mismatch	O
may	O
be	O
common	O
to	O
iGluR	O
structures	O
.	O

The	O
second	O
important	O
feature	O
is	O
swapping	O
of	O
dimer	O
pairs	O
between	O
the	O
ATD	O
and	O
LBD	O
layers	O
(	O
Fig	O
.	O
2A	O
and	O
B	O
)	O
.	O

In	O
the	O
ATD	O
layer	O
,	O
heterodimer	O
pairs	O
assemble	O
as	O
GluN1a	O
(	O
alpha	O
)	O
/	O
GluN2B	O
(	O
alpha	O
)	O
and	O
GluN1	O
(	O
beta	O
)	O
/	O
GluN2B	O
(	O
beta	O
)	O
whereas	O
in	O
the	O
LBD	O
layer	O
,	O
they	O
assemble	O
as	O
GluN1a	O
(	O
alpha	O
)	O
/	O
GluN2B	O
(	O
beta	O
)	O
and	O
GluN1	O
(	O
beta	O
)	O
/	O
GluN2B	O
(	O
alpha	O
)	O
(	O
Fig	O
.	O
2A	O
and	O
B	O
)	O
.	O

A	O
similar	O
pattern	O
of	O
domain	O
swapping	O
is	O
also	O
observed	O
in	O
the	O
homotetrameric	O
GluA2	O
AMPA	B-Complex
receptor	I-Complex
where	O
subunits	O
assemble	O
as	O
a	O
dimer	O
of	O
A	O
/	O
B	O
and	O
C	O
/	O
D	O
homodimers	O
at	O
the	O
ATD	O
and	O
as	O
a	O
dimer	O
of	O
A	O
/	O
D	O
and	O
B	O
/	O
C	O
dimers	O
at	O
the	O
LBD	O
(	O
Fig	O
.	O
2A	O
and	O
B	O
)	O
.	O

Overall	O
the	O
conformations	O
of	O
GluN1a	O
and	O
GluN2B	O
subunits	O
approximately	O
correspond	O
to	O
those	O
of	O
A	O
/	O
C	O
and	O
B	O
/	O
D	O
subunits	O
in	O
the	O
GluA2	O
AMPA	B-Complex
receptor	I-Complex
homotetramer	O
.	O

This	O
assignment	O
is	O
based	O
on	O
the	O
observation	O
that	O
the	O
ATD	O
-	O
LBD	O
linker	O
and	O
the	O
M3	O
-	O
LBD	O
linker	O
are	O
respectively	O
more	O
"	O
distal	O
"	O
and	O
"	O
proximal	O
"	O
from	O
the	O
overall	O
two	O
-	O
fold	O
symmetry	O
axis	O
for	O
GluN1a	O
than	O
GluN2B	O
similar	O
to	O
the	O
orientation	O
of	O
the	O
A	O
/	O
C	O
than	O
B	O
/	O
D	O
subunits	O
in	O
the	O
GluA2	O
AMPA	B-Complex
receptor	I-Complex
(	O
Fig	O
.	O
2	O
and	O
fig	O
.	O
S10	O
)	O
.	O

The	O
core	O
ABA	O
signaling	O
pathways	O
consist	O
of	O
ABA	O
-	O
specific	O
receptors	O
and	O
their	O
downstream	O
protein	O
phosphatases	O
and	O
kinases	O
.	O

The	O
pyrabactin	O
resistance	O
1	O
(	O
PYR1	O
)	O
and	O
PYR1	O
-	O
like	O
proteins	O
(	O
PYLs	O
)	O
,	O
also	O
known	O
as	O
the	O
regulatory	O
component	O
of	O
ABA	O
receptor	O
(	O
RCAR	O
)	O
family	O
proteins	O
,	O
are	O
ABA	O
receptors	O
.	O

PYR1	O
/	O
PYL	O
/	O
RCARs	O
interact	O
with	O
and	O
inhibit	O
clade	O
-	O
A	O
protein	O
phosphatase	O
type	O
2Cs	O
(	O
PP2Cs	O
)	O
in	O
the	O
presence	O
of	O
ABA	O
and	O
release	O
the	O
SnRK2	O
protein	O
kinases	O
from	O
inhibition	O
by	O
the	O
PP2Cs	O
.	O

Activated	O
SnRK2s	O
phosphorylate	O
transcription	O
factors	O
such	O
as	O
ABA	O
-	O
responsive	O
element	O
binding	O
factors	O
,	O
ABI5	O
,	O
enhanced	O
late	O
embryogenesis	O
abundant	O
level	O
,	O
and	O
flowering	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
-	O
type	O
transcription	O
factor	O
3	O
to	O
alter	O
gene	O
expression	O
.	O

Activated	O
SnRK2s	O
also	O
phosphorylate	O
ion	O
channels	O
such	O
as	O
slow	O
anion	O
channel	O
1	O
,	O
K	O
+	O
channel	O
in	O
Arabidopsis	O
1	O
,	O
and	O
mechanosensitive	O
channel	O
of	O
small	O
conductance	O
-	O
like	O
9	O
to	O
stimulate	O
stomatal	O
closure	O
.	O

SnRK2s	O
also	O
phosphorylate	O
the	O
nicotinamide	B-OOS
adenine	I-OOS
dinucleotide	I-OOS
phosphate	I-OOS
oxidase	I-OOS
RBOHF	O
,	O
leading	O
to	O
the	O
production	O
of	O
ROS	O
.	O

In	O
addition	O
,	O
several	O
other	O
substrates	O
of	O
SnRK2s	O
include	O
proteins	O
related	O
to	O
RNA	O
binding	O
,	O
microRNA	O
and	O
epi	O
-	O
genetic	O
regulation	O
,	O
chloroplast	O
function	O
,	O
and	O
many	O
other	O
processes	O
based	O
on	O
phosphoproteomics	O
analyses	O
.	O

Thus	O
,	O
PYR1	O
/	O
PYL	O
/	O
RCARs	O
are	O
thought	O
to	O
primarily	O
regulate	O
cellular	O
functions	O
using	O
the	O
PP2C	O
-	O
SnRK2	O
pathway	O
.	O

Each	O
protein	O
phospholipid	O
pair	O
generated	O
by	O
MD	O
was	O
treated	O
as	O
a	O
candidate	O
model	O
.	O

For	O
example	O
,	O
~	O
105	O
,	O
000	O
such	O
models	O
were	O
generated	O
for	O
AqpZ	O
and	O
filtered	O
by	O
comparison	O
of	O
calculated	O
and	O
experimental	O
CCS	O
values	O
.	O

More	O
specifically	O
,	O
within	O
each	O
MD	O
snapshot	O
there	O
are	O
~	O
80	O
lipids	O
that	O
could	O
be	O
in	O
accord	O
with	O
the	O
CCS	O
measurements	O
for	O
one	O
lipid	O
bound	O
to	O
AqpZ	O
.	O

After	O
filtering	O
by	O
agreement	O
with	O
CCS	O
,	O
an	O
ensemble	O
of	O
protein	O
phospholipid	O
complexes	O
consistent	O
with	O
our	O
data	O
was	O
identified	O
.	O

As	O
the	O
MD	O
is	O
used	O
to	O
provide	O
a	O
source	O
of	O
potential	O
lipid	O
associated	O
structures	O
,	O
the	O
results	O
are	O
largely	O
invariant	O
to	O
the	O
choice	O
of	O
force	O
field	O
and	O
lipid	O
molecule	O
.	O

Endogenous	O
Arabidopsis	O
AtGRIP	O
was	O
detected	O
as	O
a	O
92	O
kDa	O
monomer	O
by	O
western	O
blotting	O
with	O
an	O
anti	O
-	O
AtGRIP	O
antibody	O
.	O

After	O
treatment	O
with	O
the	O
chemical	O
cross	O
-	O
linker	O
3	O
,	O
3	O
'	O
-	O
dithiobis	O
(	O
sulphosuccinimidyl	O
propionate	O
)	O
(	O
DTSSP	O
)	O
,	O
western	O
blot	O
showed	O
a	O
band	O
of	O
more	O
than	O
220	O
kDa	O
in	O
the	O
extract	O
from	O
an	O
Arabidopsis	O
seedling	O
(	O
Figure	O
1A	O
Lane	O
5	O
)	O
.	O

These	O
results	O
indicated	O
that	O
the	O
AtGRIP	O
protein	O
can	O
form	O
a	O
homoligomer	O
.	O

Glycogen	O
synthase	O
kinase	O
(	O
GSK	O
)	O
3beta	O
phosphorylates	O
and	O
protects	O
nuclear	O
myosin	O
1c	O
from	O
proteasome	B-Complex
-	O
mediated	O
degradation	O
to	O
activate	O
rDNA	O
transcription	O
in	O
early	O
G1	O
cells	O
.	O

Nuclear	O
myosin	O
1c	O
(	O
NM1	O
)	O
mediates	O
RNA	B-Complex
polymerase	I-Complex
I	I-Complex
(	O
pol	B-Complex
I	I-Complex
)	O
transcription	O
activation	O
and	O
cell	O
cycle	O
progression	O
by	O
facilitating	O
PCAF	O
-	O
mediated	O
H3K9	O
acetylation	O
,	O
but	O
the	O
molecular	O
mechanism	O
by	O
which	O
NM1	O
is	O
regulated	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
report	O
that	O
at	O
early	O
G1	O
the	O
glycogen	O
synthase	O
kinase	O
(	O
GSK	O
)	O
3beta	O
phosphorylates	O
and	O
stabilizes	O
NM1	O
,	O
allowing	O
for	O
NM1	O
association	O
with	O
the	O
chromatin	O
.	O

Genomic	O
analysis	O
by	O
ChIP	O
-	O
Seq	O
showed	O
that	O
this	O
mechanism	O
occurs	O
on	O
the	O
rDNA	O
as	O
active	O
GSK3beta	O
selectively	O
occupies	O
the	O
gene	O
.	O

ChIP	O
assays	O
and	O
transmission	O
electron	O
microscopy	O
in	O
GSK3beta	O
-	O
/	O
-	O
mouse	O
embryonic	O
fibroblasts	O
indicated	O
that	O
at	O
G1	O
rRNA	O
synthesis	O
is	O
suppressed	O
due	O
to	O
decreased	O
H3K9	O
acetylation	O
leading	O
to	O
a	O
chromatin	O
state	O
incompatible	O
with	O
transcription	O
.	O

We	O
found	O
that	O
GSK3beta	O
directly	O
phosphorylates	O
the	O
endogenous	O
NM1	O
on	O
a	O
single	O
serine	O
residue	O
(	O
Ser	O
-	O
1020	O
)	O
located	O
within	O
the	O
NM1	O
C	O
-	O
terminus	O
.	O

In	O
G1	O
this	O
phosphorylation	O
event	O
stabilizes	O
NM1	O
and	O
prevents	O
NM1	O
polyubiquitination	O
by	O
the	O
E3	O
ligase	O
UBR5	O
and	O
proteasome	B-Complex
-	O
mediated	O
degradation	O
.	O

We	O
conclude	O
that	O
GSK3beta	O
-	O
mediated	O
phosphorylation	O
of	O
NM1	O
is	O
required	O
for	O
pol	B-Complex
I	I-Complex
transcription	O
activation	O
.	O

The	O
genetic	O
and	O
biochemical	O
basis	O
of	O
FANCD2	O
monoubiquitination	O
.	O

Fanconi	O
anaemia	O
(	O
FA	O
)	O
is	O
a	O
cancer	O
predisposition	O
syndrome	O
characterized	O
by	O
cellular	O
sensitivity	O
to	O
DNA	O
interstrand	O
crosslinkers	O
.	O

The	O
molecular	O
defect	O
in	O
FA	O
is	O
an	O
impaired	O
DNA	O
repair	O
pathway	O
.	O

The	O
critical	O
event	O
in	O
activating	O
this	O
pathway	O
is	O
monoubiquitination	O
of	O
FANCD2	O
.	O

In	O
vivo	O
,	O
a	O
multisubunit	O
FA	B-Complex
core	I-Complex
complex	O
catalyzes	O
this	O
step	O
,	O
but	O
its	O
mechanism	O
is	O
unclear	O
.	O

Here	O
,	O
we	O
report	O
purification	O
of	O
a	O
native	O
avian	O
FA	B-Complex
core	I-Complex
complex	O
and	O
biochemical	O
reconstitution	O
of	O
FANCD2	O
monoubiquitination	O
.	O

This	O
demonstrates	O
that	O
the	O
catalytic	O
FANCL	O
E3	O
ligase	O
subunit	O
must	O
be	O
embedded	O
within	O
the	O
complex	O
for	O
maximal	O
activity	O
and	O
site	O
specificity	O
.	O

We	O
genetically	O
and	O
biochemically	O
define	O
a	O
minimal	O
subcomplex	O
comprising	O
just	O
three	O
proteins	O
(	O
FANCB	O
,	O
FANCL	O
,	O
and	O
FAAP100	O
)	O
that	O
functions	O
as	O
the	O
monoubiquitination	O
module	O
.	O

Residual	O
FANCD2	O
monoubiquitination	O
activity	O
is	O
retained	O
in	O
cells	O
defective	O
for	O
other	O
FA	B-Complex
core	I-Complex
complex	O
subunits	O
.	O

This	O
work	O
describes	O
the	O
in	O
vitro	O
reconstitution	O
and	O
characterization	O
of	O
this	O
multisubunit	O
monoubiquitin	O
E3	O
ligase	O
,	O
providing	O
key	O
insight	O
into	O
the	O
conserved	O
FA	O
DNA	O
repair	O
pathway	O
.	O

Structural	O
characterization	O
and	O
subcellular	O
localization	O
of	O
Drosophila	O
organic	O
solute	O
carrier	O
partner	O
1	O
.	O

BACKGROUND	O
:	O
Organic	O
solute	O
carrier	O
partner	O
1	O
(	O
OSCP1	O
)	O
is	O
known	O
to	O
facilitate	O
the	O
transport	O
of	O
various	O
organic	O
solutes	O
into	O
cells	O
and	O
reported	O
to	O
play	O
a	O
role	O
in	O
cell	O
growth	O
and	O
cell	O
differentiation	O
.	O

Moreover	O
,	O
OSCP1	O
is	O
known	O
as	O
a	O
tumor	O
suppressor	O
gene	O
that	O
is	O
frequently	O
down	O
-	O
expressed	O
in	O
nasopharyngeal	O
carcinomas	O
and	O
acute	O
myeloid	O
leukemia	O
.	O

However	O
,	O
the	O
underlying	O
mechanisms	O
of	O
action	O
remain	O
unclear	O
and	O
the	O
subcellular	O
localization	O
of	O
OSCP1	O
has	O
yet	O
to	O
be	O
determined	O
in	O
detail	O
.	O

RESULTS	O
:	O
Drosophila	O
contains	O
a	O
single	O
orthologue	O
of	O
OSCP1	O
(	O
dOSCP1	O
)	O
that	O
shares	O
58	O
%	O
homology	O
with	O
its	O
human	O
counterpart	O
.	O

To	O
study	O
the	O
expression	O
pattern	O
and	O
subcellular	O
localization	O
of	O
dOSCP1	O
,	O
we	O
prepared	O
a	O
specific	O
antibody	O
.	O

Subcellular	O
localization	O
analyses	O
of	O
dOSCP1	O
with	O
these	O
revealed	O
localization	O
in	O
the	O
plasma	O
membrane	O
,	O
endoplasmic	O
reticulum	O
,	O
Golgi	O
apparatus	O
and	O
mitochondria	O
,	O
but	O
no	O
detection	O
in	O
cytosol	O
.	O

dOSCP1	O
signals	O
were	O
also	O
detected	O
in	O
the	O
nucleus	O
,	O
although	O
at	O
weaker	O
intensity	O
than	O
in	O
plasma	O
membranes	O
and	O
subcellular	O
organelles	O
.	O

In	O
addition	O
,	O
native	O
polyacrylamide	O
gel	O
electrophoresis	O
analysis	O
with	O
and	O
without	O
beta	O
-	O
mercaptoethanol	O
treatment	O
revealed	O
that	O
recombinant	O
dOSCP1	O
forms	O
dimers	O
and	O
trimers	O
in	O
solution	O
.	O

The	O
dimer	O
form	O
of	O
dOSCP1	O
could	O
also	O
be	O
detected	O
by	O
Western	O
immunoblot	O
analyses	O
in	O
third	O
instar	O
larval	O
extracts	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
revealed	O
that	O
dOSCP1	O
localizes	O
not	O
only	O
in	O
the	O
plasma	O
membrane	O
but	O
also	O
in	O
the	O
nucleus	O
,	O
ER	O
,	O
Golgi	O
apparatus	O
and	O
mitochondria	O
.	O

It	O
is	O
therefore	O
conceivable	O
that	O
this	O
protein	O
may	O
interact	O
with	O
various	O
partners	O
or	O
form	O
multimeric	O
complexes	O
with	O
other	O
proteins	O
to	O
play	O
multiple	O
roles	O
in	O
cells	O
,	O
providing	O
clues	O
to	O
understanding	O
the	O
functions	O
of	O
dOSCP1	O
during	O
Drosophila	O
development	O
.	O

Previous	O
studies	O
showed	O
that	O
ROS1	O
is	O
required	O
to	O
prevent	O
the	O
transcriptional	O
silencing	O
of	O
RD29A	O
-	O
LUC	O
and	O
35S	O
-	O
NPTII	O
trans	O
-	O
genes	O
.	O

Mutations	O
in	O
IDM1	O
cause	O
the	O
silencing	O
of	O
35S	O
-	O
NPTII	O
but	O
not	O
of	O
the	O
RD29A	O
-	O
LUC	O
transgene	O
.	O

An	O
independent	O
genetic	O
screen	O
for	O
mutants	O
impaired	O
in	O
the	O
prevention	O
of	O
silencing	O
of	O
the	O
35S	O
-	O
SUC2	O
transgene	O
led	O
to	O
the	O
isolation	O
of	O
mutant	O
alleles	O
of	O
IDM1	O
as	O
well	O
as	O
ROS1	O
.	O

This	O
later	O
genetic	O
screen	O
also	O
led	O
to	O
the	O
isolation	O
of	O
idm2	O
-	O
3	O
(	O
Figure	O
1C	O
)	O
.	O

Wild	O
-	O
type	O
35S	O
-	O
SUC2	O
trans	O
-	O
genic	O
plants	O
showed	O
an	O
inhibition	O
of	O
root	O
growth	O
on	O
Murashige	O
-	O
Skoog	O
(	O
MS	O
)	O
medium	O
with	O
2	O
%	O
sucrose	O
due	O
to	O
high	O
levels	O
of	O
SUC2	O
(	O
sucrose	O
transporter	O
2	O
)	O
expression	O
.	O

The	O
root	O
length	O
in	O
both	O
idm1	O
-	O
9	O
and	O
idm2	O
-	O
3	O
plants	O
was	O
similar	O
to	O
that	O
in	O
the	O
Col	O
-	O
0	O
control	O
that	O
did	O
not	O
have	O
the	O
35S	O
-	O
SUC2	O
transgene	O
.	O

Both	O
the	O
35S	O
-	O
SUC2	O
and	O
35S	O
-	O
HPTII	O
transgenes	O
were	O
silenced	O
in	O
idm1	O
-	O
9	O
and	O
idm2	O
-	O
3	O
mutant	O
plants	O
(	O
Figure	O
1D	O
)	O
.	O

Bisulfite	O
sequencing	O
analysis	O
showed	O
that	O
,	O
compared	O
to	O
the	O
wild	O
-	O
type	O
control	O
,	O
the	O
DNA	O
methylation	O
level	O
of	O
the	O
35S	O
promoter	O
region	O
was	O
increased	O
in	O
idm1	O
-	O
9	O
and	O
idm2	O
-	O
3	O
plants	O
(	O
Figure	O
S1E	O
)	O
.	O

The	O
At1g26400	O
region	O
was	O
also	O
hypermethylated	O
in	O
idm1	O
-	O
9	O
and	O
idm2	O
-	O
3	O
according	O
to	O
the	O
Chop	O
PCR	O
results	O
(	O
Figure	O
S1F	O
)	O
.	O

Chromatin	O
immunoprecipitation	O
(	O
ChIP	O
)	O
assays	O
showed	O
an	O
increased	O
H3K9me2	O
level	O
and	O
a	O
decreased	O
H3K4me2	O
level	O
in	O
the	O
35S	O
promoter	O
region	O
in	O
the	O
mutant	O
plants	O
(	O
Figure	O
1E	O
)	O
.	O

In	O
idm2	O
-	O
3	O
,	O
a	O
single	O
-	O
nucleotide	O
-	O
substitution	O
mutation	O
(	O
from	O
GGG	O
to	O
GAG	O
)	O
in	O
At1g54840	O
changed	O
amino	O
acid	O
glycine	O
276	O
to	O
glutamic	O
acid	O
.	O

Consistent	O
with	O
the	O
genetic	O
mapping	O
result	O
(	O
Figure	O
S1G	O
)	O
suggesting	O
that	O
the	O
idm2	O
-	O
3	O
mutation	O
was	O
responsible	O
for	O
the	O
long	O
-	O
root	O
phenotype	O
,	O
all	O
of	O
the	O
F1	O
plants	O
from	O
genetic	O
crosses	O
between	O
idm2	O
-	O
3	O
and	O
idm2	O
-	O
1	O
(	O
SALK	O
_	O
130656	O
)	O
had	O
a	O
long	O
-	O
root	O
phenotype	O
like	O
that	O
of	O
idm2	O
-	O
3	O
(	O
Figure	O
S1H	O
)	O
.	O

We	O
also	O
transferred	O
the	O
wild	O
-	O
type	O
IDM2	O
genomic	O
fragment	O
into	O
idm2	O
-	O
3	O
mutant	O
plants	O
and	O
found	O
that	O
it	O
can	O
complement	O
the	O
root	O
phenotype	O
(	O
Figure	O
S1H	O
)	O
.	O

These	O
results	O
demonstrated	O
that	O
,	O
like	O
IDM1	O
and	O
ROS1	O
,	O
IDM2	O
is	O
required	O
for	O
prevention	O
of	O
transcriptional	O
silencing	O
of	O
the	O
35	O
-	O
SUC2	O
and	O
35S	O
-	O
HPTII	O
transgenes	O
.	O

The	O
differential	O
regulation	O
of	O
human	O
ACT1	O
isoforms	O
by	O
Hsp90	O
in	O
IL	O
-	O
17	O
signaling	O
.	O

IL	O
-	O
17	O
is	O
a	O
proinflammatory	O
cytokine	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
autoimmune	O
diseases	O
including	O
psoriasis	O
.	O

ACT1	O
is	O
an	O
essential	O
adaptor	O
molecule	O
in	O
the	O
IL	O
-	O
17	O
signaling	O
pathway	O
.	O

A	O
missense	O
single	O
nucleotide	O
polymorphism	O
(	O
rs33980500	O
;	O
SNP	O
-	O
D10N	O
)	O
that	O
resulted	O
in	O
the	O
substitution	O
of	O
an	O
asparagine	O
for	O
an	O
aspartic	O
acid	O
at	O
position	O
10	O
of	O
ACT1	O
(	O
ACT1	O
-	O
D10N	O
)	O
is	O
associated	O
with	O
psoriasis	O
susceptibility	O
.	O

Due	O
to	O
alternative	O
splicing	O
in	O
humans	O
,	O
SNP	O
-	O
D10N	O
encodes	O
two	O
mutated	O
ACT1	O
proteins	O
,	O
ACT1	O
-	O
D10N	O
and	O
ACT1	O
-	O
D19N	O
.	O

Although	O
both	O
ACT1	O
isoforms	O
are	O
Hsp90	O
client	O
proteins	O
,	O
the	O
nine	O
additional	O
amino	O
acids	O
in	O
ACT1	O
-	O
D19N	O
provide	O
an	O
additional	O
Hsp90	O
binding	O
site	O
that	O
is	O
absent	O
in	O
ACT1	O
-	O
D10N	O
.	O

Therefore	O
,	O
whereas	O
ACT1	O
-	O
D10N	O
is	O
a	O
dead	O
protein	O
that	O
is	O
unable	O
to	O
transduce	O
IL	O
-	O
17	O
signals	O
for	O
gene	O
expression	O
,	O
ACT1	O
-	O
D19N	O
is	O
fully	O
responsive	O
to	O
IL	O
-	O
17	O
.	O

Intriguingly	O
,	O
the	O
two	O
ACT1	O
isoforms	O
are	O
differentially	O
expressed	O
in	O
ACT1	O
(	O
D10N	O
/	O
D10N	O
)	O
fibroblasts	O
and	O
T	O
cells	O
.	O

Fibroblasts	O
express	O
both	O
isoforms	O
equally	O
,	O
enabling	O
ACT1	O
-	O
D19N	O
to	O
compensate	O
for	O
the	O
loss	O
of	O
ACT1	O
-	O
D10N	O
function	O
.	O

ACT1	O
(	O
D10N	O
/	O
D10N	O
)	O
T	O
cells	O
,	O
however	O
,	O
express	O
predominantly	O
ACT1	O
-	O
D10N	O
.	O

Lacking	O
this	O
compensatory	O
mechanism	O
,	O
ACT1	O
(	O
D10N	O
/	O
D10N	O
)	O
T	O
cells	O
behave	O
like	O
ACT1	O
-	O
deficient	O
T	O
cells	O
,	O
exhibiting	O
a	O
dysregulated	O
and	O
hyperactive	O
Th17	O
phenotype	O
with	O
overproduction	O
of	O
IL	O
-	O
22	O
and	O
IL	O
-	O
17	O
.	O

The	O
hyperactive	O
Th17	O
response	O
combined	O
with	O
fully	O
responsive	O
fibroblasts	O
likely	O
synergized	O
to	O
contribute	O
to	O
psoriasis	O
susceptibility	O
in	O
SNP	O
-	O
D10N	O
patients	O
.	O

Posttranslational	O
regulatory	O
system	O
for	O
nitrogenase	O
activity	O
in	O
Azospirillum	O
spp	O
.	O

The	O
mechanism	O
for	O
"	O
NH4	O
+	O
switch	O
-	O
off	O
/	O
on	O
"	O
of	O
nitrogenase	O
activity	O
in	O
Azospirillum	O
brasilense	O
and	O
A	O
.	O
lipoferum	O
was	O
investigated	O
.	O

A	O
correlation	O
was	O
established	O
between	O
the	O
in	O
vivo	O
regulation	O
of	O
nitrogenase	O
activity	O
by	O
NH4Cl	O
or	O
glutamine	O
and	O
the	O
reversible	O
covalent	O
modification	O
of	O
dinitrogenase	O
reductase	O
.	O

Dinitrogenase	O
reductase	O
ADP	O
-	O
ribosyltransferase	O
(	O
DRAT	O
)	O
activity	O
was	O
detected	O
in	O
extracts	O
of	O
A	O
.	O
brasilense	O
with	O
NAD	O
as	O
the	O
donor	O
molecule	O
.	O

Dinitrogenase	O
reductase	O
-	O
activating	O
glycohydrolase	O
(	O
DRAG	O
)	O
activity	O
was	O
present	O
in	O
extracts	O
of	O
both	O
A	O
.	O
brasilense	O
and	O
A	O
.	O
lipoferum	O
.	O

The	O
DRAG	O
activity	O
in	O
A	O
.	O
lipoferum	O
was	O
membrane	O
associated	O
,	O
and	O
it	O
catalyzed	O
the	O
activation	O
of	O
inactive	O
nitrogenase	O
(	O
by	O
covalent	O
modification	O
of	O
dinitrogenase	O
reductase	O
)	O
from	O
both	O
A	O
.	O
lipoferum	O
and	O
Rhodospirillum	O
rubrum	O
.	O

A	O
region	O
homologous	O
to	O
R	O
.	O
rubrum	O
draT	O
and	O
draG	O
was	O
identified	O
in	O
the	O
genomic	O
DNA	O
of	O
A	O
.	O
brasilense	O
as	O
a	O
12	O
-	O
kilobase	O
EcoRI	O
fragment	O
and	O
in	O
A	O
.	O
lipoferum	O
as	O
a	O
7	O
-	O
kilobase	O
EcoRI	O
fragment	O
.	O

It	O
is	O
concluded	O
that	O
a	O
posttranslational	O
regulatory	O
system	O
for	O
nitrogenase	O
activity	O
is	O
present	O
in	O
A	O
.	O
brasilense	O
and	O
A	O
.	O
lipoferum	O
and	O
that	O
it	O
operates	O
via	O
ADP	O
-	O
ribosylation	O
of	O
dinitrogenase	O
reductase	O
as	O
it	O
does	O
in	O
R	O
.	O
rubrum	O
.	O

The	O
guanine	O
-	O
exchange	O
factor	O
Ric8a	O
binds	O
to	O
the	O
Ca	O
(	O
2	O
)	O
+	O
sensor	O
NCS	O
-	O
1	O
to	O
regulate	O
synapse	O
number	O
and	O
neurotransmitter	O
release	O
.	O

The	O
conserved	O
Ca	O
(	O
2	O
+	O
)	O
-	O
binding	O
protein	O
Frequenin	O
(	O
homolog	O
of	O
the	O
mammalian	O
NCS	O
-	O
1	O
,	O
neural	O
calcium	O
sensor	O
)	O
is	O
involved	O
in	O
pathologies	O
that	O
result	O
from	O
abnormal	O
synapse	O
number	O
and	O
probability	O
of	O
neurotransmitter	O
release	O
per	O
synapse	O
.	O

Both	O
synaptic	O
features	O
are	O
likely	O
to	O
be	O
co	O
-	O
regulated	O
but	O
the	O
intervening	O
mechanisms	O
remain	O
poorly	O
understood	O
.	O

We	O
show	O
here	O
that	O
Drosophila	O
Ric8a	O
(	O
a	O
homolog	O
of	O
mammalian	O
synembryn	O
,	O
which	O
is	O
also	O
known	O
as	O
Ric8a	O
)	O
,	O
a	O
receptor	O
-	O
independent	O
activator	O
of	O
G	O
protein	O
complexes	O
,	O
binds	O
to	O
Frq2	O
but	O
not	O
to	O
the	O
virtually	O
identical	O
homolog	O
Frq1	O
.	O

Based	O
on	O
crystallographic	O
data	O
on	O
Frq2	O
and	O
site	O
-	O
directed	O
mutagenesis	O
on	O
Frq1	O
,	O
the	O
differential	O
amino	O
acids	O
R94	O
and	O
T138	O
account	O
for	O
this	O
specificity	O
.	O

Human	O
NCS	O
-	O
1	O
and	O
Ric8a	O
reproduce	O
the	O
binding	O
and	O
maintain	O
the	O
structural	O
requirements	O
at	O
these	O
key	O
positions	O
.	O

Drosophila	O
Ric8a	O
and	O
Galphas	O
regulate	O
synapse	O
number	O
and	O
neurotransmitter	O
release	O
,	O
and	O
both	O
are	O
functionally	O
linked	O
to	O
Frq2	O
.	O

Frq2	O
negatively	O
regulates	O
Ric8a	O
to	O
control	O
synapse	O
number	O
.	O

However	O
,	O
the	O
regulation	O
of	O
neurotransmitter	O
release	O
by	O
Ric8a	O
is	O
independent	O
of	O
Frq2	O
binding	O
.	O

Thus	O
,	O
the	O
antagonistic	O
regulation	O
of	O
these	O
two	O
synaptic	O
properties	O
shares	O
a	O
common	O
pathway	O
,	O
Frq2	O
-	O
Ric8a	O
-	O
Galphas	O
,	O
which	O
diverges	O
downstream	O
.	O

These	O
mechanisms	O
expose	O
the	O
Frq2	O
-	O
Ric8a	O
interacting	O
surface	O
as	O
a	O
potential	O
pharmacological	O
target	O
for	O
NCS	O
-	O
1	O
-	O
related	O
diseases	O
and	O
provide	O
key	O
data	O
towards	O
the	O
corresponding	O
drug	O
design	O
.	O

Protein	O
purification	O
of	O
SelK	O
U92	O
,	O
SelK	O
U92C	O
,	O
and	O
SelK	O
U92S	O
was	O
as	O
formerly	O
detailed	O
with	O
the	O
additional	O
step	O
of	O
Strep	O
-	O
Tactin	O
affinity	O
chromatography	O
.	O

In	O
short	O
,	O
cells	O
were	O
defrosted	O
and	O
sonicated	O
in	O
amylose	O
buffer	O
.	O

Cell	O
debris	O
was	O
removed	O
by	O
centrifugation	O
at	O
20000g	O
for	O
1	O
h	O
.	O

The	O
supernatant	O
was	O
loaded	O
on	O
an	O
amylose	O
column	O
,	O
which	O
was	O
washed	O
with	O
the	O
amylose	O
buffer	O
for	O
5	O
column	O
volumes	O
(	O
CV	O
)	O
followed	O
by	O
a	O
wash	O
with	O
50	O
mM	O
sodium	O
phosphate	O
(	O
pH	O
7	O
.	O
5	O
)	O
,	O
200	O
mM	O
NaCI	O
,	O
1	O
mM	O
EDTA	O
,	O
and	O
0	O
.	O
067	O
%	O
n	O
-	O
dodecyl	O
-	O
b	O
-	O
D	O
-	O
maltopyranoside	O
(	O
DDM	O
)	O
(	O
exchange	O
buffer	O
)	O
for	O
5	O
CV	O
.	O

The	O
fusion	O
cMBP	O
-	O
SelK	O
was	O
eluted	O
using	O
5	O
CV	O
exchange	O
buffer	O
supplemented	O
with	O
20	O
mM	O
maltose	O
.	O

Cleavage	O
of	O
the	O
fusion	O
partner	O
,	O
MBP	O
,	O
was	O
carried	O
out	O
by	O
adding	O
a	O
hexahistidine	O
-	O
tagged	O
TEV	O
protease	O
to	O
the	O
dialysis	O
bag	O
overnight	O
at	O
4	O
degreesC	O
.	O

The	O
TEV	O
protease	O
was	O
added	O
at	O
a	O
molar	O
ratio	O
of	O
1	O
:	O
10	O
relative	O
to	O
the	O
fusion	O
MBP	O
-	O
SelK	O
protein	O
.	O

Following	O
cleavage	O
,	O
TEV	O
and	O
MBP	O
were	O
removed	O
using	O
immobilized	O
metal	O
ion	O
affinity	O
chromatography	O
.	O

The	O
protein	O
was	O
then	O
loaded	O
on	O
a	O
5	O
ml	O
Strep	O
Trap	O
HP	O
(	O
GE	O
Healthcare	O
)	O
equilibrated	O
with	O
exchange	O
buffer	O
.	O

SelK	O
was	O
eluted	O
in	O
the	O
exchange	O
buffer	O
,	O
with	O
a	O
linear	O
gradient	O
of	O
0	O
-	O
2	O
.	O
5	O
mM	O
desthiobiotin	O
.	O

The	O
fractions	O
containing	O
SelK	O
were	O
collected	O
,	O
concentrated	O
to	O
2	O
mg	O
/	O
mL	O
,	O
loaded	O
onto	O
a	O
sephacryl	O
200	O
(	O
GE	O
Healthcare	O
)	O
,	O
and	O
eluted	O
with	O
exchange	O
buffer	O
.	O

Protein	O
purity	O
was	O
analyzed	O
using	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
and	O
coomassie	O
blue	O
staining	O
.	O

The	O
protein	O
concentrations	O
of	O
SelK	O
U92	O
,	O
SelK	O
U92C	O
,	O
and	O
SelK	O
U92S	O
were	O
determined	O
using	O
an	O
extinction	O
coefficient	O
of	O
20970	O
M	O
-	O
1	O
cm	O
-	O
1	O
or	O
by	O
bicinchoninic	O
acid	O
(	O
BCA	O
)	O
protein	O
assay	O
.	O

The	O
free	O
thiol	O
/	O
selenol	O
count	O
of	O
SelK	O
U92	O
and	O
SelK	O
U92C	O
was	O
determined	O
using	O
Ellman	O
'	O
s	O
reagent	O
5	O
,	O
5	O
'	O
-	O
dithiobis	O
-	O
(	O
2	O
-	O
nitrobenzoic	O
acid	O
)	O
(	O
DTNB	O
)	O
.	O

The	O
extent	O
of	O
selenium	O
incorporation	O
in	O
a	O
given	O
protein	O
sample	O
was	O
measured	O
by	O
electrospray	O
mass	O
spectrometry	O
as	O
described	O
below	O
.	O

When	O
values	O
were	O
compared	O
to	O
measurements	O
by	O
Inductively	O
Coupled	O
Plasma	O
(	O
ICP	O
)	O
spectroscopy	O
,	O
the	O
agreement	O
was	O
within	O
a	O
factor	O
of	O
3	O
.	O

We	O
believe	O
that	O
in	O
this	O
specific	O
case	O
mass	O
spectrometry	O
more	O
accurately	O
reflects	O
the	O
actual	O
percent	O
incorporation	O
because	O
ICP	O
also	O
reported	O
sulfur	O
from	O
residual	O
TEV	O
protease	O
.	O

TEV	O
protease	O
contains	O
several	O
Met	O
residues	O
and	O
,	O
hence	O
,	O
can	O
bias	O
the	O
ratio	O
of	O
sulfur	O
to	O
selenium	O
.	O

The	O
incorporation	O
ratio	O
as	O
judged	O
from	O
mass	O
spectrometry	O
varied	O
from	O
80	O
%	O
to	O
90	O
%	O
between	O
batches	O
.	O

We	O
refer	O
to	O
this	O
form	O
as	O
SelK	O
U92	O
(	O
see	O
section	O
3	O
.	O
1	O
)	O
.	O

The	O
concentrations	O
given	O
in	O
the	O
paper	O
are	O
those	O
of	O
the	O
selenium	O
containing	O
SelK	O
in	O
a	O
given	O
preparation	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
two	O
isoforms	O
might	O
replace	O
each	O
other	O
under	O
certain	O
conditions	O
.	O

According	O
to	O
Han	O
et	O
al	O
.	O

p38a	O
and	O
p38b	O
appear	O
to	O
have	O
partial	O
functional	O
redundancy	O
,	O
because	O
both	O
isoforms	O
are	O
similarly	O
activated	O
in	O
response	O
to	O
stress	O
-	O
inducing	O
or	O
inflammatory	O
stimuli	O
in	O
cell	O
culture	O
experiments	O
.	O

This	O
compensatory	O
mechanism	O
may	O
be	O
vital	O
for	O
the	O
flies	O
,	O
when	O
one	O
of	O
the	O
two	O
isoforms	O
lacks	O
completely	O
.	O

But	O
the	O
compensatory	O
mechanism	O
may	O
be	O
elusive	O
when	O
one	O
isoform	O
is	O
only	O
down	O
-	O
regulated	O
in	O
specific	O
neurons	O
that	O
are	O
not	O
necessary	O
for	O
survival	O
(	O
e	O
.	O
g	O
.	O
the	O
clock	O
neurons	O
)	O
:	O
Lengthened	O
free	O
-	O
running	O
rhythms	O
in	O
DD	O
just	O
occurred	O
,	O
when	O
either	O
p38b	O
or	O
p38a	O
levels	O
in	O
clock	O
neurons	O
were	O
reduced	O
,	O
but	O
not	O
completely	O
absent	O
from	O
the	O
entire	O
fly	O
.	O

We	O
therefore	O
suppose	O
that	O
either	O
isoform	O
overtakes	O
the	O
clock	O
specific	O
function	O
of	O
the	O
other	O
one	O
only	O
in	O
its	O
complete	O
absence	O
.	O

As	O
p38a	O
mRNA	O
levels	O
were	O
not	O
increased	O
in	O
p38bDelta45	O
flies	O
and	O
p38b	O
mRNA	O
levels	O
were	O
not	O
elevated	O
in	O
p38aDelta1	O
(	O
Fig	O
.	O
S8	O
)	O
,	O
normal	O
wildtype	O
p38a	O
or	O
p38b	O
levels	O
seem	O
to	O
be	O
sufficient	O
to	O
drive	O
circadian	O
rhythms	O
in	O
complete	O
absence	O
of	O
the	O
other	O
isoform	O
.	O

Cell	O
-	O
type	O
-	O
specific	O
and	O
site	O
-	O
specific	O
N	O
-	O
glycosylation	O
of	O
type	O
I	O
and	O
type	O
II	O
human	O
tissue	O
plasminogen	O
activator	O
.	O

Tissue	O
plasminogen	O
activator	O
(	O
t	O
-	O
PA	O
)	O
is	O
an	O
important	O
initiator	O
of	O
fibrinolysis	O
.	O

The	O
t	O
-	O
PA	O
polypeptide	O
has	O
four	O
potential	O
N	O
-	O
glycosylation	O
sites	O
of	O
which	O
three	O
are	O
occupied	O
in	O
type	O
I	O
(	O
Asn	O
-	O
117	O
,	O
-	O
184	O
,	O
and	O
-	O
448	O
)	O
and	O
two	O
in	O
type	O
II	O
(	O
Asn	O
-	O
117	O
and	O
-	O
448	O
)	O
.	O

In	O
an	O
effort	O
to	O
elucidate	O
the	O
factors	O
controlling	O
the	O
expression	O
of	O
N	O
-	O
linked	O
oligosaccharides	O
on	O
this	O
polypeptide	O
,	O
we	O
have	O
used	O
a	O
combination	O
of	O
sequential	O
exoglycosidase	O
digestion	O
,	O
methylation	O
analysis	O
,	O
and	O
controlled	O
acetolysis	O
to	O
determine	O
the	O
oligosaccharide	O
structures	O
at	O
each	O
of	O
the	O
N	O
-	O
glycosylation	O
sites	O
of	O
type	O
I	O
and	O
type	O
II	O
t	O
-	O
PA	O
when	O
isolated	O
from	O
a	O
human	O
colon	O
fibroblast	O
cell	O
strain	O
and	O
from	O
a	O
Bowes	O
melanoma	O
cell	O
line	O
.	O

Our	O
results	O
suggest	O
the	O
following	O
:	O
(	O
i	O
)	O
type	O
I	O
and	O
type	O
II	O
t	O
-	O
PA	O
are	O
N	O
-	O
glycosylated	O
in	O
an	O
identical	O
way	O
at	O
Asn	O
-	O
117	O
and	O
Asn	O
-	O
448	O
,	O
when	O
isolated	O
from	O
the	O
same	O
cell	O
line	O
;	O
(	O
ii	O
)	O
Asn	O
-	O
117	O
is	O
predominantly	O
associated	O
with	O
oligomannose	O
-	O
type	O
structures	O
in	O
all	O
cases	O
;	O
(	O
iii	O
)	O
Asn	O
-	O
184	O
and	O
Asn	O
-	O
448	O
are	O
predominantly	O
associated	O
with	O
complex	O
-	O
type	O
structures	O
when	O
t	O
-	O
PA	O
is	O
isolated	O
from	O
fibroblast	O
cells	O
,	O
but	O
with	O
both	O
complex	O
-	O
and	O
oligomannose	O
-	O
type	O
structures	O
when	O
isolated	O
from	O
melanoma	O
cells	O
;	O
(	O
iv	O
)	O
fibroblast	O
cell	O
derived	O
t	O
-	O
PA	O
is	O
associated	O
with	O
both	O
neutral	O
and	O
sialylated	O
oligosaccharides	O
,	O
while	O
melanoma	O
cell	O
derived	O
t	O
-	O
PA	O
is	O
also	O
associated	O
with	O
sulfated	O
oligosaccharides	O
,	O
which	O
are	O
located	O
exclusively	O
at	O
Asn	O
-	O
448	O
of	O
type	O
II	O
t	O
-	O
PA	O
;	O
(	O
v	O
)	O
no	O
complex	O
-	O
type	O
structures	O
occur	O
in	O
common	O
between	O
t	O
-	O
PA	O
from	O
the	O
two	O
cell	O
lines	O
.	O

These	O
results	O
indicate	O
that	O
the	O
t	O
-	O
PA	O
glycoprotein	O
is	O
secreted	O
by	O
each	O
cell	O
line	O
as	O
a	O
set	O
of	O
glycoforms	O
,	O
each	O
glycoform	O
being	O
unique	O
with	O
respect	O
to	O
the	O
nature	O
and	O
disposition	O
of	O
oligosaccharides	O
on	O
a	O
common	O
polypeptide	O
.	O

Further	O
,	O
the	O
two	O
cell	O
lines	O
express	O
no	O
glycoform	O
in	O
common	O
,	O
despite	O
expressing	O
the	O
same	O
t	O
-	O
PA	O
polypeptide	O
.	O

The	O
implications	O
of	O
these	O
results	O
for	O
both	O
the	O
control	O
of	O
oligosaccharide	O
processing	O
in	O
different	O
cell	O
lines	O
and	O
the	O
genetic	O
engineering	O
of	O
mammalian	O
glycoproteins	O
are	O
discussed	O
.	O

Emi1	O
and	O
Emi2	O
also	O
exhibit	O
DB	O
-	O
independent	O
inhibitory	O
activities	O
against	O
the	O
polyubiquitylation	O
of	O
the	O
APC	B-Complex
/	I-Complex
C	I-Complex
target	O
proteins	O
.	O

The	O
inhibitory	O
activity	O
of	O
Emi1	O
requires	O
its	O
C	O
-	O
terminal	O
region	O
,	O
which	O
corresponds	O
to	O
the	O
C	O
-	O
terminal	O
tail	O
of	O
Emi2	O
.	O

The	O
ZBR	O
-	O
RL	O
fragment	O
of	O
Emi1	O
has	O
inhibitory	O
activity	O
against	O
polyubiquitin	O
chain	O
formation	O
on	O
the	O
target	O
protein	O
by	O
APC	B-Complex
/	I-Complex
C	I-Complex
-	O
Cdh1	O
,	O
in	O
combination	O
with	O
E2C	O
/	O
UBE2C	O
/	O
UBCH10	O
(	O
ubiquitin	O
chain	O
-	O
initiating	O
E2	O
)	O
and	O
/	O
or	O
E2S	O
/	O
UBE2S	O
(	O
ubiquitin	O
chain	O
-	O
extending	O
E2	O
)	O
.	O

The	O
C	O
-	O
terminal	O
tails	O
of	O
Emi1	O
and	O
Emi2	O
bind	O
to	O
APC	B-Complex
/	I-Complex
C	I-Complex
,	O
and	O
the	O
RL	O
residues	O
compete	O
with	O
the	O
tail	O
of	O
E2S	O
for	O
APC	B-Complex
/	I-Complex
C	I-Complex
binding	O
.	O

Of	O
particular	O
interest	O
is	O
the	O
observed	O
direct	O
correlation	O
between	O
intracellular	O
inositol	O
pyrophosphate	O
levels	O
and	O
the	O
time	O
that	O
S	O
.	O
pombe	O
MT	O
plus	O
-	O
ends	O
stay	O
at	O
the	O
cell	O
tip	O
before	O
a	O
catastrophe	O
event	O
.	O

Components	O
of	O
a	O
fungal	O
growth	O
zone	O
can	O
regulate	O
MT	O
plus	O
-	O
end	O
dynamics	O
as	O
has	O
been	O
shown	O
for	O
A	O
.	O
nidulans	O
Tea1	O
family	O
member	O
TeaA	O
,	O
which	O
negatively	O
regulates	O
the	O
activity	O
of	O
the	O
XMAP215	O
protein	O
AlpA	O
.	O

Thus	O
it	O
is	O
feasible	O
that	O
Asp1	O
enzymatic	O
activity	O
regulates	O
MT	O
dynamics	O
at	O
the	O
cell	O
tip	O
.	O

Although	O
immunofluorescence	O
analysis	O
of	O
S	O
.	O
pombe	O
Asp1	O
-	O
GFP	O
did	O
not	O
show	O
a	O
specific	O
cytoplasmic	O
localization	O
,	O
localization	O
of	O
the	O
human	O
Vip1	O
member	O
PPIP5K1	O
was	O
slightly	O
enhanced	O
at	O
the	O
plasma	O
membrane	O
.	O

Plasma	O
membrane	O
targeting	O
of	O
PPIP5K1	O
in	O
NIH3T3	O
cells	O
was	O
increased	O
dramatically	O
following	O
PtdIns3	O
kinase	O
activation	O
.	O

Proline	O
isomerization	O
of	O
the	O
immune	O
receptor	O
-	O
interacting	O
protein	O
RIN4	O
by	O
a	O
cyclophilin	O
inhibits	O
effector	O
-	O
triggered	O
immunity	O
in	O
Arabidopsis	O
.	O

In	O
the	O
absence	O
of	O
pathogen	O
infection	O
,	O
plant	O
effector	O
-	O
triggered	O
immune	O
(	O
ETI	O
)	O
receptors	O
are	O
maintained	O
in	O
a	O
preactivation	O
state	O
by	O
intermolecular	O
interactions	O
with	O
other	O
host	O
proteins	O
.	O

Pathogen	O
effector	O
-	O
induced	O
alterations	O
activate	O
the	O
receptor	O
.	O

In	O
Arabidopsis	O
,	O
the	O
ETI	O
receptor	O
RPM1	O
is	O
activated	O
via	O
bacterial	O
effector	O
AvrB	O
-	O
induced	O
phosphorylation	O
of	O
the	O
RPM1	O
-	O
interacting	O
protein	O
RIN4	O
at	O
Threonine	O
166	O
.	O

We	O
find	O
that	O
RIN4	O
also	O
interacts	O
with	O
the	O
prolyl	O
-	O
peptidyl	O
isomerase	O
(	O
PPIase	O
)	O
ROC1	O
,	O
which	O
is	O
reduced	O
upon	O
RIN4	O
Thr166	O
phosphorylation	O
.	O

ROC1	O
suppresses	O
RPM1	O
immunity	O
in	O
a	O
PPIase	O
-	O
dependent	O
manner	O
.	O

Consistent	O
with	O
this	O
,	O
RIN4	O
Pro149	O
undergoes	O
cis	O
/	O
trans	O
isomerization	O
in	O
the	O
presence	O
of	O
ROC1	O
.	O

While	O
the	O
RIN4	O
(	O
P149V	O
)	O
mutation	O
abolishes	O
RPM1	O
resistance	O
,	O
the	O
deletion	O
of	O
Pro149	O
leads	O
to	O
RPM1	O
activation	O
in	O
the	O
absence	O
of	O
RIN4	O
phosphorylation	O
.	O

These	O
results	O
support	O
a	O
model	O
in	O
which	O
RPM1	O
directly	O
senses	O
conformational	O
changes	O
in	O
RIN4	O
surrounding	O
Pro149	O
that	O
is	O
controlled	O
by	O
ROC1	O
.	O

RIN4	O
Thr166	O
phosphorylation	O
indirectly	O
regulates	O
RPM1	O
resistance	O
by	O
modulating	O
the	O
ROC1	O
-	O
mediated	O
RIN4	O
isomerization	O
.	O

Primary	O
mouse	O
LECs	O
were	O
isolated	O
from	O
skin	O
or	O
mesenteric	O
tissues	O
of	O
wild	O
-	O
type	O
and	O
LEC	O
-	O
DKO	O
mice	O
as	O
previously	O
described	O
.	O

Briefly	O
,	O
the	O
finely	O
minced	O
skin	O
or	O
mesentery	O
tissue	O
was	O
digested	O
with	O
enzyme	O
solution	O
(	O
2	O
mg	O
/	O
ml	O
collagenase	O
,	O
5	O
mg	O
/	O
ml	O
dispase	O
;	O
Roche	O
)	O
at	O
37degreesC	O
for	O
1	O
hour	O
,	O
then	O
the	O
cells	O
were	O
cultured	O
in	O
complete	O
endothelial	O
cell	O
medium	O
(	O
Invitrogen	O
)	O
.	O

Anti	O
-	O
Podoplanin	O
antibody	O
(	O
clone	O
8F11	O
,	O
MBL	O
)	O
was	O
first	O
labeled	O
with	O
Biotin	O
(	O
EZ	O
-	O
Link	O
(	O
R	O
)	O
Micro	O
Sulfo	O
-	O
NHS	O
-	O
LC	O
Biotinylation	O
Kit	O
)	O
according	O
to	O
the	O
manufacture	O
'	O
s	O
instructions	O
.	O

LECs	O
were	O
further	O
purified	O
by	O
streptavidin	O
-	O
conjugated	O
magnetic	O
beads	O
(	O
Pierce	O
)	O
after	O
cells	O
were	O
incubated	O
with	O
biotinylated	O
anti	O
-	O
Podoplanin	O
antibodies	O
for	O
2	O
hours	O
at	O
room	O
temperature	O
.	O

The	O
identity	O
of	O
LECs	O
was	O
confirmed	O
with	O
LYVE	O
-	O
1	O
immunofluorescence	O
staining	O
and	O
VEGFR3	O
flow	O
cytometry	O
analysis	O
.	O

LEC	O
purity	O
(	O
>	O
90	O
%	O
)	O
was	O
measured	O
by	O
expressions	O
of	O
LYVE	O
-	O
1	O
and	O
VEGFR3	O
.	O

Deletion	O
of	O
epsin	O
1	O
and	O
2	O
were	O
confirmed	O
by	O
quantitative	O
RT	O
-	O
PCR	O
and	O
Western	O
blotting	O
.	O

Cryo	O
-	O
EM	O
reveals	O
different	O
coronin	O
binding	O
modes	O
for	O
ADP	O
-	O
and	O
ADP	O
-	O
BeFx	O
actin	O
filaments	O
.	O

Essential	O
cellular	O
processes	O
involving	O
the	O
actin	O
cytoskeleton	O
are	O
regulated	O
by	O
auxiliary	O
proteins	O
that	O
can	O
sense	O
the	O
nucleotide	O
state	O
of	O
actin	O
.	O

Here	O
we	O
report	O
cryo	O
-	O
EM	O
structures	O
for	O
ADP	O
-	O
bound	O
and	O
ADP	O
-	O
beryllium	O
fluoride	O
(	O
ADP	O
-	O
BeFx	O
,	O
an	O
ADP	O
-	O
Pi	O
mimic	O
)	O
-	O
bound	O
actin	O
filaments	O
in	O
complex	O
with	O
the	O
beta	O
-	O
propeller	O
domain	O
of	O
yeast	O
coronin	O
1	O
(	O
crn1	O
)	O
,	O
at	O
8	O
.	O
6	O
-	O
Aa	O
resolution	O
.	O

Our	O
structures	O
reveal	O
the	O
main	O
differences	O
in	O
the	O
interaction	O
of	O
coronin	O
with	O
the	O
two	O
nucleotide	O
states	O
of	O
F	O
-	O
actin	O
.	O

We	O
derived	O
pseudoatomic	O
models	O
by	O
fitting	O
the	O
atomic	O
structures	O
of	O
actin	O
and	O
coronin	O
into	O
the	O
EM	O
envelopes	O
and	O
confirmed	O
the	O
identified	O
interfaces	O
on	O
actin	O
by	O
chemical	O
cross	O
-	O
linking	O
,	O
fluorescence	O
spectroscopy	O
and	O
actin	O
mutagenesis	O
.	O

The	O
models	O
offer	O
a	O
structural	O
explanation	O
for	O
the	O
nucleotide	O
-	O
dependent	O
effects	O
of	O
coronin	O
on	O
cofilin	O
-	O
assisted	O
remodeling	O
of	O
F	O
-	O
actin	O
.	O

The	O
results	O
presented	O
above	O
indicate	O
that	O
Dcs1	O
and	O
Aph1	O
are	O
involved	O
in	O
cap	O
degradation	O
in	O
yeast	O
extract	O
.	O

To	O
test	O
whether	O
these	O
proteins	O
affect	O
the	O
fate	O
of	O
cap	O
structures	O
released	O
by	O
RNA	O
degradation	O
in	O
vivo	O
in	O
cells	O
,	O
we	O
transformed	O
a	O
49	O
-	O
nt	O
RNA	O
in	O
the	O
different	O
yeast	O
strains	O
by	O
electroporation	O
.	O

This	O
artificial	O
RNA	O
was	O
radiolabeled	O
on	O
the	O
phosphate	O
in	O
position	O
gamma	O
of	O
the	O
cap	O
structure	O
.	O

Forty	O
-	O
five	O
minutes	O
post	O
-	O
electroporation	O
,	O
we	O
extracted	O
the	O
cellular	O
content	O
and	O
fractionated	O
it	O
by	O
TLC	O
after	O
protein	O
inactivation	O
and	O
removal	O
.	O

Several	O
products	O
,	O
some	O
comigrating	O
with	O
m7	O
-	O
containing	O
nucleotides	O
and	O
some	O
of	O
unknown	O
identity	O
,	O
were	O
detected	O
by	O
autoradiography	O
(	O
Figure	O
6	O
,	O
lane	O
1	O
)	O
.	O

Control	O
reactions	O
demonstrated	O
that	O
these	O
products	O
arose	O
as	O
a	O
consequence	O
of	O
RNA	O
introduction	O
in	O
cells	O
,	O
as	O
they	O
were	O
not	O
detected	O
when	O
no	O
cells	O
were	O
present	O
and	O
when	O
the	O
radiolabeled	O
RNA	O
was	O
added	O
after	O
the	O
electric	O
pulse	O
(	O
data	O
not	O
shown	O
)	O
.	O

Interestingly	O
,	O
in	O
absence	O
of	O
Dcs1	O
(	O
Deltadcs1	O
and	O
Delta	O
dcs1	O
/	O
Deltaynk1	O
strains	O
)	O
,	O
we	O
observed	O
the	O
accumulation	O
of	O
m7GDP	O
and	O
,	O
to	O
a	O
higher	O
extent	O
,	O
of	O
a	O
second	O
product	O
migrating	O
slightly	O
faster	O
(	O
labeled	O
Ypp	O
)	O
,	O
as	O
well	O
as	O
traces	O
of	O
m7GTP	O
and	O
m7GpppG	O
(	O
Figure	O
6	O
,	O
lanes	O
3	O
and	O
4	O
)	O
.	O

Product	O
Ypp	O
is	O
a	O
nucleotide	O
diphosphate	O
as	O
in	O
the	O
presence	O
of	O
ATP	O
it	O
is	O
a	O
substrate	O
of	O
NDK	O
(	O
Figure	O
6	O
compare	O
lanes	O
3	O
-	O
4	O
and	O
11	O
-	O
12	O
)	O
.	O

Moreover	O
,	O
product	O
Ypp	O
is	O
likely	O
to	O
be	O
a	O
derivative	O
of	O
m7GDP	O
as	O
it	O
accumulates	O
when	O
the	O
m7GDP	O
level	O
rises	O
(	O
Figure	O
6	O
)	O
and	O
as	O
it	O
is	O
present	O
after	O
electroporation	O
of	O
m7GDP	O
in	O
Deltadcs1Deltaynk1	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
accumulation	O
of	O
m7GDP	O
and	O
a	O
downstream	O
derivative	O
in	O
Deltadcs1	O
cells	O
provides	O
a	O
direct	O
evidence	O
for	O
the	O
role	O
of	O
Dcs1	O
in	O
cap	O
metabolism	O
in	O
vivo	O
.	O

Deletion	O
of	O
ynk1	O
encoding	O
NDK	O
had	O
little	O
effect	O
on	O
the	O
product	O
profile	O
(	O
Figure	O
6	O
,	O
compare	O
lanes	O
1	O
and	O
2	O
)	O
,	O
probably	O
because	O
other	O
enzymes	O
are	O
redundant	O
with	O
Ynk1	O
.	O

The	O
same	O
applied	O
to	O
a	O
Delta	O
aph1	O
strain	O
,	O
consistent	O
with	O
the	O
limited	O
impact	O
of	O
the	O
absence	O
of	O
Aph1	O
alone	O
on	O
m7GpppG	O
breakdown	O
in	O
vitro	O
(	O
Figure	O
6	O
,	O
lane	O
5	O
)	O
.	O

Importantly	O
,	O
however	O
,	O
the	O
simultaneous	O
elimination	O
of	O
Aph1	O
and	O
Dcs1	O
lead	O
to	O
strong	O
accumulation	O
of	O
m7GpppG	O
in	O
cells	O
(	O
Figure	O
6	O
,	O
lane	O
6	O
)	O
with	O
a	O
slight	O
reduction	O
in	O
m7GDP	O
levels	O
.	O

No	O
further	O
enhancement	O
was	O
detected	O
when	O
NDK	O
was	O
simultaneously	O
absent	O
(	O
Figure	O
6	O
,	O
lane	O
8	O
)	O
.	O

To	O
ascertain	O
our	O
identifications	O
,	O
we	O
incubated	O
purified	O
recombinant	O
Dcs1	O
protein	O
in	O
the	O
lysate	O
.	O

This	O
reaction	O
confirmed	O
that	O
m7GpppG	O
accumulated	O
in	O
Deltadcs1	O
/	O
Deltaaph1	O
electroporated	O
cells	O
as	O
this	O
product	O
was	O
hydrolyzed	O
into	O
m7GMP	O
(	O
Figure	O
5	O
,	O
compare	O
lanes	O
6	O
-	O
8	O
and	O
22	O
-	O
24	O
)	O
.	O

The	O
above	O
results	O
confirmed	O
a	O
substantially	O
more	O
severe	O
Lif1	O
interaction	O
defect	O
with	O
D800K	O
or	O
GG	O
(	O
868	O
:	O
869	O
)	O
AA	O
Dnl4	O
mutations	O
than	O
with	O
KTT	O
(	O
742	O
:	O
744	O
)	O
ATA	O
.	O

To	O
further	O
explore	O
the	O
ability	O
of	O
these	O
mutants	O
to	O
complete	O
NHEJ	O
,	O
we	O
extended	O
the	O
HO	O
suicide	O
deletion	O
screen	O
results	O
to	O
a	O
different	O
suicide	O
deletion	O
assay	O
based	O
on	O
the	O
I	O
-	O
SceI	O
endonuclease	O
.	O

In	O
this	O
system	O
,	O
it	O
was	O
again	O
true	O
that	O
the	O
KTT	O
(	O
742	O
:	O
744	O
)	O
ATA	O
mutant	O
had	O
a	O
more	O
substantial	O
NHEJ	O
defect	O
than	O
D800K	O
or	O
GG	O
(	O
868	O
:	O
869	O
)	O
AA	O
(	O
Figure	O
4A	O
)	O
.	O

The	O
more	O
focused	O
mutations	O
in	O
K742A	O
and	O
T744A	O
suggested	O
that	O
K742	O
is	O
a	O
more	O
important	O
residue	O
in	O
the	O
cluster	O
than	O
T744	O
,	O
although	O
the	O
T744A	O
mutant	O
was	O
still	O
partially	O
NHEJ	O
deficient	O
(	O
Figure	O
4A	O
)	O
.	O

The	O
partially	O
penetrant	O
phenotype	O
of	O
D800K	O
and	O
GG	O
(	O
868	O
:	O
869	O
)	O
AA	O
mutants	O
was	O
reinforced	O
by	O
the	O
observation	O
that	O
NHEJ	O
activity	O
with	O
the	O
D800K	O
,	O
GG	O
(	O
868	O
:	O
869	O
)	O
AA	O
compound	O
mutant	O
was	O
undetectable	O
and	O
equivalent	O
to	O
dnl4Delta	O
and	O
the	O
C	O
-	O
terminal	O
truncations	O
that	O
eliminated	O
the	O
inter	O
-	O
BRCT	O
linker	O
(	O
e	O
.	O
g	O
.	O
L750	O
*	O
,	O
Figure	O
4A	O
)	O
.	O

Deposition	O
of	O
histone	O
H2A	O
.	O
Z	O
by	O
the	O
SWR	O
-	O
C	O
remodeling	O
enzyme	O
prevents	O
genome	O
instability	O
.	O

The	O
yeast	O
SWR	O
-	O
C	O
chromatin	O
remodeling	O
enzyme	O
catalyzes	O
chromatin	O
incorporation	O
of	O
the	O
histone	O
variant	O
H2A	O
.	O
Z	O
which	O
plays	O
roles	O
in	O
transcription	O
,	O
DNA	O
repair	O
,	O
and	O
chromosome	O
segregation	O
.	O

Dynamic	O
incorporation	O
of	O
H2A	O
.	O
Z	O
by	O
SWR	O
-	O
C	O
also	O
enhances	O
the	O
ability	O
of	O
exonuclease	O
I	O
(	O
Exo1	O
)	O
to	O
process	O
DNA	O
ends	O
during	O
repair	O
of	O
double	O
strand	O
breaks	O
.	O

Given	O
that	O
Exo1	O
also	O
participates	O
in	O
DNA	O
replication	O
and	O
mismatch	O
repair	O
,	O
here	O
we	O
test	O
whether	O
SWR	O
-	O
C	O
influences	O
DNA	O
replication	O
fidelity	O
.	O

We	O
find	O
that	O
inactivation	O
of	O
SWR	O
-	O
C	O
elevates	O
the	O
spontaneous	O
mutation	O
rate	O
of	O
a	O
strain	O
encoding	O
a	O
L612M	O
variant	O
of	O
DNA	O
polymerase	O
(	O
Pol	O
)	O
delta	O
,	O
with	O
a	O
single	O
base	O
mutation	O
signature	O
characteristic	O
of	O
lagging	O
strand	O
replication	O
errors	O
.	O

However	O
,	O
this	O
genomic	O
instability	O
does	O
not	O
solely	O
result	O
from	O
reduced	O
Exo1	O
function	O
,	O
because	O
single	O
base	O
mutator	O
effects	O
are	O
seen	O
in	O
both	O
Exo1	O
-	O
proficient	O
and	O
Exo1	O
-	O
deficient	O
pol3	O
-	O
L612M	O
swr1Delta	O
strains	O
.	O

The	O
data	O
are	O
consistent	O
with	O
the	O
possibility	O
that	O
incorporation	O
of	O
the	O
H2A	O
.	O
Z	O
variant	O
by	O
SWR	O
-	O
C	O
may	O
stimulate	O
Exo1	O
activity	O
,	O
as	O
well	O
as	O
enhance	O
the	O
fidelity	O
of	O
replication	O
by	O
Pol	O
delta	O
,	O
the	O
repair	O
of	O
mismatches	O
generated	O
by	O
Pol	O
delta	O
,	O
or	O
both	O
.	O

Regulation	O
of	O
rhodopsin	O
dephosphorylation	O
by	O
arrestin	O
.	O

We	O
have	O
characterized	O
the	O
opsin	O
phosphatase	O
activities	O
in	O
extracts	O
of	O
rod	O
outer	O
segments	O
and	O
determined	O
their	O
relationship	O
to	O
known	O
protein	O
phosphatases	O
.	O

The	O
opsin	O
phosphatase	O
activity	O
in	O
the	O
extracts	O
was	O
not	O
due	O
to	O
protein	B-Complex
phosphatases	I-Complex
1	I-Complex
,	I-Complex
2B	I-Complex
,	O
or	O
2C	O
because	O
it	O
was	O
neither	O
stimulated	O
by	O
Mg2	O
+	O
or	O
Ca2	O
+	O
/	O
calmodulin	O
nor	O
inhibited	O
by	O
protein	O
phosphatase	O
inhibitors	O
-	O
1	O
or	O
-	O
2	O
.	O

Opsin	O
phosphatase	O
activity	O
in	O
rod	O
outer	O
segment	O
extracts	O
was	O
potently	O
inhibited	O
by	O
okadaic	O
acid	O
(	O
IC50	O
approximately	O
10	O
nM	O
)	O
,	O
a	O
preferential	O
inhibitor	O
of	O
protein	B-Complex
phosphatase	I-Complex
2A	I-Complex
.	O

Moreover	O
,	O
during	O
chromatography	O
on	O
DEAE	O
-	O
Sepharose	O
,	O
the	O
opsin	O
phosphatase	O
activity	O
co	O
-	O
eluted	O
with	O
three	O
peaks	O
of	O
protein	B-Complex
phosphatase	I-Complex
2A	I-Complex
activity	O
,	O
termed	O
protein	B-OOS
phosphatases	I-OOS
2A0	I-OOS
,	I-OOS
2A1	I-OOS
,	I-OOS
and	I-OOS
2A2	I-OOS
.	O

The	O
opsin	O
phosphatase	O
activity	O
of	O
each	O
peak	O
was	O
stimulated	O
by	O
polylysine	O
,	O
a	O
known	O
activator	O
of	O
protein	B-Complex
phosphatase	I-Complex
2A	I-Complex
.	O

Finally	O
,	O
treatment	O
of	O
rod	O
outer	O
segment	O
extracts	O
with	O
80	O
%	O
ethanol	O
at	O
room	O
temperature	O
converted	O
the	O
activity	O
from	O
a	O
high	O
molecular	O
weight	O
form	O
characteristic	O
of	O
the	O
protein	B-OOS
phosphatase	I-OOS
2A0	I-OOS
,	I-OOS
2A1	I-OOS
,	I-OOS
and	I-OOS
2A2	I-OOS
species	O
to	O
a	O
low	O
molecular	O
weight	O
form	O
characteristic	O
of	O
the	O
protein	B-Complex
phosphatase	I-Complex
2A	I-Complex
catalytic	O
subunit	O
.	O

We	O
conclude	O
that	O
protein	B-Complex
phosphatase	I-Complex
2A	I-Complex
is	O
likely	O
to	O
be	O
the	O
physiologically	O
relevant	O
rhodopsin	O
phosphatase	O
.	O

The	O
48	O
-	O
kDa	O
rod	O
outer	O
segment	O
protein	O
arrestin	O
(	O
S	O
-	O
antigen	O
)	O
was	O
found	O
to	O
inhibit	O
the	O
dephosphorylation	O
of	O
freshly	O
photolyzed	O
rhodopsin	O
by	O
protein	B-Complex
phosphatase	I-Complex
2A	I-Complex
but	O
did	O
not	O
inhibit	O
the	O
dephosphorylation	O
of	O
unbleached	O
rhodopsin	O
.	O

Arrestin	O
has	O
no	O
effect	O
on	O
the	O
dephosphorylation	O
of	O
phorphorylase	O
a	O
,	O
indicating	O
that	O
the	O
effect	O
was	O
substrate	O
-	O
directed	O
.	O

It	O
appears	O
that	O
dephosphorylation	O
of	O
the	O
photoreceptor	O
protein	O
phosphorhodopsin	O
occurs	O
only	O
after	O
decay	O
of	O
the	O
photoactivated	O
protein	O
and	O
that	O
this	O
may	O
be	O
regulated	O
in	O
vivo	O
by	O
arrestin	O
.	O

The	O
binding	O
of	O
arrestin	O
to	O
photolyzed	O
phosphorylated	O
rhodopsin	O
,	O
i	O
.	O
e	O
.	O
the	O
binding	O
of	O
a	O
regulatory	O
protein	O
to	O
a	O
protein	O
phosphatase	O
substrate	O
to	O
form	O
a	O
complex	O
resistant	O
to	O
dephosphorylation	O
represents	O
a	O
novel	O
mechanism	O
for	O
the	O
regulation	O
of	O
protein	B-Complex
phosphatase	I-Complex
2A	I-Complex
.	O

Regulation	O
of	O
the	O
Rhp26ERCC6	O
/	O
CSB	O
chromatin	O
remodeler	O
by	O
a	O
novel	O
conserved	O
leucine	O
latch	O
motif	O
.	O

CSB	O
/	O
ERCC6	O
(	O
Cockayne	O
syndrome	O
B	O
protein	O
/	O
excision	O
repair	O
cross	O
-	O
complementation	O
group	O
6	O
)	O
,	O
a	O
member	O
of	O
a	O
subfamily	O
of	O
SWI2	B-OOS
/	I-OOS
SNF2	I-OOS
(	B-Complex
SWItch	I-Complex
/	I-Complex
sucrose	I-Complex
nonfermentable	I-Complex
)	I-Complex
-	I-Complex
related	I-Complex
chromatin	I-Complex
remodelers	I-Complex
,	O
plays	O
crucial	O
roles	O
in	O
gene	O
expression	O
and	O
the	O
maintenance	O
of	O
genome	O
integrity	O
.	O

Here	O
,	O
we	O
report	O
the	O
mechanism	O
of	O
the	O
autoregulation	O
of	O
Rhp26	O
,	O
which	O
is	O
the	O
homolog	O
of	O
CSB	O
/	O
ERCC6	O
in	O
Schizosaccharomyces	O
pombe	O
.	O

We	O
identified	O
a	O
novel	O
conserved	O
protein	O
motif	O
,	O
termed	O
the	O
"	O
leucine	O
latch	O
,	O
"	O
at	O
the	O
N	O
terminus	O
of	O
Rhp26	O
.	O

The	O
leucine	O
latch	O
motif	O
mediates	O
the	O
autoinhibition	O
of	O
the	O
ATPase	O
and	O
chromatin	O
-	O
remodeling	O
activities	O
of	O
Rhp26	O
via	O
its	O
interaction	O
with	O
the	O
core	O
ATPase	O
domain	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
the	O
C	O
terminus	O
of	O
the	O
protein	O
counteracts	O
this	O
autoinhibition	O
and	O
that	O
both	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
regions	O
of	O
Rhp26	O
are	O
needed	O
for	O
its	O
proper	O
function	O
in	O
DNA	O
repair	O
in	O
vivo	O
.	O

The	O
presence	O
of	O
the	O
leucine	O
latch	O
motif	O
in	O
organisms	O
ranging	O
from	O
yeast	O
to	O
humans	O
suggests	O
a	O
conserved	O
mechanism	O
for	O
the	O
autoregulation	O
of	O
CSB	O
/	O
ERCC6	O
despite	O
the	O
otherwise	O
highly	O
divergent	O
nature	O
of	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
regions	O
.	O

Kinetic	O
gating	O
mechanism	O
of	O
DNA	O
damage	O
recognition	O
by	O
Rad4	O
/	O
XPC	O
.	O

The	O
xeroderma	O
pigmentosum	O
C	O
(	O
XPC	O
)	O
complex	O
initiates	O
nucleotide	O
excision	O
repair	O
by	O
recognizing	O
DNA	O
lesions	O
before	O
recruiting	O
downstream	O
factors	O
.	O

How	O
XPC	O
detects	O
structurally	O
diverse	O
lesions	O
embedded	O
within	O
normal	O
DNA	O
is	O
unknown	O
.	O

Here	O
we	O
present	O
a	O
crystal	O
structure	O
that	O
captures	O
the	O
yeast	O
XPC	O
orthologue	O
(	O
Rad4	O
)	O
on	O
a	O
single	O
register	O
of	O
undamaged	O
DNA	O
.	O

The	O
structure	O
shows	O
that	O
a	O
disulphide	O
-	O
tethered	O
Rad4	O
flips	O
out	O
normal	O
nucleotides	O
and	O
adopts	O
a	O
conformation	O
similar	O
to	O
that	O
seen	O
with	O
damaged	O
DNA	O
.	O

Contrary	O
to	O
many	O
DNA	O
repair	O
enzymes	O
that	O
can	O
directly	O
reject	O
non	O
-	O
target	O
sites	O
as	O
structural	O
misfits	O
,	O
our	O
results	O
suggest	O
that	O
Rad4	O
/	O
XPC	O
uses	O
a	O
kinetic	O
gating	O
mechanism	O
whereby	O
lesion	O
selectivity	O
arises	O
from	O
the	O
kinetic	O
competition	O
between	O
DNA	O
opening	O
and	O
the	O
residence	O
time	O
of	O
Rad4	O
/	O
XPC	O
per	O
site	O
.	O

This	O
mechanism	O
is	O
further	O
supported	O
by	O
measurements	O
of	O
Rad4	O
-	O
induced	O
lesion	O
-	O
opening	O
times	O
using	O
temperature	O
-	O
jump	O
perturbation	O
spectroscopy	O
.	O

Kinetic	O
gating	O
may	O
be	O
a	O
general	O
mechanism	O
used	O
by	O
site	O
-	O
specific	O
DNA	O
-	O
binding	O
proteins	O
to	O
minimize	O
time	O
-	O
consuming	O
interrogations	O
of	O
non	O
-	O
target	O
sites	O
.	O

Small	O
tRNA	O
-	O
derived	O
RNAs	O
are	O
increased	O
and	O
more	O
abundant	O
than	O
microRNAs	O
in	O
chronic	O
hepatitis	O
B	O
and	O
C	O
.	O

Persistent	O
infections	O
with	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
or	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
account	O
for	O
the	O
majority	O
of	O
cases	O
of	O
hepatic	O
cirrhosis	O
and	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
worldwide	O
.	O

Small	O
,	O
non	O
-	O
coding	O
RNAs	O
play	O
important	O
roles	O
in	O
virus	O
-	O
host	O
interactions	O
.	O

We	O
used	O
high	O
throughput	O
sequencing	O
to	O
conduct	O
an	O
unbiased	O
profiling	O
of	O
small	O
(	O
14	O
-	O
40	O
nts	O
)	O
RNAs	O
in	O
liver	O
from	O
Japanese	O
subjects	O
with	O
advanced	O
hepatitis	O
B	O
or	O
C	O
and	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
.	O

Small	O
RNAs	O
derived	O
from	O
tRNAs	O
,	O
specifically	O
30	O
-	O
35	O
nucleotide	O
-	O
long	O
5	O
'	O
tRNA	O
-	O
halves	O
(	O
5	O
'	O
tRHs	O
)	O
,	O
were	O
abundant	O
in	O
non	O
-	O
malignant	O
liver	O
and	O
significantly	O
increased	O
in	O
humans	O
and	O
chimpanzees	O
with	O
chronic	O
viral	O
hepatitis	O
.	O

5	O
'	O
tRH	O
abundance	O
exceeded	O
microRNA	O
abundance	O
in	O
most	O
infected	O
non	O
-	O
cancerous	O
tissues	O
.	O

In	O
contrast	O
,	O
in	O
matched	O
cancer	O
tissue	O
,	O
5	O
'	O
tRH	O
abundance	O
was	O
reduced	O
,	O
and	O
relative	O
abundance	O
of	O
individual	O
5	O
'	O
tRHs	O
was	O
altered	O
.	O

In	O
hepatitis	O
B	O
-	O
associated	O
HCC	O
,	O
5	O
'	O
tRH	O
abundance	O
correlated	O
with	O
expression	O
of	O
the	O
tRNA	O
-	O
cleaving	O
ribonuclease	O
,	O
angiogenin	O
.	O

These	O
results	O
demonstrate	O
that	O
tRHs	O
are	O
the	O
most	O
abundant	O
small	O
RNAs	O
in	O
chronically	O
infected	O
liver	O
and	O
that	O
their	O
abundance	O
is	O
altered	O
in	O
liver	O
cancer	O
.	O

SEPT12	O
orchestrates	O
the	O
formation	O
of	O
mammalian	O
sperm	O
annulus	O
by	O
organizing	O
core	O
octameric	O
complexes	O
with	O
other	O
SEPT	O
proteins	O
.	O

Male	O
infertility	O
has	O
become	O
a	O
worldwide	O
health	O
problem	O
,	O
but	O
the	O
etiologies	O
of	O
most	O
cases	O
are	O
still	O
unknown	O
.	O

SEPT12	O
,	O
a	O
GTP	O
-	O
binding	O
protein	O
,	O
is	O
involved	O
in	O
male	O
fertility	O
.	O

Two	O
SEPT12	O
mutations	O
(	O
SEPT12	O
(	O
T89M	O
)	O
and	O
SEPT12	O
(	O
D197N	O
)	O
)	O
have	O
been	O
identified	O
in	O
infertile	O
men	O
who	O
have	O
a	O
defective	O
sperm	O
annulus	O
with	O
a	O
bent	O
tail	O
.	O

The	O
function	O
of	O
SEPT12	O
in	O
the	O
sperm	O
annulus	O
is	O
still	O
unclear	O
.	O

Here	O
,	O
we	O
found	O
that	O
SEPT12	O
formed	O
a	O
filamentous	O
structure	O
with	O
SEPT7	O
,	O
SEPT	O
6	O
,	O
SEPT2	O
and	O
SEPT4	O
at	O
the	O
sperm	O
annulus	O
.	O

The	O
SEPT12	O
-	O
based	O
septin	O
core	O
complex	O
was	O
assembled	O
as	O
octameric	O
filaments	O
comprising	O
the	O
SEPT	O
proteins	O
12	O
-	O
7	O
-	O
6	O
-	O
2	O
-	O
2	O
-	O
6	O
-	O
7	O
-	O
12	O
or	O
12	O
-	O
7	O
-	O
6	O
-	O
4	O
-	O
4	O
-	O
6	O
-	O
7	O
-	O
12	O
.	O

In	O
addition	O
,	O
the	O
GTP	O
-	O
binding	O
domain	O
of	O
SEPT12	O
was	O
crucial	O
for	O
its	O
interaction	O
with	O
SEPT7	O
,	O
and	O
the	O
N	O
-	O
and	O
C	O
-	O
termini	O
of	O
SEPT12	O
were	O
required	O
for	O
the	O
interaction	O
of	O
SEPT12	O
with	O
itself	O
to	O
polymerize	O
octamers	O
into	O
filaments	O
.	O

Mutant	O
mice	O
carrying	O
the	O
SEPT12	O
(	O
D197N	O
)	O
mutation	O
,	O
which	O
disrupts	O
SEPT12	O
filament	O
formation	O
,	O
showed	O
a	O
disorganized	O
sperm	O
annulus	O
,	O
bent	O
tail	O
,	O
reduced	O
motility	O
and	O
loss	O
of	O
the	O
SEPT	O
ring	O
structure	O
at	O
the	O
sperm	O
annulus	O
.	O

These	O
phenotypes	O
were	O
also	O
observed	O
in	O
an	O
infertile	O
man	O
carrying	O
SEPT12	O
(	O
D197N	O
)	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrate	O
the	O
molecular	O
architecture	O
of	O
SEPT12	O
filaments	O
at	O
the	O
sperm	O
annulus	O
,	O
their	O
mechanical	O
support	O
of	O
sperm	O
motility	O
,	O
and	O
their	O
correlation	O
with	O
male	O
infertility	O
.	O

Expression	O
of	O
RCAS1	O
correlates	O
with	O
urothelial	O
bladder	O
cancer	O
malignancy	O
.	O

RCAS1	O
is	O
a	O
protein	O
that	O
participates	O
in	O
regulation	O
of	O
the	O
tumor	O
microenvironment	O
and	O
its	O
immune	O
responses	O
,	O
all	O
in	O
order	O
to	O
evade	O
the	O
immune	O
system	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
RCAS1	O
expression	O
in	O
urothelial	O
bladder	O
cancer	O
cells	O
(	O
and	O
in	O
fibroblasts	O
and	O
macrophages	O
of	O
the	O
tumor	O
stroma	O
)	O
and	O
its	O
relationship	O
with	O
the	O
histological	O
pattern	O
of	O
malignancy	O
.	O

Eighty	O
-	O
three	O
postcystectomy	O
patients	O
were	O
enrolled	O
.	O

We	O
analyzed	O
the	O
histological	O
maturity	O
(	O
grade	O
)	O
,	O
progress	O
(	O
pT	O
stage	O
)	O
,	O
tissue	O
invasion	O
type	O
(	O
TIT	O
)	O
,	O
nonclassic	O
differentiation	O
number	O
(	O
NDN	O
)	O
,	O
and	O
the	O
ability	O
to	O
metastasize	O
(	O
pN	O
)	O
.	O

The	O
expression	O
of	O
RCAS1	O
protein	O
was	O
analyzed	O
by	O
immunohistochemistry	O
.	O

Indicators	O
of	O
histological	O
malignancy	O
were	O
observed	O
solely	O
in	O
association	O
with	O
the	O
RCAS1	O
expression	O
in	O
cells	O
in	O
the	O
border	O
parts	O
(	O
BPs	O
)	O
of	O
the	O
tumor	O
.	O

Histological	O
malignancy	O
of	O
the	O
tumor	O
,	O
indicated	O
by	O
the	O
pT	O
and	O
pN	O
,	O
and	O
metastasis	O
-	O
free	O
survival	O
time	O
,	O
correlated	O
significantly	O
with	O
RCAS1	O
expression	O
in	O
tumor	O
neoplastic	O
cells	O
,	O
whereas	O
malignancy	O
determined	O
by	O
grade	O
,	O
TIT	O
,	O
and	O
NDN	O
correlated	O
with	O
RCAS1	O
expression	O
in	O
fibroblasts	O
and	O
macrophages	O
in	O
the	O
tumor	O
microenvironment	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
increased	O
RCAS1	O
expression	O
depends	O
on	O
its	O
cellular	O
source	O
and	O
that	O
RCAS1	O
expression	O
itself	O
is	O
a	O
component	O
of	O
various	O
signaling	O
pathways	O
.	O

The	O
immune	O
escape	O
occurs	O
within	O
the	O
tumor	O
BPs	O
,	O
where	O
the	O
increase	O
in	O
the	O
RCAS1	O
expression	O
occurs	O
within	O
tumor	O
cells	O
and	O
stromal	O
cells	O
in	O
its	O
microenvironment	O
.	O

We	O
conclude	O
that	O
the	O
histological	O
pattern	O
of	O
tumor	O
malignancy	O
,	O
indicated	O
by	O
grade	O
,	O
TIT	O
,	O
NDN	O
,	O
pT	O
,	O
and	O
pN	O
is	O
a	O
morphological	O
indicator	O
of	O
immune	O
escape	O
.	O

The	O
dimerization	O
of	O
the	O
yeast	O
cytochrome	B-Complex
bc1	I-Complex
complex	O
is	O
an	O
early	O
event	O
and	O
is	O
independent	O
of	O
Rip1	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
the	O
mature	O
cytochrome	B-Complex
bc1	I-Complex
complex	O
exists	O
as	O
an	O
obligate	O
homo	O
-	O
dimer	O
in	O
which	O
each	O
monomer	O
consists	O
of	O
ten	O
distinct	O
protein	O
subunits	O
inserted	O
into	O
or	O
bound	O
to	O
the	O
inner	O
mitochondrial	O
membrane	O
.	O

Among	O
them	O
,	O
the	O
Rieske	O
iron	O
-	O
sulfur	O
protein	O
(	O
Rip1	O
)	O
,	O
besides	O
its	O
catalytic	O
role	O
in	O
electron	O
transfer	O
,	O
may	O
be	O
implicated	O
in	O
the	O
bc1	B-Complex
complex	O
dimerization	O
.	O

Indeed	O
,	O
Rip1	O
has	O
the	O
globular	O
domain	O
containing	O
the	O
catalytic	O
center	O
in	O
one	O
monomer	O
while	O
the	O
transmembrane	O
helix	O
interacts	O
with	O
the	O
adjacent	O
monomer	O
.	O

In	O
addition	O
,	O
the	O
lack	O
of	O
Rip1	O
leads	O
to	O
the	O
accumulation	O
of	O
an	O
immature	O
bc1	B-Complex
intermediate	O
,	O
only	O
loosely	O
associated	O
with	O
cytochrome	B-Complex
c	I-Complex
oxidase	I-Complex
.	O

In	O
this	O
study	O
we	O
have	O
investigated	O
the	O
biogenesis	O
of	O
the	O
yeast	O
cytochrome	B-Complex
bc1	I-Complex
complex	O
using	O
epitope	O
tagged	O
proteins	O
to	O
purify	O
native	O
assembly	O
intermediates	O
.	O

We	O
showed	O
that	O
the	O
dimerization	O
process	O
is	O
an	O
early	O
event	O
during	O
bc1	B-Complex
complex	O
biogenesis	O
and	O
that	O
the	O
presence	O
of	O
Rip1	O
,	O
differently	O
from	O
previous	O
proposals	O
,	O
is	O
not	O
essential	O
for	O
this	O
process	O
.	O

We	O
also	O
investigated	O
the	O
multi	O
-	O
step	O
model	O
of	O
bc1	B-Complex
assembly	O
thereby	O
lending	O
further	O
support	O
to	O
the	O
existence	O
of	O
bona	O
fide	O
subcomplexes	O
during	O
bc1	B-Complex
maturation	O
in	O
the	O
inner	O
mitochondrial	O
membrane	O
.	O

Finally	O
,	O
a	O
new	O
model	O
of	O
cytochrome	B-Complex
bc1	I-Complex
complex	O
assembly	O
,	O
in	O
which	O
distinct	O
intermediates	O
sequentially	O
interact	O
during	O
bc1	B-Complex
maturation	O
,	O
has	O
been	O
proposed	O
.	O

To	O
map	O
the	O
regions	O
subject	O
to	O
phosphorylation	O
we	O
generated	O
a	O
number	O
of	O
deletions	O
and	O
point	O
mutations	O
and	O
assayed	O
their	O
mobility	O
with	O
or	O
without	O
lambda	O
phosphatase	O
treatment	O
.	O

Phosphorylation	O
sites	O
were	O
mapped	O
to	O
the	O
C	O
-	O
teminal	O
half	O
of	O
the	O
protein	O
,	O
beyond	O
residue	O
260	O
,	O
while	O
a	O
serine	O
-	O
rich	O
stretch	O
from	O
residue	O
175	O
to	O
199	O
was	O
dispensable	O
for	O
the	O
phosphorylation	O
of	O
Sc	O
.	O

We	O
focused	O
on	O
the	O
(	O
S	O
/	O
T	O
)	O
P	O
sites	O
of	O
the	O
C	O
-	O
terminal	O
half	O
(	O
S217	O
,	O
S268	O
and	O
T329	O
)	O
,	O
as	O
such	O
motifs	O
are	O
often	O
kinase	O
targets	O
,	O
e	O
.	O
g	O
.	O
for	O
Cdk	O
'	O
s	O
and	O
MAPK	O
'	O
s	O
.	O

S268	O
is	O
part	O
of	O
a	O
highly	O
conserved	O
SPxxS	O
motif	O
,	O
found	O
in	O
all	O
Sc	O
homologues	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
altered	O
two	O
,	O
three	O
or	O
five	O
S	O
/	O
T	O
residues	O
to	O
non	O
-	O
phosphorylatable	O
alanines	O
or	O
valines	O
and	O
named	O
the	O
mutants	O
m2p	O
,	O
m3p	O
or	O
m5p	O
,	O
respectively	O
;	O
see	O
Figure	O
1A	O
and	O
Supplementary	O
Data	O
for	O
description	O
.	O

From	O
these	O
mutants	O
we	O
concluded	O
that	O
phosphorylation	O
of	O
Sc	O
is	O
primarily	O
dependent	O
on	O
this	O
268	O
-	O
SPTSS	O
motif	O
(	O
Figure	O
1A	O
)	O
.	O

We	O
also	O
tested	O
a	O
basic	O
domain	O
point	O
mutant	O
,	O
Sc	O
[	O
RQEQ	O
]	O
.	O

This	O
carries	O
two	O
amino	O
acid	O
changes	O
,	O
R104Q	O
and	O
E108Q	O
,	O
which	O
abolish	O
DNA	O
binding	O
with	O
consequent	O
loss	O
of	O
activity	O
(	O
Supplementary	O
Figure	O
S1	O
)	O
.	O

In	O
agreement	O
with	O
the	O
Sc	O
[	O
164	O
-	O
345	O
]	O
truncation	O
,	O
which	O
lacks	O
the	O
entire	O
bHLH	O
region	O
,	O
the	O
basic	O
domain	O
mutant	O
did	O
not	O
abolish	O
phosphorylation	O
.	O

When	O
isolated	O
from	O
larval	O
wing	O
disks	O
Sc	O
[	O
m3p	O
]	O
migrated	O
faster	O
than	O
wt	O
Sc	O
,	O
consistent	O
with	O
Sc	O
being	O
phosphorylated	O
via	O
its	O
SPTSS	O
motif	O
also	O
in	O
native	O
tissues	O
(	O
Figure	O
1B	O
)	O
.	O

VHL	O
negatively	O
regulates	O
SARS	O
coronavirus	O
replication	O
by	O
modulating	O
nsp16	O
ubiquitination	O
and	O
stability	O
.	O

Eukaryotic	O
cellular	O
and	O
most	O
viral	O
RNAs	O
carry	O
a	O
5	O
'	O
-	O
terminal	O
cap	O
structure	O
,	O
a	O
5	O
'	O
-	O
5	O
'	O
triphosphate	O
linkage	O
between	O
the	O
5	O
'	O
end	O
of	O
the	O
RNA	O
and	O
a	O
guanosine	O
nucleotide	O
(	O
cap	O
-	O
0	O
)	O
.	O

SARS	O
coronavirus	O
(	O
SARS	O
-	O
CoV	O
)	O
nonstructural	O
protein	O
nsp16	O
functions	O
as	O
a	O
methyltransferase	O
,	O
to	O
methylate	O
mRNA	O
cap	O
-	O
0	O
structure	O
at	O
the	O
ribose	O
2	O
'	O
-	O
O	O
position	O
of	O
the	O
first	O
nucleotide	O
to	O
form	O
cap	O
-	O
1	O
structures	O
.	O

However	O
,	O
whether	O
there	O
is	O
interplay	O
between	O
nsp16	O
and	O
host	O
proteins	O
was	O
not	O
yet	O
clear	O
.	O

In	O
this	O
report	O
,	O
we	O
identified	O
several	O
potential	O
cellular	O
nsp16	O
-	O
interacting	O
proteins	O
from	O
a	O
human	O
thymus	O
cDNA	O
library	O
by	O
yeast	O
two	O
-	O
hybrid	O
screening	O
.	O

VHL	O
,	O
one	O
of	O
these	O
proteins	O
,	O
was	O
proven	O
to	O
interact	O
with	O
nsp16	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Further	O
studies	O
showed	O
that	O
VHL	O
can	O
inhibit	O
SARS	O
-	O
CoV	O
replication	O
by	O
regulating	O
nsp16	O
ubiquitination	O
and	O
promoting	O
its	O
degradation	O
.	O

Our	O
results	O
have	O
revealed	O
the	O
role	O
of	O
cellular	O
VHL	O
in	O
the	O
regulation	O
of	O
SARS	O
-	O
CoV	O
replication	O
.	O

Molecular	O
determinants	O
of	O
polyubiquitin	O
recognition	O
by	O
continuous	O
ubiquitin	O
-	O
binding	O
domains	O
of	O
Rad18	O
.	O

Rad18	O
is	O
a	O
key	O
factor	O
in	O
double	O
-	O
strand	O
break	O
DNA	O
damage	O
response	O
(	O
DDR	O
)	O
pathways	O
via	O
its	O
association	O
with	O
K63	O
-	O
linked	O
polyubiquitylated	O
chromatin	O
proteins	O
through	O
its	O
bipartite	O
ubiquitin	O
-	O
binding	O
domains	O
UBZ	O
and	O
LRM	O
with	O
extra	O
residues	O
between	O
them	O
.	O

Rad18	O
binds	O
K63	O
-	O
linked	O
polyubiquitin	O
chains	O
as	O
well	O
as	O
K48	O
-	O
linked	O
ones	O
and	O
monoubiquitin	O
.	O

However	O
,	O
the	O
detailed	O
molecular	O
basis	O
of	O
polyubiquitin	O
recognition	O
by	O
UBZ	O
and	O
LRM	O
remains	O
unclear	O
.	O

Here	O
,	O
we	O
examined	O
the	O
interaction	O
of	O
Rad18	O
(	O
201	O
-	O
240	O
)	O
,	O
including	O
UBZ	O
and	O
LRM	O
,	O
with	O
linear	O
polyubiquitin	O
chains	O
that	O
are	O
structurally	O
similar	O
to	O
the	O
K63	O
-	O
linked	O
ones	O
.	O

Rad18	O
(	O
201	O
-	O
240	O
)	O
binds	O
linear	O
polyubiquitin	O
chains	O
(	O
Ub2	O
-	O
Ub4	O
)	O
with	O
affinity	O
similar	O
to	O
that	O
of	O
a	O
K63	O
-	O
linked	O
one	O
for	O
diubiquitin	O
.	O

Ab	O
initio	O
modeling	O
suggests	O
that	O
LRM	O
and	O
the	O
extra	O
residues	O
at	O
the	O
C	O
-	O
terminus	O
of	O
UBZ	O
(	O
residues	O
227	O
-	O
237	O
)	O
likely	O
form	O
a	O
continuous	O
helix	O
,	O
termed	O
the	O
"	O
extended	O
LR	O
motif	O
"	O
(	O
ELRM	O
)	O
.	O

We	O
obtained	O
a	O
molecular	O
envelope	O
for	O
Rad18	O
UBZ	O
-	O
ELRM	O
:	O
linear	O
Ub2	O
by	O
small	O
-	O
angle	O
X	O
-	O
ray	O
scattering	O
and	O
derived	O
a	O
structural	O
model	O
for	O
the	O
complex	O
.	O

The	O
Rad18	O
:	O
linear	O
Ub2	O
model	O
indicates	O
that	O
ELRM	O
enhances	O
the	O
binding	O
of	O
Rad18	O
with	O
linear	O
polyubiquitin	O
by	O
contacting	O
the	O
proximal	O
ubiquitin	O
moiety	O
.	O

Consistent	O
with	O
the	O
structural	O
analysis	O
,	O
mutational	O
studies	O
showed	O
that	O
residues	O
in	O
ELRM	O
affect	O
binding	O
with	O
linear	O
Ub2	O
,	O
not	O
monoubiquitin	O
.	O

In	O
cell	O
data	O
support	O
the	O
idea	O
that	O
ELRM	O
is	O
crucial	O
in	O
the	O
localization	O
of	O
Rad18	O
to	O
DNA	O
damage	O
sites	O
.	O

Specifically	O
,	O
E227	O
seems	O
to	O
be	O
the	O
most	O
critical	O
in	O
polyubiquitin	O
binding	O
and	O
localization	O
to	O
nuclear	O
foci	O
.	O

Finally	O
,	O
we	O
reveal	O
that	O
the	O
ubiquitin	O
-	O
binding	O
domains	O
of	O
Rad18	O
bind	O
linear	O
Ub2	O
more	O
tightly	O
than	O
those	O
of	O
RAP80	O
,	O
providing	O
a	O
quantitative	O
basis	O
for	O
blockage	O
of	O
RAP80	O
at	O
DSB	O
sites	O
.	O

Taken	O
together	O
,	O
our	O
data	O
demonstrate	O
that	O
Rad18	O
(	O
201	O
-	O
240	O
)	O
forms	O
continuous	O
ubiquitin	O
-	O
binding	O
domains	O
,	O
comprising	O
UBZ	O
and	O
ELRM	O
,	O
and	O
provides	O
a	O
structural	O
framework	O
for	O
polyubiquitin	O
recognition	O
by	O
Rad18	O
in	O
the	O
DDR	O
pathway	O
at	O
a	O
molecular	O
level	O
.	O

Since	O
RNF5	O
is	O
implicated	O
in	O
the	O
clearance	O
of	O
misfolded	O
proteins	O
as	O
part	O
of	O
the	O
ERAD	O
response	O
,	O
we	O
asked	O
whether	O
RNF5	O
interaction	O
with	O
Gln	O
-	O
carrier	O
proteins	O
required	O
changes	O
in	O
protein	O
folding	O
following	O
ERS	O
.	O

To	O
do	O
so	O
,	O
we	O
subjected	O
BCa	O
cells	O
to	O
35S	O
-	O
methionine	O
-	O
cysteine	O
-	O
based	O
labeling	O
followed	O
by	O
immunopurification	O
of	O
35S	O
-	O
labeled	O
SLC1A5	O
and	O
limited	O
proteolytic	O
cleavage	O
using	O
BNPS	O
-	O
Skatole	O
.	O

SDS	O
-	O
PAGE	O
analysis	O
followed	O
by	O
autoradiography	O
revealed	O
a	O
marked	O
decrease	O
in	O
SLC1A5	O
cleavage	O
prior	O
but	O
not	O
following	O
paclitaxel	O
treatment	O
(	O
Figure	O
4G	O
,	O
S4B	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
SLC1A5	O
undergoes	O
misfolding	O
following	O
ERS	O
,	O
consistent	O
with	O
RNF5	O
recognition	O
of	O
misfolded	O
proteins	O
at	O
the	O
ER	O
membrane	O
.	O

RNF5	O
KD	O
attenuated	O
paclitaxel	O
-	O
induced	O
SLC1A5	O
/	O
38A2	O
degradation	O
(	O
Figure	O
4H	O
)	O
.	O

Likewise	O
,	O
the	O
half	O
-	O
lives	O
of	O
both	O
SLC1A5	O
/	O
38A2	O
increased	O
after	O
RNF5	O
KD	O
in	O
paclitaxel	O
-	O
treated	O
MDA	O
-	O
MB	O
-	O
231	O
cells	O
(	O
Figure	O
4I	O
)	O
.	O

A	O
homologous	O
recombination	O
-	O
based	O
method	O
was	O
used	O
to	O
tag	O
endogenous	O
Scp3	O
with	O
GFP	O
(	O
Green	O
Fluorescent	O
Protein	O
)	O
at	O
its	O
carboxyl	O
terminus	O
.	O

The	O
scp3	O
+	O
ORF	O
,	O
except	O
for	O
the	O
first	O
methionine	O
and	O
terminal	O
codon	O
,	O
was	O
amplified	O
using	O
the	O
KOD	O
-	O
Plus	O
PCR	O
kit	O
(	O
TOYOBO	O
)	O
with	O
a	O
pair	O
of	O
primers	O
carrying	O
SalI	O
and	O
NotI	O
sites	O
.	O

The	O
PCR	O
product	O
was	O
digested	O
with	O
SalI	O
and	O
NotI	O
and	O
cloned	O
into	O
the	O
plasmid	O
,	O
with	O
the	O
inserted	O
GFP	O
fragment	O
located	O
in	O
frame	O
at	O
the	O
carboxyl	O
terminus	O
.	O

For	O
ectopic	O
expression	O
of	O
Scp3	O
tagged	O
with	O
GFP	O
,	O
the	O
ORF	O
of	O
the	O
scp3	O
+	O
gene	O
,	O
except	O
for	O
the	O
terminal	O
codon	O
,	O
was	O
amplified	O
using	O
the	O
KOD	O
-	O
Plus	O
PCR	O
kit	O
(	O
TOYOBO	O
)	O
with	O
a	O
pair	O
of	O
primers	O
carrying	O
SalI	O
and	O
NotI	O
sites	O
and	O
cloned	O
into	O
the	O
pREP81	O
plasmid	O
,	O
with	O
the	O
inserted	O
GFP	O
fragment	O
located	O
at	O
the	O
carboxyl	O
terminus	O
in	O
frame	O
.	O

(	O
A	O
)	O
Schematic	O
of	O
Fun30	O
protein	O
.	O

The	O
CUE	O
motif	O
and	O
ATPase	O
domain	O
are	O
indicated	O
.	O

(	O
B	O
)	O
The	O
CUE	O
motif	O
of	O
Fun30	O
is	O
not	O
required	O
for	O
genotoxin	O
resistance	O
.	O

Growth	O
phenotypes	O
of	O
strains	O
89	O
through	O
93	O
on	O
indicated	O
media	O
are	O
shown	O
.	O

Note	O
pRS414	O
-	O
FUN30	O
-	O
CUE	O
*	O
*	O
encodes	O
a	O
Fun30	O
mutant	O
with	O
F82	O
and	O
P83	O
in	O
the	O
CUE	O
motif	O
replaced	O
by	O
alanines	O
.	O

(	O
C	O
)	O
The	O
CUE	O
motif	O
restricts	O
Fun30	O
'	O
s	O
ability	O
to	O
negatively	O
regulate	O
MMS	O
-	O
tolerance	O
.	O

Shown	O
are	O
growth	O
phenotypes	O
of	O
strains	O
94	O
through	O
98	O
on	O
indicated	O
media	O
.	O

Structure	O
of	O
the	O
TRPA1	O
ion	O
channel	O
suggests	O
regulatory	O
mechanisms	O
.	O

The	O
TRPA1	O
ion	O
channel	O
(	O
also	O
known	O
as	O
the	O
wasabi	O
receptor	O
)	O
is	O
a	O
detector	O
of	O
noxious	O
chemical	O
agents	O
encountered	O
in	O
our	O
environment	O
or	O
produced	O
endogenously	O
during	O
tissue	O
injury	O
or	O
drug	O
metabolism	O
.	O

These	O
include	O
a	O
broad	O
class	O
of	O
electrophiles	O
that	O
activate	O
the	O
channel	O
through	O
covalent	O
protein	O
modification	O
.	O

TRPA1	O
antagonists	O
hold	O
potential	O
for	O
treating	O
neurogenic	O
inflammatory	O
conditions	O
provoked	O
or	O
exacerbated	O
by	O
irritant	O
exposure	O
.	O

Despite	O
compelling	O
reasons	O
to	O
understand	O
TRPA1	O
function	O
,	O
structural	O
mechanisms	O
underlying	O
channel	O
regulation	O
remain	O
obscure	O
.	O

Here	O
we	O
use	O
single	O
-	O
particle	O
electron	O
cryo	O
-	O
microscopy	O
to	O
determine	O
the	O
structure	O
of	O
full	O
-	O
length	O
human	O
TRPA1	O
to	O
~	O
4	O
Aa	O
resolution	O
in	O
the	O
presence	O
of	O
pharmacophores	O
,	O
including	O
a	O
potent	O
antagonist	O
.	O

Several	O
unexpected	O
features	O
are	O
revealed	O
,	O
including	O
an	O
extensive	O
coiled	O
-	O
coil	O
assembly	O
domain	O
stabilized	O
by	O
polyphosphate	O
co	O
-	O
factors	O
and	O
a	O
highly	O
integrated	O
nexus	O
that	O
converges	O
on	O
an	O
unpredicted	O
transient	O
receptor	O
potential	O
(	O
TRP	O
)	O
-	O
like	O
allosteric	O
domain	O
.	O

These	O
findings	O
provide	O
new	O
insights	O
into	O
the	O
mechanisms	O
of	O
TRPA1	O
regulation	O
,	O
and	O
establish	O
a	O
blueprint	O
for	O
structure	O
-	O
based	O
design	O
of	O
analgesic	O
and	O
anti	O
-	O
inflammatory	O
agents	O
.	O

Although	O
several	O
hundred	O
proteins	O
are	O
thought	O
to	O
be	O
concentrated	O
at	O
centrioles	O
,	O
only	O
a	O
small	O
number	O
appear	O
to	O
form	O
a	O
conserved	O
'	O
core	O
'	O
pathway	O
that	O
is	O
essential	O
for	O
centriole	O
assembly	O
.	O

During	O
canonical	O
centriole	O
duplication	O
,	O
the	O
protein	O
kinase	O
Plk4	O
/	O
Sak	O
/	O
ZYG	O
-	O
1	O
is	O
recruited	O
to	O
the	O
mother	O
centriole	O
by	O
SPD	O
-	O
2	O
in	O
worms	O
,	O
by	O
Asterless	O
(	O
Asl	O
)	O
in	O
flies	O
,	O
or	O
by	O
a	O
combination	O
of	O
the	O
two	O
(	O
Cep192	O
and	O
Cep152	O
,	O
respectively	O
)	O
in	O
humans	O
.	O

The	O
protein	O
kinase	O
recruits	O
STIL	O
/	O
Ana2	O
/	O
SAS	O
-	O
5	O
and	O
Sas	O
-	O
6	O
to	O
a	O
single	O
site	O
on	O
the	O
side	O
of	O
the	O
mother	O
centriole	O
where	O
they	O
assemble	O
with	O
CPAP	O
/	O
Sas	O
-	O
4	O
into	O
a	O
cartwheel	O
structure	O
that	O
helps	O
to	O
establish	O
the	O
ninefold	O
symmetry	O
of	O
the	O
centriole	O
.	O

CPAP	O
/	O
Sas	O
-	O
4	O
can	O
interact	O
with	O
tubulin	O
and	O
is	O
required	O
to	O
recruit	O
the	O
centriole	O
MTs	O
to	O
the	O
outer	O
region	O
of	O
the	O
cartwheel	O
,	O
possibly	O
working	O
together	O
with	O
Cep135	O
/	O
Bld10	O
-	O
-	O
although	O
no	O
homologue	O
of	O
this	O
protein	O
has	O
been	O
identified	O
in	O
worms	O
,	O
and	O
it	O
does	O
not	O
appear	O
to	O
be	O
essential	O
for	O
centriole	O
duplication	O
in	O
flies	O
.	O

Upon	O
our	O
screen	O
,	O
we	O
identify	O
an	O
ER	O
-	O
enriched	O
v	O
-	O
SNARE	O
protein	O
Sec22	O
involved	O
in	O
Wg	O
trafficking	O
,	O
and	O
thus	O
we	O
generated	O
two	O
Sec22	O
mutants	O
(	O
Fig	O
.	O
3	O
A	O
)	O
.	O

Consistent	O
with	O
the	O
RNAi	O
results	O
,	O
Wg	O
protein	O
accumulates	O
significantly	O
in	O
the	O
Sec22	O
homozygous	O
mutant	O
clones	O
(	O
Fig	O
.	O
3	O
C	O
)	O
.	O

We	O
fed	O
Drosophila	O
S2	O
cells	O
with	O
dsRNA	O
of	O
Sec22	O
and	O
examined	O
the	O
Wg	O
protein	O
level	O
in	O
the	O
supernatant	O
and	O
lysate	O
.	O

We	O
observed	O
a	O
significant	O
reduction	O
of	O
the	O
secreted	O
Wg	O
in	O
the	O
supernatant	O
and	O
an	O
increased	O
level	O
of	O
Wg	O
in	O
the	O
cell	O
lysate	O
(	O
Fig	O
.	O
3	O
B	O
)	O
,	O
indicating	O
that	O
depletion	O
of	O
Sec22	O
impedes	O
Wg	O
secretion	O
.	O

Studies	O
suggest	O
that	O
the	O
proteins	O
with	O
distinct	O
roles	O
at	O
the	O
ER	O
and	O
NPC	B-Complex
are	O
specifically	O
involved	O
in	O
NPC	B-Complex
biogenesis	O
and	O
structure	O
.	O

In	O
metazoans	O
,	O
NPC	B-Complex
biogenesis	O
occurs	O
by	O
way	O
of	O
two	O
processes	O
:	O
postmitotic	O
assembly	O
and	O
interphase	O
de	O
novo	O
assembly	O
.	O

The	O
stepwise	O
progression	O
of	O
postmitotic	O
NPC	B-Complex
assembly	O
is	O
well	O
defined	O
.	O

After	O
mitosis	O
,	O
sites	O
of	O
NPC	B-Complex
assembly	O
are	O
seeded	O
by	O
the	O
ELYS	O
/	O
Nup107	O
complex	O
on	O
the	O
chromatin	O
.	O

Integral	O
pore	O
membrane	O
proteins	O
(	O
Poms	O
)	O
of	O
the	O
NPC	B-Complex
are	O
recruited	O
as	O
the	O
NE	O
reforms	O
from	O
the	O
cortical	O
ER	O
,	O
stabilizing	O
a	O
pore	O
into	O
which	O
other	O
Nups	O
assemble	O
.	O

During	O
de	O
novo	O
assembly	O
,	O
the	O
intact	O
double	O
membrane	O
of	O
the	O
NE	O
must	O
fuse	O
to	O
allow	O
the	O
formation	O
of	O
a	O
nascent	O
pore	O
.	O

Ndc1	O
is	O
the	O
only	O
Pom	O
known	O
to	O
be	O
individually	O
essential	O
for	O
this	O
process	O
.	O

Owing	O
to	O
functional	O
redundancies	O
among	O
other	O
Poms	O
,	O
the	O
mechanistic	O
steps	O
of	O
this	O
fusion	O
event	O
have	O
been	O
difficult	O
to	O
define	O
further	O
.	O

Carbonic	O
anhydrase	O
IV	O
inhibits	O
colon	O
cancer	O
development	O
by	O
inhibiting	O
the	O
Wnt	O
signalling	O
pathway	O
through	O
targeting	O
the	O
WTAP	O
-	O
WT1	O
-	O
TBL1	O
axis	O
.	O

OBJECTIVE	O
:	O
We	O
found	O
that	O
carbonic	O
anhydrase	O
IV	O
(	O
CA4	O
)	O
,	O
a	O
member	O
of	O
the	O
carbonic	O
anhydrases	O
,	O
is	O
silenced	O
in	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
.	O

We	O
analysed	O
its	O
epigenetic	O
inactivation	O
,	O
biological	O
effects	O
and	O
prognostic	O
significance	O
in	O
CRC	O
.	O

DESIGN	O
:	O
The	O
biological	O
functions	O
of	O
CA4	O
were	O
determined	O
by	O
in	O
vitro	O
and	O
in	O
vivo	O
tumorigenicity	O
assays	O
.	O

The	O
CA4	O
co	O
-	O
operator	O
was	O
identified	O
by	O
immunoprecipitation	O
and	O
mass	O
spectrometry	O
.	O

CA4	O
downstream	O
effectors	O
and	O
signalling	O
pathways	O
were	O
elucidated	O
by	O
promoter	O
luciferase	O
assay	O
,	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
chromatin	O
immunoprecipitation	O
.	O

The	O
clinical	O
impact	O
of	O
CA4	O
was	O
assessed	O
in	O
115	O
patients	O
with	O
CRC	O
.	O

RESULTS	O
:	O
CA4	O
was	O
silenced	O
in	O
all	O
nine	O
CRC	O
cell	O
lines	O
and	O
92	O
.	O
6	O
%	O
of	O
CRC	O
tumours	O
.	O

The	O
promoter	O
hypermethylation	O
contributed	O
to	O
the	O
inactivation	O
of	O
CA4	O
,	O
and	O
it	O
was	O
detected	O
in	O
75	O
.	O
7	O
%	O
of	O
the	O
patients	O
with	O
CRC	O
.	O

After	O
a	O
median	O
follow	O
-	O
up	O
of	O
49	O
.	O
3	O
months	O
,	O
multivariate	O
analysis	O
showed	O
that	O
the	O
patients	O
with	O
CA4	O
hypermethylation	O
had	O
a	O
recurrence	O
of	O
Stage	O
II	O
/	O
III	O
CRC	O
.	O

The	O
re	O
-	O
expression	O
of	O
CA4	O
inhibited	O
cell	O
proliferation	O
,	O
induced	O
apoptosis	O
and	O
cell	O
cycle	O
arrest	O
in	O
the	O
G1	O
phase	O
.	O

CA4	O
inhibited	O
the	O
activity	O
of	O
the	O
Wnt	O
signalling	O
pathway	O
and	O
mediated	O
the	O
degradation	O
of	O
beta	O
-	O
catenin	O
.	O

CA4	O
interacted	O
with	O
Wilms	O
'	O
tumour	O
1	O
-	O
associating	O
protein	O
(	O
WTAP	O
)	O
and	O
induced	O
WTAP	O
protein	O
degradation	O
through	O
polyubiquitination	O
.	O

Moreover	O
,	O
CA4	O
promoted	O
the	O
transcriptional	O
activity	O
of	O
Wilms	O
'	O
tumour	O
1	O
(	O
WT1	O
)	O
,	O
an	O
antagonist	O
of	O
the	O
Wnt	O
pathway	O
,	O
which	O
resulted	O
in	O
the	O
induction	O
of	O
transducin	O
beta	O
-	O
like	O
protein	O
1	O
(	O
TBL1	O
)	O
and	O
the	O
degradation	O
of	O
beta	O
-	O
catenin	O
.	O

CONCLUSIONS	O
:	O
CA4	O
is	O
a	O
novel	O
tumour	O
suppressor	O
in	O
CRC	O
through	O
the	O
inhibition	O
of	O
the	O
Wnt	O
signalling	O
pathway	O
by	O
targeting	O
the	O
WTAP	O
-	O
WT1	O
-	O
TBL1	O
axis	O
.	O

CA4	O
methylation	O
may	O
serve	O
as	O
an	O
independent	O
biomarker	O
for	O
the	O
recurrence	O
of	O
CRC	O
.	O

For	O
localization	O
studies	O
,	O
microtubules	O
stabilized	O
with	O
1	O
.	O
5	O
muM	O
taxol	O
were	O
incubated	O
for	O
10	O
min	O
at	O
room	O
temperature	O
with	O
100	O
nM	O
MBP	O
-	O
xMCRS1	O
,	O
KANSL1	O
or	O
KANSL3	O
,	O
as	O
indicated	O
,	O
in	O
BRB80	O
.	O

Samples	O
were	O
then	O
fixed	O
with	O
1	O
%	O
glutaraldehyde	O
,	O
5	O
muM	O
taxol	O
in	O
BRB80	O
and	O
pelleted	O
on	O
coverslips	O
through	O
a	O
25	O
%	O
glycerol	O
,	O
BRB80	O
cushion	O
at	O
4	O
,	O
000g	O
for	O
10	O
min	O
at	O
room	O
temperature	O
.	O

Coverslips	O
were	O
then	O
recovered	O
and	O
fixed	O
for	O
10	O
min	O
in	O
-	O
20	O
degreesC	O
methanol	O
and	O
processed	O
for	O
immunofluorescence	O
.	O

Binding	O
partners	O
of	O
the	O
kinase	O
domains	O
in	O
Drosophila	O
obscurin	O
and	O
their	O
effect	O
on	O
the	O
structure	O
of	O
the	O
flight	O
muscle	O
.	O

Drosophila	O
obscurin	O
(	O
Unc	O
-	O
89	O
)	O
is	O
a	O
titin	O
-	O
like	O
protein	O
in	O
the	O
M	O
-	O
line	O
of	O
the	O
muscle	O
sarcomere	O
.	O

Obscurin	O
has	O
two	O
kinase	O
domains	O
near	O
the	O
C	O
-	O
terminus	O
,	O
both	O
of	O
which	O
are	O
predicted	O
to	O
be	O
inactive	O
.	O

We	O
have	O
identified	O
proteins	O
binding	O
to	O
the	O
kinase	O
domains	O
.	O

Kinase	O
domain	O
1	O
bound	O
Baellchen	O
(	O
Ball	O
,	O
an	O
active	O
kinase	O
)	O
,	O
and	O
both	O
kinase	O
domains	O
1	O
and	O
2	O
bound	O
MASK	O
(	O
a	O
400	O
-	O
kDa	O
protein	O
with	O
ankyrin	O
repeats	O
)	O
.	O

Ball	O
was	O
present	O
in	O
the	O
Z	O
-	O
disc	O
and	O
M	O
-	O
line	O
of	O
the	O
indirect	O
flight	O
muscle	O
(	O
IFM	O
)	O
and	O
was	O
diffusely	O
distributed	O
in	O
the	O
sarcomere	O
.	O

MASK	O
was	O
present	O
in	O
both	O
the	O
M	O
-	O
line	O
and	O
the	O
Z	O
-	O
disc	O
.	O

Reducing	O
expression	O
of	O
Ball	O
or	O
MASK	O
by	O
siRNA	O
resulted	O
in	O
abnormalities	O
in	O
the	O
IFM	O
,	O
including	O
missing	O
M	O
-	O
lines	O
and	O
multiple	O
Z	O
-	O
discs	O
.	O

Obscurin	O
was	O
still	O
present	O
,	O
suggesting	O
that	O
the	O
kinase	O
domains	O
act	O
as	O
a	O
scaffold	O
binding	O
Ball	O
and	O
MASK	O
.	O

Unlike	O
obscurin	O
in	O
vertebrate	O
skeletal	O
muscle	O
,	O
Drosophila	O
obscurin	O
is	O
necessary	O
for	O
the	O
correct	O
assembly	O
of	O
the	O
IFM	O
sarcomere	O
.	O

We	O
show	O
that	O
Ball	O
and	O
MASK	O
act	O
downstream	O
of	O
obscurin	O
,	O
and	O
both	O
are	O
needed	O
for	O
development	O
of	O
a	O
well	O
defined	O
M	O
-	O
line	O
and	O
Z	O
-	O
disc	O
.	O

The	O
proteins	O
have	O
not	O
previously	O
been	O
identified	O
in	O
Drosophila	O
muscle	O
.	O

(	O
A	O
)	O
Hydrolysis	O
of	O
N	O
-	O
succinyl	O
-	O
ala	O
-	O
ala	O
-	O
pro	O
-	O
phe	O
-	O
p	O
-	O
nitroanilidine	O
(	O
peptidyl	O
prolyl	O
cis	O
-	O
trans	O
isomerase	O
or	O
PPIase	O
activity	O
)	O
in	O
the	O
presence	O
of	O
4	O
.	O
34	O
nM	O
of	O
recombinant	O
AtCyp19	O
-	O
3	O
and	O
52	O
.	O
4	O
nM	O
and	O
65	O
.	O
87	O
nM	O
each	O
of	O
AtCyp19	O
-	O
3	O
(	O
35	O
-	O
176	O
)	O
and	O
AtCyp19	O
-	O
3	O
(	O
71	O
-	O
176	O
)	O
proteins	O
.	O

The	O
rate	O
of	O
reaction	O
is	O
expressed	O
as	O
first	O
order	O
rate	O
constant	O
(	O
k	O
)	O
Bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
was	O
used	O
as	O
a	O
negative	O
control	O
.	O

(	O
B	O
)	O
Effect	O
of	O
purified	O
AtCyp19	O
-	O
3	O
on	O
rate	O
constant	O
.	O

(	O
C	O
)	O
Effect	O
of	O
cyclophilin	O
inhibitor	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
,	O
and	O
FKBP	O
inhibitor	O
,	O
FK506	O
,	O
on	O
the	O
PPIase	O
activity	O
of	O
AtCyp19	O
-	O
3	O
(	O
D	O
)	O
Determination	O
of	O
inhibition	O
constant	O
(	O
ki	O
)	O
of	O
AtCyp19	O
-	O
3	O
for	O
CsA	O
.	O

Inhibition	O
constant	O
(	O
ki	O
)	O
for	O
CsA	O
was	O
determined	O
as	O
gradient	O
of	O
the	O
line	O
of	O
the	O
best	O
fit	O
from	O
a	O
plot	O
of	O
[	O
CsA	O
]	O
/	O
(	O
1	O
-	O
k	O
/	O
ko	O
)	O
against	O
ko	O
/	O
k	O
,	O
where	O
k	O
is	O
the	O
rate	O
constant	O
at	O
any	O
given	O
CsA	O
concentration	O
and	O
ko	O
is	O
the	O
rate	O
constant	O
in	O
the	O
absence	O
of	O
CsA	O
.	O

The	O
slope	O
of	O
the	O
line	O
represents	O
the	O
ki	O
.	O

The	O
catalytic	O
domain	O
of	O
MLL4	O
(	O
tag	O
)	O
adopts	O
the	O
canonical	O
beta	O
-	O
fold	O
structure	O
observed	O
for	O
other	O
SET	O
domains	O
,	O
and	O
closely	O
resembles	O
that	O
of	O
MLL1	O
(	O
Figures	O
3C	O
and	O
3D	O
)	O
.	O

The	O
N	O
-	O
flanking	O
region	O
of	O
MLL4	O
forms	O
an	O
extended	O
helical	O
structure	O
,	O
and	O
is	O
markedly	O
different	O
from	O
the	O
extended	O
loop	O
observed	O
for	O
MLL1	O
.	O

Conserved	O
features	O
include	O
the	O
cofactor	O
binding	O
site	O
,	O
which	O
is	O
located	O
in	O
a	O
surface	O
pocket	O
created	O
by	O
the	O
intersection	O
of	O
the	O
SET	O
-	O
N	O
,	O
SET	O
-	O
C	O
,	O
and	O
postSET	O
domains	O
.	O

The	O
position	O
of	O
the	O
substrate	O
binding	O
channel	O
is	O
located	O
between	O
the	O
SET	O
-	O
I	O
and	O
postSET	O
domains	O
,	O
and	O
is	O
indicated	O
in	O
Figure	O
3C	O
.	O

The	O
C	O
-	O
terminal	O
tag	O
immediately	O
follows	O
the	O
conserved	O
Cys4Zn	O
cluster	O
and	O
enters	O
the	O
substrate	O
binding	O
channel	O
before	O
turning	O
and	O
passing	O
over	O
the	O
cofactor	O
.	O

The	O
tag	O
was	O
required	O
for	O
crystallization	O
but	O
resulted	O
in	O
a	O
catalytically	O
dead	O
construct	O
(	O
Figure	O
3B	O
)	O
,	O
and	O
its	O
impact	O
on	O
the	O
MLL4	O
SET	O
domain	O
structure	O
and	O
activity	O
is	O
discussed	O
in	O
detail	O
in	O
Figure	O
S3	O
.	O

An	O
equivalent	O
MLL4	O
construct	O
prepared	O
with	O
an	O
N	O
-	O
terminal	O
tag	O
,	O
like	O
the	O
MLL4	O
(	O
WIN	O
)	O
construct	O
,	O
had	O
high	O
intrinsic	O
activity	O
(	O
Figure	O
3B	O
)	O
,	O
indicating	O
that	O
the	O
determinants	O
of	O
this	O
intrinsic	O
activity	O
are	O
contained	O
within	O
this	O
region	O
of	O
the	O
SET	O
domain	O
.	O

The	O
lack	O
of	O
methyltransferase	O
activity	O
observed	O
with	O
the	O
C	O
-	O
terminally	O
tagged	O
construct	O
can	O
be	O
attributed	O
to	O
partial	O
blocking	O
of	O
the	O
substrate	O
binding	O
channel	O
and	O
interactions	O
with	O
the	O
cofactor	O
.	O

A	O
positive	O
effect	O
of	O
TRIM21	O
concerning	O
the	O
field	O
of	O
oncology	O
could	O
be	O
shown	O
by	O
cell	O
cycle	O
analysis	O
.	O

Within	O
this	O
test	O
a	O
correlation	O
between	O
TRIM21	O
concentration	O
and	O
a	O
higher	O
amount	O
of	O
resting	O
cells	O
in	O
G0	O
/	O
G1	O
-	O
phase	O
and	O
a	O
decrease	O
of	O
cells	O
in	O
S	O
-	O
phase	O
could	O
be	O
shown	O
.	O

A	O
contrary	O
effect	O
of	O
TRIM21	O
was	O
predicted	O
by	O
Sabile	O
et	O
al	O
,	O
who	O
described	O
TRIM21	O
as	O
an	O
essential	O
mediator	O
of	O
ubiquitinylation	O
for	O
phosphorylated	O
p27	O
,	O
a	O
tumor	O
-	O
suppressor	O
which	O
prevents	O
cells	O
from	O
entering	O
S	O
-	O
phase	O
.	O

To	O
examine	O
how	O
TRIM21	O
is	O
actually	O
expressed	O
in	O
breast	O
tumors	O
throughout	O
different	O
degrees	O
of	O
malignity	O
,	O
corresponding	O
tissue	O
samples	O
were	O
obtained	O
from	O
US	O
Biomax	O
,	O
Inc	O
.	O
and	O
TRIM21	O
was	O
detected	O
using	O
fluorescence	O
labeled	O
antibodies	O
against	O
TRIM21	O
.	O

The	O
expression	O
levels	O
of	O
TRIM21	O
do	O
not	O
differ	O
distinctly	O
throughout	O
the	O
different	O
degrees	O
of	O
malignity	O
of	O
the	O
inflamed	O
tissue	O
sample	O
but	O
all	O
of	O
these	O
samples	O
show	O
only	O
around	O
half	O
of	O
the	O
expression	O
levels	O
,	O
compared	O
to	O
native	O
tissue	O
.	O

The	O
results	O
we	O
obtained	O
are	O
,	O
however	O
,	O
more	O
consistent	O
with	O
the	O
fact	O
that	O
TRIM21	O
inhibits	O
activation	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
,	O
a	O
family	O
of	O
transcription	O
factors	O
which	O
are	O
mainly	O
responsible	O
for	O
the	O
activation	O
and	O
promotion	O
of	O
cell	O
division	O
.	O

That	O
the	O
protein	O
form	O
of	O
TRIM21	O
can	O
be	O
transported	O
into	O
the	O
cell	O
could	O
be	O
shown	O
by	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
array	O
.	O

The	O
inhibiting	O
effect	O
of	O
TRIM21	O
towards	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
becomes	O
clear	O
due	O
to	O
the	O
decrease	O
in	O
expression	O
of	O
the	O
analyzed	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
-	O
regulated	O
genes	O
.	O

A	O
possible	O
mode	O
of	O
regulation	O
of	O
LFG	O
expression	O
by	O
TRIM21	O
could	O
be	O
achieved	O
by	O
inhibition	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
-	O
activation	O
.	O

As	O
the	O
expression	O
of	O
LFG	O
is	O
regulated	O
partly	O
by	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
,	O
its	O
inhibition	O
by	O
TRIM21	O
,	O
as	O
shown	O
by	O
Niida	O
et	O
al	O
,	O
could	O
follow	O
the	O
schema	O
displayed	O
in	O
.	O

The	O
reduced	O
activity	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
would	O
therefore	O
result	O
in	O
a	O
reduced	O
expression	O
of	O
LFG	O
.	O

This	O
hypothesis	O
however	O
,	O
does	O
not	O
involve	O
an	O
interaction	O
between	O
the	O
two	O
proteins	O
.	O

The	O
first	O
distinction	O
is	O
the	O
manner	O
in	O
which	O
the	O
surface	O
of	O
the	O
S1	O
-	O
S4	O
domain	O
forms	O
its	O
contacts	O
with	O
the	O
pore	O
.	O

In	O
the	O
Kv	O
channel	O
the	O
voltage	O
sensor	O
'	O
s	O
interaction	O
with	O
the	O
pore	O
occurs	O
mainly	O
through	O
the	O
extracellular	O
half	O
of	O
S1	O
and	O
through	O
the	O
S4	O
-	O
S5	O
linker	O
(	O
Fig	O
.	O
3	O
)	O
.	O

This	O
configuration	O
leaves	O
the	O
charged	O
S4	O
helix	O
free	O
to	O
move	O
in	O
response	O
to	O
voltage	O
differences	O
across	O
the	O
membrane	O
and	O
exert	O
force	O
on	O
the	O
S4	O
-	O
S5	O
linker	O
to	O
gate	O
the	O
channel	O
.	O

In	O
Slo2	O
.	O
2	O
the	O
extracellular	O
half	O
of	O
S1	O
,	O
nearly	O
the	O
entire	O
S4	O
,	O
and	O
a	O
helix	O
from	O
the	O
S1	O
-	O
S2	O
connecting	O
segment	O
form	O
an	O
extensive	O
contact	O
surface	O
with	O
the	O
pore	O
.	O

The	O
Kv	O
voltage	O
sensor	O
and	O
Slo2	O
.	O
2	O
S1	O
-	O
S4	O
domains	O
have	O
essentially	O
the	O
same	O
helical	O
structure	O
,	O
but	O
their	O
different	O
orientations	O
with	O
respect	O
to	O
the	O
pore	O
reconfigure	O
the	O
contact	O
surface	O
(	O
Fig	O
.	O
3	O
)	O
.	O

In	O
Slo2	O
.	O
2	O
S4	O
runs	O
antiparallel	O
to	O
and	O
in	O
close	O
contact	O
with	O
S5	O
,	O
as	O
if	O
its	O
function	O
is	O
to	O
help	O
glue	O
the	O
S1	O
-	O
S4	O
domain	O
to	O
the	O
pore	O
rather	O
than	O
to	O
provide	O
a	O
mobile	O
voltage	O
sensor	O
.	O

This	O
possibility	O
is	O
consistent	O
with	O
the	O
amino	O
acid	O
sequence	O
of	O
Slo2	O
.	O
2	O
,	O
which	O
shows	O
two	O
positive	O
and	O
two	O
negative	O
charged	O
amino	O
acids	O
in	O
or	O
near	O
S4	O
instead	O
of	O
the	O
excess	O
positive	O
charges	O
observed	O
in	O
Kv	O
channel	O
S4s	O
and	O
in	O
the	O
S4	O
sequence	O
of	O
Slo1	O
and	O
Slo3	O
.	O

Further	O
,	O
mutations	O
involving	O
these	O
positive	O
and	O
negative	O
charges	O
in	O
Slo2	O
.	O
2	O
do	O
not	O
produce	O
large	O
changes	O
in	O
voltage	O
-	O
dependence	O
.	O

Thus	O
,	O
S1	O
-	O
S4	O
does	O
not	O
appear	O
to	O
function	O
as	O
a	O
mobile	O
voltage	O
sensor	O
in	O
Slo2	O
.	O
2	O
.	O

We	O
further	O
note	O
a	O
surprising	O
observation	O
,	O
which	O
may	O
be	O
related	O
to	O
the	O
differences	O
in	O
S4	O
:	O
we	O
cannot	O
detect	O
cryo	O
-	O
EM	O
density	O
for	O
an	O
S4	O
-	O
S5	O
helical	O
linker	O
in	O
Slo2	O
.	O
2	O
.	O

Higher	O
resolution	O
data	O
will	O
be	O
required	O
to	O
tell	O
whether	O
this	O
linker	O
is	O
partially	O
disordered	O
or	O
simply	O
not	O
present	O
as	O
a	O
helix	O
.	O

Its	O
absence	O
in	O
Slo2	O
.	O
2	O
is	O
conspicuous	O
,	O
and	O
implies	O
that	O
this	O
region	O
serves	O
a	O
different	O
function	O
than	O
in	O
Kv	O
channels	O
.	O

According	O
to	O
the	O
analysis	O
of	O
ccRCC	O
patient	O
data	O
obtained	O
from	O
TCGA	O
,	O
lower	O
Arkadia	O
expression	O
correlated	O
with	O
advanced	O
cancer	O
stage	O
,	O
but	O
Arkadia	O
was	O
expressed	O
in	O
all	O
ccRCC	O
tumors	O
(	O
Figure	O
5h	O
)	O
,	O
in	O
agreement	O
with	O
the	O
findings	O
that	O
Arkadia	O
suppresses	O
ccRCC	O
tumor	O
proliferation	O
.	O

To	O
determine	O
whether	O
Arkadia	O
functions	O
as	O
a	O
tumor	O
suppressor	O
in	O
ccRCC	O
,	O
we	O
performed	O
a	O
Kaplan	O
-	O
Meier	O
survival	O
analysis	O
using	O
the	O
RNA	O
-	O
seq	O
data	O
and	O
clinical	O
data	O
obtained	O
from	O
TCGA	O
.	O

Although	O
Arkadia	O
mRNA	O
expression	O
did	O
not	O
correlate	O
with	O
ESRP2	O
mRNA	O
expression	O
(	O
Supplementary	O
Figure	O
S9	O
)	O
,	O
higher	O
expression	O
of	O
Arkadia	O
mRNA	O
correlated	O
with	O
better	O
patient	O
prognosis	O
(	O
Figure	O
5i	O
)	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
splicing	O
function	O
of	O
ESRP2	O
promoted	O
by	O
Arkadia	O
results	O
in	O
tumor	O
suppression	O
and	O
a	O
better	O
outcome	O
for	O
ccRCC	O
patients	O
.	O

Although	O
CD133	O
is	O
a	O
putative	O
marker	O
for	O
CSCs	O
in	O
many	O
distinct	O
solid	O
tumor	O
types	O
and	O
is	O
associated	O
with	O
aggressive	O
cancers	O
and	O
poor	O
prognosis	O
,	O
the	O
precise	O
function	O
of	O
CD133	O
in	O
tumor	O
formation	O
remained	O
unknown	O
.	O

We	O
first	O
examined	O
whether	O
CD133	O
expression	O
is	O
essential	O
for	O
NTERA2	O
tumor	O
cell	O
growth	O
by	O
measuring	O
bromodeoxyuridine	O
(	O
BrdU	O
)	O
incorporation	O
in	O
cells	O
transfected	O
with	O
CD133	O
siRNA	O
(	O
Figure	O
5a	O
)	O
.	O

Twenty	O
-	O
six	O
percent	O
of	O
the	O
CD133	O
knockdown	O
cells	O
were	O
BrdU	O
positive	O
while	O
70	O
%	O
of	O
the	O
control	O
cells	O
were	O
BrdU	O
positive	O
(	O
Figure	O
5b	O
)	O
;	O
these	O
data	O
were	O
corroborated	O
in	O
NCCIT	O
cells	O
(	O
Supplementary	O
Figure	O
5a	O
)	O
.	O

Bub3	O
-	O
BubR1	O
-	O
dependent	O
sequestration	O
of	O
Cdc20Fizzy	O
at	O
DNA	O
breaks	O
facilitates	O
the	O
correct	O
segregation	O
of	O
broken	O
chromosomes	O
.	O

The	O
presence	O
of	O
DNA	O
double	O
-	O
strand	O
breaks	O
during	O
mitosis	O
is	O
particularly	O
challenging	O
for	O
the	O
cell	O
,	O
as	O
it	O
produces	O
broken	O
chromosomes	O
lacking	O
a	O
centromere	O
.	O

This	O
situation	O
can	O
cause	O
genomic	O
instability	O
resulting	O
from	O
improper	O
segregation	O
of	O
the	O
broken	O
fragments	O
into	O
daughter	O
cells	O
.	O

We	O
recently	O
uncovered	O
a	O
process	O
by	O
which	O
broken	O
chromosomes	O
are	O
faithfully	O
transmitted	O
via	O
the	O
BubR1	O
-	O
dependent	O
tethering	O
of	O
the	O
two	O
broken	O
chromosome	O
ends	O
.	O

However	O
,	O
the	O
mechanisms	O
underlying	O
BubR1	O
recruitment	O
and	O
function	O
on	O
broken	O
chromosomes	O
were	O
largely	O
unknown	O
.	O

We	O
show	O
that	O
BubR1	O
requires	O
interaction	O
with	O
Bub3	O
to	O
localize	O
on	O
the	O
broken	O
chromosome	O
fragments	O
and	O
to	O
mediate	O
their	O
proper	O
segregation	O
.	O

We	O
also	O
find	O
that	O
Cdc20	O
,	O
a	O
cofactor	O
of	O
the	O
E3	O
ubiquitin	O
ligase	O
anaphase	B-Complex
-	I-Complex
promoting	I-Complex
complex	I-Complex
/	I-Complex
cyclosome	I-Complex
(	O
APC	B-Complex
/	I-Complex
C	I-Complex
)	O
,	O
accumulates	O
on	O
DNA	O
breaks	O
in	O
a	O
BubR1	O
KEN	O
box	O
-	O
dependent	O
manner	O
.	O

A	O
biosensor	O
for	O
APC	B-Complex
/	I-Complex
C	I-Complex
activity	O
demonstrates	O
a	O
BubR1	O
-	O
dependent	O
local	O
inhibition	O
of	O
APC	B-Complex
/	I-Complex
C	I-Complex
around	O
the	O
segregating	O
broken	O
chromosome	O
.	O

We	O
therefore	O
propose	O
that	O
the	O
Bub3	O
-	O
BubR1	O
complex	O
on	O
broken	O
DNA	O
inhibits	O
the	O
APC	B-Complex
/	I-Complex
C	I-Complex
locally	O
via	O
the	O
sequestration	O
of	O
Cdc20	O
,	O
thus	O
promoting	O
proper	O
transmission	O
of	O
broken	O
chromosomes	O
.	O

All	O
ras	O
proteins	O
are	O
polyisoprenylated	O
but	O
only	O
some	O
are	O
palmitoylated	O
.	O

The	O
C	O
-	O
terminal	O
CAAX	O
motif	O
of	O
the	O
yeast	O
mating	O
factors	O
is	O
modified	O
by	O
proteolysis	O
to	O
remove	O
the	O
three	O
terminal	O
amino	O
acids	O
(	O
-	O
AAX	O
)	O
leaving	O
a	O
C	O
-	O
terminal	O
cysteine	O
residue	O
that	O
is	O
polyisoprenylated	O
and	O
carboxyl	O
-	O
methylated	O
.	O

Here	O
we	O
show	O
that	O
all	O
ras	O
proteins	O
are	O
polyisoprenylated	O
on	O
their	O
C	O
-	O
terminal	O
cysteine	O
(	O
Cys186	O
)	O
.	O

Mutational	O
analysis	O
shows	O
palmitoylation	O
does	O
not	O
take	O
place	O
on	O
Cys186	O
as	O
previously	O
thought	O
but	O
on	O
cysteine	O
residues	O
contained	O
in	O
the	O
hypervariable	O
domain	O
of	O
some	O
ras	O
proteins	O
.	O

The	O
major	O
expressed	O
form	O
of	O
c	O
-	O
K	O
-	O
ras	O
(	O
exon	O
4B	O
)	O
does	O
not	O
have	O
a	O
cysteine	O
residue	O
immediately	O
upstream	O
of	O
Cys186	O
and	O
is	O
not	O
palmitoylated	O
.	O

Polyisoprenylated	O
but	O
nonpalmitoylated	O
H	O
-	O
ras	O
proteins	O
are	O
biologically	O
active	O
and	O
associate	O
weakly	O
with	O
cell	O
membranes	O
.	O

Palmitoylation	O
increases	O
the	O
avidity	O
of	O
this	O
binding	O
and	O
enhances	O
their	O
transforming	O
activity	O
.	O

Polyisoprenylation	O
is	O
essential	O
for	O
biological	O
activity	O
as	O
inhibiting	O
the	O
biosynthesis	O
of	O
polyisoprenoids	O
abolishes	O
membrane	O
association	O
of	O
p21ras	O
.	O

Previously	O
we	O
uncovered	O
genes	O
required	O
for	O
the	O
trafficking	O
of	O
the	O
vesicle	O
soluble	O
N	O
-	O
ethylmaleimide	O
-	O
sensitive	O
factor	O
attachment	O
protein	O
receptor	O
(	O
v	O
-	O
SNARE	O
)	O
Snc1	O
in	O
a	O
genome	O
-	O
wide	O
screen	O
that	O
assessed	O
changes	O
in	O
the	O
surface	O
levels	O
of	O
the	O
GFP	O
-	O
Snc1	O
-	O
Suc2	O
(	O
GSS	O
)	O
reporter	O
protein	O
.	O

Genetic	O
and	O
physical	O
interaction	O
analysis	O
identified	O
a	O
cluster	O
of	O
four	O
genes	O
,	O
representing	O
three	O
AP	B-Complex
-	I-Complex
1	I-Complex
subunits	O
(	O
Apm2	O
,	O
Apl4	O
,	O
and	O
Aps1	O
)	O
and	O
the	O
uncharacterized	O
Yfl034w	O
,	O
whose	O
deletion	O
increased	O
surface	O
GSS	O
levels	O
.	O

The	O
identification	O
of	O
Apm2	O
,	O
but	O
not	O
the	O
more	O
abundant	O
mu	O
-	O
subunit	O
isoform	O
Apm1	O
,	O
was	O
unexpected	O
and	O
suggested	O
that	O
Apm2	O
-	O
containing	O
AP	B-Complex
-	I-Complex
1R	I-Complex
complex	O
has	O
a	O
specific	O
role	O
in	O
Snc1	O
sorting	O
.	O

To	O
confirm	O
these	O
observations	O
,	O
we	O
used	O
a	O
quantitative	O
assay	O
that	O
measures	O
the	O
invertase	O
(	O
Suc2	O
)	O
activity	O
of	O
GSS	O
present	O
at	O
the	O
cell	O
surface	O
(	O
Figure	O
1A	O
)	O
.	O

Loss	O
of	O
APM2	O
,	O
APL4	O
,	O
and	O
APS1	O
led	O
to	O
a	O
slight	O
but	O
significant	O
increase	O
in	O
GSS	O
surface	O
levels	O
,	O
comparable	O
to	O
that	O
of	O
the	O
endocytosis	O
mutant	O
yap1801	O
.	O

This	O
increase	O
was	O
not	O
observed	O
in	O
the	O
absence	O
of	O
APM1	O
,	O
showing	O
that	O
GSS	O
sorting	O
is	O
an	O
AP	O
-	O
1R	O
-	O
specific	O
function	O
and	O
does	O
not	O
require	O
the	O
Apm1	O
-	O
containing	O
AP	B-Complex
-	I-Complex
1	I-Complex
complex	O
,	O
which	O
we	O
will	O
refer	O
to	O
here	O
as	O
AP	B-Complex
-	I-Complex
1	I-Complex
.	O

Mcm10	O
,	O
as	O
the	O
most	O
enigmatic	O
essential	O
firing	O
factor	O
,	O
has	O
been	O
proposed	O
to	O
participate	O
in	O
a	O
novel	O
step	O
during	O
CMG	O
activation	O
and	O
origin	O
unwinding	O
through	O
Mcm10	O
depletion	O
in	O
yeast	O
and	O
Xenopus	O
.	O

To	O
directly	O
address	O
whether	O
Mcm10	O
functions	O
in	O
MCM	O
DH	O
splitting	O
prior	O
to	O
or	O
during	O
origin	O
unwinding	O
,	O
we	O
monitored	O
the	O
relative	O
DH	O
levels	O
during	O
S	O
phase	O
progression	O
in	O
a	O
conditional	O
Mcm10	O
depletion	O
background	O
.	O

We	O
combined	O
both	O
temperature	O
induced	O
(	O
td	O
)	O
and	O
auxin	O
induced	O
(	O
aid	O
)	O
degrons	O
to	O
deplete	O
endogenous	O
Mcm10	O
proteins	O
.	O

The	O
td	O
and	O
aid	O
degrons	O
were	O
turned	O
on	O
by	O
switching	O
to	O
growth	O
at	O
37degreesC	O
and	O
adding	O
indole	O
-	O
3	O
-	O
acetic	O
acid	O
(	O
IAA	O
)	O
,	O
respectively	O
.	O

The	O
Ubr1	O
and	O
Tir1	O
ubiquitin	O
ligases	O
were	O
induced	O
by	O
galactose	O
.	O

The	O
cellular	O
Mcm10	O
protein	O
was	O
barely	O
detectable	O
after	O
incubation	O
in	O
galactose	O
for	O
1h	O
and	O
shifting	O
to	O
37degreesC	O
in	O
the	O
presence	O
of	O
auxin	O
for	O
another	O
2h	O
(	O
Figure	O
2C	O
,	O
lane	O
4	O
)	O
,	O
leading	O
to	O
cell	O
death	O
in	O
the	O
absence	O
of	O
WT	O
Mcm10	O
(	O
Figure	O
S2B	O
)	O
.	O

Strikingly	O
,	O
under	O
such	O
an	O
efficient	O
Mcm10	O
depletion	O
condition	O
,	O
the	O
ratio	O
of	O
untagged	O
Mcm2	O
to	O
Mcm2	O
-	O
GFP	O
in	O
the	O
GFP	O
-	O
trap	O
remained	O
almost	O
constant	O
after	O
being	O
released	O
from	O
alpha	O
-	O
factor	O
into	O
S	O
phase	O
for	O
120	O
min	O
,	O
indicating	O
a	O
failure	O
in	O
separation	O
of	O
MCM	O
DHs	O
(	O
Figure	O
2D	O
,	O
upper	O
panel	O
and	O
2E	O
,	O
Figure	O
S2C	O
)	O
.	O

Furthermore	O
,	O
no	O
DNA	O
synthesis	O
was	O
detected	O
by	O
flow	O
cytometry	O
(	O
Figure	O
2F	O
)	O
.	O

In	O
contrast	O
,	O
if	O
WT	O
Mcm10	O
was	O
expressed	O
from	O
a	O
plasmid	O
in	O
the	O
same	O
strain	O
,	O
the	O
untagged	O
Mcm2	O
in	O
precipitates	O
decreased	O
quickly	O
upon	O
S	O
phase	O
entry	O
(	O
Figure	O
2D	O
,	O
lower	O
panel	O
and	O
2E	O
,	O
Figure	O
S2C	O
)	O
,	O
indicating	O
efficient	O
DH	O
separation	O
.	O

There	O
is	O
little	O
untagged	O
Mcm2	O
left	O
in	O
the	O
precipitates	O
at	O
60	O
min	O
,	O
which	O
correlates	O
well	O
with	O
the	O
time	O
of	O
completion	O
of	O
DNA	O
replication	O
,	O
as	O
shown	O
in	O
the	O
flow	O
cytometry	O
profiles	O
(	O
Figure	O
2F	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
an	O
essential	O
role	O
of	O
Mcm10	O
in	O
MCM	O
DH	O
splitting	O
.	O

The	O
anticodon	O
stem	O
of	O
tRNA	O
-	O
A	O
establishes	O
cross	O
-	O
subunit	O
contacts	O
with	O
the	O
catalytic	O
domain	O
of	O
MST1	O
-	O
B	O
(	O
Figure	O
1B	O
)	O
.	O

In	O
the	O
bacterial	O
complex	O
,	O
the	O
cross	O
-	O
dimer	O
interactions	O
with	O
the	O
anticodon	O
stem	O
of	O
tRNAThr	O
were	O
sequence	O
non	O
-	O
specific	O
.	O

In	O
a	O
sharp	O
contrast	O
,	O
our	O
structure	O
reveals	O
that	O
MST1	O
-	O
B	O
specifically	O
recognizes	O
the	O
first	O
two	O
base	O
pairs	O
of	O
the	O
anticodon	O
stem	O
(	O
i	O
.	O
e	O
.	O
U27	O
:	O
A43	O
and	O
U28	O
:	O
A42	O
)	O
and	O
the	O
first	O
base	O
in	O
the	O
variable	O
arm	O
(	O
i	O
.	O
e	O
.	O
A44	O
)	O
in	O
tRNA2Thr	O
(	O
Figure	O
5A	O
)	O
.	O

The	O
anticodon	O
stem	O
of	O
tRNA	O
-	O
A	O
sits	O
atop	O
alpha5	O
-	O
beta6	O
loop	O
(	O
residues	O
142	O
-	O
150	O
)	O
and	O
beta12	O
-	O
beta13	O
turn	O
(	O
residues	O
302	O
-	O
313	O
)	O
.	O

There	O
,	O
Lys306	O
forms	O
a	O
H	O
-	O
bond	O
with	O
the	O
O2	O
atom	O
in	O
the	O
base	O
of	O
U27	O
,	O
whereas	O
the	O
side	O
chain	O
of	O
Asn310	O
makes	O
contacts	O
with	O
the	O
O2	O
and	O
N3	O
atoms	O
of	O
U28	O
and	O
A43	O
,	O
respectively	O
.	O

Also	O
,	O
the	O
side	O
-	O
chain	O
NH2	O
group	O
of	O
Lys306	O
and	O
the	O
side	O
-	O
chain	O
OH	O
of	O
Tyr312	O
coordinate	O
a	O
water	O
molecule	O
that	O
,	O
in	O
turn	O
,	O
makes	O
polar	O
contacts	O
with	O
the	O
2	O
'	O
OH	O
and	O
the	O
N3	O
imino	O
of	O
A44	O
.	O

The	O
sugar	O
-	O
phosphate	O
backbone	O
flanking	O
U27	O
:	O
A43	O
,	O
U28	O
:	O
A42	O
and	O
A44	O
is	O
stabilized	O
through	O
contacts	O
with	O
side	O
chains	O
of	O
Ser146	O
,	O
Tyr147	O
and	O
Asn148	O
.	O

(	O
A	O
)	O
Rpn11	O
activation	O
during	O
proteasome	B-Complex
incorporation	O
monitored	O
by	O
ubiquitin	O
-	O
AMC	O
hydrolysis	O
.	O

Fluorescence	O
time	O
courses	O
for	O
the	O
isolated	O
WT	O
lid	O
and	O
Rpn11	O
(	O
AxA	O
)	O
lid	O
are	O
shown	O
in	O
blue	O
and	O
red	O
,	O
respectively	O
.	O

Background	O
DUB	O
activity	O
of	O
proteasomes	B-Complex
reconstituted	O
with	O
Rpn11	O
(	O
AxA	O
)	O
lid	O
is	O
shown	O
in	O
green	O
,	O
and	O
the	O
activity	O
of	O
proteasomes	B-Complex
reconstituted	O
with	O
WT	O
lid	O
is	O
shown	O
in	O
orange	O
.	O

The	O
difference	O
between	O
the	O
time	O
courses	O
for	O
proteasomes	B-Complex
reconstituted	O
with	O
WT	O
and	O
Rpn11	O
(	O
AxA	O
)	O
lid	O
corresponds	O
to	O
Rpn11	O
-	O
dependent	O
DUB	O
activity	O
.	O

(	O
B	O
)	O
Quantification	O
of	O
the	O
ubiquitin	O
-	O
AMC	O
cleavage	O
activities	O
for	O
WT	O
and	O
Rpn11	O
(	O
AxA	O
)	O
proteasomes	B-Complex
shown	O
in	O
a	O
.	O

(	O
C	O
)	O
Normalized	O
Ubiquitin	O
-	O
AMC	O
hydrolysis	O
activity	O
of	O
Rpn11	O
-	O
containing	O
complexes	O
in	O
isolation	O
(	O
grey	O
bars	O
)	O
and	O
background	O
-	O
corrected	O
activity	O
of	O
Rpn11	O
in	O
proteasomes	B-Complex
reconstituted	O
with	O
different	O
lid	O
variants	O
(	O
dark	O
grey	O
bars	O
)	O
.	O

Error	O
bars	O
in	O
b	O
and	O
c	O
correspond	O
to	O
1	O
standard	O
deviation	O
of	O
the	O
data	O
(	O
n	O
=	O
3	O
)	O
.	O

The	O
N	O
-	O
terminal	O
domain	O
of	O
BamA	O
contains	O
five	O
POTRA	O
domains	O
with	O
POTRA5	O
linked	O
to	O
the	O
membrane	O
embedded	O
C	O
-	O
terminal	O
beta	O
-	O
barrel	O
.	O

Previous	O
genetic	O
and	O
biochemical	O
data	O
suggested	O
that	O
the	O
interaction	O
with	O
BamD	O
was	O
mediated	O
by	O
POTRA5	O
.	O

BamD	O
is	O
composed	O
of	O
five	O
Tetratricopeptide	O
repeats	O
(	O
TPR	O
)	O
that	O
,	O
due	O
to	O
lipidation	O
of	O
its	O
N	O
-	O
terminal	O
cysteine	O
,	O
has	O
its	O
N	O
-	O
terminal	O
TPR	O
topologically	O
close	O
to	O
the	O
membrane	O
.	O

It	O
was	O
then	O
reasoned	O
that	O
linking	O
the	O
C	O
-	O
terminus	O
of	O
POTRA5	O
to	O
the	O
N	O
-	O
terminus	O
of	O
BamD	O
with	O
an	O
appropriately	O
long	O
,	O
flexible	O
linker	O
could	O
result	O
in	O
a	O
soluble	O
fusion	O
that	O
allows	O
formation	O
of	O
the	O
native	O
interface	O
while	O
dispensing	O
with	O
the	O
membrane	O
embedded	O
elements	O
that	O
may	O
hinder	O
crystallization	O
.	O

We	O
recently	O
utilized	O
such	O
a	O
subunit	O
fusion	O
strategy	O
to	O
successfully	O
define	O
the	O
interface	O
between	O
BamA	O
and	O
BamB	O
.	O

Choosing	O
an	O
appropriate	O
linker	O
is	O
crucial	O
,	O
as	O
one	O
that	O
is	O
too	O
short	O
would	O
prevent	O
formation	O
of	O
the	O
native	O
interface	O
while	O
an	O
overly	O
long	O
one	O
would	O
likely	O
interfere	O
with	O
crystallization	O
.	O

As	O
BamD	O
is	O
approximately	O
90	O
Aa	O
long	O
from	O
the	O
first	O
TPR	O
to	O
the	O
C	O
-	O
terminus	O
,	O
a	O
22	O
amino	O
acid	O
linker	O
was	O
initially	O
tested	O
for	O
the	O
fusions	O
.	O

With	O
a	O
stretched	O
length	O
of	O
more	O
than	O
75	O
Aa	O
,	O
it	O
would	O
accommodate	O
most	O
possible	O
orientations	O
between	O
BamA	O
and	O
BamD	O
while	O
increasing	O
the	O
"	O
local	O
concentrations	O
"	O
of	O
the	O
proteins	O
,	O
helping	O
stabilize	O
a	O
complex	O
.	O

The	O
BamA	O
periplasmic	O
domain	O
is	O
known	O
to	O
be	O
conformationally	O
flexible	O
due	O
to	O
a	O
hinge	O
between	O
POTRA2	O
and	O
POTRA3	O
.	O

Therefore	O
,	O
to	O
further	O
increase	O
the	O
chances	O
of	O
crystallization	O
,	O
fusions	O
containing	O
only	O
POTRA3	O
-	O
5	O
and	O
POTRA4	O
-	O
5	O
were	O
designed	O
in	O
addition	O
to	O
the	O
full	O
POTRA1	O
-	O
5	O
fragment	O
.	O

Screening	O
of	O
several	O
constructs	O
for	O
expression	O
and	O
crystallization	O
resulted	O
in	O
crystals	O
of	O
a	O
fusion	O
between	O
POTRA4	O
-	O
5	O
(	O
amino	O
acids	O
303	O
-	O
467	O
)	O
and	O
BamD	O
(	O
amino	O
acids	O
24	O
-	O
280	O
)	O
from	O
Rhodothermus	O
marinus	O
linked	O
by	O
a	O
22	O
amino	O
acid	O
linker	O
(	O
sequence	O
:	O
HVASGGGGSGGGGSGGGGSGTS	O
)	O
.	O

Refinement	O
of	O
the	O
crystallization	O
conditions	O
to	O
10	O
%	O
PEG	O
-	O
3000	O
,	O
15	O
%	O
2	O
-	O
Propanol	O
and	O
0	O
.	O
1	O
M	O
HEPES	O
pH	O
5	O
.	O
6	O
yielded	O
single	O
crystals	O
suitable	O
for	O
X	O
-	O
ray	O
diffraction	O
analysis	O
.	O

A	O
native	O
dataset	O
to	O
2	O
.	O
0	O
Aa	O
resolution	O
was	O
collected	O
from	O
cryoprotected	O
crystals	O
using	O
synchrotron	O
radiation	O
.	O

Data	O
collection	O
statistics	O
are	O
shown	O
in	O
Table	O
1	O
.	O

We	O
analyzed	O
the	O
MUC5AC	O
expression	O
in	O
lung	O
cancer	O
patient	O
tissues	O
.	O

Clinical	O
information	O
was	O
available	O
on	O
21	O
patients	O
with	O
a	O
median	O
age	O
at	O
diagnosis	O
of	O
63	O
years	O
(	O
range	O
:	O
44	O
-	O
79	O
years	O
)	O
.	O

Survival	O
information	O
was	O
available	O
on	O
20	O
patients	O
.	O

Patients	O
without	O
MUC5AC	O
expression	O
in	O
their	O
tumor	O
cells	O
had	O
a	O
longer	O
survival	O
compared	O
with	O
MUC5AC	O
expressing	O
tumors	O
(	O
P	O
=	O
0	O
.	O
029	O
)	O
.	O

Five	O
-	O
year	O
overall	O
survival	O
for	O
MUC5AC	O
-	O
negative	O
patients	O
was	O
93	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
59	O
-	O
99	O
%	O
)	O
compared	O
with	O
67	O
%	O
in	O
the	O
MUC5AC	O
expressing	O
patients	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
19	O
-	O
90	O
%	O
)	O
(	O
Figure	O
2a	O
)	O
,	O
indicating	O
that	O
MUC5AC	O
is	O
a	O
prognostic	O
marker	O
for	O
worse	O
outcomes	O
in	O
lung	O
cancer	O
.	O

The	O
following	O
mouse	O
monoclonal	O
antibodies	O
(	O
mAb	O
)	O
were	O
used	O
in	O
flow	O
cytometry	O
:	O
W6	O
/	O
32	O
,	O
anti	O
-	O
human	O
HLA	O
-	O
Class	O
I	O
;	O
1E8	O
,	O
anti	O
-	O
human	O
cytokeratin	O
8	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
;	O
DA	O
-	O
7	O
,	O
anti	O
-	O
human	O
cytokeratin	O
18	O
(	O
Biolegend	O
)	O
;	O
BA	O
-	O
17	O
anti	O
-	O
human	O
cytokeratin	O
19	O
,	O
(	O
R	O
&	O
D	O
systems	O
and	O
an	O
IgG2a	O
isotype	O
control	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
.	O

The	O
rabbit	O
monoclonal	O
antibody	O
EPR4628	O
,	O
anti	O
-	O
human	O
farnesly	O
diphosphate	O
synthase	O
(	O
FDPS	O
)	O
(	O
GeneTex	O
,	O
Irvine	O
,	O
CA	O
,	O
USA	O
)	O
,	O
was	O
used	O
alongside	O
negative	O
control	O
rabbit	O
IgG	B-Complex
(	O
Sigma	O
-	O
Aldrich	O
)	O
.	O

Profilin	O
-	O
PTEN	O
interaction	O
suppresses	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
via	O
inhibition	O
of	O
IKK	B-Complex
phosphorylation	O
.	O

The	O
molecular	O
mechanism	O
of	O
Profilin	O
for	O
its	O
tumour	O
suppressor	O
activity	O
is	O
still	O
unknown	O
.	O

Nuclear	B-Complex
transcription	I-Complex
factor	I-Complex
kappaB	I-Complex
(	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
)	O
is	O
known	O
to	O
activate	O
many	O
target	O
genes	O
involved	O
in	O
cell	O
proliferation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
provide	O
evidence	O
that	O
supports	O
the	O
involvement	O
of	O
Profilin	O
in	O
regulation	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
,	O
which	O
might	O
repress	O
the	O
tumorigenic	O
response	O
.	O

Profilin	O
overexpressing	O
cells	O
show	O
low	O
basal	O
activity	O
of	O
IkappaBalpha	B-Complex
kinase	I-Complex
(	O
IKK	B-Complex
)	O
,	O
high	O
amounts	O
of	O
cytoplasmic	O
inhibitory	O
subunit	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
(	O
IkappaBalpha	O
)	O
and	O
p65	O
,	O
and	O
low	O
nuclear	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
DNA	O
binding	O
activity	O
.	O

Co	O
-	O
localization	O
and	O
co	O
-	O
immunoprecipitation	O
(	O
Co	O
-	O
IP	O
)	O
studies	O
suggest	O
that	O
Profilin	O
interacts	O
with	O
a	O
protein	O
phosphatase	O
,	O
phosphatase	O
and	O
tension	O
homologue	O
(	O
PTEN	O
)	O
,	O
and	O
protects	O
it	O
from	O
degradation	O
.	O

In	O
turn	O
,	O
PTEN	O
interacts	O
physically	O
and	O
maintains	O
a	O
low	O
phosphorylated	O
state	O
of	O
the	O
IKK	B-Complex
complex	O
and	O
thereby	O
suppresses	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
signalling	O
.	O

Thus	O
,	O
Profilin	O
overexpressing	O
cells	O
show	O
a	O
decrease	O
in	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
mediated	O
by	O
most	O
of	O
the	O
inducers	O
and	O
potentiate	O
cell	O
death	O
by	O
repressing	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
-	O
dependent	O
genes	O
involved	O
in	O
cell	O
cycle	O
progression	O
.	O

For	O
the	O
first	O
time	O
,	O
we	O
provide	O
evidence	O
,	O
which	O
suggests	O
that	O
Profilin	O
increases	O
tumour	O
suppressor	O
activity	O
by	O
regulating	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
.	O

No	O
density	O
was	O
observed	O
for	O
the	O
N	O
-	O
terminal	O
TMD0	O
domain	O
of	O
both	O
TAP1	O
and	O
TAP2	O
subunits	O
(	O
Fig	O
2	O
)	O
.	O

Studies	O
have	O
shown	O
that	O
the	O
TMD0s	O
are	O
essential	O
to	O
the	O
assembly	O
of	O
the	O
large	O
peptide	O
-	O
loading	O
complex	O
but	O
dispensable	O
in	O
peptide	O
translocation	O
.	O

ICP47	O
inhibits	O
both	O
full	O
-	O
length	O
TAP	O
and	O
the	O
core	O
construct	O
.	O

Our	O
results	O
indicate	O
that	O
in	O
the	O
absence	O
of	O
tapasin	O
the	O
two	O
TMD0s	O
are	O
flexibly	O
tethered	O
to	O
the	O
core	O
region	O
of	O
TAP	O
.	O

The	O
question	O
of	O
how	O
dPIS	O
overexpression	O
could	O
change	O
the	O
level	O
of	O
PA	O
,	O
via	O
even	O
a	O
potential	O
alternative	O
pathway	O
,	O
is	O
still	O
unanswered	O
.	O

It	O
was	O
shown	O
in	O
yeast	O
that	O
the	O
amount	O
of	O
PA	O
can	O
transcriptionally	O
regulate	O
the	O
level	O
of	O
PI	O
synthase	O
.	O

The	O
soluble	O
transcriptional	O
repressor	O
Opi1p	O
is	O
inhibited	O
by	O
binding	O
to	O
PA	O
at	O
the	O
ER	O
,	O
but	O
can	O
rapidly	O
translocate	O
into	O
the	O
nucleus	O
in	O
response	O
to	O
inositol	O
-	O
induced	O
PA	O
consumption	O
.	O

In	O
the	O
Drosophila	O
retina	O
,	O
a	O
mutation	O
of	O
the	O
lipid	O
phosphate	O
phosphohydrolase	O
led	O
to	O
elevated	O
PA	O
levels	O
,	O
which	O
were	O
coupled	O
with	O
PI	O
synthase	O
transcript	O
upregulation	O
.	O

This	O
suggests	O
that	O
the	O
level	O
of	O
PA	O
and	O
the	O
level	O
of	O
PI	O
synthase	O
transcription	O
are	O
somehow	O
connected	O
with	O
each	O
other	O
.	O

This	O
is	O
consistent	O
with	O
our	O
results	O
,	O
where	O
dPIS	O
is	O
slightly	O
upregulated	O
in	O
the	O
CdsAms1	O
mutant	O
.	O

However	O
,	O
because	O
of	O
the	O
transcriptional	O
shut	O
-	O
off	O
after	O
meiosis	O
,	O
the	O
cells	O
are	O
probably	O
not	O
able	O
to	O
compensate	O
the	O
elevated	O
PA	O
level	O
in	O
the	O
mutant	O
by	O
increasing	O
the	O
amount	O
of	O
dPIS	O
and	O
other	O
factors	O
.	O

One	O
possible	O
strategy	O
to	O
find	O
the	O
precise	O
biochemical	O
pathway	O
responsible	O
for	O
the	O
suppression	O
of	O
male	O
sterility	O
of	O
CdsAms1	O
by	O
overexpression	O
of	O
dPIS	O
would	O
be	O
to	O
correlate	O
the	O
lipidomic	O
observations	O
with	O
testis	O
-	O
specific	O
gene	O
expression	O
or	O
proteomic	O
analysis	O
of	O
transcription	O
factors	O
,	O
as	O
well	O
as	O
lipid	O
metabolic	O
enzymes	O
and	O
their	O
regulators	O
.	O

Finally	O
,	O
to	O
determine	O
whether	O
the	O
observed	O
increase	O
in	O
mitochondrial	O
function	O
also	O
affects	O
cellular	O
fitness	O
,	O
we	O
studied	O
the	O
growth	O
rates	O
and	O
RLS	O
of	O
mmr1Delta	O
mfb1Delta	O
cells	O
.	O

Deletion	O
of	O
MMR1	O
in	O
a	O
wild	O
-	O
type	O
background	O
results	O
in	O
two	O
populations	O
of	O
yeast	O
cells	O
.	O

One	O
population	O
exhibits	O
extended	O
RLS	O
and	O
has	O
mitochondria	O
that	O
are	O
higher	O
functioning	O
compared	O
with	O
those	O
observed	O
in	O
wild	O
-	O
type	O
cells	O
.	O

The	O
other	O
population	O
ages	O
prematurely	O
and	O
has	O
lower	O
-	O
functioning	O
mitochondria	O
.	O

We	O
find	O
that	O
there	O
is	O
no	O
short	O
-	O
lived	O
population	O
of	O
mfb1Delta	O
mmr1Delta	O
cells	O
.	O

Moreover	O
,	O
we	O
find	O
that	O
double	O
-	O
mutant	O
cells	O
exhibit	O
an	O
RLS	O
that	O
is	O
longer	O
than	O
that	O
of	O
mfb1Delta	O
cells	O
(	O
Fig	O
.	O
4e	O
)	O
.	O

Thus	O
,	O
deletion	O
of	O
MFB1	O
extends	O
RLS	O
in	O
mmr1Delta	O
cells	O
and	O
vice	O
versa	O
.	O

Deletion	O
of	O
MMR1	O
in	O
mfb1Delta	O
cells	O
also	O
rescued	O
cellular	O
growth	O
rates	O
(	O
Fig	O
.	O
4f	O
)	O
.	O

Overall	O
,	O
these	O
results	O
indicate	O
that	O
Mfb1p	O
and	O
Mmr1p	O
have	O
antagonistic	O
effects	O
in	O
controlling	O
mitochondrial	O
partitioning	O
,	O
and	O
that	O
the	O
disproportionate	O
loss	O
of	O
mitochondria	O
from	O
mother	O
cells	O
is	O
the	O
primary	O
cause	O
for	O
cellular	O
growth	O
defects	O
and	O
premature	O
ageing	O
in	O
mfb1Delta	O
cells	O
.	O

Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
nuclear	O
antigen	O
2	O
(	O
EBNA2	O
)	O
plays	O
an	O
important	O
role	O
in	O
driving	O
immortalization	O
of	O
EBV	O
-	O
infected	O
B	O
cells	O
through	O
regulating	O
the	O
expression	O
of	O
many	O
viral	O
and	O
cellular	O
genes	O
.	O

We	O
report	O
a	O
structural	O
study	O
of	O
the	O
tumor	O
suppressor	O
BS69	O
/	O
ZMYND11	O
C	O
-	O
terminal	O
region	O
,	O
comprised	O
of	O
tandem	O
coiled	O
-	O
coil	O
-	O
MYND	O
domains	O
(	O
BS69CC	O
-	O
MYND	O
)	O
,	O
in	O
complex	O
with	O
an	O
EBNA2	O
peptide	O
containing	O
a	O
PXLXP	O
motif	O
.	O

The	O
coiled	O
-	O
coil	O
domain	O
of	O
BS69	O
self	O
-	O
associates	O
to	O
bring	O
two	O
separate	O
MYND	O
domains	O
in	O
close	O
proximity	O
,	O
thereby	O
enhancing	O
the	O
BS69	O
MYND	O
-	O
EBNA2	O
interaction	O
.	O

ITC	O
analysis	O
of	O
BS69CC	O
-	O
MYND	O
with	O
a	O
C	O
-	O
terminal	O
fragment	O
of	O
EBNA2	O
further	O
suggests	O
that	O
the	O
BS69CC	O
-	O
MYND	O
homodimer	O
synergistically	O
binds	O
to	O
the	O
two	O
EBNA2	O
PXLXP	O
motifs	O
that	O
are	O
respectively	O
located	O
in	O
the	O
conserved	O
regions	O
CR7	O
and	O
CR8	O
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
EBNA2	O
interacts	O
with	O
BS69	O
and	O
down	O
-	O
regulates	O
its	O
expression	O
at	O
both	O
mRNA	O
and	O
protein	O
levels	O
in	O
EBV	O
-	O
infected	O
B	O
cells	O
.	O

Ectopic	O
BS69CC	O
-	O
MYND	O
is	O
recruited	O
to	O
viral	O
target	O
promoters	O
through	O
interactions	O
with	O
EBNA2	O
,	O
inhibits	O
EBNA2	O
-	O
mediated	O
transcription	O
activation	O
,	O
and	O
impairs	O
proliferation	O
of	O
lymphoblastoid	O
cell	O
lines	O
(	O
LCLs	O
)	O
.	O

Substitution	O
of	O
critical	O
residues	O
in	O
the	O
MYND	O
domain	O
impairs	O
the	O
BS69	O
-	O
EBNA2	O
interaction	O
and	O
abolishes	O
the	O
BS69	O
inhibition	O
of	O
the	O
EBNA2	O
-	O
mediated	O
transactivation	O
and	O
LCL	O
proliferation	O
.	O

This	O
study	O
identifies	O
the	O
BS69	O
C	O
-	O
terminal	O
domains	O
as	O
an	O
inhibitor	O
of	O
EBNA2	O
,	O
which	O
may	O
have	O
important	O
implications	O
in	O
development	O
of	O
novel	O
therapeutic	O
strategies	O
against	O
EBV	O
infection	O
.	O

CHIP	O
controls	O
necroptosis	O
through	O
ubiquitylation	O
-	O
and	O
lysosome	O
-	O
dependent	O
degradation	O
of	O
RIPK3	O
.	O

Receptor	O
-	O
interacting	O
protein	O
kinase	O
3	O
(	O
RIPK3	O
)	O
functions	O
as	O
a	O
key	O
regulator	O
of	O
necroptosis	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
RIPK3	O
expression	O
level	O
is	O
negatively	O
regulated	O
by	O
CHIP	O
(	O
carboxyl	O
terminus	O
of	O
Hsp70	O
-	O
interacting	O
protein	O
;	O
also	O
known	O
as	O
STUB1	O
)	O
E3	O
ligase	O
-	O
mediated	O
ubiquitylation	O
.	O

Chip	O
(	O
-	O
/	O
-	O
)	O
mouse	O
embryonic	O
fibroblasts	O
and	O
CHIP	O
-	O
depleted	O
L929	O
and	O
HT	O
-	O
29	O
cells	O
exhibited	O
higher	O
levels	O
of	O
RIPK3	O
expression	O
,	O
resulting	O
in	O
increased	O
sensitivity	O
to	O
necroptosis	O
induced	O
by	O
TNF	O
(	O
also	O
known	O
as	O
TNFalpha	O
)	O
.	O

These	O
phenomena	O
are	O
due	O
to	O
the	O
CHIP	O
-	O
mediated	O
ubiquitylation	O
of	O
RIPK3	O
,	O
which	O
leads	O
to	O
its	O
lysosomal	O
degradation	O
.	O

Interestingly	O
,	O
RIPK1	O
expression	O
is	O
also	O
negatively	O
regulated	O
by	O
CHIP	O
-	O
mediated	O
ubiquitylation	O
,	O
validating	O
the	O
major	O
role	O
of	O
CHIP	O
in	O
necrosome	O
formation	O
and	O
sensitivity	O
to	O
TNF	O
-	O
mediated	O
necroptosis	O
.	O

Chip	O
(	O
-	O
/	O
-	O
)	O
mice	O
(	O
C57BL	O
/	O
6	O
)	O
exhibit	O
inflammation	O
in	O
the	O
thymus	O
and	O
massive	O
cell	O
death	O
and	O
disintegration	O
in	O
the	O
small	O
intestinal	O
tract	O
,	O
and	O
die	O
within	O
a	O
few	O
weeks	O
after	O
birth	O
.	O

These	O
phenotypes	O
are	O
rescued	O
by	O
crossing	O
with	O
Ripk3	O
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

These	O
results	O
imply	O
that	O
CHIP	O
is	O
a	O
bona	O
fide	O
negative	O
regulator	O
of	O
the	O
RIPK1	O
-	O
RIPK3	O
necrosome	O
formation	O
leading	O
to	O
desensitization	O
of	O
TNF	O
-	O
mediated	O
necroptosis	O
.	O

Characterization	O
of	O
the	O
mammalian	O
family	O
of	O
DCN	O
-	O
type	O
NEDD8	O
E3	O
ligases	O
.	O

Cullin	O
-	O
RING	O
ligases	O
(	O
CRL	O
)	O
are	O
ubiquitin	O
E3	O
enzymes	O
that	O
bind	O
substrates	O
through	O
variable	O
substrate	O
receptor	O
proteins	O
and	O
are	O
activated	O
by	O
attachment	O
of	O
the	O
ubiquitin	O
-	O
like	O
protein	O
NEDD8	O
to	O
the	O
cullin	O
subunit	O
.	O

DCNs	O
are	O
NEDD8	O
E3	O
ligases	O
that	O
promote	O
neddylation	O
.	O

Mammalian	O
cells	O
express	O
five	O
DCN	O
-	O
like	O
(	O
DCNL	O
)	O
proteins	O
but	O
little	O
is	O
known	O
about	O
their	O
specific	O
functions	O
or	O
interaction	O
partners	O
.	O

We	O
found	O
that	O
DCNLs	O
form	O
stable	O
stoichiometric	O
complexes	O
with	O
CAND1	O
and	O
cullins	O
that	O
can	O
only	O
be	O
neddylated	O
in	O
the	O
presence	O
of	O
a	O
substrate	O
adaptor	O
.	O

These	O
CAND	O
-	O
cullin	O
-	O
DCNL	O
complexes	O
might	O
represent	O
'	O
reserve	O
'	O
CRLs	O
that	O
can	O
be	O
rapidly	O
activated	O
when	O
needed	O
.	O

We	O
further	O
found	O
that	O
all	O
DCNLs	O
interact	O
with	O
most	O
cullin	O
subtypes	O
,	O
but	O
that	O
they	O
are	O
probably	O
responsible	O
for	O
the	O
neddylation	O
of	O
different	O
subpopulations	O
of	O
any	O
given	O
cullin	O
.	O

This	O
is	O
consistent	O
with	O
the	O
fact	O
that	O
the	O
subcellular	O
localization	O
of	O
DCNLs	O
in	O
tissue	O
culture	O
cells	O
differs	O
and	O
that	O
they	O
show	O
unique	O
tissue	O
-	O
specific	O
expression	O
patterns	O
in	O
mice	O
.	O

Thus	O
,	O
the	O
specificity	O
between	O
DCNL	O
-	O
type	O
NEDD8	O
E3	O
enzymes	O
and	O
their	O
cullin	O
substrates	O
is	O
only	O
apparent	O
in	O
well	O
-	O
defined	O
physiological	O
contexts	O
and	O
related	O
to	O
their	O
subcellular	O
distribution	O
and	O
restricted	O
expression	O
.	O

The	O
effects	O
of	O
ER	O
morphology	O
on	O
synaptic	O
structure	O
and	O
function	O
in	O
Drosophila	O
melanogaster	O
.	O

Hereditary	O
spastic	O
paraplegia	O
(	O
HSP	O
)	O
is	O
a	O
set	O
of	O
genetic	O
diseases	O
caused	O
by	O
mutations	O
in	O
one	O
of	O
72	O
genes	O
that	O
results	O
in	O
age	O
-	O
dependent	O
corticospinal	O
axon	O
degeneration	O
accompanied	O
by	O
spasticity	O
and	O
paralysis	O
.	O

Two	O
genes	O
implicated	O
in	O
HSPs	O
encode	O
proteins	O
that	O
regulate	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
morphology	O
.	O

Atlastin	O
1	O
(	O
ATL1	O
,	O
also	O
known	O
as	O
SPG3A	O
)	O
encodes	O
an	O
ER	O
membrane	O
fusion	O
GTPase	O
and	O
reticulon	O
2	O
(	O
RTN2	O
,	O
also	O
known	O
as	O
SPG12	O
)	O
helps	O
shape	O
ER	O
tube	O
formation	O
.	O

Here	O
,	O
we	O
use	O
a	O
new	O
fluorescent	O
ER	O
marker	O
to	O
show	O
that	O
the	O
ER	O
within	O
wild	O
-	O
type	O
Drosophila	O
motor	O
nerve	O
terminals	O
forms	O
a	O
network	O
of	O
tubules	O
that	O
is	O
fragmented	O
and	O
made	O
diffuse	O
upon	O
loss	O
of	O
the	O
atlastin	O
1	O
ortholog	O
atl	O
.	O
atl	O
or	O
Rtnl1	O
loss	O
decreases	O
evoked	O
transmitter	O
release	O
and	O
increases	O
arborization	O
.	O

Similar	O
to	O
other	O
HSP	O
proteins	O
,	O
Atl	O
inhibits	O
bone	O
morphogenetic	O
protein	O
(	O
BMP	O
)	O
signaling	O
,	O
and	O
loss	O
of	O
atl	O
causes	O
age	O
-	O
dependent	O
locomotor	O
deficits	O
in	O
adults	O
.	O

These	O
results	O
demonstrate	O
a	O
crucial	O
role	O
for	O
ER	O
in	O
neuronal	O
function	O
,	O
and	O
identify	O
mechanistic	O
links	O
between	O
ER	O
morphology	O
,	O
neuronal	O
function	O
,	O
BMP	O
signaling	O
and	O
adult	O
behavior	O
.	O

The	O
ability	O
of	O
the	O
T1	O
site	O
of	O
Rpn1	O
to	O
bind	O
both	O
ubiquitin	O
and	O
UBL	O
proteins	O
that	O
shuttle	O
ubiquitinated	O
substrates	O
to	O
the	O
proteasome	B-Complex
applies	O
to	O
all	O
intrinsic	O
substrate	O
receptor	O
sites	O
of	O
the	O
proteasome	B-Complex
.	O

The	O
multiplicity	O
of	O
intrinsic	O
substrate	O
receptors	O
on	O
the	O
proteasome	B-Complex
,	O
taken	O
together	O
with	O
the	O
combinatorial	O
array	O
of	O
states	O
associated	O
with	O
loading	O
of	O
multiple	O
extrinsic	O
receptors	O
on	O
any	O
intrinsic	O
receptor	O
,	O
should	O
allow	O
for	O
tens	O
and	O
possibly	O
hundreds	O
of	O
distinct	O
receptor	O
states	O
for	O
binding	O
of	O
ubiquitin	O
conjugates	O
.	O

The	O
utilization	O
of	O
multiple	O
sites	O
for	O
substrate	O
recognition	O
,	O
not	O
all	O
showing	O
high	O
affinity	O
,	O
is	O
consistent	O
with	O
a	O
multipoint	O
,	O
avid	O
mode	O
of	O
ubiquitin	O
chain	O
recognition	O
,	O
which	O
may	O
be	O
associated	O
with	O
highly	O
dynamic	O
interactions	O
between	O
ubiquitin	O
receptors	O
and	O
the	O
proteasome	B-Complex
-	O
bound	O
substrate	O
.	O

Substrate	O
binding	O
is	O
thought	O
to	O
be	O
productive	O
for	O
proteolysis	O
only	O
if	O
it	O
results	O
in	O
the	O
presentation	O
of	O
an	O
unstructured	O
initiation	O
site	O
into	O
the	O
substrate	O
translocation	O
channel	O
of	O
the	O
ATPase	O
ring	O
.	O

A	O
dynamic	O
mode	O
of	O
ubiquitin	O
chain	O
binding	O
may	O
allow	O
for	O
the	O
body	O
of	O
the	O
substrate	O
to	O
present	O
alternative	O
orientations	O
to	O
the	O
proteasome	B-Complex
so	O
as	O
to	O
achieve	O
productive	O
positioning	O
of	O
the	O
initiation	O
site	O
.	O

In	O
summary	O
,	O
this	O
work	O
defines	O
a	O
new	O
pathway	O
in	O
the	O
proteasome	B-Complex
that	O
engages	O
substrates	O
by	O
using	O
avid	O
low	O
affinity	O
binding	O
sites	O
,	O
and	O
places	O
them	O
in	O
the	O
neighborhood	O
of	O
deubiquitinating	O
enzyme	O
Ubp6	O
and	O
the	O
ATPase	O
ring	O
.	O

SUMO	O
-	O
Targeted	O
Ubiquitin	O
Ligase	O
(	O
STUbL	O
)	O
Slx5	O
regulates	O
proteolysis	O
of	O
centromeric	O
histone	O
H3	O
variant	O
Cse4	O
and	O
prevents	O
its	O
mislocalization	O
to	O
euchromatin	O
.	O

Centromeric	O
histone	O
H3	O
,	O
CENP	O
-	O
ACse4	O
,	O
is	O
essential	O
for	O
faithful	O
chromosome	O
segregation	O
.	O

Stringent	O
regulation	O
of	O
cellular	O
levels	O
of	O
CENP	O
-	O
ACse4	O
restricts	O
its	O
localization	O
to	O
centromeres	O
.	O

Mislocalization	O
of	O
CENP	O
-	O
ACse4	O
is	O
associated	O
with	O
aneuploidy	O
in	O
yeast	O
,	O
flies	O
and	O
tumorigenesis	O
in	O
human	O
cells	O
;	O
thus	O
,	O
defining	O
pathways	O
that	O
regulate	O
CENP	O
-	O
A	O
levels	O
is	O
critical	O
for	O
understanding	O
how	O
mislocalization	O
of	O
CENP	O
-	O
A	O
contributes	O
to	O
aneuploidy	O
in	O
human	O
cancers	O
.	O

Previous	O
work	O
in	O
budding	O
yeast	O
has	O
shown	O
that	O
ubiquitination	O
of	O
overexpressed	O
Cse4	O
by	O
Psh1	O
,	O
an	O
E3	O
ligase	O
,	O
partially	O
contributes	O
to	O
proteolysis	O
of	O
Cse4	O
.	O

Here	O
,	O
we	O
provide	O
the	O
first	O
evidence	O
that	O
Cse4	O
is	O
sumoylated	O
by	O
E3	O
ligases	O
Siz1	O
and	O
Siz2	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Ubiquitination	O
of	O
Cse4	O
by	O
Small	O
Ubiquitin	O
-	O
related	O
Modifier	O
(	O
SUMO	O
)	O
-	O
Targeted	O
Ubiquitin	O
Ligase	O
(	O
STUbL	O
)	O
Slx5	O
plays	O
a	O
critical	O
role	O
in	O
proteolysis	O
of	O
Cse4	O
and	O
prevents	O
mislocalization	O
of	O
Cse4	O
to	O
euchromatin	O
under	O
normal	O
physiological	O
conditions	O
.	O

Accumulation	O
of	O
sumoylated	O
Cse4	O
species	O
and	O
increased	O
stability	O
of	O
Cse4	O
in	O
slx5increment	O
strains	O
suggest	O
that	O
sumoylation	O
precedes	O
ubiquitin	O
-	O
mediated	O
proteolysis	O
of	O
Cse4	O
.	O

Slx5	O
-	O
mediated	O
Cse4	O
proteolysis	O
is	O
independent	O
of	O
Psh1	O
since	O
slx5increment	O
psh1increment	O
strains	O
exhibit	O
higher	O
levels	O
of	O
Cse4	O
stability	O
and	O
mislocalization	O
compared	O
to	O
either	O
slx5increment	O
or	O
psh1increment	O
strains	O
.	O

Our	O
results	O
demonstrate	O
a	O
role	O
for	O
Slx5	O
in	O
ubiquitin	O
-	O
mediated	O
proteolysis	O
of	O
Cse4	O
to	O
prevent	O
its	O
mislocalization	O
and	O
maintain	O
genome	O
stability	O
.	O

Quantitative	O
Mass	O
Spectrometry	O
Identifies	O
Novel	O
Host	O
Binding	O
Partners	O
for	O
Pathogenic	O
Escherichia	O
coli	O
Type	O
III	O
Secretion	O
System	O
Effectors	O
.	O

Enteropathogenic	O
and	O
enterohemorrhagic	O
Escherichia	O
coli	O
cause	O
enteric	O
diseases	O
resulting	O
in	O
significant	O
morbidity	O
and	O
mortality	O
worldwide	O
.	O

These	O
pathogens	O
remain	O
extracellular	O
and	O
translocate	O
a	O
set	O
of	O
type	O
III	O
secreted	O
effector	O
proteins	O
into	O
host	O
cells	O
to	O
promote	O
bacterial	O
virulence	O
.	O

Effectors	O
manipulate	O
host	O
cell	O
pathways	O
to	O
facilitate	O
infection	O
by	O
interacting	O
with	O
a	O
variety	O
of	O
host	O
targets	O
,	O
yet	O
the	O
binding	O
partners	O
and	O
mechanism	O
of	O
action	O
of	O
many	O
effectors	O
remain	O
elusive	O
.	O

We	O
performed	O
a	O
mass	O
spectrometry	O
screen	O
to	O
identify	O
host	O
targets	O
for	O
a	O
library	O
of	O
effectors	O
.	O

We	O
found	O
five	O
known	O
effector	O
targets	O
and	O
discovered	O
four	O
novel	O
interactions	O
.	O

Interestingly	O
,	O
we	O
identified	O
multiple	O
effectors	O
that	O
interacted	O
with	O
the	O
microtubule	O
associated	O
protein	O
,	O
ensconsin	O
.	O

Using	O
co	O
-	O
immunoprecipitations	O
,	O
we	O
confirmed	O
that	O
NleB1	O
and	O
EspL	O
interacted	O
with	O
ensconsin	O
in	O
a	O
region	O
that	O
corresponded	O
to	O
its	O
microtubule	O
binding	O
domain	O
.	O

Ensconsin	O
is	O
an	O
essential	O
cofactor	O
of	O
kinesin	O
-	O
1	O
that	O
is	O
required	O
for	O
intracellular	O
trafficking	O
,	O
and	O
we	O
demonstrated	O
that	O
intracellular	O
trafficking	O
was	O
severely	O
disrupted	O
during	O
wild	O
type	O
EPEC	O
infections	O
but	O
not	O
during	O
infections	O
with	O
DeltanleB1	O
or	O
DeltaespL	O
mutants	O
.	O

Our	O
findings	O
demonstrate	O
the	O
efficacy	O
of	O
quantitative	O
proteomics	O
for	O
identifying	O
effector	O
-	O
host	O
protein	O
interactions	O
and	O
suggest	O
that	O
vesicular	O
trafficking	O
is	O
a	O
crucial	O
cellular	O
process	O
that	O
may	O
be	O
targeted	O
by	O
NleB1	O
and	O
EspL	O
through	O
their	O
interaction	O
with	O
ensconsin	O
.	O

Actin	O
filament	O
networks	O
are	O
characterized	O
by	O
highly	O
dynamic	O
assembly	O
and	O
disassembly	O
.	O

Specific	O
proteins	O
crosslink	O
actin	O
filaments	O
(	O
F	O
-	O
actin	O
)	O
into	O
networks	O
with	O
distinct	O
architectures	O
.	O

Different	O
crosslinking	O
patterns	O
generate	O
morphologically	O
distinct	O
actin	O
networks	O
that	O
provide	O
mechanical	O
stability	O
and	O
force	O
-	O
generating	O
capacity	O
for	O
cellular	O
processes	O
such	O
as	O
endocytosis	O
,	O
vesicle	O
transport	O
,	O
cell	O
motility	O
and	O
adhesion	O
.	O

Filament	O
-	O
bundling	O
proteins	O
are	O
either	O
dimers	O
or	O
they	O
contain	O
multiple	O
acting	O
-	O
binding	O
domains	O
,	O
such	O
as	O
the	O
calponin	O
homology	O
domain	O
,	O
gelsolin	O
domain	O
or	O
the	O
spectrin	O
domain	O
,	O
and	O
crosslink	O
filaments	O
into	O
tightly	O
packed	O
bundles	O
.	O

Mammals	O
have	O
at	O
least	O
13	O
classes	O
of	O
F	O
-	O
actin	O
-	O
bundling	O
proteins	O
that	O
form	O
distinct	O
cellular	O
structures	O
and	O
are	O
regulated	O
by	O
different	O
signalling	O
pathways	O
.	O

During	O
cell	O
growth	O
or	O
response	O
to	O
environmental	O
changes	O
,	O
filament	O
-	O
bundling	O
proteins	O
are	O
highly	O
regulated	O
to	O
couple	O
signal	O
transduction	O
with	O
intracellular	O
structural	O
changes	O
of	O
actin	O
networks	O
.	O

Regulation	O
of	O
F	O
-	O
actin	O
-	O
bundling	O
proteins	O
often	O
involves	O
modulation	O
of	O
their	O
binding	O
,	O
mediated	O
through	O
interaction	O
or	O
competition	O
with	O
other	O
actin	O
-	O
binding	O
proteins	O
(	O
ABPs	O
)	O
,	O
or	O
through	O
signals	O
including	O
calcium	O
,	O
ionic	O
strength	O
and	O
phosphorylation	O
.	O

Phosphoregulation	O
is	O
an	O
important	O
post	O
-	O
translational	O
modification	O
to	O
modulate	O
the	O
F	O
-	O
actin	O
crosslinking	O
activity	O
of	O
bundling	O
proteins	O
.	O

The	O
ubiquitously	O
expressed	O
mammalian	O
actin	O
crosslinker	O
,	O
alpha	O
-	O
actinin	O
,	O
is	O
regulated	O
by	O
tyrosine	O
phosphorylation	O
to	O
either	O
inhibit	O
or	O
stimulate	O
actin	O
-	O
binding	O
abilities	O
,	O
and	O
therefore	O
regulate	O
the	O
formation	O
of	O
stress	O
fibres	O
and	O
maturation	O
of	O
focal	O
adhesions	O
.	O

Also	O
,	O
the	O
neuronal	O
crosslinking	O
protein	O
drebrin	O
is	O
phosphorylated	O
by	O
cyclin	O
-	O
dependent	O
kinase	O
5	O
at	O
Ser142	O
to	O
regulate	O
F	O
-	O
actin	O
bundling	O
in	O
growth	O
cone	O
filopodia	O
.	O

SCL	O
/	O
TAL1	O
in	O
Hematopoiesis	O
and	O
Cellular	O
Reprogramming	O
.	O

SCL	O
,	O
a	O
transcription	O
factor	O
of	O
the	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
family	O
,	O
is	O
a	O
master	O
regulator	O
of	O
hematopoiesis	O
.	O

Scl	O
specifies	O
lateral	O
plate	O
mesoderm	O
to	O
a	O
hematopoietic	O
fate	O
and	O
establishes	O
boundaries	O
by	O
inhibiting	O
the	O
cardiac	O
lineage	O
.	O

A	O
combinatorial	O
interaction	O
between	O
Scl	O
and	O
Vegfa	O
/	O
Flk1	O
sets	O
in	O
motion	O
the	O
first	O
wave	O
of	O
primitive	O
hematopoiesis	O
.	O

Subsequently	O
,	O
definitive	O
hematopoietic	O
stem	O
cells	O
(	O
HSCs	O
)	O
emerge	O
from	O
the	O
embryo	O
proper	O
via	O
an	O
endothelial	O
-	O
to	O
-	O
hematopoietic	O
transition	O
controlled	O
by	O
Runx1	O
,	O
acting	O
with	O
Scl	O
and	O
Gata2	O
.	O

Past	O
this	O
stage	O
,	O
Scl	O
in	O
steady	O
state	O
HSCs	O
is	O
redundant	O
with	O
Lyl1	O
,	O
a	O
highly	O
homologous	O
factor	O
.	O

However	O
,	O
Scl	O
is	O
haploinsufficient	O
in	O
stress	O
response	O
,	O
when	O
a	O
rare	O
subpopulation	O
of	O
HSCs	O
with	O
very	O
long	O
term	O
repopulating	O
capacity	O
is	O
called	O
into	O
action	O
.	O

SCL	O
activates	O
transcription	O
by	O
recruiting	O
a	O
core	O
complex	O
on	O
DNA	O
that	O
necessarily	O
includes	O
E2A	O
/	O
HEB	O
,	O
GATA1	O
-	O
3	O
,	O
LIM	O
-	O
only	O
proteins	O
LMO1	O
/	O
2	O
,	O
LDB1	O
,	O
and	O
an	O
extended	O
complex	O
comprising	O
ETO2	O
,	O
RUNX1	O
,	O
ERG	O
,	O
or	O
FLI1	O
.	O

These	O
interactions	O
confer	O
multifunctionality	O
to	O
a	O
complex	O
that	O
can	O
control	O
cell	O
proliferation	O
in	O
erythroid	O
progenitors	O
or	O
commitment	O
to	O
terminal	O
differentiation	O
through	O
variations	O
in	O
single	O
component	O
.	O

Ectopic	O
SCL	O
and	O
LMO1	O
/	O
2	O
expression	O
in	O
immature	O
thymocytes	O
activates	O
of	O
a	O
stem	O
cell	O
gene	O
network	O
and	O
reprogram	O
cells	O
with	O
a	O
finite	O
lifespan	O
into	O
self	O
-	O
renewing	O
preleukemic	O
stem	O
cells	O
(	O
pre	O
-	O
LSCs	O
)	O
,	O
an	O
initiating	O
event	O
in	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemias	O
.	O

Interestingly	O
,	O
fate	O
conversion	O
of	O
fibroblasts	O
to	O
hematoendothelial	O
cells	O
requires	O
not	O
only	O
Scl	O
and	O
Lmo2	O
but	O
also	O
Gata2	O
,	O
Runx1	O
,	O
and	O
Erg	O
,	O
indicating	O
a	O
necessary	O
collaboration	O
between	O
these	O
transcription	O
factors	O
for	O
hematopoietic	O
reprogramming	O
.	O

Nonetheless	O
,	O
full	O
reprogramming	O
into	O
self	O
-	O
renewing	O
multipotent	O
HSCs	O
may	O
require	O
additional	O
factors	O
and	O
most	O
likely	O
,	O
a	O
permissive	O
microenvironment	O
.	O

All	O
cell	O
lines	O
were	O
provided	O
by	O
the	O
University	O
of	O
Texas	O
Southwestern	O
Medical	O
Center	O
at	O
Dallas	O
with	O
the	O
approval	O
of	O
IRB	O
.	O

Patient	O
-	O
derived	O
GBM	O
(	O
Ink	O
-	O
/	O
-	O
,	O
CD133	O
+	O
,	O
EGFRvIII	O
)	O
and	O
Neuroblastoma	O
(	O
SH	O
-	O
SY5Y	O
cell	O
line	O
human	O
)	O
were	O
used	O
as	O
two	O
primary	O
cancer	O
models	O
.	O

Different	O
genetically	O
modified	O
cells	O
,	O
including	O
two	O
human	O
brain	O
tumor	O
cell	O
lines	O
(	O
D54	O
,	O
human	O
astrocytoma	O
cell	O
line	O
derived	O
from	O
a	O
patient	O
with	O
glioblastoma	O
multiforme	O
(	O
grade	O
IV	O
)	O
and	O
D54	O
-	O
EGFRvIII	O
)	O
and	O
four	O
different	O
gene	O
-	O
altered	O
mouse	O
astrocytes	O
mimicking	O
different	O
levels	O
of	O
human	O
cancerous	O
cells	O
(	O
p53	O
-	O
/	O
-	O
,	O
p53	O
-	O
/	O
-	O
PTEN	O
-	O
/	O
-	O
,	O
p53	O
-	O
/	O
-	O
Braf	O
,	O
and	O
p53	O
-	O
/	O
-	O
PTEN	O
-	O
/	O
-	O
Braf	O
astrocytes	O
)	O
were	O
used	O
.	O

These	O
four	O
types	O
of	O
mouse	O
astrocytes	O
were	O
derived	O
from	O
the	O
same	O
wild	O
-	O
type	O
mouse	O
astrocytes	O
.	O

(	O
A	O
)	O
A	O
diagram	O
describing	O
the	O
molecular	O
lesions	O
of	O
two	O
Sox21a	O
mutant	O
alleles	O
.	O

Both	O
alleles	O
carry	O
a	O
large	O
DNA	O
fragment	O
deletion	O
spanning	O
the	O
coding	O
region	O
of	O
Sox21a	O
.	O

(	O
B	O
-	O
C	O
)	O
Cross	O
-	O
section	O
of	O
midgut	O
from	O
2	O
day	O
old	O
(	O
B	O
)	O
and	O
7	O
day	O
old	O
(	O
C	O
)	O
Sox21a	O
mutant	O
flies	O
.	O

With	O
age	O
,	O
Sox21a	O
mutants	O
developed	O
tumors	O
with	O
multilayered	O
structure	O
(	O
C	O
)	O
.	O

(	O
D	O
)	O
Quantitative	O
analysis	O
of	O
the	O
tumor	O
incidence	O
at	O
different	O
regions	O
of	O
midgut	O
with	O
age	O
.	O

Genotypes	O
of	O
flies	O
analyzed	O
:	O
wild	O
type	O
(	O
WT	O
)	O
,	O
Sox21a	O
-	O
/	O
-	O
[	O
JC1	O
]	O
and	O
Sox21a	O
-	O
/	O
-	O
[	O
JC2	O
]	O
.	O

n	O
=	O
40	O
-	O
50	O
guts	O
.	O

(	O
E	O
-	O
G	O
'	O
)	O
Staining	O
of	O
NRE	O
-	O
lacZ	O
(	O
green	O
)	O
and	O
Dl	O
+	O
Pros	O
(	O
red	O
)	O
in	O
the	O
midgut	O
of	O
WT	O
(	O
E	O
)	O
,	O
Sox21a	O
mutant	O
flies	O
at	O
day	O
2	O
(	O
F	O
)	O
and	O
day	O
7	O
(	O
G	O
,	O
G	O
'	O
)	O
after	O
eclosion	O
.	O

Compared	O
to	O
WT	O
guts	O
,	O
Sox21a	O
mutant	O
guts	O
did	O
not	O
show	O
EB	O
accumulation	O
at	O
day	O
2	O
(	O
E	O
,	O
F	O
)	O
,	O
but	O
showed	O
dramatic	O
EB	O
accumulation	O
at	O
day	O
7	O
(	O
G	O
,	O
G	O
'	O
)	O
.	O

Accumulated	O
lacZ	O
+	O
cells	O
were	O
negative	O
for	O
Dl	O
or	O
Pros	O
expression	O
(	O
G	O
'	O
)	O
.	O

(	O
H	O
,	O
H	O
'	O
)	O
Staining	O
of	O
NRE	O
-	O
lacZ	O
(	O
red	O
)	O
in	O
Sox21a	O
mutant	O
clones	O
on	O
day	O
7	O
after	O
clone	O
induction	O
.	O

LacZ	O
was	O
cell	O
-	O
autonomously	O
activated	O
.	O

Non	O
-	O
cell	O
autonomous	O
LacZ	O
+	O
cell	O
clusters	O
were	O
also	O
observed	O
(	O
see	O
text	O
)	O
.	O

(	O
I	O
-	O
I	O
'	O
)	O
Staining	O
of	O
Dl	O
(	O
white	O
)	O
,	O
Pros	O
(	O
red	O
)	O
in	O
Sox21a	O
mutant	O
clones	O
.	O

The	O
Dl	O
+	O
cells	O
were	O
scatteredly	O
distributed	O
in	O
the	O
clones	O
,	O
and	O
Pros	O
+	O
cell	O
was	O
rarely	O
found	O
within	O
the	O
mutant	O
clones	O
.	O

(	O
J	O
,	O
J	O
'	O
)	O
Staining	O
of	O
Pdm1	O
(	O
red	O
)	O
in	O
Sox21a	O
mutant	O
clones	O
.	O
.	O

Pdm1	O
expression	O
was	O
absent	O
in	O
the	O
entire	O
mutant	O
clones	O
.	O

Scale	O
bars	O
:	O
20	O
mum	O
.	O

The	O
structure	O
and	O
regulation	O
of	O
Cullin	O
2	O
based	O
E3	O
ubiquitin	O
ligases	O
and	O
their	O
biological	O
functions	O
.	O

BACKGROUND	O
:	O
Cullin	O
-	O
RING	O
E3	O
ubiquitin	O
ligase	O
complexes	O
play	O
a	O
central	O
role	O
in	O
targeting	O
cellular	O
proteins	O
for	O
ubiquitination	O
-	O
dependent	O
protein	O
turnover	O
through	O
26S	B-Complex
proteasome	I-Complex
.	O

Cullin	O
-	O
2	O
is	O
a	O
member	O
of	O
the	O
Cullin	O
family	O
,	O
and	O
it	O
serves	O
as	O
a	O
scaffold	O
protein	O
for	O
Elongin	O
B	O
and	O
C	O
,	O
Rbx1	O
and	O
various	O
substrate	O
recognition	O
receptors	O
to	O
form	O
E3	O
ubiquitin	O
ligases	O
.	O

MAIN	O
BODY	O
OF	O
THE	O
ABSTRACT	O
:	O
First	O
,	O
the	O
composition	O
,	O
structure	O
and	O
the	O
regulation	O
of	O
Cullin	O
-	O
2	O
based	O
E3	O
ubiquitin	O
ligases	O
were	O
introduced	O
.	O

Then	O
the	O
targets	O
,	O
the	O
biological	O
functions	O
of	O
complexes	O
that	O
use	O
VHL	O
,	O
Lrr	O
-	O
1	O
,	O
Fem1b	O
,	O
Prame	O
,	O
Zyg	O
-	O
11	O
,	O
BAF250	O
,	O
Rack1	O
as	O
substrate	O
targeting	O
subunits	O
were	O
described	O
,	O
and	O
their	O
involvement	O
in	O
diseases	O
was	O
discussed	O
.	O

A	O
small	O
molecule	O
inhibitor	O
of	O
Cullins	O
as	O
a	O
potential	O
anti	O
-	O
cancer	O
drug	O
was	O
introduced	O
.	O

Furthermore	O
,	O
proteins	O
with	O
VHL	O
box	O
that	O
might	O
bind	O
to	O
Cullin	O
-	O
2	O
were	O
described	O
.	O

Finally	O
,	O
how	O
different	O
viral	O
proteins	O
form	O
E3	O
ubiquitin	O
ligase	O
complexes	O
with	O
Cullin	O
-	O
2	O
to	O
counter	O
host	O
viral	O
defense	O
were	O
explained	O
.	O

CONCLUSIONS	O
:	O
Cullin	O
-	O
2	O
based	O
E3	O
ubiquitin	O
ligases	O
,	O
using	O
many	O
different	O
substrate	O
recognition	O
receptors	O
,	O
recognize	O
a	O
number	O
of	O
substrates	O
and	O
regulate	O
their	O
protein	O
stability	O
.	O

These	O
complexes	O
play	O
critical	O
roles	O
in	O
biological	O
processes	O
and	O
diseases	O
such	O
as	O
cancer	O
,	O
germline	O
differentiation	O
and	O
viral	O
defense	O
.	O

Through	O
the	O
better	O
understanding	O
of	O
their	O
biology	O
,	O
we	O
can	O
devise	O
and	O
develop	O
new	O
therapeutic	O
strategies	O
to	O
treat	O
cancers	O
,	O
inherited	O
diseases	O
and	O
viral	O
infections	O
.	O

Cutting	O
Edge	O
:	O
A	O
Cullin	O
-	O
5	O
-	O
TRAF6	O
Interaction	O
Promotes	O
TRAF6	O
Polyubiquitination	O
and	O
Lipopolysaccharide	O
Signaling	O
.	O

TNFR	O
-	O
associated	O
factor	O
(	O
TRAF	O
)	O
6	O
integrates	O
signals	O
from	O
multiple	O
cell	O
surface	O
receptors	O
for	O
the	O
activation	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
.	O

However	O
,	O
the	O
mechanism	O
underlying	O
LPS	O
-	O
induced	O
TRAF6	O
signaling	O
remains	O
unclear	O
.	O

We	O
report	O
that	O
cullin	O
-	O
5	O
(	O
Cul	O
-	O
5	O
)	O
,	O
a	O
cullin	O
family	O
scaffold	O
protein	O
,	O
binds	O
to	O
TRAF6	O
and	O
promotes	O
TRAF6	O
polyubiquitination	O
at	O
Lys	O
(	O
63	O
)	O
in	O
response	O
to	O
LPS	O
stimulation	O
.	O

A	O
direct	O
interaction	O
between	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
Cul	O
-	O
5	O
and	O
the	O
TRAF	O
-	O
C	O
domain	O
of	O
TRAF6	O
facilitates	O
polyubiquitination	O
of	O
TRAF6	O
.	O

Hemizygous	O
Cul	O
-	O
5	O
knockout	O
is	O
associated	O
with	O
improved	O
survival	O
of	O
mice	O
following	O
LPS	O
challenge	O
and	O
significant	O
delays	O
in	O
the	O
phosphorylation	O
of	O
p65	O
/	O
RelA	O
,	O
ERK	O
,	O
JNK	O
,	O
and	O
p38	O
MAPKs	O
in	O
LPS	O
-	O
stimulated	O
macrophages	O
,	O
along	O
with	O
a	O
marked	O
decrease	O
in	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
.	O

These	O
findings	O
identify	O
Cul	O
-	O
5	O
as	O
a	O
signaling	O
component	O
that	O
connects	O
an	O
LPS	O
-	O
activated	O
TLR4	O
-	O
MyD88	O
complex	O
to	O
TRAF6	O
for	O
efficient	O
activation	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
.	O

Shot	O
localizes	O
to	O
the	O
anterior	O
and	O
lateral	O
cortex	O
of	O
the	O
oocyte	O
,	O
but	O
is	O
absent	O
from	O
the	O
posterior	O
,	O
following	O
the	O
predicted	O
distribution	O
of	O
MT	O
minus	O
ends	O
.	O

Shot	O
is	O
also	O
strongly	O
enriched	O
at	O
the	O
apical	O
side	O
of	O
the	O
epithelial	O
follicle	O
cells	O
that	O
surround	O
the	O
developing	O
egg	O
chamber	O
(	O
Figure	O
2A	O
,	O
left	O
)	O
.	O

YFP	O
-	O
tagged	O
Shot	O
expressed	O
from	O
a	O
transgenic	O
bacterial	O
artificial	O
chromosome	O
(	O
BAC	O
)	O
rescuing	O
construct	O
shows	O
an	O
identical	O
distribution	O
in	O
both	O
the	O
follicle	O
cells	O
and	O
oocyte	O
.	O

We	O
therefore	O
examined	O
whether	O
the	O
interaction	O
of	O
Shot	O
with	O
the	O
oocyte	O
cortex	O
is	O
under	O
the	O
control	O
of	O
the	O
cortical	O
Par	O
proteins	O
that	O
control	O
the	O
polarity	O
of	O
the	O
MT	O
cytoskeleton	O
.	O

In	O
par	O
-	O
1	O
mutant	O
oocytes	O
,	O
MTs	O
grow	O
from	O
the	O
posterior	O
cortex	O
as	O
well	O
as	O
the	O
anterior	O
/	O
lateral	O
cortex	O
,	O
and	O
the	O
MT	O
cytoskeleton	O
loses	O
its	O
asymmetry	O
,	O
whereas	O
Par	O
-	O
1T786A	O
,	O
which	O
has	O
a	O
uniform	O
cortical	O
distribution	O
,	O
abolishes	O
all	O
MT	O
growth	O
from	O
the	O
cortex	O
.	O

Shot	O
responds	O
to	O
Par	O
-	O
1	O
activity	O
in	O
the	O
same	O
way	O
as	O
MTs	O
:	O
it	O
extends	O
around	O
the	O
posterior	O
in	O
the	O
absence	O
of	O
Par	O
-	O
1	O
,	O
and	O
is	O
lost	O
from	O
the	O
cortex	O
in	O
oocytes	O
overexpressing	O
Par	O
-	O
1T786A	O
(	O
Figures	O
2A	O
and	O
2B	O
)	O
.	O

Thus	O
,	O
Shot	O
is	O
downstream	O
of	O
Par	O
-	O
1	O
,	O
consistent	O
with	O
it	O
playing	O
a	O
role	O
in	O
MT	O
minus	O
-	O
end	O
localization	O
.	O

To	O
further	O
specify	O
the	O
effects	O
caused	O
by	O
K270R	O
expression	O
,	O
endogenous	O
Syn5	O
was	O
depleted	O
by	O
RNA	O
interference	O
(	O
RNAi	O
)	O
,	O
which	O
resulted	O
in	O
Golgi	O
fragmentation	O
(	O
Fig	O
.	O
S6A	O
-	O
G	O
)	O
,	O
and	O
then	O
RNAi	O
-	O
resistant	O
WT	O
or	O
mutant	O
Syn5	O
was	O
expressed	O
to	O
rescue	O
the	O
phenotype	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

5D	O
-	O
E	O
,	O
WT	O
Syn5	O
and	O
K241R	O
,	O
but	O
not	O
K270R	O
,	O
rescued	O
the	O
fragmented	O
Golgi	O
phenotype	O
.	O

Depletion	O
of	O
endogenous	O
Syn5	O
resulted	O
in	O
Golgi	O
fragmentation	O
in	O
over	O
80	O
%	O
of	O
the	O
cells	O
;	O
expression	O
of	O
RNAi	O
-	O
resistant	O
WT	O
or	O
K241R	O
Syn5	O
reduced	O
this	O
number	O
to	O
about	O
20	O
%	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
the	O
K270R	O
mutant	O
had	O
no	O
effect	O
on	O
the	O
fragmented	O
Golgi	O
phenotype	O
in	O
Syn5	O
-	O
depleted	O
cells	O
(	O
Fig	O
.	O
5D	O
-	O
E	O
)	O
.	O

In	O
this	O
experiment	O
,	O
all	O
proteins	O
were	O
expressed	O
at	O
a	O
similar	O
level	O
(	O
Fig	O
.	O
5F	O
)	O
.	O

These	O
results	O
demonstrate	O
that	O
monoubiquitination	O
of	O
Syn5	O
on	O
lysine	O
270	O
is	O
required	O
for	O
assembly	O
of	O
the	O
Golgi	O
structure	O
.	O

USP15	O
stabilizes	O
the	O
transcription	O
factor	O
Nrf1	O
in	O
the	O
nucleus	O
,	O
promoting	O
the	O
proteasome	B-Complex
gene	O
expression	O
.	O

The	O
transcriptional	O
factor	O
Nrf1	O
(	O
NF	O
-	O
E2	O
-	O
related	O
factor	O
1	O
)	O
sustains	O
protein	O
homeostasis	O
(	O
proteostasis	O
)	O
by	O
regulating	O
the	O
expression	O
of	O
proteasome	B-Complex
genes	O
.	O

Under	O
physiological	O
conditions	O
,	O
the	O
transcriptional	O
activity	O
of	O
Nrf1	O
is	O
repressed	O
by	O
its	O
sequestration	O
into	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
furthermore	O
by	O
two	O
independent	O
ubiquitin	O
-	O
proteasome	B-Complex
pathways	O
,	O
comprising	O
Hrd1	O
and	O
beta	O
-	O
TrCP	O
in	O
the	O
cytoplasm	O
and	O
nucleus	O
,	O
respectively	O
.	O

However	O
,	O
the	O
molecular	O
mechanisms	O
underlying	O
Nrf1	O
activation	O
remain	O
unclear	O
.	O

Here	O
,	O
we	O
report	O
that	O
USP15	O
(	O
Ubiquitin	O
-	O
Specific	O
Protease	O
15	O
)	O
activates	O
Nrf1	O
in	O
the	O
nucleus	O
by	O
stabilizing	O
it	O
through	O
deubiquitination	O
.	O

We	O
first	O
identified	O
USP15	O
as	O
an	O
Nrf1	O
-	O
associated	O
factor	O
through	O
proteome	O
analysis	O
.	O

USP15	O
physically	O
interacts	O
with	O
Nrf1	O
,	O
and	O
it	O
markedly	O
stabilizes	O
Nrf1	O
by	O
removing	O
its	O
ubiquitin	O
moieties	O
.	O

USP15	O
activates	O
the	O
Nrf1	O
-	O
mediated	O
expression	O
of	O
a	O
proteasome	B-Complex
gene	O
luciferase	O
reporter	O
and	O
endogenous	O
proteasome	B-Complex
activity	O
.	O

The	O
siRNA	O
-	O
mediated	O
knockdown	O
of	O
USP15	O
diminishes	O
the	O
Nrf1	O
-	O
induced	O
proteasome	B-Complex
gene	O
expression	O
in	O
response	O
to	O
proteasome	B-Complex
inhibition	O
.	O

These	O
results	O
uncover	O
a	O
new	O
regulatory	O
mechanism	O
that	O
USP15	O
activates	O
Nrf1	O
against	O
the	O
beta	O
-	O
TrCP	O
inhibition	O
to	O
maintain	O
proteostasis	O
.	O

(	O
A	O
)	O
GIM3	O
or	O
gim3increment	O
cells	O
expressing	O
Guk1	O
-	O
7	O
-	O
GFP	O
were	O
grown	O
at	O
25degreesC	O
and	O
then	O
incubated	O
at	O
either	O
25degreesC	O
or	O
37degreesC	O
for	O
2	O
hours	O
in	O
the	O
presence	O
of	O
CHX	O
before	O
fixation	O
and	O
imaging	O
.	O

(	O
B	O
)	O
GIM3	O
and	O
gim3increment	O
cells	O
expressing	O
Guk1	O
-	O
7	O
-	O
GFP	O
along	O
with	O
an	O
empty	O
vector	O
control	O
or	O
GIM3	O
were	O
incubated	O
at	O
25degreesC	O
or	O
37degreesC	O
for	O
two	O
hours	O
in	O
the	O
presence	O
of	O
CHX	O
before	O
fixation	O
and	O
imaging	O
.	O

(	O
C	O
)	O
GIM3	O
or	O
gim3increment	O
cells	O
expressing	O
Guk1	O
-	O
7	O
-	O
GFP	O
were	O
incubated	O
at	O
25degreesC	O
and	O
then	O
shifted	O
to	O
37degreesC	O
.	O

Samples	O
were	O
collected	O
at	O
the	O
indicated	O
time	O
points	O
and	O
then	O
fixed	O
before	O
imaging	O
.	O

For	O
all	O
images	O
,	O
the	O
scale	O
bar	O
represents	O
5mum	O
and	O
dotted	O
lines	O
demark	O
cell	O
boundaries	O
.	O

Momordin	O
Ic	O
,	O
a	O
new	O
natural	O
SENP1	O
inhibitor	O
,	O
inhibits	O
prostate	O
cancer	O
cell	O
proliferation	O
.	O

SUMO	O
-	O
specific	O
protease	O
1	O
(	O
SENP1	O
)	O
,	O
a	O
member	O
of	O
the	O
de	O
-	O
SUMOylation	O
protease	O
family	O
,	O
is	O
elevated	O
in	O
prostate	O
cancer	O
(	O
PCa	O
)	O
cells	O
and	O
is	O
involved	O
in	O
PCa	O
pathogenesis	O
.	O

Momordin	O
Iotac	O
(	O
Mc	O
)	O
,	O
a	O
natural	O
pentacyclic	O
triterpenoid	O
,	O
inhibited	O
SENP1	O
in	O
vitro	O
,	O
as	O
reflected	O
by	O
reduced	O
SENP1C	O
-	O
induced	O
cleavage	O
of	O
SUMO2	O
-	O
DeltaRanGAP1	O
.	O

Mc	O
also	O
altered	O
the	O
thermal	O
stability	O
of	O
SENP1	O
in	O
a	O
newly	O
developed	O
cellular	O
thermal	O
shift	O
assay	O
,	O
indicating	O
that	O
Mc	O
directly	O
interacts	O
with	O
SENP1	O
in	O
PCa	O
cells	O
.	O

Consistent	O
with	O
SENP1	O
inhibition	O
,	O
Mc	O
increased	O
SUMOylated	O
protein	O
levels	O
,	O
which	O
was	O
further	O
confirmed	O
by	O
the	O
accumulation	O
of	O
two	O
known	O
SUMOylated	O
proteins	O
,	O
hypoxia	O
inducible	O
factor	O
-	O
1a	O
and	O
nucleus	O
accumbens	O
associated	O
protein	O
1	O
in	O
PC3	O
cells	O
.	O

Compared	O
to	O
LNCaP	O
and	O
normal	O
prostate	O
epithelial	O
RWPE	O
-	O
1	O
cells	O
,	O
PC3	O
cells	O
had	O
higher	O
levels	O
of	O
SENP1	O
mRNA	O
and	O
were	O
more	O
sensitive	O
to	O
Mc	O
-	O
induced	O
growth	O
inhibition	O
.	O

Mc	O
also	O
reduced	O
SENP1	O
mRNA	O
levels	O
in	O
PCa	O
cells	O
.	O

Overexpression	O
of	O
SENP1	O
rescued	O
PC3	O
cells	O
from	O
Mc	O
-	O
induced	O
apoptosis	O
.	O

Finally	O
,	O
Mc	O
suppressed	O
cell	O
proliferation	O
and	O
induced	O
cell	O
death	O
in	O
vivo	O
in	O
a	O
xenograft	O
PC3	O
tumor	O
mouse	O
model	O
.	O

These	O
findings	O
demonstrate	O
that	O
Mc	O
is	O
a	O
novel	O
SENP1	O
inhibitor	O
with	O
potential	O
therapeutic	O
value	O
for	O
PCa	O
.	O

Investigation	O
of	O
other	O
pentacyclic	O
triterpenoids	O
may	O
aid	O
in	O
the	O
development	O
of	O
novel	O
SENP1	O
inhibitor	O
drugs	O
.	O

TMEM166	O
/	O
EVA1A	O
interacts	O
with	O
ATG16L1	O
and	O
induces	O
autophagosome	O
formation	O
and	O
cell	O
death	O
.	O

The	O
formation	O
of	O
the	O
autophagosome	O
is	O
controlled	O
by	O
an	O
orderly	O
action	O
of	O
ATG	O
proteins	O
.	O

However	O
,	O
how	O
these	O
proteins	O
are	O
recruited	O
to	O
autophagic	O
membranes	O
remain	O
poorly	O
clarified	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
provided	O
a	O
line	O
of	O
evidence	O
confirming	O
that	O
EVA1A	O
(	O
eva	O
-	O
1	O
homolog	O
A	O
)	O
/	O
TMEM166	O
(	O
transmembrane	O
protein	O
166	O
)	O
is	O
associated	O
with	O
autophagosomal	O
membrane	O
development	O
.	O

This	O
notion	O
is	O
based	O
on	O
dotted	O
EVA1A	O
structures	O
that	O
colocalize	O
with	O
ZFYVE1	O
,	O
ATG9	O
,	O
LC3B	O
,	O
ATG16L1	O
,	O
ATG5	O
,	O
STX17	O
,	O
RAB7	O
and	O
LAMP1	O
,	O
which	O
represent	O
different	O
stages	O
of	O
the	O
autophagic	O
process	O
.	O

It	O
is	O
required	O
for	O
autophagosome	O
formation	O
as	O
this	O
phenotype	O
was	O
significantly	O
decreased	O
in	O
EVA1A	O
-	O
silenced	O
cells	O
and	O
Eva1a	O
KO	O
MEFs	O
.	O

EVA1A	O
-	O
induced	O
autophagy	O
is	O
independent	O
of	O
the	O
BECN1	O
-	O
PIK3C3	O
(	O
phosphatidylinositol	O
3	O
-	O
kinase	O
,	O
catalytic	O
subunit	O
type	O
3	O
)	O
complex	O
but	O
requires	O
ATG7	O
activity	O
and	O
the	O
ATG12	O
-	O
ATG5	O
/	O
ATG16L1	O
complex	O
.	O

Here	O
,	O
we	O
present	O
a	O
molecular	O
mechanism	O
by	O
which	O
EVA1A	O
interacts	O
with	O
the	O
WD	O
repeats	O
of	O
ATG16L1	O
through	O
its	O
C	O
-	O
terminal	O
and	O
promotes	O
ATG12	O
-	O
ATG5	O
/	O
ATG16L1	O
complex	O
recruitment	O
to	O
the	O
autophagic	O
membrane	O
and	O
enhances	O
the	O
formation	O
of	O
the	O
autophagosome	O
.	O

We	O
also	O
found	O
that	O
both	O
autophagic	O
and	O
apoptotic	O
mechanisms	O
contributed	O
to	O
EVA1A	O
-	O
induced	O
cell	O
death	O
while	O
inhibition	O
of	O
autophagy	O
and	O
apoptosis	O
attenuated	O
EVA1A	O
-	O
induced	O
cell	O
death	O
.	O

Overall	O
,	O
these	O
findings	O
provide	O
a	O
comprehensive	O
view	O
to	O
our	O
understanding	O
of	O
the	O
pathways	O
involved	O
in	O
the	O
role	O
of	O
EVA1A	O
in	O
autophagy	O
and	O
programmed	O
cell	O
death	O
.	O

Chemical	O
shift	O
perturbation	O
and	O
line	O
broadening	O
analyses	O
were	O
performed	O
by	O
comparing	O
the	O
1H	O
-	O
15N	O
HSQC	O
spectrum	O
of	O
chemically	O
reconstituted	O
15N	O
-	O
labeled	O
BOLA3	O
-	O
GLRX5	O
with	O
that	O
of	O
BOLA3	O
.	O

The	O
residues	O
of	O
the	O
loop	O
containing	O
the	O
conserved	O
Cys59	O
of	O
BOLA3	O
showed	O
strong	O
chemical	O
shift	O
changes	O
only	O
in	O
the	O
holo	O
hetero	O
-	O
complex	O
relative	O
to	O
the	O
apoform	O
(	O
Figure	O
6B	O
,	O
D	O
and	O
Figure	O
6	O
-	O
-	O
figure	O
supplement	O
1	O
,	O
right	O
parts	O
)	O
.	O

A	O
similar	O
comparison	O
for	O
the	O
15N	O
-	O
labeled	O
BOLA1	O
-	O
GLRX5	O
complex	O
showed	O
that	O
the	O
region	O
around	O
His67	O
of	O
BOLA1	O
(	O
structurally	O
close	O
to	O
Cys59	O
of	O
BOLA3	O
)	O
exhibited	O
similar	O
chemical	O
shift	O
changes	O
,	O
even	O
though	O
fewer	O
residues	O
were	O
affected	O
in	O
BOLA1	O
(	O
Figure	O
6A	O
,	O
C	O
,	O
and	O
Figure	O
6	O
-	O
-	O
figure	O
supplement	O
1	O
,	O
left	O
parts	O
)	O
.	O

The	O
chemical	O
shift	O
perturbation	O
analysis	O
for	O
15N	O
-	O
labeled	O
GLRX5	O
revealed	O
that	O
the	O
residues	O
of	O
GLRX5	O
involved	O
in	O
the	O
apo	O
interaction	O
are	O
also	O
affected	O
in	O
the	O
holo	O
-	O
complex	O
and	O
that	O
the	O
conserved	O
Cys67	O
of	O
GLRX5	O
was	O
additionally	O
altered	O
in	O
the	O
holo	O
complexes	O
only	O
(	O
Figure	O
6	O
-	O
-	O
figure	O
supplement	O
2	O
)	O
.	O

In	O
addition	O
,	O
two	O
other	O
adjacent	O
GLRX5	O
residues	O
(	O
Lys59	O
for	O
BOLA3	O
and	O
Gly60	O
for	O
BOLA1	O
interaction	O
)	O
were	O
altered	O
that	O
are	O
part	O
of	O
the	O
GSH	O
binding	O
site	O
.	O

The	O
regions	O
of	O
GLRX5	O
affected	O
by	O
the	O
interaction	O
with	O
BOLA1	O
and	O
BOLA3	O
are	O
essentially	O
the	O
same	O
as	O
those	O
in	O
the	O
[	O
2Fe	O
-	O
2S	O
]	O
2	O
+	O
GLRX5	O
homodimer	O
.	O

This	O
indicates	O
that	O
,	O
for	O
GLRX5	O
,	O
the	O
same	O
interaction	O
regions	O
are	O
involved	O
in	O
both	O
homo	O
-	O
and	O
hetero	O
-	O
dimer	O
formation	O
,	O
and	O
the	O
same	O
groups	O
(	O
the	O
conserved	O
Cys67	O
and	O
GSH	O
)	O
can	O
act	O
as	O
iron	O
ligands	O
of	O
the	O
[	O
2Fe	O
-	O
2S	O
]	O
2	O
+	O
cluster	O
.	O

Dietary	O
calorie	O
restriction	O
is	O
a	O
broadly	O
acting	O
intervention	O
that	O
extends	O
the	O
lifespan	O
of	O
various	O
organisms	O
from	O
yeast	O
to	O
mammals	O
.	O

On	O
another	O
front	O
,	O
magnesium	O
(	O
Mg	O
<	O
sup	O
>	O
2	O
+	O
<	O
/	O
sup	O
>	O
)	O
is	O
an	O
essential	O
biological	O
metal	O
critical	O
to	O
fundamental	O
cellular	O
processes	O
and	O
is	O
commonly	O
used	O
as	O
both	O
a	O
dietary	O
supplement	O
and	O
treatment	O
for	O
some	O
clinical	O
conditions	O
.	O

If	O
connections	O
exist	O
between	O
calorie	O
restriction	O
and	O
Mg	O
<	O
sup	O
>	O
2	O
+	O
<	O
/	O
sup	O
>	O
is	O
unknown	O
.	O

Here	O
,	O
we	O
show	O
that	O
Mg	O
<	O
sup	O
>	O
2	O
+	O
<	O
/	O
sup	O
>	O
,	O
acting	O
alone	O
or	O
in	O
response	O
to	O
dietary	O
calorie	O
restriction	O
,	O
allows	O
eukaryotic	O
cells	O
to	O
combat	O
genome	O
-	O
destabilizing	O
and	O
lifespan	O
-	O
shortening	O
accumulations	O
of	O
RNA	O
-	O
DNA	O
hybrids	O
,	O
or	O
R	O
-	O
loops	O
.	O

In	O
an	O
R	O
-	O
loop	O
accumulation	O
model	O
of	O
Pbp1	O
-	O
deficient	O
Saccharomyces	O
cerevisiae	O
,	O
magnesium	O
ions	O
guided	O
by	O
cell	O
membrane	O
Mg	O
<	O
sup	O
>	O
2	O
+	O
<	O
/	O
sup	O
>	O
transporters	O
Alr1	O
/	O
2	O
act	O
via	O
Mg	O
<	O
sup	O
>	O
2	O
+	O
<	O
/	O
sup	O
>	O
-	O
sensitive	O
R	O
-	O
loop	O
suppressors	O
Rnh1	O
/	O
201	O
and	O
Pif1	O
to	O
restore	O
R	O
-	O
loop	O
suppression	O
,	O
ribosomal	O
DNA	O
stability	O
and	O
cellular	O
lifespan	O
.	O

Similarly	O
,	O
human	O
cells	O
deficient	O
in	O
ATXN2	O
,	O
the	O
human	O
ortholog	O
of	O
Pbp1	O
,	O
exhibit	O
nuclear	O
R	O
-	O
loop	O
accumulations	O
repressible	O
by	O
Mg	O
<	O
sup	O
>	O
2	O
+	O
<	O
/	O
sup	O
>	O
in	O
a	O
process	O
that	O
is	O
dependent	O
on	O
the	O
TRPM7	O
Mg	O
<	O
sup	O
>	O
2	O
+	O
<	O
/	O
sup	O
>	O
transporter	O
and	O
the	O
RNaseH1	O
R	O
-	O
loop	O
suppressor	O
.	O

Thus	O
,	O
we	O
identify	O
Mg	O
<	O
sup	O
>	O
2	O
+	O
<	O
/	O
sup	O
>	O
as	O
a	O
biochemical	O
signal	O
of	O
beneficial	O
calorie	O
restriction	O
,	O
reveal	O
an	O
R	O
-	O
loop	O
suppressing	O
function	O
for	O
human	O
ATXN2	O
and	O
propose	O
that	O
practical	O
magnesium	O
supplementation	O
regimens	O
can	O
be	O
used	O
to	O
combat	O
R	O
-	O
loop	O
accumulation	O
linked	O
to	O
the	O
dysfunction	O
of	O
disease	O
-	O
linked	O
human	O
genes	O
.	O

Avian	O
DT40	O
cells	O
in	O
which	O
endogenous	O
IP3R	O
genes	O
are	O
disrupted	O
(	O
DT40	O
-	O
KO	O
cells	O
)	O
or	O
the	O
same	O
cells	O
stably	O
expressing	O
rat	O
IP3R1	O
(	O
DT40	O
-	O
IP3R1	O
)	O
were	O
used	O
to	O
determine	O
the	O
contribution	O
of	O
IP3R	O
to	O
SOCE	O
in	O
cells	O
from	O
vertebrates	O
.	O

DT40	O
cells	O
(	O
107	O
cells	O
/	O
ml	O
)	O
were	O
loaded	O
with	O
fluo	O
-	O
4	O
by	O
incubation	O
at	O
20degreesC	O
with	O
fluo	O
-	O
4	O
AM	O
(	O
2	O
microM	O
)	O
in	O
HBS	O
containing	O
BSA	O
(	O
1	O
mg	O
/	O
ml	O
)	O
and	O
Pluronic	O
F	O
-	O
127	O
(	O
0	O
.	O
02	O
%	O
w	O
/	O
v	O
)	O
[	O
HBS	O
in	O
mM	O
:	O
NaCl	O
(	O
135	O
)	O
,	O
KCl	O
(	O
5	O
.	O
8	O
)	O
,	O
MgCl2	O
(	O
1	O
.	O
2	O
)	O
,	O
CaCl2	O
(	O
1	O
.	O
5	O
)	O
,	O
HEPES	O
(	O
11	O
.	O
6	O
)	O
,	O
d	O
-	O
glucose	O
(	O
11	O
.	O
5	O
)	O
pH	O
7	O
.	O
3	O
]	O
.	O

After	O
60	O
min	O
,	O
cells	O
were	O
centrifuged	O
(	O
650	O
g	O
,	O
2	O
min	O
)	O
,	O
re	O
-	O
suspended	O
in	O
HBS	O
(	O
5x106	O
cells	O
/	O
ml	O
)	O
and	O
distributed	O
(	O
50	O
microl	O
/	O
well	O
)	O
into	O
poly	O
-	O
l	O
-	O
lysine	O
-	O
coated	O
half	O
-	O
area	O
96	O
-	O
well	O
plates	O
.	O

After	O
centrifugation	O
(	O
300	O
g	O
,	O
2	O
min	O
)	O
fluorescence	O
(	O
excitation	O
485	O
nm	O
,	O
emission	O
525	O
nm	O
)	O
was	O
recorded	O
at	O
1	O
.	O
44	O
-	O
s	O
intervals	O
at	O
20degreesC	O
in	O
a	O
FlexStation	O
3	O
plate	O
-	O
reader	O
.	O

Fluorescence	O
signals	O
(	O
F	O
)	O
were	O
calibrated	O
to	O
[	O
Ca2	O
+	O
]	O
c	O
from	O
:	O
where	O
,	O
Fmin	O
and	O
Fmax	O
are	O
the	O
fluorescence	O
values	O
determined	O
in	O
parallel	O
wells	O
by	O
addition	O
of	O
Triton	O
X	O
-	O
100	O
(	O
0	O
.	O
1	O
%	O
w	O
/	O
v	O
)	O
and	O
either	O
BAPTA	O
(	O
10	O
mM	O
)	O
for	O
Fmin	O
,	O
or	O
CaCl2	O
(	O
10	O
mM	O
)	O
for	O
Fmax	O
,	O
and	O
KDCa	O
=	O
345	O
nM	O
.	O

The	O
overexpression	O
of	O
Buffy	O
and	O
Debcl	O
in	O
DA	O
neurons	O
results	O
in	O
a	O
longer	O
lifespan	O
and	O
improved	O
locomotor	O
ability	O
(	O
Fig	O
.	O
2	O
)	O
.	O

The	O
median	O
lifespan	O
of	O
these	O
flies	O
was	O
62	O
days	O
when	O
compared	O
to	O
Buffy	O
and	O
lacZ	O
overexpressing	O
controls	O
at	O
68	O
days	O
.	O

The	O
median	O
survival	O
of	O
Debcl	O
-	O
RNAi	O
flies	O
was	O
68	O
days	O
as	O
determined	O
by	O
a	O
Log	O
-	O
rank	O
(	O
Mantel	O
-	O
Cox	O
)	O
test	O
(	O
Fig	O
.	O
2C	O
)	O
.	O

The	O
climbing	O
ability	O
of	O
these	O
flies	O
was	O
also	O
much	O
improved	O
as	O
determined	O
by	O
comparing	O
the	O
climbing	O
indices	O
at	O
95	O
%	O
CI	O
(	O
Fig	O
.	O
2D	O
)	O
.	O

Taken	O
together	O
these	O
results	O
suggest	O
that	O
Buffy	O
antagonizes	O
the	O
Debcl	O
-	O
induced	O
phenotypes	O
of	O
shortened	O
lifespan	O
and	O
poor	O
climbing	O
ability	O
to	O
markedly	O
improve	O
"	O
healthspan	O
.	O
"	O

To	O
further	O
analyze	O
the	O
molecular	O
mechanism	O
how	O
NKAP	O
regulates	O
KT	O
-	O
MT	O
attachment	O
,	O
we	O
investigated	O
whether	O
NKAP	O
depletion	O
affected	O
the	O
kinetochore	O
/	O
centromere	O
localization	O
of	O
the	O
proteins	O
,	O
which	O
have	O
been	O
known	O
to	O
play	O
critical	O
roles	O
in	O
KT	O
-	O
MT	O
attachment	O
.	O

Among	O
the	O
candidates	O
listed	O
in	O
Fig	O
.	O

2b	O
,	O
we	O
found	O
that	O
CENP	O
-	O
E	O
was	O
the	O
only	O
protein	O
whose	O
localization	O
on	O
kinetochore	O
was	O
obviously	O
affected	O
in	O
NKAP	O
-	O
knockdown	O
cells	O
(	O
Fig	O
.	O
2b	O
;	O
Supplementary	O
Fig	O
.	O
3d	O
-	O
k	O
)	O
.	O

The	O
CENP	O
-	O
E	O
signal	O
intensity	O
on	O
kinetochores	O
was	O
significantly	O
decreased	O
for	O
both	O
aligned	O
and	O
misaligned	O
chromosomes	O
in	O
NKAP	O
-	O
knockdown	O
cells	O
(	O
Fig	O
.	O
2c	O
,	O
d	O
)	O
.	O

Since	O
previous	O
reports	O
suggested	O
that	O
NKAP	O
is	O
a	O
transcriptional	O
corepressor	O
,	O
we	O
performed	O
a	O
real	O
-	O
time	O
PCR	O
analysis	O
and	O
the	O
result	O
showed	O
that	O
NKAP	O
knockdown	O
did	O
not	O
affect	O
the	O
transcription	O
of	O
CENP	O
-	O
E	O
(	O
Supplementary	O
Fig	O
.	O
3l	O
)	O
.	O

We	O
also	O
demonstrated	O
that	O
NKAP	O
knockdown	O
had	O
no	O
effect	O
on	O
the	O
protein	O
level	O
of	O
CENP	O
-	O
E	O
and	O
other	O
proteins	O
,	O
which	O
have	O
been	O
reported	O
to	O
regulate	O
CENP	O
-	O
E	O
kinetochore	O
localization	O
(	O
Fig	O
.	O
2e	O
)	O
.	O

Moreover	O
,	O
similar	O
with	O
NKAP	O
,	O
CENP	O
-	O
E	O
knockdown	O
resulted	O
in	O
a	O
marked	O
increase	O
of	O
the	O
depolymerization	O
of	O
microtubules	O
on	O
cold	O
treatment	O
,	O
which	O
is	O
consistent	O
with	O
the	O
effect	O
of	O
NKAP	O
knockdown	O
on	O
CENP	O
-	O
E	O
kinetochore	O
localization	O
(	O
Supplementary	O
Fig	O
.	O
3m	O
)	O
.	O

Different	O
Regulations	O
of	O
ROM2	O
and	O
LRG1	O
Expression	O
by	O
Ccr4	O
,	O
Pop2	O
,	O
and	O
Dhh1	O
in	O
the	O
Saccharomyces	O
cerevisiae	O
Cell	O
Wall	O
Integrity	O
Pathway	O
.	O

Ccr4	O
,	O
a	O
component	O
of	O
the	O
Ccr4	O
-	O
Not	O
cytoplasmic	O
deadenylase	O
complex	O
,	O
is	O
known	O
to	O
be	O
required	O
for	O
the	O
cell	O
wall	O
integrity	O
(	O
CWI	O
)	O
pathway	O
in	O
the	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

However	O
,	O
it	O
is	O
not	O
fully	O
understood	O
how	O
Ccr4	O
and	O
other	O
components	O
of	O
the	O
Ccr4	O
-	O
Not	O
complex	O
regulate	O
the	O
CWI	O
pathway	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
Ccr4	O
functions	O
in	O
the	O
CWI	O
pathway	O
together	O
with	O
Khd1	O
RNA	O
binding	O
protein	O
.	O

Ccr4	O
and	O
Khd1	O
modulate	O
a	O
signal	O
from	O
Rho1	O
small	O
GTPase	O
in	O
the	O
CWI	O
pathway	O
by	O
regulating	O
the	O
expression	O
of	O
ROM2	O
mRNA	O
and	O
LRG1	O
mRNA	O
,	O
encoding	O
a	O
guanine	O
nucleotide	O
exchange	O
factor	O
(	O
GEF	O
)	O
and	O
a	O
GTPase	O
-	O
activating	O
protein	O
(	O
GAP	O
)	O
for	O
Rho1	O
,	O
respectively	O
.	O

Here	O
we	O
examined	O
the	O
possible	O
involvement	O
of	O
the	O
POP2	O
gene	O
encoding	O
a	O
subunit	O
of	O
the	O
Ccr4	O
-	O
Not	O
complex	O
and	O
the	O
DHH1	O
gene	O
encoding	O
a	O
DEAD	O
box	O
RNA	O
helicase	O
that	O
associates	O
with	O
the	O
Ccr4	O
-	O
Not	O
complex	O
in	O
the	O
regulation	O
of	O
ROM2	O
and	O
LRG1	O
expression	O
.	O

Neither	O
ROM2	O
mRNA	O
level	O
nor	O
Rom2	O
function	O
was	O
impaired	O
by	O
pop2Delta	O
or	O
dhh1Delta	O
mutation	O
.	O

The	O
LRG1	O
mRNA	O
level	O
was	O
increased	O
in	O
pop2Delta	O
and	O
dhh1Delta	O
mutants	O
,	O
as	O
well	O
as	O
the	O
ccr4Delta	O
mutant	O
,	O
and	O
the	O
growth	O
defects	O
caused	O
by	O
pop2Delta	O
and	O
dhh1Delta	O
mutations	O
were	O
suppressed	O
by	O
lrg1Delta	O
mutation	O
.	O

Our	O
results	O
suggest	O
that	O
LRG1	O
expression	O
is	O
regulated	O
by	O
Ccr4	O
together	O
with	O
Pop2	O
and	O
Dhh1	O
and	O
that	O
ROM2	O
expression	O
is	O
regulated	O
by	O
Khd1	O
and	O
Ccr4	O
,	O
but	O
not	O
by	O
Pop2	O
and	O
Dhh1	O
.	O

Thus	O
,	O
Rho1	O
activity	O
in	O
the	O
CWI	O
pathway	O
is	O
precisely	O
controlled	O
by	O
modulation	O
of	O
the	O
mRNA	O
levels	O
for	O
Rho1	O
-	O
GEF	O
Rom2	O
and	O
Rho1	O
-	O
GAP	O
Lrg1	O
.	O

IMPORTANCE	O
We	O
find	O
here	O
that	O
Ccr4	O
,	O
Pop2	O
,	O
and	O
Dhh1	O
modulate	O
the	O
levels	O
of	O
mRNAs	O
for	O
specific	O
Rho1	O
regulators	O
,	O
Rom2	O
and	O
Lrg1	O
.	O

In	O
budding	O
yeast	O
,	O
Rho1	O
activity	O
is	O
tightly	O
regulated	O
both	O
temporally	O
and	O
spatially	O
.	O

It	O
is	O
anticipated	O
that	O
Ccr4	O
,	O
Pop2	O
,	O
and	O
Dhh1	O
may	O
contribute	O
to	O
the	O
precise	O
spatiotemporal	O
control	O
of	O
Rho1	O
activity	O
by	O
regulating	O
expression	O
of	O
its	O
regulators	O
temporally	O
and	O
spatially	O
.	O

Our	O
finding	O
on	O
the	O
roles	O
of	O
the	O
components	O
of	O
the	O
Ccr4	O
-	O
Not	O
complex	O
in	O
yeast	O
would	O
give	O
important	O
information	O
for	O
understanding	O
the	O
roles	O
of	O
the	O
evolutionary	O
conserved	O
Ccr4	O
-	O
Not	O
complex	O
.	O

We	O
next	O
sought	O
to	O
narrow	O
the	O
Nop9	O
-	O
binding	O
site	O
within	O
Subdomain	O
A	O
and	O
found	O
that	O
the	O
base	O
of	O
the	O
stem	O
-	O
loop	O
region	O
and	O
the	O
adjacent	O
5	O
'	O
flanking	O
region	O
were	O
critical	O
for	O
Nop9	O
binding	O
.	O

The	O
5	O
'	O
single	O
-	O
stranded	O
nucleotides	O
1	O
-	O
16	O
were	O
necessary	O
,	O
but	O
are	O
not	O
sufficient	O
for	O
binding	O
:	O
deleting	O
5	O
'	O
nucleotides	O
1	O
-	O
16	O
abrogated	O
binding	O
,	O
but	O
nucleotides	O
1	O
-	O
16	O
alone	O
did	O
not	O
bind	O
Nop9	O
(	O
Supplementary	O
Table	O
1	O
)	O
.	O

We	O
could	O
trim	O
5	O
'	O
nucleotides	O
1	O
-	O
6	O
without	O
affecting	O
binding	O
affinity	O
,	O
indicating	O
the	O
importance	O
of	O
5	O
'	O
nucleotides	O
closer	O
to	O
the	O
stem	O
.	O

Deleting	O
the	O
3	O
'	O
single	O
-	O
stranded	O
region	O
reduced	O
binding	O
affinity	O
6	O
.	O
5	O
-	O
fold	O
,	O
suggesting	O
that	O
it	O
contributes	O
to	O
binding	O
affinity	O
,	O
but	O
not	O
to	O
the	O
same	O
extent	O
as	O
the	O
5	O
'	O
flanking	O
nucleotides	O
and	O
stem	O
loop	O
.	O

Classical	O
PUF	O
proteins	O
such	O
as	O
PUM1	O
recognize	O
RNA	O
bases	O
using	O
hydrogen	O
bond	O
and	O
stacking	O
interactions	O
,	O
and	O
binding	O
is	O
insensitive	O
to	O
salt	O
concentration	O
.	O

In	O
contrast	O
,	O
interaction	O
of	O
Puf	O
-	O
A	O
/	O
Puf6	O
proteins	O
with	O
phosphate	O
groups	O
of	O
single	O
-	O
or	O
double	O
-	O
stranded	O
RNA	O
is	O
highly	O
sensitive	O
to	O
salt	O
concentration	O
.	O

Nop9	O
:	O
ITS1	O
RNA	O
binding	O
was	O
only	O
modestly	O
sensitive	O
to	O
salt	O
concentration	O
(	O
Supplementary	O
Table	O
2	O
)	O
,	O
consistent	O
with	O
specific	O
H	O
-	O
bond	O
or	O
base	O
-	O
stacking	O
interactions	O
that	O
recognize	O
RNA	O
sequence	O
elements	O
.	O

Given	O
the	O
effect	O
of	O
TRIM21	O
on	O
Par	O
-	O
4	O
in	O
response	O
to	O
cisplatin	O
,	O
we	O
hypothesized	O
that	O
TRIM21	O
could	O
contribute	O
to	O
cisplatin	O
resistance	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
performed	O
an	O
MTT	O
viability	O
assay	O
on	O
HCT	O
-	O
116	O
cells	O
that	O
had	O
either	O
been	O
transfected	O
with	O
TRIM21	O
plasmid	O
or	O
control	O
plasmid	O
,	O
followed	O
by	O
treatment	O
with	O
increasing	O
concentrations	O
of	O
cisplatin	O
.	O

The	O
data	O
show	O
that	O
TRIM21	O
decreases	O
the	O
sensitivity	O
of	O
HCT	O
-	O
116	O
cells	O
to	O
cisplatin	O
(	O
Fig	O
.	O
8A	O
)	O
.	O

Specifically	O
,	O
HCT	O
-	O
116	O
cells	O
had	O
statistically	O
significant	O
increases	O
in	O
viability	O
at	O
cisplatin	O
doses	O
between	O
0	O
.	O
5	O
-	O
10	O
mug	O
/	O
ml	O
,	O
with	O
a	O
right	O
shift	O
in	O
IC50	O
from	O
approximately	O
5	O
mug	O
/	O
ml	O
to	O
10	O
mug	O
/	O
ml	O
between	O
the	O
control	O
and	O
TRIM21	O
transfected	O
cells	O
,	O
respectively	O
.	O

Likewise	O
,	O
we	O
performed	O
an	O
analogous	O
experiment	O
in	O
Panc	O
-	O
1	O
cells	O
,	O
a	O
pancreatic	O
cancer	O
cell	O
line	O
.	O

To	O
our	O
surprise	O
,	O
ectopic	O
TRIM21expression	O
in	O
Panc	O
-	O
1	O
cells	O
had	O
no	O
effect	O
on	O
Panc	O
-	O
1	O
cell	O
viability	O
in	O
response	O
to	O
cisplatin	O
(	O
data	O
not	O
shown	O
)	O
.	O

Despite	O
that	O
finding	O
,	O
we	O
show	O
in	O
Fig	O
.	O

8B	O
that	O
ectopic	O
Par	O
-	O
4	O
expression	O
sensitizes	O
Panc	O
-	O
1	O
cells	O
to	O
cisplatin	O
-	O
induced	O
apoptosis	O
as	O
indicated	O
by	O
PARP	O
cleavage	O
,	O
specifically	O
at	O
the	O
15	O
and	O
30	O
mug	O
/	O
ml	O
doses	O
.	O

PARP	O
cleavage	O
was	O
examined	O
by	O
Western	O
blotting	O
and	O
the	O
percentage	O
of	O
the	O
cleavage	O
product	O
was	O
determined	O
using	O
densitometry	O
.	O

Densitometric	O
analysis	O
revealed	O
that	O
Par	O
-	O
4	O
overexpression	O
increased	O
the	O
levels	O
of	O
apoptosis	O
in	O
Panc	O
-	O
1	O
cells	O
by	O
2	O
-	O
to	O
3	O
-	O
fold	O
relative	O
to	O
the	O
control	O
transfected	O
cells	O
at	O
the	O
15	O
and	O
30	O
mug	O
/	O
ml	O
doses	O
of	O
cisplatin	O
(	O
Fig	O
.	O
8B	O
)	O
.	O

(	O
A	O
)	O
Representative	O
images	O
of	O
autophagic	O
bodies	O
in	O
pep4Delta	O
(	O
left	O
)	O
or	O
hrr25	O
-	O
5pep4Delta	O
(	O
right	O
)	O
cells	O
1	O
.	O
5	O
hr	O
after	O
nitrogen	O
starvation	O
at	O
37degreesC	O
.	O

Scale	O
bar	O
represents	O
500	O
nm	O
.	O

(	O
B	O
)	O
Histogram	O
showing	O
the	O
distribution	O
of	O
the	O
number	O
of	O
autophagic	O
bodies	O
per	O
cell	O
section	O
in	O
WT	O
and	O
the	O
hrr25	O
-	O
5	O
mutant	O
.	O

The	O
number	O
of	O
autophagic	O
bodies	O
was	O
quantitated	O
for	O
100	O
cell	O
sections	O
for	O
each	O
strain	O
(	O
left	O
)	O
.	O

p	O
-	O
value	O
=	O
0	O
.	O
0016	O
;	O
Mann	O
-	O
Whitney	O
Test	O
.	O

Box	O
plot	O
of	O
the	O
number	O
of	O
autophagic	O
bodies	O
per	O
cell	O
section	O
.	O

Bars	O
show	O
data	O
between	O
the	O
lower	O
and	O
upper	O
quartiles	O
,	O
the	O
median	O
is	O
a	O
horizontal	O
line	O
within	O
the	O
box	O
.	O

Whiskers	O
indicate	O
the	O
smallest	O
and	O
largest	O
observations	O
(	O
right	O
)	O
.	O

(	O
C	O
)	O
The	O
diameter	O
of	O
autophagic	O
bodies	O
was	O
determined	O
.	O

For	O
WT	O
N	O
=	O
396	O
,	O
for	O
hrr25	O
-	O
5	O
N	O
=	O
254	O
.	O

Averages	O
with	O
error	O
bars	O
as	O
s	O
.	O
e	O
.	O
m	O
.	O
are	O
shown	O
.	O

Inappropriate	O
translation	O
inhibition	O
and	O
P	O
-	O
body	O
formation	O
cause	O
cold	O
-	O
sensitivity	O
in	O
tryptophan	O
-	O
auxotroph	O
yeast	O
mutants	O
.	O

In	O
response	O
to	O
different	O
adverse	O
conditions	O
,	O
most	O
eukaryotic	O
organisms	O
,	O
including	O
Saccharomyces	O
cerevisiae	O
,	O
downregulate	O
protein	O
synthesis	O
through	O
the	O
phosphorylation	O
of	O
eIF2alpha	O
(	O
eukaryotic	O
initiation	O
factor	O
2alpha	O
)	O
by	O
Gcn2	O
,	O
a	O
highly	O
conserved	O
protein	O
kinase	O
.	O

Gcn2	O
also	O
controls	O
the	O
translation	O
of	O
Gcn4	O
,	O
a	O
transcription	O
factor	O
involved	O
in	O
the	O
induction	O
of	O
amino	O
acid	O
biosynthesis	O
enzymes	O
.	O

Here	O
,	O
we	O
have	O
studied	O
the	O
functional	O
role	O
of	O
Gcn2	O
and	O
Gcn2	O
-	O
regulating	O
proteins	O
,	O
in	O
controlling	O
translation	O
during	O
temperature	O
downshifts	O
of	O
TRP1	O
and	O
trp1	O
yeast	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
neither	O
cold	O
-	O
instigated	O
amino	O
acid	O
limitation	O
nor	O
Gcn2	O
are	O
involved	O
in	O
the	O
translation	O
suppression	O
at	O
low	O
temperature	O
.	O

However	O
,	O
loss	O
of	O
TRP1	O
causes	O
increased	O
eIF2alpha	O
phosphorylation	O
,	O
Gcn2	O
-	O
dependent	O
polysome	O
disassembly	O
and	O
overactivity	O
of	O
Gcn4	O
,	O
which	O
result	O
in	O
cold	O
-	O
sensitivity	O
.	O

Indeed	O
,	O
knock	O
-	O
out	O
of	O
GCN2	O
improves	O
cold	O
growth	O
of	O
trp1	O
cells	O
.	O

Likewise	O
,	O
mutation	O
of	O
several	O
Gcn2	O
-	O
regulators	O
and	O
effectors	O
results	O
in	O
cold	O
-	O
growth	O
effects	O
.	O

Remarkably	O
,	O
we	O
found	O
that	O
Hog1	O
,	O
the	O
osmoresponsive	O
MAPK	O
,	O
plays	O
a	O
role	O
in	O
the	O
regulatory	O
mechanism	O
of	O
Gcn2	O
-	O
eIF2alpha	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
P	O
-	O
body	O
formation	O
responds	O
to	O
a	O
downshift	O
in	O
temperature	O
in	O
a	O
TRP1	O
-	O
dependent	O
manner	O
and	O
is	O
required	O
for	O
cold	O
tolerance	O
.	O

Blood	O
pressure	O
-	O
associated	O
polymorphism	O
controls	O
ARHGAP42	O
expression	O
via	O
serum	O
response	O
factor	O
DNA	O
binding	O
.	O

We	O
recently	O
demonstrated	O
that	O
selective	O
expression	O
of	O
the	O
Rho	O
GTPase	O
-	O
activating	O
protein	O
ARHGAP42	O
in	O
smooth	O
muscle	O
cells	O
(	O
SMCs	O
)	O
controls	O
blood	O
pressure	O
by	O
inhibiting	O
RhoA	O
-	O
dependent	O
contractility	O
,	O
providing	O
a	O
mechanism	O
for	O
the	O
blood	O
pressure	O
-	O
associated	O
locus	O
within	O
the	O
ARHGAP42	O
gene	O
.	O

The	O
goals	O
of	O
the	O
current	O
study	O
were	O
to	O
identify	O
polymorphisms	O
that	O
affect	O
ARHGAP42	O
expression	O
and	O
to	O
better	O
assess	O
ARHGAP42	O
'	O
s	O
role	O
in	O
the	O
development	O
of	O
hypertension	O
.	O

Using	O
DNase	O
I	O
hypersensitivity	O
methods	O
and	O
ENCODE	O
data	O
,	O
we	O
have	O
identified	O
a	O
regulatory	O
element	O
encompassing	O
the	O
ARHGAP42	O
SNP	O
rs604723	O
that	O
exhibits	O
strong	O
SMC	O
-	O
selective	O
,	O
allele	O
-	O
specific	O
activity	O
.	O

Importantly	O
,	O
CRISPR	O
/	O
Cas9	O
-	O
mediated	O
deletion	O
of	O
this	O
element	O
in	O
cultured	O
human	O
SMCs	O
markedly	O
reduced	O
endogenous	O
ARHGAP42	O
expression	O
.	O

DNA	O
binding	O
and	O
transcription	O
assays	O
demonstrated	O
that	O
the	O
minor	O
T	O
allele	O
variation	O
at	O
rs604723	O
increased	O
the	O
activity	O
of	O
this	O
fragment	O
by	O
promoting	O
serum	O
response	O
transcription	O
factor	O
binding	O
to	O
a	O
cryptic	O
cis	O
-	O
element	O
.	O

ARHGAP42	O
expression	O
was	O
increased	O
by	O
cell	O
stretch	O
and	O
sphingosine	O
1	O
-	O
phosphate	O
in	O
a	O
RhoA	O
-	O
dependent	O
manner	O
,	O
and	O
deletion	O
of	O
ARHGAP42	O
enhanced	O
the	O
progression	O
of	O
hypertension	O
in	O
mice	O
treated	O
with	O
DOCA	O
-	O
salt	O
.	O

Our	O
analysis	O
of	O
a	O
well	O
-	O
characterized	O
cohort	O
of	O
untreated	O
borderline	O
hypertensive	O
patients	O
suggested	O
that	O
ARHGAP42	O
genotype	O
has	O
important	O
implications	O
in	O
regard	O
to	O
hypertension	O
risk	O
.	O

Taken	O
together	O
,	O
our	O
data	O
add	O
insight	O
into	O
the	O
genetic	O
mechanisms	O
that	O
control	O
blood	O
pressure	O
and	O
provide	O
a	O
potential	O
target	O
for	O
individualized	O
antihypertensive	O
therapies	O
.	O

The	O
functional	O
and	O
physical	O
relationships	O
among	O
these	O
proteins	O
,	O
and	O
the	O
function	O
of	O
SM	O
proteins	O
in	O
particular	O
,	O
have	O
remained	O
obscure	O
despite	O
extensive	O
study	O
.	O

Vps33	O
,	O
the	O
SM	O
subunit	O
of	O
HOPS	B-Complex
,	O
has	O
conserved	O
grooves	O
that	O
bind	O
the	O
alpha	O
-	O
helical	O
SNARE	O
domains	O
of	O
R	O
-	O
and	O
Qa	O
-	O
SNAREs	O
in	O
parallel	O
and	O
in	O
register	O
with	O
respect	O
to	O
the	O
arginyl	O
and	O
glutaminyl	O
residues	O
at	O
the	O
center	O
of	O
their	O
SNARE	O
domains	O
,	O
the	O
0	O
-	O
layer	O
.	O

This	O
might	O
represent	O
an	O
early	O
step	O
in	O
the	O
catalysis	O
of	O
trans	O
-	O
SNARE	B-Complex
complex	O
assembly	O
.	O

This	O
idea	O
was	O
supported	O
by	O
functional	O
studies	O
in	O
which	O
SNARE	B-Complex
complex	O
assembly	O
was	O
inferred	O
from	O
assays	O
of	O
the	O
consequent	O
fusion	O
.	O

When	O
R	O
-	O
SNARE	O
proteoliposomes	O
were	O
incubated	O
with	O
proteoliposomes	O
in	O
which	O
the	O
three	O
Q	O
-	O
SNAREs	O
were	O
preassembled	O
,	O
HOPS	B-Complex
was	O
needed	O
only	O
for	O
its	O
tethering	O
function	O
because	O
HOPS	B-Complex
with	O
mutations	O
in	O
its	O
SM	O
subunit	O
that	O
blocked	O
SNARE	O
domain	O
binding	O
supported	O
this	O
fusion	O
,	O
and	O
the	O
nonspecific	O
membrane	O
clustering	O
agent	O
polyethylene	O
glycol	O
could	O
substitute	O
for	O
HOPS	B-Complex
.	O

When	O
the	O
Q	O
-	O
SNAREs	O
were	O
not	O
preassembled	O
on	O
the	O
starting	O
proteoliposomes	O
and	O
the	O
fusion	O
reaction	O
depended	O
on	O
separate	O
addition	O
of	O
the	O
Qc	O
-	O
SNARE	O
,	O
these	O
HOPS	B-Complex
mutants	O
still	O
supported	O
vesicle	O
clustering	O
but	O
no	O
longer	O
supported	O
fusion	O
,	O
and	O
polyethylene	O
glycol	O
no	O
longer	O
sufficed	O
.	O

It	O
was	O
therefore	O
suggested	O
that	O
HOPS	B-Complex
may	O
function	O
beyond	O
tethering	O
when	O
maximal	O
SNARE	B-Complex
complex	O
assembly	O
is	O
required	O
.	O

To	O
test	O
this	O
model	O
,	O
further	O
direct	O
assays	O
of	O
the	O
amounts	O
of	O
newly	O
assembled	O
SNARE	B-Complex
complex	O
that	O
form	O
in	O
the	O
presence	O
or	O
absence	O
of	O
HOPS	B-Complex
are	O
required	O
to	O
establish	O
whether	O
HOPS	B-Complex
suffices	O
to	O
mediate	O
such	O
assembly	O
.	O

(	O
A	O
)	O
Tim17R105A	O
mutant	O
is	O
correctly	O
inserted	O
into	O
the	O
inner	O
membrane	O
.	O

Submitochondrial	O
localization	O
of	O
Tim17	O
,	O
wild	O
type	O
(	O
WT	O
)	O
and	O
R105A	O
mutant	O
(	O
tim17R105A	O
)	O
,	O
was	O
analyzed	O
by	O
its	O
accessibility	O
to	O
Proteinase	O
K	O
(	O
PK	O
)	O
in	O
intact	O
mitochondria	O
,	O
upon	O
opening	O
of	O
the	O
outer	O
membrane	O
(	O
+	O
swelling	O
)	O
and	O
upon	O
solubilization	O
of	O
both	O
mitochondrial	O
membranes	O
(	O
+	O
TX	O
-	O
100	O
)	O
.	O

In	O
addition	O
,	O
mitochondria	O
were	O
subjected	O
to	O
carbonate	O
extraction	O
(	O
CE	O
)	O
and	O
fractionated	O
into	O
supernatant	O
(	O
S	O
)	O
and	O
pellet	O
(	O
P	O
)	O
fractions	O
that	O
contain	O
soluble	O
and	O
membrane	O
proteins	O
,	O
respectively	O
.	O

All	O
samples	O
were	O
analyzed	O
by	O
SDS	O
-	O
PAGE	O
followed	O
by	O
immunoblotting	O
with	O
indicated	O
antibodies	O
.	O

Tom70	O
served	O
as	O
a	O
marker	O
for	O
a	O
membrane	O
-	O
integrated	O
outer	O
membrane	O
protein	O
,	O
Tim50	O
for	O
a	O
membrane	O
-	O
integrated	O
inner	O
membrane	O
protein	O
exposed	O
to	O
the	O
intermembrane	O
space	O
and	O
Mge1	O
for	O
a	O
soluble	O
matrix	O
protein	O
.	O

(	O
B	O
)	O
Mitochondria	O
were	O
isolated	O
from	O
wild	O
type	O
(	O
WT	O
)	O
and	O
tim17R105A	O
(	O
R105A	O
)	O
yeast	O
cells	O
grown	O
under	O
permissive	O
conditions	O
in	O
YPD	O
medium	O
at	O
24degreesC	O
.	O

In	O
vitro	O
imports	O
of	O
indicated	O
precursor	O
proteins	O
were	O
performed	O
as	O
described	O
in	O
Figure	O
2	O
-	O
-	O
figure	O
supplement	O
1	O
.	O

(	O
C	O
)	O
Ten	O
-	O
fold	O
serial	O
dilutions	O
of	O
cells	O
were	O
spotted	O
on	O
YPD	O
and	O
YPLac	O
plates	O
and	O
incubated	O
at	O
indicated	O
temperatures	O
.	O

(	O
D	O
)	O
Isolated	O
mitochondria	O
,	O
as	O
indicated	O
,	O
were	O
solubilized	O
in	O
digitonin	O
-	O
containing	O
buffer	O
and	O
cleared	O
lysates	O
were	O
incubated	O
with	O
affinity	O
purified	O
antibodies	O
to	O
Tim17	O
,	O
Tim23	O
and	O
Tim16	O
prebound	O
to	O
Protein	O
A	O
-	O
Sepharose	O
.	O

Antibodies	O
from	O
preimmune	O
(	O
PI	O
)	O
serum	O
were	O
used	O
as	O
a	O
negative	O
control	O
.	O

After	O
three	O
washing	O
steps	O
,	O
proteins	O
specifically	O
bound	O
to	O
the	O
beads	O
were	O
eluted	O
with	O
Laemmli	O
buffer	O
.	O

Total	O
(	O
20	O
%	O
)	O
and	O
bound	O
fractions	O
(	O
100	O
%	O
)	O
were	O
analyzed	O
by	O
SDS	O
-	O
PAGE	O
followed	O
by	O
immunoblotting	O
with	O
indicated	O
antibodies	O
.	O

(	O
E	O
)	O
Cells	O
carrying	O
a	O
His	O
-	O
tagged	O
version	O
of	O
Tim17	O
and	O
a	O
BPA	O
residue	O
at	O
position	O
106	O
were	O
UV	O
irradiated	O
,	O
where	O
indicated	O
.	O

Total	O
cell	O
extracts	O
were	O
prepared	O
,	O
diluted	O
with	O
Triton	O
X	O
-	O
100	O
buffer	O
and	O
incubated	O
with	O
Ni	O
-	O
agarose	O
beads	O
.	O

After	O
three	O
washing	O
steps	O
,	O
specifically	O
bound	O
proteins	O
were	O
eluted	O
.	O

Samples	O
were	O
analyzed	O
by	O
SDS	O
-	O
PAGE	O
and	O
immunoblotting	O
with	O
Tim44	O
antibodies	O
.	O

To	O
further	O
evaluate	O
the	O
role	O
of	O
Nek7	O
at	O
telomeres	O
,	O
we	O
first	O
disrupted	O
telomeric	O
structure	O
by	O
knocking	O
down	O
(	O
KD	O
)	O
the	O
shelterin	B-Complex
protein	O
TRF2	O
,	O
but	O
we	O
did	O
not	O
observe	O
Nek7	O
recruitment	O
at	O
telomeres	O
under	O
this	O
condition	O
(	O
Figure	O
S1D	O
)	O
.	O

Second	O
,	O
we	O
introduced	O
telomeric	O
DNA	O
injury	O
by	O
using	O
Flag	O
-	O
TRF1	O
-	O
Fok1	O
endonuclease	O
to	O
cut	O
telomeres	O
specifically	O
or	O
by	O
treating	O
cells	O
with	O
low	O
and	O
high	O
levels	O
of	O
the	O
DNA	B-OOS
polymerase	I-OOS
inhibitor	O
aphidicolin	O
,	O
which	O
could	O
induce	O
fragile	O
telomeres	O
,	O
an	O
indicator	O
of	O
replication	O
folk	O
stall	O
.	O

Interestingly	O
,	O
under	O
both	O
conditions	O
,	O
Nek7	O
was	O
not	O
recruited	O
to	O
the	O
damaged	O
telomere	O
sites	O
(	O
Figures	O
S1E	O
and	O
S1F	O
)	O
.	O

Thus	O
,	O
the	O
recruitment	O
of	O
Nek7	O
is	O
likely	O
restricted	O
to	O
oxidative	O
telomeric	O
DNA	O
damage	O
.	O

The	O
binding	O
of	O
pUb	O
to	O
Parkin	O
acts	O
as	O
an	O
allosteric	O
modulator	O
,	O
dissociating	O
the	O
Ubl	O
domain	O
from	O
RING1	O
and	O
making	O
Ser65	O
more	O
accessible	O
for	O
phosphorylation	O
.	O

The	O
interaction	O
between	O
the	O
phosphate	O
group	O
of	O
pUb	O
and	O
Parkin	O
occurs	O
through	O
the	O
side	O
chains	O
of	O
His302	O
and	O
Arg305	O
(	O
refs	O
)	O
.	O

As	O
shown	O
previously	O
,	O
Parkin	O
mutants	O
that	O
disrupt	O
pUb	O
binding	O
(	O
H302A	O
)	O
indeed	O
do	O
not	O
translocate	O
to	O
depolarized	O
mitochondria	O
(	O
Fig	O
.	O
2a	O
,	O
b	O
)	O
,	O
nor	O
do	O
they	O
ubiquitinate	O
mitochondrial	O
substrates	O
in	O
ubiquitination	O
assays	O
(	O
Fig	O
.	O
2c	O
,	O
d	O
)	O
.	O

In	O
addition	O
,	O
disruption	O
of	O
the	O
hydrophobic	O
interaction	O
between	O
pUb	O
and	O
Parkin	O
by	O
the	O
A320R	O
mutation	O
was	O
found	O
to	O
completely	O
block	O
Parkin	O
translocation	O
(	O
Supplementary	O
Fig	O
.	O
2	O
)	O
.	O

To	O
determine	O
whether	O
this	O
effect	O
was	O
mediated	O
through	O
the	O
inability	O
of	O
the	O
Ubl	O
domain	O
to	O
be	O
released	O
from	O
RING1	O
,	O
we	O
made	O
Parkin	O
double	O
mutants	O
that	O
disrupt	O
the	O
Ubl	O
:	O
RING1	O
interface	O
and	O
pUb	O
binding	O
,	O
and	O
tested	O
their	O
activity	O
in	O
cells	O
and	O
in	O
vitro	O
.	O

We	O
found	O
that	O
cells	O
expressing	O
H302A	O
/	O
N273K	O
or	O
A320R	O
/	O
N273K	O
Parkin	O
double	O
mutants	O
showed	O
significantly	O
delayed	O
recruitment	O
to	O
depolarized	O
mitochondria	O
compared	O
to	O
WT	O
(	O
Fig	O
.	O
2a	O
,	O
b	O
and	O
Supplementary	O
Fig	O
.	O
2	O
)	O
.	O

The	O
release	O
of	O
the	O
Ubl	O
domain	O
is	O
therefore	O
insufficient	O
to	O
rescue	O
mutant	O
Parkin	O
variants	O
defective	O
in	O
pUb	O
binding	O
.	O

Binding	O
of	O
pUb	O
to	O
Parkin	O
was	O
also	O
proposed	O
to	O
help	O
release	O
the	O
REP	O
and	O
affect	O
the	O
RING0	O
:	O
RING2	O
interface	O
.	O

Therefore	O
,	O
we	O
next	O
asked	O
whether	O
activating	O
mutations	O
that	O
release	O
the	O
REP	O
or	O
disrupt	O
the	O
RING0	O
:	O
RING2	O
interface	O
could	O
rescue	O
deficits	O
in	O
pUb	O
binding	O
by	O
making	O
Parkin	O
double	O
mutants	O
(	O
H302A	O
/	O
W403A	O
,	O
H302A	O
/	O
F146A	O
,	O
A320R	O
/	O
W403A	O
or	O
A320R	O
/	O
F146A	O
)	O
.	O

Neither	O
the	O
W403A	O
-	O
nor	O
F146A	O
-	O
activating	O
mutations	O
were	O
able	O
to	O
rescue	O
deficits	O
in	O
Parkin	O
recruitment	O
and	O
ubiquitination	O
(	O
Fig	O
.	O
2a	O
-	O
d	O
and	O
Supplementary	O
Fig	O
.	O
2	O
)	O
,	O
although	O
low	O
levels	O
of	O
mitochondrial	O
recruitment	O
could	O
be	O
observed	O
in	O
the	O
H302A	O
/	O
W403A	O
and	O
H302A	O
/	O
F146A	O
mutants	O
at	O
late	O
time	O
points	O
.	O

This	O
confirms	O
that	O
the	O
role	O
of	O
pUb	O
as	O
a	O
Parkin	O
receptor	O
is	O
primordial	O
.	O

We	O
previously	O
determined	O
CIITA	O
'	O
s	O
ubiquitination	O
status	O
to	O
include	O
mono	O
,	O
K63	O
,	O
and	O
K48	O
ubiquitination	O
.	O

Bhat	O
et	O
al	O
.	O
showed	O
the	O
three	O
sites	O
of	O
monoubiquitination	O
on	O
CIITA	O
are	O
necessary	O
for	O
CIITA	O
stability	O
and	O
for	O
increased	O
CIITA	O
transactivity	O
.	O

Additionally	O
,	O
we	O
previously	O
demonstrated	O
CIITA	O
modified	O
by	O
K63	O
linked	O
ubiquitination	O
plays	O
a	O
role	O
in	O
CIITA	O
movement	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
.	O

Knowing	O
that	O
several	O
types	O
of	O
ubiquitination	O
linkages	O
modify	O
CIITA	O
,	O
we	O
wanted	O
to	O
determine	O
if	O
pCAF	O
was	O
able	O
to	O
facilitate	O
all	O
three	O
types	O
of	O
CIITA	O
ubiquitination	O
.	O

Previously	O
,	O
we	O
demonstrated	O
pCAF	O
is	O
able	O
to	O
mediate	O
K48	O
linked	O
CIITA	O
ubiquitination	O
in	O
the	O
absence	O
of	O
CIITA	O
acetylation	O
.	O

To	O
investigate	O
if	O
pCAF	O
is	O
able	O
to	O
mediate	O
various	O
ubiquitin	O
linkages	O
on	O
CIITA	O
,	O
we	O
conducted	O
in	O
vivo	O
ubiquitination	O
assays	O
.	O

We	O
demonstrate	O
CIITA	O
monoubiquitination	O
,	O
K63	O
,	O
and	O
K48	O
linked	O
ubiquitination	O
all	O
increase	O
in	O
the	O
presence	O
of	O
WT	O
pCAF	O
as	O
compared	O
to	O
assays	O
performed	O
when	O
WT	O
CIITA	O
is	O
expressed	O
alone	O
(	O
Figures	O
8	O
(	O
a	O
)	O
,	O
8	O
(	O
b	O
)	O
,	O
and	O
8	O
(	O
c	O
)	O
,	O
compare	O
lanes	O
1	O
and	O
2	O
)	O
.	O

When	O
the	O
proteasome	B-Complex
inhibitor	O
MG132	O
inhibits	O
the	O
26S	B-Complex
proteasome	I-Complex
,	O
all	O
three	O
forms	O
of	O
ubiquitinated	O
CIITA	O
accumulated	O
indicating	O
maximum	O
ubiquitination	O
levels	O
(	O
Figures	O
8	O
(	O
a	O
)	O
,	O
8	O
(	O
b	O
)	O
,	O
and	O
8	O
(	O
c	O
)	O
,	O
lane	O
3	O
)	O
.	O

These	O
data	O
indicate	O
pCAF	O
'	O
s	O
ability	O
to	O
mediate	O
multiple	O
forms	O
of	O
ubiquitination	O
of	O
CIITA	O
.	O

As	O
an	O
integral	O
subunit	O
of	O
the	O
proteasome	B-Complex
complex	O
,	O
Rpn1	O
associates	O
with	O
several	O
neighboring	O
subunits	O
in	O
the	O
19S	B-Complex
.	O

Does	O
this	O
leave	O
sufficient	O
surface	O
area	O
exposed	O
to	O
bind	O
its	O
ligands	O
such	O
as	O
UBLs	O
or	O
polyUb	O
?	O

From	O
current	O
cryoEM	O
-	O
derived	O
proteasome	B-Complex
models	O
(	O
PDB	O
4cr2	B-OOS
)	O
,	O
Rpn1	O
is	O
situated	O
peripherally	O
on	O
the	O
19S	B-Complex
RP	O
touching	O
two	O
AAA	O
ATPase	O
subunits	O
Rpt1	O
and	O
Rpt2	O
(	O
Figure	O
S3	O
)	O
.	O

Not	O
surprisingly	O
,	O
most	O
evolutionary	O
conserved	O
residues	O
on	O
the	O
surface	O
of	O
Rpn1	O
identified	O
with	O
the	O
ConSurf	O
server	O
contacted	O
neighboring	O
subunits	O
Rpt1	O
and	O
Rpt2	O
when	O
incorporated	O
into	O
the	O
proteasome	B-Complex
,	O
although	O
a	O
few	O
exposed	O
residues	O
that	O
are	O
not	O
in	O
direct	O
contact	O
with	O
any	O
other	O
proteasome	B-Complex
subunit	O
are	O
also	O
highly	O
conserved	O
between	O
Rpn1	O
sequences	O
across	O
eukaryotes	O
(	O
Figure	O
S3	O
)	O
.	O

By	O
focusing	O
on	O
Rpn1	O
(	O
chain	O
Z	O
in	O
PDB	O
4cr2	B-OOS
)	O
and	O
its	O
two	O
nearest	O
neighbors	O
,	O
it	O
becomes	O
apparent	O
that	O
half	O
of	O
the	O
PC	O
toroid	O
(	O
see	O
previous	O
paragraph	O
)	O
is	O
solvent	O
-	O
exposed	O
suitably	O
positioned	O
to	O
serve	O
as	O
a	O
docking	O
station	O
for	O
substrates	O
or	O
substrate	O
-	O
shuttles	O
possibly	O
explaining	O
the	O
presence	O
of	O
highly	O
conserved	O
exposed	O
residues	O
(	O
Figure	O
4F	O
,	O
S3	O
)	O
.	O

Somatic	O
mutations	O
are	O
the	O
predominant	O
cause	O
of	O
cell	O
cycle	O
dysregulation	O
and	O
unrestrained	O
proliferation	O
that	O
occurs	O
during	O
the	O
development	O
of	O
sporadic	O
cancers	O
.	O

Recently	O
,	O
members	O
of	O
the	O
apolipoprotein	O
B	O
mRNA	O
editing	O
enzyme	O
catalytic	O
polypeptide	O
-	O
like	O
(	O
APOBEC	O
)	O
family	O
of	O
cytidine	O
deaminases	O
have	O
been	O
identified	O
as	O
tumor	O
-	O
specific	O
sources	O
of	O
DNA	O
damage	O
occurring	O
in	O
~	O
15	O
%	O
of	O
human	O
cancers	O
.	O

The	O
catalytically	O
active	O
enzymes	O
in	O
this	O
family	O
,	O
which	O
include	O
activation	O
-	O
induced	O
cytidine	O
deaminase	O
(	O
AID	O
)	O
,	O
APOBEC1	O
and	O
the	O
seven	O
APOBEC3	O
enzymes	O
(	O
A	O
through	O
H	O
)	O
,	O
all	O
deaminate	O
cytidines	O
in	O
single	O
-	O
strand	O
(	O
ss	O
)	O
DNA	O
substrates	O
resulting	O
in	O
cytidine	O
(	O
C	O
)	O
to	O
thymidine	O
(	O
T	O
)	O
or	O
C	O
to	O
guanidine	O
(	O
G	O
)	O
substitutions	O
.	O

Additionally	O
,	O
every	O
active	O
APOBEC	O
family	O
member	O
except	O
AID	O
and	O
APOBEC3G	O
(	O
A3G	O
)	O
deaminate	O
cytidines	O
specifically	O
within	O
TCW	O
motifs	O
(	O
where	O
the	O
underlined	O
C	O
is	O
deaminated	O
and	O
W	O
=	O
adenine	O
(	O
A	O
)	O
or	O
T	O
)	O
.	O

This	O
nucleotide	O
editing	O
capacity	O
normally	O
is	O
used	O
to	O
tailor	O
immunoglobulin	B-OOS
affinities	O
(	O
AID	O
)	O
,	O
alter	O
apolipoproteins	O
involved	O
in	O
dietary	O
lipid	O
transport	O
(	O
APOBEC1	O
)	O
and	O
as	O
an	O
anti	O
-	O
viral	O
/	O
retrotransposon	O
innate	O
immune	O
response	O
(	O
APOBEC1	O
and	O
APOBEC3	O
)	O
.	O

To	O
investigate	O
the	O
diversity	O
of	O
protein	O
complexes	O
,	O
we	O
selected	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
FBP1	O
complex	O
.	O

This	O
homotetrameric	O
complex	O
is	O
the	O
rate	O
-	O
limiting	O
enzyme	O
in	O
the	O
yeast	O
gluconeogenesis	O
pathway	O
and	O
is	O
rapidly	O
expressed	O
in	O
the	O
absence	O
of	O
sugar	O
.	O

However	O
,	O
when	O
cells	O
are	O
replenished	O
with	O
glucose	O
,	O
glycolysis	O
takes	O
place	O
and	O
FBP1	O
is	O
inactivated	O
.	O

To	O
date	O
,	O
the	O
full	O
repertoire	O
of	O
regulatory	O
events	O
enabling	O
activation	O
and	O
inactivation	O
of	O
FBP1	O
are	O
yet	O
to	O
be	O
deciphered	O
.	O

To	O
follow	O
FBP1	O
dynamics	O
,	O
we	O
have	O
grown	O
yeast	O
in	O
the	O
absence	O
of	O
glucose	O
and	O
then	O
shifted	O
the	O
cells	O
to	O
glucose	O
-	O
containing	O
medium	O
.	O

In	O
parallel	O
,	O
we	O
also	O
exposed	O
carbon	O
starved	O
yeast	O
cells	O
to	O
heat	O
shock	O
,	O
reasoning	O
that	O
this	O
treatment	O
may	O
give	O
rise	O
to	O
a	O
distinct	O
response	O
.	O

Then	O
,	O
using	O
a	O
single	O
-	O
step	O
FLAG	O
-	O
affinity	O
purification	O
protocol	O
,	O
FBP1	O
was	O
isolated	O
from	O
the	O
three	O
different	O
growth	O
conditions	O
(	O
glucose	O
,	O
carbon	O
starved	O
,	O
and	O
carbon	O
starved	O
+	O
heat	O
shock	O
)	O
and	O
the	O
composition	O
of	O
the	O
complex	O
was	O
explored	O
.	O

ChIP	O
shows	O
Sub1	O
-	O
association	O
with	O
G4	O
DNA	O
in	O
vivo	O
.	O

Chromatin	O
immunoprecipitation	O
was	O
carried	O
out	O
with	O
anti	O
-	O
FLAG	O
antibody	O
and	O
chromatin	O
fractions	O
prepared	O
from	O
yeast	O
cells	O
with	O
indicated	O
genetic	O
backgrounds	O
.	O

In	O
all	O
strains	O
,	O
3XFLAG	O
epitope	O
tagged	O
SUB1	O
allele	O
was	O
present	O
.	O

5	O
'	O
BGL	O
and	O
STP	O
primers	O
anneal	O
within	O
LYS2	O
ORF	O
,	O
~	O
100	O
and	O
~	O
3000	O
bp	O
from	O
the	O
Smu	O
sequence	O
insertion	O
site	O
,	O
respectively	O
.	O

YDR	O
primers	O
anneal	O
to	O
YDR554C	O
region	O
of	O
the	O
yeast	O
genome	O
.	O

All	O
primer	O
sequences	O
are	O
in	O
Supplementary	O
Table	O
S1	O
.	O

All	O
values	O
are	O
based	O
on	O
four	O
independent	O
experiments	O
and	O
the	O
standard	O
deviations	O
are	O
indicated	O
by	O
error	O
bars	O
.	O

(	O
A	O
)	O
Transcription	O
from	O
pTET	O
was	O
repressed	O
by	O
culturing	O
cells	O
in	O
rich	O
media	O
with	O
2mug	O
/	O
ml	O
doxycycline	O
.	O

(	O
B	O
)	O
Cells	O
were	O
cultured	O
in	O
rich	O
media	O
with	O
no	O
doxycycline	O
to	O
ensure	O
pTET	O
is	O
fully	O
turned	O
on	O
.	O

P	O
values	O
were	O
calculated	O
by	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

The	O
histone	O
variant	O
H2A	O
.	O
Z	O
promotes	O
splicing	O
of	O
weak	O
introns	O
.	O

Multiple	O
lines	O
of	O
evidence	O
implicate	O
chromatin	O
in	O
the	O
regulation	O
of	O
premessenger	O
RNA	O
(	O
pre	O
-	O
mRNA	O
)	O
splicing	O
.	O

However	O
,	O
the	O
influence	O
of	O
chromatin	O
factors	O
on	O
cotranscriptional	O
splice	O
site	O
usage	O
remains	O
unclear	O
.	O

Here	O
we	O
investigated	O
the	O
function	O
of	O
the	O
highly	O
conserved	O
histone	O
variant	O
H2A	O
.	O
Z	O
in	O
pre	O
-	O
mRNA	O
splicing	O
using	O
the	O
intron	O
-	O
rich	O
model	O
yeast	O
Schizosaccharomyces	O
pombe	O
Using	O
epistatic	O
miniarray	O
profiles	O
(	O
EMAPs	O
)	O
to	O
survey	O
the	O
genetic	O
interaction	O
landscape	O
of	O
the	O
Swr1	B-Complex
nucleosome	O
remodeling	O
complex	O
,	O
which	O
deposits	O
H2A	O
.	O
Z	O
,	O
we	O
uncovered	O
evidence	O
for	O
functional	O
interactions	O
with	O
components	O
of	O
the	O
spliceosome	B-Complex
.	O

In	O
support	O
of	O
these	O
genetic	O
connections	O
,	O
splicing	O
-	O
specific	O
microarrays	O
show	O
that	O
H2A	O
.	O
Z	O
and	O
the	O
Swr1	B-Complex
ATPase	O
are	O
required	O
during	O
temperature	O
stress	O
for	O
the	O
efficient	O
splicing	O
of	O
a	O
subset	O
of	O
introns	O
.	O

Notably	O
,	O
affected	O
introns	O
are	O
enriched	O
for	O
H2A	O
.	O
Z	O
occupancy	O
and	O
more	O
likely	O
to	O
contain	O
nonconsensus	O
splice	O
sites	O
.	O

To	O
test	O
the	O
significance	O
of	O
the	O
latter	O
correlation	O
,	O
we	O
mutated	O
the	O
splice	O
sites	O
in	O
an	O
affected	O
intron	O
to	O
consensus	O
and	O
found	O
that	O
this	O
suppressed	O
the	O
requirement	O
for	O
H2A	O
.	O
Z	O
in	O
splicing	O
of	O
that	O
intron	O
.	O

These	O
data	O
suggest	O
that	O
H2A	O
.	O
Z	O
occupancy	O
promotes	O
cotranscriptional	O
splicing	O
of	O
suboptimal	O
introns	O
that	O
may	O
otherwise	O
be	O
discarded	O
via	O
proofreading	O
ATPases	O
.	O

Consistent	O
with	O
this	O
model	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
splicing	O
ATPase	O
Prp16	O
suppresses	O
both	O
the	O
growth	O
and	O
splicing	O
defects	O
seen	O
in	O
the	O
absence	O
of	O
H2A	O
.	O
Z	O
.	O

Knockdown	O
of	O
ZFPL1	O
results	O
in	O
increased	O
autophagy	O
and	O
autophagy	O
-	O
related	O
cell	O
death	O
in	O
NCI	O
-	O
N87	O
and	O
BGC	O
-	O
823	O
human	O
gastric	O
carcinoma	O
cell	O
lines	O
.	O

Macroautophagy	O
,	O
which	O
will	O
hereafter	O
be	O
referred	O
to	O
as	O
autophagy	O
,	O
is	O
an	O
evolutionarily	O
conserved	O
process	O
,	O
during	O
which	O
cells	O
recycle	O
and	O
remove	O
damaged	O
organelles	O
and	O
proteins	O
in	O
response	O
to	O
cellular	O
stress	O
.	O

However	O
,	O
the	O
mechanisms	O
underlying	O
the	O
regulation	O
of	O
autophagy	O
remain	O
to	O
be	O
fully	O
elucidated	O
.	O

The	O
present	O
study	O
demonstrated	O
that	O
knockdown	O
of	O
zinc	O
finger	O
protein	O
like	O
1	O
(	O
ZFPL1	O
)	O
induces	O
autophagy	O
and	O
increases	O
autophagic	O
cell	O
death	O
in	O
NCI	O
-	O
N87	O
and	O
BGC	O
-	O
823	O
human	O
gastric	O
carcinoma	O
cell	O
lines	O
.	O

To	O
examine	O
the	O
role	O
of	O
ZFPL1	O
in	O
gastric	O
carcinoma	O
cells	O
,	O
ZFPL1	O
expression	O
was	O
downregulated	O
by	O
lentiviral	O
infection	O
.	O

Zinc	O
finger	O
domain	O
-	O
FLAG	O
was	O
used	O
to	O
compete	O
with	O
ZFPL1	O
for	O
golgin	O
A2	O
/	O
GM130	O
binding	O
.	O

Autophagy	O
was	O
analyzed	O
by	O
red	O
fluorescent	O
protein	O
-	O
microtubule	O
-	O
associated	O
protein	O
1A	O
/	O
1B	O
-	O
light	O
chain	O
3	O
(	O
LC3	O
)	O
puncta	O
,	O
LC3I	O
to	O
LC3II	O
conversion	O
,	O
and	O
p62	O
expression	O
.	O

The	O
results	O
demonstrated	O
that	O
knockdown	O
of	O
ZFPL1	O
was	O
able	O
to	O
significantly	O
increase	O
cell	O
death	O
rate	O
.	O

However	O
,	O
ZFPL1	O
knockdown	O
exerted	O
almost	O
no	O
effect	O
on	O
the	O
expression	O
of	O
apoptosis	O
-	O
associated	O
markers	O
,	O
including	O
B	O
cell	O
lymphoma	O
2	O
(	O
Bcl	O
-	O
2	O
)	O
,	O
Bcl	O
-	O
x	O
,	O
Bcl	O
-	O
2	O
-	O
associated	O
X	O
protein	O
,	O
BH3	O
interacting	O
domain	O
death	O
agonist	O
,	O
p53	O
,	O
and	O
the	O
classical	O
caspase	O
family	O
members	O
,	O
caspase	O
-	O
3	O
,	O
caspase	O
-	O
8	O
and	O
caspase	O
-	O
9	O
.	O

An	O
endogenous	O
ZFPL1	O
-	O
GM130	O
association	O
was	O
identified	O
in	O
NCI	O
-	O
N87	O
cells	O
and	O
BGC	O
-	O
823	O
cells	O
by	O
co	O
-	O
immunoprecipitation	O
.	O

Furthermore	O
,	O
cell	O
death	O
was	O
restricted	O
following	O
treatment	O
of	O
ZFPL1	O
knockdown	O
cells	O
with	O
an	O
autophagy	O
inhibitor	O
.	O

Therefore	O
,	O
knockdown	O
of	O
ZFPL1	O
expression	O
may	O
induce	O
cell	O
death	O
via	O
autophagy	O
,	O
rather	O
than	O
apoptosis	O
.	O

These	O
results	O
suggest	O
that	O
ZFPL1	O
may	O
serve	O
an	O
important	O
role	O
in	O
regulating	O
autophagy	O
in	O
NCI	O
-	O
N87	O
and	O
BGC	O
-	O
823	O
cells	O
.	O

Arc	O
has	O
predicted	O
consensus	O
SUMOylation	O
sites	O
at	O
lysine	O
110	O
and	O
lysine	O
286	O
(	O
Bramham	O
et	O
al	O
.	O
,	O
)	O
,	O
and	O
mutation	O
of	O
these	O
sites	O
blocks	O
in	O
vitro	O
Arc	O
SUMOylation	O
in	O
HEK	O
cells	O
(	O
Craig	O
et	O
al	O
.	O
,	O
)	O
.	O

In	O
cultured	O
hippocampal	O
neurons	O
,	O
viral	O
overexpression	O
of	O
the	O
Arc	O
-	O
KK	O
SUMO	O
mutant	O
,	O
but	O
not	O
wild	O
-	O
type	O
Arc	O
,	O
prevents	O
tetrodotoxin	O
-	O
induced	O
synaptic	O
scaling	O
,	O
indicating	O
that	O
Arc	O
SUMOylation	O
may	O
be	O
required	O
for	O
homeostatic	O
scaling	O
of	O
AMPARs	B-Complex
(	O
Craig	O
et	O
al	O
.	O
,	O
)	O
.	O

Overexpression	O
of	O
Arc	O
-	O
KK	O
does	O
not	O
affect	O
GluA1	O
endocytosis	O
,	O
suggesting	O
that	O
Arc	O
SUMOylation	O
promotes	O
the	O
forward	O
trafficking	O
of	O
GluA1	O
to	O
the	O
cell	O
surface	O
and	O
thus	O
favors	O
homeostatic	O
potentiation	O
of	O
synapses	O
during	O
chronic	O
acitivity	O
blockade	O
(	O
Craig	O
and	O
Henley	O
,	O
;	O
Craig	O
et	O
al	O
.	O
,	O
)	O
.	O

It	O
is	O
further	O
noteworthy	O
that	O
drebrin	O
A	O
,	O
which	O
we	O
have	O
shown	O
interacts	O
with	O
SUMOylated	O
Arc	O
,	O
is	O
implicated	O
in	O
the	O
activity	O
-	O
dependent	O
membrane	O
insertion	O
of	O
AMPARs	B-Complex
(	O
Kato	O
et	O
al	O
.	O
,	O
)	O
.	O

To	O
assess	O
whether	O
ACAT2	O
stability	O
is	O
regulated	O
by	O
cellular	O
redox	O
,	O
we	O
treated	O
cells	O
with	O
prooxidants	O
menadione	O
or	O
H2O2	O
and	O
found	O
that	O
both	O
oxidative	O
reagents	O
markedly	O
stabilized	O
ACAT2	O
(	O
Fig	O
.	O
4d	O
and	O
Supplementary	O
Fig	O
.	O
5a	O
)	O
.	O

In	O
addition	O
,	O
siRNA	O
depletion	O
of	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
,	O
a	O
key	O
enzyme	O
in	O
synthesizing	O
the	O
main	O
intracellular	O
reductant	O
NADPH	O
,	O
also	O
resulted	O
in	O
ACAT2	O
stabilization	O
(	O
Fig	O
.	O
4e	O
)	O
,	O
in	O
agreement	O
with	O
the	O
notion	O
that	O
G6PD	O
deficiency	O
sensitizes	O
cells	O
to	O
oxidative	O
stress	O
.	O

Furthermore	O
,	O
menadione	O
or	O
H2O2	O
dramatically	O
lessened	O
ACAT2	O
ubiquitination	O
(	O
Fig	O
.	O
4f	O
and	O
Supplementary	O
Fig	O
.	O
5b	O
)	O
,	O
whereas	O
the	O
antioxidant	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
attenuated	O
lipid	O
-	O
induced	O
stabilization	O
of	O
ACAT2	O
(	O
Fig	O
.	O
4g	O
)	O
.	O

Because	O
suppression	O
of	O
NPF	O
signaling	O
did	O
not	O
increase	O
sleep	O
behavior	O
under	O
standard	O
environmental	O
conditions	O
,	O
we	O
hypothesized	O
that	O
the	O
effects	O
of	O
reduced	O
NPF	O
function	O
on	O
sleep	O
-	O
wake	O
behavior	O
might	O
manifest	O
only	O
under	O
more	O
severe	O
nutritional	O
environments	O
where	O
NPF	O
signaling	O
is	O
normally	O
promoted	O
.	O

Indeed	O
,	O
enhanced	O
NPF	O
signaling	O
putatively	O
mimics	O
a	O
food	O
deprivation	O
state	O
that	O
promotes	O
appetitive	O
memory	O
formation	O
and	O
retrieval	O
under	O
fed	O
conditions	O
.	O

We	O
therefore	O
examined	O
whether	O
starvation	O
-	O
induced	O
sleep	O
loss	O
was	O
affected	O
by	O
loss	O
of	O
NPF	O
.	O

As	O
previously	O
shown	O
,	O
control	O
animals	O
exhibited	O
a	O
significant	O
increase	O
in	O
wake	O
approximately	O
12h	O
after	O
starvation	O
onset	O
(	O
Figure	O
2A	O
,	O
B	O
)	O
.	O

However	O
,	O
NPFSK2	O
mutants	O
did	O
not	O
exhibit	O
a	O
significant	O
change	O
in	O
wake	O
behavior	O
during	O
the	O
same	O
interval	O
compared	O
to	O
fed	O
controls	O
(	O
Figure	O
2A	O
,	O
B	O
)	O
,	O
establishing	O
that	O
NPF	O
is	O
required	O
for	O
starvation	O
-	O
induced	O
sleep	O
loss	O
during	O
this	O
period	O
.	O

Notably	O
,	O
Kir2	O
.	O
1	O
-	O
mediated	O
inhibition	O
of	O
NPF	O
+	O
neurons	O
either	O
constitutively	O
or	O
exclusively	O
as	O
adults	O
did	O
not	O
recapitulate	O
the	O
NPF	O
mutant	O
phenotype	O
,	O
suggesting	O
either	O
compensatory	O
effects	O
in	O
these	O
neurons	O
or	O
incomplete	O
silencing	O
of	O
neuron	O
function	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
NPF	O
signaling	O
plays	O
a	O
minor	O
role	O
in	O
modulating	O
sleep	O
when	O
nutrients	O
are	O
replete	O
,	O
yet	O
may	O
be	O
recruited	O
to	O
promote	O
wakefulness	O
under	O
limited	O
or	O
challenging	O
nutritional	O
environments	O
.	O

Effects	O
of	O
ML335	O
,	O
ML402	O
,	O
and	O
arachidonic	O
acid	O
on	O
K2P2	O
.	O
1	O
(	O
TREK	O
-	O
1	O
)	O
current	O
at	O
0	O
mV	O
were	O
measured	O
by	O
whole	O
cell	O
patch	O
-	O
clamp	O
experiments	O
24	O
hours	O
after	O
transfection	O
.	O

Acquisition	O
and	O
analysis	O
were	O
performed	O
using	O
pCLAMP9	O
and	O
an	O
Axopatch	O
200B	O
amplifier	O
(	O
Molecular	O
Devices	O
,	O
Sunnyvale	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Pipette	O
resistance	O
ranged	O
from	O
1	O
to	O
1	O
.	O
5	O
MOmega	O
.	O

Pipette	O
solution	O
contained	O
the	O
following	O
,	O
in	O
millimolar	O
:	O
145	O
,	O
KCl	O
;	O
3	O
,	O
MgCl2	O
;	O
5	O
,	O
EGTA	O
and	O
20	O
,	O
HEPES	O
(	O
pH	O
7	O
.	O
2	O
with	O
KOH	O
)	O
.	O

Bath	O
solution	O
contained	O
the	O
following	O
,	O
in	O
millimolar	O
:	O
145	O
,	O
NaCl	O
;	O
5	O
,	O
KCl	O
;	O
1	O
,	O
CaCl2	O
;	O
3	O
,	O
MgCl2	O
;	O
20	O
,	O
HEPES	O
(	O
pH	O
7	O
.	O
4	O
with	O
NaOH	O
)	O
.	O

K2P2	O
(	O
TREK	O
-	O
1	O
)	O
currents	O
were	O
elicited	O
by	O
a	O
1	O
second	O
ramp	O
from	O
-	O
100	O
to	O
+	O
50	O
mV	O
from	O
a	O
-	O
80	O
mV	O
holding	O
potential	O
.	O

After	O
stabilization	O
of	O
the	O
basal	O
current	O
,	O
ML335	O
and	O
ML402	O
were	O
perfused	O
at	O
200	O
ml	O
hr	O
-	O
1	O
until	O
potentiation	O
was	O
stably	O
reached	O
.	O

Plasmid	O
for	O
bacterial	O
expression	O
of	O
recombinant	O
His	O
-	O
Tda2	O
was	O
created	O
by	O
PCR	O
amplification	O
of	O
full	O
-	O
length	O
ORF	O
TDA2	O
from	O
S	O
.	O
cerevisiae	O
genomic	O
DNA	O
and	O
was	O
cloned	O
into	O
pET30a	O
(	O
+	O
)	O
using	O
NdeI	O
and	O
SalI	O
restriction	O
sites	O
.	O

The	O
6	O
-	O
histidine	O
tag	O
was	O
encoded	O
in	O
the	O
forward	O
primer	O
used	O
in	O
the	O
PCR	O
so	O
that	O
the	O
protein	O
contained	O
the	O
sequence	O
MHHHHHH	O
directly	O
attached	O
to	O
the	O
amino	O
terminus	O
of	O
Tda2	O
.	O

Plasmid	O
for	O
bacterial	O
expression	O
of	O
recombinant	O
GST	O
-	O
Aim21	O
was	O
created	O
by	O
PCR	O
amplification	O
of	O
full	O
-	O
length	O
ORF	O
AIM21	O
from	O
S	O
.	O
cerevisiae	O
genomic	O
DNA	O
and	O
cloned	O
in	O
-	O
frame	O
into	O
pGEX	O
-	O
5X	O
-	O
1	O
using	O
EcoRI	O
and	O
SalI	O
sites	O
.	O

Bicistronic	O
plasmid	O
for	O
simultaneous	O
expression	O
in	O
bacteria	O
and	O
of	O
both	O
yeast	O
actin	O
-	O
capping	O
protein	O
subunits	O
was	O
created	O
by	O
PCR	O
amplification	O
of	O
full	O
-	O
length	O
ORF	O
CAP1	O
and	O
CAP2	O
from	O
S	O
.	O
cerevisiae	O
genomic	O
DNA	O
and	O
cloned	O
into	O
pETDuet	O
using	O
restriction	O
sites	O
EcoRI	O
and	O
SalI	O
for	O
CAP1	O
(	O
multiple	O
cloning	O
site	O
I	O
)	O
and	O
FseI	O
and	O
XhoI	O
for	O
CAP2	O
(	O
multiple	O
cloning	O
site	O
II	O
)	O
.	O

The	O
pETDuet	O
plasmid	O
encodes	O
for	O
a	O
6	O
-	O
histidine	O
tag	O
attached	O
to	O
Cap1	O
for	O
protein	O
purification	O
.	O

The	O
R15A	O
and	O
Y80A	O
point	O
mutations	O
were	O
introduced	O
in	O
CAP2	O
using	O
the	O
In	O
-	O
Fusion	O
system	O
(	O
Takara	O
Bio	O
Inc	O
.	O
)	O
.	O

We	O
next	O
asked	O
whether	O
other	O
arboviruses	O
also	O
depend	O
on	O
the	O
same	O
OST	B-Complex
complexes	O
and	O
used	O
flow	O
cytometry	O
to	O
determine	O
whether	O
infection	O
was	O
impaired	O
in	O
STT3A	O
or	O
STT3B	O
knockout	O
cells	O
.	O

We	O
infected	O
cells	O
with	O
DENV	O
serotype	O
2	O
(	O
DENV	O
-	O
2	O
)	O
,	O
Zika	O
virus	O
(	O
ZIKV	O
)	O
,	O
West	O
Nile	O
virus	O
(	O
WNV	O
)	O
,	O
yellow	O
fever	O
virus	O
(	O
YFV	O
)	O
,	O
Sindbis	O
virus	O
(	O
SINV	O
)	O
,	O
Venezuelan	O
equine	O
encephalitis	O
virus	O
(	O
VEEV	O
)	O
,	O
or	O
Chikungunya	O
virus	O
(	O
CHIKV	O
)	O
and	O
compared	O
the	O
percentage	O
of	O
infected	O
cells	O
in	O
OST	B-Complex
knockout	O
cells	O
compared	O
to	O
that	O
in	O
the	O
control	O
cells	O
.	O

Consistent	O
with	O
our	O
other	O
results	O
,	O
we	O
found	O
that	O
DENV	O
-	O
2	O
infection	O
was	O
dramatically	O
reduced	O
in	O
OST	B-Complex
knockout	O
cells	O
compared	O
to	O
control	O
cells	O
(	O
Fig	O
.	O
S1	O
)	O
.	O

We	O
also	O
found	O
that	O
ZIKV	O
infection	O
was	O
moderately	O
,	O
but	O
significantly	O
,	O
reduced	O
in	O
STT3A	O
and	O
STT3B	O
knockout	O
cells	O
,	O
indicating	O
that	O
the	O
OSTs	B-Complex
may	O
also	O
play	O
a	O
role	O
during	O
ZIKV	O
infection	O
(	O
Fig	O
.	O
S1	O
)	O
.	O

However	O
,	O
we	O
did	O
not	O
find	O
a	O
significant	O
decrease	O
in	O
the	O
propagation	O
of	O
the	O
other	O
viruses	O
tested	O
.	O

To	O
better	O
correlate	O
the	O
QPRT	O
levels	O
to	O
HCV	O
infection	O
in	O
vivo	O
,	O
we	O
re	O
-	O
assessed	O
the	O
hepatic	O
QPRT	O
levels	O
in	O
the	O
previously	O
characterized	O
C	O
/	O
OTg	O
mice	O
,	O
either	O
2	O
(	O
acute	O
infection	O
)	O
or	O
4	O
weeks	O
(	O
persistent	O
infection	O
)	O
after	O
HCVcc	O
inoculation	O
(	O
Figure	O
S1B	O
for	O
hepatic	O
HCV	O
RNA	O
copies	O
)	O
.	O

Immunoblotting	O
of	O
HCV	O
infected	O
C	O
/	O
OTg	O
livers	O
indicated	O
that	O
QPRT	O
expression	O
was	O
greatly	O
reduced	O
compared	O
to	O
the	O
mock	O
infection	O
(	O
Fig	O
.	O
1C	O
)	O
.	O

To	O
delineate	O
how	O
HCV	O
would	O
affect	O
QPRT	O
levels	O
,	O
we	O
further	O
performed	O
in	O
vitro	O
analysis	O
.	O

HCV	O
infection	O
of	O
Huh7	O
.	O
5	O
.	O
1	O
cells	O
caused	O
a	O
decrease	O
of	O
QPRT	O
protein	O
in	O
a	O
time	O
dependent	O
manner	O
(	O
Fig	O
.	O
1D	O
)	O
.	O

In	O
this	O
condition	O
,	O
the	O
level	O
of	O
QPRT	O
mRNA	O
remained	O
constant	O
,	O
and	O
even	O
slightly	O
increased	O
at	O
72	O
h	O
after	O
HCV	O
infection	O
(	O
Fig	O
.	O
1E	O
)	O
.	O

Therefore	O
,	O
HCV	O
likely	O
reduced	O
QPRT	O
at	O
the	O
post	O
-	O
translational	O
level	O
.	O

Finally	O
,	O
inhibition	O
of	O
HCV	O
replication	O
in	O
Huh7	O
.	O
1	O
.	O
5	O
cells	O
by	O
either	O
NS3	O
/	O
4	O
A	O
protease	O
specific	O
inhibitor	O
VX950	O
(	O
Fig	O
.	O
1F	O
)	O
or	O
IFNalpha	O
(	O
Fig	O
.	O
1H	O
)	O
attenuated	O
the	O
declining	O
tendency	O
of	O
QPRT	O
.	O

Thus	O
,	O
QPRT	O
protein	O
level	O
would	O
specifically	O
respond	O
to	O
HCV	O
replication	O
.	O

Both	O
treatments	O
effectively	O
reduced	O
viral	O
replication	O
,	O
as	O
measured	O
by	O
the	O
drastic	O
reduction	O
of	O
NS3	O
and	O
core	O
(	O
Fig	O
.	O
1F	O
,	O
H	O
)	O
,	O
and	O
the	O
reduced	O
percentage	O
of	O
GFP	O
+	O
Huh7	O
.	O
5	O
.	O
1	O
cells	O
(	O
Fig	O
.	O
1G	O
,	O
I	O
)	O
.	O

In	O
HCVcc	O
J339EM	O
,	O
NS5A	O
was	O
fused	O
with	O
EGFP	O
that	O
was	O
expressed	O
along	O
HCV	O
replication	O
.	O

Of	O
note	O
,	O
the	O
percentage	O
of	O
GFP	O
positive	O
cells	O
was	O
in	O
good	O
linearity	O
to	O
HCV	O
genome	O
copies	O
(	O
Figure	O
S1C	O
)	O
,	O
we	O
routinely	O
used	O
the	O
percentage	O
of	O
GFP	O
+	O
cells	O
to	O
represent	O
the	O
replication	O
efficiency	O
of	O
HCV	O
in	O
Huh7	O
.	O
5	O
.	O
1	O
cells	O
.	O

Finally	O
,	O
less	O
QPRT	O
would	O
lead	O
to	O
a	O
reduced	O
consumption	O
of	O
its	O
enzymatic	O
substrate	O
QA	O
.	O

Mass	O
spectrometric	O
analysis	O
showed	O
that	O
QA	O
concentration	O
in	O
the	O
supernatant	O
was	O
indeed	O
increased	O
by	O
~	O
9	O
%	O
at	O
72	O
h	O
post	O
HCV	O
infection	O
of	O
Huh7	O
.	O
5	O
.	O
1	O
cells	O
(	O
Fig	O
.	O
1J	O
)	O
.	O

Therefore	O
,	O
QPRT	O
can	O
be	O
reduced	O
by	O
HCV	O
infection	O
,	O
indicative	O
of	O
its	O
role	O
in	O
regulation	O
of	O
HCV	O
infection	O
.	O

It	O
is	O
thus	O
desirable	O
to	O
delineate	O
the	O
biological	O
significance	O
of	O
QPRT	O
in	O
regulation	O
of	O
HCV	O
replication	O
.	O

Garcia	O
-	O
Corzo	O
and	O
co	O
-	O
workers	O
generated	O
a	O
Coq9	O
knockin	O
mouse	O
model	O
by	O
introducing	O
the	O
Coq9	O
-	O
R239X	O
mutation	O
that	O
recapitulates	O
the	O
Arg244Ter	O
human	O
COQ9	O
mutation	O
(	O
Garcia	O
-	O
Corzo	O
et	O
al	O
.	O
,	O
)	O
.	O

The	O
Coq9R239X	O
/	O
R239X	O
homozygous	O
knockin	O
mice	O
showed	O
histologic	O
and	O
behavioral	O
signs	O
that	O
mirrored	O
mitochondrial	O
encephalomyopathy	O
associated	O
with	O
primary	O
Q	O
deficiency	O
in	O
human	O
patients	O
.	O

A	O
widespread	O
Q	O
deficiency	O
was	O
noted	O
in	O
these	O
mice	O
along	O
with	O
a	O
dramatic	O
reduction	O
in	O
the	O
steady	O
state	O
level	O
of	O
the	O
COQ7	O
polypeptide	O
and	O
accumulation	O
of	O
demethoxy	O
-	O
Q9	O
(	O
DMQ9	O
)	O
(	O
Garcia	O
-	O
Corzo	O
et	O
al	O
.	O
,	O
)	O
.	O

A	O
second	O
Coq9	O
mouse	O
model	O
(	O
Coq9Q95X	O
)	O
also	O
demonstrated	O
that	O
COQ9	O
is	O
required	O
for	O
Q	O
biosynthesis	O
(	O
Luna	O
-	O
Sanchez	O
et	O
al	O
.	O
,	O
)	O
.	O

However	O
,	O
the	O
Q	O
deficiency	O
in	O
the	O
Coq9Q95X	O
/	O
Q95X	O
mice	O
is	O
less	O
severe	O
than	O
in	O
the	O
Coq9R239X	O
/	O
R239X	O
mice	O
,	O
probably	O
due	O
to	O
differences	O
in	O
nonsense	O
-	O
mediated	O
decay	O
efficiency	O
and	O
in	O
the	O
stability	O
of	O
the	O
CoQ	B-Complex
synthome	I-Complex
(	O
Luna	O
-	O
Sanchez	O
et	O
al	O
.	O
,	O
)	O
.	O

Endocytosis	O
of	O
FGF1	O
-	O
FGFR1	O
complexes	O
is	O
mediated	O
by	O
clathrin	B-Complex
and	O
dynamin	O
.	O

To	O
study	O
whether	O
scFvD2	O
-	O
Fc	O
utilizes	O
the	O
same	O
molecular	O
machinery	O
as	O
FGF1	O
for	O
its	O
delivery	O
into	O
the	O
cellular	O
interior	O
,	O
we	O
employed	O
specific	O
inhibitors	O
of	O
clathrin	B-Complex
(	O
Pitstop2	O
)	O
and	O
dynamin	O
(	O
Dynasore	O
)	O
.	O

We	O
observed	O
that	O
the	O
internalization	O
of	O
scFvD2	O
-	O
Fc	O
,	O
similarly	O
to	O
the	O
internalization	O
of	O
FGF1	O
,	O
was	O
partially	O
blocked	O
by	O
the	O
presence	O
of	O
Pitstop2	O
and	O
Dynasore	O
(	O
Fig	O
.	O
5	O
)	O
.	O

These	O
data	O
suggest	O
that	O
even	O
though	O
internalization	O
of	O
scFvD2	O
-	O
Fc	O
occurs	O
without	O
FGFR1	O
activation	O
,	O
it	O
follows	O
the	O
same	O
dynamin	O
/	O
clathrin	B-Complex
dependent	O
pathways	O
as	O
FGF1	O
.	O

Many	O
eukaryotic	O
cells	O
divide	O
by	O
assembling	O
and	O
constricting	O
an	O
actin	O
-	O
and	O
myosin	O
-	O
based	O
contractile	O
ring	O
(	O
CR	O
)	O
that	O
is	O
physically	O
linked	O
to	O
the	O
plasma	O
membrane	O
(	O
PM	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
<	O
i	O
>	O
Schizosaccharomyces	O
pombe	O
<	O
/	O
i	O
>	O
cells	O
lacking	O
<	O
i	O
>	O
efr3	O
<	O
/	O
i	O
>	O
,	O
which	O
encodes	O
a	O
conserved	O
PM	O
scaffold	O
for	O
the	O
phosphatidylinositol	O
-	O
4	O
kinase	O
Stt4	O
,	O
build	O
CRs	O
that	O
can	O
slide	O
away	O
from	O
the	O
cell	O
middle	O
during	O
anaphase	O
in	O
a	O
myosin	O
V	O
-	O
dependent	O
manner	O
.	O

The	O
Efr3	O
-	O
dependent	O
CR	O
-	O
anchoring	O
mechanism	O
is	O
distinct	O
from	O
previously	O
reported	O
pathways	O
dependent	O
on	O
the	O
Fes	O
/	O
CIP4	O
homology	O
Bin	O
-	O
Amphiphysin	O
-	O
Rvs167	O
(	O
F	O
-	O
BAR	O
)	O
protein	O
Cdc15	O
and	O
paxillin	O
Pxl1	O
.	O

In	O
<	O
i	O
>	O
efr3Delta	O
<	O
/	O
i	O
>	O
,	O
the	O
concentrations	O
of	O
several	O
membrane	O
-	O
binding	O
proteins	O
were	O
reduced	O
in	O
the	O
CR	O
and	O
/	O
or	O
on	O
the	O
PM	O
.	O

Our	O
results	O
suggest	O
that	O
proper	O
PM	O
lipid	O
composition	O
is	O
important	O
to	O
stabilize	O
the	O
central	O
position	O
of	O
the	O
CR	O
and	O
resist	O
myosin	O
V	O
-	O
based	O
forces	O
to	O
promote	O
the	O
fidelity	O
of	O
cell	O
division	O
.	O

Targeting	O
the	O
MAPK	O
Signaling	O
Pathway	O
in	O
Cancer	O
:	O
Promising	O
Preclinical	O
Activity	O
with	O
the	O
Novel	O
Selective	O
ERK1	O
/	O
2	O
Inhibitor	O
BVD	O
-	O
523	O
(	O
Ulixertinib	O
)	O
.	O

Aberrant	O
activation	O
of	O
signaling	O
through	O
the	O
RAS	O
-	O
RAF	O
-	O
MEK	O
-	O
ERK	O
(	O
MAPK	O
)	O
pathway	O
is	O
implicated	O
in	O
numerous	O
cancers	O
,	O
making	O
it	O
an	O
attractive	O
therapeutic	O
target	O
.	O

Although	O
BRAF	O
and	O
MEK	O
-	O
targeted	O
combination	O
therapy	O
has	O
demonstrated	O
significant	O
benefit	O
beyond	O
single	O
-	O
agent	O
options	O
,	O
the	O
majority	O
of	O
patients	O
develop	O
resistance	O
and	O
disease	O
progression	O
after	O
approximately	O
12	O
months	O
.	O

Reactivation	O
of	O
ERK	O
signaling	O
is	O
a	O
common	O
driver	O
of	O
resistance	O
in	O
this	O
setting	O
.	O

Here	O
we	O
report	O
the	O
discovery	O
of	O
BVD	O
-	O
523	O
(	O
ulixertinib	O
)	O
,	O
a	O
novel	O
,	O
reversible	O
,	O
ATP	O
-	O
competitive	O
ERK1	O
/	O
2	O
inhibitor	O
with	O
high	O
potency	O
and	O
ERK1	O
/	O
2	O
selectivity	O
.	O

In	O
vitro	O
BVD	O
-	O
523	O
treatment	O
resulted	O
in	O
reduced	O
proliferation	O
and	O
enhanced	O
caspase	O
activity	O
in	O
sensitive	O
cells	O
.	O

Interestingly	O
,	O
BVD	O
-	O
523	O
inhibited	O
phosphorylation	O
of	O
target	O
substrates	O
despite	O
increased	O
phosphorylation	O
of	O
ERK1	O
/	O
2	O
.	O

In	O
in	O
vivo	O
xenograft	O
studies	O
,	O
BVD	O
-	O
523	O
showed	O
dose	O
-	O
dependent	O
growth	O
inhibition	O
and	O
tumor	O
regression	O
.	O

BVD	O
-	O
523	O
yielded	O
synergistic	O
antiproliferative	O
effects	O
in	O
a	O
BRAF	O
(	O
V600E	O
)	O
-	O
mutant	O
melanoma	O
cell	O
line	O
xenograft	O
model	O
when	O
used	O
in	O
combination	O
with	O
BRAF	O
inhibition	O
.	O

Antitumor	O
activity	O
was	O
also	O
demonstrated	O
in	O
in	O
vitro	O
and	O
in	O
vivo	O
models	O
of	O
acquired	O
resistance	O
to	O
single	O
-	O
agent	O
and	O
combination	O
BRAF	O
/	O
MEK	O
-	O
targeted	O
therapy	O
.	O

On	O
the	O
basis	O
of	O
these	O
promising	O
results	O
,	O
these	O
studies	O
demonstrate	O
BVD	O
-	O
523	O
holds	O
promise	O
as	O
a	O
treatment	O
for	O
ERK	O
-	O
dependent	O
cancers	O
,	O
including	O
those	O
whose	O
tumors	O
have	O
acquired	O
resistance	O
to	O
other	O
treatments	O
targeting	O
upstream	O
nodes	O
of	O
the	O
MAPK	O
pathway	O
.	O

Assessment	O
of	O
BVD	O
-	O
523	O
in	O
clinical	O
trials	O
is	O
underway	O
(	O
NCT01781429	O
,	O
NCT02296242	O
,	O
and	O
NCT02608229	O
)	O
.	O

Mol	O
Cancer	O
Ther	O
;	O
16	O
(	O
11	O
)	O
;	O
2351	O
-	O
63	O
.	O

(	O
c	O
)	O
2017	O
AACR	O
.	O

A	O
mutually	O
exclusive	O
stem	O
-	O
loop	O
arrangement	O
in	O
roX2	O
RNA	O
is	O
essential	O
for	O
X	O
-	O
chromosome	O
regulation	O
in	O
Drosophila	O
.	O

The	O
X	O
chromosome	O
provides	O
an	O
ideal	O
model	O
system	O
to	O
study	O
the	O
contribution	O
of	O
RNA	O
-	O
protein	O
interactions	O
in	O
epigenetic	O
regulation	O
.	O

In	O
male	O
flies	O
,	O
roX	O
long	O
noncoding	O
RNAs	O
(	O
lncRNAs	O
)	O
harbor	O
several	O
redundant	O
domains	O
to	O
interact	O
with	O
the	O
ubiquitin	O
ligase	O
male	O
-	O
specific	O
lethal	O
2	O
(	O
MSL2	O
)	O
and	O
the	O
RNA	O
helicase	O
Maleless	O
(	O
MLE	O
)	O
for	O
X	O
-	O
chromosomal	O
regulation	O
.	O

However	O
,	O
how	O
these	O
interactions	O
provide	O
the	O
mechanics	O
of	O
spreading	O
remains	O
unknown	O
.	O

By	O
using	O
the	O
uvCLAP	O
(	O
UV	O
cross	O
-	O
linking	O
and	O
affinity	O
purification	O
)	O
methodology	O
,	O
which	O
provides	O
unprecedented	O
information	O
about	O
RNA	O
secondary	O
structures	O
in	O
vivo	O
,	O
we	O
identified	O
the	O
minimal	O
functional	O
unit	O
of	O
roX2	O
RNA	O
.	O

By	O
using	O
wild	O
-	O
type	O
and	O
various	O
MLE	O
mutant	O
derivatives	O
,	O
including	O
a	O
catalytically	O
inactive	O
MLE	O
derivative	O
,	O
MLEGET	O
,	O
we	O
show	O
that	O
the	O
minimal	O
roX	O
RNA	O
contains	O
two	O
mutually	O
exclusive	O
stem	O
-	O
loops	O
that	O
exist	O
in	O
a	O
peculiar	O
structural	O
arrangement	O
:	O
When	O
one	O
stem	O
-	O
loop	O
is	O
unwound	O
by	O
MLE	O
,	O
an	O
alternate	O
structure	O
can	O
form	O
,	O
likely	O
trapping	O
MLE	O
in	O
this	O
perpetually	O
structured	O
region	O
.	O

We	O
show	O
that	O
this	O
functional	O
unit	O
is	O
necessary	O
for	O
dosage	O
compensation	O
,	O
as	O
mutations	O
that	O
disrupt	O
this	O
formation	O
lead	O
to	O
male	O
lethality	O
.	O

Thus	O
,	O
we	O
propose	O
that	O
roX2	O
lncRNA	O
contains	O
an	O
MLE	O
-	O
dependent	O
affinity	O
switch	O
to	O
enable	O
reversible	O
interactions	O
of	O
the	O
MSL	B-Complex
complex	O
to	O
allow	O
dosage	O
compensation	O
of	O
the	O
X	O
chromosome	O
.	O

Prompted	O
by	O
our	O
observations	O
of	O
a	O
critical	O
function	O
of	O
FBXO32	O
during	O
EMT	O
,	O
we	O
investigated	O
its	O
expression	O
in	O
a	O
wide	O
range	O
of	O
human	O
tumors	O
.	O

A	O
large	O
-	O
scale	O
analysis	O
of	O
several	O
well	O
-	O
characterized	O
human	O
clinical	O
expression	O
data	O
sets	O
revealed	O
an	O
exceptionally	O
strong	O
amplification	O
of	O
FBXO32	O
in	O
a	O
majority	O
of	O
human	O
tumors	O
(	O
Fig	O
.	O
6a	O
)	O
.	O

Computational	O
analyses	O
revealed	O
significantly	O
higher	O
expression	O
of	O
FBXO32	O
in	O
various	O
tumors	O
compared	O
to	O
the	O
matched	O
normal	O
tissues	O
(	O
Fig	O
.	O
6b	O
,	O
c	O
and	O
Supplementary	O
Fig	O
.	O
9a	O
-	O
d	O
)	O
.	O

In	O
support	O
of	O
our	O
observations	O
,	O
FBXO32	O
levels	O
correlated	O
positively	O
with	O
the	O
levels	O
of	O
established	O
mesenchymal	O
markers	O
and	O
negatively	O
with	O
the	O
levels	O
of	O
epithelial	O
markers	O
in	O
different	O
types	O
of	O
tumor	O
examined	O
(	O
Supplementary	O
Fig	O
.	O
9e	O
-	O
f	O
)	O
.	O

A	O
survival	O
analysis	O
of	O
the	O
clinical	O
breast	O
tumor	O
data	O
sets	O
revealed	O
a	O
significant	O
correlation	O
between	O
higher	O
FBXO32	O
expression	O
and	O
poor	O
relapse	O
-	O
free	O
and	O
metastasis	O
-	O
free	O
survival	O
(	O
Fig	O
.	O
6d	O
,	O
e	O
)	O
.	O

Moreover	O
,	O
FBXO32	O
expression	O
showed	O
the	O
expected	O
correlation	O
with	O
the	O
levels	O
of	O
established	O
EMT	O
markers	O
as	O
well	O
as	O
the	O
identified	O
FBXO32	O
-	O
induced	O
EMT	O
genes	O
in	O
multiple	O
cancers	O
,	O
corroborating	O
its	O
critical	O
role	O
during	O
human	O
tumor	O
metastasis	O
(	O
Fig	O
.	O
6f	O
-	O
i	O
)	O
.	O

A	O
deeper	O
analysis	O
of	O
various	O
tumor	O
data	O
sets	O
(	O
breast	O
,	O
colon	O
,	O
gastric	O
,	O
lung	O
,	O
and	O
ovarian	O
tumor	O
)	O
further	O
validated	O
these	O
findings	O
(	O
Supplementary	O
Fig	O
.	O
9g	O
-	O
l	O
,	O
and	O
10a	O
-	O
c	O
)	O
.	O

In	O
addition	O
,	O
transcriptome	O
analysis	O
of	O
a	O
large	O
set	O
of	O
cancer	O
cell	O
lines	O
confirmed	O
an	O
enhanced	O
expression	O
of	O
FBXO32	O
in	O
mesenchymal	O
cancer	O
cell	O
lines	O
as	O
compared	O
to	O
epithelial	O
counterparts	O
(	O
Fig	O
.	O
6j	O
)	O
.	O

To	O
ultimately	O
validate	O
these	O
findings	O
in	O
clinical	O
samples	O
,	O
we	O
collected	O
non	O
-	O
invasive	O
and	O
invasive	O
breast	O
tumor	O
samples	O
(	O
n	O
=	O
20	O
each	O
)	O
and	O
analyzed	O
the	O
expression	O
of	O
FBXO32	O
in	O
these	O
samples	O
.	O

In	O
line	O
with	O
our	O
previous	O
observations	O
,	O
FBXO32	O
expression	O
was	O
significantly	O
higher	O
in	O
the	O
invasive	O
tumors	O
compared	O
to	O
the	O
non	O
-	O
invasive	O
tumors	O
(	O
Fig	O
.	O
6k	O
)	O
.	O

Overall	O
,	O
these	O
comprehensive	O
set	O
of	O
observations	O
extend	O
our	O
findings	O
to	O
the	O
clinic	O
and	O
suggest	O
a	O
role	O
for	O
FBXO32	O
in	O
promoting	O
tumorigenicity	O
and	O
metastasis	O
in	O
humans	O
.	O

ABIN	O
-	O
1	O
is	O
a	O
ubiquitin	O
binding	O
protein	O
that	O
can	O
bind	O
to	O
both	O
K63	O
and	O
M1	O
ubiquitin	O
chains	O
but	O
not	O
to	O
K48	O
chains	O
.	O

Specific	O
risk	O
haploid	O
types	O
in	O
the	O
gene	O
Abin	O
-	O
1	O
(	O
TNFAIP3	O
-	O
interacting	O
protein	O
1	O
,	O
or	O
Tnip1	O
)	O
are	O
strongly	O
associated	O
with	O
a	O
predisposition	O
for	O
autoimmune	O
inflammatory	O
diseases	O
such	O
as	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
and	O
psoriasis	O
.	O

These	O
risk	O
haplotypes	O
produce	O
lower	O
levels	O
of	O
Abin	O
-	O
1	O
mRNA	O
and	O
ABIN	O
-	O
1	O
protein	O
,	O
suggesting	O
that	O
the	O
susceptibility	O
to	O
autoimmunity	O
is	O
due	O
to	O
their	O
hypomorphic	O
function	O
.	O

Abin	O
-	O
1	O
-	O
/	O
-	O
mice	O
die	O
during	O
late	O
embryogenesis	O
due	O
to	O
fetal	O
liver	O
cell	O
death	O
,	O
anaemia	O
and	O
hypoplasia	O
,	O
which	O
can	O
be	O
blocked	O
by	O
TNFalpha	O
deficiency	O
.	O

Pex1	O
-	O
FLAG	O
and	O
His	O
-	O
Pex6	O
wild	O
type	O
and	O
mutant	O
complexes	O
were	O
co	O
-	O
expressed	O
in	O
E	O
.	O
coli	O
BL21	O
*	O
(	O
ThermoFisher	O
Scientific	O
)	O
from	O
the	O
pETDuet	O
and	O
pCOLADuet	O
vectors	O
.	O

The	O
expression	O
strain	O
was	O
grown	O
in	O
6	O
L	O
of	O
DYT	O
(	O
16	O
g	O
tryptone	O
,	O
10	O
g	O
yeast	O
extract	O
,	O
5	O
g	O
NaCl	O
)	O
and	O
appropriate	O
antibiotics	O
at	O
30	O
degreesC	O
and	O
induced	O
at	O
OD600	O
=	O
0	O
.	O
6	O
-	O
0	O
.	O
9	O
with	O
IPTG	O
(	O
final	O
concentration	O
Cf	O
=	O
0	O
.	O
3	O
mM	O
)	O
before	O
overnight	O
incubation	O
at	O
18	O
degreesC	O
.	O

The	O
E	O
.	O
coli	O
were	O
harvested	O
at	O
6000xg	O
for	O
20	O
min	O
at	O
4	O
degreesC	O
,	O
and	O
the	O
pellet	O
was	O
resuspended	O
in	O
Ni	O
-	O
A	O
buffer	O
(	O
25	O
mM	O
HEPES	O
pH	O
7	O
.	O
6	O
,	O
100	O
mM	O
NaCl	O
,	O
100	O
mM	O
KCl	O
,	O
10	O
%	O
glycerol	O
,	O
10	O
mM	O
MgCl2	O
,	O
0	O
.	O
5	O
mM	O
EDTA	O
,	O
20	O
mM	O
imidazole	O
)	O
with	O
benzonase	O
,	O
lysozyme	O
(	O
0	O
.	O
2	O
mg	O
mL	O
-	O
1	O
)	O
,	O
and	O
protease	O
inhibitors	O
and	O
frozen	O
at	O
-	O
80	O
degreesC	O
.	O

Cells	O
were	O
lysed	O
by	O
sonication	O
at	O
90	O
mA	O
with	O
15	O
s	O
pulses	O
on	O
,	O
90	O
s	O
off	O
for	O
a	O
total	O
of	O
120	O
s	O
on	O
.	O

Cell	O
debris	O
and	O
unlysed	O
cells	O
were	O
pelleted	O
at	O
30	O
,	O
000xg	O
,	O
and	O
the	O
supernatant	O
was	O
transferred	O
to	O
conical	O
tubes	O
containing	O
5	O
mL	O
of	O
pre	O
-	O
washed	O
Ni	O
-	O
NTA	O
resin	O
(	O
HisPur	O
Ni	O
-	O
NTA	O
Resin	O
,	O
Thermo	O
)	O
.	O

The	O
cell	O
lysate	O
and	O
agarose	O
were	O
incubated	O
with	O
gentle	O
rocking	O
for	O
1	O
-	O
2	O
h	O
at	O
4	O
degreesC	O
before	O
the	O
agarose	O
was	O
batch	O
washed	O
with	O
2	O
x	O
50	O
mL	O
washes	O
of	O
Ni	O
_	O
A	O
with	O
1	O
mM	O
ATP	O
.	O

After	O
the	O
batch	O
washes	O
,	O
the	O
agarose	O
was	O
poured	O
into	O
a	O
gravity	O
flow	O
column	O
and	O
washed	O
until	O
the	O
flowthrough	O
contained	O
no	O
protein	O
,	O
as	O
judged	O
by	O
a	O
Bradford	O
assay	O
.	O

The	O
bound	O
protein	O
was	O
then	O
eluted	O
with	O
Ni	O
_	O
B	O
buffer	O
(	O
25	O
mM	O
HEPES	O
pH	O
7	O
.	O
6	O
,	O
100	O
mM	O
NaCl	O
,	O
100	O
mM	O
KCl	O
,	O
10	O
%	O
glycerol	O
,	O
500	O
mM	O
imidazole	O
)	O
with	O
1	O
mM	O
ATP	O
,	O
and	O
the	O
elution	O
was	O
added	O
to	O
re	O
-	O
suspended	O
and	O
pre	O
-	O
washed	O
anti	O
-	O
FLAG	O
M2	O
affinity	O
resin	O
(	O
Sigma	O
)	O
for	O
2	O
h	O
of	O
batch	O
binding	O
at	O
4	O
degreesC	O
.	O

After	O
2	O
h	O
,	O
the	O
anti	O
-	O
FLAG	O
affinity	O
resin	O
was	O
poured	O
into	O
a	O
gravity	O
flow	O
column	O
,	O
and	O
washed	O
with	O
50	O
mL	O
of	O
Ni	O
_	O
A	O
with	O
1	O
mM	O
ATP	O
.	O

The	O
bound	O
protein	O
was	O
eluted	O
with	O
Ni	O
_	O
A	O
with	O
1	O
mM	O
ATP	O
and	O
0	O
.	O
3	O
mg	O
mL	O
-	O
1	O
FLAG	O
peptide	O
and	O
concentrated	O
on	O
a	O
100	O
MWCO	O
spin	O
concentrator	O
before	O
snap	O
-	O
freezing	O
in	O
liquid	O
nitrogen	O
.	O

To	O
separate	O
the	O
Pex1	O
-	O
FLAG	O
/	O
His	O
-	O
Pex6	O
hexamer	O
from	O
other	O
oligomers	O
,	O
the	O
concentrated	O
FLAG	O
elution	O
was	O
loaded	O
on	O
a	O
Superose6	O
size	O
exclusion	O
column	O
equilibrated	O
in	O
GF	O
buffer	O
(	O
60	O
mM	O
HEPES	O
pH	O
7	O
.	O
6	O
,	O
50	O
mM	O
NaCl	O
,	O
50	O
mM	O
KCl	O
,	O
10	O
%	O
glycerol	O
,	O
10	O
mM	O
MgCl2	O
,	O
0	O
.	O
5	O
mM	O
EDTA	O
)	O
with	O
1	O
mM	O
ATP	O
.	O

The	O
concentration	O
of	O
protein	O
was	O
determined	O
by	O
a	O
Bradford	O
assay	O
.	O

The	O
amino	O
acid	O
changes	O
in	O
the	O
ATPase	O
motifs	O
of	O
Pex1	O
and	O
Pex6	O
are	O
as	O
follows	O
:	O
Pex1	O
-	O
Walker	O
B	O
D2	O
(	O
E798Q	O
)	O
,	O
Pex6	O
-	O
WB	O
D2	O
(	O
E832Q	O
)	O
,	O
Pex1	O
-	O
D2	O
poreloop	O
(	O
F771A	O
)	O
,	O
and	O
Pex6	O
-	O
D2	O
pore	O
loop	O
(	O
Y805A	O
)	O
.	O

It	O
has	O
been	O
suggested	O
that	O
factors	O
selectively	O
expressed	O
in	O
the	O
striatum	O
may	O
render	O
GABAergic	O
projection	O
neurons	O
(	O
medium	O
-	O
sized	O
spiny	O
neurons	O
)	O
particularly	O
susceptible	O
to	O
degeneration	O
.	O

We	O
previously	O
performed	O
a	O
transcriptome	O
SAGE	O
(	O
serial	O
analysis	O
of	O
gene	O
expression	O
)	O
analysis	O
of	O
different	O
regions	O
of	O
the	O
mouse	O
brain	O
,	O
which	O
identified	O
about	O
120	O
genes	O
preferentially	O
expressed	O
in	O
the	O
striatum	O
.	O

Most	O
of	O
the	O
products	O
of	O
these	O
genes	O
were	O
confirmed	O
to	O
be	O
'	O
striatal	O
-	O
enriched	O
'	O
by	O
checking	O
against	O
a	O
freely	O
available	O
transcriptomic	O
database	O
(	O
e	O
.	O
g	O
.	O
Allen	O
Brain	O
Atlas	O
)	O
.	O

In	O
our	O
initial	O
screen	O
,	O
some	O
of	O
these	O
newly	O
identified	O
striatal	O
gene	O
products	O
displayed	O
significantly	O
lower	O
than	O
normal	O
levels	O
of	O
expression	O
in	O
the	O
brains	O
of	O
Huntington	O
'	O
s	O
disease	O
mouse	O
models	O
and	O
patients	O
.	O

More	O
recent	O
studies	O
confirmed	O
these	O
findings	O
,	O
showing	O
that	O
a	O
subset	O
of	O
approximately	O
70	O
striatal	O
gene	O
products	O
(	O
e	O
.	O
g	O
.	O
ADORA2A	O
,	O
DCLK3	O
,	O
GPR88	O
,	O
RGS2	O
,	O
RGS9	O
,	O
SCN4B	O
)	O
are	O
downregulated	O
in	O
knock	O
-	O
in	O
Huntington	O
'	O
s	O
disease	O
mice	O
.	O

However	O
,	O
the	O
functions	O
of	O
these	O
striatal	O
gene	O
products	O
are	O
frequently	O
unknown	O
,	O
and	O
their	O
potential	O
roles	O
in	O
the	O
vulnerability	O
of	O
the	O
striatum	O
in	O
Huntington	O
'	O
s	O
disease	O
remain	O
a	O
matter	O
of	O
speculation	O
.	O

Identification	O
of	O
Atg1	O
double	O
-	O
aspartate	O
mutant	O
that	O
binds	O
Atg13	O
with	O
wild	O
-	O
type	O
affinity	O
.	O

(	O
A	O
)	O
Structure	O
of	O
K	O
.	O
marxianus	O
Atg1	O
EAT	O
domain	O
and	O
Atg13	O
interaction	O
showing	O
mutated	O
residues	O
.	O

Atg1	O
EAT	O
domain	O
:	O
gray	O
;	O
Atg13	O
:	O
blue	O
;	O
mutants	O
that	O
decreased	O
binding	O
to	O
Atg13	O
(	O
L671	O
,	O
M681	O
)	O
:	O
green	O
;	O
mutants	O
that	O
retained	O
wild	O
-	O
type	O
binding	O
to	O
Atg13	O
(	O
M765	O
,	O
M816	O
)	O
:	O
red	O
.	O

(	O
B	O
)	O
Representative	O
ITC	O
thermograms	O
showing	O
binding	O
affinity	O
of	O
Atg1	O
mutants	O
with	O
Atg13	O
.	O

a	O
,	O
b	O
Expression	O
of	O
PIWIL2	O
and	O
HDAC3	O
in	O
tumor	O
and	O
adjacent	O
normal	O
tissues	O
from	O
30	O
pairs	O
of	O
cervical	O
cancer	O
patients	O
were	O
examined	O
.	O

The	O
magnification	O
is	O
x400	O
.	O

*	O
P	O
<	O
0	O
.	O
05	O
and	O
*	O
*	O
P	O
<	O
0	O
.	O
01	O
.	O

c	O
PIWIL2	O
up	O
-	O
regulates	O
HDAC3	O
expression	O
at	O
protein	O
level	O
in	O
Hela	O
cells	O
and	O
HepG2	O
cells	O
.	O

d	O
Knockdown	O
of	O
PIWIL2	O
specifically	O
decreases	O
expression	O
of	O
only	O
HDAC3	O
among	O
class	O
I	O
HDACs	O
.	O

e	O
Immunofluorescent	O
staining	O
of	O
HDAC3	O
in	O
PIWIL2	O
shRNA	O
transfected	O
Hela	O
and	O
HepG2	O
cells	O
.	O

f	O
PIWIL2	O
has	O
no	O
effect	O
on	O
HDAC3	O
mRNA	O
expression	O
(	O
N	O
.	O
S	O
.	O
,	O
not	O
significant	O
,	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

g	O
The	O
degradation	O
of	O
HDAC3	O
is	O
faster	O
in	O
cells	O
transfected	O
with	O
PIWIL2	O
shRNA	O
than	O
in	O
cells	O
transfected	O
with	O
control	O
plasmid	O
.	O

Cells	O
transfected	O
with	O
shPIWIL2	O
or	O
shNC	O
were	O
treated	O
with	O
cycloheximide	O
(	O
CHX	O
)	O
at	O
50	O
muM	O
for	O
indicated	O
time	O

Nutritional	O
Control	O
of	O
Stem	O
Cell	O
Division	O
through	O
S	O
-	O
Adenosylmethionine	O
in	O
Drosophila	O
Intestine	O
.	O

The	O
intestine	O
has	O
direct	O
contact	O
with	O
nutritional	O
information	O
.	O

The	O
mechanisms	O
by	O
which	O
particular	O
dietary	O
molecules	O
affect	O
intestinal	O
homeostasis	O
are	O
not	O
fully	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
S	O
-	O
adenosylmethionine	O
(	O
SAM	O
)	O
,	O
a	O
universal	O
methyl	O
donor	O
synthesized	O
from	O
dietary	O
methionine	O
,	O
as	O
a	O
critical	O
molecule	O
that	O
regulates	O
stem	O
cell	O
division	O
in	O
Drosophila	O
midgut	O
.	O

Depletion	O
of	O
either	O
dietary	O
methionine	O
or	O
SAM	O
synthesis	O
reduces	O
division	O
rate	O
of	O
intestinal	O
stem	O
cells	O
.	O

Genetic	O
screening	O
for	O
putative	O
SAM	O
-	O
dependent	O
methyltransferases	O
has	O
identified	O
protein	O
synthesis	O
as	O
a	O
regulator	O
of	O
the	O
stem	O
cells	O
,	O
partially	O
through	O
a	O
unique	O
diphthamide	O
modification	O
on	O
eukaryotic	O
elongation	O
factor	O
2	O
.	O

In	O
contrast	O
,	O
SAM	O
in	O
nutrient	O
-	O
absorptive	O
enterocytes	O
controls	O
the	O
interleukin	O
-	O
6	O
-	O
like	O
protein	O
Unpaired	O
3	O
,	O
which	O
is	O
required	O
for	O
rapid	O
division	O
of	O
the	O
stem	O
cells	O
after	O
refeeding	O
.	O

Our	O
study	O
sheds	O
light	O
upon	O
a	O
link	O
between	O
diet	O
and	O
intestinal	O
homeostasis	O
and	O
highlights	O
the	O
key	O
metabolite	O
SAM	O
as	O
a	O
mediator	O
of	O
cell	O
-	O
type	O
-	O
specific	O
starvation	O
response	O
.	O

Breast	O
cancer	O
E0771	O
and	O
MCF	O
-	O
7	O
tumor	O
cells	O
transfected	O
with	O
Lenti	O
-	O
SALL1	O
,	O
Lenti	O
-	O
mSALL1	O
or	O
vector	O
,	O
were	O
plated	O
in	O
6	O
-	O
well	O
plates	O
and	O
grown	O
to	O
confluence	O
.	O

A	O
wound	O
area	O
was	O
generated	O
by	O
scraping	O
cells	O
with	O
a	O
200	O
mul	O
pipette	O
tip	O
across	O
the	O
entire	O
diameter	O
of	O
the	O
dish	O
and	O
extensively	O
rinsed	O
with	O
the	O
medium	O
to	O
remove	O
all	O
cellular	O
debris	O
.	O

Low	O
-	O
serum	O
RPMI	O
1640	O
with	O
mitomycin	O
(	O
2	O
mug	O
/	O
ml	O
)	O
was	O
then	O
added	O
to	O
inhibit	O
cell	O
proliferation	O
during	O
the	O
experiment	O
and	O
the	O
closing	O
of	O
the	O
wound	O
was	O
observed	O
at	O
different	O
time	O
points	O
.	O

Here	O
,	O
we	O
describe	O
the	O
discovery	O
of	O
a	O
surveillance	O
mechanism	O
,	O
mitoCPR	O
,	O
that	O
detects	O
mitochondrial	O
import	O
stress	O
and	O
protects	O
mitochondrial	O
functions	O
in	O
response	O
.	O

We	O
propose	O
that	O
the	O
mitoCPR	O
effector	O
Cis1	O
recruits	O
Msp1	O
to	O
the	O
outer	O
membrane	O
translocase	O
to	O
clear	O
stalled	O
proteins	O
from	O
the	O
translocase	O
thereby	O
improving	O
mitochondrial	O
import	O
(	O
Fig	O
.	O
7F	O
)	O
.	O

This	O
response	O
is	O
essential	O
to	O
protect	O
mitochondrial	O
functions	O
and	O
to	O
maintain	O
the	O
mitochondrial	O
genome	O
during	O
import	O
stress	O
.	O

Recently	O
,	O
it	O
was	O
discovered	O
that	O
translation	O
by	O
ribosomes	B-OOS
at	O
the	O
surface	O
of	O
mitochondria	O
can	O
stall	O
.	O

Whether	O
the	O
Msp1	O
-	O
Cis1	O
complex	O
can	O
clear	O
preproteins	O
from	O
ribosomes	B-OOS
during	O
co	O
-	O
translational	O
import	O
or	O
whether	O
the	O
complex	O
only	O
recognizes	O
post	O
-	O
translationally	O
imported	O
proteins	O
remains	O
to	O
be	O
determined	O
.	O

We	O
also	O
do	O
not	O
yet	O
know	O
whether	O
Cis1	O
and	O
Msp1	O
improve	O
mitochondrial	O
import	O
solely	O
by	O
clearing	O
un	O
-	O
imported	O
proteins	O
.	O

Our	O
data	O
suggest	O
that	O
they	O
may	O
also	O
aid	O
in	O
the	O
import	O
process	O
itself	O
.	O

Mitochondrial	O
preproteins	O
must	O
be	O
kept	O
unfolded	O
in	O
order	O
to	O
translocate	O
into	O
mitochondria	O
.	O

A	O
delay	O
in	O
mitochondrial	O
import	O
could	O
result	O
in	O
premature	O
folding	O
and	O
perhaps	O
even	O
aggregation	O
of	O
preproteins	O
at	O
the	O
organelle	O
'	O
s	O
surface	O
.	O

We	O
speculate	O
that	O
Msp1	O
,	O
whose	O
ATPase	O
domain	O
faces	O
the	O
cytosol	O
,	O
could	O
unfold	O
prematurely	O
folding	O
or	O
aggregated	O
preproteins	O
giving	O
them	O
a	O
second	O
chance	O
to	O
translocate	O
into	O
mitochondria	O
or	O
,	O
when	O
this	O
does	O
not	O
occur	O
,	O
target	O
them	O
for	O
degradation	O
(	O
Fig	O
.	O
7F	O
)	O
.	O

To	O
ascertain	O
the	O
functionality	O
of	O
the	O
C	O
-	O
terminal	O
truncation	O
mutants	O
of	O
Hhp1	O
/	O
2	O
,	O
we	O
performed	O
growth	O
,	O
in	O
vitro	O
kinase	O
,	O
and	O
mitotic	O
checkpoint	O
assays	O
.	O

First	O
,	O
we	O
found	O
that	O
each	O
of	O
the	O
hhp1	O
/	O
2	O
C	O
-	O
terminal	O
truncation	O
mutants	O
integrated	O
as	O
the	O
sole	O
hhp1	O
/	O
2	O
allele	O
in	O
cells	O
rescued	O
the	O
severe	O
growth	O
defect	O
of	O
the	O
double	O
-	O
deletion	O
mutant	O
in	O
vivo	O
(	O
Figure	O
2D	O
)	O
.	O

Consistent	O
with	O
this	O
finding	O
and	O
previous	O
reports	O
,	O
recombinant	O
Hhp1	O
/	O
2	O
C	O
-	O
terminal	O
truncation	O
mutants	O
phosphorylated	O
the	O
exogenous	O
substrate	O
casein	O
in	O
vitro	O
even	O
more	O
robustly	O
than	O
the	O
full	O
-	O
length	O
proteins	O
(	O
Figure	O
2E	O
)	O
.	O

Importantly	O
,	O
we	O
found	O
that	O
the	O
truncation	O
mutants	O
were	O
sufficient	O
to	O
inhibit	O
the	O
SIN	O
during	O
the	O
mitotic	O
checkpoint	O
.	O

GFP	O
-	O
tagged	O
Hhp1	O
and	O
Hhp2	O
C	O
-	O
terminal	O
truncations	O
accumulated	O
at	O
SPBs	O
during	O
a	O
mitotic	O
checkpoint	O
arrest	O
(	O
Supplemental	O
Figure	O
S2	O
,	O
C	O
and	O
D	O
)	O
,	O
and	O
Sid4	O
was	O
appropriately	O
ubiquitinated	O
(	O
Figure	O
2F	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
C	O
-	O
termini	O
of	O
Hhp1	O
/	O
2	O
are	O
dispensable	O
for	O
their	O
SPB	O
localization	O
and	O
function	O
during	O
the	O
Dma1	O
-	O
mediated	O
mitotic	O
checkpoint	O
.	O

The	O
pathogenic	O
effects	O
of	O
gating	O
pore	O
mutations	O
depend	O
on	O
inward	O
leak	O
of	O
Na	O
+	O
.	O

The	O
R2S	O
gating	O
pore	O
was	O
not	O
significantly	O
selective	O
among	O
Cs	O
+	O
,	O
K	O
+	O
,	O
or	O
Na	O
+	O
(	O
Fig	O
.	O
1g	O
)	O
.	O

As	O
for	O
NaV1	O
.	O
4	O
,	O
guanidinium	O
was	O
exceptionally	O
permeant	O
in	O
the	O
gating	O
pore	O
of	O
NaVAb	O
/	O
R2S	O
,	O
with	O
a	O
ratio	O
of	O
PGua	O
:	O
PNa	O
~	O
28	O
.	O

Methylguanidine	O
and	O
ethylguanidine	O
were	O
less	O
permeant	O
(	O
Fig	O
.	O
1g	O
)	O
.	O

The	O
ion	O
selectivity	O
of	O
the	O
outward	O
gating	O
pore	O
current	O
conducted	O
by	O
NaVAb	O
/	O
R3G	O
was	O
Cs	O
+	O
>	O
K	O
+	O
~	O
Na	O
+	O
(	O
Fig	O
.	O
1h	O
)	O
.	O

However	O
,	O
the	O
permeation	O
of	O
guanidinium	O
was	O
less	O
than	O
Na	O
+	O
in	O
NaVAb	O
/	O
R3G	O
and	O
>	O
40	O
-	O
fold	O
less	O
than	O
in	O
NaVAb	O
/	O
R2S	O
(	O
Fig	O
.	O
1h	O
)	O
.	O

The	O
weak	O
selectivity	O
among	O
inorganic	O
cations	O
for	O
R2S	O
and	O
R3G	O
and	O
the	O
high	O
guanidinium	O
permeability	O
through	O
R2S	O
are	O
characteristic	O
of	O
corresponding	O
mutations	O
in	O
NaV1	O
.	O
4	O
,	O
further	O
supporting	O
NaVAb	O
as	O
a	O
valid	O
model	O
for	O
structural	O
studies	O
of	O
gating	O
pore	O
mutations	O
.	O

Therefore	O
,	O
to	O
understand	O
the	O
mechanism	O
providing	O
the	O
anterograde	O
bias	O
to	O
the	O
bulk	O
of	O
ChAT	O
movement	O
and	O
the	O
impact	O
of	O
its	O
presynaptic	O
activity	O
on	O
the	O
transport	O
,	O
we	O
estimated	O
interactions	O
between	O
ChAT	O
and	O
Kinesin	O
-	O
2	O
motor	O
subunit	O
in	O
situ	O
at	O
different	O
developmental	O
stages	O
.	O

We	O
also	O
perturbed	O
the	O
cholinergic	O
activity	O
using	O
pharmacological	O
reagents	O
and	O
studied	O
the	O
effect	O
on	O
this	O
transport	O
.	O

We	O
used	O
a	O
high	O
-	O
sensitivity	O
detector	O
for	O
data	O
acquisition	O
that	O
enhanced	O
the	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
substantially	O
as	O
compared	O
to	O
the	O
earlier	O
report	O
.	O

The	O
results	O
indicate	O
that	O
a	O
temporally	O
-	O
restricted	O
association	O
with	O
Kinesin	O
-	O
2	O
,	O
during	O
77	O
-	O
78	O
hours	O
after	O
egg	O
laying	O
(	O
AEL	O
)	O
,	O
throughout	O
the	O
neuron	O
drives	O
the	O
episodic	O
movement	O
of	O
the	O
bulk	O
of	O
ChAT	O
towards	O
synapse	O
.	O

A	O
step	O
increase	O
in	O
the	O
axonal	O
levels	O
of	O
the	O
motor	O
during	O
77	O
-	O
78	O
h	O
AEL	O
and	O
cholinergic	O
activity	O
enhanced	O
the	O
entry	O
and	O
anterograde	O
flux	O
of	O
ChAT	O
in	O
axons	O
.	O

The	O
bulk	O
movement	O
of	O
ChAT	O
appears	O
to	O
evolve	O
from	O
a	O
restricted	O
to	O
a	O
directed	O
,	O
facilitated	O
diffusion	O
during	O
this	O
period	O
.	O

Loss	O
of	O
Trim67	O
leads	O
to	O
impairments	O
in	O
spatial	O
learning	O
and	O
memory	O
.	O

A	O
,	O
Time	O
(	O
s	O
)	O
for	O
mice	O
to	O
find	O
a	O
hidden	O
platform	O
in	O
the	O
Morris	O
water	O
maze	O
,	O
with	O
a	O
threshold	O
for	O
learning	O
set	O
at	O
a	O
group	O
average	O
of	O
15	O
s	O
(	O
dashed	O
line	O
)	O
.	O

Trim67	O
-	O
/	O
-	O
mice	O
fail	O
to	O
reach	O
this	O
threshold	O
out	O
to	O
the	O
maximum	O
of	O
9	O
d	O
of	O
training	O
and	O
have	O
overall	O
significantly	O
higher	O
latencies	O
to	O
find	O
the	O
platform	O
(	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
all	O
trials	O
p	O
=	O
0	O
.	O
0225	O
)	O
.	O

B	O
,	O
Time	O
spent	O
in	O
target	O
and	O
opposite	O
quadrants	O
and	O
number	O
of	O
times	O
crossing	O
the	O
previous	O
platform	O
position	O
in	O
a	O
probe	O
trial	O
following	O
acquisition	O
day	O
9	O
.	O

Whereas	O
Trim67	O
+	O
/	O
+	O
mice	O
spent	O
a	O
higher	O
amount	O
of	O
time	O
in	O
the	O
quadrant	O
previously	O
occupied	O
by	O
the	O
platform	O
(	O
*	O
p	O
=	O
0	O
.	O
0003	O
)	O
,	O
Trim67	O
-	O
/	O
-	O
mice	O
failed	O
to	O
show	O
this	O
preference	O
and	O
spent	O
a	O
lower	O
time	O
in	O
the	O
target	O
quadrant	O
than	O
Trim67	O
+	O
/	O
+	O
mice	O
(	O
#	O
p	O
=	O
0	O
.	O
0343	O
)	O
.	O

C	O
,	O
Subsequent	O
reversal	O
trials	O
demonstrated	O
an	O
increased	O
latency	O
to	O
find	O
the	O
platform	O
in	O
the	O
Trim67	O
-	O
/	O
-	O
cohort	O
compared	O
to	O
Trim67	O
+	O
/	O
+	O
littermates	O
(	O
*	O
p	O
<	O
0	O
.	O
05	O
;	O
all	O
trials	O
p	O
=	O
0	O
.	O
0149	O
)	O
.	O

D	O
,	O
In	O
a	O
probe	O
trial	O
following	O
reversal	O
day	O
7	O
,	O
only	O
Trim67	O
+	O
/	O
+	O
mice	O
spent	O
more	O
time	O
in	O
the	O
new	O
target	O
quadrant	O
(	O
*	O
p	O
=	O
0	O
.	O
0335	O
)	O
.	O

Loss	O
of	O
PRMT5	O
Promotes	O
PDGFRalpha	O
Degradation	O
during	O
Oligodendrocyte	O
Differentiation	O
and	O
Myelination	O
.	O

The	O
oligodendrocyte	O
lineage	O
is	O
responsible	O
for	O
myelination	O
of	O
the	O
central	O
nervous	O
system	O
.	O

Post	O
-	O
translational	O
modifications	O
are	O
known	O
to	O
regulate	O
oligodendrocyte	O
precursor	O
cell	O
(	O
OPC	O
)	O
differentiation	O
into	O
mature	O
myelinating	O
oligodendrocytes	O
.	O

The	O
role	O
of	O
arginine	O
methylation	O
during	O
oligodendrocyte	O
differentiation	O
and	O
myelination	O
is	O
still	O
poorly	O
understood	O
.	O

We	O
generated	O
mice	O
depleted	O
of	O
PRMT5	O
in	O
OPCs	O
using	O
Olig2	O
-	O
Cre	O
,	O
and	O
these	O
mice	O
developed	O
severe	O
hypomyelination	O
and	O
died	O
at	O
the	O
third	O
post	O
-	O
natal	O
week	O
.	O

PRMT5	O
-	O
deficient	O
cells	O
have	O
lower	O
levels	O
of	O
PDGFRalpha	O
at	O
the	O
plasma	O
membrane	O
due	O
to	O
increased	O
degradation	O
by	O
the	O
Cbl	O
E3	O
ligase	O
.	O

Mechanistically	O
,	O
the	O
loss	O
of	O
arginine	O
methylation	O
at	O
R554	O
of	O
the	O
PDGFRalpha	O
intracellular	O
domain	O
unmasks	O
a	O
Cbl	O
binding	O
site	O
at	O
Y555	O
.	O

We	O
observed	O
the	O
progressive	O
decrease	O
in	O
PRMT5	O
during	O
oligodendrocyte	O
differentiation	O
,	O
and	O
we	O
show	O
that	O
one	O
role	O
of	O
this	O
decrease	O
is	O
to	O
downregulate	O
growth	O
signals	O
provided	O
by	O
PDGFRalpha	O
to	O
initiate	O
oligodendrocyte	O
differentiation	O
and	O
myelination	O
.	O

More	O
broadly	O
,	O
the	O
inhibition	O
of	O
PRMT5	O
may	O
be	O
used	O
therapeutically	O
to	O
manipulate	O
PDGFRalpha	O
bioavailability	O
.	O

Cloning	O
and	O
characterization	O
of	O
four	O
SIR	O
genes	O
of	O
Saccharomyces	O
cerevisiae	O
.	O

Mating	O
type	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
is	O
determined	O
by	O
the	O
MAT	O
(	O
a	O
or	O
alpha	O
)	O
locus	O
.	O

HML	O
and	O
HMR	O
,	O
which	O
usually	O
contain	O
copies	O
of	O
alpha	O
and	O
a	O
mating	O
type	O
information	O
,	O
respectively	O
,	O
serve	O
as	O
donors	O
in	O
mating	O
type	O
interconversion	O
and	O
are	O
under	O
negative	O
transcriptional	O
control	O
.	O

Four	O
trans	O
-	O
acting	O
SIR	O
(	O
silent	O
information	O
regulator	O
)	O
loci	O
are	O
required	O
for	O
repression	O
of	O
transcription	O
.	O

A	O
defect	O
in	O
any	O
SIR	O
gene	O
results	O
in	O
expression	O
of	O
both	O
HML	O
and	O
HMR	O
.	O

The	O
four	O
SIR	O
genes	O
were	O
isolated	O
from	O
a	O
genomic	O
library	O
by	O
complementation	O
of	O
sir	O
mutations	O
in	O
vivo	O
.	O

DNA	O
blot	O
analysis	O
suggests	O
that	O
the	O
four	O
SIR	O
genes	O
share	O
no	O
sequence	O
homology	O
.	O

RNA	O
blots	O
indicate	O
that	O
SIR2	O
,	O
SIR3	O
,	O
and	O
SIR4	O
each	O
encode	O
one	O
transcript	O
and	O
that	O
SIR1	O
encodes	O
two	O
transcripts	O
.	O

Null	O
mutations	O
,	O
made	O
by	O
replacement	O
of	O
the	O
normal	O
genomic	O
allele	O
with	O
deletion	O
-	O
insertion	O
mutations	O
created	O
in	O
the	O
cloned	O
SIR	O
genes	O
,	O
have	O
a	O
Sir	O
-	O
phenotype	O
and	O
are	O
viable	O
.	O

Using	O
the	O
cloned	O
genes	O
,	O
we	O
showed	O
that	O
SIR3	O
at	O
a	O
high	O
copy	O
number	O
is	O
able	O
to	O
suppress	O
mutations	O
of	O
SIR4	O
.	O

RNA	O
blot	O
analysis	O
suggests	O
that	O
this	O
suppression	O
is	O
not	O
due	O
to	O
transcriptional	O
regulation	O
of	O
SIR3	O
by	O
SIR4	O
;	O
nor	O
does	O
any	O
SIR4	O
gene	O
transcriptionally	O
regulate	O
another	O
SIR	O
gene	O
.	O

Interestingly	O
,	O
a	O
truncated	O
SIR4	O
gene	O
disrupts	O
regulation	O
of	O
the	O
silent	O
mating	O
type	O
loci	O
.	O

We	O
propose	O
that	O
interaction	O
of	O
at	O
least	O
the	O
SIR3	O
and	O
SIR4	O
gene	O
products	O
is	O
involved	O
in	O
regulation	O
of	O
the	O
silent	O
mating	O
type	O
genes	O
.	O

ANKRD9	O
is	O
associated	O
with	O
tumor	O
suppression	O
as	O
a	O
substrate	O
receptor	O
subunit	O
of	O
ubiquitin	O
ligase	O
.	O

BACKGROUND	O
:	O
Human	O
ANKRD9	O
(	O
ankyrin	O
repeat	O
domain	O
9	O
)	O
expression	O
is	O
altered	O
in	O
some	O
cancers	O
.	O

METHODS	O
:	O
We	O
tested	O
genetic	O
association	O
of	O
ANKRD9	O
with	O
gastric	O
cancer	O
susceptibility	O
and	O
examined	O
functional	O
association	O
of	O
ANKRD9	O
with	O
altered	O
proliferation	O
of	O
MKN45	O
gastric	O
cancer	O
cells	O
.	O

We	O
then	O
identified	O
ANKRD9	O
-	O
binding	O
partners	O
in	O
HEK	O
293	O
embryonic	O
kidney	O
cells	O
using	O
quantitative	O
proteomics	O
,	O
western	O
blotting	O
and	O
complex	O
reconstitution	O
assays	O
.	O

We	O
finally	O
demonstrated	O
ANKRD9	O
'	O
s	O
role	O
of	O
recognizing	O
substrates	O
for	O
ubiquitination	O
using	O
in	O
vitro	O
ubiquitylation	O
assay	O
.	O

RESULTS	O
:	O
ANKRD9	O
is	O
associated	O
with	O
cancer	O
susceptibility	O
in	O
a	O
comparison	O
of	O
single	O
-	O
nucleotide	O
polymorphisms	O
between	O
1092	O
gastric	O
cancer	O
patients	O
and	O
1206	O
healthy	O
controls	O
.	O

ANKRD9	O
depletion	O
accelerates	O
tumor	O
progression	O
by	O
increasing	O
cellular	O
proliferation	O
,	O
piling	O
up	O
,	O
and	O
anchorage	O
-	O
independent	O
growth	O
of	O
MKN45	O
cells	O
.	O

We	O
discovered	O
that	O
ANKRD9	O
is	O
a	O
ubiquitin	O
ligase	O
substrate	O
receptor	O
subunit	O
and	O
has	O
an	O
anti	O
-	O
proliferative	O
activity	O
.	O

ANKRD9	O
associates	O
with	O
CUL5	O
(	O
not	O
CUL2	O
)	O
,	O
ELOB	O
,	O
ELOC	O
,	O
and	O
presumably	O
RNF7	O
subunits	O
,	O
which	O
together	O
assemble	O
into	O
a	O
cullin	O
-	O
RING	O
superfamily	O
E3	O
ligase	O
complex	O
.	O

ANKRD9	O
belongs	O
to	O
the	O
ASB	O
family	O
of	O
proteins	O
,	O
which	O
are	O
characterized	O
by	O
the	O
presence	O
of	O
ankyrin	O
repeats	O
and	O
a	O
SOCS	O
box	O
.	O

In	O
addition	O
to	O
its	O
interactions	O
with	O
the	O
other	O
E3	O
ligase	O
subunits	O
,	O
ANKRD9	O
interacts	O
with	O
two	O
isoforms	O
of	O
inosine	O
monophosphate	O
dehydrogenase	O
(	O
IMPDH	O
)	O
.	O

These	O
IMPDH	O
isoforms	O
are	O
cognate	O
substrates	O
of	O
the	O
ANKRD9	O
-	O
containing	O
E3	O
enzyme	O
,	O
which	O
ubiquitinates	O
them	O
for	O
proteasomal	O
degradation	O
.	O

Their	O
ubiquitination	O
and	O
turnover	O
require	O
the	O
presence	O
of	O
ANKRD9	O
.	O

CONCLUSION	O
:	O
ANKRD9	O
,	O
a	O
previously	O
unidentified	O
E3	O
substrate	O
receptor	O
subunit	O
,	O
functions	O
in	O
tumor	O
suppression	O
by	O
recognizing	O
the	O
oncoprotein	O
IMPDH	O
isoforms	O
for	O
E3	O
ubiquitination	O
and	O
proteasomal	O
degradation	O
.	O

To	O
further	O
interrogate	O
the	O
interaction	O
of	O
Ssp2	O
and	O
Smk1	O
,	O
we	O
utilized	O
a	O
bacterial	O
expression	O
strategy	O
that	O
incorporates	O
non	O
-	O
natural	O
cross	O
-	O
linkable	O
amino	O
acids	O
at	O
specific	O
positions	O
within	O
a	O
target	O
protein	O
.	O

This	O
system	O
utilizes	O
an	O
aminoacyl	O
-	O
tRNA	O
synthetase	O
that	O
charges	O
an	O
engineered	O
amber	O
suppressor	O
tRNA	O
with	O
the	O
non	O
-	O
natural	O
amino	O
acid	O
p	O
-	O
benzoyl	O
-	O
l	O
-	O
phenylalanine	O
(	O
Bpa	O
)	O
.	O

Upon	O
exposure	O
to	O
UV	O
light	O
,	O
the	O
Bpa	O
side	O
chain	O
can	O
form	O
covalent	O
bonds	O
with	O
carbon	O
atoms	O
that	O
are	O
within	O
4	O
Aa	O
.	O

Amber	O
codons	O
were	O
introduced	O
at	O
various	O
positions	O
in	O
a	O
plasmid	O
that	O
directs	O
the	O
inducible	O
expression	O
of	O
both	O
SMK1	O
and	O
SSP2KAD	O
-	O
GST	O
.	O

These	O
plasmids	O
and	O
a	O
second	O
plasmid	O
that	O
directs	O
the	O
expression	O
of	O
the	O
tRNA	O
and	O
synthetase	O
were	O
co	O
-	O
transformed	O
into	O
bacteria	O
,	O
and	O
transformants	O
were	O
induced	O
in	O
medium	O
containing	O
Bpa	O
.	O

Subsequently	O
,	O
samples	O
were	O
irradiated	O
with	O
UV	O
and	O
resolved	O
by	O
electrophoresis	O
in	O
denaturing	O
gels	O
,	O
and	O
Smk1	O
or	O
Ssp2	O
proteins	O
detected	O
by	O
immunoblot	O
analyses	O
.	O

If	O
the	O
amber	O
suppressible	O
residue	O
in	O
one	O
of	O
the	O
Smk1	O
/	O
Ssp2KAD	O
-	O
GST	O
proteins	O
is	O
within	O
4	O
Aa	O
of	O
a	O
C	O
atom	O
of	O
the	O
second	O
protein	O
,	O
new	O
electrophoretic	O
species	O
approximating	O
the	O
combined	O
masses	O
of	O
Smk1	O
and	O
the	O
Ssp2KAD	O
-	O
GST	O
complex	O
may	O
be	O
detected	O
.	O

To	O
examine	O
in	O
more	O
detail	O
how	O
the	O
internal	O
oxidation	O
state	O
of	O
Pdi1p	O
relates	O
to	O
oxidative	O
refolding	O
activity	O
in	O
our	O
in	O
vitro	O
system	O
,	O
a	O
polyethylene	O
glycol	O
(	O
PEG	O
)	O
-	O
trapping	O
assay	O
was	O
exploited	O
that	O
,	O
through	O
alkylation	O
of	O
reduced	O
cysteines	O
,	O
leads	O
to	O
defined	O
shifts	O
in	O
apparent	O
molecular	O
weight	O
.	O

Analysis	O
of	O
PEG	O
-	O
treated	O
Pdi1p	O
over	O
the	O
course	O
of	O
the	O
oxidative	O
refolding	O
reaction	O
by	O
Western	O
blotting	O
showed	O
that	O
within	O
100	O
s	O
of	O
RNase	O
A	O
refolding	O
,	O
the	O
initially	O
fully	O
oxidized	O
Pdi1p	O
becomes	O
heavily	O
reduced	O
with	O
a	O
prominent	O
species	O
appearing	O
at	O
a	O
size	O
expected	O
for	O
four	O
reduced	O
cysteines	O
,	O
as	O
well	O
as	O
a	O
less	O
abundant	O
species	O
corresponding	O
to	O
six	O
reduced	O
cysteines	O
,	O
that	O
is	O
,	O
fully	O
reduced	O
Pdi1p	O
(	O
Fig	O
.	O
6A	O
,	O
B	O
;	O
Supplementary	O
Figs	O
.	O
S2	O
and	O
S3	O
)	O
.	O

The	O
pipeline	O
we	O
used	O
to	O
uncover	O
the	O
Dsn1	O
-	O
N	O
(	O
Box	O
1	O
)	O
motif	O
in	O
a	O
wide	O
distribution	O
of	O
eukaryotes	O
is	O
based	O
on	O
a	O
previously	O
established	O
workflow	O
termed	O
ConFeaX	O
(	O
Tromer	O
et	O
al	O
.	O
)	O
.	O

Orthologous	O
sequences	O
were	O
masked	O
using	O
IUpred	O
(	O
Dosztanyi	O
et	O
al	O
.	O
)	O
(	O
disorder	O
/	O
order	O
threshold	O
=	O
0	O
.	O
4	O
)	O
and	O
MARCOIL	O
(	O
Delorenzi	O
and	O
Speed	O
)	O
(	O
coiled	O
-	O
coil	O
threshold	O
=	O
90	O
)	O
.	O

ConFeaX	O
starts	O
with	O
a	O
probabilistic	O
search	O
for	O
short	O
conserved	O
regions	O
(	O
6	O
-	O
100	O
aa	O
)	O
in	O
masked	O
orthologs	O
using	O
the	O
MEME	O
algorithm	O
(	O
option	O
:	O
any	O
number	O
of	O
repeats	O
)	O
(	O
Bailey	O
et	O
al	O
.	O
)	O
.	O

Significant	O
motif	O
hits	O
are	O
extended	O
on	O
both	O
sides	O
by	O
five	O
residues	O
to	O
compensate	O
for	O
the	O
strict	O
treatment	O
of	O
alignment	O
information	O
by	O
the	O
MEME	O
algorithm	O
and	O
aligned	O
using	O
MAFFT	O
-	O
LINSI	O
(	O
Katoh	O
and	O
Standley	O
)	O
to	O
introduce	O
gaps	O
.	O

The	O
alignments	O
were	O
modelled	O
using	O
the	O
HMMER	O
packing	O
(	O
Eddy	O
)	O
and	O
sensitive	O
profile	O
HMM	O
searches	O
(	O
using	O
jackhmmer	O
)	O
were	O
iterated	O
(	O
E	O
-	O
value	O
=	O
1	O
)	O
until	O
convergence	O
.	O

In	O
some	O
cases	O
,	O
we	O
manually	O
optimised	O
the	O
HMM	O
profile	O
searches	O
using	O
permissive	O
bit	O
scores	O
and	O
removed	O
obvious	O
false	O
hits	O
.	O

Subsequently	O
,	O
for	O
each	O
of	O
the	O
conserved	O
features	O
,	O
a	O
phylogenetic	O
profile	O
was	O
derived	O
(	O
present	O
is	O
'	O
1	O
'	O
and	O
absent	O
is	O
'	O
0	O
'	O
)	O
.	O

For	O
all	O
possible	O
pairs	O
,	O
we	O
determined	O
the	O
correlation	O
/	O
similarity	O
using	O
Pearson	O
correlation	O
coefficient	O
(	O
Wu	O
et	O
al	O
.	O
)	O
.	O

Pearson	O
distances	O
(	O
D	O
=	O
1	O
-	O
r	O
)	O
were	O
used	O
to	O
map	O
the	O
phylogenetic	O
profile	O
similarity	O
of	O
kinetochore	O
proteins	O
in	O
2D	O
using	O
Barnes	O
-	O
Hut	O
t	O
-	O
SNE	O
(	O
Maaten	O
and	O
Hinton	O
)	O
(	O
R	O
-	O
package	O
'	O
Rtsne	O
'	O
[	O
perplexity	O
=	O
5	O
,	O
dimensions	O
=	O
2	O
and	O
theta	O
=	O
0	O
]	O
,	O
see	O
Fig	O
.	O
1	O
)	O
.	O

Sequence	O
logos	O
depicted	O
throughout	O
this	O
study	O
were	O
obtained	O
using	O
weblogo2	O
(	O
Crooks	O
et	O
al	O
.	O
)	O
.	O

Ets21c	O
Governs	O
Tissue	O
Renewal	O
,	O
Stress	O
Tolerance	O
,	O
and	O
Aging	O
in	O
the	O
Drosophila	O
Intestine	O
.	O

Homeostatic	O
renewal	O
and	O
stress	O
-	O
related	O
tissue	O
regeneration	O
rely	O
on	O
stem	O
cell	O
activity	O
,	O
which	O
drives	O
the	O
replacement	O
of	O
damaged	O
cells	O
to	O
maintain	O
tissue	O
integrity	O
and	O
function	O
.	O

The	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
signaling	O
pathway	O
has	O
been	O
established	O
as	O
a	O
critical	O
regulator	O
of	O
tissue	O
homeostasis	O
both	O
in	O
intestinal	O
stem	O
cells	O
(	O
ISCs	O
)	O
and	O
mature	O
enterocytes	O
(	O
ECs	O
)	O
,	O
while	O
its	O
chronic	O
activation	O
has	O
been	O
linked	O
to	O
tissue	O
degeneration	O
and	O
aging	O
.	O

Here	O
,	O
we	O
show	O
that	O
JNK	O
signaling	O
requires	O
the	O
stress	O
-	O
inducible	O
transcription	O
factor	O
Ets21c	O
to	O
promote	O
tissue	O
renewal	O
in	O
Drosophila	O
.	O

We	O
demonstrate	O
that	O
Ets21c	O
controls	O
ISC	O
proliferation	O
as	O
well	O
as	O
EC	O
apoptosis	O
through	O
distinct	O
sets	O
of	O
target	O
genes	O
that	O
orchestrate	O
cellular	O
behaviors	O
via	O
intrinsic	O
and	O
non	O
-	O
autonomous	O
signaling	O
mechanisms	O
.	O

While	O
its	O
loss	O
appears	O
dispensable	O
for	O
development	O
and	O
prevents	O
epithelial	O
aging	O
,	O
ISCs	O
and	O
ECs	O
demand	O
Ets21c	O
function	O
to	O
mount	O
cellular	O
responses	O
to	O
oxidative	O
stress	O
.	O

Ets21c	O
thus	O
emerges	O
as	O
a	O
vital	O
regulator	O
of	O
proliferative	O
homeostasis	O
in	O
the	O
midgut	O
and	O
a	O
determinant	O
of	O
the	O
adult	O
healthspan	O
.	O

PGRMC2	O
is	O
an	O
intracellular	O
haem	O
chaperone	O
critical	O
for	O
adipocyte	O
function	O
.	O

Haem	O
is	O
an	O
essential	O
prosthetic	O
group	O
of	O
numerous	O
proteins	O
and	O
a	O
central	O
signalling	O
molecule	O
in	O
many	O
physiologic	O
processes	O
(	O
1	O
,	O
2	O
)	O
.	O

The	O
chemical	O
reactivity	O
of	O
haem	O
means	O
that	O
a	O
network	O
of	O
intracellular	O
chaperone	O
proteins	O
is	O
required	O
to	O
avert	O
the	O
cytotoxic	O
effects	O
of	O
free	O
haem	O
,	O
but	O
the	O
constituents	O
of	O
such	O
trafficking	O
pathways	O
are	O
unknown	O
(	O
3	O
,	O
4	O
)	O
.	O

Haem	O
synthesis	O
is	O
completed	O
in	O
mitochondria	O
,	O
with	O
ferrochelatase	O
adding	O
iron	O
to	O
protoporphyrin	O
IX	O
.	O

How	O
this	O
vital	O
but	O
highly	O
reactive	O
metabolite	O
is	O
delivered	O
from	O
mitochondria	O
to	O
haemoproteins	O
throughout	O
the	O
cell	O
remains	O
poorly	O
defined	O
(	O
3	O
,	O
4	O
)	O
.	O

Here	O
we	O
show	O
that	O
progesterone	O
receptor	O
membrane	O
component	O
2	O
(	O
PGRMC2	O
)	O
is	O
required	O
for	O
delivery	O
of	O
labile	O
,	O
or	O
signalling	O
haem	O
,	O
to	O
the	O
nucleus	O
.	O

Deletion	O
of	O
PGMRC2	O
in	O
brown	O
fat	O
,	O
which	O
has	O
a	O
high	O
demand	O
for	O
haem	O
,	O
reduced	O
labile	O
haem	O
in	O
the	O
nucleus	O
and	O
increased	O
stability	O
of	O
the	O
haem	O
-	O
responsive	O
transcriptional	O
repressors	O
Rev	O
-	O
Erbalpha	O
and	O
BACH1	O
.	O

Ensuing	O
alterations	O
in	O
gene	O
expression	O
caused	O
severe	O
mitochondrial	O
defects	O
that	O
rendered	O
adipose	O
-	O
specific	O
PGRMC2	O
-	O
null	O
mice	O
unable	O
to	O
activate	O
adaptive	O
thermogenesis	O
and	O
prone	O
to	O
greater	O
metabolic	O
deterioration	O
when	O
fed	O
a	O
high	O
-	O
fat	O
diet	O
.	O

By	O
contrast	O
,	O
obese	O
-	O
diabetic	O
mice	O
treated	O
with	O
a	O
small	O
-	O
molecule	O
PGRMC2	O
activator	O
showed	O
substantial	O
improvement	O
of	O
diabetic	O
features	O
.	O

These	O
studies	O
uncover	O
a	O
role	O
for	O
PGRMC2	O
in	O
intracellular	O
haem	O
transport	O
,	O
reveal	O
the	O
influence	O
of	O
adipose	O
tissue	O
haem	O
dynamics	O
on	O
physiology	O
and	O
suggest	O
that	O
modulation	O
of	O
PGRMC2	O
may	O
revert	O
obesity	O
-	O
linked	O
defects	O
in	O
adipocytes	O
.	O

Mitochondrial	O
MUL1	O
E3	O
ubiquitin	O
ligase	O
regulates	O
Hypoxia	O
Inducible	O
Factor	O
(	O
HIF	O
-	O
1alpha	O
)	O
and	O
metabolic	O
reprogramming	O
by	O
modulating	O
the	O
UBXN7	O
cofactor	O
protein	O
.	O

MUL1	O
is	O
a	O
multifunctional	O
E3	O
ubiquitin	O
ligase	O
anchored	O
in	O
the	O
outer	O
mitochondrial	O
membrane	O
with	O
its	O
RING	O
finger	O
domain	O
facing	O
the	O
cytoplasm	O
.	O

MUL1	O
participates	O
in	O
various	O
biological	O
pathways	O
involved	O
in	O
apoptosis	O
,	O
mitochondrial	O
dynamics	O
,	O
and	O
innate	O
immune	O
response	O
.	O

The	O
unique	O
topology	O
of	O
MUL1	O
enables	O
it	O
to	O
"	O
sense	O
"	O
mitochondrial	O
stress	O
in	O
the	O
intermembrane	O
mitochondrial	O
space	O
and	O
convey	O
these	O
signals	O
through	O
the	O
ubiquitination	O
of	O
specific	O
cytoplasmic	O
substrates	O
.	O

We	O
have	O
identified	O
UBXN7	O
,	O
the	O
cofactor	O
protein	O
of	O
the	O
CRL2	B-Complex
(	I-Complex
VHL	I-Complex
)	I-Complex
ligase	O
complex	O
,	O
as	O
a	O
specific	O
substrate	O
of	O
MUL1	O
ligase	O
.	O

CRL2	B-Complex
(	I-Complex
VHL	I-Complex
)	I-Complex
ligase	O
complex	O
regulates	O
HIF	O
-	O
1alpha	O
protein	O
levels	O
under	O
aerobic	O
(	O
normoxia	O
)	O
or	O
anaerobic	O
(	O
hypoxia	O
)	O
conditions	O
.	O

Inactivation	O
of	O
MUL1	O
ligase	O
leads	O
to	O
accumulation	O
of	O
UBXN7	O
,	O
with	O
concomitant	O
increase	O
in	O
HIF	O
-	O
1alpha	O
protein	O
levels	O
,	O
reduction	O
in	O
oxidative	O
phosphorylation	O
,	O
and	O
increased	O
glycolysis	O
.	O

We	O
describe	O
a	O
novel	O
pathway	O
that	O
originates	O
in	O
the	O
mitochondria	O
and	O
operates	O
upstream	O
of	O
the	O
CRL2	B-Complex
(	I-Complex
VHL	I-Complex
)	I-Complex
ligase	O
complex	O
.	O

Furthermore	O
,	O
we	O
delineate	O
the	O
mechanism	O
by	O
which	O
the	O
mitochondria	O
,	O
through	O
MUL1	O
ligase	O
,	O
can	O
inhibit	O
the	O
CRL2	B-Complex
(	I-Complex
VHL	I-Complex
)	I-Complex
complex	O
leading	O
to	O
high	O
HIF	O
-	O
1alpha	O
protein	O
levels	O
and	O
a	O
metabolic	O
shift	O
to	O
glycolysis	O
under	O
normoxic	O
conditions	O
.	O

A	O
transcriptional	O
arrest	O
mechanism	O
involved	O
in	O
controlling	O
constitutive	O
levels	O
of	O
mouse	O
c	O
-	O
myb	O
mRNA	O
.	O

The	O
control	O
of	O
c	O
-	O
myb	O
mRNA	O
abundance	O
was	O
examined	O
in	O
three	O
representative	O
cell	O
lines	O
,	O
(	O
the	O
erythroleukaemia	O
F4	O
-	O
12B2	O
,	O
the	O
myeloma	O
MOPC	O
-	O
31C	O
and	O
the	O
fibroblast	O
NIH3T3	O
)	O
,	O
which	O
display	O
abundant	O
,	O
low	O
and	O
undetectable	O
levels	O
of	O
this	O
transcript	O
,	O
respectively	O
.	O

We	O
observed	O
a	O
small	O
difference	O
in	O
half	O
-	O
life	O
between	O
F4	O
-	O
12B2	O
and	O
MOPC	O
-	O
31C	O
c	O
-	O
myb	O
mRNA	O
(	O
175	O
min	O
and	O
105	O
min	O
,	O
respectively	O
)	O
insufficient	O
to	O
account	O
for	O
the	O
approximately	O
20	O
-	O
fold	O
lower	O
levels	O
of	O
this	O
transcript	O
in	O
myelomas	O
.	O

Using	O
the	O
run	O
-	O
on	O
transcription	O
assay	O
we	O
found	O
that	O
c	O
-	O
myb	O
transcripts	O
were	O
initiated	O
at	O
similar	O
rates	O
in	O
all	O
three	O
cell	O
types	O
and	O
were	O
elongated	O
at	O
this	O
relatively	O
high	O
rate	O
to	O
a	O
site	O
approximately	O
2	O
kilobases	O
into	O
the	O
first	O
intron	O
.	O

NIH3T3	O
c	O
-	O
myb	O
transcripts	O
did	O
not	O
proceed	O
detectably	O
beyond	O
this	O
pause	O
/	O
attenuation	O
site	O
,	O
while	O
in	O
F4	O
-	O
12B2	O
cells	O
transcription	O
of	O
regions	O
3	O
'	O
of	O
this	O
site	O
occurred	O
at	O
a	O
rate	O
approximately	O
12	O
-	O
fold	O
greater	O
than	O
in	O
MOPC	O
-	O
31C	O
.	O

We	O
have	O
concluded	O
that	O
this	O
transcriptional	O
arrest	O
mechanism	O
,	O
together	O
with	O
small	O
differences	O
in	O
RNA	O
turnover	O
,	O
were	O
sufficient	O
to	O
account	O
for	O
the	O
spectrum	O
of	O
c	O
-	O
myb	O
mRNA	O
abundance	O
observed	O
.	O

Despite	O
evidence	O
of	O
transcript	O
initiation	O
,	O
we	O
were	O
unable	O
to	O
detect	O
c	O
-	O
myb	O
mRNA	O
in	O
fibroblasts	O
,	O
even	O
under	O
conditions	O
(	O
e	O
.	O
g	O
.	O
serum	O
stimulation	O
)	O
which	O
induced	O
high	O
c	O
-	O
myc	O
mRNA	O
levels	O
.	O

However	O
,	O
a	O
novel	O
3	O
.	O
0	O
kilobase	O
transcript	O
with	O
homology	O
to	O
c	O
-	O
myb	O
was	O
detected	O
in	O
cycloheximide	O
-	O
treated	O
NIH3T3	O
cells	O
.	O

Partial	O
repair	O
of	O
deamidation	O
-	O
damaged	O
calmodulin	O
by	O
protein	O
carboxyl	O
methyltransferase	O
.	O

Modification	O
of	O
calmodulin	O
by	O
protein	O
carboxyl	O
methyltransferase	O
requires	O
deamidation	O
of	O
one	O
or	O
more	O
labile	O
asparagine	O
residues	O
(	O
Johnson	O
,	O
B	O
.	O
A	O
.	O
,	O
Freitag	O
,	O
N	O
.	O
E	O
.	O
,	O
and	O
Aswad	O
,	O
D	O
.	O
W	O
.	O
(	O
1985	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
260	O
,	O
10913	O
-	O
10916	O
)	O
.	O

We	O
now	O
show	O
that	O
deamidation	O
results	O
in	O
the	O
generation	O
of	O
two	O
altered	O
forms	O
of	O
calmodulin	O
,	O
designated	O
A	O
and	O
B	O
,	O
which	O
can	O
be	O
separated	O
by	O
electrophoresis	O
under	O
nondenaturing	O
conditions	O
.	O

The	O
A	O
form	O
is	O
characterized	O
by	O
a	O
larger	O
apparent	O
molecular	O
radius	O
,	O
has	O
only	O
10	O
%	O
the	O
activity	O
of	O
native	O
calmodulin	O
when	O
assayed	O
for	O
its	O
ability	O
to	O
activate	O
a	O
Ca2	O
+	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
from	O
rat	O
brain	O
,	O
and	O
serves	O
as	O
an	O
excellent	O
substrate	O
for	O
the	O
methyltransferase	O
.	O

The	O
B	O
form	O
more	O
closely	O
resembles	O
native	O
calmodulin	O
:	O
it	O
has	O
an	O
apparent	O
molecular	O
radius	O
more	O
like	O
the	O
native	O
,	O
exhibits	O
about	O
40	O
%	O
the	O
activity	O
of	O
native	O
calmodulin	O
,	O
and	O
is	O
a	O
relatively	O
poor	O
methyl	O
acceptor	O
.	O

Evidence	O
suggests	O
that	O
the	O
A	O
and	O
B	O
forms	O
probably	O
contain	O
isoaspartate	O
(	O
A	O
)	O
and	O
aspartate	O
(	O
B	O
)	O
in	O
place	O
of	O
Asn	O
-	O
60	O
and	O
/	O
or	O
Asn	O
-	O
97	O
.	O

Incubation	O
of	O
the	O
A	O
form	O
with	O
methyltransferase	O
and	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
methionine	O
converts	O
about	O
half	O
of	O
the	O
A	O
form	O
to	O
an	O
electrophoretic	O
band	O
indistinguishable	O
from	O
the	O
B	O
form	O
.	O

The	O
activity	O
of	O
this	O
partly	O
converted	O
calmodulin	O
rises	O
to	O
30	O
-	O
50	O
%	O
that	O
of	O
native	O
calmodulin	O
.	O

These	O
observations	O
imply	O
that	O
the	O
methyltransferase	O
may	O
have	O
a	O
biological	O
role	O
in	O
restoring	O
activity	O
to	O
proteins	O
which	O
contain	O
abnormal	O
isoaspartyl	O
peptide	O
bonds	O
resulting	O
from	O
asparagine	O
deamidation	O
.	O

Effect	O
of	O
propeptide	O
mutations	O
on	O
post	O
-	O
translational	O
processing	O
of	O
factor	O
IX	O
.	O

Evidence	O
that	O
beta	O
-	O
hydroxylation	O
and	O
gamma	O
-	O
carboxylation	O
are	O
independent	O
events	O
.	O

Post	O
-	O
translational	O
processing	O
of	O
Factor	O
IX	O
includes	O
glycosylation	O
,	O
cleavage	O
of	O
the	O
signal	O
peptide	O
and	O
propeptide	O
,	O
vitamin	O
K	O
-	O
dependent	O
carboxylation	O
of	O
specific	O
glutamic	O
acid	O
residues	O
to	O
form	O
gamma	O
-	O
carboxyglutamic	O
acid	O
,	O
and	O
beta	O
-	O
hydroxylation	O
of	O
aspartic	O
acid	O
at	O
residue	O
64	O
to	O
form	O
beta	O
-	O
hydroxyaspartic	O
acid	O
.	O

The	O
human	O
Factor	O
IX	O
cDNA	O
coding	O
sequence	O
was	O
modified	O
in	O
the	O
propeptide	O
region	O
(	O
residue	O
-	O
18	O
to	O
-	O
1	O
)	O
using	O
oligonucleotide	O
-	O
directed	O
site	O
-	O
specific	O
mutagenesis	O
,	O
and	O
the	O
altered	O
Factor	O
IX	O
cDNA	O
was	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

The	O
effects	O
of	O
the	O
mutations	O
on	O
proteolytic	O
processing	O
,	O
gamma	O
-	O
carboxylation	O
,	O
and	O
beta	O
-	O
hydroxylation	O
were	O
assessed	O
by	O
direct	O
structural	O
analysis	O
.	O

After	O
purification	O
,	O
the	O
molecular	O
weight	O
of	O
each	O
of	O
the	O
recombinant	O
Factor	O
IX	O
species	O
and	O
its	O
NH2	O
-	O
terminal	O
amino	O
acid	O
sequence	O
were	O
shown	O
to	O
be	O
identical	O
to	O
those	O
of	O
plasma	O
Factor	O
IX	O
.	O

gamma	O
-	O
Carboxyglutamic	O
acid	O
and	O
beta	O
-	O
hydroxyaspartic	O
acid	O
analyses	O
revealed	O
that	O
recombinant	O
wild	O
-	O
type	O
Factor	O
IX	O
contained	O
9	O
.	O
2	O
gamma	O
-	O
carboxyglutamic	O
acid	O
and	O
0	O
.	O
3	O
beta	O
-	O
hydroxyaspartic	O
acid	O
residues	O
/	O
molecule	O
compared	O
with	O
11	O
.	O
4	O
gamma	O
-	O
carboxyglutamic	O
acid	O
and	O
0	O
.	O
39	O
beta	O
-	O
hydroxyaspartic	O
acid	O
residues	O
in	O
plasma	O
Factor	O
IX	O
.	O

When	O
the	O
18	O
-	O
residue	O
propeptide	O
was	O
deleted	O
or	O
when	O
the	O
cells	O
were	O
grown	O
in	O
the	O
presence	O
of	O
sodium	O
warfarin	O
,	O
secreted	O
Factor	O
IX	O
contained	O
no	O
detectable	O
gamma	O
-	O
carboxyglutamic	O
acid	O
but	O
0	O
.	O
36	O
and	O
0	O
.	O
40	O
residues	O
of	O
beta	O
-	O
hydroxyaspartic	O
acid	O
,	O
respectively	O
.	O

Point	O
mutations	O
leading	O
to	O
substitution	O
of	O
alanine	O
for	O
phenylalanine	O
at	O
residue	O
-	O
16	O
or	O
glutamic	O
acid	O
for	O
alanine	O
at	O
residue	O
-	O
10	O
contained	O
0	O
.	O
2	O
and	O
1	O
.	O
7	O
gamma	O
-	O
carboxyglutamic	O
acid	O
residues	O
,	O
respectively	O
,	O
and	O
0	O
.	O
2	O
residues	O
of	O
beta	O
-	O
hydroxyaspartic	O
acid	O
.	O

These	O
data	O
confirm	O
that	O
the	O
propeptide	O
mutations	O
made	O
do	O
not	O
interfere	O
with	O
proteolytic	O
processing	O
and	O
that	O
the	O
Factor	O
IX	O
propeptide	O
contains	O
a	O
recognition	O
site	O
that	O
designates	O
the	O
adjacent	O
glutamic	O
acid	O
-	O
rich	O
domain	O
for	O
gamma	O
-	O
carboxylation	O
.	O

In	O
contrast	O
,	O
beta	O
-	O
hydroxylation	O
of	O
aspartic	O
acid	O
64	O
is	O
an	O
independent	O
process	O
which	O
does	O
not	O
require	O
vitamin	O
K	O
and	O
is	O
mediated	O
through	O
a	O
hydroxylation	O
recognition	O
site	O
in	O
the	O
mature	O
Factor	O
IX	O
,	O
not	O
in	O
the	O
propeptide	O
.	O

Stimulation	O
of	O
c	O
-	O
myc	O
oncogene	O
expression	O
associated	O
with	O
estrogen	O
-	O
induced	O
proliferation	O
of	O
human	O
breast	O
cancer	O
cells	O
.	O

Regulation	O
of	O
c	O
-	O
myc	O
expression	O
is	O
known	O
to	O
be	O
sensitive	O
to	O
a	O
variety	O
of	O
mitogenic	O
stimuli	O
in	O
various	O
cell	O
types	O
.	O

Since	O
estrogen	O
is	O
a	O
well	O
documented	O
mitogen	O
of	O
estrogen	O
-	O
responsive	O
human	O
breast	O
cancer	O
(	O
HBC	O
)	O
cells	O
,	O
we	O
studied	O
the	O
influence	O
of	O
estradiol	O
and	O
its	O
antagonist	O
tamoxifen	O
on	O
the	O
expression	O
of	O
c	O
-	O
myc	O
in	O
HBC	O
cell	O
lines	O
.	O

Using	O
Northern	O
hybridization	O
analysis	O
,	O
we	O
monitored	O
the	O
accumulation	O
of	O
c	O
-	O
myc	O
mRNA	O
in	O
a	O
number	O
of	O
HBC	O
cell	O
lines	O
.	O

The	O
cell	O
lines	O
studied	O
included	O
the	O
estrogen	O
-	O
responsive	O
,	O
estrogen	O
receptor	O
positive	O
(	O
ER	O
+	O
)	O
MCF	O
-	O
7	O
,	O
T	O
-	O
47D	O
,	O
the	O
nonresponsive	O
,	O
estrogen	O
receptor	O
negative	O
(	O
ER	O
-	O
)	O
MDA	O
-	O
MB	O
-	O
231	O
,	O
BT	O
-	O
20	O
,	O
and	O
a	O
nontumorous	O
breast	O
cell	O
line	O
,	O
HBL	O
-	O
100	O
.	O

The	O
effects	O
of	O
endogenous	O
estrogen	O
were	O
minimized	O
by	O
culturing	O
the	O
cells	O
in	O
medium	O
containing	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
charcoal	O
-	O
treated	O
fetal	O
bovine	O
serum	O
and	O
tamoxifen	O
(	O
10	O
(	O
-	O
6	O
)	O
M	O
)	O
for	O
48	O
h	O
prior	O
to	O
estradiol	O
(	O
10	O
(	O
-	O
7	O
)	O
M	O
)	O
treatment	O
.	O

In	O
the	O
ER	O
+	O
cell	O
lines	O
the	O
addition	O
of	O
estradiol	O
resulted	O
in	O
a	O
noticeable	O
increase	O
in	O
c	O
-	O
myc	O
expression	O
after	O
15	O
min	O
with	O
a	O
maximal	O
(	O
greater	O
than	O
10	O
-	O
fold	O
)	O
induction	O
in	O
1	O
-	O
2	O
h	O
.	O

In	O
the	O
ER	O
-	O
cell	O
lines	O
the	O
level	O
of	O
c	O
-	O
myc	O
mRNA	O
was	O
high	O
and	O
was	O
unaffected	O
by	O
estrogen	O
or	O
tamoxifen	O
;	O
in	O
the	O
ER	O
-	O
cancer	O
cell	O
lines	O
,	O
neither	O
amplification	O
nor	O
rearrangement	O
of	O
the	O
c	O
-	O
myc	O
gene	O
was	O
observed	O
.	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
another	O
oncogene	O
,	O
c	O
-	O
H	O
-	O
ras	O
,	O
remained	O
constant	O
in	O
both	O
ER	O
+	O
and	O
ER	O
-	O
cell	O
lines	O
and	O
was	O
insensitive	O
to	O
estrogen	O
and	O
antiestrogen	O
.	O

These	O
results	O
suggest	O
that	O
regulation	O
of	O
c	O
-	O
myc	O
expression	O
may	O
be	O
an	O
important	O
step	O
in	O
estrogen	O
-	O
induced	O
proliferation	O
of	O
HBC	O
cells	O
.	O

Developmental	O
changes	O
in	O
the	O
modification	O
of	O
lysosomal	O
enzymes	O
in	O
Dictyostelium	O
discoideum	O
.	O

Evidence	O
has	O
been	O
found	O
for	O
a	O
generalized	O
change	O
in	O
the	O
post	O
-	O
translational	O
modification	O
of	O
lysosomal	O
enzymes	O
during	O
development	O
of	O
Dictyostelium	O
discoideum	O
.	O

The	O
physical	O
and	O
antigenic	O
properties	O
of	O
four	O
developmentally	O
regulated	O
lysosomal	O
enzymes	O
,	O
N	O
-	O
acetylglucosaminidase	O
,	O
beta	O
-	O
glucosidase	O
,	O
alpha	O
-	O
mannosidase	O
,	O
and	O
acid	O
phosphatase	O
,	O
have	O
been	O
examined	O
throughout	O
the	O
life	O
cycle	O
.	O

In	O
vegetative	O
cells	O
,	O
a	O
single	O
major	O
isoelectric	O
species	O
is	O
detected	O
for	O
each	O
enzymatic	O
activity	O
on	O
native	O
nonequilibrium	O
isoelectric	O
focusing	O
gels	O
.	O

Between	O
6	O
and	O
10	O
hr	O
of	O
development	O
,	O
all	O
activities	O
,	O
including	O
the	O
preformed	O
enzyme	O
,	O
become	O
less	O
negatively	O
charged	O
,	O
resulting	O
in	O
a	O
modest	O
but	O
reproducible	O
shift	O
in	O
the	O
isoelectric	O
focusing	O
pattern	O
.	O

This	O
alteration	O
is	O
not	O
detected	O
by	O
native	O
gel	O
electrophoresis	O
at	O
constant	O
pH	O
.	O

As	O
development	O
continues	O
,	O
the	O
specific	O
activity	O
of	O
beta	O
-	O
glucosidase	O
,	O
alpha	O
-	O
mannosidase	O
,	O
and	O
acid	O
phosphatase	O
continues	O
to	O
increase	O
and	O
coincidentally	O
,	O
new	O
,	O
less	O
acidic	O
isozymic	O
bands	O
of	O
activity	O
can	O
be	O
observed	O
on	O
both	O
gel	O
systems	O
.	O

Some	O
of	O
these	O
new	O
isozymes	O
accumulate	O
preferentially	O
in	O
anterior	O
cells	O
,	O
while	O
others	O
accumulate	O
preferentially	O
in	O
posterior	O
cells	O
of	O
migrating	O
slugs	O
.	O

N	O
-	O
Acetylglucosaminidase	O
does	O
not	O
increase	O
in	O
specific	O
activity	O
late	O
in	O
development	O
and	O
no	O
new	O
isozymic	O
species	O
appear	O
.	O

Using	O
a	O
monoclonal	O
antibody	O
that	O
reacts	O
with	O
sulfated	O
N	O
-	O
linked	O
oligosaccharides	O
shared	O
by	O
vegetative	O
lysosomal	O
enzymes	O
in	O
D	O
.	O
discoideum	O
,	O
the	O
antigenicity	O
of	O
the	O
developmental	O
isozymes	O
has	O
been	O
characterized	O
.	O

All	O
of	O
the	O
enzymatic	O
activity	O
present	O
during	O
vegetative	O
growth	O
and	O
early	O
development	O
is	O
immunoprecipitable	O
.	O

However	O
,	O
the	O
less	O
negatively	O
charged	O
isozymes	O
that	O
accumulate	O
after	O
aggregation	O
are	O
not	O
recognized	O
by	O
the	O
antibody	O
.	O

Nonantigenic	O
acid	O
phosphatase	O
and	O
alpha	O
-	O
mannosidase	O
are	O
found	O
in	O
both	O
anterior	O
and	O
posterior	O
cells	O
from	O
migrating	O
pseudoplasmodia	O
.	O

Since	O
each	O
enzyme	O
is	O
coded	O
by	O
a	O
single	O
structural	O
gene	O
,	O
these	O
results	O
suggest	O
that	O
the	O
isozymes	O
present	O
late	O
in	O
development	O
arise	O
from	O
the	O
synthesis	O
of	O
the	O
same	O
polypeptides	O
with	O
altered	O
post	O
-	O
translational	O
modifications	O
.	O

The	O
appearance	O
of	O
anterior	O
and	O
posterior	O
specific	O
isozymes	O
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
cell	O
type	O
specific	O
changes	O
in	O
the	O
glycoprotein	O
modification	O
pathway	O
for	O
newly	O
synthesized	O
proteins	O
.	O

Kinetics	O
of	O
hemoprotein	O
reduction	O
and	O
interprotein	O
heme	O
transfer	O
.	O

The	O
transfer	O
of	O
hemin	O
from	O
one	O
protein	O
to	O
another	O
is	O
an	O
event	O
biologically	O
important	O
for	O
the	O
conservation	O
of	O
heme	O
iron	O
.	O

Hemin	O
entering	O
the	O
circulation	O
(	O
or	O
added	O
to	O
serum	O
)	O
is	O
mainly	O
bound	O
by	O
albumin	O
and	O
then	O
transferred	O
to	O
hemopexin	O
[	O
Morgan	O
,	O
W	O
.	O
T	O
.	O
,	O
Liem	O
,	O
H	O
.	O
H	O
.	O
,	O
Sutor	O
,	O
R	O
.	O
P	O
.	O
,	O
&	O
Muller	O
-	O
Eberhard	O
,	O
U	O
.	O
(	O
1976	O
)	O
Biochim	O
.	O
Biophys	O
.	O
Acta	O
444	O
,	O
435	O
-	O
445	O
]	O
,	O
and	O
we	O
are	O
now	O
investigating	O
which	O
mechanisms	O
may	O
be	O
operative	O
in	O
enhancing	O
this	O
process	O
.	O

The	O
presence	O
of	O
imidazole	O
has	O
been	O
demonstrated	O
to	O
accelerate	O
hemin	O
transfer	O
from	O
albumin	O
to	O
hemopexin	O
[	O
Pasternack	O
,	O
R	O
.	O
F	O
.	O
,	O
Gibbs	O
,	O
E	O
.	O
J	O
.	O
,	O
Hoeflin	O
,	O
E	O
.	O
,	O
Kosar	O
,	O
W	O
.	O
P	O
.	O
,	O
Kubera	O
,	O
G	O
.	O
,	O
Skowronek	O
,	O
C	O
.	O
A	O
.	O
,	O
Wong	O
,	O
N	O
.	O
M	O
.	O
,	O
&	O
Muller	O
-	O
Eberhard	O
,	O
U	O
.	O
(	O
1983	O
)	O
Biochemistry	O
22	O
,	O
1753	O
-	O
1758	O
]	O
.	O

The	O
present	O
work	O
is	O
an	O
examination	O
of	O
the	O
effect	O
of	O
the	O
reduction	O
of	O
albumin	O
-	O
bound	O
hemin	O
on	O
the	O
rate	O
of	O
its	O
transfer	O
to	O
hemopexin	O
.	O

Hemin	O
(	O
HmIII	O
.	O
,	O
ferriprotoporphyrin	O
IX	O
)	O
was	O
reduced	O
to	O
HmII	O
(	O
ferroprotoporphyrin	O
IX	O
)	O
by	O
the	O
addition	O
of	O
sodium	O
dithionite	O
under	O
argon	O
.	O

The	O
reduction	O
kinetics	O
of	O
HmIII	O
to	O
HmII	O
were	O
studied	O
separately	O
in	O
the	O
two	O
complexes	O
:	O
with	O
human	O
serum	O
albumin	O
(	O
HSA	O
)	O
,	O
which	O
binds	O
up	O
to	O
20	O
mol	O
of	O
heme	O
/	O
mol	O
(	O
the	O
first	O
mole	O
with	O
K	O
congruent	O
to	O
10	O
(	O
8	O
)	O
)	O
,	O
and	O
with	O
hemopexin	O
(	O
HHx	O
)	O
,	O
which	O
binds	O
heme	O
equimolarly	O
(	O
K	O
congruent	O
to	O
10	O
(	O
13	O
)	O
)	O
.	O

The	O
rate	O
of	O
reduction	O
of	O
HmIII	O
to	O
HmII	O
on	O
HSA	O
was	O
first	O
order	O
over	O
several	O
half	O
-	O
lives	O
and	O
linearly	O
dependent	O
on	O
[	O
S2O4	O
(	O
2	O
-	O
)	O
]	O
1	O
/	O
2	O
.	O

At	O
[	O
HSA	O
]	O
0	O
/	O
[	O
HmIII	O
]	O
=	O
3	O
,	O
the	O
kobsd	O
was	O
(	O
5	O
X	O
10	O
(	O
-	O
3	O
)	O
+	O
0	O
.	O
75	O
[	O
S2O4	O
(	O
2	O
-	O
)	O
]	O
1	O
/	O
2	O
,	O
and	O
with	O
[	O
HSA	O
]	O
/	O
[	O
HmIII	O
]	O
approximately	O
25	O
,	O
the	O
kobsd	O
was	O
(	O
2	O
X	O
10	O
(	O
-	O
3	O
)	O
)	O
+	O
0	O
.	O
25	O
[	O
S2O4	O
(	O
2	O
-	O
)	O
]	O
1	O
/	O
2	O
.	O

The	O
reduction	O
of	O
HmIII	O
to	O
HmII	O
on	O
human	O
hemopexin	O
(	O
HHx	O
)	O
is	O
much	O
more	O
rapid	O
with	O
kobsd	O
=	O
(	O
2	O
.	O
5	O
X	O
10	O
(	O
3	O
)	O
)	O
[	O
S2O4	O
(	O
2	O
-	O
)	O
]	O
1	O
/	O
2	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Two	O
genes	O
for	O
ribosomal	O
protein	O
51	O
of	O
Saccharomyces	O
cerevisiae	O
complement	O
and	O
contribute	O
to	O
the	O
ribosomes	B-OOS
.	O

We	O
cloned	O
and	O
sequenced	O
the	O
second	O
gene	O
coding	O
for	O
yeast	O
ribosomal	O
protein	O
51	O
(	O
RP51B	O
)	O
.	O

When	O
the	O
DNA	O
sequence	O
of	O
this	O
gene	O
was	O
compared	O
with	O
the	O
DNA	O
sequence	O
of	O
RP51A	O
(	O
J	O
.	O
L	O
.	O
Teem	O
and	O
M	O
.	O
Rosbash	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
U	O
.	O
S	O
.	O
A	O
.	O
80	O
:	O
4403	O
-	O
-	O
4407	O
,	O
1983	O
)	O
,	O
the	O
following	O
conclusions	O
emerged	O
:	O
both	O
genes	O
code	O
for	O
a	O
protein	O
of	O
135	O
amino	O
acids	O
;	O
both	O
open	O
reading	O
frames	O
are	O
interrupted	O
by	O
a	O
single	O
intron	O
which	O
occurs	O
directly	O
after	O
the	O
initiating	O
methionine	O
;	O
the	O
open	O
reading	O
frames	O
are	O
96	O
%	O
homologous	O
and	O
code	O
for	O
the	O
same	O
protein	O
with	O
the	O
exception	O
of	O
the	O
carboxy	O
-	O
terminal	O
amino	O
acid	O
;	O
DNA	O
sequence	O
homology	O
outside	O
of	O
the	O
coding	O
region	O
is	O
extremely	O
limited	O
.	O

The	O
cloned	O
genes	O
,	O
in	O
combination	O
with	O
the	O
one	O
-	O
step	O
gene	O
disruption	O
techniques	O
of	O
Rothstein	O
(	O
R	O
.	O
J	O
.	O
Rothstein	O
,	O
Methods	O
Enzymol	O
.	O
101	O
:	O
202	O
-	O
211	O
,	O
1983	O
)	O
,	O
were	O
used	O
to	O
generate	O
haploid	O
strains	O
containing	O
mutations	O
in	O
the	O
RP51A	O
or	O
RP51B	O
genes	O
or	O
in	O
both	O
.	O

Strains	O
missing	O
a	O
normal	O
RP51A	O
gene	O
grew	O
poorly	O
(	O
180	O
-	O
min	O
generation	O
time	O
versus	O
130	O
min	O
for	O
the	O
wild	O
type	O
)	O
,	O
whereas	O
strains	O
carrying	O
a	O
mutant	O
RP51B	O
were	O
relatively	O
normal	O
.	O

Strains	O
carrying	O
mutations	O
in	O
the	O
two	O
genes	O
grew	O
extremely	O
poorly	O
(	O
6	O
to	O
9	O
h	O
)	O
,	O
which	O
led	O
us	O
to	O
conclude	O
that	O
RP51A	O
and	O
RP51B	O
were	O
both	O
expressed	O
.	O

The	O
results	O
of	O
Northern	O
blot	O
and	O
primer	O
extension	O
experiments	O
indicate	O
that	O
strains	O
with	O
a	O
wild	O
-	O
type	O
copy	O
of	O
the	O
RP51B	O
gene	O
and	O
a	O
mutant	O
(	O
or	O
deleted	O
)	O
RP51A	O
gene	O
grow	O
slowly	O
because	O
of	O
an	O
insufficient	O
amount	O
of	O
RP51	O
mRNA	O
.	O

The	O
growth	O
defect	O
was	O
completely	O
rescued	O
with	O
additional	O
copies	O
of	O
RP51B	O
.	O

The	O
data	O
suggest	O
that	O
RP51A	O
contributes	O
more	O
RP51	O
mRNA	O
(	O
and	O
more	O
RP51	O
protein	O
)	O
than	O
does	O
RP51B	O
and	O
that	O
intergenic	O
dosage	O
compensation	O
,	O
sufficient	O
to	O
rescue	O
the	O
growth	O
defect	O
of	O
strains	O
missing	O
a	O
wild	O
-	O
type	O
RP51A	O
gene	O
,	O
does	O
not	O
take	O
place	O
.	O

Human	O
liver	O
alcohol	O
dehydrogenase	O
:	O
purification	O
and	O
kinetic	O
characterization	O
of	O
the	O
beta	O
2	O
beta	O
2	O
,	O
beta	O
2	O
beta	O
1	O
,	O
alpha	O
beta	O
2	O
,	O
and	O
beta	O
2	O
gamma	O
1	O
"	O
Oriental	O
"	O
isoenzymes	O
.	O

Four	O
alcohol	O
dehydrogenase	O
isoenzymes	O
with	O
"	O
atypical	O
"	O
pH	O
optima	O
for	O
ethanol	O
oxidation	O
at	O
8	O
.	O
8	O
were	O
isolated	O
from	O
Japanese	O
livers	O
with	O
the	O
homozygous	O
ADH2	O
2	O
-	O
2	O
and	O
the	O
heterozygous	O
ADH2	O
2	O
-	O
1	O
phenotypes	O
.	O

Agarose	O
gel	O
isoelectric	O
focusing	O
patterns	O
after	O
dissociation	O
-	O
-	O
recombination	O
of	O
three	O
isoenzymes	O
purified	O
from	O
the	O
homozygous	O
livers	O
indicate	O
that	O
they	O
are	O
beta	O
2	O
beta	O
2	O
,	O
alpha	O
beta	O
2	O
,	O
and	O
beta	O
2	O
gamma	O
1	O
.	O

A	O
fourth	O
isoenzyme	O
,	O
purified	O
from	O
livers	O
with	O
the	O
heterozygous	O
phenotype	O
by	O
agarose	O
-	O
hexane	O
-	O
-	O
AMP	O
affinity	O
chromatography	O
,	O
was	O
identified	O
as	O
beta	O
2	O
beta	O
1	O
by	O
dissociation	O
-	O
recombination	O
studies	O
.	O

The	O
kinetic	O
properties	O
of	O
the	O
three	O
heterodimers	O
,	O
beta	O
2	O
beta	O
1	O
,	O
alpha	O
beta	O
2	O
,	O
and	O
beta	O
2	O
gamma	O
1	O
,	O
are	O
intermediate	O
between	O
those	O
of	O
the	O
respective	O
homodimers	O
,	O
suggesting	O
that	O
the	O
two	O
subunits	O
act	O
independently	O
.	O

Product	O
inhibition	O
studies	O
indicate	O
that	O
beta	O
2	O
beta	O
2	O
obeys	O
an	O
ordered	O
sequential	O
mechanism	O
,	O
as	O
do	O
the	O
alpha	O
alpha	O
,	O
beta	O
1	O
beta	O
1	O
,	O
gamma	O
1	O
gamma	O
1	O
,	O
and	O
gamma	O
2	O
gamma	O
2	O
homodimers	O
which	O
have	O
the	O
"	O
typical	O
"	O
pH	O
optimum	O
for	O
ethanol	O
oxidation	O
at	O
pH	O
10	O
.	O
0	O
-	O
10	O
.	O
5	O
.	O

The	O
kinetic	O
constants	O
of	O
beta	O
2	O
beta	O
2	O
differ	O
substantially	O
from	O
those	O
of	O
the	O
other	O
homodimers	O
.	O

At	O
pH	O
7	O
.	O
5	O
,	O
the	O
Vmax	O
for	O
ethanol	O
oxidation	O
of	O
beta	O
2	O
beta	O
2	O
is	O
5	O
-	O
40	O
times	O
higher	O
than	O
that	O
of	O
alpha	O
alpha	O
,	O
beta	O
1	O
beta	O
1	O
,	O
gamma	O
1	O
gamma	O
1	O
,	O
and	O
gamma	O
2	O
gamma	O
2	O
.	O

The	O
Km	O
and	O
Ki	O
values	O
of	O
beta	O
2	O
beta	O
2	O
for	O
NAD	O
+	O
and	O
NADH	O
are	O
also	O
considerably	O
higher	O
than	O
those	O
of	O
the	O
other	O
homodimers	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Interference	O
of	O
active	O
site	O
specific	O
reagents	O
in	O
plasminogen	O
-	O
streptokinase	O
active	O
site	O
formation	O
.	O

We	O
have	O
recently	O
observed	O
slow	O
,	O
non	O
-	O
Michaelis	O
-	O
Menten	O
kinetics	O
of	O
activation	O
of	O
native	O
cat	O
plasminogen	O
by	O
catalytic	O
concentrations	O
of	O
streptokinase	O
.	O

In	O
order	O
to	O
understand	O
the	O
reasons	O
for	O
this	O
phenomenon	O
,	O
we	O
undertook	O
to	O
study	O
the	O
formation	O
of	O
the	O
plasminogen	O
-	O
streptokinase	O
activator	O
complex	O
under	O
the	O
same	O
plasminogen	O
activation	O
conditions	O
.	O

The	O
results	O
obtained	O
in	O
this	O
study	O
show	O
that	O
the	O
potential	O
active	O
site	O
in	O
both	O
cat	O
and	O
human	O
plasminogen	O
is	O
capable	O
of	O
binding	O
strongly	O
the	O
specific	O
substrates	O
(	O
S	O
)	O
p	O
-	O
nitrophenyl	O
p	O
-	O
guanidinobenzoate	O
(	O
NPGB	O
)	O
and	O
H	O
-	O
D	O
-	O
valyl	O
-	O
L	O
-	O
leucyl	O
-	O
L	O
-	O
lysyl	O
-	O
p	O
-	O
nitroanilide	O
,	O
through	O
the	O
active	O
site	O
is	O
incapable	O
of	O
hydrolyzing	O
these	O
substrates	O
.	O

Binding	O
studies	O
support	O
these	O
and	O
the	O
following	O
conclusions	O
.	O

Streptokinase	O
binds	O
to	O
this	O
zymogen	O
-	O
substrate	O
complex	O
to	O
create	O
the	O
ternary	O
plasminogen	O
-	O
S	O
-	O
streptokinase	O
complex	O
,	O
which	O
then	O
slowly	O
converts	O
to	O
an	O
acylated	O
plasminogen	O
-	O
streptokinase	O
form	O
.	O

This	O
acylation	O
reaction	O
is	O
550	O
times	O
slower	O
than	O
acylation	O
of	O
the	O
preformed	O
plasminogen	O
-	O
streptokinase	O
complex	O
by	O
NPGB	O
.	O

The	O
same	O
reaction	O
also	O
occurs	O
with	O
human	O
plasminogen	O
,	O
though	O
the	O
acylation	O
reaction	O
is	O
10	O
times	O
faster	O
than	O
when	O
the	O
cat	O
zymogen	O
is	O
used	O
.	O

NPGB	O
binds	O
specifically	O
to	O
plasminogen	O
but	O
not	O
to	O
streptokinase	O
.	O

These	O
studies	O
proved	O
that	O
inhibition	O
of	O
cat	O
plasminogen	O
activation	O
by	O
streptokinase	O
occurs	O
at	O
the	O
level	O
of	O
activator	O
complex	O
formation	O
.	O

We	O
conclude	O
from	O
our	O
studies	O
that	O
streptokinase	O
binding	O
to	O
both	O
cat	O
and	O
human	O
plasminogen	O
occurs	O
at	O
the	O
potential	O
active	O
site	O
of	O
the	O
zymogen	O
.	O

Consequently	O
,	O
it	O
is	O
probable	O
that	O
plasminogen	O
activation	O
in	O
vivo	O
is	O
inhibited	O
by	O
binding	O
of	O
active	O
site	O
specific	O
inhibitors	O
to	O
plasminogen	O
.	O

Molecular	O
cloning	O
of	O
NIPP	O
-	O
1	O
,	O
a	O
nuclear	O
inhibitor	O
of	O
protein	O
phosphatase	O
-	O
1	O
,	O
reveals	O
homology	O
with	O
polypeptides	O
involved	O
in	O
RNA	O
processing	O
.	O

NIPP	O
-	O
1	O
was	O
originally	O
isolated	O
as	O
a	O
potent	O
and	O
specific	O
nuclear	O
inhibitory	O
polypeptide	O
(	O
16	O
-	O
18	O
kDa	O
)	O
of	O
protein	O
phosphatase	O
-	O
1	O
.	O

We	O
report	O
here	O
the	O
cDNA	O
cloning	O
of	O
NIPP	O
-	O
1	O
from	O
bovine	O
thymus	O
and	O
show	O
that	O
the	O
native	O
polypeptide	O
consists	O
of	O
351	O
residues	O
and	O
has	O
a	O
calculated	O
mass	O
of	O
38	O
.	O
5	O
kDa	O
.	O

The	O
bacterially	O
expressed	O
central	O
third	O
of	O
NIPP	O
-	O
1	O
completely	O
inhibited	O
the	O
type	O
-	O
1	O
catalytic	O
subunit	O
,	O
but	O
displayed	O
a	O
reduced	O
inhibitory	O
potency	O
after	O
phosphorylation	O
by	O
protein	O
kinase	O
A	O
and	O
casein	B-Complex
kinase	I-Complex
2	I-Complex
.	O

Translation	O
of	O
NIPP	O
-	O
1	O
mRNA	O
in	O
reticulocyte	O
lysates	O
resulted	O
in	O
the	O
accumulation	O
of	O
both	O
intact	O
NIPP	O
-	O
1	O
and	O
a	O
smaller	O
polypeptide	O
generated	O
by	O
alternative	O
initiation	O
at	O
the	O
codon	O
corresponding	O
to	O
Met143	O
.	O

A	O
data	O
base	O
search	O
showed	O
that	O
the	O
COOH	O
terminus	O
of	O
NIPP	O
-	O
1	O
is	O
nearly	O
identical	O
to	O
the	O
human	O
ard	O
-	O
1	O
protein	O
(	O
13	O
kDa	O
)	O
,	O
which	O
has	O
been	O
implicated	O
in	O
RNA	O
processing	O
(	O
Wang	O
,	O
M	O
.	O
,	O
and	O
Cohen	O
,	O
S	O
.	O
N	O
.	O
(	O
1994	O
)	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
U	O
.	O
S	O
.	O
A	O
.	O
91	O
,	O
10591	O
-	O
10595	O
)	O
.	O

Comparison	O
of	O
the	O
cDNAs	O
encoding	O
ard	O
-	O
1	O
and	O
NIPP	O
-	O
1	O
suggests	O
that	O
their	O
mRNAs	O
are	O
generated	O
by	O
alternative	O
splicing	O
of	O
the	O
same	O
pre	O
-	O
mRNA	O
.	O

Western	O
blotting	O
with	O
antibodies	O
against	O
the	O
COOH	O
terminus	O
of	O
NIPP	O
-	O
1	O
,	O
however	O
,	O
showed	O
a	O
single	O
polypeptide	O
of	O
47	O
kDa	O
,	O
which	O
was	O
enriched	O
in	O
the	O
nucleus	O
.	O

Northern	O
analysis	O
revealed	O
a	O
single	O
transcript	O
of	O
2	O
.	O
2	O
kilobases	O
in	O
bovine	O
thymus	O
and	O
of	O
2	O
.	O
4	O
kilobases	O
in	O
various	O
human	O
tissues	O
.	O

Sp1	O
is	O
a	O
critical	O
factor	O
for	O
the	O
monocytic	O
specific	O
expression	O
of	O
human	O
CD14	O
.	O

CD14	O
is	O
a	O
membrane	O
glycoprotein	O
expressed	O
specifically	O
on	O
monocytes	O
and	O
macrophages	O
,	O
and	O
its	O
expression	O
is	O
markedly	O
increased	O
during	O
the	O
process	O
of	O
monocyte	O
differentiation	O
.	O

In	O
order	O
to	O
study	O
CD14	O
gene	O
regulation	O
,	O
the	O
human	O
CD14	O
gene	O
was	O
cloned	O
from	O
a	O
partial	O
EcoRI	O
digested	O
chromosome	O
5	O
library	O
.	O

A	O
5	O
.	O
5	O
-	O
kilobase	O
genomic	O
clone	O
contained	O
the	O
full	O
-	O
length	O
CD14	O
coding	O
sequence	O
and	O
4	O
.	O
2	O
kilobases	O
of	O
5	O
'	O
-	O
upstream	O
sequence	O
.	O

One	O
major	O
and	O
one	O
minor	O
transcription	O
start	O
site	O
were	O
identified	O
101	O
and	O
130	O
base	O
pairs	O
(	O
bp	O
)	O
upstream	O
,	O
respectively	O
,	O
from	O
the	O
protein	O
translation	O
start	O
ATG	O
.	O

A	O
DNA	O
fragment	O
containing	O
128	O
bp	O
of	O
upstream	O
sequence	O
had	O
strong	O
,	O
monocyte	O
-	O
specific	O
promoter	O
activity	O
in	O
the	O
CD14	O
positive	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
as	O
compared	O
to	O
the	O
nonmonocytic	O
cell	O
lines	O
HeLa	O
and	O
REX	O
.	O

Four	O
regions	O
in	O
this	O
DNA	O
fragment	O
interact	O
with	O
nuclear	O
proteins	O
isolated	O
from	O
monocytic	O
cells	O
.	O

The	O
Sp1	O
transcription	O
factor	O
bound	O
to	O
three	O
different	O
regions	O
in	O
the	O
CD14	O
promoter	O
.	O

Mutation	O
of	O
the	O
major	O
Sp1	O
binding	O
site	O
(	O
-	O
110	O
bp	O
)	O
decreased	O
tissue	O
-	O
specific	O
promoter	O
activity	O
,	O
and	O
these	O
results	O
,	O
together	O
with	O
transactivation	O
experiments	O
,	O
demonstrate	O
that	O
Sp1	O
plays	O
a	O
critical	O
role	O
in	O
the	O
tissue	O
-	O
specific	O
expression	O
of	O
CD14	O
in	O
monocytic	O
cells	O
.	O

CD14	O
Sp1	O
site	O
oligonucleotides	O
bound	O
preferentially	O
to	O
a	O
105	O
-	O
kDa	O
Sp1	O
species	O
,	O
which	O
is	O
present	O
in	O
higher	O
relative	O
levels	O
in	O
monocytic	O
than	O
non	O
-	O
monocytic	O
cells	O
,	O
suggesting	O
that	O
modification	O
of	O
Sp1	O
,	O
such	O
as	O
phosphorylation	O
,	O
may	O
explain	O
how	O
the	O
Sp1	O
site	O
mediates	O
monocytic	O
specific	O
promoter	O
activity	O
.	O

E2F	O
-	O
1	O
and	O
a	O
cyclin	O
-	O
like	O
DNA	O
repair	O
enzyme	O
,	O
uracil	O
-	O
DNA	O
glycosylase	O
,	O
provide	O
evidence	O
for	O
an	O
autoregulatory	O
mechanism	O
for	O
transcription	O
.	O

The	O
cell	O
cycle	O
-	O
dependent	O
transcription	O
factor	O
,	O
E2F	O
-	O
1	O
,	O
regulates	O
the	O
cyclin	O
-	O
like	O
species	O
of	O
the	O
DNA	O
repair	O
enzyme	O
uracil	O
-	O
DNA	O
glycosylase	O
(	O
UDG	O
)	O
gene	O
in	O
human	O
osteosarcoma	O
(	O
Saos	O
-	O
2	O
)	O
cells	O
.	O

We	O
demonstrate	O
,	O
through	O
the	O
deletion	O
of	O
the	O
human	O
UDG	O
promoter	O
sequences	O
,	O
that	O
expression	O
of	O
E2F	O
-	O
1	O
activates	O
the	O
UDG	O
promoter	O
through	O
several	O
E2F	O
sites	O
.	O

The	O
major	O
putative	O
downstream	O
site	O
for	O
E2F	O
,	O
located	O
in	O
the	O
first	O
exon	O
,	O
serves	O
as	O
a	O
target	O
for	O
E2F	O
-	O
1	O
/	O
DP1	O
complex	O
binding	O
in	O
vitro	O
.	O

We	O
also	O
provide	O
evidence	O
for	O
the	O
functional	O
relationship	O
between	O
the	O
cyclin	O
-	O
like	O
UDG	O
gene	O
product	O
and	O
E2F	O
.	O

High	O
levels	O
of	O
UDG	O
expression	O
in	O
a	O
transient	O
transfection	O
assay	O
result	O
in	O
the	O
down	O
-	O
regulation	O
of	O
transcriptional	O
activity	O
through	O
elements	O
specific	O
for	O
E2F	O
-	O
mediated	O
transcription	O
.	O

Overexpression	O
of	O
UDG	O
in	O
Saos	O
2	O
cells	O
was	O
observed	O
to	O
delay	O
growth	O
late	O
in	O
G1	O
phase	O
and	O
transiently	O
arrest	O
these	O
cells	O
from	O
progressing	O
into	O
the	O
S	O
phase	O
.	O

This	O
hypothetical	O
model	O
integrates	O
one	O
mechanism	O
of	O
DNA	O
repair	O
with	O
the	O
cell	O
cycle	O
control	O
of	O
gene	O
transcription	O
,	O
likely	O
through	O
E2F	O
.	O

This	O
implicates	O
E2F	O
as	O
a	O
multifunctional	O
target	O
for	O
proteins	O
and	O
enzymes	O
,	O
possibly	O
,	O
responsive	O
to	O
DNA	O
damage	O
through	O
the	O
negative	O
effect	O
of	O
UDG	O
on	O
E2F	O
-	O
mediated	O
transcriptional	O
activity	O
.	O

Cross	O
-	O
linking	O
of	O
CD30	O
induces	O
HIV	O
expression	O
in	O
chronically	O
infected	O
T	O
cells	O
.	O

CD30	O
,	O
a	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
family	O
,	O
is	O
expressed	O
constitutively	O
on	O
the	O
surface	O
of	O
the	O
human	O
T	O
cell	O
line	O
ACH	O
-	O
2	O
,	O
which	O
is	O
chronically	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
-	O
1	O
(	O
HIV	O
)	O
-	O
1	O
.	O

We	O
demonstrate	O
that	O
cross	O
-	O
linking	O
CD30	O
with	O
an	O
anti	O
-	O
CD30	O
-	O
specific	O
monoclonal	O
antibody	O
,	O
which	O
mimics	O
the	O
described	O
biological	O
activities	O
of	O
the	O
CD30	O
ligand	O
(	O
CD30L	O
)	O
,	O
results	O
in	O
HIV	O
expression	O
.	O

CD30	O
cross	O
-	O
linking	O
does	O
not	O
alter	O
proliferation	O
of	O
ACH	O
-	O
2	O
cells	O
and	O
the	O
induction	O
of	O
HIV	O
expression	O
is	O
not	O
mediated	O
by	O
endogenous	O
TNF	O
alpha	O
/	O
beta	O
.	O

Furthermore	O
,	O
cross	O
-	O
linking	O
of	O
CD30	O
leads	O
to	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
activation	O
and	O
enhanced	O
HIV	O
transcription	O
.	O

Thus	O
,	O
CD30	O
-	O
CD30L	O
interactions	O
mediate	O
the	O
induction	O
of	O
HIV	O
expression	O
by	O
a	O
kappa	B-Complex
B	I-Complex
-	O
dependent	O
pathway	O
that	O
is	O
independent	O
of	O
TNF	O
.	O

This	O
mechanism	O
may	O
be	O
important	O
in	O
the	O
activation	O
of	O
HIV	O
expression	O
from	O
latently	O
infected	O
CD4	O
+	O
T	O
cells	O
,	O
especially	O
in	O
lymphoid	O
organs	O
where	O
cell	O
to	O
cell	O
contact	O
is	O
conducive	O
to	O
receptor	O
-	O
ligand	O
interactions	O
.	O

Quantitation	O
of	O
procholecystokinin	O
and	O
its	O
products	O
in	O
plasma	O
by	O
processing	O
-	O
independent	O
analysis	O
.	O

A	O
procedure	O
for	O
processing	O
-	O
independent	O
quantitation	O
of	O
procholecystokinin	O
(	O
proCCK	O
)	O
and	O
its	O
products	O
has	O
been	O
applied	O
to	O
plasma	O
.	O

The	O
procedure	O
is	O
based	O
on	O
tryptic	O
cleavage	O
after	O
Lys61	O
and	O
Arg71	O
with	O
subsequent	O
monospecific	O
radioimmuno	O
-	O
analysis	O
of	O
fragment	O
62	O
-	O
71	O
of	O
human	O
proCCK	O
,	O
which	O
again	O
corresponds	O
to	O
fragment	O
1	O
-	O
10	O
of	O
CCK	O
-	O
22	O
.	O

The	O
detection	O
limit	O
of	O
the	O
analysis	O
was	O
0	O
.	O
2	O
pmol	O
/	O
l	O
.	O

Plasma	O
was	O
extracted	O
with	O
ethanol	O
.	O

In	O
plasma	O
from	O
13	O
healthy	O
volunteers	O
the	O
basal	O
concentration	O
with	O
the	O
above	O
-	O
mentioned	O
radioimmunoassay	O
was	O
1	O
.	O
1	O
+	O
/	O
-	O
0	O
.	O
1	O
pmol	O
/	O
l	O
(	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
.	O
)	O
before	O
,	O
and	O
13	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
6	O
pmol	O
/	O
l	O
after	O
,	O
incubation	O
with	O
trypsin	O
.	O

Two	O
hours	O
after	O
ingestion	O
of	O
a	O
mixed	O
meal	O
,	O
the	O
plasma	O
concentration	O
was	O
2	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
1	O
pmol	O
/	O
l	O
before	O
,	O
and	O
21	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
2	O
pmol	O
/	O
l	O
after	O
tryptic	O
cleavage	O
.	O

With	O
a	O
conventional	O
CCK	O
radioimmunoassay	O
specific	O
for	O
the	O
C	O
-	O
terminally	O
amidated	O
and	O
O	O
-	O
sulfated	O
bioactive	O
epitope	O
,	O
the	O
concentration	O
was	O
1	O
.	O
0	O
+	O
/	O
-	O
0	O
.	O
1	O
pmol	O
/	O
l	O
in	O
the	O
basal	O
state	O
and	O
4	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
4	O
pmol	O
/	O
l	O
2	O
h	O
after	O
a	O
meal	O
.	O

Tryptic	O
cleavage	O
did	O
not	O
increase	O
the	O
concentrations	O
of	O
amidated	O
,	O
bioactive	O
CCK	O
peptides	O
.	O

In	O
plasma	O
from	O
37	O
patients	O
with	O
the	O
carcinoid	O
syndrome	O
,	O
the	O
basal	O
concentration	O
of	O
proCCK	O
and	O
its	O
products	O
was	O
14	O
.	O
1	O
(	O
2	O
.	O
8	O
-	O
150	O
.	O
4	O
)	O
pmol	O
/	O
l	O
(	O
median	O
(	O
range	O
)	O
)	O
,	O
compared	O
with	O
0	O
.	O
3	O
(	O
0	O
-	O
18	O
.	O
8	O
)	O
pmol	O
/	O
l	O
for	O
carboxyamidated	O
CCK	O
.	O

Only	O
two	O
patients	O
had	O
significantly	O
elevated	O
CCK	O
concentrations	O
.	O

We	O
conclude	O
that	O
processing	O
-	O
independent	O
analysis	O
is	O
useful	O
for	O
quantitation	O
of	O
proCCK	O
and	O
its	O
products	O
in	O
plasma	O
,	O
since	O
it	O
quantitates	O
CCK	O
cell	O
secretion	O
more	O
accurately	O
than	O
conventional	O
CCK	O
assays	O
.	O

Transcriptional	O
repression	O
of	O
the	O
interleukin	O
-	O
2	O
gene	O
by	O
vitamin	O
D3	O
:	O
direct	O
inhibition	O
of	O
NFATp	O
/	O
AP	B-Complex
-	I-Complex
1	I-Complex
complex	O
formation	O
by	O
a	O
nuclear	O
hormone	O
receptor	O
.	O

T	O
-	O
lymphocyte	O
proliferation	O
is	O
suppressed	O
by	O
1	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
[	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
the	O
active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
and	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
,	O
gamma	O
interferon	O
,	O
and	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
mRNA	O
levels	O
.	O

We	O
report	O
here	O
that	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-	O
mediated	O
repression	O
in	O
Jurkat	O
cells	O
is	O
cycloheximide	O
resistant	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
direct	O
transcriptional	O
repressive	O
effect	O
on	O
IL	O
-	O
2	O
expression	O
by	O
the	O
vitamin	O
D3	O
receptor	O
(	O
VDR	O
)	O
.	O

We	O
therefore	O
examined	O
vitamin	O
D3	O
-	O
mediated	O
repression	O
of	O
activated	O
IL	O
-	O
2	O
expression	O
by	O
cotransfecting	O
Jurkat	O
cells	O
with	O
IL	O
-	O
2	O
promoter	O
/	O
reporter	O
constructs	O
and	O
a	O
VDR	O
overexpression	O
vector	O
and	O
by	O
DNA	O
binding	O
.	O

We	O
delineated	O
an	O
element	O
conferring	O
both	O
DNA	O
binding	O
by	O
the	O
receptor	O
in	O
vitro	O
and	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
-	O
mediated	O
repression	O
in	O
vivo	O
to	O
a	O
short	O
40	O
-	O
bp	O
region	O
encompassing	O
an	O
important	O
positive	O
regulatory	O
element	O
,	O
NF	O
-	O
AT	O
-	O
1	O
,	O
which	O
is	O
bound	O
by	O
a	O
T	O
-	O
cell	O
-	O
specific	O
transcription	O
factor	O
,	O
NFATp	O
,	O
as	O
well	O
as	O
by	O
AP	B-Complex
-	I-Complex
1	I-Complex
.	O

VDR	O
DNA	O
-	O
binding	O
mutants	O
were	O
unable	O
to	O
either	O
bind	O
to	O
this	O
element	O
in	O
vitro	O
or	O
repress	O
in	O
vivo	O
;	O
the	O
VDR	O
DNA	O
-	O
binding	O
domain	O
alone	O
,	O
however	O
,	O
bound	O
the	O
element	O
but	O
also	O
could	O
not	O
repress	O
IL	O
-	O
2	O
expression	O
.	O

These	O
results	O
indicate	O
that	O
DNA	O
binding	O
by	O
VDR	O
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
mediate	O
IL	O
-	O
2	O
repression	O
.	O

By	O
combining	O
partially	O
purified	O
proteins	O
in	O
vitro	O
,	O
we	O
observed	O
the	O
loss	O
of	O
the	O
bound	O
NFATp	O
/	O
AP	B-Complex
-	I-Complex
1	I-Complex
-	O
DNA	O
complex	O
upon	O
inclusion	O
of	O
VDR	O
or	O
VDR	O
-	O
retinoid	O
X	O
receptor	O
.	O

Order	O
of	O
addition	O
and	O
off	O
-	O
rate	O
experiments	O
indicate	O
that	O
the	O
VDR	O
-	O
retinoid	O
X	O
receptor	O
heterodimer	O
blocks	O
NFATp	O
/	O
AP	B-Complex
-	I-Complex
1	I-Complex
complex	O
formation	O
and	O
then	O
stably	O
associates	O
with	O
the	O
NF	O
-	O
AT	O
-	O
1	O
element	O
.	O

This	O
direct	O
inhibition	O
by	O
a	O
nuclear	O
hormone	O
receptor	O
of	O
transcriptional	O
activators	O
of	O
the	O
IL	O
-	O
2	O
gene	O
may	O
provide	O
a	O
mechanistic	O
explanation	O
of	O
how	O
vitamin	O
derivatives	O
can	O
act	O
as	O
potent	O
immunosuppressive	O
agents	O
.	O

The	O
myeloid	O
zinc	O
finger	O
gene	O
,	O
MZF	O
-	O
1	O
,	O
regulates	O
the	O
CD34	O
promoter	O
in	O
vitro	O
.	O

MZF	O
-	O
1	O
is	O
a	O
C2H2	O
zinc	O
finger	O
gene	O
encoding	O
a	O
putative	O
transcriptional	O
regulator	O
of	O
myeloid	O
differentiation	O
.	O

The	O
MZF	O
-	O
1	O
protein	O
contains	O
13	O
C2H2	O
zinc	O
fingers	O
arranged	O
in	O
bipartite	O
DNA	O
binding	O
domains	O
containing	O
zinc	O
fingers	O
through	O
4	O
and	O
,	O
in	O
the	O
carboxy	O
-	O
terminus	O
,	O
5	O
through	O
13	O
.	O

We	O
previously	O
identified	O
the	O
DNA	O
consensus	O
binding	O
site	O
recognized	O
by	O
the	O
two	O
DNA	O
binding	O
domains	O
.	O

To	O
assess	O
the	O
transcription	O
regulatory	O
function	O
of	O
MZF	O
-	O
1	O
,	O
the	O
full	O
-	O
length	O
MZF	O
-	O
1	O
coding	O
region	O
was	O
fused	O
to	O
the	O
DNA	O
binding	O
domain	O
of	O
the	O
yeast	O
transactivator	O
GAL4	O
.	O

The	O
expression	O
vector	O
was	O
cotransfected	O
with	O
the	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
regulated	O
by	O
the	O
thymidine	O
kinase	O
promoter	O
containing	O
GAL4	O
DNA	O
binding	O
sites	O
into	O
NIH	O
3T3	O
,	O
293	O
,	O
K562	O
,	O
and	O
Jurkat	O
cell	O
lines	O
.	O

MZF	O
-	O
1	O
represses	O
CAT	O
reporter	O
gene	O
expression	O
via	O
GAL4	O
binding	O
sites	O
in	O
the	O
nonhematopoietic	O
cell	O
lines	O
NIH	O
3T3	O
and	O
293	O
.	O

In	O
contrast	O
,	O
MZF	O
-	O
1	O
activates	O
CAT	O
reporter	O
gene	O
expression	O
in	O
the	O
hematopoietic	O
cell	O
lines	O
K562	O
and	O
Jurkat	O
.	O

The	O
MZF	O
-	O
1	O
binding	O
sites	O
are	O
present	O
in	O
the	O
promoters	O
of	O
several	O
genes	O
expressed	O
during	O
myeloid	O
differentiation	O
,	O
including	O
the	O
CD34	O
promoter	O
.	O

MZF	O
-	O
1	O
transcriptional	O
regulation	O
of	O
this	O
physiologically	O
relevant	O
promoter	O
was	O
assessed	O
in	O
both	O
hematopoietic	O
and	O
nonhematopoietic	O
cell	O
lines	O
.	O

Recombinant	O
MZF	O
-	O
1	O
protein	O
specifically	O
binds	O
to	O
the	O
consensus	O
binding	O
sites	O
in	O
the	O
CD34	O
promoter	O
in	O
mobility	O
shift	O
assays	O
.	O

MZF	O
-	O
1	O
expression	O
vectors	O
were	O
cotransfected	O
with	O
the	O
luciferase	O
reporter	O
plasmids	O
regulated	O
by	O
the	O
CD34	O
promoter	O
into	O
both	O
nonhematopoietic	O
and	O
hematopoietic	O
cell	O
lines	O
.	O

As	O
with	O
the	O
heterologous	O
DNA	O
binding	O
domain	O
,	O
MZF	O
-	O
1	O
represses	O
reporter	O
gene	O
expression	O
in	O
nonhematopoietic	O
cell	O
lines	O
and	O
activates	O
expression	O
in	O
hematopoietic	O
cell	O
lines	O
.	O

Activation	O
of	O
CD34	O
expression	O
in	O
hematopoietic	O
cell	O
lines	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
intact	O
MZF	O
-	O
1	O
binding	O
sites	O
.	O

The	O
cell	O
type	O
-	O
specific	O
regulation	O
of	O
the	O
CD34	O
promoter	O
by	O
MZF	O
-	O
1	O
suggests	O
the	O
presence	O
of	O
tissue	O
-	O
specific	O
regulators	O
/	O
adapters	O
or	O
differential	O
MZF	O
-	O
1	O
modifications	O
that	O
determine	O
MZF	O
-	O
1	O
transcriptional	O
regulatory	O
function	O
.	O

Stimulation	O
of	O
cloned	O
human	O
glucagon	O
-	O
like	O
peptide	O
1	O
receptor	O
expressed	O
in	O
HEK	O
293	O
cells	O
induces	O
cAMP	O
-	O
dependent	O
activation	O
of	O
calcium	O
-	O
induced	O
calcium	O
release	O
.	O

The	O
actions	O
of	O
glucagon	O
-	O
like	O
peptide	O
-	O
1	O
(	O
7	O
-	O
36	O
)	O
amide	O
(	O
GLP	O
-	O
1	O
(	O
7	O
-	O
36	O
)	O
amide	O
)	O
on	O
cellular	O
signalling	O
were	O
studied	O
in	O
human	O
embryonal	O
kidney	O
293	O
(	O
HEK	O
293	O
)	O
cells	O
stably	O
transfected	O
with	O
the	O
cloned	O
human	O
GLP	O
-	O
1	O
receptor	O
.	O

The	O
cloned	O
GLP	O
-	O
1	O
receptor	O
showed	O
a	O
single	O
high	O
-	O
affinity	O
binding	O
site	O
(	O
Kd	O
=	O
0	O
.	O
76	O
nM	O
)	O
.	O

Binding	O
of	O
GLP	O
-	O
1	O
(	O
7	O
-	O
36	O
)	O
amide	O
stimulated	O
cAMP	O
production	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
EC50	O
=	O
0	O
.	O
015	O
nM	O
)	O
and	O
caused	O
an	O
increase	O
in	O
the	O
intracellular	O
free	O
Ca2	O
+	O
concentration	O
(	O
[	O
Ca2	O
+	O
]	O
i	O
)	O
.	O

The	O
latter	O
effect	O
reflected	O
Ca	O
(	O
2	O
+	O
)	O
-	O
induced	O
Ca2	O
+	O
release	O
and	O
was	O
suppressed	O
by	O
ryanodine	O
.	O

We	O
propose	O
that	O
the	O
ability	O
of	O
GLP	O
-	O
1	O
(	O
7	O
-	O
36	O
)	O
amide	O
to	O
increase	O
[	O
Ca2	O
+	O
]	O
i	O
results	O
from	O
sensitization	O
of	O
the	O
ryanodine	O
receptors	O
by	O
a	O
protein	O
kinase	O
A	O
dependent	O
mechanism	O
.	O

Synergistic	O
activation	O
of	O
rat	O
brain	O
phospholipase	O
D	O
by	O
ADP	O
-	O
ribosylation	O
factor	O
and	O
rhoA	O
p21	O
,	O
and	O
its	O
inhibition	O
by	O
Clostridium	O
botulinum	O
C3	O
exoenzyme	O
.	O

An	O
activator	O
of	O
rat	O
brain	O
phospholipase	O
D	O
(	O
PLD	O
)	O
that	O
is	O
distinct	O
from	O
the	O
already	O
identified	O
PLD	O
activator	O
,	O
ADP	O
-	O
ribosylation	O
factor	O
(	O
ARF	O
)	O
,	O
was	O
partially	O
purified	O
from	O
bovine	O
brain	O
cytosol	O
by	O
a	O
series	O
of	O
chromatographic	O
steps	O
.	O

The	O
partially	O
purified	O
preparation	O
contained	O
a	O
22	O
-	O
kDa	O
substrate	O
for	O
Clostridium	O
botulinum	O
C3	O
exoenzyme	O
ADP	O
-	O
ribosyltransferase	O
,	O
which	O
strongly	O
reacted	O
with	O
anti	O
-	O
rhoA	O
p21	O
antibody	O
,	O
but	O
not	O
with	O
anti	O
-	O
rac1	O
p21	O
or	O
anti	O
-	O
cdc42Hs	O
p21	O
antibody	O
.	O

Treatment	O
of	O
the	O
partially	O
purified	O
PLD	O
-	O
activating	O
factor	O
with	O
both	O
C3	O
exoenzyme	O
and	O
NAD	O
significantly	O
inhibited	O
the	O
PLD	O
-	O
stimulating	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
rhoA	O
p21	O
is	O
,	O
at	O
least	O
in	O
part	O
,	O
responsible	O
for	O
the	O
PLD	O
-	O
stimulating	O
activity	O
in	O
the	O
preparation	O
.	O

Recombinant	O
isoprenylated	O
rhoA	O
p21	O
expressed	O
in	O
and	O
purified	O
from	O
Sf9	O
cells	O
activated	O
rat	O
brain	O
PLD	O
in	O
a	O
concentration	O
-	O
and	O
GTP	O
gamma	O
S	O
(	O
guanosine	O
5	O
'	O
-	O
O	O
-	O
(	O
3	O
-	O
thiotriphosphate	O
)	O
)	O
-	O
dependent	O
manner	O
.	O

In	O
contrast	O
,	O
recombinant	O
non	O
-	O
isoprenylated	O
rhoA	O
p21	O
(	O
fused	O
to	O
glutathione	O
S	O
-	O
transferase	O
)	O
expressed	O
in	O
Escherichia	O
coli	O
failed	O
to	O
activate	O
the	O
PLD	O
.	O

This	O
difference	O
cannot	O
be	O
explained	O
by	O
a	O
lower	O
affinity	O
of	O
non	O
-	O
isoprenylated	O
rhoA	O
p21	O
for	O
GTP	O
gamma	O
S	O
,	O
as	O
the	O
rates	O
of	O
[	O
35S	O
]	O
GTP	O
gamma	O
S	O
binding	O
were	O
very	O
similar	O
for	O
both	O
recombinant	O
preparations	O
and	O
the	O
GTP	O
gamma	O
S	O
-	O
bound	O
form	O
of	O
non	O
-	O
isoprenylated	O
rhoA	O
p21	O
did	O
not	O
induce	O
PLD	O
activation	O
.	O

Interestingly	O
,	O
recombinant	O
isoprenylated	O
rhoA	O
p21	O
and	O
ARF	O
synergistically	O
activated	O
rat	O
brain	O
PLD	O
;	O
a	O
similar	O
pattern	O
was	O
seen	O
with	O
the	O
partially	O
purified	O
PLD	O
-	O
activating	O
factor	O
.	O

The	O
synergistic	O
activation	O
was	O
inhibited	O
by	O
C3	O
exoenzyme	O
-	O
catalyzed	O
ADP	O
-	O
ribosylation	O
of	O
recombinant	O
isoprenylated	O
rhoA	O
p21	O
in	O
a	O
NAD	O
-	O
dependent	O
manner	O
.	O

Inhibition	O
correlated	O
with	O
the	O
extent	O
of	O
ADP	O
-	O
ribosylation	O
.	O

These	O
findings	O
suggest	O
that	O
rhoA	O
p21	O
regulates	O
rat	O
brain	O
PLD	O
in	O
concert	O
with	O
ARF	O
,	O
and	O
that	O
isoprenylation	O
of	O
rhoA	O
p21	O
is	O
essential	O
for	O
PLD	O
regulation	O
in	O
vitro	O
.	O

Immunoreceptor	O
tyrosine	O
-	O
based	O
activation	O
motif	O
is	O
required	O
to	O
signal	O
pathways	O
of	O
receptor	O
-	O
mediated	O
growth	O
arrest	O
and	O
apoptosis	O
in	O
murine	O
B	O
lymphoma	O
cells	O
.	O

The	O
B	B-Complex
cell	I-Complex
Ag	I-Complex
receptor	I-Complex
is	O
a	O
multimeric	O
protein	O
complex	O
consisting	O
of	O
the	O
ligand	O
binding	O
mlg	O
and	O
the	O
Ig	O
alpha	O
/	O
lg	O
beta	O
heterodimer	O
.	O

The	O
cytoplasmic	O
tails	O
of	O
Ig	O
alpha	O
and	O
Ig	O
beta	O
both	O
contain	O
a	O
consensus	O
sequence	O
termed	O
the	O
immunoreceptor	O
tyrosine	O
-	O
based	O
activation	O
motif	O
(	O
ITAM	O
)	O
.	O

This	O
motif	O
is	O
believed	O
to	O
play	O
a	O
critical	O
role	O
in	O
the	O
receptor	O
-	O
mediated	O
signal	O
transduction	O
.	O

To	O
explore	O
the	O
role	O
of	O
ITAM	O
in	O
signaling	O
for	O
B	O
cell	O
death	O
(	O
apoptosis	O
)	O
,	O
we	O
transfected	O
CH31	O
cells	O
,	O
an	O
immature	O
B	O
lymphoma	O
cell	O
line	O
,	O
with	O
expression	O
vectors	O
encoding	O
for	O
the	O
CD8	O
extracellular	O
/	O
transmembrane	O
domains	O
and	O
the	O
cytoplasmic	O
signal	O
-	O
transducing	O
domain	O
(	O
ITAM	O
)	O
of	O
Ig	O
alpha	O
or	O
Ig	O
beta	O
,	O
respectively	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
cross	O
-	O
linking	O
of	O
CD8	O
:	O
Ig	O
alpha	O
or	O
CD	O
:	O
Ig	O
beta	O
with	O
anti	O
-	O
CD8	O
mAb	O
effectively	O
induced	O
cell	O
growth	O
arrest	O
and	O
apoptosis	O
characterized	O
by	O
[	O
3H	O
]	O
thymidine	O
release	O
and	O
DNA	O
fragmentation	O
;	O
in	O
contrast	O
,	O
CD8	O
:	O
gamma	O
2a	O
or	O
truncated	O
CD8	O
:	O
Ig	O
alpha	O
lacking	O
the	O
ITAM	O
could	O
not	O
do	O
so	O
.	O

Moreover	O
,	O
selective	O
point	O
mutation	O
of	O
either	O
of	O
the	O
two	O
conserved	O
tyrosine	O
residues	O
within	O
the	O
ITAM	O
,	O
but	O
not	O
the	O
nonconserved	O
tyrosine	O
,	O
completely	O
abrogated	O
the	O
ability	O
of	O
this	O
motif	O
to	O
mediate	O
cell	O
death	O
signals	O
.	O

These	O
findings	O
clearly	O
indicate	O
that	O
ITAM	O
is	O
a	O
critical	O
component	O
required	O
for	O
transmitting	O
growth	O
arrest	O
and	O
apoptotic	O
signals	O
,	O
and	O
that	O
these	O
functions	O
of	O
ITAM	O
are	O
positively	O
regulated	O
by	O
tyrosine	O
phosphorylation	O
.	O

Regulation	O
of	O
transcription	O
of	O
the	O
human	O
erythropoietin	O
receptor	O
gene	O
by	O
proteins	O
binding	O
to	O
GATA	O
-	O
1	O
and	O
Sp1	O
motifs	O
.	O

Erythropoietin	O
(	O
Epo	O
)	O
,	O
the	O
primary	O
regulator	O
of	O
the	O
production	O
of	O
erythroid	O
cells	O
,	O
acts	O
by	O
binding	O
to	O
a	O
cell	O
surface	O
receptor	O
(	O
EpoR	O
)	O
on	O
erythroid	O
progenitors	O
.	O

We	O
used	O
deletion	O
analysis	O
and	O
transfection	O
assays	O
with	O
reporter	O
gene	O
constructs	O
to	O
examine	O
the	O
transcription	O
control	O
elements	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
human	O
EpoR	O
gene	O
.	O

In	O
erythroid	O
cells	O
most	O
of	O
the	O
transcription	O
activity	O
was	O
contained	O
in	O
a	O
150	O
bp	O
promoter	O
fragment	O
with	O
binding	O
sites	O
for	O
transcription	O
factors	O
AP2	O
,	O
Sp1	O
and	O
the	O
erythroid	O
-	O
specific	O
GATA	O
-	O
1	O
.	O

The	O
150	O
bp	O
hEpoR	O
promoter	O
exhibited	O
high	O
and	O
low	O
activity	O
in	O
erythroid	O
OCIM1	O
and	O
K562	O
cells	O
,	O
respectively	O
,	O
reflecting	O
the	O
high	O
and	O
low	O
levels	O
of	O
constitutive	O
hEpoR	O
expression	O
.	O

The	O
GATA	O
-	O
1	O
and	O
Sp1	O
binding	O
sites	O
in	O
this	O
promoter	O
lacking	O
a	O
TATA	O
sequence	O
were	O
necessary	O
for	O
a	O
high	O
level	O
of	O
transcription	O
activation	O
.	O

Protein	O
-	O
DNA	O
binding	O
studies	O
suggested	O
that	O
Sp1	O
and	O
two	O
other	O
CCGCCC	O
binding	O
proteins	O
from	O
erythroid	O
and	O
non	O
-	O
erythroid	O
cells	O
could	O
bind	O
to	O
the	O
Sp1	O
binding	O
motif	O
.	O

By	O
increasing	O
GATA	O
-	O
1	O
levels	O
via	O
co	O
-	O
transfection	O
,	O
we	O
were	O
able	O
to	O
transactivate	O
the	O
hEpoR	O
promoter	O
in	O
K562	O
cells	O
and	O
non	O
-	O
erythroid	O
cells	O
,	O
but	O
not	O
in	O
the	O
highly	O
active	O
OCIM1	O
cells	O
,	O
although	O
GATA	O
-	O
1	O
mRNA	O
levels	O
were	O
comparable	O
in	O
OCIM1	O
and	O
K562	O
.	O

Interestingly	O
,	O
when	O
we	O
mutated	O
the	O
Sp1	O
site	O
,	O
resulting	O
in	O
a	O
marked	O
decrease	O
in	O
hEpoR	O
promoter	O
activity	O
,	O
we	O
could	O
restore	O
transactivation	O
by	O
increasing	O
GATA	O
-	O
1	O
levels	O
in	O
OCIM1	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
while	O
GATA	O
-	O
1	O
can	O
transactivate	O
the	O
EpoR	O
promoter	O
,	O
the	O
level	O
of	O
hEpoR	O
gene	O
expression	O
does	O
not	O
depend	O
on	O
GATA	O
-	O
1	O
alone	O
.	O

Rather	O
,	O
hEpoR	O
transcription	O
activity	O
depends	O
on	O
coordination	O
between	O
Sp1	O
and	O
GATA	O
-	O
1	O
with	O
other	O
cell	O
-	O
specific	O
factors	O
,	O
including	O
possibly	O
other	O
Sp1	O
-	O
like	O
binding	O
proteins	O
,	O
to	O
provide	O
high	O
level	O
,	O
tissue	O
-	O
specific	O
expression	O
.	O

p53	O
modulation	O
of	O
TFIIH	B-Complex
-	O
associated	O
nucleotide	O
excision	O
repair	O
activity	O
.	O

p53	O
has	O
pleiotropic	O
functions	O
including	O
control	O
of	O
genomic	O
plasticity	O
and	O
integrity	O
.	O

Here	O
we	O
report	O
that	O
p53	O
can	O
bind	O
to	O
several	O
transcription	B-Complex
factor	I-Complex
IIH	I-Complex
-	O
associated	O
factors	O
,	O
including	O
transcription	O
-	O
repair	O
factors	O
,	O
XPD	O
(	O
Rad3	O
)	O
and	O
XPB	O
,	O
as	O
well	O
as	O
CSB	O
involved	O
in	O
strand	O
-	O
specific	O
DNA	O
repair	O
,	O
via	O
its	O
C	O
-	O
terminal	O
domain	O
.	O

We	O
also	O
found	O
that	O
wild	O
-	O
type	O
,	O
but	O
not	O
Arg273His	O
mutant	O
p53	O
inhibits	O
XPD	O
(	O
Rad3	O
)	O
and	O
XPB	O
DNA	O
helicase	O
activities	O
.	O

Moreover	O
,	O
repair	O
of	O
UV	O
-	O
induced	O
dimers	O
is	O
slower	O
in	O
Li	O
-	O
Fraumeni	O
syndrome	O
cells	O
(	O
heterozygote	O
p53	O
mutant	O
)	O
than	O
in	O
normal	O
human	O
cells	O
.	O

Our	O
findings	O
indicate	O
that	O
p53	O
may	O
play	O
a	O
direct	O
role	O
in	O
modulating	O
nucleotide	O
excision	O
repair	O
pathways	O
.	O

Ubiquitin	O
-	O
mediated	O
processing	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
transcriptional	O
activator	O
precursor	O
p105	O
.	O

Reconstitution	O
of	O
a	O
cell	O
-	O
free	O
system	O
and	O
identification	O
of	O
the	O
ubiquitin	O
-	O
carrier	O
protein	O
,	O
E2	O
,	O
and	O
a	O
novel	O
ubiquitin	O
-	O
protein	O
ligase	O
,	O
E3	O
,	O
involved	O
in	O
conjugation	O
.	O

In	O
most	O
cases	O
,	O
the	O
transcriptional	O
factor	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
is	O
a	O
heterodimer	O
consisting	O
of	O
two	O
subunits	O
,	O
p50	O
and	O
p65	O
,	O
which	O
are	O
encoded	O
by	O
two	O
distinct	O
genes	O
of	O
the	O
Rel	O
family	O
.	O

p50	O
is	O
translated	O
as	O
a	O
precursor	O
of	O
105	O
kDa	O
.	O

The	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
precursor	O
is	O
rapidly	O
degraded	O
,	O
forming	O
the	O
mature	O
p50	O
subunit	O
consisted	O
of	O
the	O
N	O
-	O
terminal	O
region	O
of	O
the	O
molecule	O
.	O

The	O
mechanism	O
of	O
generation	O
of	O
p50	O
is	O
not	O
known	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
ubiquitin	O
-	O
proteasome	B-Complex
system	O
is	O
involved	O
in	O
the	O
process	O
;	O
however	O
,	O
the	O
specific	O
enzymes	O
involved	O
and	O
the	O
mechanism	O
of	O
limited	O
proteolysis	O
,	O
in	O
which	O
half	O
of	O
the	O
molecule	O
is	O
spared	O
,	O
have	O
been	O
obscure	O
.	O

Palombella	O
and	O
colleagues	O
(	O
Palombella	O
,	O
V	O
.	O
J	O
.	O
,	O
Rando	O
,	O
O	O
.	O
J	O
.	O
,	O
Goldberg	O
,	O
A	O
.	O
L	O
.	O
,	O
and	O
Maniatis	O
,	O
T	O
.	O
(	O
1994	O
)	O
Cell	O
78	O
,	O
773	O
-	O
785	O
)	O
have	O
shown	O
that	O
ubiquitin	O
is	O
required	O
for	O
the	O
processing	O
in	O
a	O
cell	O
-	O
free	O
system	O
of	O
a	O
truncated	O
,	O
artificially	O
constructed	O
,	O
60	O
-	O
kDa	O
precursor	O
.	O

They	O
have	O
also	O
shown	O
that	O
proteasome	B-Complex
inhibitors	O
block	O
the	O
processing	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
reconstitution	O
of	O
a	O
cell	O
-	O
free	O
processing	O
system	O
and	O
demonstrate	O
directly	O
that	O
:	O
(	O
a	O
)	O
the	O
ubiquitin	O
-	O
proteasome	B-Complex
system	O
is	O
involved	O
in	O
processing	O
of	O
the	O
intact	O
p105	O
precursor	O
,	O
(	O
b	O
)	O
conjugation	O
of	O
ubiquitin	O
to	O
the	O
precursor	O
is	O
an	O
essential	O
intermediate	O
step	O
in	O
the	O
processing	O
,	O
(	O
c	O
)	O
the	O
recently	O
discovered	O
novel	O
species	O
of	O
the	O
ubiquitin	O
-	O
carrier	O
protein	O
,	O
E2	O
-	O
F1	O
,	O
that	O
is	O
involved	O
in	O
the	O
conjugation	O
and	O
degradation	O
of	O
p53	O
,	O
is	O
also	O
required	O
for	O
the	O
limited	O
processing	O
of	O
the	O
p105	O
precursor	O
,	O
and	O
(	O
d	O
)	O
a	O
novel	O
,	O
approximately	O
320	O
-	O
kDa	O
species	O
of	O
ubiquitin	O
-	O
protein	O
ligase	O
,	O
is	O
involved	O
in	O
the	O
process	O
.	O

This	O
novel	O
enzyme	O
is	O
distinct	O
from	O
E6	O
-	O
AP	O
,	O
the	O
p53	O
-	O
conjugating	O
ligase	O
,	O
and	O
from	O
E3	O
alpha	O
,	O
the	O
"	O
N	O
-	O
end	O
rule	O
"	O
ligase	O
.	O

Evolutionary	O
conservation	O
of	O
human	O
TATA	O
-	O
binding	O
-	O
polypeptide	O
-	O
associated	O
factors	O
TAFII31	O
and	O
TAFII80	O
and	O
interactions	O
of	O
TAFII80	O
with	O
other	O
TAFs	O
and	O
with	O
general	O
transcription	O
factors	O
.	O

Human	O
transcription	O
initiation	O
factor	O
TFIID	B-Complex
is	O
composed	O
of	O
the	O
TATA	O
-	O
binding	O
polypeptide	O
(	O
TBP	O
)	O
and	O
at	O
least	O
13	O
TBP	O
-	O
associated	O
factors	O
(	O
TAFs	O
)	O
that	O
collectively	O
or	O
individually	O
are	O
involved	O
in	O
activator	O
-	O
dependent	O
transcription	O
.	O

To	O
investigate	O
protein	O
-	O
protein	O
interactions	O
involved	O
in	O
TFIID	B-Complex
assembly	O
and	O
in	O
TAF	O
-	O
mediated	O
activator	O
functions	O
,	O
we	O
have	O
cloned	O
and	O
expressed	O
cDNAs	O
encoding	O
human	O
TAFII80	O
and	O
TAFII31	O
.	O

Coimmunoprecipitation	O
assays	O
showed	O
that	O
TAFII80	O
interacted	O
with	O
TAFII250	O
,	O
TAFII31	O
,	O
TAFII20	O
,	O
and	O
TBP	O
,	O
but	O
not	O
with	O
TAFII55	O
.	O

Similar	O
assays	O
showed	O
that	O
TAFII80	O
interacted	O
with	O
TFIIE	O
alpha	O
and	O
with	O
TFIIF	O
alpha	O
(	O
RAP74	O
)	O
but	O
not	O
with	O
TFIIB	O
,	O
TFIIE	O
beta	O
,	O
or	O
TFIIF	O
beta	O
(	O
RAP30	O
)	O
.	O

Further	O
studies	O
with	O
TAFII80	O
mutations	O
revealed	O
three	O
distinct	O
interaction	O
domains	O
which	O
fall	O
within	O
regions	O
conserved	O
in	O
human	O
TAFII80	O
,	O
Drosophila	O
TAFII60	O
,	O
and	O
yeast	O
TAFII60	O
.	O

The	O
N	O
terminus	O
of	O
TAFII80	O
(	O
residues	O
1	O
-	O
100	O
)	O
interacts	O
with	O
both	O
TAFII31	O
and	O
TAFII20	O
,	O
while	O
two	O
C	O
-	O
terminal	O
regions	O
are	O
involved	O
,	O
respectively	O
,	O
in	O
interactions	O
with	O
TAFII250	O
and	O
TFIIF	O
alpha	O
(	O
RAP74	O
)	O
(	O
residues	O
203	O
-	O
276	O
)	O
and	O
with	O
TBP	O
and	O
TFIIE	O
alpha	O
(	O
residues	O
377	O
-	O
505	O
)	O
.	O

The	O
interactions	O
between	O
TAFII80	O
and	O
general	O
factors	O
TFIIE	O
alpha	O
and	O
TFIIF	O
alpha	O
(	O
RAP74	O
)	O
could	O
be	O
important	O
for	O
recruitment	O
of	O
GTFs	O
during	O
activator	O
-	O
dependent	O
transcription	O
.	O

Because	O
TAFs	O
80	O
,	O
31	O
,	O
and	O
20	O
show	O
sequence	O
similarities	O
to	O
histones	O
H4	O
,	O
H3	O
,	O
and	O
H2B	O
,	O
as	O
well	O
as	O
some	O
parallel	O
interactions	O
,	O
this	O
subset	O
of	O
TAFs	O
may	O
form	O
a	O
related	O
core	O
structure	O
within	O
TFIID	B-Complex
.	O

Fatty	O
acylation	O
of	O
the	O
rat	O
asialoglycoprotein	O
receptor	O
.	O

The	O
three	O
subunits	O
from	O
active	O
receptors	O
contain	O
covalently	O
bound	O
palmitate	O
and	O
stearate	O
.	O

Rat	O
hepatic	O
asialoglycoprotein	O
receptors	O
(	O
ASGP	O
-	O
Rs	O
)	O
are	O
hetero	O
-	O
oligomers	O
composed	O
of	O
three	O
homologous	O
glycoprotein	O
subunits	O
,	O
designated	O
rat	O
hepatic	O
lectins	O
(	O
RHL	O
)	O
1	O
,	O
2	O
,	O
and	O
3	O
.	O

ASGP	O
-	O
Rs	O
mediate	O
the	O
endocytosis	O
and	O
degradation	O
of	O
circulating	O
glycoconjugates	O
containing	O
terminal	O
N	O
-	O
acetylgalactosamine	O
or	O
galactose	O
,	O
including	O
desialylated	O
plasma	O
glycoproteins	O
.	O

We	O
have	O
shown	O
in	O
permeable	O
rat	O
hepatocytes	O
that	O
the	O
ligand	O
binding	O
activity	O
of	O
one	O
subpopulation	O
of	O
receptors	O
(	O
designated	O
State	O
2	O
ASGP	O
-	O
Rs	O
)	O
can	O
be	O
decreased	O
or	O
increased	O
,	O
respectively	O
,	O
by	O
ATP	O
and	O
palmitoyl	O
-	O
CoA	O
(	O
Weigel	O
,	O
P	O
.	O
H	O
.	O
,	O
and	O
Oka	O
,	O
J	O
.	O
A	O
.	O
(	O
1993	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
268	O
,	O
27186	O
-	O
27190	O
)	O
.	O

We	O
proposed	O
that	O
a	O
reversible	O
and	O
cyclic	O
acylation	O
/	O
deacylation	O
process	O
may	O
regulate	O
ASGP	O
-	O
R	O
activity	O
during	O
endocytosis	O
,	O
receptor	O
-	O
ligand	O
dissociation	O
,	O
and	O
receptor	O
recycling	O
.	O

In	O
the	O
accompanying	O
paper	O
(	O
Zeng	O
,	O
F	O
-	O
Y	O
.	O
,	O
and	O
Weigel	O
,	O
P	O
.	O
H	O
.	O
(	O
1995	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
270	O
,	O
21388	O
-	O
21395	O
)	O
,	O
we	O
show	O
that	O
the	O
ligand	O
binding	O
activity	O
of	O
affinity	O
-	O
purified	O
State	O
2	O
ASGP	O
-	O
Rs	O
is	O
decreased	O
by	O
treatment	O
with	O
hydroxylamine	O
under	O
mild	O
conditions	O
consistent	O
with	O
these	O
ASGP	O
-	O
Rs	O
being	O
fatty	O
acylated	O
in	O
vivo	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
chemical	O
method	O
to	O
determine	O
the	O
presence	O
of	O
covalently	O
-	O
bound	O
fatty	O
acids	O
in	O
individual	O
ASGP	O
-	O
R	O
subunits	O
.	O

The	O
affinity	O
-	O
purified	O
ASGP	O
-	O
R	O
preparations	O
were	O
separated	O
by	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
under	O
nonreducing	O
conditions	O
,	O
and	O
the	O
gel	O
slices	O
containing	O
individual	O
RHL	O
subunits	O
were	O
treated	O
with	O
alkali	O
to	O
release	O
covalently	O
bound	O
fatty	O
acids	O
,	O
which	O
were	O
subsequently	O
analyzed	O
by	O
gas	O
chromatography	O
and	O
confirmed	O
by	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
.	O

Both	O
stearic	O
and	O
palmitic	O
acids	O
were	O
detected	O
in	O
all	O
three	O
receptor	O
subunits	O
.	O

Pretreatment	O
of	O
ASGP	O
-	O
Rs	O
with	O
hydroxylamine	O
before	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
reduced	O
the	O
content	O
of	O
both	O
fatty	O
acids	O
by	O
66	O
-	O
80	O
%	O
,	O
indicating	O
that	O
most	O
of	O
these	O
fatty	O
acids	O
are	O
attached	O
to	O
cysteine	O
residues	O
via	O
thioester	O
linkages	O
.	O

Furthermore	O
,	O
when	O
freshly	O
isolated	O
hepatocytes	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
[	O
3H	O
]	O
palmitate	O
,	O
all	O
three	O
RHL	O
subunits	O
in	O
affinity	O
-	O
purified	O
ASGP	O
-	O
Rs	O
were	O
metabolically	O
labeled	O
.	O

We	O
conclude	O
that	O
RHL1	O
,	O
RHL2	O
,	O
and	O
RHL3	O
are	O
modified	O
by	O
fatty	O
acylation	O
in	O
intact	O
cells	O
.	O

A	O
regulatory	O
element	O
in	O
the	O
human	O
interleukin	O
2	O
gene	O
promoter	O
is	O
a	O
binding	O
site	O
for	O
the	O
zinc	O
finger	O
proteins	O
Sp1	O
and	O
EGR	O
-	O
1	O
.	O

Activation	O
of	O
the	O
interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
gene	O
after	O
antigen	O
recognition	O
is	O
a	O
critical	O
event	O
for	O
T	O
cell	O
proliferation	O
and	O
effector	O
function	O
.	O

Prior	O
studies	O
have	O
identified	O
several	O
transcription	O
factors	O
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL	O
-	O
2	O
promoter	O
in	O
stimulated	O
T	O
lymphocytes	O
.	O

Here	O
we	O
describe	O
a	O
novel	O
regulatory	O
element	O
within	O
the	O
IL	O
-	O
2	O
promoter	O
located	O
immediately	O
upstream	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
(	O
NFAT	O
)	O
domain	O
.	O

This	O
region	O
(	O
termed	O
the	O
zinc	O
finger	O
protein	O
binding	O
region	O
(	O
ZIP	O
)	O
)	O
serves	O
as	O
binding	O
site	O
for	O
two	O
differently	O
regulated	O
zinc	O
finger	O
proteins	O
:	O
the	O
constitutively	O
expressed	O
transcription	O
factor	O
Sp1	O
and	O
the	O
inducible	O
early	O
growth	O
response	O
protein	O
EGR	O
-	O
1	O
.	O

In	O
unstimulated	O
cells	O
which	O
do	O
not	O
secrete	O
IL	O
-	O
2	O
,	O
only	O
Sp1	O
binds	O
to	O
this	O
region	O
,	O
while	O
in	O
stimulated	O
IL	O
-	O
2	O
secreting	O
cells	O
the	O
inducible	O
EGR	O
-	O
1	O
protein	O
recognizes	O
this	O
element	O
.	O

In	O
Jurkat	O
T	O
cells	O
,	O
the	O
ZIP	O
site	O
serves	O
as	O
an	O
activator	O
for	O
IL	O
-	O
2	O
gene	O
expression	O
,	O
and	O
a	O
combination	O
of	O
ZIP	O
and	O
NFAT	O
binding	O
sites	O
is	O
required	O
for	O
maximal	O
IL	O
-	O
2	O
promoter	O
activity	O
.	O

These	O
results	O
suggest	O
a	O
critical	O
role	O
of	O
the	O
ZIP	O
site	O
for	O
IL	O
-	O
2	O
promoter	O
activity	O
.	O

Multiple	O
cytokines	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
Shc	O
and	O
its	O
association	O
with	O
Grb2	O
in	O
hemopoietic	O
cells	O
.	O

The	O
identification	O
and	O
characterization	O
of	O
proteins	O
that	O
become	O
tyrosine	O
-	O
phosphorylated	O
in	O
response	O
to	O
growth	O
factor	O
stimulation	O
is	O
critical	O
to	O
furthering	O
our	O
understanding	O
of	O
the	O
signal	O
transduction	O
pathways	O
involved	O
in	O
regulating	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
interleukin	O
-	O
3	O
,	O
erythropoietin	O
,	O
and	O
steel	O
factor	O
all	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
the	O
SH2	O
containing	O
protein	O
,	O
p52shc	O
.	O

These	O
studies	O
were	O
carried	O
out	O
with	O
various	O
human	O
and	O
murine	O
cell	O
lines	O
to	O
document	O
that	O
this	O
is	O
a	O
common	O
event	O
in	O
hemopoietic	O
cells	O
.	O

We	O
also	O
show	O
that	O
upon	O
tyrosine	O
phosphorylation	O
,	O
p52shc	O
becomes	O
associated	O
with	O
the	O
adaptor	O
protein	O
,	O
Grb2	O
.	O

The	O
formation	O
of	O
this	O
complex	O
may	O
directly	O
link	O
tyrosine	O
phosphorylation	O
events	O
to	O
Ras	O
activation	O
in	O
hemopoietic	O
progenitors	O
and	O
may	O
be	O
a	O
critical	O
step	O
in	O
stimulating	O
these	O
cells	O
to	O
transit	O
through	O
G1	O
into	O
S	O
phase	O
.	O

Functional	O
characterization	O
of	O
novel	O
IL	O
-	O
2	O
transcriptional	O
inhibitors	O
.	O

IL	O
-	O
2	O
-	O
mediated	O
T	O
cell	O
proliferation	O
is	O
a	O
critical	O
early	O
event	O
in	O
the	O
inflammatory	O
process	O
.	O

Formation	O
of	O
the	O
NFAT	O
-	O
1	O
transcriptional	O
complex	O
on	O
the	O
IL	O
-	O
2	O
promoter	O
is	O
essential	O
for	O
IL	O
-	O
2	O
transcription	O
.	O

Using	O
a	O
cell	O
line	O
that	O
is	O
stably	O
transfected	O
with	O
a	O
trimer	O
of	O
the	O
NFAT	O
-	O
1	O
regulatory	O
element	O
linked	O
to	O
a	O
lac	O
-	O
Z	O
reporter	O
gene	O
,	O
we	O
screened	O
for	O
inhibitors	O
of	O
NFAT	O
-	O
1	O
-	O
mediated	O
beta	O
-	O
galactosidase	O
activity	O
.	O

WIN	O
61058	O
and	O
WIN	O
53071	O
were	O
identified	O
as	O
microM	O
inhibitors	O
.	O

These	O
compounds	O
also	O
inhibited	O
beta	O
-	O
galactosidase	O
mRNA	O
levels	O
.	O

Similar	O
inhibition	O
of	O
NFAT	O
-	O
1	O
-	O
mediated	O
gene	O
expression	O
was	O
observed	O
in	O
a	O
second	O
cell	O
line	O
,	O
which	O
is	O
stably	O
transfected	O
with	O
NFAT	O
-	O
1	O
regulatory	O
elements	O
linked	O
to	O
the	O
reporter	O
gene	O
for	O
sCD8	O
.	O

At	O
10	O
microM	O
,	O
both	O
compounds	O
inhibited	O
IL	O
-	O
2	O
mRNA	O
and	O
protein	O
levels	O
in	O
the	O
NFAT	O
-	O
1	O
-	O
linked	O
lac	O
-	O
Z	O
transfectants	O
,	O
and	O
in	O
human	O
lymphocytes	O
.	O

Both	O
compounds	O
inhibited	O
the	O
mixed	O
lymphocyte	O
reaction	O
,	O
and	O
this	O
inhibition	O
was	O
reversed	O
by	O
exogenous	O
IL	O
-	O
2	O
.	O

WIN	O
53071	O
inhibited	O
IL	O
-	O
2	O
production	O
induced	O
in	O
the	O
calcium	O
-	O
dependent	O
PMA	O
and	O
ionomycin	O
pathway	O
.	O

Conversely	O
,	O
calcium	O
-	O
independent	O
anti	O
-	O
CD28	O
Ab	O
and	O
PMA	O
-	O
induced	O
IL	O
-	O
2	O
production	O
was	O
resistant	O
.	O

Both	O
compounds	O
altered	O
the	O
NFAT	O
-	O
1	O
transcriptional	O
complex	O
,	O
causing	O
its	O
retarded	O
mobility	O
on	O
gels	O
.	O

By	O
these	O
functional	O
criteria	O
,	O
we	O
believe	O
we	O
have	O
identified	O
two	O
structurally	O
distinct	O
,	O
novel	O
inhibitors	O
of	O
NFAT	O
-	O
1	O
-	O
mediated	O
transcription	O
.	O

Increased	O
ubiquitin	O
expression	O
suppresses	O
the	O
cell	O
cycle	O
defect	O
associated	O
with	O
the	O
yeast	O
ubiquitin	O
conjugating	O
enzyme	O
,	O
CDC34	O
(	O
UBC3	O
)	O
.	O

Evidence	O
for	O
a	O
noncovalent	O
interaction	O
between	O
CDC34	O
and	O
ubiquitin	O
.	O

The	O
yeast	O
ubiquitin	O
(	O
Ub	O
)	O
conjugating	O
enzyme	O
CDC34	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
progression	O
of	O
the	O
cell	O
cycle	O
from	O
the	O
G1	O
to	O
S	O
phase	O
.	O

In	O
an	O
effort	O
to	O
identify	O
proteins	O
that	O
interact	O
with	O
CDC34	O
we	O
undertook	O
a	O
genetic	O
screen	O
to	O
isolate	O
genes	O
whose	O
increased	O
expression	O
suppressed	O
the	O
cell	O
cycle	O
defect	O
associated	O
with	O
the	O
cdc34	O
-	O
2	O
temperature	O
-	O
sensitive	O
allele	O
.	O

From	O
this	O
screen	O
,	O
the	O
poly	O
-	O
Ub	O
gene	O
UBI4	O
was	O
identified	O
as	O
a	O
moderately	O
strong	O
suppressor	O
.	O

The	O
fact	O
that	O
the	O
overexpression	O
of	O
a	O
gene	O
encoding	O
a	O
single	O
Ub	O
protein	O
could	O
also	O
suppress	O
the	O
cdc34	O
-	O
2	O
allele	O
indicated	O
that	O
suppression	O
was	O
related	O
to	O
the	O
increased	O
abundance	O
of	O
Ub	O
.	O

Ub	O
overexpression	O
was	O
found	O
to	O
suppress	O
two	O
other	O
structurally	O
unrelated	O
cdc34	O
mutations	O
,	O
in	O
addition	O
to	O
the	O
cdc34	O
-	O
2	O
allele	O
.	O

In	O
all	O
three	O
cases	O
,	O
suppression	O
depended	O
on	O
the	O
expression	O
of	O
Ub	O
with	O
an	O
intact	O
carboxyl	O
terminus	O
.	O

Only	O
the	O
cdc34	O
-	O
2	O
allele	O
,	O
however	O
,	O
could	O
be	O
suppressed	O
by	O
Ub	O
with	O
an	O
amino	O
acid	O
substitution	O
at	O
lysine	O
48	O
which	O
is	O
known	O
to	O
be	O
involved	O
in	O
multi	O
-	O
Ub	O
chain	O
assembly	O
.	O

Genetic	O
results	O
showing	O
allele	O
specific	O
suppression	O
of	O
cdc34	O
mutations	O
by	O
various	O
Ub	O
derivatives	O
suggested	O
a	O
specific	O
noncovalent	O
interaction	O
between	O
Ub	O
and	O
CDC34	O
.	O

Consistent	O
with	O
this	O
prediction	O
,	O
we	O
have	O
shown	O
by	O
chemical	O
cross	O
-	O
linking	O
the	O
existence	O
of	O
a	O
specific	O
noncovalent	O
Ub	O
binding	O
site	O
on	O
CDC34	O
.	O

Together	O
,	O
these	O
genetic	O
and	O
biochemical	O
experiments	O
indicate	O
that	O
Ub	O
suppression	O
of	O
these	O
cdc34	O
mutations	O
results	O
from	O
the	O
combined	O
contributions	O
of	O
Ub	O
-	O
CDC34	O
thiol	O
ester	O
formation	O
and	O
a	O
noncovalent	O
interaction	O
between	O
Ub	O
and	O
CDC34	O
and	O
therefore	O
suggest	O
that	O
the	O
correct	O
positioning	O
of	O
Ub	O
on	O
a	O
surface	O
of	O
the	O
ubiquitin	O
conjugating	O
enzyme	O
is	O
a	O
requirement	O
of	O
enzyme	O
function	O
.	O

Activation	O
of	O
transcription	O
by	O
binding	O
of	O
NF	O
-	O
E1	O
(	O
YY1	O
)	O
to	O
a	O
newly	O
identified	O
element	O
in	O
the	O
first	O
exon	O
of	O
the	O
human	O
DR	O
alpha	O
gene	O
.	O

A	O
previously	O
unrecognized	O
element	O
,	O
located	O
downstream	O
of	O
the	O
start	O
site	O
of	O
transcription	O
in	O
the	O
first	O
exon	O
of	O
the	O
DR	O
alpha	O
gene	O
,	O
has	O
been	O
defined	O
that	O
enhances	O
promoter	O
activity	O
up	O
to	O
eightfold	O
in	O
a	O
position	O
-	O
dependent	O
manner	O
.	O

Mutations	O
in	O
this	O
DNA	O
-	O
binding	O
site	O
abolished	O
binding	O
of	O
a	O
nuclear	O
factor	O
in	O
human	O
B	O
cell	O
nuclear	O
extract	O
and	O
decreased	O
the	O
activity	O
of	O
the	O
DR	O
alpha	O
promoter	O
to	O
a	O
basal	O
level	O
.	O

Significant	O
sequence	O
homology	O
of	O
this	O
element	O
was	O
found	O
in	O
the	O
DNA	O
of	O
the	O
DR	O
beta	O
,	O
DP	O
alpha	O
and	O
-	O
beta	O
,	O
and	O
DQ	O
alpha	O
genes	O
,	O
always	O
located	O
downstream	O
of	O
the	O
transcriptional	O
start	O
site	O
.	O

The	O
nuclear	O
factor	O
binds	O
to	O
the	O
DR	O
alpha	O
and	O
DP	O
alpha	O
element	O
but	O
not	O
to	O
the	O
element	O
in	O
the	O
DQ	O
alpha	O
gene	O
.	O

It	O
was	O
identified	O
as	O
NF	O
-	O
E1	O
(	O
YY1	O
)	O
.	O

This	O
protein	O
,	O
previously	O
identified	O
by	O
its	O
binding	O
to	O
the	O
Ig	O
kappa	O
3	O
'	O
enhancer	O
and	O
the	O
Ig	O
heavy	O
chain	O
mu	O
E1	O
site	O
,	O
thus	O
also	O
appears	O
to	O
be	O
quite	O
important	O
in	O
the	O
regulation	O
of	O
MHC	B-Complex
class	I-Complex
II	I-Complex
gene	O
expression	O
.	O

The	O
Saccharomyces	O
cerevisiae	O
gene	O
SDS22	O
encodes	O
a	O
potential	O
regulator	O
of	O
the	O
mitotic	O
function	O
of	O
yeast	O
type	B-Complex
1	I-Complex
protein	I-Complex
phosphatase	I-Complex
.	O

In	O
higher	O
eukaryotes	O
,	O
the	O
activity	O
and	O
specificity	O
of	O
the	O
type	B-Complex
1	I-Complex
protein	I-Complex
serine	I-Complex
-	I-Complex
threonine	I-Complex
phosphatase	I-Complex
(	O
PP1	B-Complex
)	O
catalytic	O
subunit	O
is	O
thought	O
to	O
be	O
controlled	O
by	O
its	O
association	O
with	O
a	O
number	O
of	O
regulatory	O
or	O
targeting	O
subunits	O
.	O

Here	O
we	O
describe	O
the	O
characterization	O
of	O
a	O
gene	O
encoding	O
one	O
such	O
potential	O
polypeptide	O
in	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
.	O

The	O
gene	O
which	O
we	O
have	O
isolated	O
(	O
termed	O
SDS22	O
)	O
encodes	O
a	O
product	O
with	O
a	O
high	O
degree	O
of	O
sequence	O
identity	O
to	O
the	O
fission	O
yeast	O
sds22	O
protein	O
,	O
a	O
known	O
regulator	O
of	O
the	O
mitotic	O
function	O
of	O
PP1	B-Complex
in	O
Schizosaccharomyces	O
pombe	O
.	O

Using	O
two	O
different	O
criteria	O
,	O
we	O
have	O
demonstrated	O
that	O
Sds22p	O
and	O
the	O
catalytic	O
subunit	O
of	O
PP1	B-Complex
(	O
Glc7p	O
)	O
interact	O
in	O
yeast	O
cells	O
.	O

We	O
have	O
also	O
generated	O
a	O
temperature	O
-	O
sensitive	O
allele	O
of	O
GLC7	O
(	O
glc7	O
-	O
12	O
)	O
which	O
causes	O
a	O
block	O
to	O
the	O
completion	O
of	O
mitosis	O
at	O
the	O
restrictive	O
temperature	O
.	O

Additional	O
copies	O
of	O
SDS22	O
lead	O
to	O
allele	O
-	O
specific	O
suppression	O
of	O
the	O
glc7	O
-	O
12	O
mutant	O
,	O
strongly	O
suggesting	O
that	O
the	O
interaction	O
between	O
the	O
two	O
proteins	O
is	O
of	O
functional	O
significance	O
.	O

Sds22p	O
is	O
therefore	O
likely	O
to	O
be	O
the	O
second	O
example	O
of	O
a	O
PP1	B-Complex
regulatory	O
subunit	O
identified	O
in	O
S	O
.	O
cerevisiae	O
.	O

ADP	O
-	O
ribosylation	O
of	O
Rhizobium	O
meliloti	O
glutamine	O
synthetase	O
III	O
in	O
vivo	O
.	O

The	O
control	O
of	O
glutamine	O
synthetase	O
(	O
GS	O
)	O
,	O
the	O
first	O
enzyme	O
in	O
the	O
main	O
pathway	O
used	O
by	O
Rhizobium	O
meliloti	O
to	O
assimilate	O
ammonia	O
,	O
is	O
central	O
to	O
cellular	O
nitrogen	O
metabolism	O
.	O

R	O
.	O
meliloti	O
is	O
unusual	O
in	O
having	O
three	O
distinct	O
types	O
of	O
GS	O
,	O
including	O
a	O
unique	O
GS	O
,	O
GSIII	O
,	O
that	O
differs	O
considerably	O
from	O
both	O
GSI	O
,	O
which	O
resembles	O
other	O
bacterial	O
GS	O
proteins	O
and	O
GSII	O
,	O
which	O
resembles	O
the	O
GS	O
found	O
in	O
eukaryotes	O
.	O

We	O
show	O
here	O
that	O
GSIII	O
can	O
be	O
post	O
-	O
translationally	O
modified	O
in	O
vivo	O
by	O
ADP	O
-	O
ribosylation	O
at	O
an	O
arginine	O
residue	O
.	O

32PO4	O
attached	O
to	O
GSIII	O
during	O
bacterial	O
growth	O
as	O
part	O
of	O
the	O
modifying	O
group	O
could	O
be	O
removed	O
by	O
treatment	O
with	O
snake	O
venom	O
phosphodiesterase	O
or	O
by	O
turkey	O
erythrocyte	O
ADP	O
-	O
ribosylarginine	O
hydrolase	O
.	O

Treatment	O
of	O
modified	O
GSIII	O
with	O
hydroxylamine	O
at	O
neutral	O
pH	O
releases	O
a	O
chromophore	O
that	O
has	O
the	O
retention	O
time	O
of	O
ADP	O
-	O
ribose	O
when	O
analyzed	O
by	O
reversed	O
-	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
.	O

ADP	O
-	O
ribosylation	O
inhibits	O
GSIII	O
activity	O
.	O

Biphasic	O
control	O
of	O
nuclear	B-Complex
factor	I-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
activation	O
by	O
the	O
T	B-Complex
cell	I-Complex
receptor	I-Complex
complex	O
:	O
role	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
.	O

The	O
regulation	O
of	O
nuclear	B-Complex
factor	I-Complex
(	I-Complex
NF	I-Complex
)	I-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
activation	O
by	O
the	O
T	B-Complex
cell	I-Complex
receptor	I-Complex
(	O
TcR	B-Complex
)	O
/	O
CD3	O
complex	O
in	O
primary	O
human	O
T	O
cells	O
has	O
been	O
studied	O
at	O
various	O
times	O
after	O
activation	O
.	O

Only	O
p50	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
protein	O
bound	O
the	O
kappa	B-Complex
B	I-Complex
element	O
of	O
interleukin	O
-	O
2	O
receptor	O
(	O
IL	O
-	O
2R	O
)	O
alpha	O
chain	O
promoter	O
on	O
resting	O
T	O
cells	O
.	O

However	O
,	O
immediately	O
after	O
TcR	B-Complex
/	O
CD3	O
cross	O
-	O
linking	O
(	O
after	O
approximately	O
1	O
h	O
;	O
immediate	O
)	O
binding	O
of	O
p50	O
.	O
p65	O
heterodimers	O
was	O
observed	O
.	O

p50	O
.	O
c	O
-	O
rel	O
heterodimers	O
were	O
also	O
detected	O
bound	O
to	O
this	O
sequence	O
at	O
early	O
time	O
points	O
(	O
7	O
-	O
16	O
h	O
;	O
early	O
)	O
,	O
and	O
both	O
remained	O
active	O
at	O
later	O
time	O
points	O
(	O
40	O
h	O
;	O
late	O
)	O
after	O
activation	O
.	O

This	O
regulation	O
takes	O
place	O
mainly	O
at	O
the	O
level	O
of	O
nuclear	O
translocation	O
of	O
p65	O
and	O
c	O
-	O
rel	O
,	O
at	O
immediate	O
and	O
early	O
time	O
points	O
.	O

Activation	O
also	O
induced	O
c	O
-	O
rel	O
and	O
p105	O
/	O
p50	O
mRNA	O
synthesis	O
,	O
but	O
not	O
p65	O
mRNA	O
whose	O
expression	O
was	O
constitutive	O
.	O

Interestingly	O
,	O
all	O
those	O
early	O
and	O
late	O
events	O
,	O
but	O
not	O
the	O
immediate	O
ones	O
,	O
were	O
inhibited	O
by	O
a	O
neutralizing	O
anti	O
-	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
monoclonal	O
antibody	O
.	O

Similarly	O
,	O
cycloheximide	O
prevented	O
the	O
p65	O
and	O
c	O
-	O
rel	O
translocation	O
and	O
consequent	O
formation	O
of	O
active	O
binding	O
heterodimers	O
,	O
at	O
early	O
and	O
late	O
times	O
.	O

Cyclosporin	O
A	O
impaired	O
not	O
only	O
early	O
and	O
late	O
,	O
but	O
also	O
immediate	O
events	O
;	O
however	O
,	O
addition	O
of	O
TNF	O
-	O
alpha	O
prevented	O
all	O
inhibition	O
.	O

These	O
results	O
indicate	O
that	O
the	O
regulation	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
activation	O
during	O
T	O
cell	O
activation	O
by	O
TcR	B-Complex
/	O
CD3	O
signals	O
is	O
biphasic	O
:	O
TcR	B-Complex
/	O
CD3	O
triggers	O
its	O
immediate	O
translocation	O
,	O
which	O
is	O
transient	O
if	O
no	O
TNF	O
-	O
alpha	O
is	O
present	O
.	O

TNF	O
-	O
alpha	O
,	O
therefore	O
,	O
emerges	O
as	O
the	O
main	O
factor	O
responsible	O
for	O
a	O
second	O
phase	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
regulation	O
,	O
controlling	O
both	O
translocation	O
of	O
p65	O
and	O
c	O
-	O
rel	O
,	O
and	O
new	O
mRNA	O
synthesis	O
for	O
c	O
-	O
rel	O
and	O
p105	O
/	O
p50	O
.	O

Association	O
of	O
alterations	O
in	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
moieties	O
with	O
HIV	O
type	O
1	O
proviral	O
latency	O
in	O
certain	O
monocytic	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
-	O
1	O
)	O
replication	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
virally	O
encoded	O
and	O
cellular	O
proteins	O
.	O

A	O
wide	O
spectrum	O
of	O
levels	O
of	O
HIV	O
-	O
1	O
expression	O
have	O
been	O
demonstrated	O
in	O
various	O
cells	O
,	O
both	O
in	O
cell	O
culture	O
and	O
in	O
vivo	O
.	O

Molecular	O
mechanisms	O
leading	O
to	O
restricted	O
HIV	O
-	O
1	O
replication	O
may	O
differ	O
between	O
certain	O
cell	O
types	O
.	O

It	O
is	O
now	O
demonstrated	O
that	O
HIV	O
-	O
1	O
proviral	O
latency	O
in	O
the	O
monocytic	O
cell	O
line	O
U1	O
,	O
in	O
which	O
only	O
extremely	O
low	O
levels	O
of	O
HIV	O
-	O
1	O
expression	O
are	O
detected	O
in	O
the	O
baseline	O
unstimulated	O
state	O
,	O
is	O
associated	O
with	O
alterations	O
in	O
nuclear	B-Complex
factor	I-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
(	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
)	O
moieties	O
demonstrated	O
in	O
these	O
cells	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
and	O
in	O
situ	O
UV	O
cross	O
-	O
linking	O
studies	O
.	O

A	O
predominance	O
of	O
p50	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
moieties	O
and	O
possibly	O
p50	O
homodimers	O
or	O
closely	O
related	O
species	O
,	O
rather	O
than	O
the	O
p50	O
-	O
p56	O
heterodimer	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
that	O
is	O
the	O
predominant	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
species	O
in	O
most	O
T	O
lymphocytic	O
and	O
monocytic	O
cells	O
,	O
is	O
demonstrated	O
in	O
the	O
nuclei	O
of	O
U1	O
cells	O
.	O

This	O
pattern	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
-	O
related	O
moieties	O
differs	O
from	O
the	O
latently	O
infected	O
T	O
lymphocytic	O
cell	O
line	O
ACH	O
-	O
2	O
,	O
and	O
from	O
the	O
U937	O
monocytic	O
line	O
,	O
the	O
parental	O
cell	O
line	O
of	O
the	O
U1	O
cellular	O
clone	O
.	O

As	O
such	O
,	O
these	O
data	O
suggest	O
that	O
different	O
proximal	O
mechanisms	O
may	O
lead	O
to	O
restricted	O
HIV	O
-	O
1	O
replication	O
in	O
various	O
cell	O
types	O
.	O

OBF	O
-	O
1	O
,	O
a	O
novel	O
B	O
cell	O
-	O
specific	O
coactivator	O
that	O
stimulates	O
immunoglobulin	B-OOS
promoter	O
activity	O
through	O
association	O
with	O
octamer	O
-	O
binding	O
proteins	O
.	O

Recent	O
biochemical	O
and	O
genetic	O
studies	O
indicate	O
that	O
in	O
addition	O
to	O
the	O
octamer	O
-	O
binding	O
proteins	O
Oct	O
-	O
1	O
and	O
Oct	O
-	O
2	O
,	O
other	O
B	O
cell	O
components	O
are	O
required	O
for	O
lymphoid	O
-	O
restricted	O
,	O
octamer	O
site	O
-	O
mediated	O
immunoglobulin	B-OOS
gene	O
promoter	O
activity	O
.	O

Using	O
a	O
genetic	O
screen	O
in	O
yeast	O
,	O
we	O
have	O
isolated	O
B	O
cell	O
-	O
derived	O
cDNAs	O
encoding	O
Oct	O
-	O
binding	O
factor	O
1	O
(	O
OBF	O
-	O
1	O
)	O
,	O
a	O
novel	O
protein	O
that	O
specifically	O
associates	O
with	O
Oct	O
-	O
1	O
and	O
Oct	O
-	O
2	O
.	O

Biochemical	O
studies	O
demonstrate	O
that	O
OBF	O
-	O
1	O
has	O
no	O
intrinsic	O
DNA	O
-	O
binding	O
activity	O
and	O
recognizes	O
the	O
POU	O
domains	O
of	O
Oct	O
-	O
1	O
and	O
Oct	O
-	O
2	O
,	O
but	O
not	O
those	O
of	O
Oct	O
-	O
4	O
and	O
Oct	O
-	O
6	O
.	O

The	O
OBF	O
-	O
1	O
mRNA	O
is	O
expressed	O
in	O
a	O
highly	O
cell	O
-	O
specific	O
manner	O
,	O
being	O
most	O
abundant	O
in	O
B	O
cells	O
and	O
essentially	O
absent	O
in	O
most	O
of	O
the	O
other	O
cells	O
or	O
tissues	O
tested	O
.	O

Furthermore	O
,	O
expression	O
of	O
OBF	O
-	O
1	O
in	O
HeLa	O
cells	O
selectively	O
stimulates	O
the	O
activity	O
of	O
a	O
natural	O
immunoglobulin	B-OOS
promoter	O
in	O
an	O
octamer	O
site	O
-	O
dependent	O
manner	O
.	O

Thus	O
,	O
OBF	O
-	O
1	O
has	O
all	O
the	O
properties	O
expected	O
for	O
a	O
B	O
cell	O
-	O
specific	O
transcriptional	O
coactivator	O
protein	O
.	O

Regulation	O
of	O
cell	O
-	O
type	O
-	O
specific	O
interleukin	O
-	O
2	O
receptor	O
alpha	O
-	O
chain	O
gene	O
expression	O
:	O
potential	O
role	O
of	O
physical	O
interactions	O
between	O
Elf	O
-	O
1	O
,	O
HMG	O
-	O
I	O
(	O
Y	O
)	O
,	O
and	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
family	O
proteins	O
.	O

The	O
interleukin	O
2	O
receptor	O
alpha	O
-	O
chain	O
(	O
IL	O
-	O
2R	O
alpha	O
)	O
gene	O
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	O
cells	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O

Previously	O
,	O
an	O
inducible	O
enhancer	O
between	O
nucleotides	O
-	O
299	O
and	O
-	O
228	O
that	O
contains	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
and	O
CArG	O
motifs	O
was	O
identified	O
.	O

We	O
now	O
report	O
the	O
characterization	O
of	O
a	O
second	O
essential	O
positive	O
regulatory	O
element	O
located	O
between	O
nucleotides	O
-	O
137	O
and	O
-	O
64	O
that	O
binds	O
Elf	O
-	O
1	O
and	O
HMG	O
-	O
I	O
(	O
Y	O
)	O
.	O

This	O
element	O
had	O
maximal	O
activity	O
in	O
lymphoid	O
cells	O
,	O
paralleling	O
the	O
cell	O
type	O
specificity	O
of	O
Elf	O
-	O
1	O
expression	O
.	O

Transcription	O
from	O
the	O
IL	O
-	O
2R	O
alpha	O
promoter	O
was	O
inhibited	O
when	O
either	O
the	O
Elf	O
-	O
1	O
or	O
the	O
HMG	O
-	O
I	O
(	O
Y	O
)	O
binding	O
site	O
was	O
mutated	O
.	O

Coexpression	O
of	O
both	O
proteins	O
activated	O
transcription	O
of	O
the	O
-	O
137	O
to	O
-	O
64	O
element	O
in	O
COS	O
-	O
7	O
cells	O
.	O

Elf	O
-	O
1	O
physically	O
associated	O
with	O
HMG	O
-	O
I	O
and	O
with	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p50	O
and	O
c	O
-	O
Rel	O
in	O
vitro	O
,	O
suggesting	O
that	O
protein	O
-	O
protein	O
interactions	O
might	O
functionally	O
coordinate	O
the	O
actions	O
of	O
the	O
upstream	O
and	O
downstream	O
positive	O
regulatory	O
elements	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
physical	O
interaction	O
between	O
an	O
Ets	O
family	O
member	O
and	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
family	O
proteins	O
.	O

These	O
findings	O
provide	O
significant	O
new	O
insights	O
into	O
the	O
protein	O
-	O
protein	O
and	O
protein	O
-	O
DNA	O
interactions	O
that	O
regulate	O
cell	O
-	O
type	O
-	O
specific	O
and	O
inducible	O
IL	O
-	O
2R	O
alpha	O
gene	O
expression	O
and	O
also	O
have	O
implications	O
for	O
other	O
genes	O
regulated	O
by	O
Elf	O
-	O
1	O
and	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
family	O
proteins	O
.	O

Purification	O
and	O
properties	O
of	O
a	O
palmitoyl	O
-	O
protein	O
thioesterase	O
that	O
cleaves	O
palmitate	O
from	O
H	O
-	O
Ras	O
.	O

H	O
-	O
Ras	O
,	O
the	O
protein	O
product	O
of	O
the	O
cellular	O
homologue	O
of	O
the	O
Harvey	O
ras	O
oncogene	O
,	O
undergoes	O
a	O
complex	O
series	O
of	O
post	O
-	O
translational	O
modifications	O
that	O
include	O
C	O
-	O
terminal	O
isoprenylation	O
,	O
proteolysis	O
,	O
methylation	O
,	O
and	O
palmitoylation	O
.	O

Palmitoylation	O
has	O
been	O
shown	O
to	O
enhance	O
the	O
transformation	O
efficiency	O
of	O
H	O
-	O
Ras	O
about	O
10	O
-	O
fold	O
in	O
vivo	O
.	O

A	O
recent	O
study	O
(	O
Magee	O
,	O
A	O
.	O
I	O
.	O
,	O
Gutierrez	O
,	O
L	O
.	O
,	O
McKay	O
,	O
I	O
.	O
A	O
.	O
,	O
Marshall	O
,	O
C	O
.	O
J	O
.	O
,	O
and	O
Hall	O
,	O
A	O
.	O
(	O
1987	O
)	O
EMBO	O
J	O
.	O
6	O
,	O
3353	O
-	O
3357	O
)	O
has	O
provided	O
strong	O
evidence	O
that	O
the	O
palmitate	O
undergoes	O
a	O
dynamic	O
acylation	O
-	O
deacylation	O
cycle	O
,	O
but	O
details	O
concerning	O
the	O
enzymology	O
of	O
this	O
process	O
and	O
its	O
regulation	O
are	O
lacking	O
.	O

To	O
begin	O
to	O
dissect	O
this	O
event	O
,	O
we	O
have	O
developed	O
an	O
assay	O
for	O
the	O
enzymatic	O
removal	O
of	O
palmitate	O
from	O
[	O
3H	O
]	O
palmitate	O
-	O
labeled	O
H	O
-	O
Ras	O
.	O

This	O
substrate	O
was	O
produced	O
in	O
a	O
baculovirus	O
expression	O
system	O
and	O
was	O
used	O
to	O
purify	O
to	O
homogeneity	O
a	O
novel	O
37	O
-	O
kDa	O
enzyme	O
from	O
bovine	O
brain	O
cytosol	O
that	O
removes	O
the	O
radiolabeled	O
palmitate	O
.	O

The	O
purified	O
enzyme	O
is	O
sensitive	O
to	O
diethyl	O
pyrocarbonate	O
and	O
insensitive	O
to	O
phenylmethylsulfonyl	O
fluoride	O
and	O
N	O
-	O
ethylmaleimide	O
.	O

Interestingly	O
,	O
the	O
thioesterase	O
recognizes	O
H	O
-	O
Ras	O
as	O
a	O
substrate	O
only	O
when	O
H	O
-	O
Ras	O
is	O
in	O
its	O
native	O
conformation	O
(	O
bound	O
to	O
Mg2	O
+	O
and	O
guanine	O
nucleotide	O
)	O
.	O

The	O
palmitoylated	O
alpha	O
subunits	O
of	O
the	O
heterotrimeric	O
G	O
proteins	O
are	O
also	O
substrates	O
for	O
the	O
enzyme	O
.	O

ERP	O
,	O
a	O
new	O
member	O
of	O
the	O
ets	O
transcription	O
factor	O
/	O
oncoprotein	O
family	O
:	O
cloning	O
,	O
characterization	O
,	O
and	O
differential	O
expression	O
during	O
B	O
-	O
lymphocyte	O
development	O
.	O

The	O
ets	O
gene	O
family	O
encodes	O
a	O
group	O
of	O
proteins	O
which	O
function	O
as	O
transcription	O
factors	O
under	O
physiological	O
conditions	O
and	O
,	O
if	O
aberrantly	O
expressed	O
,	O
can	O
cause	O
cellular	O
transformation	O
.	O

We	O
have	O
recently	O
identified	O
two	O
regulatory	O
elements	O
in	O
the	O
murine	O
immunoglobulin	O
heavy	O
-	O
chain	O
(	O
IgH	O
)	O
enhancer	O
,	O
pi	O
and	O
microB	O
,	O
which	O
exhibit	O
striking	O
similarity	O
to	O
binding	O
sites	O
for	O
ets	O
-	O
related	O
proteins	O
.	O

To	O
identify	O
ets	O
-	O
related	O
transcriptional	O
regulators	O
expressed	O
in	O
pre	O
-	O
B	O
lymphocytes	O
that	O
may	O
interact	O
with	O
either	O
the	O
pi	O
or	O
the	O
microB	O
site	O
,	O
we	O
have	O
used	O
a	O
PCR	O
approach	O
with	O
degenerate	O
oligonucleotides	O
encoding	O
conserved	O
sequences	O
in	O
all	O
members	O
of	O
the	O
ets	O
family	O
.	O

We	O
have	O
cloned	O
the	O
gene	O
for	O
a	O
new	O
ets	O
-	O
related	O
transcription	O
factor	O
,	O
ERP	O
(	O
ets	O
-	O
related	O
protein	O
)	O
,	O
from	O
the	O
murine	O
pre	O
-	O
B	O
cell	O
line	O
BASC	O
6C2	O
and	O
from	O
mouse	O
lung	O
tissue	O
.	O

The	O
ERP	O
protein	O
contains	O
a	O
region	O
of	O
high	O
homology	O
with	O
the	O
ETS	O
DNA	O
-	O
binding	O
domain	O
common	O
to	O
all	O
members	O
of	O
the	O
ets	O
transcription	O
factor	O
/	O
oncoprotein	O
family	O
.	O

Three	O
additional	O
smaller	O
regions	O
show	O
homology	O
to	O
the	O
ELK	O
-	O
1	O
and	O
SAP	O
-	O
1	O
genes	O
,	O
a	O
subgroup	O
of	O
the	O
ets	O
gene	O
family	O
that	O
interacts	O
with	O
the	O
serum	O
response	O
factor	O
.	O

Full	O
-	O
length	O
ERP	O
expresses	O
only	O
negligible	O
DNA	O
-	O
binding	O
activity	O
by	O
itself	O
.	O

Removal	O
of	O
the	O
carboxy	O
terminus	O
enables	O
ERP	O
to	O
interact	O
with	O
a	O
variety	O
of	O
ets	O
-	O
binding	O
sites	O
including	O
the	O
E74	O
site	O
,	O
the	O
IgH	O
enhancer	O
pi	O
site	O
,	O
and	O
the	O
lck	O
promoter	O
ets	O
site	O
,	O
suggesting	O
a	O
carboxy	O
-	O
terminal	O
negative	O
regulatory	O
domain	O
.	O

At	O
least	O
three	O
ERP	O
-	O
related	O
transcripts	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
tissues	O
.	O

However	O
,	O
within	O
the	O
B	O
-	O
cell	O
lineage	O
,	O
ERP	O
is	O
highly	O
expressed	O
primarily	O
at	O
early	O
stages	O
of	O
B	O
-	O
lymphocyte	O
development	O
,	O
and	O
expression	O
declines	O
drastically	O
upon	O
B	O
-	O
cell	O
maturation	O
,	O
correlating	O
with	O
the	O
enhancer	O
activity	O
of	O
the	O
IgH	O
pi	O
site	O
.	O

These	O
data	O
suggest	O
that	O
ERP	O
might	O
play	O
a	O
role	O
in	O
B	O
-	O
cell	O
development	O
and	O
in	O
IgH	O
gene	O
regulation	O
.	O

Signals	O
transduced	O
through	O
the	O
CD4	O
molecule	O
on	O
T	O
lymphocytes	O
activate	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O

We	O
have	O
demonstrated	O
that	O
native	O
envelope	O
glycoproteins	O
of	O
HIV	O
-	O
1	O
,	O
gp160	O
can	O
induce	O
activation	O
of	O
the	O
transcription	O
factor	O
,	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O

The	O
stimulatory	O
effects	O
of	O
gp160	O
are	O
mediated	O
through	O
the	O
CD4	O
molecule	O
,	O
since	O
pretreatment	O
with	O
soluble	O
CD4	O
abrogates	O
its	O
activity	O
.	O

The	O
gp160	O
-	O
induced	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
complex	O
consists	O
of	O
p65	O
,	O
p50	O
and	O
c	O
-	O
rel	O
proteins	O
.	O

The	O
stimulatory	O
effect	O
of	O
gp160	O
on	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
activation	O
is	O
protein	O
synthesis	O
independent	O
,	O
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
,	O
and	O
abrogated	O
by	O
inhibitors	O
of	O
protein	O
kinase	O
C	O
.	O

The	O
gp160	O
-	O
mediated	O
activation	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
in	O
CD4	O
positive	O
T	O
cells	O
may	O
be	O
involved	O
in	O
biological	O
effects	O
,	O
e	O
.	O
g	O
.	O
,	O
enhanced	O
HIV	O
replication	O
,	O
hypergammaglobulinemia	O
,	O
increased	O
cytokine	O
secretion	O
,	O
hypercellularity	O
in	O
bone	O
marrow	O
and	O
apoptosis	O
.	O

Reactions	O
catalyzed	O
by	O
5	O
-	O
aminoimidazole	O
ribonucleotide	O
carboxylases	O
from	O
Escherichia	O
coli	O
and	O
Gallus	O
gallus	O
:	O
a	O
case	O
for	O
divergent	O
catalytic	O
mechanisms	O
.	O

A	O
comparative	O
investigation	O
of	O
the	O
substrate	O
requirements	O
for	O
the	O
enzyme	O
5	O
-	O
aminoimidazole	O
ribonucleotide	O
(	O
AIR	O
)	O
carboxylase	O
from	O
E	O
.	O
coli	O
and	O
G	O
.	O
gallus	O
has	O
been	O
conducted	O
using	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
.	O

In	O
Escherichia	O
coli	O
,	O
two	O
enzymes	O
PurK	O
and	O
PurE	O
are	O
required	O
for	O
the	O
transformation	O
of	O
AIR	O
to	O
4	O
-	O
carboxy	O
-	O
5	O
-	O
aminoimidazole	O
ribonucleotide	O
(	O
CAIR	O
)	O
.	O

The	O
Gallus	O
gallus	O
PurCE	O
is	O
a	O
bifunctional	O
enzyme	O
containing	O
AIR	O
carboxylase	O
and	O
4	O
-	O
[	O
(	O
N	O
-	O
succinylamino	O
)	O
carbonyl	O
]	O
-	O
5	O
-	O
aminoimidazole	O
ribonucleotide	O
(	O
SAICAR	O
)	O
synthetase	O
.	O

The	O
E	O
.	O
coli	O
PurE	O
and	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
G	O
.	O
gallus	O
PurCE	O
protein	O
maintain	O
a	O
significant	O
degree	O
of	O
amino	O
acid	O
sequence	O
identity	O
and	O
also	O
share	O
CAIR	O
as	O
a	O
product	O
of	O
their	O
enzymatic	O
activities	O
.	O

The	O
substrate	O
requirements	O
of	O
AIR	O
carboxylases	O
from	O
E	O
.	O
coli	O
and	O
G	O
.	O
gallus	O
have	O
been	O
compared	O
by	O
a	O
series	O
of	O
in	O
vitro	O
experiments	O
.	O

The	O
carbamic	O
acid	O
,	O
N5	O
-	O
carboxyaminoimidazole	O
ribonucleotide	O
(	O
N5	O
-	O
CAIR	O
)	O
is	O
a	O
substrate	O
for	O
the	O
E	O
.	O
coli	O
PurE	O
(	O
Mueller	O
et	O
al	O
.	O
,	O
1994	O
)	O
but	O
not	O
for	O
the	O
G	O
.	O
gallus	O
AIR	O
carboxylase	O
.	O

In	O
contrast	O
,	O
AIR	O
and	O
CO2	O
are	O
substrates	O
for	O
the	O
G	O
.	O
gallus	O
AIR	O
carboxylase	O
.	O

The	O
recognition	O
properties	O
of	O
the	O
two	O
proteins	O
were	O
also	O
compared	O
using	O
inhibition	O
studies	O
with	O
4	O
-	O
nitro	O
-	O
5	O
-	O
aminoimidazole	O
ribonucleotide	O
(	O
NAIR	O
)	O
.	O

NAIR	O
is	O
a	O
tight	O
-	O
binding	O
inhibitor	O
of	O
the	O
G	O
.	O
gallus	O
AIR	O
carboxylase	O
(	O
K	O
(	O
i	O
)	O
=	O
0	O
.	O
34	O
nM	O
)	O
but	O
only	O
a	O
steady	O
-	O
state	O
inhibitor	O
(	O
K	O
(	O
i	O
)	O
=	O
0	O
.	O
5	O
microM	O
)	O
of	O
the	O
E	O
.	O
coli	O
PurE	O
.	O

These	O
data	O
suggest	O
significant	O
differences	O
in	O
the	O
transition	O
states	O
for	O
the	O
reactions	O
catalyzed	O
by	O
these	O
two	O
evolutionarily	O
related	O
enzymes	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Regulation	O
of	O
interleukin	O
-	O
2	O
receptor	O
alpha	O
chain	O
expression	O
and	O
nuclear	B-Complex
factor	I-Complex
.	I-Complex
kappa	I-Complex
B	I-Complex
activation	O
by	O
protein	O
kinase	O
C	O
in	O
T	O
lymphocytes	O
.	O

Autocrine	O
role	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
.	O

The	O
regulation	O
of	O
interleukin	O
-	O
2	O
receptor	O
alpha	O
chain	O
(	O
IL	O
-	O
2R	O
alpha	O
)	O
expression	O
and	O
nuclear	B-OOS
factor	I-OOS
(	O
NF	B-OOS
)	O
activation	O
by	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
in	O
resting	O
T	O
cells	O
,	O
has	O
been	O
studied	O
.	O

Treatment	O
of	O
human	O
resting	O
T	O
cells	O
with	O
phorbol	O
esters	O
strongly	O
induced	O
the	O
expression	O
of	O
IL	O
-	O
2R	O
alpha	O
and	O
the	O
activation	O
of	O
NF	B-Complex
.	I-Complex
kappa	I-Complex
B	I-Complex
.	O

This	O
activation	O
was	O
due	O
to	O
the	O
translocation	O
of	O
p65	O
and	O
c	O
-	O
Rel	O
NF	B-Complex
.	I-Complex
kappa	I-Complex
B	I-Complex
proteins	O
from	O
cytoplasmic	O
stores	O
to	O
the	O
nucleus	O
,	O
where	O
they	O
bound	O
the	O
kappa	B-Complex
B	I-Complex
sequence	O
of	O
the	O
IL	O
-	O
2R	O
alpha	O
promoter	O
either	O
as	O
p50	O
.	O
p65	O
or	O
as	O
p50	O
.	O
c	O
-	O
Rel	O
heterodimers	O
.	O

Interestingly	O
,	O
all	O
of	O
those	O
events	O
were	O
largely	O
indirect	O
and	O
mediated	O
by	O
endogenously	O
secreted	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
,	O
as	O
they	O
were	O
strongly	O
inhibited	O
by	O
a	O
neutralizing	O
anti	O
-	O
TNF	O
alpha	O
monoclonal	O
antibody	O
.	O

Furthermore	O
,	O
cyclosporin	O
A	O
,	O
which	O
blocked	O
TNF	O
alpha	O
production	O
induced	O
by	O
PKC	O
,	O
strongly	O
inhibited	O
IL	O
-	O
2R	O
alpha	O
and	O
NF	B-Complex
.	I-Complex
kappa	I-Complex
B	I-Complex
activation	O
.	O

The	O
addition	O
of	O
either	O
TNF	O
alpha	O
or	O
IL	O
-	O
2	O
partially	O
recovered	O
cyclosporin	O
A	O
-	O
induced	O
IL	O
-	O
2R	O
alpha	O
inhibition	O
,	O
but	O
only	O
TNF	O
alpha	O
completely	O
recovered	O
NF	B-Complex
.	I-Complex
kappa	I-Complex
B	I-Complex
activation	O
.	O

Those	O
results	O
indicate	O
that	O
,	O
in	O
resting	O
T	O
cells	O
,	O
PKC	O
activation	O
has	O
only	O
a	O
triggering	O
role	O
,	O
whereas	O
the	O
endogenously	O
secreted	O
TNF	O
alpha	O
plays	O
an	O
essential	O
role	O
in	O
the	O
quantitative	O
control	O
of	O
the	O
expression	O
of	O
IL	O
-	O
2R	O
alpha	O
chain	O
or	O
NF	B-Complex
.	I-Complex
kappa	I-Complex
B	I-Complex
activation	O
.	O

Protease	O
inhibitors	O
block	O
lipopolysaccharide	O
induction	O
of	O
tissue	O
factor	O
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
by	O
preventing	O
activation	O
of	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
.	O

Tissue	O
factor	O
(	O
TF	O
)	O
is	O
expressed	O
rapidly	O
by	O
human	O
monocytes	O
exposed	O
to	O
bacterial	O
endotoxin	O
(	O
lipopolysaccharide	O
,	O
or	O
LPS	O
)	O
.	O

Transcriptional	O
regulation	O
is	O
mediated	O
by	O
binding	O
of	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
to	O
a	O
kappa	B-Complex
B	I-Complex
-	O
like	O
site	O
in	O
the	O
TF	O
promoter	O
.	O

Nuclear	O
translocation	O
of	O
cytosolic	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
and	O
other	O
members	O
of	O
the	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
Rel	I-Complex
family	O
requires	O
dissociation	O
and	O
proteolytic	O
degradation	O
of	O
the	O
inhibitor	O
protein	O
,	O
I	O
kappa	O
B	O
alpha	O
.	O

The	O
protease	O
inhibitors	O
N	O
alpha	O
-	O
tosylphenylalanyl	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
and	O
N	O
alpha	O
-	O
tosyl	O
-	O
L	O
-	O
lysine	O
chloromethyl	O
ketone	O
(	O
TLCK	O
)	O
block	O
activation	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
Rel	I-Complex
proteins	O
by	O
preventing	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
.	O

To	O
determine	O
if	O
TPCK	O
and	O
TLCK	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
expression	O
,	O
freshly	O
isolated	O
human	O
monocytes	O
and	O
monocytic	O
THP	O
-	O
1	O
cells	O
were	O
pretreated	O
with	O
these	O
inhibitors	O
for	O
30	O
min	O
before	O
LPS	O
stimulation	O
.	O

Both	O
TPCK	O
and	O
TLCK	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
protein	O
,	O
TF	O
mRNA	O
and	O
TF	O
promoter	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

These	O
inhibitors	O
specifically	O
prevented	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
nuclear	O
translocation	O
of	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
.	O

In	O
contrast	O
,	O
TPCK	O
and	O
TLCK	O
did	O
not	O
block	O
induction	O
of	O
an	O
immediate	O
-	O
early	O
gene	O
encoding	O
the	O
transcription	O
factor	O
,	O
Egr	O
-	O
1	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicated	O
that	O
inhibiting	O
nuclear	O
translocation	O
of	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
prevented	O
LPS	O
induction	O
of	O
TF	O
gene	O
transcription	O
in	O
monocytic	O
cells	O
.	O

Identification	O
of	O
Ser38	O
as	O
the	O
site	O
in	O
cardiac	O
sarcoplasmic	O
reticulum	O
Ca	O
(	O
2	O
+	O
)	O
-	O
ATPase	O
that	O
is	O
phosphorylated	O
by	O
Ca2	O
+	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
.	O

In	O
previous	O
studies	O
(	O
Xu	O
,	O
A	O
.	O
,	O
Hawkins	O
,	O
C	O
.	O
,	O
and	O
Narayanan	O
,	O
N	O
.	O
(	O
1993	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
268	O
,	O
8394	O
-	O
8397	O
)	O
,	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
ATPase	O
of	O
cardiac	O
muscle	O
sarcoplasmic	O
reticulum	O
(	O
SERCA2	O
)	O
was	O
shown	O
to	O
be	O
phosphorylated	O
by	O
Ca2	O
+	O
/	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
II	O
(	O
CaM	O
kinase	O
)	O
on	O
a	O
serine	O
residue	O
,	O
likely	O
to	O
be	O
either	O
Ser38	O
,	O
Ser167	O
,	O
or	O
Ser531	O
.	O

SERCA2	O
and	O
SERCA2	O
mutants	O
S38A	O
,	O
S167A	O
,	O
and	O
S531A	O
were	O
expressed	O
in	O
HEK	O
-	O
293	O
cells	O
and	O
tested	O
for	O
phosphorylation	O
with	O
CaM	O
kinase	O
.	O

Mutant	O
S38A	O
was	O
not	O
phosphorylated	O
,	O
while	O
mutants	O
S167A	O
and	O
S531A	O
were	O
phosphorylated	O
,	O
suggesting	O
that	O
Ser38	O
is	O
the	O
site	O
of	O
CaM	O
kinase	O
phosphorylation	O
in	O
SERCA2	O
.	O

This	O
conclusion	O
was	O
supported	O
by	O
the	O
observation	O
that	O
phosphorylation	O
of	O
SERCA2	O
and	O
mutants	O
S167A	O
and	O
S531A	O
by	O
CaM	O
kinase	O
increased	O
the	O
Vmax	O
for	O
Ca2	O
+	O
transport	O
,	O
while	O
the	O
Vmax	O
for	O
Ca2	O
+	O
transport	O
by	O
mutant	O
S38A	O
was	O
unaffected	O
by	O
exposure	O
to	O
a	O
phosphorylation	O
reaction	O
mix	O
.	O

SERCA1	O
,	O
containing	O
a	O
potential	O
CaM	O
kinase	O
phosphorylation	O
site	O
at	O
Ser167	O
and	O
two	O
SERCA1	O
mutants	O
,	O
K35R	O
plus	O
H38S	O
and	O
T532S	O
,	O
in	O
which	O
potential	O
CaM	O
kinase	O
sites	O
were	O
created	O
,	O
were	O
not	O
phosphorylated	O
by	O
CaM	O
kinase	O
,	O
and	O
Vmax	O
for	O
Ca2	O
+	O
transport	O
was	O
unaffected	O
by	O
exposure	O
to	O
a	O
phosphorylation	O
reaction	O
mix	O
.	O

Thus	O
phosphorylation	O
of	O
Ser38	O
in	O
SERCA2	O
results	O
in	O
a	O
unique	O
activation	O
of	O
Vmax	O
for	O
Ca2	O
+	O
transport	O
,	O
providing	O
a	O
potential	O
regulatory	O
mechanism	O
for	O
Ca2	O
+	O
removal	O
from	O
cardiac	O
and	O
other	O
tissues	O
in	O
which	O
SERCA2	O
is	O
expressed	O
.	O

A	O
proteasome	B-Complex
inhibitor	O
prevents	O
activation	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
and	O
stabilizes	O
a	O
newly	O
phosphorylated	O
form	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
that	O
is	O
still	O
bound	O
to	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O

Activation	O
of	O
the	O
inducible	O
transcription	O
factor	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
involves	O
removal	O
of	O
the	O
inhibitory	O
subunit	O
I	O
kappa	O
B	O
-	O
alpha	O
from	O
a	O
latent	O
cytoplasmic	O
complex	O
.	O

It	O
has	O
been	O
reported	O
that	O
I	O
kappa	O
B	O
-	O
alpha	O
is	O
subject	O
to	O
both	O
phosphorylation	O
and	O
proteolysis	O
in	O
the	O
process	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
activation	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
evidence	O
that	O
the	O
multicatalytic	O
cytosolic	O
protease	O
(	O
proteasome	B-Complex
)	O
is	O
involved	O
in	O
the	O
degradation	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
.	O

Micromolar	O
amounts	O
of	O
the	O
peptide	O
Cbz	O
-	O
Ile	O
-	O
Glu	O
(	O
O	O
-	O
t	O
-	O
Bu	O
)	O
-	O
Ala	O
-	O
leucinal	O
(	O
PSI	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
the	O
chymotrypsin	O
-	O
like	O
activity	O
of	O
the	O
proteasome	B-Complex
,	O
prevented	O
activation	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
in	O
response	O
to	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
)	O
and	O
okadaic	O
acid	O
(	O
OA	O
)	O
through	O
inhibition	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
degradation	O
.	O

The	O
m	O
-	O
calpain	O
inhibitor	O
Cbz	O
-	O
Leu	O
-	O
leucinal	O
was	O
ineffective	O
.	O

In	O
the	O
presence	O
of	O
PSI	O
,	O
a	O
newly	O
phosphorylated	O
form	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
accumulated	O
in	O
TNF	O
-	O
and	O
OA	O
-	O
stimulated	O
cells	O
.	O

However	O
,	O
the	O
covalent	O
modification	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
was	O
not	O
sufficient	O
for	O
activation	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
:	O
no	O
substantial	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
DNA	O
binding	O
activity	O
appeared	O
in	O
cells	O
because	O
the	O
newly	O
phosphorylated	O
form	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
was	O
still	O
tightly	O
bound	O
to	O
p65	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O

Pyrrolidinedithiocarbamate	O
,	O
an	O
antioxidant	O
inhibitor	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
activation	O
which	O
did	O
not	O
interfere	O
with	O
proteasome	B-Complex
activities	O
,	O
prevented	O
de	O
novo	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
as	O
well	O
as	O
its	O
subsequent	O
degradation	O
.	O

This	O
suggests	O
that	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
-	O
alpha	O
is	O
equally	O
necessary	O
for	O
the	O
activation	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Functional	O
Myc	O
-	O
Max	O
heterodimer	O
is	O
required	O
for	O
activation	O
-	O
induced	O
apoptosis	O
in	O
T	O
cell	O
hybridomas	O
.	O

T	O
cell	O
hybridomas	O
respond	O
to	O
activation	O
signals	O
by	O
undergoing	O
apoptotic	O
cell	O
death	O
,	O
and	O
this	O
is	O
likely	O
to	O
represent	O
comparable	O
events	O
related	O
to	O
tolerance	O
induction	O
in	O
immature	O
and	O
mature	O
T	O
cells	O
in	O
vivo	O
.	O

Previous	O
studies	O
using	O
antisense	O
oligonucleotides	O
implicated	O
the	O
c	O
-	O
Myc	O
protein	O
in	O
the	O
phenomenon	O
of	O
activation	O
-	O
induced	O
apoptosis	O
.	O

This	O
role	O
for	O
c	O
-	O
Myc	O
in	O
apoptosis	O
is	O
now	O
confirmed	O
in	O
studies	O
using	O
a	O
dominant	O
negative	O
form	O
of	O
its	O
heterodimeric	O
binding	O
partner	O
,	O
Max	O
,	O
which	O
we	O
show	O
here	O
inhibits	O
activation	O
-	O
induced	O
apoptosis	O
.	O

Further	O
,	O
coexpression	O
of	O
a	O
reciprocally	O
mutant	O
Myc	O
protein	O
capable	O
of	O
forming	O
functional	O
heterodimers	O
with	O
the	O
mutant	O
Max	O
can	O
compensate	O
for	O
the	O
dominant	O
negative	O
activity	O
and	O
restore	O
activation	O
-	O
induced	O
apoptosis	O
.	O

These	O
results	O
imply	O
that	O
Myc	O
promotes	O
activation	O
-	O
induced	O
apoptosis	O
by	O
obligatory	O
heterodimerization	O
with	O
Max	O
,	O
and	O
therefore	O
,	O
by	O
regulating	O
gene	O
transcription	O
.	O

DNA	O
-	O
binding	O
studies	O
of	O
the	O
Epstein	O
-	O
Barr	O
virus	O
nuclear	O
antigen	O
2	O
(	O
EBNA	O
-	O
2	O
)	O
:	O
evidence	O
for	O
complex	O
formation	O
by	O
latent	O
membrane	O
protein	O
gene	O
promoter	O
-	O
binding	O
proteins	O
in	O
EBNA	O
-	O
2	O
-	O
positive	O
cell	O
lines	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
nuclear	O
antigen	O
2	O
(	O
EBNA	O
-	O
2	O
)	O
protein	O
is	O
essential	O
for	O
the	O
immortalization	O
of	O
human	O
primary	O
B	O
cells	O
by	O
EBV	O
.	O

EBNA	O
-	O
2	O
trans	O
-	O
activates	O
cellular	O
and	O
viral	O
genes	O
like	O
CD23	O
,	O
c	O
-	O
fgr	O
,	O
latent	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
and	O
terminal	O
protein	O
1	O
(	O
TP1	O
)	O
.	O

Trans	O
-	O
activation	O
of	O
the	O
TP1	O
promoter	O
and	O
of	O
the	O
BamHI	O
C	O
promoter	O
has	O
already	O
been	O
investigated	O
in	O
detail	O
and	O
appears	O
to	O
be	O
mediated	O
via	O
protein	O
-	O
protein	O
interactions	O
and	O
not	O
by	O
direct	O
binding	O
of	O
EBNA	O
-	O
2	O
type	O
A	O
(	O
of	O
EBV	O
type	O
1	O
)	O
to	O
the	O
DNA	O
.	O

EBNA	O
-	O
2	O
is	O
able	O
to	O
trans	O
-	O
activate	O
the	O
expression	O
of	O
the	O
LMP	O
gene	O
in	O
several	O
cell	O
lines	O
.	O

Various	O
reports	O
have	O
delineated	O
the	O
cis	O
-	O
acting	O
elements	O
of	O
the	O
LMP	O
promoter	O
through	O
which	O
EBNA	O
-	O
2	O
mediates	O
trans	O
-	O
activation	O
.	O

To	O
determine	O
whether	O
EBNA	O
-	O
2	O
also	O
trans	O
-	O
activates	O
the	O
LMP	O
promoter	O
by	O
protein	O
-	O
protein	O
interactions	O
,	O
we	O
performed	O
a	O
series	O
of	O
gel	O
retardation	O
assays	O
and	O
competition	O
experiments	O
with	O
LMP	O
promoter	O
fragments	O
of	O
different	O
sizes	O
.	O

We	O
determined	O
that	O
the	O
protein	O
-	O
binding	O
region	O
on	O
the	O
LMP	O
promoter	O
was	O
within	O
a	O
42	O
bp	O
fragment	O
encompassing	O
nucleotides	O
-	O
135	O
to	O
-	O
176	O
relative	O
to	O
the	O
LMP	O
transcriptional	O
start	O
site	O
.	O

None	O
of	O
the	O
DNA	O
fragments	O
investigated	O
indicated	O
interaction	O
of	O
EBNA	O
-	O
2	O
with	O
the	O
DNA	O
via	O
protein	O
-	O
protein	O
interactions	O
.	O

No	O
significant	O
differences	O
between	O
EBNA	O
-	O
2	O
-	O
positive	O
and	O
EBNA	O
-	O
2	O
-	O
negative	O
nuclear	O
extracts	O
could	O
be	O
seen	O
in	O
the	O
gel	O
retardation	O
assay	O
under	O
conditions	O
that	O
clearly	O
showed	O
binding	O
of	O
EBNA	O
-	O
2A	O
to	O
the	O
TP1	O
promoter	O
.	O

However	O
,	O
analysis	O
of	O
sucrose	O
gradient	O
fractions	O
in	O
the	O
gel	O
retardation	O
assay	O
provided	O
evidence	O
that	O
the	O
LMP	O
promoter	O
-	O
binding	O
proteins	O
form	O
a	O
complex	O
of	O
higher	O
M	O
(	O
r	O
)	O
in	O
EBNA	O
-	O
2	O
-	O
positive	O
cell	O
extracts	O
.	O

These	O
complexes	O
were	O
destroyed	O
by	O
detergent	O
.	O

We	O
deduce	O
from	O
these	O
results	O
that	O
EBNA	O
-	O
2	O
-	O
positive	O
cells	O
might	O
indeed	O
contain	O
specific	O
complexes	O
bound	O
to	O
the	O
LMP	O
promoter	O
which	O
are	O
,	O
however	O
,	O
too	O
labile	O
to	O
be	O
detected	O
in	O
a	O
standard	O
gel	O
retardation	O
assay	O
.	O

Rab	B-Complex
geranylgeranyl	I-Complex
transferase	I-Complex
catalyzes	O
the	O
geranylgeranylation	O
of	O
adjacent	O
cysteines	O
in	O
the	O
small	O
GTPases	O
Rab1A	O
,	O
Rab3A	O
,	O
and	O
Rab5A	O
.	O

Rab	O
proteins	O
are	O
Ras	O
-	O
related	O
small	O
GTPases	O
that	O
are	O
geranylgeranylated	O
on	O
cysteine	O
residues	O
located	O
at	O
or	O
near	O
their	O
C	O
termini	O
.	O

They	O
differ	O
from	O
other	O
geranylgeranylated	O
small	O
GTPases	O
in	O
several	O
important	O
respects	O
.	O

(	O
i	O
)	O
Most	O
Rab	O
proteins	O
contain	O
two	O
adjacent	O
cysteine	O
residues	O
within	O
one	O
of	O
the	O
following	O
C	O
-	O
terminal	O
sequence	O
motifs	O
:	O
-	O
XXCC	O
,	O
-	O
XCXC	O
,	O
or	O
-	O
CCXX	O
;	O
(	O
ii	O
)	O
a	O
Rab	O
protein	O
that	O
ends	O
in	O
a	O
-	O
XCXC	O
motif	O
has	O
been	O
shown	O
to	O
be	O
geranylgeranylated	O
on	O
both	O
adjacent	O
cysteine	O
residues	O
;	O
and	O
(	O
iii	O
)	O
Rab	O
proteins	O
are	O
substrates	O
of	O
a	O
unique	O
Rab	B-Complex
-	I-Complex
specific	I-Complex
geranylgeranyltransferase	I-Complex
.	O

Whether	O
this	O
enzyme	O
catalyzes	O
the	O
geranylgeranylation	O
of	O
both	O
cysteines	O
is	O
unknown	O
.	O

We	O
addressed	O
this	O
question	O
by	O
direct	O
structural	O
analysis	O
of	O
in	O
vitro	O
prenylated	O
proteins	O
.	O

We	O
incubated	O
recombinant	O
Rab	B-Complex
geranylgeranyltransferase	I-Complex
,	O
Rab	O
escort	O
protein	O
,	O
and	O
[	O
1	O
-	O
3H	O
]	O
geranylgeranyl	O
pyrophosphate	O
with	O
recombinant	O
wild	O
-	O
type	O
Rab1A	O
(	O
-	O
XXCC	O
)	O
,	O
Rab3A	O
(	O
-	O
XCXC	O
)	O
,	O
or	O
Rab5A	O
(	O
-	O
CCXX	O
)	O
and	O
treated	O
each	O
labeled	O
protein	O
with	O
trypsin	O
.	O

We	O
then	O
analyzed	O
the	O
resulting	O
peptides	O
by	O
HPLC	O
and	O
electrospray	O
mass	O
spectrometry	O
and	O
found	O
that	O
for	O
each	O
protein	O
both	O
C	O
-	O
terminal	O
adjacent	O
cysteines	O
were	O
geranylgeranylated	O
.	O

These	O
results	O
indicate	O
that	O
Rab	B-Complex
geranylgeranyltransferase	I-Complex
/	O
Rab	O
escort	O
protein	O
catalyzes	O
the	O
geranylgeranylation	O
of	O
both	O
cysteines	O
in	O
Rab	O
proteins	O
with	O
three	O
distinct	O
C	O
-	O
terminal	O
motifs	O
and	O
suggest	O
that	O
other	O
Rab	O
proteins	O
with	O
these	O
motifs	O
may	O
be	O
similarly	O
modified	O
.	O

The	O
neuroendocrine	O
precursor	O
7B2	O
is	O
a	O
sulfated	O
protein	O
proteolytically	O
processed	O
by	O
a	O
ubiquitous	O
furin	O
-	O
like	O
convertase	O
.	O

The	O
neuroendocrine	O
granule	O
-	O
associated	O
protein	O
7B2	O
,	O
unlike	O
many	O
other	O
neuroendocrine	O
precursor	O
proteins	O
stored	O
in	O
secretory	O
granules	O
,	O
carries	O
in	O
its	O
primary	O
structure	O
the	O
Arg	O
-	O
Xaa	O
-	O
Arg	O
/	O
Lys	O
-	O
Arg	O
processing	O
site	O
usually	O
found	O
in	O
constitutively	O
secreted	O
precursor	O
proteins	O
and	O
recognized	O
by	O
the	O
ubiquitously	O
expressed	O
convertase	O
,	O
furin	O
.	O

pro7B2	O
(	O
30	O
kDa	O
)	O
,	O
when	O
expressed	O
in	O
endocrine	O
(	O
AtT	O
-	O
20	O
,	O
PC12	O
,	O
and	O
GH4C1	O
)	O
or	O
non	O
-	O
endocrine	O
(	O
Ltk	O
-	O
)	O
cell	O
lines	O
using	O
recombinant	O
vaccinia	O
viruses	O
,	O
was	O
converted	O
to	O
a	O
23	O
-	O
kDa	O
form	O
.	O

Mutation	O
of	O
the	O
P4	O
Arg	O
to	O
Gly	O
completely	O
prevented	O
this	O
conversion	O
.	O

When	O
excess	O
pro7B2	O
was	O
coexpressed	O
with	O
the	O
pro	O
-	O
protein	O
convertases	O
PC1	O
,	O
PC2	O
,	O
or	O
furin	O
,	O
only	O
furin	O
could	O
induce	O
complete	O
processing	O
.	O

In	O
addition	O
,	O
coexpression	O
of	O
pro7B2	O
in	O
LoVo	O
cells	O
,	O
which	O
are	O
devoid	O
of	O
endogenous	O
furin	O
activity	O
,	O
with	O
each	O
one	O
of	O
the	O
three	O
convertases	O
,	O
showed	O
that	O
only	O
furin	O
was	O
able	O
to	O
induce	O
processing	O
of	O
this	O
precursor	O
.	O

pro7B2	O
processing	O
in	O
AtT	O
-	O
20	O
was	O
completely	O
abolished	O
when	O
protein	O
transport	O
into	O
Golgi	O
compartments	O
was	O
blocked	O
by	O
cell	O
incubation	O
at	O
either	O
15	O
or	O
37	O
degrees	O
C	O
in	O
the	O
presence	O
of	O
monensin	O
or	O
brefeldin	O
A	O
.	O

Furthermore	O
,	O
pulse	O
-	O
chase	O
experiments	O
in	O
the	O
presence	O
of	O
Na2	O
[	O
35S	O
]	O
SO4	O
showed	O
that	O
pro7B2	O
is	O
Tyr	O
-	O
sulfated	O
in	O
the	O
trans	O
-	O
Golgi	O
network	O
before	O
it	O
is	O
processed	O
.	O

These	O
results	O
demonstrate	O
that	O
pro7B2	O
is	O
first	O
processed	O
by	O
a	O
furin	O
-	O
like	O
enzyme	O
within	O
the	O
trans	O
-	O
Golgi	O
network	O
into	O
a	O
23	O
-	O
kDa	O
form	O
that	O
is	O
then	O
sequestered	O
into	O
secretory	O
granules	O
.	O

Botulinum	O
G	O
neurotoxin	O
cleaves	O
VAMP	O
/	O
synaptobrevin	O
at	O
a	O
single	O
Ala	O
-	O
Ala	O
peptide	O
bond	O
.	O

Similarly	O
to	O
other	O
serotypes	O
,	O
botulinum	O
neurotoxin	O
serotype	O
G	O
(	O
BoNT	O
/	O
G	O
)	O
contains	O
the	O
zinc	O
binding	O
motif	O
of	O
zinc	O
endopeptidases	O
.	O

Highly	O
purified	O
preparations	O
of	O
BoNT	O
/	O
G	O
show	O
a	O
zinc	O
-	O
dependent	O
protease	O
activity	O
specific	O
for	O
VAMP	O
/	O
synaptobrevin	O
,	O
a	O
membrane	O
protein	O
of	O
synaptic	O
vesicles	O
.	O

The	O
two	O
neuronal	O
VAMP	O
isoforms	O
are	O
cleaved	O
with	O
similar	O
rates	O
at	O
one	O
Ala	O
-	O
Ala	O
peptide	O
bond	O
present	O
in	O
the	O
same	O
region	O
,	O
out	O
of	O
the	O
several	O
such	O
peptide	O
bonds	O
present	O
in	O
their	O
sequences	O
.	O

This	O
site	O
of	O
cleavage	O
is	O
unique	O
among	O
the	O
eight	O
clostridial	O
neurotoxins	O
.	O

VAMP	O
proteolysis	O
is	O
displayed	O
only	O
after	O
reduction	O
of	O
the	O
single	O
interchain	O
disulfide	O
bond	O
present	O
in	O
the	O
toxin	O
,	O
and	O
it	O
is	O
inhibited	O
by	O
EDTA	O
,	O
o	O
-	O
phenanthroline	O
and	O
captopril	O
.	O

ECE	O
-	O
1	O
:	O
a	O
membrane	O
-	O
bound	O
metalloprotease	O
that	O
catalyzes	O
the	O
proteolytic	O
activation	O
of	O
big	O
endothelin	O
-	O
1	O
.	O

Endothelin	O
-	O
1	O
(	O
ET	O
-	O
1	O
)	O
,	O
a	O
21	O
-	O
residue	O
vasoactive	O
peptide	O
,	O
is	O
produced	O
in	O
vascular	O
endothelial	O
cells	O
from	O
the	O
38	O
-	O
residue	O
inactive	O
intermediate	O
big	O
endothelin	O
-	O
1	O
via	O
a	O
specific	O
cleavage	O
at	O
Trp	O
-	O
21	O
-	O
Val	O
-	O
22	O
.	O

The	O
protease	O
that	O
catalyzes	O
the	O
conversion	O
,	O
endothelin	O
-	O
converting	O
enzyme	O
(	O
ECE	O
)	O
,	O
constitutes	O
a	O
potential	O
regulatory	O
site	O
for	O
the	O
production	O
of	O
the	O
active	O
peptide	O
.	O

We	O
report	O
the	O
identification	O
of	O
ECE	O
-	O
1	O
,	O
a	O
novel	O
membrane	O
-	O
bound	O
neutral	O
metalloprotease	O
that	O
is	O
expressed	O
abundantly	O
in	O
endothelial	O
cells	O
in	O
vivo	O
and	O
is	O
structurally	O
related	O
to	O
neutral	O
endopeptidase	O
24	O
.	O
11	O
and	O
Kell	O
blood	O
group	O
protein	O
.	O

When	O
transfected	O
into	O
cultured	O
cells	O
that	O
normally	O
secrete	O
only	O
big	O
ET	O
-	O
1	O
,	O
the	O
ECE	O
-	O
1	O
cDNA	O
conferred	O
the	O
ability	O
to	O
secrete	O
mature	O
ET	O
-	O
1	O
.	O

In	O
transfected	O
cells	O
,	O
ECE	O
-	O
1	O
processes	O
endogenously	O
synthesized	O
big	O
ET	O
-	O
1	O
as	O
well	O
as	O
exogenously	O
supplied	O
big	O
ET	O
-	O
1	O
,	O
which	O
interacts	O
with	O
ECE	O
-	O
1	O
on	O
the	O
cell	O
surface	O
.	O

ECE	O
-	O
1	O
may	O
provide	O
a	O
target	O
for	O
pharmacological	O
intervention	O
to	O
alter	O
ET	O
-	O
1	O
production	O
.	O

Identification	O
of	O
functional	O
domains	O
of	O
the	O
aryl	O
hydrocarbon	O
receptor	O
nuclear	O
translocator	O
protein	O
(	O
ARNT	O
)	O
.	O

The	O
activated	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AHR	O
)	O
and	O
the	O
AHR	O
nuclear	O
translocator	O
(	O
ARNT	O
)	O
bind	O
DNA	O
as	O
a	O
heterodimer	O
.	O

Both	O
proteins	O
represent	O
a	O
novel	O
class	O
of	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
bHLH	O
)	O
-	O
containing	O
transcription	O
factors	O
in	O
that	O
(	O
i	O
)	O
activation	O
of	O
AHR	O
requires	O
the	O
binding	O
of	O
ligand	O
(	O
e	O
.	O
g	O
.	O
,	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
tetrachlorodibenzo	O
-	O
p	O
-	O
dioxin	O
[	O
TCDD	O
]	O
)	O
,	O
(	O
ii	O
)	O
the	O
xenobiotic	O
responsive	O
element	O
(	O
XRE	O
)	O
recognized	O
by	O
the	O
AHR	O
/	O
ARNT	O
heterodimer	O
differs	O
from	O
the	O
recognition	O
sequence	O
for	O
nearly	O
all	O
other	O
bHLH	O
proteins	O
,	O
and	O
(	O
iii	O
)	O
both	O
proteins	O
contain	O
a	O
PAS	O
homology	O
region	O
,	O
which	O
in	O
the	O
Drosophila	O
PER	O
and	O
SIM	O
proteins	O
functions	O
as	O
a	O
dimerization	O
domain	O
.	O

A	O
cDNA	O
for	O
mouse	O
ARNT	O
has	O
been	O
cloned	O
,	O
and	O
potential	O
functional	O
domains	O
of	O
ARNT	O
were	O
investigated	O
by	O
deletion	O
analysis	O
.	O

A	O
mutant	O
lacking	O
all	O
regions	O
of	O
ARNT	O
other	O
than	O
the	O
bHLH	O
and	O
PAS	O
regions	O
is	O
unimpaired	O
in	O
TCDD	O
-	O
dependent	O
dimerization	O
and	O
subsequent	O
XRE	O
binding	O
and	O
only	O
modestly	O
reduced	O
in	O
ability	O
to	O
complement	O
an	O
ARNT	O
-	O
deficient	O
mutant	O
cell	O
line	O
,	O
c4	O
,	O
in	O
vivo	O
.	O

Both	O
the	O
first	O
and	O
second	O
alpha	O
helices	O
of	O
the	O
bHLH	O
region	O
are	O
required	O
for	O
dimerization	O
.	O

The	O
basic	O
region	O
is	O
required	O
for	O
XRE	O
binding	O
but	O
not	O
for	O
dimerization	O
.	O

Deletion	O
of	O
either	O
the	O
A	O
or	O
B	O
segments	O
of	O
the	O
PAS	O
region	O
slightly	O
affects	O
TCDD	O
-	O
induced	O
heterodimerization	O
,	O
while	O
deletion	O
of	O
the	O
complete	O
PAS	O
region	O
severely	O
affects	O
(	O
but	O
does	O
not	O
eliminate	O
)	O
dimerization	O
.	O

Thus	O
,	O
ARNT	O
possesses	O
multiple	O
domains	O
required	O
for	O
maximal	O
heterodimerization	O
.	O

Mutants	O
deleted	O
for	O
PAS	O
A	O
,	O
PAS	O
B	O
,	O
and	O
the	O
complete	O
PAS	O
region	O
all	O
retain	O
some	O
degree	O
of	O
XRE	O
binding	O
,	O
yet	O
none	O
can	O
rescue	O
the	O
c4	O
mutant	O
.	O

Therefore	O
,	O
both	O
the	O
PAS	O
A	O
and	O
PAS	O
B	O
segments	O
,	O
besides	O
contributing	O
to	O
dimerization	O
,	O
apparently	O
fulfill	O
additional	O
,	O
unknown	O
functions	O
required	O
for	O
biological	O
activity	O
of	O
ARNT	O
.	O

Sequences	O
5	O
'	O
of	O
the	O
homeobox	O
of	O
the	O
Hox	O
-	O
1	O
.	O
4	O
gene	O
direct	O
tissue	O
-	O
specific	O
expression	O
of	O
lacZ	O
during	O
mouse	O
development	O
.	O

The	O
murine	O
homeobox	O
-	O
containing	O
gene	O
Hox	O
-	O
1	O
.	O
4	O
is	O
expressed	O
in	O
restricted	O
patterns	O
during	O
embryogenesis	O
and	O
in	O
male	O
germ	O
cells	O
.	O

To	O
begin	O
identification	O
of	O
the	O
cis	O
-	O
acting	O
elements	O
regulating	O
this	O
expression	O
,	O
transgenic	O
mice	O
were	O
generated	O
carrying	O
a	O
chimeric	O
construct	O
that	O
contained	O
approx	O
.	O
4	O
kb	O
of	O
5	O
'	O
flanking	O
sequence	O
and	O
approx	O
.	O
1	O
kb	O
of	O
structural	O
gene	O
,	O
fused	O
in	O
frame	O
to	O
the	O
E	O
.	O
coli	O
lacZ	O
gene	O
.	O

This	O
construct	O
directed	O
expression	O
of	O
the	O
resulting	O
Hox	O
-	O
1	O
.	O
4	O
,	O
beta	O
-	O
galactosidase	O
fusion	O
protein	O
in	O
a	O
pattern	O
that	O
reproduced	O
virtually	O
the	O
complete	O
embryonic	O
and	O
adult	O
sites	O
of	O
expression	O
of	O
the	O
endogenous	O
gene	O
.	O

Embryonic	O
expression	O
of	O
the	O
fusion	O
protein	O
was	O
first	O
detected	O
in	O
mesoderm	O
at	O
day	O
8	O
.	O
0	O
of	O
gestation	O
(	O
E	O
8	O
.	O
0	O
)	O
.	O

Between	O
gestational	O
ages	O
E	O
8	O
.	O
5	O
to	O
E	O
12	O
.	O
5	O
,	O
beta	O
-	O
gal	O
expression	O
was	O
observed	O
in	O
the	O
somites	O
,	O
the	O
lateral	O
walls	O
of	O
the	O
posterior	O
myelencephalon	O
,	O
the	O
dorsal	O
region	O
and	O
ventral	O
wall	O
of	O
the	O
spinal	O
cord	O
,	O
spinal	O
ganglia	O
and	O
prevertebrae	O
and	O
their	O
surrounding	O
mesenchyme	O
,	O
between	O
presumptive	O
ribs	O
,	O
as	O
well	O
as	O
in	O
mesenchymal	O
layers	O
in	O
the	O
lung	O
,	O
kidney	O
and	O
portions	O
of	O
the	O
gut	O
.	O

Expression	O
was	O
also	O
noted	O
in	O
the	O
pancreas	O
and	O
in	O
the	O
supporting	O
cells	O
and	O
sheath	O
around	O
subsets	O
of	O
peripheral	O
nerves	O
,	O
sites	O
that	O
had	O
not	O
been	O
detected	O
previously	O
.	O

Adult	O
expression	O
was	O
observed	O
in	O
testes	O
,	O
specifically	O
in	O
meiotic	O
and	O
post	O
-	O
meiotic	O
male	O
germ	O
cells	O
.	O

In	O
contrast	O
,	O
transgenic	O
mice	O
carrying	O
5	O
'	O
deletions	O
of	O
the	O
construct	O
which	O
leave	O
approx	O
.	O
1	O
.	O
2	O
kb	O
or	O
approx	O
.	O
2	O
.	O
0	O
kb	O
of	O
Hox	O
-	O
1	O
.	O
4	O
sequence	O
5	O
'	O
to	O
the	O
embryonic	O
promoter	O
,	O
did	O
not	O
exhibit	O
beta	O
-	O
gal	O
staining	O
.	O

These	O
deletion	O
experiments	O
defined	O
at	O
least	O
one	O
cis	O
-	O
acting	O
control	O
element	O
necessary	O
for	O
the	O
expression	O
of	O
the	O
Hox	O
-	O
1	O
.	O
4	O
gene	O
to	O
a	O
2	O
kb	O
region	O
located	O
2	O
to	O
4	O
kb	O
5	O
'	O
of	O
the	O
embryonic	O
transcription	O
start	O
site	O
.	O

Expression	O
of	O
v	O
-	O
src	O
in	O
T	O
cells	O
correlates	O
with	O
nuclear	O
expression	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O

NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
is	O
a	O
rapidly	O
inducible	O
transcriptional	O
activator	O
that	O
responds	O
to	O
a	O
variety	O
of	O
signals	O
and	O
influences	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
the	O
immune	O
response	O
.	O

Protein	O
tyrosine	O
kinases	O
transmit	O
signals	O
from	O
cytokine	O
and	O
immune	O
receptors	O
.	O

Very	O
little	O
information	O
exists	O
linking	O
these	O
two	O
important	O
classes	O
of	O
signaling	O
molecules	O
.	O

We	O
now	O
demonstrate	O
that	O
v	O
-	O
src	O
expression	O
correlates	O
with	O
nuclear	O
expression	O
of	O
a	O
kappa	B-Complex
B	I-Complex
binding	O
complex	O
similar	O
to	O
that	O
induced	O
by	O
phorbol	O
ester	O
and	O
ionomycin	O
,	O
as	O
detected	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
variety	O
of	O
kappa	B-Complex
B	I-Complex
sites	O
.	O

This	O
complex	O
was	O
blocked	O
by	O
the	O
tyrosine	O
kinase	O
inhibitor	O
,	O
herbimycin	O
A	O
.	O

The	O
v	O
-	O
src	O
-	O
induced	O
complex	O
comprised	O
the	O
p50	O
and	O
p65	O
components	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
,	O
as	O
determined	O
by	O
supershift	O
and	O
immunoblot	O
analysis	O
.	O

As	O
a	O
functional	O
correlate	O
of	O
this	O
finding	O
,	O
transient	O
co	O
-	O
transfection	O
of	O
HIV	O
-	O
1	O
LTR	O
reporter	O
constructs	O
in	O
a	O
different	O
T	O
cell	O
line	O
demonstrated	O
that	O
v	O
-	O
src	O
activated	O
this	O
promoter	O
in	O
a	O
kappa	B-Complex
B	I-Complex
-	O
dependent	O
manner	O
.	O

We	O
found	O
that	O
transactivation	O
of	O
the	O
HIV	O
-	O
1	O
LTR	O
by	O
v	O
-	O
src	O
was	O
more	O
sensitive	O
to	O
mutations	O
of	O
the	O
proximal	O
,	O
rather	O
than	O
the	O
distal	O
,	O
kappa	B-Complex
B	I-Complex
element	O
.	O

The	O
implications	O
for	O
T	B-Complex
cell	I-Complex
receptor	I-Complex
signaling	O
and	O
HIV	O
-	O
1	O
gene	O
expression	O
are	O
considered	O
.	O

Function	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
Rel	I-Complex
binding	O
sites	O
in	O
the	O
major	B-Complex
histocompatibility	I-Complex
complex	I-Complex
class	I-Complex
II	I-Complex
invariant	O
chain	O
promoter	O
is	O
dependent	O
on	O
cell	O
-	O
specific	O
binding	O
of	O
different	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
Rel	I-Complex
subunits	O
.	O

The	O
promoter	O
of	O
the	O
human	O
major	B-Complex
histocompatibility	I-Complex
complex	I-Complex
class	I-Complex
II	I-Complex
-	O
associated	O
invariant	O
-	O
chain	O
gene	O
(	O
Ii	O
)	O
contains	O
two	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
Rel	I-Complex
binding	O
sites	O
located	O
at	O
-	O
109	O
to	O
-	O
118	O
(	O
Ii	O
kappa	B-Complex
B	I-Complex
-	O
1	O
)	O
and	O
-	O
163	O
to	O
-	O
172	O
(	O
Ii	O
kappa	B-Complex
B	I-Complex
-	O
2	O
)	O
from	O
the	O
transcription	O
start	O
site	O
.	O

We	O
report	O
here	O
that	O
the	O
differential	O
function	O
of	O
each	O
of	O
these	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
Rel	I-Complex
sites	O
in	O
several	O
distinct	O
cell	O
types	O
depends	O
on	O
cell	O
-	O
specific	O
binding	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
Rel	I-Complex
transcription	O
factors	O
.	O

Ii	O
kappa	B-Complex
B	I-Complex
-	O
1	O
is	O
a	O
positive	O
regulatory	O
element	O
in	O
B	O
-	O
cell	O
lines	O
and	O
in	O
the	O
Ii	O
-	O
expressing	O
T	O
-	O
cell	O
line	O
,	O
H9	O
,	O
but	O
acts	O
as	O
a	O
negative	O
regulatory	O
element	O
in	O
myelomonocytic	O
and	O
glia	O
cell	O
lines	O
.	O

In	O
vivo	O
protein	O
-	O
DNA	O
contacts	O
are	O
detectable	O
at	O
Ii	O
kappa	B-Complex
B	I-Complex
-	O
1	O
in	O
cell	O
lines	O
in	O
which	O
this	O
site	O
is	O
functional	O
as	O
either	O
a	O
positive	O
or	O
negative	O
regulator	O
.	O

Electrophoretic	O
mobility	O
supershift	O
assays	O
determine	O
that	O
members	O
of	O
the	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
Rel	I-Complex
family	O
of	O
transcription	O
factors	O
can	O
bind	O
to	O
this	O
site	O
in	O
vitro	O
and	O
that	O
DNA	O
-	O
binding	O
complexes	O
that	O
contain	O
p50	O
,	O
p52	O
,	O
p65	O
,	O
and	O
cRel	O
correlate	O
with	O
positive	O
regulation	O
whereas	O
the	O
presence	O
of	O
p50	O
correlates	O
with	O
negative	O
regulation	O
.	O

Ii	O
kappa	B-Complex
B	I-Complex
-	O
2	O
is	O
a	O
site	O
of	O
positive	O
regulation	O
in	O
B	O
-	O
cell	O
lines	O
and	O
a	O
site	O
of	O
negative	O
regulation	O
in	O
H9	O
T	O
cells	O
,	O
myelomonocytic	O
,	O
and	O
glial	O
cell	O
lines	O
.	O

In	O
vivo	O
occupancy	O
of	O
this	O
site	O
is	O
observed	O
only	O
in	O
the	O
H9	O
T	O
-	O
cell	O
line	O
.	O

Again	O
,	O
in	O
vitro	O
supershift	O
studies	O
indicate	O
that	O
the	O
presence	O
of	O
p50	O
,	O
p52	O
,	O
p65	O
,	O
and	O
cRel	O
correlates	O
with	O
positive	O
function	O
whereas	O
the	O
presence	O
of	O
only	O
p50	O
and	O
p52	O
correlates	O
with	O
negative	O
function	O
.	O

This	O
differential	O
binding	O
of	O
specific	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
Rel	I-Complex
subunits	O
is	O
likely	O
to	O
mediate	O
the	O
disparate	O
functions	O
of	O
these	O
two	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
Rel	I-Complex
binding	O
sites	O
.	O

Alternative	O
splicing	O
of	O
RNA	O
transcripts	O
encoded	O
by	O
the	O
murine	O
p105	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
gene	O
generates	O
I	O
kappa	O
B	O
gamma	O
isoforms	O
with	O
different	O
inhibitory	O
activities	O
.	O

The	O
gene	O
encoding	O
the	O
105	O
-	O
kDa	O
protein	O
(	O
p105	O
)	O
precursor	O
of	O
the	O
p50	O
subunit	O
of	O
transcription	O
factor	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
also	O
encodes	O
a	O
p70	O
I	O
kappa	O
B	O
protein	O
,	O
I	O
kappa	O
B	O
gamma	O
,	O
which	O
is	O
identical	O
to	O
the	O
C	O
-	O
terminal	O
607	O
amino	O
acids	O
of	O
p105	O
.	O

Here	O
we	O
show	O
that	O
alternative	O
RNA	O
splicing	O
generates	O
I	O
kappa	O
B	O
gamma	O
isoforms	O
with	O
properties	O
different	O
from	O
those	O
of	O
p70	O
.	O

One	O
63	O
-	O
kDa	O
isoform	O
,	O
termed	O
I	O
kappa	O
B	O
gamma	O
-	O
1	O
,	O
which	O
lacks	O
59	O
amino	O
acids	O
C	O
-	O
terminal	O
to	O
ankyrin	O
repeat	O
7	O
,	O
has	O
a	O
novel	O
35	O
-	O
amino	O
acid	O
C	O
terminus	O
encoded	O
by	O
an	O
alternative	O
reading	O
frame	O
of	O
the	O
p105	O
gene	O
.	O

A	O
55	O
-	O
kDa	O
isoform	O
,	O
I	O
kappa	O
B	O
gamma	O
-	O
2	O
,	O
lacks	O
the	O
190	O
C	O
-	O
terminal	O
amino	O
acids	O
of	O
p70I	O
kappa	O
B	O
gamma	O
.	O

In	O
contrast	O
to	O
p70I	O
kappa	O
B	O
gamma	O
,	O
which	O
is	O
a	O
cytoplasmic	O
protein	O
,	O
I	O
kappa	O
B	O
gamma	O
-	O
1	O
is	O
found	O
in	O
both	O
the	O
cytoplasm	O
and	O
nucleus	O
,	O
whereas	O
I	O
kappa	O
B	O
gamma	O
-	O
2	O
is	O
predominantly	O
nuclear	O
.	O

The	O
I	O
kappa	O
B	O
gamma	O
isoforms	O
also	O
display	O
differences	O
in	O
specificity	O
and	O
affinity	O
for	O
Rel	B-Complex
/	I-Complex
NF	I-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
proteins	O
.	O

While	O
p70I	O
kappa	O
B	O
gamma	O
inhibits	O
p50	O
-	O
,	O
p65	O
-	O
,	O
and	O
c	O
-	O
Rel	O
-	O
mediated	O
transactivation	O
and	O
/	O
or	O
DNA	O
binding	O
,	O
both	O
I	O
kappa	O
B	O
gamma	O
-	O
1	O
and	O
I	O
kappa	O
B	O
gamma	O
-	O
2	O
are	O
specific	O
for	O
p50	O
and	O
have	O
different	O
affinities	O
for	O
this	O
subunit	O
.	O

The	O
absence	O
in	O
I	O
kappa	O
B	O
gamma	O
-	O
1	O
and	O
I	O
kappa	O
B	O
gamma	O
-	O
2	O
of	O
a	O
protein	O
kinase	O
A	O
site	O
whose	O
phosphorylation	O
modulates	O
p70I	O
kappa	O
B	O
gamma	O
inhibitory	O
activity	O
suggests	O
that	O
alternative	O
RNA	O
splicing	O
may	O
be	O
used	O
to	O
generate	O
I	O
kappa	O
B	O
gamma	O
isoforms	O
that	O
respond	O
differently	O
to	O
intracellular	O
signals	O
.	O

Lipopolysaccharide	O
induction	O
of	O
tissue	O
factor	O
gene	O
expression	O
in	O
monocytic	O
cells	O
is	O
mediated	O
by	O
binding	O
of	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
to	O
a	O
kappa	B-Complex
B	I-Complex
-	O
like	O
site	O
.	O

Exposure	O
of	O
monocytic	O
cells	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
activates	O
the	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
Rel	I-Complex
family	O
of	O
proteins	O
and	O
leads	O
to	O
the	O
rapid	O
induction	O
of	O
inflammatory	O
gene	O
products	O
,	O
including	O
tissue	O
factor	O
(	O
TF	O
)	O
.	O

TF	O
is	O
the	O
primary	O
cellular	O
initiator	O
of	O
the	O
coagulation	O
protease	O
cascades	O
.	O

Here	O
we	O
report	O
the	O
characterization	O
of	O
a	O
nuclear	O
complex	O
from	O
human	O
monocytic	O
cells	O
that	O
bound	O
to	O
a	O
kappa	O
B	O
-	O
like	O
site	O
,	O
5	O
'	O
-	O
CGGAGTTTCC	O
-	O
3	O
'	O
,	O
in	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
human	O
TF	O
gene	O
.	O

This	O
nuclear	O
complex	O
was	O
activated	O
by	O
LPS	O
with	O
kinetics	O
that	O
preceded	O
induction	O
of	O
the	O
TF	O
gene	O
.	O

In	O
vitro	O
binding	O
studies	O
demonstrated	O
that	O
the	O
TF	O
site	O
bound	O
translated	O
c	O
-	O
Rel	O
and	O
p65	O
homodimers	O
but	O
not	O
p50	O
/	O
p65	O
heterodimers	O
or	O
p50	O
homodimers	O
.	O

Base	O
-	O
pair	O
substitutions	O
in	O
the	O
TF	O
site	O
indicated	O
that	O
the	O
presence	O
of	O
a	O
cytosine	O
at	O
position	O
1	O
precluded	O
binding	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O

In	O
fact	O
,	O
under	O
low	O
-	O
ionic	O
-	O
strength	O
conditions	O
,	O
the	O
TF	O
complex	O
did	O
not	O
migrate	O
with	O
translated	O
p50	O
/	O
p65	O
dimers	O
but	O
instead	O
comigrated	O
with	O
c	O
-	O
Rel	O
/	O
p65	O
dimers	O
.	O

Antibodies	O
against	O
the	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
and	O
Rel	O
proteins	O
and	O
UV	O
cross	O
-	O
linking	O
studies	O
revealed	O
the	O
presence	O
of	O
c	O
-	O
Rel	O
and	O
p65	O
and	O
the	O
absence	O
of	O
p50	O
in	O
the	O
TF	O
complex	O
and	O
further	O
showed	O
that	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
selectively	O
bound	O
to	O
the	O
TF	O
kappa	B-Complex
B	I-Complex
-	O
like	O
site	O
.	O

Functional	O
studies	O
indicated	O
that	O
the	O
TF	O
site	O
conferred	O
LPS	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
and	O
was	O
transactivated	O
by	O
c	O
-	O
Rel	O
or	O
p65	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
binding	O
of	O
c	O
-	O
Rel	O
/	O
p65	O
heterodimers	O
to	O
a	O
novel	O
kappa	B-Complex
B	I-Complex
-	O
like	O
site	O
mediated	O
LPS	O
induction	O
of	O
TF	O
gene	O
expression	O
in	O
monocytic	O
cells	O
.	O

Tyrosine	O
sulfation	O
of	O
varicella	O
-	O
zoster	O
virus	O
envelope	O
glycoprotein	O
gpl	O
.	O

Sulfation	O
is	O
a	O
common	O
post	O
-	O
translational	O
modification	O
of	O
secreted	O
and	O
membrane	O
proteins	O
,	O
with	O
the	O
sulfate	O
attached	O
to	O
tyrosine	O
residues	O
or	O
to	O
glycan	O
side	O
-	O
chains	O
.	O

I	O
have	O
shown	O
that	O
varicella	O
-	O
zoster	O
virus	O
(	O
VZV	O
)	O
envelope	O
glycoproteins	O
gpI	O
,	O
gpII	O
,	O
and	O
gpIII	O
can	O
be	O
labeled	O
with	O
[	O
35S	O
]	O
sulfate	O
.	O

The	O
predominant	O
VZV	O
glycoprotein	O
,	O
gpI	O
,	O
was	O
shown	O
to	O
be	O
sulfated	O
on	O
asparagine	O
-	O
linked	O
glycans	O
and	O
on	O
tyrosine	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
tyrosine	O
sulfation	O
of	O
a	O
viral	O
envelope	O
glycoprotein	O
.	O

Examination	O
of	O
the	O
predicted	O
amino	O
acid	O
sequences	O
of	O
gpI	O
from	O
the	O
Dumas	O
and	O
CP	O
-	O
5262	O
VZV	O
strains	O
revealed	O
the	O
presence	O
of	O
a	O
single	O
consensus	O
sequence	O
for	O
tyrosine	O
sulfation	O
of	O
tyr88	O
:	O
IWPRNDYDGFLEN	O
.	O

Consensus	O
sequences	O
are	O
also	O
present	O
in	O
the	O
homologues	O
of	O
gpI	O
in	O
herpes	O
simplex	O
type	O
1	O
,	O
herpes	O
simplex	O
type	O
2	O
,	O
and	O
pseudorabies	O
virus	O
,	O
suggesting	O
that	O
tyrosine	O
sulfation	O
may	O
be	O
a	O
general	O
post	O
-	O
translational	O
modification	O
of	O
the	O
neurotropic	O
alphaherpesviruses	O
.	O

Posttranslational	O
regulation	O
of	O
nitrogenase	O
activity	O
by	O
anaerobiosis	O
and	O
ammonium	O
in	O
Azospirillum	O
brasilense	O
.	O

In	O
the	O
microaerophilic	O
diazotroph	O
Azospirillum	O
brasilense	O
,	O
the	O
addition	O
of	O
fixed	O
nitrogen	O
or	O
a	O
shift	O
to	O
anaerobic	O
conditions	O
leads	O
to	O
a	O
rapid	O
loss	O
of	O
nitrogenase	O
activity	O
due	O
to	O
ADP	O
-	O
ribosylation	O
of	O
dinitrogenase	O
reductase	O
.	O

The	O
product	O
of	O
draT	O
(	O
DRAT	O
)	O
is	O
shown	O
to	O
be	O
necessary	O
for	O
this	O
modification	O
,	O
and	O
the	O
product	O
of	O
draG	O
(	O
DRAG	O
)	O
is	O
shown	O
to	O
be	O
necessary	O
for	O
the	O
removal	O
of	O
the	O
modification	O
upon	O
removal	O
of	O
the	O
stimulus	O
.	O

DRAG	O
and	O
DRAT	O
are	O
themselves	O
subject	O
to	O
posttranslational	O
regulation	O
,	O
and	O
this	O
report	O
identifies	O
features	O
of	O
that	O
regulation	O
.	O

We	O
demonstrate	O
that	O
the	O
activation	O
of	O
DRAT	O
in	O
response	O
to	O
an	O
anaerobic	O
shift	O
is	O
transient	O
but	O
that	O
the	O
duration	O
of	O
DRAT	O
activation	O
in	O
response	O
to	O
added	O
NH4	O
+	O
varies	O
with	O
the	O
NH4	O
+	O
concentration	O
.	O

In	O
contrast	O
,	O
DRAG	O
appears	O
to	O
be	O
continuously	O
active	O
under	O
conditions	O
favoring	O
nitrogen	O
fixation	O
.	O

Thus	O
,	O
the	O
activities	O
of	O
DRAG	O
and	O
DRAT	O
are	O
not	O
always	O
coordinately	O
regulated	O
.	O

Finally	O
,	O
our	O
experiments	O
suggest	O
the	O
existence	O
of	O
a	O
temporary	O
period	O
of	O
futile	O
cycling	O
during	O
which	O
DRAT	O
and	O
DRAG	O
are	O
simultaneously	O
adding	O
and	O
removing	O
ADP	O
-	O
ribose	O
from	O
dinitrogenase	O
reductase	O
,	O
immediately	O
following	O
the	O
addition	O
of	O
a	O
negative	O
stimulus	O
.	O

Bet2p	O
and	O
Mad2p	O
are	O
components	O
of	O
a	O
prenyltransferase	O
that	O
adds	O
geranylgeranyl	O
onto	O
Ypt1p	O
and	O
Sec4p	O
.	O

Three	O
different	O
prenyltransferases	O
have	O
been	O
identified	O
in	O
yeast	O
and	O
higher	O
cells	O
,	O
the	O
farnesyltransferase	B-OOS
and	O
the	O
type	B-Complex
I	I-Complex
and	I-Complex
type	I-Complex
II	I-Complex
geranylgeranyltransferases	I-Complex
(	O
GGTase	B-Complex
)	O
.	O

The	O
farnesyltransferase	B-OOS
and	O
GGTase	B-Complex
-	I-Complex
I	I-Complex
modify	O
peptides	O
in	O
vitro	O
with	O
the	O
CAAX	O
(	O
C	O
,	O
Cys	O
;	O
A	O
,	O
aliphatic	O
residue	O
;	O
X	O
,	O
terminal	O
amino	O
acid	O
)	O
consensus	O
motif	O
.	O

These	O
enzymes	O
are	O
heterodimers	O
that	O
have	O
different	O
beta	O
-	O
subunits	O
and	O
a	O
shared	O
alpha	O
-	O
subunit	O
.	O

In	O
yeast	O
,	O
the	O
RAM2	O
gene	O
encodes	O
this	O
alpha	O
-	O
subunit	O
.	O

RAM2	O
is	O
also	O
homologous	O
to	O
MAD2	O
,	O
a	O
yeast	O
gene	O
whose	O
product	O
has	O
been	O
implicated	O
in	O
the	O
feedback	O
control	O
of	O
mitosis	O
.	O

We	O
have	O
shown	O
that	O
Bet2p	O
is	O
a	O
component	O
of	O
the	O
yeast	O
GGTase	B-Complex
-	I-Complex
II	I-Complex
(	O
refs	O
6	O
,	O
12	O
)	O
that	O
geranylgeranylates	O
Ypt1p	O
,	O
a	O
small	O
GTP	O
-	O
binding	O
protein	O
that	O
mediates	O
transport	O
from	O
the	O
endoplasmic	O
reticulum	O
to	O
the	O
Golgi	O
complex	O
.	O

Here	O
we	O
report	O
that	O
Mad2p	O
is	O
a	O
component	O
of	O
this	O
enzyme	O
.	O

Bet2p	O
forms	O
a	O
complex	O
with	O
Mad2p	O
that	O
appears	O
to	O
bind	O
geranylgeranyl	O
pyrophosphate	O
,	O
but	O
not	O
farnesyl	O
pyrophosphate	O
.	O

The	O
efficient	O
transfer	O
of	O
geranylgeranyl	O
onto	O
small	O
GTP	O
-	O
binding	O
proteins	O
requires	O
the	O
presence	O
of	O
an	O
additional	O
activity	O
.	O

The	O
macrophage	O
transcription	O
factor	O
PU	O
.	O
1	O
directs	O
tissue	O
-	O
specific	O
expression	O
of	O
the	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
receptor	O
.	O

The	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
receptor	O
is	O
expressed	O
in	O
a	O
tissue	O
-	O
specific	O
fashion	O
from	O
two	O
distinct	O
promoters	O
in	O
monocytes	O
/	O
macrophages	O
and	O
the	O
placenta	O
.	O

In	O
order	O
to	O
further	O
understand	O
the	O
transcription	O
factors	O
which	O
play	O
a	O
role	O
in	O
the	O
commitment	O
of	O
multipotential	O
progenitors	O
to	O
the	O
monocyte	O
/	O
macrophage	O
lineage	O
,	O
we	O
have	O
initiated	O
an	O
investigation	O
of	O
the	O
factors	O
which	O
activate	O
the	O
M	O
-	O
CSF	O
receptor	O
very	O
early	O
during	O
the	O
monocyte	O
differentiation	O
process	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
human	O
monocytic	O
M	O
-	O
CSF	O
receptor	O
promoter	O
directs	O
reporter	O
gene	O
activity	O
in	O
a	O
tissue	O
-	O
specific	O
fashion	O
.	O

Since	O
one	O
of	O
the	O
few	O
transcription	O
factors	O
which	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
monocyte	O
genes	O
is	O
the	O
macrophage	O
-	O
and	O
B	O
-	O
cell	O
-	O
specific	O
PU	O
.	O
1	O
transcription	O
factor	O
,	O
we	O
investigated	O
whether	O
PU	O
.	O
1	O
binds	O
and	O
activates	O
the	O
M	O
-	O
CSF	O
receptor	O
promoter	O
.	O

Here	O
we	O
demonstrate	O
that	O
both	O
in	O
vitro	O
-	O
translated	O
PU	O
.	O
1	O
and	O
PU	O
.	O
1	O
from	O
nuclear	O
extracts	O
bind	O
to	O
a	O
specific	O
site	O
in	O
the	O
M	O
-	O
CSF	O
receptor	O
promoter	O
just	O
upstream	O
from	O
the	O
major	O
transcription	O
initiation	O
site	O
.	O

Mutations	O
in	O
this	O
site	O
which	O
eliminate	O
PU	O
.	O
1	O
binding	O
decrease	O
M	O
-	O
CSF	O
receptor	O
promoter	O
activity	O
significantly	O
in	O
macrophage	O
cell	O
lines	O
only	O
.	O

Furthermore	O
,	O
PU	O
.	O
1	O
transactivates	O
the	O
M	O
-	O
CSF	O
receptor	O
promoter	O
in	O
nonmacrophage	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
PU	O
.	O
1	O
plays	O
a	O
major	O
role	O
in	O
macrophage	O
gene	O
regulation	O
and	O
development	O
by	O
directing	O
the	O
expression	O
of	O
a	O
receptor	O
for	O
a	O
key	O
macrophage	O
growth	O
factor	O
.	O

Association	O
of	O
the	O
human	O
papillomavirus	O
type	O
16	O
E7	O
protein	O
with	O
the	O
S	O
-	O
phase	O
-	O
specific	O
E2F	O
-	O
cyclin	O
A	O
complex	O
.	O

The	O
transcription	O
factor	O
E2F	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
the	O
expression	O
of	O
several	O
cell	O
cycle	O
-	O
regulated	O
genes	O
,	O
and	O
the	O
activity	O
of	O
this	O
factor	O
is	O
controlled	O
by	O
cellular	O
proteins	O
such	O
as	O
pRB	O
and	O
p107	O
.	O

E2F	O
is	O
also	O
a	O
target	O
of	O
the	O
DNA	O
virus	O
oncoproteins	O
(	O
adenovirus	O
E1A	O
,	O
simian	O
virus	O
40	O
T	O
antigen	O
,	O
and	O
human	O
papillomavirus	O
[	O
HPV	O
]	O
E7	O
)	O
(	O
see	O
the	O
review	O
by	O
J	O
.	O
R	O
.	O
Nevins	O
[	O
Science	O
258	O
:	O
424	O
-	O
429	O
,	O
1992	O
]	O
)	O
.	O

These	O
viral	O
oncoproteins	O
dissociate	O
an	O
inactive	O
complex	O
between	O
E2F	O
and	O
the	O
retinoblastoma	O
tumor	O
suppressor	O
protein	O
(	O
pRB	O
)	O
,	O
and	O
this	O
dissociation	O
of	O
the	O
E2F	O
-	O
pRB	O
complex	O
correlates	O
with	O
a	O
stimulation	O
of	O
the	O
E2F	O
-	O
dependent	O
transcription	O
.	O

In	O
the	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
E2F	O
forms	O
a	O
complex	O
with	O
p107	O
,	O
cyclin	O
A	O
,	O
and	O
the	O
cdk2	O
kinase	O
(	O
E2F	O
-	O
cyclin	O
A	O
complex	O
)	O
.	O

The	O
cellular	O
function	O
of	O
this	O
S	O
-	O
phase	O
-	O
specific	O
complex	O
is	O
unclear	O
.	O

The	O
adenovirus	O
E1A	O
protein	O
dissociates	O
the	O
E2F	O
-	O
cyclin	O
A	O
complex	O
.	O

The	O
HPV	O
type	O
16	O
(	O
HPV	O
-	O
16	O
)	O
E7	O
protein	O
,	O
which	O
possesses	O
significant	O
sequence	O
homology	O
with	O
E1A	O
,	O
does	O
not	O
dissociate	O
the	O
E2F	O
-	O
cyclin	O
A	O
complex	O
.	O

We	O
find	O
that	O
the	O
HPV	O
-	O
16	O
E7	O
protein	O
associates	O
very	O
efficiently	O
with	O
the	O
E2F	O
-	O
cyclin	O
A	O
complex	O
.	O

This	O
association	O
is	O
dependent	O
on	O
the	O
sequences	O
that	O
are	O
also	O
necessary	O
for	O
the	O
transforming	O
activity	O
of	O
E7	O
.	O

Moreover	O
,	O
the	O
E7	O
protein	O
of	O
a	O
low	O
-	O
risk	O
HPV	O
(	O
type	O
6b	O
)	O
is	O
much	O
less	O
efficient	O
in	O
binding	O
to	O
the	O
E2F	O
-	O
cyclin	O
A	O
complex	O
compared	O
with	O
that	O
of	O
the	O
high	O
-	O
risk	O
type	O
.	O

We	O
also	O
find	O
that	O
the	O
E2F	O
-	O
cyclin	O
A	O
complex	O
remains	O
endogenously	O
associated	O
with	O
the	O
E7	O
protein	O
in	O
extracts	O
of	O
Caski	O
cells	O
,	O
which	O
express	O
high	O
levels	O
of	O
HPV	O
-	O
16	O
E7	O
protein	O
.	O

Finally	O
,	O
we	O
have	O
extensively	O
purified	O
the	O
E2F	O
-	O
cyclin	O
A	O
complex	O
from	O
mouse	O
L	O
-	O
cell	O
extracts	O
and	O
show	O
that	O
,	O
in	O
cell	O
extracts	O
,	O
the	O
E2F	O
-	O
cyclin	O
A	O
complex	O
remains	O
associated	O
with	O
other	O
cellular	O
proteins	O
.	O

Nerve	O
growth	O
factor	O
induces	O
a	O
succession	O
of	O
increases	O
in	O
isoprenylated	O
methylated	O
small	O
GTP	O
-	O
binding	O
proteins	O
of	O
PC	O
-	O
12	O
pheochromocytoma	O
cells	O
.	O

Pheochromocytoma	O
(	O
PC	O
-	O
12	O
)	O
cells	O
exposed	O
to	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
acquire	O
a	O
sympathetic	O
neuron	O
-	O
like	O
phenotype	O
.	O

This	O
NGF	O
-	O
response	O
is	O
blocked	O
by	O
methylation	O
inhibitors	O
and	O
can	O
be	O
mimicked	O
by	O
the	O
farnesylated	O
methylated	O
small	O
GTP	O
-	O
binding	O
protein	O
p21ras	O
.	O

The	O
implicated	O
involvement	O
of	O
prenylation	O
,	O
methylation	O
and	O
a	O
small	O
GTP	O
-	O
binding	O
protein	O
in	O
the	O
NGF	O
-	O
response	O
has	O
been	O
studied	O
by	O
directly	O
measuring	O
3H	O
-	O
mevalonic	O
acid	O
(	O
MVA	O
)	O
-	O
metabolites	O
incorporated	O
into	O
proteins	O
,	O
protein	O
carboxy	O
[	O
methyl	O
-	O
3H	O
]	O
ester	O
formation	O
and	O
levels	O
of	O
[	O
alpha	O
-	O
32P	O
]	O
GTP	O
-	O
binding	O
proteins	O
in	O
NGF	O
-	O
induced	O
PC	O
-	O
12	O
cells	O
.	O

We	O
demonstrate	O
that	O
NGF	O
induces	O
a	O
2	O
-	O
3	O
-	O
fold	O
increase	O
in	O
21	O
-	O
24	O
kDa	O
methylated	O
membrane	O
proteins	O
that	O
incorporate	O
3H	O
-	O
MVA	O
-	O
metabolites	O
,	O
and	O
bind	O
GTP	O
.	O

Levels	O
of	O
[	O
alpha	O
-	O
32P	O
]	O
GTP	O
-	O
binding	O
in	O
these	O
proteins	O
were	O
increased	O
by	O
2	O
-	O
3	O
-	O
fold	O
.	O

Methylation	O
and	O
membrane	O
association	O
of	O
the	O
small	O
GTP	O
-	O
binding	O
proteins	O
were	O
blocked	O
by	O
lovastatin	O
,	O
an	O
inhibitor	O
of	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methylglutaryl	O
-	O
CoA	O
(	O
HMG	O
-	O
CoA	O
)	O
reductase	O
,	O
which	O
also	O
enhanced	O
their	O
labeling	O
by	O
3H	O
-	O
MVA	O
-	O
metabolites	O
.	O

Cycloheximide	O
reduced	O
the	O
levels	O
of	O
[	O
methyl	O
-	O
3H	O
]	O
labeled	O
21	O
-	O
24	O
kDa	O
proteins	O
and	O
of	O
the	O
overlapping	O
[	O
alpha	O
-	O
32P	O
]	O
GTP	O
binding	O
-	O
proteins	O
.	O

About	O
70	O
%	O
of	O
the	O
[	O
methyl	O
-	O
3H	O
]	O
-	O
groups	O
found	O
in	O
these	O
proteins	O
were	O
recovered	O
from	O
two	O
dimensional	O
gel	O
blots	O
in	O
nine	O
distinct	O
spots	O
of	O
[	O
alpha	O
-	O
32P	O
]	O
GTP	O
-	O
binding	O
proteins	O
.	O

Taken	O
together	O
these	O
results	O
strongly	O
suggest	O
that	O
in	O
PC	O
-	O
12	O
cells	O
,	O
NGF	O
induces	O
an	O
increase	O
in	O
the	O
synthesis	O
of	O
prenylated	O
methylated	O
small	O
GTP	O
-	O
binding	O
proteins	O
.	O

The	O
efficacy	O
of	O
lovastatin	O
blockage	O
of	O
protein	O
methylation	O
and	O
enhancement	O
of	O
3H	O
-	O
MVA	O
-	O
metabolites	O
incorporation	O
into	O
GTP	O
-	O
binding	O
proteins	O
was	O
lower	O
in	O
NGF	O
-	O
induced	O
cells	O
than	O
in	O
controls	O
.	O

This	O
suggests	O
that	O
NGF	O
also	O
induces	O
an	O
increase	O
in	O
HMG	O
-	O
CoA	O
reductase	O
activity	O
.	O

At	O
the	O
early	O
phase	O
of	O
the	O
NGF	O
response	O
in	O
PC	O
-	O
12	O
cells	O
(	O
15	O
min	O
-	O
1	O
h	O
)	O
,	O
the	O
levels	O
of	O
two	O
small	O
GTP	O
-	O
binding	O
proteins	O
(	O
molecular	O
mass	O
of	O
21	O
-	O
22	O
kDa	O
and	O
23	O
-	O
24	O
kDa	O
)	O
were	O
increased	O
.	O

Thus	O
,	O
at	O
least	O
two	O
proteins	O
,	O
of	O
which	O
one	O
but	O
not	O
the	O
other	O
may	O
be	O
p21ras	O
,	O
appear	O
to	O
be	O
involved	O
in	O
the	O
early	O
response	O
.	O

After	O
a	O
lag	O
period	O
of	O
24	O
h	O
with	O
NGF	O
,	O
a	O
second	O
more	O
robust	O
phase	O
of	O
increase	O
in	O
methylated	O
small	O
GTP	O
-	O
binding	O
proteins	O
was	O
apparent	O
.	O

This	O
relatively	O
late	O
response	O
,	O
which	O
was	O
almost	O
completed	O
within	O
24	O
h	O
,	O
may	O
reflect	O
involvement	O
of	O
small	O
GTP	O
-	O
binding	O
proteins	O
in	O
neurite	O
-	O
outgrowth	O
and	O
in	O
the	O
functional	O
activity	O
of	O
the	O
differentiated	O
cells	O
.	O

Many	O
small	O
GTP	O
-	O
binding	O
proteins	O
were	O
increased	O
during	O
the	O
second	O
phase	O
,	O
precluding	O
electrophoretic	O
separation	O
of	O
all	O
of	O
them	O
.	O

3	O
proteins	O
,	O
however	O
,	O
were	O
well	O
separated	O
(	O
one	O
23	O
-	O
24	O
kDa	O
protein	O
and	O
two	O
21	O
-	O
22	O
kDa	O
proteins	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Prenyl	O
modification	O
of	O
guanine	O
nucleotide	O
regulatory	O
protein	O
gamma	O
2	O
subunits	O
is	O
not	O
required	O
for	O
interaction	O
with	O
the	O
transducin	B-OOS
alpha	O
subunit	O
or	O
rhodopsin	O
.	O

Guanine	B-OOS
nucleotide	I-OOS
-	I-OOS
binding	I-OOS
regulatory	I-OOS
protein	I-OOS
(	I-OOS
G	I-OOS
protein	I-OOS
)	I-OOS
beta	I-OOS
gamma	I-OOS
dimers	O
that	O
were	O
active	O
in	O
reconstitution	O
assays	O
were	O
produced	O
in	O
insect	O
cells	O
using	O
the	O
baculovirus	O
/	O
Sf9	O
insect	O
cell	O
expression	O
system	O
.	O

Sf9	O
cells	O
were	O
infected	O
either	O
singly	O
or	O
in	O
combination	O
with	O
recombinant	O
baculoviruses	O
containing	O
a	O
human	O
G	O
-	O
protein	O
beta	O
1	O
gene	O
or	O
a	O
bovine	O
G	O
-	O
protein	O
gamma	O
2	O
gene	O
.	O

It	O
was	O
possible	O
to	O
express	O
the	O
beta	O
1	O
and	O
gamma	O
2	O
gene	O
products	O
independently	O
of	O
each	O
other	O
in	O
this	O
system	O
,	O
as	O
determined	O
by	O
using	O
immunological	O
and	O
metabolic	O
labeling	O
techniques	O
.	O

Further	O
,	O
the	O
ability	O
of	O
recombinant	O
beta	O
and	O
/	O
or	O
gamma	O
chains	O
to	O
function	O
in	O
defined	O
biochemical	O
assays	O
of	O
beta	B-OOS
gamma	I-OOS
activity	O
was	O
assessed	O
for	O
membrane	O
extracts	O
and	O
supernatant	O
fractions	O
from	O
infected	O
Sf9	O
cells	O
.	O

Extracts	O
of	O
cells	O
expressing	O
beta	O
or	O
gamma	O
chain	O
alone	O
were	O
inactive	O
in	O
these	O
assays	O
,	O
whereas	O
those	O
from	O
cells	O
coinfected	O
with	O
beta	O
1	O
and	O
gamma	O
2	O
did	O
display	O
activity	O
.	O

These	O
assays	O
were	O
used	O
to	O
identify	O
recombinant	O
beta	B-OOS
gamma	I-OOS
dimer	O
migration	O
during	O
chromatographic	O
purification	O
,	O
and	O
the	O
recombinant	O
dimers	O
were	O
purified	O
to	O
near	O
homogeneity	O
.	O

Both	O
the	O
membrane	O
-	O
associated	O
and	O
soluble	O
beta	B-OOS
gamma	I-OOS
dimers	O
facilitated	O
rhodopsin	O
-	O
catalyzed	O
guanosine	O
5	O
'	O
-	O
[	O
gamma	O
-	O
thio	O
]	O
triphosphate	O
binding	O
to	O
Gt	O
alpha	O
,	O
the	O
GTP	O
-	O
binding	O
subunit	O
of	O
the	O
retinal	O
G	O
protein	O
transducin	B-OOS
(	O
K0	O
.	O
5	O
of	O
13	O
+	O
/	O
-	O
2	O
and	O
36	O
+	O
/	O
-	O
5	O
nM	O
,	O
respectively	O
)	O
.	O

Both	O
recombinant	O
beta	B-OOS
gamma	I-OOS
dimers	O
also	O
facilitated	O
the	O
pertussis	O
toxin	O
-	O
catalyzed	O
ADP	O
-	O
ribosylation	O
of	O
Gt	O
alpha	O
with	O
equal	O
potency	O
(	O
K0	O
.	O
5	O
of	O
9	O
+	O
/	O
-	O
1	O
and	O
10	O
+	O
/	O
-	O
3	O
nM	O
for	O
membrane	O
and	O
soluble	O
dimers	O
,	O
respectively	O
)	O
.	O

[	O
3H	O
]	O
Mevalonolactone	O
labeling	O
showed	O
that	O
the	O
gamma	O
2	O
subunits	O
of	O
membrane	O
-	O
associated	O
beta	B-OOS
gamma	I-OOS
dimers	O
incorporated	O
radiolabel	O
,	O
whereas	O
in	O
the	O
soluble	O
form	O
they	O
did	O
not	O
.	O

Thus	O
,	O
prenyl	O
modification	O
of	O
gamma	O
2	O
directs	O
the	O
membrane	O
association	O
of	O
the	O
beta	B-OOS
1	I-OOS
gamma	I-OOS
2	I-OOS
dimer	O
and	O
increases	O
its	O
apparent	O
affinity	O
for	O
receptor	O
,	O
but	O
it	O
is	O
not	O
required	O
for	O
the	O
functional	O
interaction	O
(	O
s	O
)	O
of	O
the	O
dimer	O
.	O

Posttranslational	O
regulation	O
of	O
nitrogenase	O
in	O
Rhodobacter	O
capsulatus	O
:	O
existence	O
of	O
two	O
independent	O
regulatory	O
effects	O
of	O
ammonium	O
.	O

In	O
the	O
photosynthetic	O
bacterium	O
Rhodobacter	O
capsulatus	O
,	O
nitrogenase	O
activity	O
is	O
regulated	O
by	O
ADP	O
-	O
ribosylation	O
of	O
component	O
II	O
in	O
response	O
to	O
the	O
addition	O
of	O
ammonium	O
to	O
cultures	O
or	O
to	O
the	O
removal	O
of	O
light	O
.	O

The	O
ammonium	O
stimulus	O
results	O
in	O
a	O
fast	O
and	O
almost	O
complete	O
inhibition	O
of	O
the	O
in	O
vivo	O
acetylene	O
reduction	O
activity	O
,	O
termed	O
switch	O
-	O
off	O
,	O
which	O
is	O
reversed	O
after	O
the	O
ammonium	O
is	O
exhausted	O
.	O

In	O
the	O
present	O
study	O
of	O
the	O
response	O
of	O
cells	O
to	O
ammonium	O
,	O
ADP	O
-	O
ribosylation	O
of	O
component	O
II	O
occurred	O
but	O
could	O
not	O
account	O
for	O
the	O
extent	O
and	O
timing	O
of	O
the	O
inhibition	O
of	O
activity	O
.	O

The	O
presence	O
of	O
an	O
additional	O
response	O
was	O
confirmed	O
with	O
strains	O
expressing	O
mutant	O
component	O
II	O
proteins	O
;	O
although	O
these	O
proteins	O
are	O
not	O
a	O
substrate	O
for	O
ADP	O
-	O
ribosylation	O
,	O
the	O
strains	O
continued	O
to	O
exhibit	O
a	O
switch	O
-	O
off	O
response	O
to	O
ammonium	O
.	O

This	O
second	O
regulatory	O
response	O
of	O
nitrogenase	O
to	O
ammonium	O
was	O
found	O
to	O
be	O
synchronous	O
with	O
ADP	O
-	O
ribosylation	O
and	O
was	O
responsible	O
for	O
the	O
bulk	O
of	O
the	O
observed	O
effects	O
on	O
nitrogenase	O
activity	O
.	O

In	O
comparison	O
,	O
ADP	O
-	O
ribosylation	O
in	O
R	O
.	O
capsulatus	O
was	O
found	O
to	O
be	O
relatively	O
slow	O
and	O
incomplete	O
but	O
responded	O
independently	O
to	O
both	O
known	O
stimuli	O
,	O
darkness	O
and	O
ammonium	O
.	O

Based	O
on	O
the	O
in	O
vitro	O
nitrogenase	O
activity	O
of	O
both	O
the	O
wild	O
type	O
and	O
strains	O
whose	O
component	O
II	O
proteins	O
cannot	O
be	O
ADP	O
-	O
ribosylated	O
,	O
it	O
seems	O
likely	O
that	O
the	O
second	O
response	O
blocks	O
either	O
the	O
ATP	O
or	O
the	O
electron	O
supply	O
to	O
nitrogenase	O
.	O

Costimulation	O
of	O
peripheral	O
blood	O
T	O
cell	O
activation	O
by	O
human	O
endothelial	O
cells	O
.	O

Enhanced	O
IL	O
-	O
2	O
transcription	O
correlates	O
with	O
increased	O
c	O
-	O
fos	O
synthesis	O
and	O
increased	O
Fos	O
content	O
of	O
AP	B-Complex
-	I-Complex
1	I-Complex
.	O

Endothelial	O
cells	O
(	O
EC	O
)	O
act	O
as	O
APC	O
for	O
resting	O
PBL	O
in	O
vitro	O
,	O
and	O
may	O
have	O
important	O
roles	O
in	O
vivo	O
in	O
the	O
pathogenesis	O
of	O
allograft	O
rejection	O
and	O
delayed	O
hypersensitivity	O
.	O

We	O
previously	O
reported	O
that	O
human	O
umbilical	O
vein	O
EC	O
provide	O
costimulatory	O
signals	O
to	O
PHA	O
-	O
stimulated	O
PBL	O
via	O
CD2	O
:	O
lymphocyte	O
function	O
-	O
associated	O
Ag	O
-	O
3	O
and	O
an	O
unidentified	O
ligand	O
pair	O
,	O
resulting	O
in	O
a	O
three	O
-	O
to	O
eight	O
-	O
fold	O
enhancement	O
of	O
IL	O
-	O
2	O
production	O
.	O

The	O
physiologic	O
relevance	O
of	O
this	O
increase	O
was	O
demonstrated	O
by	O
the	O
proliferative	O
advantage	O
provided	O
by	O
EC	O
to	O
PBL	O
suboptimally	O
stimulated	O
with	O
mAb	O
OKT3	O
.	O

We	O
now	O
report	O
that	O
EC	O
costimulation	O
causes	O
increased	O
levels	O
of	O
IL	O
-	O
2	O
mRNA	O
as	O
a	O
result	O
of	O
increased	O
IL	O
-	O
2	O
transcription	O
in	O
PBL	O
.	O

We	O
therefore	O
examined	O
the	O
effects	O
of	O
EC	O
on	O
T	O
cell	O
nuclear	O
factors	O
known	O
to	O
regulate	O
IL	O
-	O
2	O
transcription	O
,	O
including	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
-	O
two	O
components	O
of	O
the	O
transcription	O
factor	O
AP	B-Complex
-	I-Complex
1	I-Complex
,	O
NFAT	O
,	O
and	O
others	O
.	O

PBL	O
constitutively	O
express	O
c	O
-	O
jun	O
transcripts	O
,	O
and	O
the	O
level	O
of	O
c	O
-	O
jun	O
mRNA	O
is	O
not	O
altered	O
by	O
PHA	O
activation	O
in	O
the	O
absence	O
or	O
presence	O
of	O
EC	O
.	O

In	O
contrast	O
,	O
c	O
-	O
fos	O
mRNA	O
is	O
absent	O
from	O
resting	O
T	O
cells	O
and	O
is	O
induced	O
on	O
PHA	O
activation	O
.	O

EC	O
alone	O
do	O
not	O
induce	O
c	O
-	O
fos	O
mRNA	O
but	O
augment	O
the	O
level	O
of	O
c	O
-	O
fos	O
mRNA	O
in	O
PHA	O
-	O
activated	O
T	O
cells	O
by	O
3	O
-	O
to	O
10	O
-	O
fold	O
.	O

This	O
effect	O
is	O
largely	O
independent	O
of	O
the	O
CD2	O
:	O
lymphocyte	O
function	O
-	O
associated	O
Ag	O
-	O
3	O
pathway	O
.	O

Gel	O
-	O
shift	O
analysis	O
reveals	O
the	O
constitutive	O
presence	O
of	O
nuclear	O
factors	O
in	O
resting	O
PBL	O
that	O
bind	O
to	O
the	O
proximal	O
AP	B-Complex
-	I-Complex
1	I-Complex
site	O
of	O
the	O
IL	O
-	O
2	O
promoter	O
and	O
that	O
contain	O
immunoreactive	O
c	O
-	O
Jun	O
but	O
not	O
c	O
-	O
Fos	O
protein	O
.	O

In	O
contrast	O
,	O
AP	B-Complex
-	I-Complex
1	I-Complex
from	O
PHA	O
-	O
activated	O
cells	O
contains	O
c	O
-	O
Jun	O
and	O
low	O
levels	O
of	O
c	O
-	O
Fos	O
.	O

Strikingly	O
,	O
costimulation	O
with	O
EC	O
results	O
in	O
a	O
dramatic	O
increase	O
(	O
up	O
to	O
15	O
-	O
fold	O
)	O
in	O
the	O
c	O
-	O
Fos	O
content	O
of	O
AP	B-Complex
-	I-Complex
1	I-Complex
.	O

Levels	O
of	O
other	O
nuclear	O
factors	O
involved	O
in	O
IL	O
-	O
2	O
regulation	O
were	O
not	O
altered	O
by	O
EC	O
,	O
although	O
NFAT	O
-	O
DNA	O
complexes	O
migrated	O
at	O
a	O
slightly	O
different	O
mobility	O
.	O

In	O
summary	O
,	O
our	O
data	O
suggest	O
that	O
changes	O
in	O
the	O
composition	O
of	O
transcription	O
factor	O
AP	B-Complex
-	I-Complex
1	I-Complex
is	O
a	O
key	O
molecular	O
mechanism	O
for	O
increasing	O
IL	O
-	O
2	O
transcription	O
and	O
may	O
underlie	O
the	O
phenomenon	O
of	O
costimulation	O
by	O
EC	O
.	O

A	O
novel	O
N	O
-	O
terminal	O
motif	O
for	O
palmitoylation	O
of	O
G	O
-	O
protein	O
alpha	O
subunits	O
.	O

We	O
have	O
examined	O
the	O
post	O
-	O
translational	O
processing	O
of	O
G	O
alpha	O
subunits	O
expressed	O
endogenously	O
in	O
rat	O
PC12	O
and	O
NG108	O
-	O
15	O
rat	O
/	O
mouse	O
hybrid	O
cells	O
,	O
and	O
after	O
transfection	O
of	O
cDNA	O
expression	O
constructs	O
into	O
COS	O
cells	O
.	O

Thioester	O
-	O
linked	O
palmitoylation	O
of	O
alpha	O
o	O
,	O
alpha	O
s	O
,	O
alpha	O
q	O
/	O
alpha	O
11	O
and	O
alpha	O
12	O
has	O
been	O
detected	O
by	O
metabolic	O
labelling	O
with	O
[	O
3H	O
]	O
palmitate	O
and	O
immunoprecipitation	O
.	O

Palmitoylation	O
of	O
alpha	O
o	O
occurs	O
post	O
-	O
translationally	O
in	O
cells	O
treated	O
with	O
protein	O
-	O
synthesis	O
inhibitors	O
,	O
suggesting	O
possible	O
dynamic	O
acylation	O
.	O

Palmitoylation	O
of	O
the	O
C	O
-	O
terminal	O
CAAX	O
motif	O
has	O
been	O
excluded	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
of	O
alpha	O
o	O
has	O
been	O
used	O
to	O
implicate	O
the	O
site	O
of	O
modification	O
as	O
a	O
cysteine	O
residue	O
next	O
to	O
the	O
N	O
-	O
terminal	O
myristoylated	O
glycine	O
,	O
in	O
a	O
novel	O
protein	O
-	O
lipid	O
modification	O
motif	O
Met	O
-	O
Gly	O
-	O
Cys	O
.	O

The	O
non	O
-	O
palmitoylated	O
alpha	O
o	O
mutant	O
is	O
still	O
myristoylated	O
but	O
shows	O
reduced	O
membrane	O
binding	O
,	O
suggesting	O
that	O
reversible	O
palmitoylation	O
may	O
regulate	O
G	O
alpha	O
localization	O
and	O
function	O
.	O

Regulation	O
of	O
the	O
Ets	O
-	O
related	O
transcription	O
factor	O
Elf	O
-	O
1	O
by	O
binding	O
to	O
the	O
retinoblastoma	O
protein	O
.	O

The	O
retinoblastoma	O
gene	O
product	O
(	O
Rb	O
)	O
is	O
a	O
nuclear	O
phosphoprotein	O
that	O
regulates	O
cell	O
cycle	O
progression	O
.	O

Elf	O
-	O
1	O
is	O
a	O
lymphoid	O
-	O
specific	O
Ets	O
transcription	O
factor	O
that	O
regulates	O
inducible	O
gene	O
expression	O
during	O
T	O
cell	O
activation	O
.	O

In	O
this	O
report	O
,	O
it	O
is	O
demonstrated	O
that	O
Elf	O
-	O
1	O
contains	O
a	O
sequence	O
motif	O
that	O
is	O
highly	O
related	O
to	O
the	O
Rb	O
binding	O
sites	O
of	O
several	O
viral	O
oncoproteins	O
and	O
binds	O
to	O
the	O
pocket	O
region	O
of	O
Rb	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Elf	O
-	O
1	O
binds	O
exclusively	O
to	O
the	O
underphosphorylated	O
form	O
of	O
Rb	O
and	O
fails	O
to	O
bind	O
to	O
Rb	O
mutants	O
derived	O
from	O
patients	O
with	O
retinoblastoma	O
.	O

Co	O
-	O
immunoprecipitation	O
experiments	O
demonstrated	O
an	O
association	O
between	O
Elf	O
-	O
1	O
and	O
Rb	O
in	O
resting	O
normal	O
human	O
T	O
cells	O
.	O

After	O
T	O
cell	O
activation	O
,	O
the	O
phosphorylation	O
of	O
Rb	O
results	O
in	O
the	O
release	O
of	O
Elf	O
-	O
1	O
,	O
which	O
is	O
correlated	O
temporally	O
with	O
the	O
activation	O
of	O
Elf	O
-	O
1	O
-	O
mediated	O
transcription	O
.	O

Overexpression	O
of	O
a	O
phosphorylation	O
-	O
defective	O
form	O
of	O
Rb	O
inhibited	O
Elf	O
-	O
1	O
-	O
dependent	O
transcription	O
during	O
T	O
cell	O
activation	O
.	O

These	O
results	O
demonstrate	O
that	O
Rb	O
interacts	O
specifically	O
with	O
a	O
lineage	O
-	O
restricted	O
Ets	O
transcription	O
factor	O
.	O

This	O
regulated	O
interaction	O
may	O
be	O
important	O
for	O
the	O
coordination	O
of	O
lineage	O
-	O
specific	O
effector	O
functions	O
such	O
as	O
lymphokine	O
production	O
with	O
cell	O
cycle	O
progression	O
in	O
activated	O
T	O
cells	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
functional	O
characterization	O
of	O
bovine	O
vitamin	O
K	O
-	O
dependent	O
gamma	O
-	O
carboxylase	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
cells	O
.	O

Coagulation	O
factor	O
IX	O
is	O
a	O
serine	O
protease	O
for	O
which	O
high	O
-	O
level	O
expression	O
of	O
biologically	O
active	O
protein	O
in	O
heterologous	O
cells	O
is	O
limited	O
due	O
to	O
inefficient	O
proteolytic	O
removal	O
of	O
the	O
propeptide	O
as	O
well	O
as	O
vitamin	O
K	O
-	O
dependent	O
carboxylation	O
of	O
multiple	O
amino	O
-	O
terminal	O
glutamic	O
acid	O
residues	O
.	O

We	O
have	O
overexpressed	O
the	O
vitamin	O
K	O
-	O
dependent	O
gamma	O
-	O
carboxylase	O
cDNA	O
and	O
monitored	O
its	O
ability	O
to	O
improve	O
factor	O
IX	O
processing	O
in	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
cells	O
.	O

From	O
amino	O
acid	O
sequence	O
analysis	O
of	O
bovine	O
liver	O
vitamin	O
K	O
-	O
dependent	O
gamma	O
-	O
carboxylase	O
,	O
degenerate	O
oligonucleotides	O
were	O
used	O
to	O
isolate	O
a	O
3	O
.	O
5	O
-	O
kbp	O
bovine	O
cDNA	O
that	O
encoded	O
a	O
758	O
-	O
residue	O
open	O
reading	O
frame	O
.	O

Expression	O
of	O
the	O
cDNA	O
in	O
COS	O
-	O
1	O
and	O
CHO	O
cells	O
yielded	O
17	O
-	O
and	O
16	O
-	O
fold	O
increases	O
in	O
the	O
in	O
vitro	O
gamma	O
-	O
carboxylase	O
activity	O
of	O
microsomal	O
preparations	O
,	O
respectively	O
.	O

Anti	O
-	O
serum	O
raised	O
against	O
a	O
predicted	O
peptide	O
sequence	O
reacted	O
with	O
a	O
94	O
-	O
kDa	O
polypeptide	O
in	O
the	O
partially	O
purified	O
bovine	O
liver	O
preparation	O
as	O
well	O
as	O
in	O
stably	O
transfected	O
CHO	O
cells	O
.	O

The	O
amount	O
of	O
antibody	O
reactivity	O
correlated	O
with	O
the	O
increased	O
ability	O
to	O
carboxylate	O
a	O
peptide	O
substrate	O
in	O
vitro	O
.	O

These	O
results	O
strongly	O
support	O
the	O
conclusion	O
that	O
the	O
cDNA	O
encodes	O
the	O
vitamin	O
K	O
-	O
dependent	O
gamma	O
-	O
carboxylase	O
.	O

Transient	O
transfection	O
of	O
the	O
gamma	O
-	O
carboxylase	O
expression	O
vector	O
into	O
factor	O
IX	O
-	O
expressing	O
CHO	O
cells	O
did	O
not	O
improve	O
the	O
specific	O
procoagulant	O
activity	O
of	O
secreted	O
factor	O
IX	O
.	O

In	O
contrast	O
,	O
transfection	O
of	O
an	O
expression	O
vector	O
encoding	O
the	O
propeptide	O
processing	O
enzyme	O
PACE	O
(	O
paired	O
basic	O
amino	O
acid	O
cleaving	O
enzyme	O
)	O
did	O
improve	O
the	O
specific	O
activity	O
of	O
secreted	O
factor	O
IX	O
by	O
3	O
-	O
fold	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
ability	O
of	O
CHO	O
cells	O
to	O
modify	O
glutamic	O
acid	O
residues	O
to	O
gamma	O
-	O
carboxyglutamic	O
acid	O
in	O
secreted	O
factor	O
IX	O
is	O
not	O
limited	O
by	O
the	O
expression	O
of	O
the	O
vitamin	O
K	O
-	O
dependent	O
gamma	O
-	O
carboxylase	O
alone	O
.	O

Molecular	O
basis	O
of	O
a	O
multiple	O
lymphokine	O
deficiency	O
in	O
a	O
patient	O
with	O
severe	O
combined	O
immunodeficiency	O
.	O

We	O
have	O
previously	O
reported	O
that	O
the	O
T	O
lymphocytes	O
of	O
a	O
child	O
with	O
severe	O
combined	O
immunodeficiency	O
are	O
defective	O
in	O
the	O
transcription	O
of	O
several	O
lymphokine	O
genes	O
that	O
include	O
IL2	O
,	O
IL3	O
,	O
IL4	O
,	O
and	O
IL5	O
,	O
which	O
encode	O
interleukins	O
2	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
(	O
IL	O
-	O
2	O
,	O
-	O
3	O
,	O
-	O
4	O
,	O
and	O
-	O
5	O
)	O
.	O

To	O
determine	O
whether	O
the	O
defect	O
in	O
the	O
patient	O
'	O
s	O
T	O
lymphocytes	O
involved	O
a	O
trans	O
-	O
acting	O
factor	O
common	O
to	O
the	O
affected	O
lymphokine	O
genes	O
,	O
we	O
examined	O
the	O
ability	O
of	O
nuclear	O
factors	O
from	O
the	O
patient	O
'	O
s	O
T	O
lymphocytes	O
to	O
bind	O
response	O
elements	O
present	O
in	O
the	O
regulatory	O
region	O
of	O
IL2	O
.	O

Nuclear	O
factor	O
NF	B-Complex
-	I-Complex
kB	I-Complex
,	O
activation	B-Complex
protein	I-Complex
1	I-Complex
(	O
AP	B-Complex
-	I-Complex
1	I-Complex
)	O
,	O
OCT	O
-	O
1	O
,	O
and	O
NF	O
-	O
IL	O
-	O
2B	O
binding	O
activity	O
were	O
normal	O
.	O

In	O
contrast	O
,	O
the	O
binding	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF	O
-	O
AT	O
)	O
to	O
its	O
response	O
element	O
in	O
the	O
IL2	O
enhancer	O
and	O
to	O
an	O
NF	O
-	O
AT	O
-	O
like	O
response	O
element	O
present	O
in	O
the	O
IL4	O
enhancer	O
was	O
abnormal	O
.	O

To	O
ascertain	O
whether	O
the	O
abnormal	O
NF	O
-	O
AT	O
binding	O
activity	O
was	O
related	O
to	O
an	O
impaired	O
function	O
,	O
we	O
transfected	O
patient	O
and	O
control	O
T	O
lymphocytes	O
with	O
constructs	O
containing	O
the	O
reporter	O
gene	O
encoding	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
under	O
the	O
control	O
of	O
the	O
entire	O
IL2	O
regulatory	O
region	O
or	O
of	O
multimers	O
of	O
individual	O
enhancer	O
sequences	O
.	O

CAT	O
expression	O
directed	O
by	O
the	O
IL2	O
regulatory	O
region	O
or	O
by	O
a	O
multimer	O
of	O
the	O
NF	O
-	O
AT	O
-	O
binding	O
site	O
was	O
markedly	O
lower	O
in	O
the	O
patient	O
relative	O
to	O
controls	O
.	O

In	O
contrast	O
,	O
CAT	O
gene	O
expression	O
directed	O
by	O
a	O
multimer	O
of	O
the	O
OCT	O
-	O
1	O
proximal	O
(	O
OCT	O
-	O
1p	O
)	O
-	O
binding	O
site	O
was	O
equivalent	O
in	O
patient	O
and	O
controls	O
.	O

These	O
results	O
indicate	O
that	O
an	O
abnormality	O
of	O
/	O
or	O
influencing	O
NF	O
-	O
AT	O
may	O
underlie	O
the	O
multiple	O
lymphokine	O
deficiency	O
in	O
this	O
patient	O
.	O

Functional	O
characterization	O
of	O
the	O
murine	O
homolog	O
of	O
the	O
B	O
cell	O
-	O
specific	O
coactivator	O
BOB	O
.	O
1	O
/	O
OBF	O
.	O
1	O
.	O

B	O
cell	O
-	O
specific	O
transcriptional	O
promoter	O
activity	O
mediated	O
by	O
the	O
octamer	O
motif	O
requires	O
the	O
Oct1	O
or	O
Oct2	O
protein	O
and	O
additional	O
B	O
cell	O
-	O
restricted	O
cofactors	O
.	O

One	O
such	O
cofactor	O
,	O
BOB	O
.	O
1	O
/	O
OBF	O
.	O
1	O
,	O
was	O
recently	O
isolated	O
from	O
human	O
B	O
cells	O
.	O

Here	O
,	O
we	O
describe	O
the	O
isolation	O
and	O
detailed	O
characterization	O
of	O
the	O
murine	O
homolog	O
.	O

Full	O
-	O
length	O
cDNAs	O
and	O
genomic	O
clones	O
were	O
isolated	O
,	O
and	O
the	O
gene	O
structure	O
was	O
determined	O
.	O

Comparison	O
of	O
the	O
deduced	O
amino	O
acids	O
shows	O
88	O
%	O
sequence	O
identity	O
between	O
mouse	O
and	O
human	O
BOB	O
.	O
1	O
/	O
OBF	O
.	O
1	O
.	O

The	O
NH2	O
-	O
terminal	O
126	O
amino	O
acids	O
of	O
BOB	O
.	O
1	O
/	O
OBF	O
.	O
1	O
are	O
both	O
essential	O
and	O
sufficient	O
for	O
interaction	O
with	O
the	O
POU	O
domains	O
of	O
either	O
Oct1	O
or	O
Oct2	O
.	O

This	O
protein	O
-	O
protein	O
interaction	O
does	O
not	O
require	O
the	O
simultaneous	O
binding	O
of	O
Oct	O
proteins	O
to	O
DNA	O
,	O
and	O
high	O
resolution	O
footprinting	O
of	O
the	O
Oct	O
-	O
DNA	O
interaction	O
reveals	O
that	O
binding	O
of	O
BOB	O
.	O
1	O
/	O
OBF	O
.	O
1	O
to	O
Oct1	O
or	O
Oct2	O
does	O
not	O
alter	O
the	O
interaction	O
with	O
DNA	O
.	O

BOB	O
.	O
1	O
/	O
OBF	O
.	O
1	O
can	O
efficiently	O
activate	O
octamer	O
-	O
dependent	O
promoters	O
in	O
fibroblasts	O
;	O
however	O
,	O
it	O
fails	O
to	O
stimulate	O
octamer	O
-	O
dependent	O
enhancer	O
activity	O
.	O

Fusion	O
of	O
subdomains	O
of	O
BOB	O
.	O
1	O
/	O
OBF	O
.	O
1	O
with	O
the	O
GAL4	O
DNA	O
binding	O
domain	O
reveals	O
that	O
both	O
NH2	O
-	O
and	O
COOH	O
-	O
terminal	O
domains	O
of	O
BOB	O
.	O
1	O
/	O
OBF	O
.	O
1	O
contribute	O
to	O
full	O
transactivation	O
function	O
,	O
the	O
COOH	O
-	O
terminal	O
domain	O
is	O
more	O
efficient	O
in	O
this	O
transactivation	O
assay	O
.	O

Consistent	O
with	O
the	O
failure	O
of	O
full	O
-	O
length	O
BOB	O
.	O
1	O
/	O
OBF	O
.	O
1	O
to	O
stimulate	O
octamer	O
-	O
dependent	O
enhancer	O
elements	O
in	O
non	O
B	O
cells	O
,	O
the	O
GAL4	O
fusions	O
likewise	O
only	O
stimulate	O
from	O
a	O
promoter	O
-	O
proximal	O
position	O
.	O

A	O
physiological	O
role	O
for	O
Saccharomyces	O
cerevisiae	O
copper	O
/	O
zinc	O
superoxide	O
dismutase	O
in	O
copper	O
buffering	O
.	O

The	O
copper	O
toxicity	O
of	O
yeast	O
lacking	O
the	O
CUP1	O
metallothionein	O
is	O
suppressed	O
by	O
overexpression	O
of	O
the	O
CRS4	O
gene	O
.	O

We	O
now	O
demonstrate	O
that	O
CRS4	O
is	O
equivalent	O
to	O
SOD1	O
,	O
encoding	O
copper	O
/	O
zinc	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
.	O

While	O
overexpression	O
of	O
SOD1	O
enhanced	O
copper	O
resistance	O
,	O
a	O
deletion	O
of	O
SOD1	O
,	O
but	O
not	O
SOD2	O
(	O
encoding	O
manganese	O
SOD	O
)	O
,	O
conferred	O
an	O
increased	O
sensitivity	O
toward	O
copper	O
.	O

This	O
role	O
of	O
SOD1	O
in	O
copper	O
buffering	O
appears	O
unrelated	O
to	O
its	O
superoxide	O
scavenging	O
activity	O
,	O
since	O
the	O
enzyme	O
protected	O
against	O
copper	O
toxicity	O
in	O
anaerobic	O
as	O
well	O
as	O
aerobic	O
conditions	O
.	O

The	O
distinct	O
roles	O
of	O
SOD1	O
in	O
copper	O
and	O
oxygen	O
radical	O
homeostasis	O
could	O
also	O
be	O
separated	O
genetically	O
:	O
the	O
pmr1	O
,	O
bsd2	O
,	O
and	O
ATX1	O
genes	O
that	O
suppress	O
oxygen	O
toxicity	O
in	O
sod1	O
mutants	O
failed	O
to	O
suppress	O
the	O
copper	O
sensitivity	O
of	O
these	O
cells	O
.	O

The	O
Saccharomyces	O
cerevisiae	O
SOD1	O
gene	O
is	O
transcriptionally	O
induced	O
by	O
copper	O
and	O
the	O
ACE1	O
transactivator	O
,	O
and	O
we	O
demonstrate	O
here	O
that	O
this	O
induction	O
of	O
SOD1	O
promotes	O
protection	O
against	O
copper	O
toxicity	O
but	O
is	O
not	O
needed	O
for	O
the	O
SOD1	O
-	O
protection	O
against	O
oxygen	O
free	O
radicals	O
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
copper	O
/	O
zinc	O
SOD	O
functions	O
in	O
the	O
homeostasis	O
of	O
copper	O
via	O
mechanisms	O
distinct	O
from	O
superoxide	O
scavenging	O
.	O

Size	O
variations	O
in	O
the	O
mucin	O
-	O
type	O
domain	O
of	O
hamster	O
oviductin	O
:	O
identification	O
of	O
the	O
polypeptide	O
precursors	O
and	O
characterization	O
of	O
their	O
biosynthetic	O
maturation	O
.	O

The	O
recent	O
sequencing	O
of	O
a	O
cDNA	O
clone	O
for	O
hamster	O
oviductin	O
revealed	O
that	O
this	O
zona	O
pellucida	O
-	O
associated	O
glycoprotein	O
is	O
a	O
particularly	O
intriguing	O
chimeric	O
molecule	O
because	O
it	O
encloses	O
regions	O
of	O
significant	O
similarity	O
with	O
chitinase	O
-	O
related	O
proteins	O
as	O
well	O
as	O
a	O
carboxyterminal	O
mucin	O
-	O
type	O
domain	O
.	O

This	O
domain	O
contains	O
contiguous	O
Ser	O
/	O
Thr	O
-	O
rich	O
repeated	O
stretches	O
of	O
15	O
amino	O
acids	O
;	O
similar	O
units	O
are	O
also	O
found	O
in	O
the	O
deduced	O
sequence	O
of	O
human	O
oviductin	O
.	O

Such	O
structural	O
domains	O
constitute	O
a	O
central	O
feature	O
of	O
mucins	O
.	O

We	O
amplified	O
this	O
region	O
from	O
16	O
hamster	O
oviductin	O
cDNA	O
clones	O
and	O
identified	O
three	O
length	O
variants	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
biosynthetic	O
maturation	O
of	O
the	O
glycoprotein	O
,	O
a	O
high	O
-	O
titer	O
antiserum	O
against	O
synthetic	O
peptides	O
derived	O
from	O
internal	O
sequences	O
of	O
hamster	O
oviductin	O
was	O
produced	O
and	O
used	O
in	O
pulse	O
-	O
chase	O
experiments	O
.	O

Two	O
major	O
and	O
one	O
minor	O
polypeptide	O
precursors	O
were	O
identified	O
from	O
tunicamycin	O
-	O
treated	O
cell	O
lysates	O
and	O
in	O
vitro	O
translated	O
products	O
from	O
oviductal	O
poly	O
(	O
A	O
)	O
+	O
RNA	O
.	O

Their	O
apparent	O
molecular	O
masses	O
correlate	O
with	O
the	O
predicted	O
lengths	O
of	O
the	O
three	O
size	O
variants	O
identified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
.	O

Using	O
glycosylation	O
and	O
transport	O
inhibitors	O
,	O
we	O
sought	O
to	O
dissect	O
the	O
posttranslational	O
sequential	O
steps	O
leading	O
to	O
the	O
final	O
maturation	O
of	O
hamster	O
oviductin	O
and	O
proposed	O
a	O
compartmental	O
model	O
for	O
its	O
biosynthesis	O
.	O

The	O
polypeptide	O
precursors	O
are	O
rapidly	O
converted	O
in	O
the	O
endoplasmic	O
reticulum	O
into	O
an	O
N	O
-	O
and	O
O	O
-	O
glycosylated	O
premature	O
form	O
of	O
80	O
-	O
90	O
kDa	O
(	O
time	O
<	O
20	O
min	O
)	O
,	O
which	O
is	O
further	O
O	O
-	O
glycosylated	O
and	O
sulfated	O
in	O
the	O
trans	O
-	O
Golgi	O
network	O
,	O
giving	O
rise	O
to	O
the	O
secreted	O
species	O
of	O
160	O
-	O
350	O
kDa	O
.	O

The	O
polymorphism	O
in	O
the	O
heavily	O
O	O
-	O
glycosylated	O
region	O
of	O
hamster	O
oviductin	O
is	O
predicted	O
to	O
increase	O
the	O
heterogeneity	O
of	O
the	O
glycoprotein	O
.	O

Such	O
changes	O
may	O
alter	O
the	O
putative	O
biological	O
function	O
of	O
the	O
different	O
variants	O
mediated	O
by	O
their	O
mucin	O
-	O
type	O
domain	O
,	O
such	O
as	O
protection	O
of	O
the	O
embryo	O
and	O
/	O
or	O
adhesion	O
-	O
related	O
phenomena	O
.	O

Coexpression	O
of	O
the	O
interleukin	O
-	O
13	O
and	O
interleukin	O
-	O
4	O
genes	O
correlates	O
with	O
their	O
physical	O
linkage	O
in	O
the	O
cytokine	O
gene	O
cluster	O
on	O
human	O
chromosome	O
5q23	O
-	O
31	O
.	O

Interleukin	O
-	O
13	O
(	O
IL	O
-	O
13	O
)	O
and	O
IL	O
-	O
4	O
are	O
cytokines	O
produced	O
by	O
T	O
cells	O
that	O
are	O
encoded	O
by	O
the	O
q23	O
-	O
31	O
region	O
of	O
human	O
chromosome	O
5	O
.	O

To	O
investigate	O
the	O
regulation	O
of	O
IL	O
-	O
13	O
gene	O
expression	O
by	O
T	O
cells	O
,	O
we	O
isolated	O
and	O
sequenced	O
the	O
human	O
IL	O
-	O
13	O
gene	O
,	O
analyzed	O
its	O
5	O
'	O
-	O
flanking	O
region	O
for	O
potential	O
transcriptional	O
activation	O
elements	O
,	O
and	O
examined	O
its	O
expression	O
in	O
nontransformed	O
T	O
-	O
lineage	O
cell	O
populations	O
.	O

The	O
human	O
IL	O
-	O
13	O
gene	O
was	O
located	O
12	O
.	O
5	O
-	O
kb	O
upstream	O
of	O
the	O
IL	O
-	O
4	O
gene	O
and	O
2	O
-	O
kb	O
downstream	O
of	O
a	O
CpG	O
island	O
.	O

The	O
IL	O
-	O
13	O
gene	O
5	O
'	O
flank	O
region	O
included	O
a	O
segment	O
with	O
sequence	O
homology	O
to	O
P	O
elements	O
of	O
the	O
IL	O
-	O
4	O
promoter	O
involved	O
in	O
transcriptional	O
activation	O
in	O
T	O
cells	O
.	O

Mutation	O
of	O
the	O
IL	O
-	O
13	O
P	O
element	O
site	O
significantly	O
reduced	O
IL	O
-	O
13	O
promoter	O
activity	O
in	O
response	O
to	O
T	O
-	O
cell	O
activation	O
.	O

Oligonucleotides	O
containing	O
the	O
IL	O
-	O
13	O
or	O
IL	O
-	O
4	O
P	O
element	O
sites	O
specifically	O
bound	O
the	O
transcriptional	O
activator	O
protein	O
,	O
nuclear	O
factor	O
-	O
activated	O
T	O
cells	O
,	O
preformed	O
(	O
NF	O
-	O
ATp	O
)	O
,	O
when	O
incubated	O
with	O
nuclear	O
protein	O
extracts	O
from	O
activated	O
T	O
cells	O
.	O

Similar	O
to	O
IL	O
-	O
4	O
,	O
IL	O
-	O
13	O
mRNA	O
expression	O
was	O
highest	O
in	O
T	O
-	O
cell	O
populations	O
enriched	O
for	O
cells	O
that	O
had	O
previously	O
been	O
primed	O
in	O
vivo	O
or	O
in	O
vitro	O
,	O
indicating	O
that	O
priming	O
increases	O
the	O
expression	O
of	O
the	O
IL	O
-	O
13	O
and	O
IL	O
-	O
4	O
genes	O
in	O
a	O
coordinate	O
manner	O
.	O

Because	O
the	O
primed	O
T	O
cells	O
contain	O
higher	O
levels	O
of	O
nuclear	O
NF	O
-	O
ATp	O
,	O
capable	O
of	O
binding	O
to	O
P	O
elements	O
of	O
the	O
IL	O
-	O
4	O
and	O
IL	O
-	O
13	O
promoters	O
,	O
than	O
do	O
freshly	O
-	O
isolated	O
T	O
cells	O
,	O
the	O
NF	O
-	O
AT	O
-	O
binding	O
P	O
elements	O
are	O
attractive	O
candidates	O
to	O
mediate	O
the	O
coordinate	O
expression	O
of	O
these	O
two	O
cytokine	O
genes	O
.	O

The	O
acylation	O
of	O
megakaryocyte	O
proteins	O
:	O
glycoprotein	O
IX	O
is	O
primarily	O
myristoylated	O
while	O
glycoprotein	B-Complex
Ib	I-Complex
is	O
palmitoylated	O
.	O

The	O
acylation	O
of	O
megakaryocyte	O
proteins	O
was	O
studied	O
with	O
special	O
emphasis	O
on	O
the	O
myristoylation	O
and	O
palmitoylation	O
of	O
the	O
glycoprotein	B-Complex
(	I-Complex
GP	I-Complex
)	I-Complex
Ib	I-Complex
complex	O
.	O

Guinea	O
pig	O
megakaryocytes	O
were	O
purified	O
and	O
separated	O
into	O
subpopulations	O
at	O
different	O
phases	O
of	O
maturation	O
.	O

Cells	O
were	O
incubated	O
with	O
[	O
3H	O
]	O
myristate	O
,	O
[	O
3H	O
]	O
palmitate	O
,	O
or	O
[	O
3H	O
]	O
acetate	O
to	O
study	O
endogenous	O
protein	O
acylation	O
.	O

Cycloheximide	O
was	O
used	O
to	O
distinguish	O
between	O
cotranslational	O
and	O
posttranslational	O
acylation	O
and	O
hydroxylamine	O
to	O
distinguish	O
between	O
thioester	O
and	O
amide	O
linkages	O
.	O

After	O
incubations	O
,	O
delipidated	O
proteins	O
or	O
GPIb	B-Complex
complex	O
subunits	O
,	O
immunoprecipitated	O
with	O
PG	O
-	O
1	O
,	O
AN	O
-	O
51	O
or	O
FMC	O
-	O
25	O
monoclonal	O
antibody	O
,	O
were	O
separated	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
and	O
assessed	O
by	O
fluorography	O
.	O

Radiolabeled	O
fatty	O
acids	O
bound	O
to	O
GPIX	O
and	O
GPIb	B-Complex
were	O
also	O
analyzed	O
by	O
high	O
pressure	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
and	O
scintillation	O
spectrometry	O
.	O

With	O
[	O
3H	O
]	O
myristic	O
acid	O
and	O
[	O
3H	O
]	O
acetate	O
,	O
GPIX	O
was	O
found	O
to	O
be	O
a	O
major	O
myristoylated	O
protein	O
in	O
megakaryocytes	O
and	O
CHRF	O
-	O
288	O
cells	O
.	O

Myristic	O
acid	O
was	O
linked	O
to	O
GPIX	O
by	O
an	O
amide	O
bond	O
,	O
and	O
this	O
process	O
occurred	O
cotranslationally	O
.	O

With	O
[	O
3H	O
]	O
acetate	O
,	O
GPIb	B-Complex
was	O
primarily	O
palmitoylated	O
,	O
but	O
with	O
[	O
3H	O
]	O
myristate	O
,	O
GPIb	B-Complex
was	O
acylated	O
with	O
about	O
equal	O
mounts	O
of	O
myristic	O
acid	O
and	O
palmitic	O
acids	O
.	O

Both	O
fatty	O
acids	O
were	O
linked	O
to	O
GPIb	B-Complex
by	O
thioester	O
bonds	O
,	O
and	O
acylation	O
was	O
posttranslational	O
.	O

The	O
myristoylation	O
of	O
GPIX	O
while	O
the	O
palmitoylation	O
of	O
GPIb	B-Complex
occurred	O
throughout	O
megakaryocyte	O
maturation	O
.	O

Myristoylation	O
and	O
palmitoylation	O
may	O
have	O
different	O
functions	O
relevant	O
to	O
the	O
assembly	O
of	O
the	O
GPIb	B-Complex
complex	O
in	O
megakaryocytes	O
.	O

Yeast	O
SNF1	O
protein	O
kinase	O
interacts	O
with	O
SIP4	O
,	O
a	O
C6	O
zinc	O
cluster	O
transcriptional	O
activator	O
:	O
a	O
new	O
role	O
for	O
SNF1	O
in	O
the	O
glucose	O
response	O
.	O

The	O
SNF1	O
protein	O
kinase	O
has	O
been	O
widely	O
conserved	O
in	O
plants	O
and	O
mammals	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
SNF1	O
is	O
essential	O
for	O
expression	O
of	O
glucose	O
-	O
repressed	O
genes	O
in	O
response	O
to	O
glucose	O
deprivation	O
.	O

Previous	O
studies	O
supported	O
a	O
role	O
for	O
SNF1	O
in	O
relieving	O
transcriptional	O
repression	O
.	O

Here	O
,	O
we	O
report	O
evidence	O
that	O
SNF1	O
modulates	O
function	O
of	O
a	O
transcriptional	O
activator	O
,	O
SIP4	O
,	O
which	O
was	O
identified	O
in	O
a	O
two	O
-	O
hybrid	O
screen	O
for	O
interaction	O
with	O
SNF1	O
.	O

The	O
N	O
terminus	O
of	O
the	O
predicted	O
96	O
-	O
kDa	O
SIP4	O
protein	O
is	O
homologous	O
to	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
GAL4	O
family	O
of	O
transcriptional	O
activators	O
,	O
with	O
a	O
C6	O
zinc	O
cluster	O
adjacent	O
to	O
a	O
coiled	O
-	O
coil	O
motif	O
The	O
C	O
terminus	O
contains	O
a	O
leucine	O
zipper	O
motif	O
and	O
an	O
acidic	O
region	O
.	O

When	O
bound	O
to	O
DNA	O
,	O
a	O
LexA	O
-	O
SIP4	O
fusion	O
activates	O
transcription	O
of	O
a	O
reporter	O
gene	O
.	O

Transcriptional	O
activation	O
by	O
SIP4	O
is	O
regulated	O
by	O
glucose	O
and	O
depends	O
on	O
the	O
SNF1	O
protein	O
kinase	O
.	O

Moreover	O
,	O
SIP4	O
is	O
differentially	O
phosphorylated	O
in	O
response	O
to	O
glucose	O
availability	O
,	O
and	O
phosphorylation	O
requires	O
SNF1	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
SNF1	O
kinase	O
interacts	O
with	O
a	O
transcriptional	O
activator	O
to	O
modulate	O
its	O
activity	O
and	O
provide	O
the	O
first	O
direct	O
evidence	O
for	O
a	O
role	O
of	O
SNF1	O
in	O
activating	O
transcription	O
in	O
response	O
to	O
glucose	O
limitation	O
.	O

The	O
role	O
of	O
G	O
protein	O
methylation	O
in	O
the	O
function	O
of	O
a	O
geranylgeranylated	O
beta	B-OOS
gamma	I-OOS
isoform	O
.	O

The	O
gamma	O
subunit	O
of	O
heterotrimeric	O
G	O
proteins	O
is	O
isoprenylated	O
and	O
methylated	O
on	O
its	O
carboxyl	O
terminal	O
cysteine	O
residue	O
.	O

While	O
retinal	O
transducin	B-OOS
is	O
farnesylated	O
,	O
all	O
other	O
gamma	O
subunits	O
are	O
modified	O
by	O
geranylgeranylation	O
.	O

An	O
immobilized	O
form	O
of	O
pig	O
liver	O
esterase	O
(	O
iPLE	O
)	O
is	O
able	O
to	O
hydrolyze	O
the	O
methyl	O
ester	O
of	O
a	O
geranylgeranylated	O
beta	B-OOS
gamma	I-OOS
isoform	O
(	O
beta	B-OOS
1	I-OOS
gamma	I-OOS
2	I-OOS
)	O
.	O

Since	O
methylation	O
is	O
the	O
only	O
reversible	O
reaction	O
in	O
the	O
isoprenylation	O
pathway	O
,	O
it	O
could	O
be	O
a	O
site	O
of	O
regulation	O
of	O
G	O
protein	O
activity	O
.	O

With	O
both	O
the	O
methylated	O
and	O
demethylated	O
beta	B-OOS
1	I-OOS
gamma	I-OOS
2	I-OOS
now	O
available	O
,	O
the	O
role	O
of	O
methylation	O
for	O
a	O
geranylgeranylated	O
heterotrimeric	O
G	O
protein	O
may	O
be	O
addressed	O
.	O

Here	O
,	O
it	O
is	O
reported	O
that	O
methylation	O
has	O
no	O
effect	O
on	O
the	O
ability	O
of	O
beta	B-OOS
gamma	I-OOS
to	O
interact	O
with	O
an	O
alpha	O
subunit	O
,	O
as	O
probed	O
by	O
ADP	O
-	O
ribosylation	O
studies	O
with	O
pertussis	O
toxin	O
,	O
and	O
has	O
a	O
small	O
effect	O
(	O
less	O
than	O
2	O
-	O
fold	O
)	O
on	O
the	O
ability	O
of	O
geranylgeranylated	O
beta	B-OOS
gamma	I-OOS
to	O
activate	O
phosphatidylinositol	O
-	O
specific	O
phospholipase	O
C	O
(	O
PIPLC	O
)	O
and	O
phosphoinositide	O
3	O
kinase	O
(	O
PI3K	O
)	O
.	O

In	O
binding	O
studies	O
,	O
demethylation	O
only	O
slightly	O
decreased	O
the	O
ability	O
of	O
beta	B-OOS
1	I-OOS
gamma	I-OOS
2	I-OOS
to	O
adhere	O
to	O
azolectin	O
vesicles	O
.	O

Therefore	O
,	O
methylation	O
of	O
heterotrimeric	O
G	O
proteins	O
appears	O
to	O
have	O
only	O
a	O
minor	O
effect	O
in	O
signal	O
transduction	O
processes	O
which	O
can	O
be	O
correlated	O
to	O
a	O
decrease	O
in	O
hydrophobicity	O
of	O
the	O
beta	B-OOS
gamma	I-OOS
subunit	O
.	O

Rate	O
limitations	O
in	O
posttranslational	O
processing	O
by	O
the	O
mammary	O
gland	O
of	O
transgenic	O
animals	O
.	O

Our	O
studies	O
in	O
transgenic	O
animal	O
bioreactors	O
sought	O
to	O
determine	O
the	O
rate	O
limitations	O
in	O
posttranslational	O
processing	O
of	O
recombinant	O
human	O
protein	O
C	O
(	O
rhPC	O
)	O
made	O
in	O
mammary	O
gland	O
of	O
mice	O
and	O
pigs	O
.	O

Human	O
protein	O
C	O
(	O
hPC	O
)	O
is	O
a	O
complex	O
plasma	O
protein	O
containing	O
nine	O
gamma	O
-	O
carboxylated	O
glutamic	O
acid	O
(	O
gla	O
)	O
residues	O
that	O
bind	O
calcium	O
at	O
about	O
1	O
to	O
3	O
mM	O
.	O

Gamma	O
carboxylation	O
is	O
a	O
vitamin	O
K	O
-	O
dependent	O
posttranslational	O
modification	O
.	O

The	O
effect	O
of	O
rhPC	O
synthesis	O
rate	O
on	O
the	O
extent	O
of	O
gamma	O
-	O
carboxylation	O
of	O
glutamic	O
acid	O
was	O
studied	O
.	O

We	O
have	O
perturbed	O
the	O
biosynthesis	O
of	O
rhPC	O
by	O
using	O
two	O
different	O
transgenes	O
to	O
direct	O
mammary	O
gland	O
-	O
specific	O
expression	O
.	O

Promoter	O
elements	O
of	O
the	O
murine	O
whey	O
acid	O
protein	O
(	O
mWAP	O
)	O
gene	O
were	O
used	O
to	O
drive	O
the	O
expression	O
of	O
hPC	O
-	O
cDNA	O
and	O
hPC	O
-	O
genomic	O
transgenes	O
.	O

Transgenic	O
mice	O
with	O
hPC	O
-	O
cDNA	O
and	O
hPC	O
-	O
genomic	O
sequences	O
gave	O
expression	O
levels	O
of	O
11	O
+	O
/	O
-	O
4	O
micrograms	O
rhPC	O
/	O
ml	O
of	O
milk	O
and	O
895	O
+	O
/	O
-	O
21	O
micrograms	O
rhPC	O
/	O
ml	O
of	O
milk	O
,	O
respectively	O
.	O

Transgenic	O
pigs	O
with	O
hPC	O
-	O
cDNA	O
and	O
hPC	O
-	O
genomic	O
sequences	O
gave	O
expression	O
levels	O
of	O
100	O
to	O
500	O
micrograms	O
rhPC	O
/	O
ml	O
of	O
milk	O
and	O
800	O
to	O
2000	O
micrograms	O
rhPC	O
/	O
ml	O
of	O
milk	O
,	O
respectively	O
.	O

A	O
monoclonal	O
antibody	O
(	O
7D7B10	O
-	O
mAb	O
)	O
that	O
binds	O
an	O
epitope	O
in	O
the	O
gla	O
domain	O
of	O
hPC	O
in	O
the	O
absence	O
of	O
calcium	O
was	O
used	O
to	O
study	O
the	O
conformational	O
behavior	O
of	O
immunopurified	O
rhPC	O
.	O

Immunopurified	O
rhPC	O
from	O
lower	O
expressing	O
mice	O
and	O
pigs	O
gave	O
a	O
calcium	O
-	O
dependent	O
binding	O
inhibition	O
by	O
7D7B10	O
-	O
mAb	O
similar	O
to	O
that	O
of	O
hPC	O
.	O

Immunopurified	O
rhPC	O
from	O
higher	O
expressing	O
mice	O
and	O
pigs	O
gave	O
a	O
less	O
calcium	O
-	O
dependent	O
response	O
.	O

This	O
study	O
suggests	O
that	O
a	O
rate	O
limitation	O
in	O
gamma	O
-	O
carboxylation	O
by	O
the	O
mammary	O
gland	O
occurs	O
at	O
expression	O
levels	O
about	O
>	O
20	O
micrograms	O
/	O
ml	O
in	O
mice	O
and	O
>	O
500	O
micrograms	O
/	O
ml	O
in	O
pigs	O
.	O

Rapid	O
identification	O
of	O
phosphopeptide	O
ligands	O
for	O
SH2	O
domains	O
.	O

Screening	O
of	O
peptide	O
libraries	O
by	O
fluorescence	O
-	O
activated	O
bead	O
sorting	O
.	O

A	O
method	O
for	O
the	O
identification	O
of	O
high	O
-	O
affinity	O
ligands	O
to	O
SH2	O
domains	O
by	O
fluorescence	O
-	O
activated	O
bead	O
sorting	O
(	O
FABS	O
)	O
was	O
established	O
.	O

Recombinant	O
SH2	O
domains	O
,	O
expressed	O
as	O
glutathione	O
S	O
-	O
transferase	O
(	O
GST	O
)	O
fusion	O
proteins	O
,	O
were	O
incubated	O
with	O
a	O
phosphotyrosine	O
(	O
Y	O
*	O
)	O
-	O
containing	O
peptide	O
library	O
.	O

6	O
.	O
4	O
x	O
10	O
(	O
5	O
)	O
individual	O
peptides	O
of	O
nine	O
amino	O
acids	O
in	O
length	O
(	O
EPX6Y	O
*	O
X19X7X19X7X6	O
)	O
were	O
each	O
displayed	O
on	O
beads	O
.	O

Phosphopeptide	O
interaction	O
of	O
a	O
given	O
SH2	O
domain	O
was	O
monitored	O
by	O
binding	O
of	O
fluorescein	O
isothiocyanate	O
-	O
labeled	O
antibodies	O
directed	O
against	O
GST	O
.	O

High	O
-	O
fluorescence	O
beads	O
were	O
isolated	O
by	O
flow	O
cytometric	O
sorting	O
.	O

Subsequent	O
pool	O
sequencing	O
of	O
the	O
selected	O
beads	O
revealed	O
a	O
distinct	O
pattern	O
of	O
phosphotyrosine	O
-	O
containing	O
motifs	O
for	O
each	O
individual	O
SH2	O
domain	O
:	O
the	O
SH2	O
domain	O
of	O
the	O
adapter	O
protein	O
Grb2	O
predominantly	O
selected	O
beads	O
with	O
the	O
sequence	O
Y	O
*	O
ENDP	O
,	O
whereas	O
the	O
C	O
-	O
terminal	O
SH2	O
domain	O
of	O
the	O
tyrosine	O
kinase	O
Syk	O
selected	O
Y	O
*	O
EELD	O
,	O
each	O
motif	O
representing	O
the	O
most	O
frequently	O
found	O
residues	O
C	O
-	O
terminal	O
to	O
the	O
phosphotyrosine	O
.	O

For	O
deconvolution	O
studies	O
,	O
soluble	O
phosphopeptides	O
comprising	O
variations	O
of	O
the	O
Grb2	O
motifs	O
were	O
resynthesized	O
and	O
analyzed	O
by	O
surface	O
plasmon	O
resonance	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
-	O
related	O
protein	O
:	O
a	O
ligand	O
and	O
specific	O
activator	O
of	O
the	O
tyrosine	O
kinase	O
receptor	O
Flt4	O
.	O

The	O
tyrosine	O
kinases	O
Flt4	O
,	O
Flt1	O
,	O
and	O
Flk1	O
(	O
or	O
KDR	O
)	O
constitute	O
a	O
family	O
of	O
endothelial	O
cell	O
-	O
specific	O
receptors	O
with	O
seven	O
immunoglobulin	O
-	O
like	O
domains	O
and	O
a	O
split	O
kinase	O
domain	O
.	O

Flt1	O
and	O
Flk1	O
have	O
been	O
shown	O
to	O
play	O
key	O
roles	O
in	O
vascular	O
development	O
;	O
these	O
two	O
receptors	O
bind	O
and	O
are	O
activated	O
by	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
.	O

No	O
ligand	O
has	O
been	O
identified	O
for	O
Flt4	O
,	O
whose	O
expression	O
becomes	O
restricted	O
during	O
development	O
to	O
the	O
lymphatic	O
endothelium	O
.	O

We	O
have	O
identified	O
cDNA	O
clones	O
from	O
a	O
human	O
glioma	O
cell	O
line	O
that	O
encode	O
a	O
secreted	O
protein	O
with	O
32	O
%	O
amino	O
acid	O
identity	O
to	O
VEGF	O
.	O

This	O
protein	O
,	O
designated	O
VEGF	O
-	O
related	O
protein	O
(	O
VRP	O
)	O
,	O
specifically	O
binds	O
to	O
the	O
extracellular	O
domain	O
of	O
Flt4	O
,	O
stimulates	O
the	O
tyrosine	O
phosphorylation	O
of	O
Flt4	O
expressed	O
in	O
mammalian	O
cells	O
,	O
and	O
promotes	O
the	O
mitogenesis	O
of	O
human	O
lung	O
endothelial	O
cells	O
.	O

VRP	O
fails	O
to	O
bind	O
appreciably	O
to	O
the	O
extracellular	O
domain	O
of	O
Flt1	O
or	O
Flk1	O
.	O

The	O
protein	O
contains	O
a	O
C	O
-	O
terminal	O
,	O
cysteine	O
-	O
rich	O
region	O
of	O
about	O
180	O
amino	O
acids	O
that	O
is	O
not	O
found	O
in	O
VEGF	O
.	O

A	O
2	O
.	O
4	O
-	O
kb	O
VRP	O
mRNA	O
is	O
found	O
in	O
several	O
human	O
tissues	O
including	O
adult	O
heart	O
,	O
placenta	O
,	O
ovary	O
,	O
and	O
small	O
intestine	O
and	O
in	O
fetal	O
lung	O
and	O
kidney	O
.	O

Precise	O
alignment	O
of	O
sites	O
required	O
for	O
mu	O
enhancer	O
activation	O
in	O
B	O
cells	O
.	O

The	O
lymphocyte	O
-	O
specific	O
immunoglobulin	B-Complex
mu	I-Complex
heavy	O
-	O
chain	O
gene	O
intronic	O
enhancer	O
is	O
regulated	O
by	O
multiple	O
nuclear	O
factors	O
.	O

The	O
previously	O
defined	O
minimal	O
enhancer	O
containing	O
the	O
muA	O
,	O
muE3	O
,	O
and	O
muB	O
sites	O
is	O
transactivated	O
by	O
a	O
combination	O
of	O
the	O
ETS	O
-	O
domain	O
proteins	O
PU	O
.	O
1	O
and	O
Ets	O
-	O
1	O
in	O
nonlymphoid	O
cells	O
.	O

The	O
core	O
GGAAs	O
of	O
the	O
muA	O
and	O
muB	O
sites	O
are	O
separated	O
by	O
30	O
nucleotides	O
,	O
suggesting	O
that	O
ETS	O
proteins	O
bind	O
to	O
these	O
sites	O
from	O
these	O
same	O
side	O
of	O
the	O
DNA	O
helix	O
.	O

We	O
tested	O
the	O
necessity	O
for	O
appropriate	O
spatial	O
alignment	O
of	O
these	O
elements	O
by	O
using	O
mutated	O
enhancers	O
with	O
altered	O
spacings	O
.	O

A	O
4	O
-	O
or	O
10	O
-	O
bp	O
insertion	O
between	O
muE3	O
and	O
muB	O
inactivated	O
the	O
mu	O
enhancer	O
in	O
S194	O
plasma	O
cells	O
but	O
did	O
not	O
affect	O
in	O
vitro	O
binding	O
of	O
Ets	O
-	O
1	O
,	O
PU	O
.	O
1	O
,	O
or	O
the	O
muE3	O
-	O
binding	O
protein	O
TFE3	O
,	O
alone	O
or	O
in	O
pairwise	O
combinations	O
.	O

Circular	O
permutation	O
and	O
phasing	O
analyses	O
demonstrated	O
that	O
PU	O
.	O
1	O
binding	O
but	O
not	O
TFE3	O
or	O
Ets	O
-	O
1	O
bends	O
mu	O
enhancer	O
DNA	O
toward	O
the	O
major	O
groove	O
.	O

We	O
propose	O
that	O
the	O
requirement	O
for	O
precise	O
spacing	O
of	O
the	O
muA	O
and	O
muB	O
elements	O
is	O
due	O
in	O
part	O
to	O
a	O
directed	O
DNA	O
bend	O
induced	O
by	O
PU	O
.	O
1	O
.	O

Interaction	O
of	O
HTLV	O
-	O
I	O
Tax	O
with	O
the	O
human	O
proteasome	B-Complex
:	O
implications	O
for	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
induction	O
.	O

The	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
has	O
been	O
etiologically	O
associated	O
with	O
the	O
development	O
of	O
the	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
as	O
well	O
as	O
degenerative	O
neurologic	O
syndrome	O
termed	O
tropical	O
spastic	O
paraparesis	O
(	O
TSP	O
)	O
.	O

HTLV	O
-	O
I	O
encodes	O
a	O
potent	O
transactivator	O
protein	O
termed	O
Tax	O
that	O
appears	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
process	O
of	O
T	O
-	O
cell	O
immortalization	O
.	O

Even	O
though	O
the	O
mechanisms	O
by	O
which	O
Tax	O
induces	O
transformation	O
are	O
still	O
unknown	O
,	O
it	O
seems	O
likely	O
that	O
the	O
ability	O
of	O
Tax	O
to	O
alter	O
the	O
expression	O
of	O
many	O
cellular	O
genes	O
plays	O
an	O
important	O
part	O
in	O
this	O
process	O
.	O

Tax	O
does	O
not	O
bind	O
directly	O
to	O
DNA	O
but	O
rather	O
deregulates	O
the	O
activity	O
of	O
cellular	O
transcription	O
factors	O
.	O

One	O
family	O
of	O
host	O
transcription	O
factors	O
whose	O
activity	O
is	O
altered	O
by	O
Tax	O
includes	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
Rel	I-Complex
.	O

These	O
transcription	O
factors	O
are	O
post	O
-	O
transcriptionally	O
regulated	O
by	O
their	O
assembly	O
with	O
a	O
second	O
family	O
of	O
inhibitory	O
proteins	O
termed	O
I	O
kappa	O
B	O
that	O
serve	O
to	O
sequester	O
the	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
Rel	I-Complex
complexes	O
in	O
the	O
cytoplasm	O
.	O

Upon	O
cellular	O
activation	O
,	O
I	O
kappa	O
B	O
alpha	O
is	O
phosphorylated	O
,	O
polyubiquitinated	O
,	O
and	O
degraded	O
in	O
the	O
proteasome	B-Complex
.	O

This	O
proteolytic	O
event	O
liberates	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
,	O
permitting	O
its	O
rapid	O
translocation	O
into	O
the	O
nucleus	O
where	O
it	O
binds	O
to	O
its	O
cognate	O
enhancer	O
elements	O
.	O

Similarly	O
,	O
the	O
p105	O
precursor	O
of	O
the	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
p50	O
subunit	O
is	O
also	O
post	O
-	O
translationally	O
processed	O
in	O
the	O
proteasome	B-Complex
.	O

The	O
mechanisms	O
by	O
which	O
Tax	O
activates	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
remain	O
unclear	O
,	O
and	O
findings	O
presented	O
in	O
the	O
literature	O
are	O
often	O
controversial	O
.	O

We	O
identified	O
a	O
physical	O
interaction	O
between	O
Tax	O
and	O
the	O
HsN3	O
subunit	O
of	O
the	O
human	O
proteasome	B-Complex
.	O

This	O
raises	O
the	O
intriguing	O
possibility	O
that	O
physical	O
association	O
of	O
the	O
HsN3	O
proteasome	B-Complex
subunit	O
with	O
HTLV	O
-	O
I	O
Tax	O
coupled	O
with	O
the	O
independent	O
interaction	O
of	O
Tax	O
with	O
either	O
p100	O
or	O
p65	O
-	O
I	O
kappa	O
B	O
alpha	O
targets	O
these	O
cytoplasmic	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
Rel	I-Complex
complexes	O
to	O
the	O
proteasome	B-Complex
for	O
processing	O
.	O

Identification	O
of	O
the	O
site	O
in	O
the	O
Syk	O
protein	O
tyrosine	O
kinase	O
that	O
binds	O
the	O
SH2	O
domain	O
of	O
Lck	O
.	O

The	O
Syk	O
protein	O
tyrosine	O
kinase	O
(	O
PTK	O
)	O
is	O
expressed	O
in	O
many	O
hematopoietic	O
cells	O
and	O
is	O
involved	O
in	O
signaling	O
from	O
various	O
receptors	O
for	O
antigen	O
and	O
Fc	O
portions	O
of	O
IgG	B-Complex
and	O
IgE	B-Complex
.	O

Upon	O
cross	O
-	O
linking	O
of	O
these	O
receptors	O
,	O
Syk	O
is	O
rapidly	O
phosphorylated	O
on	O
tyrosine	O
residues	O
and	O
enzymatically	O
activated	O
.	O

We	O
and	O
others	O
have	O
found	O
that	O
the	O
Lck	O
kinase	O
,	O
a	O
member	O
of	O
the	O
Src	O
family	O
of	O
PTKs	O
,	O
binds	O
through	O
its	O
Src	O
homology	O
(	O
SH	O
)	O
2	O
domain	O
to	O
tyrosine	O
phosphorylated	O
Syk	O
and	O
to	O
the	O
related	O
Zap	O
kinase	O
.	O

Here	O
we	O
report	O
that	O
this	O
interaction	O
is	O
direct	O
and	O
identify	O
the	O
two	O
tandem	O
tyrosines	O
at	O
the	O
autophosphorylation	O
site	O
of	O
Syk	O
,	O
Tyr518	O
,	O
and	O
Tyr519	O
,	O
as	O
the	O
binding	O
site	O
for	O
the	O
SH2	O
domain	O
of	O
Lck	O
.	O

Mutation	O
of	O
either	O
or	O
both	O
tyrosines	O
to	O
phenylalanines	O
abrogated	O
binding	O
,	O
while	O
mutation	O
of	O
a	O
second	O
repetition	O
of	O
the	O
motif	O
at	O
Tyr539	O
and	O
Tyr540	O
,	O
or	O
of	O
the	O
three	O
tyrosines	O
in	O
the	O
C	O
terminus	O
of	O
Syk	O
,	O
did	O
not	O
.	O

The	O
SH2	O
domain	O
of	O
Lck	O
bound	O
the	O
autophosphorylation	O
site	O
only	O
when	O
both	O
Tyr518	O
and	O
Tyr519	O
were	O
phosphorylated	O
.	O

In	O
intact	O
cells	O
the	O
binding	O
of	O
the	O
SH2	O
domain	O
of	O
Lck	O
correlated	O
with	O
the	O
ability	O
of	O
Syk	O
to	O
induce	O
tyrosine	O
phosphorylation	O
of	O
cellular	O
proteins	O
.	O

The	O
human	O
cardiac	O
muscle	O
ryanodine	O
receptor	O
-	O
calcium	O
release	O
channel	O
:	O
identification	O
,	O
primary	O
structure	O
and	O
topological	O
analysis	O
.	O

Rapid	O
Ca2	O
+	O
efflux	O
from	O
intracellular	O
stores	O
during	O
cardiac	O
muscle	O
excitation	O
-	O
contraction	O
coupling	O
is	O
mediated	O
by	O
the	O
ryanodine	O
-	O
sensitive	O
calcium	O
-	O
release	O
channel	O
,	O
a	O
large	O
homotetrameric	O
complex	O
present	O
in	O
the	O
sarcoplasmic	O
reticulum	O
.	O

We	O
report	O
here	O
the	O
identification	O
,	O
primary	O
structure	O
and	O
topological	O
analysis	O
of	O
the	O
ryanodine	O
receptor	O
-	O
calcium	O
release	O
channel	O
from	O
human	O
cardiac	O
muscle	O
(	O
hRyR	O
-	O
2	O
)	O
.	O

Consistent	O
with	O
sedimentation	O
and	O
immunoblotting	O
studies	O
on	O
the	O
hRyR	O
-	O
2	O
protein	O
,	O
sequence	O
analysis	O
of	O
ten	O
overlapping	O
cDNA	O
clones	O
reveals	O
an	O
open	O
reading	O
frame	O
of	O
14901	O
nucleotides	O
encoding	O
a	O
protein	O
of	O
4967	O
amino	O
acid	O
residues	O
with	O
a	O
predicted	O
molecular	O
mass	O
of	O
564	O
569	O
Da	O
for	O
hRyR	O
-	O
2	O
.	O

In	O
-	O
frame	O
insertions	O
corresponding	O
to	O
eight	O
and	O
ten	O
amino	O
acid	O
residues	O
were	O
found	O
in	O
two	O
of	O
the	O
ten	O
cDNAs	O
isolated	O
,	O
suggesting	O
that	O
novel	O
,	O
alternatively	O
spliced	O
transcripts	O
of	O
the	O
hRyR	O
-	O
2	O
gene	O
might	O
exist	O
.	O

Six	O
hydrophobic	O
stretches	O
,	O
which	O
are	O
present	O
within	O
the	O
hRyR	O
-	O
2	O
C	O
-	O
terminal	O
500	O
amino	O
acids	O
and	O
are	O
conserved	O
in	O
all	O
RyR	O
sequences	O
,	O
may	O
be	O
involved	O
in	O
forming	O
the	O
transmembrane	O
domain	O
that	O
constitutes	O
the	O
Ca	O
(	O
2	O
+	O
)	O
-	O
conducting	O
pathway	O
,	O
in	O
agreement	O
with	O
competitive	O
ELISA	O
studies	O
with	O
a	O
RyR	O
-	O
2	O
-	O
specific	O
antibody	O
.	O

Sequence	O
alignment	O
of	O
hRyR	O
-	O
2	O
with	O
other	O
RyR	O
isoforms	O
indicates	O
a	O
high	O
level	O
of	O
overall	O
identity	O
within	O
the	O
RyR	O
family	O
,	O
with	O
the	O
exception	O
of	O
two	O
important	O
regions	O
that	O
exhibit	O
substantial	O
variability	O
.	O

Phylogenetic	O
analysis	O
suggests	O
that	O
the	O
RyR	O
-	O
2	O
isoform	O
diverged	O
from	O
a	O
single	O
ancestral	O
gene	O
before	O
the	O
RyR	O
-	O
1	O
and	O
RyR	O
-	O
3	O
isoforms	O
to	O
form	O
a	O
distinct	O
branch	O
of	O
the	O
RyR	O
family	O
tree	O
.	O

Cell	O
-	O
type	O
-	O
specific	O
regulation	O
of	O
the	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
gene	O
in	O
B	O
cells	O
and	O
T	O
cells	O
by	O
NFATp	O
and	O
ATF	O
-	O
2	O
/	O
JUN	O
.	O

The	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
gene	O
is	O
one	O
of	O
the	O
earliest	O
genes	O
transcribed	O
after	O
the	O
stimulation	O
of	O
a	O
B	O
cell	O
through	O
its	O
antigen	O
receptor	O
or	O
via	O
the	O
CD	O
-	O
40	O
pathway	O
.	O

In	O
both	O
cases	O
,	O
induction	O
of	O
TNF	O
-	O
alpha	O
gene	O
transcription	O
can	O
be	O
blocked	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
and	O
FK506	O
,	O
which	O
suggested	O
a	O
role	O
for	O
the	O
NFAT	O
family	O
of	O
proteins	O
in	O
the	O
regulation	O
of	O
the	O
gene	O
in	O
B	O
cells	O
.	O

Furthermore	O
,	O
in	O
T	O
cells	O
,	O
two	O
molecules	O
of	O
NFATp	O
bind	O
to	O
the	O
TNF	O
-	O
alpha	O
promoter	O
element	O
kappa	O
3	O
in	O
association	O
with	O
ATF	O
-	O
2	O
and	O
Jun	O
proteins	O
bound	O
to	O
an	O
immediately	O
adjacent	O
cyclic	O
AMP	O
response	O
element	O
(	O
CRE	O
)	O
site	O
.	O

Here	O
,	O
using	O
the	O
murine	O
B	O
-	O
cell	O
lymphoma	O
cell	O
line	O
A20	O
,	O
we	O
show	O
that	O
the	O
TNF	O
-	O
alpha	O
gene	O
is	O
regulated	O
in	O
a	O
cell	O
-	O
type	O
-	O
specific	O
manner	O
.	O

In	O
A20	O
B	O
cells	O
,	O
the	O
TNF	O
-	O
alpha	O
gene	O
is	O
not	O
regulated	O
by	O
NFATp	O
bound	O
to	O
the	O
kappa	O
3	O
element	O
.	O

Instead	O
,	O
ATF	O
-	O
2	O
and	O
Jun	O
proteins	O
bind	O
to	O
the	O
composite	O
kappa	O
3	O
/	O
CRE	O
site	O
and	O
NFATp	O
binds	O
to	O
a	O
newly	O
identified	O
second	O
NFAT	O
site	O
centered	O
at	O
-	O
76	O
nucleotides	O
relative	O
to	O
the	O
TNF	O
-	O
alpha	O
transcription	O
start	O
site	O
.	O

This	O
new	O
site	O
plays	O
a	O
critical	O
role	O
in	O
the	O
calcium	O
-	O
mediated	O
,	O
cyclosporin	O
A	O
-	O
sensitive	O
induction	O
of	O
TNF	O
-	O
alpha	O
in	O
both	O
A20	O
B	O
cells	O
and	O
Ar	O
-	O
5	O
cells	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
quantitative	O
DNase	O
footprinting	O
of	O
the	O
TNF	O
-	O
alpha	O
promoter	O
using	O
increasing	O
amounts	O
of	O
recombinant	O
NFATp	O
demonstrated	O
that	O
the	O
-	O
76	O
site	O
binds	O
to	O
NFATp	O
with	O
a	O
higher	O
affinity	O
than	O
the	O
kappa	O
3	O
site	O
.	O

Two	O
other	O
previously	O
unrecognized	O
NFATp	O
-	O
binding	O
sites	O
in	O
the	O
proximal	O
TNF	O
-	O
alpha	O
promoter	O
were	O
also	O
identified	O
by	O
this	O
analysis	O
.	O

Thus	O
,	O
through	O
the	O
differential	O
use	O
of	O
the	O
same	O
promoter	O
element	O
,	O
the	O
composite	O
kappa	O
3	O
/	O
CRE	O
site	O
,	O
the	O
TNF	O
-	O
alpha	O
gene	O
is	O
regulated	O
in	O
a	O
cell	O
-	O
type	O
-	O
specific	O
manner	O
in	O
response	O
to	O
the	O
same	O
extracellular	O
signal	O
.	O

Cloning	O
and	O
characterization	O
of	O
the	O
beta	O
subunit	O
of	O
human	O
proximal	O
sequence	O
element	O
-	O
binding	O
transcription	O
factor	O
and	O
its	O
involvement	O
in	O
transcription	O
of	O
small	O
nuclear	O
RNA	O
genes	O
by	O
RNA	O
polymerases	O
II	O
and	O
III	O
.	O

The	O
proximal	B-Complex
sequence	I-Complex
element	I-Complex
(	I-Complex
PSE	I-Complex
)	I-Complex
-	I-Complex
binding	I-Complex
transcription	I-Complex
factor	I-Complex
(	O
PTF	B-Complex
)	O
,	O
which	O
binds	O
the	O
PSE	O
of	O
both	O
RNA	B-Complex
polymerase	I-Complex
II	I-Complex
-	O
and	O
RNA	B-Complex
polymerase	I-Complex
III	I-Complex
-	O
transcribed	O
mammalian	O
small	O
nuclear	O
RNA	O
(	O
snRNA	O
)	O
genes	O
,	O
is	O
essential	O
for	O
their	O
transcription	O
.	O

We	O
previously	O
reported	O
the	O
purification	O
of	O
human	O
PTF	B-Complex
,	O
a	O
complex	O
of	O
four	O
subunits	O
,	O
and	O
the	O
molecular	O
cloning	O
and	O
characterization	O
of	O
PTF	O
gamma	O
and	O
delta	O
subunits	O
.	O

Here	O
we	O
describe	O
the	O
isolation	O
and	O
expression	O
of	O
a	O
cDNA	O
encoding	O
PTF	O
beta	O
,	O
as	O
well	O
as	O
functional	O
studies	O
using	O
anti	O
-	O
PTF	O
beta	O
antibodies	O
.	O

Native	O
PTF	O
beta	O
,	O
in	O
either	O
protein	O
fractions	O
or	O
a	O
PTF	B-Complex
-	O
Oct	O
-	O
1	O
-	O
DNA	O
complex	O
,	O
can	O
be	O
recognized	O
by	O
polyclonal	O
antibodies	O
raised	O
against	O
recombinant	O
PTF	O
beta	O
.	O

Immunodepletion	O
studies	O
show	O
that	O
PTF	O
beta	O
is	O
required	O
for	O
transcription	O
of	O
both	O
classes	O
of	O
snRNA	O
genes	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
immunoprecipitation	O
analyses	O
demonstrate	O
that	O
substantial	O
and	O
similar	O
molar	O
amounts	O
of	O
TATA	O
-	O
binding	O
protein	O
(	O
TBP	O
)	O
and	O
TFIIIB90	O
can	O
weakly	O
associate	O
with	O
PTF	B-Complex
at	O
low	O
salt	O
conditions	O
,	O
but	O
this	O
association	O
is	O
dramatically	O
reduced	O
at	O
high	O
salt	O
concentrations	O
.	O

Along	O
with	O
our	O
previous	O
demonstration	O
of	O
both	O
physical	O
interactions	O
between	O
PTF	O
gamma	O
/	O
PTF	O
delta	O
and	O
TBP	O
and	O
the	O
involvement	O
of	O
TFIIIB90	O
in	O
the	O
transcription	O
of	O
class	O
III	O
snRNA	O
genes	O
,	O
these	O
results	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
a	O
TBP	O
-	O
containing	O
complex	O
related	O
to	O
TFIIIB	B-Complex
is	O
required	O
for	O
the	O
transcription	O
of	O
class	O
III	O
snRNA	O
genes	O
,	O
and	O
acts	O
through	O
weak	O
interaction	O
with	O
the	O
four	O
-	O
subunit	O
PTF	B-Complex
.	O

TRAF6	O
is	O
a	O
signal	O
transducer	O
for	O
interleukin	O
-	O
1	O
.	O

Many	O
cytokines	O
signal	O
through	O
different	O
cell	O
-	O
surface	O
receptors	O
to	O
activate	O
the	O
transcription	O
factor	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
.	O

Members	O
of	O
the	O
TRAF	O
protein	O
family	O
have	O
been	O
implicated	O
in	O
the	O
activation	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
by	O
the	O
tumour	O
-	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
receptor	O
superfamily	O
.	O

Here	O
we	O
report	O
the	O
identification	O
of	O
a	O
new	O
TRAF	O
family	O
member	O
,	O
designated	O
TRAF6	O
.	O

When	O
overexpressed	O
in	O
human	O
293	O
cells	O
,	O
TRAF6	O
activates	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
.	O

A	O
dominant	O
-	O
negative	O
mutant	O
of	O
TRAF6	O
inhibits	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
signalled	O
by	O
interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
but	O
not	O
by	O
TNF	O
.	O

IL	O
-	O
1	O
treatment	O
of	O
293	O
cells	O
induces	O
the	O
association	O
of	O
TRAF6	O
with	O
IRAK	O
,	O
a	O
serine	O
/	O
threonine	O
kinase	O
that	O
is	O
rapidly	O
recruited	O
to	O
the	O
IL	O
-	O
1	O
receptor	O
after	O
IL	O
-	O
1	O
induction	O
.	O

These	O
findings	O
indicate	O
that	O
TRAF	O
proteins	O
may	O
function	O
as	O
signal	O
transducers	O
for	O
distinct	O
receptor	O
families	O
and	O
that	O
TRAF6	O
participates	O
in	O
IL	O
-	O
1	O
signalling	O
.	O

Soluble	O
factors	O
secreted	O
by	O
activated	O
T	O
-	O
lymphocytes	O
modulate	O
the	O
transcription	O
of	O
the	O
immunosuppressive	O
cytokine	O
TGF	O
-	O
beta	O
2	O
in	O
glial	O
cells	O
.	O

Coordination	O
of	O
the	O
immune	O
response	O
to	O
injury	O
or	O
disease	O
in	O
the	O
brain	O
is	O
postulated	O
to	O
involve	O
bi	O
-	O
directional	O
discourse	O
between	O
the	O
immune	O
system	O
and	O
the	O
central	O
nervous	O
system	O
.	O

This	O
cross	O
communication	O
involves	O
soluble	O
mediators	O
,	O
including	O
various	O
growth	O
factors	O
,	O
cytokines	O
,	O
and	O
neuropeptides	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
supernatant	O
from	O
activated	O
T	O
-	O
lymphocytes	O
is	O
able	O
to	O
induce	O
the	O
transcription	O
of	O
a	O
potent	O
cytokine	O
,	O
TGF	O
-	O
beta	O
2	O
in	O
glial	O
cells	O
.	O

The	O
activating	O
stimulus	O
invokes	O
signaling	O
mechanisms	O
distinct	O
from	O
known	O
kinase	O
or	O
protease	O
pathways	O
.	O

Activation	O
of	O
TGF	O
-	O
beta	O
2	O
transcription	O
correlates	O
with	O
the	O
loss	O
of	O
binding	O
activity	O
for	O
an	O
80	O
kDA	O
glial	O
labile	O
repressor	O
protein	O
,	O
GLRP	O
,	O
to	O
a	O
responsive	O
region	O
within	O
the	O
TFG	O
-	O
beta	O
2	O
promoter	O
.	O

Although	O
GLRP	O
shares	O
some	O
characteristics	O
with	O
the	O
inducible	O
transcription	O
factor	O
AP	B-Complex
-	I-Complex
1	I-Complex
,	O
it	O
appears	O
to	O
be	O
distinct	O
from	O
known	O
AP	B-Complex
-	I-Complex
1	I-Complex
family	O
members	O
.	O

These	O
data	O
along	O
with	O
previous	O
observations	O
demonstrating	O
the	O
potent	O
immunosuppressive	O
activity	O
of	O
TGF	O
-	O
beta	O
2	O
,	O
support	O
a	O
model	O
for	O
a	O
feedback	O
mechanism	O
between	O
the	O
activated	O
T	O
-	O
lymphocytes	O
and	O
astrocytes	O
via	O
TGF	O
-	O
beta	O
2	O
to	O
regulate	O
the	O
immune	O
response	O
.	O

Flexibility	O
of	O
the	O
NSAID	O
binding	O
site	O
in	O
the	O
structure	O
of	O
human	O
cyclooxygenase	O
-	O
2	O
.	O

The	O
first	O
crystal	O
structure	O
of	O
human	O
cyclooxygenase	O
-	O
2	O
,	O
in	O
the	O
presence	O
of	O
a	O
selective	O
inhibitor	O
,	O
is	O
similar	O
to	O
that	O
of	O
cyclooxygenase	O
-	O
1	O
.	O

The	O
structure	O
of	O
the	O
NSAID	O
binding	O
site	O
is	O
also	O
well	O
conserved	O
,	O
although	O
there	O
are	O
differences	O
in	O
its	O
overall	O
size	O
and	O
shape	O
which	O
may	O
be	O
exploited	O
for	O
the	O
further	O
development	O
of	O
selective	O
COX	O
-	O
2	O
inhibitors	O
.	O

A	O
second	O
COX	O
-	O
2	O
structure	O
with	O
a	O
different	O
bound	O
inhibitor	O
displays	O
a	O
new	O
,	O
open	O
conformation	O
at	O
the	O
bottom	O
of	O
the	O
NSAID	O
binding	O
site	O
,	O
without	O
significant	O
changes	O
in	O
other	O
regions	O
of	O
the	O
COX	O
-	O
2	O
structure	O
.	O

These	O
two	O
COX	O
-	O
2	O
structures	O
provide	O
evidence	O
for	O
the	O
flexible	O
nature	O
of	O
cyclooxygenase	O
,	O
revealing	O
details	O
about	O
how	O
substrate	O
and	O
inhibitor	O
may	O
gain	O
access	O
to	O
the	O
cyclooxygenase	O
active	O
site	O
from	O
within	O
the	O
membrane	O
.	O

Hierarchies	O
in	O
the	O
binding	O
of	O
human	O
factor	O
XIII	O
,	O
factor	O
XIIIa	O
,	O
and	O
endothelial	O
cell	O
transglutaminase	O
to	O
human	O
plasma	O
fibrinogen	O
,	O
fibrin	O
,	O
and	O
fibronectin	O
.	O

The	O
affinities	O
of	O
Factor	O
XIII	O
(	O
FXIII	O
)	O
,	O
Factor	O
XIIIa	O
(	O
FXIIIa	O
)	O
,	O
and	O
cellular	O
transglutaminase	O
(	O
Tg	O
)	O
for	O
fibrinogen	O
(	O
Fgn	O
)	O
,	O
fibrin	O
(	O
Fbn	O
)	O
,	O
and	O
fibronectin	O
(	O
Fn	O
)	O
were	O
compared	O
using	O
a	O
solid	O
-	O
phase	O
binding	O
assay	O
.	O

Initial	O
rates	O
of	O
binding	O
were	O
as	O
follows	O
:	O
FXIII	O
bound	O
Fbn	O
3	O
-	O
fold	O
more	O
than	O
Fgn	O
.	O

FXIII	O
did	O
not	O
bind	O
Fn	O
till	O
20	O
min	O
.	O

Increasing	O
the	O
ligands	O
concentrations	O
and	O
binding	O
time	O
,	O
resulted	O
in	O
weak	O
binding	O
of	O
FXIII	O
to	O
Fn	O
.	O

FXIIIa	O
bound	O
Fbn	O
2	O
-	O
fold	O
more	O
than	O
Fgn	O
and	O
28	O
-	O
fold	O
more	O
than	O
Fn	O
.	O

Tg	O
bound	O
Fn	O
approximately	O
130	O
-	O
fold	O
more	O
than	O
either	O
Fgn	O
or	O
Fbn	O
.	O

At	O
equilibrium	O
,	O
the	O
extent	O
of	O
binding	O
was	O
determined	O
to	O
be	O
as	O
follows	O
:	O
FXIII	O
bound	O
Fbn	O
3	O
-	O
15	O
-	O
fold	O
more	O
than	O
Fgn	O
and	O
8	O
-	O
fold	O
more	O
than	O
Fn	O
.	O

FXIIIa	O
bound	O
Fgn	O
and	O
Fbn	O
equally	O
and	O
12	O
-	O
25	O
-	O
fold	O
more	O
than	O
Fn	O
.	O

FXIIIa	O
bound	O
Fgn	O
or	O
Fbn	O
2	O
-	O
fold	O
and	O
25	O
-	O
fold	O
greater	O
than	O
FXIII	O
-	O
Fbn	O
and	O
FXIII	O
-	O
Fgn	O
interactions	O
,	O
respectively	O
.	O

Tg	O
bound	O
about	O
equally	O
to	O
Fgn	O
and	O
Fbn	O
and	O
10	O
-	O
20	O
-	O
fold	O
less	O
than	O
Fn	O
.	O

The	O
Kds	O
'	O
for	O
FXIIIa	O
binding	O
to	O
Fn	O
,	O
Fgn	O
,	O
and	O
Fbn	O
were	O
100	O
,	O
23	O
,	O
and	O
19	O
nM	O
,	O
respectively	O
.	O

The	O
Kd	O
for	O
Tg	O
binding	O
to	O
Fn	O
was	O
6	O
.	O
5	O
nM	O
.	O

The	O
binding	O
hierarchies	O
are	O
:	O
[	O
Tg	O
-	O
Fn	O
]	O
>	O
[	O
FXIIIa	O
-	O
Fgn	O
]	O
=	O
[	O
FXIIIa	O
-	O
Fbn	O
]	O
>	O
[	O
FXIII	O
-	O
Fbn	O
]	O
>	O
[	O
FXIII	O
-	O
Fgn	O
]	O
=	O
[	O
FXIIIa	O
-	O
Fn	O
]	O
>	O
[	O
Tg	O
-	O
Fbn	O
]	O
=	O
[	O
Tg	O
-	O
Fgn	O
]	O
>	O
[	O
FXIII	O
-	O
Fn	O
]	O
.	O

Such	O
hierarchies	O
could	O
regulate	O
the	O
cross	O
-	O
linkings	O
by	O
FXIIIa	O
and	O
Tg	O
during	O
hemostasis	O
,	O
wound	O
healing	O
,	O
and	O
cell	O
adhesion	O
.	O

Effect	O
of	O
insulin	O
on	O
farnesyltransferase	O
activity	O
in	O
3T3	O
-	O
L1	O
adipocytes	O
.	O

Activation	O
of	O
p21	O
(	O
ras	O
)	O
by	O
GTP	O
loading	O
is	O
a	O
critical	O
step	O
in	O
a	O
cascade	O
of	O
intracellular	O
insulin	O
signaling	O
.	O

Farnesylation	O
of	O
p21	O
(	O
ras	O
)	O
protein	O
is	O
an	O
obligatory	O
event	O
that	O
facilitates	O
Ras	O
migration	O
to	O
the	O
plasma	O
membrane	O
and	O
subsequent	O
activation	O
.	O

Farnesyltransferase	B-OOS
(	O
FTase	B-OOS
)	O
is	O
a	O
ubiquitous	O
enzyme	O
that	O
catalyzes	O
the	O
lipid	O
modification	O
of	O
p21	O
(	O
ras	O
)	O
by	O
the	O
addition	O
of	O
farnesyl	O
to	O
the	O
C	O
-	O
terminal	O
"	O
CAAX	O
"	O
motif	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
FTase	B-OOS
activities	O
were	O
studied	O
in	O
3T3	O
-	O
L1	O
adipocytes	O
in	O
response	O
to	O
insulin	O
challenge	O
.	O

Insulin	O
exerted	O
a	O
biphasic	O
stimulatory	O
effect	O
on	O
FTase	B-OOS
activity	O
measured	O
in	O
vitro	O
with	O
a	O
31	O
%	O
increase	O
at	O
5	O
min	O
and	O
a	O
130	O
%	O
increase	O
at	O
60	O
min	O
.	O

Insulin	O
-	O
stimulated	O
farnesylation	O
of	O
p21	O
(	O
ras	O
)	O
pools	O
in	O
vivo	O
correlated	O
with	O
FTase	B-OOS
activity	O
seen	O
in	O
vitro	O
by	O
displaying	O
an	O
increase	O
in	O
farnesylated	O
p21	O
(	O
ras	O
)	O
from	O
40	O
%	O
of	O
total	O
cellular	O
Ras	O
in	O
control	O
cells	O
to	O
63	O
%	O
by	O
5	O
min	O
and	O
80	O
%	O
by	O
60	O
min	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
insulin	O
-	O
treated	O
cells	O
.	O

Insulin	O
challenge	O
of	O
3T3	O
-	O
L1	O
adipocytes	O
increased	O
incorporation	O
of	O
tritiated	O
mevalonic	O
acid	O
in	O
p21	O
(	O
ras	O
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
stimulated	O
a	O
2	O
-	O
fold	O
increase	O
in	O
phosphorylation	O
of	O
the	O
alpha	O
-	O
subunit	O
of	O
FTase	B-OOS
at	O
5	O
min	O
and	O
a	O
4	O
-	O
fold	O
increase	O
at	O
60	O
min	O
.	O

Cell	O
specific	O
expression	O
of	O
human	O
Bruton	O
'	O
s	O
agammaglobulinemia	O
tyrosine	O
kinase	O
gene	O
(	O
Btk	O
)	O
is	O
regulated	O
by	O
Sp1	O
-	O
and	O
Spi	O
-	O
1	O
/	O
PU	O
.	O
1	O
-	O
family	O
members	O
.	O

Bruton	O
'	O
s	O
agammaglobulinemia	O
tyrosine	O
kinase	O
(	O
Btk	O
)	O
is	O
a	O
cytoplasmic	O
tyrosine	O
kinase	O
involved	O
in	O
the	O
human	O
disease	O
X	O
-	O
linked	O
agammaglobulinemia	O
(	O
XLA	O
)	O
.	O

The	O
gene	O
is	O
expressed	O
in	O
all	O
hematopoietic	O
cells	O
with	O
the	O
exception	O
of	O
T	O
-	O
cells	O
and	O
plasma	O
cells	O
.	O

For	O
this	O
expression	O
pattern	O
the	O
first	O
280	O
bp	O
upstream	O
of	O
the	O
major	O
transcriptional	O
start	O
site	O
seems	O
to	O
be	O
sufficient	O
.	O

In	O
vitro	O
footprinting	O
analysis	O
within	O
this	O
part	O
of	O
the	O
promoter	O
revealed	O
two	O
Sp1	O
binding	O
sites	O
as	O
well	O
as	O
a	O
PU	O
-	O
box	O
.	O

The	O
transcription	O
factor	O
Spi	O
-	O
1	O
/	O
PU	O
.	O
1	O
as	O
well	O
as	O
the	O
closely	O
related	O
factor	O
Spi	O
-	O
B	O
bound	O
to	O
the	O
PU	O
-	O
box	O
in	O
B	O
-	O
cells	O
.	O

In	O
the	O
erythroleukemia	O
cell	O
line	O
K562	O
,	O
due	O
to	O
the	O
absence	O
of	O
Spi	O
-	O
B	O
,	O
only	O
PU	O
.	O
1	O
bound	O
to	O
the	O
Btk	O
promoter	O
.	O

Mutation	O
of	O
either	O
site	O
reduced	O
the	O
expression	O
in	O
transient	O
transfection	O
experiments	O
.	O

However	O
,	O
mutation	O
of	O
the	O
PU	O
box	O
had	O
no	O
effect	O
in	O
the	O
T	O
-	O
cell	O
line	O
Jurkat	O
,	O
where	O
none	O
of	O
the	O
Spi	O
-	O
1	O
family	O
members	O
is	O
expressed	O
.	O

In	O
addition	O
Spi	O
-	O
B	O
as	O
well	O
as	O
PU	O
.	O
1	O
were	O
able	O
to	O
transactivate	O
Btk	O
expression	O
.	O

In	O
fetal	O
liver	O
of	O
PU	O
.	O
1	O
-	O
/	O
-	O
mice	O
,	O
which	O
lack	O
lymphoid	O
and	O
myeloid	O
cells	O
,	O
expression	O
of	O
Btk	O
was	O
reduced	O
two	O
-	O
to	O
threefold	O
but	O
not	O
abolished	O
.	O

Collectively	O
this	O
study	O
shows	O
that	O
expression	O
of	O
the	O
Btk	O
gene	O
is	O
regulated	O
by	O
the	O
combined	O
action	O
of	O
Sp1	O
-	O
and	O
PU	O
.	O
1	O
-	O
family	O
members	O
.	O

Fatty	O
acylation	O
of	O
the	O
rat	O
and	O
human	O
asialoglycoprotein	O
receptors	O
.	O

A	O
conserved	O
cytoplasmic	O
cysteine	O
residue	O
is	O
acylated	O
in	O
all	O
receptor	O
subunits	O
.	O

Functional	O
rat	O
or	O
human	O
asialoglycoprotein	O
receptors	O
(	O
ASGP	O
-	O
Rs	O
)	O
are	O
hetero	O
-	O
oligomeric	O
integral	O
membrane	O
glycoproteins	O
.	O

Rat	B-Complex
ASGP	I-Complex
-	I-Complex
R	I-Complex
contains	O
three	O
subunits	O
,	O
designated	O
rat	O
hepatic	O
lectins	O
(	O
RHL	O
)	O
1	O
,	O
2	O
,	O
and	O
3	O
;	O
human	B-Complex
ASGP	I-Complex
-	I-Complex
R	I-Complex
contains	O
two	O
subunits	O
,	O
HHL1	O
and	O
HHL2	O
.	O

Both	O
receptors	O
are	O
covalently	O
modified	O
by	O
fatty	O
acylation	O
(	O
Zeng	O
,	O
F	O
.	O
-	O
Y	O
.	O
,	O
Kaphalia	O
,	O
B	O
.	O
S	O
.	O
,	O
Ansari	O
,	O
G	O
.	O
A	O
.	O
S	O
.	O
,	O
and	O
Weigel	O
,	O
P	O
.	O
H	O
.	O
(	O
1995	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
270	O
,	O
21382	O
-	O
21387	O
;	O
Zeng	O
,	O
F	O
.	O
-	O
Y	O
.	O
,	O
Oka	O
,	O
J	O
.	O
A	O
.	O
,	O
and	O
Weigel	O
,	O
P	O
.	O
H	O
.	O
(	O
1996	O
)	O
Biochem	O
.	O
Biophys	O
.	O
Res	O
.	O
Commun	O
.	O
218	O
,	O
325	O
-	O
330	O
)	O
.	O

We	O
report	O
here	O
that	O
the	O
single	O
Cys	O
residue	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
each	O
RHL	O
or	O
HHL	O
subunit	O
is	O
fatty	O
acylated	O
.	O

The	O
degree	O
of	O
acylation	O
is	O
>	O
/	O
=	O
90	O
%	O
per	O
subunit	O
.	O

Deacylation	O
of	O
affinity	O
-	O
purified	O
ASGP	O
-	O
Rs	O
with	O
hydroxylamine	O
results	O
in	O
the	O
spontaneous	O
formation	O
of	O
dimers	O
through	O
reversible	O
disulfide	O
bonds	O
,	O
indicating	O
that	O
deacylation	O
concomitantly	O
generates	O
free	O
thiol	O
groups	O
.	O

Reaction	O
of	O
hydroxylamine	O
-	O
treated	O
ASGP	O
-	O
R	O
with	O
[	O
14C	O
]	O
iodoacetamide	O
resulted	O
in	O
the	O
specific	O
incorporation	O
of	O
radioactivity	O
into	O
all	O
RHL	O
and	O
HHL	O
subunits	O
,	O
verifying	O
that	O
fatty	O
acids	O
are	O
attached	O
via	O
thioester	O
linkages	O
.	O

To	O
identify	O
the	O
Cys	O
residue	O
involved	O
in	O
the	O
thioester	O
linkages	O
,	O
14C	O
-	O
carboxyamidomethylated	O
RHL	O
subunits	O
were	O
separated	O
by	O
SDS	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
digested	O
in	O
-	O
gel	O
with	O
trypsin	O
,	O
and	O
the	O
resulting	O
peptides	O
were	O
separated	O
by	O
reverse	O
-	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
.	O

Amino	O
acid	O
sequence	O
of	O
radioactive	O
peptides	O
revealed	O
that	O
Cys35	O
in	O
RHL1	O
and	O
Cys54	O
in	O
RHL2	O
and	O
RHL3	O
were	O
radiolabeled	O
and	O
,	O
therefore	O
,	O
are	O
fatty	O
acylation	O
sites	O
.	O

Fatty	O
acylation	O
of	O
HHL	O
subunits	O
was	O
analyzed	O
by	O
site	O
-	O
directed	O
mutagenesis	O
.	O

Metabolic	O
labeling	O
of	O
Cos7	O
cells	O
transfected	O
with	O
wild	O
type	O
HHL1	O
cDNA	O
resulted	O
in	O
substantial	O
incorporation	O
of	O
[	O
3H	O
]	O
palmitate	O
into	O
purified	O
HHL1	O
.	O

Incorporation	O
of	O
[	O
3H	O
]	O
palmitate	O
into	O
a	O
C36S	O
mutant	O
of	O
HHL1	O
was	O
negligible	O
(	O
approximately	O
1	O
%	O
)	O
compared	O
with	O
wild	O
type	O
.	O

This	O
result	O
also	O
shows	O
that	O
Cys57	O
within	O
the	O
transmembrane	O
domain	O
of	O
HHL1	O
is	O
not	O
normally	O
palmitoylated	O
.	O

We	O
conclude	O
that	O
Cys35	O
in	O
RHL1	O
,	O
Cys54	O
in	O
RHL2	O
and	O
RHL3	O
,	O
and	O
Cys36	O
in	O
HHL1	O
are	O
fatty	O
acylated	O
.	O

Cys57	O
in	O
HHL1	O
and	O
probably	O
Cys56	O
in	O
RHL1	O
are	O
not	O
palmitoylated	O
.	O

The	O
NOT	O
,	O
SPT3	O
,	O
and	O
MOT1	O
genes	O
functionally	O
interact	O
to	O
regulate	O
transcription	O
at	O
core	O
promoters	O
.	O

Previous	O
studies	O
demonstrated	O
that	O
mutations	O
in	O
the	O
Saccharomyces	O
cerevisiae	O
NOT	O
genes	O
increase	O
transcription	O
from	O
TATA	O
-	O
less	O
promoters	O
.	O

In	O
this	O
report	O
,	O
I	O
show	O
that	O
in	O
contrast	O
,	O
mutations	O
in	O
the	O
yeast	O
MOT1	O
gene	O
decrease	O
transcription	O
from	O
TATA	O
-	O
less	O
promoters	O
.	O

I	O
also	O
demonstrate	O
specific	O
genetic	O
interactions	O
between	O
the	O
Not	O
complex	O
,	O
Mot1p	O
,	O
and	O
another	O
global	O
regulator	O
of	O
transcription	O
in	O
S	O
.	O
cerevisiae	O
,	O
Spt3p	O
.	O

Five	O
distinct	O
genetic	O
interactions	O
have	O
been	O
established	O
.	O

First	O
,	O
a	O
null	O
allele	O
of	O
SPT3	O
,	O
or	O
a	O
mutation	O
in	O
SPT15	O
that	O
disrupts	O
the	O
interaction	O
between	O
Spt3p	O
and	O
TATA	O
-	O
binding	O
protein	O
(	O
TBP	O
)	O
,	O
allele	O
specifically	O
suppressed	O
the	O
not1	O
-	O
2	O
mutation	O
.	O

Second	O
,	O
in	O
contrast	O
to	O
not	O
mutations	O
,	O
mutations	O
in	O
MOT1	O
decreased	O
HIS3	O
and	O
HIS4	O
TATA	O
-	O
less	O
transcription	O
.	O

Third	O
,	O
not	O
mutations	O
suppressed	O
toxicity	O
due	O
to	O
overexpression	O
of	O
TBP	O
in	O
mot1	O
-	O
1	O
mutants	O
.	O

Finally	O
,	O
overexpression	O
of	O
SPT3	O
caused	O
a	O
weak	O
Not	O
-	O
mutant	O
phenotype	O
in	O
mot1	O
-	O
1	O
mutants	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
a	O
novel	O
type	O
of	O
transcriptional	O
regulation	O
whereby	O
the	O
distribution	O
of	O
limiting	O
TBP	O
(	O
TFIID	B-Complex
)	O
on	O
weak	O
and	O
strong	O
TBP	O
-	O
binding	O
core	O
promoters	O
is	O
regulated	O
:	O
Mot1p	O
releases	O
stably	O
bound	O
TBP	O
to	O
allow	O
its	O
redistribution	O
to	O
low	O
-	O
affinity	O
sites	O
,	O
and	O
the	O
Not	O
proteins	O
negatively	O
regulate	O
the	O
activity	O
of	O
factors	O
such	O
as	O
Spt3p	O
that	O
favor	O
distribution	O
of	O
TBP	O
to	O
these	O
low	O
-	O
affinity	O
sites	O
.	O

Elf	O
-	O
1	O
and	O
Stat5	O
bind	O
to	O
a	O
critical	O
element	O
in	O
a	O
new	O
enhancer	O
of	O
the	O
human	O
interleukin	O
-	O
2	O
receptor	O
alpha	O
gene	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1997	O
Apr	O
;	O
17	O
(	O
4	O
)	O
:	O
2351	O
]	O

The	O
interleukin	O
2	O
receptor	O
alpha	O
-	O
chain	O
(	O
IL	O
-	O
2R	O
alpha	O
)	O
gene	O
is	O
a	O
key	O
regulator	O
of	O
lymphocyte	O
proliferation	O
.	O

IL	O
-	O
2R	O
alpha	O
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	O
cells	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O

Interleukin	O
2	O
(	O
IL	O
-	O
2	O
)	O
stimulates	O
IL	O
-	O
2R	O
alpha	O
transcription	O
,	O
thereby	O
amplifying	O
expression	O
of	O
its	O
own	O
high	O
-	O
affinity	O
receptor	O
.	O

IL	O
-	O
2R	O
alpha	O
transcription	O
is	O
at	O
least	O
in	O
part	O
controlled	O
by	O
two	O
positive	O
regulatory	O
regions	O
,	O
PRRI	O
and	O
PRRII	O
.	O

PRRI	O
is	O
an	O
inducible	O
proximal	O
enhancer	O
,	O
located	O
between	O
nucleotides	O
-	O
276	O
and	O
-	O
244	O
,	O
which	O
contains	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
and	O
SRE	O
/	O
CArG	O
motifs	O
.	O

PRRII	O
is	O
a	O
T	O
-	O
cell	O
-	O
specific	O
enhancer	O
,	O
located	O
between	O
nucleotides	O
-	O
137	O
and	O
-	O
64	O
,	O
which	O
binds	O
the	O
T	O
-	O
cell	O
-	O
specific	O
Ets	O
protein	O
Elf	O
-	O
1	O
and	O
HMG	O
-	O
I	O
(	O
Y	O
)	O
proteins	O
.	O

However	O
,	O
none	O
of	O
these	O
proximal	O
regions	O
account	O
for	O
the	O
induction	O
of	O
IL	O
-	O
2R	O
alpha	O
transcription	O
by	O
IL	O
-	O
2	O
.	O

To	O
find	O
new	O
regulatory	O
regions	O
of	O
the	O
IL	O
-	O
2R	O
alpha	O
gene	O
,	O
8	O
.	O
5	O
kb	O
of	O
the	O
5	O
'	O
end	O
noncoding	O
sequence	O
of	O
the	O
IL	O
-	O
2R	O
alpha	O
gene	O
have	O
been	O
sequenced	O
.	O

We	O
identified	O
an	O
86	O
-	O
nucleotide	O
fragment	O
that	O
is	O
90	O
%	O
identical	O
to	O
the	O
recently	O
characterized	O
murine	O
IL	O
-	O
2	O
-	O
responsive	O
element	O
(	O
mIL	O
-	O
2rE	O
)	O
.	O

This	O
putative	O
human	O
IL	O
-	O
2rE	O
,	O
designated	O
PRRIII	O
,	O
confers	O
IL	O
-	O
2	O
responsiveness	O
on	O
a	O
heterologous	O
promoter	O
.	O

PRRIII	O
contains	O
a	O
Stat	O
protein	O
binding	O
site	O
that	O
overlaps	O
with	O
an	O
EBS	O
motif	O
(	O
GASd	O
/	O
EBSd	O
)	O
.	O

These	O
are	O
essential	O
for	O
IL	O
-	O
2	O
inducibility	O
of	O
PRRIII	O
/	O
CAT	O
reporter	O
constructs	O
.	O

IL	O
-	O
2	O
induced	O
the	O
binding	O
of	O
Stat5a	O
and	O
b	O
proteins	O
to	O
the	O
human	O
GASd	O
element	O
.	O

To	O
confirm	O
the	O
physiological	O
relevance	O
of	O
these	O
findings	O
,	O
we	O
carried	O
out	O
in	O
vivo	O
footprinting	O
experiments	O
which	O
showed	O
that	O
stimulation	O
of	O
IL	O
-	O
2R	O
alpha	O
expression	O
correlated	O
with	O
occupancy	O
of	O
the	O
GASd	O
element	O
.	O

Our	O
data	O
demonstrate	O
a	O
major	O
role	O
of	O
the	O
GASd	O
/	O
EBSd	O
element	O
in	O
IL	O
-	O
2R	O
alpha	O
regulation	O
and	O
suggest	O
that	O
the	O
T	O
-	O
cell	O
-	O
specific	O
Elf	O
-	O
1	O
factor	O
can	O
serve	O
as	O
a	O
transcriptional	O
repressor	O
.	O

Phosphotyrosine	O
-	O
dependent	O
activation	O
of	O
Rac	O
-	O
1	O
GDP	O
/	O
GTP	O
exchange	O
by	O
the	O
vav	O
proto	O
-	O
oncogene	O
product	O
.	O

The	O
oncogenic	O
protein	O
Vav	O
harbours	O
a	O
complex	O
array	O
of	O
structural	O
motifs	O
,	O
including	O
leucine	O
-	O
rich	O
,	O
Dbl	O
-	O
homology	O
,	O
pleckstrin	O
-	O
homology	O
,	O
zinc	O
-	O
finger	O
,	O
SH2	O
and	O
SH3	O
domains	O
.	O

Upon	O
stimulation	O
by	O
antigens	O
or	O
mitogens	O
,	O
Vav	O
becomes	O
phosphorylated	O
on	O
key	O
tyrosine	O
residues	O
and	O
associates	O
with	O
other	O
signalling	O
proteins	O
,	O
including	O
the	O
mitogen	O
receptors	O
Zap	O
-	O
70	O
(	O
ref	O
.	O
6	O
)	O
,	O
Vap	O
-	O
1	O
(	O
ref	O
.	O
5	O
)	O
and	O
Slp	O
-	O
76	O
(	O
ref	O
.	O
7	O
)	O
.	O

Disruption	O
of	O
the	O
vav	O
locus	O
by	O
homologous	O
recombination	O
causes	O
severe	O
defects	O
in	O
signalling	O
by	O
primary	O
antigen	O
receptors	O
,	O
leading	O
to	O
abnormal	O
lymphocyte	O
proliferation	O
and	O
lymphopenia	O
.	O

Despite	O
the	O
importance	O
of	O
Vav	O
cell	O
signalling	O
,	O
the	O
function	O
of	O
this	O
protein	O
remains	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
tyrosine	O
-	O
phosphorylated	O
Vav	O
,	O
but	O
not	O
the	O
non	O
-	O
phosphorylated	O
protein	O
,	O
catalyses	O
GDP	O
/	O
GTP	O
exchange	O
on	O
Rac	O
-	O
1	O
,	O
a	O
protein	O
implicated	O
in	O
cell	O
proliferation	O
and	O
cytoskeletal	O
organization	O
,	O
causing	O
this	O
GTPase	O
to	O
switch	O
from	O
its	O
inactive	O
to	O
its	O
active	O
state	O
.	O

Transfection	O
experiments	O
also	O
show	O
that	O
phosphorylation	O
of	O
Vav	O
on	O
tyrosine	O
residues	O
leads	O
to	O
nucleotide	O
exchange	O
on	O
Rac	O
-	O
1	O
in	O
vivo	O
and	O
stimulates	O
c	O
-	O
Jun	O
kinase	O
,	O
a	O
downstream	O
element	O
in	O
the	O
signalling	O
pathway	O
involving	O
this	O
GTPase	O
.	O

Our	O
results	O
have	O
identified	O
a	O
function	O
for	O
Vav	O
and	O
define	O
a	O
mechanism	O
in	O
which	O
engaged	O
membrane	O
receptors	O
activate	O
its	O
signalling	O
pathway	O
.	O

Mutations	O
in	O
two	O
other	O
genes	O
required	O
only	O
for	O
the	O
bipolar	O
budding	O
pattern	O
,	O
BUD8	O
and	O
BUD9	O
,	O
result	O
in	O
a	O
more	O
specific	O
defect	O
,	O
a	O
unipolar	O
budding	O
pattern	O
.	O

bud8	O
mutants	O
bud	O
only	O
from	O
the	O
proximal	O
pole	O
and	O
bud9	O
mutants	O
bud	O
only	O
from	O
the	O
distal	O
pole	O
.	O

These	O
phenotypes	O
suggest	O
that	O
different	O
mechanisms	O
are	O
used	O
for	O
placing	O
the	O
cue	O
at	O
the	O
two	O
poles	O
and	O
/	O
or	O
that	O
different	O
cues	O
are	O
used	O
to	O
mark	O
the	O
distal	O
and	O
proximal	O
poles	O
.	O

Glycation	O
-	O
dependent	O
,	O
reactive	O
oxygen	O
species	O
-	O
mediated	O
suppression	O
of	O
the	O
insulin	O
gene	O
promoter	O
activity	O
in	O
HIT	O
cells	O
.	O

Prolonged	O
poor	O
glycemic	O
control	O
in	O
non	O
-	O
insulin	O
-	O
dependent	O
diabetes	O
mellitus	O
patients	O
often	O
leads	O
to	O
a	O
decline	O
in	O
insulin	O
secretion	O
from	O
pancreatic	O
beta	O
cells	O
,	O
accompanied	O
by	O
a	O
decrease	O
in	O
the	O
insulin	O
content	O
of	O
the	O
cells	O
.	O

As	O
a	O
step	O
toward	O
elucidating	O
the	O
pathophysiological	O
background	O
of	O
the	O
so	O
-	O
called	O
glucose	O
toxicity	O
to	O
pancreatic	O
beta	O
cells	O
,	O
we	O
induced	O
glycation	O
in	O
HIT	O
-	O
T15	O
cells	O
using	O
a	O
sugar	O
with	O
strong	O
deoxidizing	O
activity	O
,	O
D	O
-	O
ribose	O
,	O
and	O
examined	O
the	O
effects	O
on	O
insulin	O
gene	O
transcription	O
.	O

The	O
results	O
of	O
reporter	O
gene	O
analyses	O
revealed	O
that	O
the	O
insulin	O
gene	O
promoter	O
is	O
more	O
sensitive	O
to	O
glycation	O
than	O
the	O
control	O
beta	O
-	O
actin	O
gene	O
promoter	O
;	O
approximately	O
50	O
and	O
80	O
%	O
of	O
the	O
insulin	O
gene	O
promoter	O
activity	O
was	O
lost	O
when	O
the	O
cells	O
were	O
kept	O
for	O
3	O
d	O
in	O
the	O
presence	O
of	O
40	O
and	O
60	O
mM	O
D	O
-	O
ribose	O
,	O
respectively	O
.	O

In	O
agreement	O
with	O
this	O
,	O
decrease	O
in	O
the	O
insulin	O
mRNA	O
and	O
insulin	O
content	O
was	O
observed	O
in	O
the	O
glycation	O
-	O
induced	O
cells	O
.	O

Also	O
,	O
gel	O
mobility	O
shift	O
analyses	O
using	O
specific	O
antiserum	O
revealed	O
decrease	O
in	O
the	O
DNA	O
-	O
binding	O
activity	O
of	O
an	O
insulin	O
gene	O
transcription	O
factor	O
,	O
PDX	O
-	O
1	O
/	O
IPF1	O
/	O
STF	O
-	O
1	O
.	O

These	O
effects	O
of	O
D	O
-	O
ribose	O
seemed	O
almost	O
irreversible	O
but	O
could	O
be	O
prevented	O
by	O
addition	O
of	O
1	O
mM	O
aminoguanidine	O
or	O
10	O
mM	O
N	O
-	O
acetylcysteine	O
,	O
thus	O
suggesting	O
that	O
glycation	O
and	O
reactive	O
oxygen	O
species	O
,	O
generated	O
through	O
the	O
glycation	O
reaction	O
,	O
serve	O
as	O
mediators	O
of	O
the	O
phenomena	O
.	O

These	O
observations	O
suggest	O
that	O
protein	O
glycation	O
in	O
pancreatic	O
beta	O
cells	O
,	O
which	O
occurs	O
in	O
vivo	O
under	O
chronic	O
hyperglycemia	O
,	O
suppresses	O
insulin	O
gene	O
transcription	O
and	O
thus	O
can	O
explain	O
part	O
of	O
the	O
beta	O
cell	O
glucose	O
toxicity	O
.	O

Our	O
in	O
vitro	O
reaction	O
measures	O
the	O
last	O
step	O
of	O
inheritance	O
,	O
the	O
fusion	O
of	O
vacuoles	O
,	O
but	O
relies	O
on	O
a	O
sequence	O
of	O
coupled	O
steps	O
which	O
represents	O
earlier	O
stages	O
in	O
the	O
pathway	O
as	O
well	O
.	O

Thus	O
,	O
the	O
first	O
step	O
of	O
inheritance	O
to	O
be	O
observed	O
in	O
vivo	O
,	O
the	O
creation	O
of	O
a	O
segregation	O
structure	O
which	O
projects	O
into	O
the	O
bud	O
,	O
is	O
also	O
seen	O
in	O
our	O
in	O
vitro	O
reaction	O
and	O
requires	O
the	O
vac	O
-	O
encoded	O
proteins	O
.	O

Recent	O
studies	O
(	O
Fanton	O
,	O
V	O
.	O
,	O
and	O
W	O
.	O
Wickner	O
,	O
unpublished	O
)	O
indicate	O
that	O
structure	O
formation	O
requires	O
Sec17	O
and	O
Sec18	O
proteins	O
,	O
further	O
connecting	O
it	O
to	O
the	O
early	O
stages	O
of	O
the	O
in	O
vitro	O
reaction	O
as	O
assayed	O
biochemically	O
.	O

Analysis	O
of	O
the	O
in	O
vitro	O
reaction	O
thus	O
offers	O
insight	O
into	O
several	O
stages	O
of	O
the	O
organelle	O
inheritance	O
process	O
.	O

Interaction	O
of	O
transcription	O
factors	O
RFX1	O
and	O
MIBP1	O
with	O
the	O
gamma	O
motif	O
of	O
the	O
negative	O
regulatory	O
element	O
of	O
the	O
hepatitis	O
B	O
virus	O
core	O
promoter	O
.	O

The	O
negative	O
regulatory	O
element	O
(	O
NRE	O
)	O
of	O
the	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
core	O
promoter	O
contains	O
three	O
subregions	O
which	O
act	O
synergistically	O
to	O
suppress	O
core	O
promoter	O
activity	O
.	O

One	O
of	O
these	O
subregions	O
,	O
NRE	O
gamma	O
,	O
is	O
active	O
in	O
both	O
HeLa	O
cervical	O
carcinoma	O
cells	O
and	O
Huh7	O
hepatoma	O
cells	O
and	O
was	O
found	O
to	O
be	O
bound	O
by	O
a	O
protein	O
factor	O
present	O
in	O
both	O
cell	O
types	O
.	O

Here	O
we	O
show	O
that	O
the	O
transcription	O
factor	O
RFX1	O
can	O
bind	O
to	O
NRE	O
gamma	O
and	O
transactivate	O
the	O
core	O
promoter	O
through	O
this	O
site	O
.	O

Mutations	O
which	O
abrogated	O
the	O
gene	O
-	O
suppressive	O
activity	O
of	O
NRE	O
gamma	O
prevented	O
RFX1	O
from	O
binding	O
to	O
NRE	O
gamma	O
.	O

In	O
addition	O
,	O
RFX1	O
can	O
bind	O
simultaneously	O
,	O
most	O
likely	O
as	O
a	O
heterodimer	O
,	O
with	O
the	O
transcription	O
factor	O
MIBP1	O
to	O
NRE	O
gamma	O
.	O

In	O
the	O
absence	O
of	O
a	O
cloned	O
MIBP1	O
gene	O
for	O
further	O
studies	O
,	O
we	O
hypothesize	O
that	O
RFX1	O
acts	O
with	O
MIBP1	O
to	O
negatively	O
regulate	O
the	O
core	O
promoter	O
activity	O
through	O
the	O
NRE	O
gamma	O
site	O
.	O

The	O
ability	O
of	O
RFX1	O
to	O
transactivate	O
the	O
core	O
promoter	O
raises	O
the	O
possibility	O
that	O
RFX1	O
may	O
play	O
a	O
dual	O
role	O
in	O
regulating	O
HBV	O
gene	O
expression	O
.	O

Effect	O
of	O
association	O
with	O
adenylyl	O
cyclase	O
-	O
associated	O
protein	O
on	O
the	O
interaction	O
of	O
yeast	O
adenylyl	O
cyclase	O
with	O
Ras	O
protein	O
.	O

Posttranslational	O
modification	O
of	O
Ras	O
protein	O
has	O
been	O
shown	O
to	O
be	O
critical	O
for	O
interaction	O
with	O
its	O
effector	O
molecules	O
,	O
including	O
Saccharomyces	O
cerevisiae	O
adenylyl	O
cyclase	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
its	O
action	O
was	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
reconstituted	O
system	O
with	O
purified	O
adenylyl	O
cyclase	O
and	O
Ras	O
proteins	O
carrying	O
various	O
degrees	O
of	O
the	O
modification	O
to	O
show	O
that	O
the	O
posttranslational	O
modification	O
,	O
especially	O
the	O
farnesylation	O
step	O
,	O
is	O
responsible	O
for	O
5	O
-	O
to	O
10	O
-	O
fold	O
increase	O
in	O
Ras	O
-	O
dependent	O
activation	O
of	O
adenylyl	O
cyclase	O
activity	O
even	O
though	O
it	O
has	O
no	O
significant	O
effect	O
on	O
their	O
binding	O
affinity	O
.	O

The	O
stimulatory	O
effect	O
of	O
farnesylation	O
is	O
found	O
to	O
depend	O
on	O
the	O
association	O
of	O
adenylyl	O
cyclase	O
with	O
70	O
-	O
kDa	O
adenylyl	O
cyclase	O
-	O
associated	O
protein	O
(	O
CAP	O
)	O
,	O
which	O
was	O
known	O
to	O
be	O
required	O
for	O
proper	O
in	O
vivo	O
response	O
of	O
adenylyl	O
cyclase	O
to	O
Ras	O
protein	O
,	O
by	O
comparing	O
the	O
levels	O
of	O
Ras	O
-	O
dependent	O
activation	O
of	O
purified	O
adenylyl	O
cyclase	O
with	O
and	O
without	O
bound	O
CAP	O
.	O

The	O
region	O
of	O
CAP	O
required	O
for	O
this	O
effect	O
is	O
mapped	O
to	O
its	O
N	O
-	O
terminal	O
segment	O
of	O
168	O
amino	O
acid	O
residues	O
,	O
which	O
coincides	O
with	O
the	O
region	O
required	O
for	O
the	O
in	O
vivo	O
effect	O
.	O

Furthermore	O
,	O
the	O
stimulatory	O
effect	O
is	O
successfully	O
reconstituted	O
by	O
in	O
vitro	O
association	O
of	O
CAP	O
with	O
the	O
purified	O
adenylyl	O
cyclase	O
molecule	O
lacking	O
the	O
bound	O
CAP	O
.	O

These	O
results	O
indicate	O
that	O
the	O
association	O
of	O
adenylyl	O
cyclase	O
with	O
CAP	O
is	O
responsible	O
for	O
the	O
stimulatory	O
effect	O
of	O
posttranslational	O
modification	O
of	O
Ras	O
on	O
its	O
activity	O
and	O
that	O
this	O
may	O
be	O
the	O
mechanism	O
underlying	O
its	O
requirement	O
for	O
the	O
proper	O
in	O
vivo	O
cyclic	O
AMP	O
response	O
.	O

Activation	O
of	O
a	O
novel	O
proto	O
-	O
oncogene	O
,	O
Frat1	O
,	O
contributes	O
to	O
progression	O
of	O
mouse	O
T	O
-	O
cell	O
lymphomas	O
.	O

Acceleration	O
of	O
lymphomagenesis	O
in	O
oncogene	O
-	O
bearing	O
transgenic	O
mice	O
by	O
slow	O
-	O
transforming	O
retroviruses	O
has	O
proven	O
a	O
valuable	O
tool	O
in	O
identifying	O
cooperating	O
oncogenes	O
.	O

We	O
have	O
modified	O
this	O
protocol	O
to	O
search	O
for	O
genes	O
that	O
can	O
collaborate	O
effectively	O
with	O
the	O
transgene	O
in	O
later	O
stages	O
of	O
tumor	O
development	O
.	O

Propagation	O
of	O
tumors	O
induced	O
by	O
Moloney	O
murine	O
leukemia	O
virus	O
(	O
M	O
-	O
MuLV	O
)	O
in	O
E	O
mu	O
-	O
Pim1	O
or	O
H2	O
-	O
K	O
-	O
myc	O
transgenic	O
mice	O
by	O
transplantation	O
to	O
syngeneic	O
hosts	O
permitted	O
proviral	O
tagging	O
of	O
'	O
progression	O
'	O
genes	O
.	O

Molecular	O
cloning	O
of	O
common	O
proviral	O
insertion	O
sites	O
that	O
were	O
detected	O
preferentially	O
in	O
transplanted	O
tumors	O
led	O
to	O
the	O
identification	O
of	O
a	O
novel	O
gene	O
,	O
designated	O
Frat1	O
.	O

The	O
initial	O
selection	O
for	O
integrations	O
near	O
Frat1	O
occurs	O
in	O
primary	O
tumor	O
cells	O
that	O
have	O
already	O
acquired	O
proviruses	O
in	O
other	O
common	O
insertion	O
sites	O
,	O
yielding	O
primary	O
lymphomas	O
that	O
contain	O
only	O
a	O
minor	O
fraction	O
of	O
tumor	O
cells	O
with	O
an	O
activated	O
Frat1	O
allele	O
.	O

Transplantation	O
of	O
such	O
primary	O
lymphomas	O
allows	O
for	O
a	O
further	O
expansion	O
of	O
tumor	O
cell	O
clones	O
carrying	O
a	O
proviral	O
insertion	O
near	O
Frat1	O
,	O
resulting	O
in	O
detectable	O
Frat1	O
rearrangements	O
in	O
17	O
%	O
of	O
the	O
transplanted	O
E	O
mu	O
-	O
Pim1	O
tumors	O
and	O
30	O
%	O
of	O
the	O
transplanted	O
H2	O
-	O
K	O
-	O
myc	O
tumors	O
,	O
respectively	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
both	O
the	O
mouse	O
Frat1	O
gene	O
and	O
its	O
human	O
counterpart	O
.	O

The	O
proteins	O
encoded	O
by	O
Frat1	O
and	O
FRAT1	O
are	O
highly	O
homologous	O
and	O
their	O
functions	O
are	O
thus	O
far	O
unknown	O
.	O

Tumor	O
cell	O
lines	O
with	O
high	O
expression	O
of	O
Myc	O
and	O
Pim1	O
acquired	O
an	O
additional	O
selective	O
advantage	O
in	O
vivo	O
upon	O
infection	O
with	O
a	O
Frat1	O
-	O
IRES	O
-	O
lacZ	O
retrovirus	O
,	O
thus	O
underscoring	O
the	O
role	O
of	O
Frat1	O
in	O
tumor	O
progression	O
,	O
and	O
the	O
ability	O
of	O
Frat1	O
to	O
collaborate	O
with	O
Pim1	O
and	O
Myc	O
in	O
lymphomagenesis	O
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
CDC37	O
as	O
a	O
multicopy	O
suppressor	O
of	O
the	O
mps1	O
-	O
1	O
temperature	O
-	O
sensitive	O
(	O
ts	O
)	O
phenotype	O
.	O

In	O
addition	O
to	O
multicopy	O
suppressor	O
interactions	O
,	O
we	O
find	O
that	O
alleles	O
of	O
CDC37	O
and	O
MPS1	O
exhibit	O
synthetic	O
lethal	O
interactions	O
.	O

CDC37	O
was	O
originally	O
isolated	O
by	O
Reed	O
(	O
1980a	O
)	O
in	O
a	O
screen	O
for	O
mutations	O
that	O
cause	O
cell	O
cycle	O
arrest	O
at	O
Start	O
in	O
G1	O
in	O
a	O
matingcompetent	O
state	O
,	O
and	O
a	O
weak	O
karyogamy	O
defect	O
is	O
also	O
seen	O
in	O
cdc37	O
mutants	O
at	O
the	O
nonpermissive	O
temperature	O
.	O

Functional	O
homologues	O
of	O
this	O
gene	O
have	O
recently	O
been	O
identified	O
in	O
Drosphilia	O
melanogaster	O
and	O
mammals	O
,	O
and	O
the	O
mammalian	O
gene	O
encodes	O
a	O
subunit	O
of	O
the	O
Hsp90	O
chaperone	O
complex	O
found	O
in	O
association	O
with	O
several	O
protein	O
kinases	O
.	O

Phenotypic	O
analysis	O
demonstrates	O
that	O
cdc37	O
-	O
1	O
arrest	O
is	O
a	O
novel	O
Start	O
arrest	O
,	O
where	O
the	O
SPBs	O
have	O
begun	O
duplication	O
and	O
formed	O
an	O
aberrant	O
side	O
-	O
by	O
-	O
side	O
structure	O
,	O
although	O
the	O
cell	O
remains	O
mating	O
pheromone	O
responsive	O
.	O

One	O
SPB	O
,	O
apparently	O
the	O
newly	O
formed	O
one	O
,	O
displays	O
an	O
outer	O
plaque	O
defect	O
.	O

Mutation	O
of	O
CDC37	O
causes	O
a	O
loss	O
of	O
Mps1p	O
kinase	O
activity	O
but	O
does	O
not	O
affect	O
protein	O
stability	O
.	O

These	O
findings	O
demonstrate	O
a	O
requirement	O
for	O
CDC37	O
function	O
in	O
normal	O
SPB	O
duplication	O
and	O
may	O
also	O
suggest	O
a	O
more	O
general	O
role	O
for	O
this	O
gene	O
in	O
G1	O
control	O
.	O

The	O
yeast	O
gene	O
,	O
MDM20	O
,	O
is	O
necessary	O
for	O
mitochondrial	O
inheritance	O
and	O
organization	O
of	O
the	O
actin	O
cytoskeleton	O
.	O

In	O
Saccharomyces	O
cerevisiae	O
,	O
the	O
growing	O
bud	O
inherits	O
a	O
portion	O
of	O
the	O
mitochondrial	O
network	O
from	O
the	O
mother	O
cell	O
soon	O
after	O
it	O
emerges	O
.	O

Although	O
this	O
polarized	O
transport	O
of	O
mitochondria	O
is	O
thought	O
to	O
require	O
functions	O
of	O
the	O
cytoskeleton	O
,	O
there	O
are	O
conflicting	O
reports	O
concerning	O
the	O
nature	O
of	O
the	O
cytoskeletal	O
element	O
involved	O
.	O

Here	O
we	O
report	O
the	O
isolation	O
of	O
a	O
yeast	O
mutant	O
,	O
mdm20	O
,	O
in	O
which	O
both	O
mitochondrial	O
inheritance	O
and	O
actin	O
cables	O
(	O
bundles	O
of	O
actin	O
filaments	O
)	O
are	O
disrupted	O
.	O

The	O
MDM20	O
gene	O
encodes	O
a	O
93	O
-	O
kD	O
polypeptide	O
with	O
no	O
homology	O
to	O
other	O
characterized	O
proteins	O
.	O

Extra	O
copies	O
of	O
TPM1	O
,	O
a	O
gene	O
encoding	O
the	O
actin	O
filament	O
-	O
binding	O
protein	O
tropomyosin	O
,	O
suppress	O
mitochondrial	O
inheritance	O
defects	O
and	O
partially	O
restore	O
actin	O
cables	O
in	O
mdm20	O
delta	O
cells	O
.	O

Synthetic	O
lethality	O
is	O
also	O
observed	O
between	O
mdm20	O
and	O
tpm1	O
mutant	O
strains	O
.	O

Overexpression	O
of	O
a	O
second	O
yeast	O
tropomyosin	O
,	O
Tpm2p	O
,	O
rescues	O
mutant	O
phenotypes	O
in	O
the	O
mdm20	O
strain	O
to	O
a	O
lesser	O
extent	O
.	O

Together	O
,	O
these	O
results	O
provide	O
compelling	O
evidence	O
that	O
mitochondrial	O
inheritance	O
in	O
yeast	O
is	O
an	O
actin	O
-	O
mediated	O
process	O
.	O

MDM20	O
and	O
TPM1	O
also	O
exhibit	O
the	O
same	O
pattern	O
of	O
genetic	O
interactions	O
;	O
mutations	O
in	O
MDM20	O
are	O
synthetically	O
lethal	O
with	O
mutations	O
in	O
BEM2	O
and	O
MYO2	O
but	O
not	O
SAC6	O
.	O

Although	O
MDM20	O
and	O
TPM1	O
are	O
both	O
required	O
for	O
the	O
formation	O
and	O
/	O
or	O
stabilization	O
of	O
actin	O
cables	O
,	O
mutations	O
in	O
these	O
genes	O
disrupt	O
mitochondrial	O
inheritance	O
and	O
nuclear	O
segregation	O
to	O
different	O
extents	O
.	O

Thus	O
,	O
Mdm20p	O
and	O
Tpm1p	O
may	O
act	O
in	O
vivo	O
to	O
establish	O
molecular	O
and	O
functional	O
heterogeneity	O
of	O
the	O
actin	O
cytoskeleton	O
.	O

Positive	O
cross	O
-	O
regulation	O
and	O
enhancer	O
sharing	O
:	O
two	O
mechanisms	O
for	O
specifying	O
overlapping	O
Hox	O
expression	O
patterns	O
.	O

Vertebrate	O
Hox	O
genes	O
display	O
nested	O
and	O
overlapping	O
patterns	O
of	O
expression	O
.	O

During	O
mouse	O
hindbrain	O
development	O
,	O
Hoxb3	O
and	O
Hoxb4	O
share	O
an	O
expression	O
domain	O
caudal	O
to	O
the	O
boundary	O
between	O
rhombomeres	O
6	O
and	O
7	O
.	O

Transgenic	O
analysis	O
reveals	O
that	O
an	O
enhancer	O
(	O
CR3	O
)	O
is	O
shared	O
between	O
both	O
genes	O
and	O
specifies	O
this	O
domain	O
of	O
overlap	O
.	O

Both	O
the	O
position	O
of	O
CR3	O
within	O
the	O
complex	O
and	O
its	O
sequence	O
are	O
conserved	O
from	O
fish	O
to	O
mammals	O
,	O
suggesting	O
it	O
has	O
a	O
common	O
role	O
in	O
regulating	O
the	O
vertebrate	O
HoxB	O
complex	O
.	O

CR3	O
mediates	O
transcriptional	O
activation	O
by	O
multiple	O
Hox	O
genes	O
,	O
including	O
Hoxb4	O
,	O
Hoxd4	O
,	O
and	O
Hoxb5	O
but	O
not	O
Hoxb1	O
.	O

It	O
also	O
functions	O
as	O
a	O
selective	O
HOX	O
response	O
element	O
in	O
Drosophila	O
,	O
where	O
activation	O
depends	O
on	O
Deformed	O
,	O
Sex	O
combs	O
reduced	O
,	O
and	O
Antennapedia	O
but	O
not	O
labial	O
.	O

Taken	O
together	O
,	O
these	O
data	O
show	O
that	O
a	O
Deformed	O
/	O
Hoxb4	O
autoregulatory	O
loop	O
has	O
been	O
conserved	O
between	O
mouse	O
and	O
Drosophila	O
.	O

In	O
addition	O
,	O
these	O
studies	O
reveal	O
the	O
existence	O
of	O
positive	O
cross	O
-	O
regulation	O
and	O
enhancer	O
sharing	O
as	O
two	O
mechanisms	O
for	O
reinforcing	O
the	O
overlapping	O
expression	O
domains	O
of	O
vertebrate	O
Hox	O
genes	O
.	O

In	O
contrast	O
,	O
Drosophila	O
Hox	O
genes	O
do	O
not	O
appear	O
to	O
share	O
enhancers	O
and	O
where	O
they	O
overlap	O
in	O
expression	O
,	O
negative	O
cross	O
-	O
regulatory	O
interactions	O
are	O
observed	O
.	O

Therefore	O
,	O
despite	O
many	O
well	O
documented	O
aspects	O
of	O
Hox	O
structural	O
and	O
functional	O
conservation	O
,	O
there	O
are	O
mechanistic	O
differences	O
in	O
Hox	O
complex	O
regulation	O
between	O
arthropods	O
and	O
vertebrates	O
.	O

Regulation	O
by	O
cAMP	O
of	O
post	O
-	O
translational	O
processing	O
and	O
subcellular	O
targeting	O
of	O
endothelial	O
nitric	O
-	O
oxide	O
synthase	O
(	O
type	O
3	O
)	O
in	O
cardiac	O
myocytes	O
.	O

Cardiac	O
myocytes	O
express	O
the	O
nitric	O
-	O
oxide	O
synthase	O
isoform	O
originally	O
identified	O
in	O
endothelial	O
cells	O
,	O
termed	O
eNOS	O
or	O
NOS3	O
,	O
where	O
it	O
plays	O
a	O
role	O
in	O
regulating	O
myocyte	O
responsiveness	O
to	O
both	O
adrenergic	O
and	O
muscarinic	O
cholinergic	O
autonomic	O
nervous	O
system	O
agonists	O
.	O

eNOS	O
in	O
endothelial	O
cells	O
has	O
been	O
shown	O
to	O
undergo	O
extensive	O
post	O
-	O
translational	O
processing	O
,	O
and	O
in	O
cardiac	O
myocytes	O
as	O
well	O
as	O
endothelial	O
cells	O
,	O
eNOS	O
has	O
been	O
shown	O
to	O
be	O
targeted	O
to	O
plasmalemmal	O
caveolae	O
,	O
a	O
process	O
that	O
is	O
dependent	O
on	O
myristoylation	O
and	O
palmitoylation	O
.	O

Other	O
post	O
-	O
translational	O
modifications	O
essential	O
for	O
the	O
correct	O
subcellular	O
targeting	O
of	O
eNOS	O
have	O
not	O
been	O
described	O
previously	O
.	O

We	O
demonstrate	O
,	O
using	O
[	O
35S	O
]	O
methionine	O
pulse	O
-	O
chase	O
experiments	O
,	O
that	O
native	O
eNOS	O
in	O
adult	O
rat	O
ventricular	O
myocytes	O
is	O
initially	O
translated	O
as	O
a	O
nonpalmitoylated	O
150	O
-	O
kDa	O
isoform	O
,	O
which	O
is	O
associated	O
with	O
cytosolic	O
and	O
intracellular	O
membrane	O
-	O
enriched	O
fractions	O
.	O

This	O
is	O
subsequently	O
processed	O
to	O
a	O
palmitoylated	O
135	O
-	O
kDa	O
isoform	O
,	O
which	O
is	O
found	O
only	O
in	O
a	O
sarcolemma	O
-	O
enriched	O
membrane	O
fraction	O
.	O

Forskolin	O
,	O
an	O
agent	O
that	O
elevates	O
intracellular	O
cAMP	O
,	O
rapidly	O
inhibited	O
processing	O
of	O
the	O
150	O
-	O
kDa	O
isoform	O
to	O
the	O
135	O
-	O
kDa	O
isoform	O
and	O
transport	O
of	O
eNOS	O
to	O
the	O
sarcolemma	O
,	O
effects	O
paralleled	O
by	O
protein	O
kinase	O
A	O
-	O
dependent	O
phosphorylation	O
of	O
the	O
larger	O
eNOS	O
isoform	O
.	O

Forskolin	O
also	O
decreased	O
palmitoylation	O
of	O
the	O
135	O
-	O
kDa	O
isoform	O
,	O
although	O
it	O
did	O
not	O
accelerate	O
depalmitoylation	O
of	O
sarcolemmal	O
eNOS	O
,	O
as	O
determined	O
by	O
pulse	O
-	O
chase	O
experiments	O
with	O
[	O
3H	O
]	O
palmitate	O
.	O

Thus	O
,	O
post	O
-	O
translational	O
processing	O
of	O
a	O
150	O
-	O
kDa	O
isoform	O
of	O
myocyte	O
eNOS	O
appears	O
to	O
be	O
necessary	O
for	O
intracellular	O
trafficking	O
of	O
the	O
enzyme	O
to	O
sarcolemmal	O
caveolae	O
.	O

Both	O
the	O
post	O
-	O
translational	O
processing	O
and	O
subcellular	O
targeting	O
of	O
eNOS	O
appear	O
to	O
be	O
modified	O
by	O
changes	O
in	O
intracellular	O
cAMP	O
,	O
an	O
effect	O
that	O
may	O
have	O
important	O
implications	O
for	O
cardiac	O
myocyte	O
responsiveness	O
to	O
autonomic	O
agonists	O
in	O
vivo	O
.	O

Oncogenic	O
forms	O
of	O
NOTCH1	O
lacking	O
either	O
the	O
primary	O
binding	O
site	O
for	O
RBP	O
-	O
Jkappa	O
or	O
nuclear	O
localization	O
sequences	O
retain	O
the	O
ability	O
to	O
associate	O
with	O
RBP	O
-	O
Jkappa	O
and	O
activate	O
transcription	O
.	O

Truncated	O
forms	O
of	O
the	O
NOTCH1	O
transmembrane	O
receptor	O
engineered	O
to	O
resemble	O
mutant	O
forms	O
of	O
NOTCH1	O
found	O
in	O
certain	O
cases	O
of	O
human	O
T	O
cell	O
leukemia	O
/	O
lymphoma	O
(	O
T	O
-	O
ALL	O
)	O
efficiently	O
induce	O
T	O
-	O
ALL	O
when	O
expressed	O
in	O
the	O
bone	O
marrow	O
of	O
mice	O
.	O

Unlike	O
full	O
-	O
sized	O
NOTCH1	O
,	O
two	O
such	O
truncated	O
forms	O
of	O
the	O
protein	O
either	O
lacking	O
a	O
major	O
portion	O
of	O
the	O
extracellular	O
domain	O
(	O
DeltaE	O
)	O
or	O
consisting	O
only	O
of	O
the	O
intracellular	O
domain	O
(	O
ICN	O
)	O
were	O
found	O
to	O
activate	O
transcription	O
in	O
cultured	O
cells	O
,	O
presumably	O
through	O
RBP	O
-	O
Jkappa	O
response	O
elements	O
within	O
DNA	O
.	O

Both	O
truncated	O
forms	O
also	O
bound	O
to	O
the	O
transcription	O
factor	O
RBP	O
-	O
Jkappa	O
in	O
extracts	O
prepared	O
from	O
human	O
and	O
murine	O
T	O
-	O
ALL	O
cell	O
lines	O
.	O

Transcriptional	O
activation	O
required	O
the	O
presence	O
of	O
a	O
weak	O
RBP	O
-	O
Jkappa	O
-	O
binding	O
site	O
within	O
the	O
NOTCH1	O
ankyrin	O
repeat	O
region	O
of	O
the	O
intracellular	O
domain	O
.	O

Unexpectedly	O
,	O
a	O
second	O
,	O
stronger	O
RBP	O
-	O
Jkappa	O
-	O
binding	O
site	O
,	O
which	O
lies	O
within	O
the	O
intracellular	O
domain	O
close	O
to	O
the	O
transmembrane	O
region	O
and	O
significantly	O
augments	O
association	O
with	O
RBP	O
-	O
Jkappa	O
,	O
was	O
not	O
needed	O
for	O
oncogenesis	O
or	O
for	O
transcriptional	O
activation	O
.	O

While	O
ICN	O
appeared	O
primarily	O
in	O
the	O
nucleus	O
,	O
DeltaE	O
localized	O
to	O
cytoplasmic	O
and	O
nuclear	O
membranes	O
,	O
suggesting	O
that	O
intranuclear	O
localization	O
is	O
not	O
essential	O
for	O
oncogenesis	O
or	O
transcriptional	O
activation	O
.	O

In	O
support	O
of	O
this	O
interpretation	O
,	O
mutation	O
of	O
putative	O
nuclear	O
localization	O
sequences	O
decreased	O
nuclear	O
localization	O
and	O
increased	O
transcriptional	O
activation	O
by	O
membrane	O
-	O
bound	O
DeltaE	O
.	O

Transcriptional	O
activation	O
by	O
this	O
mutant	O
form	O
of	O
membrane	O
-	O
bound	O
DeltaE	O
was	O
approximately	O
equivalent	O
to	O
that	O
produced	O
by	O
intranuclear	O
ICN	O
.	O

These	O
data	O
are	O
most	O
consistent	O
with	O
NOTCH1	O
oncogenesis	O
and	O
transcriptional	O
activation	O
being	O
independent	O
of	O
association	O
with	O
RBP	O
-	O
Jkappa	O
at	O
promoter	O
sites	O
.	O

The	O
crystal	O
structure	O
of	O
an	O
intact	O
human	O
Max	O
-	O
DNA	O
complex	O
:	O
new	O
insights	O
into	O
mechanisms	O
of	O
transcriptional	O
control	O
.	O

BACKGROUND	O
:	O
Max	O
belongs	O
to	O
the	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
leucine	O
zipper	O
(	O
bHLHZ	O
)	O
family	O
of	O
transcription	O
factors	O
.	O

Max	O
is	O
able	O
to	O
form	O
homodimers	O
and	O
heterodimers	O
with	O
other	O
members	O
of	O
this	O
family	O
,	O
which	O
include	O
Mad	O
,	O
Mxi1	O
and	O
Myc	O
;	O
Myc	O
is	O
an	O
oncoprotein	O
implicated	O
in	O
cell	O
proliferation	O
,	O
differentiation	O
and	O
apoptosis	O
.	O

The	O
homodimers	O
and	O
heterodimers	O
compete	O
for	O
a	O
common	O
DNA	O
target	O
site	O
(	O
the	O
E	O
box	O
)	O
and	O
rearrangement	O
amongst	O
these	O
dimer	O
forms	O
provides	O
a	O
complex	O
system	O
of	O
transcriptional	O
regulation	O
.	O

Max	O
is	O
also	O
regulated	O
by	O
phosphorylation	O
at	O
a	O
site	O
preceding	O
the	O
basic	O
region	O
.	O

We	O
report	O
here	O
the	O
first	O
crystal	O
structure	O
of	O
an	O
intact	O
bHLHZ	O
protein	O
bound	O
to	O
its	O
target	O
site	O
.	O

RESULTS	O
:	O
The	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
the	O
intact	O
human	O
Max	O
protein	O
homodimer	O
in	O
complex	O
with	O
a	O
13	O
-	O
mer	O
DNA	O
duplex	O
was	O
determined	O
to	O
2	O
.	O
8	O
A	O
resolution	O
and	O
refined	O
to	O
an	O
R	O
factor	O
of	O
0	O
.	O
213	O
.	O

The	O
C	O
-	O
terminal	O
domains	O
in	O
both	O
chains	O
of	O
the	O
Max	O
dimer	O
are	O
disordered	O
.	O

In	O
contrast	O
to	O
the	O
DNA	O
observed	O
in	O
complex	O
with	O
other	O
bHLH	O
and	O
bHLHZ	O
proteins	O
,	O
the	O
DNA	O
in	O
the	O
Max	O
complex	O
is	O
bent	O
by	O
about	O
25	O
degrees	O
,	O
directed	O
towards	O
the	O
protein	O
.	O

Intimate	O
contacts	O
with	O
interdigitating	O
sidechains	O
give	O
rise	O
to	O
the	O
formation	O
of	O
tetramers	O
in	O
the	O
crystal	O
.	O

CONCLUSIONS	O
:	O
The	O
structure	O
confirms	O
the	O
importance	O
of	O
the	O
HLH	O
and	O
leucine	O
zipper	O
motifs	O
in	O
dimerization	O
as	O
well	O
as	O
the	O
mode	O
of	O
E	O
box	O
recognition	O
which	O
was	O
previously	O
analyzed	O
by	O
X	O
-	O
ray	O
crystallography	O
of	O
shortened	O
constructs	O
.	O

The	O
disorder	O
observed	O
in	O
the	O
C	O
-	O
terminal	O
domain	O
suggests	O
that	O
contacts	O
with	O
additional	O
protein	O
components	O
of	O
the	O
transcription	O
machinery	O
are	O
necessary	O
for	O
ordering	O
the	O
secondary	O
structure	O
.	O

The	O
tetramers	O
seen	O
in	O
the	O
crystal	O
are	O
consistent	O
with	O
the	O
tendency	O
of	O
Max	O
and	O
other	O
bHLHZ	O
and	O
HLH	O
proteins	O
to	O
form	O
higher	O
order	O
oligomers	O
in	O
solution	O
and	O
may	O
play	O
a	O
role	O
in	O
DNA	O
looping	O
.	O

The	O
location	O
of	O
the	O
two	O
phosphorylation	O
sites	O
at	O
Ser1	O
and	O
Ser10	O
(	O
the	O
latter	O
is	O
the	O
N	O
-	O
cap	O
of	O
the	O
basic	O
helix	O
)	O
suggests	O
how	O
phosphorylation	O
could	O
disrupt	O
DNA	O
binding	O
.	O

T	O
-	O
cell	O
oncogene	O
rhombotin	O
-	O
2	O
interacts	O
with	O
retinoblastoma	O
-	O
binding	O
protein	O
2	O
.	O

The	O
LIM	O
domain	O
protein	O
rhombotin	O
-	O
2	O
(	O
RBTN	O
-	O
2	O
/	O
TTG	O
-	O
2	O
/	O
Lmo2	O
)	O
has	O
distinct	O
functions	O
in	O
erythropoiesis	O
and	O
in	O
T	O
-	O
cell	O
leukemogenesis	O
.	O

Additional	O
functions	O
for	O
RBTN2	O
are	O
indicated	O
by	O
its	O
expression	O
in	O
non	O
-	O
hematopoietic	O
tissues	O
.	O

These	O
diverse	O
functions	O
of	O
RBTN2	O
are	O
presumed	O
to	O
be	O
accomplished	O
through	O
physical	O
interaction	O
with	O
different	O
protein	O
partners	O
that	O
bind	O
the	O
LIM	O
domains	O
of	O
RBTN2	O
.	O

To	O
identify	O
these	O
proteins	O
which	O
may	O
modulate	O
the	O
activity	O
of	O
RBTN2	O
,	O
a	O
human	O
cDNA	O
library	O
was	O
screened	O
using	O
the	O
yeast	O
two	O
-	O
hybrid	O
assay	O
.	O

Using	O
the	O
RBTN2	O
LIM	O
domain	O
region	O
as	O
'	O
bait	O
'	O
,	O
the	O
retinoblastoma	O
-	O
binding	O
protein	O
2	O
(	O
RBP2	O
)	O
was	O
identified	O
as	O
a	O
partner	O
for	O
RBTN2	O
.	O

The	O
interaction	O
between	O
RBTN2	O
and	O
RBP2	O
was	O
confirmed	O
using	O
in	O
vitro	O
binding	O
assays	O
,	O
and	O
by	O
co	O
-	O
immunoprecipitation	O
of	O
the	O
two	O
proteins	O
.	O

Deletion	O
analysis	O
showed	O
the	O
second	O
LIM	O
domain	O
of	O
RBTN2	O
was	O
necessary	O
and	O
sufficient	O
for	O
binding	O
to	O
the	O
last	O
69	O
amino	O
acids	O
of	O
RBP2	O
.	O

The	O
interaction	O
between	O
RBTN2	O
and	O
RBP2	O
had	O
a	O
functional	O
consequence	O
:	O
the	O
combination	O
of	O
RBP2	O
and	O
RBTN2	O
gave	O
higher	O
transcription	O
in	O
vitro	O
,	O
than	O
RBTN2	O
alone	O
.	O

The	O
interaction	O
with	O
RBP2	O
suggests	O
two	O
additional	O
functions	O
for	O
RBTN2	O
:	O
(	O
i	O
)	O
RBTN2	O
may	O
directly	O
affect	O
the	O
activity	O
of	O
RBP2	O
,	O
and	O
/	O
or	O
(	O
ii	O
)	O
RBTN2	O
may	O
indirectly	O
modulate	O
the	O
functions	O
of	O
the	O
retinoblastoma	O
protein	O
by	O
binding	O
to	O
RBP2	O
.	O

Jak3	O
is	O
associated	O
with	O
CD40	O
and	O
is	O
critical	O
for	O
CD40	O
induction	O
of	O
gene	O
expression	O
in	O
B	O
cells	O
.	O

CD40	O
is	O
a	O
receptor	O
that	O
is	O
critical	O
for	O
the	O
survival	O
,	O
growth	O
,	O
differentiation	O
,	O
and	O
isotype	O
switching	O
of	O
B	O
lymphocytes	O
.	O

Although	O
CD40	O
lacks	O
intrinsic	O
tyrosine	O
kinase	O
activity	O
,	O
its	O
ligation	O
induces	O
protein	O
tyrosine	O
phosphorylation	O
,	O
which	O
is	O
necessary	O
for	O
several	O
CD40	O
-	O
mediated	O
events	O
.	O

We	O
show	O
that	O
engagement	O
of	O
CD40	O
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
Jak3	O
as	O
well	O
as	O
of	O
STAT3	O
.	O

Jak3	O
is	O
constitutively	O
associated	O
with	O
CD40	O
,	O
and	O
this	O
interaction	O
requires	O
a	O
proline	O
-	O
rich	O
sequence	O
in	O
the	O
membrane	O
-	O
proximal	O
region	O
of	O
CD40	O
.	O

Deletion	O
of	O
this	O
sequence	O
abolishes	O
the	O
capacity	O
of	O
CD40	O
to	O
induce	O
expression	O
of	O
CD23	O
,	O
ICAM	O
-	O
1	O
,	O
and	O
lymphotoxin	O
-	O
alpha	O
genes	O
in	O
B	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
signaling	O
through	O
Jak3	O
is	O
activated	O
by	O
CD40	O
and	O
plays	O
an	O
important	O
role	O
in	O
CD40	O
-	O
mediated	O
functions	O
.	O

Interaction	O
of	O
the	O
DF3	O
/	O
MUC1	O
breast	O
carcinoma	O
-	O
associated	O
antigen	O
and	O
beta	O
-	O
catenin	O
in	O
cell	O
adhesion	O
.	O

The	O
DF3	O
/	O
MUC1	O
mucin	O
-	O
like	O
glycoprotein	O
is	O
aberrantly	O
overexpressed	O
in	O
human	O
breast	O
carcinomas	O
.	O

The	O
functional	O
role	O
of	O
DF3	O
is	O
unknown	O
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
DF3	O
associates	O
with	O
beta	O
-	O
catenin	O
.	O

Similar	O
findings	O
have	O
been	O
obtained	O
for	O
gamma	O
-	O
catenin	O
but	O
not	O
alpha	O
-	O
catenin	O
.	O

DF3	O
,	O
like	O
E	O
-	O
cadherin	O
and	O
the	O
adenomatous	O
polyposis	O
coli	O
gene	O
product	O
,	O
contains	O
an	O
SXXXXXSSL	O
site	O
that	O
is	O
responsible	O
for	O
direct	O
binding	O
to	O
beta	O
-	O
catenin	O
.	O

The	O
results	O
further	O
demonstrate	O
that	O
interaction	O
of	O
DF3	O
and	O
beta	O
-	O
catenin	O
is	O
dependent	O
on	O
cell	O
adhesion	O
.	O

These	O
findings	O
and	O
the	O
role	O
of	O
beta	O
-	O
catenin	O
in	O
cell	O
signaling	O
support	O
a	O
role	O
for	O
DF3	O
in	O
the	O
adhesion	O
of	O
epithelial	O
cells	O
.	O

Direct	O
demonstration	O
of	O
geranylgeranylation	O
and	O
farnesylation	O
of	O
Ki	O
-	O
Ras	O
in	O
vivo	O
.	O

It	O
has	O
recently	O
been	O
reported	O
that	O
Ki	O
-	O
Ras	O
protein	O
can	O
be	O
modified	O
in	O
vitro	O
by	O
farnesylation	O
or	O
geranylgeranylation	O
.	O

However	O
,	O
a	O
previous	O
analysis	O
of	O
Ki	O
-	O
Ras	O
prenylation	O
in	O
vivo	O
found	O
only	O
farnesylated	O
Ki	O
-	O
Ras	O
.	O

In	O
this	O
report	O
it	O
is	O
shown	O
that	O
under	O
normal	O
conditions	O
,	O
Ki	O
-	O
Ras	O
is	O
farnesylated	O
in	O
vivo	O
and	O
when	O
cells	O
are	O
treated	O
with	O
the	O
farnesyl	B-OOS
transferase	I-OOS
inhibitors	O
B956	O
or	O
B957	O
,	O
farnesylation	O
is	O
inhibited	O
and	O
Ki	O
-	O
Ras	O
becomes	O
geranylgeranylated	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O

These	O
results	O
have	O
strong	O
implications	O
in	O
the	O
design	O
of	O
anticancer	O
drugs	O
based	O
on	O
inhibition	O
of	O
prenylation	O
.	O

Specific	O
complex	O
formation	O
between	O
the	O
type	O
II	O
bare	O
lymphocyte	O
syndrome	O
-	O
associated	O
transactivators	O
CIITA	O
and	O
RFX5	O
.	O

Two	O
of	O
the	O
genes	O
defective	O
in	O
the	O
five	O
complementation	O
groups	O
identified	O
in	O
the	O
class	O
II	O
-	O
negative	O
bare	O
lymphocyte	O
syndrome	O
or	O
corresponding	O
laboratory	O
mutants	O
have	O
been	O
cloned	O
.	O

One	O
gene	O
encodes	O
a	O
protein	O
,	O
RFX5	O
,	O
that	O
is	O
a	O
member	O
of	O
the	O
RFX	O
family	O
of	O
DNA	O
binding	O
proteins	O
.	O

The	O
other	O
,	O
CIITA	O
,	O
encodes	O
a	O
large	O
protein	O
with	O
a	O
defined	O
acidic	O
transcriptional	O
activation	O
domain	O
;	O
this	O
protein	O
does	O
not	O
interact	O
with	O
DNA	O
.	O

Expression	O
plasmids	O
encoding	O
regions	O
of	O
RFX5	O
fused	O
to	O
the	O
GAL4	O
DNA	O
binding	O
domain	O
activated	O
transcription	O
from	O
a	O
reporter	O
construct	O
containing	O
GAL4	O
sites	O
in	O
a	O
cotransfection	O
assay	O
in	O
the	O
Raji	O
human	O
B	O
cell	O
line	O
.	O

However	O
,	O
these	O
plasmids	O
produced	O
transcriptional	O
activity	O
in	O
HeLa	O
cells	O
only	O
in	O
conjunction	O
with	O
interferon	O
gamma	O
stimulation	O
,	O
a	O
condition	O
in	O
which	O
expression	O
of	O
both	O
CIITA	O
and	O
class	B-Complex
II	I-Complex
major	I-Complex
histocompatibility	I-Complex
complex	I-Complex
surface	O
proteins	O
are	O
induced	O
.	O

Furthermore	O
,	O
these	O
plasmids	O
were	O
not	O
active	O
in	O
RJ2	O
.	O
2	O
.	O
5	O
,	O
an	O
in	O
vitro	O
mutagenized	O
derivative	O
of	O
Raji	O
in	O
which	O
both	O
copies	O
of	O
CIITA	O
are	O
defective	O
.	O

Transcriptional	O
activation	O
by	O
the	O
RFX5	O
fusion	O
protein	O
could	O
be	O
restored	O
in	O
RJ2	O
.	O
2	O
.	O
5	O
by	O
cotransfection	O
with	O
a	O
CIITA	O
expression	O
plasmid	O
.	O

Finally	O
,	O
a	O
direct	O
interaction	O
between	O
RFX5	O
and	O
CIITA	O
was	O
detected	O
with	O
the	O
yeast	O
two	O
-	O
hybrid	O
and	O
far	O
-	O
Western	O
blot	O
assays	O
.	O

Thus	O
,	O
RFX5	O
can	O
activate	O
transcription	O
only	O
in	O
cooperation	O
with	O
CIITA	O
.	O

RFX5	O
and	O
CIITA	O
associate	O
to	O
form	O
a	O
complex	O
capable	O
of	O
activating	O
transcription	O
from	O
class	B-Complex
II	I-Complex
major	I-Complex
histocompatibility	I-Complex
complex	I-Complex
promoters	O
.	O

In	O
this	O
complex	O
,	O
promoter	O
specificity	O
is	O
determined	O
by	O
the	O
DNA	O
binding	O
domain	O
of	O
RFX5	O
and	O
the	O
general	O
transcription	O
apparatus	O
is	O
recruited	O
by	O
the	O
acidic	O
activation	O
domain	O
of	O
CIITA	O
.	O

HSDJ	O
,	O
a	O
human	O
homolog	O
of	O
DnaJ	O
,	O
is	O
farnesylated	O
and	O
is	O
involved	O
in	O
protein	O
import	O
into	O
mitochondria	O
.	O

The	O
role	O
of	O
HSDJ	O
,	O
a	O
human	O
homolog	O
of	O
bacterial	O
DnaJ	O
and	O
yeast	O
YDJ1p	O
/	O
MAS5	O
,	O
in	O
mitochondrial	O
protein	O
import	O
was	O
examined	O
.	O

Recombinant	O
HSDJ	O
was	O
purified	O
and	O
an	O
antibody	O
was	O
prepared	O
.	O

HSDJ	O
mRNA	O
was	O
heat	O
-	O
induced	O
in	O
cultured	O
cells	O
.	O

In	O
pulse	O
-	O
labeling	O
and	O
chase	O
experiments	O
using	O
COS	O
-	O
7	O
cells	O
,	O
the	O
endogenous	O
HSDJ	O
homolog	O
was	O
prenylated	O
.	O

Transiently	O
expressed	O
HSDJ	O
was	O
also	O
prenylated	O
,	O
whereas	O
its	O
mutant	O
C394S	O
in	O
which	O
cysteine	O
of	O
the	O
"	O
CaaX	O
box	O
"	O
was	O
mutated	O
to	O
serine	O
,	O
was	O
not	O
.	O

HSDJ	O
,	O
but	O
not	O
C394S	O
,	O
synthesized	O
in	O
rabbit	O
reticulocyte	O
lysate	O
was	O
farnesylated	O
.	O

The	O
HSDJ	O
antibody	O
inhibited	O
import	O
of	O
ornithine	O
transcarbamylase	O
precursor	O
(	O
pOTC	O
)	O
into	O
isolated	O
mitochondria	O
when	O
added	O
prior	O
to	O
pOTC	O
synthesis	O
,	O
but	O
not	O
when	O
added	O
prior	O
to	O
import	O
assay	O
.	O

In	O
transient	O
expression	O
of	O
pOTC	O
in	O
COS	O
-	O
7	O
cells	O
,	O
pOTC	O
was	O
synthesized	O
and	O
processed	O
to	O
the	O
mature	O
form	O
with	O
an	O
apparent	O
half	O
-	O
life	O
of	O
2	O
-	O
3	O
min	O
.	O

Coexpression	O
of	O
HSDJ	O
or	O
C394S	O
resulted	O
in	O
slight	O
retardation	O
of	O
the	O
pOTC	O
processing	O
.	O

These	O
results	O
indicate	O
that	O
HSDJ	O
is	O
involved	O
in	O
an	O
early	O
step	O
(	O
s	O
)	O
of	O
protein	O
import	O
into	O
mitochondria	O
.	O

Cyclin	O
E	O
-	O
CDK2	O
is	O
a	O
regulator	O
of	O
p27Kip1	O
.	O

CDK	O
inhibitors	O
are	O
thought	O
to	O
prevent	O
cell	O
proliferation	O
by	O
negatively	O
regulating	O
cyclin	O
-	O
CDK	O
complexes	O
.	O

We	O
propose	O
that	O
the	O
opposite	O
is	O
also	O
true	O
,	O
that	O
cyclin	O
-	O
CDK	O
complexes	O
in	O
mammmalian	O
cells	O
can	O
promote	O
cell	O
cycle	O
progression	O
by	O
directly	O
down	O
-	O
regulating	O
CDK	O
inhibitors	O
.	O

We	O
show	O
that	O
expression	O
of	O
cyclin	O
E	O
-	O
CDK2	O
in	O
murine	O
fibroblasts	O
causes	O
phosphorylation	O
of	O
the	O
CDK	O
inhibitor	O
p27Kip1	O
on	O
T187	O
,	O
and	O
that	O
cyclin	O
E	O
-	O
CDK2	O
can	O
directly	O
phosphorylate	O
p27	O
T187	O
in	O
vitro	O
.	O

We	O
further	O
show	O
that	O
cyclin	O
E	O
-	O
CDK2	O
-	O
dependent	O
phosphorylation	O
of	O
p27	O
results	O
in	O
elimination	O
of	O
p27	O
from	O
the	O
cell	O
,	O
allowing	O
cells	O
to	O
transit	O
from	O
G1	O
to	O
S	O
phase	O
.	O

Moreover	O
,	O
mutation	O
of	O
T187	O
in	O
p27	O
to	O
alanine	O
creates	O
a	O
p27	O
protein	O
that	O
causes	O
a	O
G1	O
block	O
resistant	O
to	O
cyclin	O
E	O
and	O
whose	O
level	O
of	O
expression	O
is	O
not	O
modulated	O
by	O
cyclin	O
E	O
.	O

A	O
kinetic	O
analysis	O
of	O
the	O
interaction	O
between	O
p27	O
and	O
cyclin	O
E	O
-	O
CDK2	O
explains	O
how	O
p27	O
can	O
be	O
regulated	O
by	O
the	O
same	O
enzyme	O
it	O
targets	O
for	O
inhibition	O
.	O

We	O
show	O
that	O
p27	O
interacts	O
with	O
cyclin	O
E	O
-	O
CDK2	O
in	O
at	O
least	O
two	O
distinct	O
ways	O
:	O
one	O
resulting	O
in	O
p27	O
phosphorylation	O
and	O
release	O
,	O
the	O
other	O
in	O
tight	O
binding	O
and	O
cyclin	O
E	O
-	O
CDK2	O
inhibition	O
.	O

The	O
binding	O
of	O
ATP	O
to	O
the	O
CDK	O
governs	O
which	O
state	O
predominates	O
.	O

At	O
low	O
ATP	O
(	O
<	O
50	O
microM	O
)	O
p27	O
is	O
primarily	O
a	O
CDK	O
inhibitor	O
,	O
but	O
at	O
ATP	O
concentrations	O
approaching	O
physiological	O
levels	O
(	O
>	O
1	O
mM	O
)	O
p27	O
is	O
more	O
likely	O
to	O
be	O
a	O
substrate	O
.	O

Thus	O
,	O
we	O
have	O
identified	O
p27	O
as	O
a	O
biologically	O
relevant	O
cyclin	O
E	O
-	O
CDK2	O
substrate	O
,	O
demonstrated	O
the	O
physiological	O
consequences	O
of	O
p27	O
phosphorylation	O
,	O
and	O
developed	O
a	O
kinetic	O
model	O
to	O
explain	O
how	O
p27	O
can	O
be	O
both	O
an	O
inhibitor	O
and	O
a	O
substrate	O
of	O
cyclin	O
E	O
-	O
CDK2	O
.	O

A	O
signature	O
motif	O
in	O
transcriptional	O
co	O
-	O
activators	O
mediates	O
binding	O
to	O
nuclear	O
receptors	O
.	O

The	O
binding	O
of	O
lipophilic	O
hormones	O
,	O
retinoids	O
and	O
vitamins	O
to	O
members	O
of	O
the	O
nuclear	O
-	O
receptor	O
superfamily	O
modifies	O
the	O
DNA	O
-	O
binding	O
and	O
transcriptional	O
properties	O
of	O
these	O
receptors	O
,	O
resulting	O
in	O
the	O
activation	O
or	O
repression	O
of	O
target	O
genes	O
.	O

Ligand	O
binding	O
induces	O
conformational	O
changes	O
in	O
nuclear	O
receptors	O
and	O
promotes	O
their	O
association	O
with	O
a	O
diverse	O
group	O
of	O
nuclear	O
proteins	O
,	O
including	O
SRC	O
-	O
1	O
/	O
p160	O
,	O
TIF	O
-	O
2	O
/	O
GRIP	O
-	O
1	O
and	O
CBP	O
/	O
p300	O
which	O
function	O
as	O
co	O
-	O
activators	O
of	O
transcription	O
,	O
and	O
RIP	O
-	O
140	O
,	O
TIF	O
-	O
1	O
and	O
TRIP	O
-	O
1	O
/	O
SUG	O
-	O
1	O
whose	O
functions	O
are	O
unclear	O
.	O

Here	O
we	O
report	O
that	O
a	O
short	O
sequence	O
motif	O
LXXLL	O
(	O
where	O
L	O
is	O
leucine	O
and	O
X	O
is	O
any	O
amino	O
acid	O
)	O
present	O
in	O
RIP	O
-	O
140	O
,	O
SRC	O
-	O
1	O
and	O
CBP	O
is	O
necessary	O
and	O
sufficient	O
to	O
mediate	O
the	O
binding	O
of	O
these	O
proteins	O
to	O
liganded	O
nuclear	O
receptors	O
.	O

We	O
show	O
that	O
the	O
ability	O
of	O
SRC	O
-	O
1	O
to	O
bind	O
the	O
oestrogen	O
receptor	O
and	O
enhance	O
its	O
transcriptional	O
activity	O
is	O
dependent	O
upon	O
the	O
integrity	O
of	O
the	O
LXXLL	O
motifs	O
and	O
on	O
key	O
hydrophobic	O
residues	O
in	O
a	O
conserved	O
helix	O
(	O
helix	O
12	O
)	O
of	O
the	O
oestrogen	O
receptor	O
that	O
are	O
required	O
for	O
its	O
ligand	O
-	O
induced	O
activation	O
function	O
.	O

We	O
propose	O
that	O
the	O
LXXLL	O
motif	O
is	O
a	O
signature	O
sequence	O
that	O
facilitates	O
the	O
interaction	O
of	O
different	O
proteins	O
with	O
nuclear	O
receptors	O
,	O
and	O
is	O
thus	O
a	O
defining	O
feature	O
of	O
a	O
new	O
family	O
of	O
nuclear	O
proteins	O
.	O

The	O
immediate	O
-	O
early	O
gene	O
product	O
Egr	O
-	O
1	O
regulates	O
the	O
human	O
interleukin	O
-	O
2	O
receptor	O
beta	O
-	O
chain	O
promoter	O
through	O
noncanonical	O
Egr	O
and	O
Sp1	O
binding	O
sites	O
.	O

The	O
interleukin	O
-	O
2	O
IL	O
-	O
2	O
receptor	O
beta	O
-	O
chain	O
(	O
IL	O
-	O
2Rbeta	O
)	O
is	O
an	O
essential	O
component	O
of	O
the	O
receptors	O
for	O
IL	O
-	O
2	O
and	O
IL	O
-	O
15	O
.	O

Although	O
IL	O
-	O
2Rbeta	O
is	O
constitutively	O
expressed	O
by	O
lymphocytes	O
,	O
its	O
expression	O
can	O
be	O
further	O
induced	O
by	O
a	O
number	O
of	O
stimuli	O
,	O
including	O
phorbol	O
12	O
-	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
.	O

We	O
have	O
now	O
characterized	O
factors	O
that	O
bind	O
to	O
an	O
enhancer	O
region	O
located	O
between	O
nucleotides	O
-	O
170	O
and	O
-	O
139	O
of	O
the	O
human	O
IL	O
-	O
2Rbeta	O
promoter	O
.	O

Both	O
Sp1	O
and	O
Sp3	O
bound	O
to	O
the	O
5	O
'	O
portion	O
of	O
this	O
region	O
,	O
whereas	O
a	O
PMA	O
-	O
inducible	O
factor	O
(	O
PIF	O
)	O
mainly	O
bound	O
to	O
its	O
3	O
'	O
portion	O
and	O
bound	O
to	O
the	O
Sp	O
binding	O
motifs	O
as	O
well	O
.	O

In	O
Jurkat	O
T	O
cells	O
,	O
induction	O
of	O
PIF	O
DNA	O
binding	O
activity	O
was	O
rapidly	O
induced	O
,	O
required	O
de	O
novo	O
protein	O
synthesis	O
,	O
and	O
was	O
sustained	O
at	O
a	O
high	O
level	O
for	O
at	O
least	O
23	O
h	O
.	O

Interestingly	O
,	O
PIF	O
was	O
constitutively	O
activated	O
in	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
-	O
transformed	O
MT	O
-	O
2	O
cells	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
PIF	O
is	O
Egr	O
-	O
1	O
based	O
on	O
its	O
recognition	O
by	O
anti	O
-	O
Egr	O
-	O
1	O
antisera	O
in	O
gel	O
mobility	O
shift	O
assays	O
,	O
even	O
though	O
the	O
IL	O
-	O
2Rbeta	O
DNA	O
binding	O
motif	O
differed	O
substantially	O
from	O
the	O
canonical	O
Egr	O
-	O
1	O
binding	O
site	O
.	O

In	O
addition	O
,	O
Egr	O
-	O
1	O
bound	O
to	O
the	O
Sp	O
binding	O
site	O
.	O

In	O
Jurkat	O
cells	O
,	O
both	O
sites	O
were	O
required	O
for	O
maximal	O
IL	O
-	O
2Rbeta	O
promoter	O
activity	O
,	O
and	O
in	O
HeLaS3	O
cells	O
,	O
transfection	O
of	O
Egr	O
-	O
1	O
could	O
drive	O
activity	O
of	O
a	O
reporter	O
construct	O
containing	O
both	O
sites	O
.	O

Moreover	O
,	O
Sp1	O
and	O
Egr	O
-	O
1	O
could	O
form	O
a	O
complex	O
with	O
kinetics	O
that	O
correlated	O
with	O
the	O
production	O
of	O
Egr	O
-	O
1	O
in	O
Jurkat	O
cells	O
upon	O
PMA	O
stimulation	O
.	O

Thus	O
,	O
Sp1	O
and	O
Egr	O
-	O
1	O
physically	O
and	O
functionally	O
cooperate	O
to	O
mediate	O
maximal	O
IL	O
-	O
2Rbeta	O
promoter	O
activity	O
.	O

S	O
-	O
allyl	O
cysteine	O
inhibits	O
activation	O
of	O
nuclear	B-Complex
factor	I-Complex
kappa	I-Complex
B	I-Complex
in	O
human	O
T	O
cells	O
.	O

Reactive	O
oxygen	O
species	O
are	O
involved	O
in	O
signal	O
transduction	O
pathways	O
leading	O
to	O
nuclear	B-Complex
factor	I-Complex
kappa	I-Complex
B	I-Complex
(	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
)	O
activation	O
which	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
gene	O
transcription	O
.	O

We	O
recently	O
reported	O
that	O
a	O
garlic	O
compound	O
,	O
S	O
-	O
allyl	O
cysteine	O
(	O
SAC	O
)	O
,	O
protects	O
bovine	O
pulmonary	O
artery	O
endothelial	O
cells	O
from	O
oxidant	O
injury	O
induced	O
by	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
.	O

In	O
this	O
study	O
we	O
determined	O
the	O
effects	O
of	O
SAC	O
on	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
activation	O
in	O
human	O
T	O
lymphocytes	O
(	O
Jurkat	O
cells	O
)	O
induced	O
by	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
H2O2	O
.	O

Activated	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
in	O
nuclear	O
extracts	O
was	O
measured	O
by	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
32P	O
-	O
labeled	O
probe	O
.	O

SAC	O
consistently	O
exhibited	O
a	O
dose	O
-	O
dependent	O
inhibition	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
activation	O
induced	O
by	O
both	O
TNF	O
-	O
alpha	O
and	O
H2O2	O
.	O

Supershift	O
with	O
specific	O
antibodies	O
to	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
subunits	O
confirmed	O
that	O
the	O
inducible	O
retarded	O
bands	O
observed	O
in	O
the	O
EMSA	O
and	O
p65	O
-	O
p50	O
heterodimer	O
of	O
the	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
Rel	I-Complex
protein	O
.	O

Our	O
data	O
suggest	O
that	O
SAC	O
may	O
act	O
via	O
antioxidant	O
mechanisms	O
to	O
block	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
activation	O
in	O
Jurkat	O
cells	O
.	O

Of	O
the	O
GATA	O
-	O
binding	O
proteins	O
,	O
only	O
GATA	O
-	O
4	O
selectively	O
regulates	O
the	O
human	O
IL	O
-	O
5	O
gene	O
promoter	O
in	O
IL	O
-	O
5	O
producing	O
cells	O
which	O
express	O
multiple	O
GATA	O
-	O
binding	O
proteins	O
.	O

Interleukin	O
-	O
5	O
(	O
IL	O
-	O
5	O
)	O
is	O
produced	O
by	O
T	O
lymphocytes	O
and	O
known	O
to	O
support	O
B	O
cell	O
growth	O
and	O
eosinophilic	O
differentiation	O
of	O
the	O
progenitor	O
cells	O
.	O

Using	O
ATL	O
-	O
16T	O
cells	O
which	O
express	O
IL	O
-	O
5	O
mRNA	O
,	O
we	O
have	O
identified	O
a	O
region	O
,	O
within	O
the	O
human	O
IL	O
-	O
5	O
gene	O
promoter	O
,	O
that	O
regulates	O
IL	O
-	O
5	O
gene	O
transcription	O
.	O

This	O
cis	O
-	O
acting	O
sequence	O
contains	O
the	O
core	O
binding	O
motif	O
,	O
(	O
A	O
/	O
T	O
)	O
GATA	O
(	O
A	O
/	O
G	O
)	O
,	O
for	O
GATA	O
-	O
binding	O
family	O
proteins	O
and	O
thus	O
suggests	O
the	O
involvement	O
of	O
these	O
family	O
members	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
cloning	O
of	O
human	O
GATA	O
-	O
4	O
(	O
hGATA	O
-	O
4	O
)	O
and	O
show	O
that	O
hGATA	O
-	O
4	O
selectively	O
interacts	O
with	O
the	O
-	O
70	O
GATA	O
site	O
within	O
the	O
IL	O
-	O
5	O
proximal	O
promoter	O
region	O
.	O

By	O
promoter	O
deletion	O
and	O
mutation	O
analyses	O
,	O
we	O
established	O
this	O
region	O
as	O
a	O
positive	O
regulatory	O
element	O
.	O

Cotransfection	O
experiments	O
revealed	O
that	O
both	O
hGATA	O
-	O
4	O
and	O
PMA	O
/	O
A23187	O
stimulation	O
are	O
necessary	O
for	O
the	O
IL	O
-	O
5	O
promoter	O
activation	O
.	O

The	O
requirement	O
of	O
another	O
regulatory	O
element	O
called	O
CLE0	O
,	O
which	O
lies	O
downstream	O
of	O
the	O
-	O
70	O
GATA	O
site	O
,	O
was	O
also	O
demonstrated	O
.	O

ATL	O
-	O
16T	O
cells	O
express	O
mRNA	O
of	O
three	O
GATA	O
-	O
binding	O
proteins	O
,	O
hGATA	O
-	O
2	O
,	O
hGATA	O
-	O
3	O
and	O
hGATA	O
-	O
4	O
,	O
and	O
each	O
of	O
them	O
has	O
a	O
potential	O
to	O
bind	O
to	O
the	O
consensus	O
(	O
A	O
/	O
T	O
)	O
GATA	O
(	O
G	O
/	O
A	O
)	O
motif	O
.	O

However	O
,	O
using	O
ATL	O
-	O
16T	O
nuclear	O
extract	O
,	O
we	O
demonstrated	O
that	O
GATA	O
-	O
4	O
is	O
the	O
only	O
GATA	O
-	O
binding	O
protein	O
that	O
forms	O
specific	O
DNA	O
-	O
protein	O
complex	O
with	O
the	O
-	O
70	O
GATA	O
site	O
.	O

The	O
electrophoretic	O
mobility	O
shift	O
assay	O
with	O
extracts	O
of	O
COS	O
cells	O
expressing	O
GATA	O
-	O
binding	O
proteins	O
showed	O
that	O
GATA	O
-	O
4	O
has	O
the	O
highest	O
binding	O
affinity	O
to	O
the	O
-	O
70	O
GATA	O
site	O
among	O
the	O
three	O
GATA	O
-	O
binding	O
proteins	O
.	O

When	O
the	O
transactivation	O
ability	O
was	O
compared	O
among	O
the	O
three	O
,	O
GATA	O
-	O
4	O
showed	O
the	O
highest	O
activity	O
.	O

These	O
results	O
demonstrate	O
the	O
selective	O
role	O
of	O
GATA	O
-	O
4	O
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IL	O
-	O
5	O
gene	O
in	O
a	O
circumstance	O
where	O
multiple	O
members	O
of	O
the	O
GATA	O
-	O
binding	O
proteins	O
are	O
expressed	O
.	O

Inducible	O
expression	O
and	O
phosphorylation	O
of	O
coactivator	O
BOB	O
.	O
1	O
/	O
OBF	O
.	O
1	O
in	O
T	O
cells	O
[	O
see	O
comments	O
]	O

BOB	O
.	O
1	O
/	O
OBF	O
.	O
1	O
is	O
a	O
transcriptional	O
coactivator	O
that	O
is	O
constitutively	O
expressed	O
in	O
B	O
cells	O
and	O
interacts	O
with	O
the	O
Oct1	O
and	O
Oct2	O
transcription	O
factors	O
.	O

Upon	O
activation	O
of	O
Jurkat	O
T	O
cells	O
and	O
primary	O
murine	O
thymocytes	O
with	O
phorbol	O
esters	O
and	O
ionomycin	O
,	O
BOB	O
.	O
1	O
/	O
OBF	O
.	O
1	O
expression	O
and	O
transactivation	O
function	O
were	O
induced	O
.	O

BOB	O
.	O
1	O
/	O
OBF	O
.	O
1	O
was	O
phosphorylated	O
at	O
Ser184	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
and	O
this	O
modification	O
was	O
required	O
for	O
inducible	O
activation	O
.	O

Mutation	O
of	O
Ser184	O
also	O
diminished	O
transactivation	O
function	O
in	O
B	O
cells	O
,	O
suggesting	O
that	O
the	O
activating	O
phosphorylation	O
that	O
is	O
inducible	O
in	O
T	O
cells	O
is	O
constitutively	O
present	O
in	O
B	O
cells	O
.	O

Thus	O
,	O
BOB	O
.	O
1	O
/	O
OBF	O
.	O
1	O
is	O
a	O
transcriptional	O
coactivator	O
that	O
is	O
critically	O
regulated	O
by	O
posttranslational	O
modifications	O
to	O
mediate	O
cell	O
type	O
-	O
specific	O
gene	O
expression	O
.	O

Proteolysis	O
that	O
is	O
inhibited	O
by	O
hedgehog	O
targets	O
Cubitus	O
interruptus	O
protein	O
to	O
the	O
nucleus	O
and	O
converts	O
it	O
to	O
a	O
repressor	O
.	O

Cell	O
-	O
cell	O
communication	O
at	O
anterior	O
/	O
posterior	O
compartment	O
borders	O
in	O
Drosophila	O
involves	O
Hedgehog	O
(	O
Hh	O
)	O
,	O
a	O
protein	O
secreted	O
by	O
posterior	O
cells	O
,	O
and	O
Cubitus	O
interruptus	O
(	O
Ci	O
)	O
,	O
a	O
protein	O
in	O
the	O
Hh	O
response	O
pathway	O
in	O
anterior	O
cells	O
.	O

Although	O
Ci	O
is	O
thought	O
to	O
have	O
roles	O
as	O
a	O
transcription	O
factor	O
repressing	O
hh	O
expression	O
and	O
activating	O
target	O
genes	O
,	O
it	O
localizes	O
in	O
the	O
cytoplasm	O
of	O
anterior	O
cells	O
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
a	O
domain	O
that	O
tethers	O
Ci	O
in	O
the	O
cytoplasm	O
and	O
show	O
that	O
in	O
some	O
anterior	O
cells	O
,	O
Ci	O
is	O
cleaved	O
to	O
generate	O
a	O
form	O
that	O
lacks	O
the	O
tethering	O
domain	O
.	O

This	O
form	O
translocates	O
to	O
the	O
nucleus	O
where	O
it	O
represses	O
hh	O
and	O
other	O
target	O
genes	O
.	O

Hh	O
inhibits	O
proteolysis	O
of	O
Ci	O
,	O
and	O
we	O
suggest	O
that	O
this	O
inhibition	O
leads	O
to	O
the	O
observed	O
patterns	O
of	O
expression	O
of	O
key	O
target	O
genes	O
at	O
the	O
compartment	O
border	O
.	O

RP1	O
,	O
a	O
new	O
member	O
of	O
the	O
adenomatous	O
polyposis	O
coli	O
-	O
binding	O
EB1	O
-	O
like	O
gene	O
family	O
,	O
is	O
differentially	O
expressed	O
in	O
activated	O
T	O
cells	O
.	O

Cross	O
-	O
linking	O
of	O
the	O
CD3	O
and	O
CD28	O
molecules	O
on	O
T	O
lymphocytes	O
represents	O
one	O
of	O
the	O
most	O
effective	O
signals	O
for	O
T	O
lymphocyte	O
activation	O
and	O
triggering	O
of	O
their	O
cytotoxic	O
effector	O
function	O
.	O

To	O
identify	O
genes	O
that	O
are	O
expressed	O
in	O
T	O
cells	O
after	O
stimulation	O
,	O
mRNA	O
from	O
T	O
lymphocytes	O
that	O
had	O
been	O
activated	O
by	O
the	O
simultaneous	O
stimulation	O
of	O
the	O
CD3	O
and	O
CD28	O
trigger	O
molecules	O
was	O
transcribed	O
for	O
a	O
differential	O
mRNA	O
display	O
analysis	O
into	O
cDNA	O
and	O
was	O
compared	O
with	O
cDNA	O
from	O
CD28	O
-	O
or	O
CD3	O
-	O
activated	O
or	O
resting	O
lymphocytes	O
.	O

Differential	O
expression	O
was	O
confirmed	O
subsequently	O
by	O
Northern	O
blot	O
analysis	O
.	O

One	O
of	O
the	O
cDNA	O
fragments	O
expressed	O
specifically	O
in	O
CD3	O
-	O
and	O
CD28	O
-	O
activated	O
T	O
cells	O
was	O
designated	O
RP1	O
.	O

The	O
predictive	O
protein	O
-	O
coding	O
region	O
of	O
RP1	O
had	O
a	O
significant	O
homology	O
to	O
members	O
of	O
the	O
recently	O
found	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
protein	O
-	O
binding	O
EB1	O
gene	O
family	O
,	O
which	O
codes	O
for	O
yet	O
unknown	O
protein	O
(	O
s	O
)	O
.	O

Bacterially	O
expressed	O
RP1	O
protein	O
revealed	O
specific	O
binding	O
to	O
wild	O
-	O
type	O
but	O
not	O
to	O
mutated	O
APC	O
protein	O
.	O

The	O
rapid	O
up	O
-	O
regulation	O
of	O
RP1	O
mRNA	O
in	O
properly	O
activated	O
T	O
cells	O
suggests	O
that	O
this	O
gene	O
might	O
belong	O
to	O
the	O
immediate	O
/	O
early	O
gene	O
family	O
,	O
which	O
controls	O
the	O
signal	O
transduction	O
cascade	O
downstream	O
of	O
the	O
TCR	B-Complex
.	O

As	O
the	O
expression	O
level	O
of	O
the	O
RP1	O
gene	O
in	O
activated	O
T	O
cells	O
and	O
a	O
spectrum	O
of	O
tumor	O
-	O
derived	O
cell	O
lines	O
correlates	O
with	O
the	O
proliferative	O
status	O
of	O
the	O
cells	O
,	O
members	O
of	O
the	O
EB1	O
-	O
like	O
gene	O
family	O
may	O
not	O
only	O
be	O
involved	O
in	O
the	O
tumorigenesis	O
of	O
colorectal	O
cancers	O
but	O
may	O
also	O
play	O
a	O
role	O
in	O
the	O
proliferative	O
control	O
of	O
normal	O
cells	O
.	O

The	O
alpha	B-Complex
v	I-Complex
beta	I-Complex
3	I-Complex
integrin	I-Complex
"	O
vitronectin	B-Complex
receptor	I-Complex
"	O
.	O

The	O
alpha	B-Complex
v	I-Complex
beta	I-Complex
3	I-Complex
"	O
vitronectin	B-Complex
receptor	I-Complex
"	O
is	O
a	O
member	O
of	O
the	O
integrin	O
superfamily	O
of	O
adhesion	O
molecules	O
.	O

As	O
such	O
,	O
this	O
160	O
/	O
85	O
kDa	O
heterodimeric	O
protein	O
exhibits	O
many	O
of	O
the	O
typical	O
structural	O
and	O
functional	O
features	O
of	O
integrins	O
.	O

It	O
mediates	O
cell	O
adhesion	O
to	O
extracellular	O
matrix	O
by	O
recognizing	O
the	O
conserved	O
arg	O
-	O
gly	O
-	O
asp	O
(	O
RGD	O
)	O
sequence	O
of	O
several	O
plasma	O
and	O
matrix	O
proteins	O
.	O

Recently	O
,	O
it	O
has	O
also	O
been	O
shown	O
that	O
alpha	B-Complex
v	I-Complex
beta	I-Complex
3	I-Complex
is	O
involved	O
in	O
signal	O
transduction	O
and	O
cell	O
to	O
cell	O
interactions	O
.	O
alpha	B-Complex
v	I-Complex
beta	I-Complex
3	I-Complex
is	O
highly	O
expressed	O
in	O
bone	O
resorbing	O
cells	O
,	O
osteoclasts	O
,	O
and	O
upregulated	O
in	O
response	O
to	O
vascular	O
damage	O
,	O
during	O
angiogenesis	O
and	O
in	O
certain	O
types	O
of	O
malignancy	O
.	O

Antagonists	O
of	O
alpha	B-Complex
v	I-Complex
beta	I-Complex
3	I-Complex
are	O
being	O
developed	O
for	O
use	O
in	O
a	O
variety	O
of	O
diseases	O
associated	O
with	O
altered	O
receptor	O
function	O
or	O
level	O
.	O

A	O
functional	O
analysis	O
of	O
Notch	O
mutations	O
in	O
Drosophila	O
.	O

The	O
Notch	O
gene	O
encodes	O
a	O
receptor	O
protein	O
that	O
is	O
involved	O
in	O
many	O
processes	O
during	O
development	O
.	O

Its	O
best	O
understood	O
role	O
is	O
during	O
neurogenesis	O
in	O
a	O
process	O
called	O
"	O
lateral	O
inhibition	O
.	O
"	O
However	O
,	O
it	O
has	O
been	O
proposed	O
that	O
Notch	O
also	O
has	O
a	O
role	O
in	O
defining	O
the	O
proneural	O
clusters	O
in	O
the	O
first	O
place	O
.	O

This	O
raises	O
the	O
possibility	O
that	O
the	O
Notch	O
protein	O
is	O
acting	O
as	O
a	O
multifunctional	O
receptor	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
carried	O
out	O
a	O
genetic	O
analysis	O
of	O
molecularly	O
characterized	O
Notch	O
alleles	O
to	O
identify	O
alleles	O
that	O
affect	O
only	O
one	O
of	O
the	O
two	O
proposed	O
functions	O
.	O

Here	O
we	O
present	O
evidence	O
that	O
Notch	O
alleles	O
can	O
be	O
identified	O
that	O
appear	O
to	O
affect	O
the	O
function	O
of	O
Notch	O
during	O
either	O
lateral	O
inhibition	O
or	O
the	O
definition	O
of	O
proneural	O
clusters	O
.	O

In	O
addition	O
our	O
results	O
indicate	O
that	O
there	O
may	O
be	O
discrete	O
regions	O
of	O
the	O
Notch	O
protein	O
required	O
for	O
each	O
function	O
.	O

Inhibition	O
of	O
the	O
prenylation	O
of	O
K	O
-	O
Ras	O
,	O
but	O
not	O
H	O
-	O
or	O
N	O
-	O
Ras	O
,	O
is	O
highly	O
resistant	O
to	O
CAAX	O
peptidomimetics	O
and	O
requires	O
both	O
a	O
farnesyltransferase	B-OOS
and	O
a	O
geranylgeranyltransferase	B-Complex
I	I-Complex
inhibitor	O
in	O
human	O
tumor	O
cell	O
lines	O
.	O

The	O
farnesyltransferase	B-OOS
(	O
FTase	B-OOS
)	O
inhibitor	O
FTI	O
-	O
277	O
is	O
highly	O
effective	O
at	O
blocking	O
oncogenic	O
H	O
-	O
Ras	O
but	O
not	O
K	O
-	O
Ras4B	O
processing	O
and	O
signaling	O
.	O

While	O
inhibition	O
of	O
processing	O
and	O
signaling	O
of	O
oncogenic	O
K	O
-	O
Ras4B	O
is	O
more	O
sensitive	O
to	O
the	O
geranylgeranyltransferase	B-Complex
I	I-Complex
(	O
GGTase	B-Complex
I	I-Complex
)	O
inhibitor	O
GGTI	O
-	O
286	O
than	O
it	O
is	O
to	O
FTI	O
-	O
277	O
in	O
K	O
-	O
Ras4B	O
-	O
transformed	O
NIH3T3	O
cells	O
,	O
the	O
sensitivity	O
of	O
K	O
-	O
Ras	O
as	O
well	O
as	O
H	O
-	O
and	O
N	O
-	O
Ras	O
to	O
the	O
CAAX	O
peptidomimetics	O
in	O
human	O
tumor	O
cell	O
lines	O
is	O
not	O
known	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
panel	O
of	O
five	O
human	O
carcinoma	O
cell	O
lines	O
from	O
pancreatic	O
,	O
pulmonary	O
,	O
and	O
bladder	O
origins	O
all	O
express	O
H	O
-	O
,	O
N	O
-	O
,	O
and	O
K	O
-	O
Ras	O
,	O
and	O
their	O
respective	O
prenylation	O
sensitivities	O
to	O
the	O
FTase	B-OOS
and	O
GGTase	B-Complex
I	I-Complex
inhibitors	O
is	O
variable	O
.	O

In	O
all	O
of	O
the	O
cell	O
lines	O
investigated	O
,	O
the	O
prenylation	O
of	O
N	O
-	O
Ras	O
was	O
highly	O
sensitive	O
to	O
FTI	O
-	O
277	O
,	O
and	O
in	O
two	O
of	O
the	O
cell	O
lines	O
,	O
N	O
-	O
Ras	O
showed	O
slight	O
sensitivity	O
to	O
GGTI	O
-	O
298	O
,	O
an	O
analog	O
of	O
GGTI	O
-	O
286	O
.	O

Although	O
the	O
prenylation	O
of	O
H	O
-	O
Ras	O
was	O
also	O
sensitive	O
to	O
FTI	O
-	O
277	O
,	O
complete	O
inhibition	O
of	O
H	O
-	O
Ras	O
processing	O
even	O
at	O
high	O
concentrations	O
of	O
FTI	O
-	O
277	O
and	O
/	O
or	O
GGTI	O
-	O
298	O
was	O
never	O
achieved	O
.	O

The	O
prenylation	O
of	O
K	O
-	O
Ras	O
,	O
on	O
the	O
other	O
hand	O
,	O
was	O
highly	O
resistant	O
to	O
FTI	O
-	O
277	O
and	O
GGTI	O
-	O
298	O
.	O

Most	O
significantly	O
,	O
treatment	O
of	O
human	O
tumor	O
cell	O
lines	O
with	O
both	O
inhibitors	O
was	O
required	O
for	O
inhibition	O
of	O
K	O
-	O
Ras	O
prenylation	O
.	O

In	O
one	O
cell	O
line	O
,	O
the	O
human	O
lung	O
adenocarcinoma	O
A	O
-	O
549	O
,	O
prenylation	O
of	O
K	O
-	O
Ras	O
was	O
highly	O
resistant	O
even	O
when	O
co	O
-	O
treated	O
with	O
both	O
inhibitors	O
.	O

Furthermore	O
,	O
soft	O
agar	O
experiments	O
demonstrated	O
that	O
in	O
all	O
the	O
human	O
tumor	O
cell	O
lines	O
tested	O
inhibition	O
of	O
K	O
-	O
Ras	O
prenylation	O
was	O
not	O
necessary	O
for	O
inhibition	O
of	O
anchorage	O
-	O
independent	O
growth	O
.	O

In	O
addition	O
,	O
although	O
GGTI	O
-	O
298	O
had	O
very	O
little	O
effect	O
on	O
soft	O
agar	O
growth	O
,	O
the	O
combination	O
of	O
FTI	O
-	O
277	O
and	O
GGTI	O
-	O
298	O
resulted	O
in	O
significant	O
growth	O
inhibition	O
.	O

Therefore	O
,	O
the	O
results	O
demonstrate	O
that	O
while	O
FTI	O
-	O
277	O
inhibits	O
N	O
-	O
Ras	O
and	O
H	O
-	O
Ras	O
processing	O
in	O
the	O
human	O
tumor	O
cell	O
lines	O
evaluated	O
,	O
inhibition	O
of	O
K	O
-	O
Ras	O
processing	O
requires	O
both	O
an	O
FTase	B-OOS
inhibitor	O
as	O
well	O
as	O
a	O
GGTase	B-Complex
I	I-Complex
inhibitor	O
,	O
and	O
that	O
inhibition	O
of	O
human	O
tumor	O
growth	O
in	O
soft	O
agar	O
does	O
not	O
require	O
inhibition	O
of	O
oncogenic	O
K	O
-	O
Ras	O
processing	O
.	O

Cooperation	O
of	O
binding	O
sites	O
for	O
STAT6	O
and	O
NF	B-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
rel	I-Complex
in	O
the	O
IL	O
-	O
4	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
the	O
human	O
IgE	B-Complex
germline	O
promoter	O
.	O

Ig	O
heavy	O
chain	O
class	O
switching	O
is	O
directed	O
by	O
cytokines	O
inducing	O
transcription	O
from	O
unrearranged	O
CH	O
genes	O
.	O

Subsequently	O
,	O
such	O
primed	O
cells	O
can	O
undergo	O
switch	O
recombination	O
to	O
express	O
the	O
selected	O
new	O
isotype	O
.	O

In	O
the	O
case	O
of	O
IgE	B-Complex
class	O
switching	O
,	O
IL	O
-	O
4	O
activates	O
the	O
IgE	B-Complex
germline	O
promoter	O
by	O
inducing	O
the	O
interaction	O
of	O
the	O
transcription	O
factor	O
STAT6	O
(	O
IL	O
-	O
4STAT	O
)	O
with	O
a	O
responsive	O
DNA	O
element	O
in	O
the	O
proximal	O
region	O
of	O
the	O
promoter	O
.	O

This	O
study	O
describes	O
the	O
characterization	O
of	O
two	O
additional	O
cis	O
-	O
acting	O
elements	O
that	O
interact	O
with	O
members	O
of	O
the	O
NF	B-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
rel	I-Complex
transcription	O
factor	O
family	O
in	O
an	O
IL	O
-	O
4	O
-	O
independent	O
fashion	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
show	O
that	O
the	O
nucleoprotein	O
complex	O
formed	O
on	O
the	O
upstream	O
site	O
(	O
NF	B-Complex
kappa	I-Complex
B1	I-Complex
)	O
contains	O
the	O
classical	O
p50	O
/	O
p65	O
heterodimer	O
.	O

The	O
complex	O
on	O
the	O
proximal	O
site	O
(	O
NF	B-Complex
kappa	I-Complex
B2	I-Complex
)	O
appears	O
to	O
be	O
composed	O
of	O
p50	O
and	O
relB	O
.	O

IgE	B-Complex
germline	O
promoter	O
reporter	O
gene	O
constructs	O
carrying	O
point	O
mutations	O
in	O
the	O
NF	B-Complex
kappa	I-Complex
B2	I-Complex
site	O
were	O
largely	O
unresponsive	O
to	O
IL	O
-	O
4	O
stimulation	O
in	O
transient	O
transfection	O
experiments	O
,	O
while	O
plasmids	O
with	O
similar	O
mutations	O
in	O
the	O
NF	B-Complex
kappa	I-Complex
B1	I-Complex
site	O
responded	O
to	O
cytokine	O
stimulation	O
better	O
than	O
the	O
wild	O
-	O
type	O
promoter	O
.	O

The	O
NF	B-Complex
kappa	I-Complex
B2	I-Complex
effect	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
STAT6	O
binding	O
site	O
,	O
demonstrating	O
that	O
the	O
NF	B-Complex
kappa	I-Complex
B2	I-Complex
motif	O
is	O
necessary	O
but	O
not	O
sufficient	O
for	O
mediating	O
cytokine	O
up	O
-	O
regulation	O
.	O

In	O
addition	O
,	O
the	O
combination	O
of	O
a	O
NF	B-Complex
kappa	I-Complex
B	I-Complex
/	I-Complex
rel	I-Complex
binding	O
site	O
and	O
the	O
STAT6	O
response	O
element	O
conferred	O
IL	O
-	O
4	O
inducibility	O
to	O
a	O
heterologous	O
minimal	O
promoter	O
,	O
while	O
the	O
individual	O
sites	O
had	O
no	O
effect	O
.	O

The	O
available	O
data	O
suggest	O
that	O
the	O
NF	B-Complex
kappa	I-Complex
B2	I-Complex
nucleoprotein	O
complex	O
may	O
cooperate	O
with	O
DNA	O
-	O
bound	O
STAT6	O
to	O
achieve	O
IL	O
-	O
4	O
-	O
dependent	O
activation	O
of	O
the	O
human	O
IgE	B-Complex
germline	O
gene	O
.	O

Chip	O
,	O
a	O
widely	O
expressed	O
chromosomal	O
protein	O
required	O
for	O
segmentation	O
and	O
activity	O
of	O
a	O
remote	O
wing	O
margin	O
enhancer	O
in	O
Drosophila	O
.	O

The	O
mechanisms	O
allowing	O
remote	O
enhancers	O
to	O
regulate	O
promoters	O
several	O
kilobase	O
pairs	O
away	O
are	O
unknown	O
but	O
are	O
blocked	O
by	O
the	O
Drosophila	O
suppressor	O
of	O
Hairy	O
-	O
wing	O
protein	O
(	O
Suhw	O
)	O
that	O
binds	O
to	O
gypsy	O
retrovirus	O
insertions	O
between	O
enhancers	O
and	O
promoters	O
.	O

Suhw	O
bound	O
to	O
a	O
gypsy	O
insertion	O
in	O
the	O
cut	O
gene	O
also	O
appears	O
to	O
act	O
interchromosomally	O
to	O
antagonize	O
enhancer	O
-	O
promoter	O
interactions	O
on	O
the	O
homologous	O
chromosome	O
when	O
activity	O
of	O
the	O
Chip	O
gene	O
is	O
reduced	O
.	O

This	O
implicates	O
Chip	O
in	O
enhancer	O
-	O
promoter	O
communication	O
.	O

We	O
cloned	O
Chip	O
and	O
find	O
that	O
it	O
encodes	O
a	O
homolog	O
of	O
the	O
recently	O
discovered	O
mouse	O
Nli	O
/	O
Ldb1	O
/	O
Clim	O
-	O
2	O
and	O
Xenopus	O
Xldb1	O
proteins	O
that	O
bind	O
nuclear	O
LIM	O
domain	O
proteins	O
.	O

Chip	O
protein	O
interacts	O
with	O
the	O
LIM	O
domains	O
in	O
the	O
Apterous	O
homeodomain	O
protein	O
,	O
and	O
Chip	O
interacts	O
genetically	O
with	O
apterous	O
,	O
showing	O
that	O
these	O
interactions	O
are	O
important	O
for	O
Apterous	O
function	O
in	O
vivo	O
.	O

Importantly	O
,	O
Chip	O
also	O
appears	O
to	O
have	O
broad	O
functions	O
beyond	O
interactions	O
with	O
LIM	O
domain	O
proteins	O
.	O

Chip	O
is	O
present	O
in	O
all	O
nuclei	O
examined	O
and	O
at	O
numerous	O
sites	O
along	O
the	O
salivary	O
gland	O
polytene	O
chromosomes	O
.	O

Embryos	O
without	O
Chip	O
activity	O
lack	O
segments	O
and	O
show	O
abnormal	O
gap	O
and	O
pair	O
-	O
rule	O
gene	O
expression	O
,	O
although	O
no	O
LIM	O
domain	O
proteins	O
are	O
known	O
to	O
regulate	O
segmentation	O
.	O

We	O
conclude	O
that	O
Chip	O
is	O
a	O
ubiquitous	O
chromosomal	O
factor	O
required	O
for	O
normal	O
expression	O
of	O
diverse	O
genes	O
at	O
many	O
stages	O
of	O
development	O
.	O

We	O
suggest	O
that	O
Chip	O
cooperates	O
with	O
different	O
LIM	O
domain	O
proteins	O
and	O
other	O
factors	O
to	O
structurally	O
support	O
remote	O
enhancer	O
-	O
promoter	O
interactions	O
.	O

The	O
tax	O
protein	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
mediates	O
the	O
transactivation	O
of	O
the	O
c	O
-	O
sis	O
/	O
platelet	O
-	O
derived	O
growth	O
factor	O
-	O
B	O
promoter	O
through	O
interactions	O
with	O
the	O
zinc	O
finger	O
transcription	O
factors	O
Sp1	O
and	O
NGFI	O
-	O
A	O
/	O
Egr	O
-	O
1	O
.	O

Transcriptional	O
up	O
-	O
regulation	O
of	O
the	O
c	O
-	O
sis	O
/	O
platelet	O
-	O
derived	O
growth	O
factor	O
-	O
B	O
(	O
PDGF	O
-	O
B	O
)	O
proto	O
-	O
oncogene	O
by	O
the	O
Tax	O
protein	O
of	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
has	O
been	O
implicated	O
as	O
one	O
possible	O
mechanism	O
of	O
cellular	O
transformation	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
.	O

In	O
previous	O
work	O
,	O
we	O
identified	O
an	O
essential	O
site	O
in	O
the	O
c	O
-	O
sis	O
/	O
PDGF	O
-	O
B	O
promoter	O
,	O
Tax	O
-	O
responsive	O
element	O
1	O
(	O
TRE1	O
)	O
,	O
necessary	O
for	O
transactivation	O
by	O
Tax	O
.	O

We	O
also	O
identified	O
Sp1	O
,	O
Sp3	O
,	O
and	O
NGFI	O
-	O
A	O
/	O
Egr	O
-	O
1	O
as	O
the	O
primary	O
nuclear	O
transcription	O
factors	O
binding	O
to	O
TRE1	O
which	O
mediate	O
Tax	O
responsiveness	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
have	O
investigated	O
the	O
mechanism	O
(	O
s	O
)	O
whereby	O
Tax	O
transactivates	O
the	O
c	O
-	O
sis	O
/	O
PDGF	O
-	O
B	O
proto	O
-	O
oncogene	O
.	O

In	O
vitro	O
transcription	O
assays	O
showed	O
that	O
Tax	O
was	O
able	O
to	O
significantly	O
increase	O
the	O
transcriptional	O
activity	O
of	O
a	O
template	O
containing	O
the	O
-	O
257	O
to	O
+	O
74	O
region	O
of	O
the	O
c	O
-	O
sis	O
/	O
PDGF	O
-	O
B	O
promoter	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
showed	O
that	O
Tax	O
increased	O
the	O
DNA	O
binding	O
activity	O
of	O
both	O
Sp1	O
and	O
NGFI	O
-	O
A	O
/	O
Egr	O
-	O
1	O
using	O
a	O
TRE1	O
probe	O
.	O

Analysis	O
of	O
Tax	O
mutants	O
showed	O
that	O
two	O
mutants	O
,	O
IEXC29S	O
and	O
IEXL320G	O
,	O
were	O
unable	O
to	O
significantly	O
transactivate	O
the	O
c	O
-	O
sis	O
/	O
PDGF	O
-	O
B	O
promoter	O
.	O

Finally	O
,	O
co	O
-	O
immunoprecipitation	O
analysis	O
revealed	O
that	O
Tax	O
is	O
able	O
to	O
stably	O
bind	O
to	O
both	O
Sp1	O
and	O
NGFI	O
-	O
A	O
/	O
Egr	O
-	O
1	O
.	O

Interestingly	O
,	O
co	O
-	O
immunoprecipitation	O
analysis	O
also	O
revealed	O
that	O
Tax	O
mutant	O
IEXC29S	O
is	O
unable	O
to	O
interact	O
with	O
NGFI	O
-	O
A	O
/	O
Egr	O
-	O
1	O
,	O
whereas	O
Tax	O
mutant	O
IEXL320G	O
is	O
able	O
to	O
interact	O
with	O
NGFI	O
-	O
A	O
/	O
Egr	O
-	O
1	O
.	O

Transcriptional	O
activation	O
of	O
the	O
vascular	O
cell	O
adhesion	O
molecule	O
-	O
1	O
gene	O
in	O
T	O
lymphocytes	O
expressing	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
Tax	O
protein	O
.	O

Recruitment	O
and	O
extravasation	O
of	O
T	O
cells	O
through	O
the	O
blood	O
-	O
brain	O
barrier	O
are	O
favored	O
by	O
adhesion	O
molecule	O
-	O
mediated	O
interactions	O
of	O
circulating	O
T	O
cells	O
with	O
endothelial	O
cells	O
.	O

Since	O
a	O
common	O
pathological	O
finding	O
in	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV	O
-	O
1	O
)	O
-	O
associated	O
diseases	O
is	O
the	O
infiltration	O
of	O
HTLV	O
-	O
1	O
-	O
infected	O
T	O
lymphocytes	O
into	O
various	O
organs	O
,	O
we	O
have	O
looked	O
for	O
the	O
profile	O
of	O
adhesion	O
molecules	O
expressed	O
by	O
HTLV	O
-	O
1	O
-	O
transformed	O
T	O
cells	O
.	O

Flow	O
cytometry	O
analysis	O
indicated	O
that	O
these	O
cells	O
were	O
expressing	O
high	O
levels	O
of	O
vascular	O
cell	O
adhesion	O
molecule	O
1	O
(	O
VCAM	O
-	O
1	O
[	O
CD106	O
]	O
)	O
,	O
a	O
110	O
-	O
kDa	O
member	O
of	O
the	O
immunoglobulin	B-OOS
gene	O
superfamily	O
,	O
first	O
identified	O
on	O
endothelial	O
cells	O
stimulated	O
with	O
inflammatory	O
cytokines	O
.	O

This	O
adhesion	O
molecule	O
was	O
also	O
expressed	O
by	O
T	O
cells	O
obtained	O
from	O
one	O
patient	O
with	O
HTLV	O
-	O
1	O
-	O
associated	O
myelopathy	O
/	O
tropical	O
spastic	O
paraparesis	O
but	O
not	O
by	O
activated	O
T	O
cells	O
isolated	O
from	O
one	O
normal	O
blood	O
donor	O
.	O

The	O
role	O
of	O
the	O
viral	O
trans	O
-	O
activator	O
Tax	O
protein	O
in	O
the	O
induction	O
of	O
VCAM	O
-	O
1	O
was	O
first	O
indicated	O
by	O
the	O
detection	O
of	O
this	O
adhesion	O
molecule	O
on	O
Jurkat	O
T	O
-	O
cell	O
clones	O
stably	O
expressing	O
the	O
tax	O
gene	O
.	O

The	O
effect	O
of	O
Tax	O
on	O
VCAM	O
-	O
1	O
gene	O
transcription	O
was	O
next	O
confirmed	O
in	O
JPX	O
-	O
9	O
cells	O
,	O
a	O
subclone	O
of	O
Jurkat	O
cells	O
,	O
carrying	O
the	O
tax	O
sequences	O
under	O
the	O
control	O
of	O
an	O
inducible	O
promoter	O
.	O

Furthermore	O
,	O
deletion	O
and	O
mutation	O
analyses	O
of	O
the	O
VCAM	O
-	O
1	O
promoter	O
performed	O
with	O
chloramphenicol	O
acetyltransferase	O
constructs	O
revealed	O
that	O
Tax	O
was	O
trans	O
activating	O
the	O
VCAM	O
-	O
1	O
promoter	O
via	O
two	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
sites	O
present	O
at	O
bp	O
-	O
72	O
and	O
-	O
57	O
in	O
the	O
VCAM	O
-	O
1	O
gene	O
promoter	O
,	O
with	O
both	O
of	O
them	O
being	O
required	O
for	O
the	O
Tax	O
-	O
induced	O
expression	O
of	O
this	O
adhesion	O
molecule	O
.	O

Finally	O
,	O
gel	O
mobility	O
shift	O
assays	O
demonstrated	O
the	O
nuclear	O
translocation	O
of	O
proteins	O
specifically	O
bound	O
to	O
these	O
two	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
motifs	O
,	O
confirming	O
that	O
VCAM	O
-	O
1	O
was	O
induced	O
on	O
Tax	O
-	O
expressing	O
cells	O
in	O
a	O
kappaB	B-Complex
-	O
dependent	O
manner	O
.	O

Collectively	O
,	O
these	O
results	O
therefore	O
suggest	O
that	O
the	O
exclusive	O
Tax	O
-	O
induced	O
expression	O
of	O
VCAM	O
-	O
1	O
on	O
T	O
cells	O
may	O
represent	O
a	O
pivotal	O
event	O
in	O
the	O
progression	O
of	O
HTLV	O
-	O
1	O
-	O
associated	O
diseases	O
.	O

Function	O
of	O
yeast	O
Rad52	O
protein	O
as	O
a	O
mediator	O
between	O
replication	O
protein	O
A	O
and	O
the	O
Rad51	O
recombinase	O
.	O

The	O
RAD51	O
and	O
RAD52	O
genes	O
of	O
Saccharomyces	O
cerevisiae	O
are	O
key	O
members	O
of	O
the	O
RAD52	O
epistasis	O
group	O
required	O
for	O
genetic	O
recombination	O
and	O
the	O
repair	O
of	O
DNA	O
double	O
-	O
stranded	O
breaks	O
.	O

The	O
RAD51	O
encoded	O
product	O
mediates	O
the	O
DNA	O
strand	O
exchange	O
reaction	O
.	O

Efficient	O
strand	O
exchange	O
is	O
contingent	O
upon	O
the	O
addition	O
of	O
the	O
heterotrimeric	O
single	O
-	O
stranded	O
DNA	O
binding	O
factor	O
replication	O
protein	O
A	O
(	O
RPA	O
)	O
after	O
Rad51	O
has	O
nucleated	O
onto	O
the	O
single	O
-	O
stranded	O
DNA	O
.	O

However	O
,	O
if	O
the	O
single	O
-	O
stranded	O
DNA	O
is	O
incubated	O
with	O
Rad51	O
and	O
RPA	O
simultaneously	O
to	O
mimic	O
what	O
may	O
be	O
expected	O
to	O
occur	O
in	O
vivo	O
,	O
the	O
efficiency	O
of	O
strand	O
exchange	O
decreases	O
dramatically	O
,	O
revealing	O
an	O
inhibitory	O
effect	O
of	O
RPA	O
that	O
is	O
distinct	O
from	O
its	O
stimulatory	O
function	O
.	O

Interestingly	O
,	O
the	O
inclusion	O
of	O
Rad52	O
protein	O
,	O
which	O
has	O
been	O
purified	O
in	O
this	O
study	O
from	O
yeast	O
cells	O
,	O
restores	O
the	O
efficiency	O
of	O
strand	O
exchange	O
.	O

Thus	O
,	O
Rad52	O
functions	O
as	O
a	O
co	O
-	O
factor	O
for	O
the	O
Rad51	O
recombinase	O
,	O
acting	O
specifically	O
to	O
overcome	O
the	O
apparent	O
competition	O
by	O
RPA	O
for	O
binding	O
to	O
single	O
-	O
stranded	O
DNA	O
.	O

Na	O
,	O
K	O
-	O
ATPase	O
transport	O
from	O
endoplasmic	O
reticulum	O
to	O
Golgi	O
requires	O
the	O
Golgi	O
spectrin	O
-	O
ankyrin	O
G119	O
skeleton	O
in	O
Madin	O
Darby	O
canine	O
kidney	O
cells	O
.	O

Spectrin	O
(	O
betaISigma	O
*	O
)	O
and	O
ankyrin	O
(	O
AnkG119	O
)	O
associate	O
with	O
Golgi	O
membranes	O
and	O
the	O
dynactin	B-Complex
complex	O
,	O
but	O
their	O
role	O
in	O
vesicle	O
trafficking	O
remains	O
uncertain	O
.	O

We	O
find	O
that	O
the	O
actin	O
-	O
binding	O
domain	O
and	O
membrane	O
-	O
association	O
domain	O
1	O
(	O
MAD1	O
)	O
of	O
betaI	O
spectrin	O
together	O
form	O
a	O
constitutive	O
Golgi	O
targeting	O
signal	O
in	O
transfected	O
MDCK	O
cells	O
.	O

Expression	O
of	O
this	O
signal	O
in	O
transfected	O
cells	O
disrupts	O
the	O
endogenous	O
Golgi	O
spectrin	O
skeleton	O
and	O
blocks	O
transport	O
of	O
alpha	O
-	O
and	O
beta	O
-	O
Na	O
,	O
K	O
-	O
ATPase	O
and	O
vesicular	O
stomatitis	O
virus	O
-	O
G	O
protein	O
from	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
but	O
does	O
not	O
disrupt	O
the	O
formation	O
of	O
Golgi	O
stacks	O
,	O
the	O
distribution	O
of	O
beta	O
-	O
COP	O
,	O
or	O
the	O
transport	O
and	O
surface	O
display	O
of	O
E	O
-	O
cadherin	O
.	O

The	O
Golgi	O
spectrin	O
skeleton	O
is	O
thus	O
required	O
for	O
the	O
transport	O
of	O
a	O
subset	O
of	O
membrane	O
proteins	O
from	O
the	O
ER	O
to	O
the	O
Golgi	O
.	O

We	O
postulate	O
that	O
together	O
with	O
polyfunctional	O
adapter	O
proteins	O
such	O
as	O
AnkG119	O
,	O
Golgi	O
spectrin	O
forms	O
a	O
docking	O
complex	O
that	O
acts	O
prior	O
to	O
the	O
cis	O
-	O
Golgi	O
,	O
presumably	O
with	O
vesicular	O
-	O
tubular	O
clusters	O
(	O
VTCs	O
or	O
ERGIC	O
)	O
,	O
to	O
sequester	O
specific	O
membrane	O
proteins	O
into	O
vesicles	O
transiting	O
between	O
the	O
ER	O
and	O
Golgi	O
,	O
and	O
subsequently	O
(	O
probably	O
involving	O
other	O
isoforms	O
of	O
spectrin	O
and	O
ankyrin	O
)	O
to	O
mediate	O
cargo	O
transport	O
within	O
the	O
Golgi	O
and	O
to	O
other	O
membrane	O
compartments	O
.	O

We	O
hypothesize	O
that	O
this	O
vesicular	O
spectrin	O
-	O
ankyrin	O
adapter	O
-	O
protein	O
trafficking	O
(	O
or	O
tethering	O
)	O
system	O
(	O
SAATS	O
)	O
mediates	O
the	O
capture	O
and	O
transport	O
of	O
many	O
membrane	O
proteins	O
and	O
acts	O
in	O
conjunction	O
with	O
vesicle	O
-	O
targeting	O
molecules	O
to	O
effect	O
the	O
efficient	O
transport	O
of	O
cargo	O
proteins	O
.	O

Molecular	O
cloning	O
and	O
functional	O
characterization	O
of	O
murine	O
cDNA	O
encoding	O
transcription	O
factor	O
NFATc	O
.	O

Transcription	O
factors	O
of	O
the	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
family	O
play	O
important	O
roles	O
in	O
immune	O
and	O
inflammatory	O
responses	O
by	O
regulating	O
the	O
expression	O
of	O
genes	O
encoding	O
cytokines	O
and	O
immunoregulatory	O
proteins	O
.	O

Here	O
we	O
describe	O
cloning	O
and	O
characterization	O
of	O
full	O
-	O
length	O
cDNA	O
encoding	O
murine	O
(	O
m	O
)	O
NFATc	O
which	O
predicts	O
that	O
the	O
protein	O
has	O
all	O
the	O
conserved	O
structural	O
motifs	O
of	O
NFAT	O
family	O
members	O
,	O
including	O
the	O
rel	O
homology	O
domain	O
,	O
the	O
NFAT	O
homology	O
domain	O
and	O
the	O
nuclear	O
translocation	O
signals	O
.	O

mNFATc	O
complexed	O
with	O
AP	B-Complex
-	I-Complex
1	I-Complex
bound	O
specifically	O
to	O
the	O
murine	O
IL	O
-	O
2	O
NFAT	O
recognition	O
sequence	O
and	O
activated	O
transcription	O
from	O
the	O
co	O
-	O
transfected	O
IL	O
-	O
2	O
promoter	O
in	O
COS	O
-	O
7	O
cells	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
the	O
cDNA	O
probe	O
hybridized	O
with	O
a	O
4	O
.	O
5	O
kb	O
transcript	O
which	O
is	O
highly	O
inducible	O
in	O
murine	O
T	O
cells	O
.	O

By	O
Northern	O
and	O
in	O
situ	O
hybridization	O
,	O
mNFATc	O
transcript	O
was	O
detected	O
from	O
the	O
early	O
stage	O
of	O
development	O
.	O

In	O
the	O
mouse	O
embryo	O
,	O
mNFATc	O
transcript	O
was	O
strongly	O
expressed	O
in	O
thymus	O
,	O
lung	O
and	O
submandibular	O
gland	O
and	O
weakly	O
in	O
skeletal	O
muscle	O
and	O
heart	O
suggesting	O
that	O
mNFATc	O
may	O
have	O
a	O
role	O
both	O
in	O
embryogenesis	O
and	O
in	O
mature	O
T	O
cells	O
.	O

IL	O
-	O
2	O
and	O
IL	O
-	O
7	O
induce	O
heterodimerization	O
of	O
STAT5	O
isoforms	O
in	O
human	O
peripheral	O
blood	O
T	O
lymphoblasts	O
.	O

Despite	O
differences	O
in	O
T	O
cell	O
responses	O
induced	O
by	O
interleukin	O
(	O
IL	O
)	O
-	O
2	O
and	O
IL	O
-	O
7	O
,	O
both	O
cytokines	O
modulate	O
T	O
cell	O
functions	O
by	O
activation	O
of	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
proteins	O
.	O

We	O
examined	O
the	O
contribution	O
of	O
the	O
two	O
isoforms	O
of	O
STAT5	O
,	O
STAT5A	O
and	O
STAT5B	O
,	O
to	O
IL	O
-	O
2	O
-	O
and	O
IL	O
-	O
7	O
-	O
induced	O
activation	O
of	O
human	O
peripheral	O
blood	O
T	O
lymphoblasts	O
.	O

Both	O
cytokines	O
induced	O
assembly	O
of	O
STAT5A	O
and	O
STAT5B	O
containing	O
complexes	O
capable	O
of	O
binding	O
to	O
the	O
interferon	O
-	O
gamma	O
activation	O
sequence	O
(	O
GAS	O
)	O
,	O
and	O
these	O
complexes	O
rapidly	O
translocated	O
(	O
within	O
1	O
min	O
)	O
into	O
the	O
nucleus	O
of	O
IL	O
-	O
2	O
-	O
or	O
IL	O
-	O
7	O
-	O
treated	O
cells	O
.	O

The	O
kinetics	O
of	O
this	O
translocation	O
were	O
delayed	O
in	O
IL	O
-	O
7	O
-	O
treated	O
as	O
compared	O
to	O
IL	O
-	O
2	O
-	O
treated	O
cells	O
.	O

IL	O
-	O
2	O
and	O
IL	O
-	O
7	O
were	O
equivalent	O
in	O
their	O
ability	O
to	O
induce	O
tyrosine	O
phosphorylation	O
of	O
STAT5A	O
and	O
STAT5B	O
and	O
to	O
facilitate	O
binding	O
of	O
these	O
STATs	O
to	O
an	O
immobilized	O
GAS	O
element	O
.	O

Both	O
IL	O
-	O
2	O
and	O
IL	O
-	O
7	O
induced	O
substantial	O
amounts	O
of	O
STAT5A	O
/	O
STAT5B	O
heterodimerization	O
.	O

Moreover	O
,	O
we	O
observed	O
constitutive	O
association	O
of	O
STAT3	O
with	O
each	O
STAT5	O
isomer	O
.	O

These	O
data	O
suggest	O
that	O
IL	O
-	O
2	O
and	O
IL	O
-	O
7	O
induce	O
assembly	O
of	O
STAT	O
heterodimers	O
in	O
a	O
similar	O
manner	O
and	O
that	O
subsequent	O
cellular	O
responses	O
may	O
be	O
driven	O
by	O
induction	O
of	O
similar	O
sets	O
of	O
genes	O
.	O

Genes	O
that	O
cause	O
aberrant	O
cell	O
morphology	O
by	O
overexpression	O
in	O
fission	O
yeast	O
:	O
a	O
role	O
of	O
a	O
small	O
GTP	O
-	O
binding	O
protein	O
Rho2	O
in	O
cell	O
morphogenesis	O
.	O

To	O
identify	O
the	O
genes	O
involved	O
in	O
cell	O
morphogenesis	O
in	O
Schizosaccharomyces	O
pombe	O
,	O
we	O
screened	O
for	O
the	O
genes	O
that	O
cause	O
aberrant	O
cell	O
morphology	O
by	O
overexpression	O
.	O

The	O
isolated	O
genes	O
were	O
classified	O
on	O
the	O
basis	O
of	O
morphology	O
conferred	O
.	O

One	O
of	O
the	O
genes	O
causing	O
a	O
rounded	O
morphology	O
was	O
identified	O
as	O
the	O
rho2	O
+	O
gene	O
encoding	O
a	O
small	O
GTP	O
-	O
binding	O
protein	O
.	O

The	O
overexpression	O
of	O
rho2	O
+	O
resulted	O
in	O
a	O
randomized	O
distribution	O
of	O
cortical	O
F	O
-	O
actin	O
and	O
formation	O
of	O
a	O
thick	O
cell	O
wall	O
.	O

Analyses	O
using	O
cdc	O
mutants	O
suggested	O
that	O
the	O
overexpression	O
of	O
rho2	O
+	O
prevents	O
the	O
establishment	O
of	O
growth	O
polarity	O
in	O
G1	O
.	O

The	O
rho2	O
+	O
gene	O
was	O
not	O
essential	O
,	O
but	O
among	O
cells	O
deleted	O
for	O
rho2	O
+	O
,	O
those	O
with	O
an	O
irregular	O
shape	O
were	O
observed	O
.	O

The	O
disruptant	O
also	O
showed	O
a	O
defect	O
in	O
cell	O
wall	O
integrity	O
.	O

An	O
HA	O
-	O
Rho2	O
expressed	O
in	O
the	O
cell	O
was	O
suggested	O
to	O
be	O
present	O
as	O
a	O
membrane	O
-	O
bound	O
form	O
by	O
a	O
cell	O
fractionation	O
experiment	O
.	O

A	O
GFP	O
-	O
Rho2	O
was	O
localized	O
at	O
the	O
growing	O
end	O
(	O
s	O
)	O
of	O
the	O
cell	O
and	O
the	O
septation	O
site	O
.	O

The	O
localization	O
of	O
GFP	O
-	O
Rho2	O
during	O
interphase	O
was	O
partially	O
dependent	O
on	O
sts5	O
+	O
.	O

These	O
results	O
indicate	O
that	O
Rho2	O
is	O
involved	O
in	O
cell	O
morphogenesis	O
,	O
control	O
of	O
cell	O
wall	O
integrity	O
,	O
control	O
of	O
growth	O
polarity	O
,	O
and	O
maintenance	O
of	O
growth	O
direction	O
.	O

Analysis	O
of	O
functional	O
overlapping	O
between	O
Rho2	O
and	O
Rho1	O
revealed	O
that	O
their	O
functions	O
are	O
distinct	O
from	O
each	O
other	O
,	O
with	O
partial	O
overlapping	O
.	O

c	O
-	O
Rel	O
and	O
p65	O
subunits	O
bind	O
to	O
an	O
upstream	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
site	O
in	O
human	O
granulocyte	O
macrophage	O
-	O
colony	O
stimulating	O
factor	O
promoter	O
involved	O
in	O
phorbol	O
ester	O
response	O
in	O
5637	O
cells	O
.	O

To	O
further	O
clarify	O
the	O
complex	O
transcriptional	O
regulation	O
of	O
the	O
human	O
GM	O
-	O
CSF	O
gene	O
,	O
which	O
was	O
extensively	O
investigated	O
in	O
activated	O
T	O
cells	O
,	O
we	O
have	O
studied	O
the	O
role	O
of	O
an	O
upstream	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
like	O
site	O
in	O
the	O
5637	O
non	O
-	O
lymphoid	O
cell	O
line	O
,	O
which	O
derives	O
from	O
a	O
bladder	O
carcinoma	O
and	O
constitutively	O
produces	O
GM	O
-	O
CSF	O
.	O

This	O
sequence	O
,	O
named	O
the	O
A	O
element	O
,	O
has	O
an	O
active	O
role	O
on	O
GM	O
-	O
CSF	O
transcription	O
and	O
is	O
responsive	O
to	O
the	O
tumor	O
promoter	O
PMA	O
in	O
transient	O
transfection	O
experiments	O
.	O

We	O
describe	O
here	O
a	O
heterodimeric	O
binding	O
complex	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
subunits	O
(	O
c	O
-	O
Rel	O
and	O
p65	O
)	O
which	O
is	O
identical	O
to	O
the	O
one	O
obtained	O
using	O
the	O
HIV	O
-	O
LTR	O
-	O
kappaB	B-Complex
site	O
as	O
recognition	O
sequence	O
and	O
different	O
from	O
the	O
one	O
(	O
c	O
-	O
Rel	O
and	O
p50	O
)	O
observed	O
with	O
nuclear	O
extracts	O
from	O
Mo	O
T	O
-	O
lymphoid	O
HTLV	O
-	O
II	O
infected	O
cells	O
.	O

Constitutive	O
expression	O
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
,	O
and	O
NF	B-Complex
kappa	I-Complex
B	I-Complex
mRNA	O
is	O
in	O
nucleated	O
fetal	O
blood	O
cells	O
and	O
up	O
-	O
regulation	O
of	O
c	O
-	O
fos	O
and	O
c	O
-	O
jun	O
with	O
anti	O
-	O
CD3	O
stimulation	O
.	O

Fetal	O
and	O
neonatal	O
lymphocytes	O
are	O
relatively	O
resistant	O
to	O
activation	O
and	O
cytokine	O
production	O
when	O
stimulated	O
either	O
via	O
their	O
T	B-Complex
-	I-Complex
cell	I-Complex
antigen	I-Complex
receptors	I-Complex
or	O
lectins	O
.	O

The	O
molecular	O
mechanism	O
(	O
s	O
)	O
responsible	O
for	O
this	O
phenomenon	O
have	O
not	O
been	O
clearly	O
elucidated	O
.	O

We	O
have	O
hypothesized	O
that	O
such	O
defects	O
in	O
fetal	O
/	O
neonatal	O
T	O
-	O
cell	O
activation	O
may	O
be	O
due	O
to	O
lack	O
of	O
expression	O
of	O
the	O
transcriptional	O
regulatory	O
elements	O
required	O
for	O
T	O
-	O
cell	O
activation	O
.	O

We	O
used	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
to	O
examine	O
both	O
fetal	O
and	O
term	O
neonatal	O
cord	O
bloods	O
for	O
mRNA	O
expression	O
of	O
three	O
transcription	O
factors	O
implicated	O
in	O
T	O
-	O
cell	O
activation	O
:	O
c	O
-	O
jun	O
,	O
c	O
-	O
fos	O
,	O
and	O
NF	B-Complex
kappa	I-Complex
B	I-Complex
(	O
p50	O
subunit	O
)	O
.	O

We	O
demonstrate	O
that	O
mRNAs	O
for	O
all	O
three	O
of	O
these	O
regulatory	O
factors	O
are	O
expressed	O
in	O
fetal	O
blood	O
cells	O
by	O
the	O
27th	O
week	O
of	O
gestation	O
and	O
in	O
term	O
cord	O
bloods	O
.	O

Activation	O
of	O
term	O
infant	O
cord	O
blood	O
mononuclear	O
cells	O
with	O
anti	O
-	O
CD3	O
monoclonal	O
antibodies	O
resulted	O
in	O
up	O
-	O
regulation	O
of	O
both	O
c	O
-	O
jun	O
and	O
c	O
-	O
fos	O
mRNAs	O
within	O
15	O
min	O
of	O
stimulation	O
.	O

However	O
,	O
secretion	O
of	O
IL	O
-	O
2	O
by	O
anti	O
-	O
CD3	O
-	O
stimulated	O
cord	O
blood	O
mononuclear	O
cells	O
was	O
still	O
blunted	O
compared	O
with	O
control	O
cells	O
from	O
adults	O
.	O

We	O
conclude	O
that	O
fetal	O
nucleated	O
blood	O
cells	O
constitutively	O
express	O
important	O
genes	O
for	O
cytokine	O
regulation	O
and	O
are	O
able	O
to	O
increase	O
intracellular	O
accumulation	O
of	O
the	O
mRNAs	O
for	O
these	O
factors	O
in	O
response	O
to	O
anti	O
-	O
CD3	O
stimulation	O
.	O

Thus	O
,	O
qualitative	O
differences	O
in	O
the	O
capacity	O
to	O
regulate	O
these	O
factors	O
could	O
not	O
be	O
shown	O
in	O
fetal	O
blood	O
cells	O
.	O

Quantitative	O
experiments	O
comparing	O
binding	O
of	O
these	O
transcription	O
factors	O
to	O
the	O
IL	O
-	O
2	O
promoter	O
are	O
currently	O
under	O
investigation	O
.	O

Genomic	O
organization	O
,	O
cDNA	O
sequence	O
,	O
bacterial	O
expression	O
,	O
and	O
purification	O
of	O
human	O
seryl	O
-	O
tRNA	O
synthase	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
the	O
cDNA	O
sequence	O
and	O
deduced	O
primary	O
sequence	O
for	O
human	O
cytosolic	O
seryl	O
-	O
tRNA	O
synthetase	O
,	O
and	O
its	O
expression	O
in	O
Escherichia	O
coli	O
.	O

Two	O
human	O
brain	O
cDNA	O
clones	O
of	O
different	O
origin	O
,	O
containing	O
overlapping	O
fragments	O
coding	O
for	O
human	O
seryl	O
-	O
tRNA	O
synthetase	O
were	O
sequenced	O
:	O
HFBDN14	O
(	O
fetal	O
brain	O
clone	O
)	O
;	O
and	O
IB48	O
(	O
infant	O
brain	O
clone	O
)	O
.	O

For	O
both	O
clones	O
the	O
5	O
'	O
region	O
of	O
the	O
cDNA	O
was	O
missing	O
.	O

This	O
5	O
'	O
region	O
was	O
obtained	O
via	O
PCR	O
methods	O
using	O
a	O
human	O
brain	O
5	O
'	O
RACE	O
-	O
Ready	O
cDNA	O
library	O
.	O

The	O
complete	O
cDNA	O
sequence	O
allowed	O
us	O
to	O
define	O
primers	O
to	O
isolate	O
and	O
characterize	O
the	O
intron	O
/	O
exon	O
structure	O
of	O
the	O
serS	O
gene	O
,	O
consisting	O
of	O
10	O
introns	O
and	O
11	O
exons	O
.	O

The	O
introns	O
'	O
sizes	O
range	O
from	O
283	O
bp	O
to	O
more	O
than	O
3000	O
bp	O
and	O
the	O
size	O
of	O
the	O
exons	O
from	O
71	O
bp	O
to	O
222	O
bp	O
.	O

The	O
availability	O
of	O
the	O
gene	O
structure	O
of	O
the	O
human	O
enzyme	O
could	O
help	O
to	O
clarify	O
some	O
aspects	O
of	O
the	O
molecular	O
evolution	O
of	O
class	O
-	O
II	O
aminoacyl	O
-	O
tRNA	O
synthetases	O
.	O

The	O
human	O
seryl	O
-	O
tRNA	O
synthetase	O
has	O
been	O
expressed	O
in	O
E	O
.	O
coli	O
,	O
purified	O
(	O
95	O
%	O
pure	O
as	O
determined	O
by	O
SDS	O
/	O
PAGE	O
)	O
and	O
kinetic	O
parameters	O
have	O
been	O
measured	O
for	O
its	O
substrate	O
tRNA	O
.	O

The	O
human	O
seryl	O
-	O
tRNA	O
synthetase	O
sequence	O
(	O
514	O
amino	O
acid	O
residues	O
)	O
shows	O
significant	O
sequence	O
identity	O
with	O
seryl	O
-	O
tRNA	O
synthetases	O
from	O
E	O
.	O
coli	O
(	O
25	O
%	O
)	O
,	O
Saccharomyces	O
cerevisiae	O
(	O
40	O
%	O
)	O
,	O
Arabidopsis	O
thaliana	O
(	O
41	O
%	O
)	O
and	O
Caenorhabditis	O
elegans	O
(	O
60	O
%	O
)	O
.	O

The	O
partial	O
sequences	O
from	O
published	O
mammalian	O
seryl	O
-	O
tRNA	O
synthetases	O
are	O
very	O
similar	O
to	O
the	O
human	O
enzyme	O
(	O
94	O
%	O
and	O
92	O
%	O
identity	O
for	O
mouse	O
and	O
Chinese	O
hamster	O
seryl	O
-	O
tRNA	O
synthetase	O
,	O
respectively	O
)	O
.	O

Human	O
seryl	O
-	O
tRNA	O
synthetase	O
,	O
similar	O
to	O
several	O
other	O
class	O
-	O
I	O
and	O
class	O
-	O
II	O
human	O
aminoacyl	O
-	O
tRNA	O
synthetases	O
,	O
is	O
clearly	O
related	O
to	O
its	O
bacterial	O
counterparts	O
,	O
independent	O
of	O
an	O
additional	O
C	O
-	O
terminal	O
domain	O
and	O
a	O
N	O
-	O
terminal	O
insertion	O
identified	O
in	O
the	O
human	O
enzyme	O
.	O

In	O
functional	O
studies	O
,	O
the	O
enzyme	O
aminoacylates	O
calf	O
liver	O
tRNA	O
and	O
prokaryotic	O
E	O
.	O
coli	O
tRNA	O
.	O

Control	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
activity	O
by	O
the	O
I	O
kappa	O
B	O
beta	O
inhibitor	O
.	O

The	O
transcription	O
factor	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
is	O
maintained	O
in	O
an	O
inactive	O
cytoplasmic	O
state	O
by	O
I	O
kappa	O
B	O
inhibitors	O
.	O

In	O
mammalian	O
cells	O
,	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
proteins	O
have	O
been	O
purified	O
and	O
shown	O
to	O
be	O
the	O
inhibitors	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
through	O
their	O
association	O
with	O
the	O
p65	O
or	O
c	O
-	O
Rel	O
subunits	O
.	O

In	O
addition	O
,	O
we	O
have	O
isolated	O
a	O
third	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
inhibitor	O
,	O
I	O
kappa	O
B	O
epsilon	O
(	O
1	O
)	O
.	O

Upon	O
treatment	O
with	O
a	O
large	O
variety	O
of	O
inducers	O
,	O
I	O
kappa	O
B	O
alpha	O
,	O
I	O
kappa	O
B	O
beta	O
are	O
proteolytically	O
degraded	O
,	O
resulting	O
in	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
translocation	O
into	O
the	O
nucleus	O
.	O

Here	O
we	O
show	O
that	O
in	O
E29	O
.	O
1	O
T	O
cell	O
hybridoma	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
are	O
equally	O
associated	O
with	O
p65	O
and	O
that	O
I	O
kappa	O
B	O
beta	O
is	O
degraded	O
in	O
response	O
to	O
TNF	O
alpha	O
in	O
contrast	O
to	O
what	O
has	O
been	O
originally	O
published	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
,	O
unlike	O
I	O
kappa	O
B	O
alpha	O
,	O
I	O
kappa	O
B	O
beta	O
is	O
constitutively	O
phosphorylated	O
and	O
resynthesized	O
as	O
a	O
hypophosphorylated	O
form	O
.	O

The	O
absence	O
of	O
slow	O
migrating	O
forms	O
of	O
I	O
kappa	O
B	O
beta	O
following	O
stimulation	O
suggests	O
that	O
the	O
phosphorylation	O
does	O
not	O
necessarily	O
constitute	O
the	O
signal	O
-	O
induced	O
event	O
which	O
targets	O
the	O
molecule	O
for	O
proteolysis	O
.	O

Induction	O
of	O
interleukin	O
-	O
12	O
p40	O
transcript	O
by	O
CD40	O
ligation	O
via	O
activation	O
of	O
nuclear	B-Complex
factor	I-Complex
-	I-Complex
kappaB	I-Complex
.	O

Interleukin	B-Complex
-	I-Complex
12	I-Complex
is	O
produced	O
in	O
response	O
to	O
infection	O
with	O
bacteria	O
or	O
parasites	O
or	O
to	O
bacterial	O
constituents	O
such	O
as	O
LPS	O
in	O
monocytes	O
/	O
macrophages	O
and	O
dendritic	O
cells	O
,	O
and	O
also	O
generated	O
by	O
the	O
interaction	O
between	O
activated	O
T	O
cells	O
and	O
antigen	O
-	O
presenting	O
cells	O
via	O
CD40	O
-	O
CD40	O
ligand	O
(	O
CD40L	O
)	O
.	O

So	O
far	O
,	O
transcriptional	O
analyses	O
of	O
p40	O
have	O
been	O
carried	O
out	O
only	O
using	O
bacterial	O
constituents	O
such	O
as	O
LPS	O
as	O
stimuli	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
characterized	O
the	O
transcriptional	O
induction	O
of	O
p40	O
by	O
CD40	O
ligation	O
in	O
a	O
human	O
B	O
lymphoblastoid	O
cell	O
line	O
,	O
Daudi	O
,	O
and	O
a	O
human	O
acute	O
monocytic	O
leukemia	O
cell	O
line	O
,	O
THP	O
-	O
1	O
.	O

These	O
cells	O
,	O
stimulated	O
by	O
an	O
agonistic	O
monoclonal	O
antibody	O
against	O
CD40	O
or	O
by	O
transfection	O
with	O
a	O
CD40L	O
expression	O
vector	O
,	O
secreted	O
p40	O
and	O
showed	O
enhanced	O
p40	O
mRNA	O
expression	O
.	O

Sequence	O
analysis	O
of	O
the	O
p40	O
promoter	O
region	O
identified	O
two	O
potential	O
nuclear	B-Complex
factor	I-Complex
(	I-Complex
NF	I-Complex
)	I-Complex
-	I-Complex
kappaB	I-Complex
binding	O
sites	O
conserved	O
between	O
mouse	O
and	O
human	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
revealed	O
that	O
the	O
potential	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
binding	O
sequence	O
which	O
is	O
located	O
around	O
120	O
bp	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
in	O
murine	O
and	O
human	O
p40	O
genes	O
formed	O
an	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
complex	O
with	O
nuclear	O
extract	O
from	O
Daudi	O
cells	O
stimulated	O
by	O
CD40	O
ligation	O
.	O

Moreover	O
,	O
transfection	O
of	O
Daudi	O
cells	O
with	O
the	O
polymerized	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
binding	O
sequence	O
ligated	O
to	O
a	O
thymidine	O
kinase	O
/	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
reporter	O
plasmid	O
greatly	O
induced	O
CAT	O
activity	O
,	O
but	O
transfection	O
with	O
the	O
polymerized	O
mutated	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
binding	O
sequence	O
did	O
not	O
.	O

These	O
results	O
suggest	O
that	O
the	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
binding	O
site	O
located	O
around	O
120	O
bp	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
in	O
murine	O
and	O
human	O
p40	O
promoter	O
regions	O
could	O
be	O
important	O
for	O
the	O
p40	O
induction	O
by	O
CD40	O
ligation	O
via	O
activation	O
of	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
.	O

To	O
determine	O
whether	O
acylation	O
is	O
important	O
for	O
Vac8p	O
function	O
,	O
the	O
phenotypic	O
consequences	O
of	O
the	O
acylation	O
-	O
minus	O
mutants	O
were	O
examined	O
.	O

Strikingly	O
,	O
whereas	O
vac8	O
-	O
2	O
showed	O
normal	O
vacuole	O
inheritance	O
and	O
morphology	O
(	O
Fig	O
.	O
7	O
A	O
,	O
a	O
)	O
,	O
the	O
vacuole	O
inheritance	O
and	O
morphology	O
in	O
vac8	O
-	O
3	O
were	O
identical	O
to	O
those	O
in	O
Deltavac8	O
cells	O
(	O
b	O
)	O
.	O

Thus	O
,	O
palmitoylation	O
is	O
required	O
for	O
Vac8p	O
function	O
in	O
vacuole	O
inheritance	O
,	O
whereas	O
myristoylation	O
is	O
dispensable	O
.	O

When	O
vac8	O
-	O
2	O
or	O
vac8	O
-	O
3	O
were	O
labeled	O
with	O
FM4	O
-	O
64	O
and	O
mated	O
with	O
Deltavac8	O
,	O
only	O
9	O
%	O
of	O
the	O
zygotic	O
buds	O
inherited	O
vacuoles	O
from	O
vac8	O
-	O
3	O
parental	O
vacuoles	O
,	O
compared	O
with	O
89	O
%	O
from	O
vac8	O
-	O
2	O
parental	O
vacuoles	O
(	O
Table	O
II	O
)	O
.	O

This	O
further	O
confirms	O
the	O
importance	O
of	O
palmitoylation	O
but	O
not	O
myristoylation	O
for	O
Vac8p	O
function	O
in	O
vacuole	O
inheritance	O
.	O

Because	O
almost	O
equal	O
amounts	O
of	O
Vac8p	O
are	O
present	O
in	O
the	O
membrane	O
fraction	O
of	O
the	O
two	O
mutants	O
,	O
the	O
vacuole	O
inheritance	O
defect	O
in	O
the	O
palmitoylation	O
-	O
minus	O
mutant	O
is	O
unlikely	O
to	O
be	O
due	O
to	O
the	O
mislocalization	O
of	O
Vac8p	O
from	O
the	O
vacuolar	O
membrane	O
;	O
rather	O
,	O
the	O
palmitate	O
group	O
may	O
somehow	O
participate	O
more	O
directly	O
in	O
the	O
vacuole	O
segregation	O
process	O
.	O

To	O
test	O
whether	O
full	O
-	O
length	O
ABP	O
-	O
280	O
can	O
interact	O
with	O
the	O
TF	O
cytoplasmic	O
domain	O
,	O
we	O
expressed	O
His	O
-	O
tagged	O
fusion	O
proteins	O
of	O
wild	O
type	O
and	O
mutant	O
cytoplasmic	O
domains	O
of	O
TF	O
in	O
E	O
.	O
coli	O
for	O
affinity	O
precipitation	O
of	O
ABP	O
-	O
280	O
from	O
J82	O
cell	O
lysates	O
(	O
Fig	O
.	O
5	O
B	O
)	O
.	O

ABP	O
-	O
280	O
did	O
not	O
bind	O
to	O
the	O
His	O
-	O
tagged	O
peptide	O
encoded	O
by	O
the	O
vector	O
polylinker	O
sequence	O
,	O
but	O
ABP	O
-	O
280	O
was	O
detected	O
in	O
precipitates	O
with	O
wild	O
type	O
cytoplasmic	O
domain	O
of	O
TF	O
.	O

Precipitation	O
appeared	O
to	O
be	O
enhanced	O
with	O
constructs	O
that	O
encoded	O
Asp	O
substitutions	O
for	O
each	O
of	O
the	O
cytoplasmic	O
Ser	O
residues	O
to	O
mimic	O
phosphorylation	O
.	O

Ala	O
replacement	O
for	O
Ser253	O
and	O
Ser258	O
essentially	O
abolished	O
binding	O
of	O
ABP	O
-	O
280	O
in	O
the	O
precipitation	O
experiment	O
,	O
consistent	O
with	O
the	O
suggested	O
diminished	O
affinity	O
for	O
the	O
mutant	O
in	O
the	O
two	O
-	O
hybrid	O
assay	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
Ser	O
phosphorylation	O
of	O
the	O
TF	O
cytoplasmic	O
domain	O
can	O
modulate	O
affinity	O
for	O
ABP	O
-	O
280	O
.	O

Role	O
of	O
the	O
CLOCK	O
protein	O
in	O
the	O
mammalian	O
circadian	O
mechanism	O
.	O

The	O
mouse	O
Clock	O
gene	O
encodes	O
a	O
bHLH	O
-	O
PAS	O
protein	O
that	O
regulates	O
circadian	O
rhythms	O
and	O
is	O
related	O
to	O
transcription	O
factors	O
that	O
act	O
as	O
heterodimers	O
.	O

Potential	O
partners	O
of	O
CLOCK	O
were	O
isolated	O
in	O
a	O
two	O
-	O
hybrid	O
screen	O
,	O
and	O
one	O
,	O
BMAL1	O
,	O
was	O
coexpressed	O
with	O
CLOCK	O
and	O
PER1	O
at	O
known	O
circadian	O
clock	O
sites	O
in	O
brain	O
and	O
retina	O
.	O

CLOCK	O
-	O
BMAL1	O
heterodimers	O
activated	O
transcription	O
from	O
E	O
-	O
box	O
elements	O
,	O
a	O
type	O
of	O
transcription	O
factor	O
-	O
binding	O
site	O
,	O
found	O
adjacent	O
to	O
the	O
mouse	O
per1	O
gene	O
and	O
from	O
an	O
identical	O
E	O
-	O
box	O
known	O
to	O
be	O
important	O
for	O
per	O
gene	O
expression	O
in	O
Drosophila	O
.	O

Mutant	O
CLOCK	O
from	O
the	O
dominant	O
-	O
negative	O
Clock	O
allele	O
and	O
BMAL1	O
formed	O
heterodimers	O
that	O
bound	O
DNA	O
but	O
failed	O
to	O
activate	O
transcription	O
.	O

Thus	O
,	O
CLOCK	O
-	O
BMAL1	O
heterodimers	O
appear	O
to	O
drive	O
the	O
positive	O
component	O
of	O
per	O
transcriptional	O
oscillations	O
,	O
which	O
are	O
thought	O
to	O
underlie	O
circadian	O
rhythmicity	O
.	O

Long	O
-	O
term	O
alcohol	O
effects	O
on	O
hepatic	O
phosphoglucomutase	O
activities	O
in	O
relation	O
to	O
posttranslational	O
modification	O
of	O
the	O
protein	O
.	O

ADP	O
-	O
ribosylation	O
is	O
a	O
posttranslational	O
protein	O
modification	O
catalyzed	O
by	O
two	O
classes	O
of	O
enzymes	O
:	O
mono	O
-	O
ADP	O
-	O
ribosyltransferase	O
and	O
poly	O
-	O
ADP	O
-	O
ribose	O
polymerases	O
.	O

We	O
previously	O
demonstrated	O
that	O
long	O
-	O
term	O
alcohol	O
intake	O
remarkably	O
enhanced	O
an	O
endogenous	O
ADP	O
-	O
ribosylation	O
of	O
a	O
58	O
kDa	O
protein	O
in	O
rat	O
liver	O
and	O
also	O
identified	O
the	O
58	O
kDa	O
protein	O
as	O
phosphoglucomutase	O
(	O
PGM	O
)	O
.	O

To	O
assess	O
biological	O
significance	O
of	O
this	O
phenomenon	O
,	O
we	O
tested	O
the	O
effects	O
of	O
long	O
-	O
term	O
alcohol	O
intake	O
on	O
PGM	O
activities	O
in	O
connection	O
with	O
posttranslational	O
modification	O
of	O
the	O
protein	O
.	O

ADP	O
-	O
ribosylation	O
of	O
PGM	O
was	O
mono	O
-	O
rather	O
than	O
poly	O
-	O
ADP	O
-	O
ribosylation	O
.	O

Also	O
,	O
nonenzymatic	O
binding	O
of	O
ADP	O
-	O
ribose	O
was	O
excluded	O
.	O

It	O
was	O
of	O
note	O
that	O
ADP	O
-	O
ribosylation	O
of	O
exogenous	O
PGM	O
was	O
remarkably	O
increased	O
by	O
adding	O
rat	O
liver	O
plasma	O
membranes	O
,	O
and	O
that	O
the	O
extent	O
of	O
the	O
increase	O
was	O
greater	O
in	O
alcohol	O
-	O
fed	O
rats	O
than	O
in	O
pair	O
-	O
fed	O
controls	O
.	O

Furthermore	O
,	O
PGM	O
activities	O
were	O
significantly	O
increased	O
after	O
long	O
-	O
term	O
alcohol	O
intake	O
concomitant	O
with	O
increased	O
ADP	O
-	O
ribosyltransferase	O
activities	O
toward	O
PGM	O
.	O

In	O
view	O
of	O
the	O
variety	O
of	O
roles	O
of	O
PGM	O
in	O
the	O
liver	O
,	O
such	O
as	O
carbohydrate	O
metabolism	O
and	O
Ca2	O
+	O
homeostasis	O
,	O
it	O
is	O
tempting	O
to	O
speculate	O
that	O
increased	O
ADP	O
-	O
ribosylation	O
of	O
PGM	O
may	O
play	O
a	O
role	O
in	O
long	O
-	O
term	O
alcohol	O
effects	O
on	O
hepatocytes	O
.	O

Coactivation	O
by	O
OCA	O
-	O
B	O
:	O
definition	O
of	O
critical	O
regions	O
and	O
synergism	O
with	O
general	O
cofactors	O
.	O

Molecular	O
dissection	O
of	O
the	O
B	O
-	O
cell	O
-	O
specific	O
transcription	O
coactivator	O
OCA	O
-	O
B	O
has	O
revealed	O
distinct	O
regions	O
important	O
,	O
respectively	O
,	O
for	O
recruitment	O
to	O
immunoglobulin	B-OOS
promoters	O
through	O
interaction	O
with	O
octamer	O
-	O
bound	O
Oct	O
-	O
1	O
and	O
for	O
subsequent	O
coactivator	O
function	O
.	O

Further	O
analysis	O
of	O
general	O
coactivator	O
requirements	O
showed	O
that	O
selective	O
removal	O
of	O
PC4	O
from	O
the	O
essential	O
USA	O
fraction	O
severely	O
impairs	O
Oct	O
-	O
1	O
and	O
OCA	O
-	O
B	O
function	O
in	O
a	O
cell	O
-	O
free	O
system	O
reconstituted	O
with	O
partially	O
purified	O
factors	O
.	O

Full	O
activity	O
can	O
be	O
restored	O
by	O
the	O
combined	O
action	O
of	O
recombinant	O
PC4	O
and	O
the	O
PC4	O
-	O
depleted	O
USA	O
fraction	O
,	O
thus	O
suggesting	O
a	O
joint	O
requirement	O
for	O
PC4	O
and	O
another	O
,	O
USA	O
-	O
derived	O
component	O
(	O
s	O
)	O
for	O
optimal	O
function	O
of	O
Oct	O
-	O
1	O
/	O
OCA	O
-	O
B	O
in	O
the	O
reconstituted	O
system	O
.	O

Indeed	O
,	O
USA	O
-	O
derived	O
PC2	O
was	O
found	O
to	O
act	O
synergistically	O
with	O
PC4	O
in	O
reproducing	O
the	O
function	O
of	O
intact	O
USA	O
in	O
the	O
assay	O
system	O
.	O

Consistent	O
with	O
the	O
requirement	O
for	O
PC4	O
in	O
the	O
reconstituted	O
system	O
,	O
OCA	O
-	O
B	O
was	O
found	O
to	O
interact	O
directly	O
with	O
PC4	O
.	O

Surprisingly	O
,	O
however	O
,	O
removal	O
of	O
PC4	O
from	O
the	O
unfractionated	O
nuclear	O
extract	O
has	O
no	O
detrimental	O
effect	O
on	O
OCA	O
-	O
B	O
/	O
Oct	O
-	O
1	O
-	O
dependent	O
transcription	O
.	O

These	O
results	O
lead	O
to	O
a	O
general	O
model	O
for	O
the	O
synergistic	O
function	O
of	O
activation	O
domains	O
in	O
Oct	O
-	O
1	O
and	O
OCA	O
-	O
B	O
(	O
mediated	O
by	O
the	O
combined	O
action	O
of	O
the	O
multiple	O
USA	O
components	O
)	O
and	O
,	O
further	O
,	O
suggest	O
a	O
functional	O
redundancy	O
in	O
general	O
coactivators	O
.	O

Identification	O
of	O
Xenopus	O
SMC	B-OOS
protein	O
complexes	O
required	O
for	O
sister	O
chromatid	O
cohesion	O
.	O

The	O
structural	B-OOS
maintenance	I-OOS
of	I-OOS
chromosomes	I-OOS
(	O
SMC	B-OOS
)	O
family	O
is	O
a	O
growing	O
family	O
of	O
chromosomal	O
ATPases	O
.	O

The	O
founding	O
class	O
of	O
SMC	B-OOS
protein	O
complexes	O
,	O
condensins	B-Complex
,	O
plays	O
a	O
central	O
role	O
in	O
mitotic	O
chromosome	O
condensation	O
.	O

We	O
report	O
here	O
a	O
new	O
class	O
of	O
SMC	B-OOS
protein	O
complexes	O
containing	O
XSMC1	O
and	O
XSMC3	O
,	O
Xenopus	O
homologs	O
of	O
yeast	O
Smc1p	O
and	O
Smc3p	O
,	O
respectively	O
.	O

The	O
protein	O
complexes	O
(	O
termed	O
cohesins	B-Complex
)	O
exist	O
as	O
two	O
major	O
forms	O
with	O
sedimentation	O
coefficients	O
of	O
9S	O
and	O
14S	O
.	O

9S	B-Complex
cohesin	I-Complex
is	O
a	O
heterodimer	O
of	O
XSMC1	O
and	O
XSMC3	O
,	O
whereas	O
14S	B-Complex
cohesin	I-Complex
contains	O
three	O
additional	O
subunits	O
.	O

One	O
of	O
them	O
has	O
been	O
identified	O
as	O
a	O
Xenopus	O
homolog	O
of	O
the	O
Schizosaccharomyces	O
pombe	O
Rad21p	O
implicated	O
in	O
DNA	O
repair	O
and	O
the	O
Saccharomyces	O
cerevisiae	O
Scc1p	O
/	O
Mcd1p	O
implicated	O
in	O
sister	O
chromatid	O
cohesion	O
.	O

14S	B-Complex
cohesin	I-Complex
binds	O
to	O
interphase	O
chromatin	O
independently	O
of	O
DNA	O
replication	O
and	O
dissociates	O
from	O
it	O
at	O
the	O
onset	O
of	O
mitosis	O
.	O

Immunodepletion	O
of	O
cohesins	B-Complex
during	O
interphase	O
causes	O
defects	O
in	O
sister	O
chromatid	O
cohesion	O
in	O
subsequent	O
mitosis	O
,	O
whereas	O
condensation	O
is	O
unaffected	O
.	O

These	O
results	O
suggest	O
that	O
proper	O
assembly	O
of	O
mitotic	O
chromosomes	O
is	O
regulated	O
by	O
two	O
distinct	O
classes	O
of	O
SMC	B-OOS
protein	O
complexes	O
,	O
cohesins	B-Complex
and	O
condensins	B-Complex
.	O

The	O
CRY1	O
blue	O
light	O
photoreceptor	O
of	O
Arabidopsis	O
interacts	O
with	O
phytochrome	O
A	O
in	O
vitro	O
.	O

Plants	O
have	O
at	O
least	O
two	O
major	O
photosensory	O
receptors	O
:	O
phytochrome	O
(	O
absorbing	O
primarily	O
red	O
/	O
far	O
-	O
red	O
light	O
)	O
and	O
cryptochrome	O
(	O
absorbing	O
blue	O
/	O
UV	O
-	O
A	O
light	O
)	O
;	O
considerable	O
physiological	O
and	O
genetic	O
evidence	O
suggests	O
some	O
form	O
of	O
communication	O
or	O
functional	O
dependence	O
between	O
the	O
receptors	O
.	O

Here	O
,	O
we	O
demonstrate	O
in	O
vitro	O
,	O
using	O
purified	O
recombinant	O
photoreceptors	O
,	O
that	O
Arabidopsis	O
CRY1	O
and	O
CRY2	O
(	O
cryptochrome	O
)	O
are	O
substrates	O
for	O
phosphorylation	O
by	O
a	O
phytochrome	O
A	O
-	O
associated	O
kinase	O
activity	O
.	O

Several	O
mutations	O
within	O
the	O
CRY1	O
C	O
terminus	O
lead	O
to	O
reduced	O
phosphorylation	O
by	O
phytochrome	O
preparations	O
in	O
vitro	O
.	O

Yeast	O
two	O
-	O
hybrid	O
interaction	O
studies	O
using	O
expressed	O
C	O
-	O
terminal	O
fragments	O
of	O
CRY1	O
and	O
phytochrome	O
A	O
from	O
Arabidopsis	O
confirm	O
a	O
direct	O
physical	O
interaction	O
between	O
both	O
photoreceptors	O
.	O

In	O
vivo	O
labeling	O
studies	O
and	O
specific	O
mutant	O
alleles	O
of	O
CRY1	O
,	O
which	O
interfere	O
with	O
the	O
function	O
of	O
phytochrome	O
,	O
suggest	O
the	O
possible	O
relevance	O
of	O
these	O
findings	O
in	O
vivo	O
.	O

Specific	O
isoprenyl	O
group	O
linked	O
to	O
transducin	O
gamma	O
-	O
subunit	O
is	O
a	O
determinant	O
of	O
its	O
unique	O
signaling	O
properties	O
among	O
G	O
-	O
proteins	O
.	O

Among	O
11	O
subtypes	O
of	O
heterotrimeric	O
G	O
-	O
protein	O
gamma	O
-	O
subunit	O
,	O
gamma1	O
(	O
rod	O
)	O
,	O
gamma8	O
(	O
cone	O
)	O
and	O
gamma11	O
are	O
modified	O
with	O
farnesyl	O
while	O
the	O
others	O
are	O
modified	O
with	O
geranylgeranyl	O
at	O
the	O
C	O
-	O
terminus	O
.	O

To	O
understand	O
the	O
role	O
of	O
specific	O
isoprenylation	O
(	O
farnesylation	O
)	O
of	O
retinal	O
transducin	B-OOS
,	O
we	O
examined	O
how	O
and	O
to	O
what	O
extent	O
the	O
type	O
of	O
isoprenyl	O
group	O
affects	O
transducin	B-OOS
-	O
beta	B-OOS
gamma	I-OOS
(	O
beta1	B-OOS
gamma1	I-OOS
)	O
functions	O
such	O
as	O
interactions	O
with	O
membranes	O
,	O
Galpha	O
/	O
receptor	O
,	O
and	O
effectors	O
.	O

To	O
this	O
end	O
,	O
the	O
C	O
-	O
terminal	O
farnesylation	O
signal	O
sequence	O
(	O
CVIS	O
)	O
of	O
gamma1	O
was	O
replaced	O
by	O
a	O
geranylgeranylation	O
signal	O
(	O
CVIL	O
)	O
,	O
and	O
the	O
resultant	O
mutant	O
(	O
S74L	O
)	O
or	O
wild	O
-	O
type	O
(	O
WT	O
)	O
gamma1	O
was	O
coexpressed	O
with	O
beta1	O
in	O
the	O
baculovirus	O
-	O
Tn5	O
insect	O
cell	O
system	O
.	O

Both	O
gamma1WT	O
and	O
gamma1S74L	O
expressed	O
as	O
a	O
beta	B-OOS
gamma	I-OOS
complex	O
were	O
mixtures	O
modified	O
with	O
farnesyl	O
and	O
geranylgeranyl	O
groups	O
.	O

The	O
ratio	O
of	O
farnesyl	O
to	O
geranylgeranyl	O
in	O
preparations	O
of	O
beta1	B-OOS
gamma1WT	I-OOS
and	O
beta1	B-OOS
gamma1S74L	I-OOS
purified	O
from	O
the	O
Tn5	O
cell	O
membrane	O
fraction	O
was	O
about	O
1	O
:	O
2	O
and	O
1	O
:	O
6	O
,	O
respectively	O
.	O

These	O
two	O
forms	O
of	O
recombinant	O
beta1	B-OOS
gamma1	I-OOS
and	O
retinal	O
beta1	B-OOS
gamma1	I-OOS
were	O
different	O
in	O
their	O
abilities	O
to	O
associate	O
with	O
rod	O
outer	O
segment	O
membranes	O
with	O
the	O
following	O
rank	O
order	O
:	O
beta1	B-OOS
gamma1S74L	I-OOS
>	O
beta1	B-OOS
gamma1WT	I-OOS
>	O
retinal	O
beta1	B-OOS
gamma1	I-OOS
.	O

Functionally	O
,	O
beta1	B-OOS
gamma1S74L	I-OOS
was	O
the	O
most	O
potent	O
to	O
promote	O
pertussis	O
toxin	O
-	O
catalyzed	O
ADP	O
ribosylation	O
of	O
transducin	O
-	O
alpha	O
(	O
Talpha	O
)	O
,	O
to	O
stimulate	O
metarhodopsin	O
II	O
-	O
catalyzed	O
GTPgammaS	O
-	O
binding	O
reaction	O
to	O
Talpha	O
and	O
to	O
modulate	O
adenylyl	O
cyclase	O
and	O
phospholipase	O
C	O
activities	O
.	O

All	O
of	O
the	O
beta1	B-OOS
gamma1	I-OOS
functions	O
absolutely	O
required	O
the	O
isoprenylation	O
of	O
the	O
gamma	O
-	O
subunit	O
.	O

As	O
for	O
the	O
interaction	O
with	O
Goalpha	O
and	O
adenylyl	O
cyclase	O
,	O
predominantly	O
geranylgeranylated	O
beta1	B-OOS
gamma1S74L	I-OOS
was	O
less	O
effective	O
than	O
geranylgeranylated	O
beta1	B-OOS
gamma2	I-OOS
purified	O
from	O
bovine	O
brain	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
properties	O
of	O
Gbeta	B-OOS
gamma	I-OOS
are	O
strongly	O
affected	O
by	O
the	O
type	O
of	O
functionally	O
indispensable	O
isoprenylation	O
in	O
addition	O
to	O
the	O
amino	O
acid	O
sequence	O
of	O
Ggamma	O
.	O

The	O
relative	O
contribution	O
of	O
the	O
two	O
factors	O
depends	O
on	O
proteins	O
with	O
which	O
Gbeta	B-OOS
gamma	I-OOS
interacts	O
.	O

Erythropoietin	O
induces	O
tyrosine	O
phosphorylation	O
of	O
Jak2	O
,	O
STAT5A	O
,	O
and	O
STAT5B	O
in	O
primary	O
cultured	O
human	O
erythroid	O
precursors	O
.	O

We	O
examined	O
signaling	O
by	O
erythropoietin	O
in	O
highly	O
purified	O
human	O
colony	O
forming	O
unit	O
-	O
erythroid	O
cells	O
,	O
generated	O
in	O
vitro	O
from	O
CD34	O
(	O
+	O
)	O
cells	O
.	O

We	O
found	O
that	O
erythropoietin	O
induces	O
tyrosine	O
phosphorylation	O
of	O
Jak2	O
,	O
STAT5A	O
,	O
and	O
STAT5B	O
.	O

Tyrosine	O
phosphorylation	O
of	O
Jak2	O
reaches	O
a	O
peak	O
around	O
10	O
minutes	O
after	O
stimulation	O
and	O
is	O
maximum	O
at	O
5	O
U	O
/	O
mL	O
of	O
erythropoietin	O
.	O

Tyrosine	O
phosphorylation	O
of	O
STAT5	O
is	O
accompanied	O
by	O
the	O
translocation	O
of	O
activated	O
STAT5	O
to	O
the	O
nucleus	O
as	O
shown	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
using	O
32Pi	O
-	O
labeled	O
STAT5	O
binding	O
site	O
in	O
the	O
beta	O
-	O
casein	O
promoter	O
.	O

Tyrosine	O
phosphorylation	O
STAT1	O
or	O
STAT3	O
was	O
not	O
detected	O
in	O
human	O
erythroid	O
precursors	O
after	O
stimulation	O
with	O
erythropoietin	O
.	O

Crkl	O
,	O
an	O
SH2	O
/	O
SH3	O
adapter	O
protein	O
,	O
becomes	O
coimmunoprecipitated	O
specifically	O
with	O
STAT5	O
from	O
erythropoietin	O
-	O
stimulated	O
erythroid	O
cells	O
;	O
although	O
it	O
was	O
shown	O
to	O
become	O
associated	O
with	O
c	O
-	O
Cbl	O
in	O
the	O
studies	O
using	O
cell	O
lines	O
.	O

Thus	O
,	O
human	O
erythroid	O
precursors	O
can	O
be	O
expanded	O
in	O
vitro	O
in	O
sufficient	O
numbers	O
and	O
purity	O
to	O
allow	O
its	O
usage	O
in	O
signal	O
transduction	O
studies	O
.	O

This	O
report	O
sets	O
a	O
basis	O
for	O
further	O
studies	O
on	O
signaling	O
in	O
primary	O
cultured	O
human	O
erythroid	O
precursors	O
,	O
which	O
in	O
turn	O
contribute	O
to	O
our	O
better	O
understanding	O
in	O
the	O
differentiation	O
processes	O
of	O
erythrocytes	O
and	O
their	O
precursors	O
.	O

Recruitment	O
of	O
CBP	O
/	O
p300	O
by	O
the	O
IFN	O
beta	O
enhanceosome	B-Complex
is	O
required	O
for	O
synergistic	O
activation	O
of	O
transcription	O
.	O

Transcriptional	O
activation	O
of	O
the	O
IFN	O
beta	O
gene	O
in	O
response	O
to	O
virus	O
infection	O
requires	O
the	O
assembly	O
of	O
an	O
enhanceosome	B-Complex
,	O
consisting	O
of	O
the	O
transcriptional	O
activators	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
,	O
IRF1	O
,	O
ATF2	O
/	O
c	O
-	O
Jun	O
,	O
and	O
the	O
architectural	O
protein	O
HMG	O
I	O
(	O
Y	O
)	O
.	O

The	O
level	O
of	O
transcription	O
generated	O
by	O
all	O
of	O
these	O
activators	O
is	O
greater	O
than	O
the	O
sum	O
of	O
the	O
levels	O
generated	O
by	O
individual	O
factors	O
,	O
a	O
phenomenon	O
designated	O
transcriptional	O
synergy	O
.	O

We	O
demonstrate	O
that	O
this	O
synergy	O
,	O
in	O
the	O
context	O
of	O
the	O
enhanceosome	B-Complex
,	O
requires	O
a	O
new	O
protein	O
-	O
protein	O
interaction	O
domain	O
in	O
the	O
p65	O
subunit	O
of	O
NF	B-Complex
-	I-Complex
kappa	I-Complex
B	I-Complex
.	O

Transcriptional	O
synergy	O
requires	O
recruitment	O
of	O
the	O
CBP	O
/	O
p300	O
coactivator	O
to	O
the	O
enhanceosome	B-Complex
,	O
via	O
a	O
new	O
activating	O
surface	O
assembled	O
from	O
the	O
novel	O
p65	O
domain	O
and	O
the	O
activation	O
domains	O
of	O
all	O
of	O
the	O
activators	O
.	O

Deletion	O
,	O
substitution	O
,	O
or	O
rearrangement	O
of	O
any	O
one	O
of	O
the	O
activation	O
domains	O
in	O
the	O
context	O
of	O
the	O
enhanceosome	B-Complex
decreases	O
both	O
recruitment	O
of	O
CBP	O
and	O
transcriptional	O
synergy	O
.	O

The	O
transcriptional	O
repressor	O
ZFM1	O
interacts	O
with	O
and	O
modulates	O
the	O
ability	O
of	O
EWS	O
to	O
activate	O
transcription	O
.	O

The	O
ZFM1	O
protein	O
is	O
both	O
a	O
transcriptional	O
repressor	O
and	O
identical	O
to	O
the	O
splicing	O
factor	O
SF1	O
.	O

ZFM1	O
was	O
shown	O
to	O
interact	O
with	O
and	O
repress	O
transcription	O
from	O
the	O
glycine	O
,	O
glutamine	O
,	O
serine	O
,	O
and	O
threonine	O
-	O
rich	O
transcription	O
activation	O
domain	O
of	O
the	O
sea	O
urchin	O
transcription	O
factor	O
,	O
stage	O
-	O
specific	O
activator	O
protein	O
(	O
SSAP	O
)	O
.	O

EWS	O
,	O
a	O
human	O
protein	O
involved	O
in	O
cellular	O
transformation	O
in	O
Ewing	O
'	O
s	O
sarcoma	O
tumors	O
,	O
contains	O
an	O
NH2	O
-	O
terminal	O
transcriptional	O
activation	O
domain	O
(	O
NTD	O
)	O
which	O
resembles	O
that	O
of	O
SSAP	O
in	O
both	O
amino	O
acid	O
composition	O
and	O
the	O
ability	O
to	O
drive	O
transcription	O
to	O
levels	O
higher	O
than	O
VP16	O
in	O
most	O
cell	O
types	O
.	O

Here	O
we	O
report	O
that	O
ZFM1	O
also	O
interacts	O
with	O
EWS	O
in	O
both	O
two	O
-	O
hybrid	O
assays	O
and	O
glutathione	O
S	O
-	O
transferase	O
pull	O
-	O
down	O
experiments	O
.	O

The	O
region	O
on	O
EWS	O
which	O
interacts	O
with	O
ZFM1	O
maps	O
to	O
37	O
amino	O
acids	O
within	O
its	O
NTD	O
.	O

Overexpression	O
of	O
ZFM1	O
in	O
HepG2	O
cells	O
represses	O
the	O
transactivation	O
of	O
reporter	O
gene	O
expression	O
driven	O
by	O
Gal4	O
-	O
EWS	O
-	O
NTD	O
fusion	O
protein	O
and	O
this	O
repression	O
correlates	O
with	O
ZFM1	O
binding	O
to	O
EWS	O
.	O

Furthermore	O
,	O
two	O
proteins	O
,	O
TLS	O
and	O
hTAFII68	O
,	O
which	O
have	O
extensive	O
homology	O
to	O
EWS	O
,	O
also	O
interact	O
with	O
ZFM1	O
.	O

Recently	O
,	O
it	O
was	O
discovered	O
that	O
EWS	O
/	O
TLS	O
/	O
hTAFII68	O
are	O
each	O
present	O
in	O
distinct	O
TFIID	B-Complex
populations	O
and	O
EWS	O
and	O
hTAFII68	O
were	O
also	O
found	O
to	O
be	O
associated	O
with	O
the	O
RNA	B-Complex
polymerase	I-Complex
II	I-Complex
holoenzyme	O
.	O

The	O
association	O
of	O
ZFM1	O
with	O
these	O
proteins	O
implies	O
that	O
one	O
normal	O
cellular	O
function	O
for	O
ZFM1	O
may	O
be	O
to	O
negatively	O
modulate	O
transcription	O
of	O
target	O
genes	O
coordinated	O
by	O
these	O
cofactors	O
.	O

Thrombopoietin	O
supports	O
in	O
vitro	O
erythroid	O
differentiation	O
via	O
its	O
specific	O
receptor	O
c	O
-	O
Mpl	O
in	O
a	O
human	O
leukemia	O
cell	O
line	O
.	O

Thrombopoietin	O
(	O
TPO	O
)	O
acts	O
on	O
megakaryopoiesis	O
and	O
erythropoiesis	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
isolated	O
a	O
novel	O
subline	O
,	O
UT	O
-	O
7	O
/	O
GMT	O
,	O
from	O
the	O
human	O
leukemia	O
cell	O
line	O
UT	O
-	O
7	O
/	O
GM	O
(	O
N	O
.	O
Komatsu	O
,	O
et	O
al	O
.	O
,	O
Blood	O
,	O
89	O
:	O
4021	O
-	O
4033	O
,	O
1997	O
)	O
.	O

A	O
small	O
population	O
of	O
UT	O
-	O
7	O
/	O
GM	O
cells	O
positively	O
stained	O
for	O
hemoglobin	B-Complex
(	O
Hb	B-Complex
)	O
after	O
a	O
7	O
-	O
day	O
exposure	O
to	O
TPO	O
.	O

More	O
than	O
50	O
%	O
of	O
TPO	O
-	O
treated	O
UT	O
-	O
7	O
/	O
GMT	O
cells	O
positively	O
stained	O
for	O
Hb	B-Complex
.	O

Using	O
UT	O
-	O
7	O
/	O
GMT	O
cells	O
,	O
we	O
examined	O
how	O
TPO	O
promotes	O
hemoglobinization	O
.	O

TPO	O
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
TPO	O
receptor	O
but	O
not	O
the	O
erythropoietin	O
(	O
EPO	O
)	O
receptor	O
.	O

There	O
was	O
no	O
competition	O
between	O
TPO	O
and	O
EPO	O
for	O
binding	O
to	O
EPO	O
receptor	O
.	O

These	O
findings	O
suggest	O
that	O
TPO	O
has	O
a	O
direct	O
effect	O
on	O
hemoglobinization	O
via	O
a	O
specific	O
receptor	O
on	O
UT	O
-	O
7	O
/	O
GMT	O
cells	O
.	O

Isoelectric	O
focusing	O
demonstrated	O
that	O
TPO	O
induced	O
fetal	O
and	O
adult	O
Hb	B-Complex
synthesis	O
,	O
whereas	O
EPO	O
induced	O
embryonic	O
,	O
fetal	O
,	O
and	O
adult	O
Hb	B-Complex
synthesis	O
.	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
TPO	O
has	O
a	O
distinct	O
action	O
on	O
erythropoiesis	O
.	O

What	O
does	O
insulin	O
do	O
to	O
Ras	O
?	O

The	O
Ras	O
pathway	O
lies	O
in	O
the	O
center	O
of	O
signalling	O
cascades	O
of	O
numerous	O
growth	O
-	O
promoting	O
factors	O
.	O

The	O
Ras	O
pathway	O
appears	O
to	O
connect	O
signalling	O
events	O
that	O
begin	O
at	O
the	O
plasma	O
membrane	O
with	O
nuclear	O
events	O
.	O

Insulin	O
is	O
one	O
of	O
the	O
major	O
stimulants	O
of	O
the	O
Ras	O
signalling	O
pathway	O
.	O

The	O
influence	O
of	O
insulin	O
on	O
this	O
pathway	O
consists	O
of	O
five	O
important	O
events	O
:	O
(	O
1	O
)	O
p21Ras	O
activation	O
is	O
promoted	O
by	O
insulin	O
stimulation	O
of	O
the	O
guanine	O
nucleotide	O
exchange	O
factor	O
,	O
Sos	O
,	O
resulting	O
in	O
increased	O
GTP	O
-	O
loading	O
of	O
p21Ras	O
;	O
(	O
2	O
)	O
p21Ras	O
deactivation	O
involves	O
the	O
hyperphosphorylation	O
of	O
Sos	O
;	O
(	O
3	O
)	O
insulin	O
increases	O
farnesyltransferase	B-OOS
(	O
FTase	B-OOS
)	O
activity	O
that	O
farnesylates	O
p21Ras	O
;	O
(	O
4	O
)	O
increased	O
amounts	O
of	O
farnesylated	O
p21Ras	O
translocate	O
to	O
the	O
plasma	O
membrane	O
where	O
they	O
can	O
be	O
activated	O
by	O
other	O
growth	O
-	O
promoting	O
agents	O
;	O
and	O
(	O
5	O
)	O
cellular	O
responses	O
to	O
other	O
growth	O
factors	O
are	O
potentiated	O
by	O
insulin	O
-	O
stimulated	O
pre	O
-	O
loading	O
of	O
the	O
plasma	O
membrane	O
with	O
farnesylated	O
p21Ras	O
.	O

Epstein	O
-	O
Barr	O
virus	O
-	O
transforming	O
protein	O
latent	O
infection	O
membrane	O
protein	O
1	O
activates	O
transcription	O
factor	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
through	O
a	O
pathway	O
that	O
includes	O
the	O
NF	O
-	O
kappaB	O
-	O
inducing	O
kinase	O
and	O
the	O
IkappaB	O
kinases	O
IKKalpha	O
and	O
IKKbeta	O
.	O

The	O
Epstein	O
-	O
Barr	O
virus	O
oncoprotein	O
latent	O
infection	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
is	O
a	O
constitutively	O
aggregated	O
pseudo	O
-	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR	O
)	O
that	O
activates	O
transcription	O
factor	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
through	O
two	O
sites	O
in	O
its	O
C	O
-	O
terminal	O
cytoplasmic	O
domain	O
.	O

One	O
site	O
is	O
similar	O
to	O
activated	O
TNFRII	O
in	O
associating	O
with	O
TNFR	O
-	O
associated	O
factors	O
TRAF1	O
and	O
TRAF2	O
,	O
and	O
the	O
second	O
site	O
is	O
similar	O
to	O
TNFRI	O
in	O
associating	O
with	O
the	O
TNFRI	O
death	O
domain	O
interacting	O
protein	O
TRADD	O
.	O

TNFRI	O
has	O
been	O
recently	O
shown	O
to	O
activate	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
through	O
association	O
with	O
TRADD	O
,	O
RIP	O
,	O
and	O
TRAF2	O
;	O
activation	O
of	O
the	O
NF	O
-	O
kappaB	O
-	O
inducing	O
kinase	O
(	O
NIK	O
)	O
;	O
activation	O
of	O
the	O
IkappaB	O
alpha	O
kinases	O
(	O
IKKalpha	O
and	O
IKKbeta	O
)	O
;	O
and	O
phosphorylation	O
of	O
IkappaB	O
alpha	O
.	O

IkappaB	O
alpha	O
phosphorylation	O
on	O
Ser	O
-	O
32	O
and	O
Ser	O
-	O
36	O
is	O
followed	O
by	O
its	O
degradation	O
and	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
by	O
LMP1	O
or	O
by	O
each	O
of	O
its	O
effector	O
sites	O
is	O
mediated	O
by	O
a	O
pathway	O
that	O
includes	O
NIK	O
,	O
IKKalpha	O
,	O
and	O
IKKbeta	O
.	O

Dominant	O
negative	O
mutants	O
of	O
NIK	O
,	O
IKKalpha	O
,	O
or	O
IKKbeta	O
substantially	O
inhibited	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
activation	O
by	O
LMP1	O
or	O
by	O
each	O
of	O
its	O
effector	O
sites	O
.	O

Activation	O
of	O
E2F	O
-	O
mediated	O
transcription	O
by	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
Tax	O
protein	O
in	O
a	O
p16	O
(	O
INK4A	O
)	O
-	O
negative	O
T	O
-	O
cell	O
line	O
.	O

The	O
human	O
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV	O
-	O
I	O
)	O
is	O
a	O
causative	O
agent	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
.	O

Although	O
the	O
exact	O
mechanism	O
by	O
which	O
HTLV	O
-	O
I	O
contributes	O
to	O
leukemogenesis	O
is	O
still	O
unclear	O
,	O
the	O
Tax	O
protein	O
is	O
thought	O
to	O
play	O
a	O
major	O
role	O
in	O
this	O
process	O
.	O

This	O
40	O
-	O
kDa	O
polypeptide	O
is	O
able	O
to	O
interact	O
with	O
the	O
tumor	O
suppressor	O
p16	O
(	O
INK4A	O
)	O
.	O

Consequently	O
,	O
Tax	O
can	O
activate	O
the	O
signaling	O
pathway	O
that	O
lead	O
to	O
the	O
release	O
of	O
E2F	O
that	O
in	O
turn	O
induces	O
expression	O
of	O
factors	O
required	O
for	O
cell	O
cycle	O
progression	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
Tax	O
can	O
also	O
activate	O
E2F	O
-	O
mediated	O
transcription	O
independently	O
of	O
p16	O
(	O
INK4A	O
)	O
.	O

Indeed	O
,	O
when	O
Tax	O
is	O
coexpressed	O
with	O
the	O
E2F	O
-	O
1	O
transcription	O
factor	O
in	O
CEM	O
T	O
-	O
cells	O
,	O
which	O
lack	O
expression	O
of	O
p16	O
(	O
INK4A	O
)	O
,	O
it	O
strongly	O
potentiates	O
the	O
E2F	O
-	O
dependent	O
activation	O
of	O
a	O
reporter	O
construct	O
driven	O
by	O
a	O
promoter	O
containing	O
E2F	O
binding	O
sites	O
.	O

This	O
stimulation	O
is	O
abrogated	O
by	O
mutations	O
affecting	O
the	O
E2F	O
-	O
binding	O
sites	O
.	O

In	O
addition	O
,	O
Tax	O
also	O
stimulates	O
the	O
transcription	O
of	O
the	O
E2F	O
-	O
1	O
gene	O
itself	O
.	O

Using	O
Tax	O
mutants	O
that	O
fail	O
to	O
activate	O
either	O
ATF	O
-	O
or	O
NF	B-Complex
-	I-Complex
kappaB	I-Complex
-	O
dependent	O
promoters	O
and	O
different	O
5	O
'	O
truncation	O
mutants	O
of	O
the	O
E2F	O
-	O
1	O
promoter	O
,	O
we	O
show	O
that	O
the	O
Tax	O
-	O
dependent	O
transcriptional	O
control	O
of	O
the	O
E2F1	O
gene	O
involves	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
ATF	O
binding	O
site	O
located	O
in	O
the	O
E2F	O
-	O
1	O
promoter	O
.	O

P	O
-	O
Element	O
insertion	O
at	O
the	O
polyhomeotic	O
gene	O
leads	O
to	O
formation	O
of	O
a	O
novel	O
chimeric	O
protein	O
that	O
negatively	O
regulates	O
yellow	O
gene	O
expression	O
in	O
P	O
-	O
element	O
-	O
induced	O
alleles	O
of	O
Drosophila	O
melanogaster	O
.	O

Polyhomeotic	O
is	O
a	O
member	O
of	O
the	O
Polycomb	O
group	O
(	O
Pc	O
-	O
G	O
)	O
of	O
homeotic	O
repressors	O
.	O

The	O
proteins	O
encoded	O
by	O
the	O
Pc	O
-	O
G	O
genes	O
form	O
repressive	O
complexes	O
on	O
the	O
polycomb	O
group	O
response	O
element	O
sites	O
.	O

The	O
phP1	O
mutation	O
was	O
induced	O
by	O
insertion	O
of	O
a	O
1	O
.	O
2	O
-	O
kb	O
P	O
element	O
into	O
the	O
5	O
'	O
transcribed	O
nontranslated	O
region	O
of	O
the	O
proximal	O
polyhomeotic	O
gene	O
.	O

The	O
phP1	O
allele	O
confers	O
no	O
mutant	O
phenotype	O
,	O
but	O
represses	O
transcription	O
of	O
P	O
-	O
element	O
-	O
induced	O
alleles	O
at	O
the	O
yellow	O
locus	O
.	O

The	O
phP1	O
allele	O
encodes	O
a	O
chimeric	O
P	O
-	O
PH	O
protein	O
,	O
consisting	O
of	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
P	O
element	O
and	O
the	O
PH	O
protein	O
lacking	O
12	O
amino	O
-	O
terminal	O
amino	O
acids	O
.	O

The	O
P	O
-	O
PH	O
,	O
Polycomb	O
(	O
PC	O
)	O
,	O
and	O
Posterior	O
sex	O
combs	O
(	O
PSC	O
)	O
proteins	O
were	O
immunohistochemically	O
detected	O
on	O
polytene	O
chromosomes	O
in	O
the	O
regions	O
of	O
P	O
-	O
element	O
insertions	O
.	O

Estrogen	O
receptor	O
activation	O
function	O
1	O
works	O
by	O
binding	O
p160	O
coactivator	O
proteins	O
.	O

Estrogen	O
receptor	O
-	O
alpha	O
contains	O
two	O
transactivation	O
functions	O
,	O
a	O
weak	O
constitutive	O
activation	O
function	O
(	O
AF	O
-	O
1	O
)	O
and	O
a	O
hormone	O
-	O
dependent	O
activation	O
function	O
(	O
AF	O
-	O
2	O
)	O
.	O

AF	O
-	O
2	O
works	O
by	O
recruiting	O
a	O
large	O
coactivator	O
complex	O
,	O
composed	O
of	O
one	O
or	O
more	O
p160s	O
,	O
CREB	O
-	O
binding	O
protein	O
(	O
CBP	O
)	O
/	O
p300	O
,	O
and	O
P	O
/	O
CAF	O
(	O
p300	O
and	O
CBP	O
-	O
associated	O
factor	O
)	O
,	O
via	O
direct	O
contacts	O
with	O
the	O
p160s	O
.	O

We	O
report	O
here	O
that	O
independent	O
AF	O
-	O
1	O
activity	O
also	O
requires	O
p160	O
contacts	O
.	O

Unlike	O
AF	O
-	O
2	O
,	O
which	O
binds	O
signature	O
NR	O
boxes	O
in	O
the	O
center	O
of	O
the	O
p160	O
molecule	O
,	O
AF	O
-	O
1	O
binds	O
to	O
sequences	O
near	O
the	O
p160	O
C	O
terminus	O
.	O

We	O
propose	O
that	O
the	O
ability	O
of	O
AF	O
-	O
1	O
and	O
AF	O
-	O
2	O
to	O
interact	O
with	O
separate	O
surfaces	O
of	O
the	O
same	O
coactivator	O
is	O
important	O
for	O
the	O
ability	O
of	O
these	O
transactivation	O
functions	O
to	O
synergize	O
.	O

Human	O
monocarboxylate	O
transporter	O
2	O
(	O
MCT2	O
)	O
is	O
a	O
high	O
affinity	O
pyruvate	O
transporter	O
.	O

The	O
transport	O
of	O
pyruvate	O
and	O
lactate	O
across	O
cellular	O
membranes	O
is	O
an	O
essential	O
process	O
in	O
mammalian	O
cells	O
and	O
is	O
mediated	O
by	O
the	O
H	O
+	O
/	O
monocarboxylate	O
transporters	O
(	O
MCTs	O
)	O
.	O

We	O
have	O
molecularly	O
cloned	O
and	O
characterized	O
a	O
novel	O
human	O
monocarboxylate	O
transporter	O
,	O
MCT2	O
.	O

The	O
cDNA	O
is	O
1	O
,	O
907	O
base	O
pairs	O
long	O
and	O
encodes	O
a	O
polypeptide	O
of	O
478	O
amino	O
acids	O
with	O
12	O
predicted	O
transmembrane	O
domains	O
.	O

Human	O
MCT2	O
is	O
the	O
product	O
of	O
a	O
single	O
gene	O
that	O
mapped	O
to	O
chromosome	O
12q13	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

The	O
kinetic	O
properties	O
of	O
human	O
MCT2	O
fulfill	O
the	O
criteria	O
to	O
establish	O
it	O
as	O
a	O
H	O
+	O
/	O
monocarboxylate	O
transporter	O
;	O
however	O
,	O
the	O
unique	O
biochemical	O
feature	O
of	O
human	O
MCT2	O
is	O
its	O
high	O
affinity	O
for	O
the	O
transport	O
of	O
pyruvate	O
(	O
apparent	O
Km	O
of	O
25	O
microM	O
)	O
,	O
implying	O
that	O
it	O
is	O
a	O
primary	O
pyruvate	O
transporter	O
in	O
man	O
.	O

Comparison	O
of	O
human	O
MCT1	O
and	O
MCT2	O
with	O
regard	O
to	O
tissue	O
distribution	O
and	O
RNA	O
transcript	O
variants	O
disclosed	O
substantial	O
differences	O
.	O

Human	O
MCT2	O
mRNA	O
expression	O
was	O
restricted	O
in	O
normal	O
human	O
tissues	O
but	O
widely	O
expressed	O
in	O
cancer	O
cell	O
lines	O
,	O
suggesting	O
that	O
MCT2	O
may	O
be	O
pre	O
-	O
translationally	O
regulated	O
in	O
neoplasia	O
.	O

We	O
found	O
co	O
-	O
expression	O
of	O
human	O
MCT1	O
and	O
MCT2	O
at	O
the	O
mRNA	O
level	O
in	O
human	O
cancer	O
cell	O
lines	O
,	O
including	O
the	O
hematopoietic	O
lineages	O
HL60	O
,	O
K562	O
,	O
MOLT	O
-	O
4	O
,	O
and	O
Burkitt	O
'	O
s	O
lymphoma	O
Raji	O
,	O
and	O
solid	O
tumor	O
cells	O
such	O
as	O
SW480	O
,	O
A549	O
,	O
and	O
G361	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
two	O
monocarboxylate	O
transporters	O
,	O
MCT1	O
and	O
MCT2	O
,	O
have	O
distinct	O
biological	O
roles	O
.	O

Cleavage	O
of	O
the	O
C	O
-	O
terminus	O
of	O
NEDD8	O
by	O
UCH	O
-	O
L3	O
.	O

NEDD8	O
is	O
a	O
novel	O
ubiquitin	O
-	O
like	O
protein	O
that	O
has	O
been	O
shown	O
to	O
conjugate	O
to	O
nuclear	O
proteins	O
in	O
a	O
manner	O
analogous	O
to	O
ubiquitination	O
and	O
sentrinization	O
.	O

To	O
identify	O
proteins	O
that	O
are	O
involved	O
in	O
the	O
NEDD8	O
-	O
conjugation	O
and	O
de	O
-	O
conjugation	O
pathway	O
,	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
was	O
used	O
to	O
screen	O
a	O
human	O
heart	O
cDNA	O
library	O
using	O
NEDD8	O
as	O
a	O
bait	O
.	O

Seven	O
strongly	O
positive	O
clones	O
were	O
found	O
to	O
contain	O
a	O
cDNA	O
insert	O
encoding	O
the	O
ubiquitin	O
C	O
-	O
terminal	O
hydrolase	O
,	O
UCH	O
-	O
L3	O
.	O

In	O
vitro	O
GST	O
pull	O
-	O
down	O
assay	O
demonstrated	O
that	O
UCH	O
-	O
L3	O
bound	O
to	O
both	O
NEDD8	O
and	O
ubiquitin	O
.	O

In	O
contrast	O
,	O
UCH	O
-	O
L3	O
did	O
not	O
bind	O
to	O
sentrin	O
-	O
1	O
,	O
sentrin	O
-	O
2	O
,	O
or	O
sentrin	O
-	O
3	O
.	O

Recombinant	O
UCH	O
-	O
L3	O
,	O
but	O
not	O
UCH	O
-	O
L1	O
,	O
was	O
able	O
to	O
cleave	O
the	O
C	O
-	O
terminus	O
of	O
NEDD8	O
.	O

Thus	O
,	O
UCH	O
-	O
L3	O
can	O
function	O
as	O
a	O
C	O
-	O
terminal	O
hydrolase	O
for	O
both	O
NEDD8	O
and	O
ubiquitin	O
.	O

UCH	O
-	O
L3	O
may	O
play	O
a	O
physiologically	O
significant	O
role	O
in	O
the	O
cleavage	O
of	O
the	O
C	O
-	O
terminus	O
of	O
NEDD8	O
,	O
which	O
is	O
required	O
for	O
NEDD8	O
to	O
conjugate	O
to	O
target	O
proteins	O
.	O

Bcl3	O
,	O
an	O
IkappaB	O
protein	O
,	O
as	O
a	O
novel	O
transcription	O
coactivator	O
of	O
the	O
retinoid	O
X	O
receptor	O
.	O

We	O
have	O
recently	O
shown	O
that	O
the	O
IkappaB	O
protein	O
IkappaBbeta	O
interacted	O
with	O
the	O
retinoid	O
X	O
receptor	O
(	O
RXR	O
)	O
and	O
inhibited	O
the	O
9	O
-	O
cis	O
-	O
retinoic	O
acid	O
(	O
RA	O
)	O
-	O
dependent	O
transactivations	O
(	O
Na	O
,	O
S	O
.	O
-	O
Y	O
.	O
,	O
Kim	O
,	O
H	O
.	O
-	O
J	O
.	O
,	O
Lee	O
,	O
S	O
.	O
-	O
K	O
.	O
,	O
Choi	O
,	O
H	O
.	O
-	O
S	O
.	O
,	O
Na	O
,	O
D	O
.	O
S	O
.	O
,	O
Lee	O
,	O
M	O
.	O
-	O
O	O
.	O
,	O
Chung	O
,	O
M	O
.	O
,	O
Moore	O
,	O
D	O
.	O
D	O
.	O
,	O
and	O
Lee	O
,	O
J	O
.	O
W	O
.	O
(	O
1998	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
6	O
,	O
3212	O
-	O
3215	O
)	O
.	O

Herein	O
,	O
we	O
show	O
that	O
a	O
distinct	O
IkappaB	O
protein	O
Bcl3	O
also	O
interacts	O
with	O
RXR	O
,	O
as	O
shown	O
in	O
the	O
yeast	O
two	O
-	O
hybrid	O
tests	O
and	O
glutathione	O
S	O
-	O
transferase	O
pull	O
-	O
down	O
assays	O
.	O

The	O
Bcl3	O
interaction	O
involved	O
two	O
distinct	O
subregions	O
of	O
RXR	O
,	O
i	O
.	O
e	O
.	O
constitutive	O
interactions	O
of	O
the	O
N	O
-	O
terminal	O
ABC	O
domains	O
and	O
9	O
-	O
cis	O
-	O
RA	O
-	O
dependent	O
interactions	O
of	O
the	O
C	O
-	O
terminal	O
DEF	O
domains	O
.	O

In	O
contrast	O
to	O
IkappaBbeta	O
,	O
Bcl3	O
did	O
not	O
interact	O
with	O
the	O
AF2	O
domain	O
of	O
RXR	O
.	O

Bcl3	O
specifically	O
interacted	O
with	O
the	O
general	O
transcription	O
factors	O
TFIIB	O
,	O
TBP	O
,	O
and	O
TFIIA	O
but	O
not	O
with	O
TFIIEalpha	O
in	O
the	O
GST	O
pull	O
-	O
down	O
assays	O
.	O

TBP	O
and	O
TFIIA	O
,	O
however	O
,	O
were	O
not	O
able	O
to	O
interact	O
with	O
IkappaBbeta	O
.	O

Accordingly	O
,	O
Bcl3	O
coactivated	O
the	O
9	O
-	O
cis	O
-	O
RA	O
-	O
induced	O
transactivations	O
of	O
RXR	O
,	O
in	O
contrast	O
to	O
the	O
inhibitory	O
actions	O
of	O
IkappaBbeta	O
.	O

In	O
addition	O
,	O
coexpression	O
of	O
SRC	O
-	O
1	O
but	O
not	O
p300	O
further	O
stimulated	O
the	O
Bcl3	O
-	O
mediated	O
enhancement	O
of	O
the	O
9	O
-	O
cis	O
-	O
RA	O
-	O
induced	O
transactivations	O
of	O
RXR	O
.	O

These	O
results	O
suggest	O
that	O
distinct	O
IkappaB	O
proteins	O
differentially	O
modulate	O
the	O
9	O
-	O
cis	O
-	O
RA	O
-	O
induced	O
transactivations	O
of	O
RXR	O
in	O
vivo	O
.	O

TAL1	O
and	O
LIM	O
-	O
only	O
proteins	O
synergistically	O
induce	O
retinaldehyde	O
dehydrogenase	O
2	O
expression	O
in	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
by	O
acting	O
as	O
cofactors	O
for	O
GATA3	O
.	O

Previously	O
,	O
we	O
have	O
shown	O
that	O
TAL1	O
and	O
the	O
LIM	O
-	O
only	O
protein	O
gene	O
(	O
LMO	O
)	O
are	O
regularly	O
coactivated	O
in	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
.	O

This	O
observation	O
is	O
likely	O
to	O
relate	O
to	O
the	O
findings	O
that	O
TAL1	O
and	O
LMO	O
are	O
highly	O
synergistic	O
in	O
T	O
-	O
cell	O
tumorigenesis	O
in	O
double	O
-	O
transgenic	O
mice	O
.	O

To	O
understand	O
the	O
molecular	O
mechanisms	O
of	O
functional	O
synergy	O
between	O
TAL1	O
and	O
LMO	O
in	O
tumorigenesis	O
and	O
transcriptional	O
regulation	O
,	O
we	O
tried	O
to	O
identify	O
downstream	O
target	O
genes	O
regulated	O
by	O
TAL1	O
and	O
LMO	O
by	O
a	O
subtractive	O
PCR	O
method	O
.	O

One	O
of	O
the	O
isolated	O
genes	O
,	O
that	O
for	O
retinaldehyde	O
dehydrogenase	O
2	O
(	O
RALDH2	O
)	O
,	O
was	O
regularly	O
expressed	O
in	O
most	O
of	O
the	O
T	O
-	O
ALL	O
cell	O
lines	O
that	O
coexpressed	O
TAL1	O
and	O
LMO	O
.	O

Exogenously	O
transfected	O
TAL1	O
and	O
LMO	O
,	O
but	O
not	O
either	O
alone	O
,	O
induced	O
RALDH2	O
expression	O
in	O
a	O
T	O
-	O
ALL	O
cell	O
line	O
,	O
HPB	O
-	O
ALL	O
,	O
not	O
expressing	O
endogeneous	O
TAL1	O
or	O
LMO	O
.	O

The	O
RALDH2	O
transcripts	O
in	O
T	O
-	O
ALL	O
were	O
,	O
however	O
,	O
mostly	O
initiated	O
within	O
the	O
second	O
intron	O
.	O

Promoter	O
analysis	O
revealed	O
that	O
a	O
GATA	O
site	O
in	O
a	O
cryptic	O
promoter	O
in	O
the	O
second	O
intron	O
was	O
essential	O
and	O
sufficient	O
for	O
the	O
TAL1	O
-	O
and	O
LMO	O
-	O
dependent	O
transcriptional	O
activation	O
,	O
and	O
GATA3	O
binds	O
to	O
this	O
site	O
.	O

In	O
addition	O
,	O
forced	O
expression	O
of	O
GATA3	O
potentiated	O
the	O
induction	O
of	O
RALDH2	O
by	O
TAL1	O
and	O
LMO	O
,	O
and	O
these	O
three	O
factors	O
formed	O
a	O
complex	O
in	O
vivo	O
.	O

Furthermore	O
,	O
a	O
TAL1	O
mutant	O
not	O
binding	O
to	O
DNA	O
also	O
activated	O
the	O
transcription	O
of	O
RALDH2	O
in	O
the	O
presence	O
of	O
LMO	O
and	O
GATA3	O
.	O

Collectively	O
,	O
we	O
have	O
identified	O
the	O
RALDH2	O
gene	O
as	O
a	O
first	O
example	O
of	O
direct	O
transcriptional	O
target	O
genes	O
regulated	O
by	O
TAL1	O
and	O
LMO	O
in	O
T	O
-	O
ALL	O
.	O

In	O
this	O
case	O
,	O
TAL1	O
and	O
LMO	O
act	O
as	O
cofactors	O
for	O
GATA3	O
to	O
activate	O
the	O
transcription	O
of	O
RALDH2	O
.	O

Differential	O
regulation	O
of	O
insulin	O
receptor	O
substrate	O
-	O
2	O
and	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
tyrosine	O
phosphorylation	O
by	O
phosphatidylinositol	O
3	O
-	O
kinase	O
inhibitors	O
in	O
SH	O
-	O
SY5Y	O
human	O
neuroblastoma	O
cells	O
.	O

Insulin	O
-	O
like	O
growth	O
factor	O
I	O
(	O
IGF	O
-	O
I	O
)	O
is	O
a	O
potent	O
neurotropic	O
factor	O
promoting	O
the	O
differentiation	O
and	O
survival	O
of	O
neuronal	O
cells	O
.	O

SH	O
-	O
SY5Y	O
human	O
neuroblastoma	O
cells	O
are	O
a	O
well	O
characterized	O
in	O
vitro	O
model	O
of	O
nervous	O
system	O
growth	O
.	O

We	O
report	O
here	O
that	O
IGF	O
-	O
I	O
stimulated	O
the	O
tyrosine	O
phosphorylation	O
of	O
the	O
type	O
I	O
IGF	O
receptor	O
(	O
IGF	O
-	O
IR	O
)	O
and	O
insulin	O
receptor	O
substrate	O
-	O
2	O
(	O
IRS	O
-	O
2	O
)	O
in	O
a	O
time	O
-	O
and	O
concentration	O
-	O
dependent	O
manner	O
.	O

These	O
cells	O
lacked	O
IRS	O
-	O
1	O
.	O

After	O
being	O
tyrosine	O
phosphorylated	O
,	O
IRS	O
-	O
2	O
associated	O
transiently	O
with	O
downstream	O
signaling	O
molecules	O
,	O
including	O
phosphatidylinositol	O
3	O
-	O
kinase	O
(	O
PI	O
3	O
-	O
K	O
)	O
and	O
Grb2	O
.	O

Treatment	O
of	O
the	O
cells	O
with	O
PI	O
3	O
-	O
K	O
inhibitors	O
(	O
wortmannin	O
and	O
LY294002	O
)	O
increased	O
IGF	O
-	O
I	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
IRS	O
-	O
2	O
.	O

We	O
also	O
observed	O
a	O
concomitant	O
increase	O
in	O
the	O
mobility	O
of	O
IRS	O
-	O
2	O
,	O
suggesting	O
that	O
PI	O
3	O
-	O
K	O
mediates	O
or	O
is	O
required	O
for	O
IRS	O
-	O
2	O
serine	O
/	O
threonine	O
phosphorylation	O
,	O
and	O
that	O
this	O
phosphorylation	O
inhibits	O
IRS	O
-	O
2	O
tyrosine	O
phosphorylation	O
.	O

Treatment	O
with	O
PI	O
3	O
-	O
K	O
inhibitors	O
induced	O
an	O
increased	O
association	O
of	O
IRS	O
-	O
2	O
with	O
Grb2	O
,	O
probably	O
as	O
a	O
result	O
of	O
the	O
increased	O
IRS	O
-	O
2	O
tyrosine	O
phosphorylation	O
.	O

However	O
,	O
even	O
though	O
the	O
PI	O
3	O
-	O
K	O
inhibitors	O
enhanced	O
the	O
association	O
of	O
Grb2	O
with	O
IRS	O
-	O
2	O
,	O
these	O
compounds	O
suppressed	O
IGF	O
-	O
I	O
-	O
induced	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
activation	O
and	O
neurite	O
outgrowth	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
although	O
PI	O
3	O
-	O
K	O
participates	O
in	O
a	O
negative	O
regulation	O
of	O
IRS	O
-	O
2	O
tyrosine	O
phosphorylation	O
,	O
its	O
activity	O
is	O
required	O
for	O
IGF	O
-	O
IR	O
-	O
mediated	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
activation	O
and	O
neurite	O
outgrowth	O
.	O

Apoprotein	O
B100	O
has	O
a	O
prolonged	O
interaction	O
with	O
the	O
translocon	O
during	O
which	O
its	O
lipidation	O
and	O
translocation	O
change	O
from	O
dependence	O
on	O
the	O
microsomal	O
triglyceride	O
transfer	O
protein	O
to	O
independence	O
.	O

When	O
lipid	O
synthesis	O
is	O
limited	O
in	O
HepG2	O
cells	O
,	O
apoprotein	O
B100	O
(	O
apoB100	O
)	O
is	O
not	O
secreted	O
but	O
rapidly	O
degraded	O
by	O
the	O
ubiquitin	O
-	O
proteasome	B-Complex
pathway	O
.	O

To	O
investigate	O
apoB100	O
biosynthesis	O
and	O
secretion	O
further	O
,	O
the	O
physical	O
and	O
functional	O
states	O
of	O
apoB100	O
destined	O
for	O
either	O
degradation	O
or	O
lipoprotein	O
assembly	O
were	O
studied	O
under	O
conditions	O
in	O
which	O
lipid	O
synthesis	O
,	O
proteasomal	O
activity	O
,	O
and	O
microsomal	O
triglyceride	O
transfer	O
protein	O
(	O
MTP	O
)	O
lipid	O
-	O
transfer	O
activity	O
were	O
varied	O
.	O

Cells	O
were	O
pretreated	O
with	O
a	O
proteasomal	O
inhibitor	O
(	O
which	O
remained	O
with	O
the	O
cells	O
throughout	O
the	O
experiment	O
)	O
and	O
radiolabeled	O
for	O
15	O
min	O
.	O

During	O
the	O
chase	O
period	O
,	O
labeled	O
apoB100	O
remained	O
associated	O
with	O
the	O
microsomes	O
.	O

Furthermore	O
,	O
by	O
crosslinking	O
sec61beta	O
to	O
apoB100	O
,	O
we	O
showed	O
that	O
apoB100	O
remained	O
close	O
to	O
the	O
translocon	O
at	O
the	O
same	O
time	O
apoB100	O
-	O
ubiquitin	O
conjugates	O
could	O
be	O
detected	O
.	O

When	O
lipid	O
synthesis	O
and	O
lipoprotein	O
assembly	O
/	O
secretion	O
were	O
stimulated	O
by	O
adding	O
oleic	O
acid	O
(	O
OA	O
)	O
to	O
the	O
chase	O
medium	O
,	O
apoB100	O
was	O
deubiquitinated	O
,	O
and	O
its	O
interaction	O
with	O
sec61beta	O
was	O
disrupted	O
,	O
signifying	O
completion	O
of	O
translocation	O
concomitant	O
with	O
the	O
formation	O
of	O
lipoprotein	O
particles	O
.	O

MTP	O
participates	O
in	O
apoB100	O
translocation	O
and	O
lipoprotein	O
assembly	O
.	O

In	O
the	O
presence	O
of	O
OA	O
,	O
when	O
MTP	O
lipid	O
-	O
transfer	O
activity	O
was	O
inhibited	O
at	O
the	O
end	O
of	O
pulse	O
labeling	O
,	O
apoB100	O
secretion	O
was	O
abolished	O
.	O

In	O
contrast	O
,	O
when	O
the	O
labeled	O
apoB100	O
was	O
allowed	O
to	O
accumulate	O
in	O
the	O
cell	O
for	O
60	O
min	O
before	O
adding	O
OA	O
and	O
the	O
inhibitor	O
,	O
apoB100	O
lipidation	O
and	O
secretion	O
were	O
no	O
longer	O
impaired	O
.	O

Overall	O
,	O
the	O
data	O
imply	O
that	O
during	O
most	O
of	O
its	O
association	O
with	O
the	O
endoplasmic	O
reticulum	O
,	O
apoB100	O
is	O
close	O
to	O
or	O
within	O
the	O
translocon	O
and	O
is	O
accessible	O
to	O
both	O
the	O
ubiquitin	O
-	O
proteasome	B-Complex
and	O
lipoprotein	O
-	O
assembly	O
pathways	O
.	O

Furthermore	O
,	O
MTP	O
lipid	O
-	O
transfer	O
activity	O
seems	O
to	O
be	O
necessary	O
only	O
for	O
early	O
translocation	O
and	O
lipidation	O
events	O
.	O

Stat6	O
inhibits	O
human	O
interleukin	O
-	O
4	O
promoter	O
activity	O
in	O
T	O
cells	O
.	O

The	O
differentiation	O
of	O
naive	O
T	O
-	O
helper	O
(	O
Th	O
)	O
cells	O
into	O
cytokine	O
-	O
secreting	O
effector	O
Th	O
cells	O
requires	O
exposure	O
to	O
multiple	O
signals	O
,	O
including	O
exogenous	O
cytokines	O
.	O

Interleukin	O
-	O
4	O
(	O
IL	O
-	O
4	O
)	O
plays	O
a	O
major	O
role	O
in	O
this	O
process	O
by	O
promoting	O
the	O
differentiation	O
of	O
IL	O
-	O
4	O
-	O
secreting	O
Th2	O
cells	O
.	O

In	O
Th2	O
cells	O
,	O
IL	O
-	O
4	O
gene	O
expression	O
is	O
tightly	O
controlled	O
at	O
the	O
level	O
of	O
transcription	O
by	O
the	O
coordinated	O
binding	O
of	O
multiple	O
transcription	O
factors	O
to	O
regulatory	O
elements	O
in	O
the	O
proximal	O
promoter	O
region	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
(	O
NFAT	O
)	O
family	O
members	O
play	O
a	O
critical	O
role	O
in	O
regulating	O
IL	O
-	O
4	O
transcription	O
and	O
interact	O
with	O
up	O
to	O
five	O
sequences	O
(	O
termed	O
P0	O
through	O
P4	O
)	O
in	O
the	O
IL	O
-	O
4	O
promoter	O
.	O

The	O
molecular	O
mechanisms	O
by	O
which	O
IL	O
-	O
4	O
induces	O
expression	O
of	O
the	O
IL	O
-	O
4	O
gene	O
are	O
not	O
known	O
,	O
although	O
the	O
IL	O
-	O
4	O
-	O
activated	O
transcription	O
factor	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
6	O
(	O
Stat6	O
)	O
is	O
required	O
for	O
this	O
effect	O
.	O

We	O
report	O
here	O
that	O
Stat6	O
interacts	O
with	O
three	O
binding	O
sites	O
in	O
the	O
human	O
IL	O
-	O
4	O
promoter	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

These	O
sites	O
overlap	O
the	O
P1	O
,	O
P2	O
,	O
and	O
P4	O
NFAT	O
elements	O
.	O

To	O
investigate	O
the	O
role	O
of	O
Stat6	O
in	O
regulating	O
IL	O
-	O
4	O
transcription	O
,	O
we	O
used	O
Stat6	O
-	O
deficient	O
Jurkat	O
T	O
cells	O
with	O
different	O
intact	O
IL	O
-	O
4	O
promoter	O
constructs	O
in	O
cotransfection	O
assays	O
.	O

We	O
show	O
that	O
,	O
whereas	O
a	O
multimerized	O
response	O
element	O
from	O
the	O
germline	O
IgE	B-Complex
promoter	O
was	O
highly	O
induced	O
by	O
IL	O
-	O
4	O
in	O
Stat6	O
-	O
expressing	O
Jurkat	O
cells	O
,	O
the	O
intact	O
human	O
IL	O
-	O
4	O
promoter	O
was	O
repressed	O
under	O
similar	O
conditions	O
.	O

We	O
conclude	O
that	O
the	O
function	O
of	O
Stat6	O
is	O
highly	O
dependent	O
on	O
promoter	O
context	O
and	O
that	O
this	O
factor	O
promotes	O
IL	O
-	O
4	O
gene	O
expression	O
in	O
an	O
indirect	O
manner	O
.	O

hnRNP	O
A1	O
recruited	O
to	O
an	O
exon	O
in	O
vivo	O
can	O
function	O
as	O
an	O
exon	O
splicing	O
silencer	O
.	O

Some	O
exons	O
contain	O
exon	O
splicing	O
silencers	O
.	O

Their	O
activity	O
is	O
frequently	O
balanced	O
by	O
that	O
of	O
splicing	O
enhancers	O
,	O
and	O
this	O
is	O
important	O
to	O
ensure	O
correct	O
relative	O
levels	O
of	O
alternatively	O
spliced	O
mRNAs	O
.	O

Using	O
an	O
immunoprecipitation	O
and	O
UV	O
-	O
cross	O
-	O
linking	O
assay	O
,	O
we	O
show	O
that	O
RNA	O
molecules	O
containing	O
splicing	O
silencers	O
from	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
tat	O
exon	O
2	O
or	O
the	O
human	O
fibroblast	O
growth	O
factor	O
receptor	O
2	O
K	O
-	O
SAM	O
exon	O
bind	O
to	O
hnRNP	O
A1	O
in	O
HeLa	O
cell	O
nuclear	O
extracts	O
better	O
than	O
the	O
corresponding	O
RNA	O
molecule	O
without	O
a	O
silencer	O
.	O

Two	O
different	O
point	O
mutations	O
which	O
abolish	O
the	O
K	O
-	O
SAM	O
exon	O
splicing	O
silencer	O
'	O
s	O
activity	O
reduce	O
hnRNP	O
A1	O
binding	O
twofold	O
.	O

Recruitment	O
of	O
hnRNP	O
A1	O
in	O
the	O
form	O
of	O
a	O
fusion	O
with	O
bacteriophage	O
MS2	O
coat	O
protein	O
to	O
a	O
K	O
-	O
SAM	O
exon	O
whose	O
exon	O
splicing	O
silencer	O
has	O
been	O
replaced	O
by	O
a	O
coat	O
binding	O
site	O
efficiently	O
represses	O
splicing	O
of	O
the	O
exon	O
in	O
vivo	O
.	O

Recruitment	O
of	O
only	O
the	O
glycine	O
-	O
rich	O
C	O
-	O
terminal	O
domain	O
of	O
hnRNP	O
A1	O
,	O
which	O
is	O
capable	O
of	O
interactions	O
with	O
other	O
proteins	O
,	O
is	O
sufficient	O
to	O
repress	O
exon	O
splicing	O
.	O

Our	O
results	O
show	O
that	O
hnRNP	O
A1	O
can	O
function	O
to	O
repress	O
splicing	O
,	O
and	O
they	O
suggest	O
that	O
at	O
least	O
some	O
exon	O
splicing	O
silencers	O
could	O
work	O
by	O
recruiting	O
hnRNP	O
A1	O
.	O

Interactions	O
between	O
the	O
class	O
II	O
transactivator	O
and	O
CREB	O
binding	O
protein	O
increase	O
transcription	O
of	O
major	B-Complex
histocompatibility	I-Complex
complex	I-Complex
class	I-Complex
II	I-Complex
genes	O
.	O

Class	B-Complex
II	I-Complex
major	I-Complex
histocompatibility	I-Complex
(	I-Complex
class	I-Complex
II	I-Complex
)	I-Complex
genes	O
are	O
regulated	O
in	O
a	O
B	O
-	O
cell	O
-	O
specific	O
and	O
gamma	O
interferon	O
-	O
inducible	O
fashion	O
.	O

The	O
master	O
switch	O
for	O
the	O
expression	O
of	O
these	O
genes	O
is	O
the	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
one	O
of	O
the	O
functions	O
of	O
CIITA	O
is	O
to	O
recruit	O
the	O
CREB	O
binding	O
protein	O
(	O
CBP	O
)	O
to	O
class	B-Complex
II	I-Complex
promoters	O
.	O

Not	O
only	O
functional	O
but	O
also	O
specific	O
binding	O
interactions	O
between	O
CIITA	O
and	O
CBP	O
were	O
demonstrated	O
.	O

Moreover	O
,	O
a	O
dominant	O
negative	O
form	O
of	O
CBP	O
decreased	O
the	O
activity	O
of	O
class	B-Complex
II	I-Complex
promoters	O
and	O
levels	O
of	O
class	B-Complex
II	I-Complex
determinants	O
on	O
the	O
surface	O
of	O
cells	O
.	O

Finally	O
,	O
the	O
inhibition	O
of	O
class	B-Complex
II	I-Complex
gene	O
expression	O
by	O
the	O
glucocorticoid	O
hormone	O
could	O
be	O
attributed	O
to	O
the	O
squelching	O
of	O
CBP	O
by	O
the	O
glucocorticoid	O
receptor	O
.	O

We	O
conclude	O
that	O
CBP	O
,	O
a	O
histone	O
acetyltransferase	O
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
transcription	O
of	O
class	B-Complex
II	I-Complex
genes	O
.	O

RANK	O
is	O
the	O
essential	O
signaling	O
receptor	O
for	O
osteoclast	O
differentiation	O
factor	O
in	O
osteoclastogenesis	O
.	O

Osteoclast	O
differentiation	O
factor	O
(	O
ODF	O
)	O
is	O
a	O
ligand	O
for	O
osteoclastogenesis	O
-	O
inhibitory	O
factor	O
/	O
osteoprotegerin	O
(	O
OCIF	O
/	O
OPG	O
)	O
,	O
and	O
mediates	O
an	O
essential	O
signal	O
for	O
osteoclastogenesis	O
.	O

Soluble	O
-	O
form	O
ODF	O
binds	O
directly	O
to	O
osteoclast	O
progenitors	O
,	O
suggesting	O
the	O
presence	O
of	O
a	O
membrane	O
-	O
bound	O
receptor	O
for	O
ODF	O
(	O
ODFR	O
)	O
on	O
the	O
cells	O
.	O

To	O
understand	O
the	O
ODF	O
-	O
mediated	O
signal	O
transduction	O
mechanism	O
in	O
osteoclastogenesis	O
,	O
we	O
molecularly	O
cloned	O
ODFR	O
from	O
a	O
mouse	O
macrophage	O
-	O
like	O
osteoclast	O
progenitor	O
cell	O
line	O
,	O
C7	O
.	O

Nucleotide	O
sequence	O
analysis	O
revealed	O
that	O
ODFR	O
is	O
identical	O
to	O
RANK	O
,	O
a	O
recently	O
identified	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR	O
)	O
family	O
,	O
which	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
dendritic	O
cell	O
function	O
.	O

A	O
polyclonal	O
antibody	O
against	O
the	O
extracellular	O
domain	O
of	O
RANK	O
induced	O
osteoclastogenesis	O
in	O
the	O
presence	O
of	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
.	O

In	O
contrast	O
,	O
both	O
a	O
genetically	O
engineered	O
soluble	O
RANK	O
and	O
Fab	O
fragment	O
of	O
the	O
antibody	O
blocked	O
the	O
binding	O
of	O
ODF	O
to	O
RANK	O
and	O
ODF	O
-	O
mediated	O
osteoclastogenesis	O
.	O

These	O
results	O
indicate	O
that	O
RANK	O
is	O
the	O
signaling	O
receptor	O
essential	O
for	O
ODF	O
-	O
mediated	O
osteoclastogenesis	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
shown	O
that	O
FEZ1	O
interacts	O
with	O
PKCzeta	O
in	O
vivo	O
and	O
its	O
intracellular	O
localization	O
is	O
regulated	O
by	O
the	O
PKCzeta	O
activity	O
.	O

By	O
the	O
transient	O
expression	O
assay	O
,	O
FEZ1	O
protein	O
was	O
found	O
to	O
stimulate	O
the	O
caPKCzeta	O
-	O
induced	O
neuronal	O
differentiation	O
of	O
PC12	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
the	O
NGF	O
-	O
induced	O
neuronal	O
differentiation	O
of	O
PC12	O
cells	O
,	O
a	O
PKCzeta	O
substrate	O
"	O
nucleolin	O
"	O
was	O
proposed	O
recently	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
connection	O
between	O
cell	O
surface	O
signaling	O
and	O
nucleus	O
in	O
PC12	O
cells	O
.	O

Although	O
it	O
has	O
been	O
shown	O
that	O
the	O
intracellular	O
localization	O
of	O
nucleolin	O
is	O
changed	O
by	O
the	O
activation	O
of	O
PKCzeta	O
in	O
the	O
NGF	O
-	O
induced	O
neuronal	O
differentiating	O
PC12	O
cells	O
,	O
there	O
is	O
no	O
structural	O
similarity	O
between	O
nucleolin	O
and	O
FEZ1	O
.	O

Furthermore	O
,	O
no	O
direct	O
evidence	O
is	O
available	O
showing	O
that	O
nucleolin	O
enhances	O
the	O
caPKCzeta	O
-	O
induced	O
neuronal	O
differentiation	O
of	O
PC12	O
cells	O
.	O

Thus	O
,	O
it	O
is	O
unclear	O
whether	O
or	O
not	O
there	O
is	O
any	O
functional	O
relationship	O
between	O
nucleolin	O
and	O
FEZ1	O
.	O

Multiple	O
isoforms	O
of	O
heparan	O
sulfate	O
D	O
-	O
glucosaminyl	O
3	O
-	O
O	O
-	O
sulfotransferase	O
.	O

Isolation	O
,	O
characterization	O
,	O
and	O
expression	O
of	O
human	O
cdnas	O
and	O
identification	O
of	O
distinct	O
genomic	O
loci	O
.	O

3	O
-	O
O	O
-	O
Sulfated	O
glucosaminyl	O
residues	O
are	O
rare	O
constituents	O
of	O
heparan	O
sulfate	O
and	O
are	O
essential	O
for	O
the	O
activity	O
of	O
anticoagulant	O
heparan	O
sulfate	O
.	O

Cellular	O
production	O
of	O
the	O
critical	O
active	O
structure	O
is	O
controlled	O
by	O
the	O
rate	O
-	O
limiting	O
enzyme	O
,	O
heparan	O
sulfate	O
D	O
-	O
glucosaminyl	O
3	O
-	O
O	O
-	O
sulfotransferase	O
-	O
1	O
(	O
3	O
-	O
OST	O
-	O
1	O
)	O
(	O
EC	O
2	O
.	O
8	O
.	O
2	O
.	O
23	O
)	O
.	O

We	O
have	O
probed	O
the	O
expressed	O
sequence	O
tag	O
data	O
base	O
with	O
the	O
carboxyl	O
-	O
terminal	O
sulfotransferase	O
domain	O
of	O
3	O
-	O
OST	O
-	O
1	O
to	O
reveal	O
three	O
novel	O
,	O
incomplete	O
human	O
cDNAs	O
.	O

These	O
were	O
utilized	O
in	O
library	O
screens	O
to	O
isolate	O
full	O
-	O
length	O
cDNAs	O
.	O

Clones	O
corresponding	O
to	O
predominant	O
transcripts	O
were	O
obtained	O
for	O
the	O
367	O
-	O
,	O
406	O
-	O
,	O
and	O
390	O
-	O
amino	O
acid	O
enzymes	O
3	O
-	O
OST	O
-	O
2	O
,	O
3	O
-	O
OST	O
-	O
3A	O
,	O
and	O
3	O
-	O
OST	O
-	O
3B	O
,	O
respectively	O
.	O

These	O
type	O
II	O
integral	O
membrane	O
proteins	O
are	O
comprised	O
of	O
a	O
divergent	O
amino	O
-	O
terminal	O
region	O
and	O
a	O
very	O
homologous	O
carboxyl	O
-	O
terminal	O
sulfotransferase	O
domain	O
of	O
approximately	O
260	O
residues	O
.	O

Also	O
recovered	O
were	O
partial	O
length	O
clones	O
for	O
3	O
-	O
OST	O
-	O
4	O
.	O

Expression	O
of	O
the	O
full	O
-	O
length	O
enzymes	O
confirms	O
the	O
3	O
-	O
O	O
-	O
sulfation	O
of	O
specific	O
glucosaminyl	O
residues	O
within	O
heparan	O
sulfate	O
(	O
Liu	O
,	O
J	O
.	O
,	O
Shworak	O
,	O
N	O
.	O
W	O
.	O
,	O
Sinay	O
,	O
P	O
.	O
,	O
Schwartz	O
,	O
J	O
.	O
J	O
.	O
Zhang	O
,	O
L	O
.	O
,	O
Fritze	O
,	O
L	O
.	O
M	O
.	O
S	O
.	O
,	O
and	O
Rosenberg	O
,	O
R	O
.	O
D	O
.	O
(	O
1999	O
)	O
J	O
.	O
Biol	O
.	O
Chem	O
.	O
274	O
,	O
5185	O
-	O
5192	O
)	O
.	O

Southern	O
analyses	O
suggest	O
the	O
human	O
3OST1	O
,	O
3OST2	O
,	O
and	O
3OST4	O
genes	O
,	O
and	O
the	O
corresponding	O
mouse	O
isologs	O
,	O
are	O
single	O
copy	O
.	O

However	O
,	O
3OST3A	O
and	O
3OST3B	O
genes	O
are	O
each	O
duplicated	O
in	O
humans	O
and	O
show	O
at	O
least	O
one	O
copy	O
each	O
in	O
mice	O
.	O

Intriguingly	O
,	O
the	O
entire	O
sulfotransferase	O
domain	O
sequence	O
of	O
the	O
3	O
-	O
OST	O
-	O
3B	O
cDNA	O
(	O
774	O
base	O
pairs	O
)	O
was	O
99	O
.	O
2	O
%	O
identical	O
to	O
the	O
same	O
region	O
of	O
3	O
-	O
OST	O
-	O
3A	O
.	O

Together	O
,	O
these	O
data	O
argue	O
that	O
the	O
structure	O
of	O
this	O
functionally	O
important	O
region	O
is	O
actively	O
maintained	O
by	O
gene	O
conversion	O
between	O
3OST3A	O
and	O
3OST3B	O
loci	O
.	O

Interspecific	O
mouse	O
back	O
-	O
cross	O
analysis	O
identified	O
the	O
loci	O
for	O
mouse	O
3Ost	O
genes	O
and	O
syntenic	O
assignments	O
of	O
corresponding	O
human	O
isologs	O
were	O
confirmed	O
by	O
the	O
identification	O
of	O
mapped	O
sequence	O
-	O
tagged	O
site	O
markers	O
.	O

Northern	O
blot	O
analyses	O
indicate	O
brain	O
exclusive	O
and	O
brain	O
predominant	O
expression	O
of	O
3	O
-	O
OST	O
-	O
4	O
and	O
3	O
-	O
OST	O
-	O
2	O
transcripts	O
,	O
respectively	O
;	O
whereas	O
,	O
3	O
-	O
OST	O
-	O
3A	O
and	O
3	O
-	O
OST	O
-	O
3B	O
isoforms	O
show	O
widespread	O
expression	O
of	O
multiple	O
transcripts	O
.	O

The	O
reiteration	O
and	O
conservation	O
of	O
the	O
3	O
-	O
OST	O
sulfotransferase	O
domain	O
suggest	O
that	O
this	O
structure	O
is	O
a	O
self	O
-	O
contained	O
functional	O
unit	O
.	O

Moreover	O
,	O
the	O
extensive	O
number	O
of	O
3OST	O
genes	O
with	O
diverse	O
expression	O
patterns	O
of	O
multiple	O
transcripts	O
suggests	O
that	O
the	O
novel	O
3	O
-	O
OST	O
enzymes	O
,	O
like	O
3	O
-	O
OST	O
-	O
1	O
,	O
regulate	O
important	O
biologic	O
properties	O
of	O
heparan	O
sulfate	O
proteoglycans	O
.	O

